591 Records downloaded - Fri Aug 12 15:19:15 UTC 2016
RECORD 1
TITLE
Incidence of atrial fibrillation is associated with age and gender in
subjects practicing physical exercise: A meta-analysis and meta-regression
analysis
AUTHOR NAMES
Brunetti N.D.
Santoro F.
Correale M.
De Gennaro L.
Conte G.
Di Biase M.
AUTHOR ADDRESSES
(Brunetti N.D., natale.brunetti@unifg.it; Santoro F.; Conte G.; Di Biase M.)
Department of Medical and Surgical Sciences, University of Foggia, Italy.
(Santoro F.) Sankt Georg Asklepios Klinik, Hamburg, Germany.
(Correale M.) Cardiologia Universitaria, Ospedali Riuniti, Foggia, Italy.
(De Gennaro L.) U.O. Cardiologia, Ospedale San Paolo, Bari, Italy.
(Brunetti N.D., natale.brunetti@unifg.it; Santoro F.; Correale M.; De
Gennaro L.; Conte G.; Di Biase M.) Cardiology Department, University of
Foggia, Foggia, Italy.
CORRESPONDENCE ADDRESS
N.D. Brunetti, Cardiology Department, University of Foggia, Viale Pinto n.1,
Foggia, Italy. Email: natale.brunetti@unifg.it
SOURCE
International Journal of Cardiology (2016) 221 (1056-1060). Date of
Publication: 15 Oct 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
The link between physical activity and the risk of atrial fibrillation (AF)
remains controversial. We therefore sought to further assess by a
meta-analysis whether increased levels of physical activity may increase the
risk of AF. In October 2015, a PubMed research was conducted for studies
that investigated this topic. We identified 11 relevant studies with a total
of 81,787 participants. The pooled analysis did not show an increased risk
of AF in subjects practicing physical activity (odds ratio (OR) = 0.92, 95%
C.I. = 0.84–1.01, p = 0.077, I(2) = 90%). However, given the observed large
heterogeneity among studies, a subgroup analysis was performed in order to
identify possible variables influencing the risk of AF. Significantly higher
risk of AF in subjects with reported physical activity was found in studies
enrolling exclusively male participants (OR = 7.49, 95% C.I. = 3.12–19.01,
p < 0.001, I(2) = 0%) and subjects younger than 54 years (OR 5.30, 95%
C.I. = 3.43–8.20, p < 0.001, I(2) = 1.7%), while results were opposite in
studies enrolling male and/or female participants OR = 0.89 (95%
C.I. = 0.81–0.97, p = 0.01) and subjects older than 54 years (OR = 0.84, 95%
C.I. = 0.76–0.92, p < 0.001). A reverse correlation was also found at
meta-regression analysis between age and OR of AF (p = 0.047). In
conclusion, in our meta-analysis, there is a non-significant trend toward
lower risk of AF in subjects practicing physical activity. The risk seems
higher in male subjects. A reverse correlation between age and risk of AF
seems to be evident.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
age distribution
atrial fibrillation
exercise
incidence
sex difference
EMTREE MEDICAL INDEX TERMS
cardiovascular risk
cohort analysis
correlation analysis
disease association
high risk patient
human
physical activity
priority journal
regression analysis
review
systematic review
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160533305
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2016.07.133
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 2
TITLE
Dabigatran in clinical practice: Contemporary overview of the evidence
AUTHOR NAMES
Ageno W.
Eikelboom J.
Lip G.Y.H.
AUTHOR ADDRESSES
(Ageno W.) Department of Clinical and Experimental Medicine, University of
Insubria, Varese, Italy.
(Eikelboom J.) McMaster University, Hamilton, Canada.
(Lip G.Y.H., g.y.h.lip@bham.ac.uk) University of Birmingham Institute of
Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom.
(Lip G.Y.H., g.y.h.lip@bham.ac.uk) Aalborg Thrombosis Research Unit,
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
CORRESPONDENCE ADDRESS
G.Y.H. Lip, University of Birmingham Institute of Cardiovascular Sciences,
City Hospital, Birmingham, United Kingdom. Email: g.y.h.lip@bham.ac.uk
SOURCE
International Journal of Cardiology (2016) 220 (417-428). Date of
Publication: 1 Oct 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular
atrial fibrillation (AF) and management of venous thromboembolism (VTE),
resulting in a reduction in thrombotic complications and mortality. Benefit
of vitamin K antagonists (VKAs) in such patients has been unambiguously
confirmed, but VKA use is complicated by need for regular monitoring of the
international normalized ratio and multiple drug and food interactions.
Dabigatran is an oral direct thrombin inhibitor that can be used with fixed
doses, without the need for routine anticoagulation laboratory monitoring
and the advantage of few drug or diet interactions. Dabigatran is effective
for stroke and systemic thromboembolism in AF and for the prophylaxis and
treatment of VTE. The drug has a good safety profile and consistently shows
a reduction in intracranial hemorrhage risk compared to warfarin. A specific
reversal agent for dabigatran has been approved by FDA and EU. This review
provides a summary of publications assessing clinical utility of dabigatran
for different indications.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dabigatran (adverse drug reaction, clinical trial, drug combination, drug
comparison - placebo, drug comparison, drug dose, drug therapy, oral drug
administration)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination, drug therapy)
activated prothrombin complex (drug therapy)
antivitamin K (drug therapy)
apixaban (drug therapy)
clopidogrel (drug combination, drug therapy)
enoxaparin (adverse drug reaction, drug comparison, drug therapy)
fondaparinux (drug therapy)
heparin (drug therapy, intravenous drug administration)
idarucizumab (drug therapy)
low molecular weight heparin (drug therapy, subcutaneous drug
administration)
placebo
rivaroxaban (drug therapy)
ticagrelor (drug combination, drug therapy)
warfarin (adverse drug reaction, drug combination, drug comparison, drug
therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cerebrovascular accident (drug therapy, drug therapy, prevention)
venous thromboembolism (drug therapy, complication, drug therapy,
prevention)
EMTREE MEDICAL INDEX TERMS
aging
bleeding (drug therapy, side effect)
CHADS2 score
dose response
drug dose comparison
drug efficacy
drug response
drug safety
dyspepsia (side effect)
embolism (drug therapy, prevention)
evidence based practice
hemostasis
human
joint surgery
kidney function
liver dysfunction (side effect)
low drug dose
mechanical heart valve
multicenter study (topic)
perioperative period
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
priority journal
pulmonary vein isolation
randomized controlled trial (topic)
review
risk factor
stent thrombosis (drug therapy)
DRUG TRADE NAMES
FEIBA , AustriaBaxter
DRUG MANUFACTURERS
(Austria)Baxter
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
activated prothrombin complex (78690-13-8, 78690-39-8)
apixaban (503612-47-3)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
enoxaparin (679809-58-6)
fondaparinux (104993-28-4, 114870-03-0)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
idarucizumab (1362509-93-0)
rivaroxaban (366789-02-8)
ticagrelor (274693-27-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160507884
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2016.06.078
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 3
TITLE
Accidental Bolus of Parenteral Nutrition
AUTHOR NAMES
Lodeserto F.
Al-Jaghbeer M.
Huang D.
AUTHOR ADDRESSES
(Lodeserto F., frank.lodeserto@upmc.edu; Al-Jaghbeer M.; Huang D.)
Department of Critical Care Medicine, University of Pittsburgh, Childrens
Hospital of Pittsburgh of UPMC, Faculty Pavilion, 4401 Penn Ave, Pittsburgh,
United States.
(Huang D.) Clinical Research, Investigation, and Systems Modeling of Acute
Illness (CRISMA) Center, University of Pittsburgh, Pittsburgh, United
States.
CORRESPONDENCE ADDRESS
F. Lodeserto, Department of Critical Care Medicine, University of
Pittsburgh, Childrens Hospital of Pittsburgh of UPMC, Faculty Pavilion, 4401
Penn Ave, Pittsburgh, United States. Email: frank.lodeserto@upmc.edu
SOURCE
Journal of Parenteral and Enteral Nutrition (2016) 40:6 (883-885). Date of
Publication: 1 Aug 2016
ISSN
1941-2444 (electronic)
0148-6071
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
There is a paucity of data that exists regarding acute toxicity and
management in the setting of parental nutrition (PN) overdose. We describe a
case of a patient who received an accidental rapid bolus of PN and fat
emulsion. She developed a seizure, metabolic acidosis, arrhythmias,
myocardial ischemia, altered mental status, hypotension, and hypoxemia
likely caused by elevated triglycerides, leading to a hyperviscosity
syndrome. After failing standard therapy, she was successfully treated with
a single-volume plasma exchange with resolution of symptoms. Fat emulsion or
intravenous lipid emulsion and much of its safety have been recently
described in its use as a rescue therapy in resuscitation from drug-related
toxicity. Elevated serum triglyceride levels can result in a picture similar
to a hyperviscosity syndrome. Plasma exchange is a known therapeutic
modality for the management of hyperviscosity syndrome and a novel therapy
in the treatment of hyperviscosity syndrome due to fat emulsion therapy. In
a patient receiving PN with development of rapid deterioration of clinical
status, without an obvious etiology, there should be consideration of PN
overdose. A rapid assessment and treatment of severe electrolyte
abnormalities should be undertaken immediately to prevent life-threatening
cardiovascular and central nervous system collapse. If fat emulsion was
rapidly coadministered and there are signs and symptoms of hyperviscosity
syndrome, then consideration should be given to plasma exchange as an
effective therapeutic treatment option.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
lipid emulsion (drug toxicity)
parenteral solution (drug toxicity)
EMTREE DRUG INDEX TERMS
bicarbonate
glucose (endogenous compound)
hypertensive factor (drug therapy)
infusion fluid
insulin
oxygen
potassium (endogenous compound)
triacylglycerol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
parenteral nutrition
therapeutic error
EMTREE MEDICAL INDEX TERMS
aged
arterial gas
article
artificial ventilation
atrial fibrillation (complication)
case report
electroencephalogram
female
glucose blood level
heart infarction
heart muscle ischemia (complication)
human
hyperglycemia (complication, diagnosis)
hyperkalemia (complication, diagnosis)
hypertriglyceridemia (complication, therapy)
hyperviscosity syndrome (complication)
hypotension (complication, drug therapy)
hypoxemia (complication, therapy)
insulin infusion
intensive care unit
intensivist
intestine ischemia (complication, surgery)
intestine resection
lactic acidosis (diagnosis)
length of stay
mechanical ventilator
medical history
medical specialist
mental health
metabolic acidosis (complication, diagnosis)
metabolic encephalopathy (complication)
nursing staff
plasmapheresis
positive end expiratory pressure
postoperative complication (complication, therapy)
potassium blood level
priority journal
repeat procedure
respiratory acidosis (complication, diagnosis)
respiratory failure (complication, therapy)
seizure (complication)
short bowel syndrome (complication, therapy)
ST segment depression
treatment response
triacylglycerol blood level
CAS REGISTRY NUMBERS
bicarbonate (144-55-8, 71-52-3)
glucose (50-99-7, 84778-64-3)
insulin (9004-10-8)
oxygen (7782-44-7)
potassium (7440-09-7)
EMBASE CLASSIFICATIONS
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160549211
FULL TEXT LINK
http://dx.doi.org/10.1177/0148607115572194
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 4
TITLE
Self-rating level of perceived exertion for guiding exercise intensity
during a 12-week cardiac rehabilitation programme and the influence of heart
rate reducing medication
AUTHOR NAMES
Tang L.H.
Zwisler A.-D.
Taylor R.S.
Doherty P.
Zangger G.
Berg S.K.
Langberg H.
AUTHOR ADDRESSES
(Tang L.H., Lars.hermann.tang@regionh.dk; Zwisler A.-D.; Zangger G.; Berg
S.K.) Department of Cardiology, The Heart Centre, Rigshospitalet -
Copenhagen University Hospital, Denmark.
(Tang L.H., Lars.hermann.tang@regionh.dk; Langberg H.) CopenRehab, Section
of Social Medicine, Department of Public Health, University of Copenhagen,
Denmark.
(Tang L.H., Lars.hermann.tang@regionh.dk) Department of Rehabilitation and
Nutrition, Faculty of Health and Technology, Metropolitan University
College, Denmark.
(Tang L.H., Lars.hermann.tang@regionh.dk) The Centre for Physical Activity
Research, Rigshospitalet, University of Copenhagen, Denmark.
(Zwisler A.-D.) National Centre for Rehabilitation and Palliative Care,
University of Southern Denmark, Odense University Hospital, Denmark.
(Taylor R.S.) Institute of Health Research, University of Exeter Medical
School, United Kingdom.
(Taylor R.S.) National Institute of Public Health, University of Southern
Denmark, Denmark.
(Doherty P.) Department of Health Sciences, University of York, United
Kingdom.
CORRESPONDENCE ADDRESS
L.H. Tang, Department of Cardiology, The Heart Centre, Rigshospitalet,
Copenhagen University Hospital, Denmark. Email: Lars.hermann.tang@regionh.dk
SOURCE
Journal of Science and Medicine in Sport (2016) 19:8 (611-615). Date of
Publication: 1 Aug 2016
ISSN
1878-1861 (electronic)
1440-2440
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
Objectives: To investigate whether self-rating level of perceived exertion
can adequately guide exercise intensity during a 12-week cardiac
rehabilitation programme. Design: Linear regression analysis using
rehabilitation data from two randomised controlled trials. Methods: Patients
undergoing radiofrequency ablation for atrial fibrillation or following
heart valve surgery and participating in exercise-based rehabilitation were
included. The 12-week rehabilitation outpatient programme comprised three
weekly training sessions, each consisting of 20 min aerobic exercise divided
into three steps. Patients were asked to base their exercise intensity for
each step on a predefined rating of perceived exertion specified in a
training diary. Exercise intensity was objectively measured by heart rate
during the last 2 min for each exercise step. Comparative analysis and
linear regression of the rating of perceived exertion and heart rate were
performed. Results: A total of 2622 ratings of perceived exertion were
collected from 874 training sessions in 97 patients. Heart rate and rating
of perceived exertion were associated both across all three exercise steps
and individually for each step, with a mean of 6 to7 bpm per 1-point
difference in the rating of perceived exertion (p < 0.001). Adjusting for
rate-reducing medication slightly improved the strength of the association.
Conclusions: The association between change in the rating of perceived
exertion and change in heart rate indicates that a diary-led and
self-regulated model using rating of perceived exertion can help guide
exercise intensity in everyday clinical practice among patients with heart
disease, irrespective if they are taking heart rate-reducing medication.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
calcium antagonist
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (rehabilitation, surgery)
exercise intensity
heart rate variability
heart rehabilitation
self concept
EMTREE MEDICAL INDEX TERMS
adult
aerobic exercise
article
controlled study
female
heart valve surgery
human
kinesiotherapy
major clinical study
male
parallel design
radiofrequency ablation
randomized controlled trial
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015479544
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jsams.2015.08.004
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 5
TITLE
Contact force monitoring during catheter ablation of intraatrial reentrant
tachycardia in patients with congenital heart disease
AUTHOR NAMES
Krause U.
Backhoff D.
Klehs S.
Schneider H.E.
Paul T.
AUTHOR ADDRESSES
(Krause U., ukrause1@gwdg.de; Backhoff D.; Klehs S.; Schneider H.E.; Paul
T.) Department of Pediatric Cardiology and Intensive Care Medicine,
University Medical Center, Göttingen, Germany.
CORRESPONDENCE ADDRESS
U. Krause, Department of Pediatric Cardiology and Intensive Care Medicine,
University Medical Center, Göttingen, Germany. Email: ukrause1@gwdg.de
SOURCE
Journal of Interventional Cardiac Electrophysiology (2016) 46:2 (191-198).
Date of Publication: 1 Aug 2016
ISSN
1572-8595 (electronic)
1383-875X
BOOK PUBLISHER
Springer New York LLC, barbara.b.bertram@gsk.com
ABSTRACT
Background: Monitoring of catheter contact force during catheter ablation of
atrial fibrillation has been shown to increase efficacy and safety. However,
almost no data exists on the use of this technology in catheter ablation of
intraatrial reentrant tachycardia in patients with congenital heart disease.
The aim of the present study was to evaluate the impact of contact force
monitoring during catheter ablation of intraatrial reentrant tachycardia in
those patients. Methods: Catheter ablation of intraatrial reentrant
tachycardia using monitoring of catheter contact force was performed in 28
patients with congenital heart disease (CHD). Thirty-two patients matched
according to gender, age, and body weight with congenital heart disease
undergoing catheter ablation without contact force monitoring served as
control group. Parameters reflecting acute procedural success, long-term
efficacy, and safety were compared. Results: Acute procedural success was
statistically not different in both groups (contact force 93 % vs. control
84 %, p = 0.3). Likewise the recurrence rate 1 year after ablation as shown
by Kaplan-Meier analysis did not differ (contact force 28 % vs. control
37 %, p = 0.63). Major complications were restricted to groin vessel
injuries and occurred in 3 out of 60 patients (contact force n = 1; control
n = 2). Complications related to excessive catheter contact force were not
observed. Conclusion: The present study did not show superiority of catheter
contact force monitoring during ablation of intraatrial reentrant
tachycardia in patients with CHD in terms of efficacy and safety. Higher
contact force compared to pulmonary vein isolation might therefore be
required to increase the efficacy of catheter ablation of intraatrial
reentrant tachycardia in patients with congenital heart disease.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
catheter ablation
congenital heart disease (congenital disorder)
contact force monitoring
intraatrial reentrant tachycardia (therapy)
monitoring
reentry tachycardia (therapy)
EMTREE MEDICAL INDEX TERMS
adult
arteriovenous fistula (complication)
article
blood vessel injury (complication)
clinical article
controlled study
false aneurysm (complication)
female
follow up
human
inguinal region
male
postoperative complication (complication)
priority journal
recurrence risk
safety
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160026504
FULL TEXT LINK
http://dx.doi.org/10.1007/s10840-015-0096-z
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 6
TITLE
Ablation of Atrial Fibrillation: Patient Selection, Periprocedural
Anticoagulation, Techniques, and Preventive Measures after Ablation
AUTHOR NAMES
Link M.S.
Haïssaguerre M.
Natale A.
AUTHOR ADDRESSES
(Link M.S., Mark.Link@UTSouthwestern.edu) Cardiac Arrhythmia Center, UT
Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, United States.
(Haïssaguerre M.) Liryc Institute (Electrophysiology and Heart Modeling
Institute), Hopital Cardiologique du Haut-Leveque, Universite de Bordeaux,
France.
(Natale A.) Texas Cardiac Arrhythmia Institute, St. David's Medical Center,
Austin, United States.
CORRESPONDENCE ADDRESS
M.S. Link, Cardiac Arrhythmia Center, UT Southwestern Medical Center, 5323
Harry Hines Blvd, Dallas, United States. Email: Mark.Link@UTSouthwestern.edu
SOURCE
Circulation (2016) 134:4 (339-352). Date of Publication: 26 Jul 2016
ISSN
1524-4539 (electronic)
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Atrial fibrillation (AF) is the most common arrhythmia encountered by
cardiologists and is a major cause of morbidity and mortality. Risk factors
for AF include age, male sex, genetic predisposition, hypertension, diabetes
mellitus, sleep apnea, obesity, excessive alcohol, smoking, hyperthyroidism,
pulmonary disease, air pollution, heart failure, and possibly excessive
exercise. The management of AF involves decisions about rate versus rhythm
control. Asymptomatic patients are generally managed with rate control and
anticoagulation. Symptomatic patients will desire rhythm control. Rhythm
control options are either antiarrhythmic agents or ablation, with each
having its own risks and benefits. Ablation of AF has evolved from a rare
and complex procedure to a common electrophysiological technique. Selection
of patients to undergo ablation is an important aspect of AF care. Patients
with the highest success rates of ablation are those with normal structural
hearts and paroxysmal AF, although those with congestive heart failure have
the greatest potential benefit of the procedure. Although pulmonary vein
isolation of any means/energy source is the approach generally agreed on for
those with paroxysmal AF, optimal techniques for the ablation of
nonparoxysmal AF are not yet clear. Anticoagulation reduces thromboembolic
complications; the newer anticoagulants have eased management for both the
patient and the cardiologist. Aggressive management of modifiable risk
factors (hypertension, diabetes mellitus, sleep apnea, obesity, excessive
alcohol, smoking, hyperthyroidism, pulmonary disease, air pollution, and
possibly excessive exercise) after ablation reduces the odds of recurrent AF
and is an important element of care.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antiarrhythmic agent
anticoagulant agent
EMTREE DRUG INDEX TERMS
alcohol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
ablation therapy
anticoagulation
paroxysmal atrial fibrillation
patient selection
pulsed radiofrequency treatment
EMTREE MEDICAL INDEX TERMS
air pollution
cardiologist
clinical study
congestive heart failure
controlled study
diabetes mellitus
electrophysiological procedures
energy resource
exercise
genetic predisposition
heart arrhythmia
human
hypertension
hyperthyroidism
lung disease
male
morbidity
mortality
obesity
pulmonary vein isolation
risk factor
sleep disordered breathing
smoking
thromboembolism
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160571191
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021727
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 7
TITLE
Cardiovascular benefits and risks across the physical activity continuum
AUTHOR NAMES
Eijsvogels T.M.H.
George K.P.
Thompson P.D.
AUTHOR ADDRESSES
(Eijsvogels T.M.H.) aResearch Institute for Sports and Exercise Sciences,
Liverpool John Moores University, Liverpool, UK bDepartment of Physiology,
Radboud University Medical Center, Nijmegen, The Netherlands cDivision of
Cardiology, Hartford Hospital, Hartford, Connecticut, USA
(George K.P.; Thompson P.D.)
CORRESPONDENCE ADDRESS
T.M.H. Eijsvogels, aResearch Institute for Sports and Exercise Sciences,
Liverpool John Moores University, Liverpool, UK bDepartment of Physiology,
Radboud University Medical Center, Nijmegen, The Netherlands cDivision of
Cardiology, Hartford Hospital, Hartford, Connecticut, USA
SOURCE
Current Opinion in Cardiology (2016). Date of Publication: 22 Jul 2016
ISSN
1531-7080 (electronic)
0268-4705
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
PURPOSE OF REVIEW: Habitual physical activity can reduce the risk of future
cardiovascular morbidity and mortality. This review evaluates recent
publications that have assessed the impact of the dose of physical
(in)activity on cardiovascular outcomes. RECENT FINDINGS: Sedentary
behavior, characterized by prolonged sitting, is increasingly prevalent
across the globe and increases the risk for cardiovascular events in a
dose-dependent fashion. Similarly, the number of individuals performing
endurance exercise events has tripled over the last 2 decades, and some
studies suggest that the high volumes of exercise training and competition
may attenuate the health benefits of a physically active lifestyle. SUMMARY:
Breaking up sitting time or replacing sitting by (light) physical activity
are effective strategies to attenuate its detrimental health effects. Low
doses of physical activity, preferably at a high intensity, significantly
reduce the risk for cardiovascular and all-cause mortality. Larger doses of
exercise yield larger health benefits. Extreme doses of exercise neither
increase nor decrease the risk for adverse outcomes. Athletes demonstrate a
transient cardiac dysfunction and biomarker release directly postexercise.
Chronic exercise training may increase the risk for atrial fibrillation, but
is also associated with a superior life expectancy compared with the general
population.
EMTREE DRUG INDEX TERMS
biological marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular system
physical activity
EMTREE MEDICAL INDEX TERMS
adverse outcome
athlete
atrial fibrillation
behavior
competition
endurance training
human
human experiment
life expectancy
lifestyle
morbidity
mortality
population
publication
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160561094
FULL TEXT LINK
http://dx.doi.org/10.1097/HCO.0000000000000321
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 8
TITLE
Factors Affecting Patients’ Perception On, and Adherence To, Anticoagulant
Therapy: Anticipating the Role of Direct Oral Anticoagulants
AUTHOR NAMES
Pandya E.Y.
Bajorek B.
AUTHOR ADDRESSES
(Pandya E.Y., Ekta.Y.Pandya@student.uts.edu.au; Bajorek B.,
Beata.Bajorek@uts.edu.au) Graduate School of Health, University of
Technology Sydney, Building 7, 67 Thomas Street, Ultimo, Australia.
(Bajorek B., Beata.Bajorek@uts.edu.au) Pharmacy Department, Royal North
Shore Hospital, St Leonards, Australia.
CORRESPONDENCE ADDRESS
E.Y. Pandya, Graduate School of Health, University of Technology Sydney,
Building 7, 67 Thomas Street, Ultimo, Australia. Email:
Ekta.Y.Pandya@student.uts.edu.au
SOURCE
Patient (2016) (1-23). Date of Publication: 20 Jul 2016
ISSN
1178-1661 (electronic)
1178-1653
BOOK PUBLISHER
Springer International Publishing
ABSTRACT
The role of the direct oral anticoagulants (DOACs) in practice has been
given extensive consideration recently, albeit largely from the clinician’s
perspective. However, the effectiveness and safety of using anticoagulants
is highly dependent on the patient’s ability to manage and take these
complex, high-risk medicines. This structured narrative review explores the
published literature to identify the factors underpinning patients’
non-adherence to anticoagulants in atrial fibrillation (AF), and
subsequently contemplates to what extent the DOACs might overcome the known
challenges with traditional warfarin therapy. This review comprised a
two-tier search of various databases and search platforms (CINAHL, Cochrane,
Current Contents Connect, EMBASE, MEDLINE Ovid, EBSCO, PubMed, Google,
Google Scholar) to yield 47 articles reporting patients perspectives on, and
patients adherence to, anticoagulant therapy. The findings from the
literature were synthesised under five interacting dimensions of adherence:
therapy-related factors, patient-related factors, condition-related factors,
social–economic factors and health system factors. Factors negatively
affecting patients’ day-to-day lives (especially regular therapeutic drug
monitoring, dose adjustments, dietary considerations) predominantly underpin
a patient’s reluctance to take warfarin therapy, leading to non-adherence.
Other patient-related factors underpinning non-adherence include patients’
perceptions and knowledge about the purpose of anticoagulation;
understanding of the risks and benefits of therapy; socioeconomic status;
and expectations of care from health professionals. In considering these
findings, it is apparent that the DOACs may overcome some of the barriers to
traditional warfarin therapy at least to an extent, particularly the need
for regular monitoring, frequent dose adjustment and dietary considerations.
However, their high cost, twice-daily dosing and gastrointestinal adverse
effects may present additional challenges for patients and health systems.
The review highlights the need to explicitly incorporate patients’
perspectives in decision-making processes for anticoagulant selection, to
obtain optimum adherence and treatment outcomes. Further studies should
explore resources that can better engage patients in decision making around
the selection of anticoagulant therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
perception
EMTREE MEDICAL INDEX TERMS
adverse drug reaction
Cinahl
consensus development
decision making
diet
doctor patient relation
drug monitoring
drug therapy
Embase
expectation
gastrointestinal tract
human
Medline
SciSearch
social status
systematic review
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160550822
FULL TEXT LINK
http://dx.doi.org/10.1007/s40271-016-0180-1
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 9
TITLE
Clinical neurocardiology defining the value of neuroscience-based
cardiovascular therapeutics
AUTHOR NAMES
Shivkumar K.
Ajijola O.A.
Anand I.
Armour J.A.
Chen P.-S.
Esler M.
De Ferrari G.M.
Fishbein M.C.
Goldberger J.J.
Harper R.M.
Joyner M.J.
Khalsa S.S.
Kumar R.
Lane R.
Mahajan A.
Po S.
Schwartz P.J.
Somers V.K.
Valderrabano M.
Vaseghi M.
Zipes D.P.
AUTHOR ADDRESSES
(Shivkumar K., kshivkumar@mednet.ucla.edu; Ajijola O.A.; Armour J.A.;
Vaseghi M.) UCLA Cardiac Arrhythmia Center and Neurocardiology Research
Center of Excellence, Los Angeles, United States.
(Anand I.) Department of Cardiology, University of Minnesota Medical School,
Minneapolis, United States.
(Chen P.-S.) Krannert Institute of Cardiology, Indiana University School of
Medicine, Indianapolis, United States.
(Esler M.) Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
(De Ferrari G.M.) Department of Molecular Medicine, University of Pavia,
Pavia, Italy.
(Fishbein M.C.) Department of Pathology and Laboratory Medicine, David
Geffen School of Medicine at UCLA, Los Angeles, United States.
(Goldberger J.J.) Division of Cardiology, University of Miami Miller School
of Medicine, Miami, United States.
(Harper R.M.) Department of Neurobiology and the Brain Research Institute,
University of California, Los Angeles, United States.
(Joyner M.J.; Somers V.K.) Division of Cardiovascular Diseases, Mayo Clinic
and Mayo Foundation, Rochester, United States.
(Khalsa S.S.) Laureate Institute for Brain Research, Tulsa, United States.
(Kumar R.) Departments of Anesthesiology and Radiological Sciences, David
Geffen School of Medicine at UCLA, Los Angeles, United States.
(Lane R.) Department of Psychiatry, University of Arizona College of
Medicine, Tucson, United States.
(Mahajan A.) Department of Anesthesia, UCLA, Los Angeles, United States.
(Po S.) Heart Rhythm Institute, University of Oklahoma Health Sciences
Center, Oklahoma City, United States.
(Po S.) University of Tulsa Oxley College of Health Sciences, Tulsa, United
States.
(Schwartz P.J.) Center for Cardiac Arrhythmias of Genetic Origin, IRCCS
Instituto Auxologico Italiano, c/o Centro Diagnostico e di Ricerrca San
Carlo, Milan, Italy.
(Valderrabano M.) Methodist DeBakey Heart and Vascular Center and Methodist
Hospital Research Institute, Houston Methodist Hospital, Houston, United
States.
(Zipes D.P.) Indiana University School of Medicine, Indianapolis, United
States.
CORRESPONDENCE ADDRESS
K. Shivkumar, UCLA Cardiac Arrhythmia Center and Neurocardiology Research
Center of Excellence, Los Angeles, United States. Email:
kshivkumar@mednet.ucla.edu
SOURCE
Journal of Physiology (2016) 594:14 (3911-3954). Date of Publication: 15 Jul
2016
ISSN
1469-7793 (electronic)
0022-3751
BOOK PUBLISHER
Blackwell Publishing Ltd, customerservices@oxonblackwellpublishing.com
ABSTRACT
Abstract: The autonomic nervous system regulates all aspects of normal
cardiac function, and is recognized to play a critical role in the
pathophysiology of many cardiovascular diseases. As such, the value of
neuroscience-based cardiovascular therapeutics is increasingly evident. This
White Paper reviews the current state of understanding of human cardiac
neuroanatomy, neurophysiology, pathophysiology in specific disease
conditions, autonomic testing, risk stratification, and neuromodulatory
strategies to mitigate the progression of cardiovascular diseases.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart function
neuroscience
EMTREE MEDICAL INDEX TERMS
adrenergic transmission
aerobic exercise
article
atrial fibrillation
cardiac resynchronization therapy
cardiopulmonary function
cardiovascular risk
cholinergic transmission
functional anatomy
heart conduction
heart denervation
heart failure
holistic care
human
interoception
ischemic heart disease
kidney denervation
meditation
motoneuron
nerve cell network
nerve stimulation
neuroanatomy
neuromodulation
pressoreceptor reflex
priority journal
risk assessment
sinus rhythm
sleep disordered breathing
spinal cord stimulation
stellate ganglion block
thorax epidural anesthesia
vagus nerve stimulation
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160528001
MEDLINE PMID
27114333 (http://www.ncbi.nlm.nih.gov/pubmed/27114333)
FULL TEXT LINK
http://dx.doi.org/10.1113/JP271870
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 10
TITLE
Heart rate reduction in coronary artery disease and heart failure
AUTHOR NAMES
Ferrari R.
Fox K.
AUTHOR ADDRESSES
(Ferrari R., fri@unife.it) Department of Cardiology, Ospedale di Cona, Via
Aldo Moro 8, Cona Ferrara, Italy.
(Fox K.) National Heart and Lung Institute, Institute of Cardiovascular
Medicine and Science, Royal Brompton Hospital, Sydney Street, London, United
Kingdom.
CORRESPONDENCE ADDRESS
R. Ferrari, Department of Cardiology, Ospedale di Cona, Via Aldo Moro 8,
Cona Ferrara, Italy. Email: fri@unife.it
SOURCE
Nature Reviews Cardiology (2016) 13:8 (493-501). Date of Publication: 14 Jul
2016
ISSN
1759-5010 (electronic)
1759-5002
BOOK PUBLISHER
Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
Elevated heart rate is known to induce myocardial ischaemia in patients with
coronary artery disease (CAD), and heart rate reduction is a recognized
strategy to prevent ischaemic episodes. In addition, clinical evidence shows
that slowing the heart rate reduces the symptoms of angina by improving
microcirculation and coronary flow. Elevated heart rate is an established
risk factor for cardiovascular events in patients with CAD and in those with
chronic heart failure (HF). Accordingly, reducing heart rate improves
prognosis in patients with HF, as demonstrated in SHIFT. By contrast, data
from SIGNIFY indicate that heart rate is not a modifiable risk factor in
patients with CAD who do not also have HF. Heart rate is also an important
determinant of cardiac arrhythmias; low heart rate can be associated with
atrial fibrillation, and high heart rate after exercise can be associated
with sudden cardiac death. In this Review, we critically assess these
clinical findings, and propose hypotheses for the variable effect of heart
rate reduction in cardiovascular disease.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
ivabradine (pharmacology)
EMTREE DRUG INDEX TERMS
angiotensin II
beta adrenergic receptor blocking agent
metoprolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary artery disease
heart failure
heart rate
heart rate reduction
EMTREE MEDICAL INDEX TERMS
angina pectoris
atrial fibrillation
bradycardia
cardiovascular risk
coronary artery blood flow
coronary flow reserve
disease course
drug effect
exercise
heart arrhythmia
heart left ventricle function
heart muscle ischemia
human
microcirculation
nonhuman
outcome assessment
priority journal
prognosis
review
sudden cardiac death
CAS REGISTRY NUMBERS
angiotensin II (11128-99-7)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
metoprolol (37350-58-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160399497
FULL TEXT LINK
http://dx.doi.org/10.1038/nrcardio.2016.84
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 11
TITLE
Low preoperative selenium is associated with post-operative atrial
fibrillation in patients having intermediate-risk coronary artery surgery
AUTHOR NAMES
McDonald C.
Fraser J.
Shekar K.
Clarke A.
Coombes J.
Barnett A.
Pearse B.
Fung L.
AUTHOR ADDRESSES
(Clarke A.) Department of Cardiac Surgery, The Prince Charles Hospital,
Chermside, Queensland, Australia
(McDonald C.; Fraser J.; Shekar K.; Coombes J.; Barnett A.; Pearse B.; Fung
L.)
CORRESPONDENCE ADDRESS
A. Clarke, Department of Cardiac Surgery, The Prince Charles Hospital,
Chermside, Queensland, Australia
SOURCE
European Journal of Clinical Nutrition (2016). Date of Publication: 13 Jul
2016
ISSN
1476-5640 (electronic)
0954-3007
BOOK PUBLISHER
Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
Background/objectives:Post-operative atrial fibrillation (POAF) is a
frequent complication of cardiac surgery. Oxidative stress and reduced
antioxidant function have major roles in its development. Selenium is a key
to normal antioxidant function, and levels are often low before cardiac
surgery. This study investigated whether low preoperative selenium levels
were associated with POAF in cardiac surgical
patients.Subjects/methods:Using the Society of Thoracic Surgeons (STS)
Mortality risk score, 50 patients having primary coronary artery bypass
grafts (CABG) surgery were divided into two groups: (i) low-risk group (STS
⩽0.5%; n=26) and (ii) intermediate-risk group (STS ⩾2.0%; n=24). Plasma
levels of selenium, glutathione peroxidase (GPx) and malondialdehyde (MDA)
were measured in all patients at anaesthetic induction, after aortic
cross-clamp removal, 3 h post cardiopulmonary bypass and on post-operative
days 1 and 5. Multiple logistic regression was used to assess whether
selenium levels were associated with POAF development.Results:Seventeen
patients developed POAF (14 patients in the intermediate-risk group and 3
patients in the low-risk group). Preoperative selenium was lower in patients
who developed POAF compared with those with normal sinus rhythm (0.73±0.16
vs 0.89±0.13 μmol/l, P=0.005), and this was independently associated with
POAF (PR 0.32; 95% confidence credible interval (95%cI) 0.06–0.85, P=0.016).
Regardless of POAF, preoperative selenium was lower in the intermediate-risk
patients than in the low-risk patients (0.77±0.15 vs 0.89±0.14 μmol/l;
P=0.004).Conclusions:Intermediate-risk patients with low preoperative
selenium levels may be at a greater risk of developing POAF following CABG.
This raises the question of whether selenium supplementation in select
cardiac surgical patients may reduce their POAF risk.European Journal of
Clinical Nutrition advance online publication, 13 July 2016;
doi:10.1038/ejcn.2016.125.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
selenium
EMTREE DRUG INDEX TERMS
glutathione peroxidase
malonaldehyde
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
coronary artery bypass graft
EMTREE MEDICAL INDEX TERMS
anesthesia induction
cardiopulmonary bypass
clamp
clinical article
clinical trial
controlled study
gene expression
human
human tissue
intermediate risk patient
intermediate risk population
low risk patient
low risk population
multivariate logistic regression analysis
nutrition
plasma
publication
sinus rhythm
Society of Thoracic Surgeons score
surgery
surgical patient
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160523219
FULL TEXT LINK
http://dx.doi.org/10.1038/ejcn.2016.125
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 12
TITLE
Evaluation of the effects of olodaterol on exercise endurance in patients
with chronic obstructive pulmonary disease: Results from two 6-week
crossover studies
AUTHOR NAMES
Maltais F.
Kirsten A.-M.
Hamilton A.
De Sousa D.
Voß F.
Decramer M.
AUTHOR ADDRESSES
(Maltais F., Francois.Maltais@fmed.ulaval.ca) Centre de Recherche, Institut
Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte
Foy, , Canada.
(Kirsten A.-M.) Member of the German Center for Lung Research, Pulmonary
Research Institute at Lung Clinic Grosshansdorf, Airway Research Center
North, Grosshansdorf, Germany.
(Hamilton A.; De Sousa D.) Boehringer Ingelheim, Burlington, Canada.
(Voß F.) Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany.
(Decramer M.) University Hospitals Leuven, Department of Pulmonology,
Leuven, Belgium.
CORRESPONDENCE ADDRESS
F. Maltais, Centre de Recherche, Institut Universitaire de Cardiologie et de
Pneumologie de Québec, 2725 Chemin Sainte Foy, , Canada. Email:
Francois.Maltais@fmed.ulaval.ca
SOURCE
Respiratory Research (2016) 17:1 Article Number: 77. Date of Publication: 6
Jul 2016
ISSN
1465-993X (electronic)
1465-9921
BOOK PUBLISHER
BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
Background: Two replicate, double-blind, placebo-controlled, 6-week
crossover studies assessed the effect of the once-daily long-acting
β(2)-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance
in patients with moderate to very severe chronic obstructive pulmonary
disease. Methods: Patients received placebo, olodaterol 5 μg once daily (QD)
and olodaterol 10 μg QD in a randomised order for 6 weeks each, with a
2-week washout period in between. The primary end point was change in
endurance time during constant work-rate cycle ergometry to symptom
limitation at 75 % maximal work capacity after 6 weeks of treatment (2 h
post-dose), based on log(10)-transformed data. Key secondary end points were
inspiratory capacity at isotime and intensity of breathing discomfort at
isotime. Results: 151 and 157 patients were randomised and treated in
Studies 1222.37 and 1222.38, respectively, with 147 and 154 being included
in the full analysis sets. Mean endurance time at week 6 was increased
compared to placebo by 14.0 % (Study 1222.37; p < 0.001) and 11.8 % (Study
1222.38; p < 0.01) with olodaterol 5 μg, and by 13.8 % (Study 1222.37; p <
0.001) and 10.5 % (Study 1222.38; p < 0.01) with olodaterol 10 μg.
Inspiratory capacity at isotime increased with olodaterol 5 μg (Study
1222.37, 0.182 L, p < 0.0001; Study 1222.38, 0.084 L, p < 0.05) and 10 μg
(Study 1222.37, 0.174 L; Study 1222.38, 0.166 L; both studies, p < 0.0001),
and breathing discomfort was significantly reduced in Study 1222.37
(olodaterol 5 μg, 0.77 Borg units, p < 0.001; olodaterol 10 μg, 0.63 Borg
units, p < 0.01) but not Study 1222.38. Conclusions: These studies provide
further characterisation of the efficacy of olodaterol, showing that
improvements in airflow (forced expiratory volume in 1 s) are associated
with increases in inspiratory capacity and improvements in exercise
endurance time. Trial registrations:NCT01040130(1222.37) and
NCT01040793(1222.38).
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
olodaterol (adverse drug reaction, clinical trial, drug comparison -
placebo, drug therapy, inhalational drug administration)
EMTREE DRUG INDEX TERMS
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chronic obstructive lung disease (drug therapy, drug therapy)
endurance
exercise
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation (side effect)
bicycle ergometry
coughing (side effect)
disease exacerbation (side effect)
drug dose comparison
drug efficacy
drug withdrawal
dyspnea (side effect)
female
forced expiratory volume
functional residual capacity
headache (side effect)
human
hyperinflation
insomnia (side effect)
inspiratory capacity
major clinical study
male
multicenter study (topic)
oropharynx pain (side effect)
randomized controlled trial (topic)
rhinopharyngitis (side effect)
soft mist inhaler
DEVICE TRADE NAMES
Respimat
CAS REGISTRY NUMBERS
olodaterol (868049-49-4, 869477-96-3)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT01040130, NCT01040793)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160508803
FULL TEXT LINK
http://dx.doi.org/10.1186/s12931-016-0389-5
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 13
TITLE
Phenotype-specific treatment of heart failure with preserved ejection
fraction
AUTHOR NAMES
Shah S.J.
Kitzman D.W.
Borlaug B.A.
Van Heerebeek L.
Zile M.R.
Kass D.A.
Paulus W.J.
AUTHOR ADDRESSES
(Shah S.J.) Division of Cardiology, Feinberg Cardiovascular Research
Institute, Northwestern University Feinberg School of Medicine, Chicago,
United States.
(Kitzman D.W.) Sections on Cardiovascular Medicine and Geriatrics, Wake
Forest School of Medicine, Winston-Salem, United States.
(Borlaug B.A.) Division of Cardiovascular Diseases, Department of Internal
Medicine, Mayo Clinic, Rochester, United States.
(Van Heerebeek L.; Paulus W.J., wj.paulus@vumc.nl) Department of Physiology,
Institute for Cardiovascular Research, VU University Medical Center,
Amsterdam, Netherlands.
(Van Heerebeek L.) Department of Cardiology, Onze Lieve Vrouw Gasthuis,
Amsterdam, Netherlands.
(Zile M.R.) Department of Medicine, Medical University of South Carolina
(MUSC), RHJ Department of Veterans Affairs Medical Center, Charleston,
United States.
(Kass D.A.) Division of Cardiology, Department of Medicine, Johns Hopkins
Medical Institutions, Baltimore, United States.
CORRESPONDENCE ADDRESS
W.J. Paulus, Department of Physiology, Institute for Cardiovascular
Research, VU University Medical Center, Amsterdam, Netherlands. Email:
wj.paulus@vumc.nl
SOURCE
Circulation (2016) 134:1 (73-90). Date of Publication: 5 Jul 2016
ISSN
1524-4539 (electronic)
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for
50% of HF cases, and its prevalence relative to HF with reduced EF continues
to rise. In contrast to HF with reduced EF, large trials testing
neurohumoral inhibition in HFpEF failed to reach a positive outcome. This
failure was recently attributed to distinct systemic and myocardial
signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an
HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling
and phenotypic diversity. In HFpEF, extracardiac comorbidities such as
metabolic risk, arterial hypertension, and renal insufficiency drive left
ventricular remodeling and dysfunction through systemic inflammation and
coronary microvascular endothelial dysfunction. The latter affects left
ventricular diastolic dysfunction through macrophage infiltration, resulting
in interstitial fibrosis, and through altered paracrine signaling to
cardiomyocytes, which become hypertrophied and stiff because of low nitric
oxide and cyclic guanosine monophosphate. Systemic inflammation also affects
other organs such as lungs, skeletal muscle, and kidneys, leading,
respectively, to pulmonary hypertension, muscle weakness, and sodium
retention. Individual steps of these signaling cascades can be targeted by
specific interventions: metabolic risk by caloric restriction, systemic
inflammation by statins, pulmonary hypertension by phosphodiesterase 5
inhibitors, muscle weakness by exercise training, sodium retention by
diuretics and monitoring devices, myocardial nitric oxide bioavailability by
inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content
by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by
spironolactone. Because of phenotypic diversity in HFpEF, personalized
therapeutic strategies are proposed, which are configured in a matrix with
HFpEF presentations in the abscissa and HFpEF predispositions in the
ordinate.
EMTREE DRUG INDEX TERMS
cyclic GMP (endogenous compound)
diuretic agent (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
membrane metalloendopeptidase (endogenous compound)
nitrate
nitric oxide (endogenous compound)
nitrite
phosphodiesterase V inhibitor
sacubitril (drug therapy)
spironolactone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure with preserved ejection fraction (drug therapy, drug therapy)
phenotype
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
caloric restriction
chronotropism
comorbidity
coronary artery disease
disease predisposition
endothelial dysfunction
exercise
fibrosing alveolitis
heart left ventricle function
heart muscle fibrosis
heart ventricle remodeling
human
hypertension
kidney
kidney failure
left ventricular diastolic dysfunction
lung
lung congestion
muscle weakness
paracrine signaling
priority journal
pulmonary hypertension
skeletal muscle
sodium retention
CAS REGISTRY NUMBERS
cyclic GMP (7665-99-8)
membrane metalloendopeptidase (82707-54-8, 88201-55-2)
nitrate (14797-55-8)
nitric oxide (10102-43-9)
nitrite (14797-65-0)
sacubitril (149709-62-6)
spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160502544
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021884
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 14
TITLE
Evaluation of SAMe-TT(2)R(2) score and other clinical factors influencing
the quality of anticoagulation therapy in non-valvular atrial fibrillation:
A nationwide study in Spain
AUTHOR NAMES
Lobos-Bejarano J.M.
Barrios V.
Polo-García J.
Escobar C.
Vargas-Ortega D.
Marín-Montañés N.
Prieto-Valiente L.
Fuentes S.
Prieto M.A.
García-Ortiz L.
AUTHOR ADDRESSES
(Lobos-Bejarano J.M., jmlobos@gmail.com) Jazmin Primary Care Health Center,
East Area Primary Care, Madrid, Spain.
(Barrios V.) Cardiology Department, University Hospital Ramon y Cajal,
Madrid, Spain.
(Polo-García J.) Primary Care Health Center Casar de Cáceres, Cáceres,
Spain.
(Escobar C.) Cardiology Department, University Hospital La Paz, Madrid,
Spain.
(Vargas-Ortega D.) High Resolution Hospitalization Unit, Hospital el Toyo,
Hospital de Poniente El Ejido, Almeria, Spain.
(Marín-Montañés N.) Medical Department, Bayer Hispania, Barcelona, Spain.
(Prieto-Valiente L.) Medical Biostatistics, Universidad Católica San Antonio
de Murcia, Murcia, Spain.
(Fuentes S.) Primary Care Health Center, Barcelona, Spain.
(Prieto M.A.) Vallobín-La Florida Primary Care Health Center, Oviedo, Spain.
(Prieto M.A.) Medicine Preventive Department, Oviedo University, Spain.
(García-Ortiz L.) Unit of Clinical Research La Alamedilla, Salamanca, Spain.
()
CORRESPONDENCE ADDRESS
J.M. Lobos-Bejarano, Jazmin Primary Care Health Center, Calle del Jazmin 33,
Madrid, Spain. Email: jmlobos@gmail.com
SOURCE
Current Medical Research and Opinion (2016) 32:7 (1201-1207). Date of
Publication: 2 Jul 2016
ISSN
1473-4877 (electronic)
0300-7995
BOOK PUBLISHER
Taylor and Francis Ltd, healthcare.enquiries@informa.com
ABSTRACT
Objective: To assess the major clinical factors affecting the quality of
anticoagulation and evaluate the predictive value of the SAMe-TT(2)R(2)
score to identify patients who will achieve a high average time in
therapeutic range (T.T.R.) with vitamin K antagonist (V.K.A.) treatment.
Research design and methods: This observational, cross-sectional,
retrospective and nationwide multicenter study included 1524 patients from
the primary care setting with non-valvular atrial fibrillation receiving
V.K.A. (≥12 months). We performed a bivariate analysis to identify factors
individually associated with the T.T.R. and a multiple regression analysis
to identify the independent predictive factors. For the validation of the
SAMe-TT(2)R(2) score, the receiver operating characteristic (R.O.C.) curve
was calculated and the Hosmer–Lemeshow test was used to test calibration.
Results: A total of 94.8% of patients received acenocumarol (4.8% warfarin).
A progressive decrease in mean T.T.R. was found when the SAMe-TT(2)R(2)
score increased from 0 points (72.1 ± 17.1%) to 4 points (64.1 ± 23.2%), p <
0.001. Other risk scores (CHADS(2) and CHA(2)DS(2)-VASc, HAS-BLED) were also
associated with the mean T.T.R. We found a significant association between
low T.T.R. and the following clinical factors: female sex, three or more
comorbidities, amiodarone treatment, dietary habits, bleeding history and
the intake of ≥7 tablets per day besides V.K.A. (p < 0.01). Regarding
SAMe-TT(2)R(2) score validation, the R.O.C. curve showed significant
capability, although not high, of discriminating good anticoagulation
control (T.T.R. ≥65%) with an area under the curve of 0.562 (95% C.I.
0.533–0.592, p < 0.001) which increased, remaining modest, to 0.594 (95%
C.I. 0.564–0.624, p < 0.001) when the factors not included in SAMe-TT(2)R(2)
score were added. Conclusion: In this cohort, the SAMe-TT(2)R(2) score had a
significant, although modest, ability to assess the likelihood of good
international normalized ration (I.N.R.) control, and its predictive value
might slightly improve by adding other simple clinical factors. Further
research is needed to refine the predictive scales.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy)
EMTREE DRUG INDEX TERMS
acenocoumarol (drug therapy)
amiodarone (drug therapy)
antivitamin K (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
atrial fibrillation (drug therapy, drug therapy)
cardiovascular disease assessment
non valvular atrial fibrillation (drug therapy, drug therapy)
SAMe TT2R2 score
EMTREE MEDICAL INDEX TERMS
aged
article
bleeding
CHA2DS2 VASc score
CHADS2 score
cohort analysis
comorbidity assessment
cross-sectional study
dietary intake
female
HAS BLED score
human
major clinical study
male
medical history
multicenter study
observational study
predictive value
primary medical care
retrospective study
sex difference
Spain
time
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160288799
FULL TEXT LINK
http://dx.doi.org/10.1185/03007995.2016.1164676
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 15
TITLE
The role of comprehensive geriatric assessment and functional status in
evaluating the patterns of antithrombotic use among older people with atrial
fibrillation
AUTHOR NAMES
Mazzone A.
Bo M.
Lucenti A.
Galimberti S.
Bellelli G.
Annoni G.
AUTHOR ADDRESSES
(Mazzone A.; Lucenti A.; Galimberti S.; Bellelli G.,
giuseppe.bellelli@unimib.it; Annoni G.) School of Medicine and Surgery,
University of Milano-Bicocca, Italy.
(Mazzone A.; Bellelli G., giuseppe.bellelli@unimib.it; Annoni G.) Geriatric
Unit, S. Gerardo Hospital, Monza, Italy.
(Bellelli G., giuseppe.bellelli@unimib.it; Annoni G.) Milan Center for
Neuroscience (Neuro-Mi), Milan, Italy.
(Bo M.) SCDU Geriatria e Malattie Metaboliche dell'Osso, Città della Salute
e della Scienza-Molinette, Torino, Italy.
(Lucenti A.; Galimberti S.) Center of Biostatistics for Clinical
Epidemiology, University of Milano-Bicocca, Milan, Italy.
(Mazzone A.) Redaelli Geriatric Institute, Milan, Italy.
CORRESPONDENCE ADDRESS
G. Bellelli, School of Medicine and Surgery, University of Milano-Bicocca,
Italy. Email: giuseppe.bellelli@unimib.it
SOURCE
Archives of Gerontology and Geriatrics (2016) 65 (248-254). Date of
Publication: 1 Jul 2016
ISSN
1872-6976 (electronic)
0167-4943
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
Aim of the study is to investigate the use of antithrombotic drugs in older
patients with atrial fibrillation (AF) at the time of hospital discharge. We
enrolled 399 ≥65 years old patients with AF consecutively admitted to our
acute geriatric unit from September 2012 to February 2014. Utilization of
antithrombotic drugs, comorbidities, functional, mental and nutritional
status were evaluated through a comprehensive geriatric assessment (CGA). A
Logistic regression model was used to assess variables associated with
antithrombotic use. On admission, 198 patients (49.6%) used oral
anticoagulants (OAC), 125 (21.3%) antiplatelets, 32 (8%) low weight
molecular heparin (LMWH) and 44 (11%) none of them. At discharge the
proportion of patients on OAC increased to 55.7%. Age > 90 years (OR = 2.57,
CI = 1.28-5.16, p-value = 0.008), severe functional impairment (OR = 3.38,
CI = 1.63-7.01, p-value = 0.001), polypharmacy (OR = 2.07, CI = 1.1-3.86,
p-value = 0.023), HAS-BLED score (OR = 1.64, CI = 1.09-2.47, p-value =
0.019) and ≥1 OAC contraindication (OR = 5.01, CI = 2.68-9.34, p-value <
0.001) were all associated with OAC underuse.In conclusion, OAC is underused
in geriatric patients with AF, while antiplatelet, LMWH and no
antithrombotic therapy are relatively overused. Factors associated with the
decision to not prescribe OAC lie on a mix of clinical and geriatric
variables, among which functional status is particularly relevant.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy, oral drug administration)
EMTREE DRUG INDEX TERMS
acenocoumarol (drug therapy)
acetylsalicylic acid (drug therapy)
angiotensin receptor antagonist
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent
calcium channel blocking agent
clopidogrel (drug therapy)
dipeptidyl carboxypeptidase inhibitor
dipyridamole (drug therapy)
diuretic agent
enoxaparin (drug therapy)
glyceryl trinitrate (transdermal drug administration)
hydroxymethylglutaryl coenzyme A reductase inhibitor
nadroparin (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
drug use
functional assessment
functional status
geriatric assessment
EMTREE MEDICAL INDEX TERMS
aged
article
cohort analysis
comorbidity
controlled study
disease severity
drug contraindication
drug utilization
emergency ward
female
functional disease
hospital admission
hospital discharge
human
major clinical study
male
mental health
nutritional status
observational study
polypharmacy
priority journal
retrospective study
thromboembolism (drug therapy)
very elderly
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
enoxaparin (679809-58-6)
glyceryl trinitrate (55-63-0, 80738-44-9)
nadroparin (104521-37-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160330164
FULL TEXT LINK
http://dx.doi.org/10.1016/j.archger.2016.04.008
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 16
TITLE
The effects of rikkunshito on body weight loss after esophagectomy
AUTHOR NAMES
Nakamura M.
Nakamori M.
Ojima T.
Katsuda M.
Hayata K.
Iwahashi M.
Yamaue H.
AUTHOR ADDRESSES
(Nakamura M.; Nakamori M.; Ojima T.; Katsuda M.; Hayata K.; Iwahashi M.;
Yamaue H., yamaue-h@wakayama-med.ac.jp) Second Department of Surgery,
Wakayama Medical University, School of Medicine, Wakayama, Japan.
CORRESPONDENCE ADDRESS
H. Yamaue, Second Department of Surgery, Wakayama Medical University, School
of Medicine, Wakayama, Japan. Email: yamaue-h@wakayama-med.ac.jp
SOURCE
Journal of Surgical Research (2016) 204:1 (130-138). Date of Publication: 1
Jul 2016
ISSN
1095-8673 (electronic)
0022-4804
BOOK PUBLISHER
Academic Press Inc., apjcs@harcourt.com
ABSTRACT
Background After esophagectomy, esophageal cancer patients suffer from
malnutrition, anorexia, and dysfunction of digestion and absorption.
Rikkunshito, a traditional Japanese herbal medicine, reportedly attenuates
gastrointestinal symptoms and appetite loss after gastrointestinal surgery.
We evaluated the clinical effect of rikkunshito and its relationship with
ghrelin in esophageal cancer patients after esophagectomy. Methods This
prospective nonrandomized study included 40 patients with esophageal cancer
who underwent esophagectomy at Wakayama Medical University Hospital. They
were assigned to either the control group (n = 20, April 2011-January 2012)
or the rikkunshito group (n = 20, January 2012-August 2012). Patients in the
rikkunshito group received 2.5 g of rikkunshito before every meal for 48 wk
beginning 4 wk after surgery. During the 48-week treatment, we assessed body
weight loss, nutritional parameters, and quality of life (Functional
Assessment of Cancer Therapy-Esophageal scale). The primary end point was
the rate of body weight loss in two groups after the 48-week treatments.
Results The rate of body weight loss was significantly less in the
rikkunshito group than in the control group (P = 0.016). The acyl ghrelin
level after the 48-week treatments was significantly higher in the
rikkunshito group (131.7% ± 74.5%) than in the control group (75.6% ± 47.5%,
P = 0.039). For the Functional Assessment of Cancer Therapy-Esophageal
symptom scale, satisfaction of food consumption in the rikkunshito group was
significantly better than in the control group at 52 wk postoperatively (P =
0.031). Conclusions For esophageal cancer patients after esophagectomy,
rikkunshito is useful for improving body weight loss in connection with an
increase in plasma acyl ghrelin levels.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
prokinetic agent (drug development, pharmacology)
rikkunshito (drug development, pharmacology)
EMTREE DRUG INDEX TERMS
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
esophagus resection
weight reduction
EMTREE MEDICAL INDEX TERMS
adjuvant therapy
adult
aged
angina pectoris (complication)
anorexia
article
asthma (complication)
Atractylodis lanceae rhizoma
atrial fibrillation (complication)
Aurantii nobilis pericarpium
cancer adjuvant therapy
cancer patient
cancer surgery
cholecystitis (complication)
clinical article
comparative study
controlled study
esophagus cancer (surgery)
female
follow up
food intake
functional assessment
ginger
ginseng
Glycyrrhiza
herbal medicine
Hoelen
human
loss of appetite
male
malnutrition
medicinal plant
pericardial effusion (complication)
Pinelliae tuber
pneumonia (complication)
postoperative complication (complication)
priority journal
prospective study
quality of life
recurrent laryngeal nerve palsy (complication)
surgical patient
treatment duration
Zizyphi fructus
DRUG TRADE NAMES
rikkunshito , JapanTsumura
DRUG MANUFACTURERS
(Japan)Tsumura
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160384772
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jss.2016.04.004
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 17
TITLE
A patient with parenteral nutrition-dependent short bowel syndrome and
cardiovascular disease with 4-year exposure to teduglutide
AUTHOR NAMES
Compher C.
Levinson K.B.
Cambor C.L.
Stoner N.
Boullata J.I.
Piarulli A.
Kinosian B.
AUTHOR ADDRESSES
(Compher C., compherc@nursing.upenn.edu; Boullata J.I.; Piarulli A.)
University of Pennsylvania, School of Nursing, Claire M. Fagin Hall, 331,
418 Curie Blvd, Philadelphia, United States.
(Compher C., compherc@nursing.upenn.edu; Levinson K.B.; Cambor C.L.;
Kinosian B.) University of Pennsylvania, Perelman School of Medicine,
Philadelphia, United States.
(Compher C., compherc@nursing.upenn.edu; Stoner N.; Boullata J.I.; Kinosian
B.) Hospital of the University of Pennsylvania, Clinical Nutrition Support
Service, Philadelphia, United States.
(Levinson K.B.; Cambor C.L.) Hospital of the University of Pennsylvania,
Department of Pathology and Laboratory Medicine, Philadelphia, United
States.
(Kinosian B.) Department of Medicine, University of Pennsylvania,
Philadelphia, United States.
CORRESPONDENCE ADDRESS
C. Compher, University of Pennsylvania, School of Nursing, Claire M. Fagin
Hall, 331, 418 Curie Blvd, Philadelphia, United States. Email:
compherc@nursing.upenn.edu
SOURCE
Journal of Parenteral and Enteral Nutrition (2016) 40:5 (725-729). Date of
Publication: 1 Jul 2016
ISSN
1941-2444 (electronic)
0148-6071
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted
in approval of the drug by the Food and Drug Administration in 2012 as a
treatment for parenteral nutrition-dependent short bowel syndrome in adults.
This report presents the case study of a man with short bowel syndrome
caused by portal vein thrombosis who had 4 years exposure to the drug at the
time of his death due to cardiovascular disease.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
teduglutide (adverse drug reaction, clinical trial, drug therapy,
subcutaneous drug administration)
EMTREE DRUG INDEX TERMS
amino acid
amiodarone (drug therapy)
antibiotic agent (drug therapy, intravenous drug administration)
brain natriuretic peptide (endogenous compound)
C reactive protein (endogenous compound)
cholesterol (endogenous compound)
cimetidine
creatinine (endogenous compound)
electrolyte
enoxaparin (drug therapy)
glucose
lipid
loperamide
sodium (endogenous compound)
sodium chloride
trace element
triacylglycerol (endogenous compound)
vancomycin (adverse drug reaction, drug therapy, intravenous drug
administration)
vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease
drug exposure
long term care
long term exposure
parenteral nutrition
short bowel syndrome (drug therapy, complication, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
abdominal aorta
abdominal aorta aneurysm
abdominal radiography
acute abdomen
acute cholecystitis (surgery)
adenomatous polyp
adult
antibiotic therapy
aorta atherosclerosis
aortography
arm weakness
arousal
article
atherosclerotic plaque
atrial fibrillation (drug therapy)
bacteremia (drug therapy)
body mass
cardioversion
case report
catheter infection (complication, drug therapy)
catheter removal
central venous catheter (adverse device effect)
cholecystectomy
cholelithiasis
cholesterol blood level
chronic cholecystitis (surgery)
colon resection
congestive heart failure
coronary artery atherosclerosis
creatinine blood level
dehydration
dizziness
drug efficacy
drug safety
dry weight
dyspnea (side effect)
echocardiography
electrocardiogram
fatigue
fluid intake
food intake
heart function
heart left ventricle ejection fraction
Hickman catheter
home care
hospital admission
hospitalization
human
hypomania
ileum resection
increased appetite
intestine necrosis (complication)
jejunostomy
length of stay
liver nodule
male
medication compliance
middle aged
mitral valve regurgitation
nuclear magnetic resonance imaging
osteomyelitis
pain severity
patient compliance
peripherally inserted central venous catheter
phase 3 clinical trial (topic)
portal vein thrombosis
priority journal
psoriasis
randomized controlled trial (topic)
rectum polyp
side effect (side effect)
sigmoidoscopy
smoking
sodium urine level
sudden cardiac death
suppuration (complication)
tachycardia (therapy)
tachycardia induced cardiomyopathy
thorax pain
triacylglycerol blood level
ultrasound
urea nitrogen blood level
urine volume
virus myocarditis
weight gain
weight reduction
DRUG TRADE NAMES
gattex , United StatesNPS
DRUG MANUFACTURERS
(United States)NPS
CAS REGISTRY NUMBERS
amino acid (65072-01-7)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
brain natriuretic peptide (114471-18-0)
C reactive protein (9007-41-4)
cholesterol (57-88-5)
cimetidine (51481-61-9, 70059-30-2)
creatinine (19230-81-0, 60-27-5)
enoxaparin (679809-58-6)
glucose (50-99-7, 84778-64-3)
lipid (66455-18-3)
loperamide (34552-83-5, 53179-11-6)
sodium (7440-23-5)
sodium chloride (7647-14-5)
teduglutide (197922-42-2, 287714-30-1)
vancomycin (1404-90-6, 1404-93-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160482001
FULL TEXT LINK
http://dx.doi.org/10.1177/0148607114566466
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 18
TITLE
NOAC monitoring, reversal agents, and post-approval safety and effectiveness
evaluation: A cardiac safety research consortium think tank
AUTHOR NAMES
Reiffel J.A.
Weitz J.I.
Reilly P.
Kaminskas E.
Sarich T.
Sager P.
Seltzer J.
AUTHOR ADDRESSES
(Reiffel J.A., jar2@cumc.columbia.edu) Columbia University, New York, United
States.
(Weitz J.I.) McMaster University, Thrombosis and Atherosclerosis Research
Institute, Canada.
(Reilly P.) Employee of Boehringer Ingelheim Pharmaceuticals, Ridgefield,
United States.
(Kaminskas E.) Division of Hematology Products, CDER, FDA, Silver Springs,
United States.
(Sarich T.) Employee of Janssen Scientific Affairs, LLC, Titusville, United
States.
(Sager P.) Stanford University, Sager Consulting Experts, San Francisco,
United States.
(Seltzer J.) ACI Clinical and Lankenau Heart Institute, Wynnewood, United
States.
CORRESPONDENCE ADDRESS
J.A. Reiffel, Columbia University, c/o 202 Birkdale Lane, Jupiter, United
States. Email: jar2@cumc.columbia.edu
SOURCE
American Heart Journal (2016) 177 (74-86). Date of Publication: 1 Jul 2016
ISSN
1097-6744 (electronic)
0002-8703
BOOK PUBLISHER
Mosby Inc., customerservice@mosby.com
ABSTRACT
Four non-vitamin K antagonist oral anticoagulants (dabigatran, rivaroxaban,
apixaban, and edoxaban) have been approved in the United States for
treatment of atrial fibrillation (AF) and venous thromboembolic disease.
They have been as or more effective than the prior standards of care, with
less fatal or intracranial bleeding, fewer drug and dietary interactions,
and greater patient convenience. Nonetheless, the absence of the ability for
clinicians to assess compliance or washout with a simple laboratory test (or
to adjust dosing with a similar assessment) and the absence of an antidote
to rapidly stop major hemorrhage or to enhance safety in the setting of
emergent or urgent surgery/procedures have been limitations to greater
non-vitamin K antagonist oral anticoagulant usage and better thromboembolic
prevention. Accordingly, a Cardiac Research Safety Consortium "think tank"
meeting was held in February 2015 to address these concerns. This manuscript
reports on the discussions held and the conclusions reached at that meeting.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (oral drug administration)
non vitamin K antagonist oral anticoagulant (oral drug administration)
EMTREE DRUG INDEX TERMS
antidote
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
drug monitoring
EMTREE MEDICAL INDEX TERMS
anticoagulation
drug antigenicity
drug approval
drug efficacy
drug indication
drug safety
food and drug administration
human
nonhuman
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
phase 4 clinical trial (topic)
postmarketing surveillance
priority journal
randomized controlled trial (topic)
review
risk benefit analysis
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160433791
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ahj.2016.04.010
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 19
TITLE
Temporary transvenous pacemaker implantation during carotid endarterectomy
in patients with trifascicular block
AUTHOR NAMES
Marrocco-Trischitta M.M.
Mazzone P.
Vitale R.
Regazzoli D.
Laricchia A.
Chiesa R.
AUTHOR ADDRESSES
(Marrocco-Trischitta M.M., max_marrocco@yahoo.com; Vitale R.; Chiesa R.)
Cardiothoracic and Vascular Department, Vascular Surgery Unit, IRCCS
Ospedale San Raffaele, Via Olgettina, 60, Milan, Italy.
(Mazzone P.; Regazzoli D.) Cardiothoracic and Vascular Department,
Arrhythmology and Cardiac Pacing Unit, IRCCS Ospedale San Raffaele, Milano,
Italy.
(Laricchia A.) Cardiothoracic and Vascular Department, Cardiology Unit,
IRCCS Ospedale San Raffaele, Milano, Italy.
(Chiesa R.) Cardiothoracic and Vascular Department, IRCCS Ospedale San
Raffaele, Università Vita-Salute San Raffaele, Milano, Italy.
CORRESPONDENCE ADDRESS
M.M. Marrocco-Trischitta, Cardiothoracic and Vascular Department, Vascular
Surgery Unit, IRCCS Ospedale San Raffaele, Via Olgettina, 60, Milan, Italy.
Email: max_marrocco@yahoo.com
SOURCE
Annals of Vascular Surgery (2016) 34 (206-211). Date of Publication: 1 Jul
2016
ISSN
1615-5947 (electronic)
0890-5096
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
Background The risk of severe perioperative bradyarrhythmias in patients
with chronic left bundle branch, or bifascicular block, and an additional
first-degree atrioventricular block undergoing carotid endarterectomy (CEA)
has never been specifically addressed. In this study, we aimed to
investigate whether these conduction abnormalities entail an increased risk
of hemodynamic compromise during CEA and the role of temporary transvenous
pacemaker (TTVPM) implantation as a prophylactic measure in this subgroup of
patients. Methods Between June 2006 and June 2013, 37 CEAs were performed in
31 patients (29 men, mean age 76 ± 6 years), in whom a TTVPM was implanted
for a trifascicular block. Thirty-seven concurrent, consecutive patients
operated for other vascular pathologies also with a prophylactic TTVPM for
an asymptomatic trifascicular block served as controls. Adverse events were
considered: pacemaker activation, block progression, bradycardia ≤40
beats/min, and asystole. Results Study and control groups were overall
comparable. No perioperative mortality was recorded. All patients undergoing
CEA were asymptomatic for syncope preoperatively. Among them, in 34 cases,
indication for TTVPM was based on preoperative EKG, and in 4, a pacemaker
activation was recorded. Three additional patients were also included in the
study group in whom TTVPM was implanted due to the occurrence of adverse
advents, and not prophylactically. In 2 of these, severe bradycardia with
eventual asystole occurred intraoperatively. In both cases, the procedure
was discontinued and rescheduled for the following day after a TTVPM was
implanted. In the last additional case, the patient had a block progression
on day 1 after an uneventful CEA and was emergently treated with a TTVPM.
Overall, 7 adverse events were recorded in the study group, and none in the
control group (P < 0.011). Morbidity in the CEA group also included 1
myocardial infarction, 1 minor stroke, 1 surgical revision for cervical
hematoma, 1 new-onset atrial fibrillation, and 1 femoral artery
pseudoaneurysm. Conclusions In our experience, TTVPM implantation was a
clinically useful adjunct in patients with trifascicular block submitted to
CEA, as compared with other vascular surgical procedures. However, the risks
inherent to CEA in this subgroup of patients suggest that surgical treatment
may not be warranted for those with asymptomatic carotid disease.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrioventricular block (surgery)
carotid endarterectomy
pacemaker implantation
temporary transvenous pacemaker implantation
trifascicular block (surgery)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
bradycardia (complication)
cardiac patient
cardiovascular mortality
cerebrovascular accident
clinical article
comparative study
controlled study
faintness
false aneurysm
female
glomerulus filtration rate
heart arrest (complication)
heart infarction
hematoma
human
male
morbidity
New York Heart Association class
new-onset atrial fibrillation
peroperative complication (complication)
priority journal
retrospective study
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160421732
FULL TEXT LINK
http://dx.doi.org/10.1016/j.avsg.2015.12.025
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 20
TITLE
Characterization of the Myocarditis during the worst outbreak of dengue
infection in China
AUTHOR NAMES
Li Y.
Hu Z.
Huang Y.
Li J.
Hong W.
Qin Z.
Tong Y.
Li J.
Lv M.
Li M.
Zheng X.
Hu J.
Hua J.
Zhang F.
Xu D.-L.
AUTHOR ADDRESSES
(Li Y.; Huang Y.; Hua J.; Xu D.-L., dinglixu@fimmu.com) State Key Laboratory
of Organ Failure Research, Department of Cardiology, Nanfang Hospital,
Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, China.
(Li Y.; Hu Z.; Qin Z.; Tong Y.; Li J.; Lv M.; Li M.) Department of
Cardiology, Guangzhou 8th People's Hospital, Guangzhou Medical University,
China.
(Li J.; Hong W.; Zhang F.) Department of Infectious Disease, Guangzhou 8th
People's Hospital, Guangzhou Medical University, China.
(Zheng X.) Department of Pathology, First Affiliated Hospital, China.
(Hu J.) Department of Microbiology, Zhongshan School of Medicine, Sun
Yat-Sen University, Guangzhou, China.
CORRESPONDENCE ADDRESS
D.-L. Xu, State Key Laboratory of Organ Failure Research, Department of
Cardiology, Nanfang Hospital, Southern Medical University, 1838 North
Guangzhou Avenue, Guangzhou, China. Email: dinglixu@fimmu.com
SOURCE
Medicine (United States) (2016) 95:27 Article Number: e4051. Date of
Publication: 1 Jul 2016
ISSN
1536-5964 (electronic)
0025-7974
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Myocarditis is a common complication of severe dengue infection. However,
data about prevalence and characterization of myocarditis in dengue are
still lacking. In 2014, the worst outbreak of dengue in the last two decades
in China occurred. In this study, we described the clinical and laboratory
diagnostic features of dengue with myocarditis. Totally, 1782 diagnosed
dengue patients were admitted from August to October, 2014, all of whom were
subjected to electrocardiogram, ultrasound cardiogram, and cardiac enzyme
test. About 201 cases of dengue patients were diagnosed with myocarditis and
the prevalence of myocarditis in hospitalized dengue was 11.28%. The
prevalence of myocarditis in nonsevere dengue with warning signs and severe
dengue [NSD(WS+)/SD] and nonsevere dengue without warning signs [NSD(WS-)]
was 46.66% and 9.72%, respectively. The NSD(WS+)/SD patients with
myocarditis presented with higher incidence of cardiac symptoms,
supraventricular tachycardia (14.29% vs. 0%, P < 0.001), atrial fibrillation
(25.71% vs. 10.24%, P = 0.019) and heart failure compared with NSD (WS-)
patients with myocarditis. About 150 cases of dengue patients without
myocarditis in the same period of time in department of Cardiology were
recruited as control group. The proportion of NSD(WS+)/SD in dengue patients
with and without myocarditis was 17.41% and 2.53%, respectively. Dengue
patients with myocarditis experienced longer hospital stay than those
without myocarditis (7.17 ± 4.64 vs. 5.98 ± 2.69, P = 0.008). There was no
difference between patients with and without myocarditis in the proportion
of symptoms, auxiliary methods abnormality, arrhythmia, and heart failure on
the discharge day. Our study demonstrates the prevalence of myocarditis in
worst outbreak of dengue in China was 11.28% and the incidence of
myocarditis increased with the severity of dengue. The NSD(WS+)/SD patients
with myocarditis presented with higher incidence of cardiac complication
compared with NSD (WS-) patients with myocarditis. The prognosis of dengue
patients with and without myocarditis had no significant difference even if
myocarditis patients experienced longer hospital stay.
EMTREE DRUG INDEX TERMS
alanine aminotransferase (endogenous compound)
aspartate aminotransferase (endogenous compound)
immunoglobulin G (endogenous compound)
immunoglobulin M (endogenous compound)
nonstructural protein 1 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
dengue (diagnosis)
epidemic (diagnosis)
myocarditis (diagnosis)
EMTREE MEDICAL INDEX TERMS
abdominal pain
adult
alanine aminotransferase blood level
aphasia
arthralgia
article
aspartate aminotransferase blood level
atrial fibrillation
bleeding
cardiogenic shock
China
clinical feature
coma
controlled study
convulsion
diarrhea
disease severity
dyspnea
ECG abnormality
electrocardiogram
enzyme assay
exercise
faintness
female
headache
heart arrhythmia
heart failure
heart palpitation
hepatomegaly
hospitalization
human
jaundice
major clinical study
male
middle aged
myalgia
outcome assessment
prevalence
priority journal
prognosis
rapid test
rash
sudden cardiac death
supraventricular tachycardia
thorax pain
vomiting
CAS REGISTRY NUMBERS
alanine aminotransferase (9000-86-6, 9014-30-6)
aspartate aminotransferase (9000-97-9)
immunoglobulin G (97794-27-9)
immunoglobulin M (9007-85-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Microbiology: Bacteriology, Mycology, Parasitology and Virology (4)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160540249
FULL TEXT LINK
http://dx.doi.org/10.1097/MD.0000000000004051
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 21
TITLE
Catheter ablation versus medical rate control for persistent atrial
fibrillation in patients with heart failure: A PRISMA-compliant systematic
review and meta-analysis of randomized controlled trials
AUTHOR NAMES
Zhu M.
Zhou X.
Cai H.
Wang Z.
Xu H.
Chen S.
Chen J.
Xu X.
Xu H.
Mao W.
AUTHOR ADDRESSES
(Zhu M.; Zhou X.; Cai H.; Wang Z.; Chen S.; Chen J.; Xu X.; Xu H.; Mao W.,
maoweilw@163.com) Department of Cardiology, First Affiliated Hospital of
Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
(Xu H.) Department of Pharmacy, Second Affiliated Hospital, Zhejiang
University School of Medicine, Hangzhou, Zhejiang, China.
CORRESPONDENCE ADDRESS
W. Mao, Department of Cardiology, First Affiliated Hospital of Zhejiang
Chinese Medical University, Hangzhou, Zhejiang, China. Email:
maoweilw@163.com
SOURCE
Medicine (United States) (2016) 95:30 Article Number: 1857. Date of
Publication: 1 Jul 2016
ISSN
1536-5964 (electronic)
0025-7974
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Background: The effectiveness of restoring the sinus rhythm by catheter
ablation relative to that of medical rate control for persistent atrial
fibrillation (AF) patients with heart failure (HF) remains to be defined.
Methods: We systematically searched Embase, Pubmed, the Cochrane Library,
and ClinicalTrials.gov for articles that compared the outcomes of interest
between catheter ablation and medical rate control therapy in persistent AF
patients with HF and left ventricular systolic dysfunction (LVSD). The
primary endpoint was the change in the left ventricular ejection fraction
(LVEF) following catheter ablation or medical rate control therapy relative
to baseline. Other endpoints included changes in cardiac function and
exercise capacity, including the New York Heart Association (NYHA) class,
the brain natriuretic peptide (BNP) level, the peak oxygen consumption (peak
VO 2), the 6-minute walk test (6MWT) results, and quality of life (QOL).
Results: Three randomized controlled trials (RCTs) with 143 patients were
included. At the overall term follow-up, catheter ablation significantly
improved the LVEF (mean difference [MD]: 6.22%; 95% confidence interval
[CI]: 0.7-11.74, P = 0.03) and peak VO 2 (MD: 2.81 mL/kg/min; 95% CI:
0.78-4.85, P = 0.007) and reduced the NYHA class (MD: 0.9; 95% CI:
0.59-1.21, P < 0.001) and the Minnesota Living with Heart Failure
Questionnaires (MLHFQ) scores (MD: -11.05; 95% CI: -19.45 - 2.66, P = 0.01)
compared with the medical rate control for persistent AF patients with HF.
Alterations in parameters, such as the BNP level, 6MWT, and Short Form-36
(SF-36) questionnaire scores also revealed trends that favored catheter
ablation therapy, although these differences were not significant.
Conclusion: Catheter ablation resulted in improved LVEF, cardiac function,
exercise capacity, and QOL for persistent AF patients with HF compared with
the medical rate control strategy.
EMTREE DRUG INDEX TERMS
brain natriuretic peptide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
catheter ablation
left ventricular systolic dysfunction
persistent atrial fibrillation
EMTREE MEDICAL INDEX TERMS
aerobic capacity
Cochrane Library
confidence interval
control strategy
controlled study
doctor patient relation
Embase
exercise
follow up
heart left ventricle ejection fraction
human
Medline
meta analysis
New York Heart Association class
normal human
questionnaire
randomized controlled trial
Short Form 36
systematic review
United States
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160579986
FULL TEXT LINK
http://dx.doi.org/10.1097/MD.0000000000004377
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 22
TITLE
Erratum: Deceptive meaning of oxygen uptake measured at the anaerobic
threshold in patients with systolic heart failure and atrial fibrillation
(European Journal of Preventive Cardiology (2015) 22 (1046-1055) DOI:
10.1177/2047487314551546)
AUTHOR ADDRESSES
SOURCE
European Journal of Preventive Cardiology (2016) 23:11 (NP97). Date of
Publication: 1 Jul 2016
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
In the above paper Gianfranco Parati's affiliation was incorrect, the
correct version is below: Department of Cardiovascular, Neural and Metabolic
Sciences, San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy &
Department of Medicine and Surgery, University of Milano-Bicocca, Milan,
Italy.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
error
EMTREE MEDICAL INDEX TERMS
erratum
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160548710
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487316652336
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 23
TITLE
Left atrial remodeling, early repolarization pattern, and inflammatory
cytokines in professional soccer players
AUTHOR NAMES
Stumpf C.
Simon M.
Wilhelm M.
Zimmermann S.
Rost C.
Achenbach S.
Brem M.H.
AUTHOR ADDRESSES
(Stumpf C., ch.stumpf@web.de; Simon M.; Wilhelm M.; Zimmermann S.; Rost C.;
Achenbach S.) Department of Cardiology, University of Erlangen-Nuremberg,
Erlangen, Germany.
(Wilhelm M.) Division of Cardiovascular Prevention, Rehabilitation and
Sports Medicine, Inselspital, University Hospital and University of Bern,
Bern, Switzerland.
(Brem M.H.) Department of Traumatology and Orthopaedy, Nuremberg Hospital
South, Nuremberg, Germany.
CORRESPONDENCE ADDRESS
C. Stumpf, Medical Clinic 2, Dept. of Cardiology, University Clinic of
Erlangen, Ulmenweg 18, Erlangen, Germany. Email: ch.stumpf@web.de
SOURCE
Journal of Cardiology (2016) 68:1 (64-70). Date of Publication: 1 Jul 2016
ISSN
1876-4738 (electronic)
0914-5087
BOOK PUBLISHER
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
ABSTRACT
Objectives: Although regular physical exercise clearly reduces
cardiovascular morbidity risk, long-term endurance sports practice has been
recognized as a risk factor for atrial fibrillation (AF). However, the
mechanisms how endurance sports can lead to AF are not yet clear. The aim of
our present study was to investigate the influence of long-term endurance
training on vagal tone, atrial size, and inflammatory profile in
professional elite soccer players. Methods: A total of 25 professional major
league soccer players (mean age 24 ± 4 years) and 20 sedentary controls
(mean age 26 ± 3 years) were included in the study and consecutively
examined. All subjects underwent a sports cardiology check-up with physical
examination, electrocardiography, echocardiography, exercise testing on a
bicycle ergometer, and laboratory analysis [standard laboratory and cytokine
profile: interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-8, IL-10].
Results: Athletes were divided into two groups according to presence or
absence of an early repolarization (ER) pattern, defined as a ST-segment
elevation at the J-point (STE) ≥0.1 mm in 2 leads.Athletes with an ER
pattern showed significantly lower heart rate and an increased E/e' ratio
compared to athletes without an ER pattern. STE significantly correlated
with E/e' ratio as well as with left atrial (LA) volume. The
pro-inflammatory cytokines IL-6, IL-8, TNF-α as well as the
anti-inflammatory cytokine IL-10 were significantly elevated in all soccer
players. However, athletes with an ER pattern had significantly higher IL-6
plasma levels than athletes without ER pattern. Furthermore, athletes with
"high" level IL-6 had significantly larger LA volumes than players with
"low" level IL-6. Conclusions: Athletes with an ER pattern had significantly
higher E/e' ratios, reflecting higher atrial filling pressures, higher LA
volume, and higher IL-6 plasma levels. All these factors may contribute to
atrial remodeling over time and thus increase the risk of AF in long-term
endurance sports.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
cytokine (endogenous compound)
EMTREE DRUG INDEX TERMS
interleukin 10 (endogenous compound)
interleukin 6 (endogenous compound)
interleukin 8 (endogenous compound)
tumor necrosis factor alpha (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart atrium remodeling
heart repolarization
inflammation
EMTREE MEDICAL INDEX TERMS
adult
article
athlete
bicycle ergometer
clinical article
controlled study
echocardiography
electrocardiograph electrode
electrocardiography
endurance training
exercise test
heart left atrium
heart rate
human
male
physical examination
real time ultrasound scanner
ST segment elevation
vagus tone
young adult
DEVICE TRADE NAMES
cardiosoft 5 , GermanyGE Healthcare
Ergoline ERG 900 , GermanyErgoline
Vivid 7 Dimension machine , NorwayGE Vingmed
DEVICE MANUFACTURERS
(Germany)Ergoline
(Germany)GE Healthcare
(Norway)GE Vingmed
CAS REGISTRY NUMBERS
interleukin 8 (114308-91-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015527304
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jjcc.2015.08.013
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 24
TITLE
Community Screening for Nonischemic Cardiomyopathy in Asymptomatic Subjects
≥65 Years with Stage B Heart Failure
AUTHOR NAMES
Yang H.
Wang Y.
Nolan M.
Negishi K.
Okin P.M.
Marwick T.H.
AUTHOR ADDRESSES
(Yang H.; Wang Y.; Nolan M.; Negishi K.; Marwick T.H.,
tom.marwick@bakeridi.edu.au) Menzies Institute for Medical Research,
University of Tasmania, Hobart, Australia.
(Negishi K.; Marwick T.H., tom.marwick@bakeridi.edu.au) Baker-IDI Heart and
Diabetes Institute, Melbourne, Australia.
(Okin P.M.) Division of Cardiology, Department of Medicine, Weill Medical
College of Cornell University, New York, United States.
CORRESPONDENCE ADDRESS
T.H. Marwick, Menzies Institute for Medical Research, University of
Tasmania, Hobart, Australia. Email: tom.marwick@bakeridi.edu.au
SOURCE
American Journal of Cardiology (2016) 117:12 (1959-1965). Date of
Publication: 15 Jun 2016
ISSN
1879-1913 (electronic)
0002-9149
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
A process to identify and target a selected population at risk of heart
failure (HF) could facilitate screening and prevention. We sought to develop
an effective screening process from clinical characteristics, functional
capacity, and electrocardiogram (ECG). Asymptomatic subjects ≥65 years, with
≥1 HF risks were recruited from the community. Subjects with valvular
disease, ejection fraction <40%, and atrial fibrillation were excluded. All
underwent clinical evaluation including assessment of HF risk using
Framingham HF score and Atherosclerosis Risk in Communities (ARIC) score,
ECG, echocardiography, and 6-minute walk (6 MW) test. After 14 ± 4 months,
new HF was assessed using Framingham criteria. A randomly selected
derivation cohort was used to integrate ARIC score and 6 MW in a
classification and regression tree (CART) analysis, with the remaining
population used for validation. Of the 419 subjects (age 70 ± 5; 48% men),
52 developed HF. ARIC was more effective than the Framingham HF score (area
under the curve 0.65 vs 0.53, p = 0.01). CART selected ARIC (>9.5%) and 6 MW
(<501 m) as cutoffs to define low-, intermediate-, and high-risk groups.
Abnormal ECG further divided the intermediate group into high and low risks.
The 134 subjects identified as high risk by a combined clinical and
electrocardiographic strategy showed more echocardiographic features of
cardiac dysfunction including LV mass, mitral e′, mitral E/e′, and
longitudinal strain (p <0.01). New HF was significantly more frequent than
in the remaining patients (20% vs 10%, p = 0.003; hazard ratio 2.08, 95%
confidence interval 1.21 to 3.57, p = 0.008). Thus, initial clinical risk
and electrocardiographic assessment facilitate effective HF screening by
identifying a high-risk group.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
community care
heart failure
mass screening
nonischemic cardiomyopathy (diagnosis)
EMTREE MEDICAL INDEX TERMS
6 minute walk test
adult
aged
area under the curve
article
asymptomatic disease
Atherosclerosis Risk in Communities score
cardiovascular disease assessment
cardiovascular risk
clinical assessment
clinical classification
clinical effectiveness
clinical evaluation
clinical feature
comparative study
controlled study
diabetes mellitus
echocardiography
electrocardiogram
exercise
female
follow up
Framingham risk score
functional status
heart disease
heart left ventricle mass
high risk population
human
hypertension
low risk population
major clinical study
male
mitral valve
obesity
patient risk
physical activity
population
primary prevention
priority journal
prospective study
risk assessment
risk factor
screening test
validation study
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160338318
FULL TEXT LINK
http://dx.doi.org/10.1016/j.amjcard.2016.03.045
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 25
TITLE
Correlation between impedance cardiography and 6 min walk distance in atrial
fibrillation patients
AUTHOR NAMES
Ding L.
Quan X.-Q.
Zhang S.
Ruan L.
Zhang L.
Zheng K.
Yu W.-W.
Wu X.-F.
Mi T.
Zhang C.-T.
Zhou H.-L.
AUTHOR ADDRESSES
(Ding L.; Quan X.-Q.; Zhang S.; Yu W.-W.; Wu X.-F.; Mi T.; Zhang C.-T.; Zhou
H.-L., zhouhonglian63@163.com) Huazhong University of Science and
Technology, Department of Geriatrics, Tongji Hospital, Tongji Medical
College, Wuhan, China.
(Ruan L.; Zhang L.; Zheng K.) Huazhong University of Science and Technology,
Department of Cardiology, Tongji Hospital, Tongji Medical College, Wuhan,
China.
CORRESPONDENCE ADDRESS
H.-L. Zhou, Huazhong University of Science and Technology, Department of
Geriatrics, Tongji Hospital, Tongji Medical College, Wuhan, China. Email:
zhouhonglian63@163.com
SOURCE
BMC Cardiovascular Disorders (2016) 16:1 Article Number: 133. Date of
Publication: 10 Jun 2016
ISSN
1471-2261 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
Background: The correlation between impedance cardiography (ICG) and 6 min
walk distance (6MWD) in atrial fibrillation (AF) patients remains unknown.
Methods: We recruited 49 subjects in the study (21 AF patients and 28
patients without AF) and estimated hemodynamic parameters: cardiac output
(CO), stroke volume (SV), stroke volume index (SVI), left stroke work (LSW),
left stroke work index (LSWI), stroke systemic vascular resistance (SSVR),
stroke systemic vascular resistance index (SSVRI); 6MWD, left ventricle
ejection fraction (LVEF), NT-pro brain natriuretic peptide (NT-pro BNP) for
the two groups. Results: The AF group have apparently lower CO (2.26 ± 0.14
VS 4.11 ± 0.20 L/min, p = 0.039) and distinctly higher SVR (677.60 ± 69.10
VS 344.41 ± 22.98 dynes/cm(5), p = 0.001), SSVRI (396.97 ± 36.80 VS 199.01 ±
11.72 dynes/cm(5)/m(2), p < 0.001) than the control group. NT-pro BNP
(1409.48 ± 239.90 VS 332.59 ± 68.85 pg/ml, p = 0.001) in the AF group was
significantly higher than the control group and 6MWD (264.33 ± 14.55 VS
428.79 ± 29.98 m, p < 0.001) in the AF group was lower than the control
group. There was no significant difference in LVEF between the two groups
(62.67 ± 7.62 % VS 63.93 ± 5.03 %, p = 0.470). Pearson correlation analysis
revealed that CO (R = 0.494, p = 0.023), SV (R = 0.633, p = 0.002), LSW (R =
0.615, p = 0.003) and LSWI (R = 0.491, p = 0.024) significantly correlated
positively with 6MWD in AF patients. Conclusions: AF patients had lower
cardiac output, shorter 6MWD and higher NT-pro BNP than patients with sinus
rhythm. The cardiac output measured by impedance cardiography significantly
correlated positively with 6MWD in AF patients.
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cardiography
physical activity, capacity and performance
walk distance
EMTREE MEDICAL INDEX TERMS
aged
article
cardiovascular parameters
clinical article
controlled study
disease association
female
heart hemodynamics
heart left ventricle ejection fraction
heart output
heart stroke volume
human
left stroke work index
male
priority journal
sinus rhythm
stroke systemic vascular resistance
stroke systemic vascular resistance index
stroke volume index
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160439956
FULL TEXT LINK
http://dx.doi.org/10.1186/s12872-016-0297-0
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 26
TITLE
Mechanism of Action and Clinical Application of Tafamidis in Hereditary
Transthyretin Amyloidosis
AUTHOR NAMES
Coelho T.
Merlini G.
Bulawa C.E.
Fleming J.A.
Judge D.P.
Kelly J.W.
Maurer M.S.
Planté-Bordeneuve V.
Labaudinière R.
Mundayat R.
Riley S.
Lombardo I.
Huertas P.
AUTHOR ADDRESSES
(Coelho T., tcoelho@netcabo.pt) Hospital de Santo António, Centro Hospitalar
do Porto, Porto, Portugal.
(Merlini G.) Foundation IRCCS Policlinico San Matteo, University of Pavia,
Pavia, Italy.
(Bulawa C.E.; Fleming J.A.) Pfizer Rare Disease Research Unit, Cambridge,
United States.
(Judge D.P.) Johns Hopkins University School of Medicine, Baltimore, United
States.
(Kelly J.W.) The Scripps Research Institute, La Jolla, United States.
(Maurer M.S.) Columbia University College of Physicians and Surgeons, New
York, United States.
(Planté-Bordeneuve V.) CHU Henri Mondor, Créteil, France.
(Labaudinière R.) Labaudiniere Consulting LLC, Lewes, United States.
(Mundayat R.; Riley S.) Pfizer Inc., New York, United States.
(Huertas P.) Massachusetts General and McLean Hospitals, Harvard Medical
School, Boston, United States.
(Lombardo I.) FORUM Pharmaceuticals, Watertown, United States.
CORRESPONDENCE ADDRESS
T. Coelho, Hospital de Santo António, Centro Hospitalar do Porto, Porto,
Portugal. Email: tcoelho@netcabo.pt
SOURCE
Neurology and Therapy (2016) 5:1. Date of Publication: 1 Jun 2016
ISSN
2193-6536 (electronic)
2193-8253
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Transthyretin (TTR) transports the retinol-binding protein–vitamin A complex
and is a minor transporter of thyroxine in blood. Its tetrameric structure
undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to
aggregate or to become amyloidogenic. Mutations in the TTR gene generally
destabilize the tetramer and/or accelerate tetramer dissociation, promoting
amyloidogenesis. TTR-related amyloidoses are rare, fatal, protein-misfolding
disorders, characterized by formation of soluble aggregates of variable
structure and tissue deposition of amyloid. The TTR amyloidoses present with
a spectrum of manifestations, encompassing progressive neuropathy and/or
cardiomyopathy. Until recently, the only accepted treatment to halt
progression of hereditary TTR amyloidosis was liver transplantation, which
replaces the hepatic source of mutant TTR with the less amyloidogenic
wild-type TTR. Tafamidis meglumine is a rationally designed, non-NSAID
benzoxazole derivative that binds with high affinity and selectivity to TTR
and kinetically stabilizes the tetramer, slowing monomer formation,
misfolding, and amyloidogenesis. Tafamidis is the first pharmacotherapy
approved to slow the progression of peripheral neurologic impairment in TTR
familial amyloid polyneuropathy. Here we describe the mechanism of action of
tafamidis and review the clinical data, demonstrating that tafamidis
treatment slows neurologic deterioration and preserves nutritional status,
as well as quality of life in patients with early-stage Val30Met
amyloidosis.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
tafamidis (adverse drug reaction, clinical trial, drug therapy, oral drug
administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
diflunisal (drug therapy)
nonsteroid antiinflammatory agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
amyloidosis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (side effect)
brain hemorrhage (side effect)
Child Pugh score
creatinine clearance
crystal structure
diarrhea (side effect)
drug bioavailability
faintness (side effect)
gene mutation
gene sequence
genotype phenotype correlation
heart ejection fraction
heart failure (side effect)
human
polyneuropathy
priority journal
quality of life
randomized controlled trial (topic)
review
sequence analysis
urinary tract infection (side effect)
CAS REGISTRY NUMBERS
diflunisal (22494-42-4)
tafamidis (594839-88-0)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Internal Medicine (6)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT01655511)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160488314
FULL TEXT LINK
http://dx.doi.org/10.1007/s40120-016-0040-x
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 27
TITLE
Alcoholic beverage consumption and chronic diseases
AUTHOR NAMES
Zhou Y.
Zheng J.
Li S.
Zhou T.
Zhang P.
Li H.-B.
AUTHOR ADDRESSES
(Zhou Y., zhouyue3@mail2.sysu.edu.cn; Zheng J., zhengj37@mail2.sysu.edu.cn;
Zhou T., zwky740359@163.com; Zhang P., daidaolangman@126.com; Li H.-B.,
lihuabin@mail.sysu.edu.cn) Guangdong Provincial Key Laboratory of Food,
Nutrition and Health, School of Public Health, Sun Yat-Sen University,
Guangzhou, China.
(Li S., lishasl0308@163.com) School of Chinese Medicine, The University of
Hong Kong, Sassoon Road, , Hong Kong.
(Li H.-B., lihuabin@mail.sysu.edu.cn) South China Sea Bioresource
Exploitation and Utilization Collaborative Innovation Center, Sun Yat-Sen
University, Guangzhou, China.
CORRESPONDENCE ADDRESS
H.-B. Li, Guangdong Provincial Key Laboratory of Food, Nutrition and Health,
School of Public Health, Sun Yat-Sen University, Guangzhou, China. Email:
lihuabin@mail.sysu.edu.cn
SOURCE
International Journal of Environmental Research and Public Health (2016)
13:6 Article Number: 522. Date of Publication: 1 Jun 2016
ISSN
1660-4601 (electronic)
1661-7827
BOOK PUBLISHER
MDPI AG, Postfach, Basel, Switzerland.
ABSTRACT
Epidemiological and experimental studies have consistently linked alcoholic
beverage consumption with the development of several chronic disorders, such
as cancer, cardiovascular diseases, diabetes mellitus and obesity. The
impact of drinking is usually dose-dependent, and light to moderate drinking
tends to lower risks of certain diseases, while heavy drinking tends to
increase the risks. Besides, other factors such as drinking frequency,
genetic susceptibility, smoking, diet, and hormone status can modify the
association. The amount of ethanol in alcoholic beverages is the determining
factor in most cases, and beverage types could also make an influence. This
review summarizes recent studies on alcoholic beverage consumption and
several chronic diseases, trying to assess the effects of different drinking
patterns, beverage types, interaction with other risk factors, and provide
mechanistic explanations.
EMTREE DRUG INDEX TERMS
acetaldehyde (endogenous compound)
androstenedione (endogenous compound)
anthocyanidin
anthocyanin
apigenin
catechin
ellagic acid
epicatechin gallate
estradiol (endogenous compound)
estrone (endogenous compound)
isohumulone
kaempferol
myricetin
naringenin
nitric oxide (endogenous compound)
phenolic acid
polyphenol
prasterone sulfate (endogenous compound)
procyanidin
quercetin
resveratrol
sex hormone (endogenous compound)
sex hormone binding globulin (endogenous compound)
testosterone (endogenous compound)
unclassified drug
xanthohumol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alcohol consumption
alcoholic beverage
chronic disease
EMTREE MEDICAL INDEX TERMS
aging
androgen blood level
atrial fibrillation
breast cancer
cancer cell
carcinogenesis
carcinogenicity
cell invasion
cerebrovascular accident
chemoprophylaxis
colorectal cancer
coronary artery disease
diabetes mellitus
disease association
endometrium cancer
esophageal squamous cell carcinoma
esophagus cancer
estradiol blood level
estrone blood level
folate metabolism
heart failure
heart protection
hormone blood level
human
hypertension
insulin resistance
insulin sensitivity
kidney carcinoma
larynx cancer
liver cancer
melanoma
metastasis
mouth cancer
nonhuman
obesity
pancreas cancer
pharynx cancer
prostate cancer
review
stomach cancer
testosterone blood level
uterine cervix carcinoma in situ
CAS REGISTRY NUMBERS
acetaldehyde (75-07-0)
androstenedione (26264-53-9, 63-05-8)
apigenin (520-36-5)
catechin (13392-26-2, 154-23-4)
ellagic acid (476-66-4)
epicatechin gallate (863-03-6)
estradiol (50-28-2)
estrone (53-16-7)
kaempferol (520-18-3)
myricetin (529-44-2)
naringenin (480-41-1, 67604-48-2)
nitric oxide (10102-43-9)
polyphenol (37331-26-3)
prasterone sulfate (651-48-9)
procyanidin (4852-22-6)
quercetin (117-39-5)
resveratrol (501-36-0)
testosterone (58-22-0)
xanthohumol (6754-58-1)
EMBASE CLASSIFICATIONS
Cancer (16)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Endocrinology (3)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160393157
FULL TEXT LINK
http://dx.doi.org/10.3390/ijerph13060522
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 28
TITLE
Dietary vitamin D and risk of heart failure in the Physicians' Health Study
AUTHOR NAMES
Robbins J.
Petrone A.B.
Gaziano J.M.
Djoussé L.
AUTHOR ADDRESSES
(Robbins J.; Petrone A.B.; Gaziano J.M.; Djoussé L.,
ldjousse@rics.bwh.harvard.edu) Division of Aging, Department of Medicine,
Brigham and Women's Hospital and Harvard Medical School, Boston, United
States.
(Robbins J.; Gaziano J.M.; Djoussé L., ldjousse@rics.bwh.harvard.edu)
Massachusetts Veterans Epidemiology and Research Information Center and
Geriatric Research, Education, and Clinical Center, Boston Veterans Affairs
Healthcare System, Boston, United States.
CORRESPONDENCE ADDRESS
L. Djoussé, Division of Aging, Brigham and Women's Hospital, Harvard Medical
School, 1620 Tremont Street, 3rd Floor, Boston, United States. Email:
ldjousse@rics.bwh.harvard.edu
SOURCE
Clinical Nutrition (2016) 35:3 (650-653). Date of Publication: 1 Jun 2016
ISSN
1532-1983 (electronic)
0261-5614
BOOK PUBLISHER
Churchill Livingstone
ABSTRACT
Background: Experimental studies have demonstrated the role of vitamin D in
key pathways related to cardiovascular health. While several studies have
investigated the impact of vitamin D therapy on outcomes in subjects with
prevalent heart failure, limited research exists on the relationship of
dietary vitamin D consumption with the risk of heart failure. Thus, we
sought to investigate whether dietary vitamin D consumption was associated
with a lower risk of incident heart failure in a large prospective cohort of
male physicians. Methods and results: We prospectively studied 19,635 males
from the Physicians' Health Study. Dietary vitamin D information was
obtained from a baseline food frequency questionnaire, and heart failure
information was obtained by questionnaire and validated in a subsample. Mean
age was 66.4 years. Median dietary vitamin D consumption was 200.4 IU and
only 2.3% of the subjects used vitamin D supplements. After an average
follow-up of 9.3 years, there were 858 new cases of heart failure
identified. Higher intake of dietary vitamin D was not associated with
incident heart failure in a multivariable adjusted model: hazard ratios (95%
CI) of incident heart failure were 1.0 (reference), 1.29 (1.04-1.60), 1.17
(0.94-1.46), 1.22 (0.98-1.53), and 1.16 (0.92-1.46) from lowest to highest
age- and energy-adjusted vitamin D quintile, respectively, after adjusting
for age, BMI, race, exercise, alcohol use, smoking, calories, and prevalent
atrial fibrillation (p for linear trend = 0.64). Conclusions: These data are
consistent with a lack of an association between dietary vitamin D and
incident heart failure in this population of professionally-employed
middle-aged males.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
vitamin D
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (clinical trial, drug combination, drug comparison -
placebo, drug therapy)
alpha tocopherol (clinical trial, drug combination, drug comparison -
placebo, drug therapy)
ascorbic acid (clinical trial, drug combination, drug comparison - placebo,
drug therapy)
beta carotene (clinical trial, drug combination, drug comparison - placebo,
drug therapy)
multivitamin (clinical trial, drug combination, drug comparison - placebo,
drug therapy)
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure
vitamin intake
EMTREE MEDICAL INDEX TERMS
adult
age distribution
aged
alcohol consumption
article
atrial fibrillation
body mass
caloric intake
cardiovascular disease (drug therapy, prevention)
cardiovascular risk
cohort analysis
controlled study
disease association
exercise
factorial design
follow up
food frequency questionnaire
human
major clinical study
male
malignant neoplastic disease (drug therapy, prevention)
physician
population research
primary prevention
prospective study
race difference
randomized controlled trial (topic)
risk reduction
smoking
vitamin supplementation
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
beta carotene (7235-40-7)
EMBASE CLASSIFICATIONS
Cancer (16)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015119978
FULL TEXT LINK
http://dx.doi.org/10.1016/j.clnu.2015.04.011
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 29
TITLE
Aggregation of Marginal Gains in Cardiac Surgery: Feasibility of a
Perioperative Care Bundle for Enhanced Recovery in Cardiac Surgical Patients
AUTHOR NAMES
Fleming I.O.
Garratt C.
Guha R.
Desai J.
Chaubey S.
Wang Y.
Leonard S.
Kunst G.
AUTHOR ADDRESSES
(Fleming I.O.; Garratt C.; Guha R.; Leonard S.; Kunst G.,
gudrun.kunst@kcl.ac.uk) Anaesthesia, Denmark Hill, London, United Kingdom.
(Desai J.; Chaubey S.) Department of Cardiac Surgery, King's College
Hospital NHS Foundation Trust, London, United Kingdom.
(Wang Y.) Division of Health and Social Care Research, King's College
London, London, United Kingdom.
(Leonard S.) Department of Critical Care, King's College Hospital NHS
Foundation Trust, London, United Kingdom.
CORRESPONDENCE ADDRESS
G. Kunst, Anaesthesia, Denmark Hill, London, United Kingdom. Email:
gudrun.kunst@kcl.ac.uk
SOURCE
Journal of Cardiothoracic and Vascular Anesthesia (2016) 30:3 (665-670).
Date of Publication: 1 Jun 2016
ISSN
1532-8422 (electronic)
1053-0770
BOOK PUBLISHER
W.B. Saunders
ABSTRACT
Objectives The aim of this pilot study was to assess the feasibility of a
perioperative care bundle for enhanced recovery after cardiac surgery
(ERACS). Design A prospective, observational study. Setting A major urban
teaching and university hospital and tertiary referral center. Participants
The study included 53 patients undergoing cardiac surgery before
implementation of an ERACS protocol (pre-ERACS group) and 52 patients
undergoing cardiac surgery after implementation of an ERACS protocol (ERACS
group). Interventions Based on recommendations from a consensus review in
colorectal surgery, the following enhanced recovery perioperative care
bundle was applied: detailed preoperative information, avoidance of
prolonged fasting periods preoperatively, preoperative carbohydrate
beverages, optimization of analgesia with avoidance of long-acting opioids,
prevention of postoperative nausea and vomiting, early enteral nutrition
postoperatively, and early mobilization. Measurements and Main Results The
authors hypothesized that length of hospital stay would be reduced with
ERACS. Secondary outcome variables included a composite of postoperative
complications and pain scores. Whereas the length of stay in the group of
patients receiving the bundle of enhanced recovery interventions remained
unchanged compared with the non-ERACS group, there was a statistically
significant reduction in the number of patients in the ERACS group
presenting with one or more postoperative complications (including
hospital-acquired infections, acute kidney injury, atrial fibrillation,
respiratory failure, postoperative myocardial infarction, and death). In
addition, postoperative pain scores were improved significantly in the ERACS
group. Conclusions This pilot study demonstrated that ERACS is feasible and
has the potential for improved postoperative morbidity after cardiac
surgery. A larger multicenter quality improvement study implementing
perioperative care bundles would be the next step to further assess outcomes
in ERACS patients.
EMTREE DRUG INDEX TERMS
carbohydrate
opiate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
care bundle
heart surgery
perioperative care bundle
EMTREE MEDICAL INDEX TERMS
acute kidney failure (complication)
aged
article
atrial fibrillation (complication)
cause of death
clinical protocol
colorectal surgery
consensus
controlled study
enteric feeding
feasibility study
female
heart death (complication)
heart infarction (complication)
heart tamponade (complication)
hospital infection (complication)
hospitalization
human
length of stay
major clinical study
male
mobilization
multiple organ failure
observational study
pilot study
postoperative nausea and vomiting (complication, prevention)
preoperative evaluation
priority journal
prospective study
respiratory failure (complication)
sepsis
surgical patient
teaching hospital
tertiary care center
university hospital
CAS REGISTRY NUMBERS
opiate (53663-61-9, 8002-76-4, 8008-60-4)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160457248
FULL TEXT LINK
http://dx.doi.org/10.1053/j.jvca.2016.01.017
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 30
TITLE
Neurotrophic and neuroprotective effects of muscle contraction
AUTHOR NAMES
Arnao V.
Di Raimondo D.
Tuttolomondo A.
Pinto A.
AUTHOR ADDRESSES
(Arnao V., arnao.valentina@gmail.com; Di Raimondo D.; Tuttolomondo A.; Pinto
A.) U. O. C. Di Medicina Interna e Cardioangiologia Dipartimento Biomedico
di Medicina Interna e Specialistica, Università degli Studi di Palermo
Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (BioNeC),
Università degli Studi di Palermo, Italy.
CORRESPONDENCE ADDRESS
V. Arnao, U. O di Neurologia e Neurofisiopatologia, Università degli Studi
di Palermo, Via G. La Loggia n 1, , Italy. Email: arnao.valentina@gmail.com
SOURCE
Current Pharmaceutical Design (2016) 22:24 (3749-3763). Date of Publication:
1 Jun 2016
ISSN
1873-4286 (electronic)
1381-6128
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Background: Physical activity has been shown to be associated with reduced
risk of coronary heart disease but the same effect seems to be produced in
neurological diseases. Objective: In this review, we focused on the
interplay between physical activity and some neurological conditions
(Stroke, dementia, epilepsy, headache, Parkinson’ s disease, amyotrophic
lateral sclerosis, multiple sclerosis, insomnia, depression and anxiety)
with the aim of describing the potential role of physical activity in the
prevention of such diseases and the physiological mechanisms involved in
these processes. Results: Despite a growing body of evidence which reveals
that physical activity is able to reduce the frequency of neurological
diseases, directly or indirectly by enhancing cardiovascular conditions,
further studies are necessary to better characterize which type of exercise
is useful for each condition. Conclusion: Physical activity could represent
an additional approach to fight against such diseases.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
neuroprotective agent
neurotrophic factor
EMTREE DRUG INDEX TERMS
4 aminobutyric acid (endogenous compound)
brain derived neurotrophic factor (endogenous compound)
catecholamine (endogenous compound)
dopamine (endogenous compound)
dopamine transporter (endogenous compound)
endocannabinoid
endorphin (endogenous compound)
glutamic acid (endogenous compound)
neurotransmitter
tumor necrosis factor alpha (endogenous compound)
tumor necrosis factor alpha receptor (endogenous compound)
vasculotropin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
muscle contraction
EMTREE MEDICAL INDEX TERMS
aerobic exercise
alcohol consumption
Alzheimer disease
amyotrophic lateral sclerosis (etiology)
anxiety
atrial fibrillation
balance disorder
blood brain barrier
brain blood flow
brain ischemia
cerebrovascular accident (etiology)
cognition
cognitive defect
cycling
dementia (etiology)
dentate gyrus
depression (etiology)
dopamine brain level
dopamine release
dyslipidemia
epilepsy (etiology)
exercise
experimental autoimmune encephalomyelitis
headache (etiology)
heart infarction
hormesis
human
hyperlipidemia
hypertension
insomnia (etiology)
metabolic equivalent
middle cerebral artery occlusion
mood
multiple sclerosis (etiology)
neuroprotection
nonhuman
orthostatic hypotension
oxidative stress
Parkinson disease (etiology)
physical activity
physical inactivity
practice guideline
priority journal
quality of life
randomized controlled trial (topic)
resistance training
review
running
sedentary lifestyle
sleep disorder
smoking
spasticity
stretching
treadmill exercise
CAS REGISTRY NUMBERS
4 aminobutyric acid (28805-76-7, 56-12-2)
brain derived neurotrophic factor (218441-99-7)
dopamine (51-61-6, 62-31-7)
endorphin (60118-07-2)
glutamic acid (11070-68-1, 138-15-8, 56-86-0, 6899-05-4)
vasculotropin (127464-60-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Psychiatry (32)
Drug Literature Index (37)
General Pathology and Pathological Anatomy (5)
Epilepsy Abstracts (50)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160525532
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 31
TITLE
Delayed anaerobic threshold in heart failure patients with atrial
fibrillation
AUTHOR NAMES
Palermo P.
Magrì D.
Sciomer S.
Stefanini E.
Agalbato C.
Compagnino E.
Chircu C.M.
Maffessanti F.
Teodoru M.
Agostoni P.
AUTHOR ADDRESSES
(Palermo P.; Stefanini E.; Agalbato C.; Compagnino E.; Maffessanti F.;
Agostoni P., piergiuseppe.agostoni@unimi.it) Centro Cardiologico Monzino,
IRCCS, Via Parea 4, Milan, Italy.
(Magrì D.) Dipartimento di Medicina Clinica e Molecolare, Università degli
Studi di Roma la Sapienza, Rome, Italy.
(Sciomer S.) Dipartimento di Scienze Cardiovascolari, Respiratorie,
Anestesiologiche, Nefrologiche e Geriatriche, La Sapienza, Rome, Italy.
(Chircu C.M.) Emergency Clinical Hospital Sibiu, Sibiu, Romania.
(Teodoru M.) Faculty of Medicine, Lucian Blaga University, Sibiu, Romania.
(Agostoni P., piergiuseppe.agostoni@unimi.it) Department of Clinical
Sciences and Community Health, University of Milan, Milan, Italy.
CORRESPONDENCE ADDRESS
P. Agostoni, Centro Cardiologico Monzino, IRCCS, Via Parea 4, Milan, Italy.
Email: piergiuseppe.agostoni@unimi.it
SOURCE
Journal of Cardiopulmonary Rehabilitation and Prevention (2016) 36:3
(174-179). Date of Publication: 25 May 2016
ISSN
1932-751X (electronic)
1932-7501
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Purpose: To assess whether atrial fibrillation (AF) in heart failure (HF)
affects oxygen uptake at anaerobic threshold (V E O 2 AT) and heart rate
(HR) kinetics. METHODS: A total of 15 patients with HF and AF and 18 with HF
and sinus rhythm (SR) performed a maximal incremental and 2 constant
workload cycle ergometer cardiopulmonary exercise tests (below and above AT,
at 25% and 75% of maximal workload, respectively). At constant workload
tests, kinetics of VO(2) and HR were assessed by calculating time constant
(τ).RESULTS: HF patients with AF showed a similar peak VO(2) to those with
SR (16.7±4.5 mL/kg/min vs 16.6±3.9 mL/kg/min). However, VO(2) AT (11.3±2.9
mL/kg/min vs 9.3±2.8 mL/kg/min; P <.05), peak HR (149±18.8 bpm vs 116.4±20.4
bpm; P <.001), HR AT (125.3±19.1 bpm vs 90.3±15.5 bpm; P <.001), and HR
increase during exercise were greater in HF patients with AF. Finally,τHR
andτVO(2) below and above AT were not significantly different.CONCLUSIONS:
In HF patients with AF, despite a similar peak VO(2) compared with patients
with HF and SR, VO(2) AT is higher because of a higher HR and a greater HR
increase during exercise. One postulated mechanism would be a greater
cardiac output increase at the beginning of exercise in HF patients with AF.
The delayed AT generates uncertainty about the meaning of a VO(2) value at
AT in HF patients with AF, because a higher AT is usually associated with
better performance and a better prognosis.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anaerobic threshold
atrial fibrillation
heart failure
EMTREE MEDICAL INDEX TERMS
adult
article
bicycle ergometer
cardiopulmonary exercise test
clinical article
female
heart rate
human
male
middle aged
oxygen consumption
priority journal
sinus rhythm
workload
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160386708
FULL TEXT LINK
http://dx.doi.org/10.1097/HCR.0000000000000159
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 32
TITLE
The impact of physical training on endothelial function in myocardial
infarction survivors: Pilot study
AUTHOR NAMES
Peller M.
Balsam P.
Główczynska R.
Ossolinski K.
Gilarowska A.
Kołtowski Ł.
Grabowski M.
Filipiak K.J.
Opolski G.
AUTHOR ADDRESSES
(Peller M.; Balsam P., pawel@balsam.com.pl; Główczynska R.; Ossolinski K.;
Gilarowska A.; Kołtowski Ł.; Grabowski M.; Filipiak K.J.; Opolski G.) 1st
Department and Department of Cardiology, Medical University of Warsaw, ul.
Banacha 1a, Warsaw, Poland.
CORRESPONDENCE ADDRESS
P. Balsam, 1st Department and Department of Cardiology, Medical University
of Warsaw, ul. Banacha 1a, Warsaw, Poland. Email: pawel@balsam.com.pl
SOURCE
Kardiologia Polska (2016) 74:5 (439-446). Date of Publication: 17 May 2016
ISSN
0022-9032
BOOK PUBLISHER
Via Medica, Ul. Swietokrzyska 73, Gdansk, Poland.
ABSTRACT
Background: Endothelial dysfunction (ED) may indirectly influence the
outcome of patients with coronary artery disease. Aim: To assess the
influence of cardiac rehabilitation (CR) on endothelial function in patients
after ST-segment elevation myocardial infarction (STEMI). Methods:
Twenty-nine patients scheduled for CR were included in the study. CR began
at least four weeks after STEMI and consisted of 12 or 24 training sessions.
Endothelial function assessment was performed before and after CR, using
reactive hyperaemia peripheral arterial tonometry. Results: Before the CR,
ED was diagnosed in 16 of 29 (55.2%) patients. A total of 25 patients had
two assessments of endothelial function: before and after CR. In univariate
analysis the factors of negative response of endothelial function to CR
were: higher baseline hyperaemia index (lnRHI) (odds ratio [OR] for positive
response to CR 0.01; 95% confidence interval [CI] 0.00-0.33; p = 0.01) and
higher peak serum troponin I level during index hospitalisation (OR 0.97;
95% CI 0.94-1.00; p = 0.04). The independent, negative predictor of response
to CR was lnRHI (OR 0.01; 95% CI 0.01-0.16; p = 0.03). Patients training for
24 sessions (n = 16) had similar lnRHI changes to those of patients training
for 12 sessions (n = 9); [0.16 (-0.06)-0.30 vs. 0.10 (0.05-0.15); p = 0.44,
respectively]. Conclusions: ED is a frequent abnormality in STEMI survivors.
Despite the lack of statistically significant improvement of endothelial
function after CR in the analysed group of patients, some factors can
influence the efficacy of this type of physical activity. The best effect of
CR on endothelial function was observed in patients with baseline ED.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
angiotensin 2 receptor antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
creatine kinase MB (endogenous compound)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
hemoglobin (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
nitric acid derivative (drug therapy)
purinergic P2Y12 receptor (endogenous compound)
troponin I (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
endothelial dysfunction
physical activity
ST segment elevation myocardial infarction (diagnosis, rehabilitation,
therapy)
survivor
training
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation (drug therapy)
blood clot lysis
body mass
body weight
clinical article
clinical assessment
controlled study
coronary artery disease
diagnostic test accuracy study
diastolic blood pressure
exercise
female
heart left ventricle ejection fraction
heart rate
heart rehabilitation
hospitalization
human
hyperemia
hypertension (drug therapy)
jogging
male
myocarditis
non insulin dependent diabetes mellitus
percutaneous coronary intervention
peripheral arterial tonometry
pilot study
prediction
pregnancy
prospective study
sensitivity and specificity
swimming
systolic blood pressure
walking
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
hemoglobin (9008-02-0)
troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Polish
EMBASE ACCESSION NUMBER
20160504702
FULL TEXT LINK
http://dx.doi.org/10.5603/KP.a2015.0177
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 33
TITLE
Troponin I levels in permanent atrial fibrillation-impact of rate control
and exercise testing
AUTHOR NAMES
Horjen A.W.
Ulimoen S.R.
Enger S.
Norseth J.
Seljeflot I.
Arnesen H.
Tveit A.
AUTHOR ADDRESSES
(Horjen A.W., awhorjen@gmail.com; Ulimoen S.R.; Enger S.; Tveit A.) Vestre
Viken Hospital Trust, Department of Medical Research, Baerum Hospital,
Drammen, Norway.
(Horjen A.W., awhorjen@gmail.com; Seljeflot I.; Arnesen H.) University of
Oslo, Faculty of Medicine, Oslo, Norway.
(Norseth J.) Clinic for Medical Diagnostics, Vestre Viken Hospital Trust,
Drammen, Norway.
(Seljeflot I.; Arnesen H.) Oslo University Hospital Ullevål, Center for
Clinical Heart Research, Department of Cardiology, Oslo, Norway.
CORRESPONDENCE ADDRESS
A.W. Horjen, University of Oslo, Faculty of Medicine, Oslo, Norway. Email:
awhorjen@gmail.com
SOURCE
BMC Cardiovascular Disorders (2016) 16:1 Article Number: 79. Date of
Publication: 4 May 2016
ISSN
1471-2261 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
Background: High-sensitivity troponin I (hs-TnI) and troponin T (hs-TnT) are
moderately correlated and independently related to outcome in atrial
fibrillation (AF). Rate controlling therapy has been shown to reduce hs-TnT,
however the potential impact on hs-TnI levels, and whether this differs from
the effects on hs-TnT, has not been investigated previously. Methods: Sixty
patients with stable, permanent AF without heart failure or known ischemic
heart disease were included in a randomised crossover study (mean age 71 ± 9
years, 18 women). Diltiazem 360 mg, verapamil 240 mg, metoprolol 100 mg, and
carvedilol 25 mg were administered once daily for three weeks, in a
randomised sequence. At baseline and on the last day of each treatment
period, hs-TnI was measured at rest and after a maximal exercise test and
compared to hs-TnT. Results: Hs-TnI and hs-TnT correlated moderately at
baseline (r(s) = 0.582, p < 0.001). All drugs reduced both the resting and
the peak exercise levels of hs-TnI compared with baseline (p < 0.001 for
all). The decline in resting hs-TnI and hs-TnT values relative to baseline
levels was similar for all drugs except for verapamil, which reduced hs-TnI
more than hs-TnT (p = 0.017). Levels of hs-TnI increased significantly in
response to exercise testing at baseline and at all treatment regimens (p <
0.001 for all). The relative exercise-induced increase in hs-TnI was
significantly larger compared to hs-TnT at baseline (p < 0.001), on
diltiazem (p < 0.001) and on verapamil (p = 0.001). Conclusions: In our
population of stable, permanent AF patients, all four rate control drug
regimens reduced hs-TnI significantly, both at rest and during exercise. The
decline in hs-TnI and hs-TnT levels associated with beta-blocker and calcium
channel blocker treatment was similar, except for a larger relative decrease
in hs-TnI levels following verapamil treatment. Trial
registration:www.clinicaltrials.gov( NCT00313157 ).
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
troponin I (endogenous compound)
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide (endogenous compound)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
carvedilol (clinical trial, drug therapy)
diltiazem (clinical trial, drug therapy)
metoprolol (clinical trial, drug therapy)
troponin T (endogenous compound)
verapamil (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
disease control
exercise test
heart rate control
permanent atrial fibrillation (drug therapy, drug therapy)
randomized controlled trial (topic)
EMTREE MEDICAL INDEX TERMS
aged
article
CHADS2 score
comorbidity
comparative study
controlled study
drug response
female
human
major clinical study
male
outcome assessment
priority journal
protein analysis
resting heart rate
systolic blood pressure
treatment duration
DRUG MANUFACTURERS
Abbott
Astra Zeneca
Hexal
Hoffmann La Roche
Pfizer
CAS REGISTRY NUMBERS
carvedilol (72956-09-3)
diltiazem (33286-22-5, 42399-41-7)
metoprolol (37350-58-6)
troponin I (77108-40-8)
troponin T (60304-72-5)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
Internal Medicine (6)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00313157)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160509592
FULL TEXT LINK
http://dx.doi.org/10.1186/s12872-016-0255-x
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 34
TITLE
A MET a Day Keeps Arrhythmia at Bay: The Association between Exercise or
Cardiorespiratory Fitness and Atrial Fibrillation
AUTHOR NAMES
Kapa S.
Asirvatham S.J.
AUTHOR ADDRESSES
(Kapa S.; Asirvatham S.J., Asirvatham.samuel@mayo.edu) Department of
Pediatric and Adolescent Medicine, Mayo Clinic, 200 First St SW, Rochester,
United States.
CORRESPONDENCE ADDRESS
S.J. Asirvatham, Department of Pediatric and Adolescent Medicine, Mayo
Clinic, 200 First St SW, Rochester, United States. Email:
Asirvatham.samuel@mayo.edu
SOURCE
Mayo Clinic Proceedings (2016) 91:5 (545-550). Date of Publication: 1 May
2016
ISSN
1942-5546 (electronic)
0025-6196
BOOK PUBLISHER
Elsevier Ltd
EMTREE DRUG INDEX TERMS
troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (etiology)
cardiorespiratory fitness
exercise
EMTREE MEDICAL INDEX TERMS
atherosclerosis
autonomic nervous system
body mass
cardiovascular risk
cerebrovascular accident
diabetes mellitus
diastolic dysfunction
diet
endurance training
health care system
heart conduction
heart function
heart size
human
hypertension
lifestyle
medical practice
obesity
pathophysiology
physical activity
review
risk factor
vagus tone
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20160369558
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mayocp.2016.03.003
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 35
TITLE
Newer oral anticoagulants: Stroke prevention and pitfalls
AUTHOR NAMES
Patel A.
Goddeau R.P.
Henninger N.
AUTHOR ADDRESSES
(Patel A., Anand.Patel@umassmemorial.org; Goddeau R.P.; Henninger N.)
Department of Neurology, University of Massachusetts Medical School,
Worcester, United States.
(Henninger N.) Department of Psychiatry, University of Massachusetts Medical
School, Worcester, United States.
CORRESPONDENCE ADDRESS
A. Patel, Department of Neurology, University of Massachusetts Medical
School, 55 Lake Ave, North, Worcester, United States. Email:
Anand.Patel@umassmemorial.org
SOURCE
Open Cardiovascular Medicine Journal (2016) 10 Supplement-1, M4 (94-104).
Date of Publication: 1 May 2016
ISSN
1874-1924 (electronic)
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Warfarin is very effective in preventing stroke in patients with atrial
fibrillation. However, its use is limited due to fear of hemorrhagic
complications, unpredictable anticoagulant effects related to multiple drug
interactions and dietary restrictions, a narrow therapeutic window, frequent
difficulty maintaining the anticoagulant effect within a narrow therapeutic
window, and the need for inconvenient monitoring. Several newer oral
anticoagulants have been approved for primary and secondary prevention of
stroke in patients with non-valvular atrial fibrillation. These agents have
several advantages relative to warfarin therapy. As a group, these direct
oral anticoagulants (DOAC), which include the direct thrombin inhibitor,
dabigatran, and the factor Xa inhibitors (rivaroxaban, apixaban, and
edoxaban), are more effective than dose adjusted warfarin for prevention of
all-cause stroke (including both ischemic and hemorrhagic stroke), and have
an overall more favorable safety profile. Nevertheless, an increased risk of
gastrointestinal bleeding (with the exception of apixaban), increased risk
for thrombotic complication with sudden discontinuation, and inability to
accurately assess and reverse anticoagulant effect require consideration
prior to therapy initiation, and pose a challenge for decision making in
acute stroke therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
apixaban
EMTREE DRUG INDEX TERMS
dabigatran
edoxaban
rivaroxaban
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulation
atrial fibrillation
blood clot lysis
brain hemorrhage
brain ischemia
prevention
EMTREE MEDICAL INDEX TERMS
clinical study
complication
consensus development
decision making
diet restriction
drug combination
drug therapy
fear
gastrointestinal hemorrhage
human
monitoring
pharmacokinetics
secondary prevention
therapeutic index
thrombosis
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160572545
FULL TEXT LINK
http://dx.doi.org/10.2174/1874192401610010094
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 36
TITLE
Influence of Transiently Increased Nutritional Risk on a Left Ventricle
Myocardial Mass Assessed by Echocardiography
AUTHOR NAMES
Boban M.
Laviano A.
Persic V.
Biocina B.
Petricevic M.
Zekanovic D.
Rotim C.
Aleric I.
Vcev A.
AUTHOR ADDRESSES
(Boban M., marcoboban@yahoo.com; Persic V.) Department of Cardiology,
University Hospital 'Thalassotherapia Opatija', Medical Faculty University
of Rijeka, Rijeka, Croatia.
(Boban M., marcoboban@yahoo.com; Persic V.; Zekanovic D.; Aleric I.; Vcev
A.) Department of Internal Medicine, Medical Faculty 'J.j. Strossmayer'
University of Osijek, Osijek, Croatia.
(Biocina B.; Petricevic M.) Department of Cardiac Surgery, Medical Faculty
University of Zagreb, University Hospital Centre, Zagreb, Croatia.
(Rotim C.) Department of Surgery, University Hospital Centre 'Sestre
Milosrdnice', Zagreb, Croatia.
(Laviano A.) Department of Clinical Medicine, University 'La Sapienza',
Roma, Italy.
SOURCE
Annals of Nutrition and Metabolism (2016) 68:3 (197-202). Date of
Publication: 1 May 2016
ISSN
1421-9697 (electronic)
0250-6807
BOOK PUBLISHER
S. Karger AG
ABSTRACT
Background/Aim: Metabolic derangements due to increased nutritional risk
lead to catabolism and loss of proteins, muscle tissue and eventually mass
of parenchymatous organs. The aim of our study was to assess whether
transitory nutritional risk after heart surgery influences on the left
ventricle myocardial mass (LVMM), assessed by echocardiography. Methods:
Consecutive sample of patients scheduled for cardiovascular rehabilitation,
in period 0-3 months after surgery. Nutritional risk screening (NRS) was
analyzed using the NRS-2002 tool. Results: Study sample included 330
patients after heart surgery for ischemic 186 (56.4%); valvular 91 (27.6%)
and valvular plus ischemic 53 (16.1%) heart disease. Age was 65.5 ± 10.6
(range 23-84) and there were more male patients than female - 240 (72.7%)
and 90 (27.3%), respectively. The percentage of unintentional loss of weight
was 10.8 ± 3.4%, in range 0-23.81%, whereas NRS-2002 was 4.4 ± 1.1. LVMM was
218.7 ± 65.9 g vs. 252.3 ± 51.7 (p = 0.015); for patients with increased
nutritional risk and controls, respectively. There was no significant
correlation of LVMM with NRS-2002, while the percentage of unintentional
loss of weight displayed only weakly inverse correlation (Rho CC = -0.197; p
= 0.007). LVMM also correlated significantly with body mass index (Rho CC =
0.247; p < 0.001) and waist-to-hip ratio (Rho CC = 0.291; p < 0.001). In
conclusion, LVMM was found to decrease slightly in the period of increased
nutritional risk, following heart surgery. Changes in LVMM are partially
consequences of systemic catabolic response, as well as anthropometric
changes due to unintentional loss of weight.
EMTREE DRUG INDEX TERMS
cholesterol (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
echocardiography
left ventricle myocardial mass (diagnosis)
myocardial disease (diagnosis)
nutritional assessment
EMTREE MEDICAL INDEX TERMS
adult
aged
anthropometry
article
atrial fibrillation
body height
body mass
body weight
cardiovascular risk
cholesterol blood level
chronic kidney disease
chronic obstructive lung disease
cohort analysis
controlled study
coronary artery disease
diabetes mellitus
diagnostic test accuracy study
disease severity
electrocardiography
female
glucose intolerance
heart infarction
heart left ventricle ejection fraction
heart surgery
hip circumference
human
hypertension
major clinical study
male
middle aged
nutritional status
obesity
priority journal
sensitivity and specificity
smoking
thromboembolism
transthoracic echocardiography
triacylglycerol blood level
waist circumference
waist hip ratio
weight reduction
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160267631
FULL TEXT LINK
http://dx.doi.org/10.1159/000445301
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 37
TITLE
Exercise Capacity and Atrial Fibrillation Risk in Veterans A Cohort Study
AUTHOR NAMES
Faselis C.
Kokkinos P.
Tsimploulis A.
Pittaras A.
Myers J.
Lavie C.J.
Kyritsi F.
Lovic D.
Karasik P.
Moore H.
AUTHOR ADDRESSES
(Faselis C.; Kokkinos P., peter.kokkinos@va.gov; Tsimploulis A.; Pittaras
A.; Kyritsi F.; Lovic D.; Karasik P.; Moore H.) Cardiology Division,
Veterans Affairs Medical Center, 50 Irving St NW, Washington, United States.
(Faselis C.; Karasik P.) George Washington University, School of Medicine,
Washington, United States.
(Kokkinos P., peter.kokkinos@va.gov; Karasik P.; Moore H.) Georgetown
University, School of Medicine, Washington, United States.
(Kokkinos P., peter.kokkinos@va.gov) Department of Exercise Science, Arnold
School of Public Health, University of South Carolina, Columbia, United
States.
(Myers J.) Veterans Affairs Palo Alto Health Care System, Cardiology
Division, Palo Alto, United States.
(Myers J.) Stanford University, Stanford, United States.
(Lavie C.J.) Department of Cardiovascular Diseases, John Ochsner Heart and
Vascular Institute, Ochsner Clinical School, University Queensland, School
of Medicine, New Orleans, United States.
CORRESPONDENCE ADDRESS
P. Kokkinos, Cardiology Division, Veterans Affairs Medical Center, 50 Irving
St NW, Washington, United States. Email: peter.kokkinos@va.gov
SOURCE
Mayo Clinic Proceedings (2016) 91:5 (558-566). Date of Publication: 1 May
2016
ISSN
1942-5546 (electronic)
0025-6196
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
Objective To assess the association between exercise capacity and the risk
of developing atrial fibrillation (AF). Patients and Methods A
symptom-limited exercise tolerance test was conducted to assess exercise
capacity in 5962 veterans (mean age, 56.8±11.0 years) from the Veterans
Affairs Medical Center, Washington, DC. None had evidence of AF or ischemia
at the time of or before undergoing their exercise tolerance test. We
established 4 fitness categories based on age-stratified quartiles of peak
metabolic equivalent task (MET) achieved: least fit (4.9±1.10 METs; n=1446);
moderately fit (6.7±1.0 METs; n=1490); fit (7.9±1.0 METs; n=1585), and
highly fit (9.3±1.2 METs; n=1441). Multivariable Cox proportional hazards
regression models were used to compare the AF-exercise capacity association
between fitness categories. Results During a median follow-up period of 8.3
years, 722 (12.1%) individuals developed AF (14.5 per 1000 person-years; 95%
CI, 13.9-15.9 per 1000 person-years). Exercise capacity was inversely
related to AF incidence. The risk was 21% lower (hazard ratio, 0.79; 95% CI,
0.76-0.82) for each 1-MET increase in exercise capacity. Compared with the
least fit individuals, hazard ratios were 0.80 (95% CI, 0.67-0.97) for
moderately fit individuals, 0.55 (95% CI, 0.45-0.68) for fit individuals,
and 0.37 (95% CI, 0.29-0.47) for highly fit individuals. Similar trends were
observed in those younger than 65 years and those 65 years or older.
Conclusion Increased fitness is inversely and independently associated with
the reduced risk of developing AF. The decrease in risk was graded and
precipitous with only modest increases in exercise capacity. These findings
counter previous suggestions that even moderate increases in physical
activity, as recommended by national and international guidelines, increase
the risk of AF, with marked protection against AF noted with increasing
levels of fitness.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
cholesterol (endogenous compound)
glucose (endogenous compound)
high density lipoprotein (endogenous compound)
low density lipoprotein (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy)
cardiorespiratory fitness
exercise
veteran
EMTREE MEDICAL INDEX TERMS
adult
age
aged
article
body mass
cholesterol blood level
cohort analysis
controlled study
diabetes mellitus
diastolic blood pressure
drug use
dyslipidemia
exercise test
female
follow up
glucose blood level
human
hypertension
incidence
ischemia
lipoprotein blood level
male
middle aged
observational study
prospective study
resting heart rate
smoking
symptom limited exercise tolerance test
systolic blood pressure
triacylglycerol blood level
United States
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
glucose (50-99-7, 84778-64-3)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160369559
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mayocp.2016.03.002
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 38
TITLE
Pathological remodelling of the athlete's heart
AUTHOR NAMES
Keteepe-Arachi T.
Sharma S.
AUTHOR ADDRESSES
(Keteepe-Arachi T.; Sharma S., sasharma@sgul.ac.uk) St George's University
Hospital, University of London, United Kingdom.
CORRESPONDENCE ADDRESS
S. Sharma, Cardiac Research Centre, Department of Cardiovascular Sciences,
St George's University of London, Cranmer Terrace, UK-London, United
Kingdom. Email: sasharma@sgul.ac.uk
SOURCE
Kardiovaskulare Medizin (2016) 19:5 (147-151). Date of Publication: 1 May
2016
ISSN
1662-629X (electronic)
1423-5528
BOOK PUBLISHER
EMH Swiss Medical Publishers Ltd., verlag@emh.ch
ABSTRACT
Engaging in regular physical activity affords significant health benefits,
while a lack of exercise is associated with increased cardiovascular
morbidity and mortality. The amount of physical activity required to achieve
these benefits is relatively modest, equating to 20-30 minutes of moderate
intensity exercise per day. Most athletes far exceed these recommendations
and now perform athletic feats previously considered insurmountable. Studies
in veteran athletes have demonstrated favourable outcomes such as reduced
incidence of cardiac disease and a greater lifespan. However, in
asymptomatic athletes concealing underlying cardiac disease, intense
exercise may be associated with sudden cardiac death. Despite the
devastating and highly visible effects of life-threatening arrhythmias,
exercise has retained its reputation as a prolonger of life as it is not the
primary cause of death but merely a trigger for such catastrophes. More
recent studies, however, have suggested that the effects of regular intense
exercise may result in adverse remodelling in otherwise healthy hearts. This
article will explore this concept and whether chronic intensive exercise can
adversely impact cardiovascular health.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
heart disease
heart remodeling
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (epidemiology, prevention)
cardiovascular mortality
cardiovascular risk
coronary artery atherosclerosis
cycling
endurance training
epidemic
exercise intensity
heart arrhythmia
heart failure (prevention)
heart infarction (rehabilitation, therapy)
heart muscle fibrosis
heart rehabilitation
heart ventricle arrhythmia
heart ventricle tachycardia (epidemiology)
human
life extension
marathon runner
morbidity
nonhuman
physical activity
physical inactivity
prevalence
review
risk reduction
sedentary lifestyle
sudden cardiac death
therapy effect
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160423428
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 39
TITLE
Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart
Failure
AUTHOR NAMES
Jamil H.A.
Gierula J.
Paton M.F.
Byrom R.
Lowry J.E.
Cubbon R.M.
Cairns D.A.
Kearney M.T.
Witte K.K.
AUTHOR ADDRESSES
(Jamil H.A.; Paton M.F.; Byrom R.; Lowry J.E.; Cubbon R.M.; Kearney M.T.;
Witte K.K., k.k.witte@leeds.ac.uk) Division of Cardiovascular and Diabetes
Research, Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds
Institute of Cardiovascular and Metabolic Medicine, LIGHT Building,
University of Leeds, Clarendon Way, Leeds, United Kingdom.
(Gierula J.; Cairns D.A.) Clinical Trials Research Unit, Leeds Institute of
Clinical Trials Research, Leeds, United Kingdom.
CORRESPONDENCE ADDRESS
K.K. Witte, Division of Cardiovascular and Diabetes Research,
Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of
Cardiovascular and Metabolic Medicine, LIGHT Building, University of Leeds,
Clarendon Way, Leeds, United Kingdom. Email: k.k.witte@leeds.ac.uk
SOURCE
Journal of the American College of Cardiology (2016) 67:16 (1885-1896). Date
of Publication: 26 Apr 2016
ISSN
1558-3597 (electronic)
0735-1097
BOOK PUBLISHER
Elsevier USA
ABSTRACT
Background Limited heart rate (HR) rise (HRR) during exercise, known as
chronotropic incompetence (CI), is commonly observed in chronic heart
failure (CHF). HRR is closely related to workload, the limitation of which
is characteristic of CHF. Whether CI is a causal factor for exercise
intolerance, or simply an associated feature remains unknown. Objectives
This study sought to clarify the role of the HR on exercise capacity in CHF.
Methods This series of investigations consisted of a retrospective cohort
study and 2 interventional randomized crossover studies to assess: 1) the
relationship between HRR and exercise capacity in CHF; and 2) the effect of
increasing and lowering HR on exercise capacity in CHF as assessed by
symptom-limited treadmill exercise testing and measurement of peak oxygen
consumption in patients with CHF due to left ventricular systolic
dysfunction. Results The 3 key findings were: 1) the association of exercise
capacity and HRR is much weaker in severe CHF compared to normal left
ventricular function; 2) increasing HRR using rate-adaptive pacing (versus
fixed-rate pacing) in unselected patients with CHF does not improve peak
exercise capacity; and 3) acutely lowering baseline and peak HR by adjusting
pacemaker variables in conjunction with a single dose of ivabradine does not
adversely affect exercise capacity in unselected CHF patients. Conclusions
The data refute the contention that CI contributes to impaired exercise
capacity in CHF. This finding has widespread implications for pacemaker
programming and the use of heart-rate lowering agents. (The Influence of
Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients [TREPPE];
NCT02247245)
EMTREE DRUG INDEX TERMS
aldosterone antagonist (drug therapy)
angiotensin receptor antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
carbon dioxide
digoxin (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
furosemide (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
ivabradine (drug comparison - placebo, drug dose, drug therapy)
oxygen
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart failure (drug therapy, diagnosis, drug therapy, therapy)
heart rate
left ventricular systolic dysfunction (drug therapy, diagnosis, drug
therapy, therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation (diagnosis, drug therapy, therapy)
cardiac resynchronization therapy
cardiopulmonary exercise test
chronotropic incompetence
clinical article
cohort analysis
comorbidity
controlled study
drug contraindication
dyspnea
end tidal carbon dioxide tension
female
heart ejection fraction
heart left ventricle function
heart rate rise
heart ventricle pacing
human
intervention study
leg disease
leg weakness
lung gas exchange
lung ventilation
male
observational study
oxygen consumption
pacemaker
priority journal
resting heart rate
retrospective study
single drug dose
sinus rhythm
symptomatology
transthoracic echocardiography
treadmill exercise
very elderly
CAS REGISTRY NUMBERS
carbon dioxide (124-38-9, 58561-67-4)
digoxin (20830-75-5, 57285-89-9)
furosemide (54-31-9)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT02247245)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160311463
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jacc.2016.02.042
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 40
TITLE
Effects of oral anticoagulant therapy in older medical in-patients with
atrial fibrillation: a prospective cohort observational study
AUTHOR NAMES
Bo M.
Li Puma F.
Badinella Martini M.
Falcone Y.
Iacovino M.
Grisoglio E.
Menditto E.
Fonte G.
Brunetti E.
Isaia G.C.
D’Ascenzo F.
Gaita F.
AUTHOR ADDRESSES
(Bo M.; Li Puma F.; Badinella Martini M.; Falcone Y.,
yolanda.falcone@yahoo.it; Iacovino M.; Grisoglio E.; Menditto E.; Fonte G.;
Brunetti E.; Isaia G.C.) SCDU Geriatria e Malattie Metaboliche dell’Osso,
Città della Salute e della Scienza-Molinette., Corso Bramante 88, Turin,
Italy.
(D’Ascenzo F.; Gaita F.) SCDU Cardiologia; Città della Salute e della
Scienza-Molinette., C.so Bramante 88, Turin, Italy.
CORRESPONDENCE ADDRESS
Y. Falcone, SCDU Geriatria e Malattie Metaboliche dell’Osso, Città della
Salute e della Scienza-Molinette., Corso Bramante 88, Turin, Italy. Email:
yolanda.falcone@yahoo.it
SOURCE
Aging Clinical and Experimental Research (2016) (1-7). Date of Publication:
21 Apr 2016
ISSN
1720-8319 (electronic)
1594-0667
BOOK PUBLISHER
Springer International Publishing
ABSTRACT
Background: Uncertainties about efficacy and safety of oral anticoagulant
therapy (OAT) among older and frail medical patients with atrial
fibrillation (AF) largely contribute to under-prescription of these drugs.
Aims: In this prospective observational cohort study, we investigated
mortality, and ischemic and hemorrhagic events, in hospital-discharged older
patients with AF. Methods: Stroke and bleeding risk were evaluated using
CHA2DS2-VASC and HAS-BLED scores. Comorbidity, frailty, cognitive and
nutritional status and functional autonomy were evaluated using standardized
scales. Independent associations between clinical variables, including OAT
use, and all-cause mortality, fatal and non-fatal ischemic and hemorrhagic
events, were evaluated. Further clinical outcomes comparison between
patients treated with OAT and those untreated was performed after adjustment
for significant differences in patient baseline characteristics with
propensity score matching. Results: Of 452 patients included (mean age 81.6
years, 54.9 % women, roughly 30 % cognitively impaired and/or functionally
dependent, mean CHA2DS2-VASC and HAS-BLED scores 4.6 and 2.8, respectively),
151 (33.4 %) died during a mean follow-up period of 300.5 days; ischemic and
hemorrhagic stroke occurred in 4.0 and 0.4 % of patients, respectively, and
major bleedings in 6.2 %. Discussion: After multivariate analysis, OAT at
discharge was associated with lower overall mortality and reduced occurrence
of ischemic stroke, the first finding being confirmed in propensity score
matched analysis. Conclusions: Among older vulnerable AF patients with high
post discharge death rate, OAT was associated, among other multiple factors,
with reduced mortality and lower occurrence of ischemic stroke.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
hospital patient
observational study
EMTREE MEDICAL INDEX TERMS
aged
brain hemorrhage
brain ischemia
cohort analysis
comorbidity
controlled study
follow up
human
major clinical study
mortality rate
multivariate analysis
nutritional status
propensity score
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160319769
FULL TEXT LINK
http://dx.doi.org/10.1007/s40520-016-0569-7
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 41
TITLE
Volume and morphology of left atrial appendage as determinants of stroke
subtype in patients with atrial fibrillation
AUTHOR NAMES
Jeong W.K.
Choi J.-H.
Son J.P.
Lee S.
Lee M.J.
Choe Y.H.
Bang O.Y.
AUTHOR ADDRESSES
(Jeong W.K.; Lee M.J.; Bang O.Y., ohyoung.bang@samsung.com) Department of
Neurology, Samsung Medical Center, Sungkyunkwan University, School of
Medicine, 81, Irwon-Ro, Gangnam-gu, Seoul, South Korea.
(Choi J.-H.) Department Cardiology, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, South Korea.
(Son J.P.; Lee S.; Bang O.Y., ohyoung.bang@samsung.com) Department of Health
Sciences and Technology, Samsung Advanced Institute for Health Sciences and
Technology, Sungkyunkwan University, Seoul, South Korea.
(Choe Y.H.) Department of Radiology, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, South Korea.
CORRESPONDENCE ADDRESS
O.Y. Bang, Department of Neurology, Samsung Medical Center, Sungkyunkwan
University, School of Medicine, 81, Irwon-Ro, Gangnam-gu, Seoul, South
Korea. Email: ohyoung.bang@samsung.com
SOURCE
Heart Rhythm (2016) 13:4 (820-827). Date of Publication: 1 Apr 2016
ISSN
1556-3871 (electronic)
1547-5271
BOOK PUBLISHER
Elsevier
ABSTRACT
Background Atrial fibrillation (AF) is a leading cause of stroke, but not
all cases of stroke in patients with AF are due to AF. Objective The purpose
of this study was to determine whether morphometric or volumetric parameters
of left atrial appendage (LAA) would be related to the development of
cardioembolism in subjects with AF. Methods A total of 433 consecutive
patients with acute ischemic stroke underwent multidetector cardiac computed
tomography (MDCT). Of these patients, 88 with AF were divided into
cardioembolic stroke (CES; n = 57) and non-CES (n = 31) groups, and 95 age-
and sex-matched patients with non-CES without AF served as controls.
Clinical factors, echocardiographic findings, and MDCT parameters were
evaluated. Results Brain infarct volume, LAA orifice diameter, and LAA
volume were larger in patients with CES with AF than in those with non-CES
with AF (P<.05 in all cases), but no difference was observed between
patients with non-CES with AF and those with non-CES without AF. MDCT and
echocardiographic parameters of left atrial (LA) dysfunction were different
depending on the presence of AF but not between patients with CES with AF vs
non-CES with AF. After adjusting for covariates, LAA orifice diameter (odds
ratio 1.19, 95% confidence interval 1.06-1.33, P =.004) and LAA volume (odds
ratio 12.20, 95% confidence interval 2.58-57.79, P =.002) were independently
associated with CES with AF, as was infarct volume. Conclusion In patients
with AF, LAA orifice diameter and LAA volume, but not left atrial
dysfunction, were determinants of CES and were useful for stratifying
noncardioembolic risk in patients with AF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cerebrovascular accident
heart atrium appendage
heart volume
EMTREE MEDICAL INDEX TERMS
adult
aged
article
brain infarction size
cardioembolic stroke
computer assisted tomography
controlled study
female
human
major clinical study
male
multidetector computed tomography
priority journal
prospective study
receiver operating characteristic
risk assessment
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160107817
FULL TEXT LINK
http://dx.doi.org/10.1016/j.hrthm.2015.12.026
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 42
TITLE
Improvement of gastric emptying by enhanced recovery after
pancreaticoduodenectomy
AUTHOR NAMES
Zouros E.
Liakakos T.
MacHairas A.
Patapis P.
Agalianos C.
Dervenis C.
AUTHOR ADDRESSES
(Zouros E., stratiszouros@gmail.com; Agalianos C.; Dervenis C.) Department
of Surgery, Konstantopouleio General Hospital, 3-5 Agias Olgas Str., Athens,
Greece.
(Liakakos T.) First Department of Surgery, Laiko University Hospital, Ag.
Thoma 17, Athens, Greece.
(MacHairas A.; Patapis P.) Third Department of Surgery, Attikon University
Hospital, Rimini 1, Athens, Greece.
CORRESPONDENCE ADDRESS
E. Zouros, Department of Surgery, Konstantopouleio General Hospital, 3-5
Agias Olgas Str., Athens, Greece. Email: stratiszouros@gmail.com
SOURCE
Hepatobiliary and Pancreatic Diseases International (2016) 15:2 (198-208).
Date of Publication: 1 Apr 2016
ISSN
1499-3872
BOOK PUBLISHER
Elsevier (Singapore) Pte Ltd, 3 Killiney Road, 08-01, Winsland House I,
Singapore, Singapore.
ABSTRACT
Background Enhanced recovery after surgery (ERAS) has improved postoperative
outcomes particularly in colorectal surgery. This study aimed to assess
compliance with an ERAS protocol and evaluate its effect on postoperative
outcomes in patients undergoing pancreaticoduodenectomy. Methods Fifty
patients who had received conventional perioperative management from 2005 to
2009 (conventional group) were compared with 75 patients who had received
perioperative care with an ERAS protocol (fast-track group) from 2010 to
2014. Mortality, complications, readmissions and length of hospital stay
were evaluated and compared in the groups. Results Compliance with each
element of the ERAS protocol ranged from 74.7% to 100%. Uneventful patients
had a significant higher adherence to the ERAS protocol (87.5% vs 40.7%;
P<0.001). There were no significant differences in demographics and
perioperative characteristics between the two groups. Patients in the
fast-track group had a shorter time to remove the nasogastric tube, start
liquid diet and solid food, pass flatus and stools, and remove drains. No
difference was found in mortality, relaparotomy, readmission rates and
overall morbidity. However, delayed gastric emptying and length of hospital
stay were significantly reduced in the fast-track group. The independent
effect of the ERAS protocol in reducing delayed gastric emptying and length
of hospital stay was confirmed by multivariate analysis. Conclusion ERAS
pathway was feasible and safe in improving gastric emptying, yielding an
earlier postoperative recovery, and reducing the length of hospital stay.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
pancreaticoduodenectomy
stomach emptying
EMTREE MEDICAL INDEX TERMS
abdominal abscess (complication)
adult
article
atrial fibrillation (complication)
bile leakage (complication)
biliary tract drainage
controlled study
diet
female
flatulence
follow up
hospital readmission
hospitalization
human
length of stay
major clinical study
male
morbidity
nasogastric tube
pancreas disease
pancreas fistula (complication)
patient compliance
perioperative period
pneumonia (complication)
postoperative hemorrhage (complication)
protocol compliance
reoperation
safety
surgical infection (complication)
tertiary care center
total parenteral nutrition
EMBASE CLASSIFICATIONS
Gastroenterology (48)
Surgery (9)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160286028
FULL TEXT LINK
http://dx.doi.org/10.1016/S1499-3872(16)60061-9
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 43
TITLE
Risk of Malnutrition Is an Independent Predictor of Mortality, Length of
Hospital Stay, and Hospitalization Costs in Stroke Patients
AUTHOR NAMES
Gomes F.
Emery P.W.
Weekes C.E.
AUTHOR ADDRESSES
(Gomes F., filomena.gomes@kcl.ac.uk; Emery P.W.) Diabetes and Nutritional
Sciences Division, King's College London, Franklin Wilkins Building, 150
Stamford Street, London, United Kingdom.
(Weekes C.E.) Department of Nutrition and Dietetics, Guy's and St Thomas'
NHS Foundation Trust, London, United Kingdom.
CORRESPONDENCE ADDRESS
F. Gomes, Diabetes and Nutritional Sciences Division, King's College London,
Franklin Wilkins Building, 150 Stamford Street, London, United Kingdom.
Email: filomena.gomes@kcl.ac.uk
SOURCE
Journal of Stroke and Cerebrovascular Diseases (2016) 25:4 (799-806). Date
of Publication: 1 Apr 2016
ISSN
1532-8511 (electronic)
1052-3057
BOOK PUBLISHER
W.B. Saunders
ABSTRACT
Background Malnutrition is associated with poor outcomes after stroke.
Nutrition screening tools (NSTs) are used to identify patients at risk of
malnutrition, but so far no NST has been validated for use with patients who
have had a stroke. This study aimed to determine the ability of the
Malnutrition Universal Screening Tool (MUST) to predict poor outcomes in
stroke patients, including mortality, cumulative length of hospital stay
(LOS), and hospitalization costs. Methods Patients were recruited from
consecutive admissions at 2 hyperacute stroke units in London and were
screened for risk of malnutrition (low, medium, and high) according to MUST.
Six-month outcomes were obtained for each patient through a national
database. Results Of 543 recruited patients, 51% were males, the mean age
was 75 years, and 87% had an ischemic stroke. Results showed a highly
significant increase in mortality with increasing risk of malnutrition (P
<.001). This association remained significant after adjusting for age,
severity of stroke, and a range of stroke risk factors (P <.001). For those
patients who survived, the LOS and hospitalization costs increased with
increasing risk of malnutrition (P <.001 and P =.049, respectively). This
association remained significant in the adjusted model (P <.001 and P =.001,
respectively). Conclusions Risk of malnutrition is an independent predictor
of mortality, LOS, and hospitalization costs at 6 months post stroke.
Research is needed to determine if nutritional support for medium- or
high-risk patients results in better outcomes. Routine screening of stroke
patients for risk of malnutrition is recommended.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (disease management)
hospitalization cost
length of stay
malnutrition
Malnutrition Universal Screening Tool
screening test
stroke patient
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
brain hemorrhage
brain ischemia (disease management)
dysphagia
female
follow up
gastrointestinal disease
groups by age
high risk patient
hospital readmission
human
intermediate risk patient
low risk patient
major clinical study
male
mortality
observational study
predictive value
priority journal
prospective study
risk
risk assessment
social support
terminal care
EMBASE CLASSIFICATIONS
Health Policy, Economics and Management (36)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160087191
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.017
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 44
TITLE
The Potential Cardiotoxic Effects of Exercise
AUTHOR NAMES
La Gerche A.
AUTHOR ADDRESSES
(La Gerche A., Andre.LaGerche@bakeridi.edu.au) Baker IDI Heart and Diabetes
Institute, And Department of Cardiology, Alfred Hospital, Melbourne,
Australia.
(La Gerche A., Andre.LaGerche@bakeridi.edu.au) The Department of
Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
CORRESPONDENCE ADDRESS
A. La Gerche, Sports Cardiology, Baker IDI Heart and Diabetes Institute,
Level 4 Alfred Centre, 99 Commercial Rd, Melbourne, Australia. Email:
Andre.LaGerche@bakeridi.edu.au
SOURCE
Canadian Journal of Cardiology (2016) 32:4 (421-428). Date of Publication: 1
Apr 2016
ISSN
0828-282X
BOOK PUBLISHER
Pulsus Group Inc.
ABSTRACT
The emerging controversy related to the potential cardiotoxic effects of
high doses of intense exercise need to be considered among the much stronger
evidence that supports the pleomorphic benefits of exercise as a whole.
However, there is fairly compelling evidence to support the association
between long-term sport practice and an increased prevalence of atrial
fibrillation and the fact that this relates to a chronic altered atrial
substrate. This article was designed to challenge the reader with
speculative science that suggests that exercise might promote permanent
structural changes in the myocardium which can, in some individuals,
predispose to arrhythmias. In terms of long-term health outcomes, it would
seem that these small risks are outweighed by the many other benefits of
exercise, including a likely decrease in atherosclerotic vascular events,
although some recent results have brought into question whether the
protective benefits of exercise on vascular events also extends to
high-intensity exercise training. Above all else, in this article we sought
to highlight current controversies to stimulate research on the many
unanswered questions. In particular, there is a lack of adequately powered
prospective studies from which we can measure health outcomes and their
relationship to exercise-induced cardiac remodelling.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiotoxicity
exercise
EMTREE MEDICAL INDEX TERMS
athlete
endurance training
heart arrhythmia
heart muscle
heart right ventricle dysplasia
human
ischemic heart disease
morbidity
mortality
review
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
20160167001
FULL TEXT LINK
http://dx.doi.org/10.1016/j.cjca.2015.11.010
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 45
TITLE
Atrioventricular Junction Ablation for Atrial Fibrillation
AUTHOR NAMES
Patel D.
Daoud E.G.
AUTHOR ADDRESSES
(Patel D.; Daoud E.G., emile.daoud@osumc.edu) Electrophysiology Section,
Division of Cardiology, Ross Heart Hospital, Wexner Medical Center at The
Ohio State University, Columbus, United States.
(Daoud E.G., emile.daoud@osumc.edu) Internal Medicine, Wexner Medical Center
at The Ohio State University, 473 West 12th Avenue, DHLRI, Suite 200,
Columbus, United States.
CORRESPONDENCE ADDRESS
E.G. Daoud, Internal Medicine, 473 West 12th Avenue, DHLRI, Suite 200,
Columbus, United States. Email: emile.daoud@osumc.edu
SOURCE
Heart Failure Clinics (2016) 12:2 (245-255). Date of Publication: 1 Apr 2016
ISSN
1551-7136
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
Atrioventricular junction (AVJ) ablation is an effective therapy in patients
with symptomatic atrial fibrillation who are intolerant to or unsuccessfully
managed with rhythm control or medical rate control strategies. A drawback
is that the procedure mandates a pacing system. Overall, the safety and
efficacy of AVJ ablation is high with a majority of the patients reporting
significant improvement in symptoms and quality-of-life measures. Risk of
sudden cardiac death after device implantation is low, especially with an
appropriate postprocedure pacing rate. Mortality benefit with AVJ ablation
has been shown in patients with heart failure and cardiac resynchronization
therapy devices.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
ablation therapy
atrial fibrillation (surgery, therapy)
atrioventricular junction ablation
heart atrioventricular node
EMTREE MEDICAL INDEX TERMS
ablation catheter
cardiac resynchronization therapy
clinical effectiveness
exercise
heart atrium flutter
heart atrium pacing
heart ejection fraction
heart failure
heart rate
heart ventricle tachycardia (complication)
hemodynamics
human
long term survival
microelectrode
mortality
pacemaker
polymorphic ventricular tachycardia (complication)
review
safety
sudden cardiac death (complication)
tachycardia induced cardiomyopathy (complication)
therapy effect
treatment outcome
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160196848
FULL TEXT LINK
http://dx.doi.org/10.1016/j.hfc.2015.08.020
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 46
TITLE
Almanac 2015: Atrial fibrillation research in Heart
AUTHOR NAMES
Jawad-Ul-Qamar M.
Kirchhof P.
AUTHOR ADDRESSES
(Jawad-Ul-Qamar M.; Kirchhof P., p.kirchhof@bham.ac.uk) Institute of
Cardiovascular Sciences, University of Birmingham, Institute for Biomedical
Research, Vincent Drive, Birmingham, United Kingdom.
(Jawad-Ul-Qamar M.; Kirchhof P., p.kirchhof@bham.ac.uk) SWBH NHS Trust,
Birmingham, United Kingdom.
(Kirchhof P., p.kirchhof@bham.ac.uk) UHB NHS Trust, Birmingham, United
Kingdom.
(Kirchhof P., p.kirchhof@bham.ac.uk) Atrial Fibrillation NETwork (AFNET),
Münster, Germany.
(Kirchhof P., p.kirchhof@bham.ac.uk) Department of Cardiovascular Medicine,
Hospital of the University of Münster, Münster, Germany.
CORRESPONDENCE ADDRESS
P. Kirchhof, Institute of Cardiovascular Sciences, University of Birmingham,
Institute for Biomedical Research, Vincent Drive, Birmingham, United
Kingdom. Email: p.kirchhof@bham.ac.uk
SOURCE
Heart (2016) 102:8 (573-580). Date of Publication: 1 Apr 2016
ISSN
1468-201X (electronic)
1355-6037
BOOK PUBLISHER
BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
Atrial fibrillation continues to attract interest in the cardiovascular
community and in Heart. Over 60 original research and review papers
published in Heart in 2014-2015 cover various aspects of atrial
fibrillation, from associated conditions and precipitating factors to new
approaches to management. Here, we provide an overview of articles on atrial
fibrillation published in Heart in 2014-2015, highlighting new developments,
emerging concepts and novel approaches to treatment.
EMTREE DRUG INDEX TERMS
adiponectin (endogenous compound)
alanine aminotransferase (endogenous compound)
anticoagulant agent (drug therapy, oral drug administration)
antivitamin K (drug therapy)
aspartate aminotransferase (endogenous compound)
biological marker (endogenous compound)
gamma glutamyltransferase (endogenous compound)
ivabradine (drug therapy)
natriuretic factor (endogenous compound)
noradrenalin (endogenous compound)
troponin I (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, diagnosis, drug therapy, surgery,
therapy)
medical research
EMTREE MEDICAL INDEX TERMS
ablation therapy
anticoagulant therapy
aorta stenosis
cardiovascular disease assessment
cardiovascular mortality
cardiovascular risk
catheter ablation
cerebrovascular accident (drug therapy, prevention)
CHA2DS2Vasc score
CHADS2 score
diagnostic imaging
diastolic dysfunction
differential diagnosis
disease association
electrocardiogram
electrocardiography
exercise
heart arrhythmia
heart atrium flutter (drug therapy)
heart atrium septum defect
heart failure
heart rate
heart surgery
hemodialysis
hospital patient
human
inappropriate shock
incidence
kidney function
nuclear magnetic resonance imaging
predictive value
prevalence
priority journal
prognosis
recurrent disease
review
risk assessment
screening test
shock
silent atrial fibrillation
United Kingdom
CAS REGISTRY NUMBERS
adiponectin (283182-39-8)
alanine aminotransferase (9000-86-6, 9014-30-6)
aspartate aminotransferase (9000-97-9)
gamma glutamyltransferase (85876-02-4)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
natriuretic factor (9088-07-7)
noradrenalin (1407-84-7, 51-41-2)
troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160099385
FULL TEXT LINK
http://dx.doi.org/10.1136/heartjnl-2015-307809
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 47
TITLE
Asynchronous Bilateral Renal Infarction and Thrombophilia with Associated
Gene Mutations in a 43-Year-Old Man
AUTHOR NAMES
Zhou X.-J.
Liu L.-J.
Chen M.
Zhou F.-D.
AUTHOR ADDRESSES
(Zhou X.-J.; Liu L.-J.; Chen M.; Zhou F.-D., zhoufude1801@vip.sina.com)
Renal Division, Peking University First Hospital, Peking University
Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health
of China, China.
(Zhou X.-J.; Liu L.-J.; Chen M.; Zhou F.-D., zhoufude1801@vip.sina.com) Key
Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking
University, Ministry of Education, Beijing, China.
(Zhou F.-D., zhoufude1801@vip.sina.com) Renal Division, Peking University
First Hospital, Peking University Institute of Nephrology, Beijing, China.
CORRESPONDENCE ADDRESS
F.-D. Zhou, Renal Division, Peking University First Hospital, Peking
University Institute of Nephrology, Beijing, China. Email:
zhoufude1801@vip.sina.com
SOURCE
Medicine (United States) (2016) 95:14 Article Number: e3258. Date of
Publication: 1 Apr 2016
ISSN
1536-5964 (electronic)
0025-7974
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Renal infarction (RI) is frequently misdiagnosed or diagnosed late because
of its rarity and nonspecific clinical presentation, which may result in
irreversible damage to the renal parenchyma or increase the risk of other
embolic events affecting additional organs. Multiple causal mechanisms and
cases of idiopathic RI have been reported, but the causal factors are not
clear in most cases. Here, we report the case of a patient with
heterochronic bilateral RI caused by thrombophilia. Although he had several
risk factors for hypercoagulation disorders, two gene mutations-MTHFR 677
C>T and PLG 1858G>A-were identified by genome sequencing of the entire
exome. The findings suggest the possibility of a synergistic relationship
between the two gene mutations. Thus, screening for gene mutations may
provide additional clues for clarifying the cause of RI and thrombophilia.
EMTREE DRUG INDEX TERMS
alanine aminotransferase (endogenous compound)
albumin (endogenous compound)
amlodipine besylate (oral drug administration)
antacid agent (oral drug administration)
aspartate aminotransferase (endogenous compound)
C reactive protein (endogenous compound)
cephalosporin derivative (oral drug administration)
creatine kinase (endogenous compound)
creatinine (endogenous compound)
lactate dehydrogenase (endogenous compound)
urea (endogenous compound)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
gene mutation
kidney infarction (etiology)
thrombophilia (drug therapy, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
abdominal pain
acupuncture
acute appendicitis (diagnosis, surgery)
adult
appendectomy
article
atrial fibrillation
blood cell count
body temperature
case report
computer assisted tomography
creatinine blood level
diabetes mellitus
dyslipidemia
echography
erythrocyte sedimentation rate
follow up
genetic association
hematuria
hemoglobin determination
human
international normalized ratio
kidney function
lactate dehydrogenase blood level
leukocyte count
leukocytosis
male
nausea and vomiting
next generation sequencing
nuclear magnetic resonance imaging
pain
physical examination
priority journal
protein urine level
risk factor
smoking
systolic blood pressure
thrombocyte count
urea blood level
urinalysis
CAS REGISTRY NUMBERS
alanine aminotransferase (9000-86-6, 9014-30-6)
amlodipine besylate (111470-99-6)
aspartate aminotransferase (9000-97-9)
C reactive protein (9007-41-4)
creatine kinase (9001-15-4)
creatinine (19230-81-0, 60-27-5)
lactate dehydrogenase (9001-60-9)
urea (57-13-6)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160336311
FULL TEXT LINK
http://dx.doi.org/10.1097/MD.0000000000003258
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 48
TITLE
Propafenone shows class Ic and class II antiarrhythmic effects
AUTHOR NAMES
Stoschitzky K.
Stoschitzky G.
Lercher P.
Brussee H.
Lamprecht G.
Lindner W.
AUTHOR ADDRESSES
(Stoschitzky K., kurt.stoschitzky@medunigraz.at; Stoschitzky G.; Lercher P.;
Brussee H.) Division of Cardiology, Department of Internal Medicine, Medical
University of Graz, Graz, Austria.
(Lamprecht G.; Lindner W.) Institute of Analytical Chemistry, University of
Vienna, Vienna, Austria.
CORRESPONDENCE ADDRESS
K. Stoschitzky, Division of Cardiology, Department of Internal Medicine,
Medical University of Graz, Graz, Austria. Email:
kurt.stoschitzky@medunigraz.at
SOURCE
Europace (2016) 18:4 (568-571). Date of Publication: 1 Apr 2016
ISSN
1532-2092 (electronic)
1099-5129
BOOK PUBLISHER
Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
Aims Propafenone is a well-known Class Ic antiarrhythmic agent. It has the
typical chemical structure of a beta-blocker, but human studies on its
beta-blocking effects revealed conflicting results. Methods and results
Twelve healthy males received single oral doses of 600 mg propafenone and
placebo according to a randomized, double-blind, placebo-controlled,
cross-over protocol. Four hours following drug intake, heart rate and blood
pressure were measured, and plasma concentrations of propafenone were
determined at rest, during exercise and after recovery. At exercise,
propafenone significantly decreased heart rate (-6%, P < 0.05), systolic
blood pressure (-6%, P < 0.05), and the rate-pressure product (-11%, P <
0.05). Plasma concentrations of propafenone increased during exercise (+23%,
P < 0.05) and decreased during recovery (-33%, P < 0.05). Conclusion Both
effects on heart rate and blood pressure as well as the changes of plasma
concentrations of propafenone during exercise represent two particular
features of beta-blockers. Therefore, we conclude that propafenone is both a
Class Ic and a Class II antiarrhythmic agent, and 600 mg propafenone, i.e.
the dose recommended in current guidelines for cardioversion of paroxysmal
atrial fibrillation, cause clinically significant beta-blockade. Thus,
single oral doses of 600 mg propafenone appear also suitable for
cardioversion of paroxysmal atrial fibrillation in patients with structural
heart disease since beta-blockers are explicitly indicated in the treatment
of both coronary artery disease and heart failure.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
propafenone (clinical trial, drug comparison - placebo, drug concentration,
oral drug administration, pharmacology)
EMTREE DRUG INDEX TERMS
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
antiarrhythmic activity
beta adrenergic receptor blocking
drug mechanism
EMTREE MEDICAL INDEX TERMS
adult
article
cardioversion
controlled study
crossover procedure
diastolic blood pressure
drug blood level
electrocardiography monitoring
exercise
heart rate
human
human experiment
male
normal human
priority journal
randomized controlled trial
rest
single drug dose
systolic blood pressure
CAS REGISTRY NUMBERS
propafenone (34183-22-7, 54063-53-5)
EMBASE CLASSIFICATIONS
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
EudraCT (EudraCT200500018311)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160474538
FULL TEXT LINK
http://dx.doi.org/10.1093/europace/euv195
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 49
TITLE
Reducing Heart Failure Risks in Obese Patients
AUTHOR NAMES
Parto P.
Lavie C.J.
Ventura H.O.
AUTHOR ADDRESSES
(Parto P., parto22@gmail.com; Lavie C.J., clavie@ochsner.org; Ventura H.O.,
hventura@ochsner.org) Department of Cardiovascular Diseases, John Ochsner
Heart and Vascular Institute, Ochsner Clinical School, The University of
Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, United
States.
CORRESPONDENCE ADDRESS
C.J. Lavie, Department of Cardiovascular Diseases, John Ochsner Heart and
Vascular Institute, Ochsner Clinical School, The University of Queensland
School of Medicine, 1514 Jefferson Highway, New Orleans, United States.
Email: clavie@ochsner.org
SOURCE
Current Cardiovascular Risk Reports (2016) 10:4 (1-8) Article Number: 15.
Date of Publication: 1 Apr 2016
ISSN
1932-9563 (electronic)
1932-9520
BOOK PUBLISHER
Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
Heart failure (HF) and obesity have both become major epidemics and
recognized as public health problems. Obesity has known adverse effects on
cardiac structure and function; therefore, it is not surprising that there
is an increased prevalence and incidence of HF in obese patients.
Additionally, numerous cardiovascular (CV) risk factors associated with
obesity, such as hypertension, coronary heart disease, dyslipidemia, atrial
fibrillation, and depression, are also known to play a role in the
development of HF. Numerous studies have suggested the presence of an
“obesity paradox,” where obese patients with HF have a better prognosis than
do lean or normal-weight HF patients. This review discusses the role of
these risk factors in obese HF patients and the utility of purposeful weight
loss.
EMTREE DRUG INDEX TERMS
cholesterol (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular risk
heart failure
obesity
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
blood pressure monitoring
coronary vascular resistance
depression
dyslipidemia
echocardiography
exercise
heart function
heart hemodynamics
heart left ventricle hypertrophy
heart output
human
hypertension
ischemic heart disease
left ventricular diastolic dysfunction
left ventricular systolic dysfunction
New York Heart Association class
randomized controlled trial (topic)
review
risk assessment
thromboembolism
weight reduction
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160172240
FULL TEXT LINK
http://dx.doi.org/10.1007/s12170-016-0498-1
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 50
TITLE
Medical acupuncture for intracerebral bleed: A case history
AUTHOR NAMES
McDaniels A.
AUTHOR ADDRESSES
(McDaniels A., qmcduck@pacbell.net) Helms Medical Institute, 732 West Ninth
Street, San Pedro, United States.
CORRESPONDENCE ADDRESS
A. McDaniels, Helms Medical Institute, 732 West Ninth Street, San Pedro,
United States. Email: qmcduck@pacbell.net
SOURCE
Medical Acupuncture (2016) 28:2 (96-99). Date of Publication: 1 Apr 2016
ISSN
1933-6594 (electronic)
1933-6586
BOOK PUBLISHER
Mary Ann Liebert Inc., info@liebertpub.com
ABSTRACT
Background: A 75-year-old woman with a history of atrial fibrillation,
anticoagulant therapy, and grand mal seizures sustained a right lateral
ventricular intracerebral bleed. After being unconscious for 1 week in the
intensive care unit of a general hospital, she spent another 2 weeks in
intensive care before being transferred to a long-term acute care hospital
for a month and to a comprehensive rehabilitation hospital for 3 weeks.
Objective: To describe an important role for medical acupuncture in treating
stroke and complementing standard medical management. Methods: Medical
acupuncture was used to reverse left hemiparesis, improve mental awareness
and focus, and hasten the course of recovery. Conclusion: Medical
acupuncture should have an important role in the acute and subacute phases
of treatment of hemorrhagic stroke.
EMTREE DRUG INDEX TERMS
atenolol (drug therapy)
phenytoin (drug therapy)
warfarin (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
brain hemorrhage (therapy)
EMTREE MEDICAL INDEX TERMS
aged
anticonvulsant therapy
article
atrial fibrillation (drug therapy)
brain edema
case report
cerebrovascular accident
Chinese medicine
coma
computer assisted tomography
female
Glasgow coma scale
hemiparesis
human
international normalized ratio
neuroimaging
partial thromboplastin time
patient compliance
priority journal
prothrombin time
tonic clonic seizure (drug therapy)
DRUG TRADE NAMES
coumadin , United StatesBristol Myers Squibb
dilantin , United StatesPfizer
tenormin , United StatesAstra Zeneca
DRUG MANUFACTURERS
(United States)Astra Zeneca
(United States)Bristol Myers Squibb
(United States)Pfizer
CAS REGISTRY NUMBERS
atenolol (29122-68-7, 93379-54-5)
phenytoin (57-41-0, 630-93-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160342028
FULL TEXT LINK
http://dx.doi.org/10.1089/acu.2015.1160
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 51
TITLE
Impaired right ventricular-pulmonary arterial coupling and effect of
sildenafil in heart failure with preserved ejection fraction
AUTHOR NAMES
Hussain I.
Mohammed S.F.
Forfia P.R.
Lewis G.D.
Borlaug B.A.
Gallup D.S.
Redfield M.M.
AUTHOR ADDRESSES
(Hussain I.; Mohammed S.F.; Borlaug B.A.; Redfield M.M.,
redfield.margaret@mayo.edu) Division of Cardiovascular Diseases, Mayo
Clinic, 200 First St SW, Rochester, United States.
(Forfia P.R.) Temple University, Philadelphia, United States.
(Lewis G.D.) Cardiology Division, Massachusetts General Hospital, Harvard
Medical School, Boston, United States.
(Gallup D.S.) Duke Clinical Research Institute, Durham, United States.
CORRESPONDENCE ADDRESS
M.M. Redfield, Division of Cardiovascular Diseases, Mayo Clinic, 200 First
St SW, Rochester, United States. Email: redfield.margaret@mayo.edu
SOURCE
Circulation: Heart Failure (2016) 9:4 Article Number: e002729. Date of
Publication: 1 Apr 2016
ISSN
1941-3297 (electronic)
1941-3289
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Background - Right ventricular (RV) dysfunction (RVD) is a poor prognostic
factor in heart failure with preserved ejection fraction (HFpEF). The
physiological perturbations associated with RVD or RV function indexed to
load (RV-pulmonary arterial [PA] coupling) in HFpEF have not been defined.
HFpEF patients with marked impairment in RV-PA coupling may be uniquely
sensitive to sildenafil. Methods and Results - In a subset of HFpEF patients
enrolled in the Phosphodiesteas-5 Inhibition to Improve Clinical Status And
Exercise Capacity in Diastolic Heart Failure (RELAX) trial, physiological
variables and therapeutic effect of sildenafil were examined relative to the
severity of RVD (tricuspid annular plane systolic excursion [TAPSE]) and
according to impairment in RV-PA coupling (TAPSE/pulmonary artery systolic
pressure) ratio. The prevalence of atrial fibrillation and diuretic use,
n-terminal probrain natriuretic peptide levels, renal dysfunction,
neurohumoral activation, myocardial necrosis and fibrosis biomarkers, and
the severity of diastolic dysfunction all increased with severity of RVD.
Peak oxygen consumption decreased and ventilatory inefficiency (VE/VCO 2
slope) increased with increasing severity of RVD. Many but not all
physiological derangements were more closely associated with the
TAPSE/pulmonary artery systolic pressure ratio. Compared with placebo, at 24
weeks, TAPSE decreased, and peak oxygen consumption and VE/CO 2 slope were
unchanged with sildenafil. There was no interaction between RV-PA coupling
and treatment effect, and sildenafil did not improve TAPSE, peak oxygen
consumption, or VE/VCO 2 in patients with pulmonary hypertension and RVD.
Conclusions - HFpEF patients with RVD and impaired RV-PA coupling have more
advanced heart failure. In RELAX patients with RVD and impaired RV-PA
coupling, sildenafil did not improve RV function, exercise capacity, or
ventilatory efficiency.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
sildenafil (drug therapy)
EMTREE DRUG INDEX TERMS
aldosterone (endogenous compound)
amino terminal pro brain natriuretic peptide (endogenous compound)
beta adrenergic receptor blocking agent
biological marker (endogenous compound)
C reactive protein (endogenous compound)
c telopeptide for type I collagen (endogenous compound)
cystatin C (endogenous compound)
digoxin
endothelin 1 (endogenous compound)
galectin 3 (endogenous compound)
loop diuretic agent
phosphodiesterase V (endogenous compound)
placebo
procollagen iii n terminal peptide (endogenous compound)
troponin I (endogenous compound)
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure with preserved ejection fraction (drug therapy, drug therapy)
heart right ventricle failure
heart right ventricle function
right ventricular pulmonary arterial coupling
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
cardiovascular parameters
controlled study
diastolic dysfunction
disease severity
diuretic therapy
drug effect
enzyme inhibition
exercise
female
heart left ventricle ejection fraction
heart left ventricle function
heart left ventricle mass
heart muscle necrosis
heart muscle oxygen consumption
human
kidney dysfunction
major clinical study
male
priority journal
pulmonary artery systolic pressure ratio
pulmonary hypertension
randomized controlled trial
treatment duration
tricuspid annular plane systolic excursion
ventilatory inefficiency
CAS REGISTRY NUMBERS
aldosterone (52-39-1, 6251-69-0)
C reactive protein (9007-41-4)
digoxin (20830-75-5, 57285-89-9)
endothelin 1 (117399-94-7)
galectin 3 (208128-56-7)
sildenafil (139755-83-2)
troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
Internal Medicine (6)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (00763867)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160332538
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002729
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 52
TITLE
Exercise as an adjuvant therapy against chronic atrial fibrillation
AUTHOR NAMES
Santos-Lozano A.
Sanchis-Gomar F.
Barrero-Santalla S.
Pareja-Galeano H.
Cristi-Montero C.
Sanz-Ayan P.
Garatachea N.
Fiuza-Luces C.
Lucia A.
AUTHOR ADDRESSES
(Santos-Lozano A.; Sanchis-Gomar F., fabian.sanchis@uv.es; Pareja-Galeano
H.; Sanz-Ayan P.; Garatachea N.; Fiuza-Luces C.; Lucia A.) Research
Institute of Hospital, Edificio Actividades Ambulatorias, 12de Octubre
(i+12) 6a planta Avda. de Córdoba s/n, Madrid, Spain.
(Santos-Lozano A.) GIDFYS, European University Miguel de Cervantes,
Department of Health Sciences, Valladolid, Spain.
(Barrero-Santalla S.) School of Health Sciences, University of León, León,
Spain.
(Pareja-Galeano H.; Lucia A.) European University of Madrid, Madrid, Spain.
(Cristi-Montero C.) IRyS Group, School of Physical Education, Pontificia
Universidad Católica de Valparaíso, Valparaíso, Chile.
(Cristi-Montero C.) Universidad Autónoma de Chile, Temuco, Chile.
(Garatachea N.) Facultad de Ciencias de la Salud y Del Deporte, Universidad
de Zaragoza, Huesca, Spain.
CORRESPONDENCE ADDRESS
F. Sanchis-Gomar, Research Institute of Hospital, Edificio Actividades
Ambulatorias, 12de Octubre (i+12) 6a planta Avda. de Córdoba s/n, Madrid,
Spain. Email: fabian.sanchis@uv.es
SOURCE
International Journal of Cardiology (2016) 207 (180-184). Date of
Publication: 15 Mar 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist (drug therapy)
anticoagulant agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium antagonist (drug therapy)
digoxin (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adjuvant therapy
chronic atrial fibrillation (drug therapy, drug therapy, therapy)
exercise
EMTREE MEDICAL INDEX TERMS
article
cardiovascular parameters
coronary artery disease (drug therapy)
disease association
disease classification
disease duration
heart disease (drug therapy)
heart failure (drug therapy)
human
hypertension (drug therapy)
ischemic heart disease
outcome assessment
oxygen consumption
priority journal
quality of life
systematic review
therapy effect
treatment duration
treatment response
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20160129604
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2016.01.140
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 53
TITLE
Interaction between dietary Vitamin K intake and anticoagulation by Vitamin
K antagonists: is it really true?: A systematic review
AUTHOR NAMES
Violi F.
Lip G.Y.H.
Pignatelli P.
Pastori D.
AUTHOR ADDRESSES
(Violi F., francesco.violi@uniroma1.it; Pignatelli P.; Pastori D.) Center of
Atherothrombosis, I Medical Clinic, Department of Internal Medicine and
Medical Specialties, Sapienza University of Rome, Umberto i Policlinic of
Rome, Viale del Policlinico 155, Rome, Italy.
(Lip G.Y.H.) Centre for Cardiovascular Sciences, City Hospital, University
of Birmingham, Birmingham, United Kingdom.
CORRESPONDENCE ADDRESS
F. Violi, Center of Atherothrombosis, I Medical Clinic, Department of
Internal Medicine and Medical Specialties, Sapienza University of Rome,
Umberto i Policlinic of Rome, Viale del Policlinico 155, Rome, Italy. Email:
francesco.violi@uniroma1.it
SOURCE
Medicine (United States) (2016) 95:10 Article Number: e2895. Date of
Publication: 4 Mar 2016
ISSN
1536-5964 (electronic)
0025-7974
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Educational advice is often given to patients starting treatment with
vitamin K Antagonists (VKAs). A great emphasis is made on nutritional
information. Common belief is that dietary vitamin K intake could counteract
the anticoagulant effect by VKAs and for many years, patients have been
discouraged to consume vitamin-K-rich foods, such as green leafy vegetables.
The objective of this study is to summarize the current evidence supporting
the putative interaction between dietary vitamin K intake and changes in INR
with the VKAs. Data sources are MEDLINE via PubMed and Cochrane database.
All clinical studies investigating the relationship between dietary vitamin
K and measures of anticoagulation were included. We excluded all studies of
supplementation of vitamin K alone. We performed a systematic review of the
literature up to October 2015, searching for a combination of "food,"
"diet," "vitamin K," "phylloquinone," "warfarin," "INR," "coagulation," and
"anticoagulant." Two dietary interventional trials and 9 observational
studies were included. We found conflicting evidence on the effect of
dietary intake of vitamin K on coagulation response. Some studies found a
negative correlation between vitamin K intake and INR changes, while others
suggested that a minimum amount of vitamin K is required to maintain an
adequate anticoagulation. Median dietary intake of vitamin K1 ranged from 76
to 217mg/day among studies, and an effect on coagulation may be detected
only for high amount of vitamin intake (>150mg/day). Most studies included
patients with various indications for VKAs therapy, such as atrial
fibrillation, prosthetic heart valves, and venous thromboembolism. Thus, INR
target was dishomogeneous and no subanalyses for specific populations or
different anticoagulants were conducted. Measures used to evaluate
anticoagulation stability were variable. The available evidence does not
support current advice to modify dietary habits when starting therapy with
VKAs. Restriction of dietary vitamin K intake does not seem to be a valid
strategy to improve anticoagulation quality with VKAs. It would be, perhaps,
more relevant to maintain stable dietary habit, avoiding wide changes in the
intake of vitamin K.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antivitamin K (drug interaction, drug therapy)
vitamin K group (drug interaction)
EMTREE DRUG INDEX TERMS
phytomenadione
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulation
dietary intake
international normalized ratio
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (drug therapy)
clinical trial (topic)
Cochrane Library
diet restriction
heart valve prosthesis
human
intervention study
Medline
meta analysis (topic)
observational study
practice guideline
priority journal
systematic review
treatment indication
venous thromboembolism (drug therapy)
vitamin intake
CAS REGISTRY NUMBERS
phytomenadione (11104-38-4, 84-80-0)
vitamin K group (12001-79-5)
EMBASE CLASSIFICATIONS
Hematology (25)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160236808
FULL TEXT LINK
http://dx.doi.org/10.1097/MD.0000000000002895
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 54
TITLE
Prevention, management, and rehabilitation of stroke in low- and
middle-income countries
AUTHOR NAMES
Yan L.L.
Li C.
Chen J.
Miranda J.J.
Luo R.
Bettger J.
Zhu Y.
Feigin V.
O'Donnell M.
Zhao D.
Wu Y.
AUTHOR ADDRESSES
(Yan L.L., lijing.yan@duke.edu; Li C.) Global Health Research Center, Duke
Kunshan University, Kunshan, China.
(Yan L.L., lijing.yan@duke.edu) Duke Global Health Institute, Duke
University, Durham, United States.
(Yan L.L., lijing.yan@duke.edu; Luo R.; Zhu Y.; Wu Y., ywu@george.org.cn)
George Institute for Global Health, Peking University, Health Science
Center, Beijing, China.
(Chen J.) Institute for Medical Humanities, Peking University, Health
Science Center, Beijing, China.
(Miranda J.J.) CRONICAS Center of Excellence for Chronic Diseases,
Universidad Peruana Cayetano Heredia, Lima, Peru.
(Miranda J.J.) Department of Medicine, School of Medicine, Universidad
Peruana Cayetano Heredia, Lima, Peru.
(Bettger J.) Duke School of Nursing, Duke University, Durham, United States.
(Bettger J.) Duke Clinical Research Institute, Duke University, Durham,
United States.
(Feigin V.) National Institute for Stroke and Applied Neuroscience, Auckland
University of Technology, Auckland, New Zealand.
(O'Donnell M.) National University of Ireland Galway, Galway, Ireland.
(Zhao D.) Department of Epidemiology, Beijing Anzhen Hospital, Capital
Medical University, Beijing, China.
(Wu Y., ywu@george.org.cn) Department of Epidemiology and Biostatistics,
Peking University, School of Public Health, Clinical Research Institute,
Beijing, China.
CORRESPONDENCE ADDRESS
L.L. Yan, Duke Global Health Institute, Global Health Research Center, Duke
Kunshan University, No. 8 Duke Avenue, Kunshan, China. Email:
lijing.yan@duke.edu
SOURCE
eNeurologicalSci (2016) 2 (21-30). Date of Publication: 1 Mar 2016
ISSN
2405-6502 (electronic)
BOOK PUBLISHER
Elsevier
ABSTRACT
Although stroke incidence in high-income countries (HICs) decreased over the
past four decades, it increased dramatically in low- and middle-income
countries (LMICs). In this review, we describe the current status of primary
prevention, treatment, and management of acute stroke and secondary
prevention of and rehabilitation after stroke in LMICs. Although
surveillance, screening, and accurate diagnosis are important for stroke
prevention, LMICs face challenges in these areas due to lack of resources,
awareness, and technical capacity. Maintaining a healthy lifestyle, such as
no tobacco use, healthful diet, and physical activity are important
strategies for both primary and secondary prevention of stroke. Controlling
high blood pressure is also critically important in the general population
and in the acute stage of hemorrhagic stroke. Additional primary prevention
strategies include community-based education programs, polypill, prevention
and management of atrial fibrillation, and digital health technology. For
treatment of stroke during the acute stage, specific surgical procedures and
medications are recommended, and inpatient stroke care units have been
proven to provide high quality care. Patients with a chronic condition like
stroke may require lifelong pharmaceutical treatment, lifestyle maintenance
and self-management skills, and caregiver and family support, in order to
achieve optimal health outcomes. Rehabilitation improves physical, speech,
and cognitive functioning of disabled stroke patients. It is expected that
home- or community-based services and tele-rehabilitation may hold special
promise for stroke patients in LMICs.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (diagnosis, disease management, etiology,
prevention, rehabilitation, therapy)
lowest income group
middle income group
rehabilitation care
social status
EMTREE MEDICAL INDEX TERMS
age
atrial fibrillation
blood pressure regulation
brain hemorrhage
brain ischemia
caregiver
carotid artery obstruction
cognition
cost effectiveness analysis
diabetes mellitus
diagnostic accuracy
dietary intake
disabled person
disease control
disease surveillance
family
gender
health care quality
health education
hypertension
lifestyle
movement therapy
obesity
occupational therapy
physical activity
physical capacity
physiotherapy
primary prevention
priority journal
review
risk factor
screening
secondary prevention
self care
smoking cessation program
speech
stroke patient
stroke unit
telerehabilitation
tobacco use
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Rehabilitation and Physical Medicine (19)
Health Policy, Economics and Management (36)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160249865
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ensci.2016.02.011
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 55
TITLE
Thrombotic events in patients with antiphospholipid syndrome treated with
rivaroxaban: a series of eight cases
AUTHOR NAMES
Signorelli F.
Nogueira F.
Domingues V.
Mariz H.A.
Levy R.A.
AUTHOR ADDRESSES
(Signorelli F., flasigno@hotmail.com) Hospital Universitário Clementino
Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
(Signorelli F., flasigno@hotmail.com) Hospital Universitário Pedro Ernesto,
Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
(Nogueira F.; Levy R.A.) Faculdade de Ciências Médicas, Universidade do
Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
(Domingues V.) New York University Langone Medical Center, New York
University School of Medicine, New York, United States.
(Mariz H.A.) Faculdade de Ciências Médicas, Universidade Federal de
Pernambuco, Recife, Brazil.
(Levy R.A.) Centro de Imunoterapia de Ipanema - CITIPA, Rio de Janeiro,
Brazil.
CORRESPONDENCE ADDRESS
F. Signorelli, Hospital Universitário Clementino Fraga Filho, Universidade
Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Email:
flasigno@hotmail.com
SOURCE
Clinical Rheumatology (2016) 35:3 (801-805). Date of Publication: 1 Mar 2016
ISSN
1434-9949 (electronic)
0770-3198
BOOK PUBLISHER
Springer-Verlag London Ltd
ABSTRACT
The current treatment for antiphospholipid syndrome (APS) with thrombotic
manifestation is long-term anticoagulation. Vitamin K antagonists (VKA) are
usually the agents of choice. However, VKA limitations, such as
unpredictable anticoagulation effects due to interaction with diet and other
drugs, require regular monitoring. This may impact on patients’ quality of
life. Since the approval of new oral anticoagulants (NOAC) for non-valvular
atrial fibrillation and deep vein thrombosis prevention, much has been
speculated about its use in APS patients. We report here a series of eight
APS patients with failure of thrombotic prevention during rivaroxaban use.
All patients had venous thrombosis as the initial manifestation of APS, and
two of them also had arterial manifestations. Three patients had triple
antibody positivity. Five patients developed arterial events during the
treatment with rivaroxaban. Until the results of ongoing trials of
rivaroxaban for APS are presented, NOAC should not be recommended to APS
patients. Our preliminary experience as well cases previously reported in
the literature suggest that there is a high-risk group that is less
protected with rivaroxaban, namely those with previous arterial thrombosis
or triple positivity. VKA remains to be the mainstay treatment for
thrombotic APS.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
rivaroxaban (drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
antivitamin K (drug therapy)
beta2 glycoprotein 1 antibody (endogenous compound)
cardiolipin antibody (endogenous compound)
clopidogrel (drug therapy)
enoxaparin (drug therapy, subcutaneous drug administration)
phospholipid antibody (endogenous compound)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
antiphospholipid syndrome (drug therapy, drug therapy)
thrombosis (prevention)
EMTREE MEDICAL INDEX TERMS
adult
anticoagulant therapy
artery thrombosis (drug therapy, prevention)
cerebral artery disease (diagnosis)
clinical article
computer assisted tomography
coronary artery occlusion (drug therapy, therapy)
deep vein thrombosis (drug therapy, prevention)
drug eluting stent
drug substitution
drug treatment failure
drug withdrawal
female
human
international normalized ratio
kidney infarction (diagnosis)
lower extremity deep vein thrombosis (drug therapy, prevention)
lung embolism (drug therapy, prevention)
male
middle aged
priority journal
review
thrombosis prevention
young adult
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
enoxaparin (679809-58-6)
rivaroxaban (366789-02-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Immunology, Serology and Transplantation (26)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015232120
FULL TEXT LINK
http://dx.doi.org/10.1007/s10067-015-3030-y
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 56
TITLE
Heart Failure with Preserved Ejection Fraction: Do You Know Your Left Atrial
Strain?
AUTHOR NAMES
Jellis C.L.
Klein A.L.
AUTHOR ADDRESSES
(Jellis C.L.; Klein A.L., kleina@ccf.org) Department of Cardiovascular
Medicine, Cleveland Clinic, United States.
CORRESPONDENCE ADDRESS
A.L. Klein, Cardiovascular Imaging J1-5, Heart and Vascular Institute,
Cleveland Clinic, 9500 Euclid Ave, Cleveland, United States. Email:
kleina@ccf.org
SOURCE
Circulation: Cardiovascular Imaging (2016) 9:3 Article Number: e004521. Date
of Publication: 1 Mar 2016
ISSN
1942-0080 (electronic)
1941-9651
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure with preserved ejection fraction
heart left atrium
EMTREE MEDICAL INDEX TERMS
diastolic dysfunction
echocardiography
electrocardiogram
exercise
heart death
human
hypertension
paroxysmal atrial fibrillation
priority journal
review
systolic heart failure
tissue Doppler imaging
two dimensional echocardiography
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20160236933
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCIMAGING.116.004521
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 57
TITLE
Brugada syndrome: More than 20 years of scientific excitement
AUTHOR NAMES
Brugada P.
AUTHOR ADDRESSES
(Brugada P., pedro@brugada.org) Department of Cardiology, Heart Rhythm
Management Center, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels,
Belgium.
CORRESPONDENCE ADDRESS
P. Brugada, Department of Cardiology, Heart Rhythm Management Center, UZ
Brussel, Vrije Universiteit Brussel (VUB), 101 Laarbeeklaan, Brussels,
Belgium. Email: pedro@brugada.org
SOURCE
Journal of Cardiology (2016) 67:3 (215-220). Date of Publication: 1 Mar 2016
ISSN
1876-4738 (electronic)
0914-5087
BOOK PUBLISHER
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
ABSTRACT
In 1992 we reported on eight patients with a particular electrocardiograph
(ECG) showing ST segment elevation in the right precordial leads. All
patients had a structurally normal heart and had survived one or multiple
episodes of near sudden death caused by ventricular fibrillation. We showed
6 years later that this disease, known nowadays as Brugada syndrome, was
caused by mutations in the SCN5A gene which encodes for the cardiac sodium
channel. Other genes where mutations result in the same ECG have been also
identified, with at present more than 17 different genes published. These
data show that Brugada syndrome is a genetically heterogeneous disease as is
also the case in the long QT syndrome. In Brugada syndrome, the clue to the
initial clinical diagnosis remains the abnormal ECG. However, it was evident
from the beginning that the ECG of Brugada syndrome is variable and
sensitive to many autonomic, drug, exercise, emotions and other external
influences such as a meal, fever, changes in heart rate from any cause, and
even body position. When followed intensively, all patients with a Brugada
ECG will show a completely normal ECG at one or another moment in their
lives. The spontaneous normalization of the ECG represents a major
diagnostic challenge, because a patient with Brugada syndrome seen during
normalization of the ECG may fail to get the correct diagnosis.In these more
than 20 years great challenges have been overcome but some remain, mainly
the approach to the asymptomatic individual with a diagnosis of Brugada
syndrome. In 30-50% of individuals who die suddenly because of documented or
suspected Brugada syndrome, sudden death is the first manifestation of the
disease. Thus, these individuals were fully asymptomatic until the first
fatal event.
EMTREE DRUG INDEX TERMS
sodium channel Nav1.5 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Brugada syndrome
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
autonomic nervous system
body position
ECG abnormality
electrocardiogram
embryonic stem cell
emotion
exercise
faintness
gene mutation
genetics
heart rate
heart right bundle branch block
heart right ventricle dysplasia
heart right ventricle outflow tract
human
long QT syndrome
pathophysiology
pluripotent stem cell
review
ST segment elevation
sudden cardiac death
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151027516
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jjcc.2015.08.009
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 58
TITLE
Efficacy and safety of ablation for patients with non-paroxysmal atrial
fibrillation
AUTHOR NAMES
Amit G.
Adler A.J.
Owolabi O.O.
Nyong J.
Casas J.P.
Prieto-Merino D.
Perel P.
Lambiase P.
Morillo C.A.
AUTHOR ADDRESSES
(Amit G.) Hamilton General Hospital, Division of Cardiology, Department of
Medicine, 237 Barton Street East, Hamilton, Canada.
(Adler A.J.; Prieto-Merino D.) London School of Hygiene and Tropical
Medicine, Department of Non-communicable Disease Epidemiology, Keppel
Street, London, United Kingdom.
(Owolabi O.O.) London School of Hygiene and Tropical Medicine, Department of
Epidemiology and Population Health, Keppel Street, London, United Kingdom.
(Nyong J.) FARR Institute UCL, Clinical Epidemiology, 222 Euston Road,
London, United Kingdom.
(Casas J.P.) University College London, Institute of Health Informatics,
Faculty of Population Health Sciences, London, United Kingdom.
(Perel P.) London School of Hygiene and Tropical Medicine, Department of
Population Health, Keppel Street, London, United Kingdom.
(Lambiase P.) The Heart Hospital, University College London Hospitals,
Centre for Cardiology in the Young, 16-18 Westmoreland Street, London,
United Kingdom.
(Morillo C.A., morillo@hhsc.ca) McMaster University HHSC, Department of
Medicine, Cardiology Division, Population Health Research Institute, 237
Barton Street East, David Braley CVRSI, Hamilton, Canada.
CORRESPONDENCE ADDRESS
C.A. Morillo, McMaster University HHSC, Department of Medicine, Cardiology
Division, Population Health Research Institute, 237 Barton Street East,
David Braley CVRSI, Hamilton, Canada. Email: morillo@hhsc.ca
SOURCE
Cochrane Database of Systematic Reviews (2016) 2016:2 Article Number:
CD012088. Date of Publication: 24 Feb 2016
ISSN
1361-6137 (electronic)
1469-493X
BOOK PUBLISHER
John Wiley and Sons Ltd, Southern Gate, Chichester, West Sussex, United
Kingdom.
ABSTRACT
This is the protocol for a review and there is no abstract. The objectives
are as follows: To determine the effect of ablation to maintain sinus rhythm
in patients with persistent or long-standing persistent atrial fibrillation
compared to anti-arrhythmic drugs.
EMTREE DRUG INDEX TERMS
amiodarone
dofetilide
dronedarone
flecainide
propafenone
quinidine
sotalol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
catheter ablation
non paroxysmal atrial fibrillation (therapy)
EMTREE MEDICAL INDEX TERMS
exercise
human
persistent atrial fibrillation
pulmonary vein isolation
radiofrequency ablation
randomized controlled trial (topic)
review
sinus rhythm
systematic review
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
dofetilide (115256-11-6)
dronedarone (141626-36-0)
flecainide (54143-55-4)
propafenone (34183-22-7, 54063-53-5)
quinidine (56-54-2)
sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160262892
FULL TEXT LINK
http://dx.doi.org/10.1002/14651858.CD012088
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 59
TITLE
Safety of vasodilator stress myocardial perfusion imaging in patients with
elevated cardiac biomarkers
AUTHOR NAMES
Rai M.
Ahlberg A.W.
Marwell J.
Chaudhary W.
Savino J.A.
Alter E.L.
Henzlova M.J.
Duvall W.L.
AUTHOR ADDRESSES
(Rai M.; Ahlberg A.W.; Chaudhary W.; Duvall W.L., lane.duvall@hhchealth.org)
Division of Cardiology (Henry Low Heart Center), Hartford Hospital, 80
Seymour Street, Hartford, United States.
(Marwell J.) Department of Medicine, University of Connecticut, Farmington,
United States.
(Savino J.A.; Henzlova M.J.) Division of Cardiology (Mount Sinai Heart),
Mount Sinai Medical Center, New York, United States.
(Alter E.L.) Department of Medicine, Mount Sinai Medical Center, New York,
United States.
CORRESPONDENCE ADDRESS
W.L. Duvall, Division of Cardiology (Henry Low Heart Center), Hartford
Hospital, 80 Seymour Street, Hartford, United States. Email:
lane.duvall@hhchealth.org
SOURCE
Journal of Nuclear Cardiology (2016) (1-11). Date of Publication: 22 Feb
2016
ISSN
1532-6551 (electronic)
1071-3581
BOOK PUBLISHER
Springer New York LLC, barbara.b.bertram@gsk.com
ABSTRACT
Background: While adenosine and dipyridamole as myocardial perfusion imaging
(MPI) stress agents have literature supporting their safety in the setting
of myocardial infarction (MI), regadenoson does not. Studying a high risk
cohort of patients with elevated cardiac biomarkers may shed light on
potential safety issues of these agents which might also affect lower risk
cohorts. Methods: All patients who had undergone a clinically indicated
stress MPI study at two academic centers from 1/1/2010 through 12/31/2012
with elevated troponin ≤7 days prior to testing were included. The primary
endpoint was a composite of death, non-fatal MI, congestive heart failure
(CHF), stroke, ventricular arrhythmias, atrial fibrillation/flutter, or
atrioventricular block requiring intervention within 24 h of testing.
Results: Of the 703 stress MPI studies that met inclusion criteria, 360
(51.2%), 199 (28.3%), 74 (10.5%), 9 (1.3%), and 61 (8.7%) underwent
regadenoson, dipyridamole, adenosine, dobutamine, and exercise stress,
respectively. The primary endpoint occurred in 11 (1.6%) patients with an
incidence of 1.4% (n = 5), 1.0% (n = 2), 1.4% (n = 1), 11.1% (n = 1), and
3.3% (n = 2) following regadenoson, dipyridamole, adenosine, dobutamine, and
exercise stress, respectively (P = 0.137). The adverse events included
non-fatal MI in 7 (1.0%) patients, death in 1 (0.1%) patient, CHF in 1
(0.1%) patient, ventricular arrhythmia in 1 (0.1%) patient, and atrial
arrhythmia in 1 (0.1%) patient. Conclusion: In the setting of elevated
troponin, serious complications associated with either exercise or
vasodilator stress testing appear to be relatively rare with no increased
risk attributable to a particular vasodilator agent.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
vasodilator agent
EMTREE DRUG INDEX TERMS
adenosine
dipyridamole
dobutamine
regadenoson
troponin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart
myocardial perfusion imaging
safety
stress
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
atrioventricular block
cerebrovascular accident
chemical stress
clinical article
clinical trial
congestive heart failure
controlled clinical trial
death
exercise
heart infarction
heart ventricle arrhythmia
human
multicenter study
side effect
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160165049
FULL TEXT LINK
http://dx.doi.org/10.1007/s12350-016-0448-9
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 60
TITLE
Acute heart failure admissions in New South Wales and the Australian Capital
Territory: The NSW HF snapshot study
AUTHOR NAMES
Newton P.J.
Davidson P.M.
Reid C.M.
Krum H.
Hayward C.
Sibbritt D.W.
Banks E.
Macdonald P.S.
AUTHOR ADDRESSES
(Newton P.J., phillip.newton@uts.edu.au; Davidson P.M.) Centre for
Cardiovascular and Chronic Care, University of Technology Sydney, Sydney,
Australia.
(Davidson P.M.) Johns Hopkins University, Baltimore, United States.
(Reid C.M.) Curtin University, Perth, Australia.
(Reid C.M.; Krum H.) Monash Centre of Cardiovascular Research and Education
in Therapeutics, Monash University, Melbourne, Australia.
(Hayward C.; Macdonald P.S.) St Vincent’s Hospital, Sydney, Australia.
(Sibbritt D.W.) Australian Research Centre in Complementary and Integrative
Medicine, University of Technology Sydney, Sydney, Australia.
(Banks E.) National Centre for Epidemiology and Population Health,
Australian National University, Canberra, Australia.
SOURCE
Medical Journal of Australia (2016) 204:3 (113.e1-113.e8). Date of
Publication: 15 Feb 2016
ISSN
1326-5377 (electronic)
0025-729X
BOOK PUBLISHER
Australasian Medical Publishing Co. Ltd, ampco@ampco.com.au
ABSTRACT
The primary aim of the NSW Heart Failure (HF) Snapshot was to obtain a
representative cross-sectional view of patients with acute HF and their
management in New South Wales and Australian Capital Territory hospitals
Design and setting: A prospective audit of consecutive patients admitted to
24 participating hospitals in NSW and the ACT with a diagnosis of acute HF
was conducted from 8 July 2013 to 8 August 2013. Results: A total of 811
participants were recruited (mean age, 77 13 years; 58% were men; 42% had a
left ventricular ejection fraction 50%). The median Charlson Comorbidity
Index score was 3, with is chaemic heart disease (56%), renal disease (55%),
diabetes (38%) and chronic lung disease (32%) the most frequent
comorbidities; 71% of patients were assessed as frail. Inter-current
infection (22%), non-adherence to prescribed medication (5%) or to dietary
or fluid restrictions (16%), and atrial fibrillation/flutter (15%) were the
most commonly identified precipitants of HF. Initial treatment included
intravenous diuretics (81%), oxygen therapy (87%), and bimodal positive
airways pressure or continuous positive airways pressure ventilation (17%).
During the index admission, 6% of patients died. The median length of stay
in hospital was 6 days, but ranged between 3 and 12 days at different
hospitals. Just over half the patients (59%) were referred to a
multidisciplinary HF service. Discharge medications included
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
(59%), ß-blockers (66%) and loop diuretics (88%). Conclusions: Patients
admitted to hospital with acute HF in NSW and the ACT were generally elderly
and frail, with multiple comorbidities. Evidence-based therapies were
underused, and there was substantial inter-hospital variation in the length
of stay. We anticipate that the results of the HF Snapshot will inform the
development of strategies for improving the uptake of evidence-based
therapies, and hence outcomes, for HF patients.
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist
beta adrenergic receptor blocking agent
dipeptidyl carboxypeptidase inhibitor
diuretic agent (intravenous drug administration)
glyceryl trinitrate (intravenous drug administration)
loop diuretic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute heart failure
EMTREE MEDICAL INDEX TERMS
adolescent
adult
aged
article
artificial ventilation
Australia
Charlson Comorbidity Index
child
chronic lung disease
death
diabetes mellitus
dialysis
diet restriction
female
heart atrium flutter
heart muscle ischemia
human
infection
kidney disease
length of stay
major clinical study
male
medical audit
medication compliance
oxygen therapy
positive end expiratory pressure
resuscitation
CAS REGISTRY NUMBERS
glyceryl trinitrate (55-63-0, 80738-44-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160137355
FULL TEXT LINK
http://dx.doi.org/10.5694/mja15.00801
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 61
TITLE
Is it always Alzheimer’s? Let’s talk to our patients about
“cardiocerebrovascular” prevention
AUTHOR NAMES
Volpe R.
Sotis G.
Cianciabella M.
AUTHOR ADDRESSES
(Volpe R., roberto.volpe@cnr.it; Sotis G.) EWHETA (Eat Well for an HEalthy
Third Age) Project, Italian National Research Council, Rome, Italy.
(Cianciabella M.) EWHETA (Eat Well for an HEalthy Third Age) Project,
Italian National Research Council, Bologna, Italy.
CORRESPONDENCE ADDRESS
R. Volpe, EWHETA (Eat Well for an HEalthy Third Age) Project, Italian
National Research Council, Rome, Italy. Email: roberto.volpe@cnr.it
SOURCE
Aging Clinical and Experimental Research (2016) 28:1 (159-160). Date of
Publication: 1 Feb 2016
ISSN
1720-8319 (electronic)
1594-0667
BOOK PUBLISHER
Springer International Publishing
ABSTRACT
Unlike Alzheimer’s, vascular dementia can, in part, be prevented. The
preventive approach foresees treatment for high blood pressure, atrial
fibrillation, diabetes, high cholesterol, low HDL cholesterol, sedentary
lifestyle, smoking, alcohol abuse, obesity, and sleep apnea. Moreover, also
a well-balanced diet and physical activity are cornerstones of prevention,
with beneficial effects on the brain and cognition.
EMTREE DRUG INDEX TERMS
cholesterol (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Alzheimer disease
cerebrovascular disease (prevention)
EMTREE MEDICAL INDEX TERMS
alcohol abuse
article
atrial fibrillation
cardiovascular risk
cholesterol blood level
diabetes mellitus
genetic predisposition
human
hypertension
Mediterranean diet
obesity
physical activity
risk factor
sedentary lifestyle
sleep disordered breathing
smoking
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
Clinical and Experimental Biochemistry (29)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015507459
FULL TEXT LINK
http://dx.doi.org/10.1007/s40520-015-0480-7
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 62
TITLE
Weight loss to prevent atrial fibrillation: The role of epicardial adipose
tissue
AUTHOR NAMES
Liu F.
Li Y.
Xu Y.
AUTHOR ADDRESSES
(Liu F.; Xu Y.) Medical College of Hebei University of Engineering, Handan,
China.
(Li Y., heibeiliyan@sina.com) Affiliated Hospital of Hebei University of
Engineering, Guangming South Street 199, Handan City, China.
CORRESPONDENCE ADDRESS
Y. Li, Affiliated Hospital of Hebei University of Engineering, Guangming
South Street 199, Handan City, China. Email: heibeiliyan@sina.com
SOURCE
International Journal of Cardiology (2016) 204 (124-125). Date of
Publication: 1 Feb 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adipose tissue
atrial fibrillation
epicardial adipose tissue
weight reduction
EMTREE MEDICAL INDEX TERMS
article
autonomic nervous system
body mass
body weight management
cardiovascular risk
comorbidity
cytokine release
heart atrium remodeling
heart protection
human
lipid diet
obesity
priority journal
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20160069467
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2015.08.159
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 63
TITLE
Physical activity, symptoms, medication and subjective health among veteran
endurance athletes with atrial fibrillation
AUTHOR NAMES
Myrstad M.
Aarønæs M.
Graff-Iversen S.
Ariansen I.
Nystad W.
Ranhoff A.H.
AUTHOR ADDRESSES
(Myrstad M., m-myrsta@online.no; Aarønæs M.; Ranhoff A.H.) Department of
Internal Medicine, Diakonhjemmet Hospital, Medisinsk avdeling, Diakonhjemmet
sykehus, Pb 23 Vindern, Oslo, Norway.
(Graff-Iversen S.; Ariansen I.; Nystad W.) Division of Epidemiology,
Norwegian Institute of Public Health, Oslo, Norway.
(Ranhoff A.H.) Department of Clinical Science, Kavli Research Centre for
Geriatrics and Dementia, University of Bergen, Bergen, Norway.
CORRESPONDENCE ADDRESS
M. Myrstad, Department of Internal Medicine, Diakonhjemmet Hospital,
Medisinsk avdeling, Diakonhjemmet sykehus, Pb 23 Vindern, Oslo, Norway.
Email: m-myrsta@online.no
SOURCE
Clinical Research in Cardiology (2016) 105:2 (154-161). Date of Publication:
1 Feb 2016
ISSN
1861-0692 (electronic)
1861-0684
BOOK PUBLISHER
Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
Background: Atrial fibrillation (AF) is highly prevalent, but has not
previously been characterized in detail in veteran athletes. We aimed to
describe physical activity (PA), symptoms, medication and subjective health
in relation to AF subtype and co-morbidity among veteran cross-country
skiers with AF. Methods: In total, 4952 Norwegian men and women aged
53–85 years took part in this cohort study, 2626 veteran cross-country
skiers and 2326 from the general population. PA, endurance exercise,
functional capacity, co-morbidity, drug use and subjective health were
self-reported by questionnaires. AF was self-reported and confirmed by
electrocardiograms in a medical record review. Results: The prevalence of
self-reported AF among veteran skiers was 12.3 %. AF was confirmed in 140
skiers and 118 individuals from the general population. Among skiers with AF
(mean age 69 years), 52 % had paroxysmal, 23 % persistent and 24 % permanent
AF. AF was associated with poor subjective health, but 89 % of the veteran
skiers were physically active and 64 % engaged in regular endurance exercise
after the onset of AF. While 59 % had experienced palpitations during the
past year, 32 % reported reduced functional capacity. Two out of three with
AF and a CHA(2)DS(2)-VASc score ≥2 used oral anticoagulants (OACs).
Conclusions: AF was associated with poor subjective health, but the vast
majority of veteran athletes engaged in regular PA and endurance exercise
also after the onset of AF. This is important, as PA and exercise might
reduce AF symptoms, mortality and morbidity. Many veteran skiers with AF
were not optimally treated with OACs.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
amiodarone (drug therapy)
anticoagulant agent (drug therapy, oral drug administration)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
dabigatran (drug therapy)
digitoxin (drug therapy)
digoxin (drug therapy)
dronedarone (drug therapy)
flecainide (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation (drug therapy, drug therapy)
health status
EMTREE MEDICAL INDEX TERMS
adult
aged
article
comorbidity
drug use
electrocardiography
endurance
endurance training
female
functional status
human
major clinical study
male
medical record review
middle aged
New York Heart Association class
physical activity
questionnaire
skiing
very elderly
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digitoxin (71-63-6)
digoxin (20830-75-5, 57285-89-9)
dronedarone (141626-36-0)
flecainide (54143-55-4)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015226083
FULL TEXT LINK
http://dx.doi.org/10.1007/s00392-015-0898-0
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 64
TITLE
Weight loss and coronary heart disease: Sensitivity analysis for unmeasured
confounding by undiagnosed disease
AUTHOR NAMES
Danaei G.
Robins J.M.
Young J.G.
Hu F.B.
Manson J.E.
Hernán M.A.
AUTHOR ADDRESSES
(Danaei G., gdanaei@hsph.harvard.edu) Department of Global Health and
Population, Harvard T.H. Chan School of Public Health, 665 Huntington
Avenue, Boston, United States.
(Danaei G., gdanaei@hsph.harvard.edu; Robins J.M.; Young J.G.; Hu F.B.;
Manson J.E.; Hernán M.A.) Department of Epidemiology, Harvard T.H. Chan
School of Public Health, Boston, United States.
(Robins J.M.; Hernán M.A.) Department of Biostatistics, Harvard T.H. Chan
School of Public Health, Boston, United States.
(Hu F.B.) Department of Nutrition, Harvard T.H. Chan School of Public
Health, Boston, United States.
(Hu F.B.) Channing Laboratory, Harvard Medical School, Brigham and Women's
Hospital, Boston, United States.
(Manson J.E.) Division of Preventive Medicine, Brigham and Women's Hospital,
Harvard Medical School, Boston, United States.
(Hernán M.A.) Harvard-MIT Division of Health Sciences and Technology,
Cambridge, United States.
CORRESPONDENCE ADDRESS
G. Danaei, Department of Global Health and Population, Harvard T.H. Chan
School of Public Health, 665 Huntington Avenue, Boston, United States.
Email: gdanaei@hsph.harvard.edu
SOURCE
Epidemiology (2016) 27:2 (302-310). Date of Publication: 28 Jan 2016
ISSN
1531-5487 (electronic)
1044-3983
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Background: Evidence for the effect of weight loss on coronary heart disease
(CHD) or mortality has been mixed. The effect estimates can be confounded
due to undiagnosed diseases that may affect weight loss. Methods: We used
data from the Nurses' Health Study to estimate the 26-year risk of CHD under
several hypothetical weight loss strategies. We applied the parametric
g-formula and implemented a novel sensitivity analysis for unmeasured
confounding due to undiagnosed disease by imposing a lag time for the effect
of weight loss on chronic disease. Several sensitivity analyses were
conducted. Results: The estimated 26-year risk of CHD did not change under
weight loss strategies using lag times from 0 to 18 years. For a 6-year lag
time, the risk ratios of CHD for weight loss compared with no weight loss
ranged from 1.00 (0.99, 1.02) to 1.02 (0.99, 1.05) for different degrees of
weight loss with and without restricting the weight loss strategy to
participants with no major chronic disease. Similarly, no protective effect
of weight loss was estimated for mortality risk. In contrast, we estimated a
protective effect of weight loss on risk of type 2 diabetes. Conclusion: We
estimated that maintaining or losing weight after becoming overweight or
obese does not reduce the risk of CHD or death in this cohort of middle-age
US women. Unmeasured confounding, measurement error, and model
misspecification are possible explanations but these did not prevent us from
estimating a beneficial effect of weight loss on diabetes.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
hydroxymethylglutaryl coenzyme A reductase inhibitor
multivitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
ischemic heart disease
weight reduction
EMTREE MEDICAL INDEX TERMS
adult
alcohol consumption
Alzheimer disease
amyotrophic lateral sclerosis
angina pectoris
article
atrial fibrillation
cardiovascular risk
cerebrovascular accident
chronic disease
chronic kidney disease
depression
diabetes mellitus
emphysema
exercise
female
follow up
gout
heart failure
heart infarction
human
lung embolism
major clinical study
male
multiple sclerosis
neoplasm
non insulin dependent diabetes mellitus
Parkinson disease
peripheral vascular disease
priority journal
rheumatoid arthritis
smoking
systemic lupus erythematosus
ulcerative colitis
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151003346
FULL TEXT LINK
http://dx.doi.org/10.1097/EDE.0000000000000428
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 65
TITLE
Executive summary: Heart disease and stroke statistics-2016 update: A Report
from the American Heart Association
AUTHOR NAMES
Mozaffarian D.
Benjamin E.J.
Go A.S.
Arnett D.K.
Blaha M.J.
Cushman M.
Das S.R.
De Ferranti S.
Després J.-P.
Fullerton H.J.
Howard V.J.
Huffman M.D.
Isasi C.R.
Jiménez M.C.
Judd S.E.
Kissela B.M.
Lichtman J.H.
Lisabeth L.D.
Liu S.
MacKey R.H.
Magid D.J.
McGuire D.K.
Mohler E.R.
Moy C.S.
Muntner P.
Mussolino M.E.
Nasir K.
Neumar R.W.
Nichol G.
Palaniappan L.
Pandey D.K.
Reeves M.J.
Rodriguez C.J.
Rosamond W.
Sorlie P.D.
Stein J.
Towfighi A.
Turan T.N.
Virani S.S.
Woo D.
Yeh R.W.
Turner M.B.
AUTHOR ADDRESSES
(Mozaffarian D.; Benjamin E.J.; Go A.S.; Arnett D.K.; Blaha M.J.; Cushman
M.; Das S.R.; De Ferranti S.; Després J.-P.; Fullerton H.J.; Howard V.J.;
Huffman M.D.; Isasi C.R.; Jiménez M.C.; Judd S.E.; Kissela B.M.; Lichtman
J.H.; Lisabeth L.D.; Liu S.; MacKey R.H.; Magid D.J.; McGuire D.K.; Mohler
E.R.; Moy C.S.; Muntner P.; Mussolino M.E.; Nasir K.; Neumar R.W.; Nichol
G.; Palaniappan L.; Pandey D.K.; Reeves M.J.; Rodriguez C.J.; Rosamond W.;
Sorlie P.D.; Stein J.; Towfighi A.; Turan T.N.; Virani S.S.; Woo D.; Yeh
R.W.; Turner M.B.)
SOURCE
Circulation (2016) 133:4 (447-454). Date of Publication: 26 Jan 2016
ISSN
1524-4539 (electronic)
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Each year, the American Heart Association (AHA), in conjunction with the
Centers for Disease Control and Prevention, the National Institutes of
Health, and other government agencies, brings together the most up-to-date
statistics related to heart disease, stroke, and other cardiovascular and
metabolic diseases and presents them in its Heart Disease and Stroke
Statistical Update. The Statistical Update represents a critical resource
for the lay public, policy makers, media professionals, clinicians,
healthcare administrators, researchers, and others seeking the best
available data on these conditions. Together, cardiovascular disease (CVD)
and stroke produce immense health and economic burdens in the United States
and globally. The Statistical Update brings together in a single document
up-to-date information on the core health behaviors (including diet,
physical activity [PA], smoking, and energy balance) and health factors
(including blood pressure, cholesterol, and glucose) that define
cardiovascular health; a range of major clinical disease conditions
(including stroke, congenital heart disease, rhythm disorders, subclinical
atherosclerosis, coronary heart disease, heart failure, valvular disease,
and peripheral arterial disease); and the associated outcomes (including
quality of care, procedures, and economic costs). Since 2006, the annual
versions of the Statistical Update have been cited >28 000 times in the
literature. In 2014 alone, the various Statistical Updates were cited >5000
times. Each annual version of the Statistical Update undergoes major
revisions to include the newest nationally representative data, add
additional relevant published scientific findings, remove older information,
add new sections or chapters, and increase the number of ways to access and
use the assembled information. This year-long process, which begins as soon
as the previous Statistical Update is published, is performed by the AHA
Statistics Committee faculty volunteers and staff. For example, this year's
edition includes new data on the monitoring and benefits of cardiovascular
health in the population, new metrics to assess and monitor healthy diets,
additional information in many chapters on the global CVD and stroke burden,
new information on stroke in young adults, a new focus on underserved and
minority populations, and further evidencebased approaches to changing
behaviors, implementation strategies, and implications of the AHA's 2020
Impact Goals. Below are a few highlights from this year's Update.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
health statistics
heart disease
EMTREE MEDICAL INDEX TERMS
aorta disease
atherosclerosis
atrial fibrillation
cardiovascular disease
cholesterol blood level
diabetes mellitus
energy balance
family history
health behavior
health promotion
heart failure
human
hypertension
ischemic heart disease
medical society
metabolic syndrome X
national health organization
nutrition
obesity
peripheral occlusive artery disease
physical inactivity
priority journal
review
risk assessment
sudden cardiac death
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160100755
FULL TEXT LINK
http://dx.doi.org/10.1161/CIR.0000000000000366
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 66
TITLE
Heart disease and stroke statistics-2016 update a report from the American
Heart Association
AUTHOR NAMES
Mozaffarian D.
Benjamin E.J.
Go A.S.
Arnett D.K.
Blaha M.J.
Cushman M.
Das S.R.
Ferranti S.D.
Després J.-P.
Fullerton H.J.
Howard V.J.
Huffman M.D.
Isasi C.R.
Jiménez M.C.
Judd S.E.
Kissela B.M.
Lichtman J.H.
Lisabeth L.D.
Liu S.
MacKey R.H.
Magid D.J.
McGuire D.K.
Mohler Iii E.R.
Moy C.S.
Muntner P.
Mussolino M.E.
Nasir K.
Neumar R.W.
Nichol G.
Palaniappan L.
Pandey D.K.
Reeves M.J.
Rodriguez C.J.
Rosamond W.
Sorlie P.D.
Stein J.
Towfighi A.
Turan T.N.
Virani S.S.
Woo D.
Yeh R.W.
Turner M.B.
AUTHOR ADDRESSES
(Mozaffarian D.; Benjamin E.J.; Go A.S.; Arnett D.K.; Blaha M.J.; Cushman
M.; Das S.R.; Ferranti S.D.; Després J.-P.; Fullerton H.J.; Howard V.J.;
Huffman M.D.; Isasi C.R.; Jiménez M.C.; Judd S.E.; Kissela B.M.; Lichtman
J.H.; Lisabeth L.D.; Liu S.; MacKey R.H.; Magid D.J.; McGuire D.K.; Mohler
Iii E.R.; Moy C.S.; Muntner P.; Mussolino M.E.; Nasir K.; Neumar R.W.;
Nichol G.; Palaniappan L.; Pandey D.K.; Reeves M.J.; Rodriguez C.J.;
Rosamond W.; Sorlie P.D.; Stein J.; Towfighi A.; Turan T.N.; Virani S.S.;
Woo D.; Yeh R.W.; Turner M.B.)
SOURCE
Circulation (2016) 133:4 (e38-e48). Date of Publication: 26 Jan 2016
ISSN
1524-4539 (electronic)
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Each year, the American Heart Association (AHA), in conjunction with the
Centers for Disease Control and Prevention, the National Institutes of
Health, and other government agencies, brings together the most up-to-date
statistics related to heart disease, stroke, and other cardiovascular and
metabolic diseases and presents them in its Heart Disease and Stroke
Statistical Update. The Statistical Update represents a critical resource
for the lay public, policy makers, media professionals, clinicians,
healthcare administrators, researchers, and others seeking the best
available data on these conditions. Together, cardiovascular disease (CVD)
and stroke produce immense health and economic burdens in the United States
and globally. The Statistical Update brings together in a single document
up-to-date information on the core health behaviors (including diet,
physical activity [PA], smoking, and energy balance) and health factors
(including blood pressure, cholesterol, and glucose) that define
cardiovascular health; a range of major clinical disease conditions
(including stroke, congenital heart disease, rhythm disorders, subclinical
atherosclerosis, coronary heart disease, heart failure, valvular disease,
and peripheral arterial disease); and the associated outcomes (including
quality of care, procedures, and economic costs). Since 2006, the annual
versions of the Statistical Update have been cited >28 000 times in the
literature. In 2014 alone, the various Statistical Updates were cited >5000
times. Each annual version of the Statistical Update undergoes major
revisions to include the newest nationally representative data, add
additional relevant published scientific findings, remove older information,
add new sections or chapters, and increase the number of ways to access and
use the assembled information. This year-long process, which begins as soon
as the previous Statistical Update is published, is performed by the AHA
Statistics Committee faculty volunteers and staff. For example, this year's
edition includes new data on the monitoring and benefits of cardiovascular
health in the population, new metrics to assess and monitor healthy diets,
additional information in many chapters on the global CVD and stroke burden,
new information on stroke in young adults, a new focus on underserved and
minority populations, and further evidence-based approaches to changing
behaviors, implementation strategies, and implications of the AHA's 2020
Impact Goals. Below are a few highlights from this year's Update.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
heart disease
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
angina pectoris
aorta disease
atherosclerosis
atrial fibrillation
cardiomyopathy
cardiovascular disease
cardiovascular procedure
cholesterol blood level
chronic kidney disease
diabetes mellitus
family history
genetics
health behavior
health care cost
health care delivery
health care quality
health care utilization
heart arrhythmia
heart failure
human
hypertension
ischemic heart disease
medical society
metabolic syndrome X
mucocutaneous lymph node syndrome
nutrition
obesity
peripheral occlusive artery disease
physical activity
physical inactivity
priority journal
review
smoking
sudden cardiac death
tobacco use
valvular heart disease
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151042454
FULL TEXT LINK
http://dx.doi.org/10.1161/CIR.0000000000000350
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 67
TITLE
The metabolic exercise test data combined with Cardiac and Kidney Indexes
(MECKI) score and prognosis in heart failure. A validation study
AUTHOR NAMES
Corrà U.
Agostoni P.
Giordano A.
Cattadori G.
Battaia E.
La Gioia R.
Scardovi A.B.
Emdin M.
Metra M.
Sinagra G.
Limongelli G.
Raimondo R.
Re F.
Guazzi M.
Belardinelli R.
Parati G.
Magrì D.
Fiorentini C.
Cicoira M.
Salvioni E.
Giovannardi M.
Veglia F.
Mezzani A.
Scrutinio D.
Di Lenarda A.
Ricci R.
Apostolo A.
Iorio A.M.
Paolillo S.
Palermo P.
Contini M.
Vassanelli C.
Passino C.
Giannuzzi P.
Piepoli M.F.
AUTHOR ADDRESSES
(Corrà U., ucorra@fsm.it; Mezzani A.; Giannuzzi P.) Divisione di Cardiologia
Riabilitativa, Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di
Veruno, Veruno, Italy.
(Agostoni P.; Cattadori G.; Battaia E.; Fiorentini C.; Salvioni E.;
Giovannardi M.; Veglia F.; Apostolo A.; Palermo P.; Contini M.) Centro
Cardiologico Monzino, IRCCS, Milano, Italy.
(Agostoni P.; Fiorentini C.) Department of Clinical Sciences and Community
Health, Cardiovascular Section, Università di Milano, Milano, Italy.
(Giordano A.) Bioengineering Department, Salvatore Maugeri Foundation,
IRCCS, Veruno, Italy.
(Battaia E.; Cicoira M.; Vassanelli C.) Section of Cardiology, Department of
Medicine, University of Verona, Italy.
(La Gioia R.; Scrutinio D.) Division of Cardiology, S. Maugeri Foundation,
IRCCS, Institute of Cassano Murge, Bari, Italy.
(Scardovi A.B.; Ricci R.) UOC Cardiologia Ospedale S. Spirito, Roma
Lungotevere in Sassia 3, Roma, Italy.
(Emdin M.; Passino C.) Fondazione Gabriele Monasterio, CNR-Regione Toscana,
Pisa, Italy.
(Metra M.) Cardiology, Department of Medical and Surgical Specialties,
Radiological Sciences, and Public Health, University of Brescia, Italy.
(Sinagra G.) Cardiovascular Department, Ospedali Riuniti, University of
Trieste, Trieste, Italy.
(Limongelli G.; Iorio A.M.) Cardiologia SUN, Ospedale Monaldi (Azienda Dei
Colli), Seconda Università di Napoli, Napoli, Italy.
(Raimondo R.) Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di
Tradate, Dipartimento di Medicina e Riabilitazione Cardiorespiratoria, Unità
Operativa di Cardiologia Riabilitativa, Tradate, Italy.
(Re F.) Cardiology Division, Cardiac Arrhythmia Center, Cardiomyopathies
Unit, St.Camillo-Forlanini Hospital, Roma, Italy.
(Guazzi M.) Department of Medical Sciences, Cardiology, I.R.C.C.S. San
Donato Hospital, University of Milan, San Donato Milanese, Milano, Italy.
(Belardinelli R.) Cardiologia Riabilitativa, Azienda Ospedali Riuniti,
Ancona, Italy.
(Parati G.) Dept of Health Science, University of Milano Bicocca, Dept of
Cardiology, S.Luca Hospital, Istituto Auxologico Italiano, Milano, Italy.
(Magrì D.) Dipartimento di Medicina Clinica e Molecolare, Sapienza
Università Degli Studi di Roma, Roma, Italy.
(Di Lenarda A.) Centro Cardiovascolare, Azienda per i Servizi Sanitari no1,
Trieste, Italy.
(Paolillo S.) Department of Advanced Biomedical Sciences, Federico II
University, Italy.
(Passino C.) Scuola Superiore S. Anna, Pisa, Italy.
(Piepoli M.F.) UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy.
()
CORRESPONDENCE ADDRESS
U. Corrà, Laboratory for the Analysis of Cardio-respiratory Signals,
Divisione di Cardiologia Riabilitativa, Fondazione Salvatore Maugeri, IRCCS,
Istituto Scientifico di Veruno, Via per Revislate, 13, Veruno, Italy. Email:
ucorra@fsm.it
SOURCE
International Journal of Cardiology (2016) 203 (1067-1072). Date of
Publication: 15 Jan 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
Background The Metabolic Exercise test data combined with Cardiac and Kidney
Indexes (MECKI) score is a prognostic model to identify heart failure (HF)
patients at risk for cardiovascular mortality (CVM) and urgent heart
transplantation (uHT) based on 6 routine clinical parameters: hemoglobin,
sodium, kidney function by the Modification of Diet in Renal Disease (MDRD)
equation, left ventricle ejection fraction (LVEF), percentage of predicted
peak oxygen consumption (VO2) and VE/VCO2 slope. Objectives MECKI score must
be generalizable to be considered useful: therefore, its performance was
validated in a new sequence of HF patients. Methods Both the development
(MECKI-D) and the validation (MECKI-V) cohorts were composed of consecutive
HF patients with LVEF < 40% able to perform a symptom-limited
cardiopulmonary exercise testing. The CVM or uHT rates were analyzed at one,
two and three years in both cohorts: all patients with a censoring time
shorter than the scheduled follow-up were excluded, while those with events
occurring after 1, 2 and 3 years were considered as censored. Results
MECKI-D and MECKI-V consisted of 2009 and 992 patients, respectively.
MECKI-V patients had a higher LVEF, higher peak VO2 and lower VE/VCO2 slope,
higher prescription of beta-blockers and device therapy: after the 3-year
follow-up, CVM or uHT occurred in 206 (18%) MECKI-D and 44 (13%) MECKI-V
patients (p < 0.000), respectively. MECKI-V AUC values at one, two and three
years were 0.81 ± 0.04, 0.76 ± 0.04, and 0.80 ± 0.03, respectively, not
significantly different from MECKI-D. Conclusions MECKI score preserves its
predictive ability in a HF population at a lower risk.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (drug therapy)
amiodarone (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
digitalis (drug therapy)
hemoglobin (endogenous compound)
loop diuretic agent (drug therapy)
sodium (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular mortality
heart failure (drug therapy, diagnosis, drug therapy)
metabolic exercise test data combined with Cardiac And Kidney Indexes score
prognosis
risk assessment
scoring system
EMTREE MEDICAL INDEX TERMS
adult
anaerobic threshold
article
atrial fibrillation (drug therapy)
cardiopulmonary exercise test
cohort analysis
controlled study
criterion variable
defibrillator
female
follow up
heart left ventricle ejection fraction
heart transplantation
hemoglobin blood level
human
kidney function by the Modification of Diet in Renal Disease equation
lung gas exchange
major clinical study
male
New York Heart Association class
oxygen consumption
predictive value
priority journal
receiver operating characteristic
sodium blood level
validation study
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digitalis (8031-42-3, 8053-83-6)
hemoglobin (9008-02-0)
sodium (7440-23-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160013673
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2015.11.075
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 68
TITLE
Prognostic significance of exercise capacity and resting heart rate:
Comparison between atrial fibrillation and sinus rhythm
AUTHOR NAMES
Kato Y.
Suzuki S.
Kano H.
Semba H.
Matsuno S.
Takai H.
Otsuka T.
Uejima T.
Oikawa Y.
Nagashima K.
Kirigaya H.
Sagara K.
Kunihara T.
Yajima J.
Sawada H.
Aizawa T.
Yamashita T.
AUTHOR ADDRESSES
(Kato Y., kimuchi@nms.ac.jp; Suzuki S.; Kano H.; Semba H.; Matsuno S.; Takai
H.; Otsuka T.; Uejima T.; Oikawa Y.; Nagashima K.; Kirigaya H.; Sagara K.;
Kunihara T.; Yajima J.; Sawada H.; Aizawa T.; Yamashita T.) Department of
Cardiovascular Medicine, Cardiovascular Institute, Nishiazabu 3-2-19,
Minato-ku, Japan.
CORRESPONDENCE ADDRESS
Y. Kato, Department of Cardiovascular Medicine, Cardiovascular Institute,
Nishiazabu 3-2-19, Minato-ku, Japan. Email: kimuchi@nms.ac.jp
SOURCE
International Journal of Cardiology (2016) 203 (561-563). Date of
Publication: 15 Jan 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
oxygen consumption
peak oxygen consumption
resting heart rate
sinus rhythm
EMTREE MEDICAL INDEX TERMS
adult
article
cardiopulmonary exercise test
cohort analysis
controlled study
disease association
exercise
female
health impact assessment
heart failure
hospitalization
human
major clinical study
male
middle aged
outcome assessment
prediction
priority journal
prognosis
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20160016972
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2015.10.227
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 69
TITLE
Combined impact of healthy lifestyle factors on risk of atrial fibrillation:
Prospective study in men and women
AUTHOR NAMES
Larsson S.C.
Drca N.
Jensen-Urstad M.
Wolk A.
AUTHOR ADDRESSES
(Larsson S.C., susanna.larsson@ki.se; Wolk A.) Unit of Nutritional
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
Box 210, Stockholm, Sweden.
(Drca N.; Jensen-Urstad M.) Department of Cardiology, Karolinska University
Hospital, Karolinska Institutet, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental
Medicine, Karolinska Institutet, Box 210, Stockholm, Sweden. Email:
susanna.larsson@ki.se
SOURCE
International Journal of Cardiology (2016) 203 (46-49). Date of Publication:
15 Jan 2016
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
Background The combined impact of multiple lifestyle factors on risk of
atrial fibrillation (AF) remains unclear. We investigated the joint
association of four modifiable lifestyle factors on incidence of AF in a
prospective study of men and women. Methods The study cohort comprised 39
300 men in the Cohort of Swedish Men and 33 090 women in the Swedish
Mammography Cohort who were 45-83 years of age and free from atrial
fibrillation at baseline. Healthy lifestyle was defined as body mass index <
25 kg/m(2), regular exercise for ≥ 20 min/day, no or light-to-moderate
alcohol consumption (≤ 2 drinks/day for men and ≤ 1 drink/day for women),
and not smoking. Incident AF cases were identified through linkage with the
Swedish National Inpatient Register. Results During a mean follow-up of 10.9
years, AF occurred in 4028 men and 2539 women. Compared with men and women
with no healthy lifestyle factors, the multivariable relative risks (95%
confidence interval) of AF were 0.83 (0.65-1.07) for one, 0.74 (0.58-0.94)
for two, 0.62 (0.49-0.79) for three, and 0.50 (0.39-0.64) for four healthy
lifestyle factors (P for trend < 0.0001). The inverse association was
similar in men and women. Conclusions Four healthy lifestyle factors
combined were associated with a halving of the risk of AF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cardiovascular risk
lifestyle
EMTREE MEDICAL INDEX TERMS
adult
aged
alcohol consumption
article
body mass
cohort analysis
cycling
disease association
exercise
female
follow up
human
incidence
male
priority journal
prospective study
risk factor
sensitivity analysis
smoking
walking
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160016974
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2015.10.106
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 70
TITLE
Behavioral influences on cardiac arrhythmias
AUTHOR NAMES
Lampert R.
AUTHOR ADDRESSES
(Lampert R., rachel.lampert@yale.edu) Section of Cardiovascular Medicine,
Yale University School of Medicine, New Haven, United States.
CORRESPONDENCE ADDRESS
R. Lampert, Section of Cardiovascular Medicine, Yale University School of
Medicine, 789 Howard Avenue, Dana 319, New Haven, United States. Email:
rachel.lampert@yale.edu
SOURCE
Trends in Cardiovascular Medicine (2016) 26:1 (68-77). Date of Publication:
1 Jan 2016
ISSN
1873-2615 (electronic)
1050-1738
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
Stress can trigger both ventricular and atrial arrhythmias, as evidenced by
epidemiological, clinical, and laboratory studies, through its impact on
autonomic activity. Chronic stress also increases vulnerability to
arrhythmias. Novel therapies aimed at decreasing the psychological and
physiological response to stress may decrease arrhythmia frequency and
improve quality of life.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart arrhythmia (therapy)
EMTREE MEDICAL INDEX TERMS
acute stress
alternative medicine
atrial fibrillation (therapy)
chronic stress
cognitive therapy
disease predisposition
emotion
genetic disorder
heart electrophysiology
heart ventricle arrhythmia
human
priority journal
quality of life
review
sudden death
yoga
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015039575
FULL TEXT LINK
http://dx.doi.org/10.1016/j.tcm.2015.04.008
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 71
TITLE
The predictive role of renal function and systemic inflammation on the onset
of de novo atrial fibrillation after cardiac surgery
AUTHOR NAMES
Limite L.R.
Magnoni M.
Berteotti M.
Peretto G.
Durante A.
Cristell N.
Laricchia A.
Camici P.G.
Alfieri O.
Cianflone D.
AUTHOR ADDRESSES
(Limite L.R.; Magnoni M.; Berteotti M.; Peretto G.; Durante A.; Cristell N.;
Laricchia A.; Camici P.G.; Alfieri O.; Cianflone D.,
cianflone.domenico@hsr.it) Cardiovascular Department, San Raffaele
Scientific Institute, Italy.
CORRESPONDENCE ADDRESS
D. Cianflone, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, Italy.
Email: cianflone.domenico@hsr.it
SOURCE
European Journal of Preventive Cardiology (2016) 23:2 (206-213). Date of
Publication: 1 Jan 2016
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Background The association between postoperative atrial fibrillation (POAF)
and renal function was previously grounded in patients undergoing coronary
artery bypass grafting through unknown mechanisms. We aim to investigate the
association between renal function and POAF in a cohort composed mostly of
patients undergoing valve surgery and to explore the role of inflammation as
a pathogenic mechanism linking renal dysfunction and arrhythmogenesis.
Methods Altogether 444 patients who underwent cardiac surgery without
previous history of atrial fibrillation were analysed. Serum creatinine and
high sensitivity C-reactive protein (hs-CRP) concentrations were obtained at
baseline and on the 3rd, 8th and 15th postoperative day; estimated
glomerular filtration rate (EGFR) was calculated by the Modified Diet Renal
Disease (MDRD) formula. Patients were divided into three groups on the basis
of baseline EGFR. Results Overall, 173 (39%) patients developed POAF, 29.5%
in the group with normal EGFR (≥90 ml/min/1.73 m(2)), 43.3% among patients
with EGFR 60-90 ml/min/1.73 m(2) and 55.6% in the group with EGFR ‰60
ml/min/1.73 m. Patients developing POAF had lower EGFR on all the samples.
At baseline preoperatively hs-CRP levels did not differ in the two groups.
On multivariate analysis, age and EGFR were identified as independent
predictors of POAF. The risk of POAF progressively increased from mild
impairment (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.01-2.50) to
severe reduction of renal function (OR 2.35, 95% CI 1.25-4.48). Conclusions
Age and EGFR were identified as the strongest predictors of POAF in a
population largely composed of valve surgery patients. Renal function, even
from early stage, is independently associated with the increasing risk of
developing POAF.
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
creatinine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (epidemiology)
heart surgery
inflammation
kidney dysfunction
postoperative atrial fibrillation (epidemiology)
predictive value
EMTREE MEDICAL INDEX TERMS
adult
arrhythmogenesis
article
creatinine blood level
disease association
glomerulus filtration rate
human
major clinical study
prevalence
priority journal
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
creatinine (19230-81-0, 60-27-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160018345
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487314564896
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 72
TITLE
Adult height, nutrition, and population health
AUTHOR NAMES
Perkins J.M.
Subramanian S.V.
Smith G.D.
Özaltin E.
AUTHOR ADDRESSES
(Perkins J.M.; Subramanian S.V.) Harvard Center for Population and
Development Studies, Cambridge, United States.
(Perkins J.M.; Subramanian S.V.) Harvard T.H. Chan School of Public Health,
Boston, United States.
(Perkins J.M.; Subramanian S.V.) Massachusetts General Hospital Center for
Global Health, Boston, United States.
(Subramanian S.V.) Department of Social and Behavioral Sciences, Harvard
T.H. Chan School of Public Health, Boston, United States.
(Smith G.D.) MRC Integrative Epidemiology Unit, University of Bristol,
Bristol, United Kingdom.
(Özaltin E., eozaltin@worldbank.org) Health, Nutrition and Population Global
Practice, The World Bank, Washington, DC, United States.
CORRESPONDENCE ADDRESS
E. Özaltin, Health, Nutrition and Population Global Practice, World Bank,
1818 H St NW, MSN J-600, Washington, DC, United States. Email:
eozaltin@worldbank.org
SOURCE
Nutrition Reviews (2016) 74:3 (149-165). Date of Publication: 2016
ISSN
1753-4887 (electronic)
0029-6643
BOOK PUBLISHER
Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
In this review, the potential causes and consequences of adult height, a
measure of cumulative net nutrition, in modern populations are summarized.
The mechanisms linking adult height and health are examined, with a focus on
the role of potential confounders. Evidence across studies indicates that
short adult height (reflecting growth retardation) in low- and middle-income
countries is driven by environmental conditions, especially net nutrition
during early years. Some of the associations of height with health and
social outcomes potentially reflect the association between these
environmental factors and such outcomes. These conditions are manifested in
the substantial differences in adult height that exist between and within
countries and over time. This review suggests that adult height is a useful
marker of variation in cumulative net nutrition, biological deprivation, and
standard of living between and within populations and should be routinely
measured. Linkages between adult height and health, within and across
generations, suggest that adult height may be a potential tool for
monitoring health conditions and that programs focused on offspring outcomes
may consider maternal height as a potentially important influence.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
body height
health status
nutrition
EMTREE MEDICAL INDEX TERMS
adolescence
adult
aorta aneurysm
article
atrial fibrillation
body growth
body mass
cardiovascular disease
catch up growth
economic development
educational status
environmental factor
growth disorder
growth retardation
growth, development and aging
heritability
human
income
infant mortality
infection
inflammatory disease
ischemic heart disease
malnutrition
morbidity
mortality
occupation
pregnancy
progeny
protein intake
puberty
respiratory tract infection
sex difference
social status
venous thromboembolism
vitamin intake
wellbeing
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Developmental Biology and Teratology (21)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160329979
FULL TEXT LINK
http://dx.doi.org/10.1093/nutrit/nuv105
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 73
TITLE
Measuring appetite with the simplified nutritional appetite questionnaire
identifies hospitalised older people at risk of worse health outcomes
AUTHOR NAMES
Pilgrim A.L.
Baylis D.
Jameson K.A.
Cooper C.
Sayer A.A.
Robinson S.M.
Roberts H.C.
AUTHOR ADDRESSES
(Pilgrim A.L., alp@mrc.soton.ac.uk; Baylis D.; Sayer A.A.; Robinson S.M.;
Roberts H.C.) National Institute for Health Research Southampton Biomedical
Research Centre, University of Southampton and University Hospital
Southampton NHS Foundation Trust, Southampton, United Kingdom.
(Pilgrim A.L., alp@mrc.soton.ac.uk; Jameson K.A.; Cooper C.; Sayer A.A.;
Robinson S.M.; Roberts H.C.) MRC Lifecourse Epidemiology Unit, Southampton,
United Kingdom.
(Sayer A.A.; Roberts H.C.) Academic Geriatric Medicine, University of
Southampton, Southampton, United Kingdom.
(Sayer A.A.; Roberts H.C.) National Institute for Health Research
Collaboration for Leadership in Applied Health Research and Care: Wessex,
Southampton, United Kingdom.
CORRESPONDENCE ADDRESS
A.L. Pilgrim, National Institute for Health Research Southampton Biomedical
Research Centre, University of Southampton and University Hospital
Southampton NHS Foundation Trust, Southampton, United Kingdom. Email:
alp@mrc.soton.ac.uk
SOURCE
Journal of Nutrition, Health and Aging (2016) 20:1 (3-7). Date of
Publication: 1 Jan 2016
ISSN
1760-4788 (electronic)
1279-7707
BOOK PUBLISHER
Springer-Verlag France, 22, Rue de Palestro, Paris, France.
york@springer-paris.fr
ABSTRACT
Objectives: Poor appetite is commonly reported by older people but is rarely
measured. The Simplified Nutritional Appetite Questionnaire (SNAQ) was
validated to predict weight loss in community dwelling older adults but has
been little used in hospitals. We evaluated it in older women on admission
to hospital and examined associations with healthcare outcomes. Design:
Longitudinal observational with followup at six months. Setting: Female
acute Medicine for Older People wards at a University hospital in England.
Participants: 179 female inpatients. Measurements: Age, weight, Body Mass
Index (BMI), grip strength, SNAQ, Barthel Index Score, Mini Mental State
Examination (MMSE), Geriatric Depression Scale: Short Form (GDSSF),
Malnutrition Universal Screening Tool (MUST), category of domicile and
receipt of care were measured soon after admission and repeated at six month
follow-up. The length of hospital stay (LOS), hospital acquired infection,
readmissions and deaths by follow-up were recorded. Results: 179 female
participants mean age 87 (SD 4.7) years were recruited. 42% of participants
had a low SNAQ score (<14, indicating poor appetite). A low SNAQ score was
associated with an increased risk of hospital acquired infection (OR 3.53;
95% CI: 1.48, 8.41; p=0.004) and with risk of death (HR 2.29; 95% CI: 1.12,
4.68; p = 0.023) by follow-up. Conclusion: Poor appetite was common among
the older hospitalised women studied, and was associated with higher risk of
poor healthcare outcomes.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
appetite disorder
clinical assessment tool
geriatric nutrition
geriatric patient
hospital patient
nutritional assessment
poor appetite
Simplified Nutritional Appetite Questionnaire
EMTREE MEDICAL INDEX TERMS
aged
anemia
article
atrial fibrillation
Barthel index
body mass
body weight
collapse
comorbidity
daily life activity
disease association
dyspnea
falling
female
follow up
Geriatric Depression Scale
grip strength
heart failure
home care
hospital admission
hospital infection
hospital readmission
human
infection risk
kidney failure
length of stay
longitudinal study
major clinical study
Malnutrition Universal Screening Tool
mortality
observational study
outcome assessment
priority journal
questionnaire
thorax pain
urinary tract infection
very elderly
walking difficulty
weight reduction
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160028171
FULL TEXT LINK
http://dx.doi.org/10.1007/s12603-016-0668-3
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 74
TITLE
Burden of stroke in women
AUTHOR NAMES
Lundberg G.P.
Volgman A.S.
AUTHOR ADDRESSES
(Lundberg G.P., Gina.Lundberg@Emory.edu) Emory Women's Heart Center,
Atlanta, United States.
(Lundberg G.P., Gina.Lundberg@Emory.edu) Emory University School of
Medicine, Atlanta, United States.
(Lundberg G.P., Gina.Lundberg@Emory.edu) Emory Heart and Vascular Center
East Cobb, Marietta, United States.
(Volgman A.S.) Rush College of Medicine, Rush University Medical Center,
Chicago, United States.
(Volgman A.S.) Rush Heart Center for Women, Rush University Medical Center,
Chicago, United States.
CORRESPONDENCE ADDRESS
G.P. Lundberg, Emory Heart and Vascular East Cobb, 137 Johnson Ferry Road,
Suite 1200, Marietta, United States. Email: Gina.Lundberg@Emory.edu
SOURCE
Trends in Cardiovascular Medicine (2016) 26:1 (81-88). Date of Publication:
1 Jan 2016
ISSN
1873-2615 (electronic)
1050-1738
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
Stroke is the fifth cause of death in the United States and the first cause
of disability. While reductions in stroke mortality have occurred, stroke
remains a significant burden in women. In addition to traditional
cardiovascular risk factors, there are specific risk factors in women that
need to be addressed to further reduce deaths in women from stroke. Atrial
fibrillation is common in women and needs proper evaluation for
anticoagulation for risk reduction. Stroke in women remains a serious cause
of preventable deaths, disability, and cost. Implementation of the new
guidelines for stroke prevention in women is critical for reducing the
burden of stroke in women.
EMTREE DRUG INDEX TERMS
apixaban
dabigatran
high density lipoprotein cholesterol (endogenous compound)
rivaroxaban
tissue plasminogen activator (drug therapy)
triacylglycerol (endogenous compound)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, disease management, drug therapy,
epidemiology, prevention)
EMTREE MEDICAL INDEX TERMS
abdominal obesity
age
alcohol consumption
anticoagulation
aphasia
arm weakness
atrial fibrillation
awareness
Black person
body mass
brain hemorrhage
brain ischemia
cardiovascular mortality
cardiovascular risk
central venous thrombosis
CHADS2 score
cognitive defect
diabetes mellitus
diet
disability
dysarthria
dyslipidemia
educational status
face disorder
face drooping
female
fibrinolytic therapy
geographic distribution
health care cost
human
hypertension
insulin resistance
lifestyle modification
maternal hypertension
metabolic syndrome X
migraine with aura
oral contraceptive use
physical activity
physical inactivity
postmenopause
practice guideline
preeclampsia
pregnancy
pregnancy diabetes mellitus
priority journal
race difference
randomized controlled trial (topic)
review
risk reduction
sex difference
smoking
smoking cessation
speech disorder
subarachnoid hemorrhage
vein thrombosis
waist circumference
weight control
word recognition
CAS REGISTRY NUMBERS
apixaban (503612-47-3)
rivaroxaban (366789-02-8)
tissue plasminogen activator (105913-11-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015091967
FULL TEXT LINK
http://dx.doi.org/10.1016/j.tcm.2015.04.010
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 75
TITLE
Soluble urokinase plasminogen activator receptor and incidence of venous
thromboembolism
AUTHOR NAMES
Engström G.
Zöller B.
Svensson P.J.
Melander O.
Persson M.
AUTHOR ADDRESSES
(Engström G., Gunnar.Engstrom@med.lu.se; Svensson P.J.; Melander O.; Persson
M.) Department of Clinical Sciences, Lund University, Malmö, Sweden.
(Zöller B.) Center for Primary Health Care Research, Lund University/Region
Skåne, Sweden.
CORRESPONDENCE ADDRESS
G. Engström, Lund University, Department of Clinical Science, CRC 60:13, Jan
Waldenströms Gata 35, Malmö, Sweden. Email: Gunnar.Engstrom@med.lu.se
SOURCE
Thrombosis and Haemostasis (2016) 115:3 (657-662). Date of Publication: 2016
ISSN
0340-6245
BOOK PUBLISHER
Schattauer GmbH, info@schattauer.de
ABSTRACT
Raised plasma levels of the soluble urokinase plasminogen activator receptor
(suPAR) have been associated with increased incidence of cardiovascular
diseases. Whether suPAR is associated with venous thromboembolism (VTE) is
largely unknown. The purpose of the present study was to investigate the
relationship between suPAR and incidence of VTE in a cohort study. suPAR was
measured in 5,203 subjects (aged 46–68 years, 58 % women) from the general
population, who participated in the Malmö Diet and Cancer (MDC) study
between 1991 and 1994. Incident cases of VTE were identified from the
Swedish patient register during a mean follow-up of 15.7 years. Of 5,203
subjects with measurements of suPAR, 239 had VTE during follow-up (127
venous thrombosis, 86 lung embolism, 26 both). Incidence of VTE was
significantly higher in subjects with suPAR levels in the top quartile.
Adjusted for age and sex, the HR (4(th) vs 1(st) quartile) was 1.74 (95 %CI:
1.2–2.6, p for trend=0.003). After adjustments for risk factors, the HR was
1.66 (95 %CI: 1.1–2.5, p for trend=0.016). High level of suPAR was a risk
indicator for incidence of VTE in this populationbased cohort study. The
causal relationships between suPAR and VTE remain to be explored.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
urokinase receptor (endogenous compound)
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
venous thromboembolism
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
blood pressure
body height
body mass
body weight
controlled study
enzyme linked immunosorbent assay
female
gene mutation
glucose blood level
human
incidence
major clinical study
male
middle aged
priority journal
questionnaire
risk factor
smoking
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
Hematology (25)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160342756
FULL TEXT LINK
http://dx.doi.org/10.1160/TH15-06-0511
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 76
TITLE
NOAC or warfarin for atrial fibrillation: Does time in therapeutic range
matter?
AUTHOR NAMES
Merinopoulos I.
Venables P.
Chalmers I.
Vassiliou V.
AUTHOR ADDRESSES
(Merinopoulos I., i_merinopoulos@hotmail.com; Venables P.) Department of
Cardiology, Ipswich Hospital NHS Trust, United Kingdom.
(Chalmers I.) Department of Haematology, Ipswich Hospital NHS Trust, United
Kingdom.
(Vassiliou V.) National Heart and Lung Institute, Imperial College, Royal
Brompton Campus, London, United Kingdom.
CORRESPONDENCE ADDRESS
I. Merinopoulos, The Department of Cardiology, Ipswich Hospital, Ipswich,
United Kingdom. Email: i_merinopoulos@hotmail.com
SOURCE
Recent Advances in Cardiovascular Drug Discovery (2015) 10:1 (60-64). Date
of Publication: 1 Jan 2015
ISSN
2212-3962 (electronic)
1574-8901
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Atrial fibrillation (AF) is the commonest cardiac arrhythmia currently
affecting 1-2% of the general population, with stroke being one of its most
fearsome complications. Dose-adjusted warfarin is an established treatment
for reduction of thromboembolic risk but mandates dietary restrictions and
need for routine blood monitoring. Novel oral anticoagulants (Dabigatran -
patent: US20110082299A1, manufactured by Boehringer Ingelheim; Rivaroxaban -
patent: US20150175590A1, manufactured by Bayer; Apixaban - patent:
US20140335178A1, manufactured jointly by Pfizer and Bristol-Myers Squibb;
Edoxaban - patent: WO2013026553A1, manufactured by Daiichi Sankyo) have
recently been introduced that might provide at least equal reduction in
thromboembolic risk to patients; negating the need for dietary restrictions
and routine blood tests. The most recent National Institute of Health and
Care Excellence, UK guidelines from August 2014 suggest consideration of one
of the novel oral anticoagulants if the time in therapeutic range is less
than 65%. In this study, the evidence for four novel oral anticoagulants is
reviewed and the anticoagulation success with warfarin with atrial
fibrillation and mechanical heart valves assessed in a large UK District
General Hospital. Fifty-eight patients were identified with mechanical heart
valve and 2737 patients with atrial fibrillation. Patients with atrial
fibrillation had a significantly better TTR when compared with the patients
included in the NOAC trials. Our results were similar with the Auricula
registry. However, 25% of patients had TTR<65% and they would need to be
considered for NOACs. Our data suggest that the degree of benefit seen in
the NOAC trials might not be expected in our cohort of patients with atrial
fibrillation. Interestingly, our patients with atrial fibrillation had a
much better mean TTR of 76.4% and required less INR tests (12/year) compared
to patients with mechanical heart valve who had a mean TTR of 61.4% and
required more INR tests (26/year).
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
apixaban (clinical trial, drug therapy, oral drug administration)
dabigatran etexilate (clinical trial, drug therapy, oral drug
administration)
edoxaban (clinical trial, drug therapy, oral drug administration)
rivaroxaban (clinical trial, drug therapy, oral drug administration)
warfarin (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
atrial fibrillation (drug therapy, drug therapy, therapy)
pharmacological parameters
therapeutic range
time
EMTREE MEDICAL INDEX TERMS
article
cardiac patient
diet restriction
general hospital
human
international normalized ratio
mechanical heart valve
patent
phase 3 clinical trial (topic)
practice guideline
priority journal
randomized controlled trial (topic)
register
risk reduction
thromboembolism (drug therapy, prevention)
DRUG MANUFACTURERS
Bayer
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi Sankyo
Pfizer
CAS REGISTRY NUMBERS
apixaban (503612-47-3)
edoxaban (480449-70-5, 480449-71-6, 912273-65-5)
rivaroxaban (366789-02-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160384262
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 77
TITLE
Dietary approaches to stop hypertension diet and incidence of stroke:
Results from 2 prospective cohorts
AUTHOR NAMES
Larsson S.C.
Wallin A.
Wolk A.
AUTHOR ADDRESSES
(Larsson S.C., susanna.larsson@ki.se; Wallin A.; Wolk A.) Unit of
Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden. Email:
susanna.larsson@ki.se
SOURCE
Stroke (2016) 47:4 (986-990). Date of Publication: 2016
ISSN
1524-4628 (electronic)
0039-2499
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Background and Purpose-High adherence to the Dietary Approaches to Stop
Hypertension (DASH) diet is associated with lower risk of hypertension, the
major risk factor for stroke. We examined whether adherence to the DASH diet
is inversely associated with the incidence of stroke. Methods-The study
population comprised 74 404 men and women (45-83 years of age), without
stroke at baseline, from the Cohort of Swedish Men and the Swedish
Mammography Cohort. Diet was assessed with a food-frequency questionnaire. A
modified DASH diet score was created based on consumption of vegetables,
fruits, legumes and nuts, whole grains, low-fat dairy, red meat and
processed meat, and sweetened beverages. Stroke cases were identified
through linkage to the Swedish National Patient and Cause of Death
Registers. Relative risks and 95% confidence intervals were estimated using
Cox proportional hazards regression model. Results-During 882 727
person-years (mean, 11.9 years) of follow-up, 3896 ischemic strokes, 560
intracerebral hemorrhages, and 176 subarachnoid hemorrhages were
ascertained. The modified DASH diet score was statistically significantly
inversely associated with the risk of ischemic stroke (P for trend=0.002),
with a multivariable relative risk of 0.86 (95% confidence interval,
0.78-0.94) for the highest versus the lowest quartile of the score. The
modified DASH diet score was nonsignificantly inversely associated with
intracerebral hemorrhage (corresponding relative risk=0.81; 95% confidence
interval, 0.63-1.05) but was not associated with subarachnoid hemorrhage.
Conclusions-These findings indicate that high adherence to the DASH diet is
associated with a reduced risk of ischemic stroke. Clinical Trial
Registration-URL: http://www.clinicaltrials.gov. Unique identifiers:
NCT01127698 and NCT01127711 for the Swedish Mammography Cohort and the
Cohort of Swedish Men, respectively.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
diet therapy
dietary approaches to stop hypertension diet
hypertension
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
brain hemorrhage
brain ischemia
cohort analysis
diabetes mellitus
female
follow up
food intake
human
hypercholesterolemia
major clinical study
male
patient compliance
population research
priority journal
prospective study
risk assessment
risk factor
risk reduction
smoking
subarachnoid hemorrhage
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Clinical and Experimental Biochemistry (29)
Internal Medicine (6)
Neurology and Neurosurgery (8)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT01127698)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160126582
FULL TEXT LINK
http://dx.doi.org/10.1161/STROKEAHA.116.012675
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 78
TITLE
Physician and Patient Preferences for Nonvalvular Atrial Fibrillation
Therapies
AUTHOR NAMES
Shafrin J.
Bruno A.
MacEwan J.P.
Campinha-Bacote A.
Trocio J.
Shah M.
Tan W.
Romley J.A.
AUTHOR ADDRESSES
(Shafrin J., Jason.shafrin@precisionhealtheconomics.com; MacEwan J.P.;
Campinha-Bacote A.) Precision Health Economics, Los Angeles, CA, USA
(Bruno A.; Shah M.) Bristol-Myers Squibb, Plainsboro, NJ, USA
(Trocio J.; Tan W.) Pfizer, Inc., New York, NY, USA
(Romley J.A.) University of Southern California, Los Angeles, CA, USA
CORRESPONDENCE ADDRESS
J. Shafrin, 11100 Santa Monica Boulevard, Suite 500, Los Angeles, CA 90025
Email: Jason.shafrin@precisionhealtheconomics.com
SOURCE
Value in Health (2016). Date of Publication: 2016
ISSN
1524-4733 (electronic)
1098-3015
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
Objectives: The objective of this study was to compare patient and physician
preferences for different antithrombotic therapies used to treat nonvalvular
atrial fibrillation (NVAF). Methods: Patients diagnosed with NVAF and
physicians treating such patients completed 12 discrete choice questions
comparing NVAF therapies that varied across five attributes: stroke risk,
major bleeding risk, convenience (no regular blood testing/dietary
restrictions), dosing frequency, and patients' out-of-pocket cost. We used a
logistic regression to estimate the willingness-to-pay (WTP) value for each
attribute. Results: The 200 physicians surveyed were willing to trade off
$38 (95% confidence interval [CI] $22 to $54] in monthly out-of-pocket cost
for a 1% (absolute) decrease in stroke risk, $14 (95% CI $8 to $21) for a 1%
decrease in major bleeding risk, and $34 (95% CI $9 to $60) for more
convenience. The WTP value among 201 patients surveyed was $30 (95% CI $18
to $42) for reduced stroke risk, $16 (95% CI $9 to $24) for reduced bleeding
risk, and -$52 (95% CI -$96 to -6) for convenience. The WTP value for
convenience among patients using warfarin was $9 (95% CI $1 to $18) for more
convenience, whereas patients not currently on warfarin had a WTP value of
-$90 (95% CI -$290 to -$79). Both physicians' and patients' WTP value for
once-daily dosing was not significantly different from zero. On the basis of
survey results, 85.0% of the physicians preferred novel oral anticoagulants
(NOACs) to warfarin. NOACs (73.0%) were preferred among patients using
warfarin, but warfarin (78.2%) was preferred among patients not currently
using warfarin. Among NOACs, both patients and physicians preferred
apixaban. Conclusions: Both physicians and patients currently using warfarin
preferred NOACs to warfarin. Patients not currently using warfarin preferred
warfarin over NOACs because of an apparent preference for regular blood
testing/dietary restrictions.
EMTREE DRUG INDEX TERMS
apixaban
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
patient preference
physician
EMTREE MEDICAL INDEX TERMS
bleeding
cerebrovascular accident
clinical trial
confidence interval
controlled study
diagnosis
diet restriction
doctor patient relation
drug dosage form
human
logistic regression analysis
major clinical study
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160227631
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jval.2016.01.001
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 79
TITLE
Stroke of undetermined cause: Workup and secondary prevention
AUTHOR NAMES
Weimar C.
AUTHOR ADDRESSES
(Weimar C., christian.weimar@uk-essen.de) Department of Neurology and Stroke
Center, University Duisburg-Essen, Hufelandstr. 55, Essen, Germany.
CORRESPONDENCE ADDRESS
C. Weimar, Department of Neurology and Stroke Center, University
Duisburg-Essen, Hufelandstr. 55, Essen, Germany. Email:
christian.weimar@uk-essen.de
SOURCE
Current Opinion in Neurology (2016) 29:1 (4-8). Date of Publication: 2016
ISSN
1473-6551 (electronic)
1350-7540
BOOK PUBLISHER
Lippincott Williams and Wilkins, agents@lww.com
ABSTRACT
Purpose of review The purpose of this review is to update the reader on
current concepts of workup and secondary prevention in patients with stroke
of undetermined cause. Recent findings Clinical research in patients with
cryptogenic stroke has been hampered by the lack of standardized, widely
accepted diagnostic criteria. The new definition of Embolic stroke of
undetermined etiology postulates an embolic mechanism of ischemic stroke. It
is based on the exclusion of lacunar infarction by brain imaging, arterial
stenosis more than 50% or dissection of the respective brain-supplying
artery by computed tomography/magnetic resonance-angiography or ultrasound,
atrial fibrillation by at least 24 h EKG monitoring, as well as some rare
etiologies such as vasculitis, drug abuse, or coagulopathies. However, it
still comprises many patients with atherosclerotic etiologies (but <50%
stenosis) as well as covert paroxysmal atrial fibrillation which can be
detected by repeated Holter EKG or an implantable device. A patent foramen
ovale can be found in up to 58% of cryptogenic stroke patients, but
causality in an individual patient remains uncertain and can only be
statistically inferred. Summary The new concept of embolic stroke of
undetermined etiology enabled three ongoing randomized controlled trials
which investigate oral anticoagulation versus aspirin for secondary stroke
prevention.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
diagnostic procedure
secondary prevention
EMTREE MEDICAL INDEX TERMS
anticoagulant therapy
atrial fibrillation
blood pressure regulation
brain ischemia
computed tomographic angiography
computer assisted tomography
Doppler echography
echocardiography
exercise
human
Mediterranean diet
nuclear magnetic resonance imaging
paradoxical embolism
prognosis
review
smoking cessation
transesophageal echocardiography
transient ischemic attack
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151016713
FULL TEXT LINK
http://dx.doi.org/10.1097/WCO.0000000000000280
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 80
TITLE
Is dabigatran as effective as warfarin on cardiac thrombus in a patient with
atrial fibrillation? A challenging question
AUTHOR NAMES
Sunbul M.
Cincin A.
Mammadov C.
Mutlu B.
AUTHOR ADDRESSES
(Sunbul M., drsunbul@yahoo.com.tr; Cincin A.; Mammadov C.; Mutlu B.)
Department of Cardiology, Faculty of Medicine, Marmara University, Fevzi
CakmakM., Mimar Sinan C., No: 41, Pendik, Istanbul, Turkey.
CORRESPONDENCE ADDRESS
M. Sunbul, Department of Cardiology, Faculty of Medicine, Marmara
University, Fevzi CakmakM., Mimar Sinan C., No: 41, Pendik, Istanbul,
Turkey. Email: drsunbul@yahoo.com.tr
SOURCE
American Journal of Therapeutics (2016) 23:3 (e974-e976). Date of
Publication: 2016
ISSN
1536-3686 (electronic)
1075-2765
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Atrial fibrillation (AF) is an important risk factor for cardioembolic
stroke. Warfarin is an effective treatment in reducing the risk of
cardioembolic stroke in patients with AF. New anticoagulants have been
widely using for stroke prophylaxis in patients with nonvalvular AF.
Previous studies have suggested that thrombolytic therapy is effective
treatment choice in patients with pulmonary embolisms. Warfarin therapy is
also effective on prevention or treatment of cardiac thrombus in patients
with AF. However, there are no evidence-based data on treatment of cardiac
thrombus with new oral anticoagulants in patients with AF. In our case
report, we reported an AF patient with cardiac thrombus and pulmonary
embolism under dabigatran therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dabigatran (drug comparison, drug therapy)
warfarin (drug comparison, drug therapy)
EMTREE DRUG INDEX TERMS
alanine aminotransferase (endogenous compound)
aspartate aminotransferase (endogenous compound)
carvedilol
creatinine (endogenous compound)
D dimer (endogenous compound)
digoxin
furosemide
hemoglobin (endogenous compound)
heparin (drug therapy)
ramipril
tissue plasminogen activator (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis)
heart atrium thrombosis (drug therapy, diagnosis, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
article
case report
computed tomographic angiography
coronary artery bypass graft
Doppler ultrasonography
drug efficacy
dyspnea
echocardiography
exercise
fatigue
fibrinolytic therapy
heart rate
heart right atrium
heart surgery
human
international normalized ratio
leukocyte count
low drug dose
lung angiography
lung embolism (diagnosis, drug therapy)
male
middle aged
mitral valve disease (diagnosis)
mitral valve regurgitation (diagnosis)
priority journal
surgical risk
tachycardia
three dimensional imaging
transesophageal echocardiography
transthoracic echocardiography
CAS REGISTRY NUMBERS
alanine aminotransferase (9000-86-6, 9014-30-6)
aspartate aminotransferase (9000-97-9)
carvedilol (72956-09-3)
creatinine (19230-81-0, 60-27-5)
digoxin (20830-75-5, 57285-89-9)
furosemide (54-31-9)
hemoglobin (9008-02-0)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
ramipril (87333-19-5)
tissue plasminogen activator (105913-11-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Radiology (14)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014933224
FULL TEXT LINK
http://dx.doi.org/10.1097/MJT.0000000000000129
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 81
TITLE
Exercise and Arrhythmias: A Double-Edged Sword
AUTHOR NAMES
Manolis A.S.
Manolis A.A.
AUTHOR ADDRESSES
(Manolis A.S., asm@otenet.gr; Manolis A.A.) Third Department of Cardiology
Athens University School of Medicine Athens Greece
CORRESPONDENCE ADDRESS
A.S. Manolis, Third Department of Cardiology, Athens University School of
Medicine, Vas.So?as 114, Athens 115 27, Greece Email: asm@otenet.gr
SOURCE
PACE - Pacing and Clinical Electrophysiology (2016). Date of Publication:
2016
ISSN
1540-8159 (electronic)
0147-8389
BOOK PUBLISHER
Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
Ample evidence indicates that moderate regular exercise is beneficial for
both normal individuals and patients with cardiovascular (CV) disease.
However, intense and strenuous exercise in individuals with evident or
occult underlying CV abnormalities may have adverse effects with provocation
and exacerbation of arrhythmias that may lead to life-threatening
situations. Both of these aspects of exercise-induced effects are herein
reviewed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation
cardiomyopathy
exercise
heart ventricle extrasystole
heart ventricle tachycardia
screening
sudden cardiac death
EMTREE MEDICAL INDEX TERMS
adverse drug reaction
cardiovascular malformation
clinical study
disease exacerbation
human
normal human
provocation
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160411121
FULL TEXT LINK
http://dx.doi.org/10.1111/pace.12879
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 82
TITLE
Safety of symptom-limited exercise testing in a big cohort of a modern ICD
population
AUTHOR NAMES
Voss F.
Schueler M.
Lauterbach M.
Bauer A.
Katus H.A.
Becker R.
AUTHOR ADDRESSES
(Voss F., f.voss@bk-trier.de; Lauterbach M.) Department of Cardiology,
Krankenhaus der Barmherzigen Brueder Trier, Nordallee 1, Trier, Germany.
(Bauer A.) Department of Cardiology, Diakonie-Klinikum Schwaebisch Hall,
Diakoniestr. 10, Schwaebisch Hall, Germany.
(Schueler M.; Katus H.A.; Becker R.) Department of Cardiology, University of
Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.
CORRESPONDENCE ADDRESS
F. Voss, Department of Cardiology, Krankenhaus der Barmherzigen Brueder
Trier, Nordallee 1, Trier, Germany. Email: f.voss@bk-trier.de
SOURCE
Clinical Research in Cardiology (2016) 105:1 (53-58). Date of Publication: 1
Jan 2016
ISSN
1861-0692 (electronic)
1861-0684
BOOK PUBLISHER
Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
Background: Exercise may predispose to ventricular arrhythmias especially in
patients with congestive heart failure. As therapy with implanted
cardioverter-defibrillators (ICDs) has become standard medical care, there
is an emerging number of exercise tests that need to be performed in
patients with ICDs. In contrast, little is known about the safety of
symptom-limited exercise testing in these patients. Methods and results: 400
ICD patients performed symptom-limited exercise treadmill testing. 200
patients performed a ramp protocol with an initial workload of 0 W increased
by 15 W every minute. Another 200 ICD patients did a slightly modified ramp
protocol with again an initial workload of 0 W but with an increased
capacity of 15 W every 2 min. The study population consists mainly of
patients with ischemic (63 %) and non-ischemic (34 %) heart disease. Atrial
fibrillation was present in 16 % of the subjects. The mean ejection fraction
was 28 ± 8, and 78 % of the patients had an ejection fraction below 30 %. In
this cohort of patients, no sustained ventricular arrhythmias and no deaths
occurred during or after exercise testing. No inappropriate shock delivery
was observed. The modified ramp protocol resulted in a prolonged exercise
time with equal exercise capacity but does not result in an enhanced
susceptibility for ventricular arrhythmias. Conclusions: Symptom-limited
exercise treadmill testing in heart failure patients with ICDs is a safe
procedure. The use of a ramp protocol is sufficient in terms of safety and
is easy to perform in general practice. The exercise duration in heart
failure patients with ICDs does not predict serious adverse events.
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist
antiarrhythmic agent
beta adrenergic receptor blocking agent
brain natriuretic peptide (endogenous compound)
dipeptidyl carboxypeptidase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiac patient
exercise test
implantable cardioverter defibrillator
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
cardiac resynchronization therapy
congestive cardiomyopathy
coronary artery disease
dyspnea (complication)
electrocardiography
electrophysiology
female
heart ejection fraction
heart failure
heart rate
heart ventricle arrhythmia
heart ventricle extrasystole (complication)
human
ischemic heart disease
major clinical study
male
middle aged
New York Heart Association class
QRS interval
treadmill exercise
workload
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015168349
FULL TEXT LINK
http://dx.doi.org/10.1007/s00392-015-0885-5
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 83
TITLE
Exercise in patients with chronic atrial fibrillation
ORIGINAL (NON-ENGLISH) TITLE
Inspanning bij chronisch atriumfibrilleren
AUTHOR NAMES
Zutt J.
Smelt A.
AUTHOR ADDRESSES
(Zutt J.; Smelt A., a.f.h.smelt@lumc.nl) afdeling Public Health en
Eerstelijnsgeneeskunde, LUMC, 9600, Leiden, Netherlands.
CORRESPONDENCE ADDRESS
A. Smelt, afdeling Public Health en Eerstelijnsgeneeskunde, LUMC,
Netherlands.
SOURCE
Huisarts en Wetenschap (2016) 59:1 (38). Date of Publication: 2016
ISSN
1876-5912 (electronic)
0018-7070
BOOK PUBLISHER
Bohn Stafleu van Loghum, e.smid@ntvg.nl
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chronic atrial fibrillation
exercise
EMTREE MEDICAL INDEX TERMS
article
human
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English, Dutch
EMBASE ACCESSION NUMBER
20160046240
FULL TEXT LINK
http://dx.doi.org/10.1007/s12445-016-0026-z
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 84
TITLE
Differential Association of Exercise Intensity With Risk of Atrial
Fibrillation in Men and Women: Evidence from a Meta-Analysis
AUTHOR NAMES
Mohanty S.
Mohanty P.
Tamaki M.
Natale V.
Gianni C.
Trivedi C.
Gokoglan Y.
Di Biase L.
Natale A.
AUTHOR ADDRESSES
(Mohanty S.; Mohanty P.; Gianni C.; Trivedi C.; Gokoglan Y.; Di Biase L.;
Natale A., dr.natale@gmail.com) Texas Cardiac Arrhythmia Institute St.
David's Medical Center Austin, Texas
(Tamaki M.) Texas Cardiac Arrhythmia Research Foundation Austin, Texas
(Natale V.) Department of Natural Science University of Texas Austin, Texas
(Gianni C.) University of Milan Milan Italy
(Gokoglan Y.) Department of Cardiology Gülhane Military Academy of Medicine
Ankara Turkey
(Di Biase L.) Albert Einstein College of Medicine Montefiore Hospital Bronx,
New York
(Natale A., dr.natale@gmail.com) California Pacific Medical Center San
Francisco, California USA
(Natale A., dr.natale@gmail.com) Interventional Electrophysiology Scripps
Clinic San Diego, California USA
(Natale A., dr.natale@gmail.com) Department of Internal Medicine Dell
Medical School Austin, Texas USA
(Natale A., dr.natale@gmail.com) Division of Cardiology Stanford University
Palo Alto, California USA
CORRESPONDENCE ADDRESS
A. Natale, Texas Cardiac Arrhythmia Institute, St David's Medical Center,
3000 N. I-35, Suite 720; Austin, TX 78705, USA Email: dr.natale@gmail.com
SOURCE
Journal of Cardiovascular Electrophysiology (2016). Date of Publication:
2016
ISSN
1540-8167 (electronic)
1045-3873
BOOK PUBLISHER
Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
Gender-Specific Link of Exercise Intensity With AF: Background: Despite
widespread interest and extensive research, the association between
different levels of physical activity (PA) and risk of atrial fibrillation
(AF) is still not clearly defined. Therefore, we systematically evaluated
and summarized the evidences regarding association of different intensity of
PA with the risk of AF in this meta-analysis. Methods and Results: An
extensive literature search was performed on databases for studies showing
association of exercise with AF risk. Twenty-two studies were identified
that included 656,750 subjects. Meta-analytic estimates were derived using
random-effects models and pooled odds ratio estimates were obtained.
Potential sources of heterogeneity were examined in sensitivity analyses,
and publication biases were estimated. Pooled analysis of 7 studies with
93,995 participants reported high risk of incident AF with sedentary
lifestyle (pooled OR 2.47 [95% CI 1.25-3.7], P = 0.005). In 3 trials,
149,048 women involved in moderate PA were 8.6% less likely to develop AF
compared to women with sedentary life (OR 0.91 [95% CI 0.78-0.97], P =
0.002). Women performing intense exercise were found to have 28% lower risk
of AF (OR 0.72 [95% CI 0.57-0.88], P < 0.001). The overall pooled estimate
indicated a protective impact of moderate PA in men (pooled OR 0.8133 [95%
CI 0.26-1.004], P = 0.06) whereas vigorous PA was associated with a
significantly increased AF risk (pooled OR 3.30 [1.97-4.63], P = 0.0002).
Conclusion: Sedentary lifestyle significantly increases and moderate amount
of physical activity reduces the risk of AF in both men and women. However,
intense exercise has a gender-specific association with AF risk.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise intensity
gender
physical activity
EMTREE MEDICAL INDEX TERMS
controlled study
data base
female
human
male
meta analysis
model
odds ratio
publication
sitting
systematic review
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160523749
FULL TEXT LINK
http://dx.doi.org/10.1111/jce.13023
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 85
TITLE
Are there deleterious cardiac effects of acute and chronic endurance
exercise?
AUTHOR NAMES
Eijsvogels T.M.H.
Fernandez A.B.
Thompson P.D.
AUTHOR ADDRESSES
(Eijsvogels T.M.H.; Fernandez A.B.; Thompson P.D.) Department of Cardiology,
Hartford Hospital, Hartford, United States.
(Eijsvogels T.M.H.; Fernandez A.B.; Thompson P.D.,
Paul.Thompson@hhchealth.org) Department of Physiology, Radboud University
Medical Center, Nijmegen, Netherlands.
CORRESPONDENCE ADDRESS
P.D. Thompson, Hartford Hospital, 80 Seymour St., Hartford, United States.
Email: Paul.Thompson@hhchealth.org
SOURCE
Physiological Reviews (2016) 96:1 (1-2) Article Number: A04. Date of
Publication: 2016
ISSN
1522-1210 (electronic)
0031-9333
BOOK PUBLISHER
American Physiological Society, subscrip@the-aps.org
ABSTRACT
Multiple epidemiological studies document that habitual physical activity
reduces the risk of atherosclerotic cardiovascular disease (ASCVD), and most
demonstrate progressively lower rates of ASCVD with progressively more
physical activity. Few studies have included individuals performing
high-intensity, lifelong endurance exercise, however, and recent reports
suggest that prodigious amounts of exercise may increase markers for, and
even the incidence of, cardiovascular disease. This review examines the
evidence that extremes of endurance exercise may increase cardiovascular
disease risk by reviewing the causes and incidence of exercise-related
cardiac events, and the acute effects of exercise on cardiovascular
function, the effect of exercise on cardiac biomarkers, including
“myocardial” creatine kinase, cardiac troponins, and cardiac natriuretic
peptides. This review also examines the effect of exercise on coronary
atherosclerosis and calcification, the frequency of atrial fibrillation in
aging athletes, and the possibility that exercise may be deleterious in
individuals genetically predisposed to such cardiac abnormalities as long QT
syndrome, right ventricular cardiomyopathy, and hypertrophic cardiomyopathy.
This review is to our knowledge unique because it addresses all known
potentially adverse cardiovascular effects of endurance exercise. The best
evidence remains that physical activity and exercise training benefit the
population, but it is possible that prolonged exercise and exercise training
can adversely affect cardiac function in some individuals. This hypothesis
warrants further examination.
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide
catecholamine (endogenous compound)
creatine kinase MB (endogenous compound)
creatine kinase MM (endogenous compound)
natriuretic factor (endogenous compound)
tropomyosin (endogenous compound)
troponin C (endogenous compound)
troponin I (endogenous compound)
troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
endurance training
heart function
EMTREE MEDICAL INDEX TERMS
adaptation
aging
aorta
aorta root
aorta rupture
aorta valve stenosis
article
athlete
atrial fibrillation
blood volume
bradycardia
cardiomyopathy
cardiovascular disease
cardiovascular mortality
cardiovascular risk
channelopathy
complete heart block
coronary artery anomaly
coronary artery atherosclerosis
coronary artery calcification
coronary artery disease
dynamic exercise
emotion
exercise intensity
fatigue
gene mutation
heart atrium arrhythmia
heart atrium flutter
heart disease
heart failure
heart left ventricle contractility
heart left ventricle hypertrophy
heart muscle cell
heart muscle fibrosis
heart muscle injury
heart muscle ischemia
heart muscle necrosis
heart performance
heart rate
heart right ventricle dysplasia
heart size
heart ventricle extrasystole
heart ventricle fibrillation
heart ventricle tachycardia
human
hypertrophic cardiomyopathy
inflammatory infiltrate
long QT syndrome
longevity
lung congestion
mechanical stress
membrane damage
membrane permeability
mitral valve prolapse
muscle training
nonhuman
oxidative stress
pathophysiology
physical activity
priority journal
sarcoidosis
sleep
sport
sudden cardiac death
sweating
thermogenesis
venous return
CAS REGISTRY NUMBERS
natriuretic factor (9088-07-7)
tropomyosin (72067-79-9)
troponin C (56094-11-2)
troponin I (77108-40-8)
troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
Clinical and Experimental Biochemistry (29)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151002286
FULL TEXT LINK
http://dx.doi.org/10.1152/physrev.00029.2014
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 86
TITLE
Management of Cognitive Impairment in Heart Failure
AUTHOR NAMES
Yzeiraj E.
Tam D.M.
Gorodeski E.Z.
AUTHOR ADDRESSES
(Yzeiraj E.) Department of Internal Medicine, Medicine Institute, Cleveland
Clinic, Cleveland, United States.
(Tam D.M.) NYU Comprehensive Epilepsy Center, New York, United States.
(Gorodeski E.Z., gorodee@ccf.org) Section of Heart Failure and Cardiac
Transplantation, Tomsich Family Department of Cardiovascular Medicine, Heart
and Vascular Institute, Cleveland Clinic, Cleveland, United States.
(Gorodeski E.Z., gorodee@ccf.org) Center for Connected Care, Cleveland
Clinic, Desk J3-4, 9500 Euclid Avenue, Cleveland, United States.
CORRESPONDENCE ADDRESS
E.Z. Gorodeski, Center for Connected Care, Cleveland Clinic, Desk J3-4, 9500
Euclid Avenue, Cleveland, United States. Email: gorodee@ccf.org
SOURCE
Current Treatment Options in Cardiovascular Medicine (2016) 18:1 (1-11)
Article Number: 4. Date of Publication: 1 Jan 2016
ISSN
1534-3189 (electronic)
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Cognitive impairment (CI) is an inclusive term to describe trouble with
memory, learning, concentration, or decision-making. CI is highly prevalent
in patients with heart failure (HF) and is known to be associated with a
variety of poor outcomes. While published HF guidelines recommend screening
for CI, they do not indicate how, due to a lack of consensus in the
literature about which instrument to use. Our recommendation is to use the
Mini-Cog for this purpose because of its brevity and utility in identifying
patients with HF at high risk for hospitalization or mortality. At this
time, there is minimal published clinical trial evidence about how to manage
CI in patients with HF. Reasonable approaches to management may include
following guideline-directed medical therapy for HF, treatment of
hypertension and atrial fibrillation, management of depression, proactive
diagnosis and treatment of sleep apnea, and encouragement of aerobic
exercise and weight loss. Left ventricular assist device (LVAD) therapy in
patients with Stage D HF may improve CI in the short term after
implantation, though there is a risk of worsening CI in the intermediate and
long term. Clinicians who care for patients with HF should routinely screen
for CI and when identified should encourage interventions to support
self-care, increase family involvement, and arrange for more frequent
follow-up.
EMTREE DRUG INDEX TERMS
cholinesterase inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cognitive defect (drug therapy, complication, drug therapy, therapy)
heart failure (therapy)
EMTREE MEDICAL INDEX TERMS
aerobic exercise
assisted circulation
atrial fibrillation
depression
diet therapy
disease exacerbation
external counterpulsation device
family therapy
high risk patient
hospitalization
human
hypertension
left ventricular assist device
Mini Mental State Examination
Montreal cognitive assessment
mortality
outcome assessment
practice guideline
prevalence
review
self care
sleep disordered breathing
weight reduction
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160031648
FULL TEXT LINK
http://dx.doi.org/10.1007/s11936-015-0425-7
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 87
TITLE
Safety, feasibility, and efficacy of vagus nerve stimulation paired with
upper-limb rehabilitation after ischemic stroke
AUTHOR NAMES
Dawson J.
Pierce D.
Dixit A.
Kimberley T.J.
Robertson M.
Tarver B.
Hilmi O.
Mclean J.
Forbes K.
Kilgard M.P.
Rennaker R.L.
Cramer S.C.
Walters M.
Engineer N.
AUTHOR ADDRESSES
(Dawson J., jesse.dawson@glasgow.ac.uk; Walters M.) Institute of
Cardiovascular and Medical Sciences, College of Medical,Veterinary and Life
Sciences, University of Glasgow, Glasgow, United Kingdom.
(Robertson M.) Robertson Centre for Biostatistics, University of Glasgow,
Western Infirmary, Glasgow, United Kingdom.
(Pierce D.) MicroTransponder Inc., Austin, United States.
(Pierce D.; Tarver B.; Engineer N.) University of Texas at Dallas,
Richardson, United States.
(Dixit A.) Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, NHS
Foundation Trust, Newcastle upon Tyne, United Kingdom.
(Kimberley T.J.) Programs in Physical Therapy and Rehabilitation Science,
Department of Physical Medicine and Rehabilitation, University of Minnesota,
Minneapolis, United States.
(Hilmi O.) Department of Otolaryngology, Glasgow Royal Infirmary, Greater
Glasgow and Clyde, Glasgow, United Kingdom.
(Mclean J.; Forbes K.) Department of Neuroradiology, Institute of
Neurological Sciences, Greater Glasgow and Clyde, Glasgow, United Kingdom.
(Kilgard M.P.; Rennaker R.L.) School of Behavioral and Brain Sciences,
University of Texas at Dallas, Richardson, United States.
(Kilgard M.P.) Department of Bioengineering, Erik Jonsson School of
Engineering and Computer Science, University of Texas at Dallas, Richardson,
United States.
(Cramer S.C.) Sue and Bill Gross Stem Cell Research Center, Departments of
Neurology, Anatomy and Neurobiology, and Physical Medicine and
Rehabilitation, University of California, Irvine, United Kingdom.
CORRESPONDENCE ADDRESS
J. Dawson, Institute of Cardiovascular and Medical Sciences, College of
Medical,Veterinary and Life Sciences, University of Glasgow, Glasgow, United
Kingdom. Email: jesse.dawson@glasgow.ac.uk
SOURCE
Stroke (2016) 47:1 (143-150). Date of Publication: 1 Jan 2016
ISSN
1524-4628 (electronic)
0039-2499
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Background and Purpose - Recent animal studies demonstrate that vagus nerve
stimulation (VNS) paired with movement induces movement-specific plasticity
in motor cortex and improves forelimb function after stroke. We conducted a
randomized controlled clinical pilot study of VNS paired with rehabilitation
on upper-limb function after ischemic stroke. Methods - Twenty-one
participants with ischemic stroke >6 months before and moderate to severe
upper-limb impairment were randomized to VNS plus rehabilitation or
rehabilitation alone. Rehabilitation consisted of three 2-hour sessions per
week for 6 weeks, each involving >400 movement trials. In the VNS group,
movements were paired with 0.5-second VNS. The primary objective was to
assess safety and feasibility. Secondary end points included change in
upper-limb measures (including the Fugl-Meyer Assessment-Upper Extremity).
Results - Nine participants were randomized to VNS plus rehabilitation and
11 to rehabilitation alone. There were no serious adverse device effects.
One patient had transient vocal cord palsy and dysphagia after implantation.
Five had minor adverse device effects including nausea and taste disturbance
on the evening of therapy. In the intention-to-treat analysis, the change in
Fugl-Meyer Assessment-Upper Extremity scores was not significantly different
(between-group difference, 5.7 points; 95% confidence interval, -0.4 to
11.8). In the per-protocol analysis, there was a significant difference in
change in Fugl-Meyer Assessment-Upper Extremity score (between-group
difference, 6.5 points; 95% confidence interval, 0.4 to 12.6). Conclusions -
This study suggests that VNS paired with rehabilitation is feasible and has
not raised safety concerns. Additional studies of VNS in adults with chronic
stroke will now be performed. Clinical Trial Registration - URL:
https://www.clinicaltrials.gov. Unique identifier: NCT01669161.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
arm movement
brain ischemia (rehabilitation, therapy)
patient safety
upper limb rehabilitation
vagus nerve stimulation
EMTREE MEDICAL INDEX TERMS
adult
article
assessment of humans
clinical article
colon cancer (complication)
controlled study
dysphagia (complication)
dyspnea (complication)
feasibility study
female
Fugl Meyer Assessment Upper Extremity score
grip strength
head and neck disease (complication)
hoarseness (complication)
human
implanted vagus nerve stimulator (adverse device effect)
intention to treat analysis
male
middle aged
nausea (complication)
neck tingling (complication)
nephrolithiasis (complication, therapy)
nuclear magnetic resonance imaging
oxygen saturation
paroxysmal atrial fibrillation (complication)
phrenic nerve paralysis (complication)
pilot study
priority journal
randomized controlled trial
rectum hemorrhage (complication)
stretching exercise
taste disorder (complication)
thorax pain (complication)
treatment duration
vocal cord paralysis (complication)
DEVICE MANUFACTURERS
(United States)Cyberonics
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Biophysics, Bioengineering and Medical Instrumentation (27)
Neurology and Neurosurgery (8)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT01669161)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151016667
FULL TEXT LINK
http://dx.doi.org/10.1161/STROKEAHA.115.010477
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 88
TITLE
Metronome cueing of walking reduces gait variability after a cerebellar
stroke
AUTHOR NAMES
Wright R.L.
Bevins J.W.
Pratt D.
Sackley C.M.
Wing A.M.
AUTHOR ADDRESSES
(Wright R.L., r.wright.1@bham.ac.uk) School of Sport, Exercise and
Rehabilitation Sciences, University of Birmingham, Birmingham, United
Kingdom.
(Wright R.L., r.wright.1@bham.ac.uk; Wing A.M.) School of Psychology,
University of Birmingham, Birmingham, United Kingdom.
(Bevins J.W.) Institute of Sport and Exercise Science, University of
Worcester, Worcester, United Kingdom.
(Pratt D.) West Midlands Rehabilitation Centre, Birmingham Community
Healthcare Trust, Birmingham, United Kingdom.
(Sackley C.M.) Faculty of Life Sciences and Medicine, King's College London,
London, United Kingdom.
CORRESPONDENCE ADDRESS
R.L. Wright, School of Sport, Exercise and Rehabilitation Sciences,
University of Birmingham, Birmingham, United Kingdom. Email:
r.wright.1@bham.ac.uk
SOURCE
Frontiers in Neurology (2016) 7:JUN Article Number: 84. Date of Publication:
2016
ISSN
1664-2295 (electronic)
BOOK PUBLISHER
Frontiers Research Foundation, info@frontiersin.org
ABSTRACT
Cerebellar stroke typically results in increased variability during walking.
Previous research has suggested that auditory cueing reduces excessive
variability in conditions such as Parkinson's disease and post-stroke
hemiparesis. The aim of this case report was to investigate whether the use
of a metronome cue during walking could reduce excessive variability in gait
parameters after a cerebellar stroke. An elderly female with a history of
cerebellar stroke and recurrent falling undertook three standard gait trials
and three gait trials with an auditory metronome. A Vicon system was used to
collect 3-D marker trajectory data. The coefficient of variation was
calculated for temporal and spatial gait parameters. SDs of the joint angles
were calculated and used to give a measure of joint kinematic variability.
Step time, stance time, and double support time variability were reduced
with metronome cueing. Variability in the sagittal hip, knee, and ankle
angles were reduced to normal values when walking to the metronome. In
summary, metronome cueing resulted in a decrease in variability for step,
stance, and double support times and joint kinematics. Further research is
needed to establish whether a metronome may be useful in gait rehabilitation
after cerebellar stroke and whether this leads to a decreased risk of
falling.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
auditory system function
cerebrovascular accident
gait
metronome cueing
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
auditory stimulation
brain infarction
case report
clinical protocol
computer assisted tomography
fall risk
falling
female
human
medical history
neuroimaging
very elderly
walking speed
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160508908
FULL TEXT LINK
http://dx.doi.org/10.3389/fneur.2016.00084
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 89
TITLE
MicroRNAs as biomarkers for acute atrial remodeling in marathon runners (The
miRathon study - A sub-study of the Munich marathon study)
AUTHOR NAMES
Clauss S.
Wakili R.
Hildebrand B.
Kääb S.
Hoster E.
Klier I.
Martens E.
Hanley A.
Hanssen H.
Halle M.
Nickel T.
AUTHOR ADDRESSES
(Clauss S., sebastian.clauss@med.uni-muenchen.de; Wakili R.; Hildebrand B.;
Kääb S.; Klier I.; Martens E.; Nickel T.) Medizinische Klinik und Poliklinik
1, Campus Grosshadern, Ludwig-Maximilians-Universität München (LMU), Munich,
Germany.
(Clauss S., sebastian.clauss@med.uni-muenchen.de; Wakili R.; Kääb S.; Halle
M.) DZHK (German Centre for Cardiovascular Research), Partner Site Munich,
Munich Heart Alliance, Munich, Germany.
(Clauss S., sebastian.clauss@med.uni-muenchen.de; Hanley A.) Cardiovascular
Research Center, Massachusetts General Hospital, Charlestown, United States.
(Hoster E.) Institute for Medical Informatics Biometry and Epidemiology,
Ludwig-Maximilians-UniversitätMünchen, Munich, Germany.
(Hanssen H.; Halle M.) Department of Prevention and Sports Medicine,
Technische Universität München, Klinikumrechts der Isar (MRI), Munich,
Germany.
(Hanssen H.) Sports Medicine, Institute of Exercise and Health Sciences,
University Basel, Basel, Switzerland.
SOURCE
PLoS ONE (2016) 11:2 Article Number: e0148599. Date of Publication: 2016
ISSN
1932-6203 (electronic)
BOOK PUBLISHER
Public Library of Science, plos@plos.org
ABSTRACT
Introduction: Physical activity is beneficial for individual health, but
endurance sport is associated with the development of arrhythmias like
atrial fibrillation. The underlying mechanisms leading to this increased
risk are still not fully understood. MicroRNAs are importantmediators of
proarrhythmogenic remodeling and have potential value as biomarkers in
cardiovascular diseases. Therefore, the objective of our study was to
determine the value of circulating microRNAs as potential biomarkers for
atrial remodeling in marathon runners (miRathon study). Methods: 30 marathon
runners were recruited into our study and were divided into two age-matched
groups depending on the training status: elite (ER, ≥55 km/week, n = 15) and
non-elite runners (NER, ≤40 km/week, n = 15). All runners participated in a
10 week training program before the marathon. MiRNA plasma levels were
measured at 4 time points: at baseline (V1), after a 10 week training period
(V2), immediately after the marathon (V3) and 24h later (V4). Additionally,
we obtained clinical data including serum chemistry and echocardiography at
each time point. Results: MiRNA plasma levels were similar in both groups
over time with more pronounced changes in ER. After the marathon miR-30a
plasma levels increased significantly in both groups. MiR-1 and miR-133a
plasma levels also increased but showed significant changes in ER only. 24h
after the marathon plasma levels returned to baseline. MiR-26a decreased
significantly after the marathon in elite runners only and miR-29b showed a
non-significant decrease over time in both groups. In ER miRNA plasma levels
showed a significant correlation with LA diameter, in NER miRNA plasma
levels did not correlate with echocardiographic parameters. Conclusion:
MiRNAs were differentially expressed in the plasma of marathon runners with
more pronounced changes in ER. Plasma levels in ER correlate with left
atrial diameter suggesting that circulating miRNAs could potentially serve
as biomarkers of atrial remodeling in athletes.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
microRNA (endogenous compound)
EMTREE DRUG INDEX TERMS
creatine kinase (endogenous compound)
creatine kinase MB (endogenous compound)
troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart atrium remodeling (diagnosis)
marathon runner
EMTREE MEDICAL INDEX TERMS
adult
anaerobic threshold
article
chemiluminescence immunoassay
controlled study
diagnostic value
diastolic blood pressure
disease marker
echocardiography
endurance training
ergometry
hemolysis
human
human experiment
male
normal human
protein blood level
pulse wave
RNA analysis
systolic blood pressure
treadmill
CAS REGISTRY NUMBERS
creatine kinase (9001-15-4)
troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160175609
FULL TEXT LINK
http://dx.doi.org/10.1371/journal.pone.0148599
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 90
TITLE
Good at heart: Preserving cardiac metabolism during aging
AUTHOR NAMES
Sorriento D.
Franco A.
Rusciano M.R.
Maione A.S.
Soprano M.
Illario M.
Iaccarino G.
Ciccarelli M.
AUTHOR ADDRESSES
(Sorriento D.) Institute of Biostructure and Bioimaging (IBB), Naples,
Italy.
(Franco A.) Department of Advanced Biomedical Sciences, Federico II”
University, Naples, Italy.
(Rusciano M.R.; Maione A.S.; Soprano M.; Illario M.) Department of
Translational Medicine, Federico II” University, Naples, Italy.
(Iaccarino G.; Ciccarelli M., mciccarelli@unisa.it) Department of Medicine
and Surgery, University of Salerno, Italy.
CORRESPONDENCE ADDRESS
M. Ciccarelli, Department of Medicine and Surgery, University of Salerno,
Italy. Email: mciccarelli@unisa.it
SOURCE
Current Diabetes Reviews (2016) 12:2 (90-99). Date of Publication: 1 Jan
2016
ISSN
1875-6417 (electronic)
1573-3998
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
The natural process of aging determinates several cardiac modifications with
increased susceptibility to heart diseases and ultimately converging on
development of chronic heart failure as final stage. These changes mainly
include left ventricular hypertrophy, diastolic dysfunction, valvular
degeneration, increased cardiac fibrosis, increased prevalence of atrial
fibrillation, and decreased maximal exercise capacity, as demonstrated in
several humans and animal models of aging. While different theories have
been proposed to explain the natural process of aging, it is clear that most
of the alterations affect mechanisms involved in cell homeostasis and
maintenance. Latest research studies have in particular focused on role of
mitochondrial oxidative stress, energy production and mitochondria quality
control. This article reviews the central role played by this organelle in
aging and the role of new molecular players involved into the progression
toward heart failure and potentially susceptible of new “anti-aging”
strategies.
EMTREE DRUG INDEX TERMS
adenylate kinase (endogenous compound)
insulin (endogenous compound)
mammalian target of rapamycin (endogenous compound)
neurohormone (endogenous compound)
sirtuin (endogenous compound)
transcription factor FOXO (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aging
heart muscle metabolism
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
autophagy
diastolic dysfunction
disorders of mitochondrial functions
energy yield
exercise
heart left ventricle hypertrophy
heart muscle fibrosis
homeostasis
human
insulin resistance
mitochondrion
mitophagy
nonhuman
oxidative stress
priority journal
valvular heart disease
CAS REGISTRY NUMBERS
adenylate kinase (9013-02-9)
insulin (9004-10-8)
EMBASE CLASSIFICATIONS
Gerontology and Geriatrics (20)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160188002
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 91
TITLE
Atrial and Ventricular Arrhythmia-Associated Factors in Stable Patients with
Chronic Obstructive Pulmonary Disease
AUTHOR NAMES
Kusunoki Y.
Nakamura T.
Hattori K.
Motegi T.
Ishii T.
Gemma A.
Kida K.
AUTHOR ADDRESSES
(Kusunoki Y.; Hattori K.; Motegi T.; Ishii T.; Gemma A.; Kida K.,
kkida@nms.ac.jp) Respiratory Care Clinic, Nippon Medical School, 4-7-15-8F,
Kudan-minami, Chiyoda-ku Tokyo, Japan.
(Kusunoki Y.; Nakamura T.; Hattori K.; Motegi T.; Ishii T.; Kida K.,
kkida@nms.ac.jp) Department of Pulmonary Medicine, Infection, and Oncology,
Nippon Medical School, Tokyo, Japan.
SOURCE
Respiration (2016) 91:1 (34-42). Date of Publication: 1 Jan 2016
ISSN
1423-0356 (electronic)
0025-7931
BOOK PUBLISHER
S. Karger AG
ABSTRACT
Background: Supraventricular and ventricular premature complexes (SVPC and
VPC, respectively) are associated with chronic obstructive pulmonary disease
(COPD) and with increased mortality in COPD patients. However, there are few
reports on the causes of arrhythmia in COPD patients. Objectives: This study
explores the associations between cardiopulmonary dysfunction and COPD by
comparing patients with defined arrhythmias (>100 beats per 24 h) and those
without, based on 24-hour electrocardiogram (ECG) recordings. Methods:
Patients with arrhythmia underwent a 24-hour ECG and subsequent pulmonary
function tests, computed tomography, ECG, 6-min walk test (6MWT), and BODE
(body mass index, airflow obstruction, modified Medical Research Council
Dyspnoea Scale, exercise capacity) index calculation. Results: Of 103 study
patients (71 COPD patients and 32 at-risk patients), 36 had VPC, 45 had
SVPC, 20 had both, and 42 had neither. The predicted post-bronchodilator
forced expiratory volume in 1 s, the proportion of low-attenuation area on
computed tomography, and BODE index values were significantly worse in the
SVPC and VPC groups compared with the corresponding reference groups.
Patients in the VPC group showed significantly increased right ventricular
pressure and increased desaturation in the 6MWT compared with the reference
group. In the multivariate analyses, bronchodilator use was a significant
risk factor in the SVPC group, whereas in the VPC group, all parameters of
the BODE index except for the dyspnoea score were identified as risk
factors. Conclusions: Increased SVPC might be caused by bronchodilator use,
whereas increased VPC is likely related to the peculiar pathophysiology of
COPD.
EMTREE DRUG INDEX TERMS
beta 2 adrenergic receptor stimulating agent (drug therapy)
bronchodilating agent (drug therapy)
long acting beta 2 agonist (drug therapy)
long acting muscarinic antagonist (drug therapy)
muscarinic receptor blocking agent (drug therapy)
theophylline (drug therapy)
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chronic obstructive lung disease (drug therapy, drug therapy, epidemiology)
heart atrium arrhythmia
heart ventricle arrhythmia
EMTREE MEDICAL INDEX TERMS
6 min walk test
adult
aged
article
assessment of humans
blood chemistry
BODE index
body mass
cardiopulmonary insufficiency
cohort analysis
computer assisted tomography
controlled study
correlation coefficient
diagnostic test accuracy study
disease association
disease severity
dyspnea
electrocardiography
exercise
experimental locomotor activity test
female
forced expiratory volume
heart right ventricle pressure
heart ventricle extrasystole
heart ventricle tachycardia
human
lung function test
major clinical study
male
middle aged
multivariate analysis
oxygen desaturation
pathophysiology
predictive value
prevalence
priority journal
prospective study
risk factor
supraventricular premature beat
very elderly
CAS REGISTRY NUMBERS
theophylline (58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160029934
FULL TEXT LINK
http://dx.doi.org/10.1159/000442447
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 92
TITLE
Surgical treatment of bronchiectasis: A review of 20 years of experience
AUTHOR NAMES
Coutinho D.
Fernandes P.
Guerra M.
Miranda J.
Vouga L.
AUTHOR ADDRESSES
(Coutinho D., dpcoutinho@gmail.com) Pulmonology Department, Centro
Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal.
(Fernandes P.; Guerra M.; Miranda J.; Vouga L.) Cardiothoracic Surgery
Department, Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de
Gaia, Portugal.
CORRESPONDENCE ADDRESS
D. Coutinho, Pulmonology Department, Centro Hospitalar de Vila Nova de Gaia
e Espinho, Vila Nova de Gaia, Portugal. Email: dpcoutinho@gmail.com
SOURCE
Revista Portuguesa de Pneumologia (2016) 22:2 (82-85). Date of Publication:
2016
ISSN
0873-2159
BOOK PUBLISHER
Elsevier Doyma, editorial@elsevier.com
ABSTRACT
Background: Bronchiectasis is defined as an abnormal and irreversible
dilation and distortion of the bronchi, which has numerous causes. Surgical
treatment of this disease is usually reserved for focal disease and when the
medical treatment is no longer effective. We report our center experience
and outcomes in bronchiectasis surgery during the last 20 years. Methods:
Between 1994 and 2014, sixty-nine patients underwent surgical resection for
bronchiectasis. Patient demographics, presenting symptoms, indications for
surgical treatment, type of lung resection, morbidity and mortality, as well
as clinical follow-up and outcomes were analyzed. Results: From the 69
patients included, 31 (44.9%) were male and 38 (55.1%) were female. Surgery
was indicated because of unsuccessful medical therapy in 33 patients
(47.8%), haemoptysis in 22 patients (31.9%), nondiagnostic lung mass in 9
patients (13.0%) and lung abscess in 5 patients (7.3%). The surgical
procedures were lobectomy in 45 (65.2%) patients, pneumonectomy in 10
(14.5%) patients, bilobectomy in 8 (11.6%) patients, lobectomy plus
segmentectomy in 3 (4.3%) patients and only segmentectomy in 3 (4.3%)
patients. Morbidity rate was 14.5% and there was no perioperative mortality.
The follow-up was possible in 60 patients, with an outcome reported as
excellent in 44 (73.3%) patients, as improved in 11 (18.3%) and as unchanged
in 5 (8.3%). Conclusion: Although the number of patients with bronchiectasis
referred for surgical treatment has decreased, pulmonary resection still
plays a significant role. Surgical resection of localized bronchiectasis is
a safe procedure with proven improvement of quality of life for the majority
of patients.
EMTREE DRUG INDEX TERMS
antibiotic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
bronchiectasis (disease management, surgery, therapy)
lung resection
EMTREE MEDICAL INDEX TERMS
adolescent
adult
age distribution
aged
antibiotic therapy
article
atrial fibrillation (complication)
bleeding (complication)
breathing exercise
bronchopleural fistula (complication)
child
drug treatment failure
female
follow up
hemoptysis
hospital infection (complication)
human
human tissue
lung abscess (surgery)
lung bilobectomy
lung lobectomy
lung segmentectomy
lung tumor (surgery)
major clinical study
male
middle aged
morbidity
outcome assessment
pneumonia (complication)
pneumothorax (complication)
postoperative care
quality of life
retrospective study
surgical mortality
surgical technique
symptom
thoracotomy
treatment indication
wound dehiscence (complication)
young adult
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160495648
FULL TEXT LINK
http://dx.doi.org/10.1016/j.rppnen.2015.09.007
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 93
TITLE
Eosinophilic Myocarditis due to Toxocariasis: Not a Rare Cause
AUTHOR NAMES
Shibazaki S.
Eguchi S.
Endo T.
Wakabayashi T.
Araki M.
Gu Y.
Imai T.
Asano K.
Taniuchi N.
AUTHOR ADDRESSES
(Shibazaki S., sn1.shibazaki@gmail.com; Araki M., makoto.araki@gmail.com;
Taniuchi N., ntaniuchi@suwachuo.jp) Department of Internal Medicine, Suwa
Central Hospital, 4300 Tamagawa, Chino, Nagano, Japan.
(Eguchi S., shunsuke219ncu@yahoo.co.jp) Department of Cardiology, Nagoya
University Hospital, 65 Tsurumai, Showa, Nagoya, Aichi, Japan.
(Endo T., mamemametakashi@gmail.com) Department of Internal Medicine,
Ishinomaki City Hospital, 25-1 Minamisakai-Shinkozutsumi, Ishinomaki,
Miyagi, Japan.
(Wakabayashi T., tada_wakabayashi@yahoo.co.jp; Imai T., titi7110@aol.com)
Department of Cardiology, Suwa Central Hospital, 4300 Tamagawa, Chino,
Nagano, Japan.
(Gu Y., ygu@med.tohoku.ac.jp) Department of Infectious Disease, Tohoku
University Hospital, 1-1 Seiryou, Aoba, Sendai, Miyagi, Japan.
(Asano K., kasano@suwachuo.jp) Department of Pathology, Suwa Central
Hospital, 4300 Tamagawa, Chino, Nagano, Japan.
CORRESPONDENCE ADDRESS
S. Shibazaki, Department of Internal Medicine, Suwa Central Hospital, 4300
Tamagawa, Chino, Nagano, Japan. Email: sn1.shibazaki@gmail.com
SOURCE
Case Reports in Cardiology (2016) 2016 Article Number: 2586292. Date of
Publication: 2016
ISSN
2090-6412 (electronic)
2090-6404
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
Myocarditis is a clinically important disease because of the high mortality.
From the perspective of treatment strategy, eosinophilic myocarditis should
be distinguished from other types of myocarditis. Toxocariasis, caused by
Toxocara canis or Toxocara cati, is known as a cause of eosinophilic
myocarditis but is considered rare. As it is an unpopular disease,
eosinophilic myocarditis due to toxocariasis may be underdiagnosed. We
experienced two cases of eosinophilic myocarditis due to toxocariasis from
different geographical areas in quick succession between 2013 and 2014. Case
1 is 32-year-old man. Case 2 is 66-year-old woman. In both cases, diagnosis
was done by endomyocardial biopsy and IgG-ELISA against Toxocara
excretory-secretory antigen. Only a corticosteroid was used in Case 1,
whereas a corticosteroid and albendazole were used in Case 2 as induction
therapy. Both patients recovered. Albendazole was also used in Case 1 to
prevent recurrence after induction therapy. Eosinophilic myocarditis by
toxocariasis may in actuality not be a rare disease, and corticosteroid is
an effective drug as induction therapy even before use of albendazole.
EMTREE DRUG INDEX TERMS
albendazole (drug therapy, oral drug administration)
creatine kinase (endogenous compound)
immunoglobulin G (endogenous compound)
parasite antigen
prednisolone (drug therapy, oral drug administration)
troponin I (endogenous compound)
troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
eosinophilia (drug therapy, drug therapy)
eosinophilic myocarditis (drug therapy, complication, drug therapy)
myocarditis (drug therapy, complication, drug therapy)
toxocariasis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
angiocardiography
article
case report
chronic diarrhea
chronic kidney disease
computer assisted tomography
contrast enhancement
dyspnea
electrocardiogram
ELISA kit
enzyme linked immunosorbent assay
eosinophil count
exercise
female
heart failure
heart left ventricle ejection fraction
heart muscle biopsy
heart right bundle branch block
human
Japanese (people)
laboratory test
leukocyte count
male
persistent atrial fibrillation
pyrexia idiopathica
Q wave
T wave
thorax pain
thorax radiography
Toxocara canis
transthoracic echocardiography
visceral larva migrans syndrome
Western blotting
CAS REGISTRY NUMBERS
albendazole (54965-21-8)
creatine kinase (9001-15-4)
immunoglobulin G (97794-27-9)
prednisolone (50-24-8)
troponin I (77108-40-8)
troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160411364
FULL TEXT LINK
http://dx.doi.org/10.1155/2016/2586292
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 94
TITLE
Emerging risk factors and the dose-response relationship between physical
activity and lone atrial fibrillation: A prospective case-control study
AUTHOR NAMES
Calvo N.
Ramos P.
Montserrat S.
Guasch E.
Coll-Vinent B.
Domenech M.
Bisbal F.
Hevia S.
Vidorreta S.
Borras R.
Falces C.
Embid C.
Montserrat J.M.
Berruezo A.
Coca A.
Sitges M.
Brugada J.
Mont L.
AUTHOR ADDRESSES
(Calvo N.; Ramos P.; Montserrat S.; Guasch E.; Coll-Vinent B.; Bisbal F.;
Falces C.; Embid C.; Montserrat J.M.; Berruezo A.; Coca A.; Sitges M.;
Brugada J.; Mont L., lmont@clinic.ub.es) Unitat de Fibril.lació Auricular,
Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
(Calvo N.; Ramos P.; Montserrat S.; Guasch E.; Coll-Vinent B.; Domenech M.;
Bisbal F.; Hevia S.; Vidorreta S.; Borras R.; Falces C.; Embid C.;
Montserrat J.M.; Berruezo A.; Coca A.; Sitges M.; Brugada J.; Mont L.,
lmont@clinic.ub.es) Institut d'Investigacions Biomédiques August Pi i Sunyer
(IDIBAPS), Catalonia, Spain.
(Domenech M.; Coca A.) Unitat d'Hipertensió i Risc Vascular, Hospital
Clínic, Catalonia, Spain.
(Embid C.; Montserrat J.M.) Unitat del Son. Servei Pneumologia, Hospital
Clínic, CIBERES Barcelona, Catalonia, Spain.
CORRESPONDENCE ADDRESS
L. Mont, Unitat de Fibril.lació Auricular, Hospital Clínic, Universitat de
Barcelona, Barcelona, Catalonia, Spain. Email: lmont@clinic.ub.es
SOURCE
Europace (2015) 18:1 (57-63). Date of Publication: 28 Dec 2015
ISSN
1532-2092 (electronic)
1099-5129
BOOK PUBLISHER
Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
Aims The role of high-intensity exercise and other emerging risk factors in
lone atrial fibrillation (Ln-AF) epidemiology is still under debate. The aim
of this study was to analyse the contribution of each of the emerging risk
factors and the impact of physical activity dose in patients with Ln-AF.
Methods and results Patients with Ln-AF and age- and sex-matched healthy
controls were included in a 2:1 prospective case-control study. We obtained
clinical and anthropometric data transthoracic echocardiography, lifetime
physical activity questionnaire, 24-h ambulatory blood pressure monitoring,
Berlin questionnaire score, and, in patients at high risk for obstructive
sleep apnoea (OSA) syndrome, a polysomnography. A total of 115 cases and 57
controls were enrolled. Conditional logistic regression analysis associated
height [odds ratio (OR) 1.06 [1.01-1.11]], waist circumference (OR 1.06
[1.02-1.11]), OSA (OR 5.04 [1.44-17.45]), and 2000 or more hours of
cumulative high-intensity endurance training to a higher AF risk. Our data
indicated a U-shaped association between the extent of high-intensity
training and AF risk. The risk of AF increased with an accumulated lifetime
endurance sport activity ≥2000 h compared with sedentary individuals (OR
3.88 [1.55-9.73]). Nevertheless, a history of <2000 h of high-intensity
training protected against AF when compared with sedentary individuals (OR
0.38 [0.12-0.98]). Conclusion A history of ≥2000 h of vigorous endurance
training, tall stature, abdominal obesity, and OSA are frequently
encountered as risk factors in patients with Ln-AF. Fewer than 2000 total
hours of high-intensity endurance training associates with reduced Ln-AF
risk.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy)
brain natriuretic peptide (endogenous compound)
C reactive protein (endogenous compound)
calcium antagonist (drug therapy)
interleukin 1 (endogenous compound)
isoatrial natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
abdominal obesity
atrial fibrillation (drug therapy, drug therapy)
endurance training
sleep disordered breathing
tall stature
EMTREE MEDICAL INDEX TERMS
adult
article
cardiovascular risk
case control study
controlled study
cross-sectional study
cycling
echocardiography
endurance sport
female
heart left ventricle ejection fraction
human
inflammation
major clinical study
male
marathon runner
masked hypertension
observational study
physical activity
prevalence
priority journal
prospective study
risk assessment
risk reduction
sedentary lifestyle
team sport
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
C reactive protein (9007-41-4)
isoatrial natriuretic peptide (124147-23-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160266623
FULL TEXT LINK
http://dx.doi.org/10.1093/europace/euv216
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 95
TITLE
Risk stratification for large artery or chronic coronary artery
disease-related ischemic stroke in octogenarians undergoing exercise stress
myocardial perfusion imaging: A cohort study
AUTHOR NAMES
Katsikis A.
Theodorakos A.
Drosatos A.
Konstantinou K.
Papaioannou S.
Koutelou M.
AUTHOR ADDRESSES
(Katsikis A., tkatsikis@gmail.com; Theodorakos A.; Papaioannou S.; Koutelou
M.) Nuclear Medicine Department, Onassis Cardiac Surgery Center, Kallithea,
Greece.
(Drosatos A.) Cardiology Department, Attikon University Hospital, Athens,
Greece.
(Katsikis A., tkatsikis@gmail.com; Drosatos A.; Konstantinou K.) Cardiology
Department, 401 General Military Hospital of Athens, Athens, Greece.
(Papaioannou S.) Cardiology Department, Athens Naval Hospital, Athens,
Greece.
CORRESPONDENCE ADDRESS
A. Katsikis, Cardiology Department, 401 General Military Hospital of Athens,
Athens, Greece. Email: tkatsikis@gmail.com
SOURCE
Journal of Nuclear Cardiology (2015) (1-5). Date of Publication: 16 Dec 2015
ISSN
1532-6551 (electronic)
1071-3581
BOOK PUBLISHER
Springer New York LLC, barbara.b.bertram@gsk.com
ABSTRACT
Objectives: To test, if in octogenarians, treadmill exercise with myocardial
perfusion imaging (exercise-MPI) can risk stratify for large artery or
chronic CAD-related ischemic stroke (LACCIS). Methods: Exercise-MPI-related
data of 237 octogenarians (55% prior MI or revascularization) without
previous stroke were registered and prospective follow-up was performed to
document LACCIS. LACCIS was defined as acute onset of neurological symptoms
with CT/MRI findings of non-lacunar-type infarcts in the absence of atrial
fibrillation or intracardiac embolic sources. Results: After 7.3 years, 10
LACCIS were documented. SSS [HR 1.08 (1.02-1.13 95% CIs), SDS [HR 1.1
(1.04-1.16 95% CIs)], and non-sustained VT or transient AV block during
exercise [HR 3.9 (1.7-9.0 95% CIs)] were predictors of LACCIS (P < .01 for
all). A SSS threshold of 16 had 81% specificity for identification of future
LACCIS and risk groups formed according to this cut-off had significantly
different LACCIS-free survival (P = .015). Conclusion: Exercise-MPI in
octogenarians can provide risk stratification markers for LACCIS.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
artery
brain ischemia
cohort analysis
coronary artery disease
exercise
myocardial perfusion imaging
stratification
stress
very elderly
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
atrioventricular block
controlled study
follow up
high risk population
human
infarction
nuclear magnetic resonance imaging
revascularization
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151038951
FULL TEXT LINK
http://dx.doi.org/10.1007/s12350-015-0361-7
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 96
TITLE
Thyroidectomy in a patient with thyroid storm: report of a case
AUTHOR NAMES
Uchida N.
Suda T.
Ishiguro K.
AUTHOR ADDRESSES
(Uchida N., uchidana@pref.tottori.jp) Department of Surgery, Tottori
Prefectural Kousei Hospital, 150 Higashisyouwa-machi, Kurayoshi, Japan.
(Uchida N., uchidana@pref.tottori.jp; Suda T.; Ishiguro K.) Department of
Breast and Endocrine Surgery, Tottori University Hospital, 36-1 Nishi-cho,
Yonago, Japan.
CORRESPONDENCE ADDRESS
N. Uchida, Department of Surgery, Tottori Prefectural Kousei Hospital, 150
Higashisyouwa-machi, Kurayoshi, Japan.
SOURCE
Surgery Today (2015) 45:1 (110-114). Date of Publication: 13 Dec 2015
ISSN
1436-2813 (electronic)
0941-1291
BOOK PUBLISHER
Springer-Verlag Tokyo, orders@springer.jp
ABSTRACT
Thyroid storm is a life-threatening condition that is generally considered
to be a contradiction to surgical intervention. We herein describe the case
of a 37-year-old patient with a history of Graves’ disease who was
transferred to Tottori University Hospital with thyroid storm. She had been
followed by her family doctor since 2006, but she had stopped taking her
medication of her own volition in 2010. About ten days prior to her
admission at our hospital, she consulted her family doctor with complaints
of dyspnea, palpitations and general fatigue. Subsequent thyroid function
tests showed TSH < 0.01 μU/ml, FT3 25.0 pg/ml and FT4 8.0 ng/dl. She also
had acute heart failure, atrial fibrillation and hepatic failure. A
diagnosis of thyroid storm was made and she was transferred to our hospital.
She received steroids, beta blockade, potassium iodide, and plasma exchange,
but her hepatic failure did not resolve and her clinical condition
deteriorated. The decision was made to proceed with thyroidectomy.
Postoperatively, her hepatic function normalized. Thus, thyroidectomy is a
potential therapeutic choice for cases of thyroid storm refractory to
medical management.
EMTREE DRUG INDEX TERMS
alanine aminotransferase (endogenous compound)
aspartate aminotransferase (endogenous compound)
atrial natriuretic factor alpha (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
betamethasone sodium phosphate (drug therapy)
bilirubin (endogenous compound)
digoxin (drug therapy)
diuretic agent (drug therapy)
heparin (drug therapy)
hydrocortisone sodium succinate (drug therapy)
levothyroxine sodium (drug therapy)
potassium iodide (drug therapy)
prednisolone (drug therapy)
thiamazole (drug therapy)
thyrotropin (endogenous compound)
thyroxine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
thyroid crisis (drug therapy, diagnosis, drug therapy, surgery)
thyroidectomy
EMTREE MEDICAL INDEX TERMS
acute heart failure
adult
alanine aminotransferase blood level
article
aspartate aminotransferase blood level
atrial fibrillation
bilirubin blood level
case report
consultation
dyspnea
emergency surgery
fatigue
female
follow up
general practitioner
Graves disease
heart palpitation
hepatitis
hospital admission
human
liver failure
liver function
medical history
patient transport
plasmapheresis
postoperative period
prothrombin time
severe hepatic impairment
steroid therapy
thyroid function test
thyrotropin blood level
thyroxine blood level
university hospital
CAS REGISTRY NUMBERS
alanine aminotransferase (9000-86-6, 9014-30-6)
aspartate aminotransferase (9000-97-9)
atrial natriuretic factor alpha (89213-87-6)
betamethasone sodium phosphate (151-73-5, 360-63-4)
bilirubin (18422-02-1, 635-65-4)
digoxin (20830-75-5, 57285-89-9)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
hydrocortisone sodium succinate (125-04-2, 2203-97-6)
levothyroxine sodium (55-03-8)
potassium iodide (7681-11-0)
prednisolone (50-24-8)
thiamazole (60-56-0)
thyrotropin (9002-71-5)
thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015651971
MEDLINE PMID
24132684 (http://www.ncbi.nlm.nih.gov/pubmed/24132684)
FULL TEXT LINK
http://dx.doi.org/10.1007/s00595-013-0754-7
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 97
TITLE
Ischemic stroke: the impact of renal dysfunction on 1-year mortality
AUTHOR NAMES
Fabjan T.H.
Hojs R.
AUTHOR ADDRESSES
(Fabjan T.H., tanja.hojs@ukc-mb.si) Department of Neurology, University
Clinical Centre Maribor, Ljubljanska 5, Maribor, Slovenia.
(Hojs R.) Clinic for Internal Medicine, Department of Nephrology, University
Clinical Centre Maribor, Maribor, Slovenia.
(Fabjan T.H., tanja.hojs@ukc-mb.si; Hojs R.) University of Maribor, Maribor,
Slovenia.
CORRESPONDENCE ADDRESS
T.H. Fabjan, Department of Neurology, University Clinical Centre Maribor,
Ljubljanska 5, Maribor, Slovenia. Email: tanja.hojs@ukc-mb.si
SOURCE
Wiener Klinische Wochenschrift (2015) 127 Supplement 5 (175-180). Date of
Publication: 1 Dec 2015
ISSN
1613-7671 (electronic)
0043-5325
BOOK PUBLISHER
Springer-Verlag Wien, michaela.bolli@springer.at
ABSTRACT
Background: Atherosclerosis is accelerated in patients with different stages
of chronic renal failure. Renal dysfunction predicts mortality in patients
with myocardial infarction and congestive heart failure. Less is known about
the impact of renal dysfunction on mortality after ischemic stroke. The aim
of the study was to investigate the impact of renal dysfunction on 1-year
mortality. Patients and methods: All 390 patients (207 men and 183 women)
suffered from ischemic stroke in 1-year period were included in our study.
Telephonic follow-up after 1 year was performed. The mean age of our
patients was 71.0 ± 11.6 years, ranged from 36 to 96 years. Glomerular
filtration rate (GFR) was calculated according to abbreviated Modification
of Diet in Renal Disease formula. At admission and at discharge National
Institutes of Health Stroke Scale (NIHSS) were performed. Results: The mean
GFR in our patients was 66.0 ± 20.68 ml/min/1.73 m(2). There were 123 (31.5
%) deaths in 1-year period. Patients who died were older (P < 0.001), had
higher NIHSS at admission and at discharge (both P < 0.001), higher
high-sensitive C-reactive protein (P = 0.002), lower albumin (P < 0.001),
lower GFR (P = 0.044), had more frequent atrial fibrillation (P < 0.001),
and were less frequent actual smokers (P = 0.003). No differences in
presence of diabetes and hypertension, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol and triglycerides between patients who
died or survived were found. With Cox multivariable regression analysis age
(P = 0.037), gender (P = 0.005), NIHSS at admission (P = 0.005) and
discharge (P < 0.001), albumin (P = 0.005) and also GFR (P = 0.025) were
predictors of 1-year mortality. Conclusions: In patients with ischemic
stroke, renal dysfunction (decreased GFR) was associated with 1-year
mortality. GFR was independent predictor of mortality.
EMTREE DRUG INDEX TERMS
albumin (endogenous compound)
C reactive protein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia
kidney disease
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
controlled study
female
follow up
glomerulus filtration rate
human
major clinical study
male
mortality
National Institutes of Health Stroke Scale
very elderly
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
Urology and Nephrology (28)
Clinical and Experimental Biochemistry (29)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015846366
FULL TEXT LINK
http://dx.doi.org/10.1007/s00508-015-0705-y
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 98
TITLE
Cardiac resynchronization in patients with atrial fibrillation
AUTHOR NAMES
Barold S.S.
Herweg B.
AUTHOR ADDRESSES
(Barold S.S.) Department of Medicine, University of Rochester, School of
Medicine and Dentistry, Rochester, United States.
(Herweg B.) Arrhythmia Service, University of South Florida, College of
Medicine, Tampa General Hospital, Tampa, United States.
CORRESPONDENCE ADDRESS
S.S. Barold, Department of Medicine, University of Rochester, School of
Medicine and Dentistry, Rochester, United States.
SOURCE
Journal of Atrial Fibrillation (2015/2016) 8:4. Date of Publication: 1 Dec
2015
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, editors.office@jafib.com
ABSTRACT
Atrial fibrillation (AF) occurs in one of four patients undergoing cardiac
resynchronization therapy (CRT).-Without special therapy, the prognosis of
AF patients with CRT has been generally worse than those in sinus rhythm.
The importance of a high percentage of biventricular pacing (BIV%) was
confirmed in a large study where the mortality was inversely associated with
BIV% both in the presence of normal sinus and atrial paced rhythm and with
AF. The greatest reduction in mortality was observed with BIV% >98%.
Patients with BIV% >99.6% experienced a 24% reduction in mortality (p <
0.001) while those with BIV% <94.8% had a 19% increase in mortality. The
optimal BIV% cut-point was 98.7%. This cutoff would appear mandatory but it
would be best to approach 100%. Careful evaluation of device interrogation
data upon which the BiV% is based is essential because the memorized data
can vastly overestimate the percentage of truly resynchronized beats since
it does not account for fusion and pseudofusion between intrinsic (not
paced) and paced beats. The recently published randomized CERTIFY trial
provides unequivocal proof of the value of AV junctional (AVJ) ablation in
CRT patients with AF. This trial confirmed the favorable results of AVJ
ablation by many other studies and two important meta-analyses and therefore
established the firm recommendation that the procedure should be performed
in most, if not all, patients with permanent AF as well as those with
frequent and prolonged episodes of paroxysmal AF. Patients after AVJ have
improved mortality with a mortality similar to those in sinus rhythm. The
AVJ ablation procedure carries the theoretical risk of device failure and
death in pacemaker dependent patients. An inappropriate first ICD shock for
AF seems to increase mortality. Increased long-term mortality after an
inappropriate shock may be due to the underlying atrial arrhythmia substrate
as opposed to the effect of the shock itself.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
cardiac resynchronization therapy
EMTREE MEDICAL INDEX TERMS
ablation therapy
AV junctional ablation
cardiovascular mortality
clinical effectiveness
death
device failure
disease control
exercise
follow up
heart atrium arrhythmia
heart atrium pacing
heart beat
heart failure
heart left ventricle ejection fraction
heart left ventricle endsystolic volume
heart ventricle arrhythmia
Holter monitoring
hospitalization
human
implantable cardioverter defibrillator
incidence
meta analysis (topic)
pacemaker
paroxysmal atrial fibrillation
practice guideline
prognosis
randomized controlled trial (topic)
resting heart rate
review
sinus rhythm
treatment outcome
treatment response
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160185165
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 99
TITLE
Atrial fibrillation and physical activity Should we exercise caution?
ORIGINAL (NON-ENGLISH) TITLE
Fibrillation auriculaire et activité physique: Faut-il être prudent?
AUTHOR NAMES
John Bosomworth N.
AUTHOR ADDRESSES
(John Bosomworth N., jbosomworth@gmail.com) Department of Family Practice,
University of British Columbia, Vancouver, Canada.
CORRESPONDENCE ADDRESS
N. John Bosomworth, Department of Family Practice, University of British
Columbia, Vancouver, Canada. Email: jbosomworth@gmail.com
SOURCE
Canadian Family Physician (2015) 61:12 (1061-1070 and e542-e552). Date of
Publication: 1 Dec 2015
ISSN
0008-350X
BOOK PUBLISHER
College of Family Physicians of Canada
ABSTRACT
Objective To review the evidence on the effects of various levels of
physical activity (PA) on the incidence of atrial fibrillation (AF) in both
the general population and in endurance athletes. Data sources A PubMed
search was done initially using the MeSH headings or text words (with the
search-field descriptor TIAB [title and abstract]) atrial fibrillation and
exercise or physical activity or athlet∗or sport∗, without additional
filters. Conclusions regarding quality and strength of evidence were based
on the GRADE (grading of recommendations, assessment, development, and
evaluation) system. Study selection No interventional studies were
available. Observational studies were therefore considered acceptable, and,
although larger long-term prospective cohort studies were preferred,
case-control or cross-sectional trials were also included in this review.
Synthesis Available evidence suggests a dose-response association linking
increased exercise levels with reduced incident AF in women. The same is
true in men at low and moderate levels of exertional activity. In men only,
high levels of PA are associated with increased risk of AF in most, but not
all, studies. This risk is moderate, with a hazard ratio of 1.29 in one of
the better studies. The risk of AF for most people who exercise regularly is
lower than that of a matched sedentary population. Conclusion Atrial
fibrillation is probably less common as PA increases, with a demonstrable
dose-response relationship. Exercise at any level should be promoted for its
effect on physical well-being and mortality reduction. In men exercising at
high levels, beneficial effects on AF might be lost and risk might exceed
that of the sedentary population; however, the evidence is neither robust
nor consistent. These men should be made aware of this modest increase in
risk should they choose to continue to engage in high levels of PA.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation
endurance training
physical activity
EMTREE MEDICAL INDEX TERMS
athletic performance
borderline hypertension
bradycardia
cardiovascular mortality
cardiovascular risk
endurance
exercise intensity
follow up
heart atrium flutter
heart function
human
pathophysiology
prognosis
review
risk reduction
running
sedentary lifestyle
vagus tone
walking
wellbeing
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English, French
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
20151052505
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 100
TITLE
Atrial fibrillation in athletes: Pathophysiology, clinical presentation,
evaluation and management
AUTHOR NAMES
Turagam M.K.
Flaker G.C.
Velagapudi P.
Vadali S.
Alpert M.A.
AUTHOR ADDRESSES
(Turagam M.K.; Flaker G.C.; Velagapudi P.; Vadali S.; Alpert M.A.) Division
of Cardiovascular, Medicine University of Missouri, School of Medicine,
Health Sciences Center, 5 Hospital Drive, Columbia, United States.
CORRESPONDENCE ADDRESS
M.A. Alpert, Division of Cardiovascular, Medicine University of Missouri,
School of Medicine, Health Sciences Center, 5 Hospital Drive, Columbia,
United States.
SOURCE
Journal of Atrial Fibrillation (2015/2016) 8:4. Date of Publication: 1 Dec
2015
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, editors.office@jafib.com
ABSTRACT
Atrial fibrillation (AF) is the most common cardiac arrhythmia in athletes,
especially in middle-aged athletes. Studies have demonstrated that athletes
who engage in endurance sports such as runners, cyclists and skiers are more
prone to AF than other athletes. The effects of exercise on the onset and
progression of AF is complex. Triggers of AF in athletes may include atrial
ectopy and sports supplements. Substrates for AF in athletes include atrial
remodeling, fibrosis, and inflammation. Modulators of AF in athletes include
autonomic activation, electrolyte abnormalities, and possibly,
gastroesophageal reflux. Management of AF in athletes with rate-controlling
agents and antiarrhythmic drugs remains a challenge and can be associated
with impaired athletic performance. The value of catheter ablation is
emerging and should be considered in suitable athletes with AF.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
anabolic agent
disopyramide (drug therapy)
electrolyte
flecainide (drug therapy)
performance enhancing substance
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation (drug therapy, drug therapy, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
autonomic innervation
cardioversion
carditis
catheter ablation
clinical evaluation
clinical feature
direct current
dyspnea
electrolyte disturbance
energy drink
exercise
faintness
gastroesophageal reflux
heart muscle fibrosis
heart palpitation
Holter monitoring
human
pathogenesis
physical examination
pulmonary vein isolation
review
sport
supraventricular premature beat
transthoracic echocardiography
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
disopyramide (3737-09-5)
flecainide (54143-55-4)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160185170
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 101
TITLE
Giant Caseous Calcification on Tricuspid Annulus Mimicking Cardiac
Metastasis in a Patient with Colon Cancer
AUTHOR NAMES
Yesin M.
Toprak C.
Kalçik M.
Bayam E.
̄nanir M.
Özkan M.
AUTHOR ADDRESSES
(Yesin M., mahmutyesin@yahoo.com; Toprak C.; Bayam E.; ̄nanir M.; Özkan M.)
Department of Cardiology, Kosuyolu Kartal Heart Training and Research
Hospital, Istanbul, Turkey.
(Kalçik M.) Department of Cardiology, Iskilip Atif Hoca State Hospital,
Çorum, Turkey.
(Özkan M.) Division of Health Sciences, Ardahan University, Ardahan, Turkey.
CORRESPONDENCE ADDRESS
M. Yesin, Denizer Cad. Cevizli Kvs. No:2 Cevizli, Kartal/Istanbul, Turkey.
Email: mahmutyesin@yahoo.com
SOURCE
Echocardiography (2015) 32:12 (1885-1886). Date of Publication: 1 Dec 2015
ISSN
1540-8175 (electronic)
0742-2822
BOOK PUBLISHER
Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
Mini-Abstract Caseous calcification is usually an incidental finding on the
atrioventricular valvular annulus. The exact mechanism of pathogenicity for
the caseous calcifications has not been defined yet. Differential diagnosis
includes vegetation, thrombus, or metastatic tumors. We presented a case of
a large tricuspid mass as an incidental finding by transthoracic
echocardiography in a patient with metastatic colon cancer. The distinction
between caseous calcification and metastatic tumor was made based on the
typical location of calcification, possible extension to the whole mitral
annulus, well-defined borders, and the internal echolucent area.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
colon cancer
heart metastasis (diagnosis)
tricuspid valve annulus caseous calcification (diagnosis)
tricuspid valve disease (diagnosis)
EMTREE MEDICAL INDEX TERMS
aged
atrial fibrillation
case report
computer assisted tomography
differential diagnosis
dyspnea
electrocardiography
exercise
female
human
image analysis
mitral valve regurgitation
physical examination
pleura effusion
pneumonia
positron emission tomography
priority journal
short survey
systolic heart murmur
thorax radiography
transthoracic echocardiography
EMBASE CLASSIFICATIONS
Radiology (14)
Cancer (16)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015213337
FULL TEXT LINK
http://dx.doi.org/10.1111/echo.13018
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 102
TITLE
New insights into the pros and cons of the clinical use of vitamin K
antagonists (VKAs) versus direct oral anticoagulants (DOACs)
AUTHOR NAMES
van Gorp R.H.
Schurgers L.J.
AUTHOR ADDRESSES
(van Gorp R.H., rick.vangorp@maastrichtuniversity; Schurgers L.J.,
l.schurgers@maastrichtuniversity.nl) Department of Biochemistry,
Cardiovascular Research Institute Maastricht, Maastricht University, PO Box
616, Maastricht, Netherlands.
(van Gorp R.H., rick.vangorp@maastrichtuniversity) Nattopharma ASA, Høvik,
Norway.
CORRESPONDENCE ADDRESS
L.J. Schurgers, Department of Biochemistry, Cardiovascular Research
Institute Maastricht, Maastricht University, PO Box 616, Maastricht,
Netherlands. Email: l.schurgers@maastrichtuniversity.nl
SOURCE
Nutrients (2015) 7:11 (9538-9557). Date of Publication: 17 Nov 2015
ISSN
2072-6643 (electronic)
BOOK PUBLISHER
MDPI AG, Postfach, Basel, Switzerland.
ABSTRACT
Vitamin K-antagonists (VKA) are the most widely used anticoagulant drugs to
treat patients at risk of arterial and venous thrombosis for the past 50
years. Due to unfavorable pharmacokinetics VKA have a small therapeutic
window, require frequent monitoring, and are susceptible to drug and
nutritional interactions. Additionally, the effect of VKA is not limited to
coagulation, but affects all vitamin K-dependent proteins. As a consequence,
VKA have detrimental side effects by enhancing medial and intimal
calcification. These limitations stimulated the development of alternative
anticoagulant drugs, resulting in direct oral anticoagulant (DOAC) drugs,
which specifically target coagulation factor Xa and thrombin. DOACs also
display non-hemostatic vascular effects via protease-activated receptors
(PARs). As atherosclerosis is characterized by a hypercoagulable state
indicating the involvement of activated coagulation factors in the genesis
of atherosclerosis, anticoagulation could have beneficial effects on
atherosclerosis. Additionally, accumulating evidence demonstrates vascular
benefit from high vitamin K intake. This review gives an update on oral
anticoagulant treatment on the vasculature with a special focus on
calcification and vitamin K interaction.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (clinical trial, drug comparison, drug therapy)
antivitamin K (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
direct oral anticoagulant agent (clinical trial, drug comparison, drug
therapy)
EMTREE DRUG INDEX TERMS
acenocoumarol (drug therapy)
antistasin (drug therapy)
apixaban (clinical trial, drug comparison, drug therapy)
blood clotting factor 10a (endogenous compound)
dabigatran (clinical trial, drug comparison, drug therapy)
dabigatran etexilate (clinical trial, drug comparison, drug therapy)
dicoumarol (clinical trial, drug comparison, drug therapy)
enoxaparin (clinical trial, drug comparison, drug therapy)
fibrin (endogenous compound)
heparin (drug comparison, drug therapy)
hirudin (drug therapy)
menadione
menaquinone
osteocalcin (endogenous compound)
phenprocoumon (drug therapy)
phytomenadione
proteinase activated receptor (endogenous compound)
rivaroxaban (clinical trial, drug comparison, drug therapy)
thrombin (endogenous compound)
tick anticoagulant peptide (drug therapy)
unclassified drug
warfarin (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
blood vessel calcification (side effect, side effect)
EMTREE MEDICAL INDEX TERMS
artery thrombosis (drug therapy)
atherosclerosis
atrial fibrillation (drug therapy)
bleeding (side effect)
comparative effectiveness
drug bioavailability
drug efficacy
drug half life
drug monitoring
drug safety
human
meta analysis (topic)
nonhuman
nutrition
protein expression
prothrombin time
randomized controlled trial (topic)
review
vascularization
vein thrombosis (drug therapy)
venous thromboembolism (drug therapy)
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
antistasin (110119-38-5)
apixaban (503612-47-3)
blood clotting factor 10a (72162-96-0, 9002-05-5)
dicoumarol (66-76-2)
enoxaparin (679809-58-6)
fibrin (9001-31-4)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
hirudin (8001-27-2)
menadione (58-27-5)
osteocalcin (136461-80-8)
phenprocoumon (435-97-2)
phytomenadione (11104-38-4, 84-80-0)
rivaroxaban (366789-02-8)
thrombin (9002-04-4, 869858-13-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015525662
FULL TEXT LINK
http://dx.doi.org/10.3390/nu7115479
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 103
TITLE
Atrial fibrillation cardioversion following acupuncture
AUTHOR NAMES
Dilber D.
Čerkez-Habek J.
Barić H.
Gradišer M.
AUTHOR ADDRESSES
(Dilber D.) Departments of Cardiology, County Hospital Čakovec, Čakovec,
Croatia.
(Čerkez-Habek J.) Departments of Endocrinology and Diabetes, County Hospital
Čakovec, Čakovec, Croatia.
(Barić H., hrvojebaric00@gmail.com) Međimurje County Institute for Emergency
Medicine, Čakovec, Croatia.
(Gradišer M.) Department of Internal Medicine, University Hospital Sveti
Duh, Zagreb, Croatia.
CORRESPONDENCE ADDRESS
H. Barić, Međimurje County Institute for Emergency Medicine, Čakovec,
Croatia. Email: hrvojebaric00@gmail.com
SOURCE
Saudi Medical Journal (2015) 36:11 (1351-1353). Date of Publication: 1 Nov
2015
ISSN
1658-3175 (electronic)
0379-5284
BOOK PUBLISHER
Saudi Arabian Armed Forces Hospital, smjns.ksa@zajil.net
ABSTRACT
Atrial fibrillation (AF) is the most common arrhythmia and it is an
independent risk for serious events. Acupuncture has been growing in
popularity in the West, and there are reports of its benefits in treating
AF. We report a 57-year-old man who was admitted after having an allergic
reaction to amiodarone administered to treat paroxysmal AF with fast
ventricular response. Cardioversion with intravenous propafenone was
uneventful. Before an attempt of electric cardioversion, he was treated with
acupuncture as additional therapy to peroral propafenone. After acupuncture
treatment consisting of 10 treatments during 30 days period, both immediate
cardioversion to sinus rhythm and no paroxysmal AF during 30 days period
were recorded.
EMTREE DRUG INDEX TERMS
amiodarone (adverse drug reaction, drug therapy, intravenous drug
administration)
amlodipine (drug therapy)
bisoprolol (drug therapy)
nadroparin (drug therapy, subcutaneous drug administration)
propafenone (drug therapy, oral drug administration)
ramipril (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
atrial fibrillation (drug therapy, diagnosis, drug therapy, therapy)
cardioversion
EMTREE MEDICAL INDEX TERMS
acupuncture needle
adult
allergic reaction (side effect)
article
case report
drug substitution
drug withdrawal
echocardiography
echography
electrocardiography
heart palpitation
human
hypertension (drug therapy)
male
middle aged
nervousness
telemetry
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
amlodipine (88150-42-9, 103129-82-4, 736178-83-9)
bisoprolol (66722-44-9)
nadroparin (104521-37-1)
propafenone (34183-22-7, 54063-53-5)
ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Arabic
EMBASE ACCESSION NUMBER
20151036402
FULL TEXT LINK
http://dx.doi.org/10.15537/smj.2015.11.12891
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 104
TITLE
Dilated left ventricular cardiomyopathy secondary to noncompaction in a
patient with paroxysmal atrial fibrillation
AUTHOR NAMES
Chin J.
Seidensticker D.
Lin A.
AUTHOR ADDRESSES
(Chin J.; Seidensticker D.; Lin A.)
SOURCE
Consultant (2015) 55:11 (949-950). Date of Publication: 1 Nov 2015
ISSN
0010-7069
BOOK PUBLISHER
Cliggott Publishing Co.
EMTREE DRUG INDEX TERMS
carvedilol
dofetilide
furosemide
losartan
spironolactone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive cardiomyopathy
dilated left ventricular cardiomyopathy
paroxysmal atrial fibrillation
ventricular noncompaction
EMTREE MEDICAL INDEX TERMS
adult
anticoagulant therapy
article
cardiologist
cardiovascular magnetic resonance
case report
CHADS2 score
computed tomographic angiography
exercise
heart catheterization
heart failure
heart left ventricle ejection fraction
heart muscle ischemia
hospital admission
human
male
medical history
monomorphic ventricular tachycardia
New York Heart Association class
priority journal
QTc interval
transthoracic echocardiography
CAS REGISTRY NUMBERS
carvedilol (72956-09-3)
dofetilide (115256-11-6)
furosemide (54-31-9)
losartan (114798-26-4)
spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20160148284
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 105
TITLE
Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and
prognosis of cardiac amyloidosis
AUTHOR NAMES
Galat A.
Rosso J.
Guellich A.
Van Der Gucht A.
Rappeneau S.
Bodez D.
Guendouz S.
Tissot C.-M.
Hittinger L.
Dubois-Randé J.-L.
Plante-Bordeneuve V.
Itti E.
Meignan M.
Damy T.
AUTHOR ADDRESSES
(Galat A.; Rosso J.; Guellich A.; Van Der Gucht A.; Rappeneau S.; Bodez D.;
Guendouz S.; Tissot C.-M.; Hittinger L.; Dubois-Randé J.-L.;
Plante-Bordeneuve V.; Itti E.; Meignan M.; Damy T.,
thibaud.damy@hmn.aphp.fr) UPEC, Créteil, France.
(Galat A.; Rosso J.; Guellich A.; Van Der Gucht A.; Rappeneau S.; Bodez D.;
Guendouz S.; Tissot C.-M.; Hittinger L.; Dubois-Randé J.-L.;
Plante-Bordeneuve V.; Itti E.; Meignan M.; Damy T.,
thibaud.damy@hmn.aphp.fr) Mondor Amyloidosis Network, Créteil, France.
(Galat A.; Guellich A.; Rappeneau S.; Bodez D.; Guendouz S.; Tissot C.-M.;
Hittinger L.; Dubois-Randé J.-L.; Damy T., thibaud.damy@hmn.aphp.fr)
Department of Cardiology, AP-HP, Henri-Mondor Teaching Hospital, 51 Av de
Lattre de Tassigny, Créteil, France.
(Galat A.; Guellich A.; Damy T., thibaud.damy@hmn.aphp.fr) INSERM U955, GRC
Réseau Amylose Mondor, Créteil, France.
(Galat A.; Rosso J.; Guellich A.; Van Der Gucht A.; Rappeneau S.; Bodez D.;
Guendouz S.; Tissot C.-M.; Hittinger L.; Dubois-Randé J.-L.;
Plante-Bordeneuve V.; Itti E.; Meignan M.; Damy T.,
thibaud.damy@hmn.aphp.fr) DHU ATVB, Créteil, France.
(Rosso J.; Van Der Gucht A.; Itti E.; Meignan M.) Department of Nuclear
Medicine, AP-HP, Henri-Mondor Teaching Hospital, Créteil, France.
(Guellich A.; Rappeneau S.; Damy T., thibaud.damy@hmn.aphp.fr) INSERM
Clinical Investigation Centre 006, Créteil, France.
(Plante-Bordeneuve V.) Department of Neurology, AP-HP, Henri-Mondor Teaching
Hospital, Créteil, France.
CORRESPONDENCE ADDRESS
T. Damy, Department of Cardiology, AP-HP, Henri-Mondor Teaching Hospital, 51
Av de Lattre de Tassigny, Créteil, France. Email: thibaud.damy@hmn.aphp.fr
SOURCE
Amyloid (2015) 22:4 (210-220). Date of Publication: 2 Oct 2015
ISSN
1744-2818 (electronic)
1350-6129
BOOK PUBLISHER
Taylor and Francis Ltd, healthcare.enquiries@informa.com
ABSTRACT
Background: Amyloidosis is characterized by extracellular deposits of
insoluble proteins that cause tissue damage. The three main types are
monoclonal light chain (AL), wild-type transthyretin (wt-TTR) and mutated
transthyretin (m-TTR) amyloidosis. Cardiac amyloidosis (CA) raises
diagnostic challenges.Objective: To assess the diagnostic accuracy of
(99m)Tc-HMDP-scintigraphy for typing CA, differentiating CA from non-amyloid
left ventricle hypertrophy (LVH), and predicting outcomes.Methods: 121
patients with suspected CA underwent (99m)Tc-HMDP-scintigraphy in addition
to standard investigations.Results: CA was diagnosed in all AL (n = 14) and
wt-TTR (n = 21). Among m-TTR (n = 34), 26 had CA, 4 neuropathy without CA
and 4 were asymptomatic carriers. Of the 52 patients with non-amyloid heart
disease, 37 had LVH and served as controls. (99m)Tc-HMDP cardiac uptake
occurred in all wt-TTR, in m-TTR with CA except two and in one AL. A visual
score ≥ 2 was 100% specific for diagnosing TTR-CA. Among TTR-CA,
heart-to-skull retention (HR/SR) correlated with CA severity (LVEF and
NT-proBNP). Median follow-up was 111 days (50;343). In a multivariate Cox
model including clinical, echocardiographic and scintigraphic variables,
NYHA III-IV and HR/SR > 1.94 predicted acute heart failure and/or
death.Conclusions: This preliminary study suggests that
(99m)Tc-HMDP-scintigraphy may aid differentiation between transthyretin and
AL-CA as well as CA from other LVHs. (99m)Tc-HMDP-scintigraphy appears to
provide prognostic information in CA.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
oxidronate technetium tc 99m (intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart amyloidosis (diagnosis)
heart scintiscanning
EMTREE MEDICAL INDEX TERMS
acute heart failure
adult
aged
article
atrial fibrillation
cardiovascular magnetic resonance
carpal tunnel syndrome
computed tomography scanner
controlled study
diagnostic accuracy
diagnostic test accuracy study
diastolic dysfunction
disease severity
echocardiography
female
follow up
heart disease
heart left ventricle ejection fraction
heart left ventricle hypertrophy
heart muscle biopsy
human
human tissue
hypertension
major clinical study
male
neurologic disease
neuropathy
outcome assessment
pacemaker implantation
prediction
priority journal
DRUG MANUFACTURERS
(France)CIS
DEVICE TRADE NAMES
Philips Precedence SPECT/CT , NetherlandsPhilips Healthcare
Vivid 7 system , NorwayGE Vingmed
DEVICE MANUFACTURERS
(Netherlands)Philips Healthcare
(Norway)GE Vingmed
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Nuclear Medicine (23)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015457531
FULL TEXT LINK
http://dx.doi.org/10.3109/13506129.2015.1072089
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 106
TITLE
Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose
Acetylsalicylic Acid
AUTHOR NAMES
González-Pérez A.
Sáez M.E.
Johansson S.
Himmelmann A.
García Rodríguez L.A.
AUTHOR ADDRESSES
(González-Pérez A.; Sáez M.E.; García Rodríguez L.A., lagarcia@ceife.es)
Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Almirante 28-2,
Madrid, Spain.
(González-Pérez A.; Sáez M.E.) Andalusian Bioinformatics Research Center
(CAEBi), Seville, Spain.
(Johansson S.; Himmelmann A.) Global Medicines Development, Medical Affairs,
Observational Research Center, AstraZeneca R and D, Mölndal, Sweden.
CORRESPONDENCE ADDRESS
L.A. García Rodríguez, Spanish Centre for Pharmacoepidemiologic Research
(CEIFE), Almirante 28-2, Madrid, Spain. Email: lagarcia@ceife.es
SOURCE
Journal of Stroke and Cerebrovascular Diseases (2015) 24:10 (2321-2328).
Date of Publication: 1 Oct 2015
ISSN
1532-8511 (electronic)
1052-3057
BOOK PUBLISHER
W.B. Saunders
ABSTRACT
Background The use of antithrombotic drugs (anticoagulants and antiplatelet
drugs) has been reported to increase the risk of hemorrhagic stroke (HS)
relative to no treatment. This study was performed to characterize the
incidence and predictors of HS in users of acetylsalicylic acid (ASA) for
the secondary prevention of cardiovascular events. Methods A cohort of
36,775 ASA users aged 50-84 years in 2000-2007 was identified from The
Health Improvement Network database. The incidence of HS was calculated, and
a nested case-control analysis, adjusted for potential confounding factors,
was performed to calculate the odds ratios (ORs) and 95% confidence
intervals (CIs) for the association of potential risk factors with HS in
current users of ASA. Results The overall incidence of HS was 5.70 cases per
10,000 person-years and increased with age. In current ASA users, the
incidence of HS was 4.91 cases per 10,000 person-years. Predictors of HS in
patients taking ASA for secondary prevention included a history of HS (OR,
4.84; 95% CI, 1.48-15.88), a history of atrial fibrillation (OR, 4.03; 95%
CI, 1.53-10.62), and hypnotic/anxiolytic drug use (OR, 2.67; 95% CI,
1.17-6.05). The small number of patients using warfarin also had an
increased risk of HS (OR, 23.42; 95% CI, 4.89-112.10). Conclusions
Physicians should consider additional risk factors for HS, such as a history
of HS or atrial fibrillation, and the use of warfarin, before prescribing
ASA for the secondary prevention of cardiovascular events.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
acetylsalicylic acid (adverse drug reaction, drug dose, drug therapy)
EMTREE DRUG INDEX TERMS
anxiolytic agent
hypnotic agent
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain hemorrhage (side effect, side effect)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
cardiovascular disease (prevention)
case control study
cerebrovascular disease (drug therapy)
cohort analysis
controlled study
female
heart infarction (drug therapy)
human
ischemic heart disease (drug therapy)
low drug dose
major clinical study
male
medical history
middle aged
priority journal
retrospective study
risk factor
secondary prevention
unstable angina pectoris (drug therapy)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015418297
MEDLINE PMID
26189158 (http://www.ncbi.nlm.nih.gov/pubmed/26189158)
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.06.016
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 107
TITLE
Right ventricular changes in highly trained athletes: Between physiology and
pathophysiology
AUTHOR NAMES
D'andrea A.
Morello A.
Iacono A.M.
Scarafile R.
Cocchia R.
Riegler L.
Pezzullo E.
Golia E.
Bossone E.
Calabro R.
Russo M.G.
AUTHOR ADDRESSES
(D'andrea A., antonellodandrea@libero.it; Morello A.; Iacono A.M.; Scarafile
R.; Cocchia R.; Riegler L.; Pezzullo E.; Golia E.; Calabro R.; Russo M.G.)
Department of Cardiology, Integrated Diagnostic Cardiology, AORN Dei Colli,
Second University of Naples, Via M. Schipa, 44, Naples, Italy.
(Bossone E.) Department of Heart, Cardiology Division, Cava De' Tirreni and
Amalfi Coast Hospital, University of Salerno, Salerno, Italy.
CORRESPONDENCE ADDRESS
A. D'andrea, Department of Cardiology, Integrated Diagnostic Cardiology,
AORN Dei Colli, Second University of Naples, Via M. Schipa, 44, Naples,
Italy. Email: antonellodandrea@libero.it
SOURCE
Journal of Cardiovascular Echography (2015) 25:4 (97-102). Date of
Publication: 1 Oct 2015
ISSN
2347-193X (electronic)
2211-4122
BOOK PUBLISHER
Medknow Publications, B9, Kanara Business Centre, off Link Road, Ghatkopar
(E), Mumbai, India.
ABSTRACT
Several studies have described the adaptive remodeling of the heart during
exercise. In some more practiced endurance athletes, there is a
disproportionate load on the right ventricle (RV), at least during exercise,
and this might be the basis for a chronic pro-arrhythmic RV remodeling.
Especially, in these kinds of athletes the recovery after detraining might
be incomplete, in particular for RV changes. The observation of acute
myocardial injury based on transient elevation of biomarkers and chronic
myocardial scar, not completely reversible changes of the RV and an
increased prevalence of some arrhythmias support the existence of an
"exercise-induced cardiomyopathy." The aim of this paper is to review
current knowledge about changes in the right heart in highly trained
athletes and how these change influence cardiac function.
EMTREE DRUG INDEX TERMS
biological marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
heart function
heart right ventricle
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiomyopathy
cardiovascular magnetic resonance
color ultrasound flowmetry
disease predisposition
echocardiography
electrocardiography
endurance training
exercise intensity
exercise-induced cardiomyopathy
heart hemodynamics
heart injury
heart muscle conduction disturbance
heart muscle contractility
heart muscle fibrosis
heart muscle injury
heart right atrium
heart right bundle branch block
heart right ventricle dysplasia
heart stroke volume
heart ventricle extrasystole
heart ventricle performance
heart ventricle remodeling
human
lung artery pressure
lung circulation
marathon runner
meta analysis (topic)
muscle hypertrophy
normal human
prevalence
pulmonary artery
pulmonary valve
review
sports medicine
systole
systolic blood pressure
tricuspid valve
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160039850
FULL TEXT LINK
http://dx.doi.org/10.4103/2211-4122.172486
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 108
TITLE
Optimising the management of heart failure
AUTHOR NAMES
Bakhai A.
Backman W.
Krishnamurthy V.
AUTHOR ADDRESSES
(Bakhai A.; Krishnamurthy V.) Royal Free London NHS Foundation Trust, United
Kingdom.
(Backman W.) Boston Medical Center, Massachusetts, United States.
SOURCE
Primary Care Cardiovascular Journal (2015) 12 Supplement 1 (S12-S17). Date
of Publication: 1 Oct 2015
ISSN
1756-5146 (electronic)
1756-5138
BOOK PUBLISHER
Sherborne Gibbs Limited, agreathead@sherbornegibbs.co.uk
ABSTRACT
Heart failure (HF) is an important cause of morbidity, mortality and misery
for patients. However, there are many ways to improve and extend the lives
of people with HF, if clinicians are familiar with and apply the numerous
traditional, less mainstream and more innovative evidence-based treatment
options. This article reviews current best practice in the management of
chronic HF and of acute decompensated HF, and considers recent insights,
controversies and innovations in this important, fast moving field.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
angiotensin receptor antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
digoxin (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
dronedarone (drug therapy)
eplerenone (drug therapy)
hydralazine (drug therapy)
inotropic agent (drug therapy)
iron (drug therapy, intravenous drug administration)
isosorbide mononitrate (drug therapy)
ivabradine (drug therapy)
loop diuretic agent (drug therapy)
nitric acid derivative (drug therapy)
spironolactone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, disease management, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
acute heart failure
article
atrial fibrillation
body weight
cardiac resynchronization therapy
cardiovascular mortality
clinical trial (topic)
diuretic therapy
dyspnea
exercise
fluid retention
hospital discharge
human
implantable cardioverter defibrillator
integrated health care system
meta analysis (topic)
noninvasive ventilation
palliative therapy
patient education
positive end expiratory pressure
prognosis
pulse rate
randomized controlled trial (topic)
risk reduction
self care
sodium restriction
ultrafiltration
ventricular assist device
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digoxin (20830-75-5, 57285-89-9)
dronedarone (141626-36-0)
eplerenone (107724-20-9)
hydralazine (304-20-1, 86-54-4)
iron (14093-02-8, 53858-86-9, 7439-89-6)
isosorbide mononitrate (1320-91-8)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151051918
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 109
TITLE
The current role of Omega-3 fatty acids in the management of atrial
fibrillation
AUTHOR NAMES
Christou G.A.
Christou K.A.
Korantzopoulos P.
Rizos E.C.
Nikas D.N.
Goudevenos J.A.
AUTHOR ADDRESSES
(Christou G.A.) Laboratory of Physiology, Medical School, University of
Ioannina, Ioannina, Greece.
(Christou K.A.) First Department of Internal Medicine, University Hospital
of Ioannina, Ioannina, Greece.
(Korantzopoulos P.; Nikas D.N.; Goudevenos J.A.) First Department of
Cardiology, University Hospital of Ioannina, Ioannina, Greece.
(Rizos E.C.) Second Medical Department and Outpatient Lipid Clinic,
University Hospital of Ioannina, Ioannina, Greece.
CORRESPONDENCE ADDRESS
G.A. Christou, Laboratory of Physiology, Medical School, University of
Ioannina, Ioannina, Greece.
SOURCE
International Journal of Molecular Sciences (2015) 16:9 (22870-22887). Date
of Publication: 22 Sep 2015
ISSN
1422-0067 (electronic)
1661-6596
BOOK PUBLISHER
MDPI AG, Postfach, Basel, Switzerland. membranes@mdpi.com
ABSTRACT
Background: The main dietary source of omega-3 polyunsaturated fatty acids
(n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). In the present manuscript, we aimed to review
the current evidence regarding the clinical role of n-3 PUFA in the
prevention of atrial fibrillation (AF) and the possible underlying
mechanisms. Methods: A literature search based on PubMed listings was
performed using “Omega-3 fatty acids” and “atrial fibrilation” as key search
terms. Results: n-3 PUFA have been shown to attenuate structural atrial
remodeling, prolong atrial effective refractory period through the
prevention of reentry and suppress ectopic firing from pulmonary veins.
Dietary fish intake has been found to have no effect on the incidence of AF
in the majority of studies. Circulating DHA has been consistently reported
to be inversely associated with AF risk, whereas EPA has no such effect. The
majority of studies investigating the impact of n-3 PUFA supplementation on
the incidence of AF following cardiac surgery reported no benefit, though
most of them did not use n-3 PUFA pretreatment for adequate duration.
Studies using adequate four-week pretreatment withn-3 PUFA before
cardioversion of AF showed a reduction of the AF incidence. Conclusions:
Although n-3 PUFA have antiarrhythmogenic properties, their clinical
efficacy on the prevention of AF is not consistently supported. Further
well-designed studies are needed to overcome the limitations of the existing
studies and provide robust conclusions.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid
EMTREE DRUG INDEX TERMS
docosahexaenoic acid
farnesoid X receptor (endogenous compound)
icosapentaenoic acid
retinoid X receptor (endogenous compound)
voltage gated sodium channel (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (disease management, etiology)
EMTREE MEDICAL INDEX TERMS
cardioversion
clinical effectiveness
congestive heart failure
diet supplementation
dietary intake
food frequency questionnaire
genetic transcription
heart infarction
heart muscle refractory period
heart surgery
human
hypertension
review
upregulation
CAS REGISTRY NUMBERS
docosahexaenoic acid (25167-62-8, 32839-18-2)
icosapentaenoic acid (25378-27-2, 32839-30-8)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT01841944)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015399616
FULL TEXT LINK
http://dx.doi.org/10.3390/ijms160922870
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 110
TITLE
Fish, long-chain omega-3 polyunsaturated fatty acid intake and incidence of
atrial fibrillation: A pooled analysis of two prospective studies
AUTHOR NAMES
Larsson S.C.
Wolk A.
AUTHOR ADDRESSES
(Larsson S.C., susanna.larsson@ki.se; Wolk A.) Unit of Nutritional
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden
CORRESPONDENCE ADDRESS
S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental
Medicine, Karolinska Institutet, SE-17177 Stockholm, Sweden Email:
susanna.larsson@ki.se
SOURCE
Clinical Nutrition (2016). Date of Publication: 17 Aug 2015
ISSN
1532-1983 (electronic)
0261-5614
BOOK PUBLISHER
Churchill Livingstone
ABSTRACT
Background & aims: Whether high intakes of fish and long-chain omega-3
polyunsaturated fatty acids (PUFAs) reduce the risk of atrial fibrillation
(AF) remains uncertain. Thus, we aimed to evaluate the associations of total
fish, types of fish, and omega-3 PUFA intake with AF incidence in a large
prospective study. Methods: We used data from the Cohort of Swedish Men and
the Swedish Mammography Cohort to examine the associations of fish
consumption and long-chain omega-3 PUFA intake with AF incidence. At
baseline, information on fish and omega-3 PUFA intakes was available from
72,984 men and women, aged 45-83 years, without cardiac disease. Cases of AF
were identified through linkage with the Swedish National Patient Register.
Multivariable-adjusted relative risks were estimated with the use of Cox
proportional hazards models. Results: Over a follow-up period of 12 years,
6095 participants (3595 men and 2500 women) developed AF. Intakes of total
fish, fatty fish (herring/mackerel and salmon/whitefish/char), and
long-chain omega-3 PUFAs were not associated with AF incidence after
adjustment for other risk factors. However, high consumption of lean fish
(cod/saithe/fish fingers) was associated with a lower risk; multivariable
relative risk of AF for ≥3 servings/week compared with never consumption was
0.79 (95% confidence interval, 0.65-0.95). Conclusions: These findings do
not support a beneficial association of fatty fish or omega-3 PUFA intake
with incident AF. The association between lean fish consumption and AF risk
warrants further investigation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid
polyunsaturated fatty acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
diet
prospective study
EMTREE MEDICAL INDEX TERMS
adult
confidence interval
coregonine
female
finger
follow up
herring
human
male
mammography
meta analysis
proportional hazards model
risk factor
Swedish citizen
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160409248
FULL TEXT LINK
http://dx.doi.org/10.1016/j.clnu.2016.01.019
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 111
TITLE
Secondary stroke prevention: Challenges and solutions
AUTHOR NAMES
Esenwa C.
Gutierrez J.
AUTHOR ADDRESSES
(Esenwa C.; Gutierrez J., jg3233@cumc.columbia.edu) Department of Neurology,
College of Physicians and Surgeons, Columbia University Medical Center, New
York, United States.
CORRESPONDENCE ADDRESS
J. Gutierrez, Department of Neurology, College of Physicians and Surgeons,
Columbia University Medical Center, 710 W 168th Street, 6th floor, Suite
639, New York, United States.
SOURCE
Vascular Health and Risk Management (2015) 11 (437-450). Date of
Publication: 7 Aug 2015
ISSN
1178-2048 (electronic)
1176-6344
BOOK PUBLISHER
Dove Medical Press Ltd., PO Box 300-008, Albany, Auckland, New Zealand.
ABSTRACT
Stroke is the leading cause of disability in the USA and a major cause of
mortality worldwide. One out of four strokes is recurrent. Secondary stroke
prevention starts with deciphering the most likely stroke mechanism. In
general, one of the main goals in stroke reduction is to control vascular
risk factors such as hypertension, diabetes, dyslipidemia, and smoking
cessation. Changes in lifestyle like a healthy diet and aerobic exercise are
also recommended strategies. In the case of cardioembolism due to atrial
fibrillation, mechanical valves, or cardiac thrombus, anticoagulation is the
mainstay of therapy. The role of anticoagulation is less evident in the case
of bioprosthetic valves, patent foramen ovale, and dilated cardiomyopathy
with low ejection fraction. Strokes due to larger artery atherosclerosis
account for approximately a third of all strokes. In the case of symptomatic
extracranial carotid stenosis, surgical intervention as close as possible in
time to the index event seems highly beneficial. In the case of intracranial
large artery atherosclerosis, the best medical therapy consists of
antiplatelets, high-dose statins, aggressive controls of vascular risk
factors, and lifestyle modifications, with no role for intracranial
arterial stenting or angioplasty. For patients with small artery occlusion
(ie, lacunar stroke), the therapy is similar to that used in patients with
intracranial large artery atherosclerosis. Despite the constant new evidence
on how to best treat patients who have suffered a stroke, the risk of stroke
recurrence remains unacceptably high, thus evidencing the need for novel
therapies.
EMTREE DRUG INDEX TERMS
hydroxymethylglutaryl coenzyme A reductase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
diabetes mellitus
dyslipidemia
hypertension
prevention
risk
EMTREE MEDICAL INDEX TERMS
aerobic exercise
angioplasty
anticoagulation
artery
artery occlusion
atherosclerosis
atrial fibrillation
carotid artery obstruction
congestive cardiomyopathy
diet
disability
drug megadose
heart ejection fraction
human
lacunar stroke
lifestyle
lifestyle modification
mortality
patent foramen ovale
patient
risk factor
smoking cessation
stent
surgery
therapy
thrombus
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015323172
FULL TEXT LINK
http://dx.doi.org/10.2147/VHRM.S63791
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 112
TITLE
ESC Congress 2015
AUTHOR ADDRESSES
SOURCE
European Heart Journal (2015) 36 SUPPL. 1. Date of Publication: 1 Aug 2015
CONFERENCE NAME
European Society of Cardiology, ESC Congress 2015
CONFERENCE LOCATION
London, United Kingdom
CONFERENCE DATE
2015-08-29 to 2015-09-02
ISSN
0195-668X
BOOK PUBLISHER
Oxford University Press
ABSTRACT
The proceedings contain 4481 papers. The topics discussed include:
successful approaches in reduction of fluoroscopy time and radiation dose
during catheter ablation for atrial fibrillation; atrial high rate episodes
and silent ischemic brain lesions in patients with cardiac implantable
electronic devices: unmasking silent atrial fibrillation embolic risk;
mechanisms of improvement in claudication after exercise training in
peripheral arterial disease; clinical impact of complete revascularization
in elderly patients with multivessel coronary artery disease underwent
percutaneous coronary intervention; clinical and economic outcome of
telemonitoring versus usual care among patients with severe chronic heart
failure; direct comparison of the safety and efficacy of two rule-out
strategies for acute myocardial infarction; and direct comparison of the
safety and efficacy of two rule-out strategies for acute myocardial
infarction: 2h-algorithm versus undetectable levels at presentation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
European
society
EMTREE MEDICAL INDEX TERMS
acute heart infarction
aged
algorithm
atrial fibrillation
brain damage
catheter ablation
claudication
coronary artery disease
devices
exercise
fluoroscopy
heart failure
human
patient
percutaneous coronary intervention
peripheral occlusive artery disease
radiation dose
revascularization
risk
safety
telemonitoring
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 113
TITLE
Leriche-syndrome despite regular sport and non-compaction suggest
neuromuscular disease
AUTHOR NAMES
Finsterer J.
Stöllberger C.
AUTHOR ADDRESSES
(Finsterer J., fifigs1@yahoo.de) Krankenanstalt Rudolfstiftung, Postfach 20,
Vienna, Austria.
(Stöllberger C.) 2nd Medical Department with Cardiology and Intensive Care
Medicine, Krankenanstalt Rudolfstiftung, Vienna, Austria.
CORRESPONDENCE ADDRESS
J. Finsterer, Krankenanstalt Rudolfstiftung, Postfach 20, Vienna, Austria.
Email: fifigs1@yahoo.de
SOURCE
International Journal of Cardiology (2015) 191 (15-17). Date of Publication:
15 Jul 2015
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Leriche syndrome (diagnosis)
neuromuscular disease
ventricular noncompaction
EMTREE MEDICAL INDEX TERMS
aged
angiocardiography
article
ataxia
atrial fibrillation
case report
Caucasian
cerebrovascular accident
congestive cardiomyopathy
coronary artery atherosclerosis
coronary artery obstruction
exercise
hearing impairment
human
hypertension
left anterior descending coronary artery
male
mild cognitive impairment
muscle atrophy
myalgia
myoclonus seizure
nuclear magnetic resonance imaging
nystagmus
peripheral occlusive artery disease
priority journal
ptosis
smoking
sport
superficial femoral artery
tibial artery
transthoracic echocardiography
traumatic brain injury
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
20151060243
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2015.04.279
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 114
TITLE
Association between renal dysfunction and 3-year mortality in patients with
acute first-ever ischemic stroke
AUTHOR NAMES
Lin S.-W.
Weng W.-C.
Huang Y.-H.
Su F.-C.
Peng T.-I.
Chien Y.-Y.
Wu C.-L.
Lee K.-Y.
Yu Y.-J.
Zhu J.-X.
Huang W.-Y.
AUTHOR ADDRESSES
(Lin S.-W.; Weng W.-C.; Huang Y.-H.; Su F.-C.; Peng T.-I.; Chien Y.-Y.; Wu
C.-L.; Lee K.-Y.; Yu Y.-J.; Zhu J.-X.; Huang W.-Y.,
wenyihuang2003@yahoo.com.tw) Department of Neurology, Chang-Gung Memorial
Hospital, Keelung Branch, No. 222, Mai-Jin Road, Keelung, Taiwan.
(Lin S.-W.; Weng W.-C.; Huang Y.-H.; Su F.-C.; Peng T.-I.; Chien Y.-Y.; Wu
C.-L.; Lee K.-Y.; Yu Y.-J.; Zhu J.-X.; Huang W.-Y.,
wenyihuang2003@yahoo.com.tw) Department of Medicine, College of Medicine,
Chang Gung University, 259 Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan, Taiwan.
CORRESPONDENCE ADDRESS
W.-Y. Huang, Department of Neurology, Chang-Gung Memorial Hospital, Keelung
Branch, No. 222, Mai-Jin Road, Keelung, Taiwan.
SOURCE
Clinical Neurology and Neurosurgery (2015) 137 (15-21). Date of Publication:
10 Jul 2015
ISSN
1872-6968 (electronic)
0303-8467
BOOK PUBLISHER
Elsevier
ABSTRACT
Objective The influence of renal dysfunction on the clinical presentation
and outcomes of patients with acute ischemic stroke is still controversial.
We investigate the influence of renal dysfunction on the outcomes of
patients with acute first-ever ischemic stroke. Methods Nine-hundred
thirty-four patients with acute first-ever ischemic stroke were enrolled and
followed for 3 years. Renal function was assessed using the equation of the
Modification Diet for Renal Disease for estimated glomerular filtration rate
(eGFR). Serum creatinine levels were obtained within 3 days of acute stroke
onset. Reduced eGFR was defined as eGFR < 60 ml/min/1.73 m2.
Clinical presentation, risk factors for stroke, laboratory data,
co-morbidities, and outcomes were recorded. Results Total 264 patients
(28.3%) had a reduced eGFR. The prevalence of older age, hypertension, and
atrial fibrillation was significantly higher in patients with a reduced
eGFR. Total anterior circulation syndrome occurred more frequently among
patients with a reduced eGFR (P = 0.010). Multivariate Cox regression
revealed that a reduced eGFR is a significant predictor of 3-year mortality
(HR = 1.67, 95% CI = 1.06-2.62, P = 0.026). Conclusion Reduced eGFR during
the acute stroke stage is associated with increased risk of 3-year
mortality. Furthermore, risk of acute complications and poor functional
outcomes following discharge was significantly higher in patients with a
reduced eGFR.
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (drug therapy, drug therapy)
kidney dysfunction
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
cerebrovascular accident
circulation
controlled study
creatinine blood level
disease course
female
follow up
glomerulus filtration rate
hospital patient
human
hypertension
kidney disease
kidney function
major clinical study
male
morbidity
mortality
prevalence
recurrent disease
secondary prevention
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015188877
FULL TEXT LINK
http://dx.doi.org/10.1016/j.clineuro.2015.06.008
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 115
TITLE
Current trends in tai chi for stroke rehabilitation
AUTHOR NAMES
Zhang Y.
Ning Y.
Liu H.
Zhou L.
Zou Y.
Li Z.
AUTHOR ADDRESSES
(Zhang Y.; Zhou L.; Li Z., lee_zongheng@163.com) Department of
Rehabilitation, Dongzhimen Hospital, Beijing University of Chinese Medicine,
Beijing, China.
(Ning Y.; Liu H.; Zou Y.) Department of Neurology and Stroke Center,
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
CORRESPONDENCE ADDRESS
Z. Li, Department of Rehabilitation, Dongzhimen Hospital, Beijing University
of Chinese Medicine, Beijing, China. Email: lee_zongheng@163.com
SOURCE
Journal of Traditional Chinese Medical Sciences (2015) 2:3 (135-139). Date
of Publication: 1 Jul 2015
ISSN
2095-7548 (electronic)
BOOK PUBLISHER
Beijing University of Chinese Medicine
ABSTRACT
Background: There are an increasing number of studies focusing on the effect
of tai chi for different diseases. As a special form of physical activity,
tai chi may be beneficial for the rehabilitation of stroke, a leading cause
of disability worldwide. Objective: This review summarizes the existing
literature on the potential benefits of tai chi for stroke rehabilitation
and offers recommendations for future research. Methods: Studies on the
biomechanics and physiology of tai chi for stroke rehabilitation are
reviewed. Research on tai chi for stroke rehabilitation and related diseases
are summarized. Finally, the shortcomings of existing studies and
recommendations for future studies are discussed. Conclusions: Tai chi
appears to be beneficial for stroke rehabilitation. But reporting quality of
existing studies are sub-optimal. Future trials should define tai chi style,
apply rigorous methodology to sample size calculation, randomization,
recruiting criteria, and outcome measures. To avoid inadequacies during the
research and reporting processes, investigators may wish to follow CONSORT
guidelines and refer to well-conducted clinical studies on tai chi.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (radiotherapy)
Tai Chi
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
Barthel index
biomechanics
human
hypertension
National Institutes of Health Stroke Scale
physiology
physiotherapy
Rankin scale
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20151065728
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jtcms.2014.12.001
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 116
TITLE
Quality of anticoagulation control among patients with atrial fibrillation:
An experience of a tertiary care center in Saudi Arabia
AUTHOR NAMES
Alyousif S.M.
Alsaileek A.A.
AUTHOR ADDRESSES
(Alyousif S.M., alyousifsm@gmail.com; Alsaileek A.A.) King Abdullah
Intentional Research Centre, Riyadh, Saudi Arabia
(Alyousif S.M., alyousifsm@gmail.com; Alsaileek A.A.) King Saud bin
Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
(Alyousif S.M., alyousifsm@gmail.com) Pharmaceutical Care Department, King
Abdulaziz Medical City, Riyadh, Saudi Arabia
(Alyousif S.M., alyousifsm@gmail.com; Alsaileek A.A.) Ministry of National
Guard-Health Affair, Saudi Arabia
CORRESPONDENCE ADDRESS
S.M. Alyousif, PO Box 22490, Riyadh 11426, Saudi Arabia Email:
alyousifsm@gmail.com
SOURCE
Journal of the Saudi Heart Association (2016). Date of Publication: 9 Jun
2015
ISSN
2212-5043 (electronic)
1016-7315
BOOK PUBLISHER
Elsevier
ABSTRACT
Background: Atrial fibrillation (AF) is the most common chronic rhythm
disorder. Patients with AF are at an increased risk of ischemic stroke.
Therefore, optimal anticoagulation is essential to reduce the risk of
stroke. The aim of this study was to assess the level of anticoagulation
control achieved in patients with nonvalvular AF receiving medical care in a
tertiary care hospital. Methods: This was a retrospective cohort study in
ambulatory care clinics at tertiary care hospital in Saudi Arabia. We
included 110 nonvalvular AF patients treated with warfarin for at least 3.
months at King Abdulaziz Medical City, Riyadh, Saudi Arabia, between May 1,
2012, and July 31, 2012. Thereafter, international normalized ratio results
were collected for 1. year. Anticoagulation control was assessed by
calculating time within therapeutic range (TTR) as per the Rosendaal method.
Results: The mean age was 64.9. ±. 16.5. years; 60.9% were female. The mean
TTR was 59%. Almost one third of the patients (32.7%) had poor
anticoagulation control; TTR of <50%. Poor anticoagulation control was
significantly associated with higher CHADS2 (congestive heart failure,
hypertension, age, diabetes, stroke) score (p = 0.043). TTR was not
significantly different between men and women. Similarly, TTR was not
associated with age or duration of anticoagulation. There was no adequate
information to assess the effect of other factors such as diet, compliance,
and level of education on anticoagulation. Thirty-one patients (28.2%) had a
history of prior stroke. The overall quality of anticoagulation was not
significantly different between patients with and without stroke, (TTR was
56.3% and 60.1%, respectively; p = 0.46). Conclusion: Quality of
anticoagulation in patients with AF receiving medical care in a tertiary
care hospital was suboptimal, with nearly 40% of the time spent outside the
therapeutic range. Methods to improve anticoagulation control among patients
with AF should be implemented.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulation
atrial fibrillation
Saudi Arabia
tertiary care center
EMTREE MEDICAL INDEX TERMS
adult
ambulatory care
cerebrovascular accident
CHADS2 score
clinical trial
cohort analysis
congestive heart failure
controlled study
diabetes mellitus
dietary compliance
drug therapy
education
female
human
hypertension
international normalized ratio
major clinical study
male
medical care
normal human
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160356055
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jsha.2016.02.001
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 117
TITLE
Impact of clinical and sociodemographic patient characteristics on the
outcome of cardiac rehabilitation in older patients
AUTHOR NAMES
Salzwedel A.
Wegscheider K.
Herich L.
Rieck A.
Strandt G.
Völler H.
AUTHOR ADDRESSES
(Salzwedel A., annett.salzwedel@uni-potsdam.de; Völler H.) Department of
Clinical Pharmacology and Toxicology, Charité (CBF), Berlin, Germany.
(Salzwedel A., annett.salzwedel@uni-potsdam.de; Völler H.) Rehabilitation
Centre for Internal Medicine, Klinik am See, Rüdersdorf, Germany.
(Salzwedel A., annett.salzwedel@uni-potsdam.de; Rieck A.; Völler H.) Centre
of Rehabilitation Research, University of Potsdam, Am-Neuen-Palais 10,
Potsdam, Germany.
(Wegscheider K.; Herich L.) Department of Medical Biometry and Epidemiology,
University Medical Centre, Hamburg-Eppendorf, Germany.
(Herich L.) Institute of Medical Statistics, Informatics and Epidemiology,
University of Cologne, Cologne, Germany.
(Strandt G.) Techniker Krankenkasse Hamburg, Hamburg, Germany.
CORRESPONDENCE ADDRESS
A. Salzwedel, Centre of Rehabilitation Research, University of Potsdam,
Am-Neuen-Palais 10, Potsdam, Germany.
SOURCE
Aging Clinical and Experimental Research (2015) 27:3 (315-321). Date of
Publication: 1 Jun 2015
ISSN
1720-8319 (electronic)
1594-0667
BOOK PUBLISHER
Springer International Publishing
ABSTRACT
Methods: The impact of baseline characteristics on the success of CR,
measured by MOC, was analysed using a mixed model for 1,220 older patients
(70.9 ± 7.0 years, 78.3 % men) who enrolled in 12 CR clinics. A multitude of
potentially influential baseline patient characteristics was considered
including sociodemographic variables, comorbidity, duration of hospital
stay, exercise capacity, cardiovascular risk factors, emotional status, and
laboratory and echocardiographic data.Background: Cardiac rehabilitation
(CR) seeks to simultaneously improve several outcome parameters related to
patient risk factors, exercise capacity and subjective health. A single
score, the multiple outcome criterion (MOC), comprised of alterations in 13
outcome variables was used to measure the overall success of CR in an older
population. As this success depends on the older patient’s characteristics
at the time of admission to CR, we attempted to determine the most important
influences.Results: Overall, CR was successful, as indicated by the mean
value of the MOC (0.6 ± 0.45; min −1.0, max 2.0; positive values denoting
improvement, negative ones deterioration). Examples of association with
negative MOC values included smoking (MOC −0.15, p < 0.001), female gender
(MOC −0.07, p = 0.049), and a longer hospital stay (MOC −0.03, p = 0.03). An
example of association with positive MOC value was depression score (MOC
0.06, p = 0.003). Further associations included maximal exercise capacity,
blood pressure, heart rate and the rehabilitation centre
attended.Conclusion: Our results emphasize the necessity to take into
consideration baseline characteristics when evaluating the success of CR and
setting treatment targets for older patients.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
demography
geriatric patient
heart rehabilitation
social aspect
treatment outcome
EMTREE MEDICAL INDEX TERMS
age
aged
article
atrial fibrillation (complication)
blood pressure
comorbidity
depression
exercise
exercise electrocardiography
exercise test
female
heart arrhythmia (complication)
heart rate
Hospital Anxiety and Depression Scale
human
infection (complication)
length of stay
major clinical study
male
outcome assessment
rehabilitation center
sex difference
smoking
wound healing impairment (complication)
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015040745
FULL TEXT LINK
http://dx.doi.org/10.1007/s40520-014-0283-2
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 118
TITLE
Acute STEMI in the setting of a single coronary artery anomaly
AUTHOR NAMES
McCarthy C.
Khider W.
Caplice N.
AUTHOR ADDRESSES
(McCarthy C.; Khider W., wkhider@ucc.ie; Caplice N.) CRVB, University
College Cork, Cork, Ireland.
CORRESPONDENCE ADDRESS
W. Khider, CRVB, University College Cork, Cork, Ireland.
SOURCE
BMJ Case Reports (2015) 2015 Article Number: 210002. Date of Publication: 13
May 2015
ISSN
1757-790X (electronic)
BOOK PUBLISHER
BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
We report a case of a patient admitted with an acute ST elevation myocardial
infarction following occlusion of his right coronary artery, successfully
treated with thrombectomy and percutaneous coronary intervention (PCI).
Coronary angiography and multislice CT revealed a single right coronary
artery with two anomalous branches (constituting the left coronary system);
one branch passed between the pulmonary trunk and the aorta before dividing
into three separate branches, while the other anomalous branch passed
anterior to the pulmonary trunk, consistent with a Yamanaka R-IIIC
classification. The course of this Yamanaka R-IIIC subtype is unusual as
both anomalous branches combine to form a dual origin left anterior
descending artery. The course of these anomalous branches places the patient
at an increased risk of future myocardial ischaemia, infarction and sudden
cardiac death. As symptoms typically develop on exertion, this cohort may
benefit from exercise myocardial perfusion imaging to identify high-risk
patients.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
apixaban (oral drug administration)
bisoprolol (drug therapy)
clopidogrel (oral drug administration)
diuretic agent (drug therapy)
dobutamine (drug therapy)
eplerenone (drug therapy)
ramipril (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute disease (diagnosis, surgery, therapy)
coronary artery occlusion (diagnosis, surgery, therapy)
ST segment elevation myocardial infarction (diagnosis, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
adult
akinesia
angiocardiography
angioplasty
article
atrial fibrillation
blood vessel
body mass
case report
differential diagnosis
disease classification
drug eluting stent
electrocardiography
exercise
follow up
heart ejection fraction
heart failure (drug therapy)
heart infarction
heart left ventricle failure (drug therapy)
heart left ventricle hypertrophy
heart muscle contractility
heart muscle ischemia
high risk patient
hospitalization
human
hyperkalemia
hypotension (drug therapy)
left anterior descending coronary artery
left coronary artery
lung edema (drug therapy)
male
multidetector computed tomography
percutaneous coronary intervention
pericarditis
priority journal
pulmonary trunk
repolarization
ST segment elevation
sudden cardiac death
thorax pain
thrombectomy
thrombus aspiration
treatment outcome
ventriculography
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
apixaban (503612-47-3)
bisoprolol (66722-44-9)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dobutamine (34368-04-2, 52663-81-7, 49745-95-1, 61661-06-1)
eplerenone (107724-20-9)
ramipril (87333-19-5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015058318
FULL TEXT LINK
http://dx.doi.org/10.1136/bcr-2015-210002
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 119
TITLE
Red cell distribution width in relation to incidence of stroke and carotid
atherosclerosis: A population-based cohort study
AUTHOR NAMES
Söderholm M.
Borné Y.
Hedblad B.
Persson M.
Engström G.
AUTHOR ADDRESSES
(Söderholm M., martin.soderholm@med.lu.se; Borné Y.; Hedblad B.; Persson M.;
Engström G.) Cardiovascular Epidemiology Research Group, Department of
Clinical Sciences, Lund University, Malmö, Sweden.
SOURCE
PLoS ONE (2015) 10:5 Article Number: e0124957. Date of Publication: 7 May
2015
ISSN
1932-6203 (electronic)
BOOK PUBLISHER
Public Library of Science, plos@plos.org
ABSTRACT
Background: Increased red cell distribution width (RDW) has been related to
poor prognosis in patients with cardiovascular disease, and is a predictor
of cardiovascular mortality in the general population. The purpose of the
present study was to investigate if RDW is associated with increased
incidence of stroke and its subtypes in individuals from the general
population. Methods: Red cell distribution width was measured in 26,879
participants (16,561 women and 10,318 men aged 45-73 years) without history
of coronary events or stroke, from the population-based Malmö Diet and
Cancer Study. Incidences of total stroke and stroke subtypes over a mean
follow-up of 15.2 years were calculated in relation to sex-specific
quartiles of RDW. The presence of carotid plaque and intima-media thickness,
as assessed by ultrasound, was studied in relation to RDW in a randomly
selected subcohort (n = 5,309). Results: Incidences of total stroke (n =
1,869) and cerebral infarction (n = 1,544) were both increased in
individuals with high RDW. Hazard ratios (HRs) in the highest compared to
the lowest quartile were 1.31 for total stroke (95% confidence interval
[CI]: 1.11-1.54, p for trend = 0.004) and 1.32 for cerebral infarction (95%
CI: 1.10-1.58, p for trend = 0.004) after adjustment for stroke risk factors
and hematological parameters. The adjusted HR for intracerebral hemorrhage
(n = 230) was 1.44 (95% CI: 0.90-2.30) and the HR for subarachnoid
hemorrhage (n = 75) was 0.94 (95% CI: 0.43-2.07), in the highest compared to
the lowest quartile of RDW. Red cell distribution width was positively
associated with intima-media thickness of the common carotid artery (p for
trend = 0.011). Conclusions: Red cell distribution width in the highest
quartile was associated with increased incidence of total stroke and
cerebral infarction. There was no significant association between RDW and
incidence of intracerebral or subarachnoid hemorrhage.
EMTREE DRUG INDEX TERMS
high density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
carotid atherosclerosis (epidemiology)
cerebrovascular accident (epidemiology)
erythrocyte parameters
incidence
red cell distribution width
EMTREE MEDICAL INDEX TERMS
adult
aged
arterial wall thickness
article
atrial fibrillation
blood sampling
brain infarction
brain ischemia
cholesterol blood level
cohort analysis
controlled study
disease association
erythrocyte volume
female
follow up
hemoglobin determination
human
leukocyte
male
nutritional assessment
population research
risk factor
subarachnoid hemorrhage
triacylglycerol blood level
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Hematology (25)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015038573
FULL TEXT LINK
http://dx.doi.org/10.1371/journal.pone.0124957
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 120
TITLE
Atrial fibrillation ablation using remote magnetic navigation and the risk
of atrial-esophageal fistula: international multicenter experience
AUTHOR NAMES
Danon A.
Shurrab M.
Nair K.M.
Latcu D.G.
Arruda M.S.
Chen X.
Szili-Torok T.
Rossvol O.
Wissner E.E.
Lashevsky I.
Crystal E.
AUTHOR ADDRESSES
(Danon A., asdanon@gmail.com; Shurrab M.; Nair K.M.; Lashevsky I.; Crystal
E.) Arrhythmia service, Schulich Heart Centre, Department of Cardiology,
Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, Canada.
(Danon A., asdanon@gmail.com) Arrhythmia service, department of Cardiology,
Carmel Medical Center, 7 Michal st., Haifa, Israel.
(Latcu D.G.) Service de Cardiologie, Centre Hospitalier Princesse Grace,
Monaco (Principauté), Monaco.
(Arruda M.S.) Harrington-McLaughlin Heart and Vascular Institute, University
Hospitals, Case Western Reserve University School of Medicine, Cleveland,
United States.
(Chen X.) Department of Cardiology, The Heart Centre, Rigshospitalet,
Copenhagen University Hospital, Copenhagen, Denmark.
(Szili-Torok T.) Clinical Electrophysiology, Department of Cardiology,
Erasmus MC, Rotterdam, Netherlands.
(Rossvol O.) Section of Cardiology, Department of Medicine, University of
Trondheim, Trondheim, Norway.
(Wissner E.E.) Department of Cardiology, Asklepios Klinik St. Georg,
Lohmühlenstr. 5, Hamburg, Germany.
CORRESPONDENCE ADDRESS
A. Danon, Arrhythmia service, Schulich Heart Centre, Department of
Cardiology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto,
Canada.
SOURCE
Journal of Interventional Cardiac Electrophysiology (2015) 43:2 (169-174).
Date of Publication: 3 May 2015
ISSN
1572-8595 (electronic)
1383-875X
BOOK PUBLISHER
Kluwer Academic Publishers
ABSTRACT
Purpose: Remote magnetic navigation (RMN) has been used in various
electrophysiological procedures, including atrial fibrillation (AF)
ablation. Atrial-esophageal fistula (AEF) is one of most disastrous
complications of AF ablation. We aimed to evaluate the incidence of AEF
during AF ablation using RMN in comparison to manual ablation. Methods: We
conducted the first international survey among RMN operators for assessment
of the prevalence of AEF and procedural parameters affecting the risk. Data
from parallel survey of AEF among Canadian interventional
electrophysiologists (CIE) using only manual catheters served as control.
Results: Fifteen RMN operators (who performed 3637 procedures) and 25 manual
CIE operators (7016 procedures) responded to the survey. RMN operators were
more experienced than CIE operators (16.3 ± 8.3 vs. 9.2 ± 5.4 practice years
in electrophysiology, p = 0.007). The maximal energy output in the posterior
wall was higher in the operator using RMN (33 ± 5 vs. 28.6 ± 4.9 W; p =
0.02). Other parameters including use of preprocedural images, irrigated
catheter, pump flow rate, esophageal temperature monitoring, intracardiac
echocardiography (ICE), and general anesthesia were similar. CIE operators
administered proton-pump inhibitors postoperatively significantly more than
RMN operators (76 vs. 35 %, p = 0.01). AEF was reported in 5 of the 7016
patients in the control group (0.07 %) but in none of the RMN group (p =
0.11). Conclusions: AEF is a rare complication and its evaluation
necessitates large-scale studies. Although no AEF case with RMN was reported
in this large study or previously on the literature, the rarity of this
complication prevents firm conclusion about the risk.
EMTREE DRUG INDEX TERMS
anesthetic agent
proton pump inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
ablation therapy
atrial esophageal fistula
atrial fibrillation (therapy)
esophagus fistula (complication)
medical procedures
remote magnetic navigation
risk factor
EMTREE MEDICAL INDEX TERMS
article
controlled study
disease association
flow rate
follow up
general anesthesia
heart electrophysiology
human
intermethod comparison
intracardiac echocardiography
outcome assessment
postoperative period
priority journal
risk assessment
temperature measurement
treatment response
DEVICE TRADE NAMES
Niobe , United StatesStereotaxis
DEVICE MANUFACTURERS
(United States)Stereotaxis
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015032185
FULL TEXT LINK
http://dx.doi.org/10.1007/s10840-015-0003-7
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 121
TITLE
Physiologic and pathophysiologic changes in the right heart in highly
trained athletes
ORIGINAL (NON-ENGLISH) TITLE
Physiologische und pathophysiologische Auswirkungen auf das rechte Herz bei
Leistungssportlern
AUTHOR NAMES
D’Andrea A.
la Gerche A.
Golia E.
Padalino R.
Calabrò R.
Russo M.G.
Bossone E.
AUTHOR ADDRESSES
(D’Andrea A., antonellodandrea@libero.it) Second University of Naples,
Monaldi Hospital, Via M. Schipa 44, Naples, Italy.
(la Gerche A.) Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
(Golia E.; Padalino R.; Calabrò R.; Russo M.G.; Bossone E.) Heart
Department, Cava de’ Tirreni and Amalfi Coast Hospital, University of
Salerno, Salerno, Italy.
CORRESPONDENCE ADDRESS
A. D’Andrea, Second University of Naples, Monaldi Hospital, Via M. Schipa
44, Naples, Italy.
SOURCE
Herz (2015) . Date of Publication: 1 Apr 2015
ISSN
1615-6692 (electronic)
0340-9937
BOOK PUBLISHER
Urban und Vogel GmbH, verlag@urban-vogel.de
ABSTRACT
Exercise causes changes in the heart in response to the hemodynamic demands
of increased systemic and pulmonary requirements during exercise.
Understanding these adaptations is of great importance, since they may
overlap with those caused by pathological conditions. Initial descriptions
of athlete’s heart focused mainly on chronic adaptation of the left heart to
training. In recent years, the substantial structural and functional
adaptations of the right heart have been documented, highlighting the
complex interplay with left heart. Moreover, there is evolving evidence of
acute and chronic cardiac damage, mainly involving the right heart, which
may predispose subjects to atrial and ventricular arrhythmias, configuring
an exercise-induced cardiomyopathy. The aim of this article is to review the
current knowledge on the physiologic and pathophysiologic changes in the
right heart in highly trained athletes.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
cardiomyopathy
endurance training
exercise
heart
human
EMTREE MEDICAL INDEX TERMS
adaptation
heart injury
heart ventricle arrhythmia
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, German
EMBASE ACCESSION NUMBER
2015883230
FULL TEXT LINK
http://dx.doi.org/10.1007/s00059-015-4220-8
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 122
TITLE
Adding fentanyl to etomidate fails to reduce painful recall of external
direct current cardioversion in adults: A randomised trial
AUTHOR NAMES
Souvatzis X.
Kalogridaki M.
Mavrakis H.E.
Kanoupakis E.M.
Marouli D.
Vardas P.
Askitopoulou H.
AUTHOR ADDRESSES
(Souvatzis X., x.souvatzis@gmx.de; Kalogridaki M.) Department of
Anaesthesiology, University Hospital of Heraklion, Crete, Greece.
(Mavrakis H.E.; Kanoupakis E.M.; Vardas P.) Department of Cardiology,
University Hospital of Heraklion, Crete, Greece.
(Marouli D.) Department of Intensive Care Medicine, University Hospital of
Heraklion, Crete, Greece.
(Askitopoulou H.) Anaesthesiology, University of Crete, Heraklion, Crete,
Greece.
CORRESPONDENCE ADDRESS
X. Souvatzis, Dept. of Anaesthesiology, University Hospital of Heraklion, PO
Box 1352, Heraklion, Greece.
SOURCE
Hellenic Journal of Cardiology (2015) 56:2 (142-148). Date of Publication: 1
Mar 2015
ISSN
1109-9666
BOOK PUBLISHER
Hellenic Cardiological Society
ABSTRACT
Introduction: External electrical cardioversion under hypnotics, even when
combined with opioids, has been consistently described as distressing or
painful. The main objective of the present study was to determine if adding
an opioid to a hypnotic, in comparison to the same hypnotic alone, would
decrease the incidence of unpleasant or painful recall during anaesthesia
for external electrical cardioversion. Methods: This was a single-centre,
prospective, randomised, double-blinded clinical trial that took place from
September 2011 to March 2012. Fifty-two adult patients with persistent
atrial fibrillation, scheduled for external direct current cardioversion,
were enrolled. Exclusion criteria were age >80 years, previous cardiac
surgery, implanted pacemaker or defibrillator, and haemodynamic instability.
Patients received intravenously either (group EF) fentanyl 50 μg and after
60 s etomidate 0.1 mg/kg, or (group E) only etomidate 0.1 mg/kg. If the
patients did not lose their eyelid reflex, repeated doses of etomidate 4 mg
were given. Cardioversion was attempted with an extracardiac biphasic
electrical shock from 200 to 300 J, at most three times. The primary
endpoint was recall of something unpleasant or painful. Secondary outcome
measures were predictors of the requirement for repeat doses of etomidate,
and the number of shocks needed. Results: Fifty-one patients (35 male, 16
female), aged 62.1 ± 10.2 years, completed the study. There were no
differences between group EF and group E regarding recall (unpleasant recall
0 vs. 2 patients, p=0.235; painful recall 1 vs. 0 patients, p=0.510). The
administration of etomidate alone was a significant predictor for subsequent
repeated doses of etomidate (p=0.049, odds ratio 4.312, 95% confidence
interval 1.007-18.460). The number of shocks needed to restore sinus rhythm
did not differ between the groups (p=0.846). Conclusions: In the present
study, the addition of fentanyl to etomidate did not diminish distressing or
painful experience during anaesthesia for external cardioversion.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
etomidate (drug combination, drug comparison, drug therapy, intravenous drug
administration)
fentanyl (drug combination, drug comparison, drug therapy, intravenous drug
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardioversion
pain (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
apnea
article
atrial fibrillation (therapy)
consciousness level
controlled study
double blind procedure
electrocardiogram
eyelid reflex
female
heart left ventricle ejection fraction
human
major clinical study
male
manual ventilation
middle aged
myoclonus
prospective study
randomized controlled trial
repeated drug dose
sinus rhythm
treatment outcome
CAS REGISTRY NUMBERS
etomidate (15301-65-2, 33125-97-2, 51919-80-3)
fentanyl (437-38-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015943442
MEDLINE PMID
25854443 (http://www.ncbi.nlm.nih.gov/pubmed/25854443)
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 123
TITLE
Adherence to a Mediterranean diet and prediction of incident stroke
AUTHOR NAMES
Tsivgoulis G.
Psaltopoulou T.
Wadley V.G.
Alexandrov A.V.
Howard G.
Unverzagt F.W.
Moy C.
Howard V.J.
Kissela B.
Judd S.E.
AUTHOR ADDRESSES
(Tsivgoulis G., tsivgoulisgiorg@yahoo.gr) Second Department of Neurology,
Attikon Hospital, University of Athens, School of Medicine, Iras 39, Gerakas
Attikis, Athens, Greece.
(Psaltopoulou T.) Department of Hygiene, Epidemiology and Medical
Statistics, University of Athens, School of Medicine, Athens, Greece.
(Tsivgoulis G., tsivgoulisgiorg@yahoo.gr; Alexandrov A.V.) Department of
Neurology, University of Tennessee, Health Science Center, Memphis, United
States.
(Tsivgoulis G., tsivgoulisgiorg@yahoo.gr) International Clinical Research
Center, St. Anne's University Hospital, Brno, Czech Republic.
(Wadley V.G.) Department of Medicine, University of Alabama, Birmingham,
United States.
(Howard G.; Judd S.E.) Department of Biostatistics, School of Public Health,
University of Alabama, Birmingham, United States.
(Howard V.J.) Department of Epidemiology, School of Public Health,
University of Alabama, Birmingham, United States.
(Unverzagt F.W.) Department of Psychiatry, Indiana University, School of
Medicine, Indianapolis, United States.
(Moy C.) National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, United States.
(Kissela B.) Department of Neurology, University of Cincinnati, United
States.
CORRESPONDENCE ADDRESS
G. Tsivgoulis, Second Department of Neurology, Attikon Hospital, University
of Athens, School of Medicine, Iras 39, Gerakas Attikis, Athens, Greece.
SOURCE
Stroke (2015) 46:3 (780-785). Date of Publication: 1 Mar 2015
ISSN
1524-4628 (electronic)
0039-2499
BOOK PUBLISHER
Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
Background and Purpose: There are limited data on the potential association
of adherence to Mediterranean diet (MeD) with incident stroke. We sought to
assess the longitudinal association between greater adherence to MeD and
risk of incident stroke. Methods: We prospectively evaluated a
population-based cohort of 30 239 individuals enrolled in REasons for
Geographic and Racial Differences in Stroke (REGARDS) study, after excluding
participants with stroke history, missing demographic data or food frequency
questionnaires, and unavailable follow-up information. Adherence to MeD was
categorized using MeD score. Incident stroke was adjudicated by expert panel
review of medical records during a mean follow-up period of 6.5 years.
Results: Incident stroke was identified in 565 participants (2.8%; 497 and
68 cases of ischemic stroke [IS] and hemorrhagic stroke, respectively) of 20
197 individuals fulfilling the inclusion criteria. High adherence to MeD
(MeD score, 5-9) was associated with lower risk of incident IS in unadjusted
analyses (hazard ratio, 0.83; 95% confidence interval, 0.70-1.00; P=0.046).
The former association retained its significance (hazard ratio, 0.79; 95%
confidence interval, 0.65-0.96; P=0.016) after adjustment for demographics,
vascular risk factors, blood pressure levels, and antihypertensive
medications. When MeD was evaluated as a continuous variable, a 1-point
increase in MeD score was independently associated with a 5% reduction in
the risk of incident IS (95% confidence interval, 0-11%). We documented no
association of adherence to MeD with incident hemorrhagic stroke. There was
no interaction of race (P=0.37) on the association of adherence to MeD with
incident IS. Conclusions: High adherence to MeD seems to be associated with
a lower risk of incident IS independent of potential confounders. Adherence
to MeD is not related to the risk of incident hemorrhagic stroke.
EMTREE DRUG INDEX TERMS
antihypertensive agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
Mediterranean diet
EMTREE MEDICAL INDEX TERMS
adult
aged
antihypertensive therapy
article
atrial fibrillation
Black person
blood pressure
brain hemorrhage
brain ischemia
demography
diabetes mellitus
female
follow up
food frequency questionnaire
food intake
human
hypertension (drug therapy)
major clinical study
male
medical record review
nutritional assessment
obesity
patient compliance
prediction
priority journal
race difference
risk reduction
sedentary lifestyle
systolic blood pressure
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015424748
FULL TEXT LINK
http://dx.doi.org/10.1161/STROKEAHA.114.007894
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 124
TITLE
Clinical utility of exercise training in heart failure with reduced and
preserved ejection fraction
AUTHOR NAMES
Ul Haq M.A.
Goh C.Y.
Levinger I.
Wong C.
Hare D.L.
AUTHOR ADDRESSES
(Ul Haq M.A., muhammad.asrar@unimelb.edu.au; Goh C.Y.; Wong C.) Northern
Heart, The Northern Hospital, Melbourne, Australia.
(Ul Haq M.A.; Hare D.L.) Austin Health, Melbourne, Australia.
(Ul Haq M.A.; Wong C.; Hare D.L.) University of Melbourne, Melbourne,
Australia.
(Levinger I.) Institute of Sport, Exercise and Active Living (ISEAL),
College of Sport and Exercise Science, Victoria University, Melbourne,
Australia.
CORRESPONDENCE ADDRESS
M.A. Ul Haq, Northern Heart, The Northern Hospital, Melbourne, Australia.
SOURCE
Clinical Medicine Insights: Cardiology (2015) 9 (1-9). Date of Publication:
9 Feb 2015
ISSN
1179-5468 (electronic)
1179-5468
BOOK PUBLISHER
Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay,
Auckland, New Zealand.
ABSTRACT
Reduced exercise tolerance is an independent predictor of hospital
readmission and mortality in patients with heart failure (HF). Exercise
training for HF patients is well established as an adjunct therapy, and
there is sufficient evidence to support the favorable role of exercise
training programs for HF patients over and above the optimal medical
therapy. Some of the documented benefits include improved functional
capacity, quality of life (QoL), fatigue, and dyspnea. Major trials to
assess exercise training in HF have, however, focused on heart failure with
reduced ejection fraction (HFREF). At least half of the patients presenting
with HF have heart failure with preserved ejection fraction (HFPEF) and
experience similar symptoms of exercise intolerance, dyspnea, and early
fatigue, and similar mortality risk and rehospitalization rates. The role of
exercise training in the management of HFPEF remains less clear. This
article provides a brief overview of pathophysiology of reduced exercise
tolerance in HFREF and heart failure with preserved ejection fraction
(HFPEF), and summarizes the evidence and mechanisms by which exercise
training can improve symptoms and HF. Clinical and practical aspects of
exercise training prescription are also discussed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aerobic exercise
heart failure (etiology)
heart failure with preserved ejection fraction (etiology)
heart failure with reduced ejection fraction (etiology)
resistance training
EMTREE MEDICAL INDEX TERMS
arterial stiffness
article
atrial fibrillation
cardiovascular parameters
disease association
dyspnea
endothelial dysfunction
exercise intolerance
fatigue
heart left ventricle failure
hospital readmission
human
left ventricular enddiastolic diameter
lung congestion
mitral valve regurgitation
mortality
non insulin dependent diabetes mellitus
pathophysiology
physical activity
practice guideline
pulmonary hypertension
quality of life
randomized controlled trial (topic)
risk factor
sudden cardiac death
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015735964
FULL TEXT LINK
http://dx.doi.org/10.4137/CMC.S21372
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 125
TITLE
Abstracts of the 18th Annual SCMR Scientific Sessions
AUTHOR ADDRESSES
SOURCE
Journal of Cardiovascular Magnetic Resonance (2015) 17 SUPPL. 1. Date of
Publication: 3 Feb 2015
CONFERENCE NAME
18th Annual SCMR Scientific Sessions
CONFERENCE LOCATION
Nice, France
CONFERENCE DATE
2015-02-04 to 2015-02-07
ISSN
1097-6647
BOOK PUBLISHER
BioMed Central Ltd.
ABSTRACT
The proceedings contain 707 papers. The topics discussed include: inter
breathhold reproducibility of temporal patterns of coronary artery blood
flow; MRI assessment of aortic flow and pulse wave velocity in response to
exercise; assessment of left atrial and left atrial appendage flow and
stasis in atrial fibrillation; regional assessment of myocardial
regeneration therapies in rats using magnetic resonance tagging; ischemic
post-conditioning diminishes intramyocardial hemorrhage in acute reperfused
myocardial infarction in rats, evaluated by CMR at 7T; cardiovascular
magnetic resonance feature tracking in patients with acute myocarditis and
normal ejection fraction: potential for improved diagnosis and prognosis;
and myocardial fibrosis is associated with subsequent death and
hospitalization for heart failure in obese adults.
EMTREE MEDICAL INDEX TERMS
adult
aorta flow
atrial fibrillation
bleeding
cardiovascular magnetic resonance
conditioning
coronary artery blood flow
death
diagnosis
exercise
heart atrium appendage
heart ejection fraction
heart failure
heart infarction
heart muscle fibrosis
hospitalization
human
myocarditis
nuclear magnetic resonance
nuclear magnetic resonance imaging
patient
prognosis
pulse wave
rat
regeneration
reproducibility
therapy
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 126
TITLE
Mucosal healing and the risk of ischemic heart disease or atrial
fibrillation in patients with celiac disease; a population-based study
AUTHOR NAMES
Lebwohl B.
Emilsson L.
Fröbert O.
Einstein A.J.
Green P.H.R.
Ludvigsson J.F.
AUTHOR ADDRESSES
(Lebwohl B.; Green P.H.R.) Celiac Disease Center, Department of Medicine,
Columbia University College of Physicians and Surgeons, New York, United
States.
(Lebwohl B.; Ludvigsson J.F., jonasludvigsson@yahoo.com) Department of
Medical Epidemiology and Biostatistics, Karolinska University Hospital and
Karolinska Institute, Stockholm, Sweden.
(Emilsson L.) Primary Care Research Unit, Department of Medicine, Örebro
University, Örebro, Sweden.
(Fröbert O.) Department of Cardiology, Örebro University Hospital, Örebro,
Sweden.
(Einstein A.J.) Department of Medicine, Columbia University College of
Physicians and Surgeons, New York-Presbyterian Hospital, New York, United
States.
(Ludvigsson J.F., jonasludvigsson@yahoo.com) Department of Pediatrics,
Örebro University Hospital, Örebro, Sweden.
SOURCE
PLoS ONE (2015) 10:1 Article Number: e0117529. Date of Publication: 30 Jan
2015
ISSN
1932-6203 (electronic)
BOOK PUBLISHER
Public Library of Science, plos@plos.org
ABSTRACT
Background: Patients with celiac disease (CD), characterized histologically
by villous atrophy (VA) of the small intestine, have an increased risk of
ischemic heart disease (IHD) and atrial fibrillation (AF), risks that
persist for years after commencing the gluten-free diet. It is unknown
whether persistent VA on follow-up biopsy, rather than mucosal healing,
affects the risk of IHD or AF. Methods: We identified patients with
histologic evidence of CD diagnosed at all 28 pathology departments in
Sweden. Among patients who underwent a follow-up small intestinal biopsy, we
compared patients with persistent VA to those who showed histologic
improvement, with regard to the development of IHD (angina pectoris or
myocardial infarction) or AF. Results: Among patients with CD and a
follow-up biopsy (n = 7,440), the median age at follow-up biopsy was 25
years, with 1,063 (14%) patients who were ≥60 years at the time of follow-up
biopsy. Some 196 patients developed IHD and 205 patients developed AF. After
adjusting for age, gender, duration of CD, calendar period, and educational
attainment, there was no significant effect of persistent VA on IHD
(adjusted HR 0.97; 95%CI 0.73-1.30). Adjusting for diabetes had a negligible
effect (adjusted HR 0.98; 95%CI 0.73-1.31). There was no significant
association between persistent VA and the risk of AF (adjusted HR 0.98;
95%CI0.74-1.30). Conclusions: In this population-based study of patients
with CD, persistent VA on follow-up biopsy was not associated with an
increased risk of IHD or AF. Failed mucosal healing does not influence the
risk of these cardiac events.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
angina pectoris
atrial fibrillation
celiac disease
fatal myocardial infarction
healing
heart infarction
ischemic heart disease
mucosal healing
unstable angina pectoris
EMTREE MEDICAL INDEX TERMS
adolescent
adult
age distribution
article
child
controlled study
diabetes mellitus
disease association
disease duration
duodenum biopsy
educational status
female
follow up
gender
histology
human
human cell
human tissue
incidence
intestine villus atrophy
major clinical study
male
population research
Sweden
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015716769
FULL TEXT LINK
http://dx.doi.org/10.1371/journal.pone.0117529
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 127
TITLE
Increased left atrial size is associated with reduced atrial stiffness and
preserved reservoir function in athlete’s heart
AUTHOR NAMES
D’Ascenzi F.
Pelliccia A.
Natali B.M.
Cameli M.
Andrei V.
Incampo E.
Alvino F.
Lisi M.
Padeletti M.
Focardi M.
Bonifazi M.
Mondillo S.
AUTHOR ADDRESSES
(D’Ascenzi F., flavio.dascenzi@libero.it; Natali B.M.; Cameli M.; Andrei V.;
Incampo E.; Alvino F.; Lisi M.; Padeletti M.; Focardi M.; Mondillo S.)
Department of Cardiovascular Diseases, University of Siena, Viale M. Bracci,
Siena, Italy.
(Pelliccia A.) Institute of Sports Medicine and Science, Rome, Italy.
(Bonifazi M.) Department of Medicine, Surgery, and NeuroScience, University
of Siena, Siena, Italy.
CORRESPONDENCE ADDRESS
F. D’Ascenzi, Department of Cardiovascular Diseases, University of Siena,
Viale M. Bracci, Siena, Italy.
SOURCE
International Journal of Cardiovascular Imaging (2015) . Date of
Publication: 28 Jan 2015
ISSN
1573-0743 (electronic)
1569-5794
BOOK PUBLISHER
Kluwer Academic Publishers
ABSTRACT
Left atrial (LA) fibrosis with increased stiffness has been assumed to be
the substrates for occurrence of atrial arrhythmias in athletes. However,
this hypothesis has not yet been confirmed in humans. Aim of this study was,
therefore, to assess LA remodeling and stiffness in competitive athletes.
150 competitive athletes and 90 age and sex-matched sedentary subjects were
analyzed by speckle-tracking echocardiography to measure peak atrial
longitudinal strain (PALS) and peak atrial contraction strain (PACS). LA
stiffness was determined using E/e’ ratio in conjunction with PALS. Left
ventricular (LV) stiffness was also calculated. LA volume index was greater
in athletes as compared with controls (24.6 ± 7.3 vs. 18.4 ± 7.8 mL/m(2), p
< .0001). LA PALS, LA PACS, and E/e’ ratio were lower in athletes in
comparison with controls (p < .05, p ≤ .001, and p < .0001, respectively).
Despite greater LA size, competitive athletes had lower LA stiffness as
compared with controls (0.13 ± 0.04 vs. 0.16 ± 0.06, p ≤ .001). In addition,
LV stiffness was lower in athletes (0.84 ± 0.27 vs. 1.07 ± 0.46, p ≤ .001).
The only independent predictor of LA stiffness was LV stiffness (β = 0.46, p
< .0001), while the only independent predictor of LA volume index was LV
end-systolic volume index (β = 0.25, p = .002). Competitive athletes showed
greater LA size associated with lower stiffness as compared with controls.
Thus, LA remodeling in the context of the athlete’s heart is not associated
with increased LA stiffness. These findings support the benign nature of LA
remodeling in athletes, occurring as a physiological adaptation to exercise
conditioning.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
echocardiography
exercise
heart
heart atrium function
human
rigidity
EMTREE MEDICAL INDEX TERMS
adaptation
conditioning
fibrosis
heart atrium arrhythmia
heart atrium contraction
heart left ventricle endsystolic volume
hypothesis
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015703725
FULL TEXT LINK
http://dx.doi.org/10.1007/s10554-015-0600-7
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 128
TITLE
Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture,
biofeedback and more
AUTHOR NAMES
Kanmanthareddy A.
Reddy M.
Ponnaganti G.
Sanjani H.P.
Koripalli S.
Adabala N.
Buddam A.
Janga P.
Lakkireddy T.
Bommana S.
Vallakati A.
Atkins D.
Lakkireddy D.
AUTHOR ADDRESSES
(Kanmanthareddy A.) School of Medicine, Creighton University, Omaha, United
States.
(Kanmanthareddy A.) VA Nebraska-Western Iowa Health Care System, Omaha,
United States.
(Reddy M.; Ponnaganti G.; Sanjani H.P.; Koripalli S.; Adabala N.; Buddam A.;
Janga P.; Lakkireddy T.; Bommana S.; Atkins D.; Lakkireddy D.,
dlakkireddy@kumc.edu) The University of Kansas Medical Center and Hospital,
Kansas City, United States.
(Vallakati A.) Case Western Reserve University, MetroHealth Medical Center,
Cleveland, United States.
CORRESPONDENCE ADDRESS
D. Lakkireddy, Center for Excellence in Atrial Fibrillation and oEP
Research, Bloch Heart Rhythm Center, Mid America Cardiology, University of
Kansas Hospital, 3901 Rainbow Blvd, Kansas City, United States.
SOURCE
Journal of Thoracic Disease (2015) 7:2 (185-192). Date of Publication: 2015
ISSN
2077-6624 (electronic)
2072-1439
BOOK PUBLISHER
Pioneer Bioscience Publishing, jtd@thepbpc.org
ABSTRACT
The last decade has seen a significant improvement in the management of
atrial fibrillation (AF) with the development of newer medications and
improvement in catheter ablation techniques. Recurrence of AF remains a
significant problem in these patients and medications offer limited
supportive role. Complementary and alternative treatment strategies
therefore remain a viable option for these AF patients. Several studies have
shown improvement in AF symptoms with yoga therapy, acupuncture and
biofeedback. There are also several herbal medicine and supplements such as
omega-3 fatty acids, antioxidant vitamins, barberry, motherwort, cinchona,
Shensongyangxin, hawthorn, Kella and Wenxin Keli that have been evaluated as
potential therapeutic options in AF. These studies are however limited by
small sample sizes with mixed results. Besides the pharmacological action,
metabolism, interactions with other medications and the adverse effects of
the herbal medications and supplements remain poorly understood. In spite of
the above limitations, complementary therapies remain a promising option in
the management of AF and further studies are necessary to validate their
safety and efficacy.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent (drug therapy)
antioxidant (drug therapy)
Chinese drug (drug therapy)
Crataegus extract (drug therapy)
herbaceous agent (drug therapy)
Motherwort extract (drug therapy)
omega 3 fatty acid (drug therapy)
plant extract (drug therapy)
shensongyangxin (drug therapy)
unclassified drug
vitamin (drug therapy)
Wenxin Keli extract (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
alternative medicine
atrial fibrillation (drug therapy, drug therapy, therapy)
feedback system
yoga
EMTREE MEDICAL INDEX TERMS
Apiaceae
Berberidaceae
catheter ablation
Cinchona
clinical effectiveness
Crataegus
diet supplementation
herbal medicine
human
Khella
Lamiaceae
medicinal plant
Motherwort
nonhuman
patient safety
recurrent disease (therapy)
review
symptom
Wenxin Keli
CAS REGISTRY NUMBERS
Crataegus extract (82374-45-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015723843
FULL TEXT LINK
http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.13
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 129
TITLE
Mediterranean Dietary Patterns and Cardiovascular Health
AUTHOR NAMES
Shen J.
Wilmot K.A.
Ghasemzadeh N.
Molloy D.L.
Burkman G.
Mekonnen G.
Gongora M.C.
Quyyumi A.A.
Sperling L.S.
AUTHOR ADDRESSES
(Shen J., lsperli@emory.edu; Wilmot K.A.; Ghasemzadeh N.; Mekonnen G.;
Gongora M.C.; Quyyumi A.A.; Sperling L.S.) Emory Clinical Cardiovascular
Research Institute, United States.
(Shen J., lsperli@emory.edu; Wilmot K.A.; Ghasemzadeh N.; Molloy D.L.;
Burkman G.; Mekonnen G.; Gongora M.C.; Quyyumi A.A.; Sperling L.S.)
Department of Medicine, Division of Cardiology, Emory University, Atlanta,
United States.
SOURCE
Annual Review of Nutrition (2015) 35:1 (425-449). Date of Publication: 17
Jul 2015
ISSN
1545-4312 (electronic)
0199-9885
BOOK PUBLISHER
Annual Reviews Inc., 4139 El Camino Way, P.O. Box 10139, Palo Alto, United
States.
ABSTRACT
The Mediterranean dietary pattern has been linked with reduced
cardiovascular disease incidence and mortality. Components of the
Mediterranean diet associated with better cardiovascular health include low
consumption of meat and meat products, moderate consumption of ethanol
(mostly from wine), and high consumption of vegetables, fruits, nuts,
legumes, fish, and olive oil. Increasing evidence indicates that the synergy
among these components results in beneficial changes in intermediate
pathways of cardiometabolic risk, such as lipids, insulin sensitivity,
oxidative stress, inflammation, and vasoreactivity. As a result, consumption
of a Mediterranean dietary pattern favorably affects numerous cardiovascular
disease risk factors, such as dyslipidemia, hypertension, metabolic
syndrome, and diabetes. Moreover, strong evidence links this dietary pattern
with reduced cardiovascular disease incidence, reoccurrence, and mortality.
This review evaluates the current evidence behind the cardioprotective
effects of a Mediterranean dietary pattern.
EMTREE DRUG INDEX TERMS
apolipoprotein B
cholesterol
lipoprotein
olive oil
protein
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (prevention)
Mediterranean diet
EMTREE MEDICAL INDEX TERMS
alcohol consumption
arterial stiffness
atrial fibrillation
cardiovascular mortality
cardiovascular risk
cerebrovascular accident
cerebrovascular disease
dairy product
diabetes mellitus
food crop
herb
human
hypertension
insulin resistance
lifestyle
meta analysis (topic)
metabolic syndrome X
microangiopathy
morbidity
multicenter study (topic)
nonhuman
nut
oxidative stress
physical activity
primary prevention
priority journal
randomized controlled trial (topic)
review
secondary prevention
spice
wine
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
olive oil (8001-25-0)
protein (67254-75-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015208873
FULL TEXT LINK
http://dx.doi.org/10.1146/annurev-nutr-011215-025104
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 130
TITLE
Dietary fat intake is differentially associated with risk of paroxysmal
compared with sustained atrial fibrillation in women
AUTHOR NAMES
Chiuve S.E.
Sandhu R.K.
Moorthy M.V.
Glynn R.J.
Albert C.M.
AUTHOR ADDRESSES
(Chiuve S.E., schiuve@hsph.harvard.edu; Albert C.M.) Center for Arrhythmia
Prevention, Brigham and Women's Hospital and Harvard Medical School, Boston,
United States.
(Chiuve S.E., schiuve@hsph.harvard.edu; Sandhu R.K.; Moorthy M.V.; Glynn
R.J.; Albert C.M.) Division of Preventive Medicine, Brigham and Women's
Hospital and Harvard Medical School, Boston, United States.
(Albert C.M.) Cardiovascular Division, Department of Medicine, Brigham and
Women's Hospital and Harvard Medical School, Boston, United States.
(Chiuve S.E., schiuve@hsph.harvard.edu) Department of Nutrition, Harvard
T.H. Chan School of Public Health, Boston, United States.
(Sandhu R.K.) Division of Cardiology, University of Alberta, Edmonton,
Canada.
CORRESPONDENCE ADDRESS
S.E. Chiuve, Center for Arrhythmia Prevention, Brigham and Women's Hospital
and Harvard Medical School, Boston, United States.
SOURCE
Journal of Nutrition (2015) 145:9 (2092-2101). Date of Publication: 2015
ISSN
1541-6100 (electronic)
0022-3166
BOOK PUBLISHER
American Society for Nutrition, staff@dues.faseb.org
ABSTRACT
Background: Dietary fats have effects on biological pathways that may
influence the development and maintenance of atrial fibrillation (AF).
However, associations between n-3 (ω-3) polyunsaturated fatty acids and AF
are inconsistent, and data on other dietary fats and AF risk are sparse.
Objectives: We examined the association between dietary fatty acid (FA)
subclasses and risk of incident AF and explored whether these associations
differed for sustained and paroxysmal AF. Methods: We conducted a
prospective cohort study in 33,665 women ≥45 y old without cardiovascular
disease (CVD) and AF at baseline in 1993. Fat intake was estimated from food
frequency questionnaires at baseline and in 2004. Incident AF was confirmed
by medical records through October 2013. AF patterns were classified
according to the most sustained form of AF within 2 y of diagnosis. Cox
proportional hazards models with the use of a competing risk model approach
estimated the RR. Results: Over 19.2 y, 1441 cases of incident AF (929
paroxysmal and 467 persistent/chronic) were confirmed. Intakes of total fat
and FA subclasses were not associated with risk of AF. Saturated fatty acids
(SFAs) and monounsaturated fatty acids (MUFAs) were differentially
associated with AF patterns. The RR for a 5% increment of energy from SFAs
was 1.47 (95% CI: 1.04, 2.09) for persistent/chronic and 0.85 (95% CI: 0.66,
1.08) for paroxysmal AF (P-difference = 0.01). For MUFAs, the RR for a 5%
increment was 0.67 (95% CI: 0.46, 0.98) for persistent/chronic and 1.03 (95%
CI: 0.78, 1.34) for paroxysmal AF, although the difference between patterns
was not significant (P-difference = 0.07). Conclusions: Dietary fat was not
associated with risk of incident AF in women without established CVD or AF.
High SFA and low MUFA intakes were associated with greater risk of
persistent or chronic, but not paroxysmal, AF. Improving dietary fat quality
may play a role in the prevention of sustained forms of AF.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
fatty acid (drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
alpha tocopherol (drug therapy)
beta carotene (drug therapy)
docosahexaenoic acid (drug therapy)
icosapentaenoic acid (drug therapy)
linolenic acid (drug therapy)
monounsaturated fatty acid (drug therapy)
omega 3 fatty acid (drug therapy)
omega 6 fatty acid (drug therapy)
saturated fatty acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis, epidemiology, therapy)
fat intake
paroxysmal atrial fibrillation (diagnosis, epidemiology, therapy)
sustained atrial fibrillation (diagnosis, epidemiology, therapy)
EMTREE MEDICAL INDEX TERMS
adult
article
cardiovascular disease (drug therapy, prevention, therapy)
chronic atrial fibrillation (epidemiology, therapy)
cohort analysis
controlled study
disease association
drug efficacy
energy
female
food frequency questionnaire
human
incidence
low drug dose
major clinical study
medical record
middle aged
persistent atrial fibrillation (epidemiology, therapy)
proportional hazards model
prospective study
randomized controlled trial
risk factor
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
beta carotene (7235-40-7)
docosahexaenoic acid (25167-62-8, 32839-18-2)
icosapentaenoic acid (25378-27-2, 32839-30-8)
linolenic acid (1955-33-5, 463-40-1)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00000479)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015364105
FULL TEXT LINK
http://dx.doi.org/10.3945/jn.115.212860
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 131
TITLE
Renal function assessment in atrial fibrillation: Usefulness of chronic
kidney disease epidemiology collaboration vs reexpressed 4 variable
modification of diet in renal disease
AUTHOR NAMES
Abumuaileq R.R.-Y.
Abu-Assi E.
López-López A.
Raposeiras-Roubin S.
Rodríguez-Mañero M.
Martínez-Sande L.
García-Seara F.J.
Fernandez-López X.A.
González-Juanatey J.R.
AUTHOR ADDRESSES
(Abumuaileq R.R.-Y., drrami2012@hotmail.com; Abu-Assi E.; López-López A.;
Raposeiras-Roubin S.; Rodríguez-Mañero M.; Martínez-Sande L.; García-Seara
F.J.; Fernandez-López X.A.; González-Juanatey J.R.) Cardiology Department,
University Clinical Hospital of Santiago de Compostela, A choupana s/n,
Santiago de Compostela, Spain.
CORRESPONDENCE ADDRESS
R.R.-Y. Abumuaileq, Cardiology Department, University Clinical Hospital of
Santiago de Compostela, A choupana s/n, Santiago de Compostela, Spain.
Email: drrami2012@hotmail.com
SOURCE
World Journal of Cardiology (2015) 7:10 (685-694). Date of Publication: 2015
ISSN
1949-8462 (electronic)
BOOK PUBLISHER
Baishideng Publishing Group Co, bpg@baishideng.com
ABSTRACT
AIM: To compare the performance of the re-expressed Modification of Diet in
Renal Disease equation vs the new Chronic Kidney Disease Epidemiology
Collaboration equation in patients with non-valvular atrial fibrillation.
METHODS: We studied 911 consecutive patients with non-valvular atrial
fibrillation on vitamin-K antagonist. The performance of the re-expressed
Modification of Diet in Renal Disease equation vs the new Chronic Kidney
Disease Epidemiology Collaboration equation in patients with non-valvular
atrial fibrillation with respect to either a composite endpoint of major
bleeding, thromboembolic events and all-cause mortality or each individual
component of the composite endpoint was assessed using continuous and
categorical = 60, 59-30, and < 30 mL/min per 1.73 m2 estimated glomerular
filtration rate. RESULTS: During 10 ± 3 mo, the composite endpoint occurred
in 98 (10.8%) patients: 30 patients developed major bleeding, 18 had
thromboembolic events, and 60 died. The new equation provided lower
prevalence of renal dysfunction < 60 mL/min per 1.73 m2 (32.9%), compared
with the re-expressed equation (34.1%). Estimated glomerular filtration rate
from both equations was independent predictor of composite endpoint (HR =
0.98 and 0.97 for the re-expressed and the new equation, respectively; P <
0.0001) and all-cause mortality (HR = 0.98 for both equations, P < 0.01).
Strong association with thromboembolic events was observed only when
estimated glomerular filtration rate was < 30 mL/min per 1.73 m2: HR is 5.1
for the re-expressed equation, and HR = 5.0 for the new equation. No
significant association with major bleeding was observed for both
equations.CONCLUSION: The new equation reduced the prevalence of renal
dysfunction. Both equations performed similarly in predicting major adverse
outcomes.
EMTREE DRUG INDEX TERMS
acenocoumarol (drug therapy)
antivitamin K (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy)
chronic kidney disease (epidemiology)
Chronic Kidney Disease Epidemiology Collaboration
clinical assessment tool
diet supplementation
kidney disease (therapy)
kidney function
Modification of Diet in Renal Disease
EMTREE MEDICAL INDEX TERMS
adult
adverse outcome
aged
article
bleeding
clinical article
clinical assessment
female
glomerulus filtration rate
human
male
mortality
performance
prevalence
thromboembolism
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015526663
FULL TEXT LINK
http://dx.doi.org/10.4330/wjc.v7.i10.685
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 132
TITLE
Optimizing pain management to facilitate Enhanced Recovery After Surgery
pathways
ORIGINAL (NON-ENGLISH) TITLE
Optimiser le contrôle de la douleur pour faciliter la Récupération rapide
après la chirurgie
AUTHOR NAMES
Tan M.
Law L.S.-C.
Gan T.J.
AUTHOR ADDRESSES
(Tan M.; Law L.S.-C.) Duke-NUS Graduate Medical School, Singapore,
Singapore.
(Gan T.J., tong.gan@stonybrookmedicine.edu) Department of Anesthesiology,
Stony Brook Medicine, Stony Brook, United States.
CORRESPONDENCE ADDRESS
T.J. Gan, Department of Anesthesiology, Stony Brook Medicine, Stony Brook,
United States.
SOURCE
Canadian Journal of Anesthesia (2015) 62:2 (203-218). Date of Publication:
2015
ISSN
1496-8975 (electronic)
0832-610X
BOOK PUBLISHER
Springer New York LLC, journals@springer-sbm.com
ABSTRACT
Purpose: The optimal management of postoperative pain using multimodal
analgesia is a key component of Enhanced Recovery After Surgery (ERAS). Pain
has adverse clinical implications on postoperative recovery, including
prolonging the time to recovery milestones and length of hospital stay.
Moreover, the ubiquity of opioids in postoperative analgesic regimens
results in adverse effects, such as sedation, postoperative nausea and
vomiting, urinary retention, ileus, and respiratory depression, which can
delay discharge. Thus, multimodal analgesia, i.e., the use of more than one
analgesic modality to achieve effective pain control while reducing
opioid-related side effects, has become the cornerstone of enhanced
recovery. The purpose of this review is to address the analgesic techniques
used as part of multimodal analgesic regimens to optimize postoperative pain
control and to summarize the evidence for their use in reducing opioid
requirements and side effects.Principal findings: There is a wide variety of
analgesic techniques available for multimodal postoperative analgesia. These
modalities are divided into pharmacological and non-pharmacological
techniques. Systemic pharmacological modalities involve opioids and
non-opioids such as acetaminophen, non-steroidal anti-inflammatory drugs,
N-methyl-D-aspartate receptor antagonists, anticonvulsants (e.g.,
gamma-aminobutyric acid analogues), beta-blockers, alpha-2 agonists,
transient receptor potential vanilloid receptor agonists (capsaicin), and
glucocorticoids. Other pharmacological modalities include central neuraxial
techniques, surgical-site infiltration, and regional anesthesia. Evidence
supports the use of these pharmacological techniques as part of multimodal
analgesia, but each has its own advantages and specific safety profile,
which highlights the importance of selecting the appropriate analgesics for
each patient. Adjunctive non-pharmacological techniques include acupuncture,
music therapy, transcutaneous electrical nerve stimulation, and hypnosis.
There is mixed evidence regarding such techniques, although a lack of harm
is associated with their use.Conclusion: There are continuing advancements
in multimodal analgesic techniques; however, postoperative pain in general
continues to be undermanaged. Furthermore, a continuing challenge in
multimodal pain research related to ERAS is the difficulty in carrying out
randomized trials to determine the relative importance of any one component,
including analgesia.
EMTREE DRUG INDEX TERMS
4 aminobutyric acid
alpha 2 adrenergic receptor stimulating agent (adverse drug reaction, drug
therapy, pharmacology)
beta adrenergic receptor blocking agent (pharmacology)
bupivacaine
capsaicin (drug therapy, pharmacology)
celecoxib (oral drug administration)
clonidine (clinical trial, epidural drug administration, pharmacology)
dexamethasone (adverse drug reaction, drug therapy)
diamorphine
fentanyl
gabapentin (drug therapy, oral drug administration)
glucocorticoid (pharmacology)
ibuprofen (oral drug administration)
infusion fluid
ketamine (drug therapy, intravenous drug administration, pharmacology)
ketorolac (intravenous drug administration)
lidocaine (transdermal drug administration)
midazolam
morphine (intravenous drug administration)
n methyl dextro aspartic acid receptor blocking agent (drug therapy,
pharmacology)
nonsteroid antiinflammatory agent (adverse drug reaction, drug therapy,
pharmacology)
opiate (adverse drug reaction, drug therapy, intravenous drug
administration, parenteral drug administration, pharmacology)
oxycodone (oral drug administration)
paracetamol (drug therapy, intravenous drug administration, oral drug
administration, pharmacology)
propofol
remifentanil
ropivacaine
transient receptor potential channel (endogenous compound)
unindexed drug
vanilloid receptor agonist (pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
analgesia
Enhanced Recovery After Surgery Program
health program
postoperative pain (drug therapy, complication, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
agranulocytosis (side effect)
analgesic activity
article
atrial fibrillation
clinical practice
continuous infusion
controlled study
dermatitis (side effect)
drug mechanism
drug safety
epidural anesthesia
erythema (side effect)
hepatomegaly (side effect)
hospitalization
human
hyperglycemia (side effect)
hypnosis
ileus (side effect)
length of stay
leukocytosis (side effect)
music therapy
nausea (side effect)
postoperative analgesia
postoperative nausea and vomiting (drug therapy, side effect)
postoperative period
priority journal
regional anesthesia
respiration depression (side effect)
sedation
skin irritation (side effect)
spinal anesthesia
supraventricular tachycardia
thrombocytopenia (side effect)
transcutaneous nerve stimulation
urine retention (side effect)
urticaria (side effect)
vomiting (side effect)
CAS REGISTRY NUMBERS
4 aminobutyric acid (28805-76-7, 56-12-2)
bupivacaine (18010-40-7, 2180-92-9, 55750-21-5, 38396-39-3)
capsaicin (404-86-4)
celecoxib (169590-42-5)
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
dexamethasone (50-02-2)
diamorphine (1502-95-0, 561-27-3)
fentanyl (437-38-7)
gabapentin (60142-96-3)
ibuprofen (15687-27-1, 79261-49-7, 31121-93-4, 527688-20-6)
ketamine (1867-66-9, 6740-88-1, 81771-21-3)
ketorolac (74103-06-3)
lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
midazolam (59467-70-8)
morphine (52-26-6, 57-27-2)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
oxycodone (124-90-3, 76-42-6)
paracetamol (103-90-2)
propofol (2078-54-8)
remifentanil (132539-07-2)
ropivacaine (84057-95-4)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Anesthesiology (24)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
2014973583
MEDLINE PMID
25501696 (http://www.ncbi.nlm.nih.gov/pubmed/25501696)
FULL TEXT LINK
http://dx.doi.org/10.1007/s12630-014-0275-x
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 133
TITLE
Unexplained acute chest pain in young adults: Disease patterns and
medication use 25 years later
AUTHOR NAMES
Roll M.
Rosenqvist M.
Sjöborg B.
Wettermark B.
AUTHOR ADDRESSES
(Roll M., martin.roll@ds.se; Rosenqvist M.) Departments of Clinical
Sciences, Danderyd Hospital, Stockholm, Sweden.
(Roll M., martin.roll@ds.se; Rosenqvist M.) Departments of Cardiology,
Sweden.
(Sjöborg B.; Wettermark B.) Division of Cardiovascular Medicine, Danderyd
University, Karolinska Institutet, Stockholm, Sweden.
(Sjöborg B.; Wettermark B.) Public Healthcare Services Committee, Sweden.
(Wettermark B.) Stockholm County Council, Stockholm, Sweden.
(Wettermark B.) Centre for Pharmacoepidemiology and Clinical Pharmacology,
Karolinska Institutet, Karolinska University, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
M. Roll, Departments of Clinical Sciences, Danderyd Hospital, Stockholm,
Sweden.
SOURCE
Psychosomatic Medicine (2015) 77:5 (567-574). Date of Publication: 13 Jun
2015
ISSN
1534-7796 (electronic)
0033-3174
BOOK PUBLISHER
Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
Patients with unexplained chest pain are commonly revisiting an emergency
department with various symptoms, but comprehensive long-term studies are
lacking. Methods A total of 150 young adults (aged 18-40 years) with
unexplained chest pain who presented at an emergency unit for 16 weeks in
mid-1980s were included in a prospective cohort study. An age-And
sex-matched control group was randomly selected from the same area. Data
were retrieved from registers that recorded death, income, education,
country of birth, diagnoses, hospitalizations, outpatient visits, and
medications dispensed. Results Patients with unexplained acute chest pain
had lower levels of education and income and were more often immigrants.
Long-term mortality rates did not differ between cases (4%) and controls
(5%) during 25 years of follow-up, nor were there differences in diagnosis
of ischemic heart disease. Patients with unexplained acute chest pain had
more outpatient visits (median, 5 versus 2; p <.0001) and had more often
been hospitalized (61.6% ever versus 41.8%; p <.001) during the follow-up
period. Several disorders were more common among patients 20 to 25 years
later, including atrial fibrillation, esophageal/gastric disorders, chest
pain, palpitations, abdominal discomfort, musculoskeletal symptoms, sleeping
disturbance, and stress reactions (p values <.05). More patients had been
given antihypertensives, anticoagulants, antidepressants, analgesics, and
hypnotics/tranquilizers (p values <.05). Conclusions Young patients admitted
to the emergency department with unexplainedacute chest pain showed no
increased risk of mortality or ischemic heart disease during 25 years of
follow-up, but they had higher incidence of a wide range of disorders and
used more medications. Early identification and preventive interventions may
improve health outcomes in these patients.
EMTREE DRUG INDEX TERMS
analgesic agent
angiotensin receptor antagonist
anticoagulant agent
antidepressant agent
antihypertensive agent (drug therapy)
antithrombocytic agent
calcium channel blocking agent
dipeptidyl carboxypeptidase inhibitor
diuretic agent
hypnotic agent
tranquilizer
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
drug use
idiopathic disease
thorax pain
EMTREE MEDICAL INDEX TERMS
abdominal discomfort (diagnosis)
adult
alcoholism (diagnosis)
angina pectoris (diagnosis)
anxiety disorder (diagnosis)
article
atrial fibrillation (diagnosis)
backache (diagnosis)
cohort analysis
controlled study
diagnosis related group
differential diagnosis
dizziness (diagnosis)
educational status
emergency ward
esophagus disease (diagnosis)
fatigue (diagnosis)
female
follow up
gastroesophageal reflux (diagnosis)
headache (diagnosis)
health care utilization
heart infarction (diagnosis)
heart palpitation (diagnosis)
human
hypertension (diagnosis, drug therapy)
irritable colon (diagnosis)
ischemic heart disease
major clinical study
male
migraine (diagnosis)
mood disorder (diagnosis)
mortality
musculoskeletal disease (diagnosis)
myalgia (diagnosis)
osteoarthritis (diagnosis)
outpatient care
panic (diagnosis)
paroxysmal tachycardia (diagnosis)
patient
priority journal
prospective study
respiratory tract disease (diagnosis)
sleep disorder (diagnosis)
social status
stomach disease (diagnosis)
tendinitis (diagnosis)
tension headache (diagnosis)
unstable angina pectoris (diagnosis)
upper respiratory tract infection (diagnosis)
young adult
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015127751
FULL TEXT LINK
http://dx.doi.org/10.1097/PSY.0000000000000188
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 134
TITLE
Acupuncture antiarrhythmic effects on drug refractory persistent atrial
fibrillation: Study protocol for a randomized, controlled trial
AUTHOR NAMES
Park J.
Kim H.S.
Lee S.M.
Yoon K.
Kim W.-S.
Woo J.S.
Lee S.
Kim J.-B.
Kim W.
AUTHOR ADDRESSES
(Park J., swarmy77@hanmail.net; Lee S.M., lollymin@nate.com; Yoon K.,
kkyoe@hanmail.net; Lee S., shlee777@gmail.com) Department of Acupuncture and
Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul, South
Korea.
(Kim H.S., matheer2@gmail.com; Kim W.-S., kkabee@dreamwiz.com; Woo J.S.,
snowball77@hanmail.net; Kim J.-B., jinbbai@khu.ac.kr; Kim W.,
mylovekw@hanmail.net) Division of Cardiology, Department of Internal
Medicine, Kyung Hee University, Seoul, South Korea.
CORRESPONDENCE ADDRESS
S. Lee, Department of Acupuncture and Moxibustion, College of Korean
Medicine, Kyung Hee University, Seoul, South Korea.
SOURCE
Evidence-based Complementary and Alternative Medicine (2015) 2015 Article
Number: 613970. Date of Publication: 2015
ISSN
1741-4288 (electronic)
1741-427X
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
Background. Atrial fibrillation (AF) is the most common form of arrhythmia.
Several trials have suggested that acupuncture may prevent AF. However, the
efficacy of acupuncture for AF prevention has not been well investigated.
Therefore, we designed a prospective, two-parallel-armed, participant and
assessor blinded, randomized, sham-controlled clinical trial to investigate
acupuncture in persistent AF (ACU-AF). Methods. A total of 80 participants
will be randomly assigned to active acupuncture or sham acupuncture groups
in a 1: 1 ratio. Both groups will take the same antiarrhythmic medication
during the study period. Patients will receive 10 sessions of acupuncture
treatment once a week for 10 weeks. The primary endpoint is AF recurrence
rate. Secondary endpoints are left atrium (LA) and left atrial appendage
(LAA) changes in function and volume, and inflammatory biomarker changes.
Ethics. This study protocol was approved by the institutional review boards
(IRBs) of Kyung Hee University Hospital (number 1335-04). This trial is
registered with clinicaltrials.gov NCT02110537.
EMTREE DRUG INDEX TERMS
flecainide (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
antiarrhythmic activity
atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
bleeding (complication)
controlled study
dizziness (complication)
electroacupuncture
heart atrium appendage
heart left atrium
hematoma (complication)
human
infection (complication)
major clinical study
outcome assessment
pain (complication)
priority journal
prospective study
randomized controlled trial
recurrent disease (prevention)
sinus rhythm
therapy effect
transesophageal echocardiography
CAS REGISTRY NUMBERS
flecainide (54143-55-4)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT02110537)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015811345
FULL TEXT LINK
http://dx.doi.org/10.1155/2015/613970
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 135
TITLE
Symptom burden, Metabolic profile, Ultrasound findings, Rhythm,
neurohormonal activation, haemodynamics and health-related quality of life
in patients with atrial Fibrillation (SMURF): A protocol for an
observational study with a randomised interventional component
AUTHOR NAMES
Charitakis E.
Walfridsson U.
Nyström F.
Nylander E.
Strömberg A.
Alehagen U.
Walfridsson H.
AUTHOR ADDRESSES
(Charitakis E.; Walfridsson U.; Strömberg A.; Alehagen U.; Walfridsson H.,
hakan.walfridsson@regionostergotland.se) Department of Cardiology, Linköping
University, Linköping, Sweden.
(Nyström F.) Department of Medical and Health Sciences, Faculty of Health
Sciences, Linköping University, Linköping, Sweden.
(Nylander E.) Department of Clinical Physiology, Linköping University,
Linköping, Sweden.
CORRESPONDENCE ADDRESS
H. Walfridsson, Department of Cardiology, Linköping University, Linköping,
Sweden. Email: hakan.walfridsson@regionostergotland.se
SOURCE
BMJ Open (2015) 5:12 Article Number: e008723. Date of Publication: 2015
ISSN
2044-6055 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
Introduction: Atrial fibrillation (AF) is the most common cardiac
arrhythmia, with an estimated prevalence of 1.5-2%. It is an independent
risk factor for ischaemic stroke and is estimated to cause about 20-25% of
all stroke cases. AF has a great impact on health-related quality of life
(HRQoL); however, one unresolved issue related to AF is the wide variation
in its symptoms. Methods and analysis: The symptom burden, metabolic
profile, ultrasound findings, rhythm, neurohormonal activation,
haemodynamics and HRQoL in patients with AF (Symptom burden, Metabolic
profile, Ultrasound findings, Rhythm, neurohormonal activation,
haemodynamics and health-related quality of life in patients with atrial
Fibrillation, SMURF) study is a prospective observational, cohort study,
with a randomised interventional part. The aim of the study is to
investigate, in patients with AF, the relationship between symptom burden
and metabolic aspects, atrial function and different neurohormones, and the
effect of radiofrequency ablation (RFA). The interventional part of the
study will give an insight into the neurohormonal and intracardiac pressure
changes directly after initiation of AF. Consecutive patients with
symptomatic AF accepted for treatment with RFA for the first time at
Linköping University Hospital are eligible for participation. The enrolment
started in January 2012, and a total of 200 patients are to be included into
the study, with 45 of them being enrolled into the interventional study with
initiation of AF. The sample size of the interventional study is based on a
small pilot study with 5 patients induced to AF while 2 served as controls.
The results indicated that, in order to find a statistically significant
difference, there was a need to include 28 patients; for safety reasons, 45
patients will be included. Ethics and dissemination: The SMURF study is
approved by the Regional Ethical Review Board at the Faculty of Health
Sciences, Linköping, Sweden. The results will be presented through
peer-review journals and conference presentation.
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide (endogenous compound)
copeptin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (disease management)
EMTREE MEDICAL INDEX TERMS
article
controlled study
heart atrium function
human
major clinical study
metabolic syndrome X
observational study
prospective study
quality of life
radiofrequency ablation
randomized controlled trial
speckle tracking echocardiography
transesophageal echocardiography
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (nct01553045)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160201648
FULL TEXT LINK
http://dx.doi.org/10.1136/bmjopen-2015-008723
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 136
TITLE
Incidence of atrial fibrillation in relation to birth weight and preterm
birth
AUTHOR NAMES
Larsson S.C.
Drca N.
Jensen-Urstad M.
Wolk A.
AUTHOR ADDRESSES
(Larsson S.C., susanna.larsson@ki.se; Wolk A.) Unit of Nutritional
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
Box 210, Stockholm, Sweden.
(Drca N.; Jensen-Urstad M.) Department of Cardiology, Karolinska University
Hospital, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental
Medicine, Karolinska Institutet, Box 210, Stockholm, Sweden.
SOURCE
International Journal of Cardiology (2015) 178 (149-152). Date of
Publication: 15 Jan 2015
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
Background Hypertension, type 2 diabetes and other cardiovascular diseases,
all risk factors for atrial fibrillation, are associated with birth weight.
It remains unclear, however, whether risk of atrial fibrillation is also
associated with birth weight. We investigated the associations of birth
weight and preterm birth (i.e., born more than one month before term) with
risk of atrial fibrillation (AF).Methods The study population comprised 29
551 men and 23 454 women who were free from AF at baseline. Information on
birth weight, preterm birth, and risk factors for AF was obtained from a
questionnaire. Incident AF cases were ascertained by linkage to the Swedish
Inpatient Register.Results During 12 years of follow-up, AF developed in
2711 men and 1491 women. High birth weight (≥ 5000 g) was associated with an
increased risk of AF after adjustment for age and other risk factors for AF,
but the association did not persist after further adjustment for adult
height. In men but not in women, low birth weight was associated with an
increased risk of AF. Compared with men weighing 2500-3999 g at birth, the
multivariable RR was 1.86 (95% CI, 1.15 to 3.00) for those weighing < 1500
g. This association was stronger in men who were born full-term (RR 2.53;
95% CI, 1.35 to 4.73).Conclusions Both high birth weight and low birth
weight (in men), in particular in men born full-term, were associated with
an increased risk of AF. The association with high birth weight appeared to
be mediated through adult height.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (epidemiology)
birth weight
premature labor
EMTREE MEDICAL INDEX TERMS
adult
alcohol consumption
article
body height
body mass
cohort analysis
diet
disease association
family history
female
follow up
human
incidence
low birth weight
male
physical activity
population research
prospective study
questionnaire
risk assessment
risk factor
sex difference
smoking
Swedish citizen
waist circumference
EMBASE CLASSIFICATIONS
Obstetrics and Gynecology (10)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014962385
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2014.10.138
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 137
TITLE
Midterm renal functions following acute renal infarction
AUTHOR NAMES
Ongun S.
Bozkurt O.
Demir O.
Cimen S.
Aslan G.
AUTHOR ADDRESSES
(Ongun S., sakirongun@hotmail.com) Department of Urology, SB Siverek State
Hospital, Siverek-Sanliurfa Highway Thirteenth Kilometer, Sanliurfa, Turkey.
(Bozkurt O.; Demir O.) Department of Urology, Dokuz Eylul University, School
of Medicine, Izmir, Turkey.
(Cimen S.; Aslan G.) Department of Urology, SB Ankara Dişkapi Training
Hospital, Ankara, Turkey.
CORRESPONDENCE ADDRESS
S. Ongun, Department of Urology, SB Siverek State Hospital,
Siverek-Sanliurfa Highway Thirteenth Kilometer, Sanliurfa, Turkey. Email:
sakirongun@hotmail.com
SOURCE
Kaohsiung Journal of Medical Sciences (2015) 31:10 (529-533). Date of
Publication: 2015
ISSN
1607-551X
BOOK PUBLISHER
Elsevier (Singapore) Pte Ltd, 3 Killiney Road, 08-01, Winsland House I,
Singapore, Singapore.
ABSTRACT
The aim of this study was to explore clinical features of renal infarction
(RI) that may have a role in diagnosis and treatment in our patient cohort
and provide data on midterm renal functions. Medical records of patients
with diagnosis of acute RI, established by contrast enhanced computed
tomography (CT) and at least 1 year follow-up data, who were hospitalized in
our clinic between 1998 and 2012 were retrospectively reviewed; including
descriptive data, clinical signs and symptoms, etiologic factors, laboratory
findings, and prescribed treatments. Patients with solitary infarct were
treated with acetylsalicylic acid (ASA) only, whereas patients with atrial
fibrillation (AF) or multiple or global infarct were treated with
anticoagulants. Estimated Glomerular Filtration Rate (EGFR) referring to
renal functions was determined by the Modification of Diet in Renal Disease
(MDRD) formula. Twenty-seven renal units of 23 patients with acute RI were
identified. The mean age was 59.7 ± 15.7 years. Fourteen patients (60.8%)
with RI had atrial fibrillation (AF) as an etiologic factor of which four
had concomitant mesenteric ischemia at diagnosis. At presentation, 20
patients (86.9%) had elevated serum lactate dehydrogenase (LDH), 18 patients
(78.2%) had leukocytosis, and 16 patients (69.5%) had microscopic hematuria.
Two patients with concomitant mesenteric ischemia and AF passed away during
follow up. Mean EGFR was 70.8 ± 23.2 mL/min/1.73 m(2) at admission and
increased to 82.3 ± 23.4 mL/min/1.73 m(2) at 1 year follow up. RI should be
considered in patients with persistent flank or abdominal pain, particularly
if they are at high risk of thromboembolism. Antiplatelet and/or
anticoagulant drugs are both effective treatment options according to the
amplitude of the infarct for preserving kidney functions.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
alanine aminotransferase (endogenous compound)
alkaline phosphatase (endogenous compound)
anticoagulant agent
aspartate aminotransferase (endogenous compound)
creatine kinase (endogenous compound)
lactate dehydrogenase (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
kidney function
kidney infarction
EMTREE MEDICAL INDEX TERMS
abdominal pain
abdominal tenderness
adult
alanine aminotransferase blood level
alkaline phosphatase blood level
article
aspartate aminotransferase blood level
atrial fibrillation
body mass
cardiovascular risk
clinical article
clinical feature
computer assisted tomography
creatine kinase blood level
female
flank pain
glomerulus filtration rate
human
lactate dehydrogenase blood level
leukocyte count
leukocytosis
male
mesenteric ischemia
middle aged
thromboembolism
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alanine aminotransferase (9000-86-6, 9014-30-6)
alkaline phosphatase (9001-78-9)
aspartate aminotransferase (9000-97-9)
creatine kinase (9001-15-4)
lactate dehydrogenase (9001-60-9)
EMBASE CLASSIFICATIONS
Urology and Nephrology (28)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015324602
FULL TEXT LINK
http://dx.doi.org/10.1016/j.kjms.2015.07.005
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 138
TITLE
Risk of atrial fibrillation associated with coffee intake: Findings from the
Danish Diet, Cancer, and Health study
AUTHOR NAMES
Mostofsky E.
Johansen M.B.
Lundbye-Christensen Sø.
Tjønneland A.
Mittleman M.A.
Overvad K.
AUTHOR ADDRESSES
(Mostofsky E.; Mittleman M.A.) Cardiovascular Epidemiology Research Unit,
Beth Israel Deaconess Medical Center, Boston, United States.
(Mostofsky E.; Mittleman M.A.) Department of Epidemiology, Harvard T.H. Chan
School of Public Health, Boston, United States.
(Johansen M.B.; Overvad K., ko@ph.au.dk) Department of Cardiology, Aalborg
University Hospital, Denmark.
(Johansen M.B.; Lundbye-Christensen Sø.) Unit of Clinical Biostatistics,
Aalborg University Hospital, Denmark.
(Lundbye-Christensen Sø.) Aalborg Atrial Fibrillation Study Group,
Department of Cardiology, Aalborg University Hospital, Denmark.
(Tjønneland A.) Danish Cancer Society Research Center, Copenhagen, Denmark.
(Overvad K., ko@ph.au.dk) Section for Epidemiology, Department of Public
Health, Aarhus University, Bartholins Alle 2, , Denmark.
CORRESPONDENCE ADDRESS
K. Overvad, Section for Epidemiology, Department of Public Health, Aarhus
University, Bartholins Alle 2, , Denmark. Email: ko@ph.au.dk
SOURCE
European Journal of Preventive Cardiology (2015) 23:9 (922-930). Date of
Publication: 2015
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Background There have been discrepant findings on whether coffee consumption
is associated with the rate of developing atrial fibrillation (AF). Methods
and results We used data on 57,053 participants (27,178 men and 29,875
women) aged 50-64 years in the Danish Diet, Cancer and Health study. All
participants provided information on coffee intake via food-frequency
questionnaires at baseline. Incident AF was identified using nationwide
registries. During a median follow-up of 13.5 years, 3415 AF events
occurred. Compared with no intake, coffee consumption was inversely
associated with AF incidence, with multivariable-adjusted hazard ratios of
0.93 (95% confidence interval [CI] 0.74-1.15) for more than none to <1
cup/day, 0.88 (95% CI 0.71-1.10) for 1 cup/day, 0.86 (95% CI 0.71-1.04) for
2-3 cups/day, 0.84 (95% CI 0.69-1.02) for 4-5 cups/day, 0.79 (95% CI
0.64-0.98) for 6-7 cups/day and 0.79 (95% CI 0.63-1.00) for >7 cups/day
(p-linear trend = 0.02). Conclusions In this large population-based cohort
study, higher levels of coffee consumption were associated with a lower rate
of incident AF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
coffee
EMTREE MEDICAL INDEX TERMS
adult
article
Denmark
dietary intake
female
food frequency questionnaire
human
incidence
major clinical study
male
middle aged
priority journal
risk assessment
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160372477
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487315624524
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 139
TITLE
Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging
epidemic
AUTHOR NAMES
Hajhosseiny R.
Matthews G.K.
Lip G.Y.H.
AUTHOR ADDRESSES
(Hajhosseiny R., reza.hajhosseiny@kcl.ac.uk) British Heart Foundation,
Centre of Cardiovascular Excellence, St. Thomas' Hospital, Westminster
Bridge Rd, , United Kingdom.
(Matthews G.K.) Department of Physiology, Development and Neuroscience,
University of Cambridge, Cambridge, United Kingdom.
(Lip G.Y.H.) University of Birmingham, Centre for Cardiovascular Sciences,
City Hospital, Birmingham, United Kingdom.
(Lip G.Y.H.) Aalborg Thrombosis Research Unit, Department of Clinical
Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.
CORRESPONDENCE ADDRESS
R. Hajhosseiny, British Heart Foundation, Centre of Cardiovascular
Excellence, St. Thomas' Hospital, Westminster Bridge Rd, , United Kingdom.
SOURCE
Heart Rhythm (2015) 12:11 (2332-2343). Date of Publication: 1 Nov 2015
ISSN
1556-3871 (electronic)
1547-5271
BOOK PUBLISHER
Elsevier
ABSTRACT
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to
increase dramatically in coming decades, with developing regions such as
Latin America experiencing the greatest impact. These trends are primarily
driven by aging populations and by the increasing prevalence of the
metabolic syndrome. The metabolic syndrome describes an association between
diabetes, hypertension, obesity, and dyslipidemia and an increased risk of
cardiovascular disease. It is in large part the result of unbalanced diet
and sedentary lifestyle. These essentially modifiable risk factors are
becoming more prevalent with the widespread adoption of so-called Western
lifestyles. This review examines the physiology underlying the link between
the metabolic syndrome and AF. Next, it highlights the importance of
addressing lifestyle-related risk factors to mitigate the trend toward
increasing AF prevalence. It then goes on to discuss the importance of
stroke prevention therapy in patients with established AF, focusing on the
relative merits of various available options for anticoagulation. Given the
recent availability of comprehensive data on the 4 currently available
non-vitamin K antagonist oral anticoagulant drugs, this review concludes by
discussing the relative merits of specific agents in individual patient
groups.
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, epidemiology)
cerebrovascular accident (drug therapy, drug therapy, epidemiology)
metabolic syndrome X (epidemiology)
EMTREE MEDICAL INDEX TERMS
aging
anticoagulation
article
cardiovascular risk
Central America
diabetes mellitus
dietary intake
drug efficacy
drug safety
dyslipidemia
epidemic
evidence based medicine
human
hypertension
obesity
prevalence
priority journal
risk factor
risk reduction
sedentary lifestyle
South America
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Endocrinology (3)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015346269
FULL TEXT LINK
http://dx.doi.org/10.1016/j.hrthm.2015.06.038
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 140
TITLE
Intravenous administration of EGB 761 and 90-day functional outcome in
patients with acute ischemic stroke
AUTHOR NAMES
Shin D.-I.
Lee H.-S.
Baek S.-H.
Han H.-S.
Lee H.-L.
Kim Y.-D.
AUTHOR ADDRESSES
(Shin D.-I., sdi007@hanmail.net; Baek S.-H.; Lee H.-L.) Department of
Neurology, Chungbuk National University College of Medicine, Chungbuk
National University Hospital, Cheongju, South Korea.
(Lee H.-S.; Han H.-S.) Department of Neurology, Yuseong Sun General
Hospital, DaeJeon, South Korea.
(Kim Y.-D.) Department of Preventive Medicine, Chungbuk National University
College of Medicine, Cheongju, South Korea.
CORRESPONDENCE ADDRESS
D.-I. Shin, Department of Neurology, Chungbuk National University College of
Medicine, Chungbuk National University Hospital, Chungdae-ro 1, Seowon-ku,
Cheongju, South Korea.
SOURCE
Neurology Asia (2015) 20:3 (215-219). Date of Publication: 1 Sep 2015
ISSN
1823-6138
BOOK PUBLISHER
ASEAN Neurological Association
ABSTRACT
Background & Objective: EGB 761 is a standardized natural extract used to
treat impaired cerebral perfusion and nutrition (cerebrovascular
insufficiency) in Korea. Although several animal studies have been
conducted, few studies have investigated the clinical effects of EGB 761 in
acute stroke. This study assessed the clinical benefit of intravenous EGB
761 in patients with acute ischemic stroke. Methods: This retrospective
study examined a prospectively collected stroke database. We evaluated 232
patients with acute ischemic stroke within 48 hours of symptom onset. All
patients were treated with antiplatelet or anticoagulation agents. We
compared baseline characteristics between the EGB 761-treated and
non-treated groups. The functional outcome measure was the modified Rankin
Scale (mRS) score 90 days after stroke onset. Results: Of the 232 patients,
170 received EGB 761 during the first 3 days after arrival in the emergency
department. We found no significant differences in baseline characteristics
between the groups, with the exception of atrial fibrillation (p=0.032).
After adjusting for baseline factors, intravenous administration of EGB 761
was associated with an improved 90-day functional outcome (mRS ≤2) compared
with the control group (odds ratio, 2.56; p<0.05). Conclusions: Our results
showed a clinical benefit of intravenous EGB 761 in patients with acute
ischemic stroke.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
Ginkgo biloba extract (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacology)
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
antithrombocytic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
bleeding (diagnosis)
computer assisted tomography
controlled study
emergency ward
female
functional assessment
human
major clinical study
male
National Institutes of Health Stroke Scale
neuroprotection
nuclear magnetic resonance imaging
onset age
Rankin scale
retrospective study
treatment duration
unspecified side effect (side effect)
DRUG TRADE NAMES
tanamin , South KoreaYuyu
DRUG MANUFACTURERS
(South Korea)Yuyu
EMBASE CLASSIFICATIONS
Hematology (25)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015431065
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 141
TITLE
Cadmium exposure and incidence of heart failure and atrial fibrillation: A
population-based prospective cohort study
AUTHOR NAMES
Borné Y.
Barregard L.
Persson M.
Hedblad B.
Fagerberg B.
Engström G.
AUTHOR ADDRESSES
(Borné Y., yan.borne@med.lu.se; Persson M.; Hedblad B.; Engström G.)
Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
(Barregard L.) Department of Occupational and Environmental Medicine,
Sahlgrenska University Hospital, University of Gothenburg, Gothenburg,
Sweden.
(Persson M.) Clinical Research Unit, Emergency Department, Skåne University
Hospital, Malmö, Sweden.
(Fagerberg B.) Department of Molecular and Clinical Medicine, University of
Gothenburg, Gothenburg, Sweden.
CORRESPONDENCE ADDRESS
Y. Borné, Department of Clinical Sciences in Malmö, Lund University, Malmö,
Sweden.
SOURCE
BMJ Open (2015) 5:6 Article Number: e007366. Date of Publication: 2015
ISSN
2044-6055 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
Objectives: Cadmium is a non-essential toxic metal with multiple adverse
health effects. Cadmium has been shown to be associated with cardiovascular
diseases, but few studies have investigated heart failure (HF) and none of
them reported atrial fibrillation (AF). We examined whether cadmium exposure
is associated with incidence of HF or AF. Design: A prospective,
observational cohort study with a 17-year follow-up. Setting: The city of
Malmö, Sweden. Participants: Blood cadmium levels were measured in 4378
participants without a history of HF or AF (aged 46-67 years, 60% women),
who participated in the Malmö Diet and Cancer (MDC) study during 1992-1994.
Primary and secondary outcome measures: Incidence of HF and AF were
identified from the Swedish hospital discharge register. Results: 143
participants (53% men) were diagnosed with new-onset HF and 385 individuals
(52% men) were diagnosed with new-onset AF during follow-up for 17 years.
Blood cadmium in the sex-specific 4th quartile of the distribution was
significantly associated with incidence of HF. The (HR, 4th vs 1st quartile)
was 2.64 (95% CI 1.60 to 4.36), adjusted for age, and 1.95 (1.02 to 3.71)
after adjustment also for conventional risk factors and biomarkers. The
blood cadmium level was not significantly associated with risk of incident
AF. Conclusions: Blood cadmium levels in the 4th quartile were associated
with increased incidence of HF in this cohort with comparatively low
exposure to cadmium. Incidence of AF was not associated with cadmium.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
cadmium (drug toxicity)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
heart failure
EMTREE MEDICAL INDEX TERMS
adult
age
aged
article
female
follow up
gender
human
incidence
major clinical study
male
population based case control study
prospective study
register
CAS REGISTRY NUMBERS
cadmium (22537-48-0, 7440-43-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015203554
FULL TEXT LINK
http://dx.doi.org/10.1136/bmjopen-2014-007366
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 142
TITLE
Left atrial function following surgical ablation of atrial fibrillation:
Prospective evaluation using dual-source cardiac computed tomography
AUTHOR NAMES
Kim J.B.
Yang D.H.
Kang J.-W.
Jung S.-H.
Choo S.J.
Chung C.H.
Song J.-K.
Lee J.W.
AUTHOR ADDRESSES
(Kim J.B.; Jung S.-H.; Choo S.J.; Chung C.H.; Lee J.W., jwlee@amc.seoul.kr)
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, South Korea.
(Yang D.H.; Kang J.-W.) Department of Radiology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, South Korea.
(Song J.-K.) Department of Cardiology, Asan Medical Center, University of
Ulsan College of Medicine, Seoul, South Korea.
CORRESPONDENCE ADDRESS
J.W. Lee, Department of Thoracic and Cardiovascular Surgery, Asan Medical
Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil,
Songpa-gu Seoul, South Korea.
SOURCE
Yonsei Medical Journal (2015) 56:3 (608-616). Date of Publication: 2015
ISSN
0513-5796
BOOK PUBLISHER
Yonsei University College of Medicine
ABSTRACT
Purpose: The Maze procedure has shown excellent efficacy in the elimination
of atrial fibrillation (AF); however, little is known about the quality of
functional recovery in the left atrium (LA) following successful sinus
rhythm conversion by the Maze procedure. Materials and Methods: We
prospectively enrolled 12 patients (aged 52.5±10.1 years, 1 female) with
valvular AF undergoing mitral valve surgery combined with the Maze
procedure. Parameters of LA function in three anatomic compartments
[anterior, posterior, and LA appendage (LAA)] were evaluated using
electrocardiography-gated dual-source cardiac CT at one month and at six
months after surgery. Twelve subjects matched by age, gender, and body
surface area served as controls. Results: At one month after surgery,
ejection fraction (EF) and emptying volume (EV) of the LA were 14.9±7.4% and
21.3±9.7 mL, respectively, and they were significantly lower than those of
the control group (EF, 47.9±11.2%; EV, 46.0±10.7%; p<0001). These values did
not significantly change throughout late periods (p=0.22 and 0.21,
respectively). Functional contributions of the anterior, posterior, and
appendage compartments (EV of each compartment/overall EV) were 80.4%,
-0.9%, and 20.5%, respectively, for those with LAA preservation (n=6);
100.1%, -0.1%, and 0% for those with LAA resection (n=6; p<0.05); and 62.2%,
28.2%, and 9.7% in the control subjects (p<0.001). Conclusion: Contractile
functions of the LA significantly decreased after the Maze procedure.
Functional contributions of three compartments of the LA were also altered.
The influence of LAA preservation on postoperative LA functions needs to be
evaluated through studies of larger populations.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (surgery, disease management)
computer assisted tomography
heart atrium function
heart surgery
maze procedure
EMTREE MEDICAL INDEX TERMS
adult
article
cardiovascular parameters
clinical article
controlled study
electrocardiography
female
heart atrium contractility
heart atrium contraction
heart atrium emptying volume
heart ejection fraction
heart rhythm
human
left atrial volume
male
mitral valve
observational study
prospective study
randomized controlled trial
surgical technique
treatment outcome
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015895663
FULL TEXT LINK
http://dx.doi.org/10.3349/ymj.2015.56.3.608
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 143
TITLE
Performance of the CHARGE-AF risk model for incident atrial fibrillation in
the EPIC Norfolk cohort
AUTHOR NAMES
Pfister R.
Brägelmann J.
Michels G.
Wareham N.J.
Luben R.
Khaw K.-T.
AUTHOR ADDRESSES
(Pfister R., roman.pfister@uk-koeln.de; Brägelmann J.; Michels G.)
Department III of Internal Medicine, University of Cologne, Kerpenerstr. 62,
Cologne, Germany.
(Wareham N.J.) Medical Research Council Epidemiology Unit, Institute of
Metabolic Science, University of Cambridge, United Kingdom.
(Luben R.; Khaw K.-T.) Department of Public Health and Primary Care,
Institute of Public Health, University of Cambridge, United Kingdom.
CORRESPONDENCE ADDRESS
R. Pfister, Department III of Internal Medicine, University of Cologne,
Kerpenerstr. 62, Cologne, Germany.
SOURCE
European Journal of Preventive Cardiology (2015) 22:7 (932-939). Date of
Publication: 9 Jul 2015
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Background: Identification of individuals at risk for developing atrial
fibrillation (AF) will help to target screening and preventive
interventions. We aimed to validate the CHARGE-AF model (including variables
age, race, height, weight, blood pressure, smoking, antihypertensive
medication, diabetes, myocardial infarction and heart failure) for
prediction of five-year incident AF in a representative European population
with a wide age range. Methods and results: The CHARGE-AF model was
calculated in 24,020 participants of the population-based EPIC Norfolk study
with 236 cases of hospitalization with diagnosis of AF within five years.
The model showed good discrimination (c-statistic 0.81, 95% confidence
interval (CI) 0.75-0.85), but weak calibration (Chi -statistic 142) with an
almost two-fold overestimation of AF incidence. A recalibration to
characteristics of the European Prospective Investigation into Cancer and
Nutrition (EPIC) Norfolk cohort improved calibration considerably
(Chi2-statistic 13.3), with acceptable discrimination in participants both
≥65 and <65 years of age (c-statistics 0.70, 95% CI 0.61-0.77 and 0.83, 95%
CI 0.74-0.88). The recalibrated model also showed good discrimination in
participants free of cardiovascular disease (c-statistics 0.80, 95% CI
0.75-0.84). Categories of predicted risk (<2.5%, 2.5-5% or >5%) showed good
concordance with observed five-year AF incidence of 0.62%, 3.49% and 8.74%
(log rank test p < 0.001), respectively. Conclusion: A recalibration of the
CHARGE-AF model is necessary for accurate predictions of five-year risk of
AF in the EPIC Norfolk population. The recalibrated model showed good
discrimination across a wide age range and in individuals free of
cardiovascular disease, and hence is broadly applicable in primary care to
identify people at risk for development of AF.
EMTREE DRUG INDEX TERMS
antihypertensive agent (drug therapy)
antivitamin K (drug therapy)
digitalis (drug therapy)
high density lipoprotein cholesterol (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, diagnosis, drug therapy)
cardiovascular risk
EMTREE MEDICAL INDEX TERMS
adult
aged
antihypertensive therapy
article
blood pressure measurement
controlled study
demography
diabetes mellitus
diastolic blood pressure
female
follow up
heart failure
heart infarction
hospital admission
hospitalization
human
hypertension (drug therapy)
incidence
lifestyle
low risk population
major clinical study
male
primary medical care
priority journal
prospective study
questionnaire
self report
task performance
CAS REGISTRY NUMBERS
digitalis (8031-42-3, 8053-83-6)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015109713
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487314544045
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 144
TITLE
Coronary Heart Disease Risk Factors and Outcomes in the Twenty-First
Century: Findings from the REasons for Geographic and Racial Differences in
Stroke (REGARDS) Study
AUTHOR NAMES
Bhatt H.
Safford M.
Glasser S.
AUTHOR ADDRESSES
(Bhatt H.) Division of Cardiovascular Medicine, University of Alabama at
Birmingham, 1720 2nd Avenue South, Birmingham, United States.
(Safford M.; Glasser S., sglasser@uabmc.edu) Division of Preventive
Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South,
Birmingham, United States.
(Glasser S., sglasser@uabmc.edu) 1717 11th Avenue South, MT 634, Birmingham,
United States.
CORRESPONDENCE ADDRESS
S. Glasser, 1717 11th Avenue South, MT 634, Birmingham, United States.
SOURCE
Current Hypertension Reports (2015) 17:4. Date of Publication: 2015
ISSN
1534-3111 (electronic)
1522-6417
BOOK PUBLISHER
Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
REasons for Geographic and Racial Differences in Stroke (REGARDS) is a
longitudinal study supported by the National Institutes of Health to
determine the disparities in stroke-related mortality across USA. REGARDS
has published a body of work designed to understand the disparities in
prevalence, awareness, treatment, and control of coronary heart disease
(CHD) and its risk factors in a biracial national cohort. REGARDS has
focused on racial and geographical disparities in the quality and access to
health care, the influence of lack of medical insurance, and has attempted
to contrast current guidelines in lipid lowering for secondary prevention in
a nationwide cohort. It has described CHD risk from nontraditional risk
factors such as chronic kidney disease, atrial fibrillation, and
inflammation (i.e., high-sensitivity C-reactive protein) and has also
assessed the role of depression, psychosocial, environmental, and lifestyle
factors in CHD risk with emphasis on risk factor modification and ideal
lifestyle factors. REGARDS has examined the utility of various
methodologies, e.g., the process of medical record adjudication, proxy-based
cause of death, and use of claim-based algorithms to determine CHD risk.
Some valuable insight into less well-studied concepts such as the
reliability of current troponin assays to identify “microsize infarcts,”
caregiving stress, and CHD, heart failure, and cognitive decline have also
emerged. In this review, we discuss some of the most important findings from
REGARDS in the context of the existing literature in an effort to identify
gaps and directions for further research.
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular risk
cerebrovascular accident
ischemic heart disease (epidemiology)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiovascular mortality
cause of death
chronic kidney disease
depression
diabetes mellitus
diet
dyslipidemia
electrocardiography
environmental factor
geography
health behavior
health care quality
heart failure
heart infarction
human
impaired glucose tolerance
incidence
inflammation
lifestyle
lifestyle modification
longitudinal study
medical record
mental deterioration
obesity
outcome assessment
prehypertension
pulse pressure
race difference
resistant hypertension
review
sex difference
smoking
social psychology
systolic blood pressure
treatment refusal
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015854834
FULL TEXT LINK
http://dx.doi.org/10.1007/s11906-015-0541-5
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 145
TITLE
Respiratory sleep disorders in patients with congestive heart failure
AUTHOR NAMES
Naughton M.T.
AUTHOR ADDRESSES
(Naughton M.T., m.naughton@alfred.org.au) Department of Allergy, Immunology
and Respiratory Medicine, General Respiratory and Sleep Medicine, Melbourne,
Australia.
(Naughton M.T., m.naughton@alfred.org.au) Department of Medicine, Monash
University, The Alfred Hospital, Melbourne, Australia.
CORRESPONDENCE ADDRESS
M.T. Naughton, General Respiratory and Sleep Medicine, Department of
Allergy, Immunology and Respiratory Medicine, The Alfred Hospital,
Melbourne, Australia.
SOURCE
Journal of Thoracic Disease (2015) 7:8 (1298-1310). Date of Publication:
2015
ISSN
2077-6624 (electronic)
2072-1439
BOOK PUBLISHER
Pioneer Bioscience Publishing, jtd@thepbpc.org
ABSTRACT
Respiratory sleep disorders (RSD) occur in about 40-50% of patients with
symptomatic congestive heart failure (CHF). Obstructive sleep apnea (OSA) is
considered a cause of CHF, whereas central sleep apnea (CSA) is considered a
response to heart failure, perhaps even compensatory. In the setting of
heart failure, continuous positive airway pressure (CPAP) has a definite
role in treating OSA with improvements in cardiac parameters expected.
However in CSA, CPAP is an adjunctive therapy to other standard therapies
directed towards the heart failure (pharmacological, device and surgical
options). Whether adaptive servo controlled ventilatory support, a variant
of CPAP, is beneficial is yet to be proven. Supplemental oxygen therapy
should be used with caution in heart failure, in particular, by avoiding
hyperoxia as indicated by SpO2 values > 95%.
EMTREE DRUG INDEX TERMS
oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
central sleep apnea syndrome (etiology, therapy)
congestive heart failure (etiology)
sleep disordered breathing (etiology, therapy)
EMTREE MEDICAL INDEX TERMS
apnea
atrial fibrillation
carbon dioxide tension
cardiovascular response
causal attribution
clinical effectiveness
disease severity
fluid retention
gas exchange
heart output
heart rate
human
hypertension
hyperventilation
nonREM sleep
oxygen consumption
oxygen therapy
pathogenesis
positive end expiratory pressure
pulmonary artery occlusion pressure
quality of life
REM sleep
review
risk factor
treatment duration
treatment response
CAS REGISTRY NUMBERS
oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
General Pathology and Pathological Anatomy (5)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00733343, NCT00738179, NCT01128816)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015343039
FULL TEXT LINK
http://dx.doi.org/10.3978/j.issn.2072-1439.2015.07.02
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 146
TITLE
Is there a difference in mad honey poisoning between geriatric and
non-geriatric patient groups?
AUTHOR NAMES
Yaylaci S.
Ayyildiz O.
Aydin E.
Osken A.
Karahalil F.
Varim C.
Demir M.V.
Genç A.B.
Sahinkus S.
Can Y.
Kocayigit I.
Bilir C.
AUTHOR ADDRESSES
(Yaylaci S., yaylacis@hotmail.com) Department of Internal Medicine, Findikli
State Hospital, Rize, Turkey.
(Ayyildiz O.) Department of Emergency Medicine, Findikli State Hospital,
Rize, Turkey.
(Aydin E.) Department of Cardiology, Vakfikebir State Hospital, Trabzon,
Turkey.
(Osken A.) Department of Cardiology, Siyami Ersek Thoracic and
Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
(Karahalil F.) Department of Chemistry, Faculty of Arts and Sciences,
Karadeniz Technical University, Trabzon, Turkey.
(Varim C.) Department of Internal Medicine, Faculty of Medicine, Sakarya
University, Sakarya, Turkey.
(Demir M.V.) Department of Internal Medicine, Malatya State Hospital,
Malatya, Turkey.
(Genç A.B.) Department of Internal Medicine, Kandira State Hospital,
Kocaeli, Turkey.
(Sahinkus S.; Can Y.) Department of Cardiology, Faculty of Medicine, Sakarya
University, Sakarya, Turkey.
(Kocayigit I.) Department of Cardiology, Sakarya Yenikent State Hospital,
Sakarya, Turkey.
(Bilir C.) Department of Internal Medicine, Faculty of Medicine, Rize
University, Rize, Turkey.
CORRESPONDENCE ADDRESS
S. Yaylaci, Department of Internal Medicine, Findikli State Hospital, Rize,
Turkey. Email: yaylacis@hotmail.com
SOURCE
European Review for Medical and Pharmacological Sciences (2015) 19:23
(4647-4653). Date of Publication: 2015
ISSN
1128-3602
BOOK PUBLISHER
Verduci Editore, g.lombardi@verduci.it
ABSTRACT
OBJECTIVE: This study aims to investigate the demographic, toxicological
characteristics of the mad honey intoxication at ages 65 and above, to
analyze the electrocardiographic parameters, and to compare with the mad
honey intoxication at ages below 65 years. PATIENTS AND METHODS: Eighty-two
patients, who had been treated and followed-up between June 2013 and
November 2014 in the Emergency Service of the Findikli State Hospital,
Turkey, due to diagnosis of mad honey intoxication, were included in our
observational study. Age, gender, toxicological characteristics, laboratory
parameters, heart rates, systolic and diastolic blood pressures, laboratory
analyses and electrocardiographic data of the patients were recorded and
analyzed. Patients with known coronary artery disease, chronic renal
failure, arrhythmias, valvular heart disease, history of thyroid disease and
electrolyte imbalance were not included in the study. RESULTS: Eighty-two
(80.5% was male and the mean age was 53 ± 15 years) patients followed- up
due to mad honey intoxication were included in our study. There were 64
(78%) patients aged below 65 years, and 18 (22%) patients aged 65 and above.
The mean heart rate was 45 ± 7 beats/min, systolic blood pressure was 83 ±
12 mmHg and diastolic blood pressure was 52 ± 9 mmHg on admission. The onset
of symptoms of the patients was found as 0.84 hours on average after mad
honey consumption, the average amount of honey consumed was 3.7 ± 1.1
tablespoons, and the mean recovery time of the symptoms was found to be 1.04
hours. The most common presenting symptoms were nausea-vomiting in 82 (100%)
patients and dizziness in 73 (89%) patients. Patients were found to consume
mad honey most ly for achieving a remission in gastrointestinal complaints
(n=18, 22%), and for utilizing its blood pressure lowering properties (n=11,
13.4%), in addition to the dietary consumption. Looking at the heart rates
of the patients on admission to the emergency service, 65 (79.3%) patients
had normal sinus rhythm/sinus bradycardia, 12 (14.6%) patients had a 1st
degree atrioventricular block, 3 (3.7%) patients had nodal rhythm, 1 (1.2%)
patient had atrial fibrillation and 1 (1.2%) patient had preexcitation.
There were no significant pathological findings in the routine laboratory
examinations of patients. It was found that all patients achieved normal
sinus rhythm and normal blood pressure values after medical treatment, and
were discharged approximately 5.65 hours after observation and follow-up. In
our study, prolonged intensive-care need, pacemaker need and mortality
caused by mad honey intoxication were not found. In the comparison of data
of all patients above and below 65 years of age, there was a statistically
significant finding that the geriatric patients consume mad honey mostly for
hypotensive purposes and gastrointestinal complaints; in addition, the
symptoms were starting early and the recovery period was longer in geriatric
patients. CONCLUSIONS: The mad honey poisoning should be considered in
previously healthy patients with unexplained symptoms of bradycardia,
hypotension, and atrioventricular block. Therefore, diet history should
carefully be obtained from the patients admitted with bradycardia and
hypotension. And, in addition to the primary cardiac, neurological and
metabolic disorders, mad honey intoxication should also be considered in the
differential diagnosis. In geriatric patients admitted due to mad honey
intoxication, the mad honey is usually consumed to reduce blood pressure and
resolve gastrointestinal problems; and, their symptoms begin early, and last
longer after mad honey consumption. In terms of other parameters, the
geriatric age group has similar characteristics to non-geriatric age group.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
geriatric patient
honey poisoning
intoxication
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
atrioventricular block
atrioventricular junction arrhythmia
bradycardia
chronic kidney failure
coronary artery disease
dietary intake
dizziness
electrocardiography
electrolyte disturbance
emergency care
female
follow up
gastrointestinal symptom
gender
groups by age
heart arrhythmia
heart preexcitation
heart rate
hospital admission
human
hypotension
ingestion
intensive care
laboratory test
major clinical study
male
medical history
mortality
nausea
observational study
pacemaker
sinus bradycardia
sinus rhythm
systolic blood pressure
thyroid disease
toxicological parameters
valvular heart disease
vomiting
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160366916
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 147
TITLE
Clinical predictors of fever in stroke patients: Relevance of nasogastric
tube
AUTHOR NAMES
Muscari A.
Puddu G.M.
Conte C.
Falcone R.
Kolce B.
Lega M.V.
Zoli M.
AUTHOR ADDRESSES
(Muscari A., antonio.muscari@unibo.it; Puddu G.M.; Zoli M.) Stroke
Unit-Medical Department of Continuity of Care and Disability
S.Orsola-Malpighi Hospital Bologna Italy
(Muscari A., antonio.muscari@unibo.it; Conte C.; Falcone R.; Kolce B.; Lega
M.V.; Zoli M.) Department of Medical and Surgical Sciences University of
Bologna Bologna Italy
CORRESPONDENCE ADDRESS
A. Muscari, Department of Medical and Surgical Sciences University of
Bologna Bologna Italy
SOURCE
Acta Neurologica Scandinavica (2015). Date of Publication: 2015
ISSN
1600-0404 (electronic)
0001-6314
BOOK PUBLISHER
Blackwell Publishing Ltd, customerservices@oxonblackwellpublishing.com
ABSTRACT
Objectives: Fever frequently occurs in stroke patients and worsens their
prognosis. However, only few studies have assessed the determinants of fever
in acute stroke, and no study has specifically addressed the possible
prediction of the development of fever. Materials and methods: This
investigation included 536 patients with acute stroke and a body temperature
<=37°C during the first 24 h of stay. Ninety-two of them (17.2%)
subsequently developed fever (defined as a temperature >=37.5°C starting
after 24 h). Among the clinical variables available during the first 24 h
from admission, those predictive of the subsequent appearance of fever were
searched for. One hundred further patients had a temperature >37°C during
the first 24 h. Results: In univariate analysis, many variables were
predictive of the subsequent development of fever, but in multivariate
analysis, only the following four predictors remained significant (odds
ratio [95% confidence interval], P value): nasogastric tube (4.0 [2.2-7.4],
<0.0001), atrial fibrillation (2.3 [1.4-3.8], 0.001), total anterior
circulation syndrome (2.0 [1.2-3.5], 0.01), and urinary catheter (1.9
[1.1-3.3], 0.01). Among the 52 (9.7%) patients with three or four
predictors, 31 (59.6%) subsequently developed fever. In addition, the
factors independently associated with a temperature >37°C during the first
24 h were as follows: National Institutes of Health Stroke Scale (P <
0.0001), hemorrhagic stroke (P = 0.0008), atrial fibrillation (P = 0.002),
and total parenteral nutrition (P = 0.03). Conclusions: In patients with
acute stroke, four clinical variables were found to be independently
associated with the risk of developing fever and, of them, nasogastric tube
was the strongest and most significant one.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
fever
human
nasogastric tube
risk factor
stroke patient
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
body temperature
brain hemorrhage
confidence interval
multivariate analysis
National Institutes of Health Stroke Scale
patient
prediction
prognosis
risk
statistical significance
temperature
total parenteral nutrition
univariate analysis
urinary catheter
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015772565
FULL TEXT LINK
http://dx.doi.org/10.1111/ane.12383
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 148
TITLE
Knowledge regarding oral anticoagulation therapy among patients with stroke
and those at high risk of thromboembolic events
AUTHOR NAMES
Alphonsa A.
Sharma K.K.
Sharma G.
Bhatia R.
AUTHOR ADDRESSES
(Alphonsa A.; Sharma K.K.) College of Nursing, All India Institute of
Medical Sciences, New Delhi, India.
(Sharma G.) Department of Cardiology, All India Institute of Medical
Sciences, New Delhi, India.
(Bhatia R., rohitbhatia71@yahoo.com) Department of Neurology, All India
Institute of Medical Sciences, New Delhi, India.
CORRESPONDENCE ADDRESS
R. Bhatia, Department of Neurology, All India Institute of Medical Sciences,
New Delhi, India.
SOURCE
Journal of Stroke and Cerebrovascular Diseases (2015) 24:3 (668-672). Date
of Publication: 1 Mar 2015
ISSN
1532-8511 (electronic)
1052-3057
BOOK PUBLISHER
W.B. Saunders
ABSTRACT
Background Apart from atrial fibrillation, indications for oral
anticoagulation common in our clinical practice include rheumatic heart
disease and mechanical heart valve replacement. Evaluation of current
patient knowledge regarding oral anticoagulation therapy (OAT) is the first
step in improving the quality of anticoagulation therapy and patient care.
The aim of the present study was to assess the knowledge regarding OAT among
patients with stroke and those at high risk of thromboembolic events in a
tertiary care hospital in India. Methods A descriptive cross-sectional
design was used; 240 patients on OAT because of various indications
(mechanical heart valve replacement, rheumatic heart disease, atrial
fibrillation, and stroke) attending the neurology and cardiology outpatient
clinics and inpatient services were recruited. A structured self-developed
questionnaire was used to assess the knowledge in these patients. Results
Most patients (62.9%) were ignorant about the target prothrombin
time/international normalized ratio (PT/INR) levels with only 30% having
their recent INR within the target range; 50% of the patients had a poor
knowledge score, and the knowledge gap was most prominent in the domains of
dietary interactions followed by drug interactions, adverse effects, and
PT/INR monitoring. Knowledge score also had a significant association with
gender, education, monthly income, and place of residence (P <.05).
Conclusion Patient's knowledge about OAT was suboptimal. The findings
support the need for educational interventions to improve the knowledge
regarding OAT and, thereby, achieve an appropriate and safe secondary
prevention of stroke.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (adverse drug reaction, drug combination, drug
interaction, drug therapy, oral drug administration)
EMTREE DRUG INDEX TERMS
acenocoumarol (oral drug administration)
acetylsalicylic acid (drug combination, drug interaction)
dabigatran (oral drug administration)
prothrombin (endogenous compound)
warfarin (oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
cerebrovascular accident (drug therapy, complication, drug therapy,
prevention)
health literacy
high risk patient
knowledge
patient attitude
stroke patient
thromboembolism (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
academic achievement
adult
aged
article
bleeding (side effect)
cross-sectional study
descriptive research
drug drug interaction
drug induced disease
drug information
drug interaction
female
food drug interaction
graduate
high school
human
income
India
international normalized ratio
leafy vegetable
major clinical study
male
married person
patient monitoring
primary school
priority journal
prothrombin time
sex difference
single (marital status)
structured questionnaire
urban rural difference
widow
widower
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
prothrombin (9001-26-7)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015659160
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.007
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 149
TITLE
Copper and Zinc Deficiency in a Patient Receiving Long-Term Parenteral
Nutrition during a Shortage of Parenteral Trace Element Products
AUTHOR NAMES
Palm E.
Dotson B.
AUTHOR ADDRESSES
(Palm E.) Detroit Medical Center, Sinai-Grace Hospital, Detroit, United
States.
(Dotson B., bdotson@dmc.org) Department of Pharmacy, Harper University
Hospital, Detroit, United States.
(Dotson B., bdotson@dmc.org) Wayne State University, Detroit, United States.
CORRESPONDENCE ADDRESS
B. Dotson, Harper University Hospital, 3990 John R., Detroit, United States.
SOURCE
Journal of Parenteral and Enteral Nutrition (2015) 39:8 (986-989). Date of
Publication: 1 Nov 2015
ISSN
1941-2444 (electronic)
0148-6071
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Drug shortages in the United States, including parenteral nutrition (PN)
components, have been common in recent years and can adversely affect
patient care. Here we report a case of copper and zinc deficiency in a
patient receiving PN during a shortage of parenteral trace element products.
The management of the patient's deficiencies, including the use of an
imported parenteral multi-trace element product, is described.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
copper (endogenous compound)
trace element (endogenous compound)
zinc (endogenous compound)
EMTREE DRUG INDEX TERMS
antibiotic agent (drug therapy, intravenous drug administration)
chromium (endogenous compound)
cyanocobalamin (endogenous compound)
diatrizoate
ferritin (endogenous compound)
folic acid (endogenous compound)
hemoglobin (endogenous compound)
heparin (drug therapy, subcutaneous drug administration)
hydromorphone
insulin lispro
iron (endogenous compound)
manganese (endogenous compound)
multivitamin (oral drug administration)
pantoprazole
selenium
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
copper deficiency
long term care
parenteral nutrition
zinc deficiency
EMTREE MEDICAL INDEX TERMS
abdominal abscess (complication)
abdominal infection (drug therapy)
abdominal wall hernia (surgery)
abnormal laboratory result
absorption
adult
anemia
article
atrial fibrillation (complication)
case report
copper blood level
day hospital
enteric feeding
enterocutaneous fistula (complication, surgery)
excision
female
ferritin blood level
folic acid blood level
hematocrit
hernioplasty
hospital admission
hospitalization
human
hypertension
iron binding capacity
iron blood level
macronutrient
mean corpuscular volume
medical history
middle aged
neurologic examination
obesity
peritoneal cavity
prescription
priority journal
stomach bypass
vacuum assisted closure
venous thromboembolism (drug therapy, prevention)
vitamin blood level
wound healing impairment
zinc blood level
CAS REGISTRY NUMBERS
chromium (16065-83-1, 7440-47-3, 14092-98-9)
copper (15158-11-9, 7440-50-8)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
diatrizoate (117-96-4, 737-31-5)
ferritin (9007-73-2)
folic acid (59-30-3, 6484-89-5)
hemoglobin (9008-02-0)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
hydromorphone (466-99-9, 71-68-1)
insulin lispro (133107-64-9)
iron (14093-02-8, 53858-86-9, 7439-89-6)
manganese (16397-91-4, 7439-96-5)
pantoprazole (102625-70-7)
selenium (7782-49-2)
zinc (7440-66-6, 14378-32-6)
EMBASE CLASSIFICATIONS
Hematology (25)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015466573
FULL TEXT LINK
http://dx.doi.org/10.1177/0148607114549255
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 150
TITLE
The safety and efficacy of osteoporosis therapy
AUTHOR NAMES
Mkele G.
AUTHOR ADDRESSES
(Mkele G., gailmkele@hotmail.com)
CORRESPONDENCE ADDRESS
G. Mkele, Email: gailmkele@hotmail.com
SOURCE
SA Pharmaceutical Journal (2015) 82:9 (29-32). Date of Publication: 2015
ISSN
1015-1362
BOOK PUBLISHER
Medpharm Publications, PO Box 14804, Lyttelton, Gauteng, South Africa.
ABSTRACT
Pharmacological agents used to manage osteoporosis act by decreasing the
rate of bone resorption thus slowing down the rate of bone loss, by
promoting bone formation, and with the newer generation of medicines, by
combining both mechanisms. The aim of treating osteoporosis is to preserve
bone mass, restore bone strength and prevent fractures. Although the
treatment of osteoporosis is important, its detection and prevention are
just as important.. Prevention involves maximising peak adult bone mass and
reducing the rate of bone loss. This may be achieved by regular exercise,
adequate dietary calcium and vitamin D intake, and the identification and
management of risk factors.
EMTREE DRUG INDEX TERMS
alendronic acid (drug therapy)
bisphosphonic acid derivative (adverse drug reaction, drug therapy)
calcitonin (adverse drug reaction, drug therapy)
calcium (adverse drug reaction, drug therapy)
calcium carbonate (drug therapy)
calcium chloride (drug therapy)
calcium lactate (drug therapy)
calcium phosphate (drug therapy)
citrate calcium (drug therapy)
denosumab (adverse drug reaction, drug therapy)
dolomite (drug therapy)
gluconate calcium (drug therapy)
ibandronic acid (drug therapy)
parathyroid hormone[1-34] (adverse drug reaction, drug therapy)
raloxifene (adverse drug reaction, drug therapy)
risedronic acid (drug therapy)
strontium ranelate (adverse drug reaction, drug therapy)
unclassified drug
vitamin D (adverse drug reaction, drug therapy)
zoledronic acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
osteoporosis (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
allergic reaction (side effect)
atrial fibrillation (side effect)
backache (side effect)
bone density
bone mass
bone strength
calcium absorption
calcium intake
cystitis (side effect)
diarrhea (side effect)
dietary intake
dizziness (side effect)
eosinophilia (side effect)
esophagitis (side effect)
exercise
flu like syndrome (side effect)
fracture (prevention)
fragility fracture (side effect)
gastrointestinal irritation (side effect)
gastrointestinal symptom (side effect)
headache (side effect)
hormonal therapy
hot flush (side effect)
human
hypercalcemia (side effect)
hypercholesterolemia (side effect)
injection site pain (side effect)
jaw osteonecrosis (side effect)
leg cramp (side effect)
limb pain (side effect)
menopause
monotherapy
musculoskeletal pain (side effect)
nausea (side effect)
nose obstruction (side effect)
osteolysis
postmenopause
review
rhinitis (side effect)
risk factor
risk reduction
skin disease (side effect)
smoking cessation
sun exposure
systemic disease (side effect)
vegetable
venous thromboembolism (side effect)
vitamin intake
vitamin supplementation
weight bearing
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcium (7440-70-2, 14092-94-5)
calcium carbonate (13397-26-7, 13701-58-1, 14791-73-2, 471-34-1)
calcium chloride (10043-52-4)
calcium lactate (814-80-2)
calcium phosphate (10103-46-5, 13767-12-9, 14358-97-5, 7758-87-4)
citrate calcium (7693-13-2)
denosumab (615258-40-7)
gluconate calcium (299-28-5)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
raloxifene (82640-04-8, 84449-90-1)
risedronic acid (105462-24-6, 122458-82-6)
strontium ranelate (135459-87-9)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015521490
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 151
TITLE
Thromboembolic prevention in frail elderly patients with atrial
fibrillation: A practical algorithm
AUTHOR NAMES
Granziera S.
Cohen A.T.
Nante G.
Manzato E.
Sergi G.
AUTHOR ADDRESSES
(Granziera S., serena.granziera@gmail.com; Nante G.; Manzato E.; Sergi G.,
giuseppe.sergi@unipd.it) University of Padova, Department of Medicine-
DIMED, Padova, Italy.
(Granziera S., serena.granziera@gmail.com) King's College Hospital, London,
United Kingdom.
(Cohen A.T.) Department of Thrombosis and Hemostasis, Guy's and St Thomas'
Hospitals, London, United Kingdom.
CORRESPONDENCE ADDRESS
S. Granziera, Clinica Geriatrica - Ospedale Giustinianeo (2o piano), Via
Giustiniani 2, Padua, Italy.
SOURCE
Journal of the American Medical Directors Association (2015) 16:5 (358-364).
Date of Publication: 1 May 2015
ISSN
1538-9375 (electronic)
1525-8610
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
Atrial fibrillation is a common condition in the elderly, and the incidence
of thromboembolic events secondary to atrial fibrillation increases with
age. Antithrombotic therapy effectively prevents stroke and systemic
embolism but also exposes patients to the risk of bleeding. Because the risk
of bleeding also increases with age, clinicians tend to withhold
anticoagulation in the elderly. Anticoagulation is particularly complex in
the frail elderly patient, who presents additional risk factors affecting
both efficacy and safety of thromboembolic prevention. The main clinical
trials rarely include frail elderly patients and, consequently, the
guidelines do not provide guidance for their management. In the absence of
clear indications for this class of patients, we identified some areas that
should be taken into account both before starting and when discontinuing
anticoagulation: comorbidities, polypharmacotherapy, adherence, cognitive
impairment, mobility and monitoring barriers, nutritional status and
swallowing disorders, risk of falls, and reduced life expectancy. We also
suggest a multidimensional algorithm covering both a standard ischemic and
bleeding risk assessment and an additional anticoagulation-focused frailty
assessment. This is of particular relevance given the recent introduction of
the oral direct inhibitors, as they are likely to widen the treatment
options for the frail elderly. Depending on which aspect of frailty is
present, anticoagulation can now be tailored accordingly.
EMTREE DRUG INDEX TERMS
anticoagulant agent (adverse drug reaction, drug therapy, oral drug
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
frail elderly
thromboembolism (drug therapy, complication, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
algorithm
anticoagulation
bleeding (side effect)
cerebrovascular accident (complication, drug therapy)
clinical trial (topic)
cognitive defect
comorbidity
dysphagia
fall risk assessment
geriatric assessment
human
incidence
life expectancy
medication compliance
mobilization
nutritional status
patient monitoring
patient safety
review
risk assessment
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015783816
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jamda.2014.12.008
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 152
TITLE
AHA and ASA release guideline for prevention of future stroke in patients
with stroke or TIA
AUTHOR NAMES
Randel A.
AUTHOR ADDRESSES
(Randel A.)
SOURCE
American Family Physician (2015) 91:2 (136-137). Date of Publication: 2015
ISSN
1532-0650 (electronic)
0002-838X
BOOK PUBLISHER
American Academy of Family Physicians, foundation@aafp.org
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
antivitamin K
clopidogrel (drug therapy)
glucose (endogenous compound)
hemoglobin A1c (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (prevention)
practice guideline
transient ischemic attack (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
cardiovascular risk
coronary artery disease (drug therapy)
diastolic blood pressure
dyslipidemia
high sodium intake
human
hypertension
medical society
Mediterranean diet
nutritional assessment
obesity
oral glucose tolerance test
patient counseling
physical activity
positive end expiratory pressure
sleep disordered breathing
systolic blood pressure
thrombocyte aggregation inhibition
DRUG TRADE NAMES
plavix
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
glucose (50-99-7, 84778-64-3)
hemoglobin A1c (62572-11-6)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2015698084
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 153
TITLE
Red blood cell distribution width: A simple parameter with multiple clinical
applications
AUTHOR NAMES
Salvagno G.L.
Sanchis-Gomar F.
Picanza A.
Lippi G.
AUTHOR ADDRESSES
(Salvagno G.L.) Clinical Chemistry Section, Department of Life and
Reproductive Sciences, Academic Hospital of Verona, Verona, Italy.
(Sanchis-Gomar F.) Department of Physiology, Faculty of Medicine, University
of Valencia, Valencia, Spain.
(Picanza A.; Lippi G., glippi@ao.pr.it) Laboratory of Clinical Chemistry and
Hematology, Academic Hospital of Parma, Parma, Italy.
CORRESPONDENCE ADDRESS
G. Lippi, U.O. Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria
di Parma, Via Gramsci, 14, Parma, Italy.
SOURCE
Critical Reviews in Clinical Laboratory Sciences (2015) 52:2 (86-105). Date
of Publication: 1 Apr 2015
ISSN
1549-781X (electronic)
1040-8363
BOOK PUBLISHER
Informa Healthcare, healthcare.enquiries@informa.com
ABSTRACT
The red blood cell distribution width (RDW) is a simple and inexpensive
parameter, which reflects the degree of heterogeneity of erythrocyte volume
(conventionally known as anisocytosis), and is traditionally used in
laboratory hematology for differential diagnosis of anemias. Nonetheless,
recent evidence attests that anisocytosis is commonplace in human disorders
such as cardiovascular disease, venous thromboembolism, cancer, diabetes,
community-acquired pneumonia, chronic obstructive pulmonary disease, liver
and kidney failure, as well as in other acute or chronic conditions. Despite
some demographic and analytical issues related to the routine assessment
that may impair its clinical usefulness, an increased RDW has a high
negative predictive value for diagnosing a variety of disorders, but also
conveys important information for short- and long-term prognosis. Even more
importantly, the value of RDW is now being regarded as a strong and
independent risk factor for death in the general population. Although it has
not been definitely established whether an increased value of RDW is a risk
factor or should only be considered an epiphenomenon of an underlying
biological and metabolic imbalance, it seems reasonable to suggest that the
assessment of this parameter should be broadened far beyond the differential
diagnosis of anemias. An increased RDW mirrors a profound deregulation of
erythrocyte homeostasis involving both impaired erythropoiesis and abnormal
red blood cell survival, which may be attributed to a variety of underlying
metabolic abnormalities such as shortening of telomere length, oxidative
stress, inflammation, poor nutritional status, dyslipidemia, hypertension,
erythrocyte fragmentation and alteration of erythropoietin function. As
such, the aim of this article is to provide general information about RDW
and its routine assessment, to review the most relevant implications in
health and disease and give some insights about its potential clinical
applications.
EMTREE DRUG INDEX TERMS
tobacco smoke
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
erythrocyte
erythrocyte distribution width
EMTREE MEDICAL INDEX TERMS
acute hepatitis B
acute kidney failure
air pollution
alcohol consumption
anemia
anisocytosis
antiviral therapy
aplastic anemia
atrial fibrillation
autoimmune hemolytic anemia
beta thalassemia
blood transfusion
cardiovascular disease
cardiovascular risk
cerebrovascular accident
chemotherapy
chronic hepatitis B
chronic kidney disease
chronic liver disease
chronic obstructive lung disease
community acquired pneumonia
coronary artery disease
coronary artery ectasia
critically ill patient
cyanocobalamin deficiency
diabetes mellitus
diabetic ketoacidosis
diabetic nephropathy
diabetic neuropathy
differential diagnosis
disease classification
dust exposure
dyslipidemia
erythrocyte disorder
erythrocyte function and characteristics
erythrocyte lifespan
erythrocyte volume
erythropoiesis
folic acid deficiency
heart failure
heart infarction
heart ventricle function
hematological parameters
hematology analyzer
hemolytic anemia
hepatobiliary disease
hereditary spherocytosis
homeostasis
human
hypertension
inflammation
iron deficiency
kidney disease
kidney failure
laboratory test
liver cell carcinoma
liver cirrhosis
liver disease
liver failure
mean corpuscular volume
metabolic syndrome X
mortality
neoplasm
non ST segment elevation myocardial infarction
nonalcoholic fatty liver
nutritional status
occupational exposure
out of hospital cardiac arrest
oxidative stress
pathogenesis
peripheral occlusive artery disease
population
predictive value
primary biliary cirrhosis
priority journal
pulmonary hypertension
review
risk factor
sickle cell anemia
ST segment elevation myocardial infarction
telomere
thalassemia
thrombotic thrombocytopenic purpura
venous thromboembolism
DEVICE MANUFACTURERS
(China)Mindray
(Japan)Sysmex
(United States)Abbott Diagnostics
(United States)Beckman Coulter
(United States)Siemens Healthcare Diagnostics
EMBASE CLASSIFICATIONS
Hematology (25)
Biophysics, Bioengineering and Medical Instrumentation (27)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015121498
FULL TEXT LINK
http://dx.doi.org/10.3109/10408363.2014.992064
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 154
TITLE
Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston
Children’s Hospital Experience
AUTHOR NAMES
Murray J.M.
Hellinger A.
Dionne R.
Brown L.
Galvin R.
Griggs S.
Mittler K.
Harney K.
Manzi S.
VanderPluym C.
Baker A.
O’Brien P.
O’Connell C.
Almond C.S.
AUTHOR ADDRESSES
(Murray J.M.; Brown L.; Galvin R.; Mittler K.; VanderPluym C.; Baker A.;
O’Brien P.; O’Connell C.; Almond C.S., calmond@stanford.edu) Department of
Cardiology, Boston Children’s Hospital, Boston, United States.
(Hellinger A.; Dionne R.; Manzi S.) Departments of Pharmacy and Medicine,
Boston Children’s Hospital, Boston, United States.
(Griggs S.) Divisions of Gastroenterology and Nutrition, Boston Children’s
Hospital, Boston, United States.
(Harney K.) Division of Hematology, Boston Children’s Hospital, Boston,
United States.
(Murray J.M.; Hellinger A.; Dionne R.; Brown L.; Galvin R.; Griggs S.;
Mittler K.; Harney K.; Manzi S.; VanderPluym C.; Baker A.; O’Brien P.;
O’Connell C.; Almond C.S., calmond@stanford.edu) Department of Pediatrics,
Harvard Medical School, 300 Longwood Avenue, Boston, United States.
(Murray J.M.; Almond C.S., calmond@stanford.edu) Division of Pediatric
Cardiology, Stanford University, The Lucile Packard Children’s Hospital, 750
Welch Road Suite 325, Palo Alto, United States.
CORRESPONDENCE ADDRESS
C.S. Almond, Division of Pediatric Cardiology, Stanford University, The
Lucile Packard Children’s Hospital, 750 Welch Road Suite 325, Palo Alto,
United States.
SOURCE
Pediatric Cardiology (2015) 36:4 (842-850). Date of Publication: 2015
ISSN
1432-1971 (electronic)
0172-0643
BOOK PUBLISHER
Springer New York LLC, journals@springer-sbm.com
ABSTRACT
Congenital heart disease is the leading cause of stroke in children.
Warfarin therapy can be difficult to manage safely in this population
because of its narrow therapeutic index, multiple drug and dietary
interactions, small patient size, high-risk cardiac indications, and lack of
data to support anticoagulation recommendations. We sought to describe our
institution’s effort to develop a dedicated cardiac anticoagulation service
to address the special needs of this population and to review the
literature. In 2009, in response to Joint Commission National Patient Safety
Goals for Anticoagulation, Boston Children’s Hospital created a dedicated
pediatric Cardiac Anticoagulation Monitoring Program (CAMP). The primary
purpose was to provide centralized management of outpatient anticoagulation
to cardiac patients, to serve as a disease-specific resource to families and
providers, and to devise strategies to evolve clinical care with rapidly
emerging trends in anticoagulation care. Over 5 years the CAMP Service,
staffed by a primary pediatric cardiology attending, a full-time nurse
practitioner, and administrative assistant with dedicated support from
pharmacy and nutrition, has enrolled over 240 patients ranging in age from
5 months to 55 years. The most common indications include a prosthetic valve
(34 %), Fontan prophylaxis (20 %), atrial arrhythmias (11 %), cardiomyopathy
(10 %), Kawasaki disease (7 %), and a ventricular assist device (2 %). A
patient-centered multi-disciplinary cardiac anticoagulation clinic was
created in 2012. Overall program international normalized ratio (INR) time
in therapeutic range (TTR) is favorable at 67 % (81 % with a 0.2 margin) and
has improved steadily over 5 years. Pediatric-specific guidelines for VKOR1
and CYP2C9 pharmacogenomics testing, procedural bridging with enoxaparin,
novel anticoagulant use, and quality metrics have been developed. Program
satisfaction is rated highly among families and providers. A dedicated
pediatric cardiac anticoagulation program offers a safe and effective
strategy to standardize anticoagulation care for pediatric cardiology
patients, is associated with high patient and provider satisfaction, and is
capable of evolving care strategies with emerging trends in anticoagulation.
EMTREE DRUG INDEX TERMS
cytochrome P450 2C9 (endogenous compound)
enoxaparin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulation
child health care
dedicated pediatric vardiac anticoagulation program
health care utilization
health program
pediatric cardiology
EMTREE MEDICAL INDEX TERMS
article
cardiac patient
cardiomyopathy
child
clinical medicine
heart atrium arrhythmia
heart valve prosthesis
human
international normalized ratio
mucocutaneous lymph node syndrome
nurse practitioner
nutrition
outpatient care
patient satisfaction
pediatric hospital
pharmacogenomics
practice guideline
program development
standardization
United States
ventricular assist device
CAS REGISTRY NUMBERS
enoxaparin (679809-58-6)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015664991
FULL TEXT LINK
http://dx.doi.org/10.1007/s00246-014-1089-x
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 155
TITLE
Primary prevention of stroke by a healthy lifestyle in a high-risk group
AUTHOR NAMES
Larsson S.C.
Akesson A.
Wolk A.
AUTHOR ADDRESSES
(Larsson S.C., susanna.larsson@ki.se; Akesson A.; Wolk A.) Unit of
Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden.
SOURCE
Neurology (2015) 84:22 (2224-2228). Date of Publication: 2 Jun 2015
ISSN
1526-632X (electronic)
0028-3878
BOOK PUBLISHER
Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
Objective: To examine the impact of a healthy lifestyle on stroke risk in
men at higher risk of stroke because of other cardiovascular diseases or
conditions. Methods: Our study population comprised 11,450 men in the Cohort
of Swedish Men who had a history of hypertension, high cholesterol levels,
diabetes, heart failure, or atrial fibrillation. Participants had completed
a questionnaire about diet and lifestyle and were free from stroke and
ischemic heart disease at baseline (January 1, 1998). We defined a healthy
lifestyle as a lowrisk diet (≥5 servings/d of fruits and vegetables and <30
g/d of processed meat), not smoking, ≥150 min/wk of physical activity, body
mass index of 18.5 to 25 kg/m2, and low to moderate alcohol
consumption (>0 to ≤30 g/d). Ascertainment of stroke cases was accomplished
through linkage with the National Inpatient Register and the Swedish Cause
of Death Register. Results: During a mean follow-up of 9.8 years, we
ascertained 1,062 incident stroke cases. The risk of total stroke and stroke
types decreased with increasing number of healthy lifestyle factors. The
multivariable relative risk of total stroke for men who achieved all 5
healthy lifestyle factors compared with men who achieved 0 or 1 factor was
0.28 (95% confidence interval 0.14-0.55). The corresponding relative risks
(95% confidence interval) were 0.31 (0.15-0.66) for ischemic stroke and 0.32
(0.04-2.51) for hemorrhagic stroke. Conclusions: A healthy lifestyle is
associated with a substantially reduced risk of stroke in men at higher risk
of stroke.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (prevention, therapy)
lifestyle modification
EMTREE MEDICAL INDEX TERMS
adult
alcohol consumption
article
body mass
brain hemorrhage (prevention, therapy)
brain ischemia (prevention, therapy)
dietary intake
fruit
high risk population
human
major clinical study
male
middle aged
physical activity
priority journal
processed meat
risk assessment
risk reduction
smoking
Sweden
vegetable
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015089840
FULL TEXT LINK
http://dx.doi.org/10.1212/WNL.0000000000001637
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 156
TITLE
How to manage warfarin therapy
AUTHOR NAMES
Tideman P.A.
Tirimacco R.
St. John A.
Roberts G.W.
AUTHOR ADDRESSES
(Tideman P.A.; Tirimacco R.; St. John A.) Australian Point of Care
Practitioners Network, Adelaide, Australia.
(Tideman P.A.; Tirimacco R.) Integrated Cardiovascular Clinical Network
Country Health South Australia, Adelaide, Australia.
(Roberts G.W.) Pharmacy Department Flinders Medical Centre, Adelaide,
Australia.
SOURCE
Australian Prescriber (2015) 38:2 (44-48). Date of Publication: 2015
ISSN
0312-8008
BOOK PUBLISHER
Australian Government Publishing Service, info@australianprescriber.com
ABSTRACT
Long-term treatment with warfarin is recommended for patients with atrial
fibrillation at risk of stroke and those with recurrent venous thrombosis or
prosthetic heart valves. Patient education before commencing warfarin -
regarding signs and symptoms of bleeding, the impact of diet, potential drug
interactions and the actions to take if a dose is missed - is pivotal to
successful use. Scoring systems such as the CHADS2 score are used
to determine if patients with atrial fibrillation are suitable for warfarin
treatment. To rapidly achieve stable anticoagulation, use an age-adjusted
protocol for starting warfarin. Regular monitoring of the anticoagulant
effect is required. Evidence suggests that patients who self-monitor using
point-of-care testing have better outcomes than other patients.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
phytomenadione
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
medication therapy management
EMTREE MEDICAL INDEX TERMS
age
article
atrial fibrillation (drug therapy)
bleeding (side effect)
cerebrovascular accident (drug therapy)
CHADS2 score
clinical protocol
deep vein thrombosis (drug therapy)
diet
drug efficacy
drug monitoring
drug safety
HAS BLED score
human
international normalized ratio
laboratory diagnosis
maintenance therapy
meta analysis (topic)
patient education
pharmacodynamics
point of care testing
prophylaxis
randomized controlled trial (topic)
risk factor
scoring system
self monitoring
systematic review (topic)
treatment duration
treatment indication
treatment outcome
treatment response
valvular heart disease (drug therapy)
CAS REGISTRY NUMBERS
phytomenadione (11104-38-4, 84-80-0)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015893317
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 157
TITLE
Phytochemical Compounds and Protection from Cardiovascular Diseases: A State
of the Art
AUTHOR NAMES
Pagliaro B.
Santolamazza C.
Simonelli F.
Rubattu S.
AUTHOR ADDRESSES
(Pagliaro B., beniamino.pagliaro@libero.it; Santolamazza C.,
caterina.santolamazza@gmail.com; Simonelli F.,
francescasimonelli@hotmail.it; Rubattu S., rubattu.speranza@neuromed.it)
Department of Clinical and Molecular Medicine, School of Medicine and
Psychology, Saint Andrea Hospital, Sapienza University of Rome, Rome, Italy.
(Rubattu S., rubattu.speranza@neuromed.it) IRCCS Neuromed, Pozzilli, Italy.
CORRESPONDENCE ADDRESS
S. Rubattu, Department of Clinical and Molecular Medicine, School of
Medicine and Psychology, Saint Andrea Hospital, Sapienza University of Rome,
Rome, Italy.
SOURCE
BioMed Research International (2015) 2015 Article Number: 918069. Date of
Publication: 2015
ISSN
2314-6141 (electronic)
2314-6133
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
Cardiovascular diseases represent a worldwide relevant socioeconomical
problem. Cardiovascular disease prevention relies also on lifestyle changes,
including dietary habits. The cardioprotective effects of several foods and
dietary supplements in both animal models and in humans have been explored.
It was found that beneficial effects are mainly dependent on antioxidant and
anti-inflammatory properties, also involving modulation of mitochondrial
function. Resveratrol is one of the most studied phytochemical compounds and
it is provided with several benefits in cardiovascular diseases as well as
in other pathological conditions (such as cancer). Other relevant compounds
are Brassica oleracea, curcumin, and berberine, and they all exert
beneficial effects in several diseases. In the attempt to provide a
comprehensive reference tool for both researchers and clinicians, we
summarized in the present paper the existing literature on both preclinical
and clinical cardioprotective effects of each mentioned phytochemical. We
structured the discussion of each compound by analyzing, first, its cellular
molecular targets of action, subsequently focusing on results from
applications in both ex vivo and in vivo models, finally discussing the
relevance of the compound in the context of human diseases.
EMTREE DRUG INDEX TERMS
berberine (drug therapy, pharmacology)
curcumin (drug therapy, pharmacology)
hydroxymethylglutaryl coenzyme A reductase kinase (endogenous compound)
immunoglobulin enhancer binding protein (endogenous compound)
mitogen activated protein kinase (endogenous compound)
peroxisome proliferator activated receptor alpha (endogenous compound)
protein kinase B (endogenous compound)
resveratrol (drug analysis, drug therapy, pharmacology)
sirtuin 1 (endogenous compound)
stress activated protein kinase (endogenous compound)
transcription factor Nrf2 (endogenous compound)
uncoupling protein 2 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, drug therapy, prevention)
heart protection
phytochemistry
EMTREE MEDICAL INDEX TERMS
antiapoptotic activity
antiarrhythmic activity
antihypertensive activity
antiinflammatory activity
antioxidant activity
atherosclerosis (drug therapy, prevention)
atrial fibrillation (drug therapy, prevention)
berry
brain ischemia (drug therapy, prevention)
Brassica oleracea
cardiotoxicity (drug therapy, prevention)
drug activity
drug structure
dyslipidemia (drug therapy, prevention)
grape
heart failure (drug therapy, prevention)
heart ventricle fibrillation (drug therapy, prevention)
heart ventricle hypertrophy (drug therapy, prevention)
heart ventricle tachycardia (drug therapy, prevention)
human
hypertension (drug therapy, prevention)
ischemic heart disease (drug therapy, prevention)
lipogenesis
non insulin dependent diabetes mellitus (drug therapy, prevention)
nonhuman
obesity (drug therapy, prevention)
peanut
Polygonum cuspidatum
red wine
review
CAS REGISTRY NUMBERS
berberine (2086-83-1, 633-65-8)
curcumin (458-37-7)
hydroxymethylglutaryl coenzyme A reductase kinase (172522-01-9, 72060-32-3)
mitogen activated protein kinase (142243-02-5)
peroxisome proliferator activated receptor alpha (147258-70-6)
protein kinase B (148640-14-6)
resveratrol (501-36-0)
stress activated protein kinase (155215-87-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015478488
FULL TEXT LINK
http://dx.doi.org/10.1155/2015/918069
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 158
TITLE
Hepatobiliary and Pancreatic: Pseudoachalasia from pancreatic cancer
AUTHOR NAMES
García-Alonso F.
Hernández Tejero M.
Castanon-Deprit A.
AUTHOR ADDRESSES
(García-Alonso F.; Hernández Tejero M.) Department of Gastroenterology,
Fuenlabrada University Hospital, Fuenlabrada, Spain.
(Castanon-Deprit A.) Department of Pathology, Fuenlabrada University
Hospital, Fuenlabrada, Spain.
SOURCE
Journal of Gastroenterology and Hepatology (Australia) (2015) 30:9 (1336).
Date of Publication: 1 Sep 2015
ISSN
1440-1746 (electronic)
0815-9319
BOOK PUBLISHER
Blackwell Publishing, info@asia.blackpublishing.com.au
EMTREE DRUG INDEX TERMS
acenocoumarol
bisoprolol (drug therapy)
fluticasone propionate plus salmeterol (drug therapy)
insulin (drug therapy)
tiotropium bromide (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
esophagus achalasia
pancreas adenocarcinoma (diagnosis)
pseudoachalasia
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation (drug therapy)
cancer diagnosis
case report
chronic obstructive lung disease (drug therapy)
computer assisted tomography
diabetes mellitus (drug therapy)
diet
disease duration
dysphagia
esophagus biopsy
esophagus dilatation
follow up
gastroesophageal reflux
gastrointestinal endoscopy
human
human tissue
hypertension
liquid
male
medical history
priority journal
rare disease
stomach biopsy
thorax pain
very elderly
weight reduction
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
bisoprolol (66722-44-9)
insulin (9004-10-8)
tiotropium bromide (136310-93-5)
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Radiology (14)
Cancer (16)
Drug Literature Index (37)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2015228930
FULL TEXT LINK
http://dx.doi.org/10.1111/jgh.12961
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 159
TITLE
Cardiorespiratory fitness and risk of incident atrial fibrillation: Results
from the Henry Ford exercise testing (FIT) project
AUTHOR NAMES
Qureshi W.T.
Alirhayim Z.
Blaha M.J.
Juraschek S.P.
Keteyian S.J.
Brawner C.A.
Al-Mallah M.H.
AUTHOR ADDRESSES
(Qureshi W.T.; Alirhayim Z.; Keteyian S.J.; Brawner C.A.; Al-Mallah M.H.,
mouaz74@gmail.com) Henry Ford Hospital/Wayne State University, Detroit,
United States.
(Qureshi W.T.) Wake Forest University School of Medicine, Winston Salem,
United States.
(Alirhayim Z.) University of Kansas Medical Center, Kansas City, United
States.
(Blaha M.J.; Juraschek S.P.) Johns Hopkins Ciccarone Center for the
Prevention of Heart Disease, Baltimore, United States.
(Al-Mallah M.H., mouaz74@gmail.com) Wayne State University, Detroit, United
States.
(Al-Mallah M.H., mouaz74@gmail.com) King Abdul-Aziz Cardiac Center, National
Guard Health Affairs, Riyadh, Saudi Arabia.
CORRESPONDENCE ADDRESS
M.H. Al-Mallah, Consultant Cardiologist and Division Head, King Abdul-Aziz
Cardiac Center, Department Mail Code, 1413, PO Box 22490, Riyadh, Saudi
Arabia.
SOURCE
Circulation (2015) 131:21 (1827-1834). Date of Publication: 26 May 2015
ISSN
1524-4539 (electronic)
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
Background: Poor cardiorespiratory fitness (CRF) is an independent risk
factor for cardiovascular morbidity and mortality. However, the relationship
between CRF and atrial fibrillation (AF) is less clear. The aim of this
analysis was to investigate the association between CRF and incident AF in a
large, multiracial cohort that underwent graded exercise treadmill testing.
Methods and Results: From 1991 to 2009, a total of 64 561 adults (mean age,
54.5±12.7 years; 46% female; 64% white) without AF underwent exercise
treadmill testing at a tertiary care center. Baseline demographic and
clinical variables were collected. Incident AF was ascertained by use of
International Classification of Diseases, Ninth Revision code 427.31 and
confirmed by linkage to medical claim files. Nested, multivariable Cox
proportional hazards models were used to estimate the independent
association of CRF with incident AF. During a median follow-up of 5.4 years
(interquartile range, 3-9 years), 4616 new cases of AF were diagnosed. After
adjustment for potential confounders, 1 higher metabolic equivalent achieved
during treadmill testing was associated with a 7% lower risk of incident AF
(hazard ratio, 0.93; 95% confidence interval, 0.92-0.94; P<0.001). This
relationship remained significant after adjustment for incident coronary
artery disease (hazard ratio, 0.92; 95% confidence interval, 0.91-0.93;
P<0.001). The magnitude of the inverse association between CRF and incident
AF was greater among obese compared with nonobese individuals (P for
interaction=0.02). Conclusions: There is a graded, inverse relationship
between cardiorespiratory fitness and incident AF, especially among obese
patients. Future studies should examine whether changes in fitness increase
or decrease risk of atrial fibrillation. This association was stronger for
obese compared with nonobese, especially among obese patients.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cardiorespiratory fitness
EMTREE MEDICAL INDEX TERMS
adult
aged
article
cardiovascular risk
cohort analysis
coronary artery disease
demography
disease association
female
follow up
human
ICD-9
major clinical study
male
metabolic equivalent
obesity
priority journal
tertiary care center
treadmill test
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015414889
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014833
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 160
TITLE
The Prevalence of Arrhythmias, Predictors for Arrhythmias, and Safety of
Exercise Stress Testing in Children
AUTHOR NAMES
Ghosh R.M.
Gates G.J.
Walsh C.A.
Schiller M.S.
Pass R.H.
Ceresnak S.R.
AUTHOR ADDRESSES
(Ghosh R.M.; Gates G.J.; Walsh C.A.; Schiller M.S.; Pass R.H.) Division of
Pediatric Cardiology, Department of Pediatrics, The Children’s Hospital at
Montefiore – Albert Einstein College of Medicine, 3415 Bainbridge Ave,
Bronx, United States.
(Ceresnak S.R., ceresnak@yahoo.com) Division of Pediatric Cardiology,
Department of Pediatrics, Stanford University – Lucille Packard Children’s
Hospital, 750 Welch Road, Suite 305, Palo Alto, United States.
CORRESPONDENCE ADDRESS
S.R. Ceresnak, Division of Pediatric Cardiology, Department of Pediatrics,
Stanford University – Lucille Packard Children’s Hospital, 750 Welch Road,
Suite 305, Palo Alto, United States.
SOURCE
Pediatric Cardiology (2015) 36:3 (584-590). Date of Publication: 2015
ISSN
1432-1971 (electronic)
0172-0643
BOOK PUBLISHER
Springer New York LLC, journals@springer-sbm.com
ABSTRACT
Exercise testing is commonly performed in children for evaluation of cardiac
disease. Few data exist, however, on the prevalence, types of arrhythmias,
predictors for arrhythmias, and safety of exercise testing in children. A
retrospective review of all patients ≤21 years undergoing exercise testing
at our center from 2008 to 2012 was performed. Patients with clinically
relevant arrhythmias were compared to those not experiencing a significant
arrhythmia. 1,037 tests were performed in 916 patients. The mean age was
14 ± 4 years, 537 (55 %) were male, 281 (27 %) had congenital heart disease,
178 (17 %) had a history of a prior arrhythmia, and 17 (2 %) had a pacemaker
or ICD. 291 (28 %) patients had a rhythm disturbance during the procedure.
Clinically important arrhythmias were noted in 34 (3 %) patients and
included: 19 (1.8 %) increasing ectopy with exercise, 5 (0.5 %) VT, 5
(0.5 %) second degree AV block, 3 (0.3 %) SVT, and 2 (0.2 %) AFIB. On
multivariate logistic regression, variables associated with the development
of clinically relevant arrhythmias included severe left ventricular (LV)
dysfunction on echo (OR 1.99, CI 1.20–3.30) and prior history of a
documented arrhythmia (OR 2.94, CI 1.25–6.88). There were no adverse events
related to testing with no patient requiring cardioversion, defibrillation,
or acute anti-arrhythmic therapy. A total of 28 % of children developed a
rhythm disturbance during exercise testing and 3 % were clinically
important. Severe LV dysfunction and a history of documented arrhythmia were
associated with the development of a clinically important arrhythmia.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise test
heart arrhythmia
EMTREE MEDICAL INDEX TERMS
adolescent
article
bicycle ergometer
child
congestive cardiomyopathy
controlled study
echocardiography
exercise tolerance
female
heart palpitation
human
implantable cardioverter defibrillator
major clinical study
male
non invasive procedure
pacemaker
prevalence
retrospective study
safety
second degree atrioventricular block
thorax pain
treadmill exercise
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014892675
FULL TEXT LINK
http://dx.doi.org/10.1007/s00246-014-1053-9
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 161
TITLE
The relation of respiratory muscle strength to disease severity and abnormal
ventilation during exercise in chronic heart failure patients
AUTHOR NAMES
Kasahara Y.
Izawa K.P.
Watanabe S.
Osada N.
Omiya K.
AUTHOR ADDRESSES
(Kasahara Y., kasahara.y@marianna-u.ac.jp) Department of Rehabilitation
Medicine, St. Marianna University School of Medicine, Yokohama City Seibu
Hospital, Yokohama, Japan.
(Izawa K.P.) Graduate School of Health Sciences, Kobe University, Kobe,
Japan.
(Watanabe S.) Department of Rehabilitation Medicine, St. Marianna University
School of Medicine Hospital, Kawasaki, Japan.
(Osada N.) Division of Cardiology, St. Marianna University School of
Medicine Toyoko Hospital, Kawasaki, Japan.
(Omiya K.) Division of Cardiology, Department of Internal Medicine (NO, KO),
St. Marianna University School of Medicine, Yokohama City Seibu Hospital,
Yokohama, Japan.
CORRESPONDENCE ADDRESS
Y. Kasahara, Department of Rehabilitation Medicine, St. Marianna University
School of Medicine, Yokohama City Seibu Hospital, Yokohama, Japan.
SOURCE
Research in Cardiovascular Medicine (2015) 4:4 (1-8) Article Number: e28944.
Date of Publication: 1 Nov 2015
ISSN
2251-9580 (electronic)
2251-9572
BOOK PUBLISHER
KOWSAR Medical Publishing Company, info@kowsarmed.com
ABSTRACT
Background: Breathlessness is a common problem in chronic heart failure
(CHF) patients, and respiratory muscle strength has been proposed to play an
important role in causing breathlessness in these patients. Objectives: The
aim of this study was to investigate the relation between respiratory muscle
strength and the severity of CHF, and the influence of respiratory muscle
strength on abnormal ventilation during exercise in CHF patients. Patients
and Methods: In this case series study, we assessed clinically stable CHF
outpatients (N = 66, age: 57.7 ± 14.6 years). The peak oxygen consumption
(peak VO2), the slope relating minute ventilation to carbon dioxide
production (VE/VCO2 slope), and the slope relating tidal volume to
respiratory rate (TV/RR slope) were measured during cardiopulmonary exercise
testing. Respiratory muscle strength was assessed by measuring the maximal
inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Results:
The MIP and MEP decreased significantly as the New York Heart Association
functional class increased (MIP, P = 0.021; MEP, P < 0.01). The MIP
correlated with the TV/RR slope (r = 0.57, P < 0.001) and the VE/VCO2 slope
(r = -0.44, P < 0.001), and the MEP also correlated with the TV/RR slope (r
= 0.53, P < 0.001) and the VE/VCO2 slope (r = -0.25, P < 0.040). Stepwise
multiple regression analysis revealed that age and MIP were statistically
significant predictors of the TV/RR and VE/VCO2 slopes (both P < 0.05).
Conclusions: Respiratory muscle strength is related to the severity of CHF,
and associated with rapid and shallow ventilation or excessive ventilation
during exercise.
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist
brain natriuretic peptide (endogenous compound)
carbon dioxide
dipeptidyl carboxypeptidase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aerobic exercise
breathing disorder
breathing muscle
disease severity
heart failure
muscle strength
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
body mass
breathing rate
cardiopulmonary exercise test
echocardiography
female
heart left ventricle ejection fraction
heart muscle oxygen consumption
human
major clinical study
male
maximal expiratory pressure
maximal inspiratory pressure
respiratory tract parameters
tidal volume
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
carbon dioxide (124-38-9, 58561-67-4)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015354305
FULL TEXT LINK
http://dx.doi.org/10.5812/cardiovascmed.28944
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 162
TITLE
The controversial relationship between exercise and atrial fibrillation:
Clinical studies and pathophysiological mechanisms
AUTHOR NAMES
D'Ascenzi F.
Cameli M.
Ciccone M.M.
Maiello M.
Modesti P.A.
Mondillo S.
Muiesan M.L.
Scicchitano P.
Novo S.
Palmiero P.
Saba P.S.
Pedrinelli R.
AUTHOR ADDRESSES
(D'Ascenzi F., flavio.dascenzi@libero.it; Cameli M.; Mondillo S.)
Cardiologia Universitaria, Università degli Studi di Siena, Viale M. Bracci,
16, Siena, Italy.
(Ciccone M.M.; Scicchitano P.) Dipartimento di Emergenza e Trapianto Organi,
Università degli Studi di Bari, Bari, Italy.
(Maiello M.; Palmiero P.) Azienda Sanitaria Locale di Brindisi, Brindisi,
Italy.
(Modesti P.A.) Dipartimento di Medicina Clinica e Sperimentale, Università
degli Studi di Firenze, Firenze, Italy.
(Muiesan M.L.) Dipartimento di Scienze Cliniche e Sperimentali, Università
degli Studi di Brescia, Brescia, Italy.
(Novo S.) Dipartimentodi Medicina Interna e Malattie Cardiovascolari,
Università degli Studi di Palermo, Palermo, Italy.
(Saba P.S.) Dipartimento di Medicina Clinica e Sperimentale, Università
degli Studidi Sassari, Sassari, Italy.
(Pedrinelli R.) Dipartimento di Patologia Chirurgica, Medica, Molecolare e
dell'Area Critica, Università di Pisa, Pisa, Italy.
CORRESPONDENCE ADDRESS
F. D'Ascenzi, Cardiologia Universitaria, Università degli Studi di Siena,
Viale M. Bracci, 16, Siena, Italy.
SOURCE
Journal of Cardiovascular Medicine (2015) 16:12 (802-810). Date of
Publication: 2015
ISSN
1558-2035 (electronic)
1558-2027
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Atrial fibrillation is the most common clinically significant arrhythmia
observed both in the general population and in competitive athletes. The
most important risk factors are all preventable by regular physical
activity. However, although the benefits of moderate physical activity in
controlling cardiovascular risk factors and decreasing the risk of atrial
fibrillation have been extensively proved, concerns have arisen about the
potential negative effects of vigorous exercise, particularly in endurance
athletes. Furthermore, in a subset of patients with atrial fibrillation
younger than 60 years, routine evaluation does not reveal any cardiovascular
disease or any other known causal factor. This condition is called 'lone
atrial fibrillation', and the potential mechanisms underlying this condition
are speculative and remain to be clarified. Atrial ectopy, increased vagal
tone, changes in electrolytes, left atrial dilatation, and fibrosis have
been proposed among others as potential mechanisms. However, no convincing
data still exist. Particularly, the increase in left atrial size represents
in athletes a physiological adaptation to exercise conditioning and the
presence of biatrial fibrosis has not been demonstrated in humans. Thus,
contrary to patients with cardiovascular disorders, the atrial substrate
seems to play a secondary role in healthy athletes. This review article
analyzes the controversial relationship between atrial fibrillation and
physical activity, with a particular attention on the pathophysiological
mechanisms that could be responsible for atrial fibrillation in the athletic
population.
EMTREE DRUG INDEX TERMS
illicit drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise
physical activity
EMTREE MEDICAL INDEX TERMS
athlete
atrial ectopy
autonomic nervous system
cardiovascular risk
disease association
electrolyte disturbance
exercise intensity
genetics
heart atrium flutter
heart atrium function
heart atrium remodeling
heart disease
heart left atrium
heart left atrium fibrosis
human
jogging
multifactorial inheritance
physical performance
review
sport
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014952923
FULL TEXT LINK
http://dx.doi.org/10.2459/JCM.0000000000000211
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 163
TITLE
Exercise and the heart: The good, the bad, and the ugly
AUTHOR NAMES
Sharma S.
Merghani A.
Mont L.
AUTHOR ADDRESSES
(Sharma S., sasharma@sgul.ac.uk; Merghani A.) Department of Cardiovascular
Sciences, St Georges University of London, Cranmer Terrace, London, United
Kingdom.
(Mont L.) Hospital Clinic, Institut del Torax, Universitat de Barcelona,
Barcelona, Spain.
CORRESPONDENCE ADDRESS
S. Sharma, Department of Cardiovascular Sciences, St Georges University of
London, Cranmer Terrace, London, United Kingdom.
SOURCE
European Heart Journal (2015) 36:23 (1445-1453). Date of Publication: 2015
ISSN
1522-9645 (electronic)
0195-668X
BOOK PUBLISHER
Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
The benefits of exercise are irrefutable. Individuals engaging in regular
exercise have a favourable cardiovascular risk profile for coronary artery
disease and reduce their risk of myocardial infarction by 50%. Exercise
promotes longevity of life, reduces the risk of some malignancies, retards
the onset of dementia, and is as considered an antidepressant. Most of these
benefits are attributable to moderate exercise, whereas athletes perform way
beyond the recommended levels of physical activity and constantly push back
the frontiers of human endurance. The cardiovascular adaptation for
generating a large and sustained increase in cardiac output during prolonged
exercise includes a 10-20% increase in cardiac dimensions. In rare
instances, these physiological increases in cardiac size overlap with
morphologically mild expressions of the primary cardiomyopathies and
resolving the diagnostic dilemma can be challenging. Intense exercise may
infrequently trigger arrhythmogenic sudden cardiac death in an athlete
harbouring asymptomatic cardiac disease. In parallel with the extraordinary
athletic milieu of physical performances previously considered unachievable,
there is emerging data indicating that long-standing vigorous exercise may
be associated with adverse electrical and structural remodelling in
otherwise normal hearts. Finally, in the current era of celebrity athletes
and lucrative sport contracts, several athletes have succumbed to using
performance enhancing agents for success which are detrimental to cardiac
health. This article discusses the issues abovementioned, which can be
broadly classified as the good, bad, and ugly aspects of sports cardiology.
EMTREE DRUG INDEX TERMS
performance enhancing substance
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular function
exercise
EMTREE MEDICAL INDEX TERMS
athlete
atrial fibrillation
cardiomyopathy
cardiovascular magnetic resonance
cardiovascular mortality
cardiovascular risk
electrocardiogram
follow up
heart output
heart rehabilitation
heart size
heart ventricle arrhythmia
human
metabolic equivalent
physical activity
physical performance
priority journal
review
sedentary lifestyle
sinus node disease
sport
ST segment elevation
sudden cardiac death
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015407364
FULL TEXT LINK
http://dx.doi.org/10.1093/eurheartj/ehv090
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 164
TITLE
Exercise-induced vasodilation in healthy males: A marker of reduced
endothelial function
AUTHOR NAMES
Wethal T.
Roysland R.
Torbjorn O.
Kjekshus J.
AUTHOR ADDRESSES
(Wethal T., torgeir.wethal@medisin.uio.no; Roysland R.; Torbjorn O.;
Kjekshus J.) Institute of Clinical Medicine, University of Oslo, Norway.
(Wethal T., torgeir.wethal@medisin.uio.no) Department of Medicine, St. Olavs
Hospital, Pb. 3250 Sluppen, Trondheim, Norway.
(Torbjorn O.) Division of Medicine, Akershus University Hospital, Lorenskog,
Norway.
CORRESPONDENCE ADDRESS
T. Wethal, Department of Medicine, St. Olavs Hospital, Pb. 3250 Sluppen,
Trondheim, Norway.
SOURCE
Scandinavian Cardiovascular Journal (2015) 49:3 (123-129). Date of
Publication: 1 Jun 2015
ISSN
1651-2006 (electronic)
1401-7431
BOOK PUBLISHER
Informa Healthcare, healthcare.enquiries@informa.com
ABSTRACT
Objectives. Reduced arterial vasodilatatory capacity is a marker of coronary
heart disease. The aim was to investigate if the difference between the
vasodilatory response before and after exercise, as assessed by non-invasive
methodology, is related to endothelial and inflammatory biomarkers. Design.
Post-ischemic hyperemia after 5 min of arterial occlusion was examined
before and after a bicycle test with strain-gauge plethysmography (measuring
peak reactive hyperemia in the forearm) and peripheral arterial tonometry
(PAT hyperemia ratio: measuring pulse waves in the index finger relative to
the contra-lateral index finger) in 30 healthy males. A low PAT hyperemia
ratio or a low peak reactive hyperemia reflects endothelial dysfunction.
Inflammatory and endothelial biomarkers were assessed. Results. A low peak
reactive hyperemia and a low PAT hyperemia ratio before the bicycle test was
associated with a high percentage increase in peak reactive hyperemia after
exercise (r = - 0.68, p < 0.001; r = - 0.35, p = 0.06, respectively).
Asymmetric dimethylarginine and interleukin-10 were associated with the
percentage increase in peak reactive hyperemia in multiple linear regression
analyses (β: 165 (confidence interval [CI], 34-296), p = 0.02; β: 19 (CI, -
0.5-39), p = 0.06, respectively). Conclusions. The difference in the
vasodilatory response before and after exercise, as assessed by non-invasive
methodology, is related to endothelial and inflammatory biomarkers in
healthy males.
EMTREE DRUG INDEX TERMS
beta 2 adrenergic receptor stimulating agent (drug therapy)
biological marker (endogenous compound)
C reactive protein (endogenous compound)
glucose (endogenous compound)
hemoglobin A1c (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
interleukin 10 (endogenous compound)
interleukin 8 (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
n(g),n(g) dimethylarginine (endogenous compound)
osteoprotegerin (endogenous compound)
PADGEM protein (endogenous compound)
triacylglycerol (endogenous compound)
tumor necrosis factor receptor (endogenous compound)
von Willebrand factor (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular function
endothelial function
exercise
vasodilatation
EMTREE MEDICAL INDEX TERMS
adult
aged
arterial stiffness
article
asthma (drug therapy)
atrial fibrillation
bicycle ergometry
biochemical analysis
blood pressure measurement
borderline hypertension
cholesterol blood level
clinical article
diastolic blood pressure
endothelial dysfunction
experimental hyperemia
forearm blood flow
human
index finger
male
non insulin dependent diabetes mellitus
non invasive procedure
peripheral arterial tonometry
plethysmography
priority journal
pulse wave
strain gauge transducer
systolic blood pressure
vein occlusion
venous stasis
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
glucose (50-99-7, 84778-64-3)
hemoglobin A1c (62572-11-6)
interleukin 8 (114308-91-7)
n(g),n(g) dimethylarginine (30315-93-6)
osteoprotegerin (205944-50-9)
tumor necrosis factor receptor (129203-93-6, 184595-01-5)
von Willebrand factor (109319-16-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
Immunology, Serology and Transplantation (26)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015051650
FULL TEXT LINK
http://dx.doi.org/10.3109/14017431.2015.1021708
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 165
TITLE
Delays in Referral and Enrolment Are Associated with Mitigated Benefits of
Cardiac Rehabilitation after Coronary Artery Bypass Surgery
AUTHOR NAMES
Marzolini S.
Blanchard C.
Alter D.A.
Grace S.L.
Oh P.I.
AUTHOR ADDRESSES
(Marzolini S., Susan.marzolini@uhn.ca; Alter D.A.; Oh P.I.) Toronto
Rehabilitation Institute, University Health Network, 347 Rumsey Rd, Toronto,
Canada.
(Blanchard C.) Department of Medicine, Dalhousie University, Halifax,
Canada.
(Grace S.L.) Faculty of Health, York University, Toronto, Canada.
CORRESPONDENCE ADDRESS
S. Marzolini, Toronto Rehabilitation Institute, University Health Network,
347 Rumsey Rd, Toronto, Canada. Email: Susan.marzolini@uhn.ca
SOURCE
Circulation: Cardiovascular Quality and Outcomes (2015) 8:6 (608-620). Date
of Publication: 1 Dec 2015
ISSN
1941-7705 (electronic)
1941-7713
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Background-Cardiac rehabilitation (CR) is recommended after coronary artery
bypass graft surgery; however, the consequences of longer wait times to
start CR have not been elucidated. Method and Results-Cardiopulmonary,
demographic, and anthropometric assessments were conducted before and after
6 months of CR in consecutively enrolled patients from January 1995 to
October 2012. Wait times were ascertained from referral forms and charts.
Neighborhood characteristics were ascertained using census data and
cross-referencing with patients' home geographic location. Among 6497
post-coronary artery bypass graft participants, mean and median total wait
time (time from surgery to first exercise session) was 101.1±47.9 and 80
days, respectively. In multiple linear regression, correlates of longer
total wait time and the 2 wait-Time phases, time from surgery to CR referral
and time from CR referral to first exercise session, were determined.
Factors influencing longer wait times included female sex, greater age,
being employed, less social support, longer drive time to CR, lower
neighborhood socioeconomic status, higher systolic blood pressure, abdominal
obesity, and a complex medical history. After adjusting for correlates of
delayed entry, longer wait time for each of the total and 2 wait-Time phases
was significantly associated with less improvement in cardiopulmonary
fitness (VO2peak; β=-0.165, P<0.001), body fat percentage (β=0.032, P<0.02),
resting heart rate (β=0.066, P<0.001), and poorer attendance to CR classes
(β=-0.081, P<0.001) and completion rate (β=2.741, P<0.001).
Conclusions-Strategies for timely access to CR at each phase of the process
are important given the negative impact that wait time has on key clinical
outcomes. This is relevant because optimizing VO2peak and attendance to CR
has been shown to confer a mortality advantage.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary artery bypass surgery
heart rehabilitation
patient referral
postoperative care
EMTREE MEDICAL INDEX TERMS
abdominal obesity
adult
anthropometry
article
atrial fibrillation
body fat
cardiomyopathy
cardiopulmonary function
cerebrovascular accident
coronary artery bypass graft
demography
diabetes mellitus
diastolic blood pressure
exercise
female
functional status
heart arrest
heart failure
heart infarction
human
major clinical study
male
medical history
neighborhood
outcome assessment
peripheral vascular disease
priority journal
resting heart rate
retrospective study
sex difference
skinfold thickness
smoking
social status
social support
systolic blood pressure
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015531807
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCOUTCOMES.115.001751
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 166
TITLE
Heart failure and cognitive dysfunction
AUTHOR NAMES
Ampadu J.
Morley J.E.
AUTHOR ADDRESSES
(Ampadu J.) PGY-2, Department of Internal Medicine, Saint Louis University
Hospital, St. Louis, United States.
(Morley J.E., morley@slu.edu) Division of Geriatric Medicine, Department of
Internal Medicine, Saint Louis University School of Medicine, 1402 S. Grand
Blvd.,M238, St. Louis, United States.
(Morley J.E., morley@slu.edu) Division of Endocrinology, Department of
Internal Medicine, Saint Louis University School of Medicine, St. Louis,
United States.
CORRESPONDENCE ADDRESS
J.E. Morley, Division of Geriatric Medicine, Department of Internal
Medicine, Saint Louis University School of Medicine, 1402 S. Grand
Blvd.,M238, St. Louis, United States.
SOURCE
International Journal of Cardiology (2015) 178 (12-23). Date of Publication:
15 Jan 2015
ISSN
1874-1754 (electronic)
0167-5273
BOOK PUBLISHER
Elsevier Ireland Ltd
ABSTRACT
It has been estimated that 5.1 million Americans suffer from heart failure.
Cognitive impairment has been described as a consequence of heart failure in
numerous studies spanning the last three decades. This systematic review
helps differentiate "cognitive impairment" into mild cognitive impairment,
dementia, and delirium. We evaluate the prevalence, pathophysiology,
treatment modalities, and possible outcomes previously described with these
associations in heart failure. This review also assesses the utility of the
different screening modalities and their efficacy as they pertain to
recognizing cognitive impairment.
EMTREE DRUG INDEX TERMS
brain natriuretic peptide (endogenous compound)
C reactive protein (endogenous compound)
cardiovascular agent (adverse drug reaction)
cholinergic receptor blocking agent (adverse drug reaction)
cyclooxygenase 2 (endogenous compound)
digoxin
dipeptidyl carboxypeptidase inhibitor (drug therapy)
folic acid
homocysteine (endogenous compound)
interleukin 1 (endogenous compound)
interleukin 6 (endogenous compound)
triacylglycerol (endogenous compound)
tumor necrosis factor alpha (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cognitive defect (side effect, etiology, side effect)
heart failure (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
ADL disability
Alzheimer disease
atrial fibrillation
blood brain barrier
brain blood flow
brain hypoxia
brain perfusion
cachexia
cardiac resynchronization therapy
congestive heart failure
counterpulsation
cytokine production
delirium (side effect)
dementia
depression
exercise
heart left ventricle failure
hospital readmission
human
hyperglycemia
hyperhomocysteinemia
hypoglycemia
hyponatremia
lacunar stroke
microembolism
mild cognitive impairment
Mini Mental State Examination
Montreal cognitive assessment
mortality
neuroimaging
New York Heart Association class
nonhuman
orthostatic hypotension (side effect)
pathophysiology
prevalence
protein calorie malnutrition
review
screening test
systematic review
white matter
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
C reactive protein (9007-41-4)
digoxin (20830-75-5, 57285-89-9)
folic acid (59-30-3, 6484-89-5)
homocysteine (454-28-4, 6027-13-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014962361
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijcard.2014.10.087
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 167
TITLE
Practical approaches for the treatment of chronic heart failure: Frequently
asked questions, overlooked points and controversial issues in current
clinical practice
AUTHOR NAMES
Çavuşoğlu Y.
Altay H.
Ekmekçi A.
Eren M.
Küçükoğlu M.S.
Nalbantgil S.
Sarı İ.
Selçuk T.
Temizhan A.
Ural D.
Weinstein J.M.
Yeşilbursa D.
Yılmaz M.B.
Zoghi M.
Aydoğdu S.
Kutlu M.
Özer N.
Şahin M.
Tokgözoğlu L.
AUTHOR ADDRESSES
(Çavuşoğlu Y., yukselc@ogu.edu.tr) Department of Cardiology, Eskişehir
Osmangazi University, Eskişehir, Turkey.
(Altay H.) Department of Cardiology, Başkent University, İstanbul, Turkey.
(Ekmekçi A.; Eren M.) Department of Cardiology, Siyami Ersek Hospital,
İstanbul, Turkey.
(Küçükoğlu M.S.) Department of Cardiology, İstanbul University, Cardiology
Institute, İstanbul, Turkey.
(Nalbantgil S.; Zoghi M.) Department of Cardiology, Ege University, İzmir,
Turkey.
(Sarı İ.) Department of Cardiology, Marmara University, İstanbul, Turkey.
(Selçuk T.; Temizhan A.; Aydoğdu S.) Department of Cardiology, Ankara
Türkiye Yüksek İhtisas Hospital, Ankara, Turkey.
(Ural D.) Department of Cardiology, Kocaeli University, Turkey.
(Weinstein J.M.) Department of Cardiology, Ben Gurion University, Bersheva,
Israel.
(Yeşilbursa D.) Department of Cardiology, Uludağ University, Bursa, Turkey.
(Yılmaz M.B.) Department of Cardiology, Cumhuriyet University, Sivas,
Turkey.
(Kutlu M.) Department of Cardiology, Karadeniz Teknik University, Trabzon,
Turkey.
(Özer N.; Tokgözoğlu L.) Department of Cardiology, Hacettepe University,
Ankara, Turkey.
(Şahin M.) Department of Cardiology, 19 Mayıs University, Samsun, Turkey.
CORRESPONDENCE ADDRESS
Y. Çavuşoğlu, Eskişehir Osmangazi Üniversitesi, Kardiyoloji Anabilim Dalı,
Eskişehir, Turkey.
SOURCE
Anadolu Kardiyoloji Dergisi (2015) 15 Supplement 2 (1-60). Date of
Publication: 1 Oct 2015
ISSN
1308-0032 (electronic)
1302-8723
BOOK PUBLISHER
AVES Ibrahim Kara, 105/9 Buyukdere Cad, Mecidiyekoy,Sisli, Istanbul, Turkey.
ABSTRACT
Heart failure (HF) is a progressive disorder associated with impaired
quality of life, high morbidity, mortality and frequent hospitalization and
affects millions of people from all around the world. Despite further
improvements in HF therapy, mortality and morbidity remains to be very high.
The life-long treatment, frequent hospitalization, and sophisticated and
very expensive device therapies for HF also leads a substantial economic
burden on the health care system. Therefore, implementation of
evidence-based guideline-recommended therapy is very important to overcome
its worse clinical outcomes. However, HF therapy is a long process that has
many drawbacks and sometimes HF guidelines cannot answers to every question
which rises in everyday clinical practice. In this paper, commonly
encountered questions, overlooked points, controversial issues, management
strategies in grey zone and problems arising during follow up of a HF
patient in real life clinical practice have been addressed in the form of
expert opinions based on the available data in the literature.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
aliskiren
amiloride
bumetanide
candesartan
captopril
carvedilol
clopidogrel
digoxin
enalapril
eplerenone
furosemide
hydralazine
hydrochlorothiazide
indapamide
ivabradine
lisinopril
metolazone
nebivolol
nifedipine
perindopril
phenprocoumon
ramipril
spironolactone
tolvaptan
torasemide
trandolapril
triamterene
unindexed drug
valsartan
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
clinical practice
heart failure
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
cardioselectivity
cardiovascular mortality
diet restriction
exercise
fatigue
headache
heart ejection fraction
heart infarction
heart rate
hospital readmission
human
left ventricular diastolic dysfunction
liver microsome metabolism
oxidative stress
oxygen consumption
quality of life
sodium restriction
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
aliskiren (173334-57-1, 173334-58-2, 173399-03-6)
amiloride (2016-88-8, 2609-46-3)
bumetanide (28395-03-1)
candesartan (139481-59-7)
captopril (62571-86-2)
carvedilol (72956-09-3)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
digoxin (20830-75-5, 57285-89-9)
enalapril (75847-73-3)
eplerenone (107724-20-9)
furosemide (54-31-9)
hydralazine (304-20-1, 86-54-4)
hydrochlorothiazide (58-93-5)
indapamide (26807-65-8)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
lisinopril (76547-98-3, 83915-83-7)
metolazone (17560-51-9)
nebivolol (99200-09-6, 118457-15-1, 118457-16-2)
nifedipine (21829-25-4)
perindopril (82834-16-0, 99149-83-4)
phenprocoumon (435-97-2)
ramipril (87333-19-5)
spironolactone (52-01-7)
tolvaptan (150683-30-0)
torasemide (56211-40-6)
trandolapril (87679-37-6)
triamterene (396-01-0)
valsartan (137862-53-4)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015516339
FULL TEXT LINK
http://dx.doi.org/10.5152/AnatolJCardiol.2015.6767
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 168
TITLE
Propionibacterium acnes: A Treatable Cause of Constrictive Pericarditis
AUTHOR NAMES
Cruz D.
Ahmed H.
Gandapur Y.
Abraham M.R.
AUTHOR ADDRESSES
(Cruz D., dcruz3@jhmi.edu) Osler Medical Service, Johns Hopkins School of
Medicine, Baltimore, United States.
(Ahmed H., hahmed2@jhmi.edu; Abraham M.R., mabraha3@jhmi.edu) Division of
Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore,
United States.
(Gandapur Y., gandapuryousuf@gmail.com) Department of Medicine, Good
Samaritan Hospital, Baltimore, United States.
CORRESPONDENCE ADDRESS
D. Cruz, Osler Medical Service, Johns Hopkins School of Medicine, Baltimore,
United States.
SOURCE
Case Reports in Medicine (2015) 2015 Article Number: 193272. Date of
Publication: 2015
ISSN
1687-9635 (electronic)
1687-9627
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
In this case report we share a case of infective Pericarditis caused by
Propionibacterium acnes (P. acnes) in an immune-competent, nonsurgical
patient. This case and review will illustrate the importance of considering
P. acnes as a cause of idiopathic pericardial effusion and effusive
constrictive disease. The patient was a 61-year-old male with history of
osteoarthritis of the knee. He received an intra-articular steroid injection
in July 2013. Two months later, he presented with atrial fibrillation and
heart failure. He was found to have pericardial and bilateral pleural
effusions which grew P. acnes. This organism was initially considered to be
contaminant; however, as P. acnes was isolated from both pleural and
pericardial fluids, he was started on oral amoxicillin. He was noted to have
recurrence of effusions within 2 weeks with evidence of constrictive
physiology by echocardiography. Treatment was subsequently changed to
intravenous Penicillin G with marked symptomatic improvement, resolution of
pericardial/pleural effusions, and no echocardiographic evidence of
constrictive pericarditis at 10 weeks follow-up. Pursuit and treatment of P.
acnes could lead to prevention of constrictive pericarditis. We believe that
further studies are needed to assess prevalence of P. acnes and response to
intravenous Penicillin G in patients presenting with effusive constrictive
disease.
EMTREE DRUG INDEX TERMS
amoxicillin (drug therapy, oral drug administration)
colchicine (drug therapy)
doxycycline (drug therapy, oral drug administration)
gadolinium
penicillin G (drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
constrictive pericarditis (drug therapy, drug therapy, etiology, surgery)
Propionibacterium acnes
EMTREE MEDICAL INDEX TERMS
Actinomycetales infection (drug therapy)
adult
article
blood cell count
blood culture
case report
echocardiography
effusion
exercise
follow up
human
human cell
lymphocyte
male
middle aged
nuclear magnetic resonance imaging
pericardial effusion (drug therapy)
pericardiocentesis
pleura effusion (drug therapy)
pleura fluid
priority journal
Propionibacterium acnes infection
Propionibacterium acnes infection (drug therapy)
recurrent disease
thoracocentesis
CAS REGISTRY NUMBERS
amoxicillin (26787-78-0, 34642-77-8, 61336-70-7)
colchicine (64-86-8)
doxycycline (10592-13-9, 17086-28-1, 564-25-0, 94088-85-4)
gadolinium (7440-54-2)
penicillin G (1406-05-9, 61-33-6)
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Microbiology: Bacteriology, Mycology, Parasitology and Virology (4)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015172393
FULL TEXT LINK
http://dx.doi.org/10.1155/2015/193272
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 169
TITLE
Electrocardiogram and arrhythmias
AUTHOR NAMES
Singh R.
Murphy J.J.
AUTHOR ADDRESSES
(Singh R.; Murphy J.J.) County Durham and Darlington Foundation Trust,
United Kingdom.
(Singh R.) Centre of Integrated Health Care Research, Durham Univrsty.,
United Kingdom.
(Murphy J.J.) Durham University, United Kingdom.
SOURCE
Anaesthesia and Intensive Care Medicine (2015) 16:5 (220-223). Date of
Publication: 1 May 2015
ISSN
1878-7584 (electronic)
1472-0299
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
Introduced by Einthoven, electrocardiography remains the most common
diagnostic procedure readily available to the physician in primary and
secondary care. It is a graphical display of the electrical potential
difference as it spreads through the heart and is recorded at the body
surface. The electrocardiogram (ECG) is an indispensable tool to screen and
monitor cardiac patients. Exercise ECG is used to diagnose coronary artery
disease and ambulatory ECG to assess arrhythmias.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
electrocardiogram
heart arrhythmia
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
atrioventricular block
bradycardia
complete heart block
coronary artery disease
electric potential
exercise
first degree atrioventricular block
heart left bundle branch block
heart right bundle branch block
heart ventricle tachycardia
human
P wave
priority journal
QRS complex
second degree atrioventricular block
T wave
tachycardia
U wave
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015894020
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mpaic.2015.02.006
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 170
TITLE
Infrapopliteal Bifurcated Dual Run-off Bypass in Critical Limb Ischemia: A
Report of 2 Cases
AUTHOR NAMES
Okazaki J.
Ishida M.
Kuma S.
Morisaki K.
AUTHOR ADDRESSES
(Okazaki J., okadoc2001@yahoo.co.jp; Ishida M.; Kuma S.; Morisaki K.)
Department of Vascular Surgery, Kokura Memorial Hospital, 3-2-1, Asano,
Kokurakita-ku, Kitakyushu-shi, Japan.
CORRESPONDENCE ADDRESS
J. Okazaki, Department of Vascular Surgery, Kokura Memorial Hospital, 3-2-1,
Asano, Kokurakita-ku, Kitakyushu-shi, Japan.
SOURCE
Annals of Vascular Surgery (2015) 29:5 (1020.e17-1020.e21). Date of
Publication: 1 Jul 2015
ISSN
1615-5947 (electronic)
0890-5096
BOOK PUBLISHER
Elsevier Inc., usjcs@elsevier.com
ABSTRACT
Recently, angiosome-oriented direct revascularization was advocated for
infrapopliteal bypass in patients with critical limb ischemia. However,
angiosome-matched target vessels, which supply direct blood flow into the
ischemic tissue, are frequently small in diameter, severely calcified, have
a very poor vascular bed, and might not be suitable technically for distal
anastomosis. In such cases, creating a bifurcation in the graft could enable
perfusion of a "direct" target vessel with poor quality and an "indirect"
run-off vessel with better features. In this report, we present 2 cases of
bifurcated dual run-off bypass (BDRB) in which we added a secondary outflow
to the original single tibial bypass. Careful investigation and evaluation
of the status of the collateral vessels and additional information regarding
successful and unsuccessful cases are required to further understand the
advantages and disadvantages of BDRB.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
bifurcated dual run off bypass
critical limb ischemia (surgery)
femoropopliteal bypass
EMTREE MEDICAL INDEX TERMS
adult
aorta valve replacement
arteriography
article
atrial fibrillation
bypass surgery
case report
coronary artery bypass graft
debridement
diabetes mellitus
disease duration
follow up
foot ulcer (therapy)
heel ulcer (therapy)
human
intraoperative period
male
medical history
middle aged
mitral valve replacement
pain
postoperative period
priority journal
renal replacement therapy
saphenous vein graft
toe gangrene
ulcer healing
vacuum assisted closure
valvular heart disease
wound care
EMBASE CLASSIFICATIONS
Orthopedic Surgery (33)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015941282
FULL TEXT LINK
http://dx.doi.org/10.1016/j.avsg.2015.01.024
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 171
TITLE
Organising pneumonia due to dronedarone
AUTHOR NAMES
Thornton D.
Avery S.
Edey A.J.
Medford A.R.L.
AUTHOR ADDRESSES
(Thornton D.; Avery S.; Medford A.R.L., andrew.medford@nbt.nhs.uk) North
Bristol Lung Centre, Southmead Hospital, Bristol, United Kingdom.
(Edey A.J.) Department of Radiology, Southmead Hospital, Bristol, United
Kingdom.
CORRESPONDENCE ADDRESS
A.R.L. Medford, North Bristol Lung Centre & University of Bristol, Southmead
Hospital, Westbury-on-Trym, Bristol, United Kingdom.
SOURCE
Journal of the Royal College of Physicians of Edinburgh (2015) 45:3
(213-214). Date of Publication: 2015
ISSN
1478-2715
BOOK PUBLISHER
Royal College of Physicians of Edinburgh, k.oneill@rcpe.ac.uk
ABSTRACT
Organising pneumonia is one of the responses of the lung to injury and can
mimic bacterial pneumonia but importantly it does not respond to antibiotic
therapy. We present the case of a 67-year-old male who was diagnosed with
organising pneumonia secondary to dronedarone. Drug reactions are a common
cause and early identification of the culprit is mandatory to prevent
further morbidity and ensure a favourable outcome. On chest radiography
there may be fleeting peripheral consolidation, while computed tomography
can show a range of stereotyped patterns including perilobular
consolidation. Bronchoscopic biopsy may not always be possible but response
to steroids is often rapid following removal of the culprit drug.
Dronedarone should be included in the list of possible drugs and the
Pneumotox database remains a useful resource for the clinician when acute
drug-related pneumotoxicity is suspected.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dronedarone (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
methylprednisolone (drug therapy)
prednisolone (oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
organizing pneumonia (drug therapy, side effect, diagnosis, drug therapy,
side effect)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation (drug therapy)
case report
community acquired pneumonia
computer assisted tomography
coughing
crackle (diagnosis)
disease course
dyspnea
exercise
fever
hospital discharge
human
human tissue
hypoxemia (diagnosis)
leukocyte count
lung lavage
male
oxygen tension
physical examination
respiratory failure
thorax radiography
transbronchial biopsy
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
dronedarone (141626-36-0)
methylprednisolone (6923-42-8, 83-43-2)
prednisolone (50-24-8)
EMBASE CLASSIFICATIONS
Radiology (14)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015442235
FULL TEXT LINK
http://dx.doi.org/10.4997/JRCPE.2015.308
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 172
TITLE
Sexual counseling and cardiovascular disease: Practical approaches
AUTHOR NAMES
Steinke E.E.
Jaarsma T.
AUTHOR ADDRESSES
(Steinke E.E., elaine.steinke@wichita.edu) School of Nursing, Wichita State
University, 1845 Fairmount, Wichita, United States.
(Jaarsma T.) University of Linköping, Social and Welfare Studies,
Norrköping, Sweden.
CORRESPONDENCE ADDRESS
E.E. Steinke, School of Nursing, Wichita State University, 1845 Fairmount,
Wichita, United States.
SOURCE
Asian Journal of Andrology (2015) 17:1 (32-39). Date of Publication: 1 Jan
2015
ISSN
1745-7262 (electronic)
1008-682X
BOOK PUBLISHER
Medknow Publications, B9, Kanara Business Centre, off Link Road, Ghatkopar
(E), Mumbai, India.
ABSTRACT
Patients with cardiovascular disease and their partners expect health care
providers to provide sexual counseling to assist them in maintaining sexual
quality of life. Evidence suggests however, that there is a gap in
integrating evidence into practice and that relatively few cardiac patients
receive sexual counseling. This can result in negative psychological,
physical, and quality of life outcomes for couples who may needlessly decide
sexual activity is too risky and cease all sexual activity. Two scientific
statements now exist that provide ample guidance to health care providers in
discussing this important topic. Using a team approach that includes
physicians, nurses, physical therapists, rehabilitation staff, and others is
important to ensure that sexual counseling occurs throughout recovery. In
addition, several trials using interventional approaches for sexual
counseling provide insight into successful approaches for sexual counseling
in practice. This article provides practical strategies and evidence-based
approaches for assessment and sexual counseling for all cardiac patients and
their partners, and specific counseling for those with ischemic conditions,
heart failure, and implanted devices.
EMTREE DRUG INDEX TERMS
nitric acid derivative
phosphodiesterase V inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease
sexual counseling
EMTREE MEDICAL INDEX TERMS
angina pectoris
anxiety
atrial fibrillation
cardiac patient
depression
energy expenditure
erectile dysfunction
exercise
health care personnel
health care policy
heart failure
heart infarction
heart muscle revascularization
heart ventricle tachycardia
human
hypertrophic cardiomyopathy
male sexual dysfunction
nurse
patient education
physical activity
physician
physiotherapist
psychoeducation
quality of life
rehabilitation care
review
sexual behavior
sexual intercourse
sexual satisfaction
sexuality
stress management
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Urology and Nephrology (28)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015650567
FULL TEXT LINK
http://dx.doi.org/10.4103/1008-682X.135982
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 173
TITLE
Arrhytmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) and heart
transplantation: Case series
AUTHOR NAMES
Demirozu Z.T.
Kucukaksu D.S.
AUTHOR ADDRESSES
(Demirozu Z.T., tdemirozu@yahoo.com; Kucukaksu D.S.) Koç University Faculty
of Medicine, Clinic of Cardiovascular Surgery, Istanbul, Turkey.
CORRESPONDENCE ADDRESS
Z.T. Demirozu, Koç University Faculty of Medicine, Clinic of Cardiovascular
Surgery, Istanbul, Turkey.
SOURCE
Turkiye Klinikleri Cardiovascular Sciences (2015) 27:1 (36-42). Date of
Publication: 30 Mar 2015
ISSN
1306-7656
BOOK PUBLISHER
Turkiye Klinikleri, Turkocagi Caddesi No. 30, Balgat, Turkey.
ABSTRACT
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) usually
originates from right ventricle, has a prevalence 1 in 1000 and leading
cause of death in people aged less than 35 years of age, also desmosome
mutations and family history can be seen in this disease. We reviewed the
literature and described three patients with arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C). They had T wave inversion in
chest leads V1 to V4 and had premature ventricular complexes of left bundle
branch block and left axis deviation, or right bundle branch block (RBB) had
implantable cardioverter defibrillator (ICD) implantation and fulfilled the
task force criteria for diagnosis of ARVD/C. One patient had familial
erythrocytosis and thrombus formation in the right atrium and the right
ventricle. He was listed as status 1A and had 2 times phlebotomy during the
hospitalization. The other patient had warfarin intoxication, and had
hepatic congestion due to end-stage right heart failure. The third patient
had a history of cerebrovascular event and had a family history of ARVD/C.
All of our patients had the medical regimen for the management of ARVD/C.
All of the patients were in NYHA Class III-IV while they admitted to our
clinic and they had their final therapeutic option as an orthotopic heart
transplantation and have a good quality of life.
EMTREE DRUG INDEX TERMS
antibiotic agent (drug therapy)
anticoagulant agent (drug therapy)
anticonvulsive agent (drug therapy)
diuretic agent (drug therapy)
heparin (drug therapy)
warfarin (drug therapy, drug toxicity)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart right ventricle dysplasia (drug therapy, diagnosis, drug therapy,
surgery)
heart transplantation
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
breathing exercise
cardiovascular magnetic resonance
case report
cell degeneration
coughing
cyanosis
disease classification
diuretic therapy
drug intoxication
drug substitution
drug withdrawal
dyspnea
emotional disorder (rehabilitation, therapy)
erythrocytosis
extubation
faintness
familial disease
female
fibrosing alveolitis
focal epilepsy (drug therapy)
follow up
grief
heart atrium enlargement
heart atrium thrombosis (drug therapy)
heart catheterization
heart left bundle branch block
heart left ventricle ejection fraction
heart muscle biopsy
heart palpitation
heart right bundle branch block
heart right ventricle failure
heart ventricle extrasystole
heart ventricle tachycardia
heart ventricle thrombosis
hematocrit
hemiparesis
hepatomegaly
Holter monitoring
hospital discharge
human
human tissue
implantable cardioverter defibrillator
international normalized ratio
liver congestion (drug therapy)
liver failure
lung aspiration
lung lavage
male
mental disease (rehabilitation, therapy)
mental disease assessment
methicillin-resistant Staphylococcus epidermidis
muscle atrophy
peripheral edema
phlebotomy
pneumocystosis (drug therapy)
postoperative period
psychosocial rehabilitation
psychotherapy
quality of life
recurrent disease
respiratory acidosis (therapy)
suicide attempt
systolic heart murmur
T wave inversion
tonic clonic seizure (drug therapy)
tracheostomy
transthoracic echocardiography
treatment outcome
treatment response
tricuspid valve regurgitation
young adult
CAS REGISTRY NUMBERS
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Turkish
EMBASE ACCESSION NUMBER
2015927433
FULL TEXT LINK
http://dx.doi.org/10.5336/cardiosci.2014-42264
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 174
TITLE
A novel human R25C-phospholamban mutation is associated with
super-inhibition of calcium cycling and ventricular arrhythmia
AUTHOR NAMES
Liu G.-S.
Morales A.
Vafiadaki E.
Lam C.K.
Cai W.-F.
Haghighi K.
Adly G.
Hershberger R.E.
Kranias E.G.
AUTHOR ADDRESSES
(Liu G.-S.; Lam C.K.; Haghighi K.; Adly G.; Kranias E.G.,
litsa.kranias@uc.edu) Department of Pharmacology and Cell Biophysics,
University of Cincinnati College of Medicine, 231 Albert Sabin Way,
Cincinnati, United States.
(Morales A.; Hershberger R.E.) Division of Human Genetics, Ohio State
University College of Medicine, Columbus, United States.
(Morales A.; Hershberger R.E.) Dorothy M. Davis Heart and Lung Research
Institute, Ohio State University College of Medicine, Columbus, United
States.
(Vafiadaki E.; Kranias E.G., litsa.kranias@uc.edu) Molecular Biology
Division, Biomedical Research Foundation, Academy of Athens, Greece.
(Cai W.-F.) Department of Pathology and Laboratory Medicine, University of
Cincinnati College of Medicine, Cincinnati, United States.
(Hershberger R.E.) Division of Cardiovascular Medicine, Department of
Internal Medicine, Ohio State University College of Medicine, Columbus,
United States.
CORRESPONDENCE ADDRESS
E.G. Kranias, Department of Pharmacology and Cell Biophysics, University of
Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, United
States.
SOURCE
Cardiovascular Research (2015) 107:1 (164-174). Date of Publication: 1 Jul
2015
ISSN
1755-3245 (electronic)
0008-6363
BOOK PUBLISHER
Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
Aims Depressed sarcoplasmic reticulum (SR) Ca2+ cycling, a
universal characteristic of human and experimental heart failure, may be
associated with genetic alterations in key Ca2+-handling
proteins. In this study, we identified a novel PLN mutation (R25C) in
dilated cardiomyopathy (DCM) and investigated its functional significance in
cardiomyocyte Ca2+-handling and contractility. Methods and
results Exome sequencing identified a C73T substitution in the coding region
of PLN in a family with DCM. The four heterozygous family members had
implantable cardiac defibrillators, and three developed prominent
ventricular arrhythmias. Overexpression of R25C-PLN in adult rat
cardiomyocytes significantly suppressed the Ca2+ affinity of SR
Ca2+-ATPase (SERCA2a), resulting in decreased SR Ca2+
content, Ca2+ transients, and impaired contractile function,
compared with WT-PLN. These inhibitory effects were associated with enhanced
interaction of R25C-PLN with SERCA2, which was prevented by PKA
phosphorylation. Accordingly, isoproterenol stimulation relieved the
depressive effects of R25C-PLN in cardiomyocytes. However, R25C-PLN also
elicited increases in the frequency of Ca2+ sparks and waves as
well as stress-induced aftercontractions. This was accompanied by increased
Ca2+/calmodulin-dependent protein kinase II activity and
hyper-phosphorylation of RyR2 at serine 2814. Conclusion The findings
demonstrate that human R25C-PLN is associated with super-inhibition of
SERCA2a and Ca2+ transport as well as increased SR
Ca2+ leak, promoting arrhythmogenesis under stress conditions.
This is the first mechanistic evidence that increased PLN inhibition may
impact both SR Ca2+ uptake and Ca2+ release activities
and suggests that the human R25C-PLN may be a prognostic factor for
increased ventricular arrhythmia risk in DCM carriers.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
arginine (endogenous compound)
calcium ion (endogenous compound)
cysteine (endogenous compound)
phospholamban (endogenous compound)
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist (drug therapy)
calcium calmodulin dependent protein kinase II (endogenous compound)
cyclic AMP dependent protein kinase (endogenous compound)
isoprenaline (pharmacology)
ryanodine receptor 2 (endogenous compound)
sarcoplasmic reticulum calcium transporting adenosine triphosphatase
(endogenous compound)
serine (endogenous compound)
threonine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive cardiomyopathy
heart ventricle arrhythmia
missense mutation
EMTREE MEDICAL INDEX TERMS
adult
aged
amino acid substitution
animal cell
animal experiment
animal model
arrhythmogenesis
article
binding affinity
cardioversion
case report
chronic atrial fibrillation (therapy)
controlled study
drug effect
enzyme activity
exome
exome sequencing
female
gene overexpression
heart failure (drug therapy, surgery, therapy)
heart muscle cell
heart muscle contractility
heart transplantation
human
human cell
in vitro study
in vivo study
male
middle aged
nonhuman
priority journal
protein phosphorylation
protein protein interaction
rat
sarcoplasmic reticulum
sequence analysis
stress
sudden cardiac death
very elderly
CAS REGISTRY NUMBERS
arginine (1119-34-2, 15595-35-4, 7004-12-8, 74-79-3)
calcium calmodulin dependent protein kinase II (141467-21-2)
calcium ion (14127-61-8)
cyclic AMP dependent protein kinase ()
cysteine (4371-52-2, 52-89-1, 52-90-4)
isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
phospholamban (113610-15-4)
serine (56-45-1, 6898-95-9)
threonine (36676-50-3, 72-19-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Human Genetics (22)
Drug Literature Index (37)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015185608
FULL TEXT LINK
http://dx.doi.org/10.1093/cvr/cvv127
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 175
TITLE
Invasive electrophysiological evaluation and ablation in patients with
asymptomatic ventricular pre-excitation persistent at exercise stress test
AUTHOR NAMES
De Ponti R.
Marazzi R.
Doni L.A.
Cremona V.
Marazzato J.
Salerno-Uriarte J.A.
AUTHOR ADDRESSES
(De Ponti R., rdeponti@alice.it; Marazzi R.; Doni L.A.; Cremona V.;
Marazzato J.; Salerno-Uriarte J.A.) Department of Heart and Vessels,
Ospedale di Circolo e Fondazione Macchi, University of Insubria, Viale
Borri, 57, Varese, Italy.
CORRESPONDENCE ADDRESS
R. De Ponti, Department of Heart and Vessels, Ospedale di Circolo e
Fondazione Macchi, University of Insubria, Viale Borri, 57, Varese, Italy.
SOURCE
Europace (2015) 17:6 (946-952). Date of Publication: 2015
ISSN
1532-2092 (electronic)
1099-5129
BOOK PUBLISHER
Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
Aims In patients with asymptomatic ventricular pre-excitation (VPE)
persistent at exercise stress test, this study evaluates the proportion of
cases with adverse conduction properties of the atrioventricular accessory
pathway (AP) at invasive electrophysiological study and the long-term
follow-up after they received treatment according to pre-determined
criteria. Methods and results Over 10 years, asymptomatic patients with VPE
persistent at exercise stress test referred for invasive
electrophysiological evaluation including isoproterenol (IPN) infusion were
included. Ablation was planned if they had at least one of the following
criteria: (i) shortest pre-excited R-R interval (SPERRI) ≤250 ms and/or (ii)
inducible atrioventricular re-entrant tachycardia (AVRT). Cryoablation was
electively used in para-hisian and mid-septal APs. Patients non-eligible for
ablation received no therapy. Sixty-three patients (45 males; mean age 26±14
years) underwent electrophysiological evaluation: 7 had
fasciculo-ventricular fibres and were excluded, whereas 56 had 58 APs.
Thirty-one patients (55%)were eligible and underwent successful ablation:
87% had at least the SPERRI ≤ 250 ms and 61% had at least inducible AVRT. In
15 cases (48%) the ablation criteria were met only during IPN infusion.
During follow-up (73±33 months), one patient was successfully retreated for
resumption of VPE in the ablation group, whereas no event was observed in
the group of patients who received no treatment. Conclusion In this subset
of patients with asymptomatic VPE, invasive electrophysiological evaluation
shows fast antegrade conduction over the AP and/or inducible AVRT in about
half of the cases. Patients who received no therapy because of a benign
electrophysiological profile had an event-free follow-up.
EMTREE DRUG INDEX TERMS
isoprenaline
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cryoablation
electrophysiology
heart preexcitation
ventricular preexcitation
EMTREE MEDICAL INDEX TERMS
adolescent
adult
article
atrial fibrillation
atrioventricular reentrant tachycardia
cardiopulmonary exercise test
catheter ablation
child
cohort analysis
female
follow up
heart atrium pacing
human
major clinical study
male
priority journal
retrospective study
tachycardia
CAS REGISTRY NUMBERS
isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015397867
FULL TEXT LINK
http://dx.doi.org/10.1093/europace/euu324
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 176
TITLE
Challenging aspects of treatment strategies in heart failure with preserved
ejection fraction: "Why did recent clinical trials fail?"
AUTHOR NAMES
Becher P.M.
Fluschnik N.
Blankenberg S.
Westermann D.
AUTHOR ADDRESSES
(Becher P.M., m.becher@uke.de; Fluschnik N.; Blankenberg S.; Westermann D.)
Department of General and Interventional Cardiology, University Heart Center
Hamburg Eppendorf, Martinistraße 52, Hamburg, Germany.
CORRESPONDENCE ADDRESS
P.M. Becher, Department of General and Interventional Cardiology, University
Heart Center Hamburg Eppendorf, Martinistraße 52, Hamburg, Germany.
SOURCE
World Journal of Cardiology (2015) 7:9 (544-554). Date of Publication: 2015
ISSN
1949-8462 (electronic)
BOOK PUBLISHER
Baishideng Publishing Group Co, bpg@baishideng.com
ABSTRACT
Heart failure (HF) is the leading cause of hospitalization among older
adults and the prevalence is growing with the aging populations in the
Western countries. Epidemiologic reports suggest that approximately 50% of
patients who have signs or symptoms of HF have preserved left ventricular
ejection fraction. This HF type predominantly affects women and the elderly
with other co-morbidities, such as diabetes, hypertension, and overt volume
status. Most of the current treatment strategies are based on morbidity
benefits such as quality of life and reduction of clinical HF symptoms.
Treatment of patients with HF with preserved ejection fraction displayed
disappointing results from several large randomized controlled trials. The
heterogeneity of HF with preserved ejection fraction, understood as complex
syndrome, seems to be one of the primary reasons. Here, we present an
overview of the current management strategies with available evidence and
new therapeutic approach from drugs currently in clinical trials, which
target diastolic dysfunction, chronotropic incompetence, and risk factor
management. We provide an outline and interpretation of recent clinical
trials that failed to improve outcome and survival in patients with HF with
preserved ejection fraction.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
cardiovascular agent (drug therapy)
EMTREE DRUG INDEX TERMS
aldosterone antagonist (clinical trial)
angiotensin receptor antagonist
candesartan
digitalis
digoxin
diuretic agent
endothelin 1 (endogenous compound)
enkephalinase inhibitor
guanylate cyclase inhibitor
irbesartan
ivabradine
nebivolol
perindopril
phosphodiesterase V (endogenous compound)
phosphodiesterase V inhibitor
ranolazine (drug therapy)
sacubitril plus valsartan
sildenafil
spironolactone
valsartan
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart ejection fraction
heart failure (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
action potential
atrial fibrillation
cardiac resynchronization therapy
cardiovascular effect
cardiovascular mortality
cardiovascular risk
chronotropism
clinical trial (topic)
coronary artery blood flow
coronary artery bypass surgery
device therapy
diastolic dysfunction
diastolic heart failure (drug therapy)
drug effect
echocardiography
evidence based practice
exercise
functional status
genetic heterogeneity
heart function
heart left ventricle ejection fraction
heart muscle ischemia
heart output
heart performance
heart ventricle performance
high risk patient
hospitalization
human
managed care
multicenter study (topic)
outcome assessment
percutaneous coronary intervention
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
practice guideline
primary medical care
quality of life
randomized controlled trial (topic)
risk assessment
risk factor
short survey
survival rate
DRUG TRADE NAMES
lcz 696
nebivolol
CAS REGISTRY NUMBERS
candesartan (139481-59-7)
digitalis (8031-42-3, 8053-83-6)
digoxin (20830-75-5, 57285-89-9)
irbesartan (138402-11-6)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
nebivolol (99200-09-6, 118457-15-1, 118457-16-2)
perindopril (82834-16-0, 99149-83-4)
ranolazine (95635-55-5)
sacubitril plus valsartan (936623-90-4)
sildenafil (139755-83-2)
spironolactone (52-01-7)
valsartan (137862-53-4)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015490048
FULL TEXT LINK
http://dx.doi.org/10.4330/wjc.v7.i9.544
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 177
TITLE
Health information technologies in cardiology: Mobile devices, home
monitoring, and E-prescribing
AUTHOR NAMES
Figge H.L.
AUTHOR ADDRESSES
(Figge H.L.) Lumira (USA), Inc. Senior Vice President Global Strategic
Development, Waltham, United States.
CORRESPONDENCE ADDRESS
H.L. Figge, Lumira (USA), Inc. Senior Vice President Global Strategic
Development, Waltham, United States.
SOURCE
U.S. Pharmacist (2015) 40:2 (58-60). Date of Publication: 2015
ISSN
0148-4818
BOOK PUBLISHER
Jobson Publishing Corporation
ABSTRACT
Health information technology (HIT) is opening many new frontiers and
possibilities in cardiology and pharmacy. Revolutionary advances have been
fueled by the widespread adoption of mobile technology, the availability of
home diagnostic devices, and the widespread use of electronic prescribing.
This article presents an overview of each of these major developments.
EMTREE DRUG INDEX TERMS
anticoagulant agent
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
electronic prescribing
home monitoring
medical informatics
mobile phone
EMTREE MEDICAL INDEX TERMS
adoption
anticoagulant therapy
article
atrial fibrillation
blood pressure monitor
cardiac patient
decision support system
emotional stability
exercise
human
nutrition
pharmacist
prothrombin time
smoking cessation
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Biophysics, Bioengineering and Medical Instrumentation (27)
Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015768640
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 178
TITLE
The role of multimodality cardiac imaging for the assessment of sports
eligibility in patients with bicuspid aortic valve
AUTHOR NAMES
D'Andrea A.
Corte A.D.
Padalino R.
Limongelli G.
Scarafile R.
Fratta F.
Pezzullo E.
Fusco A.
Pisacane F.
Coppola G.
Caso P.
Calabrò R.
Russo M.G.
AUTHOR ADDRESSES
(D'Andrea A., antonellodandrea@libero.it; Padalino R.; Limongelli G.;
Scarafile R.; Fratta F.; Pezzullo E.; Fusco A.; Pisacane F.; Coppola G.;
Caso P.; Calabrò R.; Russo M.G.) Chair of Cardiology, Second University of
Naples, Monaldi Hospital, Naples, Italy.
(Corte A.D.) Department of Cardiothoracic Sciences, Second University of
Naples, Monaldi Hospital, Naples, Italy.
CORRESPONDENCE ADDRESS
A. D'Andrea, Via M. Schipa 44, Naples, Italy.
SOURCE
Journal of Cardiovascular Echography (2015) 25:1 (9-18). Date of
Publication: 1 Jan 2015
ISSN
2347-193X (electronic)
2211-4122
BOOK PUBLISHER
Medknow Publications, B9, Kanara Business Centre, off Link Road, Ghatkopar
(E), Mumbai, India.
ABSTRACT
Bicuspid aortic valve (BAV) cannot be considered an innocent finding, but it
is not necessarily a life-threatening condition. Athletes with BAV should
undergo a thorough staging of the valve anatomy, taking into consideration
hemodynamic factors, as well as aortic diameters and looking for other
associated significant cardiovascular anomalies by use of a multimodality
cardiac imaging approach. Furthermore an accurate follow-up is mandatory
with serial cardiological controls in those allowed to continue sports.
EMTREE DRUG INDEX TERMS
anabolic agent
biological marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
bicuspid aortic valve
cardiac imaging
sport
EMTREE MEDICAL INDEX TERMS
anatomy
aorta aneurysm
aorta coarctation
aorta dissection
aorta stenosis
aorta valve regurgitation
aorta valve replacement
athlete
atrial fibrillation
cardiovascular disease
cardiovascular magnetic resonance
cardiovascular malformation
color ultrasound flowmetry
congestive cardiomyopathy
diastolic dysfunction
differential diagnosis
disease association
disease course
dynamic exercise
ECG abnormality
endurance training
faintness
follow up
health care system
heart atrium enlargement
heart function
heart left ventricle enddiastolic volume
heart left ventricle hypertrophy
heart muscle ischemia
heart stroke volume
heredity
Holter monitoring
human
hypoplastic left heart syndrome
isometric exercise
isotonic exercise
life expectancy
Marfan syndrome
morphogenesis
nuclear magnetic resonance imaging
pathogenesis
prognosis
review
Ross procedure
shear stress
systole
systolic dysfunction
three dimensional echocardiography
transluminal valvuloplasty
Turner syndrome
EMBASE CLASSIFICATIONS
Radiology (14)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015149434
FULL TEXT LINK
http://dx.doi.org/10.4103/2211-4122.158418
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 179
TITLE
Postlobectomy Early Complications
AUTHOR NAMES
Ziarnik E.
Grogan E.L.
AUTHOR ADDRESSES
(Ziarnik E.) Department of Thoracic Surgery, Vanderbilt University Medical
Center, 1313 21st Avenue South, Nashville, United States.
(Grogan E.L., eric.grogan@vanderbilt.edu) Department of Thoracic Surgery,
Tennessee Valley Healthcare System, Vanderbilt University Medical Center,
Nashville Campus, 609 Oxford House, 1313 21st Avenue South, Nashville,
United States.
CORRESPONDENCE ADDRESS
E.L. Grogan, Department of Thoracic Surgery, Tennessee Valley Healthcare
System, Vanderbilt University Medical Center, Nashville Campus, 609 Oxford
House, 1313 21st Avenue South, Nashville, United States.
SOURCE
Thoracic Surgery Clinics (2015) 25:3 (355-364). Date of Publication: 1 Aug
2015
ISSN
1558-5069 (electronic)
BOOK PUBLISHER
W.B. Saunders
ABSTRACT
Immediate postoperative complications are common after lobectomy. The most
effective management of postoperative crises is prevention, which starts
with preoperative preparation and patient screening. There are many factors
that can be controlled and improved by the patient. Equally important is
patient selection, which is influenced by pulmonary function tests,
cardiopulmonary reserve, and preexisting comorbidities. After the operation,
the care team can also greatly improve outcomes with aggressive
cardiopulmonary therapies, ambulation, vigilant monitoring, and frequent
assessments of the patient. Prevention strategies can minimize risks;
however, when they occur, a proactive approach may minimize the long-term
sequelae.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
antibiotic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
collagen (drug therapy)
cyanoacrylate
digoxin (drug therapy)
diltiazem (drug therapy)
fibrin glue
magnesium sulfate (drug therapy)
politef
resorcinol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
lung lobectomy
postoperative complication (complication, disease management, epidemiology,
prevention)
EMTREE MEDICAL INDEX TERMS
adult respiratory distress syndrome (complication, epidemiology)
air leakage (complication, epidemiology, prevention, surgery, therapy)
antibiotic therapy
atelectasis (complication, diagnosis, epidemiology, prevention, therapy)
atrial fibrillation (complication, drug therapy, epidemiology, etiology,
prevention)
autotransplantation
azygous vein
breathing exercise
bronchopleural fistula (complication, epidemiology, prevention, surgery)
bronchoscopy
cauterization
chest tube
chylothorax (complication, epidemiology, surgery, therapy)
computed tomographic angiography
diaphragmatic plication
disease severity
empyema (complication, epidemiology)
erythrocyte transfusion
fluoroscopy
hospital infection (complication, drug therapy, epidemiology, prevention)
human
implant
incidence
intermittent positive pressure ventilation
laryngoscopy
lung resection
mediastinal fat pad
mobilization
mucolysis
mucus plugging (complication, epidemiology, prevention, therapy)
muscle flap
nerve injury (complication, diagnosis, epidemiology, surgery)
nonsurgical invasive therapy
pericardial patch
pleura
pleural tent
pneumonia (complication, epidemiology)
postoperative analgesia
postoperative hemorrhage (complication, epidemiology, prevention, surgery,
therapy)
postoperative lobar torsion (complication, diagnosis, epidemiology,
prevention, surgery)
practice guideline
preoperative care
pressure support ventilation
priority journal
prophylaxis
quality of life
recurrent laryngeal nerve injury (complication, diagnosis, drug therapy,
epidemiology, surgery)
reoperation
respiratory therapeutic device
respiratory tract disease (complication, epidemiology, prevention, therapy)
respirometry
review
risk factor
risk reduction
sealant
smoking cessation
strategic planning
surgical approach
surgical drainage
surgical mortality
surgical stapling
surgical technique
suturing method
thoracotomy
thorax surgery
tracheobronchial toilet
transesophageal echocardiography
treatment indication
vein
video assisted thoracoscopic surgery
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
collagen (9007-34-5)
cyanoacrylate (15802-18-3)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
magnesium sulfate (7487-88-9)
politef (9002-84-0, 9039-02-5)
resorcinol (108-46-3)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015220150
FULL TEXT LINK
http://dx.doi.org/10.1016/j.thorsurg.2015.04.003
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 180
TITLE
A systematic review of the effects of telerehabilitation in patients with
cardiopulmonary diseases
AUTHOR NAMES
Hwang R.
Bruning J.
Morris N.
Mandrusiak A.
Russell T.
AUTHOR ADDRESSES
(Hwang R., r.hwang@uq.net.au) Department of Physiotherapy, Princess
Alexandra Hospital, Metro South Health, Brisbane, Australia.
(Bruning J.) Department of Physiotherapy, Heart Failure Support Service,
Prince Charles Hospital, Brisbane, Australia.
(Morris N.) Menzies Health Institute Queensland, School of Allied Health
Sciences, Griffith University, Gold Coast, Australia.
(Mandrusiak A.; Russell T.) Physiotherapy, School of Health and
Rehabilitation Sciences, University of Queensland, Brisbane, Australia.
CORRESPONDENCE ADDRESS
R. Hwang, Department of Physiotherapy, Princess Alexandra Hospital, Metro
South Health, Brisbane, Australia.
SOURCE
Journal of Cardiopulmonary Rehabilitation and Prevention (2015) 35:6
(380-389). Date of Publication: 2015
ISSN
1932-751X (electronic)
1932-7501
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
PURPOSE: To examine the effects of telerehabilitation compared with other
delivery models for improving physical or functional outcomes in patients
with cardiopulmonary diseases. METHODS: A search was completed for English
language publications from 1990 to August 2013 across 4 electronic databases
and gray literature. Inclusion criteria were: (1) home-based
telerehabilitation as a core component; (2) at least 2 exercise sessions;
(3) randomized controlled trials; and (4) reporting of physical or
functional outcome measures in adult patients with coronary heart disease,
chronic heart failure, and chronic respiratory disease. Studies were
independently screened by 2 reviewers and graded by a reviewer according to
the Downs and Black checklist. A narrative synthesis of the included studies
was undertaken. RESULTS: Eleven studies were analyzed. It appears that
telerehabilitation is no different to other delivery models for patients
with cardiopulmonary diseases, in terms of exercise capacity expressed as
distance on the 6-minute walk test and peak oxygen consumption and quality
of life. Telerehabilitation appears to have higher adherence rates compared
with center-based exercise. There has been similar or no adverse events
reported in telerehabilitation compared with center-based exercise.
CONCLUSIONS: Although telerehabilitation shows promise in patients with
cardiopulmonary diseases, compelling evidence is still limited. There is a
need for more detailed, high-quality studies and for studies on the use of
video-based telerehabilitation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiopulmonary disease (rehabilitation)
cardiovascular disease (rehabilitation)
heart rehabilitation
pulmonary rehabilitation
respiratory tract disease (rehabilitation)
telehealth
telerehabilitation
EMTREE MEDICAL INDEX TERMS
6 minute walk test
angina pectoris (complication)
atrial fibrillation (complication)
chronic obstructive lung disease (complication)
chronic respiratory tract disease
disease severity
exercise
function test
health care utilization
heart arrhythmia (complication)
heart failure
heart ventricle extrasystole (complication)
human
hypertension (complication)
ischemic heart disease
meta analysis
muscle strength
outcome assessment
oxygen consumption
patient compliance
priority journal
quality of life
review
supraventricular contraction (complication)
systematic review
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015497950
FULL TEXT LINK
http://dx.doi.org/10.1097/HCR.0000000000000121
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 181
TITLE
How to walk the tightrope between harm and protection in selecting the
optimal antiplatelet treatment strategy after transcatheter left atrial
appendage occlusion
AUTHOR NAMES
Pracoñ R.
Demkow M.
AUTHOR ADDRESSES
(Pracoñ R., radekpracon@yahoo.pl; Demkow M.) Coronary and Structural Heart
Diseases Department, Institute of Cardiology, 42 Alpejska St, Warsaw,
Poland.
CORRESPONDENCE ADDRESS
R. Pracoñ, Coronary and Structural Heart Diseases Department, Institute of
Cardiology, 42 Alpejska St, Warsaw, Poland.
SOURCE
Postepy w Kardiologii Interwencyjnej (2015) 11:1 (5-8). Date of Publication:
2015
ISSN
1897-4295 (electronic)
1734-9338
BOOK PUBLISHER
Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antithrombocytic agent (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
anticoagulant agent
antivitamin K
apixaban
clopidogrel
fibrin
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
atrial fibrillation
left atrial appendage closure device
thromboembolism (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
bleeding (side effect)
blood clotting
cardiovascular risk
cerebrovascular accident
clinical practice
drug efficacy
drug safety
embolism prevention
fibrin formation
follow up
health care quality
heart atrium appendage
high risk patient
human
meta analysis (topic)
practice guideline
primary prevention
randomized controlled trial (topic)
review
risk benefit analysis
DEVICE TRADE NAMES
Amplatzer Cardiac Plug
WATCHMAN
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
apixaban (503612-47-3)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
fibrin (9001-31-4)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2015812248
FULL TEXT LINK
http://dx.doi.org/10.5114/pwki.2015.49177
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 182
TITLE
Heart failure: Key points and recent developments in management
AUTHOR NAMES
Davis R.
AUTHOR ADDRESSES
(Davis R.) Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich,
United Kingdom.
CORRESPONDENCE ADDRESS
R. Davis, Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich,
United Kingdom.
SOURCE
Prescriber (2015) 26:6 (25-31). Date of Publication: 19 Mar 2015
ISSN
1931-2253 (electronic)
0959-6682
BOOK PUBLISHER
Blackwell Publishing Ltd, customerservices@oxonblackwellpublishing.com
ABSTRACT
Treatment of heart failure is evolving rapidly. Our drug review highlights
recent developments in diagnosis and management and emerging new therapies.
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide (endogenous compound)
beta adrenergic receptor blocking agent (clinical trial, drug comparison -
placebo, drug therapy)
brain natriuretic peptide (endogenous compound)
diuretic agent (drug therapy, intravenous drug administration)
electrolyte (endogenous compound)
eplerenone (drug therapy)
ivabradine (drug therapy)
metformin (drug therapy)
placebo
sacubitril plus valsartan (drug therapy)
spironolactone (drug therapy)
ubidecarenone (clinical trial, drug comparison - placebo, drug therapy)
urea (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, diagnosis, drug therapy, rehabilitation)
EMTREE MEDICAL INDEX TERMS
adjuvant therapy
anemia
angiocardiography
article
atrial fibrillation
cardiovascular magnetic resonance
chronic obstructive lung disease
computer assisted tomography
contrast enhancement
diabetes mellitus (drug therapy)
echocardiography
electrolyte blood level
exercise
heart failure with preserved ejection fraction
heart infarction
heart rehabilitation
human
nuclear magnetic resonance imaging
protein blood level
sinus rhythm
terminal care
thyroid function test
urea blood level
DRUG TRADE NAMES
inspra
lcz 696
procoralan
CAS REGISTRY NUMBERS
3 (1 biphenyl 4 ylmethyl 3 ethoxycarbonyl 1 butylcarbamoyl)propionic acid
plus valsartan (936623-90-4)
brain natriuretic peptide (114471-18-0)
eplerenone (107724-20-9)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
metformin (1115-70-4, 657-24-9)
spironolactone (52-01-7)
ubidecarenone (303-98-0)
urea (57-13-6)
EMBASE CLASSIFICATIONS
Radiology (14)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Endocrinology (3)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015841469
FULL TEXT LINK
http://dx.doi.org/10.1002/psb.1325
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 183
TITLE
Masked hypertension and cardiac remodeling in middle-aged endurance athletes
AUTHOR NAMES
Trachsel L.D.
Carlen F.
Brugger N.
Seiler C.
Wilhelm M.
AUTHOR ADDRESSES
(Trachsel L.D.; Carlen F.; Brugger N.; Seiler C.; Wilhelm M.,
matthias.wilhelm@insel.ch) University Clinic for Cardiology, Inselspital,
University Hospital and University of Bern, Bern, Switzerland.
CORRESPONDENCE ADDRESS
M. Wilhelm, University Clinic for Cardiology, Inselspital, University
Hospital and University of Bern, Bern, Switzerland.
SOURCE
Journal of Hypertension (2015) 33:6 (1276-1283). Date of Publication: 6 Jun
2015
ISSN
1473-5598 (electronic)
0263-6352
BOOK PUBLISHER
Lippincott Williams and Wilkins, agents@lww.com
ABSTRACT
Objectives: Extensive endurance training and arterial hypertension are
established risk factors for atrial fibrillation. We aimed to assess the
proportion of masked hypertension in endurance athletes and the impact on
cardiac remodeling, mechanics, and supraventricular tachycardias (SVT).
Methods: Male participants of a 10-mile race were recruited and included if
office blood pressure was normal (<140/90 mmHg). Athletes were stratified
into a masked hypertension and normotension group by ambulatory blood
pressure. Primary endpoint was diastolic function, expressed as peak early
diastolic mitral annulus velocity (E'). Left ventricular global strain, left
ventricular mass/volume ratio, left atrial volume index, signal-averaged
P-wave duration (SAPWD), and SVT during 24-h Holter monitoring were
recorded. Results: From 108 runners recruited, 87 were included in the final
analysis. Thirty-three (38%) had masked hypertension. The mean age was 42 ±
8 years. Groups did not differ with respect to age, body composition,
cumulative training hours, and 10-mile race time. Athletes with masked
hypertension had a lower E' and a higher left ventricular mass/volume ratio.
Left ventricular global strain, left atrial volume index, SAPWD, and SVT
showed no significant differences between the groups. In multiple linear
regression analysis, masked hypertension was independently associated with
E' (beta = - 0.270, P = 0.004) and left ventricular mass/volume ratio (beta
= 0.206, P = 0.049). Cumulative training hours was the only independent
predictor for left atrial volume index (beta = 0.474, P < 0.001) and SAPWD
(beta = 0.481, P < 0.001). Conclusion: In our study, a relevant proportion
of middle-aged athletes had masked hypertension, associated with a lower
diastolic function and a higher left ventricular mass/volume ratio, but
unrelated to left ventricular systolic function, atrial remodeling, or SVT.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
endurance sport
heart atrium remodeling
masked hypertension
supraventricular tachycardia
EMTREE MEDICAL INDEX TERMS
adult
article
athlete
atrial fibrillation
biomechanics
blood pressure
blood pressure monitoring
body composition
cardiovascular parameters
clinical article
clinical assessment
diastolic blood pressure
disease association
endurance training
heart left ventricle mass
heart left ventricle volume
Holter monitoring
human
left atrial volume index
left ventricular global strain
male
middle aged
P wave
priority journal
race
risk factor
signal averaged p wave duration
systolic blood pressure
transthoracic echocardiography
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015010514
FULL TEXT LINK
http://dx.doi.org/10.1097/HJH.0000000000000558
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 184
TITLE
Analysis and Thoughts about the Negative Results of International Clinical
Trials on Acupuncture
AUTHOR NAMES
Liu W.-H.
Hao Y.
Han Y.-J.
Wang X.-H.
Li C.
Liu W.-N.
AUTHOR ADDRESSES
(Liu W.-H., weihongliu010@sina.com; Hao Y., sjzj2468@sina.com; Han Y.-J.,
han19920714@sina.com; Wang X.-H., laomimami@hotmail.com; Li C.,
41446417@qq.com; Liu W.-N., lwn8864@163.com) Institute of Acupuncture and
Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
CORRESPONDENCE ADDRESS
W.-N. Liu, Institute of Acupuncture and Moxibustion, China Academy of
Chinese Medical Sciences, Beijing, China.
SOURCE
Evidence-based Complementary and Alternative Medicine (2015) 2015 Article
Number: 671242. Date of Publication: 2015
ISSN
1741-4288 (electronic)
1741-427X
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
An increasing number of randomized controlled trials (RCTs) of acupuncture
have proved the clinical benefits of acupuncture; however, there are some
results that have shown negative results or placebo effects. The paper
carried out an in-depth analysis on 33 RCTs in the 2011 SCI database, the
quality of the reports was judged according to Jadad scores, and the
"Necessary Information Included in Reporting Interventions in Clinical
Trials of Acupuncture (STRICTA 2010)" was taken as the standard to analyze
the rationality of the therapeutic principle. The difference between the
methodology (Jadad) scores of the two types of research reports did not
constitute statistical significance (P>0.05). The studies with negative
results or placebo effects showed the following deficiencies with respect to
intervention details: (1) incompletely rational acupoint selection; (2)
inconsistent ability of acupuncturists; (3) negligible needling response to
needling; (4) acupuncture treatment frequency too low in most studies; and
(5) irrational setting of placebo control. Thus, the primary basis for the
negative results or placebo effects of international clinical trials on
acupuncture is not in the quality of the methodology, but in noncompliance
with the essential requirements proposed by acupuncture theory in terms of
clinical manipulation details.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
placebo effect
randomized controlled trial (topic)
EMTREE MEDICAL INDEX TERMS
acupressure
acupuncture analgesia
article
asthma (therapy)
atrial fibrillation (therapy)
cancer fatigue (therapy)
cesarean section
dysmenorrhea (therapy)
eczema (therapy)
electroacupuncture
human
infertility (therapy)
knee osteoarthritis (therapy)
low back pain (therapy)
medical research
menopausal syndrome (therapy)
methodology
migraine (therapy)
motion sickness (therapy)
moxibustion
nausea and vomiting (therapy)
neck pain (therapy)
neurosis (therapy)
obesity (therapy)
peripheral neuropathy (therapy)
physiotherapy
postoperative nausea (therapy)
premature ejaculation (therapy)
priority journal
statistical significance
tinnitus (therapy)
uterine cervix dilatation
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015172614
FULL TEXT LINK
http://dx.doi.org/10.1155/2015/671242
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 185
TITLE
Safety and efficacy of cardiac rehabilitation for patients with continuous
flow left ventricular assist devices
AUTHOR NAMES
Marko C.
Danzinger G.
Käferbäck M.
Lackner T.
Müller R.
Zimpfer D.
Schima H.
Moscato F.
AUTHOR ADDRESSES
(Marko C., christiane.marko@pensionsversicherung.at; Lackner T.)
Rehabilitation Center Felbring, Austria.
(Danzinger G.; Käferbäck M.; Schima H.; Moscato F.) Center for Medical
Physics and Biomedical Engineering, Medical University of Vienna, Austria.
(Danzinger G.; Käferbäck M.; Zimpfer D.; Schima H.; Moscato F.) Ludwig
Boltzmann Cluster for Cardiovascular Research, Austria.
(Müller R.) Pensionsversicherungsanstalt, Austria.
(Schima H.) Department of Cardiac Surgery, Medical University of Vienna,
Austria.
CORRESPONDENCE ADDRESS
C. Marko, Rehabilitationszentrum Felbring der Pensionsversicherungsanstalt,
Felbring 71, Muthmannsdorf, Austria.
SOURCE
European Journal of Preventive Cardiology (2015) 22:11 (1378-1384). Date of
Publication: 1 Nov 2015
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Background Despite the increasing use of left ventricular assist devices
(LVADs) in terminal heart failure, cardiac rehabilitation protocols have not
yet been documented in larger LVAD patient cohorts. The aim of this study
was to investigate safety and efficacy of exercise training during a
rehabilitation programme after post-operative discharge of LVAD patients.
Methods Rehabilitation data obtained between 2010-2012 from 41 LVAD patients
(mean age 54.8 ± 11.6 years; 20% female) were retrospectively analysed. The
exercise protocol consisted of strength exercises for lower limbs, bicycle
ergometry, walking and gymnastics. The numbers of training sessions, their
duration and intensity as well as adverse events were documented.
Spiroergometry was performed at least once and twice in a subgroup of 15
patients (at the beginning and end of rehabilitation). Results
Rehabilitation started 48 ± 38 days post LVAD implantation with an average
duration of 32 ± 6 days. An increase in exercise capacity was observed.
Duration (19 ± 4 vs 14 ± 2 min, p < 0.001) and intensity of bicycle
ergometry increased (module number 6.2 ± 2.8 vs 2.0 ± 1.9, p < 0.001) as
well as muscular strength all muscle groups trained (e.g. 33.6 ± 15.2 vs
26.6 ± 11.9 kg at the leg press, p = 0.002). Spiroergometry revealed an
increase of maximal oxygen consumption (14.5 ± 5.2 vs 11.3 ± 4.1 ml/min/kg,
p = 0.007) in the subgroup that underwent two examinations. In the whole
population the average increase was lower (12.81 ± 4.35 ml/min/kg). One
training-related adverse event (non-sustained ventricular tachycardia) was
observed. Conclusion Exercise training for LVAD patient as part of a
multidisciplinary rehabilitation programme is effective and safe. This
warrants the broad application of exercise training after LVAD implantation.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
dipeptidyl carboxypeptidase inhibitor
furosemide
ramipril
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
continuous flow left ventricular assist device
device safety
heart rehabilitation
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
bicycle ergometry
cardiac resynchronization therapy
clinical article
exercise
female
human
implantable cardioverter defibrillator
male
muscle strength
oxygen consumption
physical performance
priority journal
resistance training
retrospective study
DEVICE TRADE NAMES
heart mate ii , United StatesThoratec
DEVICE MANUFACTURERS
(United States)HeartWare
(United States)Thoratec
CAS REGISTRY NUMBERS
furosemide (54-31-9)
ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015446178
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487314558772
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 186
TITLE
Cross-country skiing injuries and training methods
AUTHOR NAMES
Nagle K.B.
AUTHOR ADDRESSES
(Nagle K.B., kyle.nagle@childrenscolorado.org) University of Colorado,
Department of Orthopedics, Children's Hospital Colorado Orthopedics
Institute, 13123 East 16th Avenue, Aurora, United States.
CORRESPONDENCE ADDRESS
K.B. Nagle, University of Colorado, Department of Orthopedics, Children's
Hospital Colorado Orthopedics Institute, 13123 East 16th Avenue, Aurora,
United States. Email: kyle.nagle@childrenscolorado.org
SOURCE
Current Sports Medicine Reports (2015) 14:6 (442-447). Date of Publication:
1 Nov 2015
ISSN
1537-8918 (electronic)
1537-890X
BOOK PUBLISHER
Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
Cross-country skiing is a low injury-risk sport that has many health
benefits and few long-term health risks. Some concern exists that
cross-country skiing may be associated with a higher incidence of atrial
fibrillation; however, mortality rates among skiers are lower than those
among the general population. While continuing to emphasize aerobic and
anaerobic training, training methods also should promote ski-specific
strength training to increase maximum force and its rate of delivery and to
build muscular endurance to maintain that power through a race. Multiple
tests are available to monitor training progress. Which tests are most
appropriate depends on the specific events targeted. In addition to
laboratory-based tests, there also are many simpler, more cost-effective
tests, such as short time trials, that can be used to monitor training
progress and predict performance particularly at the junior skier level
where access and cost may be more prohibitive.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cross country skiing injury (epidemiology)
skiing
sport injury (epidemiology)
EMTREE MEDICAL INDEX TERMS
aerobic capacity
aerobic exercise
anaerobic exercise
article
cost effectiveness analysis
heart
human
low back pain
lung gas exchange
oxygen consumption
resistance training
EMBASE CLASSIFICATIONS
Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015517464
FULL TEXT LINK
http://dx.doi.org/10.1249/JSR.0000000000000205
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 187
TITLE
Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study
of Serelaxin in Japanese Patients with Acute Heart Failure
AUTHOR NAMES
Sato N.
Takahashi W.
Hirayama A.
Ajioka M.
Takahashi N.
Okishige K.
Wang X.
Maki A.
Maruyama H.
Ebinger U.
Yamaguchi M.
Pang Y.
Matsumoto H.
Kawana M.
AUTHOR ADDRESSES
(Sato N., nms-ns@nms.ac.jp; Takahashi N.) Cardiology and Intensive Care
Unit, Nippon Medical School Musashi-Kosugi Hospital, Kanagawa, Japan.
(Takahashi W.) Department of Cardiology, National Hospital Organization
Shinshu Ueda Medical Center, Nagano, Japan.
(Hirayama A.) Division of Cardiology, Nihon University School of Medicine,
Tokyo, Japan.
(Ajioka M.) Department of Cardiology, Tosei General Hospital, Aichi, Japan.
(Okishige K.) Division of Cardiology, Yokohama City Minato Red Cross
Hospital, Kanagawa, Japan.
(Wang X.; Ebinger U.) Novartis Pharmaceuticals Corporation, East Hanover,
Japan.
(Pang Y.) Novartis Institute for BioMedical Research, Inc, Cambridge, United
States.
(Maki A.; Maruyama H.; Yamaguchi M.; Matsumoto H.) Novartis Pharma K.K.,
Tokyo, Japan.
(Kawana M.) Department of General Medicine, Tokyo Women’s Medical University
Hospital, Tokyo, Japan.
CORRESPONDENCE ADDRESS
N. Sato, Cardiology and Intensive Care Unit, Nippon Medical School
Musashi-Kosugi Hospital, 1-396 Kosugi-cho, Nakahra-ku, Kawasaki, Japan.
SOURCE
Circulation Journal (2015) 79:6 (1237-1247). Date of Publication: 11 May
2015
ISSN
1347-4820 (electronic)
1346-9843
BOOK PUBLISHER
Japanese Circulation Society
ABSTRACT
Background: Serelaxin, a recombinant form of human relaxin-2, is in
development for treating acute heart failure (AHF) and a Phase II study in
Japanese AHF patients was conducted. Methods and Results: A randomized,
double-blind, placebo-controlled study of serelaxin at 10 and 30 µg ·
kg–1 · day–1 continuous intravenous infusion for up to
48 h, added to standard care for Japanese AHF patients. Primary endpoints
were adverse events (AEs) through Day 5, serious AEs (SAEs) through Day 14,
and serelaxin pharmacokinetics. Secondary endpoints included changes in
systolic blood pressure (SBP) and cardiorenal biomarkers. A total of 46
patients received the study drug and were followed for 60 days. The observed
AE profile was comparable between the groups, with no AEs of concern.
Dose-dependent increase in the serum concentration of serelaxin was observed
across the 2 dose rates of serelaxin. A greater reduction in SBP was
observed with serelaxin 30 µg · kg–1 · day–1 vs.
placebo (–7.7 [–16.4, 1.0] mmHg). A greater reduction in NT-proBNP was noted
with serelaxin (–50.8% and –54.9% for 10 and 30 µg · kg–1 ·
day–1, respectively at Day 2). Conclusions: Serelaxin was well
tolerated in this study with Japanese AHF patients, with no AEs of concern
and favorable beneficial trends on efficacy. These findings support further
evaluation of serelaxin 30 µg · kg–1 · day–1 in this
patient population.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
serelaxin (adverse drug reaction, clinical trial, drug comparison - placebo,
drug therapy, intravenous drug administration, pharmacokinetics)
EMTREE DRUG INDEX TERMS
aldosterone (endogenous compound)
amino terminal pro brain natriuretic peptide (endogenous compound)
biological marker (endogenous compound)
cystatin C (endogenous compound)
dobutamine (drug therapy, intravenous drug administration)
neutrophil gelatinase associated lipocalin (endogenous compound)
placebo
troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute heart failure (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
area under the curve
article
atrial fibrillation (side effect)
clinical article
comorbidity
congestive heart failure (side effect)
constipation (side effect)
continuous infusion
controlled study
coronary artery obstruction (side effect)
dehydration (side effect)
dose response
double blind procedure
drug safety
drug tolerability
drug treatment failure
drug withdrawal
dyspnea
edema
esophagus carcinoma (side effect)
exercise
female
heart ventricle tachycardia (side effect)
human
hypokalemia (side effect)
hypotension (drug therapy)
immunogenicity
intestine ischemia (side effect)
Japanese (people)
Likert scale
liver metastasis (side effect)
lymph node metastasis (side effect)
male
maximum plasma concentration
multicenter study
multiple organ failure (side effect)
peritoneum metastasis (side effect)
pharmacodynamics
phase 2 clinical trial
pulse rate
randomized controlled trial
stomach cancer (side effect)
systolic blood pressure
visual analog scale
CAS REGISTRY NUMBERS
aldosterone (52-39-1, 6251-69-0)
dobutamine (34368-04-2, 52663-81-7, 49745-95-1, 61661-06-1)
serelaxin (99489-94-8)
troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT02002702)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015083288
FULL TEXT LINK
http://dx.doi.org/10.1253/circj.CJ-15-0227
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 188
TITLE
Efficacy of cardiopulmonary rehabilitation with adaptive servo-ventilation
in patients undergoing off-pump coronary artery bypass grafting
AUTHOR NAMES
Tashiro N.
Takahashi S.
Takasaki T.
Katayama K.
Taguchi T.
Watanabe M.
Kurosaki T.
Imai K.
Kimura H.
Sueda T.
AUTHOR ADDRESSES
(Tashiro N., tashiro@hiroshima-u.ac.jp; Kimura H.) Department of
Rehabilitation, Hiroshima University Hospital, Hiroshima, Japan.
(Takahashi S.; Takasaki T.; Katayama K.; Taguchi T.; Watanabe M.; Kurosaki
T.; Imai K.; Sueda T.) Department of Cardiovascular Surgery, Hiroshima
University Hospital, Hiroshima, Japan.
CORRESPONDENCE ADDRESS
N. Tashiro, Department of Rehabilitation, Hiroshima University Hospital,
1-2-3 Kasumi, Minami-ku, Hiroshima, Japan.
SOURCE
Circulation Journal (2015) 79:6 (1290-1298). Date of Publication: 11 May
2015
ISSN
1347-4820 (electronic)
1346-9843
BOOK PUBLISHER
Japanese Circulation Society
ABSTRACT
Background: Postoperative complications after cardiac surgery increase
mortality. This study aimed to evaluate the efficacy of cardiopulmonary
rehabilitation with adaptive servo-ventilation (ASV) in patients undergoing
off-pump coronary artery bypass grafting (OPCAB). Methods and Results: A
total of 66 patients undergoing OPCAB were enrolled and divided into 2
groups according to the use of ASV (ASV group, 30 patients; non-ASV group,
36 patients). During the perioperative period, all patients undertook
cardiopulmonary rehabilitation. ASV was used from postoperative day (POD) 1
to POD5. Hemodynamics showed a different pattern in the 2 groups. Blood
pressure (BP) on POD6 in the ASV group was significantly lower than that in
the non-ASV group (systolic BP, 112.9±12.6 vs. 126.2±15.8 mmHg, P=0.0006;
diastolic BP, 62.3±9.1 vs. 67.6±9.3 mmHg, P=0.0277). The incidence of
postoperative atrial fibrillation (POAF) was lower in the ASV group than in
the non-ASV group (10% vs. 33%, P=0.0377). The duration of oxygen inhalation
in the ASV group was significantly shorter than that in the non-ASV group
(5.1±2.2 vs. 7.6±6.0 days, P=0.0238). The duration of postoperative
hospitalization was significantly shorter in the ASV group than in the
non-ASV group (23.5±6.6 vs. 29.0±13.1 days, P=0.0392). Conclusions:
Cardiopulmonary rehabilitation with ASV after OPCAB reduces both POAF
occurrence and the duration of hospitalization.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
atrial natriuretic factor alpha
C reactive protein (endogenous compound)
diltiazem
dobutamine
dopamine
glyceryl trinitrate
landiolol
nicardipine
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adaptive servo ventilation
cardiovascular procedure
heart rehabilitation
off pump coronary surgery
EMTREE MEDICAL INDEX TERMS
aged
artery spasm
article
atrial fibrillation (complication)
blood pressure
comparative study
CPAP device
echocardiography
exercise
female
heart hemodynamics
heart index
heart rate
hospitalization
human
major clinical study
male
oxygen breathing
perioperative period
peroperative care
postoperative care
preoperative evaluation
sternotomy
therapy effect
weight gain
DEVICE TRADE NAMES
AutoSet CS , JapanResMed
DEVICE MANUFACTURERS
(Japan)ResMed
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
atrial natriuretic factor alpha (89213-87-6)
C reactive protein (9007-41-4)
diltiazem (33286-22-5, 42399-41-7)
dobutamine (34368-04-2, 52663-81-7, 49745-95-1, 61661-06-1)
dopamine (51-61-6, 62-31-7)
glyceryl trinitrate (55-63-0)
landiolol (133242-30-5)
nicardipine (54527-84-3, 55985-32-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015083295
FULL TEXT LINK
http://dx.doi.org/10.1253/circj.CJ-14-1078
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 189
TITLE
Effect of comprehensive cardiac telerehabilitation on one-year
cardiovascular rehospitalization rate, medical costs and quality of life: A
cost-effectiveness analysis
AUTHOR NAMES
Frederix I.
Hansen D.
Coninx K.
Vandervoort P.
Vandijck D.
Hens N.
Van Craenenbroeck E.
Van Driessche N.
Dendale P.
AUTHOR ADDRESSES
(Frederix I., ines.frederix@gmail.com; Dendale P.) Department of Cardiology,
Jessa Hospital, Hasselt, Belgium.
(Frederix I., ines.frederix@gmail.com; Hansen D.; Vandervoort P.; Vandijck
D.; Van Driessche N.; Dendale P.) Faculty of Medicine and Life Sciences,
Hasselt University, Belgium.
(Coninx K.) Faculty of Sciences, Expertise Centre for Digital Media, Hasselt
University, Belgium.
(Vandervoort P.) Department of Cardiology, Hospital East-Limburg, Genk,
Belgium.
(Hens N.) Interuniversity Institute of Biostatistics and Statistical
Bioinformatics, Hasselt University, Belgium.
(Hens N.) Centre for Health Economic Research and Modelling Infectious
Diseases, Vaccine and Infectious Disease Institute, University of Antwerp,
Belgium.
(Van Craenenbroeck E.) Department of Cardiology, Antwerp University
Hospital, Belgium.
CORRESPONDENCE ADDRESS
I. Frederix, Beatrijslaan 105, Rotselaar, Belgium. Email:
ines.frederix@gmail.com
SOURCE
European Journal of Preventive Cardiology (2015) 23:7 (674-682). Date of
Publication: 2015
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Background Notwithstanding the cardiovascular disease epidemic, current
budgetary constraints do not allow for budget expansion of conventional
cardiac rehabilitation programmes. Consequently, there is an increasing need
for cost-effectiveness studies of alternative strategies such as
telerehabilitation. The present study evaluated the cost-effectiveness of a
comprehensive cardiac telerehabilitation programme. Design and methods This
multi-centre randomized controlled trial comprised 140 cardiac
rehabilitation patients, randomized (1:1) to a 24-week telerehabilitation
programme in addition to conventional cardiac rehabilitation (intervention
group) or to conventional cardiac rehabilitation alone (control group). The
incremental cost-effectiveness ratio was calculated based on intervention
and health care costs (incremental cost), and the differential incremental
quality adjusted life years (QALYs) gained. Results The total average cost
per patient was significantly lower in the intervention group (€2156 ± €126)
than in the control group (€2720 ± €276) (p = 0.01) with an overall
incremental cost of €-564.40. Dividing this incremental cost by the baseline
adjusted differential incremental QALYs (0.026 QALYs) yielded an incremental
cost-effectiveness ratio of €-21,707/QALY. The number of days lost due to
cardiovascular rehospitalizations in the intervention group (0.33 ± 0.15)
was significantly lower than in the control group (0.79 ± 0.20) (p = 0.037).
Conclusions This paper shows the addition of cardiac telerehabilitation to
conventional centre-based cardiac rehabilitation to be more effective and
efficient than centre-based cardiac rehabilitation alone. These results are
useful for policy makers charged with deciding how limited health care
resources should best be allocated in the era of exploding need.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent (drug therapy)
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
insulin (drug therapy)
oral antidiabetic agent (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cost effectiveness analysis
health care cost
heart rehabilitation
hospital readmission
quality of life
telerehabilitation
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
adult
anticoagulant therapy
article
atrial fibrillation (drug therapy)
cardiac resynchronization therapy
controlled study
coronary artery disease (disease management, rehabilitation, therapy)
cost utility analysis
defibrillator
diabetes mellitus (drug therapy)
endurance training
female
heart failure (disease management, rehabilitation, therapy)
heart supraventricular arrhythmia (drug therapy)
heart ventricle arrhythmia (drug therapy)
human
in-stent restenosis
length of stay
major clinical study
male
middle aged
multicenter study
pericarditis
peripheral occlusive artery disease (drug therapy)
priority journal
prospective study
quality adjusted life year
randomized controlled trial
stable angina pectoris
thorax pain
treatment duration
CAS REGISTRY NUMBERS
insulin (9004-10-8)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160276501
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487315602257
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 190
TITLE
Impact of duration of mitral regurgitation on outcomes in asymptomatic
patients with myxomatous mitral valve undergoing exercise stress
echocardiography
AUTHOR NAMES
Naji P.
Asfahan F.
Barr T.
Rodriguez L.L.
Grimm R.A.
Agarwal S.
Thomas J.D.
Marc Gillinov A.
Mihaljevic T.
Griffin B.P.
Desai M.Y.
AUTHOR ADDRESSES
(Naji P.; Asfahan F.; Barr T.; Rodriguez L.L.; Grimm R.A.; Agarwal S.;
Thomas J.D.; Marc Gillinov A.; Mihaljevic T.; Griffin B.P.; Desai M.Y.,
desaim2@ccf.org) Heart and Vascular Institute, Cleveland Clinic, Cleveland,
United States.
CORRESPONDENCE ADDRESS
M.Y. Desai, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave,
Desk J1-5, Cleveland, United States.
SOURCE
Journal of the American Heart Association (2015) 4:2 Article Number:
e001348. Date of Publication: 2015
ISSN
2047-9980 (electronic)
BOOK PUBLISHER
John Wiley and Sons Inc., P.O.Box 18667, Newark, United States.
ABSTRACT
Background-Significant mitral regurgitation (MR) typically occurs as
holosystolic (HS) or mid-late systolic (MLS), with differences in volumetric
impact on the left ventricle (LV). We sought to assess outcomes of
degenerative MR patients undergoing exercise echocardiography, separated
based on MR duration (MLS versus HS). Methods and Results-We included 609
consecutive patients with ≥III+myxomatous MR undergoing exercise
echocardiography: HS (n=487) and MLS (n=122). MLS MR was defined as delayed
appearance of MR signal during mid-late systole on continuouswave Doppler
while HS MR occurred throughout systole. Composite events of death and
congestive heart failure were recorded. Compared to MLS MR, HS MR patients
were older (60±14 versus 53±14 years), more were males (72% versus 53%), and
had greater prevalence of atrial fibrillation (16% versus 7%; all P<0.01).
HS MR patients had higher right ventricular systolic pressure (RVSP) at rest
(33±11 versus 27±9 mm Hg), more flail leaflets (36% versus 6%), and a lower
number of metabolic equivalents (METs) achieved (9.5±3 versus 10.5±3),
compared to the MLS MR group (all P<0.05). There were 54 events during 7.1±3
years of follow-up. On step-wise multivariable analysis, HS versus MLS MR
(HR 4.99 [1.21 to 20.14]), higher LV ejection fraction (hazard ratio [HR],
0.94 [0.89 to 0.98]), atrial fibrillation (HR, 2.59 [1.33 to 5.11]), higher
RVSP (HR, 1.05 [1.03 to 1.09]), and higher percentage of age- and
gender-predicted METs (HR, 0.98 [0.97 to 0.99]) were independently
associated with adverse outcomes (all P<0.05). Conclusion-In patients with
≥III+myxomatous MR undergoing exercise echocardiography, holosystolic MR is
associated with adverse outcomes, independent of other predictors.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adverse outcome
heart myxoma
mitral valve regurgitation (surgery)
stress echocardiography
EMTREE MEDICAL INDEX TERMS
adult
age
article
asymptomatic disease
atrial fibrillation
congestive heart failure
controlled study
death
disease duration
female
gender
heart left ventricle ejection fraction
heart right ventricle pressure
human
major clinical study
male
metabolic equivalent
middle aged
mitral valve repair
mitral valve replacement
observational study
priority journal
retrospective study
survival rate
systole
transthoracic echocardiography
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015883989
FULL TEXT LINK
http://dx.doi.org/10.1161/JAHA.114.001348
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 191
TITLE
Atrial fibrillation and long-term sports practice: epidemiology and
mechanisms
AUTHOR NAMES
Wernhart S.
Halle M.
AUTHOR ADDRESSES
(Wernhart S., simon.wernhart@hotmail.com; Halle M.) Klinikum Rechts der
Isar, Centre for Prevention and Sports Medicine, Technische Universität
München, Georg-Brauchle-Ring 56 (Campus C), Munich, Germany.
(Halle M.) German Centre for Cardiovascular Research, Partner Site Munich
Heart Alliance, Munich, Germany.
(Halle M.) Klinikum Rechts der Isar, Else-Kröner-Fresenius-Zentrum, Munich,
Germany.
CORRESPONDENCE ADDRESS
S. Wernhart, Klinikum Rechts der Isar, Centre for Prevention and Sports
Medicine, Technische Universität München, Georg-Brauchle-Ring 56 (Campus C),
Munich, Germany.
SOURCE
Clinical Research in Cardiology (2014) . Date of Publication: 25 Dec 2014
ISSN
1861-0692 (electronic)
1861-0684
BOOK PUBLISHER
Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
Results: The majority of studies have methodological limitations due to
different inclusion criteria, such as age, type of sport, training level as
well as statistical bias. The inconsistency of data is reflected by the
considerable range of AF occurrence, spanning from 0.3 to 12.8
%.Conclusions: We consider it reasonable to separate a study population into
sedentary individuals, leisure time sportsmen/women and elite athletes. A
distinction between the categories may be achieved through a combination of
exercise history, capacity (e.g. MET hours/week, e.g. VO2max) and
competitive results. Since there is a large span in the analyzed age groups
(24–84 years), we claim that the focus should be laid upon the 45- to
65-year-olds due to a sound detection rate of true positives. Finally, we
discuss ways to increase the detection rate of paroxysmal AF and comment on
new therapeutic options.Background: Lone atrial fibrillation (AF) is the
most common arrhythmia of the heart and is considered to have a higher
prevalence in athletes, especially in endurance sports.Methods: We conducted
an extensive literature research in pubmed using the key words sports and
atrial fibrillation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation
endurance sport
epidemiology
human
sport
EMTREE MEDICAL INDEX TERMS
exercise
groups by age
heart
heart arrhythmia
leisure
Medline
population
prevalence
sound detection
statistical bias
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015635170
FULL TEXT LINK
http://dx.doi.org/10.1007/s00392-014-0805-0
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 192
TITLE
Critical Care Congress 2015
AUTHOR ADDRESSES
SOURCE
Critical Care Medicine (2014) 42:12 SUPPL. 1. Date of Publication: December
2014
CONFERENCE NAME
Critical Care Congress 2015
CONFERENCE LOCATION
Phoenix, AZ, United States
CONFERENCE DATE
2015-01-17 to 2015-01-21
ISSN
0090-3493
BOOK PUBLISHER
Lippincott Williams and Wilkins
ABSTRACT
The proceedings contain 1238 papers. The topics discussed include:
correlation of CHADS2 with new onset atrial fibrillation in thoracic and
vascular surgical patients; mortality risk factors with carbapenem-resistant
bacteremia: impact of combination therapy; immuno-modulating diet containing
whey protein and EPA suppressed reactive oxygen species production; simple,
reliable sepsis screening tool improves mortality in trauma patients; lower
oxygen concentration reduced systemic inflammatory response and improved the
outcome of CPR; teaching situation awareness during cardiac arrests and
rapid responses - a simulation study; epidemiology and outcomes of
in-hospital cardiac arrest across hospitals of varied center volume; ADR
surveillance using a multicenter clinical database: propofol related
infusion syndrome incidence; the obesity paradox is not observed in
critically ill patients on early internal nutrition; and epidemiologic
features and outcome of sepsis in neurologic intensive care unit patients.
EMTREE DRUG INDEX TERMS
carbapenem
protein
reactive oxygen metabolite
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
intensive care
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
bacteremia
critically ill patient
data base
diet
epidemiology
heart arrest
hospital
human
inflammation
injury
intensive care unit
mortality
nutrition
obesity
oxygen concentration
patient
propofol infusion syndrome
risk factor
screening
sepsis
simulation
surgical patient
teaching
therapy
whey
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 193
TITLE
Cardiovascular risk factors and future risk of Alzheimer's disease
AUTHOR NAMES
de Bruijn R.F.A.G.
Ikram M.A.
AUTHOR ADDRESSES
(de Bruijn R.F.A.G., r.f.a.g.debruijn@erasmusmc.nl; Ikram M.A.,
m.a.ikram@erasmusmc.nl) Department of Epidemiology, Erasmus MC University
Medical Center, Wytemaweg 80, Rotterdam, Netherlands.
(de Bruijn R.F.A.G., r.f.a.g.debruijn@erasmusmc.nl; Ikram M.A.,
m.a.ikram@erasmusmc.nl) Department of Neurology, Erasmus MC University
Medical Center, 's-Gravendijkwal 230, Rotterdam, Netherlands.
(Ikram M.A., m.a.ikram@erasmusmc.nl) Department of Radiology, Erasmus MC
University Medical Center, 's-Gravendijkwal 230, Rotterdam, Netherlands.
CORRESPONDENCE ADDRESS
M.A. Ikram, Department of Epidemiology, Erasmus MC University Medical
Center, Wytemaweg 80, Rotterdam, Netherlands.
SOURCE
BMC Medicine (2014) 12:1 Article Number: 130. Date of Publication: 11 Nov
2014
ISSN
1741-7015 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
Alzheimer's disease (AD) is the most common neurodegenerative disorder in
elderly people, but there are still no curative options. Senile plaques and
neurofibrillary tangles are considered hallmarks of AD, but cerebrovascular
pathology is also common. In this review, we summarize findings on
cardiovascular disease (CVD) and risk factors in the etiology of AD.
Firstly, we discuss the association of clinical CVD (such as stroke and
heart disease) and AD. Secondly, we summarize the relation between imaging
makers of pre-clinical vascular disease and AD. Lastly, we discuss the
association of cardiovascular risk factors and AD. We discuss both
established cardiovascular risk factors and emerging putative risk factors,
which exert their effect partly via CVD.
EMTREE DRUG INDEX TERMS
homocysteine (endogenous compound)
thyroid hormone (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Alzheimer disease (etiology)
cardiovascular disease
cardiovascular risk
EMTREE MEDICAL INDEX TERMS
arterial stiffness
article
atrial fibrillation
blood pressure
brain atrophy
brain hemorrhage
cerebrovascular accident
cerebrovascular disease
chronic kidney disease
cognitive defect
dementia
diffusion tensor imaging
disease association
disease marker
functional magnetic resonance imaging
glucose metabolism
heart disease
heart failure
human
hypercholesterolemia
hypertension
inflammation
ischemic heart disease
Mediterranean diet
non insulin dependent diabetes mellitus
obesity
physical activity
pulse wave
risk assessment
smoking
thyroid function
white matter lesion
CAS REGISTRY NUMBERS
homocysteine (454-28-4, 6027-13-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015812984
FULL TEXT LINK
http://dx.doi.org/10.1186/s12916-014-0130-5
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 194
TITLE
European Congress on e-Cardiology and e-Health 2014
AUTHOR ADDRESSES
SOURCE
European Journal of Preventive Cardiology (2014) 21:2 SUPPL. 1. Date of
Publication: November 2014
CONFERENCE NAME
European Congress on e-Cardiology and e-Health 2014
CONFERENCE LOCATION
Bern, Switzerland
CONFERENCE DATE
2014-10-29 to 2014-10-31
ISSN
2047-4873
BOOK PUBLISHER
SAGE Publications Inc.
ABSTRACT
The proceedings contain 16 papers. The topics discussed include: MART Munich
arterial hypertension register telemedicine; the revealing timely ECG
changes decreases the likelihood of undesirable cardiac events-trial
(REDUCE-Trial); telemedicine network for collaborative diagnosis and care of
heart malformations; telerehabilitation in coronary artery disease
(TRIC-study), 3 months data; smartphones, computer vision, artificial
intelligence, and their application to carbohydrate counting; predictors of
coronary heart disease patients' usage of a web-based intervention aimed at
lifestyle change. results from lebensstil-aendern.de; clinical experiences
with a mobile diet logging application; a miniature MEMS only based method
of detecting atrial fibrillation; big data: time to remodel diagnostic
paths; Skype and tele-ECG in control of home-based exercise training after
planned PCI - a useful tool?; and integrating telemedicine systems with
active learning solutions.
EMTREE DRUG INDEX TERMS
carbohydrate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
telehealth
EMTREE MEDICAL INDEX TERMS
artificial intelligence
atrial fibrillation
computer
congenital heart malformation
coronary artery disease
diagnosis
diet
electrocardiogram
exercise
human
hypertension
ischemic heart disease
learning
lifestyle modification
logging
microelectromechanical system
patient
register
telemedicine
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 195
TITLE
Impact of intensive physiotherapy on cognitive function after coronary
artery bypass graft surgery
AUTHOR NAMES
Cavalcante E.S.
Magario R.
Conforti C.A.
Júnior G.C.
Arena R.
Carvalho A.C.C.
Buffolo E.
Filho B.L.
AUTHOR ADDRESSES
(Cavalcante E.S., drelder@hotmail.com; Carvalho A.C.C.; Buffolo E.; Filho
B.L.) UNIFESP-Universidade Federal de São Paulo, Brazil.
(Magario R.) USP-Universidade de São Paulo, Brazil.
(Conforti C.A.) Santa Casa de Misericórdia de Santos, Santos, Brazil.
(Júnior G.C.) UNB-Universidade de Brasília, Brazil.
(Arena R.) Virginia Commonwealth University, Richmond, United States.
CORRESPONDENCE ADDRESS
E.S. Cavalcante, Av. Francisco Glicério 121, 63, Gonzaga, Santos, Brazil.
SOURCE
Arquivos Brasileiros de Cardiologia (2014) 103:5 (391-397). Date of
Publication: 1 Nov 2014
ISSN
1678-4170 (electronic)
0066-782X
BOOK PUBLISHER
Arquivos Brasileiros de Cardiologia, arquivos@cardiol.br
ABSTRACT
Background: Coronary artery bypass graft (CABG) is a standard surgical
option for patients with diffuse and significant arterial plaque. This
procedure, however, is not free of postoperative complications, especially
pulmonary and cognitive disorders.Objective: This study aimed at comparing
the impact of two different physiotherapy treatment approaches on pulmonary
and cognitive function of patients undergoing CABG.Methods:
Neuropsychological and pulmonary function tests were applied, prior to and
following CABG, to 39 patients randomized into two groups as follows: Group
1 (control)-20 patients underwent one physiotherapy session daily; and Group
2 (intensive physiotherapy)-19 patients underwent three physiotherapy
sessions daily during the recovery phase at the hospital. Non-paired and
paired Student t tests were used to compare continuous variables. Variables
without normal distribution were compared between groups by using
Mann-Whitney test, and, within the same group at different times, by using
Wilcoxon test. The chi-square test assessed differences of categorical
variables. Statistical tests with a p value ≤ 0.05 were considered
significant.Results: Changes in pulmonary function were not significantly
different between the groups. However, while Group 2 patients showed no
decline in their neurocognitive function, Group 1 patients showed a decline
in their cognitive functions (P ≤ 0.01).Conclusion: Those results highlight
the importance of physiotherapy after CABG and support the implementation of
multiple sessions per day, providing patients with better psychosocial
conditions and less morbidity.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cognition
coronary artery bypass graft
physiotherapy
EMTREE MEDICAL INDEX TERMS
adult
airway pressure
article
atelectasis (complication)
atrial fibrillation (complication)
breathing exercise
breathing muscle
breathing rate
clinical article
comparative study
controlled study
digit symbol substitution test
expiratory reserve volume
female
forced expiratory volume
forced vital capacity
human
intensive care
lung function
lung function test
male
medical record
middle aged
pericardial effusion (complication)
pleura effusion (complication)
pneumonia (complication)
postoperative care
prospective study
randomized controlled trial
scoring system
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Psychiatry (32)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014881436
FULL TEXT LINK
http://dx.doi.org/10.5935/abc.20140161
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 196
TITLE
Effect of Years of Endurance Exercise on Risk of Atrial Fibrillation and
Atrial Flutter
AUTHOR NAMES
Myrstad M.
Nystad W.
Graff-Iversen S.
Thelle D.S.
Stigum H.
Aarønæs M.
Ranhoff A.H.
AUTHOR ADDRESSES
(Myrstad M., marius.myrstad@fhi.no; Aarønæs M.; Ranhoff A.H.) Department of
Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway
(Myrstad M., marius.myrstad@fhi.no; Nystad W.; Graff-Iversen S.; Stigum H.)
Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway
(Thelle D.S.) Department of Biostatistics, Institute of Basal Medical
Sciences, University of Oslo, Oslo, Norway
(Stigum H.) Department of Preventive Medicine and Epidemiology, Institute of
Health and Society, University of Oslo, Oslo, Norway
(Thelle D.S.) Department of Public Health and Community Medicine, Gothenburg
University, Gothenburg, Sweden
(Ranhoff A.H.) Department of Clinical Science, Kavli Research Centre for
Geriatrics and Dementia, University of Bergen, Bergen, Norway
CORRESPONDENCE ADDRESS
M. Myrstad, Department of Internal Medicine, Diakonhjemmet Hospital, Oslo,
Norway, . Email: marius.myrstad@fhi.no
SOURCE
American Journal of Cardiology (2014)
ISSN
0002-9149
1879-1913 (electronic)
ABSTRACT
Emerging evidence suggests that endurance exercise increases the risk for
atrial fibrillation (AF) in men, but few studies have investigated the
dose-response relation between exercise and risk for atrial arrhythmias.
Both exposure to exercise and reference points vary among studies, and
previous studies have not differentiated between AF and atrial flutter. The
aim of this study was to assess the risk for atrial arrhythmias by
cumulative years of regular endurance exercise in men. To cover the range
from physical inactivity to long-term endurance exercise, the study sample
in this retrospective cohort study was based on 2 distinct cohorts: male
participants in a long-distance cross-country ski race and men from the
general population, in total 3,545 men aged ≥53 years. Arrhythmia diagnoses
were validated by electrocardiograms during review of medical records.
Regular endurance exercise was self-reported by questionnaire. A broad range
of confounding factors was available for adjustment. The adjusted odds
ratios per 10 years of regular endurance exercise were 1.16 (95% confidence
interval 1.06 to 1.29) for AF and 1.42 (95% confidence interval 1.20 to
1.69) for atrial flutter. In stratified analyses, the associations were
significant in cross-country skiers and in men from the general population.
In conclusion, cumulative years of regular endurance exercise were
associated with a gradually increased risk for AF and atrial flutter. © 2014
Elsevier Inc. All rights reserved.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
endurance training
heart atrium flutter
risk
EMTREE MEDICAL INDEX TERMS
cohort analysis
confidence interval
diagnosis
dose response
electrocardiogram
exercise
exposure
heart arrhythmia
heart atrium arrhythmia
human
male
medical record
physical inactivity
population
questionnaire
skiing
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
FULL TEXT LINK
http://dx.doi.org/10.1016/j.amjcard.2014.07.047
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 197
TITLE
Demographic and clinical characteristics of patients with atrial
fibrillation and cardioversion as planned therapeutic options in the
International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF
Polish substudy
AUTHOR NAMES
Da̧browski R.
Opolski G.
Włodarczyk P.
Kiliszek M.
Ponikowski P.
AUTHOR ADDRESSES
(Da̧browski R., rdabrowski45@gmail.com) Institute of Cardiology, ul.
Spartańska 1, 02-637 Warszawa, Poland.
(Opolski G.; Kiliszek M.) 1St Department of Cardiology, Medical University
of Warsaw, Warsaw, Poland.
(Włodarczyk P.) MSD, Poland.
(Ponikowski P.) Military Hospital, Wroclaw, Poland.
CORRESPONDENCE ADDRESS
R. Da̧browski, Institute of Cardiology, ul. Spartańska 1, 02-637 Warszawa,
Poland. Email: rdabrowski45@gmail.com
SOURCE
Kardiologia Polska (2014) 72:8 (700-706). Date of Publication: 18 Aug 2014
ISSN
0022-9032
ABSTRACT
Background: Cardioversion of atrial fibrillation (AF) and maintenance of
sinus rhythm are the basic strategies of treating AF patients. Precise data
regarding the current practice of AF cardioversion in Europe in clinical
practice is lacking. Aim: The primary objective of this prospective
observational study was to characterise patients and treatment patterns in
whom cardioversion was the planned therapeutic option. Methods: Patients
with recent onset of AF were included, regardless of when the timing of the
cardioversion was planned. Ten countries participated in the study, with
Poland contributing 501 patients. The global enrollment period lasted from
May 2010 to June 2011. Follow-up data was collected 60 days after enrollment
via a medical chart abstraction or a telephone interview. Results: The
average age of the Polish patient population was 64.2 years, and 38.5% of
patients were female. Mean duration of arrhythmia was 3.3 years. Paroxysmal
AF was diagnosed in 38.3% and persistent AF in 43.6% of patients. The most
prevalent AF risk factors were hypertension (75.0%), diabetes mellitus
(20.5%), and family history of AF (12.1%). Mean body mass index of study
patients was 29.5 kg/m2. The most pertinent factors triggering AF were
emotion (12.4%), exercise (6.5%), electrolyte disturbances (5.5%), and acute
myocardial infarction (3.7%). Only 14.2% of patients were asymptomatic.
Previous episodes of AF were present in 83.1% of patients and 58.5% of them
had previous cardioversion: 49.8% pharmacological and 50.2% electrical. The
most often used anti-arrhythmic drugs were amiodarone (53.4%) and
propafenone (32.2%). The rate of antithrombotic treatment was low: 59.6%.
Finally electrical cardioversion had been undergone by 165 (53%) patients
and pharmacological by 146 (47%) patients. Conclusions: The population of
patients with AF and planned cardioversion represented typical patients with
non-valvular AF and standard symptoms, the vast majority of whom were
symptomatic. The study group in terms of comprehensive characteristics is
representative of the general population of AF patients. Copyright © Polskie
Towarzystwo Kardiologiczne.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
amiodarone (drug therapy)
antivitamin K
beta adrenergic receptor blocking agent (drug therapy)
digoxin (drug therapy)
diltiazem (drug therapy)
flecainide (drug therapy)
propafenone (drug therapy)
verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, therapy)
cardioversion
demography
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
acute heart infarction
adult
article
asymptomatic disease
Austria
body mass
Brazil
cardiovascular risk
clinical feature
comorbidity
coronary artery disease
diabetes mellitus
disease duration
dizziness
electrolyte disturbance
emotion
exercise
family history
fatigue
female
follow up
France
Germany
health care planning
heart failure
heart left ventricle ejection fraction
heart palpitation
human
hypertension
major clinical study
male
medical record review
mitral valve regurgitation
Netherlands
observational study
paroxysmal atrial fibrillation (drug therapy, therapy)
persistent atrial fibrillation (drug therapy, therapy)
persistent atrial fibrillation (drug therapy)
Poland
prospective study
Spain
Sweden
telephone interview
thorax pain
United Kingdom
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
flecainide (54143-55-4)
propafenone (34183-22-7, 54063-53-5)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Polish
EMBASE ACCESSION NUMBER
2014582661
FULL TEXT LINK
http://dx.doi.org/10.5603/KP.a2014.0067
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 198
TITLE
Traumatic oesophageal perforation due to haematoma
AUTHOR NAMES
Larsen C.G.
Brandt B.
AUTHOR ADDRESSES
(Larsen C.G., c.gronhoj@gmail.com) Department of Oto-Rhinolaryngology, Head
and Neck Surgery and Audiology, University Hospital Rigshospitalet,
Blegdamsvej 9, Copenhagen, Denmark.
(Brandt B.) Department of Cardiothoracic Surgery, University Hospital
Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark.
CORRESPONDENCE ADDRESS
C.G. Larsen, Department of Oto-Rhinolaryngology, Head and Neck Surgery and
Audiology, University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen,
Denmark.
SOURCE
International Journal of Surgery Case Reports (2014) 5:10 (659-661). Date of
Publication: 11 Aug 2014
ISSN
2210-2612
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
INTRODUCTION: Traumatic oesophageal perforation is a rare, life-threatening
emergency that requires early recognition and prompt surgical
management.PRESENTATION OF CASE: We present an unusual case of a patient on
warfarin treatment developed an intramural oesophageal haematoma following
blunt thoracic trauma leading to perforation on the 18th day.DISCUSSION: In
treatment of oesophageal haematoma in patients on vitamin-K antagonists,
strict control of the International Normalized Ratio (INR) is essential
along with total parenteral nutrition therapy and refrainment through
nasogastric tubes. Three explanations postulated to be the cause for late
perforation which might be due to esophageal wall ischemia from pressure
built up between the hematoma, azygos vein and the lower part of thoracic
trachea; or could be an immediate rupture walled-off until the patient
became symptomatic; or the intramural hematoma gradually lysed and causing
late perforation.CONCLUSION: Although extremely rare, an oesophageal
haematoma and late complications must be considered in patients on
anti-coagulant therapy following blunt thoracic trauma and complaining only
of chest pain.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
albumin (endogenous compound)
antibiotic agent
proton pump inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
esophageal hematoma (side effect, side effect, therapy)
esophagus perforation
hematoma (side effect, side effect, therapy)
thorax blunt trauma
EMTREE MEDICAL INDEX TERMS
acidosis
aged
anticoagulant therapy
article
atrial fibrillation (drug therapy)
azygos vein
bacterial infection (complication)
case report
computer assisted tomography
conservative treatment
drug withdrawal
dysphagia
esophageal wall ischemia
esophagus disease
esophagus pressure
face injury
female
fever
human
international normalized ratio
leukocytosis
lung embolism
lung fibrosis
mycosis (complication)
nasogastric tube
parenteral nutrition
stent
tachycardia
thoracotomy
thorax pain
total parenteral nutrition
urinary tract infection
very elderly
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014840184
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ijscr.2014.04.008
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 199
TITLE
Making use of equity sensitive QALYs: A case study on identifying the worse
off across diseases
AUTHOR NAMES
Lindemark F.
Norheim O.F.
Johansson K.A.
AUTHOR ADDRESSES
(Lindemark F., frode.lindemark@igs.uib.no; Norheim O.F.,
ole.norheim@igs.uib.no; Johansson K.A., kjell.johansson@igs.uib.no)
Department of Research and Development, Haukeland University Hospital, Jonas
Liesvei 65, 5021 Bergen, Norway.
CORRESPONDENCE ADDRESS
F. Lindemark, Department of Research and Development, Haukeland University
Hospital, Jonas Liesvei 65, 5021 Bergen, Norway. Email:
frode.lindemark@igs.uib.no
SOURCE
Cost Effectiveness and Resource Allocation (2014) 12:1 Article Number: 16.
Date of Publication: 23 Jul 2014
ISSN
1478-7547 (electronic)
ABSTRACT
Background: Resource allocation decisions currently lack standard
quantitative methods for incorporating concerns about the worse off when
analysing the cost-effectiveness of medical interventions.Objective: To
explore and demonstrate how to identify who are the worse off without a new
intervention by measuring lifetime Quality-Adjusted Life Years (QALYs) for
patients across different conditions, and compare the results to using
proportional shortfall of QALYs.Methods: Case study of eight
condition-intervention pairs that are relevant to priority setting in
Norway; childhood deafness (unilateral cochlear implant), unruptured
cerebral aneurysm (coiling), morbid obesity (RY gastric bypass), adult
deafness (unilateral cochlear implant), atrial fibrillation (catheter
ablation), hip osteoarthritis (hip replacement), rheumatoid arthritis (TNF
inhibitor) and acute stroke (stroke unit). We extracted prospective QALYs
without and with new interventions from published health technology
assessments and economic evaluations.Results: Among the eight cases, the
lifetime QALY method and the proportional shortfall method yielded
conflicting worse-off rank orders. Particularly two conditions had a
substantial shift in ranking across the applications of the two methods:
childhood deafness and acute stroke. Deaf children had the lowest expected
lifetime QALYs (38.5 without a cochlear implant) and were worst off
according to the lifetime approach, while patients with acute stroke had the
second-highest lifetime QALYs (76.4 without stroke units). According to
proportional shortfall of QALYs, patients with acute stroke were ranked as
worse off than deaf children, which seems counterintuitive.Conclusion: This
study shows that it is feasible to identify who are the worse off
empirically by the application of lifetime QALYs and proportional
shortfalls. These methods ease further examination of whether there is a
true conflict between maximization and equity or whether these two concerns
actually coincide in real world cases. It is yet to be solved whether
proportional prospective health losses are more important than absolute
shortfalls in expected lifetime health in judgements about who are worse
off. © 2014 Lindemark et al.; licensee BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent (drug therapy, pharmacoeconomics)
methotrexate (drug therapy, pharmacoeconomics)
tumor necrosis factor inhibitor (drug therapy, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
quality adjusted life year
EMTREE MEDICAL INDEX TERMS
adult
adult deafness (disease management, therapy)
aged
article
atrial fibrillation (disease management, drug therapy, therapy)
brain artery aneurysm (disease management, therapy)
case study
catheter ablation
cerebrovascular accident (disease management)
child
childhood deafness (disease management, therapy)
childhood disease (disease management, therapy)
clinical article
cochlea prosthesis
coil embolization
cost effectiveness analysis
diet therapy
disability
disability severity
economic evaluation
exercise
hearing impairment (disease management, therapy)
hip arthroplasty
hip osteoarthritis (disease management, surgery)
human
morbid obesity (disease management, surgery)
Norway
patient counseling
rheumatoid arthritis (disease management, drug therapy)
Roux Y anastomosis
school child
stomach bypass
stroke unit
unruptured cerebral aneurysm (disease management, therapy)
CAS REGISTRY NUMBERS
methotrexate (15475-56-6, 59-05-2, 7413-34-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014521202
FULL TEXT LINK
http://dx.doi.org/10.1186/1478-7547-12-16
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 200
TITLE
The management of atrial fibrillation: Summary of updated NICE guidance
AUTHOR NAMES
Jones C.
Pollit V.
Fitzmaurice D.
Cowan C.
AUTHOR ADDRESSES
(Jones C., clare.jones@rcplondon.ac.uk; Pollit V.) Royal College of
Physicians, National Clinical Guideline Centre, London NW1 4LE, United
Kingdom.
(Fitzmaurice D.) Primary Care Clinical Sciences, University of Birmingham,
United Kingdom.
(Cowan C.) Department of Cardiology, Leeds General Infirmary, Leeds, United
Kingdom.
CORRESPONDENCE ADDRESS
C. Jones, Royal College of Physicians, National Clinical Guideline Centre,
London NW1 4LE, United Kingdom. Email: clare.jones@rcplondon.ac.uk
SOURCE
BMJ (Online) (2014) 348 Article Number: g3655. Date of Publication: 19 Jun
2014
ISSN
1756-1833 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, subscriptions@bmjgroup.com
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
anticoagulant agent (drug therapy)
apixaban (drug therapy)
beta adrenergic receptor blocking agent (drug combination, drug therapy)
calcium channel blocking agent (drug therapy)
dabigatran etexilate (drug therapy)
digoxin (drug combination, drug therapy)
diltiazem (drug combination, drug therapy)
nonsteroid antiinflammatory agent (drug therapy)
rivaroxaban (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, diagnosis, disease management, drug
therapy, surgery, therapy)
health care organization
National Institute for Health and Care Excellence
practice guideline
EMTREE MEDICAL INDEX TERMS
ablation therapy
age
alcohol consumption
asthma
bleeding (drug therapy)
bradycardia
cardiovascular mortality
cardiovascular risk
cardioversion
catheter ablation
cerebrovascular accident (drug therapy, prevention)
CHA2DS2 VASc score
cognition
cost effectiveness analysis
diabetes mellitus
diet
electrocardiography
has bled score
heart arrhythmia
heart atrium appendage
heart atrium flutter
heart atrium pacing
heart failure
heart left ventricle failure
heart rate
heart rhythm
human
hypertension
international normalized ratio
ischemic heart disease
palpation
patient compliance
patient referral
peripheral occlusive artery disease
peripheral vascular disease
pharmacological parameters
priority journal
recurrence risk
review
risk assessment
scoring system
sex difference
sinus rhythm
systematic review (topic)
thorax surgery
thromboembolism
time in therapeutic range
transient ischemic attack
treatment contraindication
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
apixaban (503612-47-3)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
rivaroxaban (366789-02-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2014416285
FULL TEXT LINK
http://dx.doi.org/10.1136/bmj.g3655
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 201
TITLE
11th Annual Natural Supplements Research Competition
AUTHOR ADDRESSES
SOURCE
Journal of Alternative and Complementary Medicine (2014) 20:6. Date of
Publication: June 2014
CONFERENCE NAME
11th Annual Natural Supplements Research Competition
CONFERENCE LOCATION
San Francisco, CA, United States
CONFERENCE DATE
2014-01-29 to 2014-02-01
ISSN
1075-5535
BOOK PUBLISHER
Mary Ann Liebert Inc.
ABSTRACT
The proceedings contain 9 papers. The topics discussed include: effect of
chromium dinicocysteinate supplementation on insulin resistance,
inflammation and oxidative stress in type 2 diabetic subjects: a post hoc
analysis of a double-blind, randomized, placebo-controlled trial; the
effects of homeopathic topical snake venom preparation in alleviating
muscular discomfort: a randomized, double-blind, placebo-controlled clinical
trial; an evaluation of cost versus quality in green tea dietary
supplements; too much-too fast: new onset atrial fibrillation in
bioidentical thyroid hormone supplementation; crowdsourced evidence vs.
clinical research-based evidence for rating the effectiveness of commonly
used dietary supplements; and national estimates for adult and children's
multivitamins as reported in release 2 of the dietary supplement ingredient
database (DSID).
EMTREE DRUG INDEX TERMS
chromium
multivitamin
placebo
snake venom
thyroid hormone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
competition
EMTREE MEDICAL INDEX TERMS
adult
atrial fibrillation
child
clinical research
controlled clinical trial
controlled clinical trial (topic)
controlled study
data base
diabetic patient
diet supplementation
human
inflammation
insulin resistance
oxidative stress
post hoc analysis
supplementation
tea
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 202
TITLE
3rd World Congress on Vascular Access, WoCoVA 2014
AUTHOR ADDRESSES
SOURCE
Journal of Vascular Access (2014) 15:3 (193). Date of Publication: 2014
CONFERENCE NAME
3rd World Congress on Vascular Access, WoCoVA 2014
CONFERENCE LOCATION
Berlin, Germany
CONFERENCE DATE
2014-06-18 to 2014-06-20
ISSN
1129-7298
BOOK PUBLISHER
Wichtig Publishing
ABSTRACT
The proceedings contain 155 papers. The special focus in this conference is
on Vascular Access. The topics include: A Bundle of interventions for the
safe insertion of central venous catheters in adult patients; improvement of
patient safety access for CVC – aggregation of CVC insertion and license
system at central venous catheterization (CVC) center; a descriptive study
of nerve injury related to upper arm PICC line placement; a global
prevalence study on peripheral catheters (the OMG-PIVC study); the emergency
department and peripheral cannulation; effectiveness interventions to reduce
bloodstream infection and vascular access infection in a hemodialysis unit
in Brazil; effect of a vascular access team on central-line associated
bloodstream infections in infants admitted to a neonatal intensive care
unit; a systematic review; central venous catheter placement by advanced
practice nurses demonstrates low procedural complication and infection rates
- a report from 13 years of service; beyond the bundle – health care
associated (HCA) peripheral intravenous device (PIVD) related bloodstream
infection (BSI), royal adelaide hospital (RAH) infection prevention and
control unit (IPCU) improvement intervention; descriptive study in the use
of lockings in hemodialysis catheters; benefits of ultrasound-guided early
cannulation of AV fistulas and grafts; effectiveness & acceptability of a
novel securement device in adult & teenage cancer patients with PICCs;
securing arterial lines effectively in the operating theatre and the ICU;
the accuracy of an all-in-one navigation and tip locating device based on a
real time analysis of the patients’ physiological data – ECG guidance for
CVC placement. CLB’s IV team expertise and decreasing of radiation exposure;
proposal of an algorithm for verification of tip location of central venous
access in patients with atrial fibrillation and pace-makers minimizing the
use of X-ray exposure; a new wireless device for tip location using the
intracavitary ECG technique; electrocardiographic (ECG) guidance during
implantation of femoral ports; prospective randomized trial comparing distal
(Arm Port) to central (Chest Port) technique in ambulatory cancer patients;
long-term tunneled catheter removal by nurse specialists; determining
evidence-based practice for site care; beyond the dressing for PICCs -
strategy for cost-savings and work efficiency; a multicomponent bundle to
minimize catheter-related bloodstream infection in a pediatric intensive
care unit; the quality of published central venous catheter clinical
practice guidelines; INCATIV (intravenous therapy quality indicators); the
effectiveness of a nurse-led intravenous therapy team in terms of length of
stay, venous access complications and satisfaction of patients requiring
long-term intravenous therapy; building a model central vascular access
program one change at a time; views on the value of vascular access teams –
a survey of U.S. hospital nurse leaders; a new wireless ultrasound probe for
ultrasound guided central venous access; translating vascular access
research for clinicians; the use of PICC in the peripheral blood stem cell
collection; the impact of 70% isopropyl alcohol port protection caps on
catheter related bloodstream infection in patients on home parenteral
nutrition; central vascular access for acute hemodialysis; PICCs handling in
homecare; prevalence of venous access depletion and associated risk factors
in high complexity hospitalised patients; indications and alternative for
double lumen venous ports in Europe; the economic impact of device and site
selection for peripheral artery catheterization; peripherally inserted
central catheters in children; use of peripherally inserted central
catheters in children with cancer; a new securing device to prevent
accidental dislocation of central venous access devices in non-collaborating
infants and children; assessment of guide-wire positioning in children
during insertion of the short-term central venous catheter; vascular access
training, exploitation and taking care of catheters in a new hematological
hospital; patients empowerment; Porth-A-Cath versus peripherally inserted
central catheter; a checklist for the PICC lines insertion; infections
related to central venous catheters in cancer patients; application of
association of perioperative registered nurses’ standards for bedside PICC
and CVC insertions; thromboembolic events (TE) in men treated with BEP
(Bleomycine-Etoposide-Cisplatine); the benefits of guided puncture ultrasson
and modified seldinger technique PICC in the intensive care unit; a
randomized controlled trial in the home care setting; efficiency of a CVC
insertion bundle on hospital wide Crbsi Rate - a single center report; the
role of the practice educator in facilitating expert PICC care; the use of
power PICC in the intensive care unit and its main indications in a cancer
center; a randomised experimental comparison of two safety Huber needles
(HN) allowing manual or automatic positive pressure during needle removal; a
practical pocket guide now downloadable; the formation process and
implementation of a PICC team; BED-side versus fluoroscopically guided
insertion of PICCS; the utilization of peripherally inserted central
catheter in adults and a nurse’s core formation to venous access; are
antibiotic resistant “super bugs” evaluation of a peripheral vein catheter
with blood septum; use of intravascular device assessment records for
patients admitted to sligo regional hospital – comparing risk assessments of
central line bundles used in US hospitals by applying bowtie methodology; 10
years of needless connector use – data enhanced by experience and function;
trapezius totally implantable port and skin tunnelled CVC insertion; results
of management for the 593 upper arm PICC -20,731 catheter days in single
hospital; audit process in procedures of PICC catheters passages;
complications experienced by patients that the passage of PICC catheter
underwent; arterial lines need to be part of the vascular access bundle;
starting up a midline catheter program; evaluation of peripherally inserted
central catheter (PICC) malposition rates and the impact of the Sherlock 3CG
tip confirmation system; comparison of novel TIP positioning technology
(using ECG and Doppler) and 2-D echocardiography for the placement of
central catheters; a time and motion study of peripheral venous catheter
flushing practice using manually prepared and pre-filled syringes; an
alternative procedure to improve acceptable placement of central venous
catheter tip in adults; taurolidine-citrate line locks prevent recurrent
catheter related bacteraemia - evaluation of this novel therapy in a
paediatric population; an intervention to reduce catheter related blood
stream infections in paediatric patients - a bundle of care; improving the
“global use” of ultrasound for central venous access; using smartphone
technology to calculate and monitor gravity infusions; an audit of IV
devices, practice and consumables after an organisational merger; the 1st
PICC team in Czech republic – experience of implementation of autologous
marrow transplantation by PICC line; impact of the use of micro introduction
technology in pediatric patients and newborns; the impact of the use of new
X-ray technology to ensure the best placement of catheters; SVC catheter
behavior in short trimmed catheter; evaluation of new materials “closed
system” in intravenous therapy; randomised trial comparing Hickman lines
with ports for chemotherapy; cost-effectiveness analysis of a new
CHG-dressing for preventing catheter-related bloodstream infections;
retrieval of a fractured long-term venous access device using a modified
percutaneous capturing technique; central vascular access by Tesio catheters
for chronic hemodialysis in neonates and infants; the intracavitary ECG
method for positioning the tip of central venous access devices in pediatric
patients; evaluation of the use of PICC in orthopedic patients at the day
hospital; comparison of the insertion of peripherally inserted central
catheters with ultrasound guidance and conventional methods in orthopedic
patients; evaluation of the flushing efficiency of needleless connectors
using a radioactive solution; community IV therapy – comparison of bacterial
transfer and biofilm formation on intraluminal connector-catheter systems
among eight needleless connectors in a clinically simulated in vitro model;
peripheral IV blood control catheter design and biofilm formation; on the
matter of selection of venous access systems and professionals involved in
their installation; system of medical staff preparation in Russia as a cause
of majority of complications in the treatment; the evolution of humanity and
venous access; on the selection of venous access systems and professionals
involved in their installation; experience of venous ports implantation in
patients with hunter syndrome (Mucopolysaccharidosis II Type); the mid
sternal length a practical anatomical landmark for optimal positioning of
long term central venous catheters; impact of the delay time from the use of
the ultrasonic in the insertions of central venous catheters of the
peripheral insertions; complications of peripherally inserted central
catheter in the intensive care unit; use of peripherally inserted central
catheter (PICC) in intensive care unit - epidemiological profile; a
single-incision technique for placement of implantable venous-access ports
in medial pocket via the axillary vein; ultrasonographic predictors for
feasibility of cephalic vein cut-down during totally implantable venous
access device placement; bacterial colonization of two different
antiseptic-impregnated central venous catheters in a rabbit model; the
analysis on the implementation and effect of the PICC grading management
mode; upper limb arterial tortuosity following arteriovenous fistula
formation for haemodialysis access; study outcomes of a novel sutureless
securement system; routine chest x-ray is not mandatory after
fluoroscopy-guided totally implantable venous access device insertion;
integrating performance-based needleless connector technology into clinical
practice; dressings and securement devices for central venous catheters
(CVC) and collaborative approach through simulated clinical use testing for
the development of a new safety Huber needle (SHN)
EMTREE DRUG INDEX TERMS
2 propanol
antibiotic agent
antiinfective agent
bleomycin
cisplatin
citric acid
etoposide
taurolidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
vascular access
EMTREE MEDICAL INDEX TERMS
adolescence
adult
advanced practice nurse
algorithm
arm
arterial line
arteriovenous fistula
artery
artery catheterization
atrial fibrillation
axillary vein
bacteremia
bacterial colonization
biofilm
blood
bloodstream infection
bone marrow
book
Brazil
cancer center
cancer patient
cannulation
catheter
catheter infection
catheter removal
central venous catheter
central venous catheterization
cephalic vein
checklist
chemotherapy
child
clinical practice
community
cost control
cost effectiveness analysis
Czech Republic
day hospital
devices
echocardiography
electrocardiogram
emergency ward
empowerment
Europe
evidence based practice
exposure
fluoroscopy
gravity
guide wire
health care
hemodialysis
home care
hospital
hospital infection
hospital patient
human
humanities
Hunter syndrome
implantation
in vitro study
incision
infant
infection
infection prevention
infection rate
infusion
intensive care unit
intravenous catheter
intravenous drug administration
length of stay
licence
male
medical audit
medical specialist
medical staff
methodology
model
needle
neoplasm
nerve injury
newborn
newborn intensive care
nurse
operating room
parenteral nutrition
patient
patient safety
peripheral blood stem cell
peripheral vein
peripheral venous catheter
peripherally inserted central venous catheter
population
practice guideline
prevalence
prevention and control
procedures
protection
puncture
rabbit model
radiation exposure
radioactivity
randomized controlled trial
randomized controlled trial (topic)
registered nurse
risk assessment
risk factor
Russian Federation
safety
satisfaction
skin
syringe
systematic review
systematic review (topic)
task performance
technology
therapy
thorax
thorax radiography
thromboembolism
transplantation
trapezius muscle
ultrasound
United States
X ray
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
FULL TEXT LINK
http://dx.doi.org/10.5301/jva.5000275
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 203
TITLE
Exercise-induced arterial hypertension - an independent factor for
hypertrophy and a ticking clock for cardiac fatigue or atrial fibrillation
in athletes?
AUTHOR NAMES
Leischik R.
Spelsberg N.
Niggemann H.
Dworrak B.
Tiroch K.
AUTHOR ADDRESSES
(Leischik R., info@dr-leischik.de; Spelsberg N.; Niggemann H.; Dworrak B.)
Department of Cardiology, Section of Prevention, Health Promotion and Sports
Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University,
Hagen, Germany.
(Tiroch K.) Department of Cardiology, Faculty of Health, School of Medicine,
Helios Hospital, Witten/Herdecke University, Wuppertal, Germany.
CORRESPONDENCE ADDRESS
R. Leischik, Department of Cardiology, Section of Prevention, Health
Promotion and Sports Medicine, Faculty of Health, School of Medicine,
Witten/Herdecke University, Hagen, Germany.
SOURCE
F1000Research (2014) 3 Article Number: 4001.1. Date of Publication: 12 May
2014
ISSN
1759-796X (electronic)
2046-1402
BOOK PUBLISHER
Faculty of 1000 Ltd, info@f1000.com
ABSTRACT
Background: Exercise-induced arterial hypertension (EIAH) leads to
myocardial hypertrophy and is associated with a poor prognosis. EIAH might
be related to the "cardiac fatigue"? caused by endurance training. The goal
of this study was to examine whether there is any relationship between EIAH
and left ventricular hypertrophy in Ironman-triathletes. Methods: We used
echocardiography and spiroergometry to determine the left ventricular mass
(LVM), the aerobic/anaerobic thresholds and the steady-state blood pressure
of 51 healthy male triathletes. The main inclusion criterion was the
participation in at least one middle or long distance triathlon. Results:
When comparing triathletes with LVM &<220g and athletes with LVM >220g there
was a significant difference between blood pressure values (BP) at the
anaerobic threshold (185.2± 21.5 mmHg vs. 198.8 ±22.3 mmHg, p=0.037). The
spiroergometric results were: maximum oxygen uptake (relative VO 2max) 57.3
±7.5ml/min/kg vs. 59.8±9.5ml/min/kg (p=ns). Cut-point analysis for the
relationship of BP >170 mmHg at the aerobic threshold and the probability of
LVM >220g showed a sensitivity of 95.8%, a specificity of 33.3%, with a
positive predictive value of 56.8 %, a good negative predictive value of
90%. The probability of LVM >220g increased with higher BP during exercise
(OR: 1.027, 95% CI 1.002-1.052, p= 0.034) or with higher training volume
(OR: 1.23, 95% CI 1.04 -1.47, p = 0.019). Echocardiography showed
predominantly concentric remodelling, followed by concentric hypertrophy.
Conclusion: Significant left ventricular hypertrophy with LVM >220g is
associated with higher arterial blood pressure at the aerobic or anaerobic
threshold. The endurance athletes with EIAH may require a therapeutic
intervention to at least prevent extensive stiffening of the heart muscle
and exercise-induced cardiac fatigue.
EMTREE DRUG INDEX TERMS
oxygen (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation
cardiac fatigue
exercise induced arterial hypertension
fatigue
heart hypertrophy
hypertension
EMTREE MEDICAL INDEX TERMS
adult
aerobic exercise
anaerobic exercise
article
blood pressure
controlled study
disease association
echocardiography
endurance training
ergometry
heart left ventricle hypertrophy
heart left ventricle mass
heart muscle
heart ventricle remodeling
human
major clinical study
male
muscle rigidity
oxygen consumption
physical activity
predictive value
probability
prognosis
sensitivity and specificity
steady state
CAS REGISTRY NUMBERS
oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014955152
FULL TEXT LINK
http://dx.doi.org/10.12688/f1000research.4001.1
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 204
TITLE
Heart Rhythm 2014 - 35th Annual Scientific Sessions
AUTHOR ADDRESSES
SOURCE
Heart Rhythm (2014) 11:5 SUPPL. 1. Date of Publication: May 2014
CONFERENCE NAME
35th Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm
2014
CONFERENCE LOCATION
San Francisco, CA, United States
CONFERENCE DATE
2014-05-07 to 2014-05-10
ISSN
1547-5271
BOOK PUBLISHER
Elsevier
ABSTRACT
The proceedings contain 1374 papers. The topics discussed include:
implantable defibrillator early after primary percutaneous intervention for
ST-elevation myocardial infarction: the defibrillator after primary
angioplasty (DAPA) trial; device longevity in cardiac resynchronization
therapy implantable cardioverter defibrillators differs between
manufacturers; adverse outcomes associated with lead extractions; premature
ventricular contraction-induced cardiomyopathy in children; predictors of
myocardial recovery in pediatric tachycardia-induced cardiomyopathy;
pediatric catecholaminergic polymorphic ventricular tachycardia (CPVT): a
multicenterregistry; are there any region specific differences in the
correlation between contact force and impedance fall during catheter
ablation of atrial fibrillation in humans?; and a gain-of-function mutation
of the SCN5A gene causes exercise-induced polymorphic ventricular
arrhythmias resembling CPVT.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart rhythm
society
EMTREE MEDICAL INDEX TERMS
adverse outcome
angioplasty
atrial fibrillation
cardiac resynchronization therapy
cardiomyopathy
catecholaminergic polymorphic ventricular tachycardia
catheter ablation
child
defibrillator
devices
exercise
extraction
gain of function mutation
gene
heart ventricle arrhythmia
heart ventricle extrasystole
human
impedance
implantable cardioverter defibrillator
longevity
ST segment elevation myocardial infarction
tachycardia induced cardiomyopathy
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 205
TITLE
Belgian Society of Cardiology 33rd Annual Scientific Meeting
AUTHOR ADDRESSES
SOURCE
Acta Cardiologica (2014) 69:1. Date of Publication: 2014
CONFERENCE NAME
33rd Annual Scientific Meeting of the Belgian Society of Cardiology
CONFERENCE LOCATION
Brussels, Belgium
CONFERENCE DATE
2014-01-30 to 2014-01-31
ISSN
0001-5385
BOOK PUBLISHER
Acta Cardiologica
ABSTRACT
The proceedings contain 51 papers. The topics discussed include: the
management of newly diagnosed atrial fibrillation in Belgium: data from the
international prospective GARFIELD registry; pulmonary vein isolation using
a novel multi-electrode circular catheter: first clinical experience;
episodes of subclinical atrial tachyarrhythmia are not associated with worse
outcome in cardiac resynchronization therapy patients; contact force sensing
open irrigated catheter reduces by half the early recurrence of atrial
fibrillation after pulmonary veins isolation for paroxysmal atrial
fibrillation; partial or complete isolation of the left atrial posterior
wall increase drastically the absence of AF recurrence after an index
ablation for persistent atrial fibrillation; and right ventricular fatigue
developing during endurance exercise: a real-time exercise cardiac magnetic
resonance imaging study.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
society
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
Belgium
cardiac resynchronization therapy
cardiovascular magnetic resonance
catheter
electrode
endurance training
exercise
fatigue
human
patient
pulmonary vein
pulmonary vein isolation
register
tachycardia
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 206
TITLE
Survey of the use of warfarin and the newer anticoagulant dabigatran in
patients with atrial fibrillation
AUTHOR NAMES
Choi J.C.
DiBonaventura M.D.
Kopenhafer L.
Nelson W.W.
AUTHOR ADDRESSES
(Choi J.C.) LifeScan, Inc., West Chester, PA, United States.
(DiBonaventura M.D.; Kopenhafer L.) Health Sciences Practice, Kantar Health,
New York, NY, United States.
(Nelson W.W., wnelson@its.jnj.com) Janssen Scientific Affairs LLC, Raritan,
NJ, United States.
CORRESPONDENCE ADDRESS
W. W. Nelson, Janssen Scientific Affairs, LLC, 1000 US Highway 202 South,
Raritan, NJ 08869, United States. Email: wnelson@its.jnj.com
SOURCE
Patient Preference and Adherence (2014) 8 (167-177). Date of Publication: 7
Feb 2014
ISSN
1177-889X (electronic)
BOOK PUBLISHER
Dove Medical Press Ltd, PO Box 300-008, Albany, 44 Corinthian Drive,
Albany,Auckland, New Zealand.
ABSTRACT
Background: Oral dabigatran was recently approved as an alternative to
warfarin for prevention of stroke and systemic embolism in patients with
nonvalvular atrial fibrillation. Unlike warfarin, dabigatran has a fixed
dosage and few drug interactions, and does not require anticoagulation
monitoring or dietary restrictions. Methods: This study aimed to describe
and compare characteristics of patients with atrial fibrillation who used
dabigatran or only warfarin. Patients with a self-reported diagnosis of
atrial fibrillation aged ≥18 years who were receiving (or had received)
warfarin or dabigatran completed an online survey. Differences in
characteristics of dabigatran and warfarin users were tested using
chi-squared tests and analysis of variance for categorical and continuous
variables, respectively. Results: Overall, 364 patients were surveyed (204
warfarin users, 160 dabigatran users). The mean age was 65.1 years, and
68.7% were male. Dabigatran users were more likely than warfarin users to be
female (36.9% versus 27.0%) and to have experienced adverse events,
including gastrointestinal bleeding, in the 3 months before the survey
(21.9% versus 6.9%; P<0.05). Both groups reported high medication adherence
(dabigatran users 0.65 versus warfarin users 0.63 missed doses/month).
Dabigatran users were more likely than warfarin users to discuss treatment
options with their physician before beginning therapy (36.9% versus 24.5%;
P<0.05) and less likely to switch anticoagulant medication (10.7% versus
31.9%; P<0.05). Although dabigatran users were more likely to experience
adverse events, they reported greater satisfaction with anticoagulation
treatment than warfarin users. Conclusion: The efficacy and convenience
reported by dabigatran users resulted in greater treatment satisfaction
among dabigatran users, even though adverse events decreased it. Treatment
strategies that minimize adverse events may improve treatment satisfaction
and adherence among patients with atrial fibrillation. © 2014 Choi et al.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dabigatran (adverse drug reaction, drug therapy, pharmacoeconomics)
warfarin (adverse drug reaction, drug comparison, drug therapy,
pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, disease management, drug therapy)
EMTREE MEDICAL INDEX TERMS
age distribution
aged
anticoagulant therapy
article
cerebrovascular accident (drug therapy, prevention)
Charlson Comorbidity Index
chemoprophylaxis
controlled study
cross-sectional study
disease duration
dizziness (side effect)
drug cost
drug efficacy
drug use
drug withdrawal
dyspnea (side effect)
female
gastroesophageal reflux (side effect)
gastrointestinal hemorrhage (side effect)
health insurance
health survey
heart palpitation (side effect)
heartburn (side effect)
human
indigestion (side effect)
major clinical study
male
medication compliance
nausea (side effect)
obesity
outcome assessment
patient compliance
patient decision making
patient satisfaction
sex ratio
stomach pain (side effect)
thorax pain (side effect)
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014130957
FULL TEXT LINK
http://dx.doi.org/10.2147/PPA.S56187
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 207
TITLE
Life-threatening hyperkalemia in a patient with normal renal function
AUTHOR NAMES
Ayach T.
Nappo R.W.
Paugh-Miller J.L.
Ross E.A.
AUTHOR ADDRESSES
(Ayach T.; Paugh-Miller J.L.; Ross E.A., rossea@medicine.ufl.edu) Division
of Nephrology, Hypertension and Renal Transplantation, University of
Florida, Gainesville, FL, United States.
(Nappo R.W.) Shands Hospital, University of Florida, Gainesville, FL, United
States.
CORRESPONDENCE ADDRESS
E.A. Ross, Division of Nephrology, Hypertension and Renal Transplantation,
University of Florida, Gainesville, FL, United States. Email:
rossea@medicine.ufl.edu
SOURCE
Clinical Kidney Journal (2014) 7:1 (49-52). Date of Publication: February
2014
ISSN
2048-8505
2048-8513 (electronic)
BOOK PUBLISHER
Oxford University Press, Great Clarendon Street, Oxford, United Kingdom.
ABSTRACT
With media focus on benefits from reducing sodium intake, there is increased
popularity of salt substitutes, typically potassium chloride. While viewed
by the public as a healthy alternative to standard table salt, less
appreciated is the severe risk with certain comorbidities and medications.
We report the case of an elderly female with chronically high salt
substitute intake, normal renal function, diabetes, hypertension treated
with angiotensin-converting enzyme inhibitor and beta blockade, who
developed life-threatening hyperkalemia after a minimally invasive
outpatient procedure. We describe the pathophysiology of the disruption in
potassium homeostasis and emphasize the importance of dietary history and
educating high-risk patients to avoid salt substitutes. © The Author 2013.
Published by Oxford University Press on behalf of ERA-EDTA. All rights
reserved. For permissions, please email: journals.permissions@oup.com.
EMTREE DRUG INDEX TERMS
amiodarone
atropine (intravenous drug administration)
bicarbonate (drug therapy)
chloride (endogenous compound)
furosemide (drug therapy)
gluconate calcium (drug therapy)
insulin (intravenous drug administration)
metoprolol
oral antidiabetic agent
potassium (endogenous compound)
quinapril
sodium (endogenous compound)
sodium chloride (intravenous drug administration)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hyperkalemia (drug therapy, drug therapy)
kidney function
life threat
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
atrioventricular junction arrhythmia
bradycardia
case report
chloride blood level
fatigue
female
follow up
heart right bundle branch block
hemodialysis
human
hypertension
kyphoplasty
lethargy
limb weakness
non insulin dependent diabetes mellitus
P wave
potassium blood level
priority journal
QRS complex
respiratory tract intubation
salt intake
sodium blood level
spine fracture
vomiting
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atropine (51-55-8, 55-48-1)
bicarbonate (144-55-8, 71-52-3)
chloride (16887-00-6)
furosemide (54-31-9)
gluconate calcium (299-28-5)
insulin (9004-10-8)
metoprolol (37350-58-6)
potassium (7440-09-7)
quinapril (82586-55-8, 85441-61-8)
sodium (7440-23-5)
sodium chloride (7647-14-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Urology and Nephrology (28)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014077071
FULL TEXT LINK
http://dx.doi.org/10.1093/ckj/sft151
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 208
TITLE
Yoga and meditation in cardiovascular disease
AUTHOR NAMES
Manchanda S.C.
Madan K.
AUTHOR ADDRESSES
(Manchanda S.C., doctormanchanda@yahoo.com; Madan K.) Dharma Vira Heart
Center, Sir Ganga Ram Hospital, New Delhi 110060, India.
CORRESPONDENCE ADDRESS
S.C. Manchanda, Dharma Vira Heart Center, Sir Ganga Ram Hospital, New Delhi
110060, India. Email: doctormanchanda@yahoo.com
SOURCE
Clinical Research in Cardiology (2014) 103:9 (675-680). Date of Publication:
September 2014
ISSN
1861-0692 (electronic)
1861-0684
BOOK PUBLISHER
Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
Yoga is a holistic mind-body intervention aimed at physical, mental,
emotional and spiritual well being. Several studies have shown that yoga
and/or meditation can control risk factors for cardiovascular disease like
hypertension, type II diabetes and insulin resistance, obesity, lipid
profile, psychosocial stress and smoking. Some randomized studies suggest
that yoga/meditation could retard or even regress early and advanced
coronary atherosclerosis. A recent study suggests that transcendental
meditation may be extremely useful in secondary prevention of coronary heart
disease and may reduce cardiovascular events by 48 % over a 5-year period.
Another small study suggests that yoga may be helpful in prevention of
atrial fibrillation. However, most studies have several limitations like
lack of adequate controls, small sample size, inconsistencies in baseline
and different methodologies, etc. and therefore large trials with improved
methodologies are required to confirm these findings. However, in view of
the existing knowledge and yoga being a cost-effective technique without
side effects, it appears appropriate to incorporate yoga/meditation for
primary and secondary prevention of cardiovascular disease. © 2014
Springer-Verlag.
EMTREE DRUG INDEX TERMS
procoagulant
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (prevention)
meditation
yoga
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (prevention)
body weight
cardiovascular risk
coronary artery atherosclerosis
cost effectiveness analysis
disease control
heart arrhythmia
heart rehabilitation
human
hypertension
insulin resistance
ischemic heart disease (prevention)
lipid analysis
mental stress
non insulin dependent diabetes mellitus
obesity
oxidative stress
prophylaxis
review
secondary prevention
smoking
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014541175
MEDLINE PMID
24464106 (http://www.ncbi.nlm.nih.gov/pubmed/24464106)
FULL TEXT LINK
http://dx.doi.org/10.1007/s00392-014-0663-9
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 209
TITLE
High level of education, healthy diet and moderate consumption of alcohol
are associated with lower odds for first-ever ischemic stroke in hospital
based case-control study in Varaždin County, Croatia
AUTHOR NAMES
Pikija S.
Lukić A.
Vrček E.
Malojčić B.
Juvan L.
Kudelić N.
Štefinšćak M.
Kujundžić S.
Trkulja V.
AUTHOR ADDRESSES
(Pikija S., spikija@gmail.com) Department of Neurology, Bezirkkrankenhaus
Lienz, von Hibler-Strasse 5, Lienz, Austria.
(Lukić A.; Juvan L.) Department of Anesthesiology, Resuscitation and
Intensive Care, Varaždin General Hospital, Varaždin, Croatia.
(Vrček E.) Department of Neurology, Varaždin General Hospital, Varaždin,
Croatia.
(Malojčić B.) Clinical Department of Neurology, Zagreb University Hospital
Center, Zagreb, Croatia.
(Kudelić N.; Štefinšćak M.) Department of Internal Medicine, General
Hospital Varaždin, Varaždin, Croatia.
(Kujundžić S.) General Practitioner Office Novi Marof, Croatia.
(Trkulja V.) Department of Pharmacology, School of Medicine, University of
Zagreb, Zagreb, Croatia.
CORRESPONDENCE ADDRESS
S. Pikija, Department of Neurology, Bezirkkrankenhaus Lienz, von
Hibler-Strasse 5, Lienz, Austria.
SOURCE
Neurologia Croatica (2014) 63:3-4 (73-80). Date of Publication: 2014
ISSN
0353-8842
BOOK PUBLISHER
University Hospital School of Medicine Zagreb
ABSTRACT
Croatia, a Central European middle-income country, has the highest incidence
of first-ever stroke in Europe. Th is prompted us to search for preventable
and/or treatable risk factors for ischemic stroke. We performed a
case-control study of first-ever ischemic stroke. Cases were patients with
first-ever ischemic stroke. Controls were free from stroke and were matched
to patients. All participants or their proxies were asked to fill in a
questionnaire. Biometrics and laboratory values were collected. Odds ratios
(ORs) were calculated for the association of stroke with selected risk
factors. We enrolled 219 stroke cases from Varaždin General Hospital and 144
hospital and community controls. Th e risk factors significantly associated
with higher odds for stroke were atrial fibrillation (OR 10.35, 95% CI
3.96-27.06) and current smoking (OR 4.53, 95% CI 1.45-14.17). Arterial
hypertension was not associated with higher odds for stroke. Protective
factors were education higher than high school (OR 0.36, 95% CI 0.15-0.89),
healthy diet (OR 0.40, 95% CI 0.18-0.89), high HDL cholesterol (OR 0.14, 95%
CI 0.06-0.33) and in the second model without adjustment for laboratory
values alcohol intake of 1-30 drinks per month (OR 0.51, 95% CI 0.29-0.89).
Anticoagulant therapy for atrial fibrillation, promotion of more healthy
diet patterns and smoking cessation seem to be the targets for prevention of
ischemic stroke in the population of Varaždin County, Croatia.
EMTREE DRUG INDEX TERMS
high density lipoprotein cholesterol (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
triacylglycerol (endogenous compound)
uric acid (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alcohol consumption
brain ischemia (prevention)
diet
educational status
first ever ischemic stroke (prevention)
EMTREE MEDICAL INDEX TERMS
aged
anticoagulant therapy
article
atrial fibrillation
biometry
cholesterol blood level
controlled study
Croatia
high school
hospital based case control study
human
hypertension
major clinical study
multicenter study
prospective study
risk factor
smoking
smoking cessation
triacylglycerol blood level
uric acid blood level
waist circumference
CAS REGISTRY NUMBERS
uric acid (69-93-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Internal Medicine (6)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015292704
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 210
TITLE
Critical conversations after coronary artery bypass grafting: Balancing the
evidence and dealing with uncertainty
AUTHOR ADDRESSES
SOURCE
Circulation: Cardiovascular Quality and Outcomes (2014) 7:5 (783-784). Date
of Publication: 1 Sep 2014
ISSN
1941-7705 (electronic)
1941-7713
BOOK PUBLISHER
Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary artery bypass graft
EMTREE MEDICAL INDEX TERMS
anxiety
arm pain
atrial fibrillation (complication)
blood pressure monitoring
cardiologist
doctor patient relation
electrocardiogram
exercise
home monitoring
human
jaw pain
meditation
postoperative period
practice guideline
priority journal
short survey
spiritual care
systolic blood pressure
Taoism
thorax pain
white coat hypertension
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2015863785
MEDLINE PMID
25097212 (http://www.ncbi.nlm.nih.gov/pubmed/25097212)
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCOUTCOMES.114.000951
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 211
TITLE
Plasma natriuretic peptides and incidence of subtypes of ischemic stroke
AUTHOR NAMES
Berntsson J.
Zia E.
Borné Y.
Melander O.
Hedblad B.
Engström G.
AUTHOR ADDRESSES
(Berntsson J., john.berntsson@med.lu.se; Zia E.; Borné Y.; Melander O.;
Hedblad B.; Engström G.) Department of Clinical Sciences in Malmö, Lund
University, House 60, Level 13, SE-20502 Malmo, Sweden.
SOURCE
Cerebrovascular Diseases (2014) 37:6 (444-450). Date of Publication: 2014
ISSN
1421-9786 (electronic)
1015-9770
BOOK PUBLISHER
S. Karger AG
ABSTRACT
Background and Purpose: Natriuretic peptides predict poor outcomes in
cardiovascular disease. However, the knowledge of their relationship to
stroke is limited and prospective studies from the general population are
few. The purpose of this study was to explore the relationship between
N-terminal pro-brain natriuretic peptide (NT-proBNP) and midregional
pro-atrial natriuretic peptide (MR-proANP) plasma levels and the risk for
ischemic stroke and its subtypes. Methods: NT-proBNP and MR-proANP were
measured in fasting blood samples from 4,862 subjects (40.2% men, mean age
57.5 ± 6.0 years) without cardiovascular disease from the Malmö Diet and
Cancer Study, a prospective, population-based study in Sweden. Incidence of
ischemic stroke was monitored over a mean follow-up of 14.9 ± 3.0 years.
Stroke cases were etiologically classified according to the TOAST
classification. Cox proportional-hazards regression was used to study the
incidence of stroke in relationship to NT-proBNP and MR-proANP. Results:
During follow-up, 227 had a first-ever ischemic stroke (large-artery
atherosclerosis, n = 35; cardioembolic stroke, n = 44; small-artery
occlusion, n = 80; undetermined cause, n = 68). In the age-and sex-adjusted
model, only NT-proBNP was associated with total ischemic stroke. This
association was completely explained by an increased incidence of
cardioembolic stroke. Adjusted for cardiovascular risk factors (age, sex,
hypertension, diabetes, smoking, body mass index and low-density lipoprotein
cholesterol), the hazard ratios (HRs, 95% confidence interval, 95% CI) for
cardioembolic stroke were 1.00 (reference), 1.42 (0.34-6.00), 2.79
(0.77-10.12) and 5.64 (1.66-19.20), respectively, for the 1st, 2nd, 3rd and
4th quartiles of NT-proBNP. The corresponding HRs (95% CIs) for quartiles of
MR-proANP were 1.00 (reference), 1.83 (0.55-6.14), 1.20 (0.33-4.34) and 3.96
(1.31-11.99), respectively. In total, 335 (6.9%) subjects were diagnosed
with atrial fibrillation during follow-up. Among the cardioembolic stroke
cases, 30% were diagnosed with atrial fibrillation before the stroke event
and another 36% within 6 months after the stroke. Of the cardioembolic
stroke cases with atrial fibrillation, 59% were in the top quartile of
NT-proBNP, 69% in the top quartile of MR-proANP and 79% were either in the
top quartile of NT-proBNP or in the top quartile of MR-proANP. Conclusion:
High plasma levels of NT-proBNP and MR-proANP are associated with a
substantially increased risk of cardioembolic stroke, but not with other
subtypes of ischemic stroke. The results suggest that assessment of stroke
risk, including electrocardiography, is warranted in subjects with high
NT-proBNP or MR-proANP.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
natriuretic factor (endogenous compound)
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide (endogenous compound)
atrial natriuretic factor (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
midregional pro atrial natriuretic peptide (endogenous compound)
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia
EMTREE MEDICAL INDEX TERMS
adult
aged
artery occlusion
article
atrial fibrillation
blood level
blood sampling
body mass
brain atherosclerosis
cardioembolic stroke
cardiovascular risk
diabetes mellitus
female
follow up
human
hypertension
incidence
major clinical study
male
priority journal
proportional hazards model
smoking
treatment duration
CAS REGISTRY NUMBERS
atrial natriuretic factor (85637-73-6)
natriuretic factor (9088-07-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015968074
FULL TEXT LINK
http://dx.doi.org/10.1159/000363279
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 212
TITLE
A comparative study of outcomes for endoscopic diverticulotomy versus
external diverticulectomy
AUTHOR NAMES
Shahawy S.
Janisiewicz A.M.
Annino D.
Shapiro J.
AUTHOR ADDRESSES
(Shahawy S.) Harvard Medical School, Boston, United States.
(Janisiewicz A.M.) Rhinology, Otolaryngology Head and Neck Surgery, Kaiser
Permanente, Irvine, United States.
(Annino D.; Shapiro J., Jshapiro@partners.org) Department of Otology and
Laryngology, Harvard Medical School and Department of Surgery, Brigham and
Women's Hospital, Boston, United States.
CORRESPONDENCE ADDRESS
J. Shapiro, Brigham and Womens Hospital, Division of Otolaryngology, 45
Francis St., Boston, United States.
SOURCE
Otolaryngology - Head and Neck Surgery (United States) (2014) 151:4
(646-651). Date of Publication: 12 Oct 2014
ISSN
1097-6817 (electronic)
0194-5998
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Objectives. Current literature on the treatment of Zenkers diverticulum (ZD)
favors the use of various endoscopic procedures over external surgical
techniques for patients, arguing that endoscopic approaches reduce
intraoperative time and anesthesia, length of hospital stay, and days until
oral diet is restarted. However, such techniques often have higher
symptomatic recurrence rates and require further interventions. Because of
our experience with both endoscopic diverticulotomy (ENDO) and external
diverticulectomy (EXT) using the GIA-stapler, we sought to compare these 2
procedures in terms of in-hospital parameters, complications, return to
normal diet, and rates of symptom recurrence.Study Design. Case series with
chart review.Setting. Academic tertiary care hospital.Subjects. Patients
with Zenkers diverticulum who underwent surgical repair.Methods.
Retrospective analysis of 67 patients seen at Brigham and Womens Hospital
between 1990 and 2012 with Zenkers diverticulum who underwent either an
endoscopic Zenkers procedure (36) or an external staplerassisted
diverticulectomy with cricopharyngeal myotomy (31).Results. Although the
external stapler-assisted procedure for ZD does carry a longer
intraoperative time and a slightly longer hospital stay than the endoscopic
approach, it provides similar days until initiation of an oral diet and a
similar incidence of postoperative complications. Further, it is superior to
the endoscopic approach when one considers its much lower rate of
symptomatic recurrence and need for revision procedures.Conclusion. We argue
that the external stapler-assisted diverticulectomy with cricopharyngeal
myotomy should be considered as a viable treatment in patients who need
definitive, single-session treatment for ZD, especially to prevent
lifethreatening aspiration pneumonia.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
endoscopic diverticulotomy
endoscopic surgery
esophagus surgery
external diverticulectomy
outcome assessment
EMTREE MEDICAL INDEX TERMS
abdominal pain (complication)
adult
aged
article
atrial fibrillation (complication)
bradycardia (complication)
bronchospasm (complication)
carbon dioxide laser
case study
diarrhea (complication)
diet
esophagus myotomy
esophagus perforation (complication)
esophagus stenosis (complication)
female
fever (complication)
follow up
gastrointestinal stapler
hospitalization
human
intermethod comparison
length of stay
major clinical study
male
medical record review
operation duration
pneumonia (complication)
postoperative pain (complication)
recurrent disease
retrospective study
tertiary care center
thorax pain (complication)
urine retention (complication)
vocal cord paralysis (complication)
Zenker diverticulum (surgery)
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Biophysics, Bioengineering and Medical Instrumentation (27)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014895631
FULL TEXT LINK
http://dx.doi.org/10.1177/0194599814541920
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 213
TITLE
Could some geriatric characteristics hinder the prescription of
anticoagulants in atrial fibrillation in the elderly?
AUTHOR NAMES
Denoël P.
Vanderstraeten J.
Mols P.
Pepersack T.
AUTHOR ADDRESSES
(Denoël P., doc.vds@gmail.com) Emergency Service, Europe Hospital, Brussels,
Belgium.
(Vanderstraeten J., jacques.vanderstraeten@ulb.ac.be) Centre de Recherche en
Santé Environnementale et en Santé du Travail, Ecole de Santé Publique,
Université Libre de Bruxelles, Brussels, Belgium.
(Mols P., pierre.mols@gmail.com) Emergency Service, Saint-Pierre University
Hospital, Université Libre de Bruxelles, Brussels, Belgium.
(Pepersack T., thierry.pepersack@erasme.ulb.ac.be) Department of Geriatrics,
Erasme Hospital, Université Libre de Bruxelles, Lennik Street 808, Brussels,
Belgium.
CORRESPONDENCE ADDRESS
T. Pepersack, Department of Geriatrics, Erasme Hospital, Université Libre de
Bruxelles, Lennik Street 808, Brussels, Belgium.
SOURCE
Journal of Aging Research (2014) 2014 Article Number: 693740. Date of
Publication: 2014
ISSN
2090-2212 (electronic)
2090-2204
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
Several studies have reported underprescription of anticoagulants in atrial
fibrillation (AF). We conducted an observational study on 142 out of a total
of 995 consecutive ≥75 years old patients presenting AF (14%) when admitted
in an emergency unit of a general hospital, in search of geriatric
characteristics that might be associated with the underprescription of
anticoagulation therapy (mostly antivitamin K at the time of the study). The
following data was collected from patients presenting AF: medical history
including treatment and comorbidities, CHADS2 score, ISAR scale (frailty),
Lawton's scale (ADL), GDS scale (mood status), MUST (nutrition), and blood
analysis (INR, kidney function, and albumin). Among those patients for who
anticoagulation treatment was recommended (73%), only 61% were treated with
it. In the group with anticoagulation therapy, the following characteristics
were observed more often than in the group without such therapy: a recent
(≤6 months) hospitalization and medical treatment including digoxin or based
on >3 different drugs. Neither the value of the CHADS2 score, nor the
geriatric characteristics could be correlated with the presence or the
absence of an anticoagulation therapy. More research is thus required to
identify and clarify the relative importance of patient-, physician-, and
health care system-related hurdles for the prescription of oral
anticoagulation therapy in older patients with AF.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy)
EMTREE DRUG INDEX TERMS
acenocoumarol (drug combination, drug therapy)
acetylsalicylic acid (drug combination, drug therapy)
albumin (endogenous compound)
antivitamin K (drug therapy)
digoxin
low molecular weight heparin (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
atrial fibrillation (epidemiology)
elderly care
prescription
EMTREE MEDICAL INDEX TERMS
aged
albumin blood level
article
CHADS2 score
comorbidity
controlled study
daily life activity
frail elderly
hospitalization
human
international normalized ratio
kidney function
major clinical study
mood
nutrition
observational study
prevalence
priority journal
thromboembolism (complication, drug therapy, prevention)
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015136289
FULL TEXT LINK
http://dx.doi.org/10.1155/2014/693740
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 214
TITLE
Correlation of atrial fibrillation with SCN5A and KCNE1 gene polymorphism in
chongming adults of Shanghai
AUTHOR NAMES
Lu Y.
Huang C.
Huang D.
Luo X.
Hou S.
AUTHOR ADDRESSES
(Lu Y.; Huang C.) Department of Cardiology, Renmin Hospital, Institute of
Cardiology, Wuhan University, Wuhan, Hubei, China.
(Huang D.; Luo X.; Hou S.) Department of Cardiology, Affiliated Xinhua
Hospital of Shanghai Jiaotong University in Chongming, Shanghai, China.
CORRESPONDENCE ADDRESS
C. Huang, Department of Cardiology, Renmin Hospital, Institute of
Cardiology, Wuhan University, No. 238 Jiefang Road, Wuhan, Hubei, China.
SOURCE
(2014) 30:6 (1311-1316). Date of Publication: 2014
ISSN
0393-6384
BOOK PUBLISHER
Acta Medica Mediterranea
ABSTRACT
Aims: To investigate the correlation of atrial fibrillation (AF) with
SCN5A-A1673G and KCNE1-A112G gene polymorphism in Chongming adults of
Shanghai. Materials and methods: Cluster random sampling was performed in 18
communities of 18 villages, and inhabitants aged >20 years were screened. A
total of 122 patients with AF who were recruited from this epidemiological
study served as case group, and 122 subjects without AF from the same study
served as controls. These subjects were recruited for case-control study at
a ratio of 1:1. Polymerase chain reaction - restriction endonuclease
fragment length polymorphism (PCR-RFLP) was performed to detect the SCN5A
-A1673G and KCNEl-A112G (S38G) gene polymorphism for genotyping. Samples
were randomly selected for sequencing to evaluate the reliability. SPSS
version 17.0 was used for statistical analysis. The genotype frequency and
Hardy-Weinberg equilibrium were evaluated. Chi square test was performed to
compare the genotypes and allele frequency. A value of P < 0.05 was
considered statistically significant. Multivariate logistic regression
analysis was employed to assess the correlation of AF and gene polymorphism.
Results: There were 3 genotypes of SCN5A-A1673G in the subjects
investigated: AA genotype (38.33% vs. 58.33%), AG (45% vs. 30.83%) and GG
(16.67% vs. 10.83%). In case group, G allele frequency was significantly
higher than that in control group (39.17% vs. 26.25%), and GG genotype
significantly influenced the AF (P < 0.05). Logistic regression analysis
showed G allele was associated with AF (R=1.46, 95%CI: 1.38-1.54). There
were 3 genotypes of KCNEl-A112G in the subjects investigated: AA genotype
(13.33% vs. 11.67%), AG genotype (25% vs. 38.33%) and GG genotype (61.67%
vs. 50%). The frequency of GG genotype in case group was markedly higher
than that in control group. The distribution of genotypes was different
between 2 groups without statistical significance (P > 0.05). Conclusion: In
Han Chinese of Chongming in Shanghai, AF is associated with SCN5A-A1673G
gene polymorphism, but not with KCNE1-A112G (S38G) gene polymorphism.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
potassium channel KCNE1 (endogenous compound)
sodium channel Nav1.5 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis)
DNA polymorphism
EMTREE MEDICAL INDEX TERMS
adult
agar gel electrophoresis
article
case control study
chi square test
controlled study
correlation analysis
female
gene frequency
gene sequence
genotype
Han Chinese
human
major clinical study
male
multivariate logistic regression analysis
polymerase chain reaction
restriction fragment length polymorphism
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Human Genetics (22)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014901049
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 215
TITLE
Approach to the new oral anticoagulants in family practice: Part 2:
Addressing frequently asked questions
ORIGINAL (NON-ENGLISH) TITLE
Approche à l'égard des nouveaux anticoagulants oraux en pratique familiale:
2e partie : Répondre aux questions souvent posées
AUTHOR NAMES
Douketis J.
Bell A.D.
Eikelboom J.
Liew A.
AUTHOR ADDRESSES
(Douketis J., jdouket@mcmaster.ca; Eikelboom J.; Liew A.) Department of
Medicine, McMaster University, 50 Charlton Ave E, Hamilton, Canada.
(Bell A.D.) Department of Family and Community Medicine, University of
Toronto, Canada.
CORRESPONDENCE ADDRESS
J. Douketis, Department of Medicine, McMaster University, 50 Charlton Ave E,
Hamilton, Canada.
SOURCE
Canadian Family Physician (2014) 60:11 (997-1001 and e512-e517). Date of
Publication: 1 Nov 2014
ISSN
0008-350X
BOOK PUBLISHER
College of Family Physicians of Canada
ABSTRACT
Objective To address common "what if" questions that arise relating to the
long-term clinical follow-up and management of patients receiving the new
oral anticoagulants (NOACs).Sources of information For this narrative
review, we searched the PubMed database for recent (January 2008 to week 32
of 2013) clinical studies relating to NOAC use for stroke prevention in
atrial fibrillation and for the treatment of acute venous thromboembolism.
We used this evidence base to address prespecified questions relating to
NOAC use in primary care settings.Main message Dabigatran and rivaroxaban
should be taken with meals to decrease dyspepsia and increase absorption,
respectively. There are no dietary restrictions with any of the NOACs,
beyond moderating alcohol intake, and rivaroxaban and apixaban can be
crushed if required. The use of acid suppressive therapies does not appear
to affect the efficacy of the NOACs. As with warfarin, patients taking NOACs
should avoid long-term use of nonsteroidal anti-i flammatory and
antiplatelet drugs. For patients requiring surgery, generally NOACs should
be stopped 2 to 5 days before the procedure, depending on bleeding risk, and
the NOAC should usually be resumed at least 24 hours after surgery.
Preoperative coagulation testing is generally unnecessary. In patients who
develop bleeding, minor bleeding typically does not require laboratory
testing or discontinuation of NOACs; with major bleeding, the focus should
be on local measures to control the bleeding and supportive care, and
coagulation testing should be performed. There are currently no antidotes to
reverse NOACs. The NOACs should not be used in patients with valvular heart
disease, prosthetic heart valves, cancer-associated deep vein thrombosis, or
superficial thrombophlebitis.Conclusion Management of "what if" scenarios
for patients taking NOACs have been proposed, but additional study is needed
to address these issues, especially periprocedural management and bleeding.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (adverse drug reaction, drug combination, drug
interaction, drug therapy, oral drug administration)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination, drug interaction)
alcohol
antithrombocytic agent (drug combination, drug interaction)
dabigatran (drug therapy, oral drug administration)
heparin
metformin (drug therapy)
nonsteroid antiinflammatory agent (drug combination, drug interaction)
paracetamol (drug combination, drug interaction)
ramipril (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
general practice
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome (complication)
acute disease (drug therapy)
aged
alcohol consumption
atrial fibrillation
bleeding (complication, side effect, therapy)
blood clotting test
case report
cerebrovascular accident (complication, drug therapy, prevention)
chronic disease
colon polyp (surgery)
colonoscopy
deep vein thrombosis (complication)
dental procedure
drug contraindication
drug efficacy
drug use
drug withdrawal
dyspepsia (side effect)
erythrocyte transfusion
fluid therapy
follow up
gastrointestinal clip
heart valve prosthesis
human
hypertension (drug therapy)
kidney function
long term care
male
malignant neoplastic disease
meal
non insulin dependent diabetes mellitus
obesity
polypectomy
preoperative evaluation
primary medical care
review
superficial thrombophlebitis
surgical risk
valvular heart disease
venous thromboembolism (drug therapy)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alcohol (64-17-5)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
metformin (1115-70-4, 657-24-9)
paracetamol (103-90-2)
ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English, French
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
2014918895
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 216
TITLE
Thrombocytopenia induced by a taurine-containing energy drink: An adverse
reaction to herbal medicine
AUTHOR NAMES
Pasin F.
Porro E.
Frattini F.
Vescovi P.
Franchini M.
Sansoni P.
AUTHOR ADDRESSES
(Pasin F., f.pasin@ospedale.cremona.it) Department of General Medicine,
Hospital Institutes of Cremona, viale Concordia 1, Cremona, Italy.
(Porro E.; Sansoni P.) Department of Clinical and Experimental Medicine,
University of Parma, Parma, Italy.
(Frattini F.; Vescovi P.) Medical Department, AO Carlo Poma, Mantova, Italy.
(Franchini M.) Department of Laboratory Medicine, AO Carlo Poma, Mantova,
Italy.
CORRESPONDENCE ADDRESS
F. Pasin, Department of General Medicine, Hospital Institutes of Cremona,
viale Concordia 1, Cremona, Italy.
SOURCE
Italian Journal of Medicine (2014) 8:4 (259-261). Date of Publication: 2014
ISSN
1877-9352 (electronic)
1877-9344
BOOK PUBLISHER
Page Press Publications, via Giuseppe Belli, Pavia, Italy.
ABSTRACT
Thrombocytopenia is a well-recognized adverse effect of many drugs. The
association of thrombocytopenia with herbal remedies, nutritional
supplements, foods and beverages, complementary or alternative medicines,
has been rarely described. There are reports of thrombocytopenia caused by
quinine-containing beverages, cow's milk, cranberry juice, Jui, a Chinese
herbal tea, Lupinus termis bean and tahini. A definite evidence of a causal
association with thrombocytopenia is warranted; nevertheless not always
there is provided probable or possible evidence in the association with
thrombocytopenia. We report the first case, to our knowledge, of
thrombocytopenia induced by taurine, present in an energy drink prescribed
to our patient as tonic treatment.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
herbaceous agent (drug toxicity)
taurine (drug toxicity)
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
complement component C3 (endogenous compound)
complement component C4 (endogenous compound)
guarana extract
methylprednisolone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
energy drink
herbal medicine
thrombocytopenia (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
aged
anticoagulant therapy
atrial fibrillation (drug therapy)
case report
ecchymosis
echocardiography
Eleutherococcus
erythrocyte count
female
follow up
heart hypertrophy
human
international normalized ratio
laboratory test
mitral valve prosthesis
petechia
prothrombin time
review
thrombocyte count
very elderly
CAS REGISTRY NUMBERS
complement component C3 (80295-41-6)
complement component C4 (80295-48-3, 80295-71-2)
methylprednisolone (6923-42-8, 83-43-2)
taurine (107-35-7)
EMBASE CLASSIFICATIONS
Hematology (25)
Drug Literature Index (37)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014615786
FULL TEXT LINK
http://dx.doi.org/10.4081/itjm.2014.466
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 217
TITLE
New once-weekly treatment for type 2 DM
AUTHOR NAMES
Wheeler K.
AUTHOR ADDRESSES
(Wheeler K.)
CORRESPONDENCE ADDRESS
K. Wheeler,
SOURCE
Drug Topics (2014) :SEP 2014. Date of Publication: 15 Sep 2014
ISSN
1937-8157 (electronic)
0012-6616
BOOK PUBLISHER
Advanstar Communications Inc., info@advanstar.com
EMTREE DRUG INDEX TERMS
2,4 thiazolidinedione derivative (drug therapy)
albiglutide (adverse drug reaction, clinical trial, drug therapy,
subcutaneous drug administration)
hemoglobin A1c (endogenous compound)
insulin glargine (drug therapy)
insulin lispro (drug therapy)
liraglutide (drug therapy)
metformin (drug therapy)
sulfonylurea (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
non insulin dependent diabetes mellitus (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (side effect)
backache (side effect)
coughing (side effect)
diet
drug efficacy
drug safety
exercise
gastrointestinal symptom (side effect)
glycemic control
hoarseness (side effect)
human
hypoglycemia (side effect)
influenza (side effect)
injection site reaction (side effect)
pancreatitis (side effect)
sinusitis (side effect)
stomach emptying
thyroid medullary carcinoma (side effect)
thyroid tumor (side effect)
upper respiratory tract infection (side effect)
DRUG TRADE NAMES
tanzeum Glaxo SmithKline
CAS REGISTRY NUMBERS
albiglutide (782500-75-8)
hemoglobin A1c (62572-11-6)
insulin glargine (160337-95-1)
insulin lispro (133107-64-9)
liraglutide (204656-20-2)
metformin (1115-70-4, 657-24-9)
EMBASE CLASSIFICATIONS
Drug Literature Index (37)
Adverse Reactions Titles (38)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2014807235
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 218
TITLE
Cognitive impairment and dementia in Type 2 diabetes
AUTHOR NAMES
Bruce D.G.
AUTHOR ADDRESSES
(Bruce D.G., David.Bruce@uwa.edu.au) School of Medicine and Pharmacology,
Fremantle Hospital, PO Box 480, Fremantle, Australia.
CORRESPONDENCE ADDRESS
D.G. Bruce, School of Medicine and Pharmacology, Fremantle Hospital, PO Box
480, Fremantle, Australia.
SOURCE
Diabetes Management (2014) 4:6 (467-469). Date of Publication: 1 Oct 2014
ISSN
1758-1915 (electronic)
1758-1907
BOOK PUBLISHER
Future Medicine Ltd., info@futuremedicine.com
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cognitive defect
dementia
non insulin dependent diabetes mellitus
EMTREE MEDICAL INDEX TERMS
adverse outcome
Alzheimer disease
atrial fibrillation
Australia
brain infarction
cerebrovascular disease
chronic lung disease
cognition
diabetic patient
diseases
glycemic control
hospital admission
human
hyperglycemia
hypertension
hypoglycemia
lifestyle modification
Mediterranean diet
multiinfarct dementia
neuropathology
patient compliance
physical activity
review
risk factor
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2014954519
FULL TEXT LINK
http://dx.doi.org/10.2217/dmt.14.37
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 219
TITLE
Prevention of ischemic stroke in clinical practice: A role of internists and
general practitioners
AUTHOR NAMES
Niewada M.
Członkowska A.
AUTHOR ADDRESSES
(Niewada M., maciej.niewada@wum.edu.pl; Członkowska A.) Department of
Experimental and Clinical Pharmacology, Medical University of Warsaw, ul.
Banacha 1b, Warszawa, Poland.
(Niewada M., maciej.niewada@wum.edu.pl; Członkowska A.) 2nd Neurological
Department, Institute of Psychiatry and Neurology, Warsaw, Poland.
CORRESPONDENCE ADDRESS
M. Niewada, Department of Experimental and Clinical Pharmacology, Medical
University of Warsaw, ul. Banacha 1b, Warszawa, Poland.
SOURCE
Polskie Archiwum Medycyny Wewnetrznej (2014) 124:10 (540-548). Date of
Publication: 2014
ISSN
1897-9483 (electronic)
0032-3772
BOOK PUBLISHER
Medycyna Praktyczna, listy@mp.pl
ABSTRACT
Stroke constitutes a substantial clinical and socio-economic burden. It is
currently the third cause of death worldwide and results in mortality or
disability in every third patient at the end of the first year following an
acute cerebrovascular event. Although in-hospital mortality rates in stroke
patients have decreased, prevention and cardiovascular risk control remain
critical for improving the prognosis and reducing stroke burden worldwide.
The definitions of stroke and transient ischemic attack (TIA) have been
recently modified following the findings from neuroimaging and thrombolysis
research. Both stroke and TIA are recurrent and preventable disorders. Both
patients with stroke and those with TIA require prompt clinical workup, risk
assessment, and appropriate management because the risk of recurrence,
stroke, and coronary events is significant. The 5 most common cardiovascular
risk factors (high blood pressure, smoking, abdominal obesity, diet, and
lack of physical activity) are responsible for 80% of the cases. Stroke
prevention involves lifestyle modification and specific treatment. Secondary
prevention of ischemic stroke involves early treatment (antiplatelets and
carotid interventions) and long-term management including lifestyle changes,
antihypertensive therapy, antiplatelets, antithrombotic drugs in patients
with atrial fibrillation, and the use of statins and other lipid-lowering
drugs. Stroke patients are at risk of depression, dementia, epilepsy, and
other complications that also require targeted treatment.
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
antihypertensive agent (drug therapy)
antilipemic agent (drug therapy)
antithrombocytic agent (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (drug therapy, drug therapy, epidemiology, prevention,
therapy)
general practitioner
internist
EMTREE MEDICAL INDEX TERMS
antihypertensive therapy
atrial fibrillation (drug therapy)
blood clot lysis
cardiovascular risk
clinical practice
high risk patient
human
hypertension (drug therapy)
lifestyle modification
mortality
neuroimaging
prognosis
review
risk assessment
stroke patient
transient ischemic attack (prevention)
treatment planning
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Polish
EMBASE ACCESSION NUMBER
2014875019
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 220
TITLE
Safety of herbal medicine in treatment of weight loss
AUTHOR NAMES
Najafian J.
Abdar-Esfahani M.
Arab-Momeni M.
Akhavan-Tabib A.
AUTHOR ADDRESSES
(Najafian J.; Abdar-Esfahani M.) Isfahan Cardiovascular Research Center,
Isfahan Cardiovascular Research Institute, Isfahan University of Medical
Sciences, Isfahan, Iran.
(Arab-Momeni M.) Hypertension Research Center, Isfahan Cardiovascular
Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
(Akhavan-Tabib A., afshan.akhavantabib@gmail.com) Cardiac Rehabilitation
Research Center, Isfahan Cardiovascular Research Institute, Isfahan
University of Medical Sciences, Isfahan, Iran.
CORRESPONDENCE ADDRESS
A. Akhavan-Tabib, Cardiac Rehabilitation Research Center, Isfahan
Cardiovascular Research Institute, Isfahan University of Medical Sciences,
Isfahan, Iran. Email: afshan.akhavantabib@gmail.com
SOURCE
ARYA Atherosclerosis (2014) 10:1 (55-58). Date of Publication: 2014
ISSN
2251-6638 (electronic)
1735-3955
BOOK PUBLISHER
Isfahan University of Medical Sciences, rmsj@mui.ac.iv
ABSTRACT
BACKGROUND: Obesity is a common health problem in both developed and
developing countries. There are many unconventional therapies, including
herbal medicine, to treat this condition. Some people believe that herbal
medicines are safe. This case and review is about adverse complication of
treating obesity with some herbal medicine. CASE REPORT: A 19 year old male
with sever obesity (120 KG) used green tea (15 cups of green tea per day)
and an intensive dietary regimen to lose weight. He lost 30 kg after 2
months. At that time, one day after usual exercise he suddenly lost
consciousness due to left ventricular fibrillation. CONCLUSION: Use of
herbal medicine for weight reduction is not always safe. Moreover, for some
herbal medicine the risk is sufficient to shift the risk-benefit balance
against the use that medicine.
EMTREE DRUG INDEX TERMS
caffeine
diazepam (drug therapy)
epigallocatechin
etiracetam (drug therapy)
levodopa (drug therapy)
magnesium (oral drug administration)
magnesium sulfate
midazolam (drug therapy)
oxedrine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
drug safety
herbal medicine
obesity
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
Camellia sinensis
case report
diet
Ephedra
female
guarana
heart arrest
heart ejection fraction
heart ventricle fibrillation
human
hypokinesia
magnesium blood level
male
middle aged
Pausinystalia
QT prolongation
resuscitation
seizure (drug therapy)
tea
weight reduction
young adult
CAS REGISTRY NUMBERS
caffeine (58-08-2)
diazepam (439-14-5)
epigallocatechin (970-74-1)
etiracetam (102767-28-2, 33996-58-6)
levodopa (59-92-7)
magnesium (7439-95-4)
magnesium sulfate (7487-88-9)
midazolam (59467-70-8)
oxedrine (94-07-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014212430
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 221
TITLE
Relationship Between Obesity and Driving
AUTHOR NAMES
Kay G.G.
McLaughlin D.
AUTHOR ADDRESSES
(Kay G.G., gkay@cogres.com; McLaughlin D.) Cognitive Research Corporation,
200 Central Avenue, Suite 1230, St. Petersburg, FL, 33701, United States.
CORRESPONDENCE ADDRESS
G. G. Kay, Cognitive Research Corporation, 200 Central Avenue, Suite 1230,
St. Petersburg, FL, 33701, United States. Email: gkay@cogres.com
SOURCE
Current Obesity Reports (2014) 3:3 (336-340). Date of Publication: September
2014
ISSN
2162-4968 (electronic)
BOOK PUBLISHER
Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
Obesity, which has become epidemic throughout many parts of the world, is
known to be a risk factor for a range of diseases including hypertension,
diabetes, and vascular disease. Based on this review, it also appears that
obesity is associated with increased crash risk and increased risk of
serious or fatal injury in a crash. The problem is particularly an issue for
commercial truck drivers. Data are presented showing the high prevalence of
obesity in truck drivers. Inadequate sleep, poor nutrition, lack of
exercise, and the sedentary nature of driving all contribute to the risk of
obesity. The obesity related condition of obstructive sleep apnea (OSA) is
known to increase crash risk. Treatment of this condition has been
demonstrated to improve driving performance and to reduce crash risk.
Screening truck drivers for obesity related health conditions, such as OSA,
would be expected to result in public safety benefits. © 2014 Springer
Science+Business Media New York.
EMTREE DRUG INDEX TERMS
ghrelin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
driver
obesity
EMTREE MEDICAL INDEX TERMS
apnea
arthritis
asthma
atrial fibrillation
daytime somnolence
disease association
gallbladder disease
human
hypercholesterolemia
hypertension
increased appetite
injury scale
injury severity
insulin resistance
leptin deficiency
non insulin dependent diabetes mellitus
osteoarthritis
oxygen desaturation
physical activity
positive end expiratory pressure
priority journal
review
sleep disordered breathing
sleep quality
traffic accident
CAS REGISTRY NUMBERS
ghrelin (304853-26-7)
EMBASE CLASSIFICATIONS
Occupational Health and Industrial Medicine (35)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014511386
FULL TEXT LINK
http://dx.doi.org/10.1007/s13679-014-0109-8
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 222
TITLE
Robotic ablation of atrial fibrillation with a new remote catheter system
AUTHOR NAMES
Wutzler A.
Wolber T.
Parwani A.S.
Huemer M.
Attanasio P.
Blaschke F.
Haegeli L.
Haverkamp W.
Duru F.
Boldt L.-H.
AUTHOR ADDRESSES
(Wutzler A., alexander.wutzler@charite.de; Parwani A.S.; Huemer M.;
Attanasio P.; Blaschke F.; Haverkamp W.; Boldt L.-H.) Department of
Cardiology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum,
Augustenburger Platz 1, Berlin, Germany.
(Wolber T.; Haegeli L.; Duru F.) Cardiovascular Center, Cardiology,
University Hospital, Zurich, Switzerland.
CORRESPONDENCE ADDRESS
A. Wutzler, Department of Cardiology, Charité-Universitätsmedizin Berlin,
Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin, Germany.
SOURCE
Journal of Interventional Cardiac Electrophysiology (2014) 40:3 (215-219).
Date of Publication: 2014
ISSN
1572-8595 (electronic)
1383-875X
BOOK PUBLISHER
Kluwer Academic Publishers
ABSTRACT
Purpose: Pulmonary vein isolation (PVI) is widely established as a curative
treatment option for atrial fibrillation (AF). A wide range of techniques to
improve catheter manipulation and steerability has been developed over the
past years. A new remote catheter system (RCS) has recently become available
(Amigo Remote Catheter System, Catheter Robotics, Budd Lake, NJ, USA). Here,
we present a dual-center study on the RCS for left atrial mapping and PVI in
patients with paroxysmal AF compared to a control group undergoing
conventional PVI.Methods: One hundred nineteen patients who underwent PVI
for paroxysmal AF were studied. Forty patients underwent PVI with the use of
the RCS. Seventy-nine patients, who underwent conventional PVI, served as
control group. Procedural data were compared between the two groups.Results:
PVI was achieved in all patients. In the RCS group compared to standard
ablation group, there were no significant differences in procedure duration
(159.1 ± 45.4 vs. 146 ± 30.1 min, p = 0.19), total energy delivery (78,146.3
± 26,992.4 vs. 87,963.9 ± 79,202.1 Ws, p = 0.57), and total fluoroscopy time
(21.2 ± 8.6 vs. 23.9 ± 5.4 min, p = 0.15). Operator fluoroscopy exposure was
significantly reduced in the RCS group (13.4 ± 6.1 vs. 23.9 ± 5.4 min, p <
0.001).Conclusions: These initial results suggest that left atrial mapping
and PVI are feasible with the use of the Amigo RCS. Acute procedural
efficacy is comparable to the standard approach. The use of the Amigo RCS
leads to a significant reduction of operator fluoroscopy exposure.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
catheter
pulmonary vein isolation
radiation exposure
EMTREE MEDICAL INDEX TERMS
control group
exposure
fluoroscopy
human
lake
patient
procedures
robotics
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014724681
FULL TEXT LINK
http://dx.doi.org/10.1007/s10840-014-9895-x
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 223
TITLE
A case of thyroid storm induced by iodine-containing dietary supplements and
homeopathic remedies
AUTHOR NAMES
Karkowski K.
Carroll J.L.
AUTHOR ADDRESSES
(Karkowski K.) University of Rhode Island, Kingston, RI, United States.
(Carroll J.L., James.L.Carroll@Dartmouth.edu) Geisel School of Medicine at
Dartmouth, Lebanon, NH, United States.
CORRESPONDENCE ADDRESS
J.L. Carroll, Geisel School of Medicine at Dartmouth, Lebanon, NH, United
States. Email: James.L.Carroll@Dartmouth.edu
SOURCE
Journal of Pharmacy Technology (2014) 30:3 (102-105). Date of Publication:
June 2014
ISSN
1549-4810 (electronic)
8755-1225
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
Objective: We report the case of a patient who presented to the hospital in
thyroid storm following the use of several iodine-containing dietary
supplements (DS) and homeopathic remedies (HR). Case Summary: The patient
was a 76-yearold woman with no personal or family history of thyroid or
autoimmune disease. On laboratory assessment, a thyroid panel showed that
her total T3 and T4 were elevated at 334 ng/dL and 14.6 μg/dL, respectively;
thyroid stimulating hormone was undetectable; and thyroid stimulating
immunoglobulin was positive at 7.4. The patient had been consuming 170 μg of
iodine daily for the past 2 months via her DS and HR. An objective causality
assessment using the Naranjo adverse drug reaction probability scale
revealed that an adverse effect was probable. The patient likely suffered
from iodine-induced thyrotoxicosis secondary to the consumption of numerous
DS and HR. Discussion: Dietary supplements and homeopathic remedies can pose
significant health risks. The safety of these products is not assured as
they are incompletely monitored by the Food and Drug Administration.
Individuals who take these compounds do so at their own risk and should pay
close attention to product contents. Conclusions: The labeling of DS and HR
products may be misleading. Pharmacists and clinicians are advised to
inquire about the use of DS and HR products. When use is identified, the
products should be subject to a thorough review. © The Author(s) 2014.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
homeopathic agent (adverse drug reaction)
iodine (adverse drug reaction)
EMTREE DRUG INDEX TERMS
liothyronine (endogenous compound)
thyroid stimulating immunoglobulin (endogenous compound)
thyrotropin (endogenous compound)
thyroxine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diet supplementation
thyroid crisis (diagnosis)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
case report
congestive heart failure
dyspnea
echocardiography
fatigue
female
follow up
heart left ventricle ejection fraction
human
length of stay
liothyronine blood level
peripheral edema
thyrotoxicosis (side effect)
thyrotropin blood level
thyroxine blood level
weight reduction
CAS REGISTRY NUMBERS
iodine (7553-56-2)
liothyronine (6138-47-2, 6893-02-3)
thyrotropin (9002-71-5)
thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
Clinical and Experimental Biochemistry (29)
Endocrinology (3)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014394681
FULL TEXT LINK
http://dx.doi.org/10.1177/8755122514529414
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 224
TITLE
N-3 Fatty Acids for Prevention of Cardiovascular Disease
AUTHOR NAMES
Khawaja O.A.
Gaziano J.M.
Djoussé L.
AUTHOR ADDRESSES
(Khawaja O.A., oajaz@yahoo.com) Department of Cardiology, Mercy St. Vincent
Medical Center, 2213 Cherry Street, Toledo, United States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG; Djoussé L.,
ldjousse@rics.bwh.harvard.edu) Massachusetts Veterans Epidemiology and
Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare
System, Boston, United States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG; Djoussé L.,
ldjousse@rics.bwh.harvard.edu) Geriatric Research, Education, and Clinical
Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, United
States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG; Djoussé L.,
ldjousse@rics.bwh.harvard.edu) Division of Aging, Brigham and Women’s
Hospital and Harvard Medical School, 1620 Tremont St, OBC, 3rd floor,
Boston, United States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG) Division of Preventive Medicine,
Brigham and Women’s Hospital and Harvard Medical School, Boston, United
States.
CORRESPONDENCE ADDRESS
L. Djoussé, Division of Aging, Brigham and Women’s Hospital and Harvard
Medical School, 1620 Tremont St, OBC, 3rd floor, Boston, United States.
SOURCE
Current Atherosclerosis Reports (2014) 16:11. Date of Publication: 2014
ISSN
1534-6242 (electronic)
1523-3804
BOOK PUBLISHER
Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
Cardiovascular disease (CVD) is the leading cause of death in the USA. A
diet enriched with n-3 fatty acids (FA) has been reported to play an
important role in preventing the development of CVD. Prior studies have
demonstrated beneficial effects of n-3 FA on hypertriglyceridemia, blood
pressure, inflammation, endothelial function, and platelet function.
However, data on the relation of n-3 FA consumption with CVD risk remain
inconsistent. This paper reviews current evidence on the effects of n-3 FA
on CVD, CVD risk factors, and potential biologic mechanisms. Last, we
discuss major limitations of currently available data and future directions
in the field.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid (clinical trial, drug combination, drug comparison -
placebo, drug comparison, drug dose, drug therapy, endogenous compound,
pharmacology)
EMTREE DRUG INDEX TERMS
colecalciferol (clinical trial, drug comparison, drug therapy)
docosahexaenoic acid (clinical trial, drug comparison, drug therapy)
fish oil (clinical trial, drug comparison - placebo, drug therapy)
margarine
olive oil (clinical trial, drug combination, drug comparison, drug therapy)
omega 3 acid ethyl ester (clinical trial, drug comparison, drug therapy)
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
antiinflammatory activity
atrial fibrillation (drug therapy)
blood pressure regulation
cardiovascular risk
computed tomographic angiography
coronary artery atherosclerosis (drug therapy)
defibrillation
diabetes mellitus (drug therapy, prevention)
diet supplementation
diet therapy
drug dose comparison
drug megadose
endothelial dysfunction (drug therapy)
evidence based medicine
fatty acid blood level
heart arrhythmia (drug therapy, therapy)
heart failure (drug therapy, therapy)
high risk population
human
hyperlipidemia (drug therapy)
hypertension (drug therapy)
impaired glucose tolerance (drug therapy, prevention)
inflammation (drug therapy)
low drug dose
malignant neoplastic disease (drug therapy)
outcome assessment
primary prevention
randomized controlled trial (topic)
restenosis (complication, drug therapy)
review
risk benefit analysis
risk reduction
thrombocyte function
treatment duration
DRUG TRADE NAMES
omacor
CAS REGISTRY NUMBERS
colecalciferol (1406-16-2, 67-97-0)
docosahexaenoic acid (25167-62-8, 32839-18-2)
fish oil (8016-13-5)
margarine (8029-82-1)
olive oil (8001-25-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Endocrinology (3)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015641666
FULL TEXT LINK
http://dx.doi.org/10.1007/s11883-014-0450-0
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 225
TITLE
Omega-3 supplements and cardiovascular diseases
AUTHOR NAMES
Mohebi-Nejad A.
Bikdeli B.
AUTHOR ADDRESSES
(Mohebi-Nejad A.) Cardiovascular Department, National Research Institute of
Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical
Sciences, Tehran, Iran.
(Bikdeli B., Behnood.bikdeli@yale.edu) Section of Cardiovascular Medicine,
Center for Outcomes Research and Evaluation (CORE), and Department of
Internal Medicine, Yale University School of Medicine, New Haven, CT 06510,
United States.
CORRESPONDENCE ADDRESS
B. Bikdeli, One Church Street, Suite #200, New Haven, CT 06510, United
States. Email: Behnood.bikdeli@yale.edu
SOURCE
Tanaffos (2014) 13:1 (6-14). Date of Publication: 2014
ISSN
1735-0344
BOOK PUBLISHER
Shaheed Beheshti University of Medical Sciences and Health Services,
info@tanaffosjournal.ir
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid (adverse drug reaction, drug therapy, pharmacoeconomics,
pharmacology)
EMTREE DRUG INDEX TERMS
docosahexaenoic acid (drug therapy, pharmacology)
high density lipoprotein (endogenous compound)
icosapentaenoic acid (drug therapy, pharmacology)
icosapentaenoic acid ethyl ester (drug therapy)
low density lipoprotein (endogenous compound)
omega 3 acid ethyl ester (drug therapy)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, disease management, drug therapy,
prevention, therapy)
diet supplementation
EMTREE MEDICAL INDEX TERMS
antiarrhythmic activity
antiinflammatory activity
antithrombotic activity
atrial fibrillation (drug therapy)
blood pressure regulation
brain hemorrhage (side effect)
cardiovascular mortality
cardiovascular risk
cell function
cerebrovascular accident (side effect)
drug activity
drug cost
drug effect
drug mechanism
drug safety
drug structure
epistaxis (side effect)
fatty acid synthesis
fatty fish
fish
food intake
gastrointestinal hemorrhage (side effect)
heart infarction (drug therapy)
human
Mediterranean diet
molecular dynamics
molecular interaction
nonhuman
postoperative atrial fibrillation (drug therapy)
postoperative atrial fibrillation (drug therapy)
postoperative complication (drug therapy)
primary prevention
review
risk benefit analysis
risk reduction
secondary prevention
subcutaneous hemorrhage (side effect)
tachycardia (drug therapy)
DRUG TRADE NAMES
lovaza
vascepa
CAS REGISTRY NUMBERS
docosahexaenoic acid (25167-62-8, 32839-18-2)
icosapentaenoic acid (25378-27-2, 32839-30-8)
icosapentaenoic acid ethyl ester (73310-10-8, 86227-47-6)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2014554566
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 226
TITLE
Electrocardiographic deep terminal negativity of the P wave in V1 and risk
of mortality: The national health and nutrition examination survey III
AUTHOR NAMES
Tereshchenko L.G.
Shah A.J.
Li Y.
Soliman E.Z.
AUTHOR ADDRESSES
(Tereshchenko L.G., tereshch@ohsu.edu) Knight Cardiovascular Institute,
Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, UHN62,
Portland, United States.
(Shah A.J.) Department of Epidemiology, Emory University, Atlanta, United
States.
(Shah A.J.) Atlanta VA Medical Center, Decatur, United States.
(Li Y.; Soliman E.Z.) Epidemiological Cardiology Research Center (EPICARE),
Division of Public Health Sciences, United States.
(Soliman E.Z.) Department of Medicine, Cardiology Section, Wake Forest
School of Medicine, Winston Salem, United States.
CORRESPONDENCE ADDRESS
L.G. Tereshchenko, Knight Cardiovascular Institute, Oregon Health and
Science University, 3181 SW Sam Jackson Park Rd, UHN62, Portland, United
States.
SOURCE
Journal of Cardiovascular Electrophysiology (2014) 25:11 (1242-1248). Date
of Publication: 1 Nov 2014
ISSN
1540-8167 (electronic)
1045-3873
BOOK PUBLISHER
Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
Terminal P(V1) Negativity in NHANES III Introduction Deep terminal
negativity of P wave in V1 (DTNPV1), defined as negative P prime larger than
one small box (1 mm, or 0.1 mV), could be easily detected by simple visual
inspection of the resting 12-lead ECG. The objective of this study was to
determine the relationship between DTNPV1 and all-cause-, cardiovascular
disease (CVD), and ischemic heart disease (IHD) mortality in the National
Health and Nutrition Examination Survey III (NHANES III).Methods and Results
After exclusion of participants with atrial fibrillation and missing data,
DTNPV1 was automatically measured from standard 12-lead ECG in 8,146
participants. Minnesota and Novacode algorithms were used for the
determination of major and minor ECG abnormalities. National Death Index was
used to identify the date and cause of death. During a median follow-up of
13.8 years, a total of 2,975 deaths (1,303 CVD and 742 IHD deaths) occurred.
After adjustment for age, gender, race/ethnicity, IHD, heart failure,
chronic obstructive pulmonary disease, cancer, diabetes, body mass index,
smoking, dyslipidemia, hypertension, use of antihypertensive and
lipid-lowering medications, and ECG abnormalities, DTNPV1 was associated
with significantly increased risk of all-cause death (HR [95% CI]: 1.30
[1.10, 1.53]; P = 0.002), CVD death (HR [95% CI]: 1.36 [1.08, 1.72]; P =
0.010), and IHD death (HR [95% CI]: 1.36 [1.00, 1.85]; P = 0.047).Conclusion
In a large sample of the adult United States population, DTNPV1 is
independently associated with increased risk of death due to all-cause, CVD,
and IHD, findings suggesting its potential usefulness as a simple marker to
identify individuals at risk of poor outcomes.
EMTREE DRUG INDEX TERMS
antihypertensive agent (drug therapy)
antilipemic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular mortality
cardiovascular risk
deep terminal negativity of P wave
electrocardiography
P wave
EMTREE MEDICAL INDEX TERMS
adult
aged
antihypertensive therapy
article
body mass
cause of death
chronic obstructive lung disease
controlled study
diabetes mellitus
disease association
dyslipidemia
ECG abnormality
female
follow up
heart failure
human
hypercholesterolemia (drug therapy)
hypertension (drug therapy)
major clinical study
male
neoplasm
smoking
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014729041
FULL TEXT LINK
http://dx.doi.org/10.1111/jce.12453
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 227
TITLE
Cardioprotective effects of moderate red wine consumption: Polyphenols vs.
ethanol
AUTHOR NAMES
Iriti M.
Varoni E.M.
AUTHOR ADDRESSES
(Iriti M., marcello.iriti@unimi.it) Department of Agricultural and
Environmental Sciences, Milan State University, Milan, Italy.
(Varoni E.M.) Department of Biomedical, Surgical and Dental Sciences, Milan
State University, Milan, Italy.
CORRESPONDENCE ADDRESS
M. Iriti, via G. Celoria 2, Milan, Italy.
SOURCE
Journal of Applied Biomedicine (2014) 12:4 (193-202). Date of Publication: 1
Nov 2014
ISSN
1214-0287 (electronic)
1214-021X
BOOK PUBLISHER
University of South Bohemia, Ema Destinn Street, Jirovcova 24, Ceske
Budejovic, Czech Republic. berger@jcu.cz
ABSTRACT
Since decades, it has been suggested that regular, moderate consumption of
red wine, a major component of Mediterranean diet, at main meals, may
contribute to explain the healthy properties attributed to this traditional
dietary style. Despite preclinical in vitro/ in vivo data have shown a
significant cardioprotective activity of grape phytochemicals, mostly
polyphenols, evidence in humans is still debated. This lack of consensus may
be due to the equilibrium between the two main components of wine relevant
for health: ethanol and bioactive compounds or phytochemicals, which include
not only polyphenols, but also newly detected molecules, such as melatonin
and phytosterols. The state of art related to this delicate equilibrium
represents the starting point for designing future clinical trials, in
perspective of clinical recommendations. A better comprehension of the wine
chemistry complexity with its major components embodies a pivotal issue in
biomedicine, involving the fields of diet-related environmental medicine as
well as chronomedicine. In this paper, we briefly reviewed putative
beneficial effects of moderate red wine intake in humans, focusing on the
reduction of cardiovascular risk.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
alcohol
polyphenol
EMTREE DRUG INDEX TERMS
biological marker (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (prevention)
food intake
heart protection
red wine
EMTREE MEDICAL INDEX TERMS
alcohol consumption
antiinflammatory activity
atherosclerosis
atrial fibrillation
blood pressure regulation
body mass
cardiovascular mortality
cardiovascular risk
cell activation
chronobiology
diastolic blood pressure
drug structure
endothelium cell
environmental health
genetic variability
health promotion
human
hypertension
randomized controlled trial (topic)
review
risk reduction
thrombocyte volume
white wine
CAS REGISTRY NUMBERS
alcohol (64-17-5)
polyphenol (37331-26-3)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015878947
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jab.2014.09.003
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 228
TITLE
Atrial fibrillation and stroke
ORIGINAL (NON-ENGLISH) TITLE
Fibrilação atrial e acidente vascular cerebral
AUTHOR NAMES
Gagliardi R.J.
Gagliardi V.D.B.
AUTHOR ADDRESSES
(Gagliardi R.J., rubensjg@apm.org.br) Disciplina de Neurologia da Santa Casa
de São Paulo, São Paulo-SP, Brazil.
(Gagliardi V.D.B.) Clínica Neurológica da Santa Casa de São Paulo, São
Paulo-SP, Brazil.
CORRESPONDENCE ADDRESS
R. J. Gagliardi, Disciplina de Neurologia da Santa Casa de São Paulo, Rua
Dr. Cesário Motta Jr., 112, CEP 01221-020, São Paulo-SP, Brazil. Email:
rubensjg@apm.org.br
SOURCE
Revista Neurociencias (2014) 22:1 (144-148). Date of Publication: 2014
ISSN
1984-4905 (electronic)
0104-3579
BOOK PUBLISHER
Universidade Federal de Sao Paulo, revistaneurociencias@yahoo.com
ABSTRACT
Approximately 20-30 % of strokes are cardioembolic, and atrial fibrillation
(AF) is the main cardiogenic cause. AF is not an uncommon issue in the
population, and its prevalence increases with age and is related to a more
severe stroke. The prevention of stroke in patients with AF should be
performed with oral anticoagulation, and warfarin is the most frequently
used medication; however, this medication is difficult to be managed due to
multiple drug interactions and dietary interactions, which demands a
periodical laboratory monitoring. Half of the patients who started on this
treatment interrupt it in months, and half of the treated patients do not
reach the therapeutic target. In addition, there is a risk of bleeding,
including cerebral hemorrhage, and the benefit of the medication should be
individualized to each patient. In this scenario the new oral anticoagulants
(such as dabigatran, rivaroxaban, apixaban, edoxaban) have emerged as an
option to warfarin, which present with similar or slightly better efficacy
than warfarin and risk of hemorrhage slightly lower.
EMTREE DRUG INDEX TERMS
apixaban
dabigatran
edoxaban
rivaroxaban
warfarin (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cerebrovascular accident (drug therapy, complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
article
bleeding
brain hemorrhage
cardioembolic stroke
drug efficacy
human
prevalence
CAS REGISTRY NUMBERS
apixaban (503612-47-3)
edoxaban (480449-70-5, 480449-71-6, 912273-65-5)
rivaroxaban (366789-02-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English, Portuguese
LANGUAGE OF SUMMARY
English, Portuguese
EMBASE ACCESSION NUMBER
2014317401
FULL TEXT LINK
http://dx.doi.org/10.4181/RNC.2014.22.929.5p
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 229
TITLE
Plasma natriuretic peptides and incidence of subtypes of ischemic stroke
AUTHOR NAMES
Berntsson J.
Zia E.
Borné Y.
Melander O.
Hedblad B.
Engström G.
AUTHOR ADDRESSES
(Berntsson J., john.berntsson@med.lu.se; Zia E.; Borné Y.; Melander O.;
Hedblad B.; Engström G.) Department of Clinical Sciences in Malmö,
Cardiovascular Epidemiology Skåne University, Lund University, House 60,
Level 13, SE-20502 Malmö, Lund, Sweden.
SOURCE
Cerebrovascular Diseases (2014) 37:6 (444-450). Date of Publication: August
2014
ISSN
1421-9786 (electronic)
1015-9770
BOOK PUBLISHER
S. Karger AG
ABSTRACT
Background and Purpose: Natriuretic peptides predict poor outcomes in
cardiovascular disease. However, the knowledge of their relationship to
stroke is limited and prospective studies from the general population are
few. The purpose of this study was to explore the relationship between
N-terminal pro-brain natriuretic peptide (NT-proBNP) and midregional
pro-atrial natriuretic peptide (MR-proANP) plasma levels and the risk for
ischemic stroke and its subtypes. Methods: NT-proBNP and MR-proANP were
measured in fasting blood samples from 4,862 subjects (40.2% men, mean age
57.5 ± 6.0 years) without cardiovascular disease from the Malmö Diet and
Cancer Study, a prospective, population-based study in Sweden. Incidence of
ischemic stroke was monitored over a mean follow-up of 14.9 ± 3.0 years.
Stroke cases were etiologically classified according to the TOAST
classification. Cox proportional-hazards regression was used to study the
incidence of stroke in relationship to NT-proBNP and MR-proANP. Results:
During follow-up, 227 had a first-ever ischemic stroke (large-artery
atherosclerosis, n = 35; cardioembolic stroke, n = 44; small-artery
occlusion, n = 80; undetermined cause, n = 68). In the age- and sex-adjusted
model, only NT-proBNP was associated with total ischemic stroke. This
association was completely explained by an increased incidence of
cardioembolic stroke. Adjusted for cardiovascular risk factors (age, sex,
hypertension, diabetes, smoking, body mass index and low-density lipoprotein
cholesterol), the hazard ratios (HRs, 95% confidence interval, 95% CI) for
cardioembolic stroke were 1.00 (reference), 1.42 (0.34-6.00), 2.79
(0.77-10.12) and 5.64 (1.66-19.20), respectively, for the 1st, 2nd, 3rd and
4th quartiles of NT-proBNP. The corresponding HRs (95% CIs) for quartiles of
MR-proANP were 1.00 (reference), 1.83 (0.55-6.14), 1.20 (0.33-4.34) and 3.96
(1.31-11.99), respectively. In total, 335 (6.9%) subjects were diagnosed
with atrial fibrillation during follow-up. Among the cardioembolic stroke
cases, 30% were diagnosed with atrial fibrillation before the stroke event
and another 36% within 6 months after the stroke. Of the cardioembolic
stroke cases with atrial fibrillation, 59% were in the top quartile of
NT-proBNP, 69% in the top quartile of MR-proANP and 79% were either in the
top quartile of NT-proBNP or in the top quartile of MR-proANP. Conclusion:
High plasma levels of NT-proBNP and MR-proANP are associated with a
substantially increased risk of cardioembolic stroke, but not with other
subtypes of ischemic stroke. The results suggest that assessment of stroke
risk, including electrocardiography, is warranted in subjects with high
NT-proBNP or MR-proANP. © 2014 S. Karger AG, Basel.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
amino terminal pro brain natriuretic peptide (endogenous compound)
brain natriuretic peptide (endogenous compound)
midregional pro atrial natriuretic peptide (endogenous compound)
EMTREE DRUG INDEX TERMS
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (diagnosis, epidemiology)
EMTREE MEDICAL INDEX TERMS
adult
age
aged
article
atrial fibrillation (diagnosis)
blood sampling
cardioembolic stroke (diagnosis, epidemiology)
cardiovascular risk
diet restriction
disease association
disease classification
female
follow up
human
incidence
large artery atherosclerosis (diagnosis, epidemiology)
major clinical study
male
priority journal
protein blood level
reference value
risk assessment
sex ratio
small artery occlusion (diagnosis, epidemiology)
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014563094
FULL TEXT LINK
http://dx.doi.org/10.1159/000363279
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 230
TITLE
The effect of strict rate control on B-type natriuretic peptide values and
echocardiographic parameters in chronic atrial fibrillation
AUTHOR NAMES
Ozkurt Y.
Özpelit E.
Aslan Ö.
Goldeli O.
AUTHOR ADDRESSES
(Ozkurt Y.; Özpelit E., ebru.ozpelit@gmail.com; Aslan Ö.; Goldeli O.)
Department of Cardiology, Dokuz Eylül University, Inciralti/Izmir, Turkey.
CORRESPONDENCE ADDRESS
E. Özpelit, Department of Cardiology, Dokuz Eylül University,
Inciralti/Izmir, Turkey.
SOURCE
Kardiologia Polska (2014) 72:10 (934-940). Date of Publication: 2014
ISSN
0022-9032 (electronic)
0022-9032
BOOK PUBLISHER
Via Medica, Ul. Swietokrzyska 73, Gdansk, Poland. viamedica@viamedica.com.pl
ABSTRACT
Background: There have been conflicting results about the role of strict
rate control on cardiovascular outcomes in patients with chronic atrial
fibrillation (AF). To date, large clinical studies have not shown a net
clinical benefit derived from the current trend to specify the target
ventricular rate according to the patient's own clinical and laboratory
characteristics. Although the existing literature shows no superiority of
strict rate control in clinical end points, it is difficult to assess the
pure rate effect without commonly coexisting medication side effects which
can also influence clinical end points.Aim: To determine the effects of
strict rate control in patients with chronic AF, regarding objective
parameters such as echocardiographic data and B-type natriuretic peptide
(BNP) values.Methods: 38 patients with chronic AF for whom strict rate
control had been planned were enrolled in the study. Patients'
echocardiographic parameters, BNP values and 24 h Holter electrocardiography
findings showing the average heart rate (HR), were studied at baseline and
then monthly, until the end of the 3rd month. Patients' negative dromotropic
therapy was adjusted to achieve a target resting HR of below 80 bpm.
Laboratory and echocardiographic parameters at baseline and at the end of
the study were compared in the whole study group. The whole study group was
subclassified according to the average resting HRs achieved, (group 1 with
strict rate control < 80 bpm; n = 25, and group 2 without strict rate
control; n = 13).Results: In group 1, the average HR declined from 101 ±
16.3 bpm to 77 ± 5.2 bpm. In group 2, the average HR was 96.6 ± 6.8 bpm at
baseline and there was no significant change at the end of the study (94.2 ±
5.9 bpm). In group 1, there were significant decreases in BNP, left
ventricular volumes, left atrial and right atrial areas at the end of the
study. In group 2, BNP values were significantly higher at the end of the
study despite similar ventricular and atrial dimensions according to the
baseline. Diastolic functions were assessed roughly by septal E/e', but no
significant change was observed in either group.Conclusions: Strict rate
control in patients with chronic AF yielded a significant decrease in BNP
values as well as a reduction in volumes of cardiac chambers.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
brain natriuretic peptide (endogenous compound)
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (adverse drug reaction, drug
therapy)
calcium channel blocking agent (adverse drug reaction, drug therapy)
digoxin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy)
chronic atrial fibrillation (drug therapy, drug therapy)
chronic disease (drug therapy, drug therapy)
disease control
echocardiography
radiological parameters
EMTREE MEDICAL INDEX TERMS
aged
article
clinical article
constipation (side effect)
controlled study
drug dose titration
exercise
female
follow up
heart left ventricle enddiastolic volume
heart left ventricle volume
heart rate
Holter monitoring
human
hypotension (side effect)
male
physical disease (side effect)
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Polish
EMBASE ACCESSION NUMBER
2014914182
FULL TEXT LINK
http://dx.doi.org/10.5603/KP.a2014.0092
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 231
TITLE
Self-measure of heart rate variability (HRV) and arrhythmia to monitor and
to manage atrial arrhythmias: Personal experience with high intensity
interval exercise (HIIE) for the conversion to sinus rhythm
AUTHOR NAMES
Young D.W.
AUTHOR ADDRESSES
(Young D.W., dwyoung@ieee.org) HEAL Research, Chehalis, WA, United States.
CORRESPONDENCE ADDRESS
D.W. Young, HEAL Research, Chehalis, WA, United States. Email:
dwyoung@ieee.org
SOURCE
Frontiers in Physiology (2014) 5 JUL Article Number: 00251. Date of
Publication: 2014
ISSN
1664-042X (electronic)
BOOK PUBLISHER
Frontiers Research Foundation, info@frontiersin.org
EMTREE DRUG INDEX TERMS
sotalol (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart atrium arrhythmia (drug therapy, drug therapy, therapy)
heart rate variability
high intensity interval exercise
personal experience
self examination
sinus rhythm
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (drug therapy, therapy)
cardiotachometer
cerebrovascular accident
cryoablation
disease association
disease course
ECG abnormality
electrocardiography monitoring
human
medical decision making
risk assessment
risk reduction
supraventricular premature beat (drug therapy, therapy)
survival rate
treatment outcome
CAS REGISTRY NUMBERS
sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2014477704
FULL TEXT LINK
http://dx.doi.org/10.3389/fphys.2014.00251
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 232
TITLE
Atrial fibrillation in endurance athletes
AUTHOR NAMES
Wilhelm M.
AUTHOR ADDRESSES
(Wilhelm M., matthias.wilhelm@insel.ch) University Clinic of Cardiology,
Division of Cardiovascular Prevention, Rehabilitation and Sports Cardiology,
University Hospital, CH-3010 Bern, Switzerland.
CORRESPONDENCE ADDRESS
M. Wilhelm, University Clinic of Cardiology, Division of Cardiovascular
Prevention, Rehabilitation and Sports Cardiology, University Hospital,
CH-3010 Bern, Switzerland. Email: matthias.wilhelm@insel.ch
SOURCE
European Journal of Preventive Cardiology (2014) 21:8 (1040-1048). Date of
Publication: August 2014
ISSN
2047-4881 (electronic)
2047-4873
BOOK PUBLISHER
SAGE Publications Inc., claims@sagepub.com
ABSTRACT
There is a growing population of veteran endurance athletes, regularly
participating in training and competition. Although the graded benefit of
exercise on cardiovascular health and mortality is well established, recent
studies have raised concern that prolonged and strenuous endurance exercise
may predispose to atrial and ventricular arrhythmias. Atrial fibrillation
(AF) and atrial flutter are facilitated by atrial remodelling, atrial
ectopy, and an imbalance of the autonomic nervous system. Endurance sports
practice has an impact on all of these factors and may therefore act as a
promoter of these arrhythmias. In an animal model, long-term intensive
exercise training induced fibrosis in both atria and increased
susceptibility to AF. While the prevalence of AF is low in young competitive
athletes, it increases substantially in the aging athlete, which is possibly
associated with an accumulation of lifetime training hours and participation
in competitions. A recent meta-analysis revealed a 5-fold increased risk of
AF in middle-aged endurance athletes with a striking male predominance.
Beside physical activity, height and absolute left atrial size are
independent risk factors for lone AF and the stature of men per se may
explain part of their higher risk of AF. Furthermore, for a comparable
amount of training volume and performance, male non-elite athletes exhibit a
higher blood pressure at rest and peak exercise, a more concentric type of
left ventricular remodelling, and an altered diastolic function, possibly
contributing to a more pronounced atrial remodelling. The sports
cardiologist should be aware of the distinctive features of AF in athletes.
Therapeutic recommendations should be given in close cooperation with an
electrophysiologist. Reduction of training volume is often not desired and
drug therapy not well tolerated. An early ablation strategy may be
appropriate for some athletes with an impaired physical performance,
especially when continuation of competitive activity is intended. This
review focuses on the prevalence, risk factors, and mechanisms of AF in
endurance athletes, and possible therapeutic options. © The European Society
of Cardiology 2013 Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav. © The European Society of Cardiology
2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
EMTREE DRUG INDEX TERMS
amiodarone (adverse drug reaction)
angiotensin receptor antagonist (drug therapy)
diltiazem (drug therapy)
flecainide (drug therapy)
verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy)
endurance sport
heart atrium flutter (drug therapy, drug therapy)
heart supraventricular arrhythmia
heart ventricle arrhythmia
supraventricular premature beat
EMTREE MEDICAL INDEX TERMS
autonomic nervous system
body height
cardiologist
disease predisposition
elevated blood pressure (drug therapy)
endurance training
exercise
heart electrophysiology
human
hypertension (drug therapy)
marathon runner
nonhuman
physical activity
physical performance
prevalence
priority journal
rest
review
sex difference
unspecified side effect (side effect)
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
diltiazem (33286-22-5, 42399-41-7)
flecainide (54143-55-4)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Occupational Health and Industrial Medicine (35)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014502945
FULL TEXT LINK
http://dx.doi.org/10.1177/2047487313476414
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 233
TITLE
Low diastolic wall strain is associated with raised post-exercise E/E′ ratio
in elderly patients without obvious myocardial ischemia
AUTHOR NAMES
Takagi T.
Takagi A.
Yoshikawa J.
AUTHOR ADDRESSES
(Takagi T., tcardiol@qb4.so-net.ne.jp) Takagi Cardiology Clinic, Mibu
Kayogosho-cho 3-3, Nakagyo-ku, Kyoto, Japan.
(Takagi A.) Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
(Yoshikawa J.) Nishinomiya Watanabe Cardiovascular Center, Nishinomiya,
Japan.
CORRESPONDENCE ADDRESS
T. Takagi, Takagi Cardiology Clinic, Mibu Kayogosho-cho 3-3, Nakagyo-ku,
Kyoto, Japan.
SOURCE
Journal of Echocardiography (2014) 12:3 (106-111). Date of Publication: 1
Sep 2014
ISSN
1880-344X (electronic)
1349-0222
BOOK PUBLISHER
Springer-Verlag Tokyo, orders@springer.jp
ABSTRACT
Background: It has been reported that the diastolic wall strain (DWS)
inversely correlates with the myocardial stiffness constant. The ratio of
early diastolic transmitral flow velocity to annulus velocity (E/E′)
correlates with the left ventricular (LV) filling pressure. Increased LV
wall stiffness is thought be associated with increased LV filling pressure
after exercise. The purpose of this study was to evaluate the correlation
between the DWS and post-exercise E/E′ in elderly patients without obvious
myocardial ischemia.Methods: Fifty-eight elderly patients
(age = 74 ± 6 years) who underwent treadmill stress echocardiography were
studied. All patients had normal LV wall motion at rest, and patients with
exercise-induced wall motion abnormality were excluded. The DWS was
calculated as follows: DWS = (PWTs − PWTd)/PWTs, where PWTs is the LV
posterior wall thickness at end-systole and PWTd is that at end-diastole. As
previously reported, DWS ≤ 0.33 was defined as low DWS and E/E′ ≥15.0 was
defined as a marker of increased LV filling pressure.Results: Eighteen
patients had low DWS. Patients with low DWS had greater post-exercise E/E′
(17.9 ± 3.2 vs. 12.8 ± 3.3, p < 0.0001). The DWS was inversely and strongly
correlated with post-exercise E/E′ (r2 = 0.534, p < 0.0001). Low
DWS predicted the development of raised post-exercise E/E′ ≥15.0 with a
positive predictive value of 94 % and a negative predictive value of
85 %.Conclusion: In elderly patients without obvious myocardial ischemia,
the DWS correlates strongly and inversely with post-exercise E/E′. Patients
with low DWS were likely to develop raised E/E′ after exercise.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
dipeptidyl carboxypeptidase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular parameters
diastolic wall strain
heart muscle ischemia
postexercise annulus velocity
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
blood pressure monitoring
clinical assessment
coronary artery disease
diagnostic accuracy
Doppler echocardiography
echocardiography
end systolic left atrial volume
female
heart left ventricle ejection fraction
heart left ventricle filling pressure
heart ventricle hypertrophy
hemodynamics
human
major clinical study
male
metabolic equivalent
predictive value
sensitivity and specificity
treadmill exercise
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014789228
FULL TEXT LINK
http://dx.doi.org/10.1007/s12574-014-0225-1
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 234
TITLE
Relationship between exercise-induced heart rate increase and the formation
of microbubbles and high-intensity transient signals in mechanical heart
valve implanted patients
AUTHOR NAMES
Sünbül A.
Kirba�� A.
Tanrikulu N.
��engül C.
Da��deviren B.
I��ik Ö.
AUTHOR ADDRESSES
(Sünbül A.) Department of Cardiology, Medicana Camlica Hospitals, Istanbul,
Turkey.
(Kirba�� A., ahmetkirbas@gmail.com; I��ik Ö.) Department of Cardiovascular
Surgery, Medicana Camlica Hospitals, Istanbul, Turkey.
(Tanrikulu N.) Department of Anesthesiology and Reanimation, Medicana
Camlica Hospital, Istanbul, Turkey.
(��engül C.) Department of Cardiology, Gaziosmanpa a Hospital, Istanbul,
Turkey.
(Da��deviren B.) Department of Cardiology, Medical Park Hospital, Istanbul,
Turkey.
CORRESPONDENCE ADDRESS
A. Kirba��, Department of Cardiovascular Surgery, Medicana Camlica
Hospitals, Istanbul, Turkey. Email: ahmetkirbas@gmail.com
SOURCE
Archives of Medical Science (2014) 10:4 (701-705). Date of Publication:
August 2014
ISSN
1896-9151 (electronic)
1734-1922
BOOK PUBLISHER
Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
ABSTRACT
Introduction: The formation and collapse of vapor-filled bubbles near a
mechanical heart valve is called cavitation. Microbubbles can be detected in
vivo by doppler ultrasonography (USG) as HITS (high intensity transient
signals) in cranial circulation. We investigated the relationship between
exercise induced heart rate increase and HITS formation in cranial
circulation. Material and methods: Thirty-nine mechanical heart valve
implanted (8 aortic valve replacement (AVR) + mitral valve replacement
(MVR), 9 AVR, 22 MVR) patients aged 18-80 years old were included in our
study. Microbubbles were counted in the left ventricular cavity via
transthoracic echocardiography at rest per cardiac cycle. Afterwards
transcranial Doppler USG was performed and HITS were counted in each
patient's middle cerebral artery at 5 min duration. Subsequently an exercise
test according to the Bruce protocol was performed. After achieving maximal
heart rate, microbubbles in the left ventricle and HITS were counted again.
Results: Microbubbles in the left ventricle and transcranial HITS increased
after exercise significantly compared to resting values (15.79 ±10.91
microbubbles/beat vs. 26.51 ±18.00 microbubbles/beat, p < 0.001; 6.13 ±8.07
HITS/5 min vs. 13.15 ±15.87 HITS/5 min, p = 0.001). There was a significant
correlation between microbubbles and HITS counts after peak exercise (r =
0.55, p < 0.001). Conclusions: In our study, we found that the microbubbles
were increasing as the heart rate increased and more HITS were propelled to
the cerebral circulation. As previously shown, HITS can alter cognitive
functions. Therefore heart rate control is essential in mechanical heart
valve patients to protect neurocognitive functions. Copyright © 2014
Termedia & Banach.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aorta valve replacement
exercise
exercise induced heart rate increase
heart rate
high intensity transient signal
image display
mechanical heart valve
microbubble
mitral valve replacement
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
brain circulation
clinical article
cognition
Doppler echography
exercise test
female
heart cycle
heart left ventricle ejection fraction
human
male
real time ultrasound scanner
resting heart rate
sinus rhythm
transcranial doppler
transthoracic echocardiography
ultrasound transducer
DEVICE TRADE NAMES
vivid 7 dimension General Electric
DEVICE MANUFACTURERS
General Electric
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014596453
FULL TEXT LINK
http://dx.doi.org/10.5114/aoms.2013.34990
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 235
TITLE
Kinetics of left ventricular rotation during exercise and its relation to
exercise tolerance in atrial fibrillation: assessment by two-dimensional
speckle tracking echocardiography
AUTHOR NAMES
Uchida K.
Wada Y.
Ariyoshi T.
Okuda S.
Murakami W.
Myoren T.
Harada N.
Yamamoto T.
Ueyama T.
Tanaka N.
Yano M.
AUTHOR ADDRESSES
(Uchida K.; Okuda S.; Murakami W.; Myoren T.; Harada N.; Yamamoto T.; Ueyama
T.; Yano M.) Department of Medicine and Clinical Science, Yamaguchi
University Graduate School of Medicine, Ube, Japan.
(Wada Y., wadayasu@yamaguchi-u.ac.jp; Ariyoshi T.) Division of Laboratory,
Yamaguchi University Hospital, Minami-Kogushi 1-1-1, Ube, Japan.
(Tanaka N.) Department of Laboratory Science, Yamaguchi University Graduate
School of Medicine, Ube, Japan.
CORRESPONDENCE ADDRESS
Y. Wada, Division of Laboratory, Yamaguchi University Hospital,
Minami-Kogushi 1-1-1, Ube, Japan.
SOURCE
Journal of Echocardiography (2014) 12:3 (89-97). Date of Publication: 1 Sep
2014
ISSN
1880-344X (electronic)
1349-0222
BOOK PUBLISHER
Springer-Verlag Tokyo, orders@springer.jp
ABSTRACT
Conclusions: The augmentation of apical rotation in response to exercise may
coincide with an increase of the apical derotation rate, and apical rotation
reserve may reflect exercise tolerance in patients with AF and preserved
LVEF.Methods: Twenty-nine patients (age 62 ± 13 years, 6 females) with AF
and preserved LV ejection fraction (LVEF) were studied using two-dimensional
speckle tracking echocardiography at rest and during exercise with a supine
bicycle ergometer (20 W, 10 min). We measured the systolic rotation (Rot)
and the peak rotation rate in systole and early diastole (eRotR) at the
apical and basal levels of the LV. All patients underwent cardiopulmonary
exercise testing to obtain their percent achieved of the predicted peak
oxygen consumption (% peak VO2) value.Results: During exercise,
apical Rot-related indices were significantly increased only in the
preserved % peak VO2 group. In contrast, E/e′ was significantly
elevated only in the reduced % peak VO2 group. Multivariable
stepwise regression analysis showed that apical ΔRot was independently
associated with % peak VO2 (β = 0.72; p < 0.01). Apical ΔeRotR,
which could not be selected as an independent predictor of % peak
VO2, had a good linear correlation with apical ΔRot (r = 0.81,
p < 0.01).Background: Left ventricular (LV) rotation plays an important role
in cardiac function both at rest and during exercise in sinus rhythm. The
kinetics of rotation during exercise and the relation between exercise
tolerance and rotation-related parameters in patients with atrial
fibrillation (AF) are unknown.
EMTREE DRUG INDEX TERMS
brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
echocardiography
exercise tolerance
heart left ventricle relaxation
heart ventricle contraction
two dimensional speckle tracking echocardiography
EMTREE MEDICAL INDEX TERMS
adult
aged
article
bicycle ergometer
cardiopulmonary exercise test
clinical article
computer program
diastole
Doppler echocardiography
echocardiograph
female
heart function
heart left ventricle ejection fraction
heart ventricle hypertrophy
human
male
oxygen consumption
reproducibility
sinus rhythm
ultrasound scanner
DEVICE TRADE NAMES
Echo Stress Table 750EC
EchoPAC , United StatesGE Healthcare
Vivid E9 , United StatesGE Healthcare
DEVICE MANUFACTURERS
(United States)GE Healthcare
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014761334
FULL TEXT LINK
http://dx.doi.org/10.1007/s12574-014-0205-5
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 236
TITLE
Exercise echocardiography in asymptomatic HCM: Exercise capacity, and not LV
outflow tract gradient predicts long-term outcomes
AUTHOR NAMES
Desai M.Y.
Bhonsale A.
Patel P.
Naji P.
Smedira N.G.
Thamilarasan M.
Lytle B.W.
Lever H.M.
AUTHOR ADDRESSES
(Desai M.Y., desaim2@ccf.org; Bhonsale A.; Patel P.; Naji P.; Smedira N.G.;
Thamilarasan M.; Lytle B.W.; Lever H.M.) Heart and Vascular Institute,
Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195, United
States.
CORRESPONDENCE ADDRESS
M.Y. Desai, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid
Avenue, Desk J1-5, Cleveland, OH 44195, United States. Email:
desaim2@ccf.org
SOURCE
JACC: Cardiovascular Imaging (2014) 7:1 (26-36). Date of Publication:
January 2014
ISSN
1936-878X
1876-7591 (electronic)
BOOK PUBLISHER
Elsevier Inc., 360 Park Avenue South, New York, United States.
ABSTRACT
Objectives This study sought to assess long-term outcomes in asymptomatic or
minimally symptomatic patients with hypertrophic cardiomyopathy (HCM) who
underwent exercise echocardiography, without invasive therapies for relief
of left ventricular outflow tract (LVOT) obstruction. Background Many HCM
patients present with LVOT obstruction, mitral regurgitation (MR), and
diastolic dysfunction, often requiring invasive therapies for symptomatic
relief. However, a significant proportion of truly asymptomatic patients can
be closely monitored. In HCM patients, exercise echocardiography has been
shown to be a useful assessment of functional capacity and risk
stratification. Methods We included 426 HCM patients (44 ± 14 years; 78%
men) undergoing exercise echocardiography, excluding hypertensive heart
disease of elderly, ejection fraction <50% and invasive therapy (myectomy or
alcohol ablation) during follow-up. Clinical, echocardiographic (LV
thickness, LVOT gradient, and MR) and exercise variables (percent of age-sex
predicted metabolic equivalents [METs] and heart rate recovery [HRR] at 1
min post-exercise) were recorded. A composite endpoint of death, appropriate
internal defibrillator discharge, and admission for congestive heart failure
was recorded. Results Patients were asymptomatic or minimally symptomatic on
history, but 82% of patients achieved <100% of age-sex predicted METs, and
43% had ≥II+ post-stress MR. The mean LV septal thickness, post-exercise
LVOT gradient, and HRR were 2.0 ± 0.5 cm, 62 ± 47 mm Hg, and 31 ± 14
beats/min, respectively. During a mean follow-up of 8.7 ± 3 years, there
were 52 events (12%). Patients achieving >100% of age-sex predicted METs had
1% event rate versus 12% in those achieving <85%. On stepwise multivariate
survival analysis, percent of age-sex predicted METs (hazard ratio [HR]:
0.76; 95% confidence interval [CI]: 0.64 to 0.90), abnormal HRR (HR: 0.89;
95% CI: 0.82 to 0.97), and atrial fibrillation (HR: 2.73; 95% CI: 1.30 to
5.74) (overall, p < 0.001) independently predicted outcomes. Conclusions In
asymptomatic or minimally symptomatic HCM patients, exercise stress testing
provides excellent risk stratification, with a low event rate in patients
achieving >100% of predicted METs. © 2014 BY THE AMERICAN COLLEGE OF
CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER INC.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
echocardiography
exercise echocardiography
hypertrophic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
congestive heart failure
defibrillator
Doppler echocardiography
echocardiograph
female
follow up
heart left ventricle outflow tract obstruction
heart left ventricle wall
heart rate
heart rate recovery
human
major clinical study
male
metabolic equivalent
priority journal
stress echocardiography
survival
treadmill exercise
DEVICE TRADE NAMES
Acuson Sequoia , United StatesSiemens Medical Solutions
HDI 5000 , United StatesPhilips Medical Systems
DEVICE MANUFACTURERS
(United States)Philips Medical Systems
(United States)Siemens Medical Solutions
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014046095
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jcmg.2013.08.010
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 237
TITLE
Acupuncture Needling Styles and Reports of Associated Adverse Reactions to
Acupuncture
AUTHOR NAMES
McDowell J.M.
Johnson G.M.
AUTHOR ADDRESSES
(McDowell J.M., jillianmmcdowell@gmail.com) Prohealth Physiotherapy, 124
Kelvin Street, Invercargill, New Zealand.
(Johnson G.M.) Centre for Health, School of Physiotherapy, University of
Otago, Dunedin, New Zealand.
CORRESPONDENCE ADDRESS
J.M. McDowell, Prohealth Physiotherapy, 124 Kelvin Street, Invercargill, New
Zealand.
SOURCE
Medical Acupuncture (2014) 26:5 (271-278). Date of Publication: 1 Oct 2014
ISSN
1933-6594 (electronic)
1933-6586
BOOK PUBLISHER
Mary Ann Liebert Inc., info@liebertpub.com
ABSTRACT
Introduction: Physiotherapy acupuncturists in New Zealand are encouraged to
voluntarily report adverse reactions to acupuncture (ARA) in a scheme
administered by their professional organization and provide information
regarding the style of acupuncture used in these events.Methods: This was a
cross-sectional descriptive study.Results: An analysis of 176 reports
submitted from 1998 to 2013 showed that 81% of signs and symptoms reported
as an ARA were minor in nature. Of these reports, sustained needling and dry
needling styles were associated with 76% and 18% of major ARA, respectively.
Proportionately, dry needling, however, had a 3% more major-to-minor
reactions, compared to sustained needling. Conclusions: On the basis of
these findings, recommendations are made for future ARA reporting to include
dry needling practitioners into ARA reporting systems. It is also
recommended to incorporate details of acupuncture needling style into future
reporting templates so as to understand harm associated with these different
approaches better. © Copyright 2014, Mary Ann Liebert, Inc. 2014.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
acupuncture adverse reaction (complication)
iatrogenic disease (complication)
EMTREE MEDICAL INDEX TERMS
acupressure
adolescent
adult
adverse outcome
angina pectoris (complication)
article
atrial fibrillation (complication)
child
Chinese medicine
cross-sectional study
descriptive research
faintness (complication)
female
headache (complication)
heart palpitation (complication)
hematoma (complication)
human
hyperhidrosis (complication)
infection (complication)
injection site pain (complication)
major clinical study
male
medical society
needlestick injury (complication)
New Zealand
periosteum
physiotherapist
pneumothorax (complication)
skin manifestation (complication)
swelling (complication)
trigger point
ulcerogenesis (complication)
voluntary reporting
vomiting (complication)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014934448
FULL TEXT LINK
http://dx.doi.org/10.1089/acu.2014.1060
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 238
TITLE
Three questions to the human brain
AUTHOR NAMES
Secher N.H.
AUTHOR ADDRESSES
(Secher N.H., niels.secher@regionh.dk) Department of Anesthesia,
Rigshospitalet 2041, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.
CORRESPONDENCE ADDRESS
N. H. Secher, Department of Anesthesia, Rigshospitalet 2041, Blegdamsvej 9,
DK-2100 Copenhagen Ø, Denmark. Email: niels.secher@regionh.dk
SOURCE
Periodicum Biologorum (2014) 116:1 (9-14). Date of Publication: March 2014
ISSN
0031-5362
BOOK PUBLISHER
Croatian Society of Natural Sciences
ABSTRACT
An approximately 20% increase in cerebral blood flow (CBF) and the cerebral
metabolic rate for oxygen manifest during whole body exercise with
determination of brain tissue flow and arterial inflow to the brain. Yet,
during intense exercise CBF approaches the resting level in response to the
decrease in arterial carbon dioxide tension with the exponential increase in
ventilation. Here it is illustrated that the increase in CBF during exercise
appears to depend to the ability to raise cardiac output and it is
speculated whether there is a sympathetic restrain on CBF when the increase
in cardiac output is small. Furthermore, it is considered whether the
restrain in CBF during intense exercise affects cerebral oxygenation to an
extent that it provokes so-called central fatigue. Finally it is highlighted
that the cerebral activation associated with exercise provokes uptake of
carbohydrate, notably of lactate, that cannot be accounted for by the
concomitant increase in the cerebral metabolic rate for oxygen and it is
pointed out that it remains unknown why that apparently surplus carbohydrate
uptake by the brain is in need.
EMTREE DRUG INDEX TERMS
noradrenalin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain
EMTREE MEDICAL INDEX TERMS
arterial carbon dioxide tension
article
atrial fibrillation
brain blood flow
carotid artery
cerebral metabolic rate of oxygen
exercise
heart output
human
near infrared spectroscopy
CAS REGISTRY NUMBERS
noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
Physiology (2)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014510848
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 239
TITLE
A cohort study examination of established and emerging risk factors for
atrial fibrillation: The Busselton Health Study
AUTHOR NAMES
Knuiman M.
Briffa T.
Divitini M.
Chew D.
Eikelboom J.
McQuillan B.
Hung J.
AUTHOR ADDRESSES
(Knuiman M., Matthew.knuiman@uwa.edu.au; Briffa T.; Divitini M.) School of
Population Health (M431), University of Western Australia, Crawley, WA 6009,
Australia.
(Chew D.) Department of Cardiovascular Medicine, Flinders University,
Southern Adelaide Local Health Network, Flinders Drive, Bedford Park, SA
5042, Australia.
(Eikelboom J.) Department of Medicine, McMaster Clinic, McMaster University,
237 Barton St. E., Hamilton, ON L8L, Canada.
(McQuillan B.; Hung J.) School of Medicine and Pharmacology (M503), Sir
Charles Gairdner Hospital, University of Western Australia, G Block Hospital
Avenue, Nedlands, WA 6009, Australia.
CORRESPONDENCE ADDRESS
M. Knuiman, School of Population Health (M431), University of Western
Australia, Crawley, WA 6009, Australia. Email: Matthew.knuiman@uwa.edu.au
SOURCE
European Journal of Epidemiology (2014) 29:3 (181-190). Date of Publication:
March 2014
ISSN
1573-7284 (electronic)
0393-2990
BOOK PUBLISHER
Kluwer Academic Publishers
ABSTRACT
Atrial fibrillation (AF) is the most common chronic arrhythmia in adults and
its prevalence is increasing. Due to its serious cardiovascular
complications there is a strong need to understand predisposing risk factors
to develop effective prevention strategies. There are a few established risk
factors but a number of further risk factors have been suggested including
obesity, metabolic syndrome, sleep-disordered breathing, and inflammation.
The aim of this study was to investigate established and emerging risk
factors for AF in a cohort study of 4,267 adults in Busselton, Western
Australia, without a history of AF at baseline in 1994/95 who were followed
for 15 years for incident AF events. Baseline measurement included
questionnaire, clinical assessment and blood sample. A total of 343 (8 %)
experienced AF during follow-up. Cox regression analysis confirmed advancing
age, male sex, taller height, being on hypertension treatment and higher
body mass index (BMI) as the major common risk factors (all p < 0.001).
However, further modelling showed the effect of being on hypertension
treatment may be stronger in women (p = 0.001) and the effect of BMI
stronger in men (p = 0.004). After adjustment for these factors, no other
factors were strongly related (p < 0.001) although short PR interval,
history of valvular heart disease, stroke, chronic obstructive pulmonary
disease, lung function and adiponectin level were marginally related (p <
0.05). This cohort study of predictors for incident AF has confirmed the
major established risk factors. However, recently suggested potential novel
risk factors for AF (inflammation, sleep-disordered breathing,
glucose/metabolic disorders) were not confirmed in this study. © 2014
Springer Science+Business Media.
EMTREE DRUG INDEX TERMS
adiponectin (endogenous compound)
antilipemic agent
cholesterol (endogenous compound)
glucose (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
insulin (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (epidemiology)
cardiovascular risk
EMTREE MEDICAL INDEX TERMS
adult
age distribution
aged
alcohol consumption
antihypertensive therapy
article
Australia
blood sampling
body height
body mass
cerebrovascular accident
chronic kidney disease
chronic obstructive lung disease
clinical assessment
cohort analysis
diabetes mellitus
exercise
female
follow up
heart failure
heart infarction
heart left bundle branch block
heart left ventricle hypertrophy
heart muscle revascularization
human
hypertension
lung function
major clinical study
male
medical history
metabolic syndrome X
middle aged
peripheral occlusive artery disease
PR interval
predictor variable
questionnaire
risk assessment
sex difference
sleep disordered breathing
smoking
transient ischemic attack
valvular heart disease
waist circumference
waist hip ratio
CAS REGISTRY NUMBERS
adiponectin (283182-39-8)
cholesterol (57-88-5)
glucose (50-99-7, 84778-64-3)
insulin (9004-10-8)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014320054
FULL TEXT LINK
http://dx.doi.org/10.1007/s10654-013-9875-y
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 240
TITLE
Familial arrhythmogenic right ventricular dysplasia in afrocaribbeans:
Treadmill stress test the key to early diagnosis
AUTHOR NAMES
Williams-Phillips S.
AUTHOR ADDRESSES
(Williams-Phillips S., sandrap@cwjamaica.com) Andrews Memorial Hospital, TAI
Wing, 27 Hope Road, Kingston 10, Jamaica.
CORRESPONDENCE ADDRESS
S. Williams-Phillips, Andrews Memorial Hospital, TAI Wing, 27 Hope Road,
Kingston 10, Jamaica. Email: sandrap@cwjamaica.com
SOURCE
Cardiometry (2014) :4 (86-93). Date of Publication: 2014
ISSN
2304-7232 (electronic)
BOOK PUBLISHER
Novyi Russkii Universitet, info@rosnou.ru
ABSTRACT
Arrhythmogenic right ventricular dysplasia is a rare entity and a
significant cause of sudden death especially in the Italian population and
athletes. The familial form is uncommon especially in the Afro-Caribbean
population. This Index family represents an Autosomal Dominant form in a
maternal parent who had sudden death at 39 years of age. The Index case was
diagnosed at 18 years with increasing palpitations since 8 years of age,
becoming symptomatic two decades younger than her mother. This was confirmed
using the Treadmill Stress test. This is the 1st Case of Familial
Arrhythmogenic right ventricular dysplasia documented in an Afro-Caribbean
family. Learning objective Familial Arrhythmogenic right ventricular
dysplasia is a rare entity and a significant cause of sudden death
especially in the Italian population and athletes. This the first case of
Autosomal Dominant type of ARVD with variable penetrance, documented in an
Afro-Caribbean family where diagnosis was aided by Ventricular Tachycardia
occurring during a Treadmill Stress Test.
EMTREE DRUG INDEX TERMS
atenolol (drug therapy)
digoxin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
early diagnosis
exercise test
familial arrhythmogenic right ventricular dysplasia (drug therapy,
diagnosis, drug therapy)
heart right ventricle dysplasia (drug therapy, diagnosis, drug therapy)
treadmill
treadmill stress test
EMTREE MEDICAL INDEX TERMS
adult
African Caribbean
article
athlete
atrial fibrillation
cardiovascular magnetic resonance
case report
computer assisted tomography
defibrillator
dizziness
ECG abnormality
exercise
fatigue
female
heart atrium flutter
heart palpitation
heart rate
heart ventricle contraction
heart ventricle tachycardia
human
New York Heart Association class
QRS complex
repolarization
sinus arrhythmia
sudden death
systolic heart murmur
T wave
thorax pain
transthoracic echocardiography
tricuspid valve regurgitation
young adult
CAS REGISTRY NUMBERS
atenolol (29122-68-7, 93379-54-5)
digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014396646
FULL TEXT LINK
http://dx.doi.org/10.12710/cardiometry.2014.4.8693
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 241
TITLE
Regulatory and occupational considerations in cardiology
AUTHOR NAMES
Nunain S.O.
Jagathesan T.
AUTHOR ADDRESSES
(Nunain S.O.) Royal Sussex County Hospital, Brighton, United Kingdom.
(Nunain S.O.) Civil Aviation Authority, United Kingdom.
(Jagathesan T.) Department in Occupational and Aviation Medicine, Civil
Aviation Authority, United Kingdom.
SOURCE
Medicine (United Kingdom) (2014) 42:11 (670-675). Date of Publication: 2014
ISSN
1365-4357 (electronic)
1357-3039
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
For any occupation, the level of acceptable medical incapacitation risk
needs to be defined (e.g airline pilots ≤1% per annum, HGV drivers <2% per
annum). Guidelines from Civil Aviation Authority (CAA), Driver Vehicle
Licensing Agency (DVLA) and consensus statements for athletes are the most
useful reference points when making occupational decisions in patients with
cardiological disease particularly those in higher-risk occupations. Common
findings on screening ECGs and regulatory decisions in arrhythmias, coronary
artery and structural heart disease are discussed.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
ajmaline
dipeptidyl carboxypeptidase inhibitor
flecainide
hydroxymethylglutaryl coenzyme A reductase inhibitor
isoprenaline
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
heart disease
occupational health
EMTREE MEDICAL INDEX TERMS
anticoagulant therapy
aorta valve disease
aorta valve replacement
article
atrial fibrillation
atrioventricular block
Brugada syndrome
cardiac resynchronization therapy
cardiomyopathy
catheter ablation
clinical decision making
congenital heart disease
congestive cardiomyopathy
consensus
coronary artery bypass surgery
coronary artery disease
drug eluting stent
electrocardiogram
electrocardiography
exercise
family history
first degree atrioventricular block
heart arrhythmia
heart atrium flutter
heart bundle branch block
heart infarction
heart left bundle branch block
heart pacing
heart septum defect
heart ventricle arrhythmia
high risk patient
human
hypertrophic cardiomyopathy
implantable cardioverter defibrillator
long QT syndrome
mitral valve disease
mitral valve stenosis
occupation
occupational hazard
physical examination
PR interval
priority journal
provocation test
risk factor
second degree atrioventricular block
supraventricular tachycardia
transcatheter aortic valve implantation
transluminal coronary angioplasty
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
ajmaline (4360-12-7, 73089-81-3)
flecainide (54143-55-4)
isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Occupational Health and Industrial Medicine (35)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015931099
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 242
TITLE
Predictive factors for postoperative complications in radical nephrectomy
for renal cell carcinoma
AUTHOR NAMES
Wongvittavas N.
Panumatrassamee K.
Opanuraks J.
Usawachintachit M.
Ratchanon S.
Tantiwongse K.
Bunyaratavej C.
Santi-ngamkun A.
Prasopsanti K.
AUTHOR ADDRESSES
(Wongvittavas N.; Panumatrassamee K., kamol_uro@hotmail.com; Opanuraks J.;
Usawachintachit M.; Ratchanon S.; Tantiwongse K.; Bunyaratavej C.;
Santi-ngamkun A.; Prasopsanti K.) Division of Urology, Department of
Surgery, Chulalongkorn University, Bangkok, Thailand.
CORRESPONDENCE ADDRESS
K. Panumatrassamee, Division of Urology, Department of Surgery,
Chulalongkorn University, Bangkok, Thailand.
SOURCE
Asian Biomedicine (2014) 8:6 (763-769). Date of Publication: 1 Dec 2014
ISSN
1875-855X (electronic)
1905-7415
BOOK PUBLISHER
Asian Biomedicine, chulamed@md.chula.ac.th
ABSTRACT
Background: Radical nephrectomy is the treatment of choice for large renal
cell carcinoma (RCC). Objectives: To describe the complications after
radical nephrectomy for suspected or proven RCC and analyze the risk
factors. Materials and methods: We retrospectively reviewed medical records
from 110 patients who underwent radical nephrectomy for RCC in our
institution between January 2007 and December 2013. The clinicopathological
data of all patients were recorded and complications were graded using
modified Clavien classification. Univariate and multivariate analysis was
made of the predictive factors for complications. Results: Fifty
postoperative complications occurred in 34 patients (31%) within 30 days,
including 11% transfusion related complications. There were 22% minor
complications (6% grade 1, 16% grade 2) and 9% major complication (5% grade
3, 2% grade 4, and 2% grade 5). The most common complications were
transfusion-related, re-laparotomy because of bleeding, and prolong ileus.
In univariate analysis, pathological T-stage (P = 0.001), American Society
of Anesthesiologists (ASA) score (P = 0.007), tumor size (P = 0.01), and
tumor diameter >4 cm (P = 0.03) were significant predicting factors. Major
Charlson comorbidity index (CCI >2) was the only significant factor for
major complications (P = 0.04). In multivariate analysis, ASA score was a
significant independent predictor for overall complications (odds ratio
4.83, P = 0.01). Conclusions: ASA score was a significant predictive factor
for overall postoperative complications. Comorbidities was also a predictor
for major complications in radical nephrectomy. Preoperative risk
stratification for complications should be considered during decision-making
and for proper counseling of patients.
EMTREE DRUG INDEX TERMS
antibiotic agent (drug therapy)
anticoagulant agent (drug therapy)
antihypertensive agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
kidney carcinoma (surgery)
nephrectomy
postoperative complication (drug therapy, complication, drug therapy,
therapy)
radical nephrectomy
EMTREE MEDICAL INDEX TERMS
abdominal surgery
acute kidney failure (complication, therapy)
acute kidney tubule necrosis (complication)
adult
American Society of Anesthesiologists score
anemia (complication, therapy)
aorta rupture (complication)
article
assessment of humans
atelectasis (complication, therapy)
atrial fibrillation (complication, drug therapy)
body mass
brain ischemia (complication)
breathing exercise
cancer staging
cancer surgery
Charlson Comorbidity Index
comorbidity
congestive heart failure (complication)
conservative treatment
controlled study
epilepsy (complication)
female
fever (complication)
hemodialysis
human
hypertension (complication, drug therapy)
lung embolism (complication, drug therapy)
major clinical study
male
metastasis
multiple organ failure (complication)
operation duration
patient history of surgery
percutaneous drainage
pleura effusion (complication)
pneumonia (complication, drug therapy)
postoperative hemorrhage (complication)
postoperative ileus (complication)
prolonged drain leakage (complication)
retrospective study
risk factor
septic shock (complication)
small intestine obstruction (complication, therapy)
surgical approach
surgical infection (complication)
total parenteral nutrition
transfusion
transient ischemic attack (complication, drug therapy)
tumor volume
urinary tract infection (complication, drug therapy)
vertigo (complication)
wound closure
wound dehiscence (complication)
wound dressing
EMBASE CLASSIFICATIONS
Cancer (16)
Urology and Nephrology (28)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015758100
FULL TEXT LINK
http://dx.doi.org/10.5372/1905-7415.0806.355
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 243
TITLE
Postoperative delirium: Risk factors, prevention, and treatment
AUTHOR NAMES
Trabold B.
Metterlein T.
AUTHOR ADDRESSES
(Trabold B., benedikt.trabold@klinik.uni-regensburg.de; Metterlein T.)
Department of Anesthesiology, University Hospital Regensburg, Franz-Jo-
sef-Strauss-Allee 11, Regensburg, Germany.
CORRESPONDENCE ADDRESS
B. Trabold, Department of Anesthesiology, University Hospital Regensburg,
Franz-Jo- sef-Strauss-Allee 11, Regensburg, Germany.
SOURCE
Journal of Cardiothoracic and Vascular Anesthesia (2014) 28:5 (1352-1360).
Date of Publication: 1 Oct 2014
ISSN
1532-8422 (electronic)
1053-0770
BOOK PUBLISHER
W.B. Saunders
EMTREE DRUG INDEX TERMS
albumin (endogenous compound)
antidepressant agent
antihistaminic agent
benzodiazepine derivative
cholinergic receptor blocking agent
clonidine
dexmedetomidine
fentanyl
gabapentin
haloperidol
hydroxymethylglutaryl coenzyme A reductase inhibitor
inotropic agent
olanzapine
risperidone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
postoperative delirium
EMTREE MEDICAL INDEX TERMS
anemia
atrial fibrillation
blood transfusion
cerebrovascular accident
cognitive defect
dehydration
dementia
depression
diabetes mellitus
disease predisposition
early diagnosis
electrolyte disturbance
epidemiology
EuroSCORE
exercise
functional disease
hearing aid
heart infarction
heart output
human
hyperthyroidism
hypothyroidism
hypoxia
kidney failure
malnutrition
mobilization
nutritional status
operation duration
pain
patient education
perfusion pressure
pharmaceutical care
review
risk factor
shock
sleep
sunlight
systemic inflammatory response syndrome
visual aid
CAS REGISTRY NUMBERS
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
dexmedetomidine (113775-47-6)
fentanyl (437-38-7)
gabapentin (60142-96-3)
haloperidol (52-86-8)
olanzapine (132539-06-1)
risperidone (106266-06-2)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2014853089
FULL TEXT LINK
http://dx.doi.org/10.1053/j.jvca.2014.03.017
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 244
TITLE
The ESH/ESC guidelines for the management of arterial hypertension
AUTHOR NAMES
Arden C.
AUTHOR ADDRESSES
(Arden C.)
(Arden C.) GPSI Cardiology, Southampton, United Kingdom.
CORRESPONDENCE ADDRESS
C. Arden, Chandlers Ford, United Kingdom.
SOURCE
Primary Care Cardiovascular Journal (2014) 7:2 (85-88). Date of Publication:
April-June 2014
ISSN
1756-5146 (electronic)
1756-5138
BOOK PUBLISHER
Sherborne Gibbs Limited, agreathead@sherbornegibbs.co.uk
ABSTRACT
There still remains a significant gap between the goal of optimal treatment
of hypertension and 'real life' practice. As a consequence, hypertension
remains a leading cause of cardiovascular-related morbidity and mortality.
There is a continuing need to improve both the detection and management of
hypertension, with a view to improving the efficacy of treatment including
lifestyle interventions and outcomes. In order to address these issues, the
European Society of Hypertension (ESH) and the European Society of
Cardiology (ESC) have recently published guidance on the management of
arterial hypertension.(1).
EMTREE DRUG INDEX TERMS
alcohol
alpha adrenergic receptor blocking agent
angiotensin receptor antagonist (drug combination, drug therapy)
beta adrenergic receptor blocking agent
calcium antagonist (drug combination, drug therapy)
creatinine (endogenous compound)
dipeptidyl carboxypeptidase inhibitor (drug combination, drug therapy)
mineralocorticoid antagonist
thiazide diuretic agent (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hypertension (drug therapy, drug therapy)
practice guideline
EMTREE MEDICAL INDEX TERMS
alcohol consumption
antihypertensive therapy
asymptomatic disease
atrial fibrillation
bleeding
blood pressure monitoring
blood pressure regulation
cardiovascular mortality
cardiovascular risk
cerebrovascular accident
chronic kidney disease
comorbidity
creatinine blood level
diastolic blood pressure
dynamic exercise
geriatric patient
glomerulus filtration rate
human
ischemic heart disease
lifestyle modification
long term care
medical history
medical society
microalbuminuria
papilledema
physical examination
physician
prognosis
renin angiotensin aldosterone system
resistant hypertension
review
smoking cessation
target organ
transient ischemic attack
treatment indication
CAS REGISTRY NUMBERS
alcohol (64-17-5)
creatinine (19230-81-0, 60-27-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014433725
FULL TEXT LINK
http://dx.doi.org/10.3132/pccj.2014.011
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 245
TITLE
33(rd) Annual Scientific Meeting of Belgian Society of Cardiology
AUTHOR ADDRESSES
SOURCE
Acta Cardiologica (2014) 68:1 (68). Date of Publication: 2014
CONFERENCE NAME
33(rd) Annual Scientific Meeting of Belgian Society of Cardiology
CONFERENCE LOCATION
Bruxelles, Belgium
CONFERENCE DATE
2014-01-30 to 2014-01-31
ISSN
0001-5385
0373-7934 (electronic)
ABSTRACT
The proceedings contain 51 papers. The special focus in this conference is
on Cardiology. The topics include: The management of newly diagnosed atrial
fibrillation in Belgium; duty-cycled multi-electrode RF versus irrigated
point-by-point RF for ablation of recurrent atrial fibrillation; a family
with recurrent sudden death; pulmonary vein isolation using a novel
multi-electrode circular catheter; episodes of subclinical atrial
tachyarrhythmia are not associated with worse outcome in cardiac
resynchronization therapy patients; contact force sensing open irrigated
catheter reduces by half the early recurrence of atrial fibrillation after
pulmonary veins isolation for paroxysmal atrial fibrillation; partial or
complete isolation of the left atrial posterior wall increase drastically
the absence of AF recurrence after an index ablation for persistent atrial
fibrillation; right ventricular fatigue developing during endurance
exercise; myocardial inflammation in experimental acute right ventricular
failure. effects of epoprostenol infusion; endothelin-1 contributes to the
down regulation of the BMPR2 signalling observed in patients with pulmonary
arterial hypertension; pulmonary vasoreactivity in spontaneously
hypertensive rats; high fidelity simulation is useful to improve
resuscitation skills in paediatric cardiology; myocardial expression of
cytokines influence post-operative outcome after cardiac surgery for
congenital cardiac defects; 20-year single centre experience of heart
transplantation in children and adolescents; introduction of a heart failure
nurse for the support of in-hospital management of mainly elderly patients
with acute HF results in a shorter hospitalisation duration, a higher
prescription of evidence based medication and a better outcome after 1 year
follow-up; the impact of left ventricle assist device on microvascular
function; galectin-3 testing with the Vidas® assay in patients with heart
failure; novel urinary biomarkers in detecting acute kidney injury,
persistent renal impairment and all-cause mortality following decongestive
therapy in acute decompensated heart failure; implementation of transmural
disease management in patients admitted with advanced heart failure;
uptitration of neurohumoral blockers in hospitalized heart failure patients
with reduced versus preserved ejection fraction; 3-year clinical follow-up
of the PYTON (Prospective Evaluation of the TRYTON Side-Branch Stent TMwith
an additional XIENCE-VTM Everolimus-Eluting Stent in Coronary Bifurcation
Lesions) study; drug-eluting versus bare-metal stents after rotational
atherectomy; multidimensional geriatric assessment in patients (> 75 years)
suffering from severe, symptomatic aortic valve stenosis; interstrut
cavities are associated with delayed vessel wall healing in biolimus- and
everolimus-eluting stents; evaluation of peri-strut low intensity areas
after biolimus--and everolimus-eluting stent implantation; adiponectin and
ischemia-reperfusion injury in ST elevation myocardial infarction; a useful
tool for discriminating between anterior infarction and transient left
ventricular ballooning syndrome; improvement prehospital and inhospital
delays before PCI for STEMI in a rural area over a 15-year period;
functional performance and quality of life in highrisk comorbid patients
undergoing transcatheter aortic valve implantation for symptomatic aortic
valve stenosis; a simple clinical test to predict clopidogrel resistance;
features of myocardial infarction in young patients; primary percutaneous
coronary intervention in coronary artery bypass graft patients; comparison
of temporal trends in mortality rates of cardiovascular origin in Belgium
and in the ICAPROS area; drug-eluting stents for the treatment of pulmonary
vein stenosis after atrial fibrillation ablation; cardiac malformations in
neonates born from mothers with gestational diabetes; percutaneous left
atrial appendage closure with the AmplatzerTM cardiac plug; functional
impact of transmitral gradients at rest and during exercise after
restrictive annuloplasty for ischemic mitral regurgitation; tricuspid
annuloplasty concomitant with mitral valve surgery; reference values for the
oxygen uptake efficiency slope in healthy men and women aged 20-60 years;
huge multiple myxoma of the right ventricle revealed by right heart failure
(about a case); ewing sarcoma invading the right atrium (about a single
case); low gradient severe aortic stenosis in octogenarian patients with
preserved ejection fraction; left atrium function in normal subjects,
assessed by mitral annulus speckle tracking; acute exposure to diesel
exhaust increases pulmonary arterial resistance but does not enhance
pulmonary hypoxic vasoconstriction; retrospective analysis of treatment of
hyperkalemia and prospective evaluation of the impact of remote monitoring
to follow patient with implantable device in the routine practice of an
electrophysiological centre.
EMTREE DRUG INDEX TERMS
adiponectin
biological marker
clopidogrel
cytokine
endothelin 1
everolimus
galectin 3
prostacyclin
umirolimus
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
society
EMTREE MEDICAL INDEX TERMS
acute heart failure
acute kidney failure
adolescent
aged
annuloplasty
aorta stenosis
aorta valve stenosis
artery resistance
assay
atrial fibrillation
bare metal stent
Belgium
blood vessel wall
cardiac resynchronization therapy
catheter
child
congenital malformation
coronary artery bypass graft
coronary bifurcation lesion
devices
disease management
down regulation
drug eluting stent
drug therapy
electrode
endurance training
evidence based practice
Ewing sarcoma
exercise
exhaust gas
exposure
fatigue
female
follow up
geriatric assessment
healing
heart atrium appendage
heart atrium function
heart ejection fraction
heart failure
heart infarction
heart left atrium
heart left ventricle
heart right atrium
heart right ventricle
heart right ventricle failure
heart surgery
heart transplantation
hospital management
human
hyperkalemia
implantation
infarction
infusion
male
mitral valve
mitral valve regurgitation
mortality
mother
myocarditis
myxoma
newborn
normal human
nurse
oxygen consumption
patient
percutaneous coronary intervention
pregnancy diabetes mellitus
prescription
pulmonary hypertension
pulmonary vein
pulmonary vein isolation
pulmonary vein obstruction
quality of life
reference value
remote sensing
reperfusion injury
resuscitation
rotational atherectomy
rural area
simulation
skill
spontaneously hypertensive rat
ST segment elevation myocardial infarction
stent
sudden death
tachycardia
takotsubo cardiomyopathy
therapy
transcatheter aortic valve implantation
tricuspid annuloplasty
vasoconstriction
ventricular assist device
very elderly
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
FULL TEXT LINK
http://dx.doi.org/10.2143/AC.69.1.3011350
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 246
TITLE
Safety of acupuncture treatments for patients taking warfarin or
antiplatelet medications: Retrospective chart review study
AUTHOR NAMES
Kim Y.-J.
Kim S.-K.
Cho S.-Y.
Park S.-U.
Jung W.-S.
Moon S.-K.
Ko C.-N.
Cho K.-H.
Kim S.-B.
Shin W.-C.
Park J.-M.
AUTHOR ADDRESSES
(Kim Y.-J.; Kim S.-K.) Department of Korean Medicine Graduate School, Kyung
Hee University, Seoul, South Korea.
(Cho S.-Y.; Park S.-U.; Ko C.-N.; Park J.-M., pajama@khu.ac.kr) Department
of Korean Internal Medicine, Stroke and Neurological Disorders Center, Kyung
Hee University Hospital at Gangdong Kyung Hee University, Seoul, South
Korea.
(Jung W.-S.; Moon S.-K.; Cho K.-H.) Department of Cardiology and Neurology,
College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
(Kim S.-B.; Shin W.-C.) Department of Neurology, Stroke and Neurological
Disorders Center, Kyung Hee University Hospital at Gangdong Kyung Hee
University, Seoul, South Korea.
CORRESPONDENCE ADDRESS
J.-M. Park, Department of Korean Internal Medicine, Stroke and Neurological
Disorders Center, Kyung Hee University Hospital at Gangdong, #892 Dongnam-ro
Gangdong-gu, Seoul, South Korea.
SOURCE
European Journal of Integrative Medicine (2014) 6:4 (492-496). Date of
Publication: 2014
ISSN
1876-3839 (electronic)
1876-3820
BOOK PUBLISHER
Elsevier GmbH, info@elsevier-deutschland.de
ABSTRACT
Introduction: Anticoagulant and antiplatelet therapy are widely used as
preventive measures and treatment for cardiovascular and cerebrovascular
diseases. Bleeding is a significant complication of anticoagulant and
antiplatelet medications. With the growing use of acupuncture and the
potential concomitant use of such medications, studies on the safety of
acupuncture are necessary. The objective of this study was to evaluate the
safety of acupuncture for patients taking warfarin or antiplatelet
medications by comparing the rate of side effects for patients who did not
take either of these medications. Methodology: The medical records were
searched to identify patients who had received acupuncture treatments at the
Department of Korean Internal Medicine of Stroke and Neurological Disorders
Center, Kyung Hee University Hospital at Gangdong between November 2010 and
April 2012. Prescribed medications were identified from medical records and
each patient was allocated to one of three groups based on the medication
they were taking. Group A were taking warfarin, group B were taking
antiplatelet medications but not warfarin, group C took neither warfarin nor
antiplatelet medications and acted as a control group. Potential side
effects that could be attributed to of acupuncture were identified. Results:
A total of 242 patients and 4891 acupuncture treatments were identified. No
patients experienced serious adverse events such as extensive bleeding. The
occurrence rate of microbleeding (bleeding which stopped within 30. s) was
4.8% for group A, 0.9% for group B and 3.0% for group C. Conclusion:
Acupuncture treatment appears safe even for patients taking warfarin or
antiplatelet medications. Large-scale, well-designed studies are needed to
confirm these results. This article belongs to the Special Issue:
'IG000019'.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antithrombocytic agent
warfarin
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
cilostazol
clopidogrel
indobufen
triflusal
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
anticoagulant therapy
patient safety
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation
bleeding (complication)
diabetes mellitus
dizziness (complication)
edema (complication)
exhaustion (complication)
faintness (complication)
fatigue (complication)
female
human
hypertension
international normalized ratio
major clinical study
male
nausea (complication)
pain (complication)
pneumothorax (complication)
priority journal
pruritus (complication)
rash (complication)
retrospective study
skin bruising (complication)
vomiting (complication)
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
cilostazol (73963-72-1)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
indobufen (36690-96-7, 63610-08-2)
triflusal (322-79-2)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014711094
FULL TEXT LINK
http://dx.doi.org/10.1016/j.eujim.2014.04.004
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 247
TITLE
Atrial Fibrillation and Heart Failure: Cause or Effect?
AUTHOR NAMES
Luong C.
Barnes M.E.
Tsang T.S.M.
AUTHOR ADDRESSES
(Luong C.; Barnes M.E.; Tsang T.S.M., t.tsang@ubc.ca) Division of
Cardiology, University of British Columbia, 2775 Laurel Street, Vancouver,
Canada.
CORRESPONDENCE ADDRESS
T.S.M. Tsang, Division of Cardiology, University of British Columbia, 2775
Laurel Street, Vancouver, Canada.
SOURCE
Current Heart Failure Reports (2014) 11:4 (463-470). Date of Publication:
2014
ISSN
1546-9549 (electronic)
1546-9530
BOOK PUBLISHER
Current Science Inc., info@current-reports.com
ABSTRACT
Atrial fibrillation (AF) and heart failure (HF) are two epidemics of the
century that have a close and complex relationship. The mechanisms
underlying this association remain an area of ongoing intense research. In
this review, we will describe the relationship between these two public
health concerns, the mechanisms that fuel the development and perpetuation
of both, and the evolving concepts that may revolutionize our approach to
this dual epidemic.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
heart failure
EMTREE MEDICAL INDEX TERMS
age
alcohol consumption
cardiovascular mortality
cardiovascular risk
comorbidity
coronary artery disease
diabetes mellitus
disease course
disease free survival
exercise
genetic predisposition
heart atrium contraction
heart ejection fraction
human
hypertension
incidence
inflammation
ischemic cardiomyopathy
lifestyle modification
lung disease
metabolic syndrome X
nonhuman
nonischemic cardiomyopathy
obesity
prevalence
primary prevention
quality of life
review
sleep disordered breathing
smoking
tachycardia induced cardiomyopathy
thyroid disease
valvular heart disease
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014813374
FULL TEXT LINK
http://dx.doi.org/10.1007/s11897-014-0229-1
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 248
TITLE
Dual atrioventricular nodal pathways physiology: A review of relevant
anatomy, electrophysiology, and electrocardiographic manifestations
AUTHOR NAMES
Mani B.C.
Pavri B.B.
AUTHOR ADDRESSES
(Mani B.C., bhalaghuru.cm@gmail.com; Pavri B.B.) Jefferson Medical College
of Thomas Jefferson University, 925 Chestnut Street, Mezzanine,
Philadelphia, PA19107, United States.
CORRESPONDENCE ADDRESS
B. C. Mani, Department of Medicine, Thomas Jefferson University Hospital,
803 College Building, 1025 Walnut Street, Philadelphia, PA19107, United
States. Email: bhalaghuru.cm@gmail.com
SOURCE
Indian Pacing and Electrophysiology Journal (2014) 14:1 (12-25). Date of
Publication: January/February 2014
ISSN
0972-6292 (electronic)
BOOK PUBLISHER
Indian Pacing and Electrophysiology Group, Pulikkottil Thondayad, Calicut
Kerala, India.
ABSTRACT
More than half a century has passed since the concept of dual
atrioventricular (AV) nodal pathways physiology was conceived. Dual AV nodal
pathways have been shown to be responsible for many clinical arrhythmia
syndromes, most notably AV nodal reentrant tachycardia. Although there has
been a considerable amount of research on this topic, the subject of dual AV
nodal pathways physiology remains heavily debated and discussed. Despite
advances in understanding arrhythmia mechanisms and the widespread use of
invasive electro physiologic studies, there is still disagreement on the
anatomy and physiology of the AV node that is the basis of discontinuous
antegrade AV conduction. The purpose of this paper is to review the concept
of dual AV nodal pathways physiology and its varied electro cardiographic
manifestations.
EMTREE DRUG INDEX TERMS
adenosine (drug dose, drug therapy, pharmacology)
antiarrhythmic agent (pharmacology)
atropine (drug comparison, drug therapy, pharmacology)
beta adrenergic receptor (endogenous compound)
connexin 43 (endogenous compound)
esmolol (pharmacology)
isoprenaline (drug comparison, drug therapy, pharmacology)
propranolol (pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
dual atrioventricular nodal pathway physiology
ECG abnormality (diagnosis)
heart electrophysiology
EMTREE MEDICAL INDEX TERMS
adrenergic stimulation
antiarrhythmic activity
atrial fibrillation (diagnosis, etiology)
atrioventricular conduction
atrioventricular nodal reentry tachycardia (diagnosis, drug therapy,
etiology)
beta adrenergic receptor blocking
complete heart block (diagnosis, etiology)
double fire tachycardia (diagnosis, etiology)
double ventricular response (diagnosis, etiology)
drug activity
drug efficacy
drug megadose
electrocardiography
exercise
heart arrhythmia (diagnosis, etiology)
heart atrioventricular node
heart depolarization
heart excitation
heart left ventricle filling
heart muscle refractory period
heart rate
heart ventricle extrasystole (diagnosis, etiology)
human
long RP interval (diagnosis)
low drug dose
nonhuman
parasympathetic block
pathophysiology
PR interval
prolonged PR interval (diagnosis)
protein expression
pseudointerpolation (diagnosis)
QRS complex
retrograde P wave (diagnosis)
review
RR interval
short PR interval (diagnosis)
short RP interval (diagnosis)
sinus rhythm
supraventricular premature beat (diagnosis, etiology)
sympathetic blocking
tachycardia related cardiomyopathy (diagnosis, etiology)
vagus nerve stimulation
vagus tone
Wenckebach period
CAS REGISTRY NUMBERS
adenosine (58-61-7)
atropine (51-55-8, 55-48-1)
esmolol (81147-92-4, 81161-17-3)
isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014007631
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 249
TITLE
The left atrium: From the research laboratory to the clinic
AUTHOR NAMES
Dean Boudoulas K.
Paraskevaidis I.A.
Boudoulas H.
Triposkiadis F.K.
AUTHOR ADDRESSES
(Dean Boudoulas K.; Boudoulas H.) Division of Cardiovascular Medicine, Ohio
State University, Columbus, OH, United States.
(Paraskevaidis I.A.) Medical School, University of Athens, Greece.
(Boudoulas H.) Biomedical Research Foundation, Academy of Athens, Athens,
Greece.
(Boudoulas H.) Aristotelian University of Thessaloniki, Thessaloniki,
Greece.
(Triposkiadis F.K., filtrip@yahoo.com) Medical School, University of
Thessaly, Larissa, Greece.
(Triposkiadis F.K., filtrip@yahoo.com) Department of Cardiology, Larissa
University Hospital, PO Box 1425, GR-411 10 Larissa, Greece.
SOURCE
Cardiology (Switzerland) (2014) 129:1 (1-17). Date of Publication: August
2014
ISSN
1421-9751 (electronic)
0008-6312
BOOK PUBLISHER
S. Karger AG
ABSTRACT
Studies of left atrial (LA) function, until the latter part of the 20th
century, were mostly limited to experimental animal models and to studies
related to clinical research in the cardiac catheterization laboratory. For
this reason, LA function has received considerably less attention than left
ventricular (LV) functions, even though evidence suggests that LA myopathy
and failure may exist as an isolated entity, precede and/or coexist with LV
myopathy. The introduction of echocardiography and Doppler echocardiography
in clinical practice has contributed significantly to our understanding of
LA function and its interrelationships with the LV, aorta, pulmonary artery
and other parts of the cardiovascular system. In addition, LA with the
secretion of atrial natriuretic peptides is playing an important role in
cardiovascular and neurohumoral homeostasis. Today, it is well known that LA
structural and functional abnormalities that are present in many diseases
and disorders constitute a powerful prognostic indicator. As technology
(echocardiography, magnetic resonance imaging, computed tomography and
others) continues to evolve, it is expected that, in the near future, LA
structure and function will be routinely used as LV function is used today.
© 2014 S. Karger AG, Basel.
EMTREE DRUG INDEX TERMS
atrial natriuretic factor (endogenous compound)
neurohormone (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart atrium function
heart left atrium
EMTREE MEDICAL INDEX TERMS
aging
aorta
article
atrial fibrillation
cardiomyopathy
cardiopulmonary function
cardiovascular function
cardiovascular homeostasis
cardiovascular system
clinical practice
clinical research
computer assisted tomography
Doppler echocardiography
echocardiography
electrocardiogram
endocrine function
exercise
fluoroscopy
heart atrium remodeling
heart catheterization
heart failure
heart left ventricle function
homeostasis
human
left atrium myopathy
meta analysis (topic)
myopathy
neurohumoral homeostasis
nonhuman
nuclear magnetic resonance imaging
physical examination
priority journal
prognosis
protein secretion
pulmonary artery
thorax radiography
three dimensional echocardiography
CAS REGISTRY NUMBERS
atrial natriuretic factor (85637-73-6)
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014578254
FULL TEXT LINK
http://dx.doi.org/10.1159/000360935
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 250
TITLE
Clinical characteristics and circumstances of death in the sudden arrhythmic
death syndrome
AUTHOR NAMES
Mellor G.
Raju H.
De Noronha S.V.
Papadakis M.
Sharma S.
Behr E.R.
Sheppard M.N.
AUTHOR ADDRESSES
(Mellor G.; Raju H.; De Noronha S.V.; Papadakis M.; Sharma S.; Behr E.R.;
Sheppard M.N., msheppar@sgul.ac.uk) Cardiovascular Sciences Research Centre,
St george'S, University of London, London, United Kingdom.
(De Noronha S.V.; Sheppard M.N., msheppar@sgul.ac.uk) Cardiovascular
Pathology Department, St george'S, University of London, Cranmer Terr,
London, United Kingdom.
CORRESPONDENCE ADDRESS
M.N. Sheppard, Cardiovascular Pathology Department, St george'S, University
of London, Cranmer Terr, London, United Kingdom.
SOURCE
Circulation: Arrhythmia and Electrophysiology (2014) 7:6 (1078-1083). Date
of Publication: 1 Dec 2014
ISSN
1941-3084 (electronic)
1941-3149
BOOK PUBLISHER
Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
Background: Sudden cardiac death (SCD) is a devastating event in the young.
Referral to a specialist cardiac pathologist is recommended. Age, sex, and
circumstances of death may reflect underlying diagnoses. We aim to describe
the demographics of victims and circumstances surrounding sudden cardiac
death with a normal heart (ie, sudden arrhythmic death syndrome). Methods
and Results: There were 2156 cases of sudden cardiac death from across the
United Kingdom referred to a tertiary cardiac pathology service from 1994 to
2010. We analyzed 967 consecutive cases (61% male; median age 29 years) with
a normal heart at postmortem. Information from referring coroners' reports
was used to ascertain clinical information. Familial evaluation was
performed in 5% of cases. Information from these cases was used to determine
the likely accuracy of coronial reports. Deaths during sleep or at rest were
more common than deaths during exercise or with emotional stress: 82% versus
16%. Death with exercise/stress was more common in males (relative risk,
2.33; 95% confidence interval, 1.56-3.47; P<0.001) and those under 18 years
of age: males, relative risk, 2.41 (95% confidence interval, 1.69-3.13;
P<0.001) and females, relative risk, 2.91 (95% confidence interval,
1.80-4.01; P<0.001)). Prior syncope (4.1%), documented arrhythmia (3.4%),
and family history of sudden death (4.2%) were uncommon. Epilepsy had been
diagnosed in 6.6%. Conclusions: Death caused by sudden arrhythmic death
syndrome is more common at rest or during sleep. Death with exercise/stress
is more common in males and those aged below 18 years. Up to 90% of SADS
victims have no preceding symptoms or recognized risk factors for sudden
death. Epilepsy may be considered a risk factor for SADS.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
sudden cardiac death (etiology)
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
autopsy
cause of death
clinical evaluation
clinical feature
emotional stress
epilepsy
exercise
faintness
family history
female
heart arrhythmia
heart atrioventricular node
heart left bundle branch block
heart muscle conduction disturbance
heart ventricle tachycardia
histopathology
human
long QT syndrome
major clinical study
male
priority journal
rest
risk assessment
sleep
supraventricular tachycardia
United Kingdom
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015868465
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCEP.114.001854
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 251
TITLE
P-wave dispersion and its relationship to aortic stiffness in patients with
acute myocardial infarction after cardiac rehabilitation
AUTHOR NAMES
Acar R.D.
Bulut M.
Ergün S.
Yesin M.
Boztosun B.
Akçakoyun M.
AUTHOR ADDRESSES
(Acar R.D., denizacar_1999@yahoo.com; Bulut M.; Yesin M.; Boztosun B.;
Akçakoyun M.) Department of Cardiology, Kartal Kosuyolu Education and
Research Hospital, Istanbul, Turkey.
(Ergün S.) Department of Physical Therapy and Rehabilitation, Kartal
Kosuyolu Education and Research Hospital, Istanbul, Turkey.
CORRESPONDENCE ADDRESS
R. D. Acar, Department of Cardiology, Kartal Kosuyolu Education and Research
Hospital, Istanbul, Turkey. Email: denizacar_1999@yahoo.com
SOURCE
ARYA Atherosclerosis (2014) 10:4 (185-191). Date of Publication: 2014
ISSN
2251-6638 (electronic)
1735-3955
BOOK PUBLISHER
Isfahan University of Medical Sciences(IUMS), Hezar Jerib Avenue, P.O. Box
81745-319, Isfahan, Iran.
ABSTRACT
BACKGROUND: The aim of our study was to investigate the P-wave dispersion
from standard electrocardiograms (ECGs) in patients with acute myocardial
infarction (AMI) after cardiac rehabilitation (CR) and determine its
relation to arterial stiffness. METHODS: This is a prospective study
included 33 patients with AMI and successfully re-vascularized by
percutaneous coronary intervention (PCI) underwent CR. Left ventricular
ejection fraction (LVEF) was measured by biplane Simpson's method. Left
atrium (LA) volume was calculated. The maximum and minimum durations of
P-waves (Pmax and Pmin, respectively) were detected, and the difference
between Pmax and Pmin was defined as P-wave dispersion (Pd = Pmax-Pmin).
Aortic elasticity parameters were measured. RESULTS: LVEF was better after
CR. The systolic and diastolic blood pressures decreased after CR, these
differences were statistically significant. With exercise training, LA
volume decreased significantly. Pmax and Pd values were significantly
shorter after the CR program. The maximum and minimum P-waves and P-wave
dispersion after CR were 97 ± 6 ms, 53 ± 5 ms, and 44 ± 5 ms, respectively.
Aortic strain and distensibility increased and aortic stiffness index was
decreased significantly. Aortic stiffness index was 0.4 ± 0.2 versus 0.3 ±
0.2, P = 0.001. Aortic stiffness and left atrial volume showed a moderate
positive correlation with P-wave dispersion (r = 0.52, P = 0.005; r = 0.64,
P = 0.000, respectively). CONCLUSION: This study showed decreased arterial
stiffness indexes in AMI patient's participated CR, with a significant
relationship between the electromechanical properties of the LA that may
raise a question of the preventive effect of CR from atrial fibrillation and
stroke in patients with acute myocardial infarction.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute heart infarction (rehabilitation)
arterial stiffness
heart rehabilitation
P wave
p wave dispersion
EMTREE MEDICAL INDEX TERMS
adult
annulus fibrosus
article
blood pressure
clinical article
Doppler echocardiography
exercise
female
heart atrium conduction
heart left ventricle ejection fraction
heart muscle revascularization
human
male
percutaneous coronary intervention
prospective study
tissue Doppler imaging
DEVICE TRADE NAMES
Vivid 7 , NorwayVingmed
DEVICE MANUFACTURERS
(Norway)Vingmed
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014493629
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 252
TITLE
Consumption of Nuts in the Prevention of Cardiovascular Disease
AUTHOR NAMES
Sabaté J.
Wien M.
AUTHOR ADDRESSES
(Sabaté J., jsabate@llu.edu; Wien M., mwien@llu.edu) Department of
Nutrition, School of Public Health, Loma Linda University, 24951 N. Circle
Drive, Nichol Hall 1102, Loma Linda, CA, 92350, United States.
(Sabaté J., jsabate@llu.edu) Department of Epidemiology and Biostatistics,
Loma Linda University, Loma Linda, CA, United States.
CORRESPONDENCE ADDRESS
J. Sabaté, Department of Nutrition, School of Public Health, Loma Linda
University, 24951 N. Circle Drive, Nichol Hall 1102, Loma Linda, CA, 92350,
United States. Email: jsabate@llu.edu
SOURCE
Current Nutrition Reports (2013) 2:4 (258-266). Date of Publication:
December 2013
ISSN
2161-3311 (electronic)
BOOK PUBLISHER
Current Science Inc., 400 Market Street, Suite 700, Philadelphia, United
States.
ABSTRACT
The leading cause of morbidity and mortality in highly developed and low-
and middle-income nations is cardiovascular disease (CVD). The establishment
of healthy dietary patterns is one of the cornerstones of CVD prevention,
and nuts have emerged as favorable components of dietary patterns associated
with reducing the CVD epidemic. The etiological connection between nuts for
the prevention of CVD is based upon several lines of evidence. First, nuts
are nutrient-dense whole foods that contain a distinctive mix of
macronutrients, specific micronutrients and non-nutrients that have been
associated with cardioprotection. Second, numerous human feeding trials have
demonstrated that nut intake improves the serum lipid profile, reduces
oxidation and inflammation, and improves vascular reactivity. Third, nut
consumption is consistently associated with a reduced risk of CVD in many
epidemiological studies. Lastly, a recent large randomized clinical trial
conducted in Spain demonstrated that consuming mixed nuts daily lowers CVD
risk by 30 %. © 2013 Springer Science+Business Media New York.
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
endothelial leukocyte adhesion molecule 1 (endogenous compound)
high density lipoprotein (endogenous compound)
intercellular adhesion molecule 1 (endogenous compound)
interleukin 6 (endogenous compound)
low density lipoprotein (endogenous compound)
monounsaturated fatty acid (endogenous compound)
polyunsaturated fatty acid (endogenous compound)
saturated fatty acid (endogenous compound)
trace element
triacylglycerol (endogenous compound)
unsaturated fatty acid (endogenous compound)
vascular cell adhesion molecule 1 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease
nut
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiovascular mortality
cardiovascular risk
dietary fiber
disease association
DNA damage
food intake
glycemic index
human
hypercholesterolemia
hypertension
incidence
inflammation
lipid analysis
lipid oxidation
macronutrient
Mediterranean diet
meta analysis (topic)
outcome assessment
oxidative stress
prevalence
priority journal
randomized controlled trial (topic)
review
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
endothelial leukocyte adhesion molecule 1 (128875-25-2)
intercellular adhesion molecule 1 (126547-89-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013687472
FULL TEXT LINK
http://dx.doi.org/10.1007/s13668-013-0059-x
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 253
TITLE
Role of Echocardiography in the Assessment of Right Heart Disease: Update
2013
AUTHOR NAMES
Tan T.C.
Hung J.
AUTHOR ADDRESSES
(Tan T.C.; Hung J., jhung@partners.org) Cardiac Ultrasound Laboratory, Blake
256 Division of Cardiology, Massachusetts General Hospital and Harvard
Medical School, 55 Fruit Street, Boston, MA, 02114-2696, United States.
CORRESPONDENCE ADDRESS
J. Hung, Cardiac Ultrasound Laboratory, Blake 256 Division of Cardiology,
Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street,
Boston, MA, 02114-2696, United States. Email: jhung@partners.org
SOURCE
Current Cardiovascular Imaging Reports (2013) 6:6 (486-497). Date of
Publication: December 2013
ISSN
1941-9066
1941-9074 (electronic)
BOOK PUBLISHER
Current Medicine Group LLC, 400 Market St,, Ste 700 Philadelphia, United
States.
ABSTRACT
The right heart plays a significant role in overall cardiac function, with
right heart diseases shown to have similar clinical impact as left heart
diseases. Despite the availability of a number of imaging modalities for the
assessment of the right heart, echocardiography remains the first line
imaging modality of choice based on its advantages of being safe, readily
accessible and cost effective. Currently, echocardiography whether by the
transthoracic or transesophageal approach, plays an important role in the
diagnosis and ongoing management of patients with right heart disease. While
two dimensional imaging is the mainstay of echocardiographic assessment of
the right heart, the availability of more advanced echocardiographic
techniques has improved our ability to assess right heart function and a
range of right heart pathologies. These techniques apart from overcoming
some of the inherent challenges associated with two dimensional imaging of
the right heart, have also provided invaluable insights into the physiology
of the right heart and pathophysiology of a range of right heart related
diseases. © 2013 Springer Science+Business Media New York.
EMTREE DRUG INDEX TERMS
phosphodiesterase inhibitor (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
echocardiography
heart failure (drug therapy, diagnosis, drug therapy, therapy)
heart left ventricle function
EMTREE MEDICAL INDEX TERMS
algorithm
atrial fibrillation
diabetes mellitus
Doppler echocardiography
exercise
heart atrium function
heart failure with preserved ejection fraction
heart infarction
heart left ventricle filling pressure
human
hypertension
left ventricular diastolic dysfunction
mortality
pathophysiology
pulmonary hypertension
quality of life
randomized controlled trial (topic)
review
tricuspid valve regurgitation
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013714852
FULL TEXT LINK
http://dx.doi.org/10.1007/s12410-013-9235-z
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 254
TITLE
Dramatic loss of weight in an obese patient with heart failure: A mighty
heart in a big man
AUTHOR NAMES
Di Bello V.
Conte L.
Fabiani I.
Barletta V.
Pieruzzi L.
Scartabelli G.
Santini F.
AUTHOR ADDRESSES
(Di Bello V., vitantonio.dibello@med.unipi.it; Conte L.; Fabiani I.;
Barletta V.) Department of Surgery, Medical, Molecular and Critical Area
Pathology, University of Pisa, Via Paradisa 2, Cisanello, 56100 Pisa, Italy.
(Pieruzzi L.; Scartabelli G.; Santini F.) Department of Clinical and
Experimental Medicine, University of Pisa, Pisa, Italy.
CORRESPONDENCE ADDRESS
V. Di Bello, Department of Surgery, Medical, Molecular and Critical Area
Pathology, University of Pisa, Via Paradisa 2, Cisanello, 56100 Pisa, Italy.
Email: vitantonio.dibello@med.unipi.it
SOURCE
Heart and Metabolism (2013) :61 (29-31). Date of Publication: November 2013
Heart failure and metabolic disease, Book Series Title:
ISSN
1566-0338
BOOK PUBLISHER
Les Laboratoires Seriver, 50 Rue Carnot, F-92284, Suresnes Cedex, France.
ABSTRACT
Obesity has reached global epidemic proportions and has been associated with
numerous comorbidities, including major cardiovascular diseases and heart
failure. It has many adverse effects on hemodynamics and cardiovascular
structure and function; it increases total blood volume and cardiac output,
and also activates several neurohumoral systems that play an important role
in causing cardiac dysfunction. Typically, obese patients have a higher
cardiac output but a lower level of total peripheral resistance at any given
level of arterial pressure. Over the past few years, experimental evidence
has unraveled some important pathogenetic mechanisms that may underlie a
specific form of "obesity cardiomyopathy". However, many unanswered
questions remain regarding the pathophysiological interactions between
obesity and the heart. © 2013 by ISSN.
EMTREE DRUG INDEX TERMS
albumin (intravenous drug administration)
aldosterone antagonist
brain natriuretic peptide (endogenous compound)
canrenoate potassium
carvedilol
cholinesterase (endogenous compound)
creatinine (endogenous compound)
digitalis
diuretic agent
furosemide (intravenous drug administration, oral drug administration)
hemoglobin (endogenous compound)
ramipril
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure (diagnosis)
obesity
weight reduction
EMTREE MEDICAL INDEX TERMS
adult
anasarca
anemia
angiocardiography
article
atrial fibrillation
blood gas analysis
blood sampling
body mass
body weight
cardiomegaly
case report
cholinesterase blood level
creatinine blood level
dyspnea
echocardiography
electrocardiogram
elephantiasis
emergency ward
gas exchange
glomerulus filtration rate
heart amyloidosis
heart ejection fraction
heart left ventricle enddiastolic volume
heart left ventricle function
heart left ventricle volume
heart muscle perfusion
heart right bundle branch block
hemoglobin blood level
hospital discharge
hospitalization
human
human tissue
hypergammaglobulinemia
hypokinesia
kidney failure (complication)
kidney function
light chain
limb injury
liver dysfunction
liver failure (complication)
liver function
low calory diet
lung congestion
male
middle aged
myocardial perfusion imaging
nuclear magnetic resonance imaging
priority journal
quality of life
respiratory failure (complication)
tachycardia
tachypnea
thorax radiography
water deprivation
weight gain
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
canrenoate potassium (2181-04-6)
carvedilol (72956-09-3)
cholinesterase (9001-08-5)
creatinine (19230-81-0, 60-27-5)
digitalis (8031-42-3, 8053-83-6)
furosemide (54-31-9)
hemoglobin (9008-02-0)
ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014027114
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 255
TITLE
Ankle-brachial index long-term outcome after first-ever ischaemic stroke
AUTHOR NAMES
Milionis H.
Vemmou A.
Ntaios G.
Makaritsis K.
Koroboki E.
Papavasileiou V.
Savvari P.
Spengos K.
Elisaf M.
Vemmos K.
AUTHOR ADDRESSES
(Milionis H., hmilioni@uoi.gr; Elisaf M.) Department of Internal Medicine,
School of Medicine, University of Ioannina, Ioannina, Greece.
(Vemmou A.; Koroboki E.; Savvari P.; Spengos K.; Vemmos K.) Acute Stroke
Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens,
Greece.
(Ntaios G.; Makaritsis K.; Papavasileiou V.) Department of Medicine and
Research lab, University of Thessaly, Larissa, Greece.
CORRESPONDENCE ADDRESS
H. Milionis, Department of Internal Medicine, School of Medicine, University
of Ioannina, Ioannina, Greece. Email: hmilioni@uoi.gr
SOURCE
European Journal of Neurology (2013) 20:11 (1471-1478). Date of Publication:
November 2013
ISSN
1351-5101
1468-1331 (electronic)
BOOK PUBLISHER
Blackwell Publishing Ltd, 9600 Garsington Road, Oxford, United Kingdom.
ABSTRACT
Background and purpose: Ankle-brachial blood pressure index (ABI) is a
clinical tool to identify the presence of peripheral artery disease. There
is a scarcity of data associating ABI with long-term outcome in patients
with IS. The association between ABI and long-term outcome in patients with
first-ever acute IS was assessed. Methods: Ankle-brachial blood pressure
index was assessed in all consecutive patients with a first-ever acute IS
admitted at Alexandra University hospital (Athens, Greece) between January
2005 and December 2010. ABI was considered normal when > 0.90 and ≤ 1.30.
The Kaplan-Meier product limit method was used to estimate the probability
of 5-year composite cardiovascular event-free (defined as recurrent stroke,
myocardial infarction or cardiovascular death) and overall survival. A
multivariate analysis was performed to assess whether ABI is an independent
predictor of 5-year mortality and dependence. Results: Amongst 653 patients,
129 (19.8%) with ABI ≤ 0.9 were identified. Five-year cumulative composite
cardiovascular event-free and overall survival rates were better in normal
ABI stroke patients (log-rank test: 7.22, P = 0.007 and 23.40, P < 0.001,
respectively). There was no difference in 5-year risk of stroke recurrence
between low and normal ABI groups (hazard ratio, HR = 1.23, 95%CI
0.68-2.23). In multivariate Cox regression analysis, independent predictors
of 5-year mortality included age (HR = 2.55 per 10 years, 95%CI 1.86-3.48, P
< 0.001), the National Institutes of Health Stroke Scale (per point increase
HR = 1.12, 95%CI 1.08-1.16, P < 0.001), and low ABI (HR = 2.22, 95%CI
1.22-4.03, P = 0.009). Age (HR = 1.21 per 10 years, 95%CI 1.01-1.45, P =
0.04) and low ABI (HR = 1.72, 95%CI 1.11-2.67, P = 0.01) were independent
predictors of the composite cardiovascular end-point. Conclusions: Low ABI
in patients with acute IS is associated with increased 5-year cardiovascular
event risk and mortality. However, ABI does not appear to predict long-term
stroke recurrence. © 2013 EFNS.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
anticoagulant agent (drug therapy, oral drug administration)
beta adrenergic receptor blocking agent (drug therapy)
calcium antagonist (drug therapy)
diuretic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
ankle brachial index
brain ischemia (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
anticoagulation
article
atrial fibrillation
cardiovascular mortality
cardiovascular risk
carotid endarterectomy
computer assisted tomography
diabetes mellitus
disease severity
event free survival
exercise
female
follow up
heart failure
heart infarction
human
hypertension (drug therapy)
intermittent claudication
major clinical study
male
mortality
National Institutes of Health Stroke Scale
outcome assessment
priority journal
Rankin scale
recurrent disease
sex ratio
smoking cessation
smoking habit
stroke patient
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013657511
FULL TEXT LINK
http://dx.doi.org/10.1111/ene.12208
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 256
TITLE
Patient safety and estimation of renal function in patients prescribed new
oral anticoagulants for stroke prevention in atrial fibrillation: A
cross-sectional study
AUTHOR NAMES
MacCallum P.K.
Mathur R.
Hull S.A.
Saja K.
Green L.
Morris J.K.
Ashman N.
AUTHOR ADDRESSES
(MacCallum P.K., p.k.maccallum@qmul.ac.uk; Morris J.K.) Wolfson Institute of
Preventive Medicine, Barts and The London School of Medicine and Dentistry,
Queen Mary University of London, London, United Kingdom.
(MacCallum P.K., p.k.maccallum@qmul.ac.uk; Green L.) Department of
Haematology, Barts Health NHS Trust, London, United Kingdom.
(Mathur R.; Hull S.A.) Blizard Institute, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London, London, United
Kingdom.
(Saja K.) Department of Haematology, Barking, Havering and Redbridge
University Hospitals NHS Trust, London, United Kingdom.
(Green L.) NHS Blood and Transplant, London, United Kingdom.
(Ashman N.) Department of Nephrology, Barts Health NHS Trust, London, United
Kingdom.
CORRESPONDENCE ADDRESS
P.K. MacCallum, Wolfson Institute of Preventive Medicine, Barts and The
London School of Medicine and Dentistry, Queen Mary University of London,
London, United Kingdom. Email: p.k.maccallum@qmul.ac.uk
SOURCE
BMJ Open (2013) 3:9 Article Number: e003343. Date of Publication: 2013
ISSN
2044-6055 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
Objective: In clinical trials of dabigatran and rivaroxaban for stroke
prevention in atrial fibrillation (AF), drug eligibility and dosing were
determined using the Cockcroft-Gault equation to estimate creatine clearance
as a measure of renal function. This cross-sectional study aimed to compare
whether using estimated glomerular filtration rate (eGFR) by the widely
available and widely used Modified Diet in Renal Disease (MDRD) equation
would alter prescribing or dosing of the renally excreted new oral
anticoagulants. Participants: Of 4712 patients with known AF within a
general practitioner-registered population of 930 079 in east London, data
were available enabling renal function to be calculated by both
Cockcroft-Gault and MDRD methods in 4120 (87.4%). Results: Of 4120 patients,
2706 were <80 years and 1414 were ≥80 years of age. Among those ≥80 years,
14.9% were ineligible for dabigatran according to Cockcroft-Gault equation
but would have been judged eligible applying MDRD method. For those <80
years, 0.8% would have been incorrectly judged eligible for dabigatran and
5.3% would have received too high a dose. For rivaroxaban, 0.3% would have
been incorrectly judged eligible for treatment and 13.5% would have received
too high a dose. Conclusions: Were the MDRD-derived eGFR to be used instead
of Cockcroft-Gault in prescribing these new agents, many elderly patients
with AF would either incorrectly become eligible for them or would receive
too high a dose. Safety has not been established using the MDRD equation, a
concern since the risk of major bleeding would be increased in patients with
unsuspected renal impairment. Given the potentially widespread use of these
agents, particularly in primary care, regulatory authorities and drug
companies should alert UK doctors of the need to use the Cockcroft-Gault
formula to calculate eligibility for and dosing of the new oral
anticoagulants in elderly patients with AF and not rely on the MDRD-derived
eGFR.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (oral drug administration)
dabigatran (drug dose, drug therapy)
rivaroxaban (drug therapy)
EMTREE DRUG INDEX TERMS
warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cerebrovascular accident (drug therapy, drug therapy, prevention)
kidney function
patient safety
EMTREE MEDICAL INDEX TERMS
adult
aged
article
bleeding (side effect)
controlled study
creatinine clearance
cross-sectional study
dose response
drug dose reduction
female
general practitioner
glomerulus filtration rate
human
major clinical study
male
modified diet in renal disease equation
prescription
primary medical care
renal clearance
scoring system
United Kingdom
CAS REGISTRY NUMBERS
rivaroxaban (366789-02-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013640634
FULL TEXT LINK
http://dx.doi.org/10.1136/bmjopen-2013-003343
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 257
TITLE
Physical activity ameliorates cardiovascular health in elderly subjects: The
functional role of the β adrenergic system
AUTHOR NAMES
Santulli G.
Ciccarelli M.
Trimarco B.
Iaccarino G.
AUTHOR ADDRESSES
(Santulli G., gaetano.santulli@unina.it) Department of Translational Medical
Sciences, Federico II University, Naples, Italy.
(Santulli G., gaetano.santulli@unina.it; Trimarco B.) Department of Advanced
Biomedical Sciences, Federico II University, Naples, Italy.
(Santulli G., gaetano.santulli@unina.it) College of Physicians and Surgeons,
New York Presbyterian Hospital, Columbia University in the City of New York,
Manhattan, NY, United States.
(Ciccarelli M.; Iaccarino G.) Department of Medicine and Surgery, University
of Salerno, Salerno, Italy.
(Iaccarino G.) Multimedica Research Hospital, Milan, Italy.
CORRESPONDENCE ADDRESS
G. Santulli, Department of Translational Medical Sciences, Department of
Advanced Biomedical Sciences, Federico II University, Via Sergio Pansini, 5,
n. 2, 80131 Naples, Italy. Email: gaetano.santulli@unina.it
SOURCE
Frontiers in Physiology (2013) 4 AUG Article Number: Article 209. Date of
Publication: 2013
ISSN
1664-042X (electronic)
BOOK PUBLISHER
Frontiers Media SA, EPFL Innovation Square, Building I, Lausanne,
Switzerland.
ABSTRACT
Aging is a complex process characterized by a gradual decline in organ
functional reserves, which eventually reduces the ability to maintain
homeostasis. An exquisite feature of elderly subjects, which constitute a
growing proportion of the world population, is the high prevalence of
cardiovascular disorders, which negatively affect both the quality of life
and the life expectancy. It is widely acknowledged that physical activity
represents one of the foremost interventions capable in reducing the health
burden of cardiovascular disease. Interestingly, the benefits of
moderate-intensity physical activity have been established both in young and
elderly subjects. Herein we provide a systematic and updated appraisal of
the literature exploring the pathophysiological mechanisms evoked by
physical activity in the elderly, focusing on the functional role of the ß
adrenergic system. © 2013 Santulli, Ciccarelli, Trimarco and Iaccarino.
EMTREE DRUG INDEX TERMS
beta 2 adrenergic receptor (endogenous compound)
catecholamine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adrenergic system
aging
cardiovascular disease (etiology)
physical activity
EMTREE MEDICAL INDEX TERMS
aerobic exercise
atherosclerosis (etiology)
atrial fibrillation
disease course
functional disease
functional status
health status
heart failure
heart left ventricle hypertrophy
heart muscle oxygen consumption
heart performance
heart ventricle hypertrophy
heart work
homeostasis
human
hypertension
life expectancy
molecular biology
muscle exercise
nonhuman
pathophysiology
physical capacity
prevalence
quality of life
running
short survey
skeletal muscle
treadmill exercise
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013604533
FULL TEXT LINK
http://dx.doi.org/10.3389/fphys.2013.00209
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 258
TITLE
Lymphangiopathy in neurofibromatosis 1 manifesting with chylothorax,
pericardial effusion, and leg edema
AUTHOR NAMES
Finsterer J.
Stollberger C.
Stubenberger E.
Tschakoschian S.
AUTHOR ADDRESSES
(Finsterer J., fifigs1@yahoo.de) Krankenanstalt Rudolfstiftung, Vienna,
Austria.
(Stollberger C.) Medical Department, Krankenanstalt Rudolfstiftung, Vienna,
Austria.
(Stubenberger E.) Thoracic Surgery Department, Vienna, Austria.
(Tschakoschian S.) Interne Lungenabt, Vienna, Austria.
CORRESPONDENCE ADDRESS
J. Finsterer, Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna,
Austria. Email: fifigs1@yahoo.de
SOURCE
International Journal of General Medicine (2013) 6 (743-746). Date of
Publication: 2013
ISSN
1178-7074 (electronic)
BOOK PUBLISHER
Dove Medical Press Ltd., PO Box 300-008, Albany, Auckland, New Zealand.
ABSTRACT
Background: This case report documents the affliction of the lymph vessels
as a phenotypic feature of neurofibromatosis-1 (NF-1). Methodology: Routine
transthoracic echocardiography, computed tomography scan of the thorax,
magnetic resonance angiography of the renal arteries, and conventional
digital subtraction angiography were applied. Comprehensive NF-1 mutation
analysis was carried out by fluorescence in situ hybridization analysis,
long-range reverse transcriptase polymerase chain reaction, and
multiple-ligation probe assay. All other investigations were performed using
routine, well-established techniques. Results: The subject is a 34-year-old,
half-Chinese male; NF-1 was suspected at age 15 years for the first time.
His medical history included preterm birth, mild facial dysmorphism, "café
au lait" spots, subcutaneous and paravertebral fibromas, multifocal
tachycardia, atrial fibrillation, and heart failure in early infancy.
Noncalcified bone fibromas in the femur and tibia were detected at age 8
years. Surgical right leg lengthening was carried out at age 11 years.
Bilateral renal artery stenosis, stenosis and aneurysm of the superior
mesenteric artery, and an infrarenal aortic stenosis were detected at age 15
years. Leg edema and ectasia of the basilar artery were diagnosed at age 18
years. After an episode with an erysipela at age 34 years, he developed
pericardial and pleural effusion during a 4-month period. Stenosis of the
left subclavian vein at the level of thoracic duct insertion was detected.
After repeated pleural punctures, pleural effusion was interpreted as
chylothorax. Reduction of lymph fluid production by diet and injection of
talcum into the pleural cavity had a long-term beneficial effect on the
chylothorax. Leg edema and chylothorax were attributed to affliction of the
lymph vessels by the NF-1. Discussion: Lymphangiopathy resulting in impaired
lymph fluid flow and sequestration of lymph fluid into the pleural sinus and
the legs may be a rare phenotypic feature of NF-1.
EMTREE DRUG INDEX TERMS
neurofibromin (endogenous compound)
talc (drug dose, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chylothorax (drug therapy, diagnosis, drug therapy, surgery)
lymphangiopathy
lymphatic system disease
neurofibromatosis (diagnosis)
pericardial effusion
EMTREE MEDICAL INDEX TERMS
adult
artery occlusion (diagnosis)
article
cafe au lait spot
case report
clinical feature
compression garment
coronary artery ectasia (diagnosis)
DNA determination
gene
gene mutation
human
leg edema (prevention)
lung sequestration
lymph flow
lymph vessel
magnetic resonance angiography
male
medical history
neurofibroma (diagnosis)
NF1 gene
pleura effusion
repeat procedure
repeated drug dose
reverse transcription polymerase chain reaction
thorax drainage
thorax radiography
CAS REGISTRY NUMBERS
talc (14807-96-6)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Radiology (14)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Human Genetics (22)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013597807
FULL TEXT LINK
http://dx.doi.org/10.2147/IJGM.S45825
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 259
TITLE
Performance of the cockcroft-GAULT, MDRD and CKD-EPI formulae in
non-valvular atrial fibrillation: Which one should be used for risk
stratification?
AUTHOR NAMES
Barra S.
Providência R.
Faustino C.
Paiva L.
Fernandes A.
Marques A.L.
AUTHOR ADDRESSES
(Barra S.) Cardiology Department, Papworth Hospital NHS Foundation Trust,
Papworth Everard ,Cambridge CB23 3RE, United Kingdom.
(Providência R.) Cardiology Department, Clinique Pasteur, Toulouse, France.
(Providência R.; Faustino C.; Paiva L.; Fernandes A.; Marques A.L.)
Cardiology Department, Coimbra's Hospital, University Centre, Coimbra,
Portugal.
(Providência R.) Cardiology Department, Faculty of Medicine, University of
Coimbra, Coimbra, Portugal.
CORRESPONDENCE ADDRESS
S. Barra, Cardiology Department, Papworth Hospital NHS Foundation Trust,
Papworth Everard ,Cambridge CB23 3RE, United Kingdom.
SOURCE
Journal of Atrial Fibrillation (2013) 6:3 (35-44). Date of Publication:
October-November 2013
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
Background: Renal dysfunction is a strong predictor of adverse events in
patients with atrial fibrillation (AF). The Cokcroft-Gault, Modification of
Diet in Renal Disease (MDRD) and Chronic Kidney Disease-Epidemiology
Collaboration (CKD-EPI) equations are available for estimating the
glomerular filtration rate (GFR). No comparisons between these equations
have yet been performed in patients with non-valvular AF concerning their
mid-term prognostic performance. Methods: Cross-sectional study of 555
consecutive patients with non-valvular AF undergoing transesophageal
echocardiogram. We tested the prognostic performance of the aforementioned
GFR estimation formulae, namely their ability to predict all-cause mortality
(primary endpoint) and major cardiac adverse or ischemic cerebrovascular
events (secondary endpoints) during an average follow-up of 24 months.
Results: Regarding the primary endpoint, Cockcroft-Gault (AUC=0.749±0.028)
was superior to both MDRD (AUC=0.624±0.039) and CKD-EPI (AUC=0.641±0.034)
[p<0.001 both comparisons] while CKD-EPI was superior to MDRD (p=0.011).
Cockcroft-Gault was marginally superior to both MDRD (AUC=0.673±0.049 vs.
AUC=0.586±0.054, p=0.041) and CKD-EPI (AUC=0.673±0.049 vs. AUC=0.604±0.054,
p=0.063) in the prediction of ischemic cerebrovascular events, while no
difference was found between CKD-EPI and MDRD. Concerning AUC for prediction
of MACE, Cockcroft-Gault was superior to MDRD (p=0.009) and CKD-EPI
(p=0.012), while CKD-EPI was similar to MDRD (p=0.215). Multivariate
predictive models consistently included Cockcroft-Gault formula along with
CHADS2, excluding the other two equations. Measures of reclassification
revealed a significant improvement in risk stratification for all studied
endpoints with Cockcroft-Gault instead of CKD-EPI.No adverse events were
reported. Conclusions: In patients with non-valvular AF, the Cockcroft-Gault
more appropriately classified individuals with respect to risk of all-cause
mortality, ischaemic cerebrovascular event and major adverse cardiac event.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
chronic kidney disease epidemiology collaboration formula
Cockcroft Gault formula
kidney disease
mathematical parameters
modification of diet in renal disease formula
nonvalvular atrial fibrillation
EMTREE MEDICAL INDEX TERMS
aged
area under the curve
article
CHADS2 score
cross-sectional study
female
follow up
heart disease
human
major clinical study
male
mortality
performance
prediction
prognosis
risk
transesophageal echocardiography
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014060520
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 260
TITLE
Integrated approach to treatment-resistant atrial fibrillation: additional
value of acupuncture
AUTHOR NAMES
Jonkman F.A.
Jonkman-Buidin M.L.
AUTHOR ADDRESSES
(Jonkman F.A.; Jonkman-Buidin M.L.) Department of Acupuncture, Acupuncture
Outpatient Clinic Heel de Mens, Heelsum, The Netherlands.
info@humanbalance.nl
SOURCE
Acupuncture in medicine : journal of the British Medical Acupuncture Society
(2013) 31:3 (327-330). Date of Publication: 1 Sep 2013
ISSN
1759-9873 (electronic)
ABSTRACT
A 62-year-old patient with chronic bronchitis had treatment-resistant atrial
fibrillation. Electrical cardioversion was performed, but sinus rhythm (SR)
lasted only for some minutes. Administration of amiodarone was withheld in
favour of a course of acupuncture treatment in order to increase the success
rate of a second attempt of electrical cardioversion. After two acupuncture
treatments, spontaneous conversion to SR occurred. Relapses into atrial
fibrillation in the following five winters, associated with attacks of
bronchitis, also responded to acupuncture. The mechanisms of action of the
acupuncture treatment and the value of this integrated approach to treatment
are discussed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
cardioversion
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (therapy)
case report
human
male
middle aged
pathophysiology
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
MEDLINE PMID
23884291 (http://www.ncbi.nlm.nih.gov/pubmed/23884291)
FULL TEXT LINK
http://dx.doi.org/10.1136/acupmed-2013-010380
COPYRIGHT
Copyright 2015 Medline is the source for the citation and abstract of this
record.
RECORD 261
TITLE
Precipitant profile of acute heart failure: Experience of a tertiary level
cardiac centre in Sri Lanka
AUTHOR NAMES
Matthias A.T.
Ekanayaka R.
AUTHOR ADDRESSES
(Matthias A.T., thushara.matthias@gmail.com; Ekanayaka R.) Cardiology Unit,
National Hospital of Sri Lanka, Colombo, Sri Lanka.
CORRESPONDENCE ADDRESS
A.T. Matthias, Dr C V S Corea Mawatha, Hokandara Road, Thalawathugoda, Sri
Lanka. Email: thushara.matthias@gmail.com
SOURCE
Heart Asia (2013) 5:1 (86-91). Date of Publication: 2013
ISSN
1759-1104 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
Introduction and objectives: Heart failure (HF) is a common cause of
hospitalisation in most countries. Data on acute precipitants of HF and
hospitalisation is not available in Sri Lanka. Background and methods: A
prospective study of 100 sequential admissions with HF to the cardiology
unit (National Hospital of Sri Lanka) to describe the precipitants and
clinical outcome of HF. Results: Fifty-eight male and 42 female admissions
were studied. Mean age was 60.66 years. Mean hospital stay was 5.5(SD 4.6)
days. Sixty had de novo HF and 40 had pre-existing HF. The most common
identifiable precipitants were acute ischaemia 37 (37%), anaemia 41 (41%),
respiratory tract infection 10 (10%), arrhythmia 11 (11%), worsening renal
function 11 (11%) and alcohol 5 (5.7%). Non-adherence to medication 4
(4.6%), smoking 3 (3.9%), exposure to environmental stress 3 (3.4%) and
uncontrolled hypertension 1 (1%) were also observed as precipitants. The
most common arrhythmia was atrial fibrillation. Out of 34 patients in whom
angiotensin-converting enzyme inhibitors or angiotensin-converting enzyme
receptor blockers were indicated, 11% were not on the drug. Among 29
patients in whom spironolactone was indicated, seven patients were not on
the drug. Conclusions: Most precipitating factors of HF are preventable.
Early identification and prevention of anaemia, preventing respiratory tract
infection by vaccination, aggressive revascularisation for patients with
ischaemia, monitoring of renal functions, and patient education regarding
drug and diet compliance, would reduce the number of admissions.
EMTREE DRUG INDEX TERMS
dipeptidyl carboxypeptidase inhibitor
spironolactone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute heart failure
EMTREE MEDICAL INDEX TERMS
adult
aged
anemia
article
atrial fibrillation
cross-sectional study
disease severity
environmental stress
female
heart arrhythmia
hospital admission
human
hypertension
ischemia
kidney disease
major clinical study
male
outcome assessment
priority journal
prospective study
respiratory tract infection
Sri Lanka
CAS REGISTRY NUMBERS
spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013423940
FULL TEXT LINK
http://dx.doi.org/10.1136/heartasia-2013-010250
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 262
TITLE
The rates of effective INR levels and the relationship with etiology in
patients with warfarin treatment
ORIGINAL (NON-ENGLISH) TITLE
Varfarin kullanan hastalarda etkin INR düzeyi oranlari{dotless} ve etiyoloji
ile olan İlişkisi
AUTHOR NAMES
Alişir M.F.
Keçebaş M.
Beşli F.
Çalişkan S.
Güngören F.
Yildirim A.
Baran I.
Aydinlar A.
AUTHOR ADDRESSES
(Alişir M.F.) Kardiyoloji Kliniǧi, Bingöl Devlet Hastanesi, Bingöl, Turkey.
(Keçebaş M.; Beşli F., feyzullahbesli@hotmail.com; Çalişkan S.; Güngören F.;
Yildirim A.; Baran I.; Aydinlar A.) Kardiyoloji AD, Uludaǧ Üniversitesi,
Bursa, Turkey.
CORRESPONDENCE ADDRESS
F. Beşli, Uludaǧ Üniversitesi, Kardiyoloji AD, Bursa, Turkey. Email:
feyzullahbesli@hotmail.com
SOURCE
Turkiye Klinikleri Journal of Medical Sciences (2013) 33:3 (868-873). Date
of Publication: 2013
ISSN
1300-0292
BOOK PUBLISHER
Turkiye Klinikleri Journal of Medical Sciences, Talapapa Bulvary no. 102,
Hamammonu, Turkey.
ABSTRACT
Objective: Warfarin with a narrow therapeutic window has a wide range of
use. Food and drug interactions of warfarin and the individual differences
may affect the success of the warfarin treatment. The aim of this study was
to investigate the rate of effective INR levels in patients receiving
warfarin therapy due to the mechanical prosthetic valve, atrial fibrillation
(AF), intracardiac thrombus or pulmonary embolism and the relationship
between the etiology and the efficacy of warfarin. Material and Methods:
Archive records of 6450 patients presenting to the outpatient clinic of the
Department of Cardiology, Uludaǧ University, Faculty of Medicine between
January 2012-June 2012 were reviewed retrospectively. Nine hundred and
seventy-one patients receiving warfarin treatment due to mechanical
prosthetic valve, atrial fibrillation (AF), intracardiac thrombus or
pulmonary embolism were included in the study. Medical records were reviewed
for age, gender, international normalized ratio (INR) levels and indications
for the warfarin treatment given. Results: The study revealed that 47.6% of
the patients had an effective level of INR. The lowest rate of effecitve INR
levels was in groups with pulmonary embolism with 33.3% and in patients with
mitral valve replacement (MVR) with 39.6%. The highest rate was in patients
with aortic valve replacement (AVR) with 61.9%. Conclusion: The rate of
effective INR levels was relatively low. Especially, the effective INR level
of the MVR patients was significantly lower than the rate in other groups.
For patients treated with warfarin and especially patients with mechanical
prosthetic valves targeting higher INR levels, the compliance of the
patients should be questioned. In addition, considering the use of other
concomitant medications and the nutritional habits, more frequent monitoring
of INR levels is required. © 2013 by Türkiye Klinikleri.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
international normalized ratio
EMTREE MEDICAL INDEX TERMS
aorta valve replacement
article
atrial fibrillation
drug efficacy
female
human
intracardiac thrombosis (drug therapy)
lung embolism (drug therapy)
major clinical study
male
mitral valve replacement
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English, Turkish
LANGUAGE OF SUMMARY
English, Turkish
EMBASE ACCESSION NUMBER
2013387154
FULL TEXT LINK
http://dx.doi.org/10.5336/medsci.2012-32101
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 263
TITLE
Flavonoids in atherosclerosis: An overview of their mechanisms of action
AUTHOR NAMES
Siasos G.
Tousoulis D.
Tsigkou V.
Kokkou E.
Oikonomou E.
Vavuranakis M.
Basdra E.K.
Papavassiliou A.G.
Stefanadis C.
AUTHOR ADDRESSES
(Siasos G., ger_sias@hotmail.com; Tousoulis D.; Kokkou E.; Oikonomou E.;
Vavuranakis M.; Stefanadis C.) 1st Cardiology Department, University of
Athens, Medical School, Athens, Greece.
(Siasos G., ger_sias@hotmail.com; Tsigkou V.; Basdra E.K.; Papavassiliou
A.G.) Department of Biological Chemistry, University of Athens, Medical
School, Athens, Greece.
CORRESPONDENCE ADDRESS
G. Siasos, 1st Cardiology Department, University of Athens, Medical School,
Athens, Greece. Email: ger_sias@hotmail.com
SOURCE
Current Medicinal Chemistry (2013) 20:21 (2641-2660). Date of Publication:
July 2013
ISSN
0929-8673
1875-533X (electronic)
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Polyphenols are composed of a wide variety of molecules that are classified
into several categories, according to their chemical type such as phenolic
acids, flavonoids, stilbenes, and lignans. Many studies have proven the
beneficial effects of flavonoids in atherosclerosis progression and
cardiovascular disease. Dietary flavonoids reduce oxidative stress and exert
anti-inflammatory actions. Moreover, flavonoids have the ability to avoid
the thrombus formation, improve endothelial function, modify lipid levels
and regulate glucose metabolism. In the context of this evidence in this
review article we summarize the so far acquired knowledge of the most
important mechanisms of action of flavonoids in atherosclerosis progression.
© 2013 Bentham Science Publishers.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
flavonoid (drug combination, drug therapy, pharmacology)
EMTREE DRUG INDEX TERMS
anthocyanin
atorvastatin (drug combination)
biological marker (endogenous compound)
catechin (drug combination)
flavanol derivative
flavanone derivative
isoflavone derivative
lipid (endogenous compound)
polyphenol derivative
quercetin
resveratrol (drug combination)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atherosclerosis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
antihypertensive activity
antiinflammatory activity
antioxidant activity
atrial fibrillation (drug therapy)
colon flora
conjugation
coronary artery disease (drug therapy)
diet supplementation
disease course
drug absorption
drug bioavailability
drug blood level
drug effect
drug elimination
drug metabolism
drug safety
drug transport
drug uptake
environmental factor
glycosylation
heart failure (drug therapy)
human
non insulin dependent diabetes mellitus (drug therapy)
nonhuman
oxidative stress
red wine
regulatory mechanism
review
vasodilatation
CAS REGISTRY NUMBERS
atorvastatin (134523-00-5, 134523-03-8)
catechin (13392-26-2, 154-23-4)
lipid (66455-18-3)
quercetin (117-39-5)
resveratrol (501-36-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013445544
FULL TEXT LINK
http://dx.doi.org/10.2174/0929867311320210003
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 264
TITLE
Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric
bypass surgery
AUTHOR NAMES
Lee D.
DeFilipp Z.
Judson K.
Kennedy M.
AUTHOR ADDRESSES
(Lee D., dlee@wpahs.org; DeFilipp Z.) Department of Internal Medicine, West
Penn Allegheny Health System, 320 East North Avenue, Pittsburgh, PA 15212,
United States.
(Judson K.) Division of Clinical Cardiac Electrophysiology, West Penn
Allegheny Health System, Pittsburgh, PA, United States.
(Kennedy M.) Division of Hematology and Cellular Therapy, West Penn
Allegheny Health System, Pittsburgh, PA, United States.
CORRESPONDENCE ADDRESS
D. Lee, Department of Internal Medicine, West Penn Allegheny Health System,
320 East North Avenue, Pittsburgh, PA 15212, United States. Email:
dlee@wpahs.org
SOURCE
Journal of Cardiology Cases (2013) 8:1 (e49-e50). Date of Publication: July
2013
ISSN
1878-5409 (electronic)
BOOK PUBLISHER
Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
We report a 66-year-old male with a history of Roux-en-Y gastric bypass
surgery who began dabigatran for new onset atrial fibrillation. After 5
weeks of therapy, his transesophageal echocardiogram prior to
electrocardioversion showed severe spontaneous echo contrast. Cardioversion
was postponed and anticoagulant therapy was continued. The following day, he
suffered a thromboembolic stroke. Concern arose that postoperative
malabsorption could have resulted in subtherapeutic anticoagulation. This
notion was strengthened by a second patient who had subtherapeutic serum
levels despite maximal dosing. To the best of our knowledge, we are the
first to report impaired absorption of dabigatran following Roux-en-Y
gastric bypass surgery. Learning objective: Dabigatran has a predictable
pharmacokinetic profile, allowing for a fixed-dose regimen that does not
require frequent monitoring or dietary modifications. However, its
absorption in patients who have undergone Roux-en-Y gastric bypass surgery
has not been studied. Postoperative malabsoprtion, a major complication
following Roux-en-Y gastric bypass surgery, can result in inadequate
anticoagulation. As a result of unpredictable absorption, strategies
allowing for routine monitoring may be best in this population. © 2013
Japanese College of Cardiology.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dabigatran (drug therapy, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
aged
anticoagulation
article
cardioversion
case report
cerebrovascular accident
human
malabsorption (complication)
male
morbid obesity (surgery)
priority journal
stomach bypass
transesophageal echocardiography
treatment duration
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013345612
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jccase.2013.03.013
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 265
TITLE
Routine versus aggressive upstream rhythm control for prevention of early
atrial fibrillation in heart failure: Background, aims and design of the
RACE 3 study
AUTHOR NAMES
Alings M.
Smit M.D.
Moes M.L.
Crijns H.J.G.M.
Tijssen J.G.P.
Brügemann J.
Hillege H.L.
Lane D.A.
Lip G.Y.H.
Smeets J.R.L.M.
Tieleman R.G.
Tukkie R.
Willems F.F.
Vermond R.A.
Van Veldhuisen D.J.
Van Gelder I.C.
AUTHOR ADDRESSES
(Alings M.) Department of Cardiology, Amphia Hospital, Breda, Netherlands.
(Smit M.D.; Moes M.L.; Brügemann J.; Hillege H.L.; Vermond R.A.; Van
Veldhuisen D.J.; Van Gelder I.C., i.c.van.gelder@umcg.nl) Department of
Cardiology, Thoraxcenter, University of Groningen, University Medical Center
Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands.
(Crijns H.J.G.M.) Department of Cardiology, Maastricht University Medical
Center, Maastricht, Netherlands.
(Tijssen J.G.P.) Department of Cardiology, Academic Medical Center
Amsterdam, Amsterdam, Netherlands.
(Brügemann J.) Cardiac Rehabilitation Center, University Medical Center
Groningen, Groningen, Netherlands.
(Hillege H.L.) Trial Coordination Center, Department of Epidemiology,
University of Groningen, University Medical Center Groningen, Groningen,
Netherlands.
(Lane D.A.; Lip G.Y.H.) University of Birmingham Center for Cardiovascular
Sciences, City Hospital, Birmingham, United Kingdom.
(Smeets J.R.L.M.) Department of Cardiology, University Medical Center
Nijmegen, Nijmegen, Netherlands.
(Tieleman R.G.) Department of Cardiology, Martini Hospital Groningen,
Groningen, Netherlands.
(Tukkie R.) Department of Cardiology, Kennemer Gasthuis, Haarlem,
Netherlands.
(Willems F.F.) Department of Cardiology, Rijnstate Hospital, Arnhem/Velp,
Netherlands.
CORRESPONDENCE ADDRESS
Department of Cardiology, Amphia Hospital, Breda, Netherlands.
SOURCE
Netherlands Heart Journal (2013) 21:7-8 (354-363). Date of Publication: July
2013
ISSN
1568-5888
1876-6250 (electronic)
BOOK PUBLISHER
Bohn Stafleu van Loghum, P.O. Box 75971, Amsterdam, Netherlands.
ABSTRACT
Background Rhythm control for atrial fibrillation (AF) is cumbersome because
of its progressive nature caused by structural remodelling. Upstream therapy
refers to therapeutic interventions aiming to modify the atrial substrate,
leading to prevention of AF. Objective The Routine versus Aggressive
upstream rhythm Control for prevention of Early AF in heart failure (RACE 3)
study hypothesises that aggressive upstream rhythm control increases
persistence of sinus rhythm compared with conventional rhythm control in
patients with early AF and mild-to-moderate early systolic or diastolic
heart failure undergoing electrical cardioversion. Design RACE 3 is a
prospective, randomised, open, multinational, multicenter trial. Upstream
rhythm control consists of angiotensin converting enzyme inhibitors and/or
angiotensin receptor blockers, mineralocorticoid receptor antagonists,
statins, cardiac rehabilitation therapy, and intensive counselling on
dietary restrictions, exercise maintenance, and drug adherence. Conventional
rhythm control consists of routine rhythm control therapy without cardiac
rehabilitation therapy and intensive counselling. In both arms, every effort
is made to keep patients in the rhythm control strategy, and ion channel
antiarrhythmic drugs or pulmonary vein ablation may be instituted if AF
relapses. Total inclusion will be 250 patients. If upstream therapy proves
to be effective in improving maintenance of sinus rhythm, it could become a
new approach to rhythm control supporting conventional pharmacological and
non-pharmacological rhythm control. © The Author(s) 2013.
EMTREE DRUG INDEX TERMS
adrenergic receptor blocking agent (clinical trial, drug therapy)
angiotensin receptor antagonist (clinical trial, drug therapy)
antiarrhythmic agent (clinical trial, drug therapy)
dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug
therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, prevention)
heart failure
heart rhythm
EMTREE MEDICAL INDEX TERMS
adult
article
computer assisted tomography
controlled study
follow up
heart rehabilitation
human
major clinical study
multicenter study
nuclear magnetic resonance imaging
open study
patient counseling
prospective study
randomized controlled trial
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00877643)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013488239
FULL TEXT LINK
http://dx.doi.org/10.1007/s12471-013-0428-5
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 266
TITLE
Cardiovascular toxicity of molecular targeted therapy in cancer patients: A
double-edged sword
AUTHOR NAMES
Liu K.-L.
Chen J.-S.
Chen S.-C.
Chu P.-H.
AUTHOR ADDRESSES
(Liu K.-L.; Chu P.-H., pchu@adm.cgmh.org.tw) Cardiovascular Division,
Department of Internal Medicine, Chang Gung University, Tun-Hwa North Road,
Taipei 105, Taiwan.
(Chen J.-S.) Department of Oncology, Chang GungMemorial Hospital, Taiwan.
(Chen S.-C.) Department of Surgery, Chang Gung University, College of
Medicine, Taipei, Taiwan.
CORRESPONDENCE ADDRESS
P.-H. Chu, Cardiovascular Division, Department of Internal Medicine, Chang
Gung University, Tun-Hwa North Road, Taipei 105, Taiwan. Email:
pchu@adm.cgmh.org.tw
SOURCE
Acta Cardiologica Sinica (2013) 29:4 (295-303). Date of Publication: July
2013
ISSN
1011-6842
BOOK PUBLISHER
Republic of China Society of Cardiology, 7F, No.27, Min-Chuan W.Road,
Taipei, Taiwan.
ABSTRACT
The annual incidence of cancer has increased over the past 20 years, yet the
5-year relative survival rate for cancer has improved with the increasing
availability of advanced therapies, including molecular targeted therapy.
Cardiovascular toxicity can develop with this type of targeted therapy,
which can cause serious side effects including left ventricular dysfunction,
hypertension, hypotension, QT prolongation, thromboembolism, and myocardial
ischemia. In many ways, the quality of life primarily depends on the health
status of patient cardiopulmonary function. However, risk factor assessment,
routine monitoring, and prompt intervention remain the best strategy to deal
with these patients with malignancies, to ensure that their cardiopulmonary
function is maintained at the highest possible level. Most previous studies
on cardiovascular toxicity have focused on conventional chemotherapy.
Molecular targeted therapy is a novel anticancer treatment; however, due to
potentially adverse cardiovascular events from this therapy, oncologists and
cardiologists need to work together to maximize the benefits. In this
review, we focused on target therapy-induced cardiovascular toxicities, in
particular cardiac structural, electrophysiological, and vascular effects.
EMTREE DRUG INDEX TERMS
alemtuzumab (adverse drug reaction)
anthracycline (pharmacology)
bevacizumab (pharmacology)
carvedilol
cetuximab (adverse drug reaction)
cisplatin (pharmacology)
cyclophosphamide (pharmacology)
dasatinib (adverse drug reaction, drug therapy, pharmacology)
daunorubicin
docetaxel
doxorubicin
enalapril
epirubicin
etoposide
fluorouracil
gemcitabine
ifosfamide
imatinib (drug therapy, pharmacology)
interleukin 2 (adverse drug reaction)
lapatinib
melphalan
mitomycin (pharmacology)
mitoxantrone (pharmacology)
paclitaxel
retinoic acid (adverse drug reaction, pharmacology)
rituximab (adverse drug reaction)
sorafenib (pharmacology)
sunitinib (pharmacology)
trastuzumab (pharmacology)
unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cancer patient
cardiotoxicity
heart left ventricle failure
heart muscle ischemia (complication)
hypertension
hypotension (side effect, etiology, side effect)
molecularly targeted therapy
QT prolongation
venous thromboembolism
EMTREE MEDICAL INDEX TERMS
adjuvant therapy
allergic reaction (etiology, side effect)
anaphylaxis (etiology, side effect)
atrial fibrillation
blood pressure
blood pressure monitoring
blood vessel permeability
cancer registry
cancer research
cancer therapy
cardiomyopathy (prevention)
cardiopulmonary function
cardiovascular magnetic resonance
cardiovascular mortality
cell death
cell growth
cell junction
cell proliferation
chemotherapy induced cardiomyopathy (prevention)
clinical practice
concentration (parameters)
congestive heart failure
diabetes mellitus
drug exposure
drug withdrawal
edema (drug therapy)
electrophysiology
endoplasmic reticulum stress
endothelium cell
exercise
faintness
fibrinolytic therapy
fluid retention
follow up
gold standard
heart arrhythmia
heart catheterization
heart failure
heart injury
heart left ventricle ejection fraction
heart muscle biopsy
heart rhythm
heart right ventricle failure (side effect)
heart ventricle arrhythmia
hemodynamics
high risk patient
human
hyperlipidemia
immobilization
implanted heart pacemaker
kidney carcinoma
lifestyle modification
lung artery pressure
lung capillary
medical society
membrane potential
nephrotoxicity
obesity
pericardial effusion (drug therapy)
physical examination
pleura effusion (drug therapy)
potassium current
practice guideline
predictive value
premedication
prospective study
pulmonary hypertension (complication, drug therapy)
QT interval
review
risk factor
sinus bradycardia
smoking
smooth muscle fiber
sudden death
Taiwan
thorax pain
tissue Doppler imaging
tissue pressure
treatment duration
United Kingdom
vascular resistance
vascular stent
vasoconstriction
weight reduction
CAS REGISTRY NUMBERS
alemtuzumab (216503-57-0)
bevacizumab (216974-75-3)
carvedilol (72956-09-3)
cetuximab (205923-56-4)
cisplatin (15663-27-1, 26035-31-4, 96081-74-2)
cyclophosphamide (50-18-0)
dasatinib (302962-49-8, 863127-77-9)
daunorubicin (12707-28-7, 20830-81-3, 23541-50-6)
docetaxel (114977-28-5)
doxorubicin (23214-92-8, 25316-40-9)
enalapril (75847-73-3)
epirubicin (56390-09-1, 56420-45-2)
etoposide (33419-42-0)
fluorouracil (51-21-8)
gemcitabine (103882-84-4)
ifosfamide (3778-73-2)
imatinib (152459-95-5, 220127-57-1)
interleukin 2 (85898-30-2)
lapatinib (231277-92-2, 388082-78-8, 437755-78-7)
melphalan (148-82-3)
mitomycin (1404-00-8, 50-07-7, 74349-48-7)
mitoxantrone (65271-80-9, 70476-82-3)
paclitaxel (33069-62-4)
retinoic acid (302-79-4)
rituximab (174722-31-7)
sorafenib (284461-73-0)
sunitinib (341031-54-7, 557795-19-4)
trastuzumab (180288-69-1)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013464594
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 267
TITLE
Successful management of gastric perforation in stage IV diffuse large
B-cell lymphoma with chemoradiation therapy, percutaneous endoscopy
gastrostomy for gastric drainage, and percutaneous endoscopy jejunostomy for
Nutrition
AUTHOR NAMES
Khadraoui H.
Feigin K.N.
Fox J.J.
Ong L.
Shike M.
Yahalom J.
Noy A.
AUTHOR ADDRESSES
(Khadraoui H.) Memorial Sloan-Kettering Cancer Center, New York, NY, United
States.
(Feigin K.N.; Fox J.J.) Department of Radiology, Memorial Sloan-Kettering
Cancer Center, New York, NY, United States.
(Ong L.) Graduate Medical Education, Memorial Sloan-Kettering Cancer Center,
New York, NY, United States.
(Shike M.; Noy A., noya@mskcc.org) Department of Medicine, Memorial
Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United
States.
(Yahalom J.) Department of Radiation Oncology, Memorial Sloan-Kettering
Cancer Center, New York, NY, United States.
CORRESPONDENCE ADDRESS
A. Noy, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275
York Avenue, New York, NY 10065, United States. Email: noya@mskcc.org
SOURCE
Clinical Lymphoma, Myeloma and Leukemia (2013) 13:3 (327-330). Date of
Publication: June 2013
ISSN
2152-2650
2152-2669 (electronic)
BOOK PUBLISHER
Elsevier Inc., 360 Park Avenue South, New York, United States.
EMTREE DRUG INDEX TERMS
cisplatin (drug combination, drug therapy)
cyclophosphamide (drug combination, drug therapy)
doxorubicin (drug combination, drug therapy)
etoposide (drug combination, drug therapy)
fluorodeoxyglucose f 18
prednisolone (drug combination, drug therapy)
rituximab (drug combination, drug therapy)
vincristine (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chemoradiotherapy
gastrojejunostomy
large cell lymphoma (drug therapy, drug therapy, radiotherapy, surgery)
nutrition
percutaneous drainage
percutaneous endoscopic gastrostomy
stomach perforation (radiotherapy, surgery)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
cancer chemotherapy
cancer patient
cancer radiotherapy
cancer regression
cancer staging
cancer surgery
case report
computer assisted tomography
contrast medium extravasation
febrile neutropenia
hospital admission
human
hyperlipidemia
hypermetabolism
hypertension
hypotension
hypothyroidism
immunohistochemistry
insulin dependent diabetes mellitus
intensity modulated radiation therapy
kidney biopsy
kidney carcinoma (radiotherapy)
kidney failure
lymphadenopathy
male
minimal residual disease (radiotherapy)
multimodality cancer therapy
multiple cycle treatment
pancreas tumor (drug therapy)
papillary carcinoma (radiotherapy)
physical examination
pleura effusion
systemic therapy
thorax radiography
thyroid nodule
treatment duration
tumor volume
weakness
weight reduction
CAS REGISTRY NUMBERS
cisplatin (15663-27-1, 26035-31-4, 96081-74-2)
cyclophosphamide (50-18-0)
doxorubicin (23214-92-8, 25316-40-9)
etoposide (33419-42-0)
fluorodeoxyglucose f 18 (63503-12-8)
prednisolone (50-24-8)
rituximab (174722-31-7)
vincristine (57-22-7)
EMBASE CLASSIFICATIONS
Radiology (14)
Cancer (16)
Hematology (25)
Drug Literature Index (37)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2013308345
FULL TEXT LINK
http://dx.doi.org/10.1016/j.clml.2012.11.005
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 268
TITLE
Post-exercise diastolic stunning detected by velocity vector imaging is a
useful marker for induced ischemia in ischemic heart disease
AUTHOR NAMES
Kurosawa K.
Watanabe H.
Aikawa M.
Mihara H.
Iguchi N.
Asano R.
Umemura J.
Kurabayashi M.
Sumiyoshi T.
AUTHOR ADDRESSES
(Kurosawa K., k-kuro@kss.biglobe.ne.jp; Watanabe H.; Aikawa M.; Mihara H.;
Iguchi N.; Asano R.; Umemura J.; Sumiyoshi T.) Department of Cardiology,
Sakakibara Heart Institute, Tokyo, Japan.
(Kurosawa K., k-kuro@kss.biglobe.ne.jp; Kurabayashi M.) Department of
Medicine and Biological Science, Graduate School of Medicine, Gunma
University, 3-39-15 Showamachi, Maebashi, Gunma, 371-8511, Japan.
CORRESPONDENCE ADDRESS
K. Kurosawa, Department of Medicine and Biological Science, Graduate School
of Medicine, Gunma University, 3-39-15 Showamachi, Maebashi, Gunma,
371-8511, Japan. Email: k-kuro@kss.biglobe.ne.jp
SOURCE
Journal of Echocardiography (2013) 11:2 (50-58). Date of Publication: June
2013
ISSN
1349-0222
1880-344X (electronic)
BOOK PUBLISHER
Springer Japan, 1-11-11 Kudan-kita, Chiyoda-ku, No. 2 Funato Bldg., Tokyo,
Japan.
ABSTRACT
Background: Recently, post-exercise diastolic stunning (PES) has been
reported as a new clinical marker of induced ischemia. Velocity vector
imaging (VVI) has been developed to visualize regional wall motion
abnormalities based on vectors detected by the tissue tracking technique,
which has the potential to visualize PES. Thus, the aim of this study was to
evaluate the usefulness of PES detection by VVI as an objective marker of
ischemia compared to stress thallium-201 (Tl-201) single photon emission
computed tomography (SPECT). Methods: We studied consecutive patients who
were scheduled to undergo exercise stress Tl-201 SPECT for the diagnosis of
ischemic heart disease. Transthoracic echocardiography was recorded
digitally before and 20 min after exercise for Tl-201 SPECT, and the data
were used subsequently for VVI analysis. We defined PES regions as those
with new abnormal vectors observed during isovolumic relaxation. Results:
After excluding 14 patients with old myocardial infarction and/or atrial
fibrillation, echocardiograms suitable for VVI analysis were obtained from
62 of 65 patients (feasibility, 95 %; 44 men; mean age, 64 ± 11 years).
SPECT revealed induced ischemia in 20 patients, whereas VVI identified PES
in 18 patients. VVI detected inducible ischemia with 85 % sensitivity and 98
% specificity compared to SPECT. Conclusions: VVI detection of PES is a new
clinical tool for induced ischemia. Regional diastolic wall motion
abnormalities following induced ischemia can be noninvasively detected by
VVI. © 2013 Japanese Society of Echocardiography.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
thallium 201
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
nitric acid derivative (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diagnostic value
disease marker
exercise test
ischemic heart disease (drug therapy, diagnosis, drug therapy)
post exercise diastolic stunning
single photon emission computer tomography
velocity vector imaging
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation (diagnosis)
blood pressure
computer assisted diagnosis
controlled study
diagnostic test accuracy study
feasibility study
female
heart left ventricle ejection fraction
heart left ventricle enddiastolic volume
heart muscle relaxation
heart rate
hemodynamics
human
image analysis
intermethod comparison
major clinical study
male
sensitivity and specificity
SPECT scanner
transthoracic echocardiography
DEVICE TRADE NAMES
ACUSON Sequoia 512 , United StatesSiemens
Millennium VG , United StatesGeneral Electric
DEVICE MANUFACTURERS
(United States)General Electric
(United States)Siemens
CAS REGISTRY NUMBERS
thallium 201 (15064-65-0)
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Nuclear Medicine (23)
Biophysics, Bioengineering and Medical Instrumentation (27)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013359228
FULL TEXT LINK
http://dx.doi.org/10.1007/s12574-012-0163-8
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 269
TITLE
What's in the literature?
AUTHOR NAMES
Lacomis D.
El-Dokla A.
AUTHOR ADDRESSES
(Lacomis D.; El-Dokla A.) Department of Neurology, University of Pittsburgh
School of Medicine, UPMC-Presbyterian, Pittsburgh, PA, United States.
CORRESPONDENCE ADDRESS
Department of Neurology, University of Pittsburgh School of Medicine,
UPMC-Presbyterian, Pittsburgh, PA, United States.
SOURCE
Journal of Clinical Neuromuscular Disease (2013) 14:4 (218-223). Date of
Publication: June 2013
ISSN
1522-0443
1537-1611 (electronic)
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327,
Philadelphia, United States.
ABSTRACT
We review new evidence that there is a difference in the electrophysiologic
features of fasciculation potentials from patients with amyotrophic lateral
sclerosis (ALS) versus those with benign fasciculations. A report on the
entity of fasciculation anxiety syndrome in clinicians is also covered. An
interesting association between ALS with the C9ORF72 mutation and multiple
sclerosis has been reported; ALS is more severe in this setting. The genetic
etiology of Welander distal myopathy is now known, and genetic
predispositions for ambulatory loss in Duchenne muscular dystrophy and
epilepsy were recently reported. Several recent articles on myasthenia
gravis (MG) provide updates on the incidence of late-onset MG, genetic risk
factors for MG development, and the complications of central versus
peripheral access for plasma exchange. Last, several relatively recent
articles address prevention and risk of developing paclitaxel-induced
neuropathy. Copyright © 2013 by Lippincott Williams & Wilkins.
EMTREE DRUG INDEX TERMS
caffeine
calpain
corticosteroid
cytokine
dystrophin (endogenous compound)
glucocorticoid
I kappa B kinase gamma
ibudilast
inositol 1,4,5 trisphosphate receptor
interleukin 1
leukotriene receptor blocking agent
lithium
messenger RNA
omega 3 fatty acid (drug therapy)
paclitaxel
placebo
protective agent
protein tyrosine phosphatase
pyridostigmine (drug therapy)
RNA binding protein
synapsin I
transforming growth factor beta
tumor necrosis factor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
amyotrophic lateral sclerosis
fasciculation
medical literature
EMTREE MEDICAL INDEX TERMS
acute kidney failure (complication)
allele
anxiety
atrial fibrillation (complication)
autoimmune disease
autosomal dominant inheritance
blood clotting disorder (complication)
cancer chemotherapy
cell stress
central venous catheter
clinical feature
cognitive defect
cytotoxicity
disease course
distal myopathy
double blind procedure
Duchenne muscular dystrophy
epilepsy
exercise
gene expression
gene mutation
genetic association
genetic predisposition
genetic risk
genotype
haplotype
human
hyperactivity
immunosuppressive treatment
incidence
intelligence quotient
Kugelberg Welander disease
lung embolism (complication)
lymphoblastoid cell line
medical device complication
mental deficiency
motor nerve conduction
motor unit potential
multiple sclerosis
muscular dystrophy
myasthenia gravis (drug therapy)
nervous system inflammation
neuroblastoma cell
neuropathy
pathogenesis
peripheral neuropathy (drug therapy, prevention)
peripheral vein
plasmapheresis
pneumothorax (complication)
priority journal
protein aggregation
randomized controlled trial (topic)
receptor down regulation
review
seizure
single nucleotide polymorphism
stress
upregulation
weakness
CAS REGISTRY NUMBERS
caffeine (58-08-2)
calpain (78990-62-2)
dystrophin (116978-02-0)
ibudilast (50847-11-5)
lithium (7439-93-2)
paclitaxel (33069-62-4)
protein tyrosine phosphatase (79747-53-8, 97162-86-2)
pyridostigmine (101-26-8, 155-97-5)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Neurology and Neurosurgery (8)
Human Genetics (22)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013515626
FULL TEXT LINK
http://dx.doi.org/10.1097/CND.0b013e3182997b12
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 270
TITLE
Pharmacological profile of antithrombotic, fibrinolytic and anticoagulant
drugs
AUTHOR NAMES
Kishore K.
AUTHOR ADDRESSES
(Kishore K., kamalbareilly@yahoo.co.in) Department of Pharmacy, M.J.P.
Rohilkhand University, Bareilly-243006 Uttar Pradesh, India.
CORRESPONDENCE ADDRESS
K. Kishore, Department of Pharmacy, M.J.P. Rohilkhand University,
Bareilly-243006 Uttar Pradesh, India. Email: kamalbareilly@yahoo.co.in
SOURCE
Current Trends in Biotechnology and Pharmacy (2013) 7:2 (696-707). Date of
Publication: 2013
ISSN
0973-8916
2230-7303 (electronic)
BOOK PUBLISHER
Association of Biotechnology and Pharmacy, Acharya Nagarjuna University;
Nagarjunanagar, Guntur, Andhra Pradesh, India.
ABSTRACT
The blood is a specialized fluid connective tissue or transport system which
plays an important part in the maintenance of life. the transport of gases,
nutrition, excretion, acid-base equity, body defence, water balance,
clotting, regulation of body temperature, blood pressure, ionic balance and
as a vehicle are the main functions of the blood. The anaemia, purpura,
haemophilia, thrombosis, and clotting related disorders are the major
complications of the hemopoietic system. Thrombosis is one of the leading
cause of thromboembolic disorders affecting million peoples worldwide.
Thromboembolic disorders such as pulmonary emboli, deep vein thrombosis,
strokes and heart attacks are the main causes of morbidity and mortality in
developed countries. Hence, antithrombotics play a pivotal role as agents
for the prevention and treatment of thromboembolic disorders. A current list
of various products having antithrombotic activity incorporated and
prototype agents discussed. The antithrombotic includes specific
antithrombotics agents like aspirin, cilostazol, clopidogrel, prasugrel,
epoprostenol, dipyridamole, indomethacin, sulfinpyrazone, thromboxane
receptor antagonists, thromboxane synthesis inhibitors, ticlopidine,
terutroban, abciximab, eptifibatide, tirofiban, and non-specific
antithrombotics agents like Ca(2+) antagonists, ketanserin, nafazatron,
α-receptor antagonists, β-blockers. The fibrinolytics like tissue
plasminogen activators-streptokinase; urokinase, alteplase, duteplase,
anistreplase, reteplase, saruplase, tenecteplase, snake venom, and
anticoagulants also equally effective in the treatment of thrombotic
disorders are discussed. This article includes general as well as recent
pharmacological information on different aspects of antithrombotic,
fibrinolytic and anticoagulant drugs that may be useful for their better
understanding by users and health care professionals.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy, pharmacology)
fibrinolytic agent (drug therapy, pharmacology)
EMTREE DRUG INDEX TERMS
abciximab (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacokinetics, pharmacology)
acetylsalicylic acid (adverse drug reaction, drug interaction, drug therapy,
pharmacology)
alteplase (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacology)
amiodarone (drug interaction)
anistreplase (adverse drug reaction, intravenous drug administration)
antithrombocytic agent (drug interaction, drug therapy, pharmacology)
apixaban (adverse drug reaction, drug therapy, oral drug administration,
pharmacokinetics, pharmacology)
beraprost (adverse drug reaction, drug therapy, oral drug administration,
pharmacokinetics, pharmacology)
cephalosporin (drug interaction)
clopidogrel (adverse drug reaction, drug interaction, drug therapy, oral
drug administration, pharmacokinetics, pharmacology)
dabigatran etexilate (adverse drug reaction, drug interaction, drug therapy,
oral drug administration, pharmacology)
dalteparin (adverse drug reaction, drug therapy, pharmacokinetics,
pharmacology, subcutaneous drug administration)
danaparoid (drug therapy, intravenous drug administration, pharmacokinetics,
pharmacology, subcutaneous drug administration)
dipyridamole (adverse drug reaction, drug interaction, drug therapy, oral
drug administration, pharmacokinetics, pharmacology)
eptifibatide (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacokinetics)
heparin (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacokinetics, pharmacology, subcutaneous drug
administration)
ketanserin (adverse drug reaction, drug therapy, oral drug administration,
pharmacokinetics, pharmacology)
prostacyclin (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacokinetics, pharmacology)
quinidine (drug interaction)
saruplase (drug therapy, intravenous drug administration)
streptokinase (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacology)
tenecteplase (pharmacokinetics)
terutroban (drug therapy, oral drug administration, pharmacokinetics,
pharmacology)
ticlopidine (adverse drug reaction, drug therapy, oral drug administration,
pharmacokinetics, pharmacology)
tissue plasminogen activator (drug therapy, pharmacology)
unindexed drug
urokinase (adverse drug reaction, drug therapy, intravenous drug
administration, pharmacology)
warfarin (adverse drug reaction, drug interaction, drug therapy, drug
toxicity, oral drug administration, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
acute heart infarction (drug therapy)
allergy (side effect)
alopecia (side effect)
anaphylaxis (side effect)
angina pectoris (drug therapy)
angioneurotic edema (side effect)
anorexia (side effect)
aplastic anemia (side effect)
arterial thromboembolism (drug therapy)
article
asthma (side effect)
atherosclerosis (drug therapy)
atrial fibrillation (drug therapy)
behavior disorder (drug therapy)
biliary tract disease (side effect)
bleeding (side effect)
blood clotting
blurred vision (side effect)
brain hemorrhage (side effect)
bronchospasm (side effect)
carcinoid syndrome (drug therapy)
central nervous system disease (side effect)
cerebrovascular accident (drug therapy, prevention, side effect)
cerebrovascular disease (drug therapy)
chill (side effect)
claudication (drug therapy)
constipation (side effect)
continuous infusion
coronary artery aneurysm (drug therapy)
coronary artery disease (drug therapy)
coronary artery thrombosis (drug therapy)
deep vein thrombosis (drug therapy, prevention)
depression (drug therapy)
dermatitis (side effect)
diabetic neuropathy (drug therapy)
diabetic retinopathy (drug therapy)
diarrhea (side effect)
dizziness (side effect)
drowsiness (side effect)
drug absorption
drug antagonism
drug classification
drug contraindication
drug distribution
drug eruption (side effect)
drug excretion
drug fever (side effect)
drug half life
drug hypersensitivity (side effect)
drug indication
drug induced headache (side effect)
drug mechanism
drug metabolism
drug potentiation
drug use
dyspepsia (drug therapy)
eclampsia (drug therapy)
fatigue (side effect)
gangrene (side effect)
gastroesophageal reflux (drug therapy)
gastrointestinal hemorrhage (side effect)
gastrointestinal symptom (side effect)
glaucoma (side effect)
heart arrhythmia (side effect)
heart failure (side effect)
heart infarction (drug therapy, prevention)
heart palpitation (side effect)
heart ventricle tachycardia (drug therapy)
hematoma (side effect)
hematuria (side effect)
hemolysis (side effect)
hot flush (side effect)
human
hypercholesterolemia (side effect)
hyperglycemia (side effect)
hyperkalemia (side effect)
hypertension (drug therapy)
hypotension (side effect)
ileus (side effect)
immune deficiency (side effect)
inflammation (drug therapy)
injection site erythema (side effect)
injection site irritation (side effect)
irritable colon (drug therapy)
ischemia (drug therapy)
jaundice (side effect)
kidney dysfunction (side effect)
leukopenia (side effect)
liver disease (side effect)
liver dysfunction (side effect)
lung embolism (drug therapy, prevention)
migraine (drug therapy)
myalgia (side effect)
nausea (side effect)
necrosis (side effect)
neutropenia (side effect)
nonhuman
orthostatic hypotension (side effect)
osteoporosis (side effect)
pain (side effect)
pancreatitis (side effect)
parkinsonism (drug therapy)
pathologic fracture (side effect)
peripheral occlusive artery disease (drug therapy)
peripheral vascular disease (drug therapy)
pulmonary hypertension (drug therapy)
restenosis (drug therapy, prevention)
rheumatic heart disease (drug therapy)
schizophrenia (drug therapy)
sedation
side effect (side effect)
skin necrosis (side effect)
stable angina pectoris (drug therapy)
stomach paresis (drug therapy)
supraventricular tachycardia (drug therapy)
tachycardia (side effect)
thorax pain (side effect)
thrombocytopenia (drug therapy, side effect)
thromboembolism (drug therapy)
thrombophlebitis (drug therapy)
thrombosis (drug therapy, prevention)
tinnitus (side effect)
transient ischemic attack (drug therapy)
unstable angina pectoris (drug therapy)
urine retention (side effect)
urticaria (drug therapy, side effect)
vein thrombosis (drug therapy)
venous thromboembolism (drug therapy)
vertigo (side effect)
vomiting (drug therapy, side effect)
Wolff Parkinson White syndrome (drug therapy)
wound healing impairment (side effect)
xerostomia (side effect)
CAS REGISTRY NUMBERS
abciximab (143653-53-6)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alteplase (105857-23-6)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
anistreplase (81669-57-0)
apixaban (503612-47-3)
beraprost (88430-50-6, 88475-69-8)
cephalosporin (11111-12-9)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
danaparoid (83513-48-8)
dipyridamole (58-32-2)
eptifibatide (148031-34-9)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
ketanserin (74050-98-9)
prostacyclin (35121-78-9, 61849-14-7)
quinidine (56-54-2)
saruplase (99149-95-8)
streptokinase (9002-01-1)
tenecteplase (191588-94-0)
terutroban (165537-73-5, 165538-40-9, 609340-89-8)
ticlopidine (53885-35-1, 55142-85-3)
tissue plasminogen activator (105913-11-9)
urokinase (139639-24-0)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Hematology (25)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013301737
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 271
TITLE
Alternative therapies in the treatment of atrial fibrillation
AUTHOR NAMES
Lombardi F.
Belletti S.
Lomuscio A.
AUTHOR ADDRESSES
(Lombardi F.; Belletti S.; Lomuscio A.) Cardiologia Osp. San Paolo, Dep. of
Health Sciences, University of Milan, Via A. di Rudinì 8, 20142 Milan,
Italy.
CORRESPONDENCE ADDRESS
F. Lombardi, Cardiologia Osp. San Paolo, Dep. of Health Sciences, University
of Milan, Via A. di Rudinì 8, 20142 Milan, Italy.
SOURCE
Journal of Atrial Fibrillation (2013) 5:6 (175-181). Date of Publication:
2013
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
Atrial fibrillation (AF) is the most common clinical arrhythmia and
represents a major social and economic problem. The number of subjects with
AF is constantly increasing as a result of aging and improved survival in
several cardiac and non-cardiac diseases. Patients with AF are often
symptomatic, have a reduced physical capacity and are at high risk for
thromboembolic events. Moreover, AF is associated with increased mortality
and independent of the management, based either on rhythm or rate control
strategy, The safety and efficacy of most anti-arrhythmic drugs are
questionable. Increasing attention has therefore been addressed to evaluate
the possible therapeutic and/or preventive effects of forms of treatment
coming from ancient medical traditions of Far East, like acupuncture and
yoga. In traditional Chinese medicine, acupuncture has been found effective
in managing patients with paroxysmal supraventricular tachycardia. Recently,
also in the Western literature, reports have been published supporting the
clinical efficacy of acupuncture to treat arterial hypertension and to
reduce chest pain. Other studies have evaluated the effects of acupuncture
and other methods of Eastern Medicine, i.e., Qigong, Tai Chi Chuan and Yoga,
in the treatment of cardiac illnesses associated with supraventricular
arrhythmias. Two reports on the effects of acupuncture in preventing or
reducing the rate of AF recurrences in patients with persistent or
paroxysmal AF have been recently reported . Another ancient traditional
eastern form of therapy and prevention, i.e., yoga, has been recently shown
to reduce episodes of atrial fibrillation and improve the symptoms of
anxiety and depression often associated with this arrhythmia. Growing
evidence indicates that acupuncture and yoga are safe, without any
pro-arrhythmic effect and with limited cost. All these factors should be
considered when evaluating the efficacy of therapeutic intervention for an
epidemic disease such as AF.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
flecainide (drug therapy)
propafenone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alternative medicine
atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
anxiety
Chinese medicine
depression
electroacupuncture
heart beat
heart disease (therapy)
heart supraventricular arrhythmia (therapy)
human
hypertension (therapy)
mortality
paroxysmal supraventricular tachycardia (therapy)
physical capacity
qigong
recurrent disease
review
risk
risk factor
survival
Tai Chi
thorax pain (therapy)
thromboembolism
traditional medicine
yoga
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
flecainide (54143-55-4)
propafenone (34183-22-7, 54063-53-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013283320
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 272
TITLE
Myocardial ischemia as a genuine cause responsible for the organization and
"fertilization" of conflictogenic atrial fibrillation: New conceptual
insights into arrhythmogenicity
AUTHOR NAMES
Stirbys P.
AUTHOR ADDRESSES
(Stirbys P.) Department of Cardiology, Hospital of Lithuanian University of
Health Sciences, Kaunas Clinic, Kaunas, Lithuania.
CORRESPONDENCE ADDRESS
P. Stirbys, A. Ramanausko-Vanago str. 4-7, 49306 Kaunas, Lithuania.
SOURCE
Journal of Atrial Fibrillation (2013) 5:6 (101-109). Date of Publication:
2013
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
Atrial fibrillation continues to be a challenging arrhythmia. There are some
conventional, time-tested explanations of atrial fibrillation genesis,
however some uncertainty of its complete understanding still exists. We
focused on atrial ischemia which, hypothetically, could be responsible for
manifestation of the arrhythmia, irrespective of the underlying heart
disease. Evidences abounds that atrial fibrillation has an extremely strong
association with nutritional/oxidative status of myocardium. This arrhythmia
seemingly may stem from the electrophysiological differences taking place in
the boundary areas. To validate such assumptions we have surveyed widely
accepted theories based on clinical and experimental evidence. There was an
attempt to integrate some well-known theoretical explanations (focal,
multifocal, ectopic, reentrant activity, atrial remodeling, etc.) into a new
conceptually systematized arrhythmogenesis. Confronting ischemic and
non-ischemic atrial zones electrophysiologically on their borderlines
presumably creates a substrate vulnerable to the development of atrial
fibrillation. The behavior of these interrelated areas is likely
ischemia-dependent; the separating borderline(s) may be treated as
conflictogenic, releasing triggers/drivers to commence and to perpetuate the
arrhythmia. Ischemically damaged and non-damaged myocardial areas likely
participate in the relay-race carousel of arrhythmogenicity due to their
mutual interactions, accompanied by the "fireworks" at the separating
borderlines. It could be concluded that myocardial ischemia as a nonspecific
proarrhythmic factor presumably plays a key role in the genesis and
sustenance of atrial fibrillation. Theoretically the most important step in
eradication of arrhythmogenic substrate might be an overall abolition of
ischemia regardless of the characteristics of underlying heart disease.
Innovative intellectual and explorative research is needed to render
innocuous the ischemia that might help us win the century's
cardioarrhythmological battle.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (etiology)
heart muscle ischemia
EMTREE MEDICAL INDEX TERMS
arrhythmogenesis
artery blood flow
calcium current
defibrillation
heart atrium enlargement
heart conduction
heart electrophysiology
heart muscle fibrosis
heart muscle injury
human
inflammation
potassium current
review
vascularization
vasospasm
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013283313
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 273
TITLE
Heart failure: Best options when ejection fraction is preserved
AUTHOR NAMES
Mills G.D.
Scott K.C.
AUTHOR ADDRESSES
(Mills G.D., Geoffrey.Mills@jefferson.edu; Scott K.C.) Department of Family
and Community Medicine, Jefferson Medical College, 833 Chestnut Street,
Philadelphia, PA 19107, United States.
(Mills G.D., Geoffrey.Mills@jefferson.edu) Department of Physiology,
Jefferson Medical College, Philadelphia, PA, United States.
CORRESPONDENCE ADDRESS
G.D. Mills, Department of Family and Community Medicine, Jefferson Medical
College, 833 Chestnut Street, Philadelphia, PA 19107, United States. Email:
Geoffrey.Mills@jefferson.edu
SOURCE
Journal of Family Practice (2013) 62:5 (236-243). Date of Publication: May
2013
ISSN
0094-3509
1533-7294 (electronic)
BOOK PUBLISHER
Dowden Health Media,Inc, 110 Summit Avenue, Montvale, United States.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
aldosterone antagonist (drug therapy)
angiotensin receptor antagonist (adverse drug reaction, drug combination,
drug therapy)
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
bisoprolol (drug therapy)
brain natriuretic peptide (endogenous compound)
calcium channel blocking agent (adverse drug reaction, drug therapy)
candesartan (adverse drug reaction, clinical trial, drug therapy)
carvedilol (drug therapy)
digoxin
diltiazem (drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, drug
combination, drug therapy)
diuretic agent (adverse drug reaction, clinical trial, drug therapy)
dobutamine
eplerenone (drug therapy)
hydrochlorothiazide (drug comparison, drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
irbesartan (clinical trial, drug therapy)
lisinopril
losartan (drug comparison, drug therapy)
low density lipoprotein cholesterol (endogenous compound)
metoprolol (drug therapy)
mevinolin
nebivolol (clinical trial, drug therapy)
nitrate (adverse drug reaction, drug therapy)
perindopril (clinical trial, drug therapy)
spironolactone (drug therapy)
verapamil (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure with preserved ejection fraction (drug therapy, diagnosis,
disease management, drug therapy, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
acute kidney failure (side effect)
anamnesis
article
atrial fibrillation (therapy)
cardiopulmonary exercise test
cardiovascular mortality
cardioversion
clinical trial (topic)
consensus development
coronary artery disease
diet therapy
disease course
disease exacerbation
Doppler echocardiography
drug dose increase
drug withdrawal
echocardiography
electrocardiogram
evidence based medicine
exercise
fluid balance
fluid retention
heart atrium contraction
heart atrium pressure
heart catheterization
heart left ventricle contraction
heart left ventricle filling
heart left ventricle hypertrophy
heart muscle ischemia (prevention)
heart rate
human
hypertension
hypertrophic cardiomyopathy
hypotension (side effect)
lifestyle modification
quality of life
renin angiotensin aldosterone system
screening
sinus tachycardia
sodium restriction
tachycardia (prevention)
thorax radiography
unspecified side effect (side effect)
vasoconstriction
weight reduction
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
bisoprolol (66722-44-9)
brain natriuretic peptide (114471-18-0)
candesartan (139481-59-7)
carvedilol (72956-09-3)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
dobutamine (34368-04-2, 49745-95-1, 52663-81-7, 61661-06-1)
eplerenone (107724-20-9)
hydrochlorothiazide (58-93-5)
irbesartan (138402-11-6)
lisinopril (76547-98-3, 83915-83-7)
losartan (114798-26-4)
metoprolol (37350-58-6)
mevinolin (75330-75-5)
nebivolol (118457-15-1, 118457-16-2, 99200-09-6)
nitrate (14797-55-8)
perindopril (82834-16-0, 99149-83-4)
spironolactone (52-01-7)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2013534555
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 274
TITLE
Einthoven dissertation prizes 2012
AUTHOR NAMES
Van der Wall E.E.
Van Gilst W.H.
Schalij M.J.
Umans V.
AUTHOR ADDRESSES
(Van der Wall E.E., e.e.van_der_wall@lumc.nl; Van Gilst W.H.)
Interuniversity Cardiology Institute of the Netherlands (ICIN), Netherlands
Heart Institute (NHI), Utrecht, Netherlands.
(Schalij M.J.) Department of Cardiology, Leiden University Medical Center,
Leiden, Netherlands.
(Umans V.) Department of Cardiology, Medical Center Alkmaar, Alkmaar,
Netherlands.
CORRESPONDENCE ADDRESS
E. E. Van der wall, Interuniversity Cardiology Institute of the Netherlands
(ICIN), Netherlands Heart Institute (NHI), Utrecht, Netherlands. Email:
e.e.van_der_wall@lumc.nl
SOURCE
Netherlands Heart Journal (2013) 21:5 (256-261). Date of Publication: May
2013
ISSN
1568-5888
1876-6250 (electronic)
BOOK PUBLISHER
Bohn Stafleu van Loghum, P.O. Box 75971, Amsterdam, Netherlands.
EMTREE DRUG INDEX TERMS
anticoagulant agent
apixaban (adverse drug reaction, drug therapy, oral drug administration)
dabigatran (adverse drug reaction, drug therapy, oral drug administration)
potassium channel KCNQ1 (endogenous compound)
sodium channel Nav1.5 (endogenous compound)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
awards and prizes
scientific literature
EMTREE MEDICAL INDEX TERMS
3' untranslated region
article
atrial fibrillation
bleeding (side effect)
Brugada syndrome
cardiac resynchronization therapy
cardiovascular disease (drug therapy)
exercise
fever
follow up
health survey
heart arrhythmia
heart failure
human
long QT syndrome
phenotype
risk factor
scoring system
single nucleotide polymorphism
treatment outcome
CAS REGISTRY NUMBERS
apixaban (503612-47-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2013288943
FULL TEXT LINK
http://dx.doi.org/10.1007/s12471-013-0404-0
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 275
TITLE
Heart disease as a risk factor for dementia
AUTHOR NAMES
Ng J.B.
Turek M.
Hakim A.M.
AUTHOR ADDRESSES
(Ng J.B.) Departments of Neuroscience and Psychology, McGill University,
Montreal, QC, Canada.
(Turek M.) Division of Cardiology, The Ottawa Hospital, Ottawa, Canada.
(Turek M.) Department of Medicine, University of Ottawa, Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Division of Neurology, The Ottawa Hospital,
Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Brain and Mind Research Institute, University
of Ottawa, Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Ottawa Hospital Research Institute, The Ottawa
Hospital, Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Canadian Stroke Network, Ottawa, ON, Canada.
CORRESPONDENCE ADDRESS
A. M. Hakim, University of Ottawa, 2413-451 Smyth Road, Ottawa, ON K1H 8M5,
Canada. Email: ahakim@ohri.ca
SOURCE
Clinical Epidemiology (2013) 5:1 (135-145). Date of Publication: 25 Apr 2013
ISSN
1179-1349 (electronic)
BOOK PUBLISHER
Dove Medical Press Ltd, Beechfield House, Winterton Way, Macclesfield,
United Kingdom.
ABSTRACT
As life expectancy lengthens, dementia is becoming a significant human
condition in terms of its prevalence and cost to society worldwide. It is
important in that context to understand the preventable and treatable causes
of dementia. This article exposes the link between dementia and heart
disease in all its forms, including coronary artery disease, myocardial
infarction, atrial fibrillation, valvular disease, and heart failure. This
article also explores the cardiovascular risk factors and emphasizes that
several of them are preventable and treatable. In addition to medical
therapies, the lifestyle changes that may be useful in retarding the onset
of dementia are also summarized. © 2013 Ng et al, publisher and licensee
Dove Medical Press Ltd.
EMTREE DRUG INDEX TERMS
advanced glycation end product (endogenous compound)
amyloid beta protein (endogenous compound)
antihypertensive agent (clinical trial, drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
donepezil (drug therapy, pharmacology)
gelatinase B (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
nitrendipine (clinical trial, drug therapy)
omega 3 fatty acid
placebo
tau protein (endogenous compound)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
dementia (complication, etiology, prevention)
heart disease (prevention)
EMTREE MEDICAL INDEX TERMS
Alzheimer disease (drug therapy, etiology, therapy)
atherosclerosis
atrial fibrillation (drug therapy)
blood brain barrier
brain blood flow
brain embolism
brain hemorrhage
brain perfusion
brain size
cardiovascular risk
cerebrovascular accident (drug therapy)
cognitive defect (prevention)
coronary artery disease
disease association
drug efficacy
drug mechanism
enzyme inhibition
exercise
food intake
heart failure (drug therapy)
heart infarction
human
hypercholesterolemia (drug therapy)
hypertension (drug therapy)
hypotension
lifestyle modification
Mediterranean diet
multiinfarct dementia (etiology, prevention)
obesity
pathogenesis
review
risk assessment
risk factor
risk reduction
smoking
valvular heart disease
CAS REGISTRY NUMBERS
amyloid beta protein (109770-29-8)
donepezil (120011-70-3, 120014-06-4, 142057-77-0)
gelatinase B (146480-36-6)
nitrendipine (39562-70-4)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013280054
FULL TEXT LINK
http://dx.doi.org/10.2147/CLEP.S30621
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 276
TITLE
The YOGA my heart study
AUTHOR NAMES
Baliga R.
AUTHOR ADDRESSES
(Baliga R.) Division of Cardiovascular Medicine, Wexner Medical Center,
United States.
(Baliga R.) The Ohio State University, Columbus, United States.
CORRESPONDENCE ADDRESS
R. Baliga, Division of Cardiovascular Medicine, Wexner Medical Center,
United States.
SOURCE
Cardiology Review (2013) 29:2. Date of Publication: April 2013
ISSN
1092-6607
BOOK PUBLISHER
Ascend Media, 103 College Road East, Princeton, United States.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
yoga
EMTREE MEDICAL INDEX TERMS
anxiety
clinical effectiveness
depression
diastolic blood pressure
functional status
heart rate
human
mental health
outcome assessment
patient safety
physical performance
quality of life
review
Short Form 36
social interaction
systolic blood pressure
therapy effect
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2013336286
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 277
TITLE
EuroHeartCare 2013
AUTHOR ADDRESSES
SOURCE
European Journal of Cardiovascular Nursing (2013) 12 SUPPL. 1. Date of
Publication: April 2013
CONFERENCE NAME
EuroHeartCare 2013
CONFERENCE LOCATION
Glasgow, United Kingdom
CONFERENCE DATE
2013-03-22 to 2013-03-23
ISSN
1474-5151
BOOK PUBLISHER
SAGE Publications Inc.
ABSTRACT
The proceedings contain 156 papers. The topics discussed include:
deactivation of the implantable cardioverter defibrillator: the patient
perspective; cost-effectiveness of a nurse-led integrated chronic care
program for patients with atiral fibrillation; psychometric testing of the
self-care of chronic angina Index (SCCAI); a nurse led pre admission
education program for elective adult cardiac surgical patients- a pilot
study using an interdiscplinary approach; the natural history of coronary
calcification: a meta-analysis from St Francis and EBEAT trials; the burden
of caregiving in chronic heart failure: a qualitative study; impact of acute
hyperglycemia after angioplasty for acute myocardial infarction; effects of
medical yoga in quality of life, blood pressure and heart rate in patients
with paroxysmal atrial fibrillation; region-wide automatic referral to
cardiac rehabilitation is associated with improved referral rates; and
evidence of persisting Yentl syndrome in Romania.
EMTREE MEDICAL INDEX TERMS
acute heart infarction
adult
angina pectoris
angioplasty
atrial fibrillation
blood pressure
calcification
cost effectiveness analysis
education program
heart failure
heart rate
heart rehabilitation
history
human
hyperglycemia
implantable cardioverter defibrillator
meta analysis
meta analysis (topic)
nurse
patient
pilot study
qualitative research
quality of life
Romania
self care
surgical patient
yoga
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 278
TITLE
Winter cardiovascular diseases phenomenon
AUTHOR NAMES
Fares A.
AUTHOR ADDRESSES
(Fares A., audafares@yahoo.com) Department of Internal Medicine, Uinversity
Hospital Bochum, Bedburg, Germany.
CORRESPONDENCE ADDRESS
A. Fares, Albert-Schlangen Str. 36, 50181 Bedburg, Germany. Email:
audafares@yahoo.com
SOURCE
North American Journal of Medical Sciences (2013) 5:4 (266-279). Date of
Publication: April 2013
ISSN
2250-1541
1947-2714 (electronic)
BOOK PUBLISHER
North American Journal of Medical Sciences, T3330-50-B Charlton Ave,
Hamilton, Canada.
ABSTRACT
This paper review seasonal patterns across twelve cardiovascular diseases:
Deep venous thrombosis, pulmonary embolism, aortic dissection and rupture,
stroke, intracerebral hemorrhage, hypertension, heart failure, angina
pectoris, myocardial infarction, sudden cardiac death, venricular arrythmia
and atrial fibrillation, and discuss a possible cause of the occurrence of
these diseases. There is a clear seasonal trend of cardiovascular diseases,
with the highest incidence occurring during the colder winter months, which
have been described in many countries. This phenomenon likely contributes to
the numbers of deaths occurring in winter. The implications of this finding
are important for testing the relative importance of the proposed
mechanisms. Understanding the influence of season and other factors is
essential when seeking to implement effective public health measures.
EMTREE DRUG INDEX TERMS
aldosterone (endogenous compound)
blood clotting factor 7 (endogenous compound)
catecholamine (endogenous compound)
cholesterol (endogenous compound)
noradrenalin (endogenous compound)
renin (endogenous compound)
vitamin D (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease
seasonal affective disorder
EMTREE MEDICAL INDEX TERMS
acute heart infarction
age
air pollution
angina pectoris
aorta aneurysm
aorta dissection
aorta rupture
atrial fibrillation
blood pressure
brain hemorrhage
cardiovascular risk
cerebrovascular accident
death
deep vein thrombosis
diet
disease association
heart failure
heart ventricle arrhythmia
human
hypertension
incidence
infection
lung embolism
meta analysis (topic)
nonhuman
obesity
oxidative stress
physical activity
public health
review
seasonal variation
sex
sudden death
systematic review (topic)
temperature
transient ischemic attack
venous thromboembolism
winter
CAS REGISTRY NUMBERS
aldosterone (52-39-1, 6251-69-0)
blood clotting factor 7 (9001-25-6)
cholesterol (57-88-5)
noradrenalin (1407-84-7, 51-41-2)
renin (61506-93-2, 9015-94-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Public Health, Social Medicine and Epidemiology (17)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013236266
FULL TEXT LINK
http://dx.doi.org/10.4103/1947-2714.110430
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 279
TITLE
The influence of systematic pulse-limited physical exercise on the
parameters of the cardiovascular system in patients over 65 years of age
AUTHOR NAMES
Chomiuk T.
Folga A.
Mamcarz A.
AUTHOR ADDRESSES
(Chomiuk T.; Folga A., and.folga@gmail.com; Mamcarz A.) 3rd Department of
Internal Medicine and Cardiology, Medical University of Warsaw, 93 Solec St,
00-382 Warsaw, Poland.
CORRESPONDENCE ADDRESS
A. Folga, 3rd Department of Internal Medicine and Cardiology, Medical
University of Warsaw, 93 Solec St, 00-382 Warsaw, Poland. Email:
and.folga@gmail.com
SOURCE
Archives of Medical Science (2013) 9:2 (201-209). Date of Publication: April
2013
ISSN
1734-1922
BOOK PUBLISHER
Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
ABSTRACT
Introduction: The influence of physical exercise on the parameters of the
cardiovascular system of elderly persons has not been sufficiently
investigated yet. The aim of the study was to assess the influence of
regular 6-week physical exercise using the Nordic walking (NW) method in a
group of elderly persons on their physical performance and regulation of
selected parameters assessing the cardiovascular system. Material and
methods: Fifty patients over 65 years of age participated in the study. The
study encompassed: medical interview, physical examination, resting ECG,
spiroergometry examination, 6MWT (6-minute walk test) and 24-hour ambulatory
blood pressure monitoring (ABPM). During the exercise programme, the pulse
was monitored using pulsometers. After the completion of the training,
check-up tests assessing the same parameters were performed. The control
group consisted of 18 persons over 65 years of age with similar
cardiovascular problems. Results: In the test group, duration of the
physical effort increased by 1.02 min (p = 0.0001), the maximum load
increased by 10.68 W (p = 0.0001), values of VO(2max) by 2.10 (p = 0.0218),
distance improved in 6MWT by 75.04 m (p = 0.00001), systolic blood pressure
decreased by 5.50 mm Hg (p = 0.035) and diastolic blood pressure by 3.50 mm
Hg (p = 0.054) as compared to the control group. Conclusions: Systematic NW
physical exercise limited by the pulse had a beneficial effect on the
physical performance of elderly persons as assessed with main parameters. A
short 6-week programme of endurance exercises had a hypotensive effect in
elderly persons over 65 years of age. Copyright © 2013 Termedia & Banach.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular system
exercise
pulse rate
EMTREE MEDICAL INDEX TERMS
6 minute walk test
aged
anaerobic exercise
article
asthma
atrial fibrillation
blood pressure monitoring
body surface
cerebrovascular accident
chronic obstructive lung disease
clinical assessment
clinical assessment tool
controlled study
diabetes mellitus
diastolic blood pressure
dyslipidemia
echocardiography
endurance training
ergometry
female
heart failure
heart infarction
human
hypertension
hypothyroidism
interview
ischemic heart disease
major clinical study
male
maximum allowable concentration
medical history
Nordic walking method
osteoporosis
physical examination
physical performance
smoking
systolic blood pressure
walking
EMBASE CLASSIFICATIONS
Physiology (2)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013277981
FULL TEXT LINK
http://dx.doi.org/10.5114/aoms.2013.34559
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 280
TITLE
The effect of integrated cardiac rehabilitation versus treatment as usual
for atrial fibrillation patients treated with ablation: The randomised
CopenHeart(RFA) trial protocol
AUTHOR NAMES
Risom S.S.
Zwisler A.-D.O.
Rasmussen T.B.
Sibilitz K.L.
Svendsen J.H.
Gluud C.
Hansen J.L.
Winkel P.
Thygesen L.C.
Perhonen M.
Hansen J.
Dunbar S.B.
Berg S.K.
AUTHOR ADDRESSES
(Risom S.S., signe.stelling.risom@rh.regionh.dk; Zwisler A.-D.O.; Rasmussen
T.B.; Sibilitz K.L.; Svendsen J.H.; Berg S.K.) Heart Centre, Copenhagen
University Hospital, Rigshospitalet, Copenhagen, Denmark.
(Zwisler A.-D.O.; Thygesen L.C.) National Institute of Public Health,
University of Southern Denmark, Copenhagen, Denmark.
(Rasmussen T.B.; Hansen J.; Berg S.K.) Danish National Research Foundation
Centre for Cardiac Arrhythmia (DARC), Copenhagen, Denmark.
(Svendsen J.H.) Department of Cardiology, Gentofte Hospital, Gentofte,
Denmark.
(Gluud C.; Hansen J.L.; Winkel P.) Copenhagen Trial Unit, Centre for
Clinical Intervention Research, Copenhagen University Hospital, Copenhagen,
Denmark.
(Perhonen M.) CorusFit, Jyväskylä, Finland.
(Dunbar S.B.) Nell Hodgson Woodruff School of Nursing, Emory University
Atlanta, Druid Hills, GA, United States.
CORRESPONDENCE ADDRESS
S.S. Risom, Heart Centre, Copenhagen University Hospital, Rigshospitalet,
Copenhagen, Denmark. Email: signe.stelling.risom@rh.regionh.dk
SOURCE
BMJ Open (2013) 3:2 Article Number: e002377. Date of Publication: 2013
ISSN
2044-6055 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
Introduction: Atrial fibrillation affects almost 2% of the population in the
Western world. To preserve sinus rhythm, ablation is undertaken in
symptomatic patients. Observational studies show that patients with atrial
fibrillation often report a low quality of life and are less prone to be
physically active due to fear of triggering fibrillation. Small trials
indicate that exercise training has a positive effect on exercise capacity
and mental health, and both patients with recurrent atrial fibrillation and
in sinus rhythm may benefit from rehabilitation in managing life after
ablation. No randomised trials have been published on cardiac rehabilitation
for atrial fibrillation patients treated with ablation that includes
exercise and psychoeducational components. Aim: To test the effects of an
integrated cardiac rehabilitation programme versus treatment as usual for
patients with atrial fibrillation treated with ablation. Methods and
analysis design: The trial is a multicentre parallel arm design with 1:1
randomisation to the intervention and control group with blinded outcome
assessment. 210 patients treated for atrial fibrillation with radiofrequency
ablation will be included. The intervention consists of a rehabilitation
programme including four psychoeducative consultations with a specially
trained nurse and 12 weeks of individualised exercise training, plus the
standard medical follow-up. Patients in the control group will receive the
standard medical follow-up. The primary outcome measure is exercise capacity
measured by the VO(2) peak. The secondary outcome measure is self-rated
mental health measured by the Short Form 36 questionnaire. Postintervention,
qualitative interviews will be conducted in 10% of the intervention group.
Ethics and dissemination: The protocol is approved by the regional research
ethics committee (number H-1-2011-135), the Danish Data Protection Agency
(reg. nr. 2007-58-0015) and follows the latest version of the Declaration of
Helsinki. The results will be published in peer-reviewed journals and may
possibly impact on rehabilitation guidelines.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (rehabilitation, surgery, therapy)
heart rehabilitation
radiofrequency ablation
EMTREE MEDICAL INDEX TERMS
article
consultation
controlled study
exercise
female
follow up
human
intermethod comparison
interview
major clinical study
male
multicenter study
randomized controlled trial
Short Form 36
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT01523145)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013164643
FULL TEXT LINK
http://dx.doi.org/10.1136/bmjopen-2012-002377
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 281
TITLE
Effect of yoga on arrhythmia burden, anxiety, depression, and quality of
life in paroxysmal atrial fibrillation: The YOGA my heart study
AUTHOR NAMES
Lakkireddy D.
Atkins D.
Pillarisetti J.
Ryschon K.
Bommana S.
Drisko J.
Vanga S.
Dawn B.
AUTHOR ADDRESSES
(Lakkireddy D., dlakkireddy@mac.md; Atkins D.; Pillarisetti J.; Bommana S.;
Dawn B.) EP Research-KU Cardiovascular Research Institute, Bloch Heart
Rhythm Center, University of Kansas Hospital, 3901 Rainbow Boulevard, Kansas
City, KS 66160, United States.
(Ryschon K.) Ryschon Consulting Services LLC, Omaha, NB, United States.
(Drisko J.) Program in Integrative Medicine, University of Kansas, Medical
Center, Kansas City, KS, United States.
(Vanga S.) Christiana Hospital, Newark, DE, United States.
CORRESPONDENCE ADDRESS
D. Lakkireddy, EP Research-KU Cardiovascular Research Institute, Bloch Heart
Rhythm Center, University of Kansas Hospital, 3901 Rainbow Boulevard, Kansas
City, KS 66160, United States. Email: dlakkireddy@mac.md
SOURCE
Journal of the American College of Cardiology (2013) 61:11 (1177-1182). Date
of Publication: 19 Mar 2013
ISSN
0735-1097
1558-3597 (electronic)
BOOK PUBLISHER
Elsevier USA, 6277 Sea Harbor Drive, Orlando, United States.
ABSTRACT
Objectives: The purpose of this study was to examine the impact of yoga on
atrial fibrillation (AF) burden, quality of life (QoL), depression, and
anxiety scores. Background: Yoga is known to have significant benefit on
cardiovascular health. The effect of yoga in reducing AF burden is unknown.
Methods: This single-center, pre-post study enrolled patients with
symptomatic paroxysmal AF with an initial 3-month noninterventional
observation period followed by twice-weekly 60-min yoga training for next 3
months. AF episodes during the control and study periods as well as SF-36,
Zung self-rated anxiety, and Zung self-rated depression scores at baseline,
before, and after the study phase were assessed. Results: Yoga training
reduced symptomatic AF episodes (3.8 ± 3 vs. 2.1 ± 2.6, p < 0.001),
symptomatic non-AF episodes (2.9 ± 3.4 vs. 1.4 ± 2.0; p < 0.001),
asymptomatic AF episodes (0.12 ± 0.44 vs. 0.04 ± 0.20; p < 0.001), and
depression and anxiety (p < 0.001), and improved the QoL parameters of
physical functioning, general health, vitality, social functioning, and
mental health domains on SF-36 (p = 0.017, p < 0.001, p < 0.001, p = 0.019,
and p < 0.001, respectively). There was significant decrease in heart rate,
and systolic and diastolic blood pressure before and after yoga (p < 0.001).
Conclusions: In patients with paroxysmal AF, yoga improves symptoms,
arrhythmia burden, heart rate, blood pressure, anxiety and depression
scores, and several domains of QoL. © 2013 by the American College of
Cardiology Foundation.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
angiotensin receptor antagonist (drug therapy)
antiarrhythmic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anxiety disorder (therapy)
atrial fibrillation (drug therapy, drug therapy, therapy)
depression (therapy)
heart arrhythmia (therapy)
quality of life
yoga
EMTREE MEDICAL INDEX TERMS
adult
article
cardiovascular function
clinical article
clinical effectiveness
controlled clinical trial
controlled study
correlation analysis
diastolic blood pressure
female
health status
heart rate
hemodynamics
human
male
mental health
percutaneous coronary intervention
priority journal
prospective study
social interaction
systolic blood pressure
therapy effect
treatment duration
treatment response
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Psychiatry (32)
Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00798356)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014076347
MEDLINE PMID
23375926 (http://www.ncbi.nlm.nih.gov/pubmed/23375926)
FULL TEXT LINK
http://dx.doi.org/10.1016/j.jacc.2012.11.060
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 282
TITLE
Exercise testing for risk stratification of ventricular arrhythmias in the
athlete
AUTHOR NAMES
Schmied C.
Brunckhorst C.
Duru F.
Haegeli L.
AUTHOR ADDRESSES
(Schmied C., christian.schmied@usz.ch; Brunckhorst C.; Duru F.; Haegeli L.)
Cardiovascular Centre, Division of Cardiology, University Hospital Zürich,
Raemistrasse 100, Zürich 8091, Switzerland.
CORRESPONDENCE ADDRESS
C. Schmied, Clinic for Cardiology, Cardiovascular Center, Division of
Cardiology, University Hospital Zürich, Raemistrasse 100, Zürich 8091,
Switzerland. Email: christian.schmied@usz.ch
SOURCE
Cardiac Electrophysiology Clinics (2013) 5:1 (53-64). Date of Publication:
2013
ISSN
1877-9182
1877-9190 (electronic)
BOOK PUBLISHER
W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
Exercise testing is an important diagnostic tool that creates an environment
of automaticity at the electrical membrane, which tolerates premature beats
and re-entrant arrhythmogenic circuits. Exercise testing mimics the
authentic situation of physical activity and stress, recognized as a fatal
trigger of critical arrhythmias in cases of underlying cardiac risk
constellation. Although it is established as a second-line diagnostic tool,
exercise testing can provide crucial information in an earlier setting, if
there are exercise-dependent symptoms in an athlete's history, clinical
suspicion of an underlying structural or primarily electrical heart disease,
or known structural or electrical disease. © 2013 Elsevier Inc.
EMTREE DRUG INDEX TERMS
adrenergic receptor stimulating agent (drug therapy)
antiarrhythmic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium ion (endogenous compound)
potassium (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, diagnosis, drug therapy, epidemiology,
therapy)
cardiovascular disease (diagnosis, epidemiology, therapy)
catecholaminergic polymorphic ventricular tachycardia (drug therapy,
diagnosis, drug therapy, epidemiology, therapy)
exercise test
heart ventricle arrhythmia (drug therapy, diagnosis, drug therapy,
epidemiology, therapy)
ischemic heart disease (drug therapy, diagnosis, drug therapy, epidemiology,
therapy)
EMTREE MEDICAL INDEX TERMS
athlete
Chagas disease
clinical protocol
congenital heart disease (congenital disorder)
cytosol
defibrillation
exercise
heart right ventricle dysplasia
heart ventricle tachycardia (drug therapy, therapy)
Holter monitor
Holter monitoring
human
hypertrophic cardiomyopathy
implantable cardioverter defibrillator
long QT syndrome
mortality
nonsustained ventricular tachycardia (therapy)
pathophysiology
potassium blood level
priority journal
prognosis
QRS complex
review
risk assessment
risk factor
sports medicine
sudden death
Wolff Parkinson White syndrome
CAS REGISTRY NUMBERS
calcium ion (14127-61-8)
potassium (7440-09-7)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Occupational Health and Industrial Medicine (35)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013138838
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ccep.2012.11.003
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 283
TITLE
Safety and tolerability of inhalational anticholinergics in COPD
AUTHOR NAMES
Sharafkhaneh A.
Majid H.
Gross N.J.
AUTHOR ADDRESSES
(Sharafkhaneh A., amirs@bcm.edu) Baylor College of Medicine, Department of
Medicine, Houston, United States.
(Sharafkhaneh A., amirs@bcm.edu) Sleep Disorders Center, Michael E DeBakey
VA Medical Center, Houston, United States.
(Majid H.) Aga Khan University, Karachi, Pakistan.
(Gross N.J.) Stritch School of Medicine Illinois, St Francis Hospital,
Hartford, United States.
CORRESPONDENCE ADDRESS
A. Sharafkhaneh, Baylor College of Medicine, Department of Medicine, MEDVA
Medical Center Bldg. 100 (111i), Houston, TX 77030, United States. Email:
amirs@bcm.edu
SOURCE
Drug, Healthcare and Patient Safety (2013) 5:1 (49-55). Date of Publication:
7 Mar 2013
ISSN
1179-1365 (electronic)
BOOK PUBLISHER
Dove Medical Press Ltd, Beechfield House, Winterton Way, Macclesfield,
United Kingdom.
ABSTRACT
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity
and mortality. With the significant toll of the disease, more resources have
been invested in developing new treatment modalities. Among these
medications, inhalational anticholinergics are widely used for the
management of stable COPD. The newer agents, with longer half-lives and
better safety profiles, have emerged and helped to improve management of
COPD patients. The available data from randomized clinical trials support
use of these agents. Multiple randomized clinical trials show safety and
efficacy of the newer long-acting inhaled anticholinergics, including
tiotropium and aclidinium. A recent meta-analysis of tiotropium delivered
with Respimat® raised some safety concerns. A large trial, comparing
different doses and delivery methods of inhaled tiotropium, is ongoing to
determine the effect on mortality. As clinical trials may not
comprehensively represent the entire COPD population, caution should be
exercised when these agents are used in higher-risk populations, like
individuals with cardiac arrhythmias or urinary obstruction. In this
publication, we review the safety of inhalational anticholinergics. © 2013
Sharafkhaneh et al, publisher and licensee Dove Medical Press Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
cholinergic receptor blocking agent (adverse drug reaction, drug therapy,
inhalational drug administration)
EMTREE DRUG INDEX TERMS
aclidinium bromide (adverse drug reaction, drug concentration, drug therapy,
inhalational drug administration, pharmacokinetics)
beta adrenergic receptor stimulating agent (drug combination, drug therapy,
inhalational drug administration)
ipratropium bromide (adverse drug reaction, drug combination, drug therapy,
inhalational drug administration, pharmacokinetics)
oxitropium bromide (drug combination, drug therapy, inhalational drug
administration)
placebo
salbutamol (drug combination, drug therapy)
tiotropium bromide (adverse drug reaction, clinical trial, drug therapy,
inhalational drug administration, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chronic obstructive lung disease (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
angina pectoris (side effect)
atrial fibrillation (side effect)
blurred vision (side effect)
bronchospasm (side effect)
cardiovascular disease (side effect)
cardiovascular risk
cataract (side effect)
cerebrovascular accident (side effect)
closed angle glaucoma (side effect)
combination chemotherapy
congestive heart failure (side effect)
constipation (side effect)
coughing (side effect)
disease exacerbation
drug absorption
drug blood level
drug clearance
drug efficacy
drug elimination
drug excretion
drug half life
drug metabolism
drug safety
drug tolerability
dysgeusia (side effect)
dyspepsia (side effect)
dysphagia (side effect)
edema (side effect)
epistaxis (side effect)
exercise
heart arrhythmia (side effect)
heart infarction (side effect)
high risk population
human
intraocular pressure abnormality (side effect)
laryngitis (side effect)
mean residence time
monotherapy
mortality
nausea (side effect)
pain (side effect)
paralytic ileus (side effect)
pharyngitis (side effect)
quality of life
recommended drug dose
review
rhinitis (side effect)
rhinorrhea (side effect)
sinusitis (side effect)
sore throat (side effect)
stomatitis (side effect)
supraventricular tachycardia (side effect)
throat irritation (side effect)
upper respiratory tract infection (side effect)
urinary tract infection (side effect)
urinary tract obstruction
urine retention (side effect)
urogenital tract disease (side effect)
vomiting (side effect)
xerostomia (side effect)
DRUG TRADE NAMES
atrovent Boehringer Ingelheim
DRUG MANUFACTURERS
Boehringer Ingelheim
CAS REGISTRY NUMBERS
aclidinium bromide (320345-99-1)
ipratropium bromide (22254-24-6)
oxitropium bromide (30286-75-0)
salbutamol (18559-94-9, 35763-26-9)
tiotropium bromide (136310-93-5)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013168937
FULL TEXT LINK
http://dx.doi.org/10.2147/DHPS.S7771
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 284
TITLE
Communications to the British Geriatrics Society Autumn Meeting 2012
AUTHOR ADDRESSES
SOURCE
Age and Ageing (2013) 42 SUPPL. 2. Date of Publication: March 2013
CONFERENCE NAME
British Geriatrics Society Autumn Meeting 2012
CONFERENCE LOCATION
Harrogate, United Kingdom
CONFERENCE DATE
2012-11-28 to 2012-11-30
ISSN
0002-0729
BOOK PUBLISHER
Oxford University Press
ABSTRACT
The proceedings contain 104 papers. The topics discussed include:
deprivation in cold weather increases the risk of hospital admission with
hypothermia in older people; depression associates with mini nutritional
assessment (MNA), vitamin B12 and folate status; findings in the BELFAST
elderly longitudinal free-living ageing study (BELFAST); outcomes of trauma
admissions in the centenarian population; inflammaging: powering the
biological clock of telomere length?; comparison of three fracture
prediction tools in an osteoporosis clinic population; use of ace
inhibitors, statins or thiazides is not associated with slower decline in
grip strength in older people - results from the hertfordshire cohort study;
relationship of orthostatic hypotension and bone mineral density; and atrial
fibrillation is under recognised and inappropriately treated in older
adults: cross-sectional findings from the Irish longitudinal study on ageing
(TILDA).
EMTREE DRUG INDEX TERMS
cyanocobalamin
dipeptidyl carboxypeptidase inhibitor
folic acid
hydroxymethylglutaryl coenzyme A reductase inhibitor
thiazide diuretic agent
vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
autumn
geriatrics
interpersonal communication
society
EMTREE MEDICAL INDEX TERMS
adult
aged
aging
atrial fibrillation
biological rhythm
bone density
cohort analysis
cold exposure
fracture
grip strength
hospital
hospital admission
human
hypothermia
injury
longitudinal study
nutritional assessment
orthostatic hypotension
osteoporosis
population
prediction
risk
telomere
very elderly
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 285
TITLE
Effects of pharmacologic therapy on health-related quality of life in
elderly patients with atrial fibrillation: A systematic review of randomized
and nonrandomized trials
AUTHOR NAMES
Pepine C.J.
AUTHOR ADDRESSES
(Pepine C.J., carl.pepine@medicine.ufl.edu) Division of Cardiovascular
Medicine, University of Florida College of Medicine, Gainesville, FL, United
States.
CORRESPONDENCE ADDRESS
C. J. Pepine, Division of Cardiovascular Medicine, University of Florida
College of Medicine, Gainesville, FL, United States. Email:
carl.pepine@medicine.ufl.edu
SOURCE
Clinical Medicine Insights: Cardiology (2013) 7 (1-20). Date of Publication:
2013
ISSN
1179-5468
BOOK PUBLISHER
Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay,
Auckland, New Zealand.
ABSTRACT
This systematic review assessed the impact of atrial fibrillation (AF) and
pharmacotherapy on health-related quality of life (HRQOL) in elderly
patients. Highly prevalent in the elderly, AF is associated with morbidity
and symptoms affecting HRQOL. A PubMed and EMBASE search (1999-2010) was
conducted using the terms atrial fibrillation, elderly, quality of life,
Medicare, and Medicaid. In all, 504 articles were identified and 15 were
selected (studies examining pharmacotherapy [rate or rhythm control] and
HRQOL in AF patients with a mean age ≥ 65 years). Information, including
study design, cohort size, and HRQOL instruments utilized, was extracted.
Five observational studies, 5 randomized trials comparing rate and rhythm
control, 3 randomized trials investigating pharmacologic agents, and 2
trials examining HRQOL, depression, and anxiety were identified. Elderly AF
patients had reduced HRQOL versus patients in normal sinus rhythm,
particularly in domains related to physical functioning. HRQOL may be
particularly affected in older AF patients. Although data do not indicate
whether a pharmacologic intervention or single treatment strategy-namely
rate versus rhythm control-is better at improving HRQOL, either of these
strategies and many pharmacologic interventions may improve HRQOL in elderly
AF patients. Based on reviewed data, an algorithm is suggested to optimize
HRQOL among elderly patients. © the author(s), publisher and licensee
Libertas Academica Ltd.
EMTREE DRUG INDEX TERMS
amiodarone (clinical trial, drug comparison, drug therapy)
beta adrenergic receptor blocking agent (clinical trial, drug comparison,
drug therapy)
calcium antagonist (clinical trial, drug comparison, drug therapy)
digitalis (clinical trial, drug therapy)
placebo
propafenone (clinical trial, drug comparison, drug therapy)
sotalol (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, therapy)
pharmaceutical care
quality of life
EMTREE MEDICAL INDEX TERMS
anxiety
cardioversion
depression
disease severity
drug effect
drug efficacy
exercise
heart rate
heart rhythm
human
paroxysmal atrial fibrillation
questionnaire
randomized controlled trial (topic)
review
Short Form 36
sinus rhythm
symptom
systematic review
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digitalis (8031-42-3, 8053-83-6)
propafenone (34183-22-7, 54063-53-5)
sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013078519
FULL TEXT LINK
http://dx.doi.org/10.4137/CMC.S10628
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 286
TITLE
Paget's disease of bone
AUTHOR NAMES
Ralston S.H.
AUTHOR ADDRESSES
(Ralston S.H., stuart.ralston@ed.ac.uk) University of Edinburgh, Institute
of Genetics and Molecular Medicine, Western General Hospital, Edinburgh EH4
2XU, United Kingdom.
CORRESPONDENCE ADDRESS
S.H. Ralston, University of Edinburgh, Institute of Genetics and Molecular
Medicine, Western General Hospital, Edinburgh EH4 2XU, United Kingdom.
Email: stuart.ralston@ed.ac.uk
SOURCE
New England Journal of Medicine (2013) 368:7 (644-650). Date of Publication:
14 Feb 2013
ISSN
0028-4793
1533-4406 (electronic)
BOOK PUBLISHER
Massachussetts Medical Society, 860 Winter Street, Waltham, United States.
ABSTRACT
A 73-year-old man presents with a 5-year history of low back pain that is
exacerbated by standing. During the past year, pain has developed in his
buttocks and legs when he walks, and it is not relieved by acetaminophen.
The neurologic examination is unremarkable. Radiographs of the spine show
coarsening of the trabecular pattern in several lumbar and lower thoracic
vertebrae and expansion of several lumbar vertebral bodies. The total serum
alkaline phosphatase level is 350 U per liter (reference range, 40 to 125);
the results of liver-function tests and other routine laboratory tests are
normal. How should he be further evaluated and treated? Copyright © 2013
Massachusetts Medical Society.
EMTREE DRUG INDEX TERMS
alendronic acid (adverse drug reaction, drug therapy)
alkaline phosphatase (endogenous compound)
bisphosphonic acid derivative (adverse drug reaction, clinical trial, drug
therapy, intravenous drug administration)
calcitonin (drug therapy)
etidronic acid (adverse drug reaction, clinical trial, drug therapy, oral
drug administration)
pamidronic acid (adverse drug reaction, drug therapy, oral drug
administration)
risedronic acid (adverse drug reaction, clinical trial, drug combination)
tiludronic acid (adverse drug reaction, clinical trial, drug therapy, oral
drug administration)
zoledronic acid (adverse drug reaction, clinical trial, drug combination,
drug dose, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Paget bone disease (drug therapy, diagnosis, drug therapy, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
acupuncture
alkaline phosphatase blood level
article
atrial fibrillation (side effect)
bone necrosis (side effect)
bone pain (drug therapy, side effect)
clinical feature
diagnostic test
diarrhea (side effect)
differential diagnosis
disease association
disease exacerbation
disease severity
dose response
drug efficacy
drug eruption (side effect)
drug fever (side effect)
drug induced headache (side effect)
drug safety
dyspepsia (side effect)
esophagitis (side effect)
fatigue (side effect)
femur subtrochanteric fracture (side effect)
human
hydrotherapy
hypocalcemia (side effect)
myalgia (side effect)
nausea (side effect)
osteotomy
physiotherapy
practice guideline
priority journal
single drug dose
transcutaneous nerve stimulation
treatment indication
uveitis (side effect)
vomiting (side effect)
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
alkaline phosphatase (9001-78-9)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
pamidronic acid (40391-99-9, 57248-88-1)
risedronic acid (105462-24-6, 122458-82-6)
tiludronic acid (96538-83-9)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013101059
MEDLINE PMID
23406029 (http://www.ncbi.nlm.nih.gov/pubmed/23406029)
FULL TEXT LINK
http://dx.doi.org/10.1056/NEJMcp1204713
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 287
TITLE
Walking unsteadily: A case of acute cerebellar ataxia
AUTHOR NAMES
Simonetta F.
Christou F.
Vandoni R.E.
Nierle T.
AUTHOR ADDRESSES
(Simonetta F.; Christou F.; Nierle T., tomnierle@hotmail.com) Department of
Internal Medicine, Hôpital du Jura Bernois SA, Moutier, Switzerland.
(Vandoni R.E.) Department of Surgery, Hôpital du Jura Bernois SA, Moutier,
Switzerland.
CORRESPONDENCE ADDRESS
T. Nierle, Department of Internal Medicine, Hôpital du Jura Bernois SA,
Moutier, Switzerland. Email: tomnierle@hotmail.com
SOURCE
BMJ Case Reports (2013) Article Number: 007688. Date of Publication: 2013
ISSN
1757-790X (electronic)
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
Acute cerebellar ataxia is an infrequent neurological syndrome in adults
especially if complicated by additional neurological deficits. We report the
case of a 69-year-old woman who presented with sudden onset of left facial
droop, dizziness, slurred speech and impaired balance. Her medical history
included paroxysmal atrial fibrillation and a sigmoid diverticular abscess
treated with ciprofloxacin and metronidazole. Cranial computed tomographic
angiography and MRI showed no signs of acute ischaemia or haemorrhage but
demonstrated symmetrically distributed lesions in the cerebellar dentate
nuclei. A diagnosis of metronidazole-induced encephalopathy was suspected.
Metronidazole was stopped and the patient completely recovered.
Metronidazole is a commonly prescribed medication. Clinicians should be
aware of the clinical and radiological presentation of metronidazole-induced
encephalopathy so that this serious but completely reversible condition can
be promptly diagnosed. Copyright © 2013 BMJ Publishing Group.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
metronidazole (adverse drug reaction, drug combination, drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
alprazolam (drug therapy)
ciprofloxacin (drug combination, drug therapy, oral drug administration)
flupentixol (drug therapy)
melitracen (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebellar ataxia (side effect, diagnosis, side effect)
walking difficulty
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation (diagnosis, drug therapy)
balance impairment
brain disease (side effect)
brain hemorrhage (diagnosis)
brain infection (diagnosis)
brain ischemia (diagnosis)
brain tumor (diagnosis)
case report
cerebellum injury
colon diverticulosis (diagnosis, drug therapy)
computed tomographic angiography
dentate nucleus
differential diagnosis
dizziness
drug withdrawal
dysarthria
face asymmetry
facial nerve paralysis
female
human
immunopathology (diagnosis)
leukocyte count
leukocytosis
metabolic disorder (diagnosis)
mixed anxiety and depression (drug therapy)
nuclear magnetic resonance imaging
nystagmus
priority journal
sigmoid diverticular abscess (diagnosis, drug therapy)
sigmoid diverticular abscess (drug therapy)
slurred speech
traumatic brain injury (diagnosis)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alprazolam (28981-97-7)
ciprofloxacin (85721-33-1)
flupentixol (2413-38-9, 2709-56-0)
melitracen (5118-29-6)
metronidazole (39322-38-8, 443-48-1)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013054356
FULL TEXT LINK
http://dx.doi.org/10.1136/bcr-2012-007688
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 288
TITLE
Obesity and cardiovascular disease: Steps to reduce the risk
AUTHOR NAMES
Hodara R.
Kacharava A.
AUTHOR ADDRESSES
(Hodara R.; Kacharava A.) Department of medicine, Emory University, School
of Medicine, Atlanta, GA, United States.
CORRESPONDENCE ADDRESS
R. Hodara, Department of medicine, Emory University, School of Medicine,
Atlanta, GA, United States.
SOURCE
Consultant (2013) 53:2 (67-72). Date of Publication: February 2013
ISSN
0010-7069
BOOK PUBLISHER
Cliggott Publishing Co., 330 Boston Post Road, Box 4027, Darien, United
States.
ABSTRACT
Obesity is associated with conditions such as hypertension, insulin
resistance, dyslipidemia, and thrombosis that markedly increase the risk of
cardiovascular disease and overall mortality. In addition, the
pro-inflammatory and pro-thrombotic cascades triggered by the extra adipose
tissue appear to increase cardiovascular risk independently. For primary and
secondary prevention of cardiovascular disease, expert panels recommend that
obese patients, as well as those who are overweight with comorbid
conditions, lose 10% of their initial body weight. A first approach should
include a program of lifestyle modification, composed of diet, exercise, and
behavioral changes. Given the limited long-term efficacy of pharmacological
and behavioral interventions, bariatric surgery has emerged as a prominent
and durable alterative to combating obesity and its related conditions.
EMTREE DRUG INDEX TERMS
amfepramone (drug therapy)
fatty acid (endogenous compound)
fenfluramine (drug therapy)
lorcaserin (drug therapy)
phentermine (drug combination, drug therapy)
sibutramine (drug therapy)
tetrahydrolipstatin (adverse drug reaction, drug therapy)
topiramate (drug combination, drug therapy)
triacylglycerol (endogenous compound)
very low density lipoprotein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease
obesity (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
atherosclerosis
atrial fibrillation
bariatric surgery
body mass
cardiovascular risk
cerebrovascular accident
childhood obesity
diet therapy
dyslipidemia
gastrointestinal symptom (side effect)
heart failure
heart infarction
human
hypertension
insulin resistance
ischemic heart disease
metabolic syndrome X
non insulin dependent diabetes mellitus
priority journal
review
waist circumference
waist hip ratio
weight reduction
CAS REGISTRY NUMBERS
amfepramone (134-80-5, 90-84-6)
fenfluramine (404-82-0, 458-24-2)
lorcaserin (616202-92-7)
phentermine (1197-21-3, 122-09-8)
sibutramine (106650-56-0)
tetrahydrolipstatin (96829-58-2)
topiramate (97240-79-4)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013129846
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 289
TITLE
The Relationship between physical activity and risk of atrial fibrillation-A
systematic review and meta-Analysis
AUTHOR NAMES
Nielsen J.R.
Wachtell K.
Abdulla J.
AUTHOR ADDRESSES
(Nielsen J.R.; Wachtell K.) Division of Cardiology, Department of Medicine,
Glostrup University Hospital, Copenhagen, Denmark.
(Abdulla J.) Glostrup Hospital, Ndr. Ringvej 57, DK-2600 Glostrup, Denmark.
CORRESPONDENCE ADDRESS
J. Abdulla, Glostrup Hospital, Ndr. Ringvej 57, DK-2600 Glostrup, Denmark.
SOURCE
Journal of Atrial Fibrillation (2013) 5:5 (20-27). Date of Publication:
February-March 2013
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
The aim of this systematic literature review and meta-Analyses was to
explore the relationship between physical activity and risk of new-onset
atrial fibrillation (AF) or flutter (AFlu).Results: The search revealed 10
published studies that were eligible for three different meta-Analyses. A
meta-Analysis of six case-control studies showed that risk of AF increased
more than 5-fold in athletes compared to non-Athletic controls, OR=5.3
[(3.6, 7.9; 95% confidence interval (CI)], p<0.0001. A second meta-Analysis
of three case-control studies showed a significantly higher prevalence of
athletes among AF populations compared to their healthy controls, OR=4.7
(3.1-6.9; 95% CI), p<0.0001. A third meta-Analysis of three prospective
large-scale long-Term studies showed that moderate/high habitual physical
activity was associated with significantly reduced risk of AF compared with
none or very low intensity physical activity OR=0.89(0.83, 0.96; 95% CI),
p=002.Conclusions: Long-Term vigorous physical training or lack of physical
activity both are associated with increased risk of AF, while habitual
moderate physical activity may be associated with reduced risk. Further
large-scale prospective randomized controlled studies particularly in
athletes are needed to further confirm these findings.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (epidemiology)
cardiovascular risk
heart atrium flutter
physical activity
EMTREE MEDICAL INDEX TERMS
athlete
case control study
exercise intensity
high risk population
human
meta analysis
prevalence
prospective study
review
risk reduction
systematic review
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013200941
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 290
TITLE
Electroacupuncture reduces duration of postoperative ileus after
laparoscopic surgery for colorectal cancer
AUTHOR NAMES
Ng S.S.M.
Leung W.W.
Mak T.W.C.
Hon S.S.F.
Li J.C.M.
Wong C.Y.N.
Tsoi K.K.F.
Lee J.F.Y.
AUTHOR ADDRESSES
(Ng S.S.M., simonng@surgery.cuhk.edu.hk; Leung W.W.; Mak T.W.C.; Hon S.S.F.;
Li J.C.M.; Wong C.Y.N.; Tsoi K.K.F.; Lee J.F.Y.) Department of Surgery,
Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong
Kong.
CORRESPONDENCE ADDRESS
S.S.M. Ng, Department of Surgery, Chinese University of Hong Kong, Prince of
Wales Hospital, Shatin, Hong Kong. Email: simonng@surgery.cuhk.edu.hk
SOURCE
Gastroenterology (2013) 144:2 (307-313.e1). Date of Publication: Feb 2013
ISSN
0016-5085
1528-0012 (electronic)
BOOK PUBLISHER
W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
BACKGROUND & AIMS: We investigated the efficacy of electroacupuncture in
reducing the duration of postoperative ileus and hospital stay after
laparoscopic surgery for colorectal cancer. METHODS: We performed a
prospective study of 165 patients undergoing elective laparoscopic surgery
for colonic and upper rectal cancer, enrolled from October 2008 to October
2010. Patients were assigned randomly to groups that received
electroacupuncture (n = 55) or sham acupuncture (n = 55), once daily from
postoperative days 1-4, or no acupuncture (n = 55). The acupoints Zusanli,
Sanyinjiao, Hegu, and Zhigou were used. The primary outcome was time to
defecation. Secondary outcomes included postoperative analgesic requirement,
time to ambulation, and length of hospital stay. RESULTS: Patients who
received electroacupuncture had a shorter time to defecation than patients
who received no acupuncture (85.9 ± 36.1 vs 122.1 ± 53.5 h; P<.001) and
length of hospital stay (6.5±2.2 vs 8.5±4.8 days; P = .007). Patients who
received electroacupuncture also had a shorter time to defecation than
patients who received sham acupuncture (85.9 ± 36.1 vs 107.5 ± 46.2 h; P =
.007). Electroacupuncture was more effective than no or sham acupuncture in
reducing postoperative analgesic requirement and time to ambulation. In
multiple linear regression analysis, an absence of complications and
electroacupuncture were associated with a shorter duration of postoperative
ileus and hospital stay after the surgery. CONCLUSIONS: In a clinical trial,
electroacupuncture reduced the duration of postoperative ileus, time to
ambulation, and postoperative analgesic requirement, compared with no or
sham acupuncture, after laparoscopic surgery for colorectal cancer. © 2013
by the AGA Institute.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
colorectal cancer (surgery)
electroacupuncture
hospitalization
laparoscopic surgery
postoperative ileus (complication, surgery)
EMTREE MEDICAL INDEX TERMS
acupuncture
acute coronary syndrome (complication)
adult
aged
article
atrial fibrillation (complication)
cancer surgery
chest infection (complication)
cholangitis (complication)
comparative effectiveness
confusion (complication)
controlled study
defecation
disease duration
female
human
intestine function
major clinical study
male
mobilization
postoperative complication (complication)
priority journal
prospective study
randomized controlled trial
single blind procedure
surgical infection (complication)
treatment duration
treatment outcome
urinary tract infection (complication)
urine retention (complication)
EMBASE CLASSIFICATIONS
Surgery (9)
Internal Medicine (6)
Cancer (16)
Gastroenterology (48)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00464425)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014112624
MEDLINE PMID
23142625 (http://www.ncbi.nlm.nih.gov/pubmed/23142625)
FULL TEXT LINK
http://dx.doi.org/10.1053/j.gastro.2012.10.050
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 291
TITLE
2013 SYR Accepted Poster Abstracts
AUTHOR ADDRESSES
SOURCE
International journal of yoga therapy (2013) 23 Supplement (32-53). Date of
Publication: 2013
ISSN
1531-2054
ABSTRACT
SYR 2013 Accepted Poster abstracts: 1. Benefits of Yoga as a Wellness
Practice in a Veterans Affairs (VA) Health Care Setting: If You Build It,
Will They Come? 2. Yoga-based Psychotherapy Group With Urban Youth Exposed
to Trauma. 3. Embodied Health: The Effects of a Mind�Body Course for Medical
Students. 4. Interoceptive Awareness and Vegetable Intake After a Yoga and
Stress Management Intervention. 5. Yoga Reduces Performance Anxiety in
Adolescent Musicians. 6. Designing and Implementing a Therapeutic Yoga
Program for Older Women With Knee Osteoarthritis. 7. Yoga and Life Skills
Eating Disorder Prevention Among 5th Grade Females: A Controlled Trial. 8. A
Randomized, Controlled Trial Comparing the Impact of Yoga and Physical
Education on the Emotional and Behavioral Functioning of Middle School
Children. 9. Feasibility of a Multisite, Community based Randomized Study of
Yoga and Wellness Education for Women With Breast Cancer Undergoing
Chemotherapy. 10. A Delphi Study for the Development of Protocol Guidelines
for Yoga Interventions in Mental Health. 11. Impact Investigation of
Breathwalk Daily Practice: Canada�India Collaborative Study. 12. Yoga
Improves Distress, Fatigue, and Insomnia in Older Veteran Cancer Survivors:
Results of a Pilot Study. 13. Assessment of Kundalini Mantra and Meditation
as an Adjunctive Treatment With Mental Health Consumers. 14. Kundalini Yoga
Therapy Versus Cognitive Behavior Therapy for Generalized Anxiety Disorder
and Co-Occurring Mood Disorder. 15. Baseline Differences in Women Versus Men
Initiating Yoga Programs to Aid Smoking Cessation: Quitting in Balance
Versus QuitStrong. 16. Pranayam Practice: Impact on Focus and Everyday Life
of Work and Relationships. 17. Participation in a Tailored Yoga Program is
Associated With Improved Physical Health in Persons With Arthritis. 18.
Effects of Yoga on Blood Pressure: Systematic Review and Meta-analysis. 19.
A Quasi-experimental Trial of a Yoga based Intervention to Reduce Stress and
Promote Health and Well-being Among Middle School Educators. 20. A
Systematic Review of Yoga-based Interventions for Objective and Subjective
Balance Measures. 21. Disparities in Yoga Use: A Multivariate Analysis of
2007 National Health Interview Survey Data. 22. Implementing Yoga Therapy
Adapted for Older Veterans Who Are Cancer Survivors. 23. Randomized,
Controlled Trial of Yoga for Women With Major Depressive Disorder: Decreased
Ruminations as Potential Mechanism for Effects on Depression? 24. Yoga
Beyond the Metropolis: A Yoga Telehealth Program for Veterans. 25. Yoga
Practice Frequency, Relationship Maintenance Behaviors, and the Potential
Mediating Role of Relationally Interdependent Cognition. 26. Effects of
Medical Yoga in Quality of Life, Blood Pressure, and Heart Rate in Patients
With Paroxysmal Atrial Fibrillation. 27. Yoga During School May Promote
Emotion Regulation Capacity in Adolescents: A Group Randomized, Controlled
Study. 28. Integrated Yoga Therapy in a Single Session as a Stress
Management Technique in Comparison With Other Techniques. 29. Effects of a
Classroom-based Yoga Intervention on Stress and Attention in Second and
Third Grade Students. 30. Improving Memory, Attention, and Executive
Function in Older Adults with Yoga Therapy. 31. Reasons for Starting and
Continuing Yoga. 32. Yoga and Stress Management May Buffer Against Sexual
Risk-Taking Behavior Increases in College Freshmen. 33. Whole-systems
Ayurveda and Yoga Therapy for Obesity: Outcomes of a Pilot Study. 34.
Women�s Phenomenological Experiences of Exercise, Breathing, and the Body
During Yoga for Smoking Cessation Treatment. 35. Mindfulness as a Tool for
Trauma Recovery: Examination of a Gender-responsive Trauma-informed
Integrative Mindfulness Program for Female Inmates. 36. Yoga After Stroke
Leads to Multiple Physical Improvements. 37. Tele-Yoga in Patients With
Chronic Obstructive Pulmonary Disease and Heart Failure: A Mixed-methods
Study of Feasibility, Acceptability, and Safety. 38. Effects of an Ashtanga
Yoga-based Health and Wellness Curriculum on Physical and Emotional
Well-being, Engagement Toward School, and Academic Performance of K-6
Students. 39. Yoga as a Facilitator for Participation Following an 8-week
Yoga for Individuals With Chronic Stroke. 40. Standardization of Design and
Reporting of Yoga Interventions for Musculoskeletal Conditions: A Delphi
Approach. 41. Creating S.P.A.C.E. Through Yoga: Africa Yoga Project Teachers
Promote Personal Transformation, Peaceful Communities, and Purpose-filled
Service.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anxiety
quality of life
EMTREE MEDICAL INDEX TERMS
controlled study
human
major depression
meta analysis
national health organization
pilot study
psychology
randomized controlled trial
therapy
yoga
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
MEDLINE PMID
24176784 (http://www.ncbi.nlm.nih.gov/pubmed/24176784)
COPYRIGHT
Copyright 2016 Medline is the source for the citation and abstract of this
record.
RECORD 292
TITLE
Non-communicable disease epidemic: epidemiology in action (EuroEpi 2013 and
NordicEpi 2013): Aarhus, Denmark from 11 August to 14 August 2013
AUTHOR NAMES
Tsukinoki R.
Murakami Y.
AUTHOR ADDRESSES
(Tsukinoki R., tukinoki@envi.med.osaka-u.ac.jp) Department of Public Health
Nursing, Osaka Medical College, Takatsuki, Japan.
(Murakami Y.) Department of Medical Statistics, Shiga University of Medical
Science, Otsu, Japan.
CORRESPONDENCE ADDRESS
R. Tsukinoki, Department of Public Health Nursing, Osaka Medical College,
Takatsuki, Japan.
SOURCE
European Journal of Epidemiology (2013) 28:1 (1-270). Date of Publication:
2013
ISSN
1573-7284 (electronic)
0393-2990
BOOK PUBLISHER
Kluwer Academic Publishers
EMTREE DRUG INDEX TERMS
11beta hydroxysteroid dehydrogenase 2 (endogenous compound)
anti human immunodeficiency virus agent (drug therapy)
BCG vaccine (drug therapy)
C reactive protein (endogenous compound)
caffeine
clozapine (drug therapy)
corticosteroid (adverse drug reaction, drug therapy, topical drug
administration)
diazepam (adverse drug reaction)
diphtheria pertussis tetanus vaccine
endothelial nitric oxide synthase (endogenous compound)
enterolactone (endogenous compound)
fibrinogen (endogenous compound)
hemoglobin A1c (endogenous compound)
hydrocortisone (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor
immunoglobulin G antibody (endogenous compound)
maternal antibody (endogenous compound)
neuronal nitric oxide synthase (endogenous compound)
nonsteroid antiinflammatory agent (drug combination)
paracetamol (adverse drug reaction, drug combination)
prostaglandin synthase inhibitor (drug combination)
serotonin uptake inhibitor (drug combination)
tamoxifen
temazepam (adverse drug reaction)
tissue antigen (endogenous compound)
tricyclic antidepressant agent
unindexed drug
virus antibody (endogenous compound)
vitamin D (endogenous compound)
zopiclone (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
epidemic (epidemiology)
non communicable disease (epidemiology)
EMTREE MEDICAL INDEX TERMS
2009 H1N1 influenza
abortion
absence
absenteeism
academic achievement
accidental death
acquired immune deficiency syndrome
acute heart failure
acute heart infarction
acute kidney failure
acute liver failure
acute lymphoblastic leukemia
adipose tissue
adolescence
adolescent behavior
adolescent disease
adolescent health
adolescent pregnancy
adulthood
adverse outcome
African
air pollution
air quality
air temperature
Albanian (people)
alcohol consumption
alcohol intoxication
allele
allergy
allostatic load
alternative medicine
Alzheimer disease
ambient air
ambulance transportation
anorectal malformation
anorexia
antibiotic therapy
antibody blood level
anticoagulant therapy
antihypertensive therapy
anxiety disorder
arterial stiffness
artery thrombosis
article
assessment of humans
asthma
atherosclerosis
atopic dermatitis
atrial fibrillation
attributable risk
Australian Aborigine
autism
automutilation
awareness
axillary lymph node
bacterial load
Bangladeshi
bariatric surgery
Barrett esophagus
BCG vaccination
behavior disorder (side effect)
benign childhood epilepsy
bereavement
billing and claims
binge drinking
biomechanics
bipolar disorder
birth rate
birth weight
blood pressure
body composition
body fat
body fat distribution
body height
body mass
body size
body weight
Bosnia and Herzegovina
Braden Scale
brain hemorrhage
brain ischemia
Brazil
Brazilian
breast cancer (diagnosis)
breast feeding
bronchitis
burn
caloric intake
cancer chemotherapy
cancer diagnosis
cancer epidemiology
cancer incidence
cancer localization
cancer mortality
cancer patient
cancer prevention
cancer prognosis
cancer radiotherapy
cancer recurrence
cancer risk
cancer screening
cancer staging
cancer surgery
cancer survival
cancer survivor
cancer susceptibility
cancer therapy
carbohydrate intake
cardiac patient
cardiometabolic risk
cardiovascular disease
cardiovascular mortality
cardiovascular risk
cardiovascular system
caregiver
carpal tunnel syndrome
Caucasian
cause of death
celiac disease
cellular immunity
central nervous system tumor
cerebral palsy
cerebrovascular accident (prevention)
cesarean section
child death
child health
child parent relation
child welfare
childbirth
childhood
childhood cancer
childhood disease
childhood injury
childhood leukemia
childhood obesity
cholestatic hepatitis
cholesterol blood level
chronic disease
chronic fatigue syndrome
chronic inflammation
chronic kidney disease
chronic liver disease
chronic obstructive lung disease
chronic stress
chronology
clinical assessment tool
clinical decision making
clinical effectiveness
clinical examination
clinical protocol
clinical research
cognition
cohabitation
cold
colic
colon cancer
colorectal cancer
comorbidity
computer assisted tomography
conduct disorder
congenital diaphragm hernia
congenital heart disease
congenital heart malformation
congenital malformation (side effect)
consumer
coping behavior
cost effectiveness analysis
Crimean Congo hemorrhagic fever
cubital tunnel syndrome
cutaneous melanoma
cytokine release
cytopathology
daily life activity
daughter
death certificate
decubitus (prevention)
delivery
dementia
demography
dengue
Denmark
dental caries
dental fluorosis
dental health
depression (diagnosis)
developmental disorder
diabetes mellitus
diarrhea
diet supplementation
diet therapy
dietary fiber
dietary intake
dietary recall assessment tool
diphtheria
disability
disease association
disease course
disease exacerbation
disease marker
disease severity
disease surveillance
distress syndrome
diverticulosis
drinking behavior
drug classification
drug efficacy
drug metabolism
drug safety
drug surveillance program
drug transport
drug use
drug utilization
eating disorder
economic aspect
ectopic pregnancy
education
educational status
Egypt
electronic medical record
embryo disposition
emergency ward
emphysema
encephalomyelitis
endocrine tumor
endometrium carcinoma
enteric virus
environmental exposure
environmental factor
environmental temperature
epidemiology
ethnicity
evaluation study
exhaust gas
extrapulmonary tuberculosis
family
family history
family planning
family violence
fast food
fat free mass
fat intake
fat mass
fatality
feedback system
feeding behavior
female fertility
female genital mutilation
fertilization in vitro
fetus death
fetus growth
fetus mortality
fetus wastage
fever
fibrinogen blood level
Finland
first degree relative
first trimester pregnancy
fish meat
follow up
food
food intake
food poisoning
food preference
food security
food selectivity
forced expiratory volume
France
fruit
fruit juice
gender
gene interaction
gene locus
General Health Questionnaire
general practice
genetic association
genetic epidemiology
genetic polymorphism
genetic predisposition
genetic variability
genotype
genotype environment interaction
geographic distribution
geriatric patient
germ cell tumor
Germany
gestational age
Giardia intestinalis
giardiasis
Gilles de la Tourette syndrome
glucose blood level
glucose tolerance
groups by age
Guinea-Bissau
head circumference
health behavior
health care access
health care management
health care planning
health care policy
health care quality
health care system
health care utilization
health disparity
health program
health status
health survey
hearing
hearing impairment
heart contraction
heart failure
heart infarction
heart rate variability
heart rehabilitation
heart transplantation
heatwave
Helicobacter infection
hematologic malignancy
hemoglobin blood level
hemorrhoid (drug therapy)
hepatitis A
hepatitis B
hepatitis C
Hepatitis C virus
Hepatitis E virus
hereditary nonpolyposis colorectal cancer
heredity
Herpes simplex virus 1
herpes zoster
high risk population
highly active antiretroviral therapy
hip fracture
HIV test
Hodgkin disease
home accident
honey
hormone blood level
hospital admission
hospital care
hospitalization
household
human
Human immunodeficiency virus infected patient
Human immunodeficiency virus infection (drug therapy)
hyperactivity (side effect)
hyperkinetic disorder
hypertension
hypospadias
Iceland
immigrant
immune response
income
industrial noise
industrial worker
infertility
infertility therapy
inflammatory bowel disease
injury
insomnia
insulin blood level
insulin resistance
intelligence quotient
intensive care unit
Internet
interpregancy interval
intestine flora
intestine parasite
intoxication
intracytoplasmic sperm injection
intravenous drug abuse
ischemia
ischemic heart disease
Italy
Japanese (people)
job stress
Kazakhstan
kidney function
kinesiotherapy
larynx cancer
latitude
lean body weight
leisure
Lennox Gastaut syndrome
leukemia
life
lifestyle
lipoprotein blood level
liver cell carcinoma
liver cirrhosis
liver fibrosis
liver transplantation
long term care
long term survival
low back pain
low birth weight
low risk population
lung cancer (surgery)
lung development
lung function
lymphoma
Madagascar
malignant neoplastic disease
Malmo diet
market
marketing
marriage
maternal age
maternal diabetes mellitus
maternal disease
maternal hypertension
maternal mortality
maternal obesity
maternal serum
maternal smoking
measles
measles vaccination
medical care
medical history
medical information
medical leave
medical school
medical specialist
medical student
medication compliance
melanoma
melanoma skin cancer
menarche
menstrual cycle
mental deterioration
mental disease
mental health
mental patient
mesothelioma
metabolic syndrome X
microcephaly
midwife
migrant
mobilization
modifiable risk factor
mother
motor development
multiple sclerosis
mumps
musculoskeletal disease
musculoskeletal pain
Muslim
myeloid leukemia
myeloma
Namibia
needlestick injury
neighborhood
neonatal hyperbilirubinemia
nerve conduction
neural tube defect
newborn mortality
nicotine replacement therapy
noise
non insulin dependent diabetes mellitus (etiology)
nonalcoholic fatty liver
nonhodgkin lymphoma
North African
Norwegian (people)
nursery
nutrition
nutritional assessment
nutritional status
obesity
obsessive compulsive disorder
obstetrician
occupation and occupation related phenomena
occupational accident
occupational exposure
occupational hazard
occupational prestige
offender
onset age
organ donor
ovary cancer
overeducation
Pakistani
Papanicolaou test
parent
parental age
parental attitude
parental deprivation
Parkinson disease
patient care
patient compliance
patient counseling
patient information
patient participation
patient satisfaction
pedigree
pedometer
peer group
pension
percutaneous coronary intervention
perinatal care
peritoneal dialysis
personality
pertussis
pet animal
pharmacoepidemiology
physical activity
physical inactivity
physician
physiological process
placenta weight
pneumonia
policy
poliomyelitis
pollen allergy
polypharmacy
Portugal
postmenopause
postnatal stress
prediction
predictive value
preeclampsia
pregnancy
pregnancy outcome
premature labor
premature mortality
premenopause
prenatal care
prenatal drug exposure
prenatal exposure
prenatal period
prenatal stress
prescription
primary health care
primary medical care
primary prevention
primary tumor
productivity
progeny
prostate cancer
protection
protein blood level
protein intake
protein polymorphism
psoriasis
psychiatric department
psychodynamics
psychological aspect
psychological well being
psychophysiology
psychosomatic disorder
puberty
public health problem
publication
puerperal depression
puerperium
quality of life
radiation exposure
rapid response team
reading
recreation
recurrence risk
recurrent disease
religion
reproduction
reproductive health
respiratory tract disease
retirement
return to work
reward
rheumatoid arthritis
risk assessment
risk factor
rubella
rural area
rural population
Russian Federation
saliva level
salt intake
sandstorm
sanitation
sarcoidosis
schizophrenia (drug therapy)
school
scientist
screening test
season
second trimester pregnancy
Serbia
seroprevalence
sex difference
sexual behavior
sexual intercourse
shoulder impingement syndrome (etiology)
sibling
single nucleotide polymorphism
skin disease
sleep disordered breathing
sleep pattern
small for date infant
smoking
smoking cessation
social class
social interaction
social norm
social status
social support
socioeconomic inequality
socioeconomics
sodium excretion
soft drink
soft tissue sarcoma
solutio placentae
South Africa
South American
Spain
speech
sperm
spontaneous abortion
sport
spouse
standardization
standing
stillbirth
stomach cancer
Strengths and Difficulties Questionnaire
stress
student
substance abuse
suicidal ideation
suicide (epidemiology)
suicide attempt
summer
surgical patient
Sweden
systemic lupus erythematosus
Tanzania
telephone interview
television viewing
temperature related phenomena
testis cancer
tetanus
thalassemia
thorax pain
thorax surgery
thyroid cancer
thyroid disease
time series analysis
time to pregnancy
tobacco
tonsil cancer
topical treatment
total knee replacement
toxoplasmosis
traffic and transport
triacylglycerol blood level
tuberculosis (drug therapy)
tumor associated leukocyte
Turk (people)
twins
undergraduate student
underweight
United Kingdom
urban area
uric acid blood level
urinalysis
urine incontinence
uterine cervix cancer
uterine cervix carcinoma
uterine cervix small cell neuroendocrine carcinoma
uterus cancer
vaccination
vacuum extraction
vaginitis
vagus reflex
varicosis
vegetable
vegetarian diet
vein thrombosis
venous thromboembolism
veterinary clinic
viral clearance
vitamin blood level
volcano
waist circumference
weather
Wegener granulomatosis
weight change
weight gain
weight reduction
welfare
wild boar
work capacity
work disability
work environment
zoonosis
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
caffeine (58-08-2)
clozapine (5786-21-0)
diazepam (439-14-5)
endothelial nitric oxide synthase (503473-02-7)
enterolactone (78473-71-9)
fibrinogen (9001-32-5)
hemoglobin A1c (62572-11-6)
hydrocortisone (50-23-7)
neuronal nitric oxide synthase (506430-87-1)
paracetamol (103-90-2)
tamoxifen (10540-29-1)
temazepam (846-50-4)
zopiclone (43200-80-2)
EMBASE CLASSIFICATIONS
Obstetrics and Gynecology (10)
Cancer (16)
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2015648089
FULL TEXT LINK
http://dx.doi.org/10.1007/s10654-013-9820-0
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 293
TITLE
Abstracts for the Cardiac Society of Australia and New Zealand Annual
Scientific Meeting and the International Society for Heart Research
Australasian Section Annual Scientific Meeting 2013
AUTHOR ADDRESSES
SOURCE
Heart Lung and Circulation (2013) 22 SUPPL. 1. Date of Publication: 2013
CONFERENCE NAME
Cardiac Society of Australia and New Zealand Annual Scientific Meeting and
the International Society for Heart Research Australasian Section Annual
Scientific Meeting 2013
CONFERENCE LOCATION
Gold Coast, QLD, Australia
CONFERENCE DATE
2013-08-08 to 2013-08-11
ISSN
1443-9506
BOOK PUBLISHER
Elsevier Ltd
ABSTRACT
The proceedings contain 613 papers. The topics discussed include: atrial
fibrillation and obesity: impact of weight reduction on the atrial
substrate; intramyocardial adiposity of left ventricular (LV) scar borders
postinfarction contributes to greater ventricular tachycardia susceptibility
than collagen; abnormal left ventricular contractile response to exercise
without obstructive coronary disease: a newly described phenomenon
associated with subclinical myocardial dysfunction; impact of multivessel
coronary artery disease on serum biochemical markers and clinical outcomes
following acute myocardial infarction treated with percutaneous coronary
intervention; poor health status and depression are associated with
excessive daytime sleepiness in stable heart failure patients; an evaluation
of peripheral vascular access site complications following cardiac
angiography and percutaneous coronary intervention (PCI); and clinical
utility of visual left ventricular ejection fraction assessment by
echocardiography: comparison with three-dimensional echocardiography.
EMTREE DRUG INDEX TERMS
biochemical marker
collagen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Australia and New Zealand
heart
society
EMTREE MEDICAL INDEX TERMS
acute heart infarction
angiography
atrial fibrillation
coronary artery disease
daytime somnolence
echocardiography
exercise
health status
heart failure
heart left ventricle ejection fraction
heart ventricle tachycardia
human
obesity
patient
percutaneous coronary intervention
scar
serum
three dimensional echocardiography
vascular access
weight reduction
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 294
TITLE
Competitive sports and the heart: Benefit or risk?
ORIGINAL (NON-ENGLISH) TITLE
Herz und Leistungssport: Nutzen oder Schaden?
AUTHOR NAMES
Scharhag J.
Löllgen H.
Kindermann W.
AUTHOR ADDRESSES
(Scharhag J., juergen.scharhag@med.uni-heidelberg.de) Department of Internal
Medicine III: Cardiology, Angiology and Pneumology, Heidelberg University
Hospital, Im Neuenheimer Feld 410, Heidelberg, Germany.
(Löllgen H.) Internal Medicine, Cardiology and Sports Medicine Office,
Remscheid, Germany.
(Kindermann W.) Institute of Sports and Preventive Medicine, Saarland
University, Germany.
CORRESPONDENCE ADDRESS
J. Scharhag, Department of Internal Medicine III: Cardiology, Angiology and
Pneumology, Heidelberg University Hospital, Im Neuenheimer Feld 410,
Heidelberg, Germany.
SOURCE
Deutsches Arzteblatt International (2013) 110:1-2 (14-24). Date of
Publication: 7 Jan 2013
ISSN
1866-0452
BOOK PUBLISHER
Deutscher Arzte-Verlag GmbH, Dieselstrasse 2 (Postfach 0254), Cologne,
Germany. verlag@aerzteblatt.de
ABSTRACT
Background: Controversy surrounds the cardiac effects of competitive sports
and the athlete's heart. In this review, we present and discuss the main
cardiological findings in competitive athletes.Method: Selective review of
pertinent literature retrieved by a search with the keywords "athlete's
heart," "ECG," "echocardiography," "endurance exercise," "longevity," and
others.Results: Regular exercise leads to functional and structural
adaptations that improve cardiac function. Athlete's heart, which develops
rarely, is a typical finding in endurance athletes. This condition is
characterized by physiological, harmonically eccentric hypertrophy of all
cardiac chambers. The athlete's ECG can be used to distinguish
physiological, training-related changes from pathological training-unrelated
changes. The athlete's heart function is normal at rest and increases
appropriately during exercise. The cardiac markers troponin and B-type
natriuretic peptide are within the normal range in healthy athletes at rest,
but can temporarily be mildly elevated after exhausting endurance-exercise,
without evidence of myocardial damage. The epidemiological data suggest that
participation in competitive sports increases life expectancy.Conclusion:
Competitive exercise does not induce cardiac damage in individuals with
healthy hearts, but does induce physiological functional and structural
cardiac adaptations which have positive effects on life expectancy.
EMTREE DRUG INDEX TERMS
biological marker (endogenous compound)
brain natriuretic peptide (endogenous compound)
troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart
risk benefit analysis
sport
EMTREE MEDICAL INDEX TERMS
arterial wall thickness
article
athlete
atrial fibrillation
cardiovascular magnetic resonance
diastolic blood pressure
dynamic exercise
dynamic stress
echocardiography
electrocardiography
endurance
endurance sport
endurance training
exercise intensity
first degree atrioventricular block
heart function
heart left bundle branch block
heart left ventricle ejection fraction
heart left ventricle hypertrophy
heart output
heart rate
heart repolarization
heart right bundle branch block
heart right ventricle ejection fraction
heart stroke volume
heart ventricle extrasystole
heart volume
Holter monitoring
human
life expectancy
oxygen consumption
paroxysmal supraventricular tachycardia
QT interval
second degree atrioventricular block
ST segment depression
ST segment elevation
static exercise
stress
supraventricular premature beat
systolic blood pressure
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
Radiology (14)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English, German
LANGUAGE OF SUMMARY
English, German
EMBASE ACCESSION NUMBER
2015113872
FULL TEXT LINK
http://dx.doi.org/10.3238/arztebl.2013.0014
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 295
TITLE
Chronotropic incompetence: Causes, implications, and management
AUTHOR NAMES
Kitzman D.W.
AUTHOR ADDRESSES
(Kitzman D.W., dkitzman@wfubmc.edu) Department of Internal Medicine
(Cardiology), Wake Forest School of Medicine, Winston-Salem, United States.
CORRESPONDENCE ADDRESS
D.W. Kitzman, Cardiology Section, Wake Forest University School of Medicine,
Medical Center Boulevard, Winston-Salem, United States.
SOURCE
Dialogues in Cardiovascular Medicine (2013) 18:3 (139-153). Date of
Publication: 2013
ISSN
1272-9949
BOOK PUBLISHER
Les Laboratoires Seriver, 50 Rue Carnot, F-92284, Suresnes Cedex, France.
sarah.novack@fr.netgrs.com
ABSTRACT
The important role of heart rate (HR) in cardiovascular disease is well
established, but attention to HR is usually limited to discussion of resting
HR or HR at peak exercise. This article discusses the importance of
evaluating HR profiles during and after exercise. Increasing HR to tightly
match cardiac output with metabolic demand during exercise is critical to
physical performance. The increase in HR during exercise is the greatest
contributor to the ability to perform physical work, an important
determinant of quality of life, and a strong predictor of prognosis. The
high prevalence of impaired exercise HR response and its easy assessment in
clinical practice provides the rationale for routine screening for
inadequate HR response, particularly because this condition is potentially
treatable and its management can lead to significant improvements in
exercise tolerance and quality of life.
EMTREE DRUG INDEX TERMS
adenylate cyclase
adrenalin
amiodarone
beta adrenergic receptor blocking agent
catecholamine
digitalis
isoprenaline
noradrenalin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chronotropism
exercise tolerance
heart rate
EMTREE MEDICAL INDEX TERMS
aerobic exercise
age distribution
anaerobic threshold
article
atrial fibrillation
cardiac resynchronization therapy
cardiovascular disease
cause of death
cholinergic system
clinical practice
convalescence
coronary artery disease
endurance training
exercise test
functional status
heart failure
heart muscle perfusion
heart output
heart stroke volume
human
implanted heart pacemaker
ischemic heart disease
lung gas exchange
manual labor
muscle contraction
oxygen consumption
parasympathetic tone
physical performance
prevalence
prognosis
quality of life
rest
sinoatrial conduction
stress
sympathetic tone
CAS REGISTRY NUMBERS
adenylate cyclase (9012-42-4)
adrenalin (51-43-4, 55-31-2, 6912-68-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digitalis (8031-42-3, 8053-83-6)
isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2015666585
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 296
TITLE
Late-Breaking Clinical Trial and Clinical Science: Special Reports Abstracts
from the American Heart Association's Scientific Sessions 2012
AUTHOR ADDRESSES
SOURCE
Circulation (2012) 126:23. Date of Publication: 4 Dec 2012
CONFERENCE NAME
American Heart Association 2012 Scientific Sessions and Resuscitation
Science Symposium
CONFERENCE LOCATION
Los Angeles, CA, United States
CONFERENCE DATE
2012-11-03 to 2012-11-06
ISSN
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins
ABSTRACT
The proceedings contain 62 papers. The topics discussed include: Aspirin for
the prevention of recurrent venous thromboembolism after a first unprovoked
event: results of the aspire randomized controlled trial; a randomized trial
of bedside platelet function monitoring to adjust antiplatelet therapy
versus standard of care in patients undergoing drug eluting stent
implantation: the ARCTIC study; main results of the future revascularization
evaluation in patients with diabetes mellitus: optimal management of
multivessel disease (FREEDOM) trial; economic outcomes of percutaneous
coronary intervention performed at sites with and without on-site cardiac
surgery; prospective evaluation of outcomes with stress perfusion imaging
versus stress wall motion imaging during dobutamine or exercise
echocardiography; and fish oil for the prevention of post-operative atrial
fibrillation - the omega-3 fatty acids for prevention of post-operative
atrial fibrillation (OPERA) trial.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid
dobutamine
fish oil
omega 3 fatty acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
clinical trial
human
medical society
resuscitation
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
clinical trial (topic)
diabetes mellitus
drug eluting stent
echocardiography
exercise
health care quality
heart surgery
imaging
implantation
monitoring
patient
percutaneous coronary intervention
prevention
randomized controlled trial
randomized controlled trial (topic)
revascularization
scintigraphy
therapy
thrombocyte function
venous thromboembolism
wall stress
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 297
TITLE
Omega-3 fatty acids and vitamin D in cardiology
AUTHOR NAMES
Güttler N.
Zheleva K.
Parahuleva M.
Chasan R.
Bilgin M.
Neuhof C.
Burgazli M.
Niemann B.
Erdogan A.
Böning A.
AUTHOR ADDRESSES
(Güttler N., norbertguettler@bundeswehr.org; Zheleva K.,
kirillas2002@hotmail.com; Parahuleva M.,
mariana.parahuleva@innere.med.uni-giessen.de; Chasan R.,
ridvan.chasan@hotmail.de; Erdogan A., a.erdogan@web.de) Department of
Cardiology and Angiology, University Hospital Giessen, 35390 Giessen,
Germany.
(Bilgin M., mehmetbilgin62@yahoo.de) Department of Radiology, Bezmialem
University of Istanbul, Istanbul, Turkey.
(Neuhof C., christiane.neuhof@innere.med.uni-giessen.de) Department of
Cardiology, University of Giessen, 35390 Giessen, Germany.
(Burgazli M., mehmetburgazli@hotmail.de) Department of Internal Medicine,
University of Giessen, 35390 Giessen, Germany.
(Niemann B., bernd.niemann@chiru.med.uni-giessen.de) Department of Cardiac
Surgery, University of Giessen, 35390 Giessen, Germany.
(Böning A., andreas.boening@chiru.med.uni-giessen.de) Department of
Cardiovascular Surgery, University Hospital Giessen, 35390 Giessen, Germany.
CORRESPONDENCE ADDRESS
M. Bilgin, Department of Radiology, Bezmialem University of Istanbul,
Istanbul, Turkey. Email: mehmetbilgin62@yahoo.de
SOURCE
Cardiology Research and Practice (2012) 1:1 Article Number: 729670. Date of
Publication: 2012
ISSN
2090-0597 (electronic)
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
Dietary modification and supplementation play an increasingly important role
in the conservative treatment of cardiovascular disease. Current interest
has focused on n-3 polyunsaturated fatty acids (PUFA) and vitamin D.
Clinical trial results on this subject are contradictory in many aspects.
Several studies indicate that n-3 PUFA consumption improves vascular and
cardiac hemodynamics, triglycerides, and possibly endothelial function,
autonomic control, inflammation, thrombosis, and arrhythmia. Experimental
studies show effects on membrane structure and associated functions, ion
channel properties, genetic regulation, and production of anti-inflammatory
mediators. Clinical trials evaluating a possible reduction in cardiovascular
disease by n-3 PUFA have shown different results. Supplementation of vitamin
D is common regarding prevention and treatment of osteoporosis. But vitamin
D also seems to have several effects on the cardiovascular system. Vitamin D
deficiency appears to be related to an increase in parathyroid hormone
levels and can predispose to essential hypertension and left ventricular
hypertrophy, increased insulin resistance, and eventually to atherosclerosis
and adverse cardiovascular events. Randomized prospective clinical trials
are needed to determine whether vitamin D and omega-3 FA supplementation
therapy should be recommended as a routine therapy for primary or secondary
prevention of cardiovascular disease. © 2012 Norbert Güttler et al.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid (adverse drug reaction, clinical trial, drug combination,
drug interaction, drug therapy, intravenous drug administration,
pharmacology)
vitamin D (drug therapy, endogenous compound)
EMTREE DRUG INDEX TERMS
25 hydroxyvitamin D (endogenous compound)
angiotensin (endogenous compound)
anticoagulant agent (drug combination, drug interaction)
antithrombocytic agent (drug combination, drug interaction)
calcium
docosahexaenoic acid
docosapentaenoic acid
fish oil
icosapentaenoic acid
insulin (endogenous compound)
mercury
omega 3 acid ethyl ester
parathyroid hormone (endogenous compound)
paricalcitol (drug therapy)
placebo
polychlorinated biphenyl
renin (endogenous compound)
sodium channel (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, drug therapy, etiology, prevention,
therapy)
diet supplementation
EMTREE MEDICAL INDEX TERMS
acute heart infarction (drug therapy, etiology, prevention, therapy)
angiotensin blood level
antiarrhythmic activity
antiinflammatory activity
atherogenesis
atherosclerosis (etiology, prevention, therapy)
atrial fibrillation (complication, prevention, therapy)
biological activity
bleeding (side effect)
bleeding time
blood pressure regulation
cardiovascular risk
cerebrovascular accident (drug therapy)
chronic kidney disease (drug therapy)
congestive heart failure (etiology, prevention, therapy)
coronary artery bypass graft
diastolic blood pressure
disease association
disease predisposition
essential hypertension (etiology, prevention, therapy)
genetic regulation
heart arrhythmia (drug therapy, etiology, prevention, therapy)
heart left ventricle hypertrophy (etiology, prevention, therapy)
heart muscle cell
heart protection
heart rate
human
hypercalcemia
inflammation
insulin resistance
kidney injury
membrane structure
non insulin dependent diabetes mellitus (side effect)
nonhuman
osteoporosis (drug therapy, prevention)
parathyroid hormone blood level
pathophysiology
patient compliance
peripheral vascular disease (etiology, prevention, therapy)
plasma renin activity
postoperative complication (complication, prevention, therapy)
priority journal
proteinuria (drug therapy)
review
risk factor
risk reduction
side effect (side effect)
sudden death
systolic blood pressure
thrombocyte aggregation
thrombosis (drug therapy, etiology, prevention, therapy)
triacylglycerol blood level
unspecified side effect (side effect)
vascular endothelium
vasodilatation
vitamin blood level
vitamin D deficiency (etiology)
DRUG TRADE NAMES
lovaza
omacor
CAS REGISTRY NUMBERS
25 hydroxyvitamin D (64719-49-9)
angiotensin (1407-47-2)
calcium (14092-94-5, 7440-70-2)
docosahexaenoic acid (25167-62-8, 32839-18-2)
docosapentaenoic acid (25448-00-4, 32839-34-2)
fish oil (8016-13-5)
icosapentaenoic acid (25378-27-2, 32839-30-8)
insulin (9004-10-8)
mercury (14302-87-5, 7439-97-6)
parathyroid hormone (12584-96-2, 68893-82-3, 9002-64-6)
paricalcitol (131918-61-1)
renin (61506-93-2, 9015-94-5)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013059377
FULL TEXT LINK
http://dx.doi.org/10.1155/2012/729670
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 298
TITLE
Hypertension in the elderly
AUTHOR NAMES
Pinna G.
Pascale C.
La Regina M.
Orlandini F.
AUTHOR ADDRESSES
(Pinna G., giuliano.pinna@gmail.com; Pascale C.) Ospedale Cottolengo,
Torino, Italy.
(La Regina M.; Orlandini F.) Ospedale S. Andrea, Presidio Unico Del Levante
Ligure, La Spezia, Italy.
CORRESPONDENCE ADDRESS
G. Pinna, Via Bertola 86, 10122 Torino, Italy. Email:
giuliano.pinna@gmail.com
SOURCE
Italian Journal of Medicine (2012) 6:4 (285-294). Date of Publication:
December 2012
ISSN
1877-9344
1877-9352 (electronic)
BOOK PUBLISHER
Elsevier Masson s.r.l., Via P. Paleocapa 7, Milan, Italy.
ABSTRACT
Introduction: There is a high prevalence of hypertension in the elderly, as
evidenced by clinical and health behavioral policies. Still, there are
uncertainties on the treatment of hypertension, especially treatment of the
very elderly. These considerations have largely been ignored in clinical
trials due to concern regarding contamination by other pathologies that are
difficult to frame and manage. Methods: We performed an effective and ample
literature review and provided reflections on the Consensus Conference
ACCF/AHA 2011 on the principle types of hypertension found in the elderly.
We also considered the associated principle pathologies for various
treatments and related organs. Discussion: Even if the goal of treatment of
elevated blood pressure in the elderly is same as in younger population, it
is no longer certain that a target systolic blood pressure (SBP) <140 mmHg
should be persistently reached in the very elderly. It is important to note
that for all studies these values have never been reached. In the treatment
of isolated systolic hypertension (ISH) the preferred target is a SBP >160
mmHg. Treating hypertension in the elderly and very elderly reduces the risk
of stroke and heart failure, though the evidence is inconclusive for
all-cause mortality. Conclusion: Hypertension in the elderly is very common
and needs to be treated with criteria that consider the patient's age,
comorbidities, lifestyle and adherence. Above all, in the very elderly,
therapeutic treatment should be personalized according to the above
criteria. Where possible pharmaceutical therapy should be limited at the
preference of healthy lifestyle changes (physical activity, diet, etc.). ©
2012 Elsevier Srl. All rights reserved.
EMTREE DRUG INDEX TERMS
alpha adrenergic receptor blocking agent (drug therapy)
angiotensin receptor antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
blocking agent (drug therapy)
calcium channel blocking agent (adverse drug reaction, drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (adverse drug reaction, drug therapy)
renin inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
geriatric patient
hypertension (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
blood pressure regulation
cardiovascular risk
cerebrovascular accident
cerebrovascular disease
coronary artery disease
dementia
edema (side effect)
glucose metabolism
gout
health care policy
heart failure
high risk patient
human
hyperglycemia (side effect)
hyponatremia (side effect)
obesity
osteoarthritis
quality of life
risk
risk reduction
social status
systolic blood pressure
systolic hypertension
vascular resistance
very elderly
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012709750
FULL TEXT LINK
http://dx.doi.org/10.1016/j.itjm.2012.02.003
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 299
TITLE
Stroke prevention: Recent achievements and new challenges
AUTHOR NAMES
Katsnelson M.J.
Della-Morte D.
Sacco R.L.
Rundek T.
AUTHOR ADDRESSES
(Katsnelson M.J., trundek@med.miami.edu; Della-Morte D.; Sacco R.L.; Rundek
T.) Department of Neurology, Miller School of Medicine, University of Miami,
Miami, FL 33136, United States.
(Della-Morte D.) Department of Advanced Biotechnologies and Bioimaging,
IRCCS San Raffaele Pisana, 00163 Rome, Italy.
CORRESPONDENCE ADDRESS
M. J. Katsnelson, Department of Neurology, Miller School of Medicine,
University of Miami, CRB13, 1120 NW 14th Street, Miami, FL 33136, United
States. Email: trundek@med.miami.edu
SOURCE
Periodicum Biologorum (2012) 114:3 (409-419). Date of Publication: 2012
ISSN
0031-5362
BOOK PUBLISHER
Croatian Society of Natural Sciences, Ilica 16/III, Zagreb, Croatia.
ABSTRACT
Stroke remains a major health problem despite the great efforts made
worldwide to fight against it. Despite therapeutic achievements to treat
ischemic stroke patients in stroke units with tissue plasminogen activator
(tPA), prevention remains the most powerful strategy to cure this complex
disease. Stroke is a heterogeneous and multi-factorial disease caused by the
combination of vascular risk factors, environment, and genetic factors.
These risk factors can be subdivided into non-modifiable (age, sex,
race-ethnicity, genetic variations and predispositions) and modifiable
(hypertension, diabetes, dyslipidemia, atrial fibrillation, carotid artery
stenosis, smoking, poor diet, physical inactivity and obesity). The
metabolic syndrome, a cluster of metabolic risk factors within an
individual, has been recognized as and important factor associated with an
increased risk of stroke. Recently, a great emphasis has been given to the
investigations of genetic factors and stroke risk, which may lead to the
discovery of new biomarkers for prevention, diagnosis and to the alternative
strategies for stroke treatment. In this review we sought to discuss the
main risk factors for stroke and the current strategies of stroke
prevention.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
angiotensin receptor antagonist (drug therapy)
antidiabetic agent (drug therapy, oral drug administration)
apixaban (adverse drug reaction, drug therapy)
beta adrenergic receptor blocking agent (drug combination, drug therapy)
C reactive protein (endogenous compound)
calcium channel blocking agent (drug therapy)
cholesterol (endogenous compound)
cobalamin (drug combination, drug therapy)
dabigatran (adverse drug reaction, drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
ezetimibe (drug combination, drug therapy)
fibric acid derivative (drug combination, drug therapy)
folic acid (drug combination, drug therapy)
high density lipoprotein (endogenous compound)
homocysteine (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
insulin (drug therapy)
low density lipoprotein (endogenous compound)
nicotinic acid (drug combination, drug therapy)
omega 3 fatty acid (drug combination, drug therapy)
rivaroxaban (adverse drug reaction, drug therapy)
rosuvastatin (drug therapy)
selectin (endogenous compound)
thiazide diuretic agent (drug combination, drug therapy)
tissue plasminogen activator (drug therapy, endogenous compound)
varenicline
warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
abdominal obesity
alcohol consumption
anticoagulant therapy
atherosclerosis
atrial fibrillation (drug therapy)
brain hemorrhage (side effect)
brain ischemia
cardiomyopathy
cardiovascular disease
carotid artery stenting
congestive heart failure
diabetes mellitus (drug therapy)
dyslipidemia (drug therapy)
endarterectomy
glycemic control
heart infarction (drug therapy)
heredity
human
hyperhomocysteinemia (drug therapy)
hyperlipidemia
hypertension (drug therapy)
immobilization
incidence
lifestyle modification
meta analysis (topic)
metabolic syndrome X
morbidity
mortality
prevalence
public health problem
randomized controlled trial (topic)
retinopathy
review
risk factor
risk reduction
single nucleotide polymorphism
sleep disordered breathing
smoking
substance abuse
transient ischemic attack
valvular heart disease
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
apixaban (503612-47-3)
cholesterol (57-88-5)
cobalamin (13408-78-1)
ezetimibe (163222-33-1)
folic acid (59-30-3, 6484-89-5)
homocysteine (454-28-4, 6027-13-0)
insulin (9004-10-8)
nicotinic acid (54-86-4, 59-67-6)
rivaroxaban (366789-02-8)
rosuvastatin (147098-18-8, 147098-20-2)
tissue plasminogen activator (105913-11-9)
varenicline (249296-44-4, 375815-87-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013107164
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 300
TITLE
Omega-3 polyunsaturated fatty acid supplementation: Mechanism and current
evidence in atrial fibrillation
AUTHOR NAMES
Nodari S.
Triggiani M.
Campia U.
Cas L.D.
AUTHOR ADDRESSES
(Nodari S., savinanodari@gmail.com; Triggiani M.; Cas L.D.) Department of
Experimental and Applied Medicine, Section of Cardiovascular Diseases,
University of Brescia, Brescia, Italy.
(Campia U.) Northwestern University Feinberg School of Medicine, Chicago
(IL), United States.
CORRESPONDENCE ADDRESS
S. Nodari, Department of Experimental and Applied Medicine, Section of
Cardiovascular Diseases, University of Brescia, Brescia, Italy. Email:
savinanodari@gmail.com
SOURCE
Journal of Atrial Fibrillation (2012/2013) 5:4 (49-63). Date of Publication:
December 2012-January 2013
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated
with considerable morbidity and mortality. Available pharmacologic
antiarrhythmic therapies are often ineffective in preventing the recurrence
of AF, possibly because these drugs target a single pathophysiological
mechanism. Given their beneficial effects on ventricular arrhythmias,
omega-3 polyunsaturated fatty acids (n-3 PUFAs) have recently been
investigated as possible candidates in the treatment of supraventricular
arrhythmias. In this review, we explore the current understanding of the
antiarrhythmic effects attributed to n-3 PUFAs including direct modulation
of ionic channels, improvement of membrane fluidity, anti-inflammatory and
antifibrotic effects, and modulation of sympatho-vagal balance. We will then
focus on the results of epidemiologic studies exploring the associations
between nutritional intake of n3 PUFAs and the incidence of AF, and will
review the findings of the clinical trials investigating the effects of n-3
PUFAs supplementation in the prophylaxis of AF and in the prevention of its
recurrences.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid (clinical trial, drug combination, drug therapy,
intravenous drug administration, oral drug administration)
EMTREE DRUG INDEX TERMS
alpha tocopherol (drug combination, drug therapy)
amiodarone (clinical trial, drug therapy)
ascorbic acid (drug combination, drug therapy)
fish oil (clinical trial, drug therapy)
flecainide (clinical trial, drug therapy)
placebo
propafenone (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, surgery)
EMTREE MEDICAL INDEX TERMS
antiinflammatory activity
clinical trial
dietary intake
drug effect
heart electrophysiology
human
nonhuman
nutritional parameters
postoperative period
review
vitamin supplementation
CAS REGISTRY NUMBERS
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
fish oil (8016-13-5)
flecainide (54143-55-4)
propafenone (34183-22-7, 54063-53-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00597220, NCT00970489)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013200927
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 301
TITLE
Exploring barriers to optimal anticoagulation for atrial fibrillation:
Interviews with clinicians
AUTHOR NAMES
Decker C.
Garavalia L.
Garavalia B.
Simon T.
Loeb M.
Spertus J.A.
Daniel W.C.
AUTHOR ADDRESSES
(Decker C., c1decker@saint-lukes.org; Garavalia B.) Mid America Heart
Institute at Saint Luke's Hospital in Kansas City Missouri, University of
Missouri-Kansas City, School of Nursing, Kansas City, MO, United States.
(Garavalia L.) University of Missouri-Kansas City, School of Pharmacy,
Kansas City, MO, United States.
(Simon T.) Bristol-Myers Squibb, Princeton, NJ, United States.
(Loeb M.) Plaza Primary Care and Geriatrics, Kansas City, MO, United States.
(Daniel W.C.) Saint Luke's Cardiovascular Consultants, Kansas City, MO,
United States.
(Spertus J.A.) Mid America Heart Institute at Saint Luke's Hospital in
Kansas City Missouri, University of Missouri-Kansas City, School of
Medicine, Kansas City, MO, United States.
CORRESPONDENCE ADDRESS
C. Decker, Mid America Heart Institute, Saint Luke's Hospital, 4401 Wornall
Road, Kansas City, MO 64111, United States. Email: c1decker@saint-lukes.org
SOURCE
Journal of Multidisciplinary Healthcare (2012) 5 (129-135). Date of
Publication: 2012
ISSN
1178-2390 (electronic)
BOOK PUBLISHER
Dove Medical Press Ltd, Beechfield House, Winterton Way, Macclesfield,
United Kingdom.
ABSTRACT
Background: Warfarin, the most commonly used antithrombotic agent for stroke
prophylaxis in atrial fibrillation (AF), requires regular monitoring,
frequent dosage adjustments, and dietary restrictions. Clinicians'
perceptions of barriers to optimal AF management are an important factor in
treatment. Anticoagulation management for AF is overseen by both cardiology
and internal medicine (IM) practices. Thus, gaining the perspective of
specialists and generalists is essential in understanding barriers to
treatment. We used qualitative research methods to define key issues in the
prescription of warfarin therapy for AF by cardiology specialists and IM
physicians. Methods and results: Clinicians were interviewed to identify
barriers to warfarin treatment in a large Midwestern city. Interviews were
conducted until thematic saturation occurred. Content analysis yielded
several themes. The most salient theme that emerged from clinician
interviews was use of characteristics other than the patient's CHADS(2)
score to enact a treatment plan, such as the patient's social situation and
past medication-taking behavior. Other themes included patient knowledge,
real-world problems, breakdown in communication, and clinician reluctance.
Conclusion: Warfarin treatment is associated with many challenges. The
barriers identified by clinicians highlight the unmet need associated with
stroke prophylaxis in AF and the opportunity to improve anticoagulation
treatment in AF. Social and lifestyle factors were important considerations
in determining treatment. © 2012 Decker et al, publisher and licensee Dove
Medical Press Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulation
atrial fibrillation
EMTREE MEDICAL INDEX TERMS
article
attitude to health
cardiologist
cerebrovascular accident
CHADS2 score
clinical decision making
content analysis
controlled study
descriptive research
female
human
interdisciplinary communication
internist
lifestyle
male
patient attitude
physician attitude
prescription
prophylaxis
qualitative research
semi structured interview
social aspect
social status
treatment planning
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013151696
FULL TEXT LINK
http://dx.doi.org/10.2147/JMDH.S33045
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 302
TITLE
High E/e′ disrupts the rapid lowering of blood glucose in response to
exercise training
AUTHOR NAMES
Fukuda Y.
Yoshimura K.
Fukuda Y.
Fukuda N.
AUTHOR ADDRESSES
(Fukuda Y., svx@muse.dti.ne.jp; Fukuda N.) Department of Cardiology and
Clinical Research, National Hospital Organization Zentsuji Hospital,
Senyu-cho 2-1-1, Zentsuji, Kagawa, 765-0806, Japan.
(Yoshimura K.; Fukuda Y.) Department of Cardiology, Fukuda Cardiovascular
Surgery and Digestive Internal Medicine Clinic, Higashijinzenji 67-1, Kochi,
780-0023, Japan.
CORRESPONDENCE ADDRESS
Y. Fukuda, Department of Cardiology and Clinical Research, National Hospital
Organization Zentsuji Hospital, Senyu-cho 2-1-1, Zentsuji, Kagawa, 765-0806,
Japan. Email: svx@muse.dti.ne.jp
SOURCE
Journal of Echocardiography (2012) 10:4 (119-124). Date of Publication:
December 2012
ISSN
1349-0222
1880-344X (electronic)
BOOK PUBLISHER
Springer Japan, 1-11-11 Kudan-kita, Chiyoda-ku, No. 2 Funato Bldg., Tokyo,
Japan.
ABSTRACT
Background: No relationship between the ratio of peak early velocity of left
ventricular inflow to peak systolic longitudinal velocity of the mitral
annulus velocity (E/e′) and insulin resistance has yet been shown in
patients with cardiac disease. We hypothesized that patients with high E/e′
values would tend not to show the rapid blood glucose-lowering in response
to exercise training characteristic of impaired glucose tolerance (IGT) or
diabetes mellitus (DM) patients. Methods: The subjects were continuous
IGT/DM patients (n = 27) participating in cardiac rehabilitation. All
patients' E/e′ values were measured by echocardiography. The patients' blood
glucose levels (mg/dl) were measured just before (pre-BS) and after
(post-BS) exercise training. Post-BS was subtracted from pre-BS to obtain
ΔBS, and the relationship between E/e′ and ΔBS was investigated. Results:
E/e′ correlated negatively with ΔBS. Moreover, E/e′ was a significant
predictor of ΔBS and as such was independent of hemoglobin A1c (HbA1c),
pre-BS, and presence of atrial fibrillation on multivariate analysis.
Conclusions: Patients with high E/e′, indicating high left ventricular
filling pressure, were unlikely to exhibit the rapid glucose-lowering
response. © 2012 Japanese Society of Echocardiography.
EMTREE DRUG INDEX TERMS
glucose (endogenous compound)
hemoglobin A1c (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
blood glucose monitoring
cardiovascular parameters
diabetes mellitus
exercise
impaired glucose tolerance
peak systolic longitudinal velocity of the mitral annulus velocity
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
clinical article
controlled study
coronary artery bypass graft
correlation analysis
echocardiography
female
glucose blood level
heart failure (rehabilitation)
heart hemodynamics
heart left ventricle filling pressure
heart rehabilitation
human
ischemic heart disease
male
multivariate analysis
outcome assessment
CAS REGISTRY NUMBERS
glucose (50-99-7, 84778-64-3)
hemoglobin A1c (62572-11-6)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012721277
FULL TEXT LINK
http://dx.doi.org/10.1007/s12574-012-0134-0
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 303
TITLE
Exercise tolerance in asymptomatic patients with moderate-severe valvular
heart disease and preserved ejection fraction
AUTHOR NAMES
Olaf S.
Debora B.
Ricarda B.
Gunnar B.
Jochen K.
Schimke I.
Halle M.
Jaffe A.
AUTHOR ADDRESSES
(Olaf S., oschulz@cath-lab-spandau.de; Debora B.; Ricarda B.; Gunnar B.;
Jochen K.) Interventionelle Kardiologie Spandau, Neuendorfer Str. 70, 13585
Berlin, Germany.
(Schimke I.) Department of Cardiology, Charité Universitätsmedizin, Berlin,
Germany.
(Halle M.) Department of Prevention and Sports Medicine, Technische
Universität Munich, Germany.
(Jaffe A.) Mayo Clinic and Medical School, Rochester, MN, United States.
CORRESPONDENCE ADDRESS
S. Olaf, Interventionelle Kardiologie Spandau, Neuendorfer Str. 70, 13585
Berlin, Germany. Email: oschulz@cath-lab-spandau.de
SOURCE
Archives of Medical Science (2012) 8:6 (1018-1026). Date of Publication:
December 2012
ISSN
1734-1922
BOOK PUBLISHER
Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
ABSTRACT
Introduction: For asymptomatic patients with moderate-severe valvular heart
disease, in whom symptoms may be obscured, objective exercise tolerance
measures are warranted for decisions concerning physical activities and
surgical treatment. Material and methods: We compared 61 patients (39 with
aortic stenosis, 22 with aortic or mitral regurgitation) to 23 controls
without valvular heart disease but with indications for stress testing. All
participants underwent cardiopulmonary function testing and dobutamine
stress echocardiography. Blood was drawn before as well as after bicycle
stress to assess high-sensitivity cardiac troponin T (hscTnT). Patients who
underwent surgery were re-evaluated 1.5 ±0.9 years after the operation.
Results: Conventional bicycle test following guideline criteria revealed a
pathologic result in 26% of the patients, whereas spiroergometry showed an
objectively reduced exercise tolerance in 59%, reaching a prognostically
relevant feature in 39%. Stress echocardiography detected a reduced systolic
reserve in 33% and elevated filling pressures in 62%. These abnormalities
were significantly less present in the control group (4, 17, 9, 9, 4%
respectively, p <0.05 each). Baseline hscTnT detected patients with the
prognostically important feature of reduced exercise tolerance (area under
the curve 0.689 (95% CI:0.546-0.831), p = 0.015). Objective preoperative
exercise tolerance predicted sustained cardiocirculatory and myocardial
dysfunction postoperatively. Conclusions: Cardiopulmonary function testing
and dobutamine stress echocardiography identify exercise intolerance in
patients with asymptomatic valvular heart disease beyond stress-test
criteria recommended in recent guidelines. High-sensitivity cardiac troponin
I may be of additional value. Results of these tests presage post-operative
function. Copyright © 2012 Termedia & Banach.
EMTREE DRUG INDEX TERMS
dobutamine
troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aorta valve regurgitation (surgery)
exercise tolerance
heart left ventricle ejection fraction
mitral valve regurgitation (surgery)
EMTREE MEDICAL INDEX TERMS
adult
aorta stenosis
article
atrial fibrillation (complication)
bicycle ergometry
blood sampling
cardiopulmonary hemodynamics
cerebrovascular accident (complication)
circulation
disease severity
exercise test
female
heart function test
heart left ventricle enddiastolic volume
heart left ventricle filling pressure
heart left ventricle mass
heart rate
human
ischemia (complication)
lung function test
major clinical study
male
myocardial disease
postoperative period
prognosis
respiratory quotient
ST segment depression
stress echocardiography
CAS REGISTRY NUMBERS
dobutamine (34368-04-2, 49745-95-1, 52663-81-7, 61661-06-1)
troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013078217
FULL TEXT LINK
http://dx.doi.org/10.5114/aoms.2012.32409
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 304
TITLE
Thigh haematoma following acupuncture treatment in a patient on warfarin
AUTHOR NAMES
Kenz S.
Webb H.
Laggan S.
AUTHOR ADDRESSES
(Kenz S., samikenz71@yahoo.co.uk; Webb H.; Laggan S.) Department of Diabetes
and Endocrinology, Trafford General Hospital, Manchester, United Kingdom.
CORRESPONDENCE ADDRESS
S. Kenz, Department of Diabetes and Endocrinology, Trafford General
Hospital, Manchester, United Kingdom. Email: samikenz71@yahoo.co.uk
SOURCE
BMJ Case Reports (2012). Date of Publication: 2012
ISSN
1757-790X (electronic)
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (drug therapy)
EMTREE DRUG INDEX TERMS
hemoglobin (endogenous compound)
vitamin K group (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
hematoma (drug therapy, complication, drug therapy)
thigh hematoma (drug therapy, complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation (drug therapy)
bursitis (therapy)
case report
drug withdrawal
echography
female
hemoglobin blood level
human
international normalized ratio
priority journal
trochanteric bursitis (therapy)
CAS REGISTRY NUMBERS
hemoglobin (9008-02-0)
vitamin K group (12001-79-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Orthopedic Surgery (33)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2013025820
MEDLINE PMID
23087270 (http://www.ncbi.nlm.nih.gov/pubmed/23087270)
FULL TEXT LINK
http://dx.doi.org/10.1136/bcr-2012-006676
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 305
TITLE
All that glitters is not gold: Apical hypertrophic cardiomyopathy mimicking
acute coronary syndrome
AUTHOR NAMES
Lakshmanadoss U.
Kulkarni A.
Balakrishnan S.
Shree N.
Harjai K.
Jagasia D.
AUTHOR ADDRESSES
(Lakshmanadoss U.; Kulkarni A., abhi30882@gmail.com; Harjai K.; Jagasia D.)
Division of Cardiology, Department of Medicine, Guthrie Health System,
Sayre, PA, 18840, United States.
(Balakrishnan S.; Shree N.) Division of Hospital Medicine, Johns Hopkins
Bayview Medical Center, Baltimore, MD, United States.
CORRESPONDENCE ADDRESS
A. Kulkarni, Division of Cardiology, Department of Medicine, Guthrie Health
System, Sayre, PA, 18840, United States. Email: abhi30882@gmail.com
SOURCE
Cardiology Research (2012) 3:3 (137-139). Date of Publication: 2012
ISSN
1923-2829
1923-2837 (electronic)
BOOK PUBLISHER
Elmer Press, 8230 Boul Taschereau, CP 50577,Brossard, Quebec, Canada.
ABSTRACT
Hypertrophic cardiomyopathy is characterized by the idiopathic hypertrophy
of the left ventricle (and occasionally right ventricle). HCM is an
autosomal dominant disease, with variable penetration. In Asian population,
apical hypertrophic cardiomyopathy is relatively common (25%). However, this
is relatively rare in Caucasian population (0.2%). Patients with HCM, often
presents with typical exertional chest pain and shortness of breath. Apical
HCM patients tend to have milder symptoms. However, the clinical
presentation and electrocardiographic features of Apical HCM often mimic
acute coronary syndrome and high index of suspicion is warranted in
differentiating this condition. Patients with apical HCM have relatively
better prognosis when compare to the other varieties. Here, we are
presenting a patient who presented with typical exertional chest pain whose
electrocardiographic changes are concerning for acute ischemic changes. ©
The authors | Journal compilation © Cardiol Res and Elmer Press™.
EMTREE DRUG INDEX TERMS
diltiazem
lisinopril
metoprolol
pantoprazole
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute coronary syndrome
hypertrophic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
aged
arteriovenous malformation
article
ascending colon
auscultation
blood cell count
case report
CHADS2 score
duodenal ulcer bleeding (surgery)
electrocardiography
emergency ward
essential hypertension
exercise
heart catheterization
heart left ventricle hypertrophy
heart palpitation
heart ventricle tachycardia
human
laser coagulation
male
medical history
paroxysmal atrial fibrillation
prostate hypertrophy
supraventricular tachycardia
T wave inversion
thorax pain
transient ischemic attack
CAS REGISTRY NUMBERS
diltiazem (33286-22-5, 42399-41-7)
lisinopril (76547-98-3, 83915-83-7)
metoprolol (37350-58-6)
pantoprazole (102625-70-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2013604514
FULL TEXT LINK
http://dx.doi.org/10.4021/cr180w
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 306
TITLE
Perioperative optimization of patients undergoing bariatric surgery
AUTHOR NAMES
Owers C.E.
Abbas Y.
Ackroyd R.
Barron N.
Khan M.
AUTHOR ADDRESSES
(Owers C.E., corinneowers@doctors.org.uk; Abbas Y., yabbas@doctors.org.uk;
Ackroyd R., roger.ackroyd@sth.nhs.uk; Khan M., manskhan@doctors.org.uk)
Department of Upper GI Surgery, Sheffield Teaching Hospitals, South
Yorkshire, Sheffield S5 7AU, United Kingdom.
(Barron N., nicholas.barron@sth.nhs.uk) Department of Anaesthesia, Sheffield
Teaching Hospitals, South Yorkshire, Sheffield S10 2JF, United Kingdom.
CORRESPONDENCE ADDRESS
C.E. Owers, Department of Upper GI Surgery, Sheffield Teaching Hospitals,
South Yorkshire, Sheffield S5 7AU, United Kingdom. Email:
corinneowers@doctors.org.uk
SOURCE
Journal of Obesity (2012) 2012 Article Number: 781546. Date of Publication:
2012
ISSN
2090-0708
2090-0716 (electronic)
BOOK PUBLISHER
Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New
York, United States.
ABSTRACT
Bariatric surgery is fast becoming an efficient and safe method of weight
reduction, especially for patients in whom conservative measures have
failed. As the obese population of the world increases, so will the number
of patients requesting or requiring surgical weight loss methods. Bariatric
patients however have numerous co-morbidities that make their operative
course more difficult, and therefore is important to have a good
understanding of the important issues surrounding their pre, peri and post
operative management. This article aims to educate the reader about optimal
management of the bariatric surgical patient. © 2012 C. E. Owers et al.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
bariatric surgery
perioperative period
surgical patient
EMTREE MEDICAL INDEX TERMS
alpha tocopherol deficiency (complication)
anastomosis leakage (complication)
anemia (complication)
article
asthma
atrial fibrillation
body mass
cerebrovascular accident
culture optimization
deep vein thrombosis
dyspnea
emphysema
fatty liver
gastric sleeve
health behavior
health practitioner
heart atrium flutter
heart failure
hemoptysis
hepatomegaly
human
hyperlipidemia
hypertension
hypoglycemia
insulin resistance
intestine injury (complication)
laparoscopic surgery
limb swelling
low calory diet
lung embolism (etiology)
meta analysis (topic)
mortality
non insulin dependent diabetes mellitus
nutritional deficiency (etiology)
obesity
oxygenation
pain assessment
patient positioning
peroperative complication (complication)
pneumothorax (complication)
polysomnography
positive end expiratory pressure
postoperative complication (complication)
psychological aspect
retinol deficiency (complication)
sleep disordered breathing (etiology)
smoking cessation
stomach bypass
thiamine deficiency (complication)
vein thrombosis
venous thromboembolism
vitamin D deficiency (complication)
vitamin K deficiency (complication)
weight reduction
EMBASE CLASSIFICATIONS
Surgery (9)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012646536
FULL TEXT LINK
http://dx.doi.org/10.1155/2012/781546
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 307
TITLE
Recommendations regarding dietary intake and caffeine and alcohol
consumption in patients with cardiac arrhythmias: What do you tell your
patients to do or not to do?
AUTHOR NAMES
Glatter K.A.
Myers R.
Chiamvimonvat N.
AUTHOR ADDRESSES
(Glatter K.A., kaglatter@gmail.com) Woodland Clinic Medical Group, 632 West
Gibson Road, Woodland, CA 95695, United States.
(Myers R.; Chiamvimonvat N.) Division of Cardiovascular Medicine, University
of California, Davis, One Shields Avenue, GBSF 6315, Davis, CA 95616, United
States.
(Chiamvimonvat N.) Department of Veteran's Affairs, Northern California
Health Care System, Mather, CA, United States.
CORRESPONDENCE ADDRESS
K.A. Glatter, Woodland Clinic Medical Group, 632 West Gibson Road, Woodland,
CA 95695, United States. Email: kaglatter@gmail.com
SOURCE
Current Treatment Options in Cardiovascular Medicine (2012) 14:5 (529-535).
Date of Publication: October 2012
ISSN
1092-8464
1534-3189 (electronic)
BOOK PUBLISHER
Current Science Inc., 34-42 Cleveland Street, London, United Kingdom.
ABSTRACT
The etiology of arrhythmias including atrial fibrillation is multifactorial.
Most arrhythmias are associated with comorbid illnesses like hypertension,
diabetes, thyroid disease, or advanced age. Although it is tempting to blame
a stimulant like caffeine as a trigger for arrhythmias, the literature does
not support this idea. There is no real benefit to having patients with
arrhythmias limit their caffeine intake. Caffeine is a vasoactive substance
that also may promote the release of norepinephrine and epinephrine.
However, acute ingestion of caffeine (as coffee or tea) does not cause
atrial fibrillation. Even patients suffering a myocardial infarction do not
have an increased incidence of ventricular or other arrhythmias after
ingesting several cups of coffee. Large epidemiologic studies have also
failed to find a connection between the amount of coffee/caffeine used and
the development of arrhythmias. As such, it does not make sense to suggest
that patients with palpitations, paroxysmal atrial fibrillation, or
supraventricular tachycardia, abstain from caffeine use. Energy drinks are a
new phenom.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
caffeine
EMTREE DRUG INDEX TERMS
adrenalin
noradrenalin
sugar
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alcohol consumption
dietary intake
heart arrhythmia (etiology)
EMTREE MEDICAL INDEX TERMS
adrenalin release
aging
article
atrial fibrillation (diagnosis, etiology)
beverage
coffee
comorbidity
diabetes mellitus
energy drink
exercise
heart infarction
heart palpitation
heart ventricle arrhythmia
human
hypertension
noradrenalin release
sudden death
supraventricular tachycardia
tea
thyroid disease
CAS REGISTRY NUMBERS
adrenalin (51-43-4, 55-31-2, 6912-68-1)
caffeine (58-08-2)
noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012701778
FULL TEXT LINK
http://dx.doi.org/10.1007/s11936-012-0193-6
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 308
TITLE
Association of angiotensin-converting enzyme gene I/D and CYP11B2 gene
-344T/C polymorphisms with lone atrial fibrillation and its recurrence after
catheter ablation
AUTHOR NAMES
Zhang X.-L.
Wu L.-Q.
Liu X.
Yang Y.-Q.
Tan H.-W.
Wang X.-H.
Zhou L.
Jiang W.-F.
Li Z.
AUTHOR ADDRESSES
(Zhang X.-L.; Liu X., xkliuxu@126.com; Tan H.-W.; Wang X.-H.; Zhou L.; Jiang
W.-F.; Li Z.) Department of Cardiology, Shanghai Chest Hospital, Shanghai
Jiaotong University School of Medicine, Shanghai, China.
(Zhang X.-L.) Department of Cardiology, Shanghai Tenth People's Hospital,
Tongji University, Shanghai, China.
(Wu L.-Q.) Department of Cardiology, Shanghai Ruijin Hospital, Shanghai
Jiaotong University School of Medicine, Shanghai, China.
(Yang Y.-Q.) Department of Cardiovascular Research, Shanghai Chest Hospital,
Shanghai Jiaotong University School of Medicine, Shanghai, China.
CORRESPONDENCE ADDRESS
X. Liu, Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong
University School of Medicine, 241 West Huaihai Road, Shanghai 200030,
China. Email: xkliuxu@126.com
SOURCE
Experimental and Therapeutic Medicine (2012) 4:4 (741-747). Date of
Publication: 2012
ISSN
1792-0981
1792-1015 (electronic)
BOOK PUBLISHER
Spandidos Publications Ltd., 10 Vriaxidos Street, Athens, Greece.
ABSTRACT
The renin-angiotensin-aldosterone system (RAAS) plays a key role in atrial
structural and electrical remodeling. The aim of this study was to
investigate the potential associations of angiotensin--converting enzyme
(ACE) gene insertion/deletion (I/D) and aldosterone synthase (CYP11B2) gene
-344T/C polymorphisms with the risk and recurrence of lone atrial
fibrillation (AF). One hundred and ninety-three patients who underwent
successful catheter ablation for lone AF were recruited. Two hundred and
ninety-seven sinus rhythm subjects without a history of arrhythmia served as
controls. The subjects were genotyped for ACE gene I/D and CYP11B2 gene
-344T/C polymorphisms. Results showed that the ACE gene DD genotype and D
allele were associated with a greater prevalence of lone AF (both P<0.01).
In addition, the ACE gene DD genotype had a significantly larger left atrial
dimension (LAD; 41.6±5.7 mm vs. 39.6±5.2 mm; P=0.043) and higher risk of AF
recurrence [44.7% vs. 23.2%; odds ratio (OR), 2.68; 95% confidence interval
(CI), 1.28-5.61; P=0.008] compared with the II+ID genotype in lone AF
patients. After adjustment for a variety of risk factors, the ACE gene DD
genotype had a 1.97--fold increased risk for lone AF (OR, 1.97; 95% CI,
1.15-3.37; P=0.013) and 2.35-fold increased risk for AF recurrence (RR,
2.35; 95% CI, 1.10-5.04; P=0.028) compared with the ACE gene II+ID genotype.
However, no correlation between the CYP11B2 gene -344T/C polymorphism and
lone AF or its recurrence was observed in this cohort. In conclusion, the
ACE gene DD genotype was associated with an increased incidence of lone AF
and its recurrence following ablation, which was partly mediated by LAD.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
aldosterone synthase (endogenous compound)
dipeptidyl carboxypeptidase (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
DNA polymorphism
gene deletion
gene insertion
EMTREE MEDICAL INDEX TERMS
adult
article
catheter ablation
Chinese
controlled study
female
genotype
human
major clinical study
male
recurrent disease
risk factor
sinus rhythm
CAS REGISTRY NUMBERS
aldosterone synthase (122933-89-5)
dipeptidyl carboxypeptidase (9015-82-1)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Human Genetics (22)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012500031
FULL TEXT LINK
http://dx.doi.org/10.3892/etm.2012.650
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 309
TITLE
Abstracts of the 15th Congress of Chest Pain Centers
AUTHOR ADDRESSES
SOURCE
Critical Pathways in Cardiology (2012) 11:3. Date of Publication: September
2012
CONFERENCE NAME
15th Congress of Chest Pain Centers
CONFERENCE LOCATION
Orlando, FL, United States
CONFERENCE DATE
2012-05-02 to 2012-05-03
ISSN
1535-282X
BOOK PUBLISHER
Lippincott Williams and Wilkins
ABSTRACT
The proceedings contain 18 papers. The topics discussed include: does
limiting prehospital 12 lead ECGs to patients who complain of chest pain
delay diagnosing AMI?; STEMI door-to-balloon times: EMS transmitted 12 lead
EKGs to Geisinger Wyoming Valley versus other arrival modalities;
exercise-induced nonsustained ventricular tachycardia; impact of
point-of-care testing and a physician in triage on the timely assessment of
patients with chest pain; validation of high-sensitivity troponin I method
in ACS patients; clopidogrel provision for indigent patients with
ST-elevation; cost analysis in acute coronary syndrome patients using a
high-sensitivity troponin I method; allowing EMS to activate the Cath lab
from the field will decrease D2B times; there is no level of cTnI that is
safe to discharge from the ED; a protocol for definitive therapy with
flecainide in patients with rapid atrial fibrillation: pill in the pocket;
and qualitative analysis of chest pain center education.
EMTREE DRUG INDEX TERMS
clopidogrel
flecainide
troponin I
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
pain clinic
thorax pain
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
atrial fibrillation
cost benefit analysis
education
emergency health service
exercise
heart ventricle tachycardia
human
indigent
patient
physician
pill
point of care testing
qualitative analysis
ST segment elevation
ST segment elevation myocardial infarction
therapy
United States
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 310
TITLE
Stroke: Causes and clinical features
AUTHOR NAMES
Markus H.
AUTHOR ADDRESSES
(Markus H.) Department of Neurology, St George's University of London,
United Kingdom.
CORRESPONDENCE ADDRESS
H. Markus, Department of Neurology, St George's University of London, United
Kingdom.
SOURCE
Medicine (United Kingdom) (2012) 40:9 (484-489). Date of Publication:
September 2012
ISSN
1357-3039
1365-4357 (electronic)
BOOK PUBLISHER
Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
Stroke represents a clinical syndrome rather than a specific disease. It can
be caused by a number of different pathologies which all result in a usually
sudden-onset focal cerebral damage. This article reviews risk factors for
stroke, and the different pathologies that can cause stroke. Approximately
20% of strokes are due to cerebral haemorrhage, most of which is
intracerebral, with a significant minority due to subarachnoid haemorrhage.
The remaining 80% are due to ischaemic stroke which itself has a number of
different subtypes, including large artery disease, cardio-embolism, and
small vessel disease. Differentiation of cerebral ischaemia from haemorrhage
is impossible without brain imaging. Assessment of a patient with ischaemic
stroke requires knowledge of the cerebral arterial supply and cerebral
anatomy, which allows one to determine which particular vascular territory
(anterior versus posterior) is involved. © 2012 Published by Elsevier Ltd.
EMTREE DRUG INDEX TERMS
cholesterol (endogenous compound)
homocysteine (endogenous compound)
oral contraceptive agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
age
alcohol consumption
blood pressure
body mass
cerebrovascular accident (etiology)
diabetes mellitus
ethnicity
exercise
gender
smoking
EMTREE MEDICAL INDEX TERMS
arterial circulation
atrial fibrillation
brain hemorrhage
brain ischemia
cerebrovascular disease
clinical feature
heart failure
human
migraine
neuroimaging
priority journal
review
subarachnoid hemorrhage
transient ischemic attack
vascular disease
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
homocysteine (454-28-4, 6027-13-0)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012496945
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mpmed.2012.06.005
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 311
TITLE
Stroke and mortality in patients with incident heart failure: The Diet,
Cancer and Health (DCH) cohort study
AUTHOR NAMES
Lip G.Y.H.
Rasmussen L.H.
Skjøth F.
Overvad K.
Larsen T.B.
AUTHOR ADDRESSES
(Lip G.Y.H., g.y.h.lip@bham.ac.uk) Centre for Cardiovascular Sciences,
University of Birmingham, City Hospital, Birmingham, United Kingdom.
(Lip G.Y.H., g.y.h.lip@bham.ac.uk; Rasmussen L.H.; Skjøth F.; Larsen T.B.)
Thrombosis Research Centre, Clinical Institute, Aalborg University, Denmark,
Denmark.
(Rasmussen L.H.; Skjøth F.; Overvad K.; Larsen T.B.) Department of
Cardiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
(Overvad K.) School of Public Health, Aarhus University, Aarhus, Denmark.
CORRESPONDENCE ADDRESS
G.Y.H. Lip, Centre for Cardiovascular Sciences, University of Birmingham,
City Hospital, Birmingham, United Kingdom. Email: g.y.h.lip@bham.ac.uk
SOURCE
BMJ Open (2012) 2:4 Article Number: e000975. Date of Publication: 2012
ISSN
2044-6055 (electronic)
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
Objective: The objective was to test the hypothesis that the risk of stroke,
death and the composite of 'stroke and death' would be increased among
patients with incident heart failure (HF). While HF increases the risk of
mortality, stroke and thromboembolism in general, the 'extreme high-risk'
nature of incident HF is perhaps under-recognised in everyday clinical
practice. Design: Prospective cohort study. Setting: Large Danish
prospective epidemiological cohort. Participants: Subjects in the Diet,
Cancer and Health study. Outcome measures: Stroke, death and the composite
of 'stroke and death' among patients with incident cases of HF, without
concomitant atrial fibrillation. Results: From the original cohort, 1239
patients with incident HF were identified. Incidence rates show a higher
incidence in the initial period following the diagnosis of HF, with a
markedly higher rate of death and stroke (ischaemic or haemorrhagic) in the
initial 30 days following the diagnosis of incident HF. While lower than the
risk at 0-30 days, the higher risk did not return to normal at 6+ months
after the diagnosis of incident HF. This risk increase was apparent for the
end points of stroke (ischaemic or haemorrhagic or both) whether or not a
vitamin K antagonist (VKA) was used. With VKA use, there was a lower
adjusted HR for death and the composite of 'death or stroke' compared to
non-VKA use at the three time intervals following diagnosis of HF, whether
0-30 days, 30 days to 6 months and 6+ months. On multivariate analysis,
previous stroke/ transient ischaemic attack/thromboembolism was a predictor
of higher risk of stroke, death and the composite of 'stroke and death',
while VKA treatment was a highly significant predictor of a lower risk for
death (adjusted HR 0.46, 95% CI 0.28 to 0.74, p<0.001) and the combined end
point of death or stroke (adjusted HR 0.64, 95% CI 0.43 to 0.96, p=0.003).
Conclusions: Based on relative hazards, incident HF is clearly a major risk
factor for stroke, death and the composite of 'stroke and death', especially
in the initial 30 days following initial diagnosis. The use of VKA therapy
was associated with a lower risk of these end points. These findings would
have major implications for the approach to management of patients
presenting with incident HF, given the high risk of this population for
death and stroke, which may be ameliorated by VKA therapy.
EMTREE DRUG INDEX TERMS
antivitamin K (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (etiology)
heart failure
EMTREE MEDICAL INDEX TERMS
adult
aged
article
brain hemorrhage (drug therapy)
brain ischemia (drug therapy)
cardiac patient
clinical practice
cohort analysis
controlled study
death
Denmark
female
hazard ratio
high risk population
human
incidence
major clinical study
male
mortality
multivariate analysis
patient identification
prospective study
risk
thromboembolism (etiology)
transient ischemic attack
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012433787
FULL TEXT LINK
http://dx.doi.org/10.1136/bmjopen-2012-000975
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 312
TITLE
Effect of omega-3 polyunsaturated fatty acid supplementation in patients
with atrial fibrillation
AUTHOR NAMES
Kumar S.
Qu S.
Kassotis J.T.
AUTHOR ADDRESSES
(Kumar S.; Qu S.; Kassotis J.T., John.Kassotis@downstate.edu) Department of
Cardiovascular Diseases, Electrophysiology Section, SUNY Downstate Medical
Center, 450 Clarkson Avenue-Box 1199, Brooklyn, NY 11203, United States.
CORRESPONDENCE ADDRESS
J.T. Kassotis, Department of Cardiovascular Diseases, Electrophysiology
Section, SUNY Downstate Medical Center, 450 Clarkson Avenue-Box 1199,
Brooklyn, NY 11203, United States. Email: John.Kassotis@downstate.edu
SOURCE
Journal of Atrial Fibrillation (2012) 5:2. Date of Publication: August 2012
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
Atrial fibrillation (AF) is the most common sustained atrial arrhythmia
conferring a higher morbidity and mortality. Despite the increasing
incidence of AF; available therapies are far from perfect. Dietary fish
oils, containing omega 3 fatty acids, also called polyunsaturated fatty acid
[PUFA] have demonstrated beneficial electrophysiological, autonomic and
anti-inflammatory effects on both atrial and ventricular tissue. Multiple
clinical trials, focusing on various subsets of patients with AF, have
studied the role of PUFA and their potential role in reducing the incidence
of this common arrhythmia. While PUFA appears to have a beneficial effect in
the primary prevention of AF in the elderly with structural heart disease,
this benefit has not been universally observed. In the secondary prevention
of AF, PUFA seems to have a greater impact in the reducing AF in patients
with paroxysmal or persistent AF, stages of AF associated with less atrial
fibrosis and negative structural remodeling. However, AF suppression has not
been consistently demonstrated in clinical trials. In patients undergoing
heart surgery, increasing PUFA intake has yielded mixed results in terms of
AF prevention post-operatively; however, increased PUFA has been associated
with a reduction in hospital stay. Therefore recommending the use of PUFA
for the purpose of AF reduction remains controversial. This is in part
attributable to the complexity of AF. Other conflicting variables include:
heterogeneous patient populations studied; variable dosing; duration of
follow-up; comorbidities; and, concomitant pharmacotherapy. This review
article reviews in detail available basic and clinical research studies of
fish oil in the treatment of AF, and its role in the treatment of this
common disorder.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antiarrhythmic agent (clinical trial, drug therapy)
omega 3 fatty acid (clinical trial, drug therapy)
EMTREE DRUG INDEX TERMS
connexin 40
fish oil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, complication, drug therapy, etiology,
prevention)
EMTREE MEDICAL INDEX TERMS
antiarrhythmic activity
autonomic nerve
calcium transport
coronary artery bypass surgery
disease classification
fat intake
fibrosing alveolitis
genetic association
heart atrium pressure
heart depolarization
heart muscle fibrosis
heart muscle potential
heart muscle refractory period
human
inflammation
intention to treat analysis
multicenter study (topic)
nonhuman
paroxysmal atrial fibrillation
pathogenesis
postoperative complication (complication)
primary prevention
randomized controlled trial (topic)
review
secondary prevention
sleep
supplementation
sympathetic tone
vagus tone
CAS REGISTRY NUMBERS
fish oil (8016-13-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00552084, NCT00597220, NCT00791089, NCT00841451, NCT01235130)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012524422
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 313
TITLE
Acupuncture for paroxysmal and persistent atrial fibrillation: An effective
non-pharmacological tool?
AUTHOR NAMES
Lombardi F.
Belletti S.
Battezzati P.M.
Lomuscio A.
AUTHOR ADDRESSES
(Lombardi F., federico.lombardi@unimi.it; Belletti S.; Battezzati P.M.;
Lomuscio A.) Department of Medicine, Surgery and Dentistry, University of
Milan, 20147 Milan, Italy.
(Lombardi F., federico.lombardi@unimi.it; Belletti S.; Lomuscio A.)
Cardiology, San Paolo Hospital, 20147 Milan, Italy.
(Battezzati P.M.) Internal Medicine Section VI, San Paolo Hospital, 20147
Milan, Italy.
CORRESPONDENCE ADDRESS
F. Lombardi, Department of Medicine, Surgery and Dentistry, University of
Milan, Via A. di Rudinì 8, 20147 Milan, Italy. Email:
federico.lombardi@unimi.it
SOURCE
World Journal of Cardiology (2012) 4:3 (60-65). Date of Publication: 2012
ISSN
1949-8462 (electronic)
BOOK PUBLISHER
Baishideng Publishing Group Co, Room 1701, 17/F, Henan Bulding,, No.90 Jaffe
Road, Wanchai,Hong Kong, China, China.
ABSTRACT
In Traditional Chinese Medicine, stimulation of the Neiguan spot has been
utilized to treat palpitations and symptoms related to different
cardiovascular diseases. We evaluated whether acupuncture might exert an
antiarrhythmic effect on patients with paroxysmal or persistent atrial
fibrillation (AF). Two sets of data are reviewed. The first included
patients with persistent AF who underwent electrical cardioversion to
restore sinus rhythm. The second included patients with symptomatic
paroxysmal AF. All subjects had normal ventricular function. Acupuncture
treatment consisted of 10 acupuncture sessions on a once a week basis with
puncturing of the Neiguan, Shenmen and Xinshu spots. In patients with
persistent AF, the recurrence rate after acupuncture treatment was similar
to that observed in patients on amiodarone, but significantly smaller than
that measured after sham acupuncture treatment or in the absence of any
antiarrhythmic drugs. In a small group of patients with paroxysmal AF,
acupuncture resulted in a significant reduction in the number and duration
of symptomatic AF episodes. In conclusion, we observed that acupuncture of
the Neiguan spot was associated with an antiarrhythmic effect, which was
evident in patients with both persistent and paroxysmal AF. These
preliminary data, observed in 2 small groups of AF patients, need to be
validated in a larger population but strongly suggest that acupuncture may
be an effective non-invasive and safe antiarrhythmic tool in the management
of these patients. © 2012 Baishideng.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, therapy)
paroxysmal atrial fibrillation (therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
adult
aged
cardioversion
controlled study
female
heart ventricle function
human
major clinical study
male
randomized controlled trial
recurrence risk
review
sham procedure
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012382569
FULL TEXT LINK
http://dx.doi.org/10.4330/wjc.v4.i3.60
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 314
TITLE
25th World Congress of the International Union of Angiology, IUA 2012
AUTHOR NAMES
Baumgartner I.
AUTHOR ADDRESSES
(Baumgartner I.) , Switzerland.
SOURCE
Phlebolymphology (2013) 20:1 (6). Date of Publication: 2013
CONFERENCE NAME
25th World Congress of the International Union of Angiology, IUA 2012
CONFERENCE LOCATION
Prague, Czech Republic
CONFERENCE DATE
2012-07-01 to 2012-07-05
ISSN
1286-0107
BOOK PUBLISHER
Les Laboratoires Servier
ABSTRACT
The proceedings contain 69 papers. The special focus in this conference is
on Angiology. The topics include: The Amsterdam ruptured aneurysm trial;
screening for abdominal aortic aneurysm; pharmacological therapy for
abdominal aortic aneurysm; role of conventional and endovascular treatment
of abdominal aortic aneurysms; medical management of carotid stenosis;
determination of the stability of atherosclerotic plaques in vivo and its
clinical relevance; emergency carotid interventions; restenosis after open
carotid endarterectomy and after carotid stenting; exercise prescription for
peripheral arterial disease; inflammation markers and assessment of vascular
risk; management of hypertension in patients with peripheral arterial
disease; critical limb ischemia; percutaneous transluminal angioplasty
versus primary stenting in below the knee arteries in critical limb
ischemia; long-term results of intra-arterial infusion of autologous bone
marrow mononuclear cells in patients with critical limb ischemia; clinical
efficacy and safety issues with newer anticoagulants in atrial fibrillation;
impact of newer anticoagulants on the management of atrial fibrillation;
high risk patients for stroke can now be identified using TCD, silent brain
infarcts on CT or carotid plaque image analysis; management of patients with
polyvascular atherosclerotic disease; upper extremity arterial disease;
Loeys-Dietz syndrome; controlled compression ultrasound for peripheral and
central venous pressure measurement; endovascular abdominal aortic surgery,
our experience; robot-assisted vascular surgery, state of the art; venous
thrombosis in hospitalized patients; thrombotic risk in cancer patients;
predicting the risk of recurrent venous thrombosis; treatment of venous
thrombosis; oral anti-IIa and anti-Xa drugs. pharmacological and clinical
differentiation and their impact on therapeutic outcome; inhibition of FVIII
with TB-402 for the prevention of venous thromboembolism after total knee
and hip replacement; venous thromboembolism prophylaxis in spinal surgery;
prophylaxis in high-risk abdominal surgery; home treatment of pulmonary
embolism; interplay of inflammation and venous thrombosis; facts and
controversies on the new anticoagulants; an update on the clinical
development of defibrotide; generic and biosimilar low-molecular-weight
heparins; heparin-induced thrombocytopenia and its management;
interrelationship between arterial atherosclerotic and venous thromboembolic
disease; a European perspective on generic anticoagulants drugs;
contemporary outcome following catheter thrombolysis for iliofemoral deep
vein thrombosis; diagnostic algorithm for superficial thrombophlebitis; a
new consensus on management of superficial thrombophlebitis; venous
hypertension in chronic venous insufficiency; hemodynamic performance using
four compression stockings in postthrombotic syndrome correlates with the
degree of reflux; inelastic compression in mixed ulcers increases arterial
inflow and venous output; severely dilated truncal varicose veins treated
with endovenous laser therapy; radiofrequency ablation of the great
saphenous vein as a part of the therapy of chronic venous insufficiency;
evaluation of the efficacy of adjunctive treatment with endovenous thermal
ablation; infrequent indications of endovenous laser therapy; low thrombotic
risk following endovenous laser ablation for chronic venous disease and
management of chronic venous disease.
EMTREE DRUG INDEX TERMS
anticoagulant agent
defibrotide
low molecular weight heparin
marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
angiology
EMTREE MEDICAL INDEX TERMS
abdominal aorta aneurysm
abdominal surgery
algorithm
aneurysm rupture
arm
artery
artery disease
atherosclerotic plaque
atrial fibrillation
blood clot lysis
bone marrow
brain infarction
cancer patient
carotid artery
carotid artery obstruction
carotid artery stenting
carotid artery surgery
carotid endarterectomy
catheter
central venous pressure
cerebrovascular accident
chronic vein insufficiency
compression
compression stocking
consensus
critical limb ischemia
deep vein thrombosis
descending aorta surgery
diagnosis
disease management
drug therapy
emergency
exercise
heparin induced thrombocytopenia
high risk patient
hip arthroplasty
home care
hospital patient
human
hypertension
image analysis
inflammation
intraarterial drug administration
knee
laser surgery
Loeys Dietz syndrome
low level laser therapy
lung embolism
mononuclear cell
patient
percutaneous transluminal angioplasty
peripheral occlusive artery disease
postthrombosis syndrome
prescription
pressure measurement
prevention
prophylaxis
radiofrequency ablation
restenosis
risk
robotics
safety
saphenous vein
screening
spine surgery
stent
superficial thrombophlebitis
therapy
thromboembolism
ulcer
ultrasound
varicosis
vascular surgery
vein disease
vein thrombosis
venous thromboembolism
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 315
TITLE
Association Between Adiponectin and Heart Failure Risk in the Physicians'
Health Study
AUTHOR NAMES
Djoussé L.
Wilk J.B.
Hanson N.Q.
Glynn R.J.
Tsai M.Y.
Gaziano J.M.
AUTHOR ADDRESSES
(Djoussé L.; Gaziano J.M.) 1] Department of Medicine, Brigham and Women's
Hospital and Harvard Medical School, Boston, Massachusetts, USA
(Djoussé L.; Gaziano J.M.) Department of Medicine, Division of Aging, The
Massachusetts Veterans Epidemiology and Research Information Center
(MAVERIC) and Geriatric Research, Education, and Clinical Center (GRECC),
Boston Veterans Affairs Healthcare System, Boston, Massachusetts, USA
(Wilk J.B.; Glynn R.J.) Department of Medicine, Brigham and Women's Hospital
and Harvard Medical School, Boston, Massachusetts, USA
(Hanson N.Q.; Tsai M.Y.) Department of Laboratory Medicine and Pathology,
University of Minnesota, Minneapolis, Minnesota, USA
CORRESPONDENCE ADDRESS
1] Department of Medicine, Brigham and Women's Hospital and Harvard Medical
School, Boston, Massachusetts, USA
SOURCE
Obesity (2012). Date of Publication: 15 Jun 2012
ISSN
1930-7381
1930-739X (electronic)
BOOK PUBLISHER
The Obesity Society
ABSTRACT
Limited data are available on the association between adiponectin and
incident heart failure (HF). In the current ancillary study to the
Physicians' Health Study (PHS), we used a prospective nested case-control
design to examine whether plasma adiponectin concentration was related to
the risk of HF. We selected 787 incident HF cases and 787 matched controls
for the current analysis. Each control was selected using a risk set
sampling technique at the time of the occurrence of the index case and
matched on year of birth, age at blood collection, and race. Adiponectin was
measured using enzyme-linked immunosorbent assay. HF occurrence was
self-reported in annual follow-up questionnaire. Validation of self-reported
HF in this cohort has been published. The mean age was 58.7 years. In a
conditional logistic regression adjusting for age, race, time of blood
collection, year of birth, hypertension, atrial fibrillation, smoking,
alcohol intake, and exercise, estimates of the relative risk (95% confidence
interval) were 1.0 (reference), 0.74 (0.53-1.04), 0.67 (0.48-0.94), 0.70
(0.50-0.99), and 0.92 (0.65-1.30) from the lowest to the highest quintile of
adiponectin, respectively, P for quadratic trend 0.004. Additional
adjustment for potential mediating factors including diabetes, C-reactive
protein, and BMI led to the attenuation of the estimate of effect (1.0
(reference), 0.81 (0.57-1.15), 0.75 (0.53-1.06), 0.83 (0.58-1.18), and 1.26
(0.87-1.81) across consecutive quintiles of adiponectin). Our data are
consistent with a J-shaped association between total adiponectin and the
risk of HF among US male physicians.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
adiponectin
EMTREE DRUG INDEX TERMS
C reactive protein
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
health
heart failure
human
physician
risk
EMTREE MEDICAL INDEX TERMS
alcohol consumption
atrial fibrillation
attenuation
blood sampling
confidence interval
diabetes mellitus
enzyme linked immunosorbent assay
exercise
follow up
hypertension
logistic regression analysis
male
plasma
questionnaire
risk factor
sampling
smoking
LANGUAGE OF ARTICLE
English
FULL TEXT LINK
http://dx.doi.org/10.1038/oby.2012.153
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 316
TITLE
Prevention and treatment of osteoporosis in women: An update
AUTHOR NAMES
Daroszewska A.
AUTHOR ADDRESSES
(Daroszewska A.) The Molecular Medicine Centre, MRC Institute of Genetics
and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
CORRESPONDENCE ADDRESS
A. Daroszewska, The Molecular Medicine Centre, MRC Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
SOURCE
Obstetrics, Gynaecology and Reproductive Medicine (2012) 22:6 (162-169).
Date of Publication: June 2012
ISSN
1751-7214
1879-3622 (electronic)
BOOK PUBLISHER
Churchill Livingstone, 1-3 Baxter's Place, Leith Walk, Edinburgh, United
Kingdom.
ABSTRACT
Osteoporosis is a growing health problem in the ageing population. A
postmenopausal woman has an approximately 50% lifetime risk of suffering an
osteoporotic fracture with hip fractures carrying the highest morbidity and
mortality. Non-pharmacological prevention strategies focus on attainment and
maintenance of a high peak bone mass and include a healthy lifestyle,
nutritious and balanced diet, maintenance of optimal vitamin D level and
physical exercise with skeletal mechanical loading. Pharmacological
interventions include hormone replacement therapy in women with early
menopause and postmenopausal women until the age of 60 in the absence of
contraindications. Bisphosphonates (e.g. alendronate, risedronate and
zoledronate) remain the mainstay of antiresorptive treatment and the novel
biologic antiresorptive agent, denosumab is a safe option in patients
intolerant or with contraindications to bisphosphonates. Anabolic therapy
with PTH peptides is currently reserved for severe osteoporosis. A number of
novel treatments e.g. cathepsin K inhibitors, calcilytic drugs
anti-sclerostin antibodies are being assessed in clinical trials. © 2012
Elsevier Ltd.
EMTREE DRUG INDEX TERMS
25 hydroxyvitamin D (endogenous compound)
alendronic acid (adverse drug reaction, clinical trial, drug comparison,
drug therapy, oral drug administration)
bazedoxifene (drug therapy)
calcium (clinical trial, drug therapy)
cathepsin K inhibitor (clinical trial, drug therapy)
clodronic acid (drug therapy)
colecalciferol (clinical trial, drug therapy)
denosumab (adverse drug reaction, clinical trial, drug comparison, drug
therapy, pharmacokinetics)
estrogen (drug combination, drug therapy)
etidronic acid (drug therapy)
ibandronic acid (adverse drug reaction, drug therapy, intravenous drug
administration)
lasofoxifene (drug therapy)
medroxyprogesterone acetate (drug combination, drug therapy)
mk 5442 (clinical trial, drug therapy)
odanacatib (clinical trial, drug therapy)
ono 5334 (clinical trial, drug therapy)
parathyroid hormone (drug therapy)
parathyroid hormone[1-34] (clinical trial, drug comparison, drug therapy,
subcutaneous drug administration)
placebo
raloxifene (drug therapy)
risedronic acid (adverse drug reaction, drug therapy, oral drug
administration)
romosozumab (clinical trial, drug comparison, drug therapy, subcutaneous
drug administration)
salcatonin (adverse drug reaction, drug therapy, intranasal drug
administration)
strontium ranelate (adverse drug reaction, clinical trial, drug therapy,
oral drug administration)
tiludronic acid (drug therapy)
unclassified drug
zoledronic acid (adverse drug reaction, clinical trial, drug therapy,
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
postmenopause osteoporosis (drug therapy, disease management, drug therapy,
prevention)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
aging
alcohol abstinence
alcohol consumption
article
atrial fibrillation (side effect)
body mass
bone density
bone mass
bone mineralization
bone remodeling
breast cancer (drug therapy, prevention)
calcium intake
cellulitis (side effect)
corticosteroid induced osteoporosis (drug therapy)
creatine kinase blood level
creatinine clearance
diarrhea (side effect)
diet
drug approval
drug cost
drug efficacy
drug half life
drug tolerability
drug withdrawal
eophageal irritation (side effect)
eophageal irritation (side effect)
esophagus disease (side effect)
exercise
fall risk
fever (side effect)
flushing
fragility fracture
hip fracture (drug therapy, prevention)
hormone substitution
human
hypocalcemia
instillation site irritation (side effect)
jaw osteonecrosis
lifestyle
lymphocytopenia (side effect)
menopause
meta analysis (topic)
morbidity
mortality
myalgia (side effect)
nausea (side effect)
obesity
osteolysis
osteomalacia
osteopenia
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
postmenopause
randomized controlled trial (topic)
side effect (side effect)
smoking cessation
spine fracture (drug therapy, prevention)
vitamin blood level
vitamin D deficiency
X ray absorption spectroscopy
CAS REGISTRY NUMBERS
25 hydroxyvitamin D (64719-49-9)
alendronic acid (66376-36-1)
bazedoxifene (198481-32-2, 198481-33-3)
calcium (14092-94-5, 7440-70-2)
clodronic acid (10596-23-3, 22560-50-5)
colecalciferol (1406-16-2, 67-97-0)
denosumab (615258-40-7)
etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
lasofoxifene (180915-85-9, 180916-16-9, 190791-29-8)
medroxyprogesterone acetate (71-58-9)
odanacatib (603139-19-1)
parathyroid hormone (12584-96-2, 68893-82-3, 9002-64-6)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
raloxifene (82640-04-8, 84449-90-1)
risedronic acid (105462-24-6, 122458-82-6)
romosozumab (909395-70-6)
salcatonin (47931-85-1)
strontium ranelate (135459-87-9)
tiludronic acid (96538-83-9)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Obstetrics and Gynecology (10)
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012267380
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ogrm.2012.02.007
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 317
TITLE
Left main coronary artery origin from the right coronary sinus: Rare,
dangerous, and easy to miss on routine transoesophageal echocardiography
AUTHOR NAMES
Robaei D.
Nayyar D.
Buchholz S.
AUTHOR ADDRESSES
(Robaei D.; Nayyar D.) Department of Cardiology, St Vincent's Hospital,
Sydney, NSW, Australia.
(Buchholz S., stefanbuchholz@hotmail.com) Cardiac Services, Mackay Base
Hospital, 475 Bridge Road, Mackay, QLD 4740, Australia.
CORRESPONDENCE ADDRESS
S. Buchholz, Cardiac Services, Mackay Base Hospital, 475 Bridge Road,
Mackay, QLD 4740, Australia. Email: stefanbuchholz@hotmail.com
SOURCE
Journal of Echocardiography (2012) 10:2 (72-73). Date of Publication: June
2012
ISSN
1349-0222
1880-344X (electronic)
BOOK PUBLISHER
Springer Japan, 1-11-11 Kudan-Kita,, Chiyoda-ku,Tokyo, Japan.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anomalous left coronary artery arising from the right coronary sinus
(diagnosis)
cardiac imaging
coronary artery anomaly (diagnosis)
coronary sinus
left coronary artery
transesophageal echocardiography
EMTREE MEDICAL INDEX TERMS
angiocardiography
article
atrial fibrillation
computer assisted tomography
exercise
faintness
heart dilatation
heart ventricle arrhythmia
human
image analysis
image processing
single coronary artery (congenital disorder, diagnosis)
sudden death
thorax pain
EMBASE CLASSIFICATIONS
Radiology (14)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2012325149
FULL TEXT LINK
http://dx.doi.org/10.1007/s12574-012-0113-5
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 318
TITLE
Hemodynamic findings in severe tricuspid regurgitation
AUTHOR NAMES
Rao S.
Tate D.A.
Stouffer G.A.
AUTHOR ADDRESSES
(Rao S.; Tate D.A.; Stouffer G.A., rstouff@med.unc.edu) Division of
Cardiology, University of North Carolina, Chapel Hill, NC
CORRESPONDENCE ADDRESS
G.A. Stouffer, Division of Cardiology, University of North Carolina, Chapel
Hill, NC 27599-7075, . Email: rstouff@med.unc.edu
SOURCE
Catheterization and Cardiovascular Interventions (2012) 45:4. Date of
Publication: 2012
ISSN
1522-1946
1522-726X (electronic)
BOOK PUBLISHER
Blackwell Publishing Ltd
ABSTRACT
Tricuspid regurgitation (TR) most commonly occurs in response to right
ventricular (RV) dilation with structural abnormalities in the tricuspid
valve being rarer. In addition to RV size and valvular integrity, the amount
of TR is influenced by RV preload and afterload, the respiratory cycle, left
heart function and atrial fibrillation. Hemodynamic changes in right atrial
(RA) pressures in severe TR include elevated mean pressures, a large
systolic wave called an "s" wave, a prominent 'Y' descent and a blunted 'X'
descent. In addition, RV end diastolic pressure is elevated and cardiac
output is reduced, especially with exercise. "Ventricularization" of the RA
pressure tracing, in which the contour of the RA pressure is similar to, but
of lower amplitude than, the contour of the RV pressure is the most specific
finding but is found in a minority of patients with severe TR. In summary,
alterations in the RA pressure tracing are common in patients with severe TR
but specific hemodynamic findings lack sensitivity, which may in part be due
to the large effects of RV preload, RV afterload and RA compliance on the
amount of TR. © 2012 Wiley Periodicals, Inc.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diagnosis
heart catheterization
heart right ventricle
hemodynamics
tricuspid valve regurgitation
valvular heart disease
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
breathing pattern
exercise
heart afterload
heart function
heart output
heart preload
heart right atrium pressure
heart ventricle enddiastolic pressure
human
patient
tricuspid valve
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
FULL TEXT LINK
http://dx.doi.org/10.1002/ccd.24309
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 319
TITLE
Tai chi exercise for patients with heart disease: a systematic review of
controlled clinical trials.
AUTHOR NAMES
Ng S.M.
Wang C.W.
Tin-Hung Ho R.
Tat-Chi Ziea E.
He J.
Chi-Woon Taam Wong V.
Lai-Wan Chan C.
AUTHOR ADDRESSES
(Ng S.M.) Centre on Behavioral Health and Department of Social Work and
Social Administration, University of Hong Kong.
(Wang C.W.; Tin-Hung Ho R.; Tat-Chi Ziea E.; He J.; Chi-Woon Taam Wong V.;
Lai-Wan Chan C.)
CORRESPONDENCE ADDRESS
S.M. Ng, Centre on Behavioral Health and Department of Social Work and
Social Administration, University of Hong Kong.
SOURCE
Alternative therapies in health and medicine (2012) 18:3 (16-22). Date of
Publication: 2012 May-Jun
ISSN
1078-6791
ABSTRACT
To summarize and evaluate the available evidence from controlled clinical
trials of tai chi (TC) exercise for patients with heart disease. Fourteen
databases were searched up to November 2010 with the terms tai chi, taichi,
tai ji, taiji, taijichuan, cardiac, heart, coronary, myocardial, and atrial
fibrillation in the title, abstract, or key words. No language restrictions
were imposed. The quality and validity of randomized clinical trials (RCTs)
were evaluated using the Jadad Scale. The strength of the evidence for all
included studies was evaluated using the Oxford Centre for Evidence-based
Medicine Levels of Evidence. Nine studies including 5 RCTs and 4
nonrandomized controlled clinical trials met the inclusion criteria. Three
studies examined the effectiveness of TC exercise for patients with chronic
heart failure (CHF), and 6 studies examined the effectiveness of TC exercise
among patients with coronary heart disease (CHD). Overall, these studies
demonstrated favorable effects of TC exercise for the patients with heart
disease. The existing evidence suggests that TC exercise is a good option
for heart patients with very limited exercise tolerance and can be an
adjunct to rehabilitation programs for patients with CHD or CHF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary artery disease (rehabilitation)
evidence based medicine
quality of life
Tai Chi
EMTREE MEDICAL INDEX TERMS
controlled clinical trial (topic)
daily life activity
health behavior
heart infarction (rehabilitation)
human
methodology
outcome assessment
randomized controlled trial (topic)
review
LANGUAGE OF ARTICLE
English
MEDLINE PMID
22875558 (http://www.ncbi.nlm.nih.gov/pubmed/22875558)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 320
TITLE
Chronic pain management in the elderly: An update on safe, effective options
AUTHOR NAMES
King S.A.
AUTHOR ADDRESSES
(King S.A.) New York University, School of Medicine, New York, NY, United
States.
CORRESPONDENCE ADDRESS
S.A. King, New York University, School of Medicine, New York, NY, United
States.
SOURCE
Consultant (2012) 52:5 (326-331). Date of Publication: May 2012
ISSN
0010-7069
BOOK PUBLISHER
Cliggott Publishing Co., 330 Boston Post Road, Box 4027, Darien, United
States.
ABSTRACT
Chronic pain is a significant problem for many elderly patients.
Unfortunately, it is often accepted as a normal part of aging, and these
patients may be undertreated for it. There are many challenges that can make
it difficult to treat pain in this age group, most notably the presence of
other significant health problems and the difficulty of assessing pain in
the cognitively impaired. Medication management remains a mainstay of the
treatment of chronic pain. Recent literature has called into question the
use of NSAIDs as one of the first-line drugs and indicates that it may be
safer to try an opioid before an NSAID. The decision about which medication
to use should be based on the type of pain, the side-effect profile of the
drugs, and the overall health status of the individual patient.
EMTREE DRUG INDEX TERMS
amitriptyline (adverse drug reaction, drug therapy)
anticonvulsive agent (adverse drug reaction, drug therapy)
antidepressant agent (adverse drug reaction, drug therapy)
benzodiazepine derivative (adverse drug reaction, drug therapy)
celecoxib (adverse drug reaction, drug therapy)
choline magnesium trisalicylate (drug therapy)
cyclooxygenase 2 inhibitor (adverse drug reaction, drug therapy)
desipramine (adverse drug reaction, drug therapy)
diclofenac (adverse drug reaction, drug therapy)
duloxetine (drug therapy)
etodolac (adverse drug reaction, drug therapy)
gabapentin (adverse drug reaction, drug therapy)
ibuprofen (adverse drug reaction, drug therapy)
lidocaine (adverse drug reaction, drug therapy, topical drug administration)
milnacipran (drug therapy)
naproxen (adverse drug reaction, drug therapy)
nonsteroid antiinflammatory agent (adverse drug reaction, drug
administration, drug therapy, oral drug administration, topical drug
administration)
nortriptyline (adverse drug reaction, drug therapy)
opiate (adverse drug reaction, drug therapy)
oxycodone (adverse drug reaction, drug therapy)
paracetamol (adverse drug reaction, drug therapy)
pethidine (adverse drug reaction, drug therapy)
pregabalin (adverse drug reaction, drug therapy)
rofecoxib (adverse drug reaction, drug therapy)
salsalate (drug therapy)
serotonin noradrenalin reuptake inhibitor (drug therapy)
tricyclic antidepressant agent (adverse drug reaction, drug therapy)
unindexed drug
venlafaxine (drug therapy)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aging
chronic pain (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
anticholinergic syndrome (side effect)
arthritis (drug therapy)
atrial fibrillation (side effect)
backache (drug therapy)
bone pain (drug therapy)
cardiotoxicity (side effect)
cerebrovascular accident (side effect)
cognitive defect (side effect)
constipation (side effect)
delirium (side effect)
diabetic neuropathy (drug therapy)
drug efficacy
drug indication
drug safety
drug withdrawal
fibromyalgia (drug therapy)
fracture (side effect)
gastrointestinal hemorrhage (side effect)
gastrointestinal toxicity (side effect)
geriatric patient
health status
heart atrium flutter (side effect)
heart infarction (side effect)
heart muscle conduction disturbance (side effect)
human
low back pain (drug therapy)
medical decision making
micturition disorder (side effect)
musculoskeletal pain (drug therapy)
nephrotoxicity (side effect)
occupational therapy
opiate addiction (side effect)
osteoarthritis (drug therapy)
pain assessment
physiotherapy
postherpetic neuralgia (drug therapy)
priority journal
psychotherapy
respiration depression (side effect)
review
risk benefit analysis
risk reduction
sedation
side effect (side effect)
transcutaneous nerve stimulation
unspecified side effect (side effect)
CAS REGISTRY NUMBERS
amitriptyline (50-48-6, 549-18-8)
celecoxib (169590-42-5)
choline magnesium trisalicylate (64425-90-7)
desipramine (50-47-5, 58-28-6)
diclofenac (15307-79-6, 15307-86-5)
duloxetine (116539-59-4, 136434-34-9)
etodolac (41340-25-4)
gabapentin (60142-96-3)
ibuprofen (15687-27-1, 31121-93-4, 527688-20-6, 79261-49-7)
lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
milnacipran (101152-94-7, 175131-60-9, 86181-08-0, 92623-85-3, 96847-55-1)
naproxen (22204-53-1, 26159-34-2)
nortriptyline (72-69-5, 894-71-3)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
oxycodone (124-90-3, 76-42-6)
paracetamol (103-90-2)
pethidine (28097-96-3, 50-13-5, 57-42-1)
pregabalin (148553-50-8)
rofecoxib (162011-90-7, 186912-82-3)
salsalate (552-94-3)
venlafaxine (93413-69-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Gerontology and Geriatrics (20)
Arthritis and Rheumatism (31)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012283547
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 321
TITLE
Variants of the lamin AC (LMNA) gene in non-valvular atrial fibrillation
patients: A possible pathogenic role of the Thr528Met mutation
AUTHOR NAMES
Saj M.
Dabrowski R.
Labib S.
Jankowska A.
Szperl M.
Broda G.
Szwed H.
Tesson F.
Bilinska Z.T.
Ploski R.
AUTHOR ADDRESSES
(Saj M.; Szperl M.) Laboratory of Molecular Biology, Institute of
Cardiology, Warsaw, Poland.
(Dabrowski R.; Jankowska A.; Szwed H.) 2nd Ischemic Heart Disease and
Clinical Department, Institute of Cardiology, Warsaw, Poland.
(Labib S.; Tesson F.) Faculty of Health Sciences, University of Ottawa,
Ottawa, ON, Canada.
(Broda G.) Department of Cardiovascular Epidemiology and Prevention, And
Health Promotion, Institute of Cardiology, Warsaw, Poland.
(Bilinska Z.T.) Department of Coronary Artery and Structural Heart Diseases,
Institute of Cardiology, Warsaw, Poland.
(Bilinska Z.T.) Unit for Screening Studies in Inherited Cardiovascular
Diseases, Institute of Cardiology, Warsaw, Poland.
(Ploski R., rploski@wp.pl) Department of Medical Genetics, Centre of
Biostructure, Medical University of Warsaw, Pawinskiego 3C, 02-106 Warsaw,
Poland.
CORRESPONDENCE ADDRESS
R. Ploski, Department of Medical Genetics, Centre of Biostructure, Medical
University of Warsaw, Pawinskiego 3C, 02-106 Warsaw, Poland. Email:
rploski@wp.pl
SOURCE
Molecular Diagnosis and Therapy (2012) 16:2 (99-107). Date of Publication:
2012
ISSN
1177-1062
1179-2000 (electronic)
BOOK PUBLISHER
Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay,
Auckland 10, New Zealand.
ABSTRACT
Background and Objective: Lamin A/C (LMNA) gene mutations cause dilated
cardiomyopathy, often accompanied by conduction disturbances. Our aim was to
search for LMNA mutations in individuals with atrial fibrillation. Methods:
A cohort of Polish subjects (N = 103) with non-valvular atrial fibrillation
with a high (48.5%) prevalence of conduction system disturbances was
screened for LMNA variants by direct DNA sequencing. Results: We found a
single non-synonymous variant (Thr528Met) in a 72-year-old patient with
normal left ventricular function and episodes of advanced atrioventricular
block. One of his two mutation-carrying daughters had episodes of type I
second-degree atrioventricular block on a 24-hour Holter ECG and peak
exercise arrhythmia. Interpretation of cardiac anomalies observed in the
other daughter was complicated by thyroid insufficiency. A Thr528Met weak
pathogenic effect was supported by transient transfections of C2C12 mouse
myoblasts and computationally. Another interesting variant was Ile26Ile
(c.78C>T), found in a New York Heart Association class III patient with a
depressed left ventricular ejection fraction (30%), left bundle branch
block, and a family history of heart disease. Ile26Ile was absent in 246
healthy individuals and was computationally predicted to interfere with
splicing. Conclusion: LMNA mutations are not a frequent cause of atrial
fibrillation even when conduction disease is present. Unlike the majority of
LMNA mutations clearly associated with a severe clinical phenotype and a
poor prognosis, Thr528Met results in a more subtle pathogenic effect, while
Ile26Ile should be considered as a variant of unknown significance. © 2012
Springer International Publishing AG. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
lamin A (endogenous compound)
lamin C (endogenous compound)
EMTREE DRUG INDEX TERMS
isoleucine (endogenous compound)
methionine (endogenous compound)
threonine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis, epidemiology, etiology)
genetic variability
nonvalvular atrial fibrillation (diagnosis, epidemiology, etiology)
EMTREE MEDICAL INDEX TERMS
adult
aged
amino acid substitution
article
atrioventricular block (diagnosis, epidemiology, etiology)
case report
cohort analysis
conduction system disturbance
controlled study
DNA isolation
DNA sequence
exercise
family history
female
gene mutation
genetic screening
genetic transfection
heart arrhythmia
heart left bundle branch block
heart left ventricle ejection fraction
heart left ventricle function
heart ventricle function
heterozygote
Holter monitoring
human
hypothyroidism
major clinical study
male
myoblast
pathogenesis
prevalence
priority journal
RNA splicing
CAS REGISTRY NUMBERS
isoleucine (7004-09-3, 73-32-5)
methionine (59-51-8, 63-68-3, 7005-18-7)
threonine (36676-50-3, 72-19-5)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Human Genetics (22)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012217749
FULL TEXT LINK
http://dx.doi.org/10.2165/11594880-000000000-00000
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 322
TITLE
Integrating pain management in clinical practice
AUTHOR NAMES
Jamison R.N.
Edwards R.R.
AUTHOR ADDRESSES
(Jamison R.N., RJamison@partners.org; Edwards R.R.) Departments of
Anesthesiology, Perioperative, and Pain Medicine and Psychiatry, Brigham and
Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
(Jamison R.N., RJamison@partners.org) Pain Management Center, Brigham and
Women's Hospital, 850 Boylston Street, Chestnut Hill, MA 02467, United
States.
CORRESPONDENCE ADDRESS
R.N. Jamison, Pain Management Center, Brigham and Women's Hospital, 850
Boylston Street, Chestnut Hill, MA 02467, United States. Email:
RJamison@partners.org
SOURCE
Journal of Clinical Psychology in Medical Settings (2012) 19:1 (49-64). Date
of Publication: March 2012
Preparing Psychologists for a Rapidly Changing Healthcare Environment, Book
Series Title:
ISSN
1068-9583
1573-3572 (electronic)
BOOK PUBLISHER
Springer New York, 233 Spring Street, New York, United States.
ABSTRACT
There is much evidence to suggest that psychological and social issues are
predictive of pain severity, emotional distress, work disability, and
response to medical treatments among persons with chronic pain.
Psychologists can play an important role in the identification of
psychological and social dysfunction and in matching personal
characteristics to effective interventions as part of a multidisciplinary
approach to pain management, leading to a greater likelihood of treatment
success. The assessment of different domains using semi-structured clinical
interviews and standardized self-report measures permits identification of
somatosensory, emotional, cognitive, behavioral and social issues in order
to facilitate treatment planning. In this paper, we briefly describe
measures to assess constructs related to pain and intervention strategies
for the behavioral treatment of chronic pain and discuss related psychiatric
and substance abuse issues. Finally, we offer a future look at the role of
integrating pain management in clinical practice in the psychological
assessment and treatment for persons with chronic pain. © 2012 Springer
Science+Business Media, LLC.
EMTREE DRUG INDEX TERMS
morphine (drug therapy, intravenous drug administration)
opiate (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
analgesia
chronic pain (drug therapy, disease management, drug therapy, therapy)
clinical practice
EMTREE MEDICAL INDEX TERMS
advanced cancer
anger
anxiety
anxiety disorder
atrial fibrillation
Beck Depression Inventory
behavioral science
catastrophizing
Center for Epidemiological Studies Depression Scale
chronic obstructive lung disease
clinical assessment tool
clinical trial (topic)
cognition
comorbidity
constipation (side effect)
coping behavior
cultural factor
depression
dizziness (side effect)
electronic medical record
emotional stress
ethnicity
facial expression
fatigue (side effect)
fibromyalgia
General Health Questionnaire
health care personnel
health program
helplessness
Hospital Anxiety and Depression Scale
human
hypnosis
limb injury
low back pain
mental disease
microcomputer
Minnesota Multiphasic Personality Inventory
mobile phone
mood
mood disorder
muscle strain
nausea (side effect)
neuroimaging
nociception
patient monitoring
personality
personality test
priority journal
prognosis
pruritus (side effect)
psychiatry
psychologic assessment
psychological aspect
psychologist
psychopathy
quality of life
relaxation training
review
rheumatoid arthritis
risk assessment
self concept
self esteem
self monitoring
self report
semi structured interview
sexual abuse
sexual dysfunction
Short Form 36
Sickness Impact Profile
smoking
social psychology
stretching
substance abuse
Symptom Checklist 90
tension headache
treatment planning
urine retention (side effect)
visual analog scale
CAS REGISTRY NUMBERS
morphine (52-26-6, 57-27-2)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Psychiatry (32)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012210182
MEDLINE PMID
22383018 (http://www.ncbi.nlm.nih.gov/pubmed/22383018)
FULL TEXT LINK
http://dx.doi.org/10.1007/s10880-012-9295-2
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 323
TITLE
Czech Society of Cardiology guidelines for the diagnosis and treatment of
chronic heart failure 2011
AUTHOR NAMES
Špmar J.
Vítovec J.
Hradec J.
Málek I.
Meluzín J.
Špmarová L.
Hošková L.
Hegarová M.
Ludka O.
Táhorský M.
AUTHOR ADDRESSES
(Špmar J.; Ludka O.) Department of Internal Medicine - Cardiology, Masaryk
University, University Hospital Brno, Jihlavska 20, Brno, Czech Republic.
(Vítovec J., jiri.vitovec@fnusa.cz; Meluzín J.; Špmarová L.) 1st Department
of Internal Medicine - Cardioangiology, Masaryk University, St. Anne's
University Hospital Brno, Pekařska 53, Brno, Czech Republic.
(Hradec J.) 3rd Department of Internal Medicine, Charles University, General
University Hospital in Prague, U Nemocnice 2, Prague 2, Czech Republic.
(Málek I.; Hošková L.; Hegarová M.) Department of Cardiology, Institute of
Clinical and Experimental Medicine, Vídeňská 1958/9, Prague 4, Czech
Republic.
(Táhorský M.) 1st. Department of Internal Medicine - Cardiology, Faculty of
Medicine, Palacký University and University Hospital, I. P. Pavlova 6,
Olomouc, Czech Republic.
CORRESPONDENCE ADDRESS
J. Vítovec, 1st Department of Internal Medicine - Cardioangiology, Masaryk
University, St. Anne's University Hospital Brno, Pekařska 53, Brno, Czech
Republic. Email: jiri.vitovec@fnusa.cz
SOURCE
Cor et Vasa (2012) 54:2 (E113-E134). Date of Publication: March-April 2012
ISSN
0010-8650
1803-7712 (electronic)
BOOK PUBLISHER
Elsevier Science B.V., P.O. Box 1527, Amsterdam, Netherlands.
ABSTRACT
Guidelines of Czech Society of Cardiology are released in accordance with
ESC guidelines for the diagnosis and treatment of acute and chronic heart
failure. Guidelines summarise and evaluate all currently available knowledge
about a particular issue, and whenever it is possible they are based on
EBM-Evidence Based Medicine. Two classifications of level of evidence and
the strength of recommendation are used as seen below. © 2012 The Czech
Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (drug therapy)
amino terminal pro brain natriuretic peptide
amiodarone (drug therapy)
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
brain natriuretic peptide (endogenous compound)
candesartan (drug therapy)
captopril (drug therapy)
corticosteroid (drug therapy)
creatinine (endogenous compound)
diclofenac (drug therapy)
digoxin (drug therapy)
dihydropyridine (drug therapy)
diltiazem (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
enalapril (drug therapy)
ibuprofen (drug therapy)
influenza vaccine (drug therapy)
inotropic agent (drug therapy)
lisinopril (drug therapy)
losartan (drug therapy)
perindopril tert butylamine (drug therapy)
ramipril (drug therapy)
spironolactone (drug therapy)
trandolapril (drug therapy)
tricyclic antidepressant agent (drug therapy)
unindexed drug (drug therapy)
valsartan (drug therapy)
vasodilator agent (drug therapy)
verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, diagnosis, drug therapy, epidemiology,
etiology, surgery, therapy)
medical society
EMTREE MEDICAL INDEX TERMS
alcohol consumption
angina pectoris
aorta valve replacement
article
ascites
asthma
atrial fibrillation
auscultation
blood cell count
body mass
cachexia
cardiac resynchronization therapy
catabolism
central venous pressure
clinical trial (topic)
computed tomographic angiography
constipation
coronary artery bypass graft
coughing
creatinine blood level
cyanosis
defibrillator
diabetes mellitus
diet
disease classification
disease course
disease severity
dyspnea
electrocardiogram
electrolyte blood level
epidemiology
evidence based medicine
exercise
fatigue
health program
heart catheterization
heart dilatation
heart left ventricle ejection fraction
heart left ventricle hypertrophy
heart left ventricle overload
heart muscle revascularization
heart palpitation
heart preload
heart transplantation
hematocrit
hemodialysis
hepatomegaly
human
influenza vaccination
insomnia
kidney dysfunction
left ventricular assist device
liver function test
lung congestion
morbidity
mortality
nausea
nocturia
nuclear magnetic resonance imaging
oliguria
oxygen saturation
pathophysiology
percutaneous coronary intervention
peripheral edema
phase 3 clinical trial (topic)
pleura effusion
prognosis
pulmonary hypertension
quality of life
sexual behavior
smoking
systolic dysfunction
tachycardia
thorax pain
thorax radiography
three dimensional echocardiography
tissue Doppler imaging
transthoracic echocardiography
travel
treatment contraindication
treatment indication
urinalysis
vomiting
weight gain
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
brain natriuretic peptide (114471-18-0)
candesartan (139481-59-7)
captopril (62571-86-2)
creatinine (19230-81-0, 60-27-5)
diclofenac (15307-79-6, 15307-86-5)
digoxin (20830-75-5, 57285-89-9)
dihydropyridine (27790-75-6)
diltiazem (33286-22-5, 42399-41-7)
enalapril (75847-73-3)
ibuprofen (15687-27-1, 31121-93-4, 527688-20-6, 79261-49-7)
lisinopril (76547-98-3, 83915-83-7)
losartan (114798-26-4)
perindopril tert butylamine (107133-36-8)
ramipril (87333-19-5)
spironolactone (52-01-7)
trandolapril (87679-37-6)
valsartan (137862-53-4)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012336285
FULL TEXT LINK
http://dx.doi.org/10.1016/j.crvasa.2012.03.002
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 324
TITLE
The use of mobile cardiac telemetry to improve diagnostic accuracy and
enable more efficient patient care
AUTHOR NAMES
Zweibel S.
Trelfa M.
AUTHOR ADDRESSES
(Zweibel S., szweibel@harthosp.org) Hartford Hospital, University of
Connecticut School of Medicine, United States.
(Trelfa M.) eCardio, United States.
CORRESPONDENCE ADDRESS
S. Zweibel, Hartford Hospital, University of Connecticut School of Medicine,
80 Seymour Street, Hartford, CT 06102, United States. Email:
szweibel@harthosp.org
SOURCE
US Cardiology (2012) 9:1 (43-46). Date of Publication: February 2012
ISSN
1758-3896
1758-390X (electronic)
BOOK PUBLISHER
Touch Briefings, Saffron House, 6-10 Kirby St,, London, United Kingdom.
ABSTRACT
Mobile cardiac telemetry (MCT) is a relatively new technology, first
approved in 2002 by the US Food and Drug Administration (FDA), which
provides continuous realtime outpatient electrocardiographic monitoring for
extended periods of time. MCT allows detection of both symptomatic and
asymptomatic arrhythmias and has been proven to provide superior diagnostic
capability for patients with palpitations, syncope, and pre-syncope. It also
allows accurate monitoring of a patient's rhythm during outpatient drug
titration, as well as detection of both symptomatic and asymptomatic atrial
fibrillation after cardiac ablation. Since recording of the rhythm is
continuous, monitoring of a patient's heart rate (as well as specific
documentation of the initiation and termination of arrhythmias) is possible.
This article will focus on how the use of MCT can improve diagnostic
accuracy and, when combined with the use of a monitoring service that
integrates the patient's tracings within an electronic medical record, can
also improve the efficiency of care given to patients. © Touch Briefings
2012.
EMTREE DRUG INDEX TERMS
flecainide (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mobile cardiac telemetry
telemetry
EMTREE MEDICAL INDEX TERMS
adult
aerobic exercise
article
atrial fibrillation (diagnosis, drug therapy)
case report
clinical effectiveness
diagnostic accuracy
diagnostic test accuracy study
diagnostic value
electronic medical record
heart palpitation
histogram
human
male
outpatient care
patient monitoring
sinus tachycardia (diagnosis)
supraventricular tachycardia (diagnosis, drug therapy)
CAS REGISTRY NUMBERS
flecainide (54143-55-4)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012572491
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 325
TITLE
Dexmedetomidine: Current Role in Anesthesia and Intensive Care
ORIGINAL (NON-ENGLISH) TITLE
Dexmedetomidina: Papel Atual em Anestesia e Cuidados Intensivos
AUTHOR NAMES
Afonso J.
Reis F.
AUTHOR ADDRESSES
(Afonso J., joanaafonsoo@gmail.com) Anesthesiology Consultant, Coimbra
University, Portugal.
(Reis F.) Laboratory of Pharmacology and Experimental Therapeutics, IBILI,
Medicine Faculty, Coimbra University, Portugal.
CORRESPONDENCE ADDRESS
J. Afonso, Hospital Pedro Hispano, Rua Dr. Eduardo Torres 4464-513,
Matosinhos, Portugal. Email: joanaafonsoo@gmail.com
SOURCE
Revista Brasileira de Anestesiologia (2012) 62:1 (118-133). Date of
Publication: January 2012
ISSN
0034-7094
1806-907X (electronic)
BOOK PUBLISHER
Elsevier Editora Ltda, Rua Sete de Setembro, 111 15, 16 and 17th floor, Rio
de Janeiro, Brazil.
ABSTRACT
Background and objectives: To update and review the application of
dexmedetomidine in anesthesia and intensive care. This study is a
comprehensive review of clinical uses, pharmacology, pharmacokinetics,
mechanism of action and adverse effects of dexmedetomidine. Content: The
effective use of sedative-hypnotic agents and analgesics is an integral part
of comfort and safety of patients. Dexmedetomidine is a potent and highly
selective α-2 adrenoceptor agonist with sympatholytic, sedative, amnestic,
and analgesic properties, which has been described as a useful and safe
adjunct in many clinical applications. It provides a unique " conscious
sedation" , analgesia, without respiratory depression. The current reviewed
uses include sedation at Intensive Care Unit - ICU (both adult and
pediatric), emergency department, regional and general anesthesia,
neurosurgery, sedation for pediatric procedures, awake fiber-optic
intubation, cardiac surgery and bariatric surgery. Conclusions:
Dexmedetomidine offers a unique ability of providing both sedation and
analgesia without respiratory depression. It is a new agent with a wide
safety margin, excellent sedative capacity and moderate analgesic
properties. Although its wide use is currently in patients of surgical and
non-surgical intensive care units, dexmedetomidine seems to have promising
future applications in neuroprotection, cardioprotection and renoprotection.
More detailed studies are required to define its role as sedative in
critical, neurosurgical and pediatric patients, as anesthesia adjunct and
sedative during procedures. © 2012 Elsevier Editora Ltda.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dexmedetomidine (adverse drug reaction, drug comparison, drug therapy,
intramuscular drug administration, intravenous drug administration, oral
drug administration, pharmacokinetics, pharmacology, transdermal drug
administration)
EMTREE DRUG INDEX TERMS
alpha 2 adrenergic receptor (endogenous compound)
atropine (drug therapy)
calcium activated potassium channel (endogenous compound)
clonidine (drug comparison)
ephedrine (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anesthesia
intensive care
EMTREE MEDICAL INDEX TERMS
adrenergic activity
analgesic activity
atrial fibrillation (side effect)
bariatric surgery
bradycardia (drug therapy, side effect)
brain ischemia (drug therapy, prevention)
cardiovascular response
conscious sedation
drug absorption
drug bioavailability
drug clearance
drug distribution
drug efficacy
drug elimination
drug half life
drug metabolism
drug safety
drug structure
emergency ward
fiber optics
first degree atrioventricular block (side effect)
general anesthesia
heart arrest (side effect)
heart arrest (side effect)
heart muscle ischemia (drug therapy, prevention)
heart protection
heart surgery
human
hyperpolarization
hypertension (side effect)
hypnosis
hypotension (side effect)
hypoxia (side effect)
hypoxic ischemic encephalopathy (drug therapy, prevention)
liver metabolism
nausea (side effect)
negative feedback
neuroprotection
neurosurgery
neurotransmitter release
nonhuman
noradrenalin release
patient safety
pediatric surgery
regional anesthesia
renal protection
respiration depression
review
second degree atrioventricular block (side effect)
single drug dose
steady state
thermoregulation
tranquilizing activity
withdrawal syndrome (drug therapy)
DRUG TRADE NAMES
precedex , United StatesAbbott
DRUG MANUFACTURERS
(United States)Abbott
CAS REGISTRY NUMBERS
atropine (51-55-8, 55-48-1)
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
dexmedetomidine (113775-47-6)
ephedrine (299-42-3, 50-98-6)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English, Portuguese
LANGUAGE OF SUMMARY
English, Portuguese
EMBASE ACCESSION NUMBER
2012037260
MEDLINE PMID
22248773 (http://www.ncbi.nlm.nih.gov/pubmed/22248773)
FULL TEXT LINK
http://dx.doi.org/10.1016/S0034-7094(12)70110-1
COPYRIGHT
Copyright 2013 Elsevier B.V., All rights reserved.
RECORD 326
TITLE
Neural mechanisms of atrial arrhythmias
AUTHOR NAMES
Shen M.J.
Choi E.-K.
Tan A.Y.
Lin S.-F.
Fishbein M.C.
Chen L.S.
Chen P.-S.
AUTHOR ADDRESSES
(Shen M.J.) Department of Internal Medicine, University of Illinois at
Chicago, Advocate Christ Medical Center, 4440 West 95th Street, 131 NO, Oak
Lawn, IL 60453, United States.
(Choi E.-K.) Department of Internal Medicine, Seoul National University
Hospital, 28 Yongon-dong, Chongno-gu Seoul 110-744, South Korea.
(Tan A.Y.) Beth Israel Deaconess Medical Center, Harvard Medical School, 330
Brookline Avenue, Boston, MA 02215, United States.
(Lin S.-F.; Chen P.-S., chenpp@iupui.edu) Department of Medicine, Indiana
University, School of Medicine, 1801 North Capitol Avenue, E475,
Indianapolis, IN 46202, United States.
(Fishbein M.C.) Department of Pathology and Laboratory Medicine, David
Geffen School of Medicine, University of California Los Angeles, 10833 Le
Conte Avenue, Los Angeles, CA 90095, United States.
(Chen L.S.) Department of Neurology, Indiana University, School of Medicine,
545 Barnhill Drive, EH 125, Indianapolis, IN 46202, United States.
CORRESPONDENCE ADDRESS
P.-S. Chen, Department of Medicine, Indiana University, School of Medicine,
1801 North Capitol Avenue, E475, Indianapolis, IN 46202, United States.
Email: chenpp@iupui.edu
SOURCE
Nature Reviews Cardiology (2012) 9:1 (30-39). Date of Publication: January
2012
ISSN
1759-5002
1759-5010 (electronic)
BOOK PUBLISHER
Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
The past 5 years have seen great advances in the knowledge of neural
mechanisms of atrial arrhythmogenesis. Direct autonomic nerve recordings
demonstrate that simultaneous sympathovagal discharges and intrinsic cardiac
nerve activities are common triggers of paroxysmal atrial tachycardia and
atrial fibrillation. While activity of the autonomous nervous system (ANS)
is crucial in triggering paroxysmal atrial fibrillation, a high incidence of
sympathovagal co-activation at baseline is associated with a high
vulnerability to pacing-induced sustained atrial fibrillation, suggesting
that ANS has a role in the development of persistent atrial fibrillation.
Modulation of ANS activity may constitute an important therapeutic strategy
for the management of atrial tachyarrhythmias. Specifically, continuous,
low-level stimulation of the left cervical vagus nerve effectively
suppresses atrial tachyarrhythmias by reducing the nerve activity of the
stellate ganglion. Clinically, compared with pulmonary vein isolation alone,
the addition of ablation of intrinsic cardiac ganglia may confer better
outcomes for patients with paroxysmal atrial fibrillation. These findings
suggest that further investigation of the neural mechanisms of atrial
arrhythmias might lead to better management of patients with atrial
arrhythmias. In this article, we review the role of the ANS in the induction
and maintenance of atrial arrhythmias and the role of neural modulation as a
treatment strategy for atrial arrhythmias. © 2011 Macmillan Publishers
Limited. All rights reserved.
EMTREE DRUG INDEX TERMS
acetylcholine
dopachrome
melanin
stem cell factor receptor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart atrium arrhythmia
EMTREE MEDICAL INDEX TERMS
acupuncture
atrial fibrillation
atrioventricular canal
autonomic nervous system
catheter ablation
electrostimulation
follow up
heart atrioventricular node
heart failure
heart nerve
heart rate
inferior cava vein
long QT syndrome
nerve cell network
nerve conduction
nonhuman
parasympathetic innervation
priority journal
refractory period
review
sarcoplasmic reticulum
sinus node disease
spinal cord
superior cervical ganglion
supraventricular tachycardia
sympathetic tone
tachycardia
vagus nerve
CAS REGISTRY NUMBERS
acetylcholine (51-84-3, 60-31-1, 66-23-9)
dopachrome (3571-34-4)
melanin (8049-97-6)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011693515
MEDLINE PMID
21946776 (http://www.ncbi.nlm.nih.gov/pubmed/21946776)
FULL TEXT LINK
http://dx.doi.org/10.1038/nrcardio.2011.139
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 327
TITLE
Heart failure with a normal ejection fraction: Treatments for a complex
syndrome?
AUTHOR NAMES
Bernard S.
Maurer M.S.
AUTHOR ADDRESSES
(Bernard S., msm10@columbia.edu; Maurer M.S.) Clinical Cardiovascular
Research Laboratory for the Elderly, Columbia University, Allen Hospital of
New York, 5141 Broadway, New York, NY 10034, United States.
CORRESPONDENCE ADDRESS
S. Bernard, Clinical Cardiovascular Research Laboratory for the Elderly,
Columbia University, Allen Hospital of New York, 5141 Broadway, New York, NY
10034, United States. Email: msm10@columbia.edu
SOURCE
Current Treatment Options in Cardiovascular Medicine (2012) 14:4 (305-318).
Date of Publication: August 2012
ISSN
1534-3189 (electronic)
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Heart failure with a normal ejection fraction (HFNEF) now comprises more
than 50 % of all patients with heart failure. As the population ages, HFNEF
will continue to be a growing public health problem. Recent studies
highlight the heterogeneity of this syndrome with regards to underlying
pathophysiologic mechanisms. It has been recognized that multiple
physiologic domains of cardiovascular function are abnormal in afflicted
patients resulting in a reduced reserve capacity, which contributes in an
integrated fashion to produce the observed phenotype. Additionally, the
realization that differing aspects of this syndrome (eg, exercise
limitations, pulmonary edema, and labile blood pressure) likely each have
distinct physiologic causes further adds to the complexity. As a result of
the heterogeneous nature of the pathophysiologic processes and comorbid
illnesses in this population, there is a wide range of clinical outcomes.
Accordingly, appreciation of the global nature of HFNEF ideally will better
inform optimal design for future diagnostic and therapeutic strategies.
Completed clinical trials have not resulted in any evidence-based treatments
available for improving survival. Given the disappointing results of these
investigations, there has been renewed interest in developing interventions
that target underlying comorbidities and peripheral mechanisms.
Additionally, nonpharmacologic interventions such as diet and exercise have
shown promise in early, small clinical investigations. Finally, methods to
more rationally subgroup patients to identify cohorts that could respond to
targeted intervention are essential. Recognizing the success achieved in the
treatment of systolic heart failure, or heart failure with a reduced
ejection fraction (HFREF) by addressing neurohormonal and renal mechanisms,
new therapies for HFNEF may be achieved by a similar shift in attention away
from the heart. © Springer Science+Business Media, LLC 2012.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (clinical trial, drug therapy)
amlodipine (clinical trial, drug comparison, drug therapy)
angiotensin receptor antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug comparison, drug therapy)
calcium channel blocking agent (drug comparison, drug therapy)
candesartan (clinical trial, drug therapy)
digoxin (drug comparison, drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (clinical trial, drug comparison, drug therapy, intravenous
drug administration)
doxazosin (clinical trial, drug comparison, drug therapy)
irbesartan (clinical trial, drug therapy)
lisinopril (clinical trial, drug comparison, drug therapy)
loop diuretic agent (drug therapy, intravenous drug administration)
losartan (drug therapy)
nebivolol (clinical trial, drug therapy)
perindopril (clinical trial, drug therapy)
placebo
thiazide diuretic agent (clinical trial, drug therapy)
verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, complication, drug therapy, etiology, surgery,
therapy)
heart failure with normal ejection fraction (drug therapy, complication,
drug therapy, etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
alcohol abstinence
aorta valve stenosis (surgery)
atrial fibrillation (drug therapy)
blood pressure regulation
cardiac resynchronization therapy
clinical feature
comorbidity
coronary artery bypass surgery
diabetes mellitus (drug therapy)
diastolic dysfunction (drug therapy)
evidence based medicine
glycemic control
heart failure with reduced ejection fraction (drug therapy, surgery,
therapy)
heart failure with reduced ejection fraction (drug therapy)
heart left ventricle ejection fraction
human
hypertension (drug therapy, therapy)
hypertrophic cardiomyopathy (drug therapy)
hypervolemia (drug therapy)
kidney failure (drug therapy)
kinesiotherapy
lung edema (drug therapy)
nonhuman
pathophysiology
percutaneous coronary intervention
quality of life
review
sodium restriction
speech therapy
systolic heart failure (therapy)
systolic hypertension (therapy)
transcatheter aortic valve implantation
treatment outcome
weight reduction
CAS REGISTRY NUMBERS
amlodipine (88150-42-9, 103129-82-4, 736178-83-9)
candesartan (139481-59-7)
digoxin (20830-75-5, 57285-89-9)
doxazosin (74191-85-8)
irbesartan (138402-11-6)
lisinopril (76547-98-3, 83915-83-7)
losartan (114798-26-4)
nebivolol (99200-09-6, 118457-15-1, 118457-16-2)
perindopril (82834-16-0, 99149-83-4)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012516213
FULL TEXT LINK
http://dx.doi.org/10.1007/s11936-012-0187-4
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 328
TITLE
The functional role of fish protein hydrolysate derived bioactive compounds
in cardioprotection and antioxdative functions
AUTHOR NAMES
Vignesh R.
Srinivasan M.
Jayaprabha N.
Badhul Haq M.A.
AUTHOR ADDRESSES
(Vignesh R.; Srinivasan M.; Jayaprabha N.; Badhul Haq M.A.) Centre of
Advanced Study in Marine Biology, Faculty of Marine Sciences Annamalai
University, Parangipettai, Tamilnadu, India.
CORRESPONDENCE ADDRESS
R Vignesh, Centre of Advanced Study in Marine Biology, Faculty of Marine
Sciences Annamalai University, Parangipettai, Tamilnadu, India.
SOURCE
International Journal of Pharma and Bio Sciences (2012) 3:1 (B560-B566).
Date of Publication: 2012
ISSN
0975-6299 (electronic)
BOOK PUBLISHER
International Journal of Pharma and Bio Sciences, prasmol@rediffmail.com
ABSTRACT
Bioactive peptides isolated from various fish protein hydrolysates have
shown a numerous bioactivities such as antihypertensive, antithrombotic,
immunomodulatory and antioxidative activities. Fish protein hydrolysate
extracts performs the regulation of the immune system, gastrointestinal
functions, blood pressure, glucose inhibitory activity, antihypertensive
effect, antioxidant properties and angiotensin converting enzyme inhibitory
activity. Fish waste is rich in potentially valuable oils, minerals,
enzymes, pigments and flavors etc. These may also have many alternative uses
in food, pharmaceutical, agricultural, aquaculture and industrial
applications. Fish proteins can have not only nutritional but also
functional and biological applications. Intake of fish oil, which is an
excellent source of omega- 3 fatty acids, has been linked to promotion of
human health to fight against numerous diseases. Peptides derived from fish
proteins have shown the ability of exerting potent antioxidative activities
in different oxidative systems. This review paper focuses on the important
role of fish protein extracts in various pharmacological aspects.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
fish protein (pharmacology)
EMTREE DRUG INDEX TERMS
docosahexaenoic acid
doxorubicin (adverse drug reaction, drug therapy)
fish oil (pharmacology)
icosapentaenoic acid
linoleic acid
muscle protein
omega 3 fatty acid (drug therapy)
omega 6 fatty acid
protein hydrolysate
reactive oxygen metabolite (endogenous compound)
taurine (clinical trial, drug therapy)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
antioxidant activity
heart protection
EMTREE MEDICAL INDEX TERMS
acute heart failure (side effect)
antiarrhythmic activity
atrial fibrillation (drug therapy)
calcium absorption
congestive heart failure (drug therapy, side effect)
coronary artery atherosclerosis
coronary artery disease
diet supplementation
grass carp
heart arrhythmia (side effect)
heart muscle ischemia
heart ventricle arrhythmia (drug therapy)
heart ventricle extrasystole (drug therapy)
human
hydrolysis
hypertension (drug therapy)
ischemic heart disease (drug therapy, prevention)
leukemia (drug therapy)
lipid peroxidation
lymphoma (drug therapy)
nonhuman
reperfusion injury
review
sea food
solid tumor (drug therapy)
sudden death
Tilapia
tuna
CAS REGISTRY NUMBERS
docosahexaenoic acid (25167-62-8, 32839-18-2)
doxorubicin (23214-92-8, 25316-40-9)
fish oil (8016-13-5)
icosapentaenoic acid (25378-27-2, 32839-30-8)
linoleic acid (1509-85-9, 2197-37-7, 60-33-3, 822-17-3)
protein hydrolysate (76773-71-2, 9015-54-7)
taurine (107-35-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2014901991
COPYRIGHT
Copyright 2015 Elsevier B.V., All rights reserved.
RECORD 329
TITLE
A randomized, double-blind, placebo-controlled, crossover, dose-ranging
multicenter study to determine the effect of sublingual nitroglycerin spray
on exercise capacity in patients with chronic stable angina
AUTHOR NAMES
Thadani U.
Wittig T.
AUTHOR ADDRESSES
(Thadani U., udho-thadani@ouhsc.edu) Department of Medicine, Cardiovascular
Section, University of Oklahoma Health Sciences Center and VA Medical
Center, Oklahoma City, OK, Germany.
(Wittig T.) G. Pohl-Boskamp GmbH and Co. KG, Germany.
CORRESPONDENCE ADDRESS
U. Thadani, Department of Medicine, Cardiovascular Section, University of
Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, OK,
Germany. Email: udho-thadani@ouhsc.edu
SOURCE
Clinical Medicine Insights: Cardiology (2012) 6 (87-95). Date of
Publication: 2012
ISSN
1179-5468 (electronic)
1179-5468
BOOK PUBLISHER
Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay,
Auckland, New Zealand.
ABSTRACT
Background: Sublingual nitroglycerin increases exercise duration in patients
with stable angina. Brief results from this study were published previously
in German. Here, we more fully describe the study methodology, patient
characteristics, and detailed results. Methods: This double-blind, crossover
study enrolled 51 patients with stable angina. Patients were randomized to 1
of 5 treatment sequences and were administered placebo or nitroglycerin
spray (0.2 mg, 0.4 mg, 0.8 mg, or 1.6 mg). Patients carried out 1 control
exercise tolerance test (ETT) and 1 investigational ETT at each visit.
Results: Dose-dependent increases in time to onset of angina, time to onset
of moderate angina, and the occurrence of a minimum 1.0-mm ST-segment
depression were seen following administration of nitroglycerin spray.
Conclusions: These results support the use of sublingual nitroglycerin spray
in patients with stable angina who are being managed with medical therapy
and in patients who have persistent angina post-revascularization. © the
author(s). publisher and licensee Libertas Academica Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
glyceryl trinitrate (adverse drug reaction, clinical trial, drug dose, drug
therapy, sublingual drug administration)
EMTREE DRUG INDEX TERMS
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise tolerance
stable angina pectoris (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aerosol
aged
article
atrial fibrillation (complication, therapy)
cardioversion
controlled study
crossover procedure
dizziness (side effect)
dose response
double blind procedure
drug efficacy
drug induced headache (side effect)
drug safety
exercise
exercise duration
female
heart ventricle tachycardia (complication, therapy)
human
hypotension (side effect)
major clinical study
male
multicenter study
open study
outcome assessment
pharmacologic stress testing
quality of life
randomized controlled trial
side effect (side effect)
ST segment depression
systolic blood pressure
time
time to onset angina
time to onset moderate angina
DRUG TRADE NAMES
nitrolingual , GermanyPohl Boskamp
DRUG MANUFACTURERS
(Germany)Pohl Boskamp
CAS REGISTRY NUMBERS
glyceryl trinitrate (55-63-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012387954
FULL TEXT LINK
http://dx.doi.org/10.4137/CMC.S9132
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 330
TITLE
Complementary and alternative medicine treatments among stroke patients in
India
AUTHOR NAMES
Pandian J.
Toor G.
Arora R.
Kaur P.
Dheeraj K.V.
Bhullar R.
Sylaja P.
AUTHOR ADDRESSES
(Pandian J.; Toor G.; Kaur P.; Bhullar R.) Stroke Unit, Department of
Neurology, Christian Medical College, Ludhiana, Punjab, India.
(Arora R.; Dheeraj K.V.) College of Physiotherapy, Christian Medical
College, Ludhiana, Punjab, India.
(Sylaja P.) Stroke Unit, Department of Neurology, Sree Chitra Tirunal
Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala,
India.
CORRESPONDENCE ADDRESS
J. Pandian, Stroke Unit, Department of Neurology, Christian Medical College,
Ludhiana, Punjab, India.
SOURCE
Topics in Stroke Rehabilitation (2012) 19:5 (384-394). Date of Publication:
1 Jan 2012
ISSN
1074-9357
1945-5119 (electronic)
BOOK PUBLISHER
Thomas Land Publishers Inc., 255 Jefferson Road, St. Louis, United States.
ABSTRACT
Background: Complementary and alternative medicine (CAM) is commonly used by
persons with stroke throughout the world, particularly in Asia. Objective:
The objectives of this study were to determine the frequency of CAM use and
the factors that predict the use of CAM in stroke patients. Methods: This
study was carried out in the stroke units of Christian Medical College,
Ludhiana, and Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Thiruvananthapuram, India, from June 2010 to December 2010.
Participants were interviewed using a structured questionnaire (≥6 months
post stroke). Outcomes were assessed using a modifi ed Rankin Scale (mRS).
Results: Three hundred fourteen stroke patients were interviewed; mean age
was 57.4 ± 12.9 years, and 230 (73.2%) patients were men. Of 314 patients,
114 (36.3%) had used the following CAM treatments: ayurvedic massage, 67
(59.3%); intravenous fl uids, 22 (19.5%); herbal medicines, 17 (15%);
homeopathy, 15 (13.3%); witchcraft, 3 (2.7%); acupuncture, 3 (2.7%); opium
intake, 10 (8.8%); and other nonconventional treatments, 10 (8.8%). Patients
with severe stroke (P < .0001), limb weakness (P < .0001), dysphagia (P =
.02), dyslipidemia (P = .007), hypertension (P = .03), or hemorrhagic stroke
(P<.0001) and patients with poor outcome (mRS >2;P < .0001) often used CAM
treatments. Conclusion: More than one-third of the patients in this study
opted for CAM. Presence of limb weakness, dysphagia, dyslipidemia,
hypertension, hemorrhagic stroke, severe stroke, and poor outcome predicted
the use of CAM. © 2012 Thomas Land Publishers, Inc.
EMTREE DRUG INDEX TERMS
opiate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alternative medicine
cerebrovascular accident (disease management, rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
adult
aged
alcohol consumption
aphasia
article
atrial fibrillation
Ayurveda
brain hemorrhage
carotid artery obstruction
clinical effectiveness
consciousness disorder
coronary artery disease
cost effectiveness analysis
diabetes mellitus
diplopia
dizziness
dyslipidemia
dysphagia
dysphasia
educational status
emergency treatment
employment status
female
fluid therapy
headache
health care system
herbal medicine
homeopathy
human
hyperlipidemia
hypertension
India
limb weakness
major clinical study
male
massage
outcome assessment
prospective study
Rankin scale
Reiki
religion
seizure
slurred speech
smoking
stroke patient
stroke unit
structured questionnaire
transient ischemic attack
treatment duration
unsteadiness
visual field defect
witchcraft
CAS REGISTRY NUMBERS
opiate (53663-61-9, 8002-76-4, 8008-60-4)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Rehabilitation and Physical Medicine (19)
Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012561157
MEDLINE PMID
22982825 (http://www.ncbi.nlm.nih.gov/pubmed/22982825)
FULL TEXT LINK
http://dx.doi.org/10.1310/tsr1905-384
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 331
TITLE
Does collateral circulation protect against acute myocardial infarction? Two
hemodynamically important collateral circulation examples: Case report
AUTHOR NAMES
Bostan M.
Şatiroǧlu Ö.
Mungan U.
Çanga A.
Bozkurt E.
AUTHOR ADDRESSES
(Bostan M., drmehmetbostan@hotmail.com; Şatiroǧlu Ö.; Bozkurt E.) Rize
University, Faculty of Medicine, Department of Cardiology, Rize, Turkey.
(Mungan U.) Clinic of Cardiovascular Surgery, Rize Training and Research
Hospital, Rize, Turkey.
(Çanga A.) Clinic of Cardiology, Rize Training and Research Hospital, Rize,
Turkey.
CORRESPONDENCE ADDRESS
M. Bostan, Rize University, Faculty of Medicine, Department of Cardiology,
Rize, Turkey. Email: drmehmetbostan@hotmail.com
SOURCE
Turkiye Klinikleri Cardiovascular Sciences (2011) 23:3 (256-259). Date of
Publication: 2011
ISSN
1306-7656
BOOK PUBLISHER
Turkiye Klinikleri, Turkocagi Caddesi No. 30, Balgat, Turkey.
ABSTRACT
Coronary collateral vessels interconnect the major coronary arteries. They
are small in (<200 μm) caliber. Collateral channels can not be seen in
patients with normal or mildly diseased coronary arteries. The coronary
collateral circulation is a complementary source of blood supply to
myocardium jeopardized by stenosis of a coronary vessel. If they are
adequate size, collaterals may protect against myocardial infarction in
cases of total occlusion. The myocardial infarct size is smaller in patients
with abundant collateral vessels than in patients without collaterals.
Therefore total occlusion of a major epicardial artery may not lead to left
ventricule dysfunction. Presented cases are important examples that the
myocardium was protected against left ventricule dysfunction owing to total
occlusion of one or more major coronary arteries. Copyright © 2011 by
Türkiye Klinikleri.
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
fibrinogen (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acute heart infarction
collateral circulation
EMTREE MEDICAL INDEX TERMS
adult
aged
anastomosis
angiocardiography
aorta valve regurgitation
article
atrial fibrillation
case report
daily life activity
diabetes mellitus
echocardiography
electrocardiography
exercise
female
heart atrium enlargement
heart hemodynamics
heart infarction size
heart left ventricle failure
heart muscle revascularization
human
left anterior descending coronary artery
male
mitral valve regurgitation
right coronary artery
smoking
ST segment elevation
stable angina pectoris
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
fibrinogen (9001-32-5)
troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Turkish
EMBASE ACCESSION NUMBER
2011676413
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 332
TITLE
Epidemiology and risk factors
AUTHOR NAMES
Elkind M.S.V.
AUTHOR ADDRESSES
(Elkind M.S.V., mse13@mail.cumc.columbia.edu) Neurological Institute, 710
West 168th Street, New York, NY 10032, United States.
CORRESPONDENCE ADDRESS
M.S.V. Elkind, Neurological Institute, 710 West 168th Street, New York, NY
10032, United States. Email: mse13@mail.cumc.columbia.edu
SOURCE
CONTINUUM Lifelong Learning in Neurology (2011) 17:6 (1213-1232). Date of
Publication: December 2011
ISSN
1080-2371
1538-6899 (electronic)
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327,
Philadelphia, United States.
ABSTRACT
Purpose of Review: This article presents current knowledge on stroke
epidemiology. It covers recent data on the global burden of stroke,
disparities, silent stroke, traditional and novel risk factors, and stroke
triggers as well as the clinical implications of these findings. Recent
Findings: Stroke is the third leading cause of death and the leading cause
of chronic disability in the United States, and the burden of stroke
worldwide is even greater. Large international and US case-control and
prospective cohort studies have demonstrated disparities in stroke mortality
and incidence. They have also shed light on the relative importance of
several well-established, modifiable risk factors for ischemic stroke, such
as hypertension, atrial fibrillation, other cardiac diseases,
hyperlipidemia, diabetes, cigarette smoking, physical inactivity, alcohol
consumption, abdominal obesity, diet, and TIA. Research on other putative
stroke risk factors (including inflammation, infection, renal disease,
depression, stress, and others) is ongoing. Identifying stroke triggers may
be another way to minimize stroke incidence if high-risk time windows can be
determined. Summary: Stroke is a major global health burden. While many of
the risk factors for stroke are well known and have been studied for
decades, recent studies continue to shed light on the distribution and
severity of these problems. © 2011, American Academy of Neurology. All
rights reserved.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination)
alpha smooth muscle actin (endogenous compound)
antithrombocytic agent
arachidonate 5 lipoxygenase (endogenous compound)
arachidonate 5 lipoxygenase activating protein (endogenous compound)
C reactive protein (endogenous compound)
clopidogrel
collagen type 4 (endogenous compound)
copeptin (endogenous compound)
cyclin dependent kinase inhibitor 2A (endogenous compound)
cyclin dependent kinase inhibitor 2B (endogenous compound)
cystatin C (endogenous compound)
dipyridamole (drug combination)
hydrochlorothiazide
hydroxymethylglutaryl coenzyme A reductase inhibitor
low density lipoprotein cholesterol (endogenous compound)
oral contraceptive agent (adverse drug reaction)
phosphodiesterase (endogenous compound)
phosphodiesterase 4D (endogenous compound)
pravastatin
serotonin uptake inhibitor (adverse drug reaction)
tissue plasminogen activator (intravenous drug administration)
tricyclic antidepressant agent (adverse drug reaction)
unclassified drug
very low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (diagnosis, epidemiology, etiology, prevention)
EMTREE MEDICAL INDEX TERMS
African American
alcohol consumption
Alzheimer disease
aortic arch atheroma
atheroma
atrial fibrillation
autosomal recessive disorder
basal ganglion
blood pressure
brain atherosclerosis
brain hemorrhage
brain infarction
CADASIL
carotid artery obstruction
Cerebral autosomal recessive arteriopathy with subcortical infarct and
leukoencephalopathy
cerebrovascular accident
cerebrovascular accident (side effect)
childhood disease (etiology)
Chlamydia pneumoniae
chromosome 9p
chronic kidney disease
Cytomegalovirus
dementia
diabetes mellitus
diffusion weighted imaging
disease classification
disease duration
drug dose increase
Fabry disease
fatality
genetic association
genetic disorder
genetic variability
glomerulus filtration rate
heart infarction
heart left ventricle aneurysm
Helicobacter pylori
Herpes simplex virus 1
Herpes simplex virus 2
Hispanic
human
Human immunodeficiency virus
hyperlipidemia
immobilization
inflammation
influenza (prevention)
influenza vaccination
insulin resistance
leukoencephalopathy
malnutrition
Marfan syndrome
metabolic syndrome X
microalbuminuria
migraine with aura
mitral valve disease
mitral valve strand
mortality
obesity
onset age
patent foramen ovale
periodontal disease
prediction
prevalence
prognosis
protein blood level
race difference
review
risk assessment
salt intake
sanitation
scoring system
secondary prevention
sedentary lifestyle
sex difference
sickle cell anemia
silent stroke
smoking
speech disorder
stroke patient
subarachnoid hemorrhage
systolic hypertension
transient ischemic attack (diagnosis)
upper respiratory tract infection
urinary tract infection
valvular heart disease
weakness
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
arachidonate 5 lipoxygenase (80619-02-9)
arachidonate 5 lipoxygenase activating protein (137546-36-2)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
hydrochlorothiazide (58-93-5)
pravastatin (81093-37-0, 81131-70-6)
tissue plasminogen activator (105913-11-9)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012046802
FULL TEXT LINK
http://dx.doi.org/10.1212/01.CON.0000410031.34477.8d
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 333
TITLE
Tongue hematoma induced by warfarin overdose
AUTHOR NAMES
Bilen M.N.
Kara H.
AUTHOR ADDRESSES
(Bilen M.N.) Department of Cardiology, Bingol State Hospital, Bingol,
Turkey.
(Kara H.) Department of Emergency Medicine, Konya Numune Education and
Research Hospital, Konya, Turkey.
CORRESPONDENCE ADDRESS
M. N. Bilen, Department of Cardiology, Bingol State Hospital, Bingol,
Turkey.
SOURCE
Cardiology (Pakistan) (2011) 6:3 (18-19). Date of Publication: 2011
ISSN
1811-8194
1993-6117 (electronic)
BOOK PUBLISHER
Medwell Journals, ANSInet Building, 308-Lasani Town Sargodha Road,
Faisalabad, Pakistan.
ABSTRACT
Warfarin is one of the common oral anticoagulants. Anticoagulant response is
affected by the amount of dietary Vitamin K, various drugs, foods and herbal
treatments. Although, hemorrhage is one of the side effects of warfarin,
tongue hematoma is a rare complication. In this research, 50 years old male
patient developed tongue hematoma during the prophylactic warfarin treatment
due to the atrial fibrillation is presented. © Medwell Journals, 2011.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
fresh frozen plasma (drug therapy)
low molecular weight heparin (drug therapy)
propylthiouracil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, diagnosis, drug therapy)
drug induced disease
hematoma (drug therapy, side effect, diagnosis, drug therapy, side effect,
therapy)
tongue disease (side effect, diagnosis, side effect, therapy)
tongue hematoma (drug therapy, diagnosis, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
abnormal laboratory result
adult
article
blood substitution
case report
clinical feature
coronary artery bypass graft
drug overdose
drug substitution
drug withdrawal
electrocardiogram
human
hyperthyroidism
international normalized ratio
male
physical examination
tongue swelling
treatment outcome
DRUG TRADE NAMES
coumadin
CAS REGISTRY NUMBERS
propylthiouracil (51-52-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012392496
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 334
TITLE
Prevention of stroke in patients with atrial fibrillation
AUTHOR NAMES
Moukabary T.
Naccarelli G.V.
AUTHOR ADDRESSES
(Moukabary T.; Naccarelli G.V., gnaccarelli@hmc.psu.edu) Electrophysiology
Program, Heart and Vascular Institute, Penn. State University College of
Medicine, Hershey, PA, United States.
CORRESPONDENCE ADDRESS
G.V. Naccarelli, Heart and Vascular Institute, Penn. State University
College of Medicine, MC H047, 500 University Drive, Hershey, PA 17033,
United States. Email: gnaccarelli@hmc.psu.edu
SOURCE
Journal of Atrial Fibrillation (2011) 2:8. Date of Publication: December
2011
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
The presence of atrial fibrillation (AF) increases the risk of stroke,
especially in patients with risk factors as outlined by the CHADS(2) and
CHA2DS(2)-VASc scoring systems. Although warfarin can reduce stroke rates by
over 65%, only 55% of patients, in the USA, who should be on warfarin for AF
and stroke prevention are taking the drug due to the need of INR monitoring,
difficulties in maintaining a therapeutic INR in the therapeutic range and
dietary and drug interactions. Dabigatran, an oral direct thrombin inhibitor
and rivaroxaban and apixaban, factor Xa inhibitors, have demonstrated
efficacy in reducing stroke in large clinical trials. These novel
anticoagulants will change the therapeutic landscape since patients will be
able to prevent stroke with a lower risk of intracranial hemorrhage and
without the need for INR monitoring and less drug-dietary interactions.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (clinical trial, drug combination, drug comparison,
drug therapy)
apixaban (clinical trial, drug comparison, drug therapy, pharmacokinetics)
betrixaban
clopidogrel (clinical trial, drug combination, drug therapy)
dabigatran (clinical trial, drug comparison, drug therapy, oral drug
administration, pharmacokinetics)
dabigatran etexilate
edoxaban (clinical trial, drug comparison, drug therapy, pharmacokinetics)
multidrug resistance protein (endogenous compound)
placebo
rivaroxaban (clinical trial, drug therapy, pharmacokinetics)
warfarin (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy)
cerebrovascular accident (drug therapy, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
comparative study
drug excretion
drug half life
embolism (drug therapy)
embolism prevention
human
international normalized ratio
randomized controlled trial (topic)
review
thromboembolism (drug therapy)
United States
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
apixaban (503612-47-3)
betrixaban (330942-05-7)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
edoxaban (480449-70-5, 480449-71-6, 912273-65-5)
rivaroxaban (366789-02-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011709011
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 335
TITLE
Maintenance of sinus rhythm and treatment of atrial fibrillation in mitral
stenosis
AUTHOR NAMES
Sahin M.
Simsek H.
Ekici B.
Akdag S.
Tuncer M.
AUTHOR ADDRESSES
(Sahin M.; Ekici B.) Department of Cardiology, Bitlis State Hospital,
Bitlis, Turkey.
(Simsek H., dr.hsimsek@hotmail.com) Department of Cardiology, Osmaniye State
Hospital, Osmaniye, Turkey.
(Akdag S.; Tuncer M.) Department of Cardiology, Yuzunci Yil University,
Faculty of Medicine, Van, Turkey.
CORRESPONDENCE ADDRESS
H. Simsek, Department of Cardiology, Bitlis State Hospital, Bitlis, Turkey.
Email: dr.hsimsek@hotmail.com
SOURCE
Eastern Journal of Medicine (2011) 16:4 (235-239). Date of Publication: 2011
ISSN
1301-0883
BOOK PUBLISHER
Yuzuncu Yil University, Eastern Journal of Medicine, Van, Turkey.
ABSTRACT
Rheumatic fever is the most common cause of mitral stenosis. The most common
complication of mitral stenosis is atrial fibrillation (AF). AF precipitates
symptoms, greatly increases the risk of systemic embolisation, and reduces
cardiac output and exercise capacity. Systemic embolization most often
occurs in patients with both AF and mitral stenosis. Maintenance of the
sinus rhythm in patients with mitral stenosis is very important because of
reduce the risk of cerebral embolism, conservation of cardiac output and
exercise capacity, and reduction of symptoms.
EMTREE DRUG INDEX TERMS
amiodarone (intravenous drug administration, oral drug administration)
anticoagulant agent (drug therapy)
atenolol
digoxin (drug therapy, intravenous drug administration)
heparin (drug therapy, intravenous drug administration)
metoprolol
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, complication, drug therapy, prevention,
surgery, therapy)
mitral valve stenosis (drug therapy, drug therapy)
sinus rhythm
EMTREE MEDICAL INDEX TERMS
age distribution
angina pectoris
article
brain embolism (prevention)
cardiovascular risk
cardioversion
disease association
disease severity
dyspnea
embolism (drug therapy)
exercise
heart atrium thrombosis (drug therapy)
heart infarction
heart output
heart ventricle pressure
human
hypertension (complication)
kidney artery embolism
lung edema
mitral valve repair
mitral valve replacement
rheumatic fever
rheumatic heart disease
risk reduction
sex difference
treatment duration
valvuloplasty
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atenolol (29122-68-7, 93379-54-5)
digoxin (20830-75-5, 57285-89-9)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
metoprolol (37350-58-6)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012525086
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 336
TITLE
DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in
adults full-text version
AUTHOR ADDRESSES
SOURCE
Osteologie (2011) 20:1 (55-74). Date of Publication: 2011
ISSN
1019-1291
BOOK PUBLISHER
Schattauer GmbH, Hoelderlinstr 3 Stuttgart, , Germany.
ABSTRACT
The letters (A -D) show the relevant grade of recommendation with reference
to fracture prediction or fracture reduction according to the SIGN criteria
(therapy) and Oxford criteria (diagnosis). Recommendations which were
included after 2006 are marked by "(E)". One is referred to the basic
full-text version of the pre-version from 2006 with regard to the other
recommendations. © Schattauer 2011.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
alendronic acid (adverse drug reaction, drug combination, drug therapy, oral
drug administration)
calcium (adverse drug reaction, drug combination, drug therapy)
colecalciferol (adverse drug reaction, drug combination, drug therapy, oral
drug administration)
raloxifene (adverse drug reaction, drug therapy, oral drug administration)
recombinant parathyroid hormone (adverse drug reaction, subcutaneous drug
administration)
risedronic acid (adverse drug reaction, drug combination, drug therapy, oral
drug administration)
EMTREE DRUG INDEX TERMS
alfacalcidol (drug therapy)
alkaline phosphatase (endogenous compound)
anticonvulsive agent (adverse drug reaction)
antidepressant agent (adverse drug reaction)
aromatase inhibitor
C reactive protein (endogenous compound)
calcitonin (drug therapy)
calcitriol
cyanocobalamin (endogenous compound)
etidronic acid (drug therapy)
fluoride (drug therapy)
folic acid (endogenous compound)
glitazone derivative
homocysteine (endogenous compound)
ibandronic acid (adverse drug reaction, intravenous drug administration,
oral drug administration)
levothyroxine (drug therapy)
nandrolone decanoate (drug therapy)
neuroleptic agent (adverse drug reaction)
parathyroid hormone[1-34]
phosphate (endogenous compound)
prednisolone (adverse drug reaction, drug therapy, oral drug administration)
proton pump inhibitor (adverse drug reaction)
sedative agent (adverse drug reaction)
strontium ranelate
thyrotropin (endogenous compound)
unindexed drug
zoledronic acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
osteoporosis (drug therapy, side effect, diagnosis, drug therapy,
epidemiology, etiology, prevention, rehabilitation, side effect)
practice guideline
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
Addison disease (drug therapy)
alkaline phosphatase blood level
arthralgia (side effect)
atrial fibrillation (side effect)
biochemistry
blood cell count
body mass
bone density
bone necrosis (side effect)
bone pain (side effect)
cardiovascular risk
cerebrovascular accident (side effect)
clinical examination
clinical feature
constipation (side effect)
creatinine clearance
Cushing syndrome
diarrhea (side effect)
dizziness (side effect)
drug megadose
drug withdrawal
dual energy X ray absorptiometry
esophagitis (side effect)
exercise
fall risk
flu like syndrome (side effect)
follow up
fracture reduction
fragility fracture (drug therapy, etiology, rehabilitation, side effect)
gastrectomy
gastroesophageal reflux
gender
growth hormone deficiency
headache (side effect)
hip fracture (etiology, rehabilitation)
human
hypercalcemia (side effect)
hypercalciuria (side effect)
hypercortisolism
hyperthyroidism (drug therapy)
hypocalcemia (side effect)
hypogonadotropic hypogonadism
hypophosphatemia (side effect)
hypophysis disease
immobilization
incidence
insulin dependent diabetes mellitus
jaw osteonecrosis (side effect)
kyphoplasty
limb pain (side effect)
medical history
mortality
motor coordination
muscle cramp (side effect)
muscle strength
muscle training
nausea (side effect)
orthosis
osteomalacia
pain
patient care
percutaneous vertebroplasty
peripheral edema (side effect)
phosphate blood level
physiotherapy
postmenopause
postmenopause osteoporosis (drug therapy)
prevalence
primary hyperparathyroidism
quality of life
randomized controlled trial (topic)
review
rheumatoid arthritis
risk assessment
secondary osteoporosis
side effect (side effect)
smoking
spine fracture (etiology, rehabilitation, side effect, surgery)
sun exposure
thromboembolism (side effect)
thyrotropin blood level
underweight
vasodilatation
vitamin D deficiency (drug therapy, therapy)
vomiting (side effect)
DRUG TRADE NAMES
aclasta
actonel
bonviva
evista
forsteo
fosamax
optruma
preotact
protelos
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
alendronic acid (66376-36-1)
alfacalcidol (41294-56-8)
alkaline phosphatase (9001-78-9)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcitriol (32222-06-3, 32511-63-0, 66772-14-3)
calcium (14092-94-5, 7440-70-2)
colecalciferol (1406-16-2, 67-97-0)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
fluoride (16984-48-8)
folic acid (59-30-3, 6484-89-5)
homocysteine (454-28-4, 6027-13-0)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
levothyroxine (51-48-9)
nandrolone decanoate (360-70-3)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
phosphate (14066-19-4, 14265-44-2)
prednisolone (50-24-8)
raloxifene (82640-04-8, 84449-90-1)
risedronic acid (105462-24-6, 122458-82-6)
strontium ranelate (135459-87-9)
thyrotropin (9002-71-5)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Gerontology and Geriatrics (20)
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012046271
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 337
TITLE
Physiotherapy of patients with motoric or neurological dysfunctions,
simultaneously treated for arrhythmia - Physiotherapist's viewpoint
ORIGINAL (NON-ENGLISH) TITLE
Fizjoterapia osób z dysfunkcjami narza̧du ruchu lub różnymi schorzeniami
neurologicznymi, leczonych równolegle z powodu zaburzeń rytmu serca - Punkt
widzenia fizjoterapeuty
AUTHOR NAMES
Domosławska D.
AUTHOR ADDRESSES
(Domosławska D., agaavi@poczta.fm) Wydział Wychowania Fizycznego, Szkoła
Wyzsza Im. Pawła Włodkowica, Płocku, Poland.
CORRESPONDENCE ADDRESS
D. Domosławska, Szkoła Wyzsza Im. Pawła Włodkowica, Sekretariat Wydziału
Wychowania Fizycznego, al. Kilińskiego 12, 09-402 Płock, Poland. Email:
agaavi@poczta.fm
SOURCE
Fizjoterapia (2011) 19:3 (50-62). Date of Publication: 2011
ISSN
1230-8323
BOOK PUBLISHER
Academy of Physical Education, Rzezbiarska 4, Wroclaw, Poland.
ABSTRACT
A high percentage of patients undergoing physiotherapeutic treatment due to
motor organ dysfunctions or neurological problems are the ones who
additionally suffer from heart rhythm disorder (arrhythmia). This paper
presents the most common types of heart rhythm disorders, the health risk
factors they involve as well as the treatment methods. Some important
aspects of kinesiotherapy and physiotherapy of patients treated
pharmacologically or with implanted pacemaker or cardioverter-defibrillator
have been considered. The general rules for contraindications against
physiotherapy have also been raised. The significance of patient education,
the psychical effects and safety during physiotherapy have been emphasized.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
digitalis (drug therapy)
sotalol (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart arrhythmia (drug therapy, drug therapy, therapy)
motor dysfunction (therapy)
neurologic disease (therapy)
physiotherapy
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (drug therapy, therapy)
cardioversion
defibrillator
exercise
faintness
heart ventricle arrhythmia (therapy)
human
pacemaker
patient education
patient safety
review
risk factor
sudden death
supraventricular tachycardia (therapy)
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digitalis (8031-42-3, 8053-83-6)
sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
Polish, English
LANGUAGE OF SUMMARY
English, Polish
EMBASE ACCESSION NUMBER
2012347342
FULL TEXT LINK
http://dx.doi.org/10.2478/v10109-011-0019-1
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 338
TITLE
Heart failure in the elderly
AUTHOR NAMES
Baker S.
Ramani G.V.
AUTHOR ADDRESSES
(Baker S.) Saint Joseph's Cardiovascular Associates, Towson, MD, United
States.
(Ramani G.V.) Department of Medicine, University of Maryland, School of
Medicine, Baltimore, United States.
CORRESPONDENCE ADDRESS
S. Baker, Saint Joseph's Cardiovascular Associates, Towson, MD, United
States.
SOURCE
Clinical Geriatrics (2011) 19:12 (21-28). Date of Publication: December 2011
ISSN
1095-1598
BOOK PUBLISHER
HMP Communications LLP, 4365 U.S. Highway 1 Suite 250, Princeton, United
States.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, drug comparison, drug therapy)
beta adrenergic receptor blocking agent (adverse drug reaction)
captopril (clinical trial, drug comparison, drug therapy)
dabigatran (oral drug administration)
digoxin (adverse drug reaction, drug concentration, drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, drug
combination, drug therapy)
diuretic agent (adverse drug reaction, drug combination)
eplerenone
hydralazine (adverse drug reaction, drug combination)
loop diuretic agent
losartan (clinical trial, drug comparison, drug therapy)
metoprolol succinate (clinical trial, drug therapy)
nebivolol (clinical trial, drug therapy)
nitrate (adverse drug reaction, drug combination, oral drug administration)
non prescription drug
nonsteroid antiinflammatory agent (adverse drug reaction)
prescription drug
spironolactone (adverse drug reaction, clinical trial, drug therapy)
warfarin (adverse drug reaction, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
geriatric disorder (disease management, surgery)
heart failure (drug therapy, side effect, disease management, drug therapy,
side effect, surgery)
EMTREE MEDICAL INDEX TERMS
age
aging
angioneurotic edema (side effect)
anticoagulant therapy
article
atrial fibrillation
brain hemorrhage (side effect)
cardiac resynchronization therapy
cerebrovascular accident (complication, drug therapy, prevention)
clinical assessment tool
congestive heart failure (drug therapy)
coronary artery disease
coughing (side effect)
defibrillator
depression
disease association
diuretic therapy
dizziness (side effect)
drug efficacy
drug tolerability
drug withdrawal
dyspnea
exercise
gynecomastia (side effect)
health education
heart arrest
heart failure with preserved ejection fraction
heart infarction
heart left ventricle ejection fraction
heart transplantation
heart ventricle arrhythmia (therapy)
heart ventricle pacing
hospital readmission
hospitalization
human
hyperkalemia (side effect)
hypertension
kidney dysfunction (side effect)
left ventricular assist device
leg edema
low drug dose
meta analysis (topic)
mortality
multidimensional prognostic index
orthostatic hypotension
overall survival
palliative therapy
patient compliance
personalized medicine
physician attitude
QRS complex
quality of life
randomized controlled trial (topic)
risk assessment
risk factor
sedentary lifestyle
sleep disordered breathing
sodium restriction
systolic heart failure (drug therapy)
unspecified side effect (side effect)
very elderly
veteran
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
captopril (62571-86-2)
digoxin (20830-75-5, 57285-89-9)
eplerenone (107724-20-9)
hydralazine (304-20-1, 86-54-4)
losartan (114798-26-4)
metoprolol succinate (98418-47-4)
nebivolol (118457-15-1, 118457-16-2, 99200-09-6)
nitrate (14797-55-8)
spironolactone (52-01-7)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2012011276
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 339
TITLE
Chronic non-communicable diseases in Cameroon - burden, determinants and
current policies
AUTHOR NAMES
Echouffo-Tcheugui J.B.
Kengne A.P.
AUTHOR ADDRESSES
(Echouffo-Tcheugui J.B., jechouf@emory.edu) Hubert Department of Global
Health, Rollins School of Public Health, Emory University, Atlanta, GA,
United States.
(Kengne A.P., apkengne@yahoo.com) Medical Research Council of South Africa,
University of Cape Town, South Africa.
CORRESPONDENCE ADDRESS
J.B. Echouffo-Tcheugui, Hubert Department of Global Health, Rollins School
of Public Health, Emory University, Atlanta, GA, United States. Email:
jechouf@emory.edu
SOURCE
Globalization and Health (2011) 7 Article Number: 44. Date of Publication:
23 Nov 2011
ISSN
1744-8603 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., Floor 6, 236 Gray's Inn Road, London, United Kingdom.
ABSTRACT
Cameroon is experiencing an increase in the burden of chronic
non-communicable diseases (NCDs), which accounted for 43% of all deaths in
2002. This article reviews the published literature to critically evaluate
the evidence on the frequency, determinants and consequences of NCDs in
Cameroon, and to identify research, intervention and policy gaps. The rising
trends in NCDs have been documented for hypertension and diabetes, with a
2-5 and a 10-fold increase in their respective prevalence between 1994 and
2003. Magnitudes are much higher in urban settings, where increasing
prevalence of overweight/obesity (by 54-82%) was observed over the same
period. These changes largely result from the adoption of unfavorable eating
habits, physical inactivity, and a probable increasing tobacco use. These
behavioral changes are driven by the economic development and social
mobility, which are part of the epidemiologic transition. There is still a
dearth of information on chronic respiratory diseases and cancers, as well
as on all NDCs and related risk factors in children and adolescents. More
nationally representative data is needed to tract risk factors and
consequences of NCDs. These conditions are increasingly been recognized as a
priority, mainly through locally generated evidence. Thus, national-level
prevention and control programs for chronic diseases (mainly diabetes and
hypertension) have been established. However, the monitoring and evaluation
of these programs is necessary. Budgetary allocations data by the ministry
of health would be helpful, to evaluate the investment in NCDs prevention
and control. Establishing more effective national-level tobacco control
measures and food policies, as well as campaigns to promote healthy diets,
physical activity and tobacco cessation would probably contribute to
reducing the burden of NCDs. © 2011 Echouffo-Tcheugui and Kengne; licensee
BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
steroid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
chronic disease (epidemiology, prevention)
chronic respiratory tract disease (epidemiology)
diabetes mellitus (epidemiology, prevention)
hypertension (epidemiology, prevention)
neoplasm (epidemiology)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
anemia
asthma (epidemiology)
atrial fibrillation
body mass
breast cancer (epidemiology)
Cameroon
cancer screening
cerebrovascular accident
child
chronic obstructive lung disease (epidemiology)
comorbidity
cross-sectional study
diabetic foot (complication)
diabetic macular edema (complication)
diabetic neuropathy (complication)
diabetic retinopathy (complication)
diastolic blood pressure
diastolic heart failure (complication)
dietary intake
disease control
dyslipidemia (epidemiology)
eating habit
economic development
glycemic control
gout
health care cost
health care policy
health care system
heart failure (complication)
heart left ventricle failure (complication)
human
hypercholesterolemia (epidemiology)
immobilization
ischemic heart disease
kidney dysfunction
microalbuminuria (complication)
obesity
organization and management
physical activity
prevalence
priority journal
prostate cancer (epidemiology)
review
risk factor
social class
spirometry
systematic review
systolic blood pressure
systolic dysfunction (complication)
urban area
urban rural difference
urbanization
uterine cervix cancer (epidemiology)
waist hip ratio
wheezing
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012012736
FULL TEXT LINK
http://dx.doi.org/10.1186/1744-8603-7-44
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 340
TITLE
Anaesthesia for cardioversion: A prospective randomised comparison of
propofol and etomidate combined with fentanyl
AUTHOR NAMES
Kalogridaki M.
Souvatzis X.
Mavrakis H.E.
Kanoupakis E.M.
Panteli A.
Kasotaki S.
Vardas P.
Askitopoulou H.
AUTHOR ADDRESSES
(Kalogridaki M.; Souvatzis X., x.souvatzis@gmx.de; Panteli A.; Askitopoulou
H.) Department of Anaesthesiology, University Hospital of Heraklion,
Heraklion, Greece.
(Mavrakis H.E.; Kanoupakis E.M.; Vardas P.) Department of Cardiology,
University Hospital of Heraklion, Heraklion, Greece.
(Kasotaki S.) Department of Computer Science, University of Crete,
Heraklion, Greece.
CORRESPONDENCE ADDRESS
X. Souvatzis, Department of Anaesthesiology, University Hospital of
Heraklion, PO Box 1352, 71110 Heraklion, Greece. Email: x.souvatzis@gmx.de
SOURCE
Hellenic Journal of Cardiology (2011) 52:6 (483-488). Date of Publication:
November / December 2011
ISSN
1011-7970
BOOK PUBLISHER
Hellenic Cardiological Society, Potamianou 8, Athens, Greece.
ABSTRACT
Introduction: External electrical cardioversion is mostly performed solely
under sedatives or hypnotics, although the procedure is painful. The aim of
this prospective randomised study was to compare two anaesthetic protocols
that included analgesia. Methods: Patients with persistent atrial
fibrillation were randomised to receive intravenously either fentanyl 50 μg
and propofol 0.5 mg/kg (group P) or fentanyl 50 μg and etomidate 0.1 mg/kg
(group E), while breathing spontaneously 100% oxygen. In the case of
inadequate anaesthesia, repeated doses of 20 mg propofol (group P) or 4 mg
etomidate (group E) were given as often as necessary until loss of eyelid
reflex. Cardioversion was achieved with an extracardiac biphasic electrical
shock ranging from 200 to 300 J, performed three times at most. Results:
Forty-six patients (25 in group P, 21 in group E), aged 64 ± 9 years, were
enrolled in the study. There were no differences between the study groups
concerning left ventricular ejection fraction, the dimension of the left
atrium, the number of shocks needed or the number of unsuccessful
cardioversions. Patients in group E had a shorter time from injection of the
induction agents until loss of consciousness (49 vs. 118 s, p=0.003) and
until the first shock was given (61 vs. 135 s, p=0.004). Systolic blood
pressure decreased significantly (repeated measurements ANOVA with
Bonferroni adjustment) in group P when the baseline value was compared to
that after anaesthesia induction (mean decrease 15.2 mmHg, 95% CI 5.6-24.8
mmHg, p=0.001) and to the value after recovery (mean decrease 15.2 mmHg, 95%
CI 4.8-25.7 mmHg, p=0.002). Manual ventilation was required in 7 and 9
patients in groups P and E, respectively (p=0.360). Conclusion: Both
anaesthetic regimens provided excellent conditions for external electric
cardioversion. In addition, etomidate in combination with fentanyl had a
shorter induction time and ensured haemodynamic stability.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
etomidate (clinical trial, drug combination, drug comparison, intravenous
drug administration)
fentanyl (clinical trial, drug combination, intravenous drug administration)
propofol (clinical trial, drug combination, drug comparison, intravenous
drug administration)
EMTREE MEDICAL INDEX TERMS
adult
analgesia
anesthesia induction
article
atrial fibrillation
cardioversion
clinical article
consciousness
controlled study
female
heart left ventricle ejection fraction
human
male
manual ventilation
oxygen breathing
randomized controlled trial
reflex
systolic blood pressure
CAS REGISTRY NUMBERS
etomidate (15301-65-2, 33125-97-2, 51919-80-3)
fentanyl (437-38-7)
propofol (2078-54-8)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011674263
MEDLINE PMID
22143010 (http://www.ncbi.nlm.nih.gov/pubmed/22143010)
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 341
TITLE
High Blood Pressure Research 2011 Scientific Sessions Abstracts, HBPR 2011
AUTHOR ADDRESSES
SOURCE
Hypertension (2011) 58:5. Date of Publication: November 2011
CONFERENCE NAME
High Blood Pressure Research 2011 Scientific Sessions, HBPR 2011
CONFERENCE LOCATION
Orlando, FL, United States
CONFERENCE DATE
2011-09-20 to 2011-09-24
ISSN
0194-911X
BOOK PUBLISHER
Lippincott Williams and Wilkins
ABSTRACT
The proceedings contain 625 papers. The topics discussed include:
postprandial hypertension, an overlooked risk factor for arterial stiffness;
different mechanisms in weight loss and weight loss-induced blood pressure
reduction between a calorie restricted diet and exercise; clinical
differences between resistant hypertensive patients and patients treated and
controlled with 3 or less drugs; impact of blood pressure and pulse rate on
the risk of incident atrial fibrillation in the Suita study: an urban cohort
study; the inhibition of phosphodiesterase 5 improves the diastolic
dysfunction in resistant hypertensive patients an independent mechanism of
blood pressure and endothelial function; bone marrow deficiency of ACE2
promotes macrophage infiltration into adipose tissue and disrupts glucose
homeostasis in high fat-fed mice; and comparison between central and
peripheral pulse pressure as determinants of intermediate cardiovascular
phenotypes.
EMTREE DRUG INDEX TERMS
phosphodiesterase V
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hypertension
EMTREE MEDICAL INDEX TERMS
adipose tissue
arterial stiffness
atrial fibrillation
blood pressure
bone marrow depression
calorie
cohort analysis
diastolic dysfunction
diet restriction
exercise
glucose homeostasis
human
macrophage
mouse
patient
phenotype
pulse pressure
pulse rate
risk
risk factor
weight reduction
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 342
TITLE
The use of acupuncture in the emergency room
AUTHOR NAMES
Cecconi A.
AUTHOR ADDRESSES
(Cecconi A., cecconi@scuolatao.com) Montegiorgio and Sant'Elpidio A Mare
Hospital, Italy.
(Cecconi A., cecconi@scuolatao.com) Scuolatao, Bologna, Italy.
(Cecconi A., cecconi@scuolatao.com) La Sapienza University, Rome, Italy.
CORRESPONDENCE ADDRESS
A. Cecconi, Scuolatao, Bologna, Italy. Email: cecconi@scuolatao.com
SOURCE
Journal of Chinese Medicine (2011) :97 (60-64). Date of Publication: October
2011
ISSN
0143-8042
BOOK PUBLISHER
Journal of Chinese Medicine, 22 Cromwell Road, Hove, Sussex, United Kingdom.
ABSTRACT
Emergency Room (ER) doctors have to deal with severe health conditions that
require swift intervention, usually with rapidly-acting drugs. There may
appear to be no space for traditional Chinese medicine (TCM) - and
acupuncture in particular - in this context, thanks to the widespread belief
that this kind of traditional medicine requires more time to act. This
article describes the use of TCM in an ER in Italy. Through the description
of several cases the author shows that acupuncture can be effective either
alone, or in combination with Western medicine, for both diagnosis and
treatment of conditions not normally seen in private TCM clinics.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
emergency ward
EMTREE MEDICAL INDEX TERMS
article
asthma
atrial fibrillation
Chinese medicine
epistaxis
fever
human
hypertensive crisis
Italy
nephrolithiasis
panic
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011611168
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 343
TITLE
Treadmill exercise stress echocardiography in patients with no history of
coronary artery disease: A single-center experience in Korean population
AUTHOR NAMES
Jang J.Y.
Sohn I.S.
Kim J.N.
Park J.H.
Park C.B.
Jin E.S.
Cho J.M.
Kim C.J.
Bae J.H.
AUTHOR ADDRESSES
(Jang J.Y.; Sohn I.S., issohn@khu.ac.kr; Kim J.N.; Park J.H.; Park C.B.; Jin
E.S.; Cho J.M.; Kim C.J.; Bae J.H.) Department of Cardiology, Kyung Hee
University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul
134-727, South Korea.
CORRESPONDENCE ADDRESS
I.S. Sohn, Department of Cardiology, Kyung Hee University Hospital at
Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, South Korea. Email:
issohn@khu.ac.kr
SOURCE
Korean Circulation Journal (2011) 41:9 (528-534). Date of Publication:
September 2011
ISSN
1738-5520
1738-5555 (electronic)
BOOK PUBLISHER
Korean Society of Circulation, 553 Dowha-dong, Mapo-gu, Seoul, South Korea.
ABSTRACT
Background and Objectives: Treadmill exercise stress echocardiography (TSE)
has superior diagnostic accuracy than exercise electrocardiography (ECG).
The objectives of the study are 1) to define the diagnostic accuracy and
safety of TSE in patients without a history of coronary artery disease
(CAD), 2) to identify the clinical characteristics that predict positive TSE
results and 3) to assess the differential predictive value between TSE and
concomitant exercise ECG in a Korean population. Subjects and Methods: A
total of 1,287 patients among 1,500 consecutive patients with no prior
history of CAD and who were referred for TSE during a 4-year 3-month period
were enrolled. Results: Of the 1,287 patients, 95 (7.4%) showed positive TSE
results (newly developed regional wall motion abnormality). Among the 154
patients with coronary angiography, 94 patients (61%) showed significant CAD
(30 of 77 patients with negative TSE results and 64 of 77 patients with
positive TSE results). The TSE positive population had more cardiovascular
risk factors and showed a higher Duke treadmill score and wall motion score
index than the TSE negative group. TSE showed relatively good sensitivity
(68%), specificity (78%) and positive and negative predictive values (83%
and 61%, respectively), and TSE also had higher diagnostic accuracy than
concomitant exercise ECG (72% vs. 64%, respectively). Conclusion: TSE is
safe and offers greater diagnostic power for CAD than exercise ECG in Korean
population without a history of CAD. Its prognostic value in this population
needs to be confirmed in a larger prospective study. Copyright © 2011 The
Korean Society of Cardiology.
EMTREE DRUG INDEX TERMS
high density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary artery disease (diagnosis)
diagnostic accuracy
patient safety
stress echocardiography
treadmill exercise
treadmill exercise stress echocardiography
EMTREE MEDICAL INDEX TERMS
adult
angiography
article
atrial fibrillation (complication)
cardiovascular risk
cholesterol blood level
clinical effectiveness
clinical feature
comparative study
controlled study
coronary artery recanalization
diagnostic test accuracy study
electrocardiography monitoring
faintness (complication)
female
heart ejection fraction
heart ventricle wall motion
human
hypotension
Korea
major clinical study
male
paroxysmal supraventricular tachycardia (complication)
predictive value
sensitivity and specificity
thorax pain (complication)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011579682
FULL TEXT LINK
http://dx.doi.org/10.4070/kcj.2011.41.9.528
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 344
TITLE
Nitric oxide-mediated coronary flow regulation in patients with coronary
artery disease: Recent advances
AUTHOR NAMES
Toda N.
Tanabe S.
Nakanishi S.
AUTHOR ADDRESSES
(Toda N., n.toda.toyama-bldg@orion.ocn.ne.jp) Toyama Institute for
Cardiovascular Pharmacology Research, 7-13, 1-Chome, Azuchi-machi, Chuo-ku,
Osaka 541-0052, Japan.
(Tanabe S.) Cardiology Section, Department of Internal Medicine, Social
Insurance Kyoto Hospital, Japan.
(Nakanishi S.) Department of Internal Medicine, Kyoto Prefectural University
of Medicine, Japan, Kyoto, Japan.
CORRESPONDENCE ADDRESS
N. Toda, Toyama Institute for Cardiovascular Pharmacology Research, 7-13,
1-Chome, Azuchi-machi, Chuo-ku, Osaka 541-0052, Japan. Email:
n.toda.toyama-bldg@orion.ocn.ne.jp
SOURCE
International Journal of Angiology (2011) 20:3 (121-134). Date of
Publication: September 2011
ISSN
1061-1711
1615-5939 (electronic)
BOOK PUBLISHER
Thieme Medical Publishers, Inc., 333 7th Avenue, New York, United States.
ABSTRACT
Nitric oxide (NO) formed via endothelial NO synthase (eNOS) plays crucial
roles in the regulation of coronary blood flow through vasodilatation and
decreased vascular resistance, and in inhibition of platelet aggregation and
adhesion, leading to the prevention of coronary circulatory failure,
thrombosis, and atherosclerosis. Endothelial function is impaired by several
pathogenic factors including smoking, chronic alcohol intake,
hypercholesterolemia, obesity, hyperglycemia, and hypertension. The
mechanisms underlying endothelial dysfunction include reduced NO synthase
(NOS) expression and activity, decreased NO bioavailability, and increased
production of oxygen radicals and endogenous NOS inhibitors. Atrial
fibrillation appears to be a risk factor for endothelial dysfunction.
Endothelial dysfunction is an important predictor of coronary artery disease
(CAD) in humans. Penile erectile dysfunction, associated with impaired
bioavailability of NO produced by eNOS and neuronal NOS, is also considered
to be highly predictive of ischemic heart disease. There is evidence
suggesting an important role of nitrergic innervation in coronary blood flow
regulation. Prophylactic and therapeutic measures to eliminate pathogenic
factors inducing endothelial and nitrergic nerve dysfunction would be quite
important in preventing the genesis and development of CAD. Copyright © 2011
by Thieme.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
endothelial nitric oxide synthase (endogenous compound)
EMTREE DRUG INDEX TERMS
alloprinol (drug dose, drug therapy)
angiotensin 2 receptor antagonist (drug therapy)
antioxidant (drug therapy)
arginine (drug combination, drug therapy, intravenous drug administration)
atorvastatin (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
C reactive protein (endogenous compound)
caveolin (endogenous compound)
celiprolol (drug therapy)
citrulline
colony stimulating factor 1 (endogenous compound)
folic acid (drug therapy)
garlic extract (drug therapy)
Ginkgo biloba extract (drug therapy)
glyceryl trinitrate
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
losartan (drug combination, drug therapy, oral drug administration)
placebo
Rho kinase (endogenous compound)
superoxide dismutase (endogenous compound)
temocapril (drug therapy)
tetrahydrobiopterin (drug therapy)
unclassified drug
urapidil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary artery blood flow
coronary artery disease (drug therapy, drug therapy, etiology, surgery)
EMTREE MEDICAL INDEX TERMS
angina pectoris (drug therapy)
angiocardiography
atrial fibrillation
bioavailability
blood clot lysis
coronary artery bypass graft
coronary flow reserve
cytokine production
drug megadose
endothelial dysfunction
endothelium
enzyme activity
erectile dysfunction
exercise
human
hypertension (drug therapy)
macrophage
mucocutaneous lymph node syndrome
obesity
oxygen consumption
pathogenesis
percutaneous coronary intervention
priority journal
protein binding
protein degradation
protein expression
protein function
protein synthesis
review
risk factor
shear stress
ST segment depression
stable angina pectoris (drug therapy)
thrombocyte adhesion
thrombocyte aggregation
variable number of tandem repeat
vascular resistance
vasodilatation
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
arginine (1119-34-2, 15595-35-4, 7004-12-8, 74-79-3)
atorvastatin (134523-00-5, 134523-03-8)
celiprolol (56980-93-9, 57470-78-7)
citrulline (372-75-8)
colony stimulating factor 1 (81627-83-0)
endothelial nitric oxide synthase (503473-02-7)
folic acid (59-30-3, 6484-89-5)
glyceryl trinitrate (55-63-0)
losartan (114798-26-4)
superoxide dismutase (37294-21-6, 9016-01-7, 9054-89-1)
temocapril (110221-44-8)
tetrahydrobiopterin (17528-72-2)
urapidil (34661-75-1)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011526713
FULL TEXT LINK
http://dx.doi.org/10.1055/s-0031-1283220
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 345
TITLE
Vascular contributions to cognitive impairment and dementia: A statement for
healthcare professionals from the American Heart Association/American Stroke
Association
AUTHOR NAMES
Gorelick P.B.
Scuteri A.
Black S.E.
Decarli C.
Greenberg S.M.
Iadecola C.
Launer L.J.
Laurent S.
Lopez O.L.
Nyenhuis D.
Petersen R.C.
Schneider J.A.
Tzourio C.
Arnett D.K.
Bennett D.A.
Chui H.C.
Higashida R.T.
Lindquist R.
Nilsson P.M.
Roman G.C.
Sellke F.W.
Seshadri S.
AUTHOR ADDRESSES
(Gorelick P.B.; Scuteri A.; Black S.E.; Decarli C.; Greenberg S.M.; Iadecola
C.; Launer L.J.; Laurent S.; Lopez O.L.; Nyenhuis D.; Petersen R.C.;
Schneider J.A.; Tzourio C.; Arnett D.K.; Bennett D.A.; Chui H.C.; Higashida
R.T.; Lindquist R.; Nilsson P.M.; Roman G.C.; Sellke F.W.; Seshadri S.)
CORRESPONDENCE ADDRESS
P.B. Gorelick,
SOURCE
Stroke (2011) 42:9 (2672-2713). Date of Publication: September 2011
ISSN
0039-2499
1524-4628 (electronic)
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327,
Philadelphia, United States.
ABSTRACT
Background and Purpose-This scientific statement provides an overview of the
evidence on vascular contributions to cognitive impairment and dementia.
Vascular contributions to cognitive impairment and dementia of later life
are common. Definitions of vascular cognitive impairment (VCI),
neuropathology, basic science and pathophysiological aspects, role of
neuroimaging and vascular and other associated risk factors, and potential
opportunities for prevention and treatment are reviewed. This statement
serves as an overall guide for practitioners to gain a better understanding
of VCI and dementia, prevention, and treatment. Methods-Writing group
members were nominated by the writing group co-chairs on the basis of their
previous work in relevant topic areas and were approved by the American
Heart Association Stroke Council Scientific Statement Oversight Committee,
the Council on Epidemiology and Prevention, and the Manuscript Oversight
Committee. The writing group used systematic literature reviews (primarily
covering publications from 1990 to May 1, 2010), previously published
guidelines, personal files, and expert opinion to summarize existing
evidence, indicate gaps in current knowledge, and, when appropriate,
formulate recommendations using standard American Heart Association
criteria. All members of the writing group had the opportunity to comment on
the recommendations and approved the final version of this document. After
peer review by the American Heart Association, as well as review by the
Stroke Council leadership, Council on Epidemiology and Prevention Council,
and Scientific Statements Oversight Committee, the statement was approved by
the American Heart Association Science Advisory and Coordinating Committee.
Results-The construct of VCI has been introduced to capture the entire
spectrum of cognitive disorders associated with all forms of cerebral
vascular brain injury-not solely stroke-ranging from mild cognitive
impairment through fully developed dementia. Dysfunction of the
neurovascular unit and mechanisms regulating cerebral blood flow are likely
to be important components of the pathophysiological processes underlying
VCI. Cerebral amyloid angiopathy is emerging as an important marker of risk
for Alzheimer disease, microinfarction, microhemorrhage and macrohemorrhage
of the brain, and VCI. The neuropathology of cognitive impairment in later
life is often a mixture of Alzheimer disease and microvascular brain damage,
which may overlap and synergize to heighten the risk of cognitive
impairment. In this regard, magnetic resonance imaging and other
neuroimaging techniques play an important role in the definition and
detection of VCI and provide evidence that subcortical forms of VCI with
white matter hyperintensities and small deep infarcts are common. In many
cases, risk markers for VCI are the same as traditional risk factors for
stroke. These risks may include but are not limited to atrial fibrillation,
hypertension, diabetes mellitus, and hypercholesterolemia. Furthermore,
these same vascular risk factors may be risk markers for Alzheimer disease.
Carotid intimal-medial thickness and arterial stiffness are emerging as
markers of arterial aging and may serve as risk markers for VCI. Currently,
no specific treatments for VCI have been approved by the US Food and Drug
Administration. However, detection and control of the traditional risk
factors for stroke and cardiovascular disease may be effective in the
prevention of VCI, even in older people. Conclusions-Vascular contributions
to cognitive impairment and dementia are important. Understanding of VCI has
evolved substantially in recent years, based on preclinical,
neuropathologic, neuroimaging, physiological, and epidemiological studies.
Transdisciplinary, translational, and transactional approaches are
recommended to further our understanding of this entity and to better
characterize its neuropsychological profile. There is a need for
prospective, quantitative, clinical-pathological-neuroimaging studies to
improve knowledge of the pathological basis of neuroimaging change and the
complex interplay between vascular and Alzheimer disease pathologies in the
evolution of clinical VCI and Alzheimer disease. Long-term vascular risk
marker interventional studies beginning as early as midlife may be required
to prevent or postpone the onset of VCI and Alzheimer disease. Studies of
intensive reduction of vascular risk factors in high-risk groups are another
important avenue of research. © 2011 American Heart Association. All rights
reserved.
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist (clinical trial, drug combination, drug
comparison, drug therapy)
atenolol (clinical trial, drug therapy)
beta adrenergic receptor blocking agent (clinical trial, drug therapy)
candesartan hexetil (clinical trial, drug therapy)
chlortalidone (clinical trial, drug therapy)
choline derivative (clinical trial, drug therapy)
cholinesterase inhibitor (clinical trial, drug therapy)
cytidinediphosphocholine (clinical trial, drug therapy)
dihydropyridine (clinical trial, drug combination, drug therapy)
diuretic agent (clinical trial, drug combination, drug therapy)
donepezil (clinical trial, drug therapy)
enalapril maleate (clinical trial, drug combination, drug therapy)
galantamine (clinical trial, drug therapy)
huperzine A (clinical trial, drug therapy)
hydrochlorothiazide (clinical trial, drug combination, drug therapy)
indapamide (clinical trial, drug combination, drug therapy)
indapamide plus perindopril (clinical trial, drug therapy)
lisinopril (clinical trial, drug comparison, drug therapy)
memantine (drug therapy)
nimodipine (clinical trial, drug therapy)
nitrendipine (drug therapy)
perindopril (clinical trial, drug combination, drug therapy)
piracetam (clinical trial, drug therapy)
placebo
reserpine (clinical trial, drug therapy)
rivastigmine (clinical trial, drug therapy)
sertraline (drug therapy)
telmisartan (clinical trial, drug therapy)
unclassified drug
unindexed drug
vinpocetine (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cognitive defect (drug therapy, diagnosis, drug therapy, prevention,
rehabilitation, therapy)
dementia (drug therapy, diagnosis, drug therapy, prevention)
vascular cognitive impairment (drug therapy, diagnosis, drug therapy,
prevention, rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
alcohol consumption
Alzheimer disease (drug therapy, prevention)
arterial stiffness
arterial wall thickness
atrial fibrillation
blood pressure
brain blood flow
brain hemorrhage
brain infarction
cardiovascular risk
cerebrovascular accident
cerebrovascular disease
chronic kidney disease
cognitive rehabilitation
coronary artery disease
depression
diabetes mellitus
diet
disease association
disease course
education
forward heart failure
health care personnel
heredity
homeostasis
human
hypercholesterolemia
hyperglycemia
hypertension (drug therapy)
inflammation
insulin resistance
lifestyle
medical society
metabolic syndrome X
microangiopathy
mild cognitive impairment (diagnosis)
multiinfarct dementia (drug therapy, therapy)
neuroimaging
neuropsychological test
nonhuman
nuclear magnetic resonance imaging
obesity
oxidative stress
pathophysiology
peripheral occlusive artery disease
physical activity
priority journal
randomized controlled trial (topic)
review
small vessel vasculitis (drug therapy)
smoking
social network
social support
vascular amyloidosis
DRUG TRADE NAMES
preterax
CAS REGISTRY NUMBERS
atenolol (29122-68-7, 93379-54-5)
candesartan hexetil (145040-37-5)
chlortalidone (77-36-1)
dihydropyridine (27790-75-6)
donepezil (120011-70-3, 120014-06-4, 142057-77-0)
enalapril maleate (76095-16-4)
galantamine (1953-04-4, 357-70-0)
huperzine A (102518-79-6, 92138-20-0)
hydrochlorothiazide (58-93-5)
indapamide (26807-65-8)
lisinopril (76547-98-3, 83915-83-7)
memantine (19982-08-2, 41100-52-1)
nimodipine (66085-59-4)
nitrendipine (39562-70-4)
perindopril (82834-16-0, 99149-83-4)
piracetam (7491-74-9)
reserpine (50-55-5, 8001-95-4)
rivastigmine (129101-54-8)
sertraline (79617-96-2)
telmisartan (144701-48-4)
vinpocetine (42971-09-5)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011492251
MEDLINE PMID
21778438 (http://www.ncbi.nlm.nih.gov/pubmed/21778438)
FULL TEXT LINK
http://dx.doi.org/10.1161/STR.0b013e3182299496
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 346
TITLE
Gastroparesis: Pathogenesis, diagnosis and management
AUTHOR NAMES
Hasler W.L.
AUTHOR ADDRESSES
(Hasler W.L., whasler@umich.edu) Division of Gastroenterology, University of
Michigan Hospital, 3912 Taubman Center, Ann Arbor, MI 5362, United States.
CORRESPONDENCE ADDRESS
W.L. Hasler, Division of Gastroenterology, University of Michigan Hospital,
3912 Taubman Center, Ann Arbor, MI 5362, United States. Email:
whasler@umich.edu
SOURCE
Nature Reviews Gastroenterology and Hepatology (2011) 8:8 (438-453). Date of
Publication: August 2011
ISSN
1759-5045
1759-5053 (electronic)
BOOK PUBLISHER
Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
Gastroparesis is a prevalent condition that produces symptoms of delayed
gastric emptying in the absence of physical blockage. The most common
etiologies of gastroparesis are idiopathic, diabetic, and postsurgical
disease, although some cases stem from autoimmune, paraneoplastic,
neurologic or other conditions. Histologic examination of gastric tissues
from patients with severe gastroparesis reveals heterogeneous and
inconsistent defects in the morphology of enteric neurons, smooth muscle and
interstitial cells of Cajal, and increased levels of inflammatory cells.
Diagnosis is most commonly made by gastric emptying scintigraphy; however,
wireless motility capsules and nonradioactive isotope breath tests have also
been validated. A range of treatments have been used for gastroparesis
including dietary modifications and nutritional supplements, gastric motor
stimulatory or antiemetic medications, endoscopic or surgical procedures,
and psychological interventions. Most treatments have not been subjected to
controlled testing in patients with gastroparesis. The natural history of
this condition is poorly understood. Active ongoing research is providing
important insights into the pathogenesis, diagnosis, treatment and outcomes
of this disease. © 2011 Macmillan Publishers Limited. All rights reserved.
EMTREE DRUG INDEX TERMS
azithromycin (drug comparison, drug therapy, intravenous drug
administration, oral drug administration)
bethanechol (adverse drug reaction, drug therapy)
botulinum toxin (clinical trial, drug therapy)
clarithromycin (drug comparison, drug therapy)
domperidone (adverse drug reaction, drug comparison, drug therapy,
intravenous drug administration, oral drug administration)
erythromycin (adverse drug reaction, drug comparison, drug therapy,
intravenous drug administration, oral drug administration)
metoclopramide (adverse drug reaction, drug comparison, drug therapy,
intravenous drug administration, subcutaneous drug administration)
mirtazapine (drug therapy)
placebo
pyridostigmine (drug therapy)
ulimorelin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
stomach paresis (drug therapy, complication, diagnosis, drug therapy,
etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
abdominal cramp (side effect)
abdominal pain (side effect)
acupuncture
agitation
amenorrhea (side effect)
anastomosis leakage (complication)
anastomosis stenosis (complication)
article
atrial fibrillation (side effect)
breath analysis
clinical feature
diabetes mellitus
diet supplementation
disease course
drug dose comparison
dystonia (side effect)
electrostimulation therapy
endoscopic surgery
fatigue (side effect)
galactorrhea (side effect)
heart arrhythmia (side effect)
histopathology
human
hyperprolactinemia (side effect)
hypotension (side effect)
idiopathic disease (etiology, therapy)
intestine obstruction (complication)
nausea (side effect)
nonhuman
pathogenesis
postoperative complication (complication)
priority journal
psychologic assessment
QT prolongation (side effect)
side effect (side effect)
sleep disorder (side effect)
stomach emptying
stomach motility
stomach scintiscanning
sudden death
tardive dyskinesia (side effect)
treatment outcome
urinary urgency (side effect)
vomiting (side effect)
wheezing (side effect)
DRUG TRADE NAMES
tzp 101
CAS REGISTRY NUMBERS
azithromycin (83905-01-5)
bethanechol (590-63-6, 674-38-4, 91609-06-2)
clarithromycin (81103-11-9)
domperidone (57808-66-9)
erythromycin (114-07-8, 70536-18-4)
metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
mirtazapine (61337-67-5)
pyridostigmine (101-26-8, 155-97-5)
ulimorelin (842131-33-3, 951326-02-6)
EMBASE CLASSIFICATIONS
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011439418
MEDLINE PMID
21769117 (http://www.ncbi.nlm.nih.gov/pubmed/21769117)
FULL TEXT LINK
http://dx.doi.org/10.1038/nrgastro.2011.116
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 347
TITLE
Stroke: Classification and diagnosis
AUTHOR NAMES
Parmar P.
Sumaria S.
Hashi S.
AUTHOR ADDRESSES
(Parmar P., pareshparmar@nhs.net) Northwick Park Hospital, North West London
Hospitals NHS Trust, United Kingdom.
(Sumaria S.; Hashi S.) University College London Hospitals NHS Foundation
Trust, United Kingdom.
CORRESPONDENCE ADDRESS
P. Parmar, Northwick Park Hospital, North West London Hospitals NHS Trust,
United Kingdom. Email: pareshparmar@nhs.net
SOURCE
Clinical Pharmacist (2011) 3:7 (200-202). Date of Publication: July-August
2011
ISSN
1758-9061
BOOK PUBLISHER
Pharmaceutical Press, 1 Lambeth High Street, London, United Kingdom.
ABSTRACT
Stroke is a major cause of morbidity and mortality in the UK, yet about 80%
of strokes are preventable. Factors that are known to increase the risk of
stroke include age, gender, hypertension, atrial fibrillation, diabetes and
cigarette smoking. Broadly, a stroke can be classified as either ischaemic
(caused by a thrombus) or haemorrhagic (caused by the rupture of blood
vessels). Stroke is a medical emergency and the sooner that it is diagnosed
and treated the better the outcome.
EMTREE DRUG INDEX TERMS
cholesterol (endogenous compound)
electrolyte (endogenous compound)
glucose (endogenous compound)
urea (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (diagnosis)
EMTREE MEDICAL INDEX TERMS
age
arm weakness
artery dissection
atrial fibrillation
blood cell count
brain hemorrhage
brain ischemia
cardiovascular risk
carotid artery disease
carotid duplex ultrasonograpy
cholesterol blood level
computer assisted tomography
delirium
dementia
diabetes mellitus
diet
disease classification
disorders of mitochondrial functions
drug overdose
electrocardiography
electrolyte blood level
erythrocyte sedimentation rate
ethnicity
Fabry disease
family history
fibromuscular dysplasia
gender
glucose blood level
health care personnel
hematologic disease
heredity
homocystinuria
hormonal contraception
human
hyperlipidemia
hypertension
hypoxia
infection
injury
intravascular ultrasound
ischemic heart disease
migraine
moyamoya disease
nuclear magnetic resonance imaging
obesity
paradoxical embolism
peripheral occlusive artery disease
pregnancy
seizure
sepsis
short survey
sleep disordered breathing
slurred speech
smoking
Sneddon syndrome
spinal cord lesion
stroke patient
thyroid function test
urea blood level
urinalysis
vasculitis
vestibular disorder
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
glucose (50-99-7, 84778-64-3)
urea (57-13-6)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011649384
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 348
TITLE
Yoga may help reduce episodes of atrial fibrillation. The calming and
balancing effects of yoga may cut down on common triggers for AF episodes
and may have other health benefits, too.
AUTHOR ADDRESSES
SOURCE
Heart advisor / the Cleveland Clinic (2011) 14:6 (7). Date of Publication:
Jun 2011
ISSN
1523-9004
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (etiology, prevention)
yoga
EMTREE MEDICAL INDEX TERMS
article
human
psychological aspect
LANGUAGE OF ARTICLE
English
MEDLINE PMID
23189370 (http://www.ncbi.nlm.nih.gov/pubmed/23189370)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 349
TITLE
Belgian Society of Cardiology, 30th Annual Scientific Meeting
AUTHOR ADDRESSES
SOURCE
Acta Cardiologica (2011) 66:1. Date of Publication: 2011
CONFERENCE NAME
30th Annual Scientific Meeting of the Belgian Society of Cardiology
CONFERENCE LOCATION
Brussels, Belgium
CONFERENCE DATE
2011-02-10 to 2011-02-11
ISSN
0001-5385
BOOK PUBLISHER
Acta Cardiologica
ABSTRACT
The proceedings contain 61 papers. The topics discussed include: underuse of
anticoagulation in older patients with atrial fibrillation; appropriateness
of anticoagulation in older patients with atrial fibrillation; usefulness of
the magnetic navigation system in ablation of ventricular tachycardia: acute
and mid-term follow-up results compared to manual ablation; predicting the
occurrence of atrial aarhythmia after closure of an atrial septal defect
type secundum; cryotherapy is a very effective and safe method for ablation
of parahissian accessory pathways; suppressed increase in blood endothelial
progenitor cell content as result of single exhaustive exercise bout in male
revascularized coronary artery disease patients; effects of diesel exhaust
microparticles on vascular endothelial function; and in vivo assessment of
hemodynamic effects of nanobodies therapy for neutralizing scorpion toxin
effects in a small animal model.
EMTREE DRUG INDEX TERMS
scorpion venom
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
society
EMTREE MEDICAL INDEX TERMS
animal model
anticoagulation
atrial fibrillation
blood
book
coronary artery disease
cryotherapy
endothelial progenitor cell
exercise
exhaust gas
follow up
heart atrium septum defect
heart ventricle tachycardia
hemodynamics
human
male
patient
therapy
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 350
TITLE
Arrhythmogenic Cardiomyopathy: Natural History and Risk Stratification
AUTHOR NAMES
Migliore F.
Baritussio A.
Rigato I.
Perazzolo Marra M.
Bauce B.
Basso C.
Iliceto S.
Corrado D.
AUTHOR ADDRESSES
(Migliore F.; Baritussio A.; Rigato I.; Perazzolo Marra M.; Bauce B.;
Iliceto S.; Corrado D., domenico.corrado@unipd.it) Division of Cardiology,
Department of Cardiac, Thoracic and Vascular Sciences, University of Padua
Medical School, Via Giustiniani, 2-35121 Padua, Italy.
(Basso C.) Cardiovascular Pathology, Department of Medical-Diagnostic
Sciences and Special Therapies, University of Padua Medical School, Via A.
Gabelli, 35121 Padua, Italy.
CORRESPONDENCE ADDRESS
D. Corrado, Division of Cardiology, Department of Cardiac, Thoracic and
Vascular Sciences, University of Padua Medical School, Via Giustiniani,
2-35121 Padua, Italy. Email: domenico.corrado@unipd.it
SOURCE
Cardiac Electrophysiology Clinics (2011) 3:2 (281-291). Date of Publication:
June 2011
ISSN
1877-9182
BOOK PUBLISHER
W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
Arrhythmogenic cardiomyopathy (AC) is an inherited heart muscle disease
whose clinical manifestations are related to ventricular electrical
instability, which may lead to sudden cardiac death, mostly in young people.
Later in the disease history, the right ventricle becomes more diffusely
affected and the involvement of the left ventricle may result in
biventricular heart failure. This article addresses the disease natural
history and analyzes the clinical predictors of sudden arrhythmic death and
clinical outcome of patients with AC. © 2011.
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart right ventricle dysplasia (congenital disorder, diagnosis, therapy)
EMTREE MEDICAL INDEX TERMS
anticoagulant therapy
atrial fibrillation (complication, drug therapy, therapy)
cardiac patient
defibrillator
diagnostic test accuracy study
disease course
echocardiography
electrocardiogram
electrophysiology
exercise
faintness
genotype
heart arrest
heart arrhythmia (drug therapy)
heart failure (therapy)
heart left bundle branch block
heart right bundle branch block
heart right ventricle
heart right ventricle ejection fraction
heart right ventricle outflow tract obstruction
heart ventricle tachycardia
history
Holter monitoring
human
incidence
phenotype
priority journal
QRS complex
review
sensitivity and specificity
stratified sample
sudden death
thromboembolism (complication, drug therapy, therapy)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011215887
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ccep.2011.02.012
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 351
TITLE
Precipitating factors leading to decompensation of chronic heart failure in
the elderly patient in South-American community hospital
AUTHOR NAMES
Diaz A.
Ciocchini C.
Esperatti M.
Becerra A.
Mainardi S.
Farah A.
AUTHOR ADDRESSES
(Diaz A., alejandrounicen@gmail.com; Becerra A.; Mainardi S.; Farah A.)
Department of Cardiology, Hospital Privado de Comunidad, Cordoba 4545, Mar
del Plata 7600, Argentina.
(Ciocchini C.; Esperatti M.) Department of Internal Medicine, Hospital
Privado de Comunidad, Cordoba 4545, Mar del Plata 7600, Argentina.
CORRESPONDENCE ADDRESS
A. Diaz, Department of Medical Physiology, School of Health Sciences,
Universidad Nacional del Centro de la Provincia de Buenos Aires, 4 de abril
618, Tandil (7000), Argentina. Email: alejandrounicen@gmail.com
SOURCE
Journal of Geriatric Cardiology (2011) 8:1 (12-14). Date of Publication:
2011
ISSN
1671-5411
BOOK PUBLISHER
Institute of Geriatric Cardiology, 28 Fuxing Road, Beijing, China.
ABSTRACT
Background: Exacerbations of heart failure appear frequently associated with
precipitating factors not directly related to the evolution of cardiac
disease. There still a paucity of data on the proportional distribution of
precipitating factors specifically in elderly patients. The aim of this
study was to examine prospectively the precipitating factors leading to
hospitalization in elderly patients with heart failure in our community
hospital. Methods: We evaluate elderly patients who need admissions for
decompensate heart failure. All patients were reviewed daily by the study
investigators at the first 24 h and closely followed-up. Decompensation was
defined as the worsening in clinical NYHA class associated with the need for
an increase in medical treatment (at minimum intravenously diuretics).
Results: We included 102 patients (mean age 79 ± 12 years). Precipitating
factors were identified in 88.5%. The decompensation was sudden in 35% of
the cases. Noncompliance with diet was identified in 52% of the patients,
lack of adherence to the prescribed medications amounted to 30%. Others
precipitating factors were infections (29%), arrhythmias (25%), acute
coronary ischemia (22%), and uncontrolled hypertension (15%), miscellaneous
causes were detected in 18% of the cases (progression of renal disease 60%,
anemia 30% and iatrogenic factors 10%). Concomitant cause was not
recognizable in 11.5%. Conclusions: Large proportion heart failure
hospitalizations are associated with preventable precipitating factors.
Knowledge of potential precipitating factors may help to optimize treatment
and provide guidance for patients with heart failure. The presence of
potential precipitating factors should be routinely evaluated in patients
presenting chronic heart failure. ©2011 IGC All rights reserved.
EMTREE DRUG INDEX TERMS
diuretic agent (drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
coronary risk
geriatric patient
heart failure (drug therapy, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
aged
anemia
article
atrial fibrillation
bacterial endocarditis
blood pressure regulation
diet therapy
disease course
disease exacerbation
disease predisposition
follow up
heart arrhythmia
heart atrium flutter
heart ejection fraction
heart muscle ischemia
heart ventricle tachycardia
hospital admission
hospitalization
human
hypertension
iatrogenic disease
kidney disease
kidney dysfunction
major clinical study
patient compliance
South America
supraventricular tachycardia
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011196344
FULL TEXT LINK
http://dx.doi.org/10.3724/SP.J.1263.2011.00012
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 352
TITLE
Efficacy of acupuncture in preventing atrial fibrillation recurrences after
electrical cardioversion
AUTHOR NAMES
Lomuscio A.
Belletti S.
Battezzati P.M.
Lombardi F.
AUTHOR ADDRESSES
(Lomuscio A.; Belletti S.; Lombardi F., Federico.Lombardi@unimi.it)
Cardiologia Osp. San Paolo, DMCO, University of Milan, Via A. di Rudunì 8,
20147 Milan, Italy.
(Battezzati P.M.) Medicina Interna VI, Osp. San Paolo, Dipartimento di
Medicina, Chirurgia e Odontoiatria, Università Degli Studi di Milano, Milan,
Italy.
CORRESPONDENCE ADDRESS
F. Lombardi, Cardiologia Osp. San Paolo, DMCO, University of Milan, Via A.
di Rudunì 8, 20147 Milan, Italy. Email: Federico.Lombardi@unimi.it
SOURCE
Journal of Cardiovascular Electrophysiology (2011) 22:3 (241-247). Date of
Publication: March 2011
ISSN
1045-3873
1540-8167 (electronic)
BOOK PUBLISHER
Blackwell Publishing Inc., 350 Main Street, Malden, United States.
ABSTRACT
Antiarrhythmic Effect of Acupuncture. Introduction: In traditional Chinese
medicine, stimulation of the Neiguan spot has been utilized to treat
palpitations. We evaluated whether acupuncture might prevent or reduce the
rate of arrhythmia recurrences in patients with persistent atrial
fibrillation (AF). Methods and Results: We studied 80 patients with
persistent AF after restoring sinus rhythm with electrical cardioversion.
Twenty-six subjects who were already on amiodarone treatment constituted the
AMIO reference group. The remaining patients were randomly allocated to
receive acupuncture (ACU group, n = 17), sham acupuncture (ACU-sham group, n
= 13), or neither acupuncture nor antiarrhythmic therapy (CONTROL group, n =
24). Patients in the ACU and ACU-sham groups attended 10 acupuncture
sessions on a once-a-week basis. Only in the former group the Neiguan,
Shenmen, and Xinshu spots were punctured. During a 12-month follow-up, AF
recurred in 35 patients. Cumulative AF recurrence rates in the AMIO, ACU,
ACU-sham, and CONTROL patients were 27%, 35%, 69%, and 54%, respectively (P
= 0.0075, log-rank test). Ejection fraction (P = 0.0005), hypertension
(0.0293), and left atrial diameter (P = 0.0361) were also significantly
associated with AF recurrence. Compared with AMIO group, recurrence rate was
similar in ACU patients (hazard ratio: 1.15, 95% CI: 0.38-3.49; P = 0.801)
but significantly higher in ACU-sham and CONTROL patients (3.77, 1.39-10; P
= 0.009 and 3.15, 1.23-8.06; P = 0.017, respectively) after adjustment for
ejection fraction, hypertension, and left atrial diameter using Cox
modeling. Conclusion: Our data indicate that acupuncture treatment prevents
arrhythmic recurrences after cardioversion in patients with persistent AF.
This minimally invasive procedure was safe and well tolerated. © 2010 Wiley
Periodicals, Inc.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
oral antidiabetic agent (drug therapy)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
recurrent disease (prevention, therapy)
EMTREE MEDICAL INDEX TERMS
anticoagulant therapy
antihypertensive therapy
article
cardioversion
clinical article
diabetes mellitus (drug therapy)
female
follow up
heart ejection fraction
heart left atrium
human
hypertension (drug therapy)
male
priority journal
randomized controlled trial
sinus rhythm
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011141897
MEDLINE PMID
20807278 (http://www.ncbi.nlm.nih.gov/pubmed/20807278)
FULL TEXT LINK
http://dx.doi.org/10.1111/j.1540-8167.2010.01878.x
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 353
TITLE
Warfarin and supplement interactions: Survey of published literature
AUTHOR NAMES
Marino J.
Motz D.
Shields K.
AUTHOR ADDRESSES
(Marino J.) Walgreens, Alexandria, VA, United States.
(Motz D.) Case Medical Center Rainbow Babies and Children, Cleveland, OH,
United States.
(Shields K., k-shields@onu.edu) Department of Pharmacy Practice, Ohio
Northern University, Raabe College of Pharmacy, Ada, OH, United States.
CORRESPONDENCE ADDRESS
K. Shields, Department of Pharmacy Practice, Ohio Northern University, Raabe
College of Pharmacy, Ada, OH, United States. Email: k-shields@onu.edu
SOURCE
Journal of Pharmacy Technology (2011) 27:2 (63-70). Date of Publication:
March-April 2011
ISSN
8755-1225
BOOK PUBLISHER
Harvey Whitney Books Company, 8044 Montgomery Road, Suite 415, Cincinnati,
United States.
ABSTRACT
Objective: To review published literature related to potential interactions
between warfarin and common dietary supplement products. Data Sources:
Tertiary databases including Micromedex, LexiComp, and Natural Medicines
Comprehensive Database were used to assess drug interactions with warfarin.
Searches of literature from database inception through July 2010 were
conducted in MEDLINE, International Pharmaceutical Abstracts, and Iowa Drug
Information Service and were restricted to the English language. The
following search terms were used: warfarin, ginkgo biloba, St. John's wort,
garlic, coenzyme Q10, ginger, ginseng, red clover, fish oil, dong quai,
cranberry, green tea, saw palmetto, bilberry, soy, chamomile, glucosamine,
chondroitin, echinacea, interactions, anticoagulation/antiplatelet,
bleeding, herbals, and pharmacokinetics/ pharmacodynamics. Study Selection
and Data Extraction: Thirty-two English language publications were
identified and analyzed. Reference lists of each of the included articles
were reviewed to obtain related articles for further analysis. Data
Synthesis: Quality of existing data for interactions between warfarin and
commonly available dietary supplements varies greatly. The majority of
information available is derived from case reports, although for some
products pharmacokinetic studies have been performed to assess the effect of
supplement use in patients concurrently using warfarin. Some of the data
that suggest interactions with warfarin were gleaned from case reports or
from an understanding of supplement mechanisms of action that would indicate
such an interaction. The strength of evidence for the majority of the herbal
products studied seems to be lacking and therefore it is difficult to draw
firm conclusions. Conclusions: Based on the narrow therapeutic window of
warfarin therapy, practitioners should be encouraged to document any
potential drug interaction. However, it seems inappropriate to suggest
absolute avoidance of all dietary supplements in all patients using warfarin
therapy. Instead, diligent monitoring and reporting should be implemented to
detect such events.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (clinical trial, drug combination, drug dose, drug interaction,
drug therapy, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (clinical trial, drug combination)
Angelica sinensis extract (drug interaction, drug therapy, pharmacokinetics)
chamomile (drug interaction, pharmacokinetics)
chondroitin (drug interaction, drug therapy, pharmacokinetics)
cranberry extract (clinical trial, drug interaction)
Echinacea purpurea extract (clinical trial, drug interaction,
pharmacokinetics, pharmacology)
garlic extract (clinical trial, drug interaction, drug therapy,
pharmacokinetics, pharmacology)
ginger extract (clinical trial, drug interaction, drug therapy,
pharmacokinetics, pharmacology)
Ginkgo biloba extract (clinical trial)
ginseng extract (clinical trial, drug combination, drug interaction, oral
drug administration, pharmacokinetics, pharmacology)
glucosamine (drug interaction, drug therapy, pharmacokinetics)
green tea extract (drug interaction)
Hypericum perforatum extract (clinical trial, drug combination, drug
interaction, drug therapy, pharmacokinetics, pharmacology)
omega 3 fatty acid (clinical trial, drug combination, drug interaction)
placebo
red clover extract (drug interaction, drug therapy)
Sabal extract (drug combination, drug interaction, drug therapy)
ubidecarenone (clinical trial, drug interaction, drug therapy)
Vaccinium myrtillus extract (drug interaction, drug therapy, oral drug
administration, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diet supplementation
herb drug interaction
EMTREE MEDICAL INDEX TERMS
Angelica sinensis
anxiety disorder (drug therapy)
atrial fibrillation (drug therapy)
bilberry
cardiovascular disease (drug therapy)
cataract (drug therapy)
cerebrovascular accident (drug therapy)
clinical trial
cranberry
depression (drug therapy)
diabetes mellitus (drug therapy)
drug effect
drug mechanism
dyspepsia (drug therapy)
Echinacea
flatulence (drug therapy)
gastrointestinal symptom (drug therapy)
ginger
Ginkgo biloba
ginseng
health survey
herbal medicine
human
Hypericum perforatum
hyperlipidemia (drug therapy)
hypertension (drug therapy)
ischemic heart disease (drug therapy)
mastalgia (drug therapy)
menopausal syndrome (drug therapy)
menstrual irregularity (drug therapy)
mood disorder (drug therapy)
morning sickness (drug therapy)
motion sickness (drug therapy)
nausea and vomiting (drug therapy)
nonhuman
obsessive compulsive disorder (drug therapy)
osteoarthritis (drug therapy)
premenstrual syndrome (drug therapy)
prostate hypertrophy (drug therapy)
red clover
review
rheumatic heart disease (drug therapy)
Sabal
seasonal affective disorder (drug therapy)
single drug dose
soybean
tea
visual disorder (drug therapy)
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
chondroitin (9007-27-6)
glucosamine (3416-24-8, 4607-22-1)
ubidecarenone (303-98-0)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011274185
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 354
TITLE
Year in review: Medication mishaps in the elderly
AUTHOR NAMES
Peron E.P.
Marcum Z.A.
Boyce R.
Hanlon J.T.
Handler S.M.
AUTHOR ADDRESSES
(Peron E.P.; Marcum Z.A.; Hanlon J.T., jth14@pitt.edu; Handler S.M.)
Department of Medicine, School of Medicine, University of Pittsburgh,
Pittsburgh, PA, United States.
(Boyce R.; Hanlon J.T., jth14@pitt.edu; Handler S.M.) Department of
Biomedical Informatics, School of Medicine, University of Pittsburgh,
Pittsburgh, PA, United States.
(Hanlon J.T., jth14@pitt.edu; Handler S.M.) Geriatric Research Education and
Clinical Center, Center for Health Equity Research and Promotion, Veterans
Affairs Pittsburgh Health System, Pittsburgh, PA, United States.
(Hanlon J.T., jth14@pitt.edu) Department of Pharmacy and Therapeutics,
School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
(Hanlon J.T., jth14@pitt.edu) Department of Epidemiology, Graduate School of
Public Health, University of Pittsburgh, Pittsburgh, PA, United States.
CORRESPONDENCE ADDRESS
J. T. Hanlon, Department of Medicine (Geriatrics), University of Pittsburgh,
Kaufmann Medical Building, 3471 5th Avenue, Pittsburgh, PA 15213, United
States. Email: jth14@pitt.edu
SOURCE
American Journal Geriatric Pharmacotherapy (2011) 9:1 (1-10). Date of
Publication: February 2011
ISSN
1543-5946
BOOK PUBLISHER
Excerpta Medica Inc., 105 Raider Blvd, Suite 101, Hillsborough, United
States.
ABSTRACT
Objective: This paper reviews articles from 2010 that examined medication
mishaps (ie, medication errors and adverse drug events [ADEs]) in the
elderly. Methods: The MEDLINE and EMBASE databases were searched for
English-language articles published in 2010 using a combination of search
terms including medication errors, medication adherence, medication
compliance, suboptimal prescribing, monitoring, adverse drug events, adverse
drug withdrawal events, therapeutic failures, and aged. A manual search of
the reference lists of the identified articles and the authors' article
files, book chapters, and recent reviews was conducted to identify
additional publications. Five studies of note were selected for annotation
and critique. From the literature search, this paper also generated a
selected bibliography of manuscripts published in 2010 (excluding those
previously published in the American Journal of Geriatric Pharmacotherapy or
by one of the authors) that address various types of medication errors and
ADEs in the elderly. Results: Three studies focused on types of medication
errors. One study examined underuse (due to prescribing) as a type of
medication error. This before-and-after study from the Netherlands reported
that those who received comprehensive geriatric assessments had a reduction
in the rate of undertreatment of chronic conditions by over one third (from
32.9% to 22.3%, P < 0.05). A second study focused on reducing medication
errors due to the prescribing of potentially inappropriate medications. This
quasi-experimental study found that a computerized provider order entry
clinical decision support system decreased the number of potentially
inappropriate medications ordered for patients < 65 years of age who were
hospitalized (11.56 before to 9.94 orders per day after, P < 0.001). The
third medication error study was a cross-sectional phone survey of
managed-care elders, which found that more blacks than whites had low
antihypertensive medication adherence as per a self-reported measure (18.4%
vs 12.3%, respectively; P < 0.001). Moreover, blacks used more complementary
and alternative medicine (CAM) than whites for the treatment of hypertension
(30.5% vs 24.7%, respectively; P = 0.005). In multivariable analyses
stratified by race, blacks who used CAM were more likely than those who did
not to have low antihypertensive medication adherence (prevalence rate ratio
= 1.56; 95% CI, 1.14-2.15; P = 0.006). The remaining two studies addressed
some form of medication-related adverse patient events. A case-control study
of Medicare Advantage patients revealed for the first time that the use of
skeletal muscle relaxants was associated significantly with an increased
fracture risk (adjusted odds ratio = 1.40; 95% CI, 1.15-1.72; P < 0.001).
This increased risk was even more pronounced with the concomitant use of
benzodiazepines. Finally, a randomized controlled trial across 16 centers in
France used a 1-week educational intervention about high-risk medications
and ADEs directed at rehabilitation health care teams. Results indicated
that the rate of ADEs in the intervention group was lower than that in the
usual care group (22% vs 36%, respectively, P = 0.004). Conclusion:
Information from these studies may advance health professionals'
understanding of medication errors and ADEs and may help guide research and
clinical practices in years to come. © 2011 Elsevier HS Journals, Inc.
EMTREE DRUG INDEX TERMS
anticoagulant agent (oral drug administration)
antihypertensive agent (drug therapy)
arginine
benzodiazepine (adverse drug reaction)
beta adrenergic receptor blocking agent
bisphosphonic acid derivative
carisoprodol (adverse drug reaction)
chlorzoxazone (adverse drug reaction)
cholinergic receptor blocking agent (adverse drug reaction)
corticosteroid
cyclobenzaprine (adverse drug reaction)
dipeptidyl carboxypeptidase inhibitor
fish oil
laxative
metaxalone (adverse drug reaction)
methocarbamol (adverse drug reaction)
morphine
nonsteroid antiinflammatory agent (adverse drug reaction)
opiate
proton pump inhibitor
steroid (oral drug administration)
ubidecarenone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adverse drug reaction
geriatric patient
medication error
EMTREE MEDICAL INDEX TERMS
African American
aged
alternative medicine
angina pectoris
antihypertensive therapy
atrial fibrillation
case control study
cerebrovascular accident
Chinese herb
chronic disease
chronic drug administration
clinical assessment
clinical decision making
computerized provider order entry
corticosteroid therapy
cross-sectional study
diabetes mellitus
diet supplementation
drug dose titration
Embase
ethnicity
European American
falling
fiber
fracture (side effect)
France
geriatric care
health care personnel
health survey
heart failure
heart infarction
hospital patient
human
hypertension (drug therapy)
leisure
meditation
Medline
osteoporosis
patient compliance
patient education
patient monitoring
peripheral occlusive artery disease
prescription
priority journal
quasi experimental study
race
randomized controlled trial (topic)
rehabilitation care
review
risk reduction
self report
transient ischemic attack
treatment failure
treatment withdrawal
unspecified side effect (side effect)
yoga
CAS REGISTRY NUMBERS
arginine (1119-34-2, 15595-35-4, 7004-12-8, 74-79-3)
benzodiazepine (12794-10-4)
carisoprodol (78-44-4)
chlorzoxazone (95-25-0)
cyclobenzaprine (303-53-7, 6202-23-9)
fish oil (8016-13-5)
metaxalone (1665-48-1)
methocarbamol (532-03-6)
morphine (52-26-6, 57-27-2)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
ubidecarenone (303-98-0)
EMBASE CLASSIFICATIONS
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011187510
MEDLINE PMID
21459304 (http://www.ncbi.nlm.nih.gov/pubmed/21459304)
FULL TEXT LINK
http://dx.doi.org/10.1016/j.amjopharm.2011.01.003
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 355
TITLE
Dabigatran: A new orally available anticoagulant for prevention of strokes
and thrombosis in patients with atrial fibrillation
AUTHOR NAMES
Talati R.
White M.C.
AUTHOR ADDRESSES
(Talati R.) Hartford Hospital, Hartford, CT, United States.
(Talati R.; White M.C.) Department of Pharmacy, University of Connecticut,
Storrs, United States.
(White M.C.) UCONN/Hartford Hospital, Evidence-based Practice Center,
Hartford, CT, United States.
CORRESPONDENCE ADDRESS
R. Talati, Hartford Hospital, Hartford, CT, United States.
SOURCE
Formulary (2011) 46:2 (44-53). Date of Publication: February 2011
ISSN
1082-801X
BOOK PUBLISHER
Advanstar Communications, One Park Avenue, New York, United States.
ABSTRACT
Atrial fibrillation (AF) is the most common clinically significant cardiac
arrhythmia in the United States and increases the risk of stroke 4.5-fold.
Stroke can result in substantial morbidity, mortality, decreased quality of
life, and related healthcare costs. Vitamin K antagonists such as warfarin
are effective for stroke prevention in AF, but have several drawbacks. There
is a need for new anticoagulant agents that are effective, safe, and
convenient to use. Dabigatran etexilate (Pradaxa) is an orally administered
reversible direct thrombin inhibitor approved by FDA on October 19, 2010,
for the prevention of stroke and thrombosis in patients with AF. In clinical
studies, it was given orally by fixed once-or twice-daily dosing, does not
require dietary adjustments or routine laboratory monitoring, and is not
expected to have cytochrome P450-dependent drug interactions, although it
does have P-glycoprotein interactions. In the RE-LY trial, in patients with
AF and at least 1 other risk factor for stroke (average CHADS2 score 2.1),
dabigatran etexilate 150 mg twice daily was superior to warfarin at
preventing the combination of stroke and systemic embolic events with a
similar rate of major bleeding.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dabigatran (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug concentration, drug dose, drug interaction, drug therapy,
oral drug administration, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (clinical trial, drug combination, drug comparison,
drug therapy)
amiodarone (drug interaction, pharmacokinetics)
atorvastatin (drug interaction, pharmacokinetics)
clarithromycin (drug interaction, pharmacokinetics)
clopidogrel (drug interaction, pharmacokinetics)
cytochrome P450 (endogenous compound)
dabigatran etexilate
diclofenac (drug interaction, pharmacokinetics)
digoxin (drug interaction, pharmacokinetics)
multidrug resistance protein (endogenous compound)
pantoprazole (drug interaction, pharmacokinetics)
ranitidine (drug interaction, pharmacokinetics)
rifampicin (drug interaction)
thrombin (endogenous compound)
warfarin (adverse drug reaction, clinical trial, drug comparison, drug
therapy, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
cerebrovascular accident (drug therapy, complication, drug therapy,
prevention)
thrombosis (drug therapy, complication, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
alanine aminotransferase blood level
area under the curve
article
aspartate aminotransferase blood level
bleeding (side effect)
brain hemorrhage (side effect)
drug absorption
drug approval
drug bioavailability
drug contraindication
drug cost
drug efficacy
drug half life
drug hydrolysis
drug protein binding
drug safety
dyspepsia (side effect)
food and drug administration
human
maximum plasma concentration
morbidity
mortality
quality of life
randomized controlled trial (topic)
recommended drug dose
side effect (side effect)
thromboembolism (drug therapy)
time to maximum plasma concentration
DRUG TRADE NAMES
pradaxa Boehringer Ingelheim
DRUG MANUFACTURERS
Boehringer Ingelheim
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atorvastatin (134523-00-5, 134523-03-8)
clarithromycin (81103-11-9)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
cytochrome P450 (9035-51-2)
diclofenac (15307-79-6, 15307-86-5)
digoxin (20830-75-5, 57285-89-9)
pantoprazole (102625-70-7)
ranitidine (66357-35-5, 66357-59-3)
rifampicin (13292-46-1)
thrombin (869858-13-9, 9002-04-4)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011134125
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 356
TITLE
Diffuse idiopathic skeletal hyperostosis (DISH)-A rare etiology of dysphagia
AUTHOR NAMES
Krishnarasa B.
Vivekanandarajah A.
Ripoll L.
Chang E.
Wetz R.
AUTHOR ADDRESSES
(Krishnarasa B., doc_bala@yahoo.com; Vivekanandarajah A.; Ripoll L.; Chang
E.; Wetz R.) Staten Island University Hospital, Staten Island, NY, United
States.
CORRESPONDENCE ADDRESS
B. Krishnarasa, Staten Island University Hospital, Staten Island, NY, United
States. Email: doc_bala@yahoo.com
SOURCE
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders (2011) 4
(71-75). Date of Publication: 2011
ISSN
1179-5441 (electronic)
1179-5441
BOOK PUBLISHER
Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay,
Auckland, New Zealand.
ABSTRACT
A 72-year-old gentleman presented to the hospital with progressively
worsening dysphagia to soft foods and liquids. He was diagnosed with severe
pharyngeal dysphagia by modified barium swallow. A CT scan of the neck with
IV contrast showed anterior flowing of bridging osteophytes from C3-C6,
indicative of DISH, resulting in esophageal impingement. He underwent
resection of the DISH segments. Following the surgery, a PEG tube for
nutrition supplementation was placed. However, the PEG tube was removed
after five months when the speech and swallow evaluation showed no residual
dysphagia. DISH is a rare non-inflammatory condition that results in
pathological ossification and calcification of the anterolateral spinal
ligaments. © the author(s), publisher and licensee Libertas Academica Ltd.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diffuse idiopathic skeletal hyperostosis (diagnosis, surgery)
dysphagia (complication, diagnosis)
hyperostosis (diagnosis, surgery)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
bone demineralization
case report
cervical spine radiography
computer assisted tomography
coronary artery disease
diet supplementation
disease association
disease exacerbation
disease severity
dysarthria
dyspnea
fatigue
gout
hoarseness
human
hypertension
limb weakness
male
neck dissection
neck pain
ossification
osteophyte
paresthesia
pathogenesis
ptosis
rare disease (diagnosis)
sleep disordered breathing
stomach tube
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Orthopedic Surgery (33)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011609845
FULL TEXT LINK
http://dx.doi.org/10.4137/CMAMD.S6949
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 357
TITLE
Safety and efficacy of dronedarone in the treatment of atrial
fibrillation/flutter
AUTHOR NAMES
Naccarelli G.V.
Wolbrette D.L.
Levin V.
Samii S.
Banchs J.E.
Penny-Peterson E.
Gonzalez M.D.
AUTHOR ADDRESSES
(Naccarelli G.V., gnaccarelli@hmc.psu.edu; Wolbrette D.L.; Samii S.; Banchs
J.E.; Penny-Peterson E.; Gonzalez M.D.) State Hershey Heart and vascular
Institute, Hershey, PA, United States.
(Levin V.) Lehigh valley Hospital Electrophysiology Laboratory, Allentown,
PA, United States.
CORRESPONDENCE ADDRESS
G. V. Naccarelli, State Hershey Heart and vascular Institute, Hershey, PA,
United States. Email: gnaccarelli@hmc.psu.edu
SOURCE
Clinical Medicine Insights: Cardiology (2011) 5 (103-119) Article Number: 3.
Date of Publication: 2011
ISSN
1179-5468 (electronic)
1179-5468
BOOK PUBLISHER
Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay,
Auckland, New Zealand.
ABSTRACT
Dronedarone is an amiodarone analog but differs structurally from amiodarone
in that the iodine moiety was removed and a methane-sulfonyl group was
added. These modifcations reduced thyroid and other end-organ adverse
effects and makes dronedarone less lipophilic, shortening its half-life.
Dronedarone has been shown to prevent atrial fbrillation/futter (AF/AFl)
recurrences in several multi-center trials. In addition to its rhythm
control properties, dronedarone has rate control properties and slows the
ventricular response during AF. Dronedarone is approved in Europe for rhythm
and rate control indications. In patients with decompensated heart failure,
dronedarone treatment increased mortality and cardiovascular
hospitalizations. However, when dronedarone was used in elderly high risk
AF/AFl patients excluding such high risk heart failure, cardiovascular
hospitalizations were signifcantly reduced and the drug was approved in the
USA for this indication in 2009 by the Food and Drug Administration. Updated
guidelines suggest dronedarone as a front-line antiarrhythmic in many
patients with AF/Fl but caution that the drug should not be used in patients
with advanced heart failure. In addition, the recent results of the PALLAS
trial suggest that dronedarone should not be used in the long-term treatment
of patients with permanent AF. © the author(s), publisher and licensee
Libertas Academica Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dronedarone (adverse drug reaction, drug combination, drug comparison, drug
concentration, drug dose, drug interaction, drug therapy, intravenous drug
administration, oral drug administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
amiodarone (adverse drug reaction, drug combination, drug comparison, drug
interaction, drug therapy, intravenous drug administration, oral drug
administration, pharmacokinetics, pharmacology)
angiotensin receptor antagonist (drug therapy)
anticoagulant agent (drug combination, oral drug administration)
atorvastatin (drug interaction)
calcium channel blocking agent (drug therapy)
calcium channel L type (endogenous compound)
cytochrome P450 2C9 (endogenous compound)
cytochrome P450 2D6 (endogenous compound)
cytochrome P450 3A4 (endogenous compound)
cytochrome P450 inhibitor (drug combination, drug interaction)
dabigatran (drug combination, drug concentration, drug dose, drug
interaction)
digoxin (drug combination, drug concentration, drug dose, drug interaction,
drug therapy)
diltiazem (drug combination, drug dose, drug interaction)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
drug metabolite
lidocaine (drug comparison, drug therapy)
metoprolol (drug interaction, pharmacokinetics)
placebo
pravastatin (drug interaction)
ranolazine (drug combination, drug comparison, drug therapy)
rosuvastatin (drug interaction)
simvastatin (drug combination, drug concentration, drug dose, drug
interaction)
sodium channel (endogenous compound)
sotalol (drug comparison, drug therapy)
verapamil (drug combination, drug dose, drug interaction)
warfarin (adverse drug reaction, drug combination, drug dose, drug
interaction, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, therapy)
heart atrium flutter (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
acute heart failure (drug therapy)
antiarrhythmic activity
beta adrenergic receptor blocking
bleeding (side effect)
bradycardia (side effect)
brain hemorrhage (side effect)
brain ischemia
cardioversion
cerebrovascular accident (prevention)
congestive heart failure (drug therapy, side effect)
creatinine blood level
defibrillator
diarrhea (side effect)
drug absorption
drug bioavailability
drug blood level
drug contraindication
drug dose comparison
drug dose increase
drug dose reduction
drug efficacy
drug excretion
drug fatality (side effect)
drug half life
drug indication
drug metabolism
drug monitoring
drug potency
drug protein binding
drug safety
drug structure
drug tolerability
drug withdrawal
eye toxicity (side effect)
faintness
first pass effect
food
food drug interaction
gastrointestinal symptom (side effect)
heart arrest
heart arrhythmia (drug therapy)
heart atrioventricular node
heart electrophysiology
heart repolarization
heart ventricle arrhythmia (drug therapy)
heart ventricle fibrillation (drug therapy, prevention)
hemoglobin blood level
high risk patient
hospitalization
human
hyperthyroidism (side effect)
international normalized ratio
interstitial lung disease (side effect)
lipid diet
liver dysfunction (side effect)
liver function test
liver toxicity (side effect)
low drug dose
lung toxicity (side effect)
mortality
nausea (side effect)
neurotoxicity (side effect)
nonhuman
pneumonia (side effect)
potassium current
QT interval
QT prolongation (side effect)
recommended drug dose
recurrence risk
review
risk reduction
side effect (side effect)
skin toxicity (side effect)
sodium current
systolic blood pressure
tachycardia (drug therapy)
teratogenicity
thyroid disease (side effect)
torsade des pointes (side effect)
transient ischemic attack
vasodilatation
volume of distribution
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atorvastatin (134523-00-5, 134523-03-8)
cytochrome P450 3A4 (329736-03-0)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
dronedarone (141626-36-0)
lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
metoprolol (37350-58-6)
pravastatin (81093-37-0, 81131-70-6)
ranolazine (95635-55-5)
rosuvastatin (147098-18-8, 147098-20-2)
simvastatin (79902-63-9)
sotalol (3930-20-9, 80456-07-1, 959-24-0)
verapamil (152-11-4, 52-53-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2012010528
FULL TEXT LINK
http://dx.doi.org/10.4137/CMC.S6677
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 358
TITLE
Evaluation of anticoagulation management and chronic disease state control
in a pharmacist-run pharmacotherapy/anticoagulation clinic
AUTHOR NAMES
Sease J.M.
Blake E.W.
Gowan M.
Shealy K.M.
AUTHOR ADDRESSES
(Sease J.M., jmsease@presby.edu; Gowan M.) Department of Pharmacy Practice,
School of Pharmacy, Presbyterian College, Clinton, SC, United States.
(Blake E.W.) Department of Clinical Pharmacy and Outcomes Sciences, South
Carolina College of Pharmacy, Columbia, SC, United States.
(Gowan M.) Critical Care, Barnes-Jewish Hospital, St. Louis, MO, United
States.
(Shealy K.M.) Department of Pharmacy Practice, School of Pharmacy,
Presbyterian College, United States.
CORRESPONDENCE ADDRESS
J. M. Sease, Department of Pharmacy Practice, School of Pharmacy,
Presbyterian College, Clinton, SC, United States. Email: jmsease@presby.edu
SOURCE
Journal of Pharmacy Technology (2011) 27:1 (3-8). Date of Publication:
January-February 2011
ISSN
8755-1225
BOOK PUBLISHER
Harvey Whitney Books Company, 8044 Montgomery Road, Suite 415, Cincinnati,
United States.
ABSTRACT
Background: The benefit of pharmacist-run clinics for anticoagulation,
dyslipidemia, diabetes, and hypertension has been described in the
literature as individual services. We describe a clinic model in which
anticoagulation and other chronic disease states are managed concomitantly.
Objective: To evaluate the control of anticoagulation, hypertension,
dyslipidemia, and diabetes in anticoagulation patients enrolled in a
pharmacotherapy/anticoagulation clinic. Methods: Patients seen in the
pharmacotherapy/anticoagulation clinic for management of anticoagulation
were included in a retrospective review. Demographic information, blood
pressure measurements, and laboratory values were recorded. Initial and
final results were compared and statistically analyzed. Benchmark goals were
set for each parameter analyzed. Results: Between August 2007 and July 2008,
282 patients were enrolled in the clinic. While slightly increasing the
average time in therapeutic range from 69.9% to 70.7%, the clinical
pharmacists also managed hypertension, dyslipidemia, and diabetes, if
present. Systolic (p = 0.0075; 95% CI 0.98 to 6.31) and diastolic (p =
0.004; 95% CI 1.26 to 4.33) blood pressures decreased during the study
period such that the number of patients with controlled blood pressure
increased to 81%. Low-density lipoprotein cholesterol measurements decreased
by an average of 5.9 mg/dL (p < 0.0001; 95% CI 3.121 to 8.789), with an
increase in number of patients at goal to 86%. Although not significant,
mean hemoglobin A (1c) (A1C) values decreased an average of 0.12% (p =
0.1138; 95% CI 0.029 to 0.271), with an increase to 59% of those achieving a
goal A1C. Conclusions: A pharmacotherapy/anticoagulation clinic can be
considered a practice model for effective management of anticoagulation
patients who require management of other chronic disease states.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy)
EMTREE DRUG INDEX TERMS
hemoglobin A1c (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS
aged
anticoagulant therapy
article
atrial fibrillation (drug therapy)
blood pressure measurement
cerebrovascular accident (drug therapy)
chronic disease
deep vein thrombosis (drug therapy)
demography
diabetes mellitus
dyslipidemia
female
human
hypertension
lung embolism (drug therapy)
major clinical study
male
peripheral vascular disease (drug therapy)
pharmaceutical care
pharmacist
transient ischemic attack (drug therapy)
CAS REGISTRY NUMBERS
hemoglobin A1c (62572-11-6)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011157653
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 359
TITLE
Musculoskeletal rehabilitation after hip fracture: A review
AUTHOR NAMES
Pfeifer M.
Minne H.W.
AUTHOR ADDRESSES
(Pfeifer M., iko_pyrmont@t-online.de; Minne H.W.) Institute of Clinical
Osteology Gustav Pommer, Clinic der FURSTENHOF, Am Hylligen Born 7, Bad
Pyrmont 31812, Germany.
CORRESPONDENCE ADDRESS
M. Pfeifer, Institute of Clinical Osteology Gustav Pommer, Clinic der
FURSTENHOF, Am Hylligen Born 7, Bad Pyrmont 31812, Germany. Email:
iko_pyrmont@t-online.de
SOURCE
Archives of Osteoporosis (2010) 5:1-2 (49-59). Date of Publication: December
2010
ISSN
1862-3522
1862-3514 (electronic)
BOOK PUBLISHER
Springer London, The Guildway, Old Portsmouth Road, Artington, Guildford,
United Kingdom.
ABSTRACT
This review article on musculoskeletal rehabilitation after hip fractures
summarizes current scientific evidence concerning prevention, treatment and
post-fracture surveillance of patients who sustained a low-trauma hip
fracture due to osteoporosis. Introduction: With increasing longevity, hip
fractures become more and more a serious burden not only for societies in
developed civilization, but also for emerging countries. According to
world-wide projections 1.5 million people are affected each year. Although a
lot of research has been performed over the last decade, there is still a
lack of standardized and evidence-based approaches for prevention, treatment
and rehabilitation of this worst complication of osteoporosis. Therefore,
the evidence base for this article was synthesized in accordance with SIGN
methodology. Databases searched include Medline, Embase, CINAHL and the
Cochrane Library between January 1996 and March 2010. The following terms
are used: osteoporosis, hip fracture, rehabilitation, falls, muscle
strength, nutrition, exercise, balance, sway, and hip protectors. Moreover,
reference lists from included studies were checked and author's names were
searched for additional studies. Possibly, the best approach to
rehabilitation after hip fracture is a multi-disciplinary team co-ordinating
medical, social, educational and vocational measure for training or
retraining the individual to the highest possible level of function. In
order to prevent thromboembolism fondaparinux should be used for 28 days
starting 6 h after surgery. This should be accompanied by a daily
nutritional intake of at least 20-g protein, 1,200 mg of elemental calcium
and 800 IU of vitamin D; whereas in severe vitamin D insufficiencies,
recommendations may be certainly higher. After surgical repair of the hip
fracture, an anti-resorptive medication should be started. While balance
training and performing of Tai Chi has been shown to reduce fall risk and
thereby also decrease hip fracture risk, the use of hip protectors is still
under evaluation and cannot be generally advocated. © 2010 International
Osteoporosis Foundation and National Osteoporosis Foundation and National
Osteoporosis Foundation.
EMTREE DRUG INDEX TERMS
alendronic acid (drug therapy)
calcium
fondaparinux (drug therapy)
placebo
risedronic acid (drug therapy)
strontium ranelate (drug therapy)
vitamin D
zoledronic acid (adverse drug reaction, clinical trial, drug therapy,
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hip fracture (drug therapy, drug therapy, prevention, rehabilitation,
surgery, therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (side effect)
body equilibrium
bone pain (side effect)
cardiovascular disease (side effect)
cerebrovascular accident (side effect)
clinical practice
decubitus (complication)
deep vein thrombosis (complication)
diet supplementation
drug fever (side effect)
evidence based practice
exercise
fall risk
functional assessment
heterotopic ossification (complication)
hip pain (complication)
human
jaw osteonecrosis (side effect)
kidney disease (side effect)
kyphosis
longevity
mobilization
muscle strength
musculoskeletal pain (side effect)
myalgia (side effect)
neurological complication (complication)
nutrition
osteoporosis
oxygen saturation
priority journal
protective equipment
quality of life
rehabilitation medicine
resistance training
review
risk assessment
risk reduction
Tai Chi
thromboembolism (complication, drug therapy, prevention)
vitamin D deficiency
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcium (14092-94-5, 7440-70-2)
fondaparinux (104993-28-4, 114870-03-0)
risedronic acid (105462-24-6, 122458-82-6)
strontium ranelate (135459-87-9)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011064229
FULL TEXT LINK
http://dx.doi.org/10.1007/s11657-010-0050-8
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 360
TITLE
2nd International Symposium on Hypertension
AUTHOR ADDRESSES
SOURCE
Kidney and Blood Pressure Research (2010) 33:6. Date of Publication:
December 2010
CONFERENCE NAME
2nd International Symposium on Hypertension
CONFERENCE LOCATION
Osijek, Croatia
CONFERENCE DATE
2010-11-18 to 2010-11-21
CONFERENCE EDITORS
Drenjancevic I.
ISSN
1420-4096
BOOK PUBLISHER
S. Karger AG
ABSTRACT
The proceedings contain 50 papers. The topics discussed include: prevalence
of arterial hypertension and obesity in seven year old children;
hypertension as the most prevalent etiological condition in chronic and
transitory atrial fibrillation in patients at canton hospital zenica;
arterial hypertension in peritoneal dialysis patients; investigation of
parameters of blood vessels with the finometer device in diabetic and
non-diabetic hypertensive patients; artery plaque score and arterial
hypertension; influence of high salt diet on microvascular reactivity in
young healthy female human subjects; vasomotor effects of hemolyzed blood in
isolated rat cerebral arteries; prevalence, treatment, control and
distribution of hypertension in endemic nephropathy; hypertension protective
allele of toll-like receptor 2 polymorphic gene; and cumulative incidence of
arterial hypertension in normotensive subjects cohorta.
EMTREE DRUG INDEX TERMS
toll like receptor 2
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hypertension
EMTREE MEDICAL INDEX TERMS
allele
artery
atrial fibrillation
blood
blood vessel
brain artery
child
devices
diabetes mellitus
diet
female
gene
hemodialysis patient
hospital
human
kidney disease
obesity
patient
peritoneal dialysis
prevalence
rat
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 361
TITLE
Factors influencing concomitant use of complementary and alternative
medicines with warfarin
AUTHOR NAMES
Hasan S.S.
Feng S.R.
Ahmadi K.
Ahmad K.M.
Chong D.W.K.
Anwar M.
Badarudin N.Z.
AUTHOR ADDRESSES
(Hasan S.S., shahzad_hasan@imu.edu.my; Feng S.R.; Ahmadi K.; Anwar M.)
Department of Pharmacy Practice, School of Pharmacy and Health Sciences,
International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
(Ahmad K.M.; Chong D.W.K.) Clinical Coordinator, Hospital Serdang, Selangor,
Malaysia.
(Badarudin N.Z.) Pharmacistin-Charge, Anticoagulation Clinic, Hospital
Serdang, Selangor, Malaysia.
CORRESPONDENCE ADDRESS
S. S. Hasan, Department of Pharmacy Practice, School of Pharmacy and Health
Sciences, International Medical University, Bukit Jalil 57000, Kuala Lumpur,
Malaysia. Email: shahzad_hasan@imu.edu.my
SOURCE
Journal of Pharmacy Practice and Research (2010) 40:4 (294-299). Date of
Publication: December 2010
ISSN
1445-937X
BOOK PUBLISHER
Society of Hospital Pharmacists of Australia, P.O.Box 1774, Collingwood,
Australia.
ABSTRACT
Aim: To investigate factors influencing complementary and alternative
medicines (CAM) use among patients on warfarin. Method: Cross-sectional
study of randomly selected patients at a hospital-based anticoagulation
clinic in Malaysia. A 38- item validated data collection form was used to
interview patients and investigate the reasons, perceived efficacy and
adverse drug events experienced. Data were also collected on potential drug
interactions and the international normalised ratio (INR). Results: Of the
138 randomly selected patients, 76 (55%) reported using CAM - 46 (61%) used
biologically based practices such as herbal products, vitamins and
supplements. Monthly household income (p = 0.05, r = 0.13) and family
history of CAM use (p = 0.001, r = 0.32) were significantly associated and
positively correlated with CAM use. 19 patients reported adverse events with
warfarin use while none reported adverse events with CAM use. 19 and 58
patients, respectively, were identified as being at risk of potential
interactions between warfarin-CAM and warfarin-conventional medicines. No
significant difference in the mean INR was found between CAM and non-CAM
users. Conclusion: A large number of patients attending the anticoagulation
clinic reported using CAM. Socioeconomic factors such as monthly household
income, education level and family history of CAM use were significantly
related with CAM use. Routine medication interviews should include questions
about concomitant CAM use.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
warfarin (adverse drug reaction, drug interaction)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug interaction)
allopurinol (drug interaction)
alpha tocopherol (drug interaction)
fish oil (drug interaction)
glucosamine (drug interaction)
mineral
Panax notoginseng extract (drug therapy)
vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alternative medicine
EMTREE MEDICAL INDEX TERMS
acupuncture
adult
adverse outcome
anorexia (side effect)
anticoagulant therapy
article
atrial fibrillation
Chinese medicine
cross-sectional study
cryotherapy
dizziness (side effect)
drug efficacy
drug induced headache (side effect)
female
flatulence (side effect)
gingiva bleeding (drug therapy, side effect, therapy)
heart valve replacement
herbal medicine
human
international normalized ratio
kinesiotherapy
major clinical study
Malaysia
male
massage
myalgia (side effect, therapy)
skin bruising (drug therapy, side effect, therapy)
stomach pain (side effect)
traditional medicine
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
allopurinol (315-30-0)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
fish oil (8016-13-5)
glucosamine (3416-24-8, 4607-22-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Drug Literature Index (37)
Adverse Reactions Titles (38)
Pharmacy (39)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011039705
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 362
TITLE
Atrial fibrillation ablation: Safety and efficacy
AUTHOR NAMES
Lyne J.
AUTHOR ADDRESSES
(Lyne J., j.lyne@rbht.nhs.uk) Royal Brompton and Harefield NHS Trust, Sydney
Street, London, SW3 6NP, United Kingdom.
CORRESPONDENCE ADDRESS
J. Lyne, Royal Brompton and Harefield NHS Trust, Sydney Street, London, SW3
6NP, United Kingdom. Email: j.lyne@rbht.nhs.uk
SOURCE
British Journal of Cardiology (2010) 17:6 (255-256). Date of Publication:
November-December 2010
ISSN
0969-6113
BOOK PUBLISHER
MediNews (Cardiology) Ltd, 3 Duchess Place, Edgbaston, Birmingham, United
Kingdom.
ABSTRACT
This study is a single centre historical cohort of 100 consecutive patients
treated in a UK centre with catheter ablation for symptomatic drug
refractory AF. The results document outcomes in keeping with published case
series with acceptable complication rates. Although medical therapy is the
cornerstone of treatment for AF, ablation is assuming an ever greater role.
As these procedures become more common and both centres and operators alike
become more experienced and comfortable in addressing more advanced disease,
the indications for this procedure are likely to expand and encompass more
patients. Copyright Medinews (Cardiology) Limited Reproduction Prohibited.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent (drug therapy)
dabigatran (drug therapy)
dronedarone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
allergy (complication)
catheter ablation
cerebrovascular accident (drug therapy)
electrocardiogram
exercise
heart failure
heart left ventricle function
heart tamponade (complication)
hospitalization
human
mortality
pain (complication)
patient selection
pericarditis (complication)
prognosis
pulmonary vein isolation
quality of life
review
supraventricular tachycardia (complication)
thromboembolism
CAS REGISTRY NUMBERS
dronedarone (141626-36-0)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011539962
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 363
TITLE
Endurance sport practice and atrial fibrillation
AUTHOR NAMES
Calvo N.
Mont L.
AUTHOR ADDRESSES
(Calvo N.; Mont L., lmont@clinic.ub.es) Thorax Institute (ICT), Hospital
Clinic, University of Barcelona, Villarroel 170, Barcelona 08036, Catalonia,
Spain.
CORRESPONDENCE ADDRESS
L. Mont, Thorax Institute (ICT), Hospital Clinic, University of Barcelona,
Villarroel 170, Barcelona 08036, Catalonia, Spain. Email: lmont@clinic.ub.es
SOURCE
Journal of Atrial Fibrillation (2010) 2:2 (762-769). Date of Publication:
October 2010
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
endurance sport
EMTREE MEDICAL INDEX TERMS
athlete
autonomic nervous system
cardiovascular risk
dilatation
exercise
fibrosis
heart arrhythmia
human
inflammation
pathophysiology
review
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2010607326
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 364
TITLE
Epidemiology and risk factors of cerebral ischemia and ischemic heart
diseases: Similarities and differences
AUTHOR NAMES
Soler E.P.
Ruiz V.C.
AUTHOR ADDRESSES
(Soler E.P., epalomeras@csdm.cat; Ruiz V.C.) Unitat de Neurologia, Hospital
de Mataró, Carretera de Cirera, s/n, 08304 Mataró, Spain.
CORRESPONDENCE ADDRESS
E. P. Soler, Unitat de Neurologia, Hospital de Mataró, Carretera de Cirera,
s/n, 08304 Mataró, Spain. Email: epalomeras@csdm.cat
SOURCE
Current Cardiology Reviews (2010) 6:3 (138-149). Date of Publication: 2010
ISSN
1573-403X
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Cerebral ischemia and ischemic heart diseases, common entities nowadays, are
the main manifestation of circulatory diseases. Cardiovascular diseases,
followed by stroke, represent the leading cause of mortality worldwide. Both
entities share risk factors, pathophisiology and etiologic aspects by means
of a main common mechanism, atherosclerosis. However, each entity has its
own particularities. Ischemic stroke shows a variety of pathogenic
mechanisms not present in ischemic heart disease. An ischemic stroke
increases the risk of suffering a coronary heart disease, and viceversa. The
aim of this chapter is to review data on epidemiology, pathophisiology and
risk factors for both entities, considering the differences and similarities
that could be found in between them. We discuss traditional risk factors,
obtained from epidemiological data, and also some novel ones, such as
hyperhomocisteinemia or sleep apnea. We separate risk factors, as
clasically, in two groups: nonmodifiables, which includes age, sex, or
ethnicity, and modifiables, including hypertension, dyslipidemia or
diabetis, in order to discuss the role of each factor in both ischemic
events, ischemic stroke and coronary heart disease. © 2010 Bentham Science
Publishers Ltd.
EMTREE DRUG INDEX TERMS
alcohol
biological marker (endogenous compound)
C reactive protein (endogenous compound)
lipoprotein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (epidemiology)
cerebrovascular accident (epidemiology)
ischemic heart disease (epidemiology, prevention)
EMTREE MEDICAL INDEX TERMS
age distribution
alcohol consumption
artery embolism (epidemiology, etiology)
article
atherosclerosis (epidemiology, etiology)
atrial fibrillation (epidemiology, etiology)
blood clotting disorder (epidemiology, etiology)
cardiovascular disease (diagnosis, epidemiology, prevention)
cerebrovascular disease (epidemiology)
clinical trial
cohort analysis
comorbidity
coronary artery embolism (epidemiology, etiology)
diabetes mellitus (epidemiology, etiology)
diet
dyslipidemia (epidemiology, etiology)
epidemiological data
ethnicity
heart infarction (epidemiology, prevention)
heredity
human
hypercholesterolemia (epidemiology, etiology)
hypercoagulopathy (epidemiology, etiology)
hyperhomocysteinemia (epidemiology, etiology)
hypertension (epidemiology, etiology)
immobilization
incidence
inflammation
lipoprotein blood level
Mediterranean diet
mortality
obesity (etiology)
pathophysiology
physical activity
prevalence
priority journal
prospective study
risk factor
sex difference
sleep disordered breathing (epidemiology, etiology)
smoking
thrombophilia (epidemiology, etiology)
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
alcohol (64-17-5)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010496000
FULL TEXT LINK
http://dx.doi.org/10.2174/157340310791658785
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 365
TITLE
Is lenient rate control effective for atrial fibrillation?
AUTHOR NAMES
Moon K.T.
AUTHOR ADDRESSES
(Moon K.T.)
CORRESPONDENCE ADDRESS
K. T. Moon,
SOURCE
American Family Physician (2010) 82:6 (684-686). Date of Publication:
September 15, 2010
ISSN
0002-838X
0002-838X (electronic)
BOOK PUBLISHER
American Academy of Family Physicians, 11400 Tomahawk Creek Parkway, Suite
440, Leawood, United States.
ABSTRACT
Background: Rate control is the cornerstone of atrial fibrillation
management, but the optimal target heart rate is unknown. Guidelines
recommend strict rate control, but whether this approach actually improves
patient outcomes has not been proven. Van Gelder and colleagues studied
lenient rate control to determine if it is as effective as strict rate
control in preventing cardiovascular morbidity and mortality in persons with
atrial fibrillation. The Study: The authors evaluated data from the Rate
Control Efficacy in Permanent Atrial Fibrillation: A Comparison between
Lenient versus Strict Rate Control II study, a prospective randomized trial
examining whether lenient rate control (less than 110 beats per minute [bpm]
at rest) was noninferior to strict rate control (less than 80 bpm at rest
and less than 110 bpm with moderate exercise) in preventing cardiovascular
events over two to three years. Eligible patients were younger than 80
years, had permanent atrial fibrillation for up to 12 months, were receiving
anticoagulant therapy, and had a mean resting heart rate greater than 80
bpm. A total of 614 patients were given one or more rate-controlling drugs
(i.e., beta blockers, nondihydropyridine calcium channel blockers, and
digoxin) to achieve their target heart rate. The primary outcome was a
composite of cardiovascular-associated outcomes, including death, embolism,
sustained ventricular tachycardia, syncope, hospitalization for heart
failure, and implantation of a cardioverter-defibrillator. Results:
Significantly more patients were able to achieve their target heart rates in
the lenient rate-control group compared with the strict rate-control group
(97.7 versus 75.2 percent, respectively), and significantly fewer followup
visits were needed in the lenient rate-control group to achieve the target
heart rate. No difference was noted between the groups regarding the primary
outcome. There was also no difference between the groups with regard to
all-cause mortality, heart failure stage, hospitalization rate, or adverse
events, although the lenient ratecontrol group had a lower risk of stroke
(hazard ratio = 0.35). There was no difference between the groups in the
prevalence of atrial fibrillation symptoms, including palpitations, dyspnea,
or fatigue. Conclusion: The authors conclude that lenient rate control is
easier to achieve than strict rate control in patients with permanent atrial
fibrillation, with a similar rate of major clinical events. © 2010 by the
American Academy of Family Physicians.
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
digoxin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy)
heart rate
EMTREE MEDICAL INDEX TERMS
adult
aged
article
cardiovascular disease (prevention)
cerebrovascular accident
controlled study
dyspnea
exercise
fatigue
heart failure
heart palpitation
hospitalization
human
major clinical study
mortality
outcome assessment
prevalence
randomized controlled trial (topic)
symptomatology
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2011283797
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 366
TITLE
The role of medical practitioners in clinical pathways for stroke
AUTHOR NAMES
Kondo T.
AUTHOR ADDRESSES
(Kondo T., taro-mail-1122@dance.ocn.ne.jp) Kondo Clinic, Tokyo, Japan.
CORRESPONDENCE ADDRESS
T. Kondo, Kondo Clinic, Tokyo, Japan. Email: taro-mail-1122@dance.ocn.ne.jp
SOURCE
Japan Medical Association Journal (2010) 53:5 (290-293). Date of
Publication: September/October 2010
ISSN
1346-8650
BOOK PUBLISHER
Japan Medical Association, 2-28-16 Hongkomagome, Bunkyo-Ku, tokyo, Japan.
ABSTRACT
Stroke is the number one causative disease for conditions requiring care.
Considering the sequelae of stroke as well as vascular dementia, vascular
parkinsonism, fall-related fractures, and disuse syndrome, involvement in
clinical pathways for stroke is perhaps the most important issue for
healthcare practitioners. In order to initiate medical treatment immediately
after the onset of stroke, first it is vital to suspect that a patient is
having a stoke. If one or more symptoms of "facial distortion," "arm
paralysis," and "dysarthria" are present, there is a high possibility of
stroke. Spreading the use and knowledge of the Cincinnati Prehospital Stroke
Scale (CPSS) broadly would help people not to hesitate to call an ambulance.
In order to prevent the onset and recurrence of stroke, I wish to address
risk factors that can be corrected or modified, such as hypertension,
diabetes, hyperlipidemia, atrial fibrillation, obesity, smoking, alcohol
consumption, and lack of physical exercise. Increased efforts to carefully
respond to transient cerebral ischemic attacks can further reduce the
overall need for long-term care from stroke.
EMTREE DRUG INDEX TERMS
tissue plasminogen activator (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (prevention)
medical care
medical practice
EMTREE MEDICAL INDEX TERMS
alcohol consumption
article
atrial fibrillation
brain infarction (drug therapy)
brain ischemia
cincinnati prehospital stroke scale
diabetes mellitus
disuse syndrome
dysarthria
exercise
face disorder
fracture
health promotion
home care
hospital care
human
hyperlipidemia
hypertension
long term care
multiinfarct dementia
obesity
paralysis
parkinsonism
patient care
preventive health service
primary medical care
rating scale
recurrent disease (prevention)
risk factor
risk management
smoking
symptom
syndrome
transient ischemic attack
CAS REGISTRY NUMBERS
tissue plasminogen activator (105913-11-9)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010634751
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 367
TITLE
Acupuncture-induced intramuscular hematoma in patients taking
anticoagulation drugs: An emerging clinical entity
AUTHOR NAMES
Han Z.-Q.
Zhou X.
Jiang T.-M.
Li Y.-M.
AUTHOR ADDRESSES
(Han Z.-Q.; Zhou X.; Jiang T.-M.; Li Y.-M., cardiolab@gmail.com) Institute
of Cardiovascular Disease, Pingjin Hospital, Medical College of Chinese
People's Armed Police Forces, 220, Cheng-Lin Road, Tianjin 300162, China.
CORRESPONDENCE ADDRESS
Y.-M. Li, Institute of Cardiovascular Disease, Pingjin Hospital, Medical
College of Chinese People's Armed Police Forces, 220, Cheng-Lin Road,
Tianjin 300162, China. Email: cardiolab@gmail.com
SOURCE
Medical Acupuncture (2010) 22:3 (207-211). Date of Publication: 1 Sep 2010
ISSN
1933-6586
BOOK PUBLISHER
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, United States.
ABSTRACT
Background: Oral anticoagulation is used extensively for prevention of
thromboembolic events. Whether acupuncture is safe for patients taking
anticoagulants is not clear. Objective: To describe a patient with a history
of ischemic stroke and paroxysmal nonvalvular atrial fibrillation who was in
stroke rehabilitation including acupuncture. Design, Setting, and Patient
The patient developed sudden calf hematoma when optimal therapeutic
intensity of international normalized ratio (INR) was achieved. Results:
This patient was treated conservatively, without symptoms of compartment
syndrome, and calf hematomas were resolved in 3 months. Conclusions: With
increased acceptance of acupuncture worldwide and enforcement of clinical
guidelines for prevention of thromboembolism, acupuncture-induced hematoma
will be an emerging clinical entity. To minimize hemorrhagic complications,
caution should be exercised when patients receiving oral anticoagulation
request acupuncture treatment. © 2010, Mary Ann Liebert, Inc.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy, oral drug administration)
warfarin (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
muscle hematoma (complication, etiology)
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation (rehabilitation, therapy)
brain ischemia (drug therapy, prevention, rehabilitation, therapy)
case report
conservative treatment
drug use
female
human
international normalized ratio
practice guideline
priority journal
thromboembolism (prevention)
venous thromboembolism (drug therapy)
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Rehabilitation and Physical Medicine (19)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010498695
FULL TEXT LINK
http://dx.doi.org/10.1089/acu.2009.0736
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 368
TITLE
Primary and secondary prevention of cerebral ischemia
AUTHOR NAMES
Diener H.-C.
Aichner F.
Bode C.
Böhm M.
Eckstein H.-H.
Einhäupl K.
Endres M.
Forsting F.
Gesenhues S.
Grond M.
Haberl R.L.
Hacke W.
Hennerici M.
Lyrer P.
Link A.
Ringelstein B.
Ringleb P.A.
Schrader J.
Weimar C.
AUTHOR ADDRESSES
(Diener H.-C., h.diener@uni-essen.de; Weimar C.) Department of Neurology,
University Hospital Essen, Hufelandstr. 55, 45147 Essen, Belgium.
(Aichner F.) Neurological Department, Wagner-Jauregg-Krankenhaus, Linz,
Austria.
(Bode C.) Department of Cardiology, University Hospital, Freiburg, Germany.
(Böhm M.) Department of Internal Medicine III, University of the Saarland,
Homburg/Saar, Germany.
(Eckstein H.-H.) Department of Vascular Surgery, TU, Munich, Germany.
(Einhäupl K.) Department of Neurology, University Hospital, Charité, Berlin,
Germany.
(Endres M.) Department of Neurology und Clinical Neurophysiology, Charité,
Campus Benjamin Franklin, Berlin, Germany.
(Forsting F.) Department of Diagnostic und Interventional Radiology and
Neuroradiology, University Hospital, Essen, Belgium.
(Gesenhues S.) Institute of General Medicine, University Hospital, Essen,
Belgium.
(Grond M.) Department of Neurology, Kreisklinikum Siegen (DSG), Germany.
(Haberl R.L.) Department of Neurology, Klinikum Harlaching, Städt. Klinikum
München GmbH, Germany.
(Hacke W.; Ringleb P.A.) Department of Neurology, University Hospital
Heidelberg (DSG), Germany.
(Hennerici M.) University Department of Neurology, University of Mannheim,
Germany.
(Lyrer P.) Neurological Department, University Hospital, Basel, Switzerland.
(Link A.) Neurologist in Private Practice, Celle, Germany.
(Ringelstein B.) Department of Neurology, University Hospital Münster,
Germany.
(Schrader J.) Department of Internal Medicine, St. Joseph-Hospital,
Cloppenburg, Germany.
CORRESPONDENCE ADDRESS
H.-C. Diener, Department of Neurology, University Hospital Essen,
Hufelandstr. 55, 45147 Essen, Belgium. Email: h.diener@uni-essen.de
SOURCE
Aktuelle Neurologie (2010) 37:4 (e2-e22). Date of Publication: 2010
ISSN
0302-4350
1438-9428 (electronic)
BOOK PUBLISHER
Georg Thieme Verlag, Rudigerstrasse 14, Stuttgart, Germany.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug combination, drug therapy, oral drug
administration)
antithrombocytic agent (drug combination, drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug dose, drug therapy)
acetylsalicylic acid plus dipyridamole (adverse drug reaction, drug
comparison, drug dose, drug therapy)
amfebutamone (drug comparison, drug therapy)
antihypertensive agent (drug therapy)
atenolol (drug combination, drug comparison, drug therapy)
atorvastatin (clinical trial, drug comparison, drug dose, drug therapy)
calcium antagonist (drug combination, drug comparison)
clopidogrel (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug dose, drug therapy)
cyanocobalamin (clinical trial, drug combination, drug therapy,
pharmacology)
dipeptidyl carboxypeptidase inhibitor (drug combination, drug comparison,
drug therapy)
dipyridamole (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug therapy)
folic acid (clinical trial, drug combination, drug therapy, pharmacology)
hydrochlorothiazide (drug combination, drug comparison, drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy,
pharmacology)
indapamide (clinical trial, drug combination, drug comparison, drug therapy)
low density lipoprotein cholesterol (endogenous compound)
perindopril (clinical trial, drug combination, drug comparison, drug
therapy)
placebo
pravastatin (drug comparison, drug therapy)
proton pump inhibitor (drug combination, drug therapy)
pyridoxine (clinical trial, drug combination, drug therapy, pharmacology)
rimonabant (drug therapy)
sex hormone
simvastatin (clinical trial, drug therapy)
telmisartan (drug therapy)
unindexed drug
varenicline (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
warfarin (adverse drug reaction, drug comparison, drug therapy, oral drug
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (drug therapy, complication, drug therapy, etiology,
prevention)
cerebrovascular accident (drug therapy, complication, drug therapy,
etiology, prevention)
primary prevention
secondary prevention
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome
amino acid blood level
anticoagulant therapy
antihypertensive therapy
artery disease (drug therapy)
atrial fibrillation (drug therapy)
bleeding (side effect)
brain hemorrhage (side effect)
carotid angioplasty
carotid artery stenting
carotid endarterectomy
clinical trial
combination chemotherapy
diabetes mellitus
diet
drug contraindication
drug dose comparison
drug dose reduction
drug induced headache (side effect)
drug withdrawal
duodenum ulcer (drug therapy)
dyspepsia (side effect)
embolism (drug therapy)
gastrointestinal hemorrhage (side effect)
gastrointestinal symptom (side effect)
heart infarction (drug therapy)
homocysteine blood level
hormone substitution
human
hypercholesterolemia (drug therapy)
hyperhomocysteinemia (drug therapy)
hypertension (drug therapy)
insomnia (side effect)
internal carotid artery occlusion (surgery)
international normalized ratio
lifestyle
migraine
mitral valve replacement
monotherapy
mortality
nausea (side effect)
obesity (drug therapy)
patent foramen ovale
physical activity
postmenopause
prophylaxis
recommended drug dose
review
risk factor
risk reduction
smoking cessation
stomach ulcer (drug therapy)
transient ischemic attack (complication, drug therapy, prevention)
withdrawal syndrome (drug therapy)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amfebutamone (31677-93-7, 34911-55-2)
atenolol (29122-68-7)
atorvastatin (134523-00-5, 134523-03-8)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
dipyridamole (58-32-2)
folic acid (59-30-3, 6484-89-5)
hydrochlorothiazide (58-93-5)
indapamide (26807-65-8)
perindopril (82834-16-0, 99149-83-4)
pravastatin (81131-74-0)
pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
rimonabant (158681-13-1, 168273-06-1)
simvastatin (79902-63-9)
telmisartan (144701-48-4)
varenicline (249296-44-4, 375815-87-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2010322386
FULL TEXT LINK
http://dx.doi.org/10.1055/s-0029-1223537
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 369
TITLE
Blinding assessment in clinical trials: A review of statistical methods and
a proposal of blinding assessment protocol
AUTHOR NAMES
Bang H.
Flaherty S.P.
Kolahi J.
Park J.
AUTHOR ADDRESSES
(Bang H., heb2013@med.cornell.edu) Division of Biostatics and Epidemiology,
Department of Public Health, Weill Medical College of Cornell University,
New York, NY, United States.
(Flaherty S.P.; Park J.) Asian Medicine and Acupuncture Research, Department
of Physical Medicine and Rehabilitation, University of North Carolina at
Chapel Hill, Chapel Hill, NC, United States.
(Kolahi J.) Torabinejad Research Center, Isfahan University of Medical
Sciences, Isfahan, Iran.
CORRESPONDENCE ADDRESS
H. Bang, 402 East 67th Street, New York, NY 10065, United States. Email:
heb2013@med.cornell.edu
SOURCE
Clinical Research and Regulatory Affairs (2010) 27:2 (42-51). Date of
Publication: June 2010
ISSN
1060-1333
1532-2521 (electronic)
BOOK PUBLISHER
Informa Healthcare, 69-77 Paul Street, London, United Kingdom.
ABSTRACT
There is strong consensus in the clinical trial community that blinding is
an important issue in randomized controlled trials. At present grossly
incomplete reporting of procedures and the use of any assessment for
blinding still prevails. The term 'double-blind' has almost become a
convention without any checks or balances. Also there is a lack of consensus
on quantitative procedures for evaluating the success of blinding in the
literature. This article reviews statistical methods of blinding assessment
along with software options, and discusses some of the most pressing issues
surrounding the acquisition, interpretation, and reporting of blinding data.
Finally, it proposes a sample blinding assessment protocol to address some
of these issues. © 2010 Informa UK Ltd.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (clinical trial, drug comparison)
warfarin (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
clinical research
statistical analysis
EMTREE MEDICAL INDEX TERMS
acupuncture
atrial fibrillation
cerebrovascular accident (drug therapy, prevention, rehabilitation)
chi square test
clinical trial
human
kappa statistics
McNemar test
methodology
quantitative analysis
questionnaire
randomization
review
sham procedure
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010289387
FULL TEXT LINK
http://dx.doi.org/10.3109/10601331003777444
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 370
TITLE
Approved treatments for osteoporosis and what's in the pipeline
AUTHOR NAMES
Davis S.
Sachdeva A.
Goeckeritz B.
Oliver A.
AUTHOR ADDRESSES
(Davis S.; Sachdeva A.; Goeckeritz B.; Oliver A.) Section of Rheumatology,
Department of Medicine, Medical College of Georgia, Augusta, GA, United
States.
CORRESPONDENCE ADDRESS
S. Davis, Section of Rheumatology, Department of Medicine, Medical College
of Georgia, Augusta, GA, United States.
SOURCE
Drug Benefit Trends (2010) 22:4 (121-124). Date of Publication: May 2010
ISSN
1080-5826
BOOK PUBLISHER
CMP Healthcare Media LLC, 330 Boston Post Road, Darien, United States.
ABSTRACT
Along with the release of revised guidelines, several pharmacological
therapies have become available or are under investigation to help improve
outcomes in patients with osteoporosis. Lifestyle modifications have been
shown to be useful in osteoporosis management, and the use of medications
associated with the risk of osteoporosis should be minimized. Adherence to
therapy remains a challenge. Continued research and the development of
additional diagnostic and therapeutic modalities are needed.
EMTREE DRUG INDEX TERMS
alendronic acid (clinical trial, drug therapy, oral drug administration)
anabolic agent (drug therapy)
arzoxifene (drug development, drug therapy)
bazedoxifene (drug development, drug therapy)
bisphosphonic acid derivative (adverse drug reaction, drug therapy, oral
drug administration)
calcitonin (drug therapy, intranasal drug administration)
calcium (drug therapy)
collagen (endogenous compound)
creatinine (endogenous compound)
denosumab (drug development, drug therapy, subcutaneous drug administration)
estrogen (drug therapy, oral drug administration, transdermal drug
administration)
ibandronic acid (drug therapy, intravenous drug administration, oral drug
administration)
lasofoxifene (drug development, drug therapy)
odanacatib (drug development, drug therapy)
osteocalcin (clinical trial)
parathyroid hormone derivative (drug development, inhalational drug
administration)
parathyroid hormone[1-34] (adverse drug reaction, drug therapy, subcutaneous
drug administration)
raloxifene (drug therapy, oral drug administration)
risedronic acid (drug therapy, oral drug administration)
strontium (drug development, drug therapy)
tibolone (drug therapy)
unclassified drug
vitamin D (drug therapy)
zoledronic acid (adverse drug reaction, clinical trial, drug therapy,
intravenous drug administration)
zt 031 (drug development, drug therapy, inhalational drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
corticosteroid induced osteoporosis (drug therapy, drug therapy)
osteoporosis (drug therapy, drug therapy)
postmenopause osteoporosis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
arthralgia (side effect)
article
atrial fibrillation (side effect)
bone density
clinical trial
creatinine clearance
diet
dual energy X ray absorptiometry
estrogen therapy
exercise
fragility fracture
human
hypercalcemia (side effect)
hypercalciuria (side effect)
hypogonadal osteoporosis (drug therapy)
hypogonadal osteoporosis (drug therapy)
jaw osteonecrosis (side effect)
lifestyle modification
morbidity
mortality
myalgia (side effect)
osteosarcoma (side effect)
patient compliance
recommended drug dose
risk
smoking cessation
spine radiography
DRUG TRADE NAMES
zt 031
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
arzoxifene (182133-25-1, 182133-27-3)
bazedoxifene (198481-32-2, 198481-33-3)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcium (14092-94-5, 7440-70-2)
collagen (9007-34-5)
creatinine (19230-81-0, 60-27-5)
denosumab (615258-40-7)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
lasofoxifene (180915-85-9, 180916-16-9, 190791-29-8)
odanacatib (603139-19-1)
osteocalcin (136461-80-8)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
raloxifene (82640-04-8, 84449-90-1)
risedronic acid (105462-24-6, 122458-82-6)
strontium (7440-24-6)
tibolone (5630-53-5)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Obstetrics and Gynecology (10)
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010337571
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 371
TITLE
2010 CAEP/ACMU Scientific Abstracts
AUTHOR ADDRESSES
SOURCE
Canadian Journal of Emergency Medicine (2010) 12:3. Date of Publication: May
2010
CONFERENCE NAME
2010 CAEP/ACMU
CONFERENCE LOCATION
Montreal, QC, Canada
CONFERENCE DATE
2010-05-29 to 2010-06-02
ISSN
1481-8035
BOOK PUBLISHER
BC Decker Inc.
ABSTRACT
The proceedings contain 166 papers. The topics discussed include: the impact
of a triage nurse ordering on ED overcrowding: a systematic review;
prospective evaluation of the ABCD and ABCD2 scores in a Canadian ED
setting; additive value of codeine for pain management of children
presenting to the emergency department with a musculoskeletal trauma; the
impact of ED admission delays on inpatient outcomes; emergency physician
survey of American and Canadian emergency department management of
recent-onset atrial fibrillation; visibility of the urethral opening does
not correlate with risk of urinary tract infection in uncircumcised boys;
the development and validation of a simulation-based OSCE with basic
resuscitation scenarios in emergency medicine; road testing a new ED before
going live: how to use exercises to design and test a new patient flow
model; and short-term functional impacts of minor injuries in community
elders seen in an emergency department.
EMTREE DRUG INDEX TERMS
codeine
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
boy
child
community
crowding (area)
emergency health service
emergency medicine
emergency physician
emergency ward
exercise
hospital patient
human
injury
male
model
musculoskeletal injury
nurse
pain
patient
resuscitation
risk
simulation
systematic review
systematic review (topic)
urinary tract infection
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 372
TITLE
Toxicology of Dysosma versipallis rhizome: A review
AUTHOR NAMES
Liang M.
Liu Y.
Ananda S.
Zhuo L.
Liu L.
AUTHOR ADDRESSES
(Liang M.; Liu Y.; Ananda S.; Zhuo L.) Department of Forensic Medicine,
Tongji Medical College, Huazhong University of Science and Technology,
430030, Wuhan, China.
(Liu L., casper603@gmail.com) Key Laboratory of Evidence Science (China
University of Political Science and Law), Ministry of Education, 100040,
Beijing, China.
CORRESPONDENCE ADDRESS
L. Liu, Key Laboratory of Evidence Science (China University of Political
Science and Law), Ministry of Education, 100040, Beijing, China. Email:
casper603@gmail.com
SOURCE
Journal of Medicinal Plants Research (2010) 4:9 (717-721). Date of
Publication: May 2010
ISSN
1996-0875
1996-0875 (electronic)
BOOK PUBLISHER
Academic Journals, PO Box 5170-00200 Nairobi, Victoria Island, Lagos,
Nigeria.
ABSTRACT
According to the World Health Organization and the National Institutes of
Health, Traditional Chinese medicine originated more than 3000 years ago.
While there are quite obvious medical values suggesting that Dysosma
versipallis rhizome is both desirable and achievable, there are still
obstacles. Since the therapeutic dose and toxic dose are very close, D.
versipallis rhizome poisoning cases were frequently reported. In this paper,
the plant source, chemical constituent, toxicity reason, toxic dose,
mechanism of toxicity, poisoning symptoms, pathological changes of body
tissues after ingestion of D. versipallis rhizome poisoning and medical
management are reviewed. © 2010 Academic Journals.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
Dysosma versipallis extract (drug analysis, drug dose, drug toxicity,
intraperitoneal drug administration, oral drug administration)
plant extract (drug analysis, drug dose, drug toxicity, intraperitoneal drug
administration, oral drug administration)
EMTREE DRUG INDEX TERMS
activated carbon (drug therapy)
adenosine triphosphate (drug therapy)
ascorbic acid (drug therapy)
coenzyme A (drug therapy)
immunoglobulin (drug therapy, intravenous drug administration)
podophyllotoxin (drug analysis, drug therapy, drug toxicity, intragastric
drug administration, intraperitoneal drug administration, subcutaneous drug
administration)
unclassified drug
EMTREE MEDICAL INDEX TERMS
acupuncture
atrial fibrillation (drug therapy, therapy)
blood clotting disorder (drug therapy, therapy)
cardiotoxicity
central nervous system disease
chemical composition
Chinese medicine
clinical feature
condyloma acuminatum (drug therapy)
dermatitis
drug efficacy
drug overdose
drug structure
Dysosma versipallis
fluid resuscitation
gastrointestinal toxicity
hemodialysis
herbal medicine
high performance liquid chromatography
histopathology
human
intoxication (drug therapy, therapy)
LD50
medicinal plant
myocarditis
nonhuman
review
rhizome
stomach lavage
thin layer chromatography
thrombocyte transfusion
toxicity testing
CAS REGISTRY NUMBERS
activated carbon (64365-11-3, 82228-96-4)
adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
coenzyme A (85-61-0)
immunoglobulin (9007-83-4)
podophyllotoxin (518-28-5)
EMBASE CLASSIFICATIONS
Drug Literature Index (37)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010330621
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 373
TITLE
Impact of aerobic physical activity on cardiovascular and noncardiovascular
outcomes: Is anyone too old to exercise?
AUTHOR NAMES
Sawyer K.
Castaneda-Sceppa C.
AUTHOR ADDRESSES
(Sawyer K., sawyer.k@husky.neu.edu; Castaneda-Sceppa C., c.sceppa@neu.edu)
Bouve College of Health Sciences, Northeastern University, 360 Huntington
Avenue, Boston, MA 02115, United States.
CORRESPONDENCE ADDRESS
C. Castaneda-Sceppa, Bouve College of Health Sciences, Northeastern
University, 360 Huntington Avenue, Boston, MA 02115, United States. Email:
c.sceppa@neu.edu
SOURCE
Aging Health (2010) 6:2 (251-260). Date of Publication: April 2010
ISSN
1745-509X
1745-5103 (electronic)
BOOK PUBLISHER
Future Medicine Ltd., 2nd Albert Place, Finchley Central, London, United
Kingdom.
ABSTRACT
The aim of this review is to discuss the impact of physical activity on
cardiovascular and noncardiovascular outcomes in the older adult population.
While age, gender and family history are nonmodifiable risk factors of
cardiovascular disease, physical inactivity is a modifiable risk factor at
all ages. Regular physical activity throughout life is a key component in
reducing chronic diseases such as cardiovascular disease. This review
specifically emphasizes walking as the preferred modality of physical
activity, since it is known to have an effect on the traditional and
nontraditional risk factors of cardiovascular disease. © 2010 Future
Medicine Ltd.
EMTREE DRUG INDEX TERMS
C reactive protein (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aerobic exercise
cardiovascular disease
physical activity
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
body composition
cardiovascular risk
cerebrovascular accident
chronic inflammation
dyslipidemia
energy expenditure
exercise intensity
functional status
glycemic control
health promotion
human
hypertension
impaired glucose tolerance
insulin resistance
ischemic heart disease
lifestyle modification
mortality
obesity
prognosis
review
risk reduction
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010193606
FULL TEXT LINK
http://dx.doi.org/10.2217/ahe.10.10
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 374
TITLE
Heart and athlete
AUTHOR NAMES
Alasti M.
Omidvar B.
Jadbabaei M.H.
AUTHOR ADDRESSES
(Alasti M., alastip@gmail.com) Department of Cardiology, Jondishpour
University of Medical Sciences, Imam Khomeini Hospital, Azadegan Avenue,
Ahwaz, Iran.
(Omidvar B.; Jadbabaei M.H.) Golestan Hospital, Jondishapour University of
Medical Sciences, Ahwaz, Iran.
CORRESPONDENCE ADDRESS
M. Alasti, Department of Cardiology, Jondishpour University of Medical
Sciences, Imam Khomeini Hospital, Azadegan Avenue, Ahwaz, Iran. Email:
alastip@gmail.com
SOURCE
Journal of Tehran University Heart Center (2010) 5:1 (1-8). Date of
Publication: 2010
ISSN
1735-8620
BOOK PUBLISHER
Tehran University of Medical Sciences, North Kargar Street, Tehran, Iran.
ABSTRACT
Regular participation in intensive physical exercise is associated with
electro-morphological changes in the heart. This benign process is called
athlete's heart. Athlete's heart resembles few pathologic conditions in some
aspects. So differentiation of these conditions is very important which
otherwise may lead to a catastrophic event such as sudden death. The most
common causes of sudden death in young athletes are cardiomyopathies,
congenital coronary anomalies, and ion channelopathies. The appropriate
screening strategy to prevent sudden cardiac death in athletes remains a
challenging issue. The purpose of this review is to describe the
characteristics of athlete's heart and demonstrate how to differentiate it
from pathologic conditions that can cause sudden death.
EMTREE DRUG INDEX TERMS
amino terminal pro brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athletic heart syndrome
heart disease
EMTREE MEDICAL INDEX TERMS
anamnesis
angiocardiography
athlete
atrial fibrillation
cardiac patient
cardiovascular disease (epidemiology)
cardiovascular risk
cause of death
commotio cordis
computed tomographic angiography
congestive cardiomyopathy (diagnosis)
coronary artery anomaly (diagnosis)
diagnostic value
differential diagnosis
Doppler echocardiography
ECG abnormality
electrocardiogram
exercise
faintness
first degree atrioventricular block
functional assessment
heart arrhythmia
heart death (epidemiology)
heart function
heart left ventricle hypertrophy (diagnosis)
heart muscle oxygen consumption
heart right bundle branch block
heart right ventricle dysplasia (diagnosis)
heart size
heart stress
heart ventricle tachycardia
high risk population
human
hypertrophic cardiomyopathy (diagnosis)
incidence
nuclear magnetic resonance imaging
patient participation
physical examination
presyncope
prevalence
Q wave
QRS complex
review
screening test
second degree atrioventricular block
sinus bradycardia (diagnosis)
sport
ST segment elevation
sudden death
T wave inversion
training
Wolff Parkinson White syndrome
EMBASE CLASSIFICATIONS
Radiology (14)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010096249
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 375
TITLE
Atrial fibrillation in athletes - The story behind the running hearts
AUTHOR NAMES
Li S.
Zhang Z.
Scherlag B.J.
Po S.S.
AUTHOR ADDRESSES
(Li S.) Department of Cardiology, Yun-Nan St. John Cardiology Hospital,
Yun-Nan, China.
(Zhang Z.) Department of Cardiology, Third Xiangya Hospital, Central South
University, HuNan, China.
(Scherlag B.J.; Po S.S., sunny-po@ouhsc.edu) Heart Rhythm Research
Institute, Department of Medicine, University of Oklahoma Health Sciences
Center, Oklahoma City, OK, United States.
CORRESPONDENCE ADDRESS
S. S. Po, Heart Rhythm Research Institute, Department of Medicine,
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United
States. Email: sunny-po@ouhsc.edu
SOURCE
Journal of Atrial Fibrillation (2010) 1:11 (626-631). Date of Publication:
March 2010
ISSN
1941-6911 (electronic)
BOOK PUBLISHER
CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation (drug therapy, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
autonomic nervous system
clinical feature
endurance
exercise
heart atrium enlargement
heart left ventricle ejection fraction
heart muscle refractory period
human
incidence
inflammation
nonhuman
review
sinus rhythm
training
vagus tone
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2010278189
FULL TEXT LINK
http://dx.doi.org/10.4022/jafib.v1i11.563
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 376
TITLE
Obesity and preclinical changes of cardiac geometry and function
AUTHOR NAMES
Sung J.K.
Kim J.-Y.
AUTHOR ADDRESSES
(Sung J.K.; Kim J.-Y., kimjy@yonsei.ac.kr) Department of Internal Medicine,
Wonju Christian Hospital, Yonsei University, 162 Ilsan-dong, Wonju 220-701,
South Korea.
(Kim J.-Y., kimjy@yonsei.ac.kr) Institute of Genomic Cohort, Yonsei
University, Wonju College of Medicine, Wonju, South Korea.
CORRESPONDENCE ADDRESS
J.-Y. Kim, Department of Internal Medicine, Wonju Christian Hospital, Yonsei
University, 162 Ilsan-dong, Wonju 220-701, South Korea. Email:
kimjy@yonsei.ac.kr
SOURCE
Korean Circulation Journal (2010) 40:2 (55-61). Date of Publication:
February 2010
ISSN
1738-5520
1738-5555 (electronic)
BOOK PUBLISHER
Korean Society of Circulation, 553 Dowha-dong, Mapo-gu, Seoul, South Korea.
ABSTRACT
Overweight and obesity are rapidly increasing in prevalence due to adoption
of the westernized life style in Korea. Obesity is strongly associated with
the development of cardiovascular risk factors such as diabetes,
hypertension, and dyslipidemia. In addition, accumulating evidence suggests
that obesity per se has a direct effect on cardiac functional and structural
changes that may not be the result of atherosclerosis. In this review, we
focus on the view that obesity can influence on the structural and
functional changes of the heart, drawing evidence from human and animal
studies. We also review influencing factors such as physical, neurohormonal,
and metabolic alterations that are associated with changes of the heart in
obesity. Copyright © 2010 The Korean Society of Cardiology.
EMTREE DRUG INDEX TERMS
adenosine triphosphate (endogenous compound)
adipocytokine (endogenous compound)
adiponectin (endogenous compound)
angiotensinogen (endogenous compound)
C reactive protein (endogenous compound)
catecholamine (endogenous compound)
CD36 antigen (endogenous compound)
fatty acid (endogenous compound)
fatty acid transporter (endogenous compound)
fatty acid transporter protein 1 (endogenous compound)
gelatinase A (endogenous compound)
interleukin 1beta (endogenous compound)
interleukin 6 (endogenous compound)
leptin (endogenous compound)
monocyte chemotactic protein 1 (endogenous compound)
neurohormone (endogenous compound)
peroxisome proliferator activated receptor gamma (endogenous compound)
reactive oxygen metabolite (endogenous compound)
rimonabant
sibutramine
somatomedin C (endogenous compound)
somatomedin C receptor (endogenous compound)
tetrahydrolipstatin
tissue inhibitor of metalloproteinase (endogenous compound)
tumor necrosis factor alpha (endogenous compound)
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart function
heart size
obesity
EMTREE MEDICAL INDEX TERMS
adipocyte
adipose tissue
apoptosis
atrial fibrillation
blood volume
body mass
collagen synthesis
diet
disorders of mitochondrial functions
echocardiography
epicardial adipose tissue
extracellular matrix
fatty acid oxidation
fibrosis
glucose metabolism
heart atrium enlargement
heart left atrium
heart left ventricle contraction
heart left ventricle filling
heart left ventricle hypertrophy
heart left ventricle mass
heart muscle cell
heart muscle metabolism
heart muscle oxygen consumption
heart output
heart ventricle overload
heart ventricle remodeling
hemodynamics
human
hyperinsulinemia
hyperlipidemia
hypertension
hypoxemia
insulin resistance
oxidative stress
oxygen consumption
protein blood level
protein expression
renin angiotensin aldosterone system
review
sleep disordered breathing
thorax pressure
weight reduction
CAS REGISTRY NUMBERS
C reactive protein (9007-41-4)
adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
adiponectin (283182-39-8)
angiotensinogen (11002-13-4, 64315-16-8)
gelatinase A (146480-35-5)
rimonabant (158681-13-1, 168273-06-1)
sibutramine (106650-56-0)
somatomedin C (67763-96-6)
tetrahydrolipstatin (96829-58-2)
tissue inhibitor of metalloproteinase (97837-28-0)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Immunology, Serology and Transplantation (26)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010169944
FULL TEXT LINK
http://dx.doi.org/10.4070/kcj.2010.40.2.55
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 377
TITLE
Abstracts - Belgian Society of Cardiology 29th Annual Scientific Meeting
AUTHOR ADDRESSES
SOURCE
Acta Cardiologica (2010) 65:1. Date of Publication: February 2010
CONFERENCE NAME
29th Annual Scientific Meeting of the Belgian Society of Cardiology
CONFERENCE LOCATION
Brussels, Belgium
CONFERENCE DATE
2010-01-28 to 2010-01-30
ISSN
0001-5385
BOOK PUBLISHER
Acta Cardiologica
ABSTRACT
The proceedings contain 66 papers. The topics discussed include: clinical
characteristics and 1-year outcome of patients aged 75 years or older
hospitalised for heart failure; pulmonary vein isolation with the high
density mesh ablation catheter: acute results and long-term clinical
outcome; triggering pulmonary veins: a paradoxical predictor for atrial
fibrillation recurrence after PV isolation; BNP as a predictive factor of
recurrence of atrial fibrillation after external electrical cardioversion;
microvolt T-wave alternans in risk stratification of patients with ischemic
and nonischemic dilated cardiomyopathy: can it help to better select
candidates for lCD implantation? first experience of a single Belgian
centre; prospective randomized comparison between conventional
electroanatomical system and 3D rotational angiography during catheter
ablation for atrial fibrillation; Effects of pharmacologic 2-adrenergic
blockade and 2-adrenergic stimulation on exercise capacity in normal
subjects.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiology
society
EMTREE MEDICAL INDEX TERMS
adrenergic receptor blocking
adrenergic stimulation
angiography
atrial fibrillation
cardioversion
catheter
catheter ablation
congestive cardiomyopathy
density
exercise
heart failure
implantation
patient
pulmonary vein
risk
stratification
T wave
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 378
TITLE
Heart Failure in NCVC Jakarta and 5 hospitals in Indonesia
AUTHOR NAMES
Siswanto B.B.
Radi B.
Kalim H.
Santoso A.
Suryawan R.
Erwinanto
Antono E.
Santoso T.
AUTHOR ADDRESSES
(Siswanto B.B., bambbs@cbn.net.id; Radi B.; Kalim H.) Department of
Cardiology and Vascular Medicine, University of Indonesia, Indonesia.
(Santoso A.) Indonesia and Department of Cardiology and Vascular Medicine,
University Udayana, Sanglah Hospital Denpasar Bali, Indonesia.
(Suryawan R.) Department of Cardiology and Vascular Medicine, University
Airlangga Dr Sutomo Hospital, Surabaya, Indonesia.
(Erwinanto; Antono E.) Department of Cardiology, Vascular Medicine
University Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
(Santoso T.) Medistra Hospital Jakarta, Indonesia.
CORRESPONDENCE ADDRESS
B. B. Siswanto, Department of Cardiology and Vascular Medicine, University
of Indonesia, Indonesia. Email: bambbs@cbn.net.id
SOURCE
CVD Prevention and Control (2010) 5:1 (35-38). Date of Publication: January
2010
ISSN
1875-4570
BOOK PUBLISHER
Elsevier, P.O. Box 211, Amsterdam, Netherlands.
ABSTRACT
Indonesia is an archipelago consisting of 17,000 islands (6000 inhabited) to
spanning by the equator in South East Asia. The total area is 741,096 sq mil
(1,919,440 km sq). The population in 2005 was 241,973,879, with a population
growth rate of 1.5%, a birth rate of 20.7/1000 population and a life
expectancy of 69.6 years. There are 1246 hospitals in Indonesia, of which
49.8% are in private hospitals and 50.5% are located in Java. There is a
total of 132,231 beds or one hospital bed per 1628 population. In 2005 we
did a pilot cohort study of 100 consecutive new cases of Acute Decompensated
Heart Failure (ADHF) at NCVC Jakarta to search for predictors of mortality
and re-hospitalization. We found the independent predictors for mortality
and re-hospitalization are high NT proBNP at entry, NT proBNP at discharge,
not decreased >35% during hospitalization, NYHA functional class 4, edema
with a BMI >30 kg/m (2), ejection fraction <20%, acute pulmonary edema, not
on a beta-blocker, hemoglobin <12 g/dl and Hyponatremia <130 mmol/L. More
than 78% using ACEI/ARB, diuretic and aldosterone antagonist, but only 32%
using beta-blocker. In 2006, we conducted an Acute Decompensated Heart
Failure Registry (ADHERE) with the participation of five hospitals including
National Cardiovascular Center (NCVC) Jakarta, the top cardiovascular
referral hospital. In total, there were 1687 patients admitted with ADHF.
The mean age was 60 years and male patients were 64.5%. Compared to other
countries, our heart failure patients were younger, had more severe symptoms
and there were more new patients (de novo acute ADHF). Hypertension (54.8%),
coronary artery disease (49.9%), diabetes (31.2%), myocardial infarction
(23.3%) and atrial fibrillation (14.6%) are the leading etiologies of our
ADHF patients. There were 62.7% patients with ejection fraction (EF) <40%
and the mean EF was 33%. The median hospital length of stay was 7.1 days and
the hospital mortality was 6.7% [15]. In NCVC Jakarta, compliance with
medical evaluation and drugs and diets are the predictors of
hospitalizations. There were 47%, non compliant patients and the survival
probability at 5 years was only 54%. The 5 year predictors of mortality are
poor EF, Diabetes and male gender. The 5 year survival of males with poor EF
and Diabetes was only 36%. Among socio-economic factors, only 33.5% had
health insurance and 54.5% lived >20 km from hospital [16]. There are
increasing numbers of hospitalized heart failure patients in NCVC Jakarta.
In 2007 there were 1409 patients and an increase in 2008 to 1476 hospital
admissions. Also there has been an increase in in-hospital morality to
around 12 %. Conclusion: Heart failure is a leading cause of hospitalization
and readmission in NCVC. Indonesian heart failure patients were younger,
sicker, with a poor EF and Diabetes compared to others. The in-hospital
mortality ranges from 6% to 12% and the re-hospitalization rate is 29%. Poor
compliance, poor EF and Diabetes are the predictor for readmission. Health
insurance improves survival probability. There is a need for better heart
failure services. © 2010 World Heart Federation. Published by Elsevier Ltd.
All rights reserved.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, disease management, drug therapy, epidemiology,
etiology)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
Asia
atrial fibrillation
birth rate
cohort analysis
controlled study
coronary artery disease
diabetes mellitus
disease registry
female
health insurance
heart ejection fraction
heart infarction
hospital admission
hospital bed
hospital charge
hospital readmission
hospitalization
human
hypertension
hyponatremia
Indonesia
length of stay
life expectancy
lung edema
major clinical study
male
medical assessment
morality
mortality
patient compliance
patient referral
population growth
priority journal
private hospital
probability
survival rate
symptom
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Internal Medicine (6)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010503382
FULL TEXT LINK
http://dx.doi.org/10.1016/j.cvdpc.2010.03.005
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 379
TITLE
Thrombi of different pathologies: Implications for diagnosis and treatment
AUTHOR NAMES
Santos-Gallego C.G.
Bayón J.
Badimón J.J.
AUTHOR ADDRESSES
(Santos-Gallego C.G.; Badimón J.J., juan.badimon@mssm.edu) Atherothrombosis
Research Unit, Zena and Michael A. Wiener Cardiovascular Institute, Mount
Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, United
States.
(Bayón J.) Cardiology Department, Hospital Central de Asturias, Oviedo,
Spain.
CORRESPONDENCE ADDRESS
J. J. Badimón, Atherothrombosis Research Unit, Zena and Michael A. Wiener
Cardiovascular Institute, Mount Sinai School of Medicine, 1 Gustave Levy
Place, New York, NY 10029, United States. Email: juan.badimon@mssm.edu
SOURCE
Current Treatment Options in Cardiovascular Medicine (2010) 12:3 (274-291).
Date of Publication: June 2010
ISSN
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Stroke is the second leading cause of cardiovascular mortality in the modern
world, accounting for 80% of strokes of ischemic origin. There are two main
etiologies of ischemic stroke: 70% to 80% are caused by carotid
atherosclerotic plaque rupture and superimposed thrombus formation, whereas
30% are caused by systemic embolism of a cardiac thrombus (mainly in atrial
fibrillation [AF] patients). Therefore, antithrombotic therapy is the
cornerstone of stroke treatment. In AF patients, thrombotic risk should be
assessed by means of the CHADS2 score. Patients with a score of 0 should be
treated with aspirin; for those with a score of 1, oral anticoagulation
(target international normalized ratio, 2-3) or aspirin is recommended. For
patients with a CHADS2 score ≥2, oral anticoagulation with warfarin should
be initiated (unless contraindicated). If warfarin is contraindicated,
antithrombotic treatment should be prescribed (the combination of aspirin
and clopidogrel seems to be superior to aspirin alone). For primary
prevention in atherosclerotic patients, low-dose aspirin is useful only in
women older than 45 years who are not at risk for intracranial hemorrhage
and do not have gastrointestinal intolerance (a very small but significant
effect). For secondary prevention in atherosclerotic patients,
antithrombotic therapy should be administered. It is recommended that
patients who do not require anticoagulation receive clopidogrel or a
combination of aspirin and dipyridamole. Alternatively, aspirin alone or
triflusal may be used. Within 4.5 h of onset of acute stroke, thrombolytic
therapy (recombinant tissue plasminogen activator) must be injected urgently
(unless contraindicated). Dabigatran is a new oral anticoagulant
(competitive thrombin inhibitor) with a promising role in stroke prevention;
at low doses, it is noninferior to warfarin for stroke prevention and is
safer, whereas at high doses, it is superior to warfarin in stroke
prevention with the same incidence of bleeding. Percutaneous left atrial
appendage occluders recently were approved for systemic embolism prevention.
The use of warfarin after implantation is still under discussion.
Dronedarone, a new antiarrhythmic agent, has been shown to decrease
cardiovascular mortality and stroke in patients with AF. Carotid
endarterectomy surgery is indicated in symptomatic patients with stenosis
greater than 70% and in selected patients with 50% to 70% stenosis.
Currently, carotid endarterectomy surgery is superior to carotid angioplasty
and stenting. © Springer Science+Business Media, LLC 2010.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (clinical trial, drug therapy, pharmacoeconomics,
pharmacology)
antithrombocytic agent (clinical trial, drug therapy, pharmacoeconomics,
pharmacology)
fibrinolytic agent (clinical trial, drug therapy, pharmacoeconomics,
pharmacology)
EMTREE DRUG INDEX TERMS
acetazolamide (drug interaction)
acetylsalicylic acid (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug interaction, drug therapy,
pharmacoeconomics, pharmacology)
alteplase (adverse drug reaction, clinical trial, drug therapy, intravenous
drug administration, pharmacology)
antidiabetic agent (drug interaction)
apixaban (drug comparison, drug therapy)
beta adrenergic receptor blocking agent (drug interaction)
cilostazol (drug comparison, drug therapy)
clopidogrel (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug interaction, drug therapy, pharmacoeconomics, pharmacology)
dabigatran (clinical trial, drug comparison, drug therapy, pharmacology)
dabigatran etexilate (adverse drug reaction, drug comparison, drug dose,
drug therapy, oral drug administration)
dipyridamole (adverse drug reaction, clinical trial, drug combination, drug
interaction, drug therapy, pharmacoeconomics, pharmacology)
dronedarone (adverse drug reaction, clinical trial, drug therapy,
pharmacology)
fluoxetine (drug interaction)
irbesartan (drug combination, drug therapy)
ketoconazole (drug interaction)
methotrexate (drug interaction)
nonsteroid antiinflammatory agent (drug interaction)
omeprazole (drug interaction)
placebo
prasugrel (clinical trial, drug comparison, drug therapy)
psychostimulant agent (drug interaction)
rivaroxaban (drug comparison, drug therapy)
terutroban (drug comparison, drug therapy)
tissue plasminogen activator (adverse drug reaction, drug therapy)
unindexed drug
valproic acid (drug interaction)
warfarin (adverse drug reaction, clinical trial, drug comparison, drug
interaction, drug therapy, oral drug administration, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain ischemia (drug therapy, side effect, disease management, drug therapy,
etiology, prevention, side effect, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
angioneurotic edema (side effect)
anticoagulant therapy
asthma
atherosclerosis (drug therapy)
atrial fibrillation (drug therapy)
bleeding (side effect)
bleeding disorder
blood clotting
body mass
brain atherosclerosis
brain edema (side effect)
brain hemorrhage (side effect)
brain hernia (side effect)
bronchospasm (side effect)
cardiovascular disease
cardiovascular risk
carotid angioplasty
carotid artery stenting
carotid artery surgery
carotid atherosclerosis
carotid endarterectomy
catheter ablation
catheter occlusion
cerebrovascular accident (drug therapy)
clinical evaluation
clinical trial
clip
cost effectiveness analysis
creatinine blood level
diet
drug activity
drug contraindication
drug cost
drug efficacy
drug hypersensitivity
drug induced headache (side effect)
drug safety
dyspepsia (side effect)
embolism (drug therapy)
epistaxis (side effect)
exercise
food intake
fruit
gastrointestinal hemorrhage (side effect)
gastrointestinal symptom (side effect)
gout
headache (side effect)
heart atrium appendage
heart atrium flutter (drug therapy)
heart infarction (drug therapy, side effect)
human
hypertension
hypotension
intermethod comparison
international normalized ratio
kidney disease
kidney dysfunction
lifestyle modification
liver disease
liver dysfunction
nausea and vomiting (side effect)
neutropenia (side effect)
peptic ulcer
pregnancy
pruritus (side effect)
purpura (side effect)
rash (side effect)
recanalization
review
risk factor
seizure (side effect)
side effect (side effect)
skin necrosis (side effect)
smoking
smoking cessation
thromboembolism (drug therapy)
thrombosis (drug therapy)
thrombotic thrombocytopenic purpura (side effect)
transient ischemic attack (drug therapy)
treatment contraindication
treatment outcome
treatment planning
unstable angina pectoris
urticaria (side effect)
vasculitis (side effect)
vegetable
virus infection
vitamin supplementation
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetazolamide (1424-27-7, 59-66-5)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alteplase (105857-23-6)
apixaban (503612-47-3)
cilostazol (73963-72-1)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
dronedarone (141626-36-0)
fluoxetine (54910-89-3, 56296-78-7, 59333-67-4)
irbesartan (138402-11-6)
ketoconazole (65277-42-1)
methotrexate (15475-56-6, 59-05-2, 7413-34-5)
omeprazole (73590-58-6, 95510-70-6)
prasugrel (389574-19-0, 150322-43-3)
rivaroxaban (366789-02-8)
terutroban (165537-73-5, 165538-40-9, 609340-89-8)
tissue plasminogen activator (105913-11-9)
valproic acid (1069-66-5, 99-66-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Internal Medicine (6)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010330925
FULL TEXT LINK
http://dx.doi.org/10.1007/s11936-010-0075-8
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 380
TITLE
Omega-3 fatty acids for cardiovascular disease prevention
AUTHOR NAMES
DeFilippis A.P.
Blaha M.J.
Jacobson T.A.
AUTHOR ADDRESSES
(DeFilippis A.P., APDeF@yahoo.com; Blaha M.J.; Jacobson T.A.) Johns Hopkins
Ciccarone Center, Prevention of Heart Disease, 600 North Wolfe Street,
Carnegie 568, Baltimore, MD 21224, United States.
CORRESPONDENCE ADDRESS
A. P. DeFilippis, Johns Hopkins Ciccarone Center, Prevention of Heart
Disease, 600 North Wolfe Street, Carnegie 568, Baltimore, MD 21224, United
States. Email: APDeF@yahoo.com
SOURCE
Current Treatment Options in Cardiovascular Medicine (2010) 12:4 (365-380).
Date of Publication: August 2010
ISSN
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Major dietary sources of omega-3 fatty acids are fish containing
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as nuts,
seeds, and vegetable oils containing α-linolenic acid (ALA). Omega-3 fatty
acids, especially those derived from marine sources, may be a useful tool
for the primary and secondary prevention of cardiovascular disease. Omega-3s
exert their cardioprotective effects through multiple mechanisms, including
reducing arrhythmias and altering production of prostaglandins, which
reduces inflammation and improves platelet and endothelial function. To
date, no serious adverse effects of omega-3s have been identified, despite
extensive study. In adults, any potential harm from mercury exposure from
consuming fish rich in omega-3s is outweighed by the proven cardiovascular
benefits of eating fish. Concerns over increased bleeding complications have
not materialized despite the increased concomitant use of aspirin and
clopidogrel. We recommend one serving (200-400 g) of fatty fish two times
per week and a diet that includes foods rich in ALA for the primary
prevention of cardiovascular disease. We recommend one serving (200-400 g)
of fatty fish or a fish oil supplement containing 900 mg of EPA + DHA every
day and a diet rich in ALA for patients with known cardiovascular disease or
congestive heart failure. © Springer Science+Business Media, LLC 2010.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
omega 3 fatty acid (adverse drug reaction, clinical trial, drug combination,
drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination)
alpha tocopherol (drug combination, drug therapy)
atorvastatin (drug combination, drug therapy)
C reactive protein (endogenous compound)
clopidogrel (drug combination)
dioxin
docosahexaenoic acid (drug combination)
fish oil (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug
combination, drug therapy)
icosapentaenoic acid (clinical trial, drug combination, drug therapy)
interleukin 6 (endogenous compound)
linolenic acid
methylmercury
placebo
polychlorinated biphenyl
simvastatin (drug combination, drug therapy)
stromelysin (endogenous compound)
thromboxane A2 (endogenous compound)
tumor necrosis factor alpha (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
adjuvant therapy
antiinflammatory activity
article
atrial fibrillation (drug therapy, prevention)
bleeding (side effect)
clinical trial
congestive heart failure
contaminated fish
defibrillator
diet supplementation
dietary reference intake
fatty acid metabolism
gastrointestinal symptom (side effect)
heart arrhythmia
heart failure (drug therapy)
heart protection
human
hypercholesterolemia (drug therapy)
hypertriglyceridemia (drug therapy)
ischemic heart disease (prevention)
Mediterranean diet
primary prevention
secondary prevention
telomere
thrombocyte aggregation inhibition
water pollutant
DRUG TRADE NAMES
lovaza , United StatesGlaxo SmithKline
DRUG MANUFACTURERS
(United States)Glaxo SmithKline
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
atorvastatin (134523-00-5, 134523-03-8)
C reactive protein (9007-41-4)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
docosahexaenoic acid (25167-62-8, 32839-18-2)
fish oil (8016-13-5)
icosapentaenoic acid (25378-27-2, 32839-30-8)
linolenic acid (1955-33-5, 463-40-1)
methylmercury (16056-34-1, 593-74-8)
simvastatin (79902-63-9)
stromelysin (79955-99-0)
thromboxane A2 (57576-52-0)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00127452)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010688790
FULL TEXT LINK
http://dx.doi.org/10.1007/s11936-010-0079-4
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 381
TITLE
Highlights of the 2009 Scientific Sessions of the Heart Failure Society of
America, Boston, MA, September 13-16, 2009
AUTHOR NAMES
O'Connor C.M.
Koch W.J.
Mann D.L.
AUTHOR ADDRESSES
(O'Connor C.M., oconn@mc.duke.edu) Duke University Medical Center, Durham,
NC, United States.
(Koch W.J.) Thomas Jefferson University, Jefferson Medical College,
Philadelphia, PA, United States.
(Mann D.L.) Washington University School of Medicine, St. Louis, MO, United
States.
CORRESPONDENCE ADDRESS
C.M. O'Connor, Duke University Medical Center, Durham, NC, United States.
Email: oconn@mc.duke.edu
SOURCE
Journal of Cardiac Failure (2010) 16:1 (2-8). Date of Publication: January
2010
ISSN
1071-9164
1532-8414 (electronic)
BOOK PUBLISHER
Churchill Livingstone Inc., 650 Avenue of the Americas, New York, United
States.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (clinical trial, drug therapy)
amiodarone (clinical trial, drug therapy)
anthracycline derivative (adverse drug reaction, clinical trial, drug
therapy)
anticoagulant agent (clinical trial, drug therapy)
beta adrenergic receptor blocking agent (clinical trial, drug combination,
drug therapy)
biological marker (endogenous compound)
digoxin (clinical trial, drug combination, drug therapy)
dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
diuretic agent (clinical trial, drug therapy, intravenous drug
administration)
dopamine (clinical trial, drug combination, drug therapy)
furosemide (clinical trial, drug combination, drug therapy)
G protein coupled receptor kinase (endogenous compound)
galectin 3 (endogenous compound)
hydralazine (clinical trial, drug therapy)
irbesartan (clinical trial, drug therapy)
isosorbide dinitrate (clinical trial, drug therapy)
metoprolol (clinical trial, drug therapy)
placebo
rolofylline (adverse drug reaction, clinical trial, drug therapy)
vardenafil (drug therapy, pharmacology)
warfarin (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, diagnosis, drug therapy, etiology, prevention,
surgery, therapy)
EMTREE MEDICAL INDEX TERMS
acute heart failure (drug therapy)
acute heart failure (drug therapy)
acute heart failure (drug therapy)
anticoagulation
atrial fibrillation (drug therapy)
cancer radiotherapy
cancer therapy
cardiac resynchronization therapy
cardiomyopathy (drug therapy)
cardiotoxicity (side effect)
cardiovascular effect
cardiovascular risk
cell therapy
cerebrovascular accident (side effect)
childhood cancer (drug therapy, radiotherapy)
clinical research
clinical trial
comparative study
congestive cardiomyopathy (drug therapy)
congestive heart failure (etiology, therapy)
death
defibrillator
Dressler syndrome (drug therapy, therapy)
drug effect
drug megadose
drug safety
evidence based practice
exercise
fibrosis
health education
heart arrhythmia (drug therapy)
heart atrium arrhythmia (therapy)
heart catheterization
heart left ventricle ejection fraction
heart muscle perfusion
heart ventricle arrhythmia (therapy)
hospital patient
hospitalization
human
hydrothorax
hypertension
implantation
kidney disease (drug therapy)
low drug dose
medical personnel
medical research
medical society
medicine
mortality
myoblast
North America
outpatient care
patient education
patient monitoring
priority journal
prognosis
protein expression
renal protection
review
scientific literature
seizure (side effect)
thromboembolism (drug therapy, prevention)
United States
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digoxin (20830-75-5, 57285-89-9)
dopamine (51-61-6, 62-31-7)
furosemide (54-31-9)
galectin 3 (208128-56-7)
hydralazine (304-20-1, 86-54-4)
irbesartan (138402-11-6)
isosorbide dinitrate (87-33-2)
metoprolol (37350-58-6)
rolofylline (136199-02-5)
vardenafil (224785-90-4, 224785-91-5, 224789-15-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2009661975
FULL TEXT LINK
http://dx.doi.org/10.1016/j.cardfail.2009.11.001
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 382
TITLE
Disease management programs for heart failure
AUTHOR NAMES
McDonald K.
AUTHOR ADDRESSES
(McDonald K., Kenneth.mcdonald@ucd.ie) Heart Failure Unit, St. Vincent's
University Hospital, Dublin, Ireland.
CORRESPONDENCE ADDRESS
K. McDonald, Heart Failure Unit, St. Vincent's University Hospital, Dublin,
Ireland. Email: Kenneth.mcdonald@ucd.ie
SOURCE
Current Treatment Options in Cardiovascular Medicine (2010) 12:6 (578-586).
Date of Publication: December 2010
ISSN
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Opinion statement: The impact of the very significant advances in the
management of heart failure over the past several decades had been limited
by a lack of appropriate infrastructure for heart failure care delivery in
the community. The development of disease management programs has brought
about significant advances in ensuring improved care of the wider heart
failure population, allowing for effective prescription of proven
strategies, structured follow-up, and education of patients and families to
encourage involvement in self-care. The impact of these programs on
reduction in hard cardiovascular endpoints, including death and heart
failure rehospitalization, has been substantial. Continued research aims to
optimize this strategy in terms of what additional aspects are necessary to
enhance this approach. From recent work, it is clear that heart failure
patients may derive incremental benefit from exercise programs as an
adjunctive therapy; additional work is required to address how we should use
the rapidly developing home telemonitoring technologies. © 2010 Springer
Science+Business Media, LLC.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (drug therapy)
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
candesartan (drug therapy)
hydralazine plus isosorbide dinitrate (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
Pneumococcus vaccine
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
adjuvant therapy
atrial fibrillation (drug therapy)
clinical effectiveness
exercise
exercise intensity
family counseling
health care cost
home care
hospitalization
human
medicare
mortality
non invasive measurement
patient attitude
patient compliance
patient education
quality of life
review
self care
survival time
teleconsultation
telemonitoring
treadmill exercise
treatment outcome
walking
CAS REGISTRY NUMBERS
candesartan (139481-59-7)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010673755
FULL TEXT LINK
http://dx.doi.org/10.1007/s11936-010-0094-5
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 383
TITLE
Ventricular rhythm in atrial fibrillation under anaesthetic infusion with
propofol
AUTHOR NAMES
Cervigón R.
Moreno J.
Reilly R.B.
Pérez-Villacastín J.
Castells F.
AUTHOR ADDRESSES
(Cervigón R., raquel.cervigon@uclm.es) Escuela Universitaria Politécnica,
Campus Universitario, Group of Bioengineering Innovation (GIBI), Camino del
Pozuelo sn. 16071, Spain.
(Moreno J.; Pérez-Villacastín J.) Unidad de Arritmias, Hospital Clínico San
Carlos, Plaza de Cristo Rey sn, Madrid, 28040, Spain.
(Reilly R.B.) Trinity Centre for Bioengineering, Trinity College Dublin,
Dublin 2, Ireland.
(Castells F.) Universidad Politécnica de Valencia, Bioengineering Electronic
Telemedicine (BET), DIE, Camino de la Vera sn., Valencia, 46022, Spain.
CORRESPONDENCE ADDRESS
R. Cervigón, Escuela Universitaria Politécnica, Campus Universitario, Group
of Bioengineering Innovation (GIBI), Camino del Pozuelo sn. 16071, Spain.
Email: raquel.cervigon@uclm.es
SOURCE
Physiological Measurement (2009) 30:8 (833-845). Date of Publication: 2009
ISSN
0967-3334
1361-6579 (electronic)
BOOK PUBLISHER
Institute of Physics Publishing, Temple Circus, Temple Way, Bristol, United
Kingdom.
ABSTRACT
Changes in patients' autonomic tone and specific pharmacologic interventions
may modify the ventricular response (actual heart rate) during atrial
fibrillation (AF). Hypnotic agents such as propofol may modify autonomic
balance as they promote a sedative state. It has been shown that propofol
slightly slows atrial fibrillatory activity, but the net global effect on
the ventricular response remains unknown. We aimed to evaluate in patients
in AF the effect of a propofol bolus on the ventricular rate and regularity
at ECG. We analysed the possible relation with local atrial fibrillatory
activities, as ratios between atrial and ventricular rates (AVRs), analysing
atrial activity from intracardiac electrograms at the free wall of the right
and left atria and at the interatrial septum. We compared data at the
baseline and after complete hypnosis. Propofol was associated with a more
homogeneous ventricular response and lower AVR values at the interatrial
septum. © 2009 Institute of Physics and Engineering in Medicine.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
propofol (drug therapy, intravenous drug administration, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anesthesia induction
atrial fibrillation (drug therapy, drug therapy)
heart rate
heart rhythm
EMTREE MEDICAL INDEX TERMS
adult
article
controlled study
drug effect
electrocardiography
female
heart atrium septum
heart ventricle function
human
male
priority journal
CAS REGISTRY NUMBERS
propofol (2078-54-8)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009580487
MEDLINE PMID
19590112 (http://www.ncbi.nlm.nih.gov/pubmed/19590112)
FULL TEXT LINK
http://dx.doi.org/10.1088/0967-3334/30/8/008
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 384
TITLE
Coenzyme Q10 effects in neurodegenerative disease
AUTHOR NAMES
Spindler M.
Flint Beal M.
Henchcliffe C.
AUTHOR ADDRESSES
(Spindler M., mes9051@nyp.org; Flint Beal M.; Henchcliffe C.) Department of
Neurology, Weill Medical College, Cornell University, 525 East 68th Street,
New York, NY, United States.
(Flint Beal M.; Henchcliffe C.) Department of Neuroscience, Weill Medical
College, Cornell University, New York, NY, United States.
CORRESPONDENCE ADDRESS
M. Spindler, Department of Neurology, Weill Medical College, Cornell
University, 525 East 68th Street, New York, NY, United States. Email:
mes9051@nyp.org
SOURCE
Neuropsychiatric Disease and Treatment (2009) 5:1 (597-610). Date of
Publication: 2009
ISSN
1176-6328
1178-2021 (electronic)
BOOK PUBLISHER
DOVE Medical Press Ltd., PO Box 300-008, Albany, Auckland, New Zealand.
ABSTRACT
Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial
respiratory chain, and as a dietary supplement it has recently gained
attention for its potential role in the treatment of neurodegenerative
disease. Evidence for mitochondrial dysfunction in neurodegenerative
disorders derives from animal models, studies of mitochondria from patients,
identification of genetic defects in patients with neurodegenerative
disease, and measurements of markers of oxidative stress. Studies of in
vitro models of neuronal toxicity and animal models of neurodegenerative
disorders have demonstrated potential neuroprotective effects of CoQ10. With
this data in mind, several clinical trials of CoQ10 have been performed in
Parkinson's disease and atypical Parkinson's syndromes, Huntington's
disease, Alzheimer disease, Friedreich's ataxia, and amyotrophic lateral
sclerosis, with equivocal findings. CoQ10 is widely available in multiple
formulations and is very well tolerated with minimal adverse effects, making
it an attractive potential therapy. Phase III trials of high-dose CoQ10 in
large sample sizes are needed to further ascertain the effects of CoQ10 in
neurodegenerative diseases. © 2009 Spindler et al, publisher and licensee
Dove Medical Press Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
ubidecarenone (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug concentration, drug dose, drug interaction, drug therapy,
oral drug administration, pharmaceutics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
creatine (drug combination, drug interaction, drug therapy)
idebenone (clinical trial, drug therapy, pharmacology)
minocycline (drug combination)
placebo
remacemide (drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Alzheimer disease (drug therapy, drug therapy)
amyotrophic lateral sclerosis (drug therapy, drug therapy)
Friedreich ataxia (drug therapy, drug therapy)
Huntington chorea (drug therapy, drug therapy)
Parkinson disease (drug therapy, drug therapy)
progressive supranuclear palsy (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
anxiety
arthralgia (side effect)
atrial fibrillation (side effect)
blood cell count
blood chemistry
clinical trial
coenzyme Q10 deficiency (drug therapy)
coenzyme Q10 deficiency (drug therapy)
constipation (side effect)
coughing (side effect)
degenerative disease (drug therapy)
diarrhea (side effect)
disorders of mitochondrial functions
diverticulosis (side effect)
drug absorption
drug bioavailability
drug blood level
drug delivery system
drug dose escalation
drug efficacy
drug eruption (side effect)
drug formulation
drug induced headache (side effect)
drug megadose
drug response
drug safety
drug structure
drug tolerability
enzyme deficiency (drug therapy)
faintness (side effect)
falling
gallbladder disease (side effect)
gastroesophageal reflux (side effect)
gastrointestinal symptom (side effect)
heartburn (side effect)
human
in vitro study
infection (side effect)
low drug dose
nausea (side effect)
nephrolithiasis (side effect)
neuroprotection
nonhuman
peripheral edema (side effect)
review
side effect (side effect)
structure analysis
suicide attempt (side effect)
upper respiratory tract infection (side effect)
urinalysis
urinary tract infection (side effect)
CAS REGISTRY NUMBERS
creatine (57-00-1)
idebenone (58186-27-9)
minocycline (10118-90-8, 11006-27-2, 13614-98-7)
remacemide (111686-79-4)
ubidecarenone (303-98-0)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
ClinicalTrials.gov (NCT00382824, NCT00608881, NCT00740714)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009601145
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 385
TITLE
Abdominal angina due to recurrence of cancer of the papilla of Vater: A case
report
AUTHOR NAMES
Biolato M.
Gabrieli M.L.
Parente A.
Racco S.
Costantini M.
Bonomo L.
Rapaccini G.L.
Gasbarrini G.
Grieco A.
AUTHOR ADDRESSES
(Biolato M., marcobiolato@alice.it; Gabrieli M.L., letigabri@libero.it;
Parente A., aparente73@libero.it; Racco S., simonaracco@libero.it; Rapaccini
G.L., rapaccini@rm.unicatt.it; Gasbarrini G., ggasbarrini@rm.unicatt.it;
Grieco A., agrieco@rm.unicatt.it) Department of Internal Medicine, Catholic
University of Rome, 8 Largo A Gemelli, Rome 00168, Italy.
(Costantini M., mcostantini@rm.unicatt.it; Bonomo L., lbonomo@rm.unicatt.it)
Department of Radiology, Institute of Internal Medicine, Catholic University
of Rome, 8 Largo A Gemelli, Rome 00168, Italy.
CORRESPONDENCE ADDRESS
A. Grieco, Department of Internal Medicine, Catholic University of Rome, 8
Largo A Gemelli, Rome 00168, Italy. Email: agrieco@rm.unicatt.it
SOURCE
Journal of Medical Case Reports (2009) 3 Article Number: 9314. Date of
Publication: 2009
ISSN
1752-1947
1752-1947 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., 34 - 42 Cleveland Street, London, United Kingdom.
ABSTRACT
Introduction. Abdominal angina is usually caused by atherosclerotic disease,
and other causes are considered uncommon. This is the first report of a case
of abdominal angina secondary to neoplastic vascular stenosis caused by
local recurrence of an adenocarcinoma of the papilla of Vater. Case
presentation. An 80-year-old woman of Caucasian origin presented with
abdominal pain and diarrhea. She had undergone a pancreaticoduodenectomy for
adenocarcinoma of the papilla of Vater four years earlier. Computed
tomography revealed a mass surrounding her celiac trunk and superior
mesenteric artery. Her abdominal pain responded poorly to analgesic drugs,
but disappeared when oral feedings were withheld. A duplex ultrasonography
of the patient's splanchnic vessels was consistent with vascular stenosis.
Parenteral nutrition was started and the patient remained pain free until
her death. Conclusion. Pain relief is an important therapeutic target in
patients with cancer. In this case, abdominal pain was successfully managed
only after the ischemic cause had been identified. The conventional
analgesic therapy algorithm based on nonsteroidal anti-inflammatory drugs
and opioids had been costly and pointless, whereas the simple withdrawal of
oral feeding spared the patient of the discomfort of additional invasive
procedures and allowed her to spend her remaining days in a completely
pain-free state. © 2009 Biolato et al; licensee BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
celecoxib
cocodamol
enoxaparin (drug combination, drug therapy, subcutaneous drug
administration)
esomeprazole
fentanyl (drug therapy, transdermal drug administration)
glyceryl trinitrate (drug combination, drug therapy, transdermal drug
administration)
manidipine
paracetamol (drug therapy, oral drug administration)
scopolamine (drug therapy, intravenous drug administration)
tramadol (drug therapy, oral drug administration)
zofenopril
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
abdominal angina (drug therapy, complication, diagnosis, drug therapy)
cancer recurrence
Vater papilla carcinoma (surgery)
EMTREE MEDICAL INDEX TERMS
abdominal pain (drug therapy)
aged
article
atrial fibrillation (drug therapy)
cancer surgery
case report
Caucasian
computer assisted tomography
diarrhea
Doppler echography
female
human
pancreaticoduodenectomy
parenteral nutrition
priority journal
superior mesenteric artery
Vater papilla
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
celecoxib (169590-42-5)
enoxaparin (9041-08-1)
esomeprazole (119141-88-7, 202742-32-3, 217087-09-7, 217087-10-0)
fentanyl (437-38-7)
glyceryl trinitrate (55-63-0)
manidipine (89226-50-6)
paracetamol (103-90-2)
scopolamine (138-12-5, 51-34-3, 55-16-3)
tramadol (27203-92-5, 36282-47-0)
zofenopril (81872-10-8)
EMBASE CLASSIFICATIONS
Cancer (16)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2010038582
FULL TEXT LINK
http://dx.doi.org/10.1186/1752-1947-3-9314
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 386
TITLE
The use of intravenous aminobisphosphonates for the treatment of Paget's
disease of bone
AUTHOR NAMES
Gennari L.
Merlotti D.
Mossetti G.
Rendina D.
De Paola V.
Martini G.
Nuti R.
AUTHOR ADDRESSES
(Gennari L., gennari@unisi.it) Department of Internal Medicine,
Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Viale
Bracci 1, 53100 Siena, Italy.
(Merlotti D.; Mossetti G.; Rendina D.; De Paola V.; Martini G.; Nuti R.)
CORRESPONDENCE ADDRESS
L. Gennari, Department of Internal Medicine, Endocrine-Metabolic Sciences
and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy.
Email: gennari@unisi.it
SOURCE
Mini-Reviews in Medicinal Chemistry (2009) 9:9 (1052-1063). Date of
Publication: 2009
ISSN
1389-5575
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Paget's disease of bone is a focal skeletal disorder characterized by the
formation of structurally abnormal bone, deformity and other complications
leading to significant disability and bone pain. Recently, the availability
of newer, more potent nitrogen-containing bisphosphonates has improved
treatment outcomes, allowing a more effective and convenient management of
this disorder. © 2009 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
aminobisphosphonic acid derivative (adverse drug reaction, drug analysis,
drug therapy, intravenous drug administration, oral drug administration,
pharmacology)
bisphosphonic acid derivative (adverse drug reaction, drug analysis, drug
comparison, drug therapy, intravenous drug administration, oral drug
administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
alendronic acid (adverse drug reaction, drug analysis, drug therapy, oral
drug administration, pharmacokinetics, pharmacology)
antibiotic agent (drug therapy)
calcitonin (drug comparison, drug therapy, pharmacology, subcutaneous drug
administration)
calcium (drug therapy)
clodronic acid (drug therapy, intravenous drug administration)
etidronic acid (adverse drug reaction, drug comparison, drug therapy, oral
drug administration, pharmacology)
ibandronic acid (drug analysis, drug therapy)
narcotic analgesic agent (drug therapy)
neridronic acid (adverse drug reaction, clinical trial, drug analysis, drug
comparison, drug therapy, intramuscular drug administration, intravenous
drug administration, oral drug administration, pharmacoeconomics,
pharmacology)
pamidronic acid (adverse drug reaction, clinical trial, drug analysis, drug
comparison, drug dose, drug therapy, intravenous drug administration,
pharmacology)
paracetamol (drug therapy)
placebo
risedronic acid (adverse drug reaction, clinical trial, drug analysis, drug
comparison, drug therapy, oral drug administration, pharmacokinetics,
pharmacology)
tiludronic acid (drug comparison, drug therapy)
unclassified drug
vitamin D (drug therapy)
zoledronic acid (adverse drug reaction, clinical trial, drug analysis, drug
comparison, drug dose, drug therapy, intravenous drug administration,
pharmacoeconomics, pharmacology, subcutaneous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Paget bone disease (drug therapy, diagnosis, drug resistance, drug therapy,
epidemiology, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
Albers Schoenberg disease (side effect)
arthritis (drug therapy)
atrial fibrillation (side effect)
bone disease (drug therapy)
bone malformation
bone pain
bone structure
bone turnover
clinical effectiveness
clinical trial
cost effectiveness analysis
creatinine blood level
dosage schedule comparison
drug absorption
drug bioavailability
drug choice
drug dose comparison
drug efficacy
drug mechanism
drug megadose
drug potency
drug safety
drug structure
electrostimulation
esophagus disease (side effect)
fever (side effect)
flu like syndrome (drug therapy, side effect)
gastrointestinal symptom (side effect)
heart arrhythmia (side effect)
hematologic disease (side effect)
human
hyperparathyroidism (drug therapy)
hypocalcemia (drug therapy, side effect)
jaw osteonecrosis (drug therapy, side effect)
kidney dysfunction (side effect)
multiple myeloma (drug therapy)
musculoskeletal pain (side effect)
nephrotoxicity (side effect)
nerve stimulation
nonhuman
osteogenesis imperfecta (drug therapy)
osteomalacia (side effect)
osteoporosis (drug therapy)
patient compliance
physical disability
postmenopause osteoporosis (drug therapy)
prevalence
review
side effect (side effect)
single drug dose
structure activity relation
tachyphylaxis
treatment indication
treatment response
walking aid
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcium (14092-94-5, 7440-70-2)
clodronic acid (10596-23-3, 22560-50-5)
etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
neridronic acid (79778-41-9)
pamidronic acid (40391-99-9, 57248-88-1)
paracetamol (103-90-2)
risedronic acid (105462-24-6, 122458-82-6)
tiludronic acid (96538-83-9)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Clinical and Experimental Pharmacology (30)
Orthopedic Surgery (33)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009606270
MEDLINE PMID
19689402 (http://www.ncbi.nlm.nih.gov/pubmed/19689402)
FULL TEXT LINK
http://dx.doi.org/10.2174/138955709788922683
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 387
TITLE
Treatment of hypertension in the elderly
AUTHOR NAMES
Eaton-Maxwell A.
Ebeid A.
Azuike C.
Crain D.
AUTHOR ADDRESSES
(Eaton-Maxwell A.; Ebeid A.; Azuike C.; Crain D.) Texas Southern University,
College of Pharmacy and Health Sciences, Houston, TX, United States.
CORRESPONDENCE ADDRESS
A. Eaton-Maxwell, Texas Southern University, College of Pharmacy and Health
Sciences, Houston, TX, United States.
SOURCE
U.S. Pharmacist (2009) 34:6 (HS12-HS18). Date of Publication: 2009
ISSN
0148-4818
BOOK PUBLISHER
Jobson Publishing Corporation, 100 Avenue of the Americas, New York, United
States.
EMTREE DRUG INDEX TERMS
alpha adrenergic receptor blocking agent (adverse drug reaction, clinical
trial, drug therapy, pharmacology)
amlodipine (clinical trial, drug comparison, drug therapy)
angiotensin receptor antagonist (adverse drug reaction, clinical trial, drug
therapy, pharmacology)
antihypertensive agent (adverse drug reaction, clinical trial, drug therapy)
atenolol (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
beta adrenergic receptor (endogenous compound)
beta adrenergic receptor blocking agent (adverse drug reaction, clinical
trial, drug comparison, drug therapy, pharmacology)
calcium channel blocking agent (adverse drug reaction, clinical trial, drug
comparison, drug therapy, pharmacology)
candesartan (adverse drug reaction, clinical trial, drug therapy)
chlortalidone (clinical trial, drug comparison, drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical
trial, drug comparison, drug therapy, pharmacology)
diuretic agent (adverse drug reaction, clinical trial, drug comparison, drug
therapy, pharmacology)
doxazosin (clinical trial, drug comparison, drug therapy)
enalapril (clinical trial, drug therapy)
hydrochlorothiazide (clinical trial, drug therapy)
lisinopril (clinical trial, drug therapy)
loop diuretic agent (drug therapy)
losartan (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
potassium sparing diuretic agent (drug therapy)
thiazide diuretic agent (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hypertension (drug therapy, diagnosis, drug therapy, epidemiology, etiology,
therapy)
EMTREE MEDICAL INDEX TERMS
aged
angioneurotic edema (side effect)
anorexia (side effect)
antihypertensive activity
atrial fibrillation (side effect)
atrioventricular block (side effect)
bradycardia (side effect)
bronchospasm (side effect)
cause of death
clinical practice
clinical protocol
clinical trial
congestive heart failure
constipation (side effect)
coughing (side effect)
depression (side effect)
diarrhea (side effect)
diet therapy
dizziness (side effect)
drug efficacy
drug eruption (side effect)
drug receptor binding
drug tolerability
dysgeusia (side effect)
exercise
faintness (side effect)
fatigue (side effect)
floppy iris syndrome (side effect)
floppy iris syndrome (side effect)
flushing
heart disease
heart ventricle fibrillation (side effect)
human
hyperglycemia (side effect)
hyperkalemia (side effect)
hyperuricemia (side effect)
hypochloremia (side effect)
hypoglycemia (side effect)
hypokalemia (side effect)
hypomagnesemia (side effect)
hypotension (side effect)
impotence (side effect)
insomnia (side effect)
iris disease (side effect)
lifestyle modification
myalgia (side effect)
nausea and vomiting (side effect)
nose obstruction (side effect)
orthostatic hypotension (side effect)
ototoxicity (side effect)
pathophysiology
peripheral edema (side effect)
prevalence
priapism (side effect)
review
side effect (side effect)
sinus tachycardia (side effect)
tachycardia (side effect)
unspecified side effect (side effect)
vertigo (side effect)
CAS REGISTRY NUMBERS
amlodipine (88150-42-9)
atenolol (29122-68-7)
candesartan (139481-59-7)
chlortalidone (77-36-1)
doxazosin (74191-85-8)
enalapril (75847-73-3)
hydrochlorothiazide (58-93-5)
lisinopril (76547-98-3, 83915-83-7)
losartan (114798-26-4)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2010010403
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 388
TITLE
Identification and Evaluation of the Patient with Lung Disease
AUTHOR NAMES
Sweitzer B.J.
Smetana G.W.
AUTHOR ADDRESSES
(Sweitzer B.J., bsweitzer@dacc.uchicago.edu) Department of Anesthesia and
Critical Care, University of Chicago, 5841 S, Maryland Avenue, Chicago, IL
60637, United States.
(Sweitzer B.J., bsweitzer@dacc.uchicago.edu) Department of Medicine,
University of Chicago, 5841 S, Maryland Avenue, Chicago, IL 60637, United
States.
(Sweitzer B.J., bsweitzer@dacc.uchicago.edu) Anesthesia Perioperative
Medicine Clinic, University of Chicago Medical Center, 5841 S, Maryland
Avenue, Chicago, IL 60637, United States.
(Smetana G.W.) Division of General Medicine and Primary Care, Beth Israel
Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue,
Boston, MA, United States.
CORRESPONDENCE ADDRESS
B.J. Sweitzer, Department of Anesthesia and Critical Care, University of
Chicago, 5841 S, Maryland Avenue, Chicago, IL 60637, United States. Email:
bsweitzer@dacc.uchicago.edu
SOURCE
Anesthesiology Clinics (2009) 27:4 (673-686). Date of Publication: December
2009
ISSN
1932-2275
BOOK PUBLISHER
W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
Preoperative pulmonary evaluation and optimization improves postoperative
patient outcomes. Clinicians frequently evaluate patients with pulmonary
disease before surgery who are at increased risk for pulmonary and
nonpulmonary perioperative complications. Postoperative pulmonary
complications are as common and costly as cardiac complications. In this
article, the evaluation of patients with the most common conditions
encountered in the preoperative setting, including unexplained dyspnea,
asthma, chronic obstructive pulmonary disease, obstructive sleep apnea, and
cigarette use, are discussed. Risk stratification for postoperative
pulmonary complications and strategies to reduce them for high-risk patients
are also discussed. From the available literature, high-risk patients and
those patients for whom a multidisciplinary collaboration will be most
helpful can be accurately identified. © 2009 Elsevier Inc. All rights
reserved.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy, inhalational drug
administration)
beta adrenergic receptor stimulating agent (drug comparison, drug therapy)
bronchodilating agent (drug comparison, drug therapy)
cholinergic receptor blocking agent (drug therapy, inhalational drug
administration)
corticosteroid (drug combination, drug therapy, inhalational drug
administration)
prednisone (drug therapy, oral drug administration)
salbutamol (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
lung disease (rehabilitation, therapy)
patient assessment
preoperative evaluation
EMTREE MEDICAL INDEX TERMS
airflow
airway obstruction
anesthesist
asthma (drug therapy)
atrial fibrillation
bradycardia
breathing exercise
bronchospasm (drug therapy)
cerebrovascular accident
chronic obstructive lung disease (drug therapy, rehabilitation, therapy)
clinical practice
comorbidity
congestive heart failure
diastolic dysfunction
dyspnea
echocardiography
elective surgery
endotracheal intubation
epidural anesthesia
general anesthesia
heart left ventricle ejection fraction
high risk patient
human
lung infection
muscle training
nerve block
patient compliance
physiotherapy
pneumonia (complication)
polysomnography
positive end expiratory pressure
postoperative complication (complication)
practice guideline
pulmonary hypertension
pulmonary rehabilitation
review
risk factor
risk reduction
sleep disordered breathing (therapy)
smoking
smoking cessation
spinal anesthesia
spirometry
surgeon
surgical risk
thorax radiography
weight reduction
wheezing
CAS REGISTRY NUMBERS
prednisone (53-03-2)
salbutamol (18559-94-9)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Rehabilitation and Physical Medicine (19)
Anesthesiology (24)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009603749
FULL TEXT LINK
http://dx.doi.org/10.1016/j.anclin.2009.09.004
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 389
TITLE
Managing risk factors to prevent stroke
AUTHOR NAMES
Dunbabin D.W.
AUTHOR ADDRESSES
(Dunbabin D.W.) Royal Hobart Hospital, .
(Dunbabin D.W.) University of Tasmania, TAS.
CORRESPONDENCE ADDRESS
D. W. Dunbabin, Royal Hobart Hospital, .
SOURCE
Medicine Today (2009) 10:9 (58-68). Date of Publication: 2009
ISSN
1443-430X
BOOK PUBLISHER
Medicine Today Pty Ltd, P.O. Box 1473, Neutral Bay, Australia.
ABSTRACT
Preventing stroke by modifying risk factors in the individual and the
population as a whole still represents the most potent and cost-effective
way of reducing the burden of stroke in our community. Important risk
factors for stroke include elevated blood pressure, smoking,
hypercholesterolaemia, diabetes mellitus, atrial fibrillation and lifestyle
factors. Patients who have had a previous stroke or TIA are at especially
high risk of further stroke and require early assessment and therapy.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy, pharmacoeconomics)
angiotensin receptor antagonist (drug therapy)
anticoagulant agent
antihypertensive agent
antioxidant
antithrombocytic agent
atorvastatin (drug therapy)
calcium channel blocking agent (drug therapy)
cholesterol (endogenous compound)
clopidogrel (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug therapy)
cyanocobalamin
dipeptidyl carboxypeptidase inhibitor (drug therapy)
dipyridamole (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug therapy, pharmacoeconomics)
folic acid
homocysteine (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor
pravastatin (drug therapy)
pyridoxine
ramipril (adverse drug reaction, drug combination, drug comparison, drug
therapy)
simvastatin (drug therapy)
telmisartan (adverse drug reaction, drug combination, drug comparison, drug
therapy)
thiazide diuretic agent (drug therapy)
ticlopidine (drug therapy)
warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, disease management, drug therapy,
prevention)
risk factor
EMTREE MEDICAL INDEX TERMS
alcohol consumption
angioplasty
antihypertensive therapy
atrial fibrillation (drug therapy)
attributable risk
Australia
bleeding (side effect)
blood pressure
cardiovascular risk
carotid artery obstruction (surgery)
carotid endarterectomy
cerebrovascular accident (drug therapy)
cholesterol blood level
clinical trial
coronary artery disease (drug therapy)
cost effectiveness analysis
diabetes mellitus
diarrhea (side effect)
diet
drug cost
drug efficacy
faintness (side effect)
general practitioner
headache (side effect)
high risk patient
human
hypercholesterolemia
hypertension (drug therapy)
hypotension (side effect)
kidney dysfunction (side effect)
lifestyle
lifestyle modification
morbidity
mortality
nausea (side effect)
patient compliance
rash (side effect)
review
risk reduction
smoking
transient ischemic attack (drug therapy)
vitamin supplementation
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
atorvastatin (134523-00-5, 134523-03-8)
cholesterol (57-88-5)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
dipyridamole (58-32-2)
folic acid (59-30-3, 6484-89-5)
homocysteine (454-28-4, 6027-13-0)
pravastatin (81131-74-0)
pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
ramipril (87333-19-5)
simvastatin (79902-63-9)
telmisartan (144701-48-4)
ticlopidine (53885-35-1, 55142-85-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009543814
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 390
TITLE
Current pharmacological approaches to prevent and treat post-menopausal
osteoporosis
AUTHOR NAMES
Yang R.S.
Liu S.H.
AUTHOR ADDRESSES
(Yang R.S., rsyang@ntuh.gov.tw) Department of Orthopaedics, College of
Medicine, National Taiwan University, Jen-Ai Road, Taipei 10051, Taiwan.
(Liu S.H., shinghwaliu@ntu.edu.tw) Institute of Toxicology, College of
Medicine, National Taiwan University, Jen-Ai Road, Taipei 10051, Taiwan.
(Liu S.H., shinghwaliu@ntu.edu.tw) Department of Surgery, National Taiwan
University Hospital, Taipei, Taiwan.
CORRESPONDENCE ADDRESS
R.S. Yang, Department of Orthopaedics, College of Medicine, National Taiwan
University, Taipei 10051, Taiwan. Email: rsyang@ntuh.gov.tw
SOURCE
Recent Patents on Endocrine, Metabolic and Immune Drug Discovery (2009) 3:1
(42-53). Date of Publication: 2009
ISSN
1872-2148
BOOK PUBLISHER
Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
Osteoporosis characterized by low bone mass and structural deterioration of
bone tissue; has a huge impact on public health through high morbidity,
mortality and economic costs associated with resultant fractures. The
prevention and treatment of fragility fractures in the osteoporosis patients
worldwide becomes an important issue in the current clinical practice. Women
often have an accelerated bone loss after menopause and result in a lower
bone mass than men. Since the bone loss is irreversible, early prevention
and treatment of osteoporosis is important in the early postmenopausal
period. The goal of prevention needs to be not only effective, but also
safe, to diminish the risk of vertebral, hip and other nonvertebral
fractures. Non-pharmacological treatments, such as calcium, vitamin D,
exercise and reduction of risk factors may diminish the impact of menopause
and age-mediated bone loss. Current pharmacological options available
include bisphosphonates, calcitonin, hormone replacement therapy, selective
estrogen receptor modulators, teriparatide, and strontium ranelate, etc.
Lots of natural products including dietary components and herbal products
have also been demonstrated to be capable of modifying bone metabolism,
particularly of inhibiting bone resorption. These natural products may
provide as an alternative treatment for osteoporosis. More than 150 patents
have recently been issued for the prevention and treatment of postmenopausal
osteoporosis. The development of other new medications also sheds light on
either prevention or treatment of osteoporosis, such as human monoclonal
anti-RANKL antibody, cathepsin K inhibitors, and cannabinoid-based drugs. ©
2009 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS
25 acetylcimigenol xylopyranoside (pharmacology)
adlay (drug therapy)
alendronic acid (drug therapy)
bisphosphonic acid derivative (adverse drug reaction, drug therapy,
pharmacokinetics, pharmacology)
calcitonin (adverse drug reaction, drug therapy, intranasal drug
administration, oral drug administration, subcutaneous drug administration)
calcium (drug therapy)
calcium carbonate
Chinese drug (drug therapy)
colecalciferol
conjugated estrogen
estradiol (adverse drug reaction, drug therapy)
estradiol plus norethisterone acetate
glycoside (pharmacology)
herbaceous agent (drug therapy)
ibandronic acid (drug therapy, intravenous drug administration, oral drug
administration)
isoflavone (drug therapy)
parathyroid hormone[1-34] (adverse drug reaction, drug therapy, subcutaneous
drug administration)
piperazine estrone sulfate
raloxifene (adverse drug reaction, drug therapy)
risedronic acid (drug therapy)
salcatonin
soybean protein (drug therapy)
unclassified drug
vitamin D
zoledronic acid (drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
postmenopause osteoporosis (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (side effect)
bone mass
bone necrosis (side effect)
bone pain (side effect)
breast cancer (side effect)
calcium blood level
cerebrovascular accident (side effect)
continuous infusion
cost effectiveness analysis
deep vein thrombosis (side effect)
dementia (side effect)
dizziness (side effect)
drug approval
drug bioavailability
drug contraindication
drug induced headache (side effect)
drug safety
drug tolerability
dysphagia (side effect)
environmental factor
epistaxis (side effect)
esophagitis (side effect)
esophagus ulcer (side effect)
exercise
falling
flu like syndrome (side effect)
gastrointestinal symptom (side effect)
hormonal therapy
hot flush (side effect)
human
ischemic heart disease (side effect)
leg cramp (side effect)
limb pain (side effect)
musculoskeletal pain (side effect)
myalgia (side effect)
nausea (side effect)
nonhuman
orthostatic hypotension (side effect)
phlebitis (side effect)
priority journal
rhinitis (side effect)
risk factor
side effect (side effect)
stomach ulcer (side effect)
vein thrombosis (side effect)
venous thromboembolism (side effect)
visual disorder (side effect)
weight bearing
DRUG TRADE NAMES
activella
actonel
boniva
calcimar
climara
estrace
estraderm
estratab
evista
forteo
fortical
fosamax
miacalcin
ogen
ortho est
premarin
reclast
vivelle
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcium (7440-70-2)
calcium carbonate (13397-26-7, 13701-58-1, 14791-73-2, 471-34-1)
colecalciferol (1406-16-2, 67-97-0)
estradiol (50-28-2)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
isoflavone (574-12-9)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
piperazine estrone sulfate (7280-37-7)
raloxifene (82640-04-8, 84449-90-1)
risedronic acid (105462-24-6, 122458-82-6)
salcatonin (47931-85-1)
soybean protein (9010-10-0)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Obstetrics and Gynecology (10)
Clinical and Experimental Pharmacology (30)
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009495112
FULL TEXT LINK
http://dx.doi.org/10.2174/187221409787002958
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 391
TITLE
Comparing ablation and antiarrhythmic drug therapy for atrial fibrillation
AUTHOR NAMES
Callans D.J.
AUTHOR ADDRESSES
(Callans D.J., david.callans@uphs.upenn.edu) University of Pennsylvania
School of Medicine, Department of Medicine, Philadelphia, PA, United States.
(Callans D.J., david.callans@uphs.upenn.edu) University of Pennsylvania
Health System, Department of Electrophysiology, Philadelphia, PA, United
States.
(Callans D.J., david.callans@uphs.upenn.edu) 3400 Spruce Street,
Philadelphia, PA 19104, United States.
CORRESPONDENCE ADDRESS
D.J. Callans, 3400 Spruce Street, Philadelphia, PA 19104, United States.
Email: david.callans@uphs.upenn.edu
SOURCE
Current Cardiology Reports (2009) 11:5 (321-322). Date of Publication: 2009
ISSN
1523-3782
BOOK PUBLISHER
Current Medicine Group, 5 Marine View Plaza, Suite 218, Hoboken, United
States.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antiarrhythmic agent (clinical trial, drug combination, drug therapy)
EMTREE DRUG INDEX TERMS
amiodarone (clinical trial, drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
catheter ablation
EMTREE MEDICAL INDEX TERMS
abdominal disease (complication)
clinical trial
comparative study
drug efficacy
drug safety
exercise
hematoma (complication)
human
percutaneous drainage
pericardial effusion (complication, surgery)
pulmonary vein obstruction (therapy)
quality of life
short survey
stent
therapy effect
treatment failure
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2009497698
FULL TEXT LINK
http://dx.doi.org/10.1007/s11886-009-0055-3
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 392
TITLE
Management of Osteoporosis in elderly women
AUTHOR NAMES
Aguirre L.E.
Lewiecki E.M.
AUTHOR ADDRESSES
(Aguirre L.E.) University of New Mexico, Health Sciences Center,
Albuquerque, United States.
(Lewiecki E.M.) New Mexico Clinical Research, Osteoporosis Center,
Albuquerque, United States.
CORRESPONDENCE ADDRESS
L. E. Aguirre, University of New Mexico, Health Sciences Center,
Albuquerque, United States.
SOURCE
Annals of Long-Term Care (2009) 17:10 (35-39). Date of Publication: October
2009
ISSN
1524-7929
BOOK PUBLISHER
HMP Communications LLP, 4365 U.S. Highway 1 Suite 250, Princeton, United
States.
ABSTRACT
Osteoporosis is characterized by low bone mineral density (BMD) and poor
bone quality, resulting in reduced bone strength and increased risk of
fracture. Osteoporotic fractures are associated with increased morbidity and
mortality, particularly in the elderly, as well as high healthcare costs.
The risk of fragility fractures increases with aging, independently of BMD.
Many therapeutic agents are available for the treatment of osteoporosis, yet
there are limited data on their efficacy and safety in the elderly. Post-hoc
analyses of data from prospective, randomized, placebo-controlled clinical
trials evaluating drugs for the treatment of postmenopausal osteoporosis
have shown a similar response in elderly postmenopausal women as compared
with younger postmenopausal women. This article reviews the evidence
regarding the treatment of osteoporosis in elderly women and provides
suggestions for long-term management in clinical practice.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
bisphosphonic acid derivative (adverse drug reaction, clinical trial, drug
therapy)
parathyroid hormone[1-34] (clinical trial, drug comparison, drug therapy)
EMTREE DRUG INDEX TERMS
alendronic acid (clinical trial, drug comparison, drug therapy, oral drug
administration)
calcium (drug therapy)
colecalciferol (clinical trial, drug therapy)
ibandronic acid (clinical trial, drug therapy)
placebo
risedronic acid (clinical trial, drug therapy)
vitamin D (clinical trial, drug therapy)
zoledronic acid (clinical trial, drug therapy, intravenous drug
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
postmenopause osteoporosis (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
atrial fibrillation (side effect)
body mass
calcium intake
clinical practice
clinical trial
conservative treatment
corticosteroid induced osteoporosis (drug therapy)
drug safety
exercise
falling
female
femur fracture (complication, prevention, side effect)
fragility fracture (complication, prevention)
gastrointestinal symptom (side effect)
geriatric patient
hip fracture (complication, prevention)
human
hypocalcemia (side effect)
jaw osteonecrosis (side effect)
kidney dysfunction (side effect)
lifestyle modification
long term care
musculoskeletal pain (side effect)
osteopenia
patient compliance
review
risk reduction
smoking
spine fracture (complication, prevention)
vitamin D deficiency (drug therapy)
vitamin supplementation
weight bearing
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcium (7440-70-2)
colecalciferol (1406-16-2, 67-97-0)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
risedronic acid (105462-24-6, 122458-82-6)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Obstetrics and Gynecology (10)
Gerontology and Geriatrics (20)
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009588572
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 393
TITLE
Electrocardiogram and arrhythmias
AUTHOR NAMES
Singh R.
Murphy J.J.
AUTHOR ADDRESSES
(Singh R.; Murphy J.J.) County Durham and Darlington Foundation Trust,
Centre of Integrated Health Care Research, Durham University, United
Kingdom.
(Singh R.; Murphy J.J.) County Durham and Darlington Foundation Trust,
Durham University, United Kingdom.
CORRESPONDENCE ADDRESS
R. Singh, County Durham and Darlington Foundation Trust, Centre of
Integrated Health Care Research, Durham University, United Kingdom.
SOURCE
Anaesthesia and Intensive Care Medicine (2009) 10:8 (381-384). Date of
Publication: August 2009
ISSN
1472-0299
BOOK PUBLISHER
Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
Introduced by Einthoven, electrocardiography remains the most common
diagnostic procedure readily available to the physician in primary and
secondary care. It is a graphical display of the electrical potential
difference as it spreads through the heart and is recorded at the body
surface. The electrocardiogram (ECG) is an indispensable tool to screen and
monitor cardiac patients. Exercise ECG is used to diagnose coronary artery
disease and ambulatory ECG to assess arrhythmias. © 2009 Elsevier Ltd. All
rights reserved.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy)
digitalis (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
electrocardiogram
heart arrhythmia (diagnosis)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (diagnosis)
atrioventricular block (diagnosis, drug therapy, side effect)
bradycardia
cardiac patient
complete heart block
coronary artery disease (diagnosis)
diagnostic procedure
electric potential
electrocardiography monitoring
exercise
heart atrium flutter (diagnosis)
heart left bundle branch block (diagnosis)
heart right bundle branch block (diagnosis)
heart ventricle tachycardia (diagnosis)
human
P wave
patient monitoring
primary medical care
priority journal
QRS complex
review
second degree atrioventricular block
T wave
tachycardia
CAS REGISTRY NUMBERS
digitalis (8031-42-3, 8053-83-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009386916
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mpaic.2009.04.017
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 394
TITLE
QT interval disturbances in hospitalized elderly patients
AUTHOR NAMES
Lubat E.
Segal R.
Yearovoi A.
Fridenson A.
Baumoehl Y.
Leobovitz A.
AUTHOR ADDRESSES
(Lubat E.; Segal R., rsegal@post.tau.ac.il; Yearovoi A.; Fridenson A.;
Baumoehl Y.; Leobovitz A.) Shmuel Harofe Hospital, Geriatric Medical Center,
P.O. Box 2, Beer Yaakov 60350, Israel.
(Segal R., rsegal@post.tau.ac.il) Sackler Faculty of Medicine, Tel Aviv
University, Ramat Aviv, Israel.
CORRESPONDENCE ADDRESS
R. Segal, Shmuel Harofe Hospital, Geriatric Medical Center, P.O. Box 2, Beer
Yaakov 60350, Israel. Email: rsegal@post.tau.ac.il
SOURCE
Israel Medical Association Journal (2009) 11:3 (147-150). Date of
Publication: 2009
ISSN
1565-1088
BOOK PUBLISHER
Israel Medical Association, 2 Twin Towers,11th Floor,35 Jabotinsky Street,PO
Box 3566, Ramat Gan, Israel.
ABSTRACT
Background: The QT interval reflects the total duration of ventricular
myocardial repolarization. Its prolongation is associated with increased
risk of polymorphic ventricular tachycardia, or torsade de pointes, which
can be fatal. Objectives: To assess the prevalence of both prolonged and
short QT interval in patients admitted to an acute geriatric ward. Methods:
This retrospective study included the records over 6 months of all patients
hospitalized in an acute geriatric ward. Excluded were patients with
pacemaker, bundle branch block and slow or rapid atrial fibrillation. The
standard 12 lead electrocardiogram of each patient was used for the QT
interval evaluation. Results: We screened the files of 422 patients. QTc
prolongation based on the mean of 12 ECG leads was detected in 115 patients
(27%). Based on lead L2 only, QTc was prolonged in 136 (32%). Associated
factors with QT prolongation were congestive heart failure and use of
hypnotics. Short QT was found in 30 patients (7.1%) in lead L2 and in 19
(4.5%) by the mean 12 leads. Short QT was related to a higher heart rate,
chronic atrial fibrillation and schizophrenia. Conclusions: Our study
detected QT segment disturbances in a considerable number of elderly
patients admitted acutely to hospital. Further studies should confirm these
results and clinicians should consider a close QT interval follow-up in
predisposed patients.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent
antidepressant agent
benzodiazepine derivative
cholinergic receptor blocking agent
digoxin
hypnotic agent
neuroleptic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
elderly care
QT prolongation (diagnosis)
short QT interval (diagnosis)
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation
congestive heart failure
drug use
electrocardiogram
female
follow up
geriatric patient
heart rate
high risk population
hospital patient
human
major clinical study
male
prevalence
retrospective study
schizophrenia
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009301710
MEDLINE PMID
19544703 (http://www.ncbi.nlm.nih.gov/pubmed/19544703)
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 395
TITLE
Follow your heart: Optimal care after a heart attack - A guide for you and
your patients
AUTHOR NAMES
Sivers F.
Begg A.
Milne D.
Morrell J.
Neely D.
Norton M.
Nuttall M.
Walker M.
Ellis B.
Ratcliffe C.
Thomas A.
Bosworth R.
Ong S.
AUTHOR ADDRESSES
(Sivers F., fransivers@pccs.org.uk; Begg A.; Milne D.; Morrell J.; Norton
M.; Nuttall M.) Primary Care Cardiovascular Society, 36 Berrymede Road,
London, W4 5JD.
(Neely D.; Ellis B.; Ratcliffe C.) HEART UK, 7 North Road, Maidenhead, SL6
1PE.
(Walker M.) University College Hospital, London, NW1 2BU.
(Thomas A.; Bosworth R.; Ong S.) Pfizer Ltd., Walton Oaks, Dorking Road,
Tadworth, Surrey, KT20 7NS.
CORRESPONDENCE ADDRESS
F. Sivers, Primary Care Cardiovascular Society, 36 Berrymede Road, London,
W4 5JD. Email: fransivers@pccs.org.uk
SOURCE
British Journal of Cardiology (2009) 16:4 (187-191). Date of Publication:
July/August 2009
ISSN
0969-6113
BOOK PUBLISHER
MediNews (Cardiology) Ltd, 3 Duchess Place, Edgbaston, Birmingham, United
Kingdom.
ABSTRACT
Considerable variation exists in adherence to and implementation of
post-myocardial infarction (post-MI) clinical guidelines in the UK. The
Follow Your Heart Steering Group has consolidated existing clinical evidence
and published guidance into a consensus of succinct recommendations for
optimal post-MI management, which includes separate healthcare professional
and patient-focused components. This guidance should help encourage two-way
dialogues between patients and healthcare professionals, reduce practice
variation, raise standards of care, maximise healthcare resource utilisation
and improve outcomes in post-MI patients. It is our intention to develop and
widely disseminate a simple algorithm for healthcare professionals and for
patients that summarises the guidance.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
aldosterone antagonist (drug therapy)
angiotensin receptor antagonist (drug therapy)
antithrombocytic agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
antilipemic agent (drug therapy)
atorvastatin (drug dose, drug therapy)
beta adrenergic receptor blocking agent (drug dose, drug therapy)
bisoprolol (drug dose, drug therapy)
cholesterol
clopidogrel (drug therapy)
eplerenone (drug therapy)
ezetimibe (drug dose, drug therapy)
hemoglobin A1c (endogenous compound)
high density lipoprotein cholesterol
losartan (drug therapy)
low density lipoprotein cholesterol
perindopril (drug therapy)
ramipril (drug therapy)
rosuvastatin (drug dose, drug therapy)
simvastatin (drug dose, drug therapy)
spironolactone (drug dose, drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart infarction (drug therapy, disease management, drug therapy,
rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
add on therapy
algorithm
anticoagulant therapy
atrial fibrillation
blood pressure regulation
clinical practice
coronary stent
drug dose titration
drug substitution
drug withdrawal
evidence based practice
exercise
glucose blood level
heart failure (complication, drug therapy)
heart rehabilitation
hospital discharge
human
hyperlipidemia (drug therapy)
hypertension (drug therapy)
kidney function test
laboratory test
lifestyle modification
lipid blood level
liver function test
low drug dose
low fat diet
Mediterranean diet
national health service
patient care
patient monitoring
percutaneous coronary intervention
practice guideline
primary medical care
recommended drug dose
review
risk benefit analysis
smoking cessation
sodium restriction
thromboembolism (complication, drug therapy, prevention)
treatment indication
United Kingdom
weight reduction
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
atorvastatin (134523-00-5, 134523-03-8)
bisoprolol (66722-44-9)
cholesterol (57-88-5)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
eplerenone (107724-20-9)
ezetimibe (163222-33-1)
hemoglobin A1c (62572-11-6)
losartan (114798-26-4)
perindopril (82834-16-0)
ramipril (87333-19-5)
rosuvastatin (147098-18-8, 147098-20-2)
simvastatin (79902-63-9)
spironolactone (52-01-7)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009425790
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 396
TITLE
Howtoavoidaheartattack: Putting it all together
AUTHOR NAMES
Haffey T.A.
AUTHOR ADDRESSES
(Haffey T.A., thaffey@yahoo.com) Department of Medicine, Western University,
Health Sciences College of Osteopathic Medicine of the Pacific, Pomona, CA,
United States.
(Haffey T.A., thaffey@yahoo.com) Department of Medicine, Kirksville College
of Osteopathic Medicine, A.T. Still University, Kirksville, MO, United
States.
(Haffey T.A., thaffey@yahoo.com) American College of Cardiology Colorado, .
(Haffey T.A., thaffey@yahoo.com) 9141 Grant St, Thornton, CO 80229-4367,
United States.
CORRESPONDENCE ADDRESS
T. A. Haffey, 9141 Grant St, Thornton, CO 80229-4367, United States. Email:
thaffey@yahoo.com
SOURCE
Journal of the American Osteopathic Association (2009) 109:5 SUPPL. 1
(S14-S20). Date of Publication: May 2009
ISSN
0098-6151
0098-6151 (electronic)
BOOK PUBLISHER
American Osteopathic Association, 142 East Ontario Street, Chicago, United
States.
ABSTRACT
Cardiovascular disease (eg, myocardial infarction, ischemic stroke) is the
leading cause of death in patients who have metabolic syndrome and diabetes
mellitus. By effectively treating the whole patient, however, the risk of
death from cardiovascular disease can be reduced or prevented. The author
describes clinical approaches for achieving this goal. He reviews
information that is useful to know about patients regarding modifiable and
potentially modifiable risk factors for cardiovascular disease, including
hypertension, hyperlipidemia, smoking, activity levels, dietary habits,
obesity, carotid artery stenosis, and atrial fibrillation. He also notes the
importance of evaluating patients for relevant psychosocial factors such as
depression. Finally, the author analyzes treatment options for patients,
including effective medications, dietary modification, and exercise -
emphasizing the use of pedometers - as well as participation by patients in
weight-control support groups.
EMTREE DRUG INDEX TERMS
apolipoprotein A (endogenous compound)
apolipoprotein B (endogenous compound)
high density lipoprotein cholesterol (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
abdominal obesity
diabetes mellitus
heart infarction
EMTREE MEDICAL INDEX TERMS
alcohol consumption
diet
exercise
fruit
human
pedometer
review
risk
risk factor
smoking
smoking
social psychology
vegetable
weight control
EMBASE CLASSIFICATIONS
Endocrinology (3)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009281280
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 397
TITLE
Recent landmark studies in cardiology presented at American College of
Cardiology '09
AUTHOR NAMES
Jain P.
Chopra H.K.
AUTHOR ADDRESSES
(Jain P., peeyush.jain@fortishealthcare.com) Deapartment of Preventive
Cardiolofy, Escorts Heart Institute and Research Centre, Okhla Road, New
Delhi 110 025, India.
(Chopra H.K.) Moolchand Medicity, New Delhi 11 0024, India.
CORRESPONDENCE ADDRESS
P. Jain, Deapartment of Preventive Cardiolofy, Escorts Heart Institute and
Research Centre, Okhla Road, New Delhi 110 025, India. Email:
peeyush.jain@fortishealthcare.com
SOURCE
Indian Heart Journal (2009) 61:3 (292-295). Date of Publication: May-June
2009
ISSN
0019-4832
0019-4832 (electronic)
BOOK PUBLISHER
Cardiology Society of India, Okhla Road, New Delhi, India.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination, drug therapy)
alteplase (intravenous drug administration)
atorvastatin (drug therapy)
brain natriuretic peptide (endogenous compound)
clopidogrel (drug combination, drug therapy)
creatine kinase (endogenous compound)
diuretic agent (drug therapy)
eptifibatide (drug therapy)
fluindostatin (drug therapy)
heparin (drug therapy)
high density lipoprotein cholesterol (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor
low density lipoprotein cholesterol (endogenous compound)
pitavastatin (drug therapy)
placebo
pravastatin (drug therapy)
rosuvastatin
troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease
EMTREE MEDICAL INDEX TERMS
acute coronary syndrome (drug therapy)
atrial fibrillation (drug therapy)
bleeding
catheter ablation
cause of death
cerebrovascular disease
coronary artery atherosclerosis (drug therapy)
coronary artery bypass graft
drug megadose
exercise
heart catheterization
heart failure (epidemiology)
heart infarction (drug therapy)
heart muscle ischemia
hemodiafiltration
human
hypertension (drug therapy)
kidney failure (therapy)
morbidity
mortality
non st segment elevation acute coronary syndrome (drug therapy)
non st segment elevation acute coronary syndrome (drug therapy)
percutaneous coronary intervention
review
stable angina pectoris (drug therapy)
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alteplase (105857-23-6)
atorvastatin (134523-00-5, 134523-03-8)
brain natriuretic peptide (114471-18-0)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
creatine kinase (9001-15-4)
eptifibatide (148031-34-9)
fluindostatin (93957-54-1)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
pitavastatin (147526-32-7)
pravastatin (81131-74-0)
rosuvastatin (147098-18-8, 147098-20-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2010013492
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 398
TITLE
Improving outcomes in cardiovascular disease: An Invest to Save guide for
practice based commissioners
AUTHOR NAMES
Kearney M.
Chellaswamy H.
AUTHOR ADDRESSES
(Kearney M.) NHS Knowsley, Westmorland Road, Huyton, L36 6GA, United
Kingdom.
(Chellaswamy H.) Deputy Director of Public Health, NHS Sefton, Burlington
House, Crosby Rd North, Liverpool, L22 0QB, United Kingdom.
CORRESPONDENCE ADDRESS
M. Kearney, NHS Knowsley, Westmorland Road, Huyton, L36 6GA, United Kingdom.
SOURCE
Primary Care Cardiovascular Journal (2009) 2:2 (83-86). Date of Publication:
April/May/June 2009
ISSN
1756-5138
1756-5146 (electronic)
BOOK PUBLISHER
Sherborne Gibbs Limited, 3 Duchess Place, Edgbaston Birmingham, United
Kingdom.
ABSTRACT
Context: Cardiovascular disease has an enormous impact on people's lives. It
is a major cause of disability and reduced life expectancy, and accounts for
one third of all deaths. It consumes vast resources in primary and secondary
care. It is also very preventable. Comparison of our mortality rates with
those in countries such as Japan, France and Spain suggests that eight out
of 10 CVD deaths in England could be avoided through improved treatment and
active prevention. Yet, although many patients receive excellent care, there
is significant variation between practices in the diagnosis and treatment of
this group of conditions. In common with other long-term conditions, there
is also substantial under-diagnosis. Such variation in management and delay
in detection worsens patient outcomes and heightens health inequalities. It
is also very expensive as it increases rates of complication and hospital
admission. Design: The Invest to Save guide reviews the extensive evidence
base for promoting prevention and optimising treatment in CVD. It examines
current gaps in prevention and treatment in primary care and provides a
framework for practice based commissioning (PBC) groups to use savings to
fund a more systematic approach to the management of CVD in primary care.
The framework focuses on increasing case-finding in CVD risk, hypertension,
atrial fibrillation and diabetes, targeting preventive interventions on
those at high CVD risk and improving the management of those with
established disease.
EMTREE DRUG INDEX TERMS
cholesterol (endogenous compound)
hydroxymethylglutaryl coenzyme A reductase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (disease management, prevention)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiovascular risk
cholesterol blood level
clinical practice
diabetes mellitus
diet
disability
funding
health care quality
health promotion
heart death
hospital admission
human
hypertension
life expectancy
mortality
obesity
outcome assessment
patient care
physical activity
primary medical care
review
smoking
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009282404
FULL TEXT LINK
http://dx.doi.org/10.3132/pccj.2009.021
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 399
TITLE
Alternative and Complementary Medicine for Preventing and Treating
Cardiovascular Disease
AUTHOR NAMES
Frishman W.H.
Beravol P.
Carosella C.
AUTHOR ADDRESSES
(Frishman W.H.; Beravol P.; Carosella C.)
SOURCE
Disease-a-Month (2009) 55:3 (121-192). Date of Publication: March 2009
ISSN
0011-5029
BOOK PUBLISHER
Mosby Inc., 11830 Westline Industrial Drive, St. Louis, United States.
EMTREE DRUG INDEX TERMS
alpha tocopherol (clinical trial, drug therapy, pharmacology)
ascorbic acid (adverse drug reaction, drug therapy, pharmacology)
beta carotene (drug therapy, pharmacology)
carotenoid (drug therapy)
chondroitin (drug combination, drug therapy)
cyanocobalamin
Echinacea extract (drug therapy)
flavonoid
folic acid
garlic extract (drug therapy)
Ginkgo biloba extract (drug therapy)
ginseng extract (drug therapy)
glucosamine (drug combination, drug therapy)
herbaceous agent (drug therapy)
lycopene (drug therapy)
magnesium (drug therapy, intravenous drug administration)
nicotinamide (drug therapy, pharmacology)
nicotinic acid (adverse drug reaction, drug therapy, pharmaceutics,
pharmacokinetics, pharmacology)
placebo
polyphenol derivative
proanthocyanidin derivative
pyridoxine
quercetin
reserpine (drug therapy)
resveratrol (pharmacology)
thiamine
unindexed drug
vitamin B group (clinical trial, drug therapy)
vitamin D (drug therapy)
vitamin K group
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
acanthosis nigricans (side effect)
alternative medicine
angina pectoris (complication, drug therapy)
antioxidant activity
aromatherapy
asthma (side effect)
atherosclerosis (drug therapy)
atrial fibrillation (drug therapy, prevention)
behavior therapy
breathing exercise
cacao
cardiovascular risk
cerebrovascular accident (drug therapy, prevention)
chelation therapy
Chinese medicine
clinical trial
coronary artery disease (drug therapy, prevention)
coronary artery spasm
diet supplementation
drug formulation
drug megadose
drug metabolism
drug safety
feedback system
flushing
gastrointestinal symptom (side effect)
grape juice
guided imagery
heart infarction (drug therapy, prevention)
heart protection
heart ventricle arrhythmia (drug therapy, prevention)
herbal medicine
homeopathy
human
humor
hypercholesterolemia (drug therapy)
hyperhomocysteinemia (drug therapy)
hyperlipidemia (drug therapy)
hypertension (drug therapy)
iron overload (side effect)
liver toxicity (side effect)
magnesium deficiency
magnetotherapy
medical practice
meditation
muscle cramp (drug therapy)
music therapy
nonhuman
nonverbal communication
osteopathic medicine
patient satisfaction
pet therapy
Polygalaceae
prophylaxis
pruritus (side effect)
red wine
reflexology
review
sauna
side effect (side effect)
spinal cord stimulation
Stephania
sustained drug release
Tai Chi
tea
transcutaneous nerve stimulation
vasodilatation
vitamin supplementation
yoga
DRUG TRADE NAMES
niaspan
CAS REGISTRY NUMBERS
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
beta carotene (7235-40-7)
chondroitin (9007-27-6)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
folic acid (59-30-3, 6484-89-5)
glucosamine (3416-24-8, 4607-22-1)
lycopene (502-65-8)
magnesium (7439-95-4)
nicotinamide (11032-50-1, 98-92-0)
nicotinic acid (54-86-4, 59-67-6)
pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
quercetin (117-39-5)
reserpine (50-55-5, 8001-95-4)
resveratrol (501-36-0)
thiamine (59-43-8, 67-03-8)
vitamin B group (12001-76-2)
vitamin K group (12001-79-5)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Pharmacy (39)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2009064269
MEDLINE PMID
19215737 (http://www.ncbi.nlm.nih.gov/pubmed/19215737)
FULL TEXT LINK
http://dx.doi.org/10.1016/j.disamonth.2008.12.002
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 400
TITLE
Detection and treatment of sublesional osteoporosis among patients with
chronic spinal cord injury: Proposed paradigms
AUTHOR NAMES
Craven B.C.
Robertson L.A.
McGillivray C.F.
Adachi J.D.
AUTHOR ADDRESSES
(Craven B.C.; Robertson L.A.) Toronto Rehabilitation Institute, Lyndhurst
Centre, Toronto, ON, Canada.
(Craven B.C.; McGillivray C.F.) Department of Medicine, University of
Toronto, Toronto, ON, Canada.
(McGillivray C.F.) Toronto Rehabilitation Institute, Lyndhurst Centre,
Spinal Cord Rehab. Program, Toronto, ON, Canada.
(Adachi J.D.) Department of Medicine, McMaster University, St. Joseph's
Hospital, Hamilton, ON, Canada.
CORRESPONDENCE ADDRESS
B. C. Craven, Toronto Rehabilitation Institute, Lyndhurst Centre, Toronto,
ON, Canada.
SOURCE
Topics in Spinal Cord Injury Rehabilitation (2009) 14:4 (1-22). Date of
Publication: 1 Mar 2009
ISSN
1082-0744
BOOK PUBLISHER
Thomas Land Publishers Inc., 255 Jefferson Road, St. Louis, United States.
ABSTRACT
Low hip and knee region bone mineral density (BMD) after spinal cord injury
(SCI) results in an increased risk of lower extremity fragility fractures or
sublesional osteoporosis (SLOP). There are currently no guidelines for the
identification and treatment of SLOP among patients with chronic SCI. A
paradigm for identification (medical screening, fracture risk, and bone
mineral density assessment) of persons with SLOP who warrant treatment and
selection of appropriate SLOP treatment(s) (lifestyle/nutrition
modifications, bisphosphonate/rehabilitation therapies) is proposed. Content
is based on the authors' opinions/expertise and available published and
unpublished literature and is intended for use by rehabilitation
professionals. © 2009 Thomas Land Publishers, Inc.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction)
alendronic acid (adverse drug reaction, clinical trial, drug comparison,
drug therapy, oral drug administration)
bisphosphonic acid derivative (drug therapy, oral drug administration)
caffeine
calcium (clinical trial, drug comparison)
carbamazepine (drug therapy)
colecalciferol (drug therapy)
corticosteroid (adverse drug reaction)
nonsteroid antiinflammatory agent (adverse drug reaction)
pregabalin (drug therapy)
valproic acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
fragility fracture (complication, diagnosis, prevention, rehabilitation,
therapy)
osteoporosis (drug therapy, complication, diagnosis, drug therapy,
prevention, rehabilitation, therapy)
spinal cord injury (rehabilitation, therapy)
sublesional osteoporosis (complication, diagnosis, prevention,
rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
aging
alcohol consumption
atrial fibrillation (side effect)
bone densitometry
bone density
chronic disease
clinical assessment
clinical trial
coffee
diagnostic test
diarrhea (side effect)
drug substitution
drug withdrawal
dyspepsia (side effect)
flatulence (side effect)
gastrointestinal reflux (side effect)
gastrointestinal symptom (side effect)
health
health program
health status
hip
human
hypocalcemia (side effect)
hypogonadism (drug therapy)
jaw osteonecrosis (side effect)
knee
lifestyle modification
liver toxicity (side effect)
neuropathic pain (drug therapy)
nutritional assessment
patient identification
practice guideline
quadriplegia
review
risk factor
screening
smoking
smoking cessation
sport
stomach ulcer (side effect)
vitamin supplementation
world health organization
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alendronic acid (66376-36-1)
caffeine (58-08-2)
calcium (7440-70-2)
carbamazepine (298-46-4, 8047-84-5)
colecalciferol (1406-16-2, 67-97-0)
pregabalin (148553-50-8)
valproic acid (1069-66-5, 99-66-1)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Neurology and Neurosurgery (8)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009376334
FULL TEXT LINK
http://dx.doi.org/10.1310/sci1404-1
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 401
TITLE
Ventricular hypertrophy and heart failure in elderly and very old population
with high blood pressure
AUTHOR NAMES
Cârstea D.
Streba L.M.
Cârstea A.P.
AUTHOR ADDRESSES
(Cârstea D., dag_carstea@yahoo.com; Streba L.M.; Cârstea A.P.) Department of
Cardiology, Clinical Municipals Hospital Filantropia, University of Medicine
and Pharmacy of Craiova, No. 3 Street Constantin Brâncusi, 200314 Craiova,
Romania.
CORRESPONDENCE ADDRESS
D. Cârstea, Department of Cardiology, Clinical Municipals Hospital
Filantropia, University of Medicine and Pharmacy of Craiov, No. 3 Street
Constantin Brâncusi, 200314 Craiova, Romania. Email: dag_carstea@yahoo.com
SOURCE
Archives of the Balkan Medical Union (2009) 44:1 (56-60). Date of
Publication: March 2009
ISSN
1584-9244
BOOK PUBLISHER
Celsius Publishing House, G. Clemenceau Street 1, Bucharest, Romania.
ABSTRACT
Framingham Study reveals in 2003 that from the patients with heart failure,
about 75% of them had a history of arterial hypertension and only 25%
suffered a myocardial infarction. During the evolution of high blood
pressure (HBP), in years, the increase of left ventricular mass, appears to
be initially a useful compensatory process, but with ages might reflect the
influence that other risk factors exert with time. From hypertrophy to
dilatation of the left ventricular and to the heart failure are only two
steps! Hypertesion in elderly (those over the age of 65), and very old
people (over 80 years old), is an extremely increasing public health
concern. Prospective studies have examined the potential benefits of
regression of the left ventricular hypertrophy, and have demonstrated that
changes in left ventricular mass, during treatment may imply an important
benefit. Hypertension usually is followed by left ventricular hypertrophy,
but can also lead directly to the developement of heart failure by several
mechanisms, alone or in combination. Hospitalizations for congestive heart
failure (CHF) are increasing dramatically all over the world reason for
which the prevention of CHF should be a major treatment goal. Copyright ©
2009 Celsius.
EMTREE DRUG INDEX TERMS
antihypertensive agent (drug therapy)
brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure (diagnosis, prevention)
elderly care
heart ventricle hypertrophy (diagnosis)
hypertension (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
blood pressure monitoring
blood pressure regulation
capillary pressure
comorbidity
coronary artery blood flow
diabetes mellitus
Doppler echocardiography
echocardiography
electrocardiography
exercise
heart dilatation
heart ejection fraction
heart hemodynamics
heart left ventricle mass
heart muscle contractility
heart repolarization
hospitalization
human
morbidity
mortality
prevalence
protein blood level
regression analysis
review
CAS REGISTRY NUMBERS
brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
2009257815
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 402
TITLE
Atrial fibrillation: Pathogenesis, medical-surgical management and dental
implications
AUTHOR NAMES
Friedlander A.H.
Yoshikawa T.T.
Chang D.S.
Feliciano Z.
Scully C.
AUTHOR ADDRESSES
(Friedlander A.H., arthur.friedlander@med.va.gov) VA Greater Los Angeles
Healthcare System, 11301 Wilshire Blvd., Los Angeles, CA 90073, United
States.
(Yoshikawa T.T.) Geriatric Research Education and Clinical Center, VA
Greater Los Angeles Healthcare System, David Geffen School of Medicine at
UCLA, Los Angeles, United States.
(Chang D.S.) UCLA-VA, VA Greater Los Angeles/San Fernando Valley Program,
David Geffen School of Medicine at UCLA, Los Angeles, United States.
(Feliciano Z.) VA Greater Los Angeles Healthcare System, David Geffen School
of Medicine at UCLA, Los Angeles, United States.
(Scully C.) University College London Eastman Dental Institute, .
CORRESPONDENCE ADDRESS
A.H. Friedlander, VA Greater Los Angeles Healthcare System, 11301 Wilshire
Blvd., Los Angeles, CA 90073, United States. Email:
arthur.friedlander@med.va.gov
SOURCE
Journal of the American Dental Association (2009) 140:2 (167-177). Date of
Publication: February 2009
ISSN
0002-8177
BOOK PUBLISHER
American Dental Association, 211 E. Chicago Avenue, Chicago, United States.
ABSTRACT
Background. Atrial fibrillation (AF) is a cardiac rhythm disturbance arising
from disorganized electrical activity in the atria, and it is accompanied by
an irregular and often rapid ventricular response. It is the most common
clinically significant dysrhythmia in the general and older population.
Types of Studies Reviewed. The authors conducted a MEDLINE search using the
key terms "atrial fibrillation," "epidemiology," "pathophysiology,"
"treatment" and "dentistry." They selected contemporaneous articles
published in peer-reviewed journals and gave preference to articles
reporting randomized controlled trials. Clinical Implications. The
anticoagulant warfarin frequently is prescribed to prevent stroke caused by
cardiogenic thromboemboli arising from stagnant blood in poorly contracting
atria. Most dental procedures and a limited number of surgical procedures
can be performed without altering warfarin dosage if the international
normalized ratio value is within the therapeutic range of 2.0 to 3.0.
Certain analgesic agents, antibiotic agents, antifungal agents and sedative
hypnotics, however, should not be prescribed without consultation with the
patient's physician because these medications may alter the patient's risk
of hemorrhage and stroke. Conclusions. AF affects nearly 2.5 million
Americans, most of who are older than 60 years. Consultation with the
patient's physician to discuss the planned dental treatment often is
appropriate, especially for people who frequently have comorbid diseases
such as coronary artery disease, congestive heart failure, diabetes and
thyrotoxicosis, which are treated with multiple drug regimens.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
dental procedure
EMTREE MEDICAL INDEX TERMS
bleeding (prevention)
cerebrovascular accident (prevention)
drug contraindication
human
oral surgery
pathophysiology
review
CAS REGISTRY NUMBERS
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
MEDLINE PMID
19188413 (http://www.ncbi.nlm.nih.gov/pubmed/19188413)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 403
TITLE
American Society for Clinical Pharmacology and Therapeutics - Abstracts of
Papers, 2009 Annual Meeting
AUTHOR ADDRESSES
SOURCE
Clinical Pharmacology and Therapeutics (2009) 85 SUPPL. 1. Date of
Publication: February 2009
CONFERENCE NAME
110th Annual Meeting of the American Society for Clinical Pharmacology and
Therapeutics, ASCPT 2009
CONFERENCE LOCATION
National Harbor, MD, United States
CONFERENCE DATE
2009-03-18 to 2009-03-21
ISSN
0009-9236
BOOK PUBLISHER
Nature Publishing Group
ABSTRACT
The proceedings contain 303 papers. The topics discussed include: prediction
of infant drug exposure through breastfeeding: population PK modeling and
simulation of fluoxetine; atrial fibrillation and inflammation: modulation
by ACE inhibitors and statins; effect of genetic variation in ABCC2 on the
renal clearance of cisplatin; validation of physiologically-based
simulations for cidofovir pharmacokinetics in critically ill paediatric
patients; norepinephrine transporter polymorphisms affect blood pressure
response to exercise; the application of pharmacometabolomics to predict the
pharmacokinetics of tacrolimus in healthy Korean subjects; design,
synthesis, and in vivo pharmacologic actions of a novel peptide integrating
human C-type natriuretic peptide, urodilatin, and B-type natriuretic
peptide; and matrix metalloproteinase-9 functional polymorphism affects the
enzyme plasma levels in HIV patients in antiretroviral therapy.
EMTREE DRUG INDEX TERMS
brain natriuretic peptide
cidofovir
cisplatin
dipeptidyl carboxypeptidase inhibitor
enzyme
fluoxetine
gelatinase B
hydroxymethylglutaryl coenzyme A reductase inhibitor
natriuretic peptide type C
noradrenalin transporter
peptide
tacrolimus
urodilatin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
clinical pharmacology
society
therapy
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
blood level
blood pressure
critically ill patient
drug exposure
drug mechanism
exercise
genetic variability
human
Human immunodeficiency virus
infant
inflammation
model
modulation
patient
pharmacokinetics
population
prediction
renal clearance
simulation
synthesis
LANGUAGE OF ARTICLE
English
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 404
TITLE
Interventions to improve treatment of osteoporosis following fracture
AUTHOR NAMES
Schafer A.L.
Sellmeyer D.E.
AUTHOR ADDRESSES
(Schafer A.L., anne.schafer@ucsf.edu) Division of Endocrinology, Metabolism,
and Osteoporosis, University of California, San Francisco, San Francisco,
CA.
(Sellmeyer D.E.) Division of Endocrinology and Metabolism, Johns Hopkins
Bayview Medical Center, Baltimore, MD.
(Schafer A.L., anne.schafer@ucsf.edu) 2200 Post St., San Francisco, CA
94115.
CORRESPONDENCE ADDRESS
A. L. Schafer, 2200 Post St., San Francisco, CA 94115. Email:
anne.schafer@ucsf.edu
SOURCE
Journal of Clinical Outcomes Management (2008) 15:12 (587-594). Date of
Publication: December 2008
ISSN
1079-6533
BOOK PUBLISHER
Turner White Communications Inc., 125 Strafford Avenue, Suite 220, Wayne,
United States.
ABSTRACT
Objective: To review the approach to osteoporosis treatment following
fracture. Methods: Review of the literature. Results: Despite the tremendous
medical and economic impact of osteoporotic fractures, the majority of older
patients with fragility fractures do not subsequently receive appropriate
evaluation and therapy for osteoporosis. Relatively simple interventions can
increase the likelihood that a patient who sustains a fracture will receive
subsequent evaluation and therapy; however, the implementation of
interdisciplinary approaches and coordination of fracture treatment among
primary care providers, orthopedists, metabolic bone experts, dietitians,
physical therapists, and other pertinent health care professionals has been
a challenge for health care delivery systems. The comprehensive management
of osteoporosis includes evaluation of bone mineral density, assessment for
secondary causes of low bone density, initiation of nonpharmacologic
therapies such as improved nutrition and physical activity, and selection of
appropriate pharmacologic therapy. Effective pharmacologic options now
include oral or intravenous bisphosphonates, anabolic therapy with
parathyroid hormone, selective estrogen receptor modulator therapy with
raloxifene, intranasal calcitonin, and estrogen therapy. Conclusion:
Individual clinicians and health systems alike must minimize missed
opportunities for meaningful secondary prevention of fractures, especially
as the options expand for safe and efficacious treatment of osteoporosis.
EMTREE DRUG INDEX TERMS
alendronic acid (adverse drug reaction, clinical trial, drug combination,
drug therapy, oral drug administration)
anticonvulsive agent
calcitonin (adverse drug reaction, clinical trial, drug therapy, intranasal
drug administration)
calcium (clinical trial, drug therapy)
estrogen (clinical trial, drug combination, drug therapy)
gestagen (clinical trial, drug combination, drug therapy)
glucocorticoid
heparin
ibandronic acid (adverse drug reaction, clinical trial, drug combination,
drug therapy, intravenous drug administration, oral drug administration)
parathyroid hormone (clinical trial, drug combination, drug therapy)
parathyroid hormone[1-34] (adverse drug reaction, drug therapy)
placebo
raloxifene (clinical trial, drug combination, drug therapy, pharmacology)
risedronic acid (adverse drug reaction, clinical trial, drug combination,
drug therapy, oral drug administration)
vitamin D (clinical trial, drug dose, drug therapy)
zoledronic acid (adverse drug reaction, clinical trial, drug combination,
drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
fragility fracture (complication, drug therapy, prevention, therapy)
osteoporosis (diagnosis, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (side effect)
bone density
bone pain (side effect)
caregiver
clinical trial
continuous infusion
diet supplementation
dietitian
disease exacerbation
drug substitution
drug withdrawal
fever (side effect)
flu like syndrome (side effect)
groups by age
health care delivery
human
jaw osteonecrosis (side effect)
myalgia (side effect)
nose irritation (side effect)
osteosarcoma (side effect)
physical activity
physiotherapist
recommended drug dose
review
vitamin supplementation
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcium (7440-70-2)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
parathyroid hormone (12584-96-2, 68893-82-3, 9002-64-6)
parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
raloxifene (82640-04-8, 84449-90-1)
risedronic acid (105462-24-6, 122458-82-6)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Orthopedic Surgery (33)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009079882
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 405
TITLE
Early complications of ischemic stroke
AUTHOR NAMES
Bart van der Worp H.
Dianne Raaijmakers T.W.M.
Jaap Kappelle L.
AUTHOR ADDRESSES
(Bart van der Worp H., h.b.vanderworp@umcutrecht.nl; Dianne Raaijmakers
T.W.M.; Jaap Kappelle L.) Department of Neurology, Rudolf Magnus Institute
of Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584
CX Utrecht, Netherlands.
CORRESPONDENCE ADDRESS
H. Bart van der Worp, Department of Neurology, Rudolf Magnus Institute of
Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX
Utrecht, Netherlands. Email: h.b.vanderworp@umcutrecht.nl
SOURCE
Current Treatment Options in Neurology (2008) 10:6 (440-449). Date of
Publication: 2008
ISSN
1092-8480
BOOK PUBLISHER
Current Science Ltd, 34-42 Cleveland Street, London, United Kingdom.
ABSTRACT
Patients with acute ischemic stroke are at high risk of neurologic and
medical complications, such as space-occupying edema formation, hemorrhagic
transformation of the infarct, epileptic seizures, depression, and venous
thromboembolism. They should therefore be monitored closely for early
detection of these complications. Care is best when the patient is admitted
to a specialized stroke unit. The multidisciplinary approach provided by
stroke units, including specialized medical, nursing, and remedial
therapies, reduces the duration of hospitalization and improves functional
outcome. For many complications, however, optimal treatment and its effect
on functional outcome after stroke has not been established. Therefore, in
addition to the ongoing acute intervention trials, well-designed, large
randomized trials are needed to address the prevention and treatment of
complications and their effect on functional outcome. © Springer
Science+Business Media, LLC 2008.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
alteplase (drug therapy)
antibiotic agent (drug therapy)
anticoagulant agent (adverse drug reaction, drug therapy)
antihypertensive agent (drug therapy)
chlorpromazine (adverse drug reaction, drug therapy)
glucose (clinical trial, drug combination, drug therapy)
haloperidol (drug dose, drug therapy)
heparin (drug dose, drug therapy, subcutaneous drug administration)
insulin (clinical trial, drug combination, drug therapy)
labetalol (drug therapy, intravenous drug administration)
low molecular weight heparin (drug therapy, subcutaneous drug
administration)
meclofenoxate (drug therapy)
nitroprusside sodium (drug therapy)
paracetamol (drug dose, drug therapy)
potassium (clinical trial, drug combination, drug therapy)
serotonin uptake inhibitor (drug therapy)
tricyclic antidepressant agent (adverse drug reaction, drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (complication, drug therapy)
brain edema (complication, surgery, therapy)
brain hemorrhage (complication, drug therapy, side effect)
clinical trial
compression therapy
coronary artery disease (complication, diagnosis)
decompression surgery
decubitus (complication, prevention, therapy)
deep vein thrombosis (complication, diagnosis, drug therapy, therapy)
delirium (complication, drug therapy)
depression (complication, drug therapy)
diet supplementation
drug megadose
drug treatment failure
dysphagia (complication, therapy)
ECG abnormality (complication)
exercise
feeding apparatus
fever (complication, drug therapy)
functional status
hiccup (complication, drug therapy)
human
hyperglycemia (complication, drug therapy)
hypertension (complication, drug therapy)
hypotension (complication)
intracranial pressure
leg phlebography
low drug dose
lung embolism (complication)
malnutrition (complication, therapy)
mortality
physiotherapy
pneumonia (complication, drug therapy, prevention)
prognosis
recurrent disease
respiratory tract infection (complication, drug therapy, prevention)
review
sedation
seizure (complication, drug therapy, prevention)
shoulder pain (complication, prevention, therapy)
side effect (side effect)
therapeutic hyperventilation
unspecified side effect (side effect)
urine incontinence (complication, drug therapy)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alteplase (105857-23-6)
chlorpromazine (50-53-3, 69-09-0)
glucose (50-99-7, 84778-64-3)
haloperidol (52-86-8)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
insulin (9004-10-8)
labetalol (32780-64-6, 36894-69-6)
meclofenoxate (3685-84-5, 51-68-3)
nitroprusside sodium (14402-89-2, 15078-28-1)
paracetamol (103-90-2)
potassium (7440-09-7)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009044554
FULL TEXT LINK
http://dx.doi.org/10.1007/s11940-008-0046-5
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 406
TITLE
Ivabradine - A novel treatment for chronic stable angina
AUTHOR NAMES
Jackson J.M.
Kassianos G.
AUTHOR ADDRESSES
(Jackson J.M.; Kassianos G., editor@csfmedical.com) CSF Medical
Communications Ltd, Montpellier Drive, Cheltenham GL50 1TA, United Kingdom.
CORRESPONDENCE ADDRESS
G. Kassianos, CSF Medical Communications Ltd, Montpellier Drive, Cheltenham
GL50 1TA, United Kingdom. Email: editor@csfmedical.com
SOURCE
Drugs in Context (2008) 4:2 (135-152). Date of Publication: 2008
ISSN
1745-1981
1740-4398 (electronic)
BOOK PUBLISHER
CSF Medical Communications Ltd, Suite 119, Eagle TowerMontpellier Drive,
Cheltenham, United Kingdom.
ABSTRACT
Heart rate is an important determinant of myocardial oxygen consumption and
elevated heart rate is a known risk factor in coronary artery disease. Heart
rate reduction has been the cornerstone of antianginal and antiischemic
therapy for many years and is most often achieved by β-blockers. The
discovery of the f-channel and its role in regulating pacemaker activity in
the sinoatrial node led to the development of new pharmacological agents
such as ivabradine, which target these f-channels causing a reduction in
heart rate by inhibiting the I(f) current. Due to its specific and selective
action, ivabradine does not display any of the negative inotropic peripheral
vascular or central nervous system side-effects that have limited the use of
β-blockers in some patients. Ivabradine efficacy has been investigated in a
large clinical development programme involving 5000 participants including
over 3500 patients with chronic stable angina, and was shown to reduce
resting and exercise induced heart rate without modifying any
electrophysiological parameters. It has been shown to reduce heart rate at
rest and during exercise and improve measurable parameters of angina in a
dose-dependent manner. Its antiianginal and antiischemic effects have also
has been shown to be non-inferior to commonly use doses of atenolol and
amlodipine. Ivabradine is currently licensed for oral use at 5 and 7.5mg
twice daily for symptomatic treatment of chronic stable angina in patients
with normal sinus rhythm who are either intolerant of β-blockers or for whom
they are contraindicated. © 2008 CSF Medical Communications Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
ivabradine (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug concentration, drug dose, drug interaction, drug therapy,
oral drug administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
amlodipine (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
anticoagulant agent (drug combination, drug therapy)
antilipemic agent (drug combination, drug therapy)
atenolol (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
cytochrome P450 3A4 (endogenous compound)
dihydropyridine derivative (drug combination, drug therapy)
diltiazem
erythromycin
ketoconazole
lansoprazole (drug combination, drug interaction, oral drug administration)
nitrate (drug combination, drug therapy)
omeprazole (drug combination, drug interaction, oral drug administration)
oxygen (endogenous compound)
placebo
propranolol (clinical trial, drug comparison, drug therapy)
verapamil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
stable angina pectoris (drug therapy)
EMTREE MEDICAL INDEX TERMS
angina pectoris (side effect)
article
atrial fibrillation (side effect)
atrioventricular block (side effect)
channel gating
clinical trial
coronary artery disease
drug absorption
drug bioavailability
drug blood level
drug clearance
drug contraindication
drug dose comparison
drug dose increase
drug efficacy
drug half life
drug mechanism
drug metabolism
drug protein binding
drug safety
drug selectivity
drug targeting
drug tolerability
evening dosage
exercise
heart electrophysiology
heart infarction (side effect)
heart left ventricle function
heart muscle
heart muscle ischemia (side effect)
heart palpitation (side effect)
heart rate
heart ventricle extrasystole (side effect)
heart ventricle tachycardia (side effect)
human
inotropism
maximum plasma concentration
morning dosage
nonhuman
oxygen consumption
pacemaker
prognosis
rest
risk factor
single drug dose
sinus bradycardia (side effect)
sinus node
sinus rhythm
supraventricular premature beat (side effect)
supraventricular tachycardia (side effect)
time to maximum plasma concentration
treatment outcome
unstable angina pectoris (side effect)
visual disorder (side effect)
DRUG TRADE NAMES
procoralan
s 16257
CAS REGISTRY NUMBERS
amlodipine (88150-42-9)
atenolol (29122-68-7)
cytochrome P450 3A4 (329736-03-0)
diltiazem (33286-22-5, 42399-41-7)
erythromycin (114-07-8, 70536-18-4)
ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
ketoconazole (65277-42-1)
lansoprazole (103577-45-3)
nitrate (14797-55-8)
omeprazole (73590-58-6, 95510-70-6)
oxygen (7782-44-7)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008508969
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 407
TITLE
Predictors of Intention to Reduce Stroke Risk Among People at Risk of
Stroke: An Application of an Extended Health Belief Model
AUTHOR NAMES
Sullivan K.A.
White K.M.
Young R.M.
Chang A.
Roos C.
Scott C.
AUTHOR ADDRESSES
(Sullivan K.A., ka.sullivan@qut.edu.au; White K.M.; Young R.M.; Chang A.;
Roos C.; Scott C.) Institute of Health and Biomedical Innovation, .
(Sullivan K.A., ka.sullivan@qut.edu.au; White K.M.; Roos C.; Scott C.)
School of Psychology and Counselling, Queensland University of Technology,
QLD, Australia.
(Chang A.) School of Nursing, Queensland University of Technology, QLD,
Australia.
CORRESPONDENCE ADDRESS
K.A. Sullivan, Institute of Health and Biomedical Innovation, . Email:
ka.sullivan@qut.edu.au
SOURCE
Rehabilitation Psychology (2008) 53:4 (505-512). Date of Publication:
November 2008
ISSN
0090-5550
BOOK PUBLISHER
American Psychological Association Inc., 750 First Street NE, Washington,
United States.
ABSTRACT
Purpose: To examine predictors of intention to reduce stroke risk in a
sample of at risk individuals through the application of an expanded Health
Belief Model. Research Method: Predictors included stroke knowledge,
demographic variables, beliefs about stroke, and measures of subjective norm
and self-efficacy. The dependent variable was intention to reduce stroke
risk. Of the 276 surveys distributed to bowling clubs, senior citizens clubs
or retirement villages, 101 surveys were returned. Data from 76 of these
respondents were used for analysis. Results: With regard to exercise
intention, a pattern of significant correlations between HBM variables,
subjective norm, and self-efficacy was observed. Results of multiple
hierarchical regression analyses showed that perceived benefits of
undertaking exercise and self-efficacy in relation exercise were the two
most important determinants of exercise intentions. Conclusions: Findings
suggest that health beliefs may play an important role in stroke prevention.
Practice Implications: Stroke education and prevention programs that
selectively target beliefs about the perceived benefits of, and
self-efficacy related to, exercise to reduce stroke risk may prove most
efficacious. © 2008 American Psychological Association.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (etiology)
health behavior
Health Belief Model
EMTREE MEDICAL INDEX TERMS
adult
aged
alcohol consumption
article
atrial fibrillation
bowling
cardiovascular disease
diabetes mellitus
exercise
female
health survey
high risk patient
human
hypercholesterolemia
hypertension
immobilization
major clinical study
male
obesity
retirement
risk factor
risk reduction
self concept
smoking
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Neurology and Neurosurgery (8)
Public Health, Social Medicine and Epidemiology (17)
Psychiatry (32)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008603874
FULL TEXT LINK
http://dx.doi.org/10.1037/a0013359
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 408
TITLE
Paget disease of bone: Therapeutic options
AUTHOR NAMES
Silverman S.L.
AUTHOR ADDRESSES
(Silverman S.L., stuarts@slsdss.net) OMC Clinical Research Center, Beverly
Hills, CA.
(Silverman S.L., stuarts@slsdss.net) Department of Medicine and
Rheumatology, Cedars-Sinai/UCLA, 8641 Wilshire Blvd, Beverly Hills, CA.
CORRESPONDENCE ADDRESS
S. L. Silverman, Department of Medicine and Rheumatology, Cedars-Sinai/UCLA,
8641 Wilshire Blvd, Beverly Hills, CA. Email: stuarts@slsdss.net
SOURCE
Journal of Clinical Rheumatology (2008) 14:5 (299-305). Date of Publication:
October 2008
ISSN
1076-1608
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327,
Philadelphia, United States.
ABSTRACT
Paget disease of bone is a disorder of unknown etiology involving
disturbances in bone remodeling, typically leading to bone pain and other
complications such as skeletal deformities, fractures, hearing loss, and
neurologic complications. Bisphosphonates (BPs), both oral and intravenous,
have improved Paget treatment by reducing and normalizing bone turnover, as
measured by biochemical markers and by alleviating symptoms. Six BPs are
currently approved by the US Food and Drug Administration (FDA) for the
treatment of Paget disease, and each has unique characteristics, such as
response rates and requirements for dosage and administration, relevant to
clinical outcome. This review provides an overview of these agents-including
oral drugs such as alendronate and risedronate, and the intravenous agent
zoledronic acid-and briefly discusses other options for managing Paget
disease and monitoring treatment efficacy. © 2008 Lippincott Williams &
Wilkins.
EMTREE DRUG INDEX TERMS
alendronic acid (adverse drug reaction, clinical trial, drug comparison,
drug therapy, oral drug administration)
analgesic agent (drug combination, drug therapy)
bisphosphonic acid derivative (drug comparison, drug therapy, intravenous
drug administration, oral drug administration, pharmacoeconomics,
pharmacology)
calcitonin (drug therapy)
calcium (drug therapy)
clodronic acid (drug therapy, intravenous drug administration)
cyclooxygenase 2 inhibitor (drug therapy)
dactinomycin (drug therapy)
etidronic acid (adverse drug reaction, clinical trial, drug comparison, drug
therapy, oral drug administration, pharmacology)
gallium nitrate (drug therapy)
glucagon derivative (drug therapy)
mithramycin (drug therapy)
nonsteroid antiinflammatory agent (drug therapy)
olpadronic acid (drug therapy, pharmacology)
opiate (drug therapy)
pamidronic acid (adverse drug reaction, drug therapy, intravenous drug
administration, oral drug administration, pharmacology)
placebo
risedronic acid (adverse drug reaction, clinical trial, drug comparison,
drug therapy, oral drug administration)
tiludronic acid (adverse drug reaction, drug comparison, drug therapy,
pharmacology)
tricyclic antidepressant agent (drug combination, drug therapy)
vitamin D (drug therapy)
zoledronic acid (adverse drug reaction, clinical trial, drug comparison,
drug therapy, intravenous drug administration, pharmacoeconomics,
pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Paget bone disease (drug therapy, diagnosis, disease management, drug
therapy)
EMTREE MEDICAL INDEX TERMS
abdominal pain (side effect)
acupuncture
atrial fibrillation (side effect)
backache (side effect)
bone biopsy
bone pain (drug therapy, therapy)
bone scintiscanning
clinical assessment
clinical feature
clinical trial
diet supplementation
disease severity
drug approval
drug cost
drug efficacy
drug fever (side effect)
drug mechanism
drug safety
drug tolerability
drug withdrawal
dyspepsia (side effect)
esophagus stenosis (side effect)
esophagus ulcer (side effect)
flu like syndrome (side effect)
fracture (complication)
gastrointestinal symptom (side effect)
heartburn (side effect)
human
hydrotherapy
hypocalcemia (drug therapy, side effect)
iritis (side effect)
joint prosthesis
laboratory test
low back pain (complication)
low drug dose
morning dosage
nausea (side effect)
nerve root compression (complication, drug therapy, therapy)
nerve stimulation
neurologic disease (complication)
osteoarthritis (complication)
priority journal
radiculopathy (complication)
recommended drug dose
review
single drug dose
treatment response
walking aid
X ray
DRUG TRADE NAMES
actonel
aredia
didronel
fosamax
reclast
skelid
CAS REGISTRY NUMBERS
alendronic acid (66376-36-1)
calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
calcium (14092-94-5, 7440-70-2)
clodronic acid (10596-23-3, 22560-50-5)
dactinomycin (1402-38-6, 1402-58-0, 50-76-0)
etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
gallium nitrate (13494-90-1)
mithramycin (18378-89-7)
olpadronic acid (63132-39-8)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
pamidronic acid (40391-99-9, 57248-88-1)
risedronic acid (105462-24-6, 122458-82-6)
tiludronic acid (96538-83-9)
zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
Arthritis and Rheumatism (31)
Orthopedic Surgery (33)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2009259168
MEDLINE PMID
18838910 (http://www.ncbi.nlm.nih.gov/pubmed/18838910)
FULL TEXT LINK
http://dx.doi.org/10.1097/RHU.0b013e318188b1f3
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 409
TITLE
The prone position: A short clinical piece
AUTHOR NAMES
Traffas M.
Lewis C.B.
AUTHOR ADDRESSES
(Traffas M., marktraffas@yahoo.com) Vista Manor Nursing and Rehabilitation,
San Jose, CA.
(Lewis C.B.) George Washington College of Medicine, Bethesda, MD.
(Traffas M., marktraffas@yahoo.com) Vista Manor Nursing and Rehabilitation,
San Jose, CA 95116.
CORRESPONDENCE ADDRESS
M. Traffas, Vista Manor Nursing and Rehabilitation, San Jose, CA 95116.
Email: marktraffas@yahoo.com
SOURCE
Topics in Geriatric Rehabilitation (2008) 24:4 (354-356). Date of
Publication: October-December 2008
ISSN
0882-7524
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street, Philadelphia, United
States.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
body posture
geriatric patient
patient positioning
EMTREE MEDICAL INDEX TERMS
acute kidney failure
adult
aged
aspiration pneumonia
atrial fibrillation
bronchitis
cardiopulmonary hemodynamics
cardiovascular function
cerebrovascular accident
clinical assessment
exercise
gout
heart infarction
hip fracture
human
knee amputation
oxygen saturation
Parkinson disease
pneumonia
respiratory failure
risk benefit analysis
safety
short survey
sitting
subarachnoid hemorrhage
total knee replacement
treatment planning
EMBASE CLASSIFICATIONS
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2009346915
FULL TEXT LINK
http://dx.doi.org/10.1097/TGR.0b013e31818cd117
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 410
TITLE
Challenges to consider in practicing specialized medicine
AUTHOR NAMES
Kannel W.B.
AUTHOR ADDRESSES
(Kannel W.B., billkannel@yahoo.com) Boston University, Framingham Study,
Framingham, MA, United States.
(Kannel W.B., billkannel@yahoo.com) Boston University, Framingham Study, 73
Mount Wayte Avenue, Framingham, MA 01702, United States.
CORRESPONDENCE ADDRESS
W. B. Kannel, Boston University, Framingham Study, 73 Mount Wayte Avenue,
Framingham, MA 01702, United States. Email: billkannel@yahoo.com
SOURCE
Ochsner Journal (2008) 8:3 (105-107). Date of Publication: Fall 2008
ISSN
1524-5012
BOOK PUBLISHER
Ochsner Clinic, 1514 Jefferson Highway, New Orleans, United States.
EMTREE DRUG INDEX TERMS
uric acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
clinical research
medical education
EMTREE MEDICAL INDEX TERMS
abdominal aorta aneurysm
acute myeloblastic leukemia
Alzheimer disease
asthma
atherosclerosis
atrial fibrillation
breast cancer
bronchitis
cardiovascular disease
cataract
cerebrovascular accident
cholecystitis
colon cancer
coronary artery disease
dementia
diabetes mellitus
dyslipidemia
eating disorder
emphysema
endometrium cancer
environmental exposure
esophagus cancer
exercise
gallstone
genetic predisposition
gout
health care
health care organization
health care personnel
health status
heart failure
heart ventricle hypertrophy
human
hypertension
infertility
insulin resistance
kidney cancer
lung cancer
medical practice
medicine
menstrual irregularity
mortality
mouth cancer
nephrolithiasis
obesity
osteoarthritis
osteoporosis
pancreas cancer
periodontitis
pharynx cancer
pneumonia
preeclampsia
pregnancy diabetes mellitus
prematurity
prostate cancer
proteinuria
review
risk assessment
risk factor
sleep disorder
sleep disordered breathing
smoking
smoking cessation
stomach cancer
stress incontinence
uterine cervix cancer
weight gain
CAS REGISTRY NUMBERS
uric acid (69-93-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2008494709
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 411
TITLE
Management of gastroparesis
AUTHOR NAMES
Hasler W.L.
AUTHOR ADDRESSES
(Hasler W.L., whasler@umich.edu) Division of Gastroenterology, University of
Michigan Health System, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109,
United States.
CORRESPONDENCE ADDRESS
W.L. Hasler, Division of Gastroenterology, University of Michigan Health
System, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, United States.
Email: whasler@umich.edu
SOURCE
Expert Review of Gastroenterology and Hepatology (2008) 2:3 (411-423). Date
of Publication: June 2008
ISSN
1747-4124
BOOK PUBLISHER
Expert Reviews Ltd., 2 Albert Place, London, United Kingdom.
ABSTRACT
Gastroparesis presents with nausea, vomiting, early satiety and abdominal
discomfort, as well as a range of nongastrointestinal manifestations in
association with delays in gastric emptying. The disorder may be a
consequence of systemic illnesses, such as diabetes mellitus, occur as a
complication of gastroesophageal surgery or develop in an idiopathic fashion
and may mimic other disorders with normal gastric emptying. Some cases of
idiopathic gastroparesis present after a viral infection. Management relies
primarily on therapies that accelerate gastric emptying or reduce vomiting,
although endoscopic or surgical options are available for refractory cases.
Current research is focusing on the cellular and molecular mechanisms
underlying development of delayed gastric emptying, as well as factors
unrelated to motor dysfunction that may elicit some symptoms. Future
pharmaceuticals will target the contractile and nonmotor defects via novel
pathways. Novel electrical stimulation techniques will be employed either
alone or in combination with medications. © 2008 Expert Reviews Ltd.
EMTREE DRUG INDEX TERMS
antidepressant agent (drug interaction)
antiemetic agent (drug combination, drug interaction, drug therapy)
azithromycin (drug therapy)
benzodiazepine derivative (drug therapy)
bethanechol (adverse drug reaction, drug therapy, pharmacology)
botulinum toxin (clinical trial, drug dose, drug therapy)
cannabinoid (drug therapy)
cisapride (adverse drug reaction, drug therapy)
clarithromycin (drug therapy)
corticosteroid (drug therapy)
domperidone (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, oral drug administration,
pharmacokinetics, pharmacology)
dopamine receptor blocking agent (drug therapy)
erythromycin (adverse drug reaction, clinical trial, drug comparison, drug
dose, drug interaction, drug therapy, intravenous drug administration, oral
drug administration, pharmacology)
ghrelin (drug therapy, parenteral drug administration)
histamine H1 receptor antagonist (drug therapy)
macrolide (drug therapy)
metoclopramide (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, pharmacology, subcutaneous drug
administration)
mirtazapine (drug therapy)
mitemcinal (drug therapy, oral drug administration)
mosapride (drug therapy)
muscarinic receptor blocking agent (drug therapy)
neurokinin 1 receptor antagonist (drug therapy)
phenothiazine derivative (drug therapy)
prokinetic agent (drug combination, drug therapy)
pyridostigmine (drug therapy, pharmacology)
serotonin 3 antagonist (drug therapy)
tegaserod (adverse drug reaction, clinical trial, drug therapy)
thiethylperazine (drug therapy)
tricyclic antidepressant agent (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
stomach paresis (complication, diagnosis, drug therapy, etiology, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
abdominal discomfort
abdominal pain (side effect)
acupressure
agitation
amenorrhea (side effect)
atrial fibrillation (side effect)
bronchospasm (side effect)
cardiovascular disease (side effect)
central nervous system disease (side effect)
clinical feature
clinical trial
combination chemotherapy
diabetes mellitus
diaphoresis
diet therapy
differential diagnosis
drug dose comparison
drug fatality (side effect)
drug mechanism
drug megadose
drug penetration
drug potentiation
dystonia (side effect)
electrostimulation therapy
enteric feeding
esophagus candidiasis (diagnosis)
fatigue (side effect)
galactorrhea (side effect)
gastrointestinal surgery
gastrointestinal symptom (side effect)
heart arrhythmia (side effect)
human
hyperprolactinemia (side effect)
hypotension (side effect)
monotherapy
myoelectricity
nausea (side effect)
pathogenesis
pathophysiology
physical examination
psychotherapy
QT interval
review
satiety
sedation
side effect (side effect)
sleep disorder (side effect)
stomach emptying
stomach function disorder
stomach scintiscanning
sudden death
tardive dyskinesia (side effect)
urinary urgency (side effect)
virus infection
vomiting (side effect)
CAS REGISTRY NUMBERS
azithromycin (83905-01-5)
bethanechol (590-63-6, 674-38-4, 91609-06-2)
cisapride (81098-60-4)
clarithromycin (81103-11-9)
domperidone (57808-66-9)
erythromycin (114-07-8, 70536-18-4)
ghrelin (258279-04-8, 304853-26-7)
metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
mirtazapine (61337-67-5)
mitemcinal (154738-42-8, 154802-96-7)
mosapride citrate (112885-42-4)
pyridostigmine (101-26-8, 155-97-5)
tegaserod (145158-71-0, 189188-57-6)
thiethylperazine (1420-55-9)
EMBASE CLASSIFICATIONS
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008517750
MEDLINE PMID
19072389 (http://www.ncbi.nlm.nih.gov/pubmed/19072389)
FULL TEXT LINK
http://dx.doi.org/10.1586/17474124.2.3.411
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 412
TITLE
History-taking in cardiology
AUTHOR NAMES
Cripps T.
AUTHOR ADDRESSES
(Cripps T.) Bristol Royal Infirmary, United Kingdom.
CORRESPONDENCE ADDRESS
T. Cripps, Bristol Royal Infirmary, United Kingdom.
SOURCE
Foundation Years (2008) 4:3 (92-98). Date of Publication: June 2008
ISSN
1744-1889
BOOK PUBLISHER
Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
History taking is central to making a diagnosis in patients with heart
disease. Chest pain should be evaluated with particular attention to its
reproducible precipitation by exertion and prompt relief by rest. Only four
common arrhythmias cause palpitation. Ectopic beats present as a sensation
of missed beats and thumps; paroxysmal supraventricular tachycardia with
very clearly defined attacks usually lasting minutes only; paroxysmal atrial
fibrillation with longer but still clearly defined attacks. In sinus
tachycardia there is an almost constant feeling of palpitation, often with
other symptoms of anxiety. Cardiac breathlessness may be associated with
orthopnoea, paroxysmal nocturnal dyspnoea and peripheral oedema, though can
be very difficult to distinguish from other causes. Syncope is most commonly
vasovagal with recognisable precipitants; when due to arrhythmia is very
sudden in onset and recovery. Epilepsy is distinguished by an aura and
abnormal movements at the onset; maintained (rather than floppy) body tone
during the attack and a post-ictal phase. Time spent taking a careful
history will yield more towards a diagnosis than any number of sophisticated
and expensive tests. © 2008 Elsevier Ltd. All rights reserved.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anamnesis
cardiology
heart disease (diagnosis)
EMTREE MEDICAL INDEX TERMS
anxiety
atrial fibrillation
dyspnea
epilepsy (diagnosis)
exercise
extrasystole
faintness (diagnosis, etiology)
heart arrhythmia
heart palpitation
human
paroxysmal supraventricular tachycardia
peripheral edema
priority journal
rest
review
sinus tachycardia
thorax pain
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008329363
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mpfou.2008.04.008
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 413
TITLE
Propofol infusion syndrome: An overview of a perplexing disease
AUTHOR NAMES
Fodale V.
La Monaca E.
AUTHOR ADDRESSES
(Fodale V., vfodale@unime.it; La Monaca E.) Department of Neurosciences,
Psychiatric and Anaesthesiological Sciences, University of Messina, Messina,
Italy.
(Fodale V., vfodale@unime.it) Department of Neurosciences, Psychiatric and
Anaesthesiological Sciences, University of Messina, Policlinico
Universitario, via C. Valeria, Messina, 98125, Italy.
CORRESPONDENCE ADDRESS
V. Fodale, Department of Neurosciences, Psychiatric and Anaesthesiological
Sciences, University of Messina, Policlinico Universitario, via C. Valeria,
Messina, 98125, Italy. Email: vfodale@unime.it
SOURCE
Drug Safety (2008) 31:4 (293-303). Date of Publication: 2008
ISSN
0114-5916
BOOK PUBLISHER
Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay,
Auckland 10, New Zealand.
ABSTRACT
Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent
that is widely used in adults and children for sedation and the induction
and maintenance of anaesthesia. Propofol has gained popularity for its rapid
onset and rapid recovery even after prolonged use, and for the
neuroprotection conferred. However, a review of the literature reveals
multiple instances in which prolonged propofol administration (>48 hours) at
high doses (>4 mg/kg/h) may cause a rare, but frequently fatal complication
known as propofol infusion syndrome (PRIS). PRIS is characterized by
metabolic acidosis, rhabdomyolysis of both skeletal and cardiac muscle,
arrhythmias (bradycardia, atrial fibrillation, ventricular and
supraventricular tachycardia, bundle branch block and asystole), myocardial
failure, renal failure, hepatomegaly and death. PRIS has been described as
an 'all or none' syndrome with sudden onset and probable death. The
literature does not provide evidence of degrees of symptoms, nor of mildness
or severity of signs in the clinical course of the syndrome. Recently, a
fatal case of PRIS at a low infusion rate (1.9-2.6 mg/kg/h) has been
reported. Common laboratory and instrumental findings in PRIS are
myoglobinuria, downsloping ST-segment elevation, an increase in plasma
creatine kinase, troponin I, potassium, creatinine, azotaemia,
malonylcarnitine and C5-acylcarnitine, whereas in the mitochondrial
respiratory electron transport chain, the activity of complex IV and
cytochrome oxidase ratio is reduced. Propofol should be used with caution
for sedation in critically ill children and adults, as well as for long-term
anesthesia in otherwise healthy patients, and doses exceeding 4-5 mg/kg/h
for long periods (>48 h) should be avoided. If PRIS is suspected, propofol
must be stopped immediately and cardiocirculatory stabilization and
correction of metabolic acidosis initiated. So, PRIS must be kept in mind as
a rare, but highly lethal, complication of propofol use, not necessarily
confined to its prolonged use. Furthermore, the safe dosage of propofol may
need re-evaluation, and new studies are needed. © 2008 Adis Data Information
BV. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
propofol (adverse drug reaction, intravenous drug administration)
EMTREE DRUG INDEX TERMS
barbituric acid derivative
benzodiazepine derivative
catecholamine
corticosteroid
dexmedetomidine
dopamine (endogenous compound)
midazolam
noradrenalin (endogenous compound)
pentobarbital
serotonin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anesthesia induction
sedation
EMTREE MEDICAL INDEX TERMS
anesthetic recovery
atrial fibrillation (side effect)
blood clotting disorder (side effect)
bradycardia (side effect)
brain disease (side effect)
coma (side effect)
creatine kinase blood level
creatinine blood level
critically ill patient
death
differential diagnosis
drug withdrawal
fatality
fever (side effect)
heart arrest (side effect)
heart arrhythmia (side effect)
heart bundle branch block (side effect)
heart failure (side effect)
heart right bundle branch block (side effect)
heart ventricle fibrillation (side effect)
heart ventricle tachycardia (side effect)
hepatomegaly (side effect)
human
hyperkalemia (side effect)
hyperlipidemia (side effect)
hyperphosphatemia (side effect)
hypotension (side effect)
hypoxia (side effect)
kidney failure (side effect)
metabolic acidosis (side effect)
muscle necrosis (side effect)
muscle weakness (side effect)
myoglobinuria (side effect)
neuroprotection
oliguria (side effect)
pathophysiology
potassium blood level
priority journal
propofol infusion syndrome (side effect)
propofol infusion syndrome (side effect)
rare disease
respiratory acidosis (side effect)
respiratory chain
review
rhabdomyolysis (side effect)
risk factor
shock (side effect)
side effect (side effect)
ST segment elevation
supraventricular tachycardia (side effect)
syndrome
tachycardia (side effect)
uremia (side effect)
urine color
CAS REGISTRY NUMBERS
dexmedetomidine (113775-47-6)
dopamine (51-61-6, 62-31-7)
midazolam (59467-70-8)
noradrenalin (1407-84-7, 51-41-2)
pentobarbital (57-33-0, 76-74-4)
propofol (2078-54-8)
serotonin (50-67-9)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008150653
MEDLINE PMID
18366240 (http://www.ncbi.nlm.nih.gov/pubmed/18366240)
FULL TEXT LINK
http://dx.doi.org/10.2165/00002018-200831040-00003
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 414
TITLE
Challenges of implementing a feasibility study of acupuncture in acute and
critical care settings.
AUTHOR NAMES
Lindquist R.
Sendelbach S.
Windenburg D.C.
Vanwormer A.
Treat-Jacobson D.
Chose D.
AUTHOR ADDRESSES
(Lindquist R.; Sendelbach S.; Windenburg D.C.; Vanwormer A.; Treat-Jacobson
D.; Chose D.) University of Minnesota School of Nursing, Minneapolis, MN
55455, USA.
CORRESPONDENCE ADDRESS
R. Lindquist, University of Minnesota School of Nursing, Minneapolis, MN
55455, USA. Email: lindq002@umn.edu
SOURCE
AACN advanced critical care (2008) 19:2 (202-210). Date of Publication: 2008
Apr-Jun
ISSN
1559-7768
ABSTRACT
A majority of people in the United States use complementary and alternative
therapies, and this use is increasing. With the increasing interest,
providers must evaluate potential risks and benefits of these therapies.
This article describes challenges of a feasibility study of acupuncture as a
potential therapeutic adjunct to prevent atrial fibrillation following
coronary artery bypass graft surgery. Institutional review board approval,
consent logistics, implementation issues, and rapid changes in clinical
practice were the primary challenges faced. Unique technological features of
the institution helped address these challenges. The study protocol was
acceptable to staff, patients, and family and was considered safe for these
patients. However, the protocol was not feasible as designed; therefore, the
efficacy of acupuncture could not be determined. Continued research is
needed to evaluate the effectiveness of acupuncture to prevent atrial
fibrillation following coronary artery bypass graft surgery. Recommendations
for future studies of complementary and alternative therapies in acute and
critical care settings are offered.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
intensive care
EMTREE MEDICAL INDEX TERMS
acute disease
article
feasibility study
pilot study
LANGUAGE OF ARTICLE
English
MEDLINE PMID
18560289 (http://www.ncbi.nlm.nih.gov/pubmed/18560289)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 415
TITLE
Gastroparesis - Current concepts and considerations
AUTHOR NAMES
Hasler W.L.
AUTHOR ADDRESSES
(Hasler W.L., whasler@umich.edu) Department of Internal Medicine, Division
of Gastroenterology, University of Michigan Health System, Ann Arbor, MI,
United States.
CORRESPONDENCE ADDRESS
W.L. Hasler, Department of Internal Medicine, Division of Gastroenterology,
University of Michigan Health System, Ann Arbor, MI, United States. Email:
whasler@umich.edu
SOURCE
MedGenMed Medscape General Medicine (2008) 10:1 Article Number: 16. Date of
Publication: 2008
ISSN
1531-0132
BOOK PUBLISHER
Medscape Health Network, 224 W. 30th Street, New York, United States.
EMTREE DRUG INDEX TERMS
antiarrhythmic agent (adverse drug reaction, drug combination, drug
interaction)
antidepressant agent (adverse drug reaction, drug combination, drug
interaction)
antiemetic agent (adverse drug reaction, drug combination, drug interaction,
drug therapy)
antifungal agent (adverse drug reaction, drug combination, drug interaction)
antineoplastic agent (adverse drug reaction)
azithromycin (drug comparison, drug therapy)
bethanechol (adverse drug reaction, drug therapy)
buspirone (drug therapy)
calcium antagonist (adverse drug reaction, drug combination, drug
interaction)
cholinesterase inhibitor (drug therapy)
cisapride (adverse drug reaction, drug therapy)
clarithromycin (drug comparison, drug therapy)
corticosteroid (drug therapy)
domperidone (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, oral drug administration)
erythromycin (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug dose, drug interaction, drug therapy, intravenous drug
administration, oral drug administration)
ghrelin (drug therapy, parenteral drug administration)
ginger extract (drug therapy)
metoclopramide (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, oral drug administration,
subcutaneous drug administration)
mirtazapine (drug therapy)
mitemcinal (drug therapy, oral drug administration)
neuroleptic agent (adverse drug reaction, drug combination, drug
interaction)
pertechnetic acid tc 99m (intravenous drug administration)
prochlorperazine (drug therapy)
prokinetic agent (clinical trial, drug combination, drug therapy)
pyridostigmine (drug therapy)
sumatriptan (drug therapy)
tegaserod (adverse drug reaction, clinical trial, drug therapy)
thiethylperazine (drug therapy)
tricyclic antidepressant agent (drug therapy)
unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
stomach paresis (complication, diagnosis, drug therapy, epidemiology,
etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
abdominal cramp (side effect)
abdominal pain (side effect)
acupressure
agitation
amenorrhea (side effect)
article
atrial fibrillation (side effect)
bronchospasm (side effect)
cardiovascular disease (side effect)
chemotherapy induced emesis (drug therapy, prevention, side effect)
clinical feature
clinical trial
diabetic stomach paresis (diagnosis, drug therapy, epidemiology, etiology,
surgery, therapy)
diaphoresis
diet therapy
differential diagnosis
digestive system function disorder
disease association
disease severity
drug dose regimen
drug fatality (side effect)
drug megadose
drug potentiation
drug withdrawal
dystonia (side effect)
electrogastrography
electrostimulation
enteric feeding
fatigue (side effect)
feedback system
galactorrhea (side effect)
heart arrhythmia (side effect)
human
hyperprolactinemia (side effect)
hypnosis
hypotension (side effect)
idiopathic gastroparesis (diagnosis, drug therapy, epidemiology, etiology,
surgery, therapy)
monotherapy
nausea (side effect)
nausea and vomiting (drug therapy)
parenteral nutrition
pathogenesis
postoperative nausea (complication, prevention, therapy)
QT prolongation (side effect)
side effect (side effect)
single photon emission computer tomography
sleep disorder (side effect)
stomach disease (diagnosis, drug therapy, epidemiology, etiology, surgery,
therapy)
stomach emptying
stomach motility
sudden death
tardive dyskinesia (side effect)
urinary urgency (side effect)
vomiting (side effect)
CAS REGISTRY NUMBERS
azithromycin (83905-01-5)
bethanechol (590-63-6, 674-38-4, 91609-06-2)
buspirone (33386-08-2, 36505-84-7)
cisapride (81098-60-4)
clarithromycin (81103-11-9)
domperidone (57808-66-9)
erythromycin (114-07-8, 70536-18-4)
ghrelin (258279-04-8, 304853-26-7)
metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
mirtazapine (61337-67-5)
mitemcinal (154738-42-8, 154802-96-7)
pertechnetic acid tc 99m (23288-60-0)
prochlorperazine (58-38-8)
pyridostigmine (101-26-8, 155-97-5)
sumatriptan (103628-46-2)
tegaserod (145158-71-0, 189188-57-6)
thiethylperazine (1420-55-9)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Radiology (14)
Public Health, Social Medicine and Epidemiology (17)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2008077376
MEDLINE PMID
18324326 (http://www.ncbi.nlm.nih.gov/pubmed/18324326)
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 416
TITLE
Clinical hypnosis for reduction of atrial fibrillation after coronary artery
bypass graft surgery.
AUTHOR NAMES
Novoa R.
Hammonds T.
AUTHOR ADDRESSES
(Novoa R.; Hammonds T.) Aultman Heart Center, Aultman Health Foundation,
Canton, OH 44714, USA.
CORRESPONDENCE ADDRESS
R. Novoa, Aultman Heart Center, Aultman Health Foundation, Canton, OH 44714,
USA. Email: rnovoa@neo.rr.com
SOURCE
Cleveland Clinic journal of medicine (2008) 75 Suppl 2 (S44-47). Date of
Publication: Mar 2008
ISSN
0891-1150
ABSTRACT
The belief that postoperative atrial fibrillation (PAF) results from
transient autonomic dysfunction suggests that interventions such as clinical
hypnosis may reduce the incidence of PAF. To explore this hypothesis, we
retrospectively compared outcomes between two groups of patients undergoing
coronary artery bypass graft surgery: 50 consecutive patients who received
preoperative hypnoidal explanation of the surgical procedure and 50
case-matched historical controls who received no clinical hypnosis. The
patients who received hypnosis were significantly less likely to experience
an episode of PAF (P = .003) and showed nonsignificant trends toward
superior outcomes in terms of length of stay, narcotic use, and total
hospital charges. Our findings indicate that prospective randomized trials
are warranted to further delineate the potential benefit of clinical
hypnosis for prevention of PAF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (etiology, prevention, therapy)
coronary artery bypass graft (adverse drug reaction)
hypnosis
EMTREE MEDICAL INDEX TERMS
aged
article
autonomic nervous system
case control study
female
human
incidence
male
pathophysiology
retrospective study
risk factor
LANGUAGE OF ARTICLE
English
MEDLINE PMID
18540146 (http://www.ncbi.nlm.nih.gov/pubmed/18540146)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 417
TITLE
Possible effects of acupuncture on atrial fibrillation and post-herpetic
neuralgia - A case report
AUTHOR NAMES
Valaskatgis P.
Macklin E.A.
Schachter S.C.
Wayne P.M.
AUTHOR ADDRESSES
(Valaskatgis P., peterval@comcast.net) New England School of Acupuncture,
Newton, MA, United States.
(Macklin E.A.) Massachusetts General Hospital, Boston, MA, United States.
(Macklin E.A.) Department of Medicine, Harvard Medical School, Boston, MA,
United States.
(Schachter S.C.) Osher Research Center, Harvard Medical School, Boston, MA,
United States.
(Wayne P.M.) Tai Chi Research Programs, Osher Research Center, Harvard
Medical School, Boston, MA, United States.
CORRESPONDENCE ADDRESS
P. Valaskatgis, New England School of Acupuncture, Newton, MA, United
States. Email: peterval@comcast.net
SOURCE
Acupuncture in Medicine (2008) 26:1 (51-56). Date of Publication: March 2008
ISSN
0964-5284
BOOK PUBLISHER
BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
A 72 year old female with a main complaint of severe post-herpetic neuralgia
and a secondary complaint of atrial fibrillation (AF) received two series of
acupuncture treatments totalling 20 treatments over a four month period. Her
standard medical treatment remained unchanged. The primary focus of the
acupuncture was pain relief; however, two acupuncture points (PC6, SP4) were
included in both treatment series because of possible effects on both costal
or chest pain and cardiac arrhythmias, according to Traditional Chinese
Medicine (TCM) teaching and limited research. As recorded by her pacemaker,
estimated weekly episodes of AF in the patient decreased significantly, and
percentage time in AF decreased with borderline statistical significance,
from the pretreatment estimates during the second series of treatments
(weekly AF episode estimates: pretreatment =71.4; second series =16.5,
difference estimates =-54.9, 95% CI -6.5 to -103.3, P=0.02; percentage time
in AF estimates: pretreatment =30.6; 2 second series =18.0, difference
estimates =-12.6, 95% CI 0.9 to -26.0, P=0.08). The pain levels were also
significantly reduced following the acupuncture treatment series by more
than 67%. Further studies are warranted to further explore these
observations of a possible effect of acupuncture on both atrial fibrillation
and post-herpetic neuralgia.
EMTREE DRUG INDEX TERMS
amitriptyline
analgesic agent (drug therapy)
atorvastatin
calcium carbonate
digoxin
gabapentin (drug therapy)
glibenclamide
levothyroxine
meprednisone (drug therapy)
paracetamol
verapamil
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
atrial fibrillation (therapy)
postherpetic neuralgia (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
aged
analgesia
article
case report
confidence interval
diabetes mellitus
female
heart arrhythmia
human
hyperlipidemia
hypothyroidism
pacemaker
pain assessment
skin sensitivity
statistical significance
thorax pain
CAS REGISTRY NUMBERS
amitriptyline (50-48-6, 549-18-8)
atorvastatin (134523-00-5, 134523-03-8)
calcium carbonate (13397-26-7, 13701-58-1, 14791-73-2, 471-34-1)
digoxin (20830-75-5, 57285-89-9)
gabapentin (60142-96-3)
glibenclamide (10238-21-8)
levothyroxine (51-48-9)
meprednisone (1247-42-3)
paracetamol (103-90-2)
verapamil (152-11-4, 52-53-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008164524
MEDLINE PMID
18356799 (http://www.ncbi.nlm.nih.gov/pubmed/18356799)
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 418
TITLE
Use of dietary supplements by patients taking digoxin
AUTHOR NAMES
Ting L.S.L.
Shalansky S.J.
Neall E.
Ensom M.H.H.
AUTHOR ADDRESSES
(Ting L.S.L., lting@shaw.ca; Neall E.) Faculty of Pharmaceutical Sciences,
University of British Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3,
Canada.
(Shalansky S.J.) Department of Pharmacy, St Paul's Hospital, Providence
Health Care, Vancouver, BC, Canada.
(Ensom M.H.H.) Children's and Women's Health Care of British Columbia,
Faculty of Pharmaceutical Sciences, University of British Columbia,
Vancouver, BC, Canada.
CORRESPONDENCE ADDRESS
L.S.L. Ting, Faculty of Pharmaceutical Sciences, University of British
Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada. Email:
lting@shaw.ca
SOURCE
Canadian Journal of Hospital Pharmacy (2008) 61:1 (30-40). Date of
Publication: January/February 2008
ISSN
0008-4123
BOOK PUBLISHER
Canadian Society of Hospital Pharmacists, 30 Concourse Gate, Unit 3, Ottawa,
Canada.
ABSTRACT
Background: The use of dietary supplements is common, and interactions with
digoxin have been proposed. However, little is known about usage patterns of
these supplements among patients taking digoxin. Objectives: To determine
the prevalence of use of dietary supplements and over-the-counter (OTC)
medications among patients taking digoxin, and to correlate the occurrence
of symptoms related to digoxin toxicity with supplement use. Methods: One
hundred and seventy-two adult patients who had been receiving digoxin
therapy for at least 3 months were recruited. An open-label,
cross-sectional, interviewer-administered survey was conducted to assess
demographic characteristics, health status, details of digoxin therapy, and
use of prescription and nonprescription medications. The use of supplements
and interacting prescription medications was compared between participants
reporting symptoms of digoxin toxicity and those who did not report such
symptoms. Results: Most of the patients (122 or 70.9%) were men; the mean
age ± standard deviation was 65.2 ± 12.0 years, and patients had been taking
digoxin for a mean of 5.9 years at 174.8 ± 77.9 μg/day. Thirty-seven (21.5%)
of the patients were using herbal supplements, and 153 (89.0%) were taking
OTC medications or nonherbal supplements. Four (2.3%) patients were taking
herbal supplements that might interact with digoxin, and 50 (29.1%) took OTC
drugs or nonherbal supplements with potential interactions. Between patients
who reported symptoms of digoxin toxicity and those who did not reports such
symptoms, there was no difference in the use of OTC medications or nonherbal
supplements, herbal supplements, or prescription medications (except for
diltiazem). Conclusions: In this study, few of the patients were taking
herbal supplements that could interact with digoxin, and no clinically
significant herb-digoxin interactions were observed.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digoxin (adverse drug reaction, drug combination, drug concentration, drug
therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination)
amiodarone (drug combination)
antacid agent (drug combination)
carvedilol (drug combination)
cascara sagrada (drug combination)
Cassia augustifolia extract (drug combination)
Cassia extract (drug combination)
cranberry extract (drug combination)
diltiazem (drug combination)
Echinacea extract (drug combination)
furosemide (drug combination)
garlic extract (drug combination)
Ginkgo biloba extract (drug combination)
ginseng extract (drug combination)
Glycyrrhiza extract (drug combination)
herbaceous agent (drug combination)
hydrochlorothiazide (drug combination)
kaolin pectin (drug combination)
mineral (drug combination)
non prescription drug (drug combination)
omeprazole (drug combination)
paracetamol (drug combination)
potassium (drug combination)
primrose oil (drug combination)
quinine (drug combination)
Sabal extract (drug combination)
spironolactone (drug combination)
unclassified drug
unindexed drug
vitamin (drug combination)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diet supplementation
EMTREE MEDICAL INDEX TERMS
adult
aged
anorexia (side effect)
article
atrial fibrillation (drug therapy)
controlled study
cross-sectional study
diarrhea (side effect)
digoxin blood level
female
health status
heart failure (drug therapy)
herb drug interaction
human
major clinical study
male
nausea (side effect)
open study
prescription
prevalence
visual disorder (side effect)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
carvedilol (72956-09-3)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
furosemide (54-31-9)
hydrochlorothiazide (58-93-5)
kaolin pectin (8047-39-0)
omeprazole (73590-58-6, 95510-70-6)
paracetamol (103-90-2)
potassium (7440-09-7)
primrose oil (65546-85-2)
quinine (130-89-2, 130-95-0, 14358-44-2, 549-48-4, 549-49-5, 60-93-5,
7549-43-1)
spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
2008113869
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 419
TITLE
Thoracic epidural analgesia in cardiac surgery: impact on postoperative
morbidity
AUTHOR NAMES
Bracco D.
Hemmerling T.M.
AUTHOR ADDRESSES
(Bracco D., David.Bracco@mcgill.ca; Hemmerling T.M.) Department of
Anesthesia, Perioperative Cardiac Research Group, McGill University,
Montreal, Canada.
CORRESPONDENCE ADDRESS
D. Bracco, Department of Anesthesia, Perioperative Cardiac Research Group,
McGill University, Montreal, Canada. Email: David.Bracco@mcgill.ca
SOURCE
Techniques in Regional Anesthesia and Pain Management (2008) 12:1 (32-40).
Date of Publication: January 2008
Regional anesthesia for Cardiac Surgery, Book Series Title:
ISSN
1084-208X
BOOK PUBLISHER
W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
Application of thoracic epidural analgesia in cardiac surgery offers several
advantages but requires an adaptation of the postoperative clinical
pathways. These adaptations are mandatory to minimize the risks related to
the use of epidural catheters in cardiac anesthesia and to gain the maximum
benefits from the technique. It involves lower doses of opioids, aggressive
temperature and fluid management, strict anticoagulation guidelines, and
clear staff information. Thoracic epidural analgesia has the potential to
improve outcome after cardiac surgery: better analgesia, better
postoperative respiratory physiotherapy, better pulmonary outcome, better
myocardial protection, attenuation of stress response, and possibly shorter
hospital stay. This potential needs to be supported by a change in all
aspects of postoperative patient management and the creation of new clinical
pathways. © 2008 Elsevier Inc. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
narcotic analgesic agent
EMTREE DRUG INDEX TERMS
catecholamine (endogenous compound)
small heat shock protein
troponin I (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
epidural anesthesia
heart surgery
morbidity
EMTREE MEDICAL INDEX TERMS
acute kidney failure
anticoagulant therapy
article
artificial ventilation
atrial fibrillation
breathing exercise
coronary artery bypass graft
delirium
extubation
fluid resuscitation
health care utilization
heart protection
human
intensive care unit
length of stay
mortality
pneumonia
postoperative analgesia
sedation
surgical stress
warming
CAS REGISTRY NUMBERS
troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007619457
FULL TEXT LINK
http://dx.doi.org/10.1053/j.trap.2007.10.005
COPYRIGHT
Copyright 2008 Elsevier B.V., All rights reserved.
RECORD 420
TITLE
Functional capacity after traditional Chinese medicine (qi gong) training in
patients with chronic atrial fibrillation: a randomized controlled trial.
AUTHOR NAMES
Pippa L.
Manzoli L.
Corti I.
Congedo G.
Romanazzi L.
Parruti G.
AUTHOR ADDRESSES
(Pippa L.; Manzoli L.; Corti I.; Congedo G.; Romanazzi L.; Parruti G.)
Camillo de Lellis per la Ricera Clinica Applicata, Pescara, Italy.
CORRESPONDENCE ADDRESS
L. Pippa, Camillo de Lellis per la Ricera Clinica Applicata, Pescara, Italy.
SOURCE
Preventive cardiology (2007) 10:1 (22-25). Date of Publication: 2007 Winter
ISSN
1520-037X
ABSTRACT
Evidence indicates that low energy expenditure protocols derived from
traditional Chinese medicine may benefit patients with cardiac impairment;
therefore, the authors carried out a randomized controlled trial to test a
16-week medically assisted qi gong training program for the physical
rehabilitation of patients with stable chronic atrial fibrillation and
preserved left ventricular function. Functional capacity variation was
evaluated using the 6-minute walk test, which was performed at baseline, at
the end of the intervention, and after 16 weeks. Thirty men and 13 women
(mean age, 68+/-8 years) were randomized to the intervention protocol or to
a wait-list control group. Qi gong training was well tolerated and, compared
with baseline, trained patients walked an average 114 meters more (27%) at
the end of treatment (P<.001) and 57 meters more (13.7%) 16 weeks later
(P=.008). Control subjects showed no variation in functional capacity. These
results seem promising and deserve confirmation with further research.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
breathing exercise
Chinese medicine
EMTREE MEDICAL INDEX TERMS
aged
article
chronic disease
clinical trial
controlled clinical trial
controlled study
exercise tolerance
female
human
male
middle aged
pathophysiology
randomized controlled trial
LANGUAGE OF ARTICLE
English
MEDLINE PMID
17215629 (http://www.ncbi.nlm.nih.gov/pubmed/17215629)
FULL TEXT LINK
http://dx.doi.org/10.1111/j.1520-037X.2007.05721.x
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 421
TITLE
Toxicity of Panax genseng - An herbal medicine and dietary supplement
AUTHOR NAMES
Chan P.-C.
Fu P.P.
AUTHOR ADDRESSES
(Chan P.-C., chanp@niehs.nih.gov) National Institute of Environmental Health
Sciences, Research Triangle Park, NC 27709, United States.
(Fu P.P., peter.fu@fda.hhs.gov) National Center for Toxicological Research,
Jefferson, AR 72079, United States.
CORRESPONDENCE ADDRESS
P.-C. Chan, National Institute of Environmental Health Sciences, Research
Triangle Park, NC 27709, United States. Email: chanp@niehs.nih.gov
SOURCE
Journal of Food and Drug Analysis (2007) 15:4 (416-427). Date of
Publication: December 2007
Quality Assurance and Safety of Herbal Dietary Supplements, Book Series
Title:
ISSN
1021-9498
BOOK PUBLISHER
National Laboratories of Foods and Drugs, 161-2 Kuen Yang Street, Nankang,
Taipei, Taiwan.
ABSTRACT
Ginseng is one of the most popular herbal dietary supplements in the U.S.
market, with five to six million persons using it even before the recent
boom in the herbal supplement industry. Ginsana (G115 ginseng), a
standardized extract of Panax ginseng (Asian ginseng, also called Chinese or
Korean ginseng) controls half of this market. Numerous reports of adverse
effects from products containing ginseng have been filed with the U.S. Food
and Drug Administration (FDA). The literature also documents "ginseng abuse
syndrome" among regular users. The chronic effects of ginseng are not well
characterized. Because of its significant human exposure and little
information on toxicity is available, Panax ginseng has been nominated by
the U.S. National Institutes of Health (NTH) to the U.S. National Toxicology
Program (NTP) for assessing its carcinogenic potential. In this review, we
discuss the environmental occurrence, purported therapeutic effects,
biological effects, and toxicity of ginseng, with focus on Panax ginseng. To
demonstrate how NTP chronic tumorigenicity bioassays are conducted, the
turnorigenicity bioassay of Panax ginseng is detailed described.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
ginseng extract (adverse drug reaction, drug analysis, drug dose, drug
interaction, drug therapy, drug toxicity, oral drug administration,
pharmacology)
EMTREE DRUG INDEX TERMS
2,3,7,8 tetrachlorodibenzo para dioxin (drug therapy)
cyclophosphamide (adverse drug reaction, drug toxicity)
cytochrome P450 (drug interaction)
ginseng saponin (drug toxicity, pharmacology)
ginsenoside (drug analysis, pharmacology)
ginsenoside Rb 1 (drug analysis, drug therapy, oral drug administration,
pharmacokinetics)
ginsenoside Rb 2 (drug analysis, drug therapy, oral drug administration,
pharmacokinetics)
ginsenoside Rc (drug analysis, oral drug administration)
ginsenoside Rd (drug analysis)
ginsenoside Re (drug analysis)
ginsenoside Rf (drug analysis)
ginsenoside Rg 1 (drug analysis, drug therapy, pharmacokinetics)
ginsenoside Rg 2 (drug analysis)
ginsenoside Rg 3 (oral drug administration, pharmacokinetics, pharmacology)
ginsenoside rh 1 (drug analysis)
ginsenoside Rh 2 (drug toxicity, pharmacology)
protopanaxadiol (pharmacokinetics)
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diet supplementation
herbal medicine
EMTREE MEDICAL INDEX TERMS
agitation
atrial fibrillation (side effect)
blurred vision (side effect)
bone marrow necrosis (side effect)
cerebrovascular accident (side effect)
chemical composition
coma (side effect)
concentration loss (side effect)
dermatomyositis (side effect)
diabetes mellitus (drug therapy)
diarrhea (side effect)
dizziness (side effect)
drug absorption
drug eruption (side effect)
drug fatality (side effect)
drug half life
drug induced headache (side effect)
drug megadose
drug metabolism
edema (side effect)
environmental exposure
esophagus injury (side effect)
euphoria
genotoxicity (side effect)
heart palpitation (side effect)
human
hypertension (side effect)
insomnia (side effect)
jaundice (side effect)
liver injury (drug therapy)
mastalgia (side effect)
mental health
nausea (side effect)
nausea and vomiting (side effect)
neurologic disease (drug therapy)
neuroprotection
nonhuman
pain (side effect)
Parkinson disease (drug therapy)
pruritus (side effect)
rash (side effect)
reproductive toxicity (side effect)
restlessness (side effect)
review
side effect (side effect)
spinal cord injury (drug therapy)
standardization
Stevens Johnson syndrome (side effect)
stomach pain (side effect)
sweating
thorax pain (side effect)
thrombocytopenia (side effect)
tonic clonic seizure (side effect)
uterus bleeding (side effect)
vagina bleeding (side effect)
vomiting (side effect)
CAS REGISTRY NUMBERS
2,3,7,8 tetrachlorodibenzo para dioxin (1746-01-6)
cyclophosphamide (50-18-0)
cytochrome P450 (9035-51-2)
ginsenoside (74749-74-9)
ginsenoside Rb 1 (41753-43-9)
ginsenoside Rb 2 (11021-13-9)
ginsenoside Rc (11021-14-0)
ginsenoside Rd (52705-93-8)
ginsenoside Re (52286-59-6)
ginsenoside Rg 1 (22427-39-0)
ginsenoside Rg 2 (52286-74-5)
ginsenoside rf (52286-58-5)
ginsenoside rh 1 (63223-86-9)
protopanaxadiol (7755-01-3)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Clinical and Experimental Biochemistry (29)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008130783
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 422
TITLE
Congestive heart failure in the elderly
AUTHOR NAMES
Chiu C.-Z.
Cheng J.-J.
AUTHOR ADDRESSES
(Chiu C.-Z.; Cheng J.-J., juice243@hotmail.com) School of Medicine, Fu Jen
Catholic University, Taipei Medical University, Taipei, Taiwan.
(Chiu C.-Z.; Cheng J.-J., juice243@hotmail.com) Division of Cardiology,
Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, 95
Wen-Chan Road, Shih-Lin, Taipei, Taiwan.
(Cheng J.-J., juice243@hotmail.com) School of Medicine, Taipei Medical
University, Taipei, Taiwan.
CORRESPONDENCE ADDRESS
J.-J. Cheng, Division of Cardiology, Department of Internal Medicine,
Shin-Kong Wu Ho-Su Memorial Hospital, 95 Wen-Chan Road, Shih-Lin, Taipei,
Taiwan. Email: juice243@hotmail.com
SOURCE
International Journal of Gerontology (2007) 1:4 (143-152). Date of
Publication: December 2007
ISSN
1873-9598
BOOK PUBLISHER
Elsevier (Singapore) Pte Ltd, 3 Killiney Road, 08-01, Winsland House I,
Singapore, Singapore.
ABSTRACT
Over the past 30 years, the prevalence and incidence of heart failure (HF)
have increased markedly with age, with increases of approximately fivefold
from the age of 40 to 70 years. HF is predominantly a disorder of the
elderly, and over 70% of HF patients are over 65 years old. The most
important factor in the increasing prevalence and incidence of HF is the
growing proportion of elderly with new-onset diastolic HF resulting from
chronic hypertension and coronary heart disease. Other predictors of HF
include diabetes, prior stroke, atrial fibrillation, renal dysfunction,
reduced ankle-brachial index, increased C-reactive protein, left ventricular
hypertrophy, reduced forced expiratory volume, and obesity. At least half of
all elderly HF patients have preserved left ventricular systolic function,
and they are classified as diastolic HF. There was a strong female
predominance (67%) in diastolic HF when compared with male HF patients. The
morbidity and mortality of older HF patients are the highest of any chronic
cardiovascular disorder. Mortality increases markedly with age. Mortality
from diastolic HF is about half of that reported for systolic HF. There are
some comorbidities in older HF patients, including renal dysfunction,
chronic lung disease, cognitive dysfunction, depression, postural
hypotension, urine incontinence, sensory deprivation, nutritional disorders,
polypharmacy and frailty, which may precipitate and exacerbate the
underlying HF symptoms. Clinical diagnosis of HF may be more difficult in
the elderly because of frequently inadequate history taking, less evident HF
symptoms for reduced daily activity, and similar symptoms to other frequent
disorders. The treatment goals in older HF patients resemble those for any
chronic disorder and include relief of symptoms, improvement in functional
status, exercise tolerance, quality of life, prevention of acute
exacerbation, and finally, prolongation of long-term survival. © 2007
Elsevier.
EMTREE DRUG INDEX TERMS
aldosterone antagonist (clinical trial, drug combination, drug therapy)
angiotensin receptor antagonist (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy)
beta adrenergic receptor blocking agent (adverse drug reaction, clinical
trial, drug combination, drug dose, drug therapy)
calcium antagonist (adverse drug reaction, clinical trial, drug comparison,
drug therapy)
calcium channel blocking agent (clinical trial, drug therapy)
candesartan (clinical trial, drug combination, drug therapy)
captopril (clinical trial, drug comparison, drug therapy)
carvedilol (clinical trial, drug combination, drug dose, drug therapy)
catecholamine derivative (drug therapy)
digoxin (clinical trial, drug combination, drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical
trial, drug combination, drug comparison, drug therapy)
diuretic agent (clinical trial, drug combination, drug comparison, drug
dose, drug therapy, intravenous drug administration)
dobutamine (drug therapy)
dopamine (drug combination, drug dose, drug therapy)
enalapril (clinical trial, drug therapy)
loop diuretic agent (drug therapy)
losartan (clinical trial, drug comparison, drug therapy)
metolazone (drug combination, drug therapy)
perindopril (clinical trial, drug therapy)
placebo
thiazide diuretic agent (drug combination, drug therapy)
valsartan (clinical trial, drug therapy)
verapamil (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure (diagnosis, drug therapy, epidemiology, etiology,
therapy)
elderly care
EMTREE MEDICAL INDEX TERMS
acute heart infarction (drug therapy)
aerobic exercise
aneurysm surgery
ankle brachial index
aorta stenosis (surgery)
aorta valve replacement
artery compliance
atrial fibrillation (drug therapy)
cardiac resynchronization therapy
chronic disease (complication)
clinical trial
comorbidity
coronary artery recanalization
coughing (side effect)
defibrillation
diastolic heart failure (drug therapy)
disease exacerbation
dose response
drug choice
drug contraindication
drug dose titration
drug efficacy
drug hypersensitivity (side effect)
echocardiography
exercise tolerance
heart left ventricle aneurysm (surgery)
heart left ventricle ejection fraction
heart left ventricle relaxation
human
hypertension (complication)
hypertrophic cardiomyopathy (drug therapy)
incidence
ischemic heart disease (complication)
kidney disease (side effect)
low drug dose
outcome assessment
pathophysiology
prediction
prevalence
priority journal
review
sex difference
side effect (side effect)
sodium restriction
systolic heart failure (drug therapy)
unspecified side effect (side effect)
CAS REGISTRY NUMBERS
candesartan (139481-59-7)
captopril (62571-86-2)
carvedilol (72956-09-3)
digoxin (20830-75-5, 57285-89-9)
dobutamine (34368-04-2, 52663-81-7)
dopamine (51-61-6, 62-31-7)
enalapril (75847-73-3)
losartan (114798-26-4)
metolazone (17560-51-9)
perindopril (82834-16-0, 99149-83-4)
valsartan (137862-53-4)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008092191
FULL TEXT LINK
http://dx.doi.org/10.1016/S1873-9598(08)70038-3
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 423
TITLE
Atrial fibrillation-related cardiomyopathy: A case report
AUTHOR NAMES
Peake S.T.C.
Mehta P.A.
Dubrey S.W.
AUTHOR ADDRESSES
(Peake S.T.C., s_peake@doctors.org.uk; Mehta P.A., p.mehta@imperial.ac.uk;
Dubrey S.W., simon.dubrey@thh.nhs.uk) Department of Cardiology, The
Hillingdon Hospital, Middlesex, United Kingdom.
CORRESPONDENCE ADDRESS
S.T.C. Peake, Department of Cardiology, The Hillingdon Hospital, Middlesex,
United Kingdom. Email: s_peake@doctors.org.uk
SOURCE
Journal of Medical Case Reports (2007) 1 Article Number: 111. Date of
Publication: 22 Oct 2007
ISSN
1752-1947
1752-1947 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., 34 - 42 Cleveland Street, London, United Kingdom.
ABSTRACT
Sustained chronic tachyarrhythmias often cause a deterioration of cardiac
function known as tachycardia-induced cardiomyopathy or tachycardiomyopathy.
The incidence of tachycardia-induced cardiomyopathy is unknown, but in
selected studies of patients with atrial fibrillation, approximately 25% to
50% of those with left ventricular dysfunction had some degree of
tachycardia-induced cardiomyopathy. It is an important clinical entity due
to the high incidence and potential reversibility of the disease process.
This case describes a cardiomyopathy induced by excess caffeine consumption.
Six months following withdrawal of caffeine from the subject's diet, full
resolution of symptoms occurred. © 2007 Peake et al; licensee BioMed Central
Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
caffeine
EMTREE DRUG INDEX TERMS
digoxin (drug therapy)
ramipril (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis, drug therapy)
congestive cardiomyopathy (complication, diagnosis, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
adult
angiocardiography
article
case report
clinical feature
dietary intake
disease association
dyspnea
electrocardiogram
follow up
heart ejection fraction
heart left ventricle hypertrophy (diagnosis)
heart palpitation
human
male
priority journal
tachycardia induced cardiomyopathy (complication, etiology)
transthoracic echocardiography
treatment response
CAS REGISTRY NUMBERS
caffeine (30388-07-9, 58-08-2)
digoxin (20830-75-5, 57285-89-9)
ramipril (87333-19-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008286713
FULL TEXT LINK
http://dx.doi.org/10.1186/1752-1947-1-111
COPYRIGHT
Copyright 2008 Elsevier B.V., All rights reserved.
RECORD 424
TITLE
The current role of photodynamic therapy in oesophageal dysplasia and cancer
AUTHOR NAMES
Gray J.
Fullarton G.
AUTHOR ADDRESSES
(Gray J., jojo.gray@gmail.com; Fullarton G., grant.fullarton@btinternet.com)
Department of Gastrointestinal Surgery, Gartnavel General Hospital, 1053
Great Western Road, Glasgow, G12 0YN, United Kingdom.
CORRESPONDENCE ADDRESS
G. Fullarton, Department of Gastrointestinal Surgery, Gartnavel General
Hospital, 1053 Great Western Road, Glasgow, G12 0YN, United Kingdom. Email:
grant.fullarton@btinternet.com
SOURCE
Photodiagnosis and Photodynamic Therapy (2007) 4:3 (151-159). Date of
Publication: September 2007
ISSN
1572-1000
BOOK PUBLISHER
Elsevier, P.O. Box 211, Amsterdam, Netherlands.
ABSTRACT
Over the last 15 years photodynamic therapy (PDT) has become a viable
treatment for pre-malignant and malignant disease of the oesophagus. Its
initial use was in the palliation of oesophageal malignant obstruction
bringing improved swallowing hence increasing nutritional intake and
improving general quality of life. As the therapeutic boundaries of PDT have
stretched, current studies look at the role of PDT in the treatment of
pre-malignant dysplastic Barrett's epithelium and early malignancy as a
curative mucosal ablative technique. As a curative treatment in early
oesophageal cancer, PDT provides an alternative treatment to oesophagectomy
for those more elderly or less medically fit patients. This paper reviews
the uses of photodynamic therapy in oesophageal cancer with reference to the
available publications on its use in the palliation of oesophageal cancer
and treatment of early cancer and high grade dysplasia in Barrett's mucosa.
© 2007 Elsevier B.V. All rights reserved.
EMTREE DRUG INDEX TERMS
aminolevulinic acid (adverse drug reaction, clinical trial, drug
concentration, drug therapy, oral drug administration)
omeprazole (drug therapy)
photofrin (adverse drug reaction, clinical trial, drug concentration, drug
therapy, intravenous drug administration)
temoporfin (adverse drug reaction, drug concentration, drug therapy,
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
esophagus cancer (drug therapy, radiotherapy, surgery)
esophagus malformation
photodynamic therapy
EMTREE MEDICAL INDEX TERMS
argon plasma coagulation
atrial fibrillation (side effect)
Barrett esophagus (drug therapy, surgery)
bleeding (complication)
brachytherapy
cancer palliative therapy
cancer patient
cancer survival
clinical trial
congestive heart failure (side effect)
dosimetry
dysphagia (side effect)
endoscopic echography
endoscopic mucosal resection
esophagitis (side effect)
esophagus resection
esophagus stenosis (complication)
external beam radiotherapy
fever (side effect)
fistula (side effect)
human
leukocytosis (side effect)
neodymium laser
perforation (side effect)
photosensitivity (side effect)
phototoxicity (complication)
pleura effusion (side effect)
pneumonia (side effect)
priority journal
review
stenosis (side effect)
supraventricular tachycardia (complication)
DRUG TRADE NAMES
foscan , Irelandbiolitec
photofrin , United KingdomAxcan
DRUG MANUFACTURERS
(United Kingdom)Axcan
(Ireland)biolitec
(Germany)Medac
CAS REGISTRY NUMBERS
aminolevulinic acid (106-60-5)
omeprazole (73590-58-6, 95510-70-6)
photofrin (85189-42-0)
temoporfin (122341-38-2)
EMBASE CLASSIFICATIONS
Radiology (14)
Cancer (16)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007395104
FULL TEXT LINK
http://dx.doi.org/10.1016/j.pdpdt.2007.04.003
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 425
TITLE
Type 1 diabetes and gastroparesis: Diagnosis and treatment
AUTHOR NAMES
Hasler W.L.
AUTHOR ADDRESSES
(Hasler W.L., whasler@umich.edu) Division of Gastroenterology, University of
Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109, United
States.
CORRESPONDENCE ADDRESS
W.L. Hasler, Division of Gastroenterology, University of Michigan Health
System, 3912 Taubman Center, Ann Arbor, MI 48109, United States. Email:
whasler@umich.edu
SOURCE
Current Gastroenterology Reports (2007) 9:4 (261-269). Date of Publication:
August 2007
ISSN
1522-8037
BOOK PUBLISHER
Current Medicine Group LLC, 400 Market St,, Ste 700 Philadelphia, United
States.
ABSTRACT
Patients with gastroparesis present with gastrointestinal symptoms and
non-gastrointestinal manifestations in association with objective delays in
gastric emptying. The condition complicates the course of many patients with
type 1 diabetes mellitus, usually in those with longstanding poor glycemic
control with other associated diabetic complications. The diagnosis is made
by directed evaluation to exclude organic diseases that can mimic the
clinical presentation of gastroparesis, coupled with verification of gastric
retention. Current therapy relies on dietary modifications, medications to
stimulate gastric evacuation, and agents to reduce vomiting. Endoscopic and
surgical options are increasingly used in patients who are refractory to
drug treatment. Copyright © 2007 by Current Medicine Group LLC.
EMTREE DRUG INDEX TERMS
azithromycin (drug comparison, drug therapy, pharmacology)
bethanechol (adverse drug reaction, drug therapy, pharmacology)
botulinum toxin (drug dose, drug therapy, pharmacology)
buspirone (pharmacology)
cisapride (adverse drug reaction, drug therapy, pharmacology)
clarithromycin (drug comparison, drug therapy, pharmacology)
clonidine (drug therapy, pharmacology)
domperidone (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, oral drug administration,
pharmacology)
erythromycin (adverse drug reaction, clinical trial, drug comparison, drug
dose, drug therapy, intravenous drug administration, pharmacology)
ghrelin (pharmacology)
ginger extract (drug therapy, pharmacology)
glucose (endogenous compound)
macrolide (drug therapy, pharmacology)
metoclopramide (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, pharmacology, subcutaneous drug
administration)
mirtazapine (drug therapy)
mitemcinal (drug therapy)
mosapride (drug therapy)
nitrate (pharmacology)
phenothiazine (drug therapy, pharmacology)
prochlorperazine (drug therapy, pharmacology)
prokinetic agent (drug therapy, pharmacology)
pyridostigmine (drug therapy, pharmacology)
renzapride (drug therapy)
serotonin agonist (drug therapy)
serotonin uptake inhibitor (pharmacology)
sumatriptan (pharmacology)
tegaserod (adverse drug reaction, drug therapy, pharmacology)
thiethylperazine (drug therapy, pharmacology)
tricyclic antidepressant agent (drug therapy)
unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
insulin dependent diabetes mellitus (drug therapy, prevention, therapy)
stomach paresis (complication, diagnosis, drug therapy, etiology, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
abdominal cramp (side effect)
abdominal pain (side effect)
acupuncture
agitation
amenorrhea (side effect)
antiemetic activity
anxiety disorder (complication)
atrial fibrillation (side effect)
bronchospasm (side effect)
cardiovascular disease (side effect)
clinical feature
clinical trial
depression (complication)
device removal
diabetic neuropathy (complication, prevention)
diabetic retinopathy (complication, prevention)
diaphoresis
diet therapy
drug efficacy
drug megadose
drug potency
drug tolerance
drug withdrawal
dystonia (side effect)
electrogastrography
electrostimulation therapy
endoscopic surgery
enteric feeding
fatality
fatigue (side effect)
galactorrhea (side effect)
gastroenterostomy
gastrointestinal endoscopy
glucose blood level
glycemic control
heart arrhythmia (side effect)
heart death (side effect)
human
hyperprolactinemia (side effect)
hypotension (side effect)
impotence (side effect)
infection (complication)
jejunostomy
long term care
mental disease (complication)
muscle spasm (side effect)
nausea and vomiting (side effect)
pancreas transplantation
parenteral nutrition
pathophysiology
pyloroplasty
review
side effect (side effect)
single photon emission computer tomography
sleep disorder (side effect)
somatization (complication)
stomach emptying
stomach obstruction (complication, diagnosis)
stomach scintiscanning
tardive dyskinesia (side effect)
total stomach resection
treatment indication
urinary urgency (side effect)
CAS REGISTRY NUMBERS
azithromycin (83905-01-5)
bethanechol (590-63-6, 674-38-4, 91609-06-2)
buspirone (33386-08-2, 36505-84-7)
cisapride (81098-60-4)
clarithromycin (81103-11-9)
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
domperidone (57808-66-9)
erythromycin (114-07-8, 70536-18-4)
ghrelin (258279-04-8, 304853-26-7)
glucose (50-99-7, 84778-64-3)
metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
mirtazapine (61337-67-5)
mitemcinal (154738-42-8, 154802-96-7)
mosapride citrate (112885-42-4)
nitrate (14797-55-8)
phenothiazine (92-84-2)
prochlorperazine (58-38-8)
pyridostigmine (101-26-8, 155-97-5)
renzapride (109872-41-5)
sumatriptan (103628-46-2)
tegaserod (145158-71-0, 189188-57-6)
thiethylperazine (1420-55-9)
EMBASE CLASSIFICATIONS
Endocrinology (3)
General Pathology and Pathological Anatomy (5)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007475140
MEDLINE PMID
17883972 (http://www.ncbi.nlm.nih.gov/pubmed/17883972)
FULL TEXT LINK
http://dx.doi.org/10.1007/s11894-007-0029-9
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 426
TITLE
Ultrasoundcardiography in mitral stenosis, with particular reference to the
relationship to hemodynamic and surgical findings
AUTHOR NAMES
Gustafson A.
AUTHOR ADDRESSES
(Gustafson A.) Cardiol. Clin., Dept. of Int. Med., Univ. Hosp., Lund.
CORRESPONDENCE ADDRESS
Cardiol. Clin., Dept. of Int. Med., Univ. Hosp., Lund.
SOURCE
Acta medica Scandinavica (1973) 1966:SUPPL. 461
ISSN
0001-6101
ABSTRACT
The purpose of the present investigation was to study the place of the
ultrasoundcardiogram (UCG) in the preoperative evaluation of patients with
mitral valvular disease. In addition a methodological study of UCG was
performed. It was shown that measurements of the diastolic descent-rate of
the UCG during 10 heart cycles and of the maximal amplitude during 5 heart
cycles provide a determination of the two variables in each UCG-tracing that
is sufficiently accurate for clinical use. The method showed a good
reproducibility in duplicate recordings and in recordings performed on
different days. The most important cause for the variation of the
UCG-findings was the site on the chest wall from which the recording was
performed. The diastolic descent-rate showed no significant difference
between recordings performed during atrial fibrillation and during sinus
rhythm in the same patients. The influence of the respiratory movements upon
the UCG-tracing was also studied. In a series of 71 patients with
predominant mitral stenosis the UCG-findings were related to clinical,
hemodynamic and surgical findings. Patients with descent-rates of ≤ 15 mm/s.
and > 15 mm/s. were compared. In those with sinus rhythm the mean values of
pulmonary arterial and pulmonary arterial wedge pressures at rest and during
exercise were significantly higher in the group with the lower descent-rate.
The mitral valve area calculated on the basis of hemodynamic data showed a
statistically significant correlation to the descent-rate of UCG in the
patients with sinus rhythm but not in those with atrial fibrillation. The
mitral valve area was determined in square centimeters by a method which
showed a relatively good reproducibility. The descent-rate of UCG showed a
highly significant correlation to the mitral valve area in the whole
material. This correlation was poor in patients with an UCG-tracing of low
maximal amplitude (≤ 15 mm). The best correlation between descent-rate and
valve area was found in patients with sinus rhythm. The maximal amplitude of
UCG was related to the mobility of the anterior mitral leaflet and to the
degree of calcification of the mitral valve: patients with an UCG-tracing of
low amplitude often had a mitral valve with restricted mobility of the
anterior leaflet and advanced calcifications. By analysis of variance these
relationships were shown to be statistically highly significant. The origin
and significance of the UCG-tracing in relation to the movements of the
anterior mitral leaflet studied by angiocardiography in different anatomical
types of mitral stenosis is discussed. The slow descent-rate is postulated
to be mainly caused by the narrowing of the mitral orifice in patients with
a thin and pliable anterior leaflet in contrast to those with an immobile
and calcified valve where it may be mainly caused by the rigidity of the
leaflet. The accuracy of the UCG and of the mitral valve area calculated by
the Gorlin formula, in predicting the valve area found at operation was
compared. It was concluded that the former method is probably slightly
better for predicting the degree of mitral stenosis. Finally, the
descent-rate of UCG, the calculated mitral valve area and the valve area
estimated by the surgeon were correlated to hemodynamic data obtained by
right heart catheterization. The coefficients of correlation for the three
estimates of the degree of mitral stenosis were on the whole of the same
order.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mitral valve stenosis
EMTREE MEDICAL INDEX TERMS
analysis of variance
angiocardiography
atrial fibrillation
breathing mechanics
calcification
echocardiography
exercise
heart catheterization
heart cycle
mitral valve
mitral valve disease
patient
preoperative evaluation
recording
reproducibility
restenosis
rigidity
sinus rhythm
surgeon
thorax wall
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007875080
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 427
TITLE
Adverse events among high-risk participants in a home-based walking study: A
descriptive study
AUTHOR NAMES
Goodrich D.E.
Larkin A.R.
Lowery J.C.
Holleman R.G.
Richardson C.R.
AUTHOR ADDRESSES
(Goodrich D.E., david.goodrich2@va.gov; Larkin A.R., angela.larkin@va.gov;
Lowery J.C., julie.lowery@va.gov; Holleman R.G., rholle@umich.edu;
Richardson C.R., caroli@umich.edu) HSRandD Center for Excellence, VA Health
Care Medical Center, P.O. Box 130170, Ann Arbor, MI 48113-0170, United
States.
(Goodrich D.E., david.goodrich2@va.gov; Holleman R.G., rholle@umich.edu;
Richardson C.R., caroli@umich.edu) Department of Family Medicine, University
of Michigan, 1018 Fuller St., Ann Arbor, MI 48109-5708, United States.
CORRESPONDENCE ADDRESS
C.R. Richardson, HSRandD Center for Excellence, VA Health Care Medical
Center, P.O. Box 130170, Ann Arbor, MI 48113-0170, United States. Email:
caroli@umich.edu
SOURCE
International Journal of Behavioral Nutrition and Physical Activity (2007) 4
Article Number: 20. Date of Publication: 23 May 2007
ISSN
1479-5868 (electronic)
BOOK PUBLISHER
BioMed Central Ltd., 34 - 42 Cleveland Street, London, United Kingdom.
ABSTRACT
Background: For high-risk individuals and their healthcare providers,
finding the right balance between promoting physical activity and minimizing
the risk of adverse events can be difficult. More information on the
prevalence and influence of adverse events is needed to improve providers'
ability to prescribe effective and safe exercise programs for their
patients. Methods: This study describes the type and severity of adverse
events reported by participants with cardiovascular disease or at-risk for
cardiovascular disease that occurred during an unsupervised, home-based
walking study. This multi-site, randomized controlled trial tested the
feasibility of a diet and lifestyle activity intervention over 1.5 years. At
month 13, 274 eligible participants (male veterans) were recruited who were
ambulatory, BMI > 28, and reporting one or more cardiovascular disease risk
factors. All participants attended five, face-to-face dietitian-delivered
counseling sessions during the six-month intervention. Participants were
randomized to three study arms: 1) time-based walking goals, 2) simple
pedometer-based walking goals, and 3) enhanced pedometer-based walking goals
with Internet-mediated feedback. Two physicians verified adverse event
symptom coding. Results: Enrolled participants had an average of five
medical comorbidities. During 1110 person months of observation, 87 of 274
participants reported 121 adverse events. One serious study-related adverse
event (atrial fibrillation) was reported; the individual resumed study
participation within three days. Non-serious, study related adverse events
made up 12% of all symptoms - predominantly minor musculoskeletal events.
Serious, non-study related adverse events represented 32% of all symptoms
while non-serious, non-study related adverse events made up 56% of symptoms.
Cardiovascular disease events represented over half of the non-study related
adverse event symptoms followed by musculoskeletal complaints. Adverse
events caused 50 temporary suspensions averaging 26 days in duration before
physician medical clearance was obtained to resume walking. Conclusion: Men
at high risk for adverse cardiovascular events can safely be advised to
start a progressive walking program. Results suggest that minor to serious
medical problems unrelated to exercise are a major barrier to walking
adherence. Helping individuals with chronic illness return to physical
activity quickly but safely after an adverse event is an important component
of any physical activity intervention targeting this population. © 2007
Goodrich et al; licensee BioMed Central Ltd.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (complication)
exercise
home rehabilitation
walking
EMTREE MEDICAL INDEX TERMS
adult
aged
article
cardiovascular risk
clinical trial
controlled clinical trial
controlled study
coronary artery disease
diabetes mellitus
exercise recovery
health care personnel
health care policy
health program
health promotion
high risk population
home care
human
hypercholesterolemia
hypertension
lifestyle modification
male
multicenter study
nutrition education
obesity
patient safety
physical activity
randomized controlled trial
rehabilitation
weight reduction
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007296223
FULL TEXT LINK
http://dx.doi.org/10.1186/1479-5868-4-20
COPYRIGHT
Copyright 2010 Elsevier B.V., All rights reserved.
RECORD 428
TITLE
Combination sedoanalgesia with remifentanil and propofol versus remifentanil
and midazolam for elective cardioversion after coronary artery bypass
grafting
AUTHOR NAMES
Yildirim V.
Doganci S.
Bolcal C.
Oz B.S.
Kucukarslan N.
Cosar A.
Guzeldemir M.E.
AUTHOR ADDRESSES
(Yildirim V.; Cosar A.; Guzeldemir M.E.) Department of Anesthesiology and
Reanimation, Gulhane Military Academy of Medicine, Ankara, Turkey.
(Doganci S., suat_doganci@yahoo.com; Bolcal C.; Oz B.S.; Kucukarslan N.)
Department of Cardiovascular Surgery, Gulhane Military Academy of Medicine,
Ankara, Turkey.
(Doganci S., suat_doganci@yahoo.com) Department of Cardiovascular Surgery,
Gulhane Military Academy of Medicine, 06018 Etlik-Ankara, Turkey.
CORRESPONDENCE ADDRESS
S. Doganci, Department of Cardiovascular Surgery, Gulhane Military Academy
of Medicine, 06018 Etlik-Ankara, Turkey. Email: suat_doganci@yahoo.com
SOURCE
Advances in Therapy (2007) 24:3 (662-670). Date of Publication: May/June
2007
ISSN
0741-238X
BOOK PUBLISHER
Springer Healthcare Communications, Lower Makefield Corporate Center South,
770 Township Line RD, Suite 300, Yardley, United States.
ABSTRACT
Postoperative atrial fibrillation (AF) occurs in up to 50% of cardiac
surgery patients and represents the most common postoperative arrhythmic
complication. Elective cardioversion, a short but painful procedure, remains
an option for patients who do not convert to sinus rhythm with medical
therapy. Combinations of remifentanil (a potent analgesic with a short
elimination time) with propofol (a hypnotic agent) or midazolam (a sedative
agent) produce a synergistic interaction. This study was undertaken to
compare these combinations in terms of effectiveness and pain relief when
given as sedoanalgesia for elective cardioversion. In this prospective,
randomized trial, 60 adult patients with postoperative AF after coronary
artery bypass grafting were given a single dose of propofol 1 mg/kg combined
with remifentanil 0.1 μg/kg (group 1), or midazolam 0.05 mg/kg combined with
remifentanil 0.1 μg/kg (group 2). Cardiorespiratory parameters were
monitored and recorded. Demographic data were similar (P>.05) and sufficient
sedoanalgesia and successful cardioversion were achieved in both groups.
Hemodynamic parameters revealed no significant differences between groups
(P>.05); however, induction time, time to eye opening, recuperation time,
and time to full recovery of psychomotor function were faster in group 1
than in group 2 (P<.05). The remifentanil/propofol combination provided
sufficient analgesia, satisfactory hemodynamic stability, and mild
respiratory depression, along with faster recovery and discharge times from
the intensive care unit. ©2007 Health Communications Inc.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
midazolam (adverse drug reaction, drug combination, drug therapy,
intravenous drug administration, pharmacokinetics, pharmacology)
propofol (adverse drug reaction, drug combination, drug therapy, intravenous
drug administration, pharmacokinetics, pharmacology)
remifentanil (drug combination, drug dose, drug therapy, intravenous drug
administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
midazolam maleate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (complication, drug therapy)
cardioversion
coronary artery bypass graft
EMTREE MEDICAL INDEX TERMS
adult
aged
analgesia
anesthesia mechanism
anesthesiological procedure
anesthetic recovery
apnea (side effect)
article
combination chemotherapy
coughing (side effect)
drug mechanism
elective surgery
female
heart surgery
human
major clinical study
male
oxygen saturation
postoperative period
respiration depression (side effect)
sedation
side effect (side effect)
DRUG TRADE NAMES
diprivan , SwedenAstra Zeneca
dormicum , SwitzerlandHoffmann La Roche
ultiva , BelgiumGlaxo SmithKline
DRUG MANUFACTURERS
(Sweden)Astra Zeneca
(Belgium)Glaxo SmithKline
(Switzerland)Hoffmann La Roche
CAS REGISTRY NUMBERS
midazolam (59467-70-8)
midazolam maleate (59467-94-6, 65506-68-5)
propofol (2078-54-8)
remifentanil (132539-07-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007412506
MEDLINE PMID
17660177 (http://www.ncbi.nlm.nih.gov/pubmed/17660177)
FULL TEXT LINK
http://dx.doi.org/10.1007/BF02848791
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 429
TITLE
Influence of CYP2C9 genotype on warfarin dose among African-Americans and
European-Americans
AUTHOR NAMES
Limdi N.A.
Goldstein J.A.
Blaisdell J.A.
Beasley T.M.
Rivers C.A.
Acton R.T.
AUTHOR ADDRESSES
(Limdi N.A., nlimdi@uab.edu) University of Alabama at Birmingham, Department
of Neurology, 1719 6th Avenue South, Birmingham, AL 35294-0021, United
States.
(Goldstein J.A.; Blaisdell J.A.) University of Alabama at Birmingham,
National Institute of Environmental Health Sciences, Birmingham, AL, United
States.
(Beasley T.M.) University of Alabama at Birmingham, Section on Statistical
Genetics, Department of Biostatistics, Birmingham, AL, United States.
(Rivers C.A.) University of Alabama at Birmingham, Department of
Microbiology, Birmingham, AL, United States.
(Acton R.T.) University of Alabama at Birmingham, Department of Medicine
Genetics and Epidemiology, Department of International Health, Birmingham,
AL, United States.
CORRESPONDENCE ADDRESS
N.A. Limdi, University of Alabama at Birmingham, Department of Neurology,
1719 6th Avenue South, Birmingham, AL 35294-0021, United States. Email:
nlimdi@uab.edu
SOURCE
Personalized Medicine (2007) 4:2 (157-169). Date of Publication: May 2007
ISSN
1741-0541
1744-828X (electronic)
BOOK PUBLISHER
Future Medicine Ltd., 2nd Albert Place, Finchley Central, London, United
Kingdom.
ABSTRACT
Background: Cytochrome P450 (CYP)2C9 plays a vital role in drug metabolism.
There has been an increased effort to identify polymorphisms within the gene
and to determine their clinical consequences. However, most of these efforts
have focused on populations of European descent. Herein we report the
influence of CYP2C9 genotype on warfarin dose among European-American and
African-American patients. We also identify two new mutations, one in the
coding region and one in the noncoding region of the CYP2C9 gene. Methods:
Patients (aged >20 years) were enrolled after obtaining medical, lifestyle
and concomitant medication history. Changes in international normalized
ratio, warfarin dose, co-medications, diet, physical activity and the
occurrence of complications were documented. CYP2C9 genotype was determined
using PCR with restriction fragment length polymorphisms, and
pyrosequencing. Differences in genotype frequencies and Hardy-Weinberg
equilibrium assumptions were assessed using X(2) statistics and exact tests.
The genotype-dose association was evaluated using multivariable linear
regression. Results: This report includes 490 patients (mean age: 60.6 ±
15.6 years; 51.3% men). African-American patients comprised 48.9% of the
cohort, with a mean follow-up of 13.5 (±10.6) months. Both the CYP2C9*2 and
*3 allele were more frequent in European-Americans (11.24 and 5.1 %,
respectively) compared with African-Americans (1.1 and 1.8%). CYP2C9*5
(0.9%), *6 (0.4%) and *11 (1.1%) variants were only observed in
African-Americans. The variant genotype is more frequent among
European-Americans compared with African-Americans (29.8 vs 9.73%; p <
0.0001). Warfarin dose was significantly related to CYP2C9 genotype (p <
0.0001), both in univariate and multivariate analyses. Multivariable
race-specific analyses highlight the contribution of CYP2C9 genotype among
European-American but not among African-American patients. Conclusion: The
variant CYP2C9 genotype is more frequent among European-Americans compared
with African-Americans. Among African-Americans the variant genotype.
frequency is higher than previously reported. CYP2C9 genotype predicts
warfarin dose in European-Americans, but not in African-Americans. © 2007
Future Medicine Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
cytochrome P450 2C9 (endogenous compound)
warfarin (drug dose, drug therapy)
EMTREE DRUG INDEX TERMS
vitamin K group
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
pharmacogenetics
EMTREE MEDICAL INDEX TERMS
adult
African American
aged
allele
anamnesis
article
atrial fibrillation (drug therapy)
cerebrovascular accident (drug therapy)
cohort analysis
comorbidity
controlled study
dietary intake
dose response
European American
female
gene frequency
gene mutation
genetic variability
genotype
human
international normalized ratio
linear regression analysis
major clinical study
male
multivariate analysis
physical activity
polymerase chain reaction
prediction
priority journal
race difference
restriction fragment length polymorphism
thromboembolism (drug therapy)
treatment indication
univariate analysis
CAS REGISTRY NUMBERS
vitamin K group (12001-79-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Human Genetics (22)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007266718
FULL TEXT LINK
http://dx.doi.org/10.2217/17410541.4.2.157
COPYRIGHT
Copyright 2008 Elsevier B.V., All rights reserved.
RECORD 430
TITLE
Incident atrial fibrillation: Impact of obstructive sleep apnea and obesity
AUTHOR NAMES
Somers V.K.
Gami A.S.
Block P.C.
AUTHOR ADDRESSES
(Somers V.K.; Gami A.S.; Block P.C.)
SOURCE
ACC Cardiosource Review Journal (2007) 16:5 (6-8). Date of Publication: May
2007
ISSN
1556-8571
BOOK PUBLISHER
Elsevier USA, 6277 Sea Harbor Drive, Orlando, United States.
ABSTRACT
In the United States, the major clinical risk factors for atrial
fibrillation (AF) include age, diabetes, hypertension, heart failure, and
coronary artery disease. Recently, long-term follow-up data of more than
5,000 subjects in the Framingham Heart Study and nearly 48,000 subjects in
the Danish Diet, Cancer, and Health Study showed that AF also is predicted
by obesity, and this association is independent of other clinical
characteristics. However, the mechanisms by which obesity leads to AF are
unknown. This is an important question given the magnitude of both the
obesity and AF epidemics. Obstructive sleep apnea (OSA) is highly prevalent
in obese individuals, and it is estimated that more than 25 million US
adults have OSA. We have previously shown in a cross-sectional analysis that
OSA is strongly associated with AF, independent of age, gender,
hypertension, heart failure, and obesity (Slide 1). It is estimated that
about one-half of patients with medically complicated AF and about one-third
of patients with lone AF have OSA. However, no study yet has identified the
risk of incident AF attributable to OSA during long-term follow-up. We
report in the Journal of the American College of Cardiology a historical
cohort study that included 3,542 consecutive adult residents of our county
who underwent their first diagnostic polysomnography between 1987 and 2003.
Individuals with AF or a previous history of AF were excluded. Those
enrolled in our study were followed up until death or last follow-up for the
occurrence of incident AF or flutter, which was confirmed by an
electrocardiogram. After an average of 5 years of follow-up (maximum 15
years), the cumulative frequency of AF was 14% and this was predicted by
several well-established risk factors, such as male sex, age, hypertension,
coronary artery disease, and heart failure. We also found that body mass
index, OSA, the apnea-hypopnea index, and several oxygen saturation
parameters strongly predicted AF (Slide 2). In multivariate regression
models, age, male sex, coronary artery disease, body mass index (per 1
kg/m(2); hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.05-1.10; p
< 0.001), and a decrease in nocturnal oxygen saturation (per 0.5 unit change
in the log; HR, 3.29; 95% CI, 1.35-8.04; p = 0.009) were independent
predictors of incident AE For subjects ≥65 years old, only heart failure
independently predicted incident AF (HR, 7.68; 95% CI, 4.32-13.66; p <
0.001).
EMTREE DRUG INDEX TERMS
oxygen (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis)
obesity
sleep disordered breathing (diagnosis)
EMTREE MEDICAL INDEX TERMS
adult
age
article
body mass
comorbidity
coronary artery disease
cross-sectional study
death
diabetes mellitus
disease association
electrocardiography
female
follow up
heart failure
human
hypertension
male
multivariate analysis
oxygen saturation
pathophysiology
polysomnography
prediction
prevalence
risk factor
sex difference
United States
CAS REGISTRY NUMBERS
oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Neurology and Neurosurgery (8)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007428098
COPYRIGHT
Copyright 2008 Elsevier B.V., All rights reserved.
RECORD 431
TITLE
Oral anticoagulation in atrial fibrillation: A pan-European patient survey
AUTHOR NAMES
Lip G.Y.H.
Agnelli G.
Thach A.A.
Knight E.
Rost D.
Tangelder M.J.D.
AUTHOR ADDRESSES
(Lip G.Y.H., g.y.h.lip@bham.ac.uk) Haemostasis, Thrombosis and Vascular
Biology Unit, University Department of Medicine, Birmingham, B18 7QH, United
Kingdom.
(Agnelli G.) Division of Internal and Cardiovascular Medicine, Department of
Internal Medicine, University of Perugia, Perugia, Italy.
(Thach A.A.) IPSOS Health, Harrow, United Kingdom.
(Knight E.) Anticoagulation Europe, Bromley, United Kingdom.
(Rost D.) Christiansfeld, Denmark.
(Tangelder M.J.D.) AstraZeneca R and D, Clinical Science, Mölndal, Sweden.
CORRESPONDENCE ADDRESS
G.Y.H. Lip, Haemostasis, Thrombosis and Vascular Biology Unit, University
Department of Medicine, Birmingham, B18 7QH, United Kingdom. Email:
g.y.h.lip@bham.ac.uk
SOURCE
European Journal of Internal Medicine (2007) 18:3 (202-208). Date of
Publication: May 2007
ISSN
0953-6205
BOOK PUBLISHER
Elsevier, P.O. Box 211, Amsterdam, Netherlands.
ABSTRACT
Background: Anticoagulation with vitamin K antagonists (VKAs) provides
effective stroke prophylaxis in patients with atrial fibrillation (AF).
Optimisation of such therapy requires frequent monitoring, dose adjustments
and stringent lifestyle restrictions. We conducted a large multinational
survey in patients with chronic AF to gain insights into their perceptions
and understanding of VKA use. Methods: Eligible patients were adults with AF
who had been prescribed VKAs for at least 1 year. A total of 711 patient
interviews were conducted in seven European countries during June and July
2004. Results: The majority of patients (58% male; mean age 68 years)
claimed to understand their treatment programme; despite this, only 7% knew
that VKA use is aimed at preventing strokes and 24% stated that they would
have liked more information. Patients attended an average of 14 monitoring
sessions in the previous year; however, 21% missed appointments, especially
younger patients (< 65 years). The International Normalized Ratio (INR) was
within the target range in most or all of the last five to ten visits in 64%
of patients; nonetheless, 38% were not aware that an INR outside the target
range is associated with health risks. On average, patients required dose
adjustments every four sessions. VKA treatment impacted 67% of patients in
terms of diet, socialising, career and independence, especially younger
patients (74%). Conclusions: Monitoring, dose adjustments and lifestyle
restrictions to optimise the intensity of anticoagulation with VKAs are
problematic for patients with AF, and their knowledge of the consequences of
such therapy is often poor. © 2007 European Federation of Internal Medicine.
EMTREE DRUG INDEX TERMS
antivitamin K (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
career
cerebrovascular accident (drug therapy, prevention)
female
health hazard
health survey
human
independence
interview
lifestyle
major clinical study
male
patient monitoring
social life
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007197113
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ejim.2006.11.005
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 432
TITLE
Postoperative care of adult cardiac surgery patients
AUTHOR NAMES
Walcot N.
Marchbank A.
AUTHOR ADDRESSES
(Walcot N.; Marchbank A.) Derriford Hospital, Plymouth, United Kingdom.
(Walcot N.; Marchbank A.) Derriford Hospital, Plymouth, United Kingdom.
CORRESPONDENCE ADDRESS
N. Walcot, Derriford Hospital, Plymouth, United Kingdom.
SOURCE
Surgery (2007) 25:5 (211-214). Date of Publication: May 2007
Heart, Book Series Title:
ISSN
0263-9319
BOOK PUBLISHER
Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
Cardiac surgical patients require intensive management postoperatively.
Bleeding, infection, cardiovascular disturbances, respiratory problems and
other end-organ dysfunction may be encountered. © 2007.
EMTREE DRUG INDEX TERMS
adrenalin (drug therapy)
amiodarone (drug therapy)
aprotinin (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
digoxin (drug therapy)
dobutamine (drug therapy)
dopamine (drug therapy)
fresh frozen plasma (drug therapy)
milrinone (drug therapy)
noradrenalin (drug therapy)
oxygen (drug therapy)
protamine (drug therapy)
prothrombin (endogenous compound)
thromboplastin (endogenous compound)
tranexamic acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular surgery
postoperative care
EMTREE MEDICAL INDEX TERMS
acute kidney failure (complication, therapy)
aorta balloon
artificial heart pacemaker
artificial ventilation
atrial fibrillation (complication, drug therapy, surgery, therapy)
blood clotting
breathing exercise
cardiovascular disease (complication, drug therapy, prevention, surgery,
therapy)
cardioversion
cerebrovascular accident (complication)
cerebrovascular disease (complication)
coma (complication)
confusion (complication)
cryoprecipitate
debridement
delirium (complication)
extubation
forward heart failure (complication, drug therapy)
gastrointestinal hemorrhage (complication)
hemodialysis
human
intensive care
intestine ischemia (complication, prevention)
nose feeding
partial thromboplastin time
peritoneal dialysis
physiotherapy
positive end expiratory pressure
postoperative hemorrhage (complication, drug therapy, prevention, surgery,
therapy)
postoperative infection (complication, surgery)
postoperative period
priority journal
prothrombin time
reoperation
respiratory tract disease (complication, drug therapy, therapy)
review
surgical patient
surgical technique
thorax radiography
thrombocyte count
thrombocyte transfusion
thromboelastography
vasodilatation
wound dressing
CAS REGISTRY NUMBERS
adrenalin (51-43-4, 55-31-2, 6912-68-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
aprotinin (11004-21-0, 12407-79-3, 50936-63-5, 52229-70-6, 58591-29-0,
9050-74-2, 9075-10-9, 9087-70-1)
digoxin (20830-75-5, 57285-89-9)
dobutamine (34368-04-2, 52663-81-7)
dopamine (51-61-6, 62-31-7)
milrinone (78415-72-2)
noradrenalin (1407-84-7, 51-41-2)
oxygen (7782-44-7)
protamine (11061-43-1, 9007-31-2, 9012-00-4)
prothrombin (9001-26-7)
thromboplastin (9035-58-9)
tranexamic acid (1197-18-8, 701-54-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
Drug Literature Index (37)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007269388
FULL TEXT LINK
http://dx.doi.org/10.1016/j.mpsur.2007.04.017
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 433
TITLE
Cardiac resynchronization therapy in patients with congestive heart failure
and atrial fibrillation
AUTHOR NAMES
Adornato E.M.F.
Adornato E.
AUTHOR ADDRESSES
(Adornato E.M.F.) Dipartimento di Cardiologia, Azienda Ospedaliera Bianchi
Melacrino Morelli, Reggio Calabria, Italy.
(Adornato E.) Casa di Cura S. Feliciano, Roma, Italy.
(Adornato E.) Via Vicenza 8, 89100 Reggio Calabria, Italy.
CORRESPONDENCE ADDRESS
E. Adornato, Via Vicenza 8, 89100 Reggio Calabria, Italy.
SOURCE
Mediterranean Journal of Pacing and Electrophysiology (2007) 9:2 (102-105).
Date of Publication: April/June 2007
ISSN
1128-4293
BOOK PUBLISHER
Edizioni Luigi Pozzi S.r.l., Via Panama 68, Roma, Italy.
ABSTRACT
AF is a very frequent cardiac arrhythmia in patients with congestive HF and
this association represents a major public health problem because of the
negative impact on quality of life and survival of patients. The prevalence
of AF in HF patients progressively increases with age and with the degree of
left ventricular dysfunction, tipically judged by NYHA functional class.
Clinical studies have documented that in patients with congestive HF the
presence of AF confers a greater risk for death, largely because of an
increase of risk for pump failure, in comparison with patients with sinus
rhythm. In the last decade biventricular pacing at optimum AV delay has been
proposed as supplemental treatment for moderate to severe congestive HF and
a meta-analysis of 4 randomized trials has documented a significant
improvement in cardiac performance, exercise capacity and quality of life.
These results of biventricular pacing have been obtained from patients who
had sinus rhythm, but recently the results of some prospective trials have
confirmed the usefulness of biventricular pacing systems also in patients
with congestive HF and chronic AF independently of any optimisation of AV
interval and of contribution of atrial systole to the diastolic ventricular
filling.
EMTREE DRUG INDEX TERMS
dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
cardiac resynchronization therapy
congestive heart failure (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
catheter ablation
clinical trial
exercise
functional status
heart left bundle branch block
heart left ventricle ejection fraction
heart left ventricle failure
heart performance
heart ventricle filling
human
mortality
prevalence
prognosis
public health problem
quality of life
review
sinus rhythm
survival rate
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008368554
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 434
TITLE
NYHA functional class IV patients: Cardiac Resynchronization therapy with
defibrillator back up
AUTHOR NAMES
Fusco A.
AUTHOR ADDRESSES
(Fusco A.) Department of Cardioloy, Pederzoli Clinic, 37019 Peschiera del
Garda, VR, Italy.
CORRESPONDENCE ADDRESS
A. Fusco, Department of Cardioloy, Pederzoli Clinic, 37019 Peschiera del
Garda, VR, Italy.
SOURCE
Mediterranean Journal of Pacing and Electrophysiology (2007) 9:2 (106-108).
Date of Publication: April/June 2007
ISSN
1128-4293
BOOK PUBLISHER
Edizioni Luigi Pozzi S.r.l., Via Panama 68, Roma, Italy.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiac resynchronization therapy
defibrillator
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
cardiomyopathy
clinical trial
exercise
functional status
heart arrhythmia (prevention, therapy)
heart failure
hospitalization
human
mortality
quality of life
sudden death
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2008368555
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 435
TITLE
Rate control in atrial fibrillation
AUTHOR NAMES
Zagaria M.A.E.
AUTHOR ADDRESSES
(Zagaria M.A.E.) MZ Associates Inc., Staten Island, NY, United States.
CORRESPONDENCE ADDRESS
M.A.E. Zagaria, MZ Associates Inc., Staten Island, NY, United States.
SOURCE
U.S. Pharmacist (2007) 32:2. Date of Publication: 20 Mar 2007
ISSN
0148-4818
BOOK PUBLISHER
Jobson Publishing Corporation, 100 Avenue of the Americas, New York, United
States.
ABSTRACT
Atrial fibrillation is one of the most common types of arrhrythmias. Its
prevalence increases with age and tends to occur in individuals with a
cardiac disorder. The risk of cardiovascular morbidity and mortality is
considerably increased in seniors with atrial fibrillation, even if they do
not have organic heart disease. The longer the duration of atrial
fibrillation, the less likely spontaneous conversion will occur and the more
difficult cardioversion is to attain. Chronic tachycardias can potentially
result in a progressive decline in left ventricular function. Effective
ventricular rate control benefits patients by reducing the risk of
tachycardia-induced atrial remodeling in patients who have poor rate
control. The treatment of atrial fibrillation focuses on ventricular rate
control with medications, prevention of thromboembolism with anticoagulant
therapy, and if necessary, conversion to normal sinus rhythm using
medications or procedural cardioversion. Medications and ablation are
effective for both rate and rhythm control.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, drug comparison, drug therapy)
adenosine (drug therapy, intravenous drug administration, pharmacology)
amiodarone (adverse drug reaction, drug therapy)
angiotensin receptor antagonist (drug therapy, pharmacology)
antiarrhythmic agent (adverse drug reaction, drug therapy)
beta adrenergic receptor blocking agent (drug combination, drug therapy,
intravenous drug administration, oral drug administration, pharmacology)
calcium channel blocking agent (drug combination, drug therapy, intravenous
drug administration, oral drug administration, pharmacology)
digitalis (drug therapy, intravenous drug administration, pharmacology)
digoxin (adverse drug reaction, drug combination, drug therapy, intravenous
drug administration, oral drug administration, pharmacology)
dipeptidyl carboxypeptidase inhibitor (drug therapy, pharmacology)
esmolol (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy,
pharmacology)
lidocaine (drug therapy, intravenous drug administration, pharmacology)
metoprolol (drug therapy)
warfarin (adverse drug reaction, drug comparison, drug dose, drug therapy)
ximelagatran (drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis, drug therapy, epidemiology, etiology,
prevention, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
age distribution
antiarrhythmic activity
article
artificial heart pacemaker
bleeding (side effect)
cardioversion
cerebrovascular disease (complication, drug therapy, prevention)
clinical feature
dizziness
drug contraindication
drug dose titration
drug mechanism
drug substitution
drug withdrawal
dyspnea
electrocardiography
exercise
fatigue
heart failure (drug therapy)
heart left ventricle function
heart palpitation
heart rhythm
human
morbidity
mortality
prevalence
QT prolongation (side effect)
radiofrequency ablation
recurrent disease (complication, drug therapy, prevention)
renal clearance
risk reduction
side effect (side effect)
sinus rhythm
tachycardia (complication)
thorax pain
thromboembolism (complication, drug therapy, prevention)
torsade des pointes (side effect)
unspecified side effect (side effect)
weakness
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
adenosine (58-61-7)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digitalis (8031-42-3, 8053-83-6)
digoxin (20830-75-5, 57285-89-9)
esmolol (81147-92-4, 81161-17-3)
lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
metoprolol (37350-58-6)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008360952
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 436
TITLE
Evidence-based guidelines for cardiovascular disease prevention in women:
2007 Update
AUTHOR NAMES
Mosca L.
Banka C.L.
Benjamin E.J.
Berra K.
Bushnell C.
Dolor R.J.
Ganiats T.G.
Gomes A.S.
Gornik H.L.
Gracia C.
Gulati M.
Haan C.K.
Judelson D.R.
Keenan N.
Kelepouris E.
Michos E.D.
Newby L.K.
Oparil S.
Ouyang P.
Oz M.C.
Petitti D.
Pinn V.W.
Redberg R.F.
Scott R.
Sherif K.
Smith S.C.
Sopko G.
Steinhorn R.H.
Stone N.J.
Taubert K.A.
Todd B.A.
Urbina E.
Wenger N.K.
AUTHOR ADDRESSES
(Mosca L.; Banka C.L.; Benjamin E.J.; Berra K.; Bushnell C.; Dolor R.J.;
Gomes A.S.; Gornik H.L.; Kelepouris E.; Michos E.D.; Newby L.K.; Oparil S.;
Ouyang P.; Oz M.C.; Redberg R.F.; Steinhorn R.H.; Stone N.J.; Taubert K.A.;
Urbina E.; Wenger N.K.) American Heart Association, United States.
(Ganiats T.G.) American Academy of Family Physicians, United States.
(Gracia C.) American College of Obstetricians and Gynecologists, United
States.
(Gulati M.) American College of Cardiology Foundation, United States.
(Haan C.K.) Society of Thoracic Surgeons, United States.
(Judelson D.R.) American Medical Women's Association, United States.
(Keenan N.) Centers for Disease Control and Prevention, United States.
(Pinn V.W.) Office of Research on Women's Health, United States.
(Scott R.) Association of Black Cardiologists, .
(Sherif K.) American College of Physicians, United States.
(Smith S.C.) World Heart Federation, .
(Sopko G.) National Heart, Lung, and Blood Institute, United States.
(Todd B.A.) American College of Nurse Practitioners, United States.
(Petitti D.)
CORRESPONDENCE ADDRESS
L. Mosca, American Heart Association, United States.
SOURCE
Circulation (2007) 115:11 (1481-1501). Date of Publication: March 2007
ISSN
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327,
Philadelphia, United States.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
alcohol
aldosterone antagonist (drug therapy)
alpha tocopherol
angiotensin receptor antagonist (drug therapy)
antiarrhythmic agent (drug therapy)
antilipemic agent (drug therapy)
antioxidant
antithrombocytic agent (drug therapy)
ascorbic acid
beta adrenergic receptor blocking agent (drug therapy)
beta carotene
clopidogrel (drug therapy)
cyanocobalamin
dipeptidyl carboxypeptidase inhibitor (drug therapy)
docosapentaenoic acid (drug therapy)
fibric acid derivative (drug therapy)
folic acid
hormone
icosapentaenoic acid (drug therapy)
lipid (endogenous compound)
lipoprotein (endogenous compound)
nicotine
nicotinic acid (drug therapy)
omega 3 fatty acid (drug therapy)
pyridoxine
selective estrogen receptor modulator
thiazide diuretic agent (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (drug therapy, prevention, rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
adjuvant therapy
alcohol consumption
algorithm
atrial fibrillation (drug therapy)
body weight
cardiovascular risk
cerebrovascular accident (rehabilitation)
cholesterol intake
congestive heart failure (rehabilitation)
depression
diabetes mellitus
diet
diet supplementation
diet therapy
drug substitution
evidence based medicine
fat intake
female
heart rehabilitation
high risk patient
hormone substitution
human
hyperlipidemia (drug therapy)
hypertension (drug therapy)
kinesiotherapy
lifestyle modification
medical research
nicotine replacement therapy
peripheral vascular disease (rehabilitation)
physical activity
practice guideline
primary prevention
priority journal
prophylaxis
review
risk factor
smoking
smoking cessation
social psychology
sodium restriction
stress management
systematic review
vitamin supplementation
weight control
weight reduction
yoga
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alcohol (64-17-5)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
beta carotene (7235-40-7)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
docosapentaenoic acid (25448-00-4, 32839-34-2)
folic acid (59-30-3, 6484-89-5)
icosapentaenoic acid (25378-27-2, 32839-30-8)
lipid (66455-18-3)
nicotine (54-11-5)
nicotinic acid (54-86-4, 59-67-6)
pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2007203716
MEDLINE PMID
17309915 (http://www.ncbi.nlm.nih.gov/pubmed/17309915)
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCULATIONAHA.107.181546
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 437
TITLE
Pulmonary hypertension in connective tissue disease
AUTHOR NAMES
Upadhyaya S.K.
Kumar A.
AUTHOR ADDRESSES
(Upadhyaya S.K., sundeepupadhyaya@hotmail.com) Rheumatology Service,
Indraprastha Apollo Hospital, India.
(Kumar A.) Department of Medicine, All India Institute of Medical Sciences,
New Delhi, India.
CORRESPONDENCE ADDRESS
S.K. Upadhyaya, Rheumatology Service, Indraprastha Apollo Hospital, India.
Email: sundeepupadhyaya@hotmail.com
SOURCE
Indian Journal of Rheumatology (2007) 2:3 (114-119). Date of Publication:
September 2007
ISSN
0973-3698
BOOK PUBLISHER
Elsevier (India) Pte Ltd
ABSTRACT
Pulmonary hypertension (PH) is common to a large number of cardiac,
pulmonary, and connective tissue diseases (CTDs). Chronic thromboembolism is
a well-recognized cause. A substantial proportion of cases are idiopathic.
Miscellaneous categories include familial pulmonary hypertension, HIV
disease related PH and portal hypertension related PH. CTD-related PH may be
secondary to interstitial lung disease or isolated, i.e. "classical" (in
absence of pulmonary fibrosis). The latter is more commonly associated with
the CREST Syndrome and MCTD. CTD-related isolated PH and idiopathic PH (IPH)
are similar in their clinical presentation, histopathology and response to
treatment. Early in CTD, the signs and symptoms of PH are subtle and
non-specific and easily overlooked. There are now many guidelines for proper
evaluation and treatment of idiopathic PH, which apply equally well to
CTD-related PH. Doppler echocardiogram is an excellent screening tool to
evaluate early PH. Rheumatologists and cardiologists should insist on the
right-sided cardiac catheterization in these patients to help stage the
disease and guide therapy. Until recently, clinicians were able to offer
patients only symptomatic therapy but now there are several specific and
effective therapies like prostacyclins, endothelin-receptor antagonists and
phosphodiesterase inhibitors.
EMTREE DRUG INDEX TERMS
adenosine (intravenous drug administration)
bosentan (adverse drug reaction, drug dose, drug therapy)
calcium channel blocking agent (drug therapy)
digoxin (drug therapy)
diuretic agent (drug therapy)
endothelin receptor antagonist (drug therapy)
iloprost (drug comparison, drug therapy, inhalational drug administration,
pharmacokinetics)
nitric oxide (inhalational drug administration)
oxygen
phosphodiesterase inhibitor (drug therapy)
phosphodiesterase V inhibitor (pharmacology)
placebo
prostacyclin (adverse drug reaction, clinical trial, drug comparison, drug
therapy, intravenous drug administration, pharmacology, subcutaneous drug
administration)
sildenafil (drug therapy, oral drug administration, pharmacology)
sitaxsentan (drug therapy)
treprostinil (adverse drug reaction, drug comparison, drug dose, drug
therapy, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
connective tissue disease
pulmonary hypertension (diagnosis, drug therapy, etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (drug therapy)
bone pain (side effect)
clinical feature
clinical trial
computer assisted tomography
diarrhea (side effect)
Doppler echocardiography
drug fatality (side effect)
drug half life
drug induced headache (side effect)
drug mechanism
drug safety
drug tolerance
drug withdrawal
dyspnea (drug therapy)
electrocardiogram
exercise
flushing
heart catheterization
heart disease
hemodynamics
histopathology
human
Human immunodeficiency virus infection
idiopathic disease
injection site pain (side effect)
interstitial lung disease
leg pain (side effect)
lung artery pressure
lung disease
lung function test
lung transplantation
lung ventilation perfusion ratio
mixed connective tissue disease
pathogenesis
pathophysiology
portal hypertension
priority journal
prognosis
quality of life
review
risk factor
side effect (side effect)
survival rate
syndrome CREST
thorax radiography
thromboembolism
treatment response
vomiting (side effect)
CAS REGISTRY NUMBERS
adenosine (58-61-7)
bosentan (147536-97-8, 157212-55-0)
digoxin (20830-75-5, 57285-89-9)
iloprost (78919-13-8, 82889-99-4)
nitric oxide (10102-43-9)
oxygen (7782-44-7)
prostacyclin (35121-78-9, 61849-14-7)
sildenafil (139755-83-2)
sitaxsentan (184036-34-8, 210421-74-2)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Clinical and Experimental Pharmacology (30)
Arthritis and Rheumatism (31)
Drug Literature Index (37)
Adverse Reactions Titles (38)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008088443
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 438
TITLE
Reducing risk in type 2 diabetes: A practical approach
AUTHOR NAMES
Rivera-Woll L.
Newnham H.H.
AUTHOR ADDRESSES
(Rivera-Woll L.; Newnham H.H.) Box Hill Hospital, Box Hill, VIC, Australia.
CORRESPONDENCE ADDRESS
L. Rivera-Woll, Box Hill Hospital, Box Hill, VIC, Australia.
SOURCE
Medicine Today (2007) 8:1 (14-19). Date of Publication: January 2007
ISSN
1443-430X
BOOK PUBLISHER
Medicine Today Pty Ltd, P.O. Box 1473, Neutral Bay, Australia.
ABSTRACT
• Even before patients are diagnosed with diabetes they are at increased
risk of macrovascular disease. • The complications of diabetes do not
develop in isolation so the effects of one complication may profoundly
impact on others. • Attention to detail is essential to detect and manage
effectively the risk factors and complications of diabetes. • The ability to
view the patient 'globally', directing attention to where treatment is most
likely to be of benefit and least likely to cause harm, is the key to
diabetes management. • Multifactorial approaches to diabetes care appear to
be the most effective.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
amlodipine plus atorvastatin (drug therapy)
angiotensin II antagonist (drug combination, drug therapy,
pharmacoeconomics)
antidiabetic agent (drug therapy, pharmacoeconomics)
aylide
beta adrenergic receptor blocking agent (drug therapy)
diapride
dimirel
dipeptidyl carboxypeptidase inhibitor (drug combination, drug therapy,
pharmacoeconomics)
ezetimibe plus simvastatin (drug therapy)
fibric acid derivative (adverse drug reaction, drug combination, drug
therapy)
glibenclamide plus metformin (drug therapy)
gliclazide (drug therapy)
glimepiride (drug therapy)
glitazone derivative (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (adverse drug reaction,
drug combination, drug therapy, pharmacoeconomics)
insulin (drug comparison, drug therapy)
metformin (drug comparison, drug therapy)
metformin plus rosiglitazone (drug therapy)
pioglitazone (drug therapy)
sulfonylurea (drug comparison, drug therapy)
thiazide diuretic agent (drug combination, drug therapy)
unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
non insulin dependent diabetes mellitus (disease management, drug therapy,
prevention)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
blood glucose monitoring
cerebrovascular accident (complication, drug therapy, prevention)
cost benefit analysis
cost effectiveness analysis
diabetic angiopathy (complication, disease management, drug therapy,
prevention)
diabetic microangiopathy (complication, drug therapy, prevention)
diabetic nephropathy (complication, drug therapy, prevention)
diabetic neuropathy (complication, prevention)
diabetic retinopathy (complication, drug therapy, prevention)
disease severity
drug cost
drug efficacy
electrocardiogram
exercise
high risk patient
human
hyperglycemia
hypertension
ischemic heart disease (complication, disease management, drug therapy,
prevention)
lifestyle modification
low drug dose
myositis (side effect)
peripheral vascular disease (complication, drug therapy, prevention)
primary prevention
review
risk factor
risk reduction
DRUG TRADE NAMES
amaryl
aspirin
avandamet
aylide
caduet
diabex
diamicron
diapride
dimirel
glucovance
vytorin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
gliclazide (21187-98-4)
glimepiride (93479-97-1)
insulin (9004-10-8)
metformin (1115-70-4, 657-24-9)
pioglitazone (105355-27-9, 111025-46-8)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007101900
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 439
TITLE
Remifentanil: A review of its analgesic and sedative use in the Intensive
Care Unit
AUTHOR NAMES
Battershill A.J.
Keating G.M.
AUTHOR ADDRESSES
(Battershill A.J.; Keating G.M., demail@adis.co.nz) Adis International
Limited, Auckland, New Zealand.
(Keating G.M., demail@adis.co.nz) Adis International Limited, 41 Centorian
Drive, Mairangi Bay, Auckland 1311, New Zealand.
CORRESPONDENCE ADDRESS
G.M. Keating, Adis International Limited, 41 Centorian Drive, Mairangi Bay,
Auckland 1311, New Zealand. Email: demail@adis.co.nz
SOURCE
Drugs (2006) 66:3 (365-385). Date of Publication: 2006
ISSN
0012-6667
0012-6667 (electronic)
BOOK PUBLISHER
Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay,
Auckland 10, New Zealand.
ABSTRACT
Remifentanil (Ultiva™), a 4-anilidopiperidine derivative of fentanyl, is an
ultra-short-acting μ-opioid receptor agonist indicated to provide analgesia
and sedation in mechanically ventilated intensive care unit (ICU) patients.
Analgesia-based sedation with remifentanil is a useful option for
mechanically ventilated patients in the ICU setting. Its unique properties
(e.g. organ-independent metabolism, lack of accumulation, rapid offset of
action) set it apart from other opioid agents. Remifentanil is at least as
effective as comparator opioids such as fentanyl, morphine and sufentanil in
providing pain relief and sedation in mechanically ventilated ICU patients.
Moreover, it allows fast and predictable extubation, as well as being
associated with a shorter duration of mechanical ventilation and quicker ICU
discharge than comparators in some studies. In addition, remifentanil is
generally well tolerated in this patient population. Thus, remifentanil is a
welcome addition to the currently available pharmacological agents employed
in the management of mechanically ventilated ICU patients. Pharmacological
Properties: Remifentanil is a 4-anilidopiperidine derivative of fentanyl
containing an ester linkage to propanoic acid. It is ultra-short acting and
displays analgesic effects, consistent with its agonist activity at the
μ-receptor. The primary metabolite, remifentanil acid, has negligible
activity compared with remifentanil. Remifentanil has a rapid onset of
action (≈1 minute) and a rapid offset of action following discontinuation
(≈3-10 minutes). The time to offset of action was not prolonged to a
clinically significant extent by renal impairment or prolonged infusion in
post-surgical or medical ICU patients who received remifentanil for up to 72
hours. In mechanically ventilated ICU patients, the median time to offset of
action was significantly shorter with remifentanil than with morphine or
fentanyl after 10 days' treatment. The effect of remifentanil on
haemodynamics is typical of opioids (e.g. decreased blood pressure and heart
rate). In ICU patients, remifentanil was generally associated with an
acceptable degree of haemodynamic stability. There were no significant
differences between remifentanil, fentanyl and morphine recipients in mean
intracranial pressure (ICP) or cerebral perfusion pressure in mechanically
ventilated ICU patients with acute brain injury or who had undergone
neurosurgery. However, compared with baseline, ICP was significantly
increased and cerebral perfusion pressure was significantly reduced with
remifentanil in mechanically ventilated patients with severe traumatic brain
injury in another study. Remifentanil is rapidly distributed throughout the
body and demonstrates linear, dose-dependent, multicompartmental
pharmacokinetics. The drug undergoes widespread extravascular metabolism and
is rapidly metabolised via extrahepatic, nonspecific blood and tissue
esterases to remifentanil acid. The pharmacokinetics of remifentanil were
not altered to a clinically significant extent in ICU patients with moderate
to severe renal impairment who received the drug for up to 72 hours,
compared with ICU patients with normal renal function or mild renal
impairment. The pharmacokinetics of remifentanil were also not altered to a
clinically significant extent in patients with severe chronic liver disease.
Remifentanil has a context-sensitive half-time of ≈3-4 minutes, irrespective
of the duration of infusion. Age-related changes in clearance and volume of
distribution occurred in paediatric patients receiving remifentanil.
Therapeutic Efficacy: A number of well designed trials have compared the use
of analgesia-based sedation with remifentanil with that of morphine,
fentanyl or sufentanil in post-surgical, trauma and/or medical patients (n ≥
20) who were being mechanically ventilated in an ICU setting. Remifentanil
provided effective analgesia-based sedation in mechanically ventilated
patients in the ICU setting. Optimal sedation was achieved for ≥78% of the
time with remifentanil. Moreover, with remifentanil, the duration of optimal
sedation and the percentage of hours during which patients had no or mild
pain was generally similar to that with fentanyl or morphine. In addition,
compared with remifentanil, the need for additional sedation generally
appeared greater with fentanyl and morphine regimens, but not with
sufentanil regimens. Remifentanil was at least as effective as fentanyl,
morphine and sufentanil in terms of recovery parameters. In some studies,
including a study examining longer-term mechanical ventilation, remifentanil
was associated with a significantly shorter duration of mechanical
ventilation than fentanyl or morphine. In addition, remifentanil was
associated with a significantly shorter extubation time than fentanyl,
morphine or sufentanil and a shorter time to ICU discharge than fentanyl or
morphine in some studies. Two studies noted an absence of tolerance to
remifentanil, although tolerance was seen in 29% of remifentanil recipients
in another study. A remifentanil-based regimen may also be associated with
savings in staff costs, according to the results of a prospective
cost-consequence analysis. Remifentanil was associated with rapid and
predictable emergence from sedation in mechanically ventilated ICU patients
with acute brain injury or who had undergone neurosurgery in a randomised,
nonblind study. Significantly less between-patient variability in the time
to neurological assessment occurred in patients receiving analgesia-based
sedation with remifentanil than in those receiving hypnotic-based sedation
incorporating fentanyl or morphine. Remifentanil patients requiring
mechanical ventilation were extubated significantly earlier than patients
receiving the morphine-based regimen. The extubation time and time until ICU
discharge were also significantly shorter with remifentanil plus propofol
than with fentanyl plus midazolam in mechanically ventilated ICU patients
who had undergone supratentorial brain surgery in a retrospective study.
Remifentanil provided similar analgesia-based sedation to fentanyl in
paediatric patients aged 3-16 years who were being mechanically ventilated
following orthopaedic spinal surgery. Remifentanil also demonstrated
efficacy in mechanically ventilated newborns. Remifentanil provided adequate
analgesia in ICU patients with severe burns during dressing changes, and an
intravenous infusion of remifentanil effectively reduced stress during
endotracheal suctioning in mechanically ventilated post-surgical ICU
patients sedated with sufentanil. Tolerability: Remifentanil was generally
well tolerated in ICU patients requiring mechanical ventilation. The most
commonly occurring adverse events in remifentanil recipients relate to its
μ-opioid agonist properties (e.g. bradycardia, hypotension). The
tolerability of remifentanil was generally similar to that of fentanyl or
morphine in ICU patients requiring short-term mechanical ventilation for up
to ≈3 days. In terms of the proportion of patients experiencing drug-related
adverse effects, there was no significant difference between remifentanil
and morphine recipients (22% vs 16%), or between remifentanil and fentanyl
recipients (23% vs 17%). Moreover, there was no significant difference
between remifentanil and fentanyl recipients in the incidence of
hypotension, nausea, fever or vomiting. In critically ill patients
mechanically ventilated for up to 10 days, drug-related adverse events
occurred in 11% of recipients and in 8% of patients receiving a comparator
regimen (midazolam with fentanyl or morphine). The most commonly occurring
adverse events in remifentanil recipients (occurring in ≥5% of patients, not
necessarily drug related) included hypotension, atrial fibrillation and
vomiting. Muscle rigidity did not occur in either treatment group.
Remifentanil was also generally well tolerated in mechanically ventilated
paediatric patients in the ICU setting. © 2006 Adis Data Information BV. All
rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
remifentanil (adverse drug reaction, clinical trial, drug analysis, drug
combination, drug comparison, drug dose, drug therapy, intravenous drug
administration, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
alfentanil (drug comparison)
fentanyl (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug dose, intravenous drug administration)
isoflurane (drug combination)
midazolam (clinical trial, drug combination, drug comparison, drug dose,
intravenous drug administration)
morphine (clinical trial, drug combination, drug comparison, intravenous
drug administration)
placebo
propofol (clinical trial, drug combination, drug comparison, drug dose,
intravenous drug administration)
sufentanil (clinical trial, drug combination, drug comparison, drug dose,
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
analgesia
intensive care unit
pain (drug therapy)
sedation
EMTREE MEDICAL INDEX TERMS
analgesic activity
anesthesia induction
artificial ventilation
atrial fibrillation (side effect)
blood pressure
bradycardia (side effect)
brain injury
brain perfusion
clinical trial
drug accumulation
drug activity
drug distribution
drug dose titration
drug effect
drug infusion
drug mechanism
drug metabolism
drug tolerability
drug use
extubation
fever (side effect)
heart rate
hemodynamics
hospital discharge
hospitalization
human
hypotension (side effect)
intensive care
intracranial pressure
metabolite
nausea (side effect)
review
septic shock (side effect)
tracheobronchial toilet
traumatic brain injury
treatment duration
vomiting (side effect)
DRUG TRADE NAMES
ultiva
CAS REGISTRY NUMBERS
alfentanil (69049-06-5, 71195-58-9)
fentanyl (437-38-7)
isoflurane (26675-46-7)
midazolam (59467-70-8)
morphine (52-26-6, 57-27-2)
propofol (2078-54-8)
remifentanil (132539-07-2)
sufentanil (56030-54-7)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Clinical and Experimental Pharmacology (30)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007103492
MEDLINE PMID
16526829 (http://www.ncbi.nlm.nih.gov/pubmed/16526829)
FULL TEXT LINK
http://dx.doi.org/10.2165/00003495-200666030-00013
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 440
TITLE
Atrial fibrillation as a prognostic factor in patients with systolic heart
failure
AUTHOR NAMES
Grzybczak R.
Nessler J.
Piwowarska W.
AUTHOR ADDRESSES
(Grzybczak R., rafal_grzybczak@interia.pl; Nessler J.; Piwowarska W.)
Department of Coronary Heart Disease, Jagiellonian University, John Paul II
Hospital, Cracow, Poland.
(Grzybczak R., rafal_grzybczak@interia.pl) Os. Dywizjonu 303 41/47, 31-875
Cracow, Poland.
CORRESPONDENCE ADDRESS
R. Grzybczak, Os. Dywizjonu 303 41/47, 31-875 Cracow, Poland. Email:
rafal_grzybczak@interia.pl
SOURCE
Folia Cardiologica (2006) 13:6 (503-510). Date of Publication: 2006
ISSN
1507-4145
ABSTRACT
Background: Atrial fibrillation (AF) decreases left ventricular stroke
volume, impaires the mechanical function of heart valves, and disturbes
neurohumoral activity of the miocardium. This study evaluated the influence
of AF on clinical presentation and long-term follow-up of the patients with
systolic heart failure. Methods: A retrospective analysis of the data on
clinical presentation of 152 patients (38 women and 114 men) with systolic
heart failure (EF < 40%) was performed. The following parameters were
compared between patients with and without AF: heart rate and presence of
LBBB, several echocardiographic parameters (EF, LVEDV, size of LA, LVEDd,
LVESd), oxygen consumption per minute, and frequency of end-point's (death,
stroke, rehospitalization, CABG) during mean 936-day follow-up. Results: The
53 (35%) AF patients in comparison with 99 non-AF were characterized by:
lower exercise performance (VO(2) max = 10.9 vs. 17.2 ml/kg/min), greater
diameter of the left atrium (49.9 vs. 45.9 mm) and decreased end-diastolic
volume (LVEDV = 159.5 vs. 183.7 ml), ess frequent occurrence of LBBB (7.5%
vs. 13.0%), higher overall mortality (28.3% vs. 17.1%), and more frequent
rehospitalizations (15% vs. 8%). In patients with persistent AF (40%) with
HR < 75/min the mortality was 29% and was statistically significantly lower
than in patients with HR > 75/ min in whom it was 54%. Conclusions: Atrial
fibrillation in patients with systolic heart failure is a disadvantageous,
but not independent risk factor. In patients with persistent atrial
fibrillation the control of heart rate < 75/min was associated with
significant decrease in mortality. Copyright © 2006 Via Medica.
EMTREE DRUG INDEX TERMS
oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (surgery)
heart failure
EMTREE MEDICAL INDEX TERMS
adult
aged
article
artificial heart pacemaker
cerebrovascular accident
controlled study
coronary artery bypass graft
echocardiography
exercise
female
follow up
heart left bundle branch block
heart left ventricle ejection fraction
heart left ventricle enddiastolic volume
heart muscle oxygen consumption
heart rate
hospital readmission
human
major clinical study
male
mortality
prognosis
retrospective study
statistical significance
systole
CAS REGISTRY NUMBERS
oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006518470
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 441
TITLE
Efficacy of CRT on exercise tolerance and disease progression: The
importance of AV junction ablation in patients with atrial fibrillation
AUTHOR NAMES
Gasparini M.
Block P.C.
AUTHOR ADDRESSES
(Gasparini M.; Block P.C.)
SOURCE
ACC Cardiosource Review Journal (2006) 15:11 (39-42). Date of Publication:
November 2006
ISSN
1556-8571
BOOK PUBLISHER
Elsevier USA, 6277 Sea Harbor Drive, Orlando, United States.
ABSTRACT
In summary, this study found that heart failure patients with ventricular
conduction disturbance and permanent AF treated with CRT showed large and
sustained long-term (up to 4 years) improvement of LV function and
functional capacity, similar to patients in SR, but only if AVJ ablation was
performed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (surgery, therapy)
atrioventricular junction ablation
cardiac resynchronization therapy
heart surgery
EMTREE MEDICAL INDEX TERMS
adult
aged
article
clinical effectiveness
clinical trial
controlled clinical trial
controlled study
disease course
drug use
exercise tolerance
female
functional status
heart failure (therapy)
heart left ventricle enddiastolic volume
heart ventricle function
human
implantation
major clinical study
male
outcome assessment
sinus rhythm
statistical significance
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007203165
COPYRIGHT
Copyright 2008 Elsevier B.V., All rights reserved.
RECORD 442
TITLE
Antithrombotic therapy in secondary stroke prevention
AUTHOR NAMES
Akhtar N.
Deleu D.
Shuaib A.
AUTHOR ADDRESSES
(Akhtar N.; Deleu D., ddeleu@hmc.org.qa) Department of Neurology (Medicine),
Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
(Shuaib A.) Department of Neurology, University of Edmonton, Edmonton, AB,
Canada.
CORRESPONDENCE ADDRESS
D. Deleu, Department of Neurology (Medicine), Hamad Medical Corporation,
P.O. Box 3050, Doha, Qatar. Email: ddeleu@hmc.org.qa
SOURCE
Aging Health (2006) 2:5 (787-797). Date of Publication: Oct 2006
ISSN
1745-509X
1745-5103 (electronic)
ABSTRACT
Ischemic stroke is a major cause of morbidity and mortality. The choice of
antithrombotic therapy is largely dependent on the type of stroke. In this
article, the authors focus on the secondary prevention of stroke, providing
evidence from the literature. The mechanism of action of each of the
antithrombotic drugs is discussed. Anticoagulation with warfarin for
cardioembolic stroke, particularly atrial fibrillation, is strongly
recommended, while no clear advantage for warfarin over aspirin exists for
ischemic stroke secondary to atherothrombotic or patent foramen ovale.
Combination therapies of aspirin plus warfarin do not offer any additional
therapeutic benefit and carry an increased risk of hemorrhage. Aspirin and
clopidogrel present similar risks for stroke recurrence. The combination of
aspirin with extended-release dipyridamole has a lower risk of stroke than
aspirin alone and does not enhance the risk of hemorrhage. Finally, some
recommendations and future perspectives are included. © 2006 Future Medicine
Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy, oral drug administration,
pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy, pharmacology)
adenosine diphosphate (endogenous compound)
antihypertensive agent (drug therapy)
antithrombocytic agent (drug therapy)
cell adhesion molecule (endogenous compound)
clopidogrel (clinical trial, drug combination, drug comparison, drug
therapy, pharmacology)
cyclic AMP (endogenous compound)
cyclooxygenase 1 (endogenous compound)
dipyridamole (adverse drug reaction, clinical trial, drug combination, drug
therapy, pharmacology)
fibrinogen (endogenous compound)
fibrinogen receptor antagonist (drug therapy, pharmacology)
irbesartan (clinical trial, drug combination, drug therapy)
nonsteroid antiinflammatory agent (adverse drug reaction)
phosphodiesterase (endogenous compound)
placebo
prostacyclin (endogenous compound)
telmisartan (clinical trial, drug combination, drug comparison, drug
therapy)
thrombin inhibitor (adverse drug reaction, clinical trial, drug therapy,
oral drug administration)
thromboxane A2 (endogenous compound)
ticlopidine (adverse drug reaction, clinical trial, drug comparison, drug
therapy, pharmacology)
vitamin K group (endogenous compound)
warfarin (adverse drug reaction, clinical trial, drug combination, drug
comparison, drug therapy, pharmacology)
ximelagatran (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (complication, drug therapy, prevention, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
acute heart infarction (drug therapy)
anticoagulation
artery calcification (drug therapy)
atherosclerosis (drug therapy)
atrial fibrillation (drug therapy)
behavior modification
bleeding (side effect)
brain hemorrhage (side effect)
carotid artery surgery
clinical trial
deep vein thrombosis (complication, drug therapy, prevention)
diarrhea (side effect)
dietary intake
drug choice
drug mechanism
drug safety
drug withdrawal
enzyme inhibition
evidence based medicine
exercise
gastrointestinal hemorrhage (side effect)
headache (side effect)
heart atrium septum defect
human
international normalized ratio
lifestyle
liver dysfunction (side effect)
medical literature
morbidity
mortality
neutropenia (side effect)
paradoxical embolism (complication, drug therapy, prevention)
patient monitoring
prostaglandin synthesis inhibition
rash (side effect)
recurrence risk
review
risk assessment
risk factor
secondary prevention
smoking cessation
sustained release formulation
thrombotic thrombocytopenic purpura (side effect)
transient ischemic attack (drug therapy, prevention)
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
adenosine diphosphate (20398-34-9, 58-64-0)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
cyclic AMP (60-92-4)
dipyridamole (58-32-2)
fibrinogen (9001-32-5)
irbesartan (138402-11-6)
prostacyclin (35121-78-9, 61849-14-7)
telmisartan (144701-48-4)
thromboxane A2 (57576-52-0)
ticlopidine (53885-35-1, 55142-85-3)
vitamin K group (12001-79-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Internal Medicine (6)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006558234
FULL TEXT LINK
http://dx.doi.org/10.2217/1745509X.2.5.787
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 443
TITLE
Mechanical events and the pressure-volume relationships
AUTHOR NAMES
Kirkman E.
AUTHOR ADDRESSES
(Kirkman E.) University of Durham, United Kingdom.
CORRESPONDENCE ADDRESS
E. Kirkman, University of Durham, United Kingdom.
SOURCE
Anaesthesia and Intensive Care Medicine (2006) 7:9 (313-316). Date of
Publication: 1 Sep 2006
Cardiac, Physiology and Statistics, Book Series Title:
ISSN
1472-0299
ABSTRACT
Depolarization of cardiac muscle fibres spreads from fibre to fibre
throughout the myocardium. In a single fibre, contraction starts just after
depolarization and lasts until just after repolarization is complete. The
atria contract, completing the filling of the ventricles and thus enhancing
their action. In the absence of effective atrial contraction (e.g. atrial
fibrillation) cardiac output is decreased on average by 15%. During
diastole, when cardiac muscle is relaxed, blood returns to the heart and
passes through the atrioventricular (AV) valves into the ventricles. The
semilunar valves, between the ventricles and the arteries, are closed as
arterial pressure exceeds ventricular pressure. Under normal circumstances,
70% of ventricular filling occurs by late diastole. © 2006.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart contraction
heart ventricle pressure
heart volume
EMTREE MEDICAL INDEX TERMS
arterial pressure
atrial fibrillation
bleeding
coronary artery blood flow
diastole
exercise
heart atrioventricular valve
heart atrium
heart depolarization
heart function
heart muscle
heart muscle cell
heart output
heart ventricle
human
muscle relaxation
priority journal
review
EMBASE CLASSIFICATIONS
Physiology (2)
Anesthesiology (24)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006601622
FULL TEXT LINK
http://dx.doi.org/10.1053/j.mpaic.2006.06.004
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 444
TITLE
Cardiac resynchronization therapy: Redefining the role of device therapy in
heart failure
AUTHOR NAMES
Viswanathan K.
Ghosh J.
Kaye G.C.
Cleland J.G.F.
AUTHOR ADDRESSES
(Viswanathan K., drkarthikv@hotmail.com; Ghosh J., justinmg@doctors.org.uk;
Cleland J.G.F., j.g.cleland@hull.ac.uk) Castle Hill Hospital, Department of
Cardiology, Kingston-upon-Hull HU16 5JQ, United Kingdom.
(Kaye G.C., Gerald_Kaye@health.qld.gov.au) Department of Cardiology,
Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.
CORRESPONDENCE ADDRESS
J.G.F. Cleland, Department of Cardiology, Castle Hill Hospital,
Kingston-upon-Hull HU16 5JQ, United Kingdom. Email: j.g.cleland@hull.ac.uk
SOURCE
Expert Review of Pharmacoeconomics and Outcomes Research (2006) 6:4
(455-469). Date of Publication: Aug 2006
ISSN
1473-7167
1744-8379 (electronic)
ABSTRACT
That cardiac dyssynchrony can contribute to a decline in cardiac efficiency
has been recognized in one form or another for at least 50 years. Although
revascularization and β-blockers can improve cardiac synchrony, there was
little interest in or awareness of this clinical entity until the advent of
specific, highly effective therapy using atriobiventricular pacing, often
described as cardiac resynchronization therapy. Over the last few years,
significant advances in cardiac resynchronization therapy technology and the
publication of large-scale clinical trials using cardiac resynchronization
therapy devices in patients with heart failure have led to the widespread
use of these devices. This review will briefly describe the complex nature
of cardiac dyssynchrony, what is known about its epidemiology, the effects
of cardiac resynchronization therapy, appropriate patient selection,
practical aspects, such as implantation and monitoring, and some still
unanswered questions. © 2006 Future Drugs Ltd.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent (drug therapy)
cardiovascular agent (clinical trial, drug therapy, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiac resynchronization therapy
heart dyssynchrony (diagnosis, disease management, epidemiology, therapy)
heart failure (disease management, drug therapy, surgery, therapy)
heart muscle conduction disturbance (diagnosis, disease management,
epidemiology, therapy)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (disease management, therapy)
atrioventricular block (disease management, prevention, therapy)
clinical trial
complete heart block (complication)
cost effectiveness analysis
defibrillator
echocardiography
epidemiological data
exercise
fatality
heart assist device
heart hemodynamics
heart left bundle branch block
heart muscle revascularization
heart pacing
heart tamponade (complication)
hospitalization
human
long term care
mortality
patient monitoring
patient selection
publication
QRS complex
quality of life
review
survival
symptom
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006418343
FULL TEXT LINK
http://dx.doi.org/10.1586/14737167.6.4.455
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 445
TITLE
ACC/AHA 2006 guidelines for the management of patients with valvular heart
disease: Executive summary. A report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines
(Writing Committee to Revise the 1998 Guidelines for the Management of
Patients with Valvular Heart Disease)
AUTHOR NAMES
Bonow R.O.
Carabello B.A.
Chatterjee K.
De Leon Jr. A.C.
Faxon D.P.
Freed M.D.
Gaasch W.H.
Lytle B.W.
Nishimura R.A.
O'Gara P.T.
O'Rourke R.A.
Otto C.M.
Shah P.M.
Shanewise J.S.
AUTHOR ADDRESSES
(Bonow R.O.; Carabello B.A.; Chatterjee K.; De Leon Jr. A.C.; Faxon D.P.;
Freed M.D.; Gaasch W.H.; Lytle B.W.; Nishimura R.A.; O'Gara P.T.; O'Rourke
R.A.; Otto C.M.; Shah P.M.; Shanewise J.S.)
SOURCE
Circulation (2006) 114:5 (450-527). Date of Publication: August 2006
ISSN
0009-7322
BOOK PUBLISHER
Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327,
Philadelphia, United States.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug dose, drug therapy)
amiodarone (drug administration, drug therapy, intravenous drug
administration, oral drug administration)
anorexigenic agent (adverse drug reaction)
antibiotic agent (drug therapy)
antihypertensive agent (drug therapy)
antiinfective agent (drug therapy)
antilipemic agent (drug therapy)
antithrombocytic agent (drug therapy)
atorvastatin (drug therapy)
calcium channel blocking agent (drug therapy)
carvedilol (drug therapy)
dexfenfluramine (adverse drug reaction)
digoxin (clinical trial, drug comparison, drug therapy, intravenous drug
administration)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
dipyridamole (adverse drug reaction)
dobutamine (drug combination, drug therapy)
dopamine (drug therapy)
enalapril (drug comparison, drug therapy)
ergotamine (adverse drug reaction)
fenfluramine (adverse drug reaction)
heparin (adverse drug reaction, drug administration, drug comparison, drug
therapy, intravenous drug administration, subcutaneous drug administration)
inotropic agent (drug combination, drug therapy)
low molecular weight heparin (adverse drug reaction, drug comparison, drug
therapy, subcutaneous drug administration)
methysergide (adverse drug reaction)
nifedipine (clinical trial, drug comparison, drug therapy)
nitroprusside sodium (drug combination, drug therapy)
pergolide (adverse drug reaction)
unindexed drug
vasodilator agent (drug therapy)
warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
practice guideline
valvular heart disease (congenital disorder, diagnosis, drug therapy, side
effect, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
aorta disease (drug therapy)
aorta root
aorta stenosis (diagnosis, drug therapy)
aorta valve
aorta valve disease (drug therapy, surgery)
aorta valve regurgitation (diagnosis, drug therapy, surgery, therapy)
aorta valve replacement
aorta valve stenosis (drug therapy, surgery)
ascending aorta
atherosclerosis (drug therapy)
atrial fibrillation (drug therapy, surgery, therapy)
autotransplantation
bacterial endocarditis (complication, drug therapy, etiology, prevention)
bleeding (side effect)
cerebrovascular accident (drug therapy)
clinical trial
coronary artery bypass graft
coronary artery disease (diagnosis, drug therapy)
disease severity
echocardiography
electrocardiography
embryopathy (side effect)
endocarditis (complication, drug therapy, etiology, prevention)
exercise
exercise test
fetal hemorrhage (side effect)
fetus risk
heart auscultation
heart catheterization
heart disease (diagnosis, drug therapy, surgery, therapy)
heart left ventricle function
heart murmur (diagnosis)
heart surgery
heart valve
heart valve surgery
human
hypertension (drug therapy)
infection (side effect)
lung blood flow
Marfan syndrome
mitral valve
mitral valve commissurotomy
mitral valve prolapse (drug therapy)
mitral valve regurgitation (diagnosis, drug therapy)
mitral valve stenosis (diagnosis, drug therapy)
nuclear magnetic resonance imaging
osteoporosis (side effect)
physical activity
physical examination
pregnancy
prematurity (side effect)
priority journal
review
rheumatic fever (drug therapy, etiology, prevention)
short stature
side effect (side effect)
stillbirth
thorax radiography
thrombocytopenia (side effect)
thromboembolism (side effect)
transthoracic echocardiography
tricuspid valve disease (diagnosis, drug therapy, surgery)
valvuloplasty
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atorvastatin (134523-00-5, 134523-03-8)
carvedilol (72956-09-3)
dexfenfluramine (3239-44-9, 3239-45-0)
digoxin (20830-75-5, 57285-89-9)
dipyridamole (58-32-2)
dobutamine (34368-04-2, 52663-81-7)
dopamine (51-61-6, 62-31-7)
enalapril (75847-73-3)
ergotamine (113-15-5, 52949-35-6)
fenfluramine (404-82-0, 458-24-2)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
methysergide (16509-15-2, 361-37-5, 62288-72-6)
nifedipine (21829-25-4)
nitroprusside sodium (14402-89-2, 15078-28-1)
pergolide (66104-22-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
General Pathology and Pathological Anatomy (5)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2006405009
FULL TEXT LINK
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177303
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 446
TITLE
Dexmedetomidine: as safe as safe can be
AUTHOR NAMES
Wagner D.S.
Brummett C.M.
AUTHOR ADDRESSES
(Wagner D.S., debbiew@umich.edu; Brummett C.M.) Department of
Anesthesiology, University of Michigan Health Systems, Ann Arbor, MI, United
States.
CORRESPONDENCE ADDRESS
D.S. Wagner, Department of Anesthesiology, University of Michigan Health
Systems, Ann Arbor, MI, United States. Email: debbiew@umich.edu
SOURCE
Seminars in Anesthesia, Perioperative Medicine and Pain (2006) 25:2 (77-83).
Date of Publication: Jun 2006
ISSN
0277-0326
ABSTRACT
Dexmedetomidine (DMET) is an alpha-2 adrenoceptor agonist approved for
short-term use as a sedative for mechanically ventilated patients. Alpha-2
adrenoceptor agonists exhibit sedative-hypnotic, analgesic, anxiolytic, and
sympatholytic effects. The ability of DMET to produce a readily arousable
state of moderate-deep sedation and analgesia with a lack of respiratory
depression has led to an increased interest in its use. Very little
published data exists on the side effects/adverse event profile of the drug,
especially with high-dose prolonged infusions. In addition, the ceiling dose
is not really known. This article reviews the current literature with
regards to multiple organ systems and the effects of DMET. © 2006 Elsevier
Inc. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dexmedetomidine (adverse drug reaction, drug combination, drug
concentration, drug dose, drug therapy, drug toxicity, pharmacology)
EMTREE DRUG INDEX TERMS
alpha 2 adrenergic receptor stimulating agent (adverse drug reaction, drug
combination, drug concentration, drug dose, drug therapy, drug toxicity,
pharmacology)
atipamezole (pharmacology)
clonidine (pharmacology)
midazolam (clinical trial, drug dose, pharmacology)
nitric oxide synthase inhibitor (pharmacology)
noradrenalin (endogenous compound)
phenylephrine (adverse drug reaction, drug combination)
placebo
EMTREE MEDICAL INDEX TERMS
adrenergic activity
analgesia
analgesic activity
article
atrial fibrillation (side effect)
blood pressure regulation
bradycardia (side effect)
cancer pain (drug therapy)
cardiovascular system
clinical trial
drug dose regimen
drug effect
drug megadose
drug overdose
drug potentiation
drug safety
electrocardiography
endocrine system
epidural anesthesia
epileptic discharge (side effect)
heart rate
human
hypnosis
hypotension (side effect)
medical literature
neuromuscular blocking
nonhuman
noradrenalin release
priority journal
respiration depression (side effect)
respiratory system
sedation
seizure (side effect)
tranquilizing activity
unspecified side effect (side effect)
ventilated patient
CAS REGISTRY NUMBERS
atipamezole (104054-27-5)
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
dexmedetomidine (113775-47-6)
midazolam (59467-70-8)
noradrenalin (1407-84-7, 51-41-2)
phenylephrine (532-38-7, 59-42-7, 61-76-7)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006260167
FULL TEXT LINK
http://dx.doi.org/10.1053/j.sane.2006.02.003
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 447
TITLE
3, 5-diiodothyronine: Biological actions and therapeutic perspectives
AUTHOR NAMES
Lombardi A.
Lanni A.
Silvestri E.
de Lange P.
Goglia F.
Moreno M.
AUTHOR ADDRESSES
(Lombardi A.) Dipartimento delle Scienze Biologiche, Sezione Fisiologia ed
Igiene, Università degli Studi di Napoli Federico II, Via Mezzocannone 8,
80134 Napoli, Italy.
(Lanni A.; de Lange P.) Dipartimento di Scienze della Vita, Seconda
Università degli Studi di Napoli, Via Vivaldi 43, 81100 Caserta, Italy.
(Silvestri E.; Goglia F., goglia@unisannio.it; Moreno M.,
moreno@unisannio.it) Dipartimento di Scienze Biologiche ed Ambientali,
Università degli Studi del Sannio, Via Port' Arsa 11, 82100 Benevento,
Italy.
CORRESPONDENCE ADDRESS
F. Goglia, Dipartimento di Scienze Biologiche ed Ambientali, Via Port' Arsa
11, 82100 Benevento, Italy. Email: goglia@unisannio.it
SOURCE
Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry (2006) 6:3
(255-265). Date of Publication: Jun 2006
ISSN
1871-5214
ABSTRACT
The purpose of this review is to summarize the current state of knowledge
concerning the biological activities of 3, 5-diiodothyronine (T(2)) and its
potential use as a pharmacological agent Until recent years, T(2) was
considered an inactive metabolite of thyroid hormones thyroxine (T(4)) and
triiodo-L-thyronine (T(3)). Several observations, however, led to a
reconsideration of this idea. Early studies dealing with the biological
activities of this iodothyronine revealed its ability to stimulate cellular
/mitochondrial respiration, essentially by a nuclear-independent pathway.
Mitochondria and the energy-transduction apparatus seem to be major targets
of T(2), although outside the mitochondria T(2) also has effects on
carriers, ion-exchangers and enzymes. Recent studies suggest that T(2) may
also affect the transcription of some genes, but again the underlying
mechanisms seem to differ from those actuated by T(3). The accumulated
evidence permits the conclusion that the actions of T(2) do not simply mimic
those of T(3) but instead are specific actions exerted through mechanisms
that are independent of those actuated by T(3) and do not involve thyroid
hormone receptors. In addition, very recent evidence leads us to suggest
that T(2) may be a potentially useful agent for the treatment of
diet-dependent overweight (and the consequent hypertriglyceridemia and high
cholesterol level) without inducing thyrotoxicosis. © 2006 Bentham Science
Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
diiodothyronine (adverse drug reaction, drug therapy, drug toxicity,
pharmacology)
EMTREE DRUG INDEX TERMS
acetyl coenzyme A carboxylase (endogenous compound)
cholesterol (endogenous compound)
liothyronine (adverse drug reaction, pharmacology)
malonyl coenzyme A (endogenous compound)
sodium ion (endogenous compound)
sodium proton exchange protein (endogenous compound)
thyroid hormone receptor (endogenous compound)
thyroxine (adverse drug reaction, pharmacology)
triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (side effect)
cell nucleus
cell respiration
dietary intake
drug mechanism
drug targeting
energy expenditure
energy metabolism
energy transfer
evidence based medicine
fatty acid oxidation
fatty liver (drug therapy)
genetic transcription
human
hypercholesterolemia (drug therapy)
hypertriglyceridemia (drug therapy)
ion exchange
mammal
metabolic rate
mitochondrial respiration
mitochondrion
nonhuman
obesity (drug therapy)
rat
review
sodium current
tachycardia (side effect)
thyrotoxicosis (side effect)
weight reduction
CAS REGISTRY NUMBERS
acetyl coenzyme A carboxylase (9023-93-2)
cholesterol (57-88-5)
diiodothyronine (1041-01-6)
liothyronine (6138-47-2, 6893-02-3)
malonyl coenzyme A (524-14-1)
sodium ion (17341-25-2)
sodium proton exchange protein (204597-32-0)
thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
Clinical and Experimental Biochemistry (29)
Endocrinology (3)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Toxicology (52)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006353305
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 448
TITLE
The investigation and treatment of chronic heart failure
AUTHOR NAMES
Gardner R.S.
McDonagh T.A.
AUTHOR ADDRESSES
(Gardner R.S.) Roy S Gardner MRCP is a Specialist Registrar in Cardiology in
Glasgow with a specialist interest in, .
(McDonagh T.A.) Royal Brompton Hospital, London, United Kingdom.
CORRESPONDENCE ADDRESS
R.S. Gardner, Roy S Gardner MRCP is a Specialist Registrar in Cardiology in
Glasgow with a specialist interest in, .
SOURCE
Medicine (2006) 34:6 (215-219). Date of Publication: 1 Jun 2006
Cardiovascular Disorders III, Book Series Title:
ISSN
1357-3039
ABSTRACT
Chronic heart failure (CHF) is a clinical syndrome defined by the presence
of symptoms (primarily breathlessness, fatigue and fluid retention),
objective evidence of cardiac dysfunction, and in cases where the diagnosis
is in doubt, a response to treatment directed towards it. It is not only
important to investigate to ascertain the diagnosis, but also to identify
the aetiology (as this might be reversible) and to give some indication of
the prognosis of the condition. The treatment of CHF has been
revolutionalized by large randomized controlled clinical trials studying the
effects of antagonism of the renin-angiotensin-aldosterone and sympathetic
nervous systems, as well as more recently, device therapy. These therapies
now form the cornerstones in the management of the condition, and prognosis
for this syndrome has improved as a result. However, cardiac transplantation
remains an option for patients who remain severely symptomatic, and at high
risk, despite optimal medical and appropriate device therapy. © 2006
Elsevier Ltd. All rights reserved.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
aldosterone antagonist (drug combination, drug therapy)
allopurinol (clinical trial, drug therapy)
angiotensin 2 receptor antagonist (clinical trial, drug combination, drug
therapy)
beta adrenergic receptor blocking agent (clinical trial, drug combination,
drug therapy)
brain natriuretic peptide (endogenous compound)
candesartan (clinical trial, drug combination, drug therapy)
captopril (clinical trial, drug therapy, pharmacology)
carvedilol (clinical trial, drug comparison, drug therapy)
digoxin (clinical trial, drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical
trial, drug combination, drug therapy)
diuretic agent (drug combination, drug therapy)
electrolyte (endogenous compound)
enalapril (clinical trial, drug therapy, pharmacology)
eplerenone (drug therapy)
erythropoietin (drug therapy)
ferritin (endogenous compound)
hydralazine (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug
therapy)
immunosuppressive agent (adverse drug reaction)
iron (drug therapy, intravenous drug administration)
metoprolol succinate (clinical trial, drug comparison, drug therapy)
metoprolol tartrate (clinical trial, drug therapy)
nitrate (drug therapy)
placebo
spironolactone (clinical trial, drug combination, drug therapy)
unindexed drug
urate (endogenous compound)
urea (endogenous compound)
warfarin (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (complication, diagnosis, drug therapy, etiology, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
aerobic exercise
anemia (drug therapy)
angiocardiography
angioneurotic edema
article
atrial fibrillation (diagnosis, drug therapy)
blood cell count
bradycardia (diagnosis)
cardiac resynchronization therapy
cardiomegaly (diagnosis)
clinical trial
coughing (side effect)
defibrillator
disease exacerbation
drug contraindication
drug dose titration
drug mechanism
drug megadose
echocardiography
electrocardiography
exercise test
fluid retention
heart left ventricle hypertrophy (complication, diagnosis)
heart muscle conduction disturbance (diagnosis, therapy)
heart muscle revascularization
heart transplantation
hemochromatosis
human
hypertension
hyperuricemia
hyponatremia
hypothyroidism
ischemic heart disease (drug therapy, prevention)
kidney disease
liver function test
low drug dose
mortality
nuclear magnetic resonance imaging
priority journal
prognosis
radioisotope ventriculography
smoking cessation
thorax radiography
thyroid function test
thyrotoxicosis
unspecified side effect (side effect)
weight reduction
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
allopurinol (315-30-0)
brain natriuretic peptide (114471-18-0)
candesartan (139481-59-7)
captopril (62571-86-2)
carvedilol (72956-09-3)
digoxin (20830-75-5, 57285-89-9)
enalapril (75847-73-3)
eplerenone (107724-20-9)
erythropoietin (11096-26-7)
ferritin (9007-73-2)
hydralazine (304-20-1, 86-54-4)
iron (14093-02-8, 53858-86-9, 7439-89-6)
metoprolol succinate (98418-47-4)
metoprolol tartrate (56392-17-7)
nitrate (14797-55-8)
spironolactone (52-01-7)
urate (1198-77-2, 3106-08-9, 59216-10-3)
urea (57-13-6)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006601493
FULL TEXT LINK
http://dx.doi.org/10.1383/medc.2006.34.6.215
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 449
TITLE
Re - Appraisal of risk factors for stroke in Nigerian Africans - A
prospective case - Control study
AUTHOR NAMES
Amu E.
Ogunrin O.
Danesi M.
AUTHOR ADDRESSES
(Amu E., bfunmi@uniben.edu; Ogunrin O.) Department of Medicine, University
Teaching Hospital, Benin City, Nigeria.
(Danesi M.) Dept. of Medicine, LUTH, Lagos.
CORRESPONDENCE ADDRESS
E. Amu, Department of Medicine, University Teaching Hospital, Benin City,
Nigeria. Email: bfunmi@uniben.edu
SOURCE
African Journal of Neurological Sciences (2005) 24:2 (20-27). Date of
Publication: 2005
ISSN
1015-8618
1015-8618 (electronic)
ABSTRACT
Stroke is one of the major challenges facing medicine with a frightening
statistics of being the second leading cause of death and the leading cause
of physical disability worldwide. Identification and management of risk
factors remains the key to reducing morbidity and mortality from stroke.
Eighty patients with clinical presentation of stroke were recruited
consecutively from the Emergency Departments of the University Teaching
Hospital and Specialist Hospital - both situated in Benin City, Nigeria. The
patients were followed up for a two year period (June 2000 - June 2002) and
risk factors analysis was done on all patients. The patients were compared
with eighty age and sex matched subjects without stroke (controls).
Hypertension remained the dominant risk factor with an odds ratio of 2.68
(95% CI 1.29 - 5.59). Diabetes mellitus independently conferred a risk of
3.23 (95% CI 1.09 - 5.71) and in combination with hypertension enhanced
stroke risk (odds ratio 7.21; 95% CI 5.79 - 13.27; p<0.05). Cigarette
smoking, obesity, atrial fibrillation and physical inactivity significantly
increased stroke risk (p<0.05). On the other hand, dietary habits, alcohol
consumption and serum cholesterol were not important risk factors in
Nigerians. This study emphasized the significance of optimal blood pressure
and glycemic control in stroke prevention. The message for all is to
exercise, maintain a healthy weight, avoid smoking and monitor blood
pressure and glucose levels regularly.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident
EMTREE MEDICAL INDEX TERMS
adult
aged
alcohol consumption
article
atrial fibrillation
blood pressure measurement
body weight
case control study
cause of death
cholesterol blood level
clinical feature
comparative study
confidence interval
controlled study
diabetes mellitus
diet
disability
emergency ward
exercise
female
follow up
glucose blood level
glycemic control
human
hypertension
immobilization
major clinical study
male
morbidity
mortality
Nigeria
obesity
prospective study
risk assessment
risk factor
smoking
statistics
time series analysis
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, French
EMBASE ACCESSION NUMBER
2006166775
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 450
TITLE
Symptomatic despite multiple drug therapy: Where do you turn next?
AUTHOR NAMES
Maggioni A.P.
AUTHOR ADDRESSES
(Maggioni A.P., maggioni@anmco.it) ANMCO Research Centre, Florence, Italy.
CORRESPONDENCE ADDRESS
A.P. Maggioni, ANMCO Research Centre, Florence, Italy. Email:
maggioni@anmco.it
SOURCE
JRAAS - Journal of the Renin-Angiotensin-Aldosterone System (2005) 6:SUPPL.
2 (S13-S14). Date of Publication: Dec 2005
ISSN
1470-3203
ABSTRACT
Clinicians may be reluctant to implement evidence-based guideline
recommendations because they believe that patients with chronic heart
failure (CHF) who are enrolled into clinical trials are not truly
representative of those seen in routine practice. Moreover, there may also
be perceived safety issues associated with polypharmacy in patients with
CHF. Clinicians should strive to implement guideline recommendations for the
management of CHF to ensure optimal patient outcome in routine clinical
practice. This case report demonstrates that symptom control may require a
large number of pharmacological treatments, to be administered in accordance
with guidelines.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination, drug therapy)
amiodarone (drug therapy)
bisoprolol (drug combination, drug dose, drug therapy)
brain natriuretic peptide (endogenous compound)
candesartan (drug combination, drug dose, drug therapy)
creatinine (endogenous compound)
furosemide (drug combination, drug therapy, intravenous drug administration)
low density lipoprotein cholesterol (endogenous compound)
ramipril (drug combination, drug dose, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (diagnosis, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation (drug therapy, therapy)
blood pressure measurement
cardioversion
case report
chronic obstructive lung disease
coronary artery disease
diet
disease association
disease course
drug efficacy
dyspnea (drug therapy, therapy)
echocardiography
follow up
heart arrhythmia (drug therapy, prevention)
heart infarction (complication)
heart left bundle branch block (diagnosis)
heart left ventricle failure (diagnosis, drug therapy)
hospital readmission
human
impaired glucose tolerance
lifestyle
male
maximum permissible dose
maximum tolerated dose
QRS complex
sinus rhythm
smoking cessation
symptomatology
thorax radiography
treatment contraindication
treatment outcome
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
bisoprolol (66722-44-9)
brain natriuretic peptide (114471-18-0)
candesartan (139481-59-7)
creatinine (19230-81-0, 60-27-5)
furosemide (54-31-9)
ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006088684
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 451
TITLE
Industry pulse (Editorial development by Adis International Limited, Italy)
AUTHOR ADDRESSES
SOURCE
High Blood Pressure and Cardiovascular Prevention (2005) 12:4 (239-243).
Date of Publication: 2005
ISSN
1120-9879
1120-9879 (electronic)
ABSTRACT
To help the reader keep up-to-date with the very latest developments in
experimental and clinical research, this section of the journal aims to
provide the reader with information selected by the journal sponsors
regarding emerging clinical evidence on their compounds, new areas of
research interest, and any other topic which might be potentially relevant
to the reader. © 2005 Adis Data Information BV. All rights reserved.
EMTREE DRUG INDEX TERMS
2,4 thiazolidinedione derivative (drug therapy)
acarbose (clinical trial, drug therapy)
atenolol (drug comparison, drug therapy, pharmacology)
beta adrenergic receptor blocking agent (drug comparison, drug therapy,
pharmacology)
dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
enalapril (clinical trial, drug therapy)
losartan (clinical trial, drug comparison, drug therapy, pharmacology)
metformin (drug therapy, pharmacoeconomics)
pioglitazone (clinical trial, drug therapy)
rosiglitazone (clinical trial, drug therapy)
trandolapril (clinical trial, drug therapy)
troglitazone (adverse drug reaction, clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, epidemiology)
diabetes mellitus (disease management, drug therapy, epidemiology,
prevention)
essential hypertension (drug therapy)
EMTREE MEDICAL INDEX TERMS
body mass
cardiovascular risk
clinical research
clinical trial
cost benefit analysis
diet
exercise
high risk population
human
impaired glucose tolerance
lifestyle
liver toxicity (side effect)
medical information
metabolic syndrome X (diagnosis)
non insulin dependent diabetes mellitus (drug therapy)
nutrition
obesity (epidemiology)
priority journal
review
risk assessment
screening
CAS REGISTRY NUMBERS
acarbose (56180-94-0)
atenolol (29122-68-7)
enalapril (75847-73-3)
losartan (114798-26-4)
metformin (1115-70-4, 657-24-9)
pioglitazone (105355-27-9, 111025-46-8)
rosiglitazone (122320-73-4, 155141-29-0)
trandolapril (87679-37-6)
troglitazone (97322-87-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006108092
FULL TEXT LINK
http://dx.doi.org/10.2165/00151642-200512040-00006
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 452
TITLE
Overcoming gaps in the management of asthma in older patients: New insights
AUTHOR NAMES
Barua P.
O'Mahony M.S.
AUTHOR ADDRESSES
(Barua P.; O'Mahony M.S., omahonyms@cf.ac.uk) University Department of
Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, United
Kingdom.
(O'Mahony M.S., omahonyms@cf.ac.uk) Academic Centre, Llandough Hospital,
Penlan Road, Penarth, CF64 2XX, United Kingdom.
CORRESPONDENCE ADDRESS
M.S. O'Mahony, Academic Centre, Llandough Hospital, Penlan Road, Penarth,
CF64 2XX, United Kingdom. Email: omahonyms@cf.ac.uk
SOURCE
Drugs and Aging (2005) 22:12 (1029-1059). Date of Publication: 2005
ISSN
1170-229X
1170-229X (electronic)
BOOK PUBLISHER
Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay,
Auckland 10, New Zealand.
ABSTRACT
Asthma is under-recognised and undertreated in older populations. This is
not surprising, given that one-third of older people experience significant
breathlessness. The differential diagnosis commonly includes asthma, chronic
obstructive pulmonary disease (COPD), heart failure, malignancy, aspiration
and infections. Because symptoms and signs of several cardiorespiratory
diseases are nonspecific in older people and diseases commonly co-exist,
investigations are important. A simple strategy for the investigation of
breathlessness in older people should include a full blood count, chest
radiograph, ECG, peak flow diary and/or spirometry with reversibility as a
minimum. If there are major abnormalities on the ECG, an echocardiogram
should also be performed. Diurnal variability in peak flow readings ≥20% or
≥15% reversibility in forced expiratory volume in 1 second, spontaneously or
with treatment, support a diagnosis of asthma. Distinguishing asthma from
COPD is important to allow appropriate management of disease based on
aetiology, accurate prediction of treatment response, correct prognosis and
appropriate management of the chest condition and co-morbidities. The two
conditions are usually readily differentiated by clinical features,
particularly age at onset, variability of symptoms and nocturnal symptoms in
asthma, supported by the results of reversibility testing. Full lung
function tests may not necessarily help in differentiating the two entities,
although gas transfer factor is characteristically reduced in COPD and
usually normal or high in asthma. Methacholine challenge tests previously
mainly used in research are now also used widely and safely to confirm
asthma in clinical settings. Interest in exhaled nitric oxide as a biomarker
of airways inflammation is increasing as a noninvasive tool in the diagnosis
and monitoring of asthma. Regular inhaled corticosteroids (ICS) are the
mainstay of treatment of asthma. Even in mild disease in older adults,
regular preventive treatment should be considered, given the poor perception
of bronchoconstriction by older asthmatic patients. If symptoms persist
despite ICS, addition of long-acting β2-adrenoceptor agonists (LABA) should
be considered. Addition of LABA to ICS improves asthma control and allows
reduction in ICS dose. However, older people have been grossly
under-represented in trials of LABA, many trials having excluded those ≥65
years of age. On meta-analysis, β2-adrenoceptor agonists (both short acting
and long acting) are associated with increased cardiovascular mortality and
morbidity in asthma and COPD. While the evidence for excess cardiovascular
mortality is stronger for short-acting β2-adrenoceptor agonists, it would be
prudent to exercise particular care in using β2-adrenoceptor agonists (long
acting and short acting) in those at risk of adverse cardiovascular
outcomes, including older people. Regular review of cardiovascular status
(and monitoring of serum potassium concentration) in patients taking
β2-adrenoceptor agonists is crucial. The response to LABA should be
carefully monitored and alternative 'add-on' therapy such as leukotriene
receptor antagonists (LRA) should be considered. LRA have fewer adverse
effects and in individual cases may be more effective and appropriate than
LABA. Long-term trials evaluating β2-adrenoceptor agonists and other
bronchodilator strategies are needed particularly in the elderly and in
patients with cardiovascular co-morbidities. There is no evidence that
addition of anticholinergics improves control of asthma further, although
the role of long-acting anticholinergics in the prevention of disease
progression is currently being researched. Older patients need to be taught
good inhaler technique to improve delivery of medications to lungs, minimise
adverse effects and reduce the need for oral corticosteroids. Nurse-led
education programmes that include a written asthma self-management plan have
the potential to improve outcomes. © 2005 Adis Data Information BV. All
rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antiasthmatic agent (adverse drug reaction, clinical trial, drug comparison,
drug concentration, drug dose, drug interaction, drug therapy, inhalational
drug administration, oral drug administration, pharmaceutics,
pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction)
antifungal agent (drug therapy, oral drug administration)
beclometasone (adverse drug reaction, drug comparison, drug dose, drug
therapy)
beta 2 adrenergic receptor stimulating agent (adverse drug reaction,
clinical trial, drug combination, drug therapy, pharmacology)
bisphosphonic acid derivative (drug therapy, oral drug administration)
budesonide (drug therapy)
calcium (drug therapy)
cholinergic receptor blocking agent (adverse drug reaction, drug dose, drug
therapy, inhalational drug administration, pharmacology)
cholinergic receptor stimulating agent (adverse drug reaction, drug therapy)
cimetidine (drug interaction)
corticosteroid (adverse drug reaction, drug dose, drug therapy, oral drug
administration, pharmacokinetics, pharmacology)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction)
fluticasone propionate (drug comparison, drug therapy)
formoterol (clinical trial, drug therapy)
histamine (adverse drug reaction, drug comparison)
ipratropium bromide (adverse drug reaction, drug therapy, pharmacology)
methacholine (adverse drug reaction, drug comparison)
methylxanthine (adverse drug reaction, drug concentration, drug dose, drug
interaction, drug therapy, oral drug administration, pharmaceutics,
pharmacokinetics, pharmacology)
mometasone furoate (drug comparison, drug therapy)
nonsteroid antiinflammatory agent (adverse drug reaction, drug therapy)
orciprenaline (drug therapy, pharmacology)
prednisolone (drug therapy, oral drug administration)
salbutamol (drug therapy, inhalational drug administration, pharmacology)
salmeterol (clinical trial, drug therapy)
theophylline (adverse drug reaction, drug concentration, drug dose, drug
interaction, drug therapy, oral drug administration, pharmaceutics,
pharmacokinetics, pharmacology)
tiopropium bromide (drug therapy, pharmacology)
unclassified drug
unindexed drug
vitamin D (drug therapy)
zileuton (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
asthma (diagnosis, drug therapy, side effect)
EMTREE MEDICAL INDEX TERMS
adrenal suppression
airway obstruction
allergy test
arterial gas
aspiration
atrial fibrillation (side effect)
attention disturbance (side effect)
blood analysis
blood cell count
bronchospasm (side effect)
bronchus secretion
cataract (side effect)
chronic obstructive lung disease
clinical trial
convulsion (side effect)
coughing (side effect)
depression (drug therapy)
diabetes mellitus (side effect)
diagnostic test
differential diagnosis
dizziness (side effect)
drug half life
drug induced headache (side effect)
drug tolerability
dysphonia (side effect)
electrocardiogram
essential tremor (drug therapy)
exercise
flushing
forced expiratory flow
fracture (drug therapy, side effect)
gastroesophageal reflux (side effect)
gastrointestinal disease (side effect)
glaucoma (drug therapy, side effect)
heart disease (drug therapy)
heart left ventricle failure
heart palpitation (side effect)
heart ventricle arrhythmia (side effect)
human
hypertension (drug therapy, side effect)
hypokalemia (side effect)
hypothalamus hypophysis adrenal system
immune paralysis (side effect)
immunotherapy
intraocular pressure abnormality (side effect)
lung embolism
lung function test
malignant neoplastic disease
memory disorder (side effect)
meta analysis
mood disorder (side effect)
morbidity
mortality
myopathy (side effect)
nervousness
osteoporosis (drug therapy, side effect)
priority journal
QT prolongation (side effect)
respiratory tract infection
review
side effect (side effect)
spirometry
supraventricular tachycardia (side effect)
symptomatology
systematic review
tachycardia (side effect)
thorax radiography
throat irritation (side effect)
thrush (drug therapy, side effect)
tremor (side effect)
urine retention (drug therapy, side effect)
yoga
DRUG TRADE NAMES
aspirin
DEVICE TRADE NAMES
Autohaler
Diskhaler
Nebuhaler
Rotahaler
Spinhaler
Turbohaler
volumatic
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
beclometasone (4419-39-0)
budesonide (51333-22-3)
calcium (7440-70-2)
cimetidine (51481-61-9, 70059-30-2)
fluticasone propionate (80474-14-2)
formoterol (73573-87-2)
histamine (51-45-6, 56-92-8, 93443-21-1)
ipratropium bromide (22254-24-6)
methacholine (55-92-5)
methylxanthine (28109-92-4)
mometasone furoate (83919-23-7)
orciprenaline (586-06-1, 5874-97-5)
prednisolone (50-24-8)
salbutamol (18559-94-9)
salmeterol (89365-50-4)
theophylline (58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9)
zileuton (111406-87-2, 132880-11-6)
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Pharmacy (39)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005580856
MEDLINE PMID
16363886 (http://www.ncbi.nlm.nih.gov/pubmed/16363886)
FULL TEXT LINK
http://dx.doi.org/10.2165/00002512-200522120-00004
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 453
TITLE
Ximelagatran: An oral direct thrombin inhibitor for anticoagulant therapy
AUTHOR NAMES
Rossi M.L.
Zavalloni D.
Belli G.
Presbitero P.
AUTHOR ADDRESSES
(Rossi M.L., marcolrossi@hotmail.com; Zavalloni D.; Belli G.; Presbitero P.)
Unità Operativa di Emodinamica e Cardiologia Interventistica, Istituto
Clinico Humanitas, Rozzano, Milan, Italy.
(Rossi M.L., marcolrossi@hotmail.com) Unità Operativa di Emodinamica e
Cardiologia Interventistica, Istituto Clinico Humanitas, Via Manzoni, 56,
20089 Rozzano, Milan, Italy.
CORRESPONDENCE ADDRESS
M.L. Rossi, Unità Operativa di Emodinamica e Cardiologia Interventistica,
Istituto Clinico Humanitas, Via Manzoni, 56, 20089 Rozzano, Milan, Italy.
Email: marcolrossi@hotmail.com
SOURCE
Letters in Drug Design and Discovery (2005) 2:7 (503-506). Date of
Publication: Nov 2005
ISSN
1570-1808
ABSTRACT
Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct,
competitive and reversible inhibitor of the active site of human α-thrombin.
Its effect is independent from diet, plasma antithrombin levels, obesity or
ethnicity. It has little effect on bleeding time at doses up to twice those
required, and interference with other drugs is avoided by the absence of
interaction with cytochrome P450. Ximelagatran has been documented in a
large clinical programme with proven efficacy in prevention and treatment of
venous thromboembolism, prevention of stroke in patients with atrial
fibrillation and prevention of major cardiovascular events following a
recent myocardial infarction. Bleeding has not been a problem, but increase
in liver enzymes is a cause of concern for long term use until more
information is available. © 2005 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
melagatran (drug administration, drug therapy, oral drug administration,
pharmacokinetics, pharmacology, subcutaneous drug administration)
thrombin inhibitor (drug therapy, oral drug administration, pharmacology)
ximelagatran (drug combination, drug therapy, oral drug administration,
pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination, drug therapy)
cytochrome P450 (endogenous compound)
enoxaparin (drug comparison, drug therapy, subcutaneous drug administration)
liver enzyme (endogenous compound)
low molecular weight heparin (drug therapy)
prodrug
warfarin (drug therapy, oral drug administration, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
venous thromboembolism (drug therapy)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (drug therapy)
blood clotting
cardiovascular disease
cerebrovascular accident
diet
drug effect
drug efficacy
ethnology
human
nonhuman
obesity
priority journal
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
cytochrome P450 (9035-51-2)
enoxaparin (9041-08-1)
melagatran (159776-70-2)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005550309
FULL TEXT LINK
http://dx.doi.org/10.2174/157018005774479168
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 454
TITLE
Dexmedetomidine as a sole sedating agent with local anesthesia in a
high-risk patient for axillofemoral bypass graft: A case report
AUTHOR NAMES
Rich J.M.
AUTHOR ADDRESSES
(Rich J.M., jrofdallas@gmail.com)
(Rich J.M., jrofdallas@gmail.com) Baylor University Medical Center, Dallas,
TX, United States.
CORRESPONDENCE ADDRESS
J.M. Rich, Baylor University Medical Center, Dallas, TX, United States.
Email: jrofdallas@gmail.com
SOURCE
AANA Journal (2005) 73:5 (357-360). Date of Publication: October 2005
ISSN
0094-6354
BOOK PUBLISHER
AANA Publishing Inc., 222 South Prospect Road, Park Ridge, United States.
ABSTRACT
The α(2)-agonist dexmedetomidine is indicated for sedation of patients
receiving mechanical ventilation in the intensive care unit. It has
additional off-label uses for coadministration with local, regional, and
general anesthesia. This report describes the use of dexmedetomidine as a
sole sedating agent in conjunction with local anesthesia for major vascular
surgery. A PubMed literature search produced no previous report of the use
of dexmedetomidine as a sole sedating agent used in conjunction with local
anesthesia. The anxiolytic, hypnotic-sedative, anesthetic-sparing, and
analgesic actions of the drug along with the lack of significant respiratory
depressant effects are described. The patient required no airway management
with the exception of supplemental mask oxygen. He tolerated the procedure
well and was discharged without sequelae on the third postoperative day.
Dexmedetomidine should be used judiciously, and understanding the potential
adverse effects and how to treat them is of paramount importance. However,
with vigilant intraoperative monitoring of blood pressure, heart rate, and
level of consciousness, it can be administered safely, thus lessening the
anesthetic requirements and possibly improving the surgical outcome of the
high-risk patient. This report describes the indications, dosing, off-label
uses, pharmacodynamics, pharmacokinetics, and common adverse effects of
dexmedetomidine.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
dexmedetomidine (adverse drug reaction, drug comparison, drug dose, drug
interaction, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
alpha 2 adrenergic receptor stimulating agent (adverse drug reaction, drug
comparison, drug dose, drug interaction, pharmacoeconomics,
pharmacokinetics, pharmacology)
amlodipine (drug therapy)
calcium acetate
famotidine
fluticasone (drug therapy)
furosemide (drug therapy)
lidocaine
local anesthetic agent
losartan (drug therapy)
midazolam (drug comparison, pharmacokinetics)
opiate (drug interaction)
prednisone
propofol (drug comparison, pharmacoeconomics, pharmacokinetics)
salmeterol (drug therapy)
sedative agent (adverse drug reaction, drug comparison, drug dose, drug
interaction, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
axillofemoral artery anastomosis
local anesthesia
sedation
EMTREE MEDICAL INDEX TERMS
aged
anemia (side effect)
article
atrial fibrillation
bradycardia (side effect)
case report
chronic obstructive lung disease (drug therapy)
congestive heart failure (drug therapy)
drug indication
drug monitoring
drug use
fever (side effect)
geriatric patient
high risk patient
human
hypertension (drug therapy, side effect)
hypotension (side effect)
hypoxia (side effect)
male
nausea (side effect)
off label drug use
rating scale
surgical patient
tachycardia (side effect)
thromboembolism (complication, drug therapy, prevention)
vascular surgery
vomiting (side effect)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amlodipine (88150-42-9)
calcium acetate (62-54-4)
dexmedetomidine (113775-47-6)
famotidine (76824-35-6)
fluticasone (90566-53-3)
furosemide (54-31-9)
lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
losartan (114798-26-4)
midazolam (59467-70-8)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
prednisone (53-03-2)
propofol (2078-54-8)
salmeterol (89365-50-4)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Clinical and Experimental Pharmacology (30)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005460125
MEDLINE PMID
16261851 (http://www.ncbi.nlm.nih.gov/pubmed/16261851)
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 455
TITLE
Clinical experience in acupuncture treatment of apoplexy
AUTHOR NAMES
Liu R.
AUTHOR ADDRESSES
(Liu R.) Pukou Hospital, Nanjing, Jiangsu 210031, China.
CORRESPONDENCE ADDRESS
R. Liu, Pukou Hospital, Nanjing, Jiangsu 210031, China.
SOURCE
Journal of Traditional Chinese Medicine (2005) 25:3 (190-192). Date of
Publication: September 2005
ISSN
0255-2922
BOOK PUBLISHER
Journal of Traditional Chinese Medicine, 18 Beixincang, Dongzhimen Nei,
Beijing, China.
EMTREE DRUG INDEX TERMS
antihypertensive agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
cerebrovascular accident (therapy)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (therapy)
brain circulation
brain hemorrhage (drug therapy)
hemiplegia
human
hypertension (drug therapy)
ischemic heart disease (therapy)
mental disease (therapy)
muscle rigidity (therapy)
paralysis (therapy)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2005530005
MEDLINE PMID
16334721 (http://www.ncbi.nlm.nih.gov/pubmed/16334721)
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 456
TITLE
A 68-year-old woman with multiple NSAID-induced adverse effects
AUTHOR NAMES
Collins R.J.
Brokaw D.K.
AUTHOR ADDRESSES
(Collins R.J., rjcollins@vcu.edu; Brokaw D.K.) Virginia Commonwealth
University, School of Pharmacy, Richmond, VA, United States.
(Collins R.J., rjcollins@vcu.edu) Virginia Commonwealth University, School
of Pharmacy, P.O. Box 980533, Richmond, VA 23298-0533, United States.
CORRESPONDENCE ADDRESS
R.J. Collins, Virginia Commonwealth University, School of Pharmacy, P.O. Box
980533, Richmond, VA 23298-0533, United States. Email: rjcollins@vcu.edu
SOURCE
Consultant Pharmacist (2005) 20:8 (685-688). Date of Publication: Aug 2005
ISSN
0888-5109
ABSTRACT
Common comorbid conditions such as atrial fibrillation, hypertension,
congestive heart failure, and osteoarthritis put geriatric patients at risk
for toxicity while using nonsteroidal anti-inflammatory drugs (NSAIDs).
Concomitant medications also can contribute to complications associated with
NSAID therapy. However, NSAID therapy is widely used for pain management in
this patient population. This case describes a 68-year-old patient, with a
history of hypertension and osteoarthritis, who presented with multiple
NSAID-induced adverse effects. Upon admission to the hospital, this patient
was found to have renal and hepatic failure, fluid overload, and
electrocardiogram changes, most likely as a result of excessive naproxen
ingestion. This patient also was taking hydrochlorothiazide and had not had
any laboratory values drawn to monitor her medication regimen. Subsequently,
she required hemodialysis and a long hospital course. Her hepatic failure,
fluid overload, and electrocardiogram changes resolved with treatment.
Multiple health care providers could have detected probl ems with this
patient's pain management. Adverse events associated with NSAIDs can be
prevented with patient monitoring and education. Health care providers also
need education to learn how to optimize the pain management of their
geriatric patients. Recommendations for preventing NSAID-induced adverse
effects and for optimizing pain management are presented. Copyright© 2005,
American Society of Consultant Pharmacists, Inc. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
nonsteroid antiinflammatory agent (adverse drug reaction, drug combination)
EMTREE DRUG INDEX TERMS
capsaicin (drug combination, drug therapy, topical drug administration)
cyclooxygenase 2 inhibitor (drug combination)
dimethyl sulfone
diuretic agent (drug combination)
herbaceous agent
hydrochlorothiazide (drug combination, drug interaction, drug therapy, oral
drug administration)
levofloxacin (drug therapy)
naproxen (adverse drug reaction, drug combination, drug interaction, drug
therapy)
paracetamol (drug therapy)
prednisone (drug therapy, oral drug administration)
promethazine (drug therapy, rectal drug administration)
salicylic acid methyl ester (drug combination, drug therapy, topical drug
administration)
tramadol (drug combination)
EMTREE MEDICAL INDEX TERMS
acute kidney tubule necrosis (side effect)
aged
article
atrial fibrillation
blood pressure
case report
comorbidity
congestive heart failure
digestive system ulcer (side effect)
drug withdrawal
edema (side effect)
electrocardiogram
electrolyte disturbance (side effect)
exercise
female
fluid retention
gastrointestinal disease (side effect)
gastrointestinal hemorrhage (side effect)
geriatric patient
heart failure (side effect)
hemodialysis
hospitalization
human
hypertension (side effect)
kidney failure (side effect, therapy)
kidney injury (side effect)
knee osteoarthritis (drug therapy)
liver dysfunction (side effect)
liver failure (side effect)
nausea (drug therapy)
nephrotoxicity (side effect)
oliguria (side effect)
osteoarthritis
pain (drug therapy, therapy)
patient education
patient monitoring
pharmacist
potassium blood level
risk factor
side effect (side effect)
sodium absorption
stomach disease (side effect)
urinary tract infection (drug therapy)
vomiting (drug therapy)
weight reduction
CAS REGISTRY NUMBERS
capsaicin (404-86-4)
dimethyl sulfone (67-71-0)
hydrochlorothiazide (58-93-5)
levofloxacin (100986-85-4, 138199-71-0)
naproxen (22204-53-1, 26159-34-2)
paracetamol (103-90-2)
prednisone (53-03-2)
promethazine (58-33-3, 60-87-7)
salicylic acid methyl ester (119-36-8)
tramadol (27203-92-5, 36282-47-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Gastroenterology (48)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2006597199
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 457
TITLE
Preventing dementia
AUTHOR NAMES
Purandare N.
Ballard C.
Burns A.
AUTHOR ADDRESSES
(Purandare N., nitin.purandare@man.ac.uk) University of Manchester, School
of Psychiatry and Behavioural Sciences, Wythenshawe Hospital, Manchester M23
9LT, United Kingdom.
(Ballard C.) Department of Old Age Psychiatry, King's College, London,
United Kingdom.
(Burns A.) Department of Old Age Psychiatry, School of Psychiatry and
Behavioural Sciences, University of Manchester, Manchester M23 9LT, United
Kingdom.
CORRESPONDENCE ADDRESS
N. Purandare, University of Manchester, School of Psychiatry and Behavioural
Sciences, Wythenshawe Hospital, Manchester M23 9LT, United Kingdom. Email:
nitin.purandare@man.ac.uk
SOURCE
Advances in Psychiatric Treatment (2005) 11:3 (176-183). Date of
Publication: May 2005
ISSN
1355-5146
ABSTRACT
Epidemiological evidence has identified key strategies that may be used in
the prevention of both Alzheimer's disease and vascular dementia. These
strategies may be loosely divided into three areas: treatment of vascular
risk factors, neuroprotection and increasing neuronal reserves. Evidence
from randomised controlled trials already exists for treatment of
hypertension but results for statins have been disappointing. Most of the
intervention trials currently in progress focus on one or two risk factors
and include cognition or dementia only as a secondary outcome. The potential
of intervention strategies awaits confirmation by randomised controlled
trials that target multiple risk factors in at-risk people with mild
cognitive impairment, with incident dementia as the primary outcome.
EMTREE DRUG INDEX TERMS
alpha tocopherol (clinical trial, drug combination, drug comparison, drug
therapy)
antidiabetic agent (clinical trial, drug therapy)
antihypertensive agent (clinical trial, drug therapy)
apolipoprotein E (endogenous compound)
ascorbic acid (drug therapy)
calcium channel blocking agent (drug therapy)
compactin (adverse drug reaction, clinical trial, drug therapy)
cyanocobalamin (drug therapy)
dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
folic acid (drug therapy)
green tea extract (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (adverse drug reaction,
clinical trial, drug therapy)
mevinolin (adverse drug reaction, clinical trial, drug therapy)
nonsteroid antiinflammatory agent (clinical trial, drug therapy)
placebo
pravastatin (adverse drug reaction, clinical trial, drug therapy)
selegiline (clinical trial, drug combination, drug comparison, drug therapy)
simvastatin (adverse drug reaction, clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Alzheimer disease (drug therapy, prevention)
multiinfarct dementia (drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
article
atherosclerosis
atrial fibrillation
cardiovascular risk
carotid artery obstruction
clinical trial
cognition
cognitive defect (side effect)
diabetes mellitus (drug therapy)
epidemiological data
evidence based medicine
exercise
heart infarction
human
hypercholesterolemia (drug therapy)
hypertension (drug therapy)
leisure
meta analysis
neuroprotection
physical activity
risk factor
risk management
risk reduction
smoking
social behavior
systematic review
treatment outcome
CAS REGISTRY NUMBERS
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
compactin (73573-88-3)
cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
folic acid (59-30-3, 6484-89-5)
mevinolin (75330-75-5)
pravastatin (81131-74-0)
selegiline (14611-51-9, 14611-52-0, 2079-54-1, 2323-36-6)
simvastatin (79902-63-9)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Psychiatry (32)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005223499
FULL TEXT LINK
http://dx.doi.org/10.1192/apt.11.3.176
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 458
TITLE
High-dose torasemide is equivalent to high-dose furosemide with hypertonic
saline in the treatment of refractory congestive heart failure
AUTHOR NAMES
Paterna S.
Fasullo S.
Di Pasquale P.
AUTHOR ADDRESSES
(Paterna S.) Department of Internal Medicine, University of Palermo,
Palermo, Italy.
(Fasullo S.; Di Pasquale P.) Div. of Cardiology Paolo Borsellino, G.F.
Ingrassia Hospital, Palermo, Italy.
(Di Pasquale P.) Div. of Cardiology Paolo Borsellino, Via Val Platani 3,
Palermo, 90144, Italy.
CORRESPONDENCE ADDRESS
P. Di Pasquale, Div. of Cardiology Paolo Borsellino, Via Val Platani 3,
Palermo, 90144, Italy.
SOURCE
Clinical Drug Investigation (2005) 25:3 (165-173). Date of Publication: 2005
ISSN
1173-2563
ABSTRACT
Objective: A randomised, double-blind study was performed to evaluate the
effects of the combination of high-dose torasemide and hypertonic saline
solution (HSS) infusion versus high-dose furosemide (frusemide) and HSS in
the treatment of refractory New York Heart Association class IV congestive
heart failure (CHF). Materials and methods: Eighty-four patients (55 males,
29 females) with refractory CHF, aged 55-84 years, with an ejection fraction
<35%, serum creatinine <2 mg/dL, blood urea nitrogen ≤60 mg/dL, a reduced
urinary volume and a low natriuresis, were randomised to two groups. Group 1
(27 males, 15 females) received an intravenous infusion of furosemide 500mg
plus HSS (150mL of 1.4-4.6% sodium chloride) twice daily in 30 minutes.
Group 2 (28 males, 14 females) received torasemide 200mg twice daily plus
HSS during a period lasting 4-8 days. Physical examination, measurement of
bodyweight, blood pressure, heart rate, evaluation of signs of CHF, and
serum and urinary parameters were controlled daily during hospitalisation.
Chest x-ray, ECG and echocardiogram were obtained at entry, during
hospitalisation and at discharge. During the treatment and after discharge
the daily dietary sodium intake was 120 mmol, with a fluid intake of
1.0-1.5L in both groups. Bodyweight and 24-hour urinary volume, serum and
urinary laboratory parameters, until reaching a compensated state, were
controlled daily, when intravenous furosemide and torasemide were replaced
with oral furosemide administration only (250-500mg twice daily). After
discharge the double-blind design was discontinued and the subsequent period
was an open-label study with furosemide only; the patients were followed up
as outpatients weekly for the first 3 months and subsequently once a month.
Results: Baseline clinical characteristics of patients were similar in both
groups. A significant increase in daily diuresis and natriuresis was
observed in both groups. No difference was observed in serum sodium or
potassium. Bodyweight was reduced in both groups. Blood pressure values
decreased, and heart rate was corrected to normal values in both groups. In
the follow-up period (12 ± 3.9 months), 17 patients were re-admitted to the
hospital for heart failure. Thirteen patients died during follow-up.
Conclusion: We conclude that high-dose torasemide is equivalent to high-dose
furosemide in the treatment of refractory CHF. © 2005 Adis Data Information
BV. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
furosemide (clinical trial, drug combination, drug comparison, drug dose,
drug therapy, intravenous drug administration, oral drug administration)
torasemide (clinical trial, drug comparison, drug dose, drug therapy,
intravenous drug administration)
EMTREE DRUG INDEX TERMS
aldosterone antagonist (drug combination, drug therapy)
beta adrenergic receptor blocking agent (drug combination, drug therapy)
captopril (drug combination, drug therapy)
creatinine (endogenous compound)
digoxin (drug combination, drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug combination, drug therapy)
nitrate (drug combination, drug therapy)
nitrogen (endogenous compound)
potassium (endogenous compound)
sodium (endogenous compound)
sodium chloride
urea (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure (drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation (drug therapy)
bioequivalence
blood pressure
body weight
clinical trial
congestive cardiomyopathy (drug therapy)
controlled study
coronary artery disease (drug therapy)
creatinine blood level
death
double blind procedure
drug megadose
echocardiography
electrocardiography
female
fluid intake
follow up
heart ejection fraction
heart rate
human
hypertension (drug therapy)
major clinical study
male
natriuresis
open study
physical examination
potassium blood level
priority journal
randomized controlled trial
sodium blood level
sodium intake
statistical analysis
thorax radiography
urea nitrogen blood level
urine volume
CAS REGISTRY NUMBERS
captopril (62571-86-2)
creatinine (19230-81-0, 60-27-5)
digoxin (20830-75-5, 57285-89-9)
furosemide (54-31-9)
nitrate (14797-55-8)
nitrogen (7727-37-9)
potassium (7440-09-7)
sodium chloride (7647-14-5)
sodium (7440-23-5)
torasemide (56211-40-6)
urea (57-13-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005150059
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 459
TITLE
Fast-track cardiac anesthesia: Choice of anesthetic agents and techniques
AUTHOR NAMES
Myles P.S.
McIlroy D.
AUTHOR ADDRESSES
(Myles P.S., p.myles@alfred.org.au; McIlroy D.) Dept. of Anaesthesia and
Pain Mgmt., Alfred Hospital, Australia.
(Myles P.S., p.myles@alfred.org.au) Depts. Anaesthesia, Epidemiol. P.,
Monash University, Australia.
(Myles P.S., p.myles@alfred.org.au) Ctr. for Clin. Research Excellence,
Canberra, ACT, Australia.
(Myles P.S., p.myles@alfred.org.au) Dept. of Anaesthesia and Pain Mgmt.,
Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
CORRESPONDENCE ADDRESS
P.S. Myles, Dept. of Anaesthesia and Pain Mgmt., Alfred Hospital, Commercial
Road, Melbourne, Vic. 3004, Australia. Email: p.myles@alfred.org.au
SOURCE
Seminars in Cardiothoracic and Vascular Anesthesia (2005) 9:1 (5-16). Date
of Publication: March 2005
ISSN
1089-2532
BOOK PUBLISHER
SAGE Publications Inc., 2455 Teller Road, Thousand Oaks, United States.
ABSTRACT
Fast-track cardiac anesthesia (FTCA) incorporates early tracheal extubation,
decreased length of intensive care unit (ICU) and hospital stay, and
(ideally) should avoid or reduce complications to safely achieve
cost-savings. A growing body of evidence from randomized trials has
identified many anesthetic interventions that can improve outcome after
cardiac surgery. These include new short-acting hypnotic, opioid, and
neuromuscular blocking drugs. An effective FTCA program requires the
appropriate selection of suitable patients, a low-dose opioid anesthetic
technique, early tracheal extubation, a short stay in the ICU, and
coordinated perioperative care. It is also dependent on the avoidance of
postoperative complications such as excessive bleeding, myocardial ischemia,
low cardiac output state, arrhythmias, sepsis, and renal failure. These
complications will have a much greater adverse effect on hospital length of
stay and healthcare costs. A number of clinical trials have identified
interventions that can reduce some of these complications. The adoption of
effective treatments into clinical practice should improve the effectiveness
of FTCA. ©2005 Westminster Publications, Inc.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
adrenergic receptor stimulating agent (drug therapy)
amiodarone (drug comparison, drug therapy)
anesthetic agent (drug therapy, epidural drug administration)
aprotinin (drug therapy)
bupivacaine (drug combination, drug comparison, drug therapy, epidural drug
administration)
calcium channel stimulating agent (drug therapy)
catecholamine (endogenous compound)
clonidine (drug combination, drug concentration, drug therapy, epidural drug
administration)
creatinine (endogenous compound)
desmopressin (drug therapy)
dexmedetomidine (drug therapy)
diclofenac (drug therapy)
dopamine
dopexamine
enflurane (drug comparison, drug therapy)
fentanyl (drug combination, drug comparison, drug dose, drug therapy)
hydrocortisone (endogenous compound)
isoflurane (drug combination, drug therapy)
methylprednisolone
morphine (drug combination, drug therapy, intrathecal drug administration)
nonsteroid antiinflammatory agent (drug combination, drug therapy)
opiate (drug therapy, intrathecal drug administration)
pancuronium (drug comparison)
propofol (drug combination, drug comparison, drug therapy)
remifentanil (drug comparison, drug therapy, pharmacoeconomics)
rocuronium (drug comparison)
sotalol (drug comparison, drug therapy)
tranexamic acid (drug therapy)
unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Fast Track cardiac anesthesia
heart surgery
postoperative analgesia
EMTREE MEDICAL INDEX TERMS
anesthesia
atrial fibrillation (complication, drug therapy, prevention)
coronary artery bypass graft
cost control
extubation
general anesthesia
health care cost
heart arrhythmia (complication, drug therapy, prevention)
heart muscle ischemia (complication, drug therapy, prevention)
hospitalization
human
intensive care unit
kidney failure (complication, drug therapy, prevention)
neuromuscular blocking
perioperative period
postoperative care
postoperative complication (complication, prevention, therapy)
postoperative hemorrhage (complication, drug therapy, prevention)
postoperative pain (disease management, drug therapy, prevention)
review
sepsis (complication, prevention)
thorax epidural anesthesia
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
aprotinin (11004-21-0, 12407-79-3, 50936-63-5, 52229-70-6, 58591-29-0,
9050-74-2, 9075-10-9, 9087-70-1)
bupivacaine (18010-40-7, 2180-92-9, 55750-21-5)
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
creatinine (19230-81-0, 60-27-5)
desmopressin (16679-58-6)
dexmedetomidine (113775-47-6)
diclofenac (15307-79-6, 15307-86-5)
dopamine (51-61-6, 62-31-7)
dopexamine (86197-47-9, 86484-91-5)
enflurane (13838-16-9)
fentanyl (437-38-7)
hydrocortisone (50-23-7)
isoflurane (26675-46-7)
methylprednisolone (6923-42-8, 83-43-2)
morphine (52-26-6, 57-27-2)
opiate (53663-61-9, 8002-76-4, 8008-60-4)
propofol (2078-54-8)
remifentanil (132539-07-2)
rocuronium (119302-91-9)
sotalol (3930-20-9, 80456-07-1, 959-24-0)
tranexamic acid (1197-18-8, 701-54-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005110938
MEDLINE PMID
15735840 (http://www.ncbi.nlm.nih.gov/pubmed/15735840)
FULL TEXT LINK
http://dx.doi.org/10.1177/108925320500900102
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 460
TITLE
Concomitant drug, dietary, and lifestyle issues in patients with atrial
fibrillation receiving anticoagulation therapy for stroke prophylaxis
AUTHOR NAMES
Nutescu E.A.
Helgason C.M.
AUTHOR ADDRESSES
(Nutescu E.A., enutescu@uic.edu) Antithrombosis Service, College of Pharmacy
- Pharmacy Practice, University of Illinois at Chicago, 833 South Wood
Street, Chicago, IL 60612, United States.
(Helgason C.M.)
CORRESPONDENCE ADDRESS
E.A. Nutescu, Antithrombosis Service, College of Pharmacy - Pharmacy
Practice, University of Illinois at Chicago, 833 South Wood Street, Chicago,
IL 60612, United States. Email: enutescu@uic.edu
SOURCE
Current Treatment Options in Cardiovascular Medicine (2005) 7:3 (241-250).
Date of Publication: July 2005
ISSN
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Atrial fibrillation is a common cardiac arrhythmia and the leading risk
factor for stroke. In those at moderate to high risk of stroke, oral
anticoagulation therapy with warfarin (a vitamin K antagonist) significantly
reduces not only the frequency of such events but also their severity and
the associated risk of death. However, achieving optimal anticoagulation
with this agent is clinically challenging in view of its complex
pharmacokinetic and pharmacodynamic profile. In this regard, concomitant
drug therapy (both prescription and over-the-counter medications, including
herbal products, vitamins, and various nutritional supplements), along with
alcohol intake, dietary factors, and changes in lifestyle, can significantly
affect anticoagulation control and thereby expose patients to the risk of
bleeding or thromboembolic complications (due to over- and
underanticoagulation, respectively). Therefore, it is recommended that
intensified monitoring of anticoagulation be performed at initiation and
discontinuation of concomitant drug therapy, and in the case of significant
dietary and lifestyle changes. Moreover, many patients receive inadequate
education and are unaware of such risks and their implications, highlighting
the need for better awareness and education on this important aspect of
anticoagulation therapy. Copyright © 2005 by Current Science Inc.
EMTREE DRUG INDEX TERMS
amiodarone (adverse drug reaction, drug interaction)
analgesic agent (drug interaction)
antiarrhythmic agent (drug interaction)
antiinflammatory agent (drug interaction)
carbamazepine (drug interaction)
chlordiazepoxide (drug interaction)
cimetidine (drug interaction)
clofibrate (drug interaction)
colestyramine (drug interaction)
cotrimoxazole (drug interaction)
erythromycin (drug interaction)
fluconazole (drug interaction)
griseofulvin (drug interaction)
herbaceous agent (drug therapy)
isoniazid (drug interaction)
metronidazole (drug interaction)
miconazole (drug interaction)
nafcillin (drug interaction)
non prescription drug (drug therapy)
omeprazole (drug interaction)
phenylbutazone (drug interaction)
piroxicam (drug interaction)
propafenone (drug interaction)
propranolol (drug interaction)
rifampicin (drug interaction)
sucralfate (drug interaction)
sulfinpyrazone (drug interaction)
unindexed drug
vitamin (drug therapy)
warfarin (adverse drug reaction, drug dose, drug interaction, drug therapy,
oral drug administration, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
atrial fibrillation (drug therapy, therapy)
cerebrovascular accident (complication, drug therapy, etiology, prevention,
therapy)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
anticoagulation
awareness
bleeding (complication)
diet
diet therapy
disease severity
drug mechanism
drug metabolism
drug sensitivity
drug use
food intake
frequency analysis
human
hypothyroidism (side effect)
lifestyle
mortality
patient compliance
patient education
patient monitoring
pharmacodynamics
prescription
prophylaxis
review
risk assessment
risk factor
risk reduction
thyrotoxicosis (side effect)
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
carbamazepine (298-46-4, 8047-84-5)
chlordiazepoxide (438-41-5, 58-25-3)
cimetidine (51481-61-9, 70059-30-2)
clofibrate (637-07-0)
colestyramine (11041-12-6, 58391-37-0)
cotrimoxazole (8064-90-2)
erythromycin (114-07-8, 70536-18-4)
fluconazole (86386-73-4)
griseofulvin (126-07-8)
isoniazid (54-85-3, 62229-51-0, 65979-32-0)
metronidazole (39322-38-8, 443-48-1)
miconazole (22916-47-8)
nafcillin (147-52-4, 985-16-0)
omeprazole (73590-58-6, 95510-70-6)
phenylbutazone (129-18-0, 50-33-9, 8054-70-4)
piroxicam (36322-90-4)
propafenone (34183-22-7, 54063-53-5)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
rifampicin (13292-46-1)
sucralfate (54182-58-0)
sulfinpyrazone (57-96-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Hematology (25)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005517671
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 461
TITLE
Treatment of heart failure with a normal ejection fraction
AUTHOR NAMES
Bhakta S.
Dunlap M.E.
AUTHOR ADDRESSES
(Bhakta S.; Dunlap M.E., mark.dunlap@med.va.gov) Heart Failure Program,
Louis B. Stokes Veterans Affairs Medical Center, 10701 East Boulevard,
Cleveland, OH 44106, United States.
CORRESPONDENCE ADDRESS
S. Bhakta, Heart Failure Program, Louis B. Strokes Veterans Affairs Medical
Center, 10701 East Boulevard, Cleveland, OH 44106, United States.
SOURCE
Current Treatment Options in Cardiovascular Medicine (2005) 7:4 (317-325).
Date of Publication: August 2005
ISSN
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
Treatment of diastolic heart failure is divided into acute and chronic
management. During acute management, the focus should be treatment of the
presenting syndrome, including correction of volume overload, treating
hypertension, alleviating ischemia, and controlling tachyarrhythmias.
Therefore, acute treatment should include several components: treating
volume overload with sodium restriction and diuretics; treating ischemic
heart disease with antiplatelet therapy, anticoagulants, and β blockers;
treating hypertension aggressively, using multiple agents if necessary; and
treating atrial tachyarrhythmias such as atrial fibrillation with
rate-controlling agents, such as β blockers and possibly nondihydropyridine
calcium channel blockers such as diltiazem and verapamil. Antiarrhythmic
agents with or without electrical cardioversion may be necessary. Thoroughly
evaluate and manage extracardiac precipitants such as anemia and renal
failure. Chronic management should also focus on precipitating factors, for
which adequate control of hypertension is paramount. Patient education
regarding dietary and medication compliance and lifestyle changes is also
important. If ischemic heart disease is present, aggressive anti-ischemic
therapy is necessary, including revascularization when indicated. Copyright
© 2005 by Current Science Inc.
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist (adverse drug reaction, clinical trial, drug
combination, drug dose, drug interaction, drug therapy, pharmacoeconomics)
antiarrhythmic agent (drug therapy)
anticoagulant agent (drug therapy)
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent (adverse drug reaction, clinical
trial, drug combination, drug comparison, drug dose, drug interaction, drug
therapy, pharmacoeconomics)
calcium channel blocking agent (drug combination, drug interaction, drug
therapy)
candesartan (adverse drug reaction, drug combination, drug comparison, drug
dose, drug interaction, drug therapy, pharmacoeconomics)
carvedilol (adverse drug reaction, drug combination, drug comparison, drug
dose, drug interaction, drug therapy, pharmacoeconomics)
diltiazem (drug combination, drug interaction, drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical
trial, drug combination, drug dose, drug interaction, drug therapy,
pharmacoeconomics)
diuretic agent (drug therapy)
esmolol (drug therapy)
glyceryl trinitrate (drug therapy)
loop diuretic agent (drug therapy)
mineralocorticoid receptor (endogenous compound)
nesiritide (drug therapy)
placebo
verapamil (drug combination, drug interaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (diagnosis, disease management, drug therapy, etiology,
therapy)
EMTREE MEDICAL INDEX TERMS
anemia
atrial fibrillation (drug therapy)
bradycardia (side effect)
cardioversion
clinical protocol
clinical trial
cost effectiveness analysis
coughing (side effect)
diet therapy
disease control
drowsiness (side effect)
drug contraindication
drug cost
drug dose regimen
drug eruption (side effect)
drug potentiation
drug tolerability
fatigue (side effect)
follow up
heart ejection fraction
heart muscle ischemia (drug therapy)
heart ventricle overload (drug therapy)
human
hyperkalemia (side effect)
hypertension (drug therapy)
hypotension (side effect)
kidney failure (side effect)
lifestyle
patient education
prognosis
review
risk factor
tachycardia
CAS REGISTRY NUMBERS
candesartan (139481-59-7)
carvedilol (72956-09-3)
diltiazem (33286-22-5, 42399-41-7)
esmolol (81147-92-4, 81161-17-3)
glyceryl trinitrate (55-63-0)
nesiritide (124584-08-3, 189032-40-4)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005487432
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 462
TITLE
Managing stroke survivors in the community
AUTHOR NAMES
Faux S.
AUTHOR ADDRESSES
(Faux S.) Rehabilitation Medicine, St. Vincent's Hospital, Sydney, NSW,
Australia.
CORRESPONDENCE ADDRESS
S. Faux, Rehabilitation Medicine, St. Vincent's Hospital, Sydney, NSW,
Australia.
SOURCE
Medicine Today (2005) 6:1 (12-19). Date of Publication: Jan 2005
ISSN
1443-430X
ABSTRACT
• To optimise a stroke survivor's quality of life it is important to become
re-acquainted with the patient and to be aware of all aspects of his or her
new care infrastructure. • As stroke survivors have a 6 to 10% yearly risk
of recurrence, secondary prevention is essential. Tight control of blood
pressure and diabetes, the use of antiplatelet agents (or warfarin in those
with atrial fibrillation), cholesterol level reduction, smoking cessation, a
healthy diet and avoiding excessive alcohol intake are all important. •
Daily exercise is central to maintaining mobility and quality of life in
stroke survivors. • General deterioration in a stroke survivor is not always
'the final curtain' once acute causes have been excluded; quite often some
simple rehabilitation is all that is required. • Stroke rehabilitation helps
patients maximise their potential for recovery and provides practical ways
of dealing with ongoing disability. It involves an intense multidisciplinary
program that can be undertaken in the community or as an inpatient.
EMTREE DRUG INDEX TERMS
alcohol
anticonvulsive agent (adverse drug reaction)
antithrombocytic agent (drug therapy)
carbamazepine (adverse drug reaction)
carbamazepine bc
carbamazepine sandoz
celepram
cholesterol (endogenous compound)
citalopram (drug therapy)
citalopram
genrx citalopram
phenytoin (adverse drug reaction)
phenytoin injection
serotonin uptake inhibitor (adverse drug reaction, drug therapy)
sertraline (drug therapy)
talohexal
tricyclic antidepressant agent (adverse drug reaction, drug therapy)
valproic acid (adverse drug reaction)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (diagnosis, prevention, rehabilitation, therapy)
community care
EMTREE MEDICAL INDEX TERMS
alcohol consumption
anamnesis
article
atrial fibrillation (drug therapy)
awareness
blood pressure regulation
cholesterol blood level
cognitive defect (side effect)
daily life activity
depression (drug therapy)
diabetes control
dietary intake
dysphagia (side effect)
exercise
follow up
general condition deterioration
health care facility
health program
hospital discharge
hospital patient
human
interpersonal communication
liver dysfunction (side effect)
medical examination
mobilization
patient care
physical disability (prevention, rehabilitation, therapy)
quality of life
recurrent disease (prevention, rehabilitation, therapy)
risk assessment
rural health care
skill
smoking cessation
survival
treatment planning
urinary tract disease (side effect)
DRUG TRADE NAMES
carbamazepine bc
carbamazepine sandoz
celepram
cipramil
coumadin
dilantin
epilim
genrx citalopram
marevan
phenytoin injection
talam
talohexal
tegretol
teril
valpro
zoloft
CAS REGISTRY NUMBERS
alcohol (64-17-5)
carbamazepine (298-46-4, 8047-84-5)
cholesterol (57-88-5)
citalopram (59729-33-8)
phenytoin (57-41-0, 630-93-3)
sertraline (79617-96-2)
valproic acid (1069-66-5, 99-66-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005076164
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 463
TITLE
Biofeedback training in clinical settings
AUTHOR NAMES
Saito I.
Saito Y.
AUTHOR ADDRESSES
(Saito I., yaiku@u01.gate01.com) Medical Service Center, Muroran Institute
of Technology, 27-1 Mizumoto-cho, Muroran, Hokkaido 050-8585, Japan.
(Saito Y.) Sapporo Hukujuji Clinic, Sapporo 060-0808, Japan.
CORRESPONDENCE ADDRESS
I. Saito, Medical Service Center, Muroran Institute of Technology, 27-1
Mizumoto-cho, Muroran, Hokkaido 050-8585, Japan. Email: yaiku@u01.gate01.com
SOURCE
Biogenic Amines (2004) 18:3-6 (463-476). Date of Publication: 2004
ISSN
0168-8561
ABSTRACT
Self-control of body functions by biofeedback training (BFT) has been
developed and BFT is now employed in treatment over all medical sections as
a complementary and alternative medicine (CAM). BFT is also useful in
education and sports training. BFT uses electrical equipment to monitor very
small signals from the body which are unrecognizable in usual life. Subjects
are requested to learn physiology and the mechanism of BFT and then they
make a voluntary effort to accomplish the stepwise task goal of BFT. This
mini-review includes history and current application of BFT and also
discusses future usefulness of BFT. © VSP 2004.
EMTREE DRUG INDEX TERMS
alpha adrenergic receptor blocking agent (endogenous compound)
anxiolytic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium antagonist (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
neuroleptic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
psychophysiology
EMTREE MEDICAL INDEX TERMS
alternative medicine
anxiety disorder (drug therapy, therapy)
article
asthma (therapy)
atrial fibrillation (therapy)
attention deficit disorder (therapy)
autogenic training
blepharospasm (therapy)
blood pressure measurement
body movement
bruxism (therapy)
cardiovascular disease (therapy)
cerebral palsy (therapy)
cerebrovascular accident (therapy)
cervical dystonia (therapy)
chronic pain (therapy)
depression (therapy)
dysmenorrhea (therapy)
education
electrical equipment
electromyography
emphysema (therapy)
erectile dysfunction (therapy)
essential hypertension (drug therapy, therapy)
feces incontinence (therapy)
foot disease (therapy)
hand disease (therapy)
headache (therapy)
heart ejection fraction
heart rate
heart ventricle extrasystole (therapy)
human
hyperventilation (therapy)
hypnosis
insomnia (therapy)
intermethod comparison
irritable colon (therapy)
learning disorder (therapy)
low back pain (therapy)
mental stress
myalgia (therapy)
myopia (therapy)
nystagmus (therapy)
Parkinson disease (therapy)
Raynaud phenomenon (therapy)
relaxation training
schizophrenia (therapy)
scoliosis (therapy)
self control
sexual dysfunction (therapy)
signal transduction
sleep disorder (therapy)
strabismus (therapy)
stuttering (therapy)
temporomandibular joint disorder (therapy)
tension headache (therapy)
tinnitus (therapy)
training
transcendental meditation
urine incontinence (therapy)
vascular resistance
yoga
EMBASE CLASSIFICATIONS
Otorhinolaryngology (11)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Urology and Nephrology (28)
Psychiatry (32)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004372200
FULL TEXT LINK
http://dx.doi.org/10.1163/1569391041501870
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 464
TITLE
Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial
fibrillation: A study based on interviews with 100 patients seeking hospital
assistance
AUTHOR NAMES
Hansson A.
Madsen-Härdig B.
Olsson S.B.
AUTHOR ADDRESSES
(Hansson A., Anders.Hansson@kard.lu.se; Madsen-Härdig B.,
Bjarne.Madsen-Hardig@kard.lu.se; Olsson S.B., Bertil.Olsson@kard.lu.se)
Department of Cardiology, University Hospital, Lund, Sweden.
CORRESPONDENCE ADDRESS
A. Hansson, Department of Cardiology, University Hospital, Lund, Sweden.
Email: Anders.Hansson@kard.lu.se
SOURCE
BMC Cardiovascular Disorders (2004) 4. Date of Publication: 3 Aug 2004
ISSN
1471-2261
ABSTRACT
Background: Surprisingly little information on symptoms of paroxysmal atrial
fibrillation is available in scientific literature. Using questionnaires, we
have analyzed the symptoms associated with arrhythmia attacks. Methods: One
hundred randomly-selected patients with idiopathic paroxysmal atrial
fibrillation filled in a structured questionnaire. Results: Psychic stress
was the most common factor triggering arrhythmia (54%), followed by physical
exertion (42%), tiredness (41%) coffee (25%) and infections (22%).
Thirty-four patients cited alcohol, 26 in the form of red wine, 16 as white
wine and 26 as spirits. Among these 34, red wine and spirits produced
significantly more episodes of arrhythmia than white wine (p = 0.01 and
0.005 respectively). Symptoms during arrhythmia were palpitations while
exerting (88%), reduced physical ability (87%), palpitations at rest (86%),
shortage of breath during exertion (70%) and anxiety (59%). Significant
differences between sexes were noted regarding swollen legs (women 21%, men
6%, p = 0.027), nausea (women 36%, men 13%, p = 0.012) and anxiety (females
79%, males 51%, p = 0.014). Conclusion: Psychic stress was the commonest
triggering factor in hospitalized patients with paroxysmal atrial
fibrillation. Red wine and spirits were more proarrhythmic than white wine.
Symptoms in women in connection with attacks of arrhythmia vary somewhat
from those in men. © 2004 Hansson et al; licensee BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
amiodarone (endogenous compound)
atenolol (drug therapy)
bisoprolol (drug therapy)
digoxin (drug therapy)
disopyramide (drug therapy)
flecainide (drug therapy)
metoprolol (drug therapy)
propranolol (drug therapy)
sotalol (drug therapy)
verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
adult
aged
alcoholic beverage
anxiety
article
coffee
controlled study
dyspnea
exercise
fatigue
female
heart palpitation
hospital care
hospital patient
human
infection
interview
leg edema
major clinical study
male
mental stress
nausea
patient selection
physical capacity
priority journal
questionnaire
randomization
red wine
risk factor
sex difference
statistical analysis
symptom
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atenolol (29122-68-7)
bisoprolol (66722-44-9)
digoxin (20830-75-5, 57285-89-9)
disopyramide (3737-09-5)
flecainide (54143-55-4)
metoprolol (37350-58-6)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
sotalol (3930-20-9, 80456-07-1, 959-24-0)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005059545
FULL TEXT LINK
http://dx.doi.org/10.1186/1471-2261-4-13
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 465
TITLE
Cardiac rehabilitation of older patients
AUTHOR NAMES
West R.
AUTHOR ADDRESSES
(West R.) Univ. of Wales College of Medicine, Cardiff, Wales, United
Kingdom.
(West R.) Wales Heart Research Institute, Univ. of Wales College of
Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom.
CORRESPONDENCE ADDRESS
R. West, Wales Heart Research Institute, Univ. of Wales College of Medicine,
Heath Park, Cardiff CF14 4XN, United Kingdom.
SOURCE
Reviews in Clinical Gerontology (2003) 13:3 (241-255). Date of Publication:
Aug 2004
ISSN
0959-2598
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular disease (rehabilitation, therapy)
heart rehabilitation
EMTREE MEDICAL INDEX TERMS
acute heart infarction
adult
age
aged
anxiety
atrial fibrillation
clinical trial
coronary artery bypass surgery
depression
dietary intake
exercise
geriatric care
health education
health promotion
heart failure
human
leisure
mobilization
outcomes research
patient counseling
patient education
patient referral
physiotherapy
psychological aspect
quality of life
review
risk factor
secondary prevention
social support
transluminal coronary angioplasty
treatment planning
unstable angina pectoris
vocational rehabilitation
work capacity
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2004316190
FULL TEXT LINK
http://dx.doi.org/10.1017/S0959259804001066
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 466
TITLE
Older man with exertional dyspnea and leg swelling
AUTHOR NAMES
Quick G.
Walker J.S.
Kerns C.
AUTHOR ADDRESSES
(Quick G.) Emergency Medicine, .
(Walker J.S.; Kerns C.) Oklahoma Heart Hospital, .
(Quick G.; Walker J.S.; Kerns C.) Oklahoma Heart Hospital, Oklahoma City,
OK, United States.
CORRESPONDENCE ADDRESS
G. Quick, Oklahoma Heart Hospital, Oklahoma City, OK, United States.
SOURCE
Consultant (2004) 44:9 (1283-1285). Date of Publication: Aug 2004
ISSN
0010-7069
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
dyspnea (diagnosis)
leg swelling (diagnosis)
EMTREE MEDICAL INDEX TERMS
aged
anamnesis
article
atrial fibrillation
case report
clinical feature
computer assisted tomography
coughing
deep vein thrombosis
dizziness
echocardiography
faintness
fever
hemoptysis
human
lung embolism (diagnosis)
male
primary medical care
priority journal
thorax pain
EMBASE CLASSIFICATIONS
Chest Diseases, Thoracic Surgery and Tuberculosis (15)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2005087739
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 467
TITLE
The secondary prevention of ischemic stroke
AUTHOR NAMES
Tabereaux P.B.
Brass L.M.
Bravata D.M.
AUTHOR ADDRESSES
(Tabereaux P.B.; Bravata D.M.) Department of Internal Medicine, Yale
University School of Medicine, 333 Cedar St., New Haven, CT 06520-8088,
United States.
(Brass L.M.) Department of Neurology, Yale University School of Medicine,
333 Cedar St., New Haven, CT 06520-8088, United States.
CORRESPONDENCE ADDRESS
D.M. Bravata, Yale University School of Medicine, 333 Cedar St., New Haven,
CT 06520-8088, United States.
SOURCE
Journal of Clinical Outcomes Management (2004) 11:6 (371-382). Date of
Publication: Jun 2004
ISSN
1079-6533
ABSTRACT
• Objective: To provide an overview of the evidence and clinical approach to
secondary stroke prevention for patients following an ischemic stroke or
transient ischemic attack (TIA). • Methods: Overview of the literature. •
Results: Patients with acute ischemic strokes and TIAs are at increased risk
for secondary vascular events, including recurrent stroke. Nonmodifiable
risk factors should be evaluated to identify patients who are at high risk
of recurrent stroke. Risk factor modification includes diagnosing and
treating hypertension, hyperlipidemia, and diabetes. Patients with
high-grade symptomatic carotid artery stenosis should be evaluated for
carotid endarterectomy Stroke patients with atrial fibrillation should
receive warfarin unless a contraindication is present. All other stroke
patients should receive an antiplatelet agent unless contraindicated.
Recommendations for lifestyle changes, including stopping smoking, avoiding
heavy alcohol use, reducing overweight, and increasing exercise, should be
made during the acute stroke period. • Conclusion: Post-stroke care should
involve an assessment of both nonmodifiable and modifiable risk factors in
all patients. Risk factor modifications should be initiated early after the
first event.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy)
alpha tocopherol (drug therapy)
angiotensin receptor antagonist (clinical trial, drug combination, drug
comparison, drug therapy)
anticoagulant agent (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy, oral drug administration)
antidiabetic agent (drug therapy)
antihypertensive agent (clinical trial, drug combination, drug comparison,
drug therapy)
antithrombocytic agent (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug therapy, oral drug administration)
ascorbic acid (drug therapy)
beta adrenergic receptor blocking agent (drug therapy, intravenous drug
administration)
beta carotene (drug therapy)
clopidogrel (clinical trial, drug combination, drug comparison, drug
therapy)
dipeptidyl carboxypeptidase inhibitor (clinical trial, drug combination,
drug comparison, drug therapy)
dipyridamole (drug combination, drug comparison, drug therapy)
diuretic agent (drug combination, drug therapy)
estrogen (clinical trial, drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug
therapy)
perindopril (clinical trial, drug combination, drug therapy)
thrombin inhibitor (clinical trial, drug comparison, drug therapy, oral drug
administration)
ticlopidine (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
warfarin (adverse drug reaction, clinical trial, drug comparison, drug
therapy, oral drug administration)
ximelagatran (clinical trial, drug comparison, drug therapy, oral drug
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
alcohol abstinence
atrial fibrillation (drug therapy)
behavior modification
bleeding (side effect)
carotid artery obstruction (surgery)
carotid endarterectomy
clinical trial
diabetes mellitus (diagnosis, drug therapy)
diarrhea (side effect)
diet therapy
drug eruption (side effect)
exercise
high risk patient
human
hyperlipidemia (diagnosis, drug therapy)
hypertension (diagnosis, drug therapy)
laboratory diagnosis
lifestyle
medical literature
neutropenia (side effect)
recurrent disease (prevention)
review
risk assessment
risk factor
secondary prevention
smoking cessation
transient ischemic attack (prevention)
weight reduction
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
beta carotene (7235-40-7)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
perindopril (82834-16-0)
ticlopidine (53885-35-1, 55142-85-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004409261
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 468
TITLE
Prevention and treatment of erectile dysfunction using lifestyle changes and
dietary supplements: What works and what is worthless, part I
AUTHOR NAMES
Moyad M.A.
Barada J.H.
Lue T.F.
Mulhall J.P.
Goldstein I.
Fawzy A.
AUTHOR ADDRESSES
(Moyad M.A., moyad@umich.edu) Department of Urology, Univ. of Michigan
Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330,
United States.
(Barada J.H.) Center for Male Sexual Health, Albany Medical College, 43 New
Scotland Avenue, Albany, NY 12208, United States.
(Lue T.F.) Univ. of California, San Francisco, 505 Parnassus Avenue, San
Francisco, CA 94122, United States.
(Mulhall J.P.) Sexual Medicine Program, Weill Medical College, Cornell
University, 445 East 69th Street, New York, NY 10021, United States.
(Goldstein I.) Institute for Sexual Medicine, Center for Sexual Medicine,
Boston University School of Medicine, 715 Albany Street, Boston, MA 02118,
United States.
(Fawzy A.) Department of Urology, Louisiana State University, School of
Medicine, 1532 Tulane Avenue, New Orleans, LA 70112, United States.
CORRESPONDENCE ADDRESS
M.A. Moyad, Department of Urology, Univ. of Michigan Medical Center, 1500
East Medical Center Drive, Ann Arbor, MI 48109-0330, United States. Email:
moyad@umich.edu
SOURCE
Urologic Clinics of North America (2004) 31:2 (249-257). Date of
Publication: May 2004
ISSN
0094-0143
BOOK PUBLISHER
W.B. Saunders, Independence Square West, Philadelphia, United States.
EMTREE DRUG INDEX TERMS
16 dehydroepiandrosterone
ascorbic acid (drug therapy, pharmacology)
Echinacea extract (drug interaction)
Ephedra extract (drug interaction)
epiandrosterone
garlic extract (drug interaction)
Ginkgo biloba extract (drug interaction)
ginseng extract (drug interaction)
hydroxymethylglutaryl coenzyme A reductase inhibitor
Hypericum perforatum extract (drug interaction)
kava extract (drug interaction)
placebo
sildenafil (clinical trial, drug dose, drug therapy, oral drug
administration, pharmacology)
tadalafil (drug therapy, oral drug administration, pharmacology)
unclassified drug
valerian (drug interaction)
vardenafil (drug therapy, oral drug administration, pharmacology)
yohimbine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diet supplementation
erectile dysfunction (disease management, prevention, therapy)
lifestyle
EMTREE MEDICAL INDEX TERMS
acupuncture
alternative medicine
atrial fibrillation (drug therapy, prevention)
cardiovascular system
clinical trial
dose response
electroacupuncture
electrostimulation
health
health care cost
heat
human
laser
practice guideline
prescription
priority journal
quality control
quality of life
review
sexual function
urology
vitamin supplementation
DRUG TRADE NAMES
viagra
CAS REGISTRY NUMBERS
ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
epiandrosterone (481-29-8)
sildenafil (139755-83-2)
tadalafil (171596-29-5)
valerian (8057-49-6)
vardenafil (224785-90-4, 224785-91-5, 224789-15-5)
yohimbine (146-48-5, 65-19-0)
EMBASE CLASSIFICATIONS
Urology and Nephrology (28)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2004198191
MEDLINE PMID
15123405 (http://www.ncbi.nlm.nih.gov/pubmed/15123405)
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ucl.2004.01.006
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 469
TITLE
Anticoagulation in the Elderly
AUTHOR NAMES
Dowd M.B.
AUTHOR ADDRESSES
(Dowd M.B., mdowd@wpahs.org) A-K. Med. Ctr.-West P.A. Hlth. Syst., Pharmacy
Department, 1301 Carlisle Street, Natrona Heights, PA 15065, United States.
CORRESPONDENCE ADDRESS
M.B. Dowd, A-K. Med. Ctr.-West P.A. Hlth. Syst., Pharmacy Department, 1301
Carlisle Street, Natrona Heights, PA 15065, United States. Email:
mdowd@wpahs.org
SOURCE
Journal of Pharmacy Practice (2004) 17:2 (94-102). Date of Publication: Apr
2004
ISSN
0897-1900
ABSTRACT
Oral anticoagulation has been shown to provide great benefit in preventing
and treating thromboembolic disorders. The challenges of oral
anticoagulation management in the elderly involve balancing the risks of
bleeding versus the benefits of a life-saving treatment. Due to the complex
nature of warfarin, therapy must be individualized with frequent monitoring,
reeducation, and adjustments based on concurrent illness and drug therapy.
This review focuses on the use of warfarin, including indications, dosing
recommendations, drug and dietary interactions, and reversal of
anticoagulation. Methods to determine bleeding risks in this population and
barriers that interfere with the prescribing of warfarin are discussed.
Strategies to improve patient outcome and reduce adverse events are provided
to assist clinicians in their decision-making skills. The potential
advantages of anticoagulation clinics are summarized with regards to
coordinating the care and minimizing the risks of anticoagulant therapy. The
role of new-generation anticoagulants is also discussed as to their place in
therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (adverse drug reaction, drug dose, drug interaction,
drug therapy, oral drug administration)
warfarin (adverse drug reaction, drug dose, drug interaction, drug therapy,
oral drug administration)
EMTREE DRUG INDEX TERMS
azithromycin (drug interaction)
barbituric acid derivative (drug interaction)
capecitabine (drug interaction)
carbamazepine (drug interaction)
clofibrate (drug interaction)
corticosteroid (drug interaction)
dicloxacillin (drug interaction)
fenofibrate (drug interaction)
fluorouracil (drug interaction)
gefitinib (drug interaction)
gemfibrozil (drug interaction)
isoniazid (drug interaction)
mevinolin (drug interaction)
nafcillin (drug interaction)
nonsteroid antiinflammatory agent (drug interaction)
paracetamol (drug interaction)
phenytoin (drug interaction)
propylthiouracil (drug interaction)
rifampicin (drug interaction)
salicylic acid derivative (drug interaction)
sucralfate (drug interaction)
tamsulosin (drug interaction)
tetracycline derivative (drug interaction)
thyroid hormone (drug interaction)
tramadol (drug interaction)
ximelagatran (drug interaction, drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aging
anticoagulation
EMTREE MEDICAL INDEX TERMS
aged
atrial fibrillation (drug therapy)
bleeding (side effect)
dose response
drug indication
drug monitoring
human
outcomes research
prescription
review
risk benefit analysis
risk factor
venous thromboembolism (drug therapy, prevention)
CAS REGISTRY NUMBERS
azithromycin (83905-01-5)
capecitabine (154361-50-9)
carbamazepine (298-46-4, 8047-84-5)
clofibrate (637-07-0)
dicloxacillin (13412-64-1, 3116-76-5, 343-55-5)
fenofibrate (49562-28-9)
fluorouracil (51-21-8)
gefitinib (184475-35-2, 184475-55-6, 184475-56-7)
gemfibrozil (25812-30-0)
isoniazid (54-85-3, 62229-51-0, 65979-32-0)
mevinolin (75330-75-5)
nafcillin (147-52-4, 985-16-0)
paracetamol (103-90-2)
phenytoin (57-41-0, 630-93-3)
propylthiouracil (51-52-5)
rifampicin (13292-46-1)
sucralfate (54182-58-0)
tamsulosin (106133-20-4, 106138-88-9, 106463-17-6, 80223-99-0, 94666-07-6)
tramadol (27203-92-5, 36282-47-0)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004129696
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 470
TITLE
Improving secondary prevention of coronary heart disease: Using the new GP
contract to drive change
AUTHOR ADDRESSES
SOURCE
British Journal of Cardiology (2004) 11:2 (106-111). Date of Publication:
Mar 2004
ISSN
0969-6113
ABSTRACT
The evidence for implementing the NSF is overwhelming. Ranging from the
simple to the innovative, there are some excellent ways of achieving this,
bolstering practice income and enhancing the care and experience of
patients. • For more information about the work of the CHDC, visit
www.modern.nhs.uk/chd where you can find contact details for your local CHDC
programme.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
general practice
ischemic heart disease (drug therapy, prevention)
secondary prevention
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (drug therapy)
cerebrovascular accident (prevention)
diet restriction
doctor patient relation
exercise
heart death (prevention)
heart infarction (drug therapy, prevention)
heart left ventricle failure (drug therapy)
human
lifestyle
medical fee
national health service
patient care
patient counseling
primary medical care
risk reduction
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004179153
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 471
TITLE
Complementary and alternative medicine in cardiovascular disease: A review
of biologically based approaches
AUTHOR NAMES
Miller K.L.
Liebowitz R.S.
Newby L.K.
AUTHOR ADDRESSES
(Miller K.L.; Liebowitz R.S.) Div. of General Internal Medicine, Department
of Medicine, Duke University Medical Center, Durham, NC, United States.
(Newby L.K., newby001@mc.duke.edu) Division of Cardiology, Department of
Medicine, Duke University Medical Center, Durham, NC, United States.
(Newby L.K., newby001@mc.duke.edu) Duke Clinical Research Institute, PO Box
17969, Durham, NC 27715-7969, United States.
CORRESPONDENCE ADDRESS
L.K. Newby, Duke Clinical Research Institute, PO Box 17969, Durham, NC
27715-7969, United States. Email: newby001@mc.duke.edu
SOURCE
American Heart Journal (2004) 147:3 (401-411). Date of Publication: March
2004
ISSN
0002-8703
BOOK PUBLISHER
Mosby Inc., 11830 Westline Industrial Drive, St. Louis, United States.
ABSTRACT
Background The use of complementary and alternative medical (CAM) practices
in the United States is growing rapidly. In this manuscript, we review some
of the most commonly used biologically based approaches, including herbs,
supplements, and other pharmacological therapies, that are encountered in
caring for patients with cardiovascular disease, focusing on potential
effects, adverse effects, and treatment interactions. Methods Between
November 2002 and April 2003, we searched Medline and the National Center
for Complementary and Alternative Medicine (NCCAM) web site and its various
references and several complementary medicine text books. The key words used
were: "cardiovascular diseases," "coronary disease," "heart failure,
congestive," "complementary and alternative medicine," "complementary
therapies," "drug interactions," and "plants, medicinal." A keyword search
of each individual supplement identified was also performed. Additionally,
we relied on expert opinion in the field. Results Potentially serious
adverse effects and interactions with conventional cardiovascular therapies
exist for many herbs and supplements. There are currently scarce mechanistic
data and very limited data on the effect of CAM therapies on clinical
outcomes. Conclusions Randomized clinical trials with adequate power to
detect effects of CAM therapies on clinical outcomes and safety are needed.
Until these data are available, clinicians must be aware of the increasing
use of CAM approaches by their patients and the potential for interactions
with conventional therapies and should focus on treatment with proven,
evidence-based strategies.
EMTREE DRUG INDEX TERMS
alpha tocopherol (drug interaction, drug therapy, pharmacology)
amiodarone (adverse drug reaction, drug interaction, drug therapy)
antiemetic agent (drug interaction, drug therapy, pharmacology)
antiinfective agent (drug interaction, drug therapy, pharmacology)
antithrombocytic agent (drug interaction, drug therapy)
cardiovascular agent (drug interaction, drug therapy)
carnitine (drug interaction, drug therapy, pharmacology)
Crataegus extract (clinical trial, drug interaction, drug therapy,
pharmacology)
cyclosporin (clinical trial, drug interaction, drug therapy, pharmacology)
digoxin (clinical trial, drug interaction, pharmacology)
diltiazem (drug interaction, pharmacology)
garlic extract (drug interaction, drug therapy, pharmacology)
ginger extract (drug interaction, drug therapy, pharmacology)
ginseng extract (drug interaction, drug therapy, pharmacology)
guggulsterone (drug interaction, drug therapy, pharmacology)
herbaceous agent (drug interaction, drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (adverse drug reaction,
drug interaction, drug therapy, pharmacology)
kava extract (adverse drug reaction, drug therapy, pharmacology)
ketoconazole (drug interaction)
macrolide (drug interaction)
policosanol (drug interaction, drug therapy, pharmacology)
propranolol derivative (drug interaction)
proteinase inhibitor (drug interaction)
spasmolytic agent (drug interaction, drug therapy, pharmacology)
Tanacetum parthenium extract (drug interaction, drug therapy, pharmacology)
ubidecarenone (adverse drug reaction, clinical trial, drug dose, drug
interaction, drug therapy, oral drug administration, pharmacology)
unindexed drug
vasoactive agent (drug interaction, drug therapy, pharmacology)
verapamil (drug interaction)
warfarin (drug dose, drug interaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alternative medicine
cardiovascular disease (drug therapy)
congestive heart failure (drug therapy)
coronary artery disease (drug therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
Alzheimer disease (drug therapy)
angina pectoris (drug therapy)
anxiety disorder (drug therapy)
atherosclerosis (drug therapy)
atrial fibrillation (drug therapy)
bleeding
blood clotting
cardiomyopathy (side effect)
Chinese medicine
clinical trial
coronary artery dilatation
depression
diet supplementation
exercise
gastrointestinal symptom (side effect)
heart muscle
herbal medicine
homeopathy
human
hypertension (drug therapy)
hypocholesterolemia (drug therapy)
immunosuppressive treatment
insomnia (drug therapy)
leukocytosis (drug therapy)
liver disease (side effect)
liver toxicity (side effect)
lung fibrosis (side effect)
medicinal plant
myopathy
photosensitivity (side effect)
priority journal
review
thrombocyte function
thyroid disease (side effect)
vitamin supplementation
DRUG TRADE NAMES
ws 1442
CAS REGISTRY NUMBERS
Crataegus extract (82374-45-6)
alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
carnitine (461-06-3, 541-15-1, 56-99-5)
cyclosporin (79217-60-0)
digoxin (20830-75-5, 57285-89-9)
diltiazem (33286-22-5, 42399-41-7)
guggulsterone (39025-23-5, 39025-24-6, 95975-55-6)
ketoconazole (65277-42-1)
policosanol (142583-61-7)
proteinase inhibitor (37205-61-1)
ubidecarenone (303-98-0)
verapamil (152-11-4, 52-53-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004290656
MEDLINE PMID
14999187 (http://www.ncbi.nlm.nih.gov/pubmed/14999187)
FULL TEXT LINK
http://dx.doi.org/10.1016/j.ahj.2003.10.021
COPYRIGHT
Copyright 2012 Elsevier B.V., All rights reserved.
RECORD 472
TITLE
Current status of cardiac resynchronization therapy
AUTHOR NAMES
Breithardt O.A.
Stellbrink C.
AUTHOR ADDRESSES
(Breithardt O.A., olebreithardt@gmx.de; Stellbrink C.) Department of
Cardiology, University Hospital Aachen, D-52057 Aachen, Germany.
(Breithardt O.A., olebreithardt@gmx.de) Medizinische Klinik I, University
Klinikum Aachen, Pauwelsstrasse 30, D-52057 Aachen, Germany.
CORRESPONDENCE ADDRESS
O.A. Breithardt, Medizinische Klinik I, University Klinikum Aachen,
Pauwelsstrasse 30, D-52057 Aachen, Germany. Email: olebreithardt@gmx.de
SOURCE
Current Opinion in Anaesthesiology (2004) 17:1 (75-83). Date of Publication:
Feb 2004
ISSN
0952-7907
ABSTRACT
Purpose of review: Cardiac resynchronization therapy with biventricular
pacing has rapidly emerged as an indispensable treatment option in patients
with moderate-to-advanced heart failure and left bundle branch block. New
findings on the pathophysiology of cardiac resynchronization therapy and its
clinical effects are reviewed. Recent findings: Several randomized trials
have evaluated the effects of cardiac resynchronization therapy on cardiac
haemodynamics and clinical parameters in selected heart failure patients
with left bundle branch block. The effects of cardiac resynchronization
therapy on mechanical synchrony have been evaluated by different imaging
modalities, such as echocardiography and radionuclide angiography. Cardiac
resynchronization therapy leads to improved haemodynamics at a diminished
energy cost, and improves functional mitral regurgitation. This haemodynamic
improvement is associated with a significantly better quality of life,
improved exercise capacity, and less frequent hospitalization. Recent
preliminary data suggest a positive effect on cardiac mortality. However,
approximately a third of implanted patients do not benefit from cardiac
resynchronization therapy, and therefore additional criteria for the
identification of mechanical dyssynchrony are needed to identify those
patients who will respond before implantation. Summary Many randomized
trials have confirmed the benefits of cardiac resynchronization therapy in
selected heart failure patients. The successful resynchronization of the
ventricular activation-contraction sequence is the major determinant of
acute haemodynamic and long-term clinical improvement. The diagnostic
sensitivity and specificity of the non-invasive identification of mechanical
dyssynchrony may be improved by echocardiography, but further research is
needed to identify the optimal strategy for patient identification.
EMTREE DRUG INDEX TERMS
angiotensin receptor antagonist (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
digoxin (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
diuretic agent (drug therapy)
spironolactone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiac resynchronization therapy
electrostimulation therapy
heart failure (drug therapy, therapy)
heart ventricle pacing
EMTREE MEDICAL INDEX TERMS
artery dissection (complication)
artery perforation (complication)
artificial heart pacemaker
atrial fibrillation (complication)
cardiomyopathy (therapy)
clinical trial
defibrillator
devices
echocardiography
electrocardiogram
exercise
heart hemodynamics
heart infarction (therapy)
heart left bundle branch block
heart left ventricle contraction
heart ventricle contraction
hemodynamic monitoring
hospitalization
human
implantation
meta analysis
mitral valve regurgitation
mortality
pathophysiology
peroperative complication (complication)
phrenic nerve
priority journal
quality of life
review
scintiangiography
surgical risk
survival rate
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Anesthesiology (24)
Biophysics, Bioengineering and Medical Instrumentation (27)
Drug Literature Index (37)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004093623
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 473
TITLE
Cardiac pacing for bradycardia support: Evidence-based approach to pacemaker
selection and programming
AUTHOR NAMES
Galtes I.
Lamas G.A.
AUTHOR ADDRESSES
(Lamas G.A., most95@aol.com) Mount Sinai Medical Center, Butler Building,
4300 Alton Road, Miami Beach, FL 33140, United States.
(Galtes I.)
CORRESPONDENCE ADDRESS
G.A. Lamas, Mount Sinai Medical Center, Butler Building, 4300 Alton Road,
Miami Beach, FL 33140, United States. Email: most95@aol.com
SOURCE
Current Treatment Options in Cardiovascular Medicine (2004) 6:5 (385-395).
Date of Publication: October 2004
ISSN
1092-8464
BOOK PUBLISHER
Springer Healthcare
ABSTRACT
The vast majority of pacemakers implanted in the United States for the
treatment of symptomatic bradycardia are dual-chamber systems with a complex
array of functions, such as rate responsiveness, dynamic atrioventricular
delay, and automatic mode switching. Basic hemodynamic studies have
convincingly demonstrated the superiority of maintaining atrioventricular
synchrony. However, clinical trials have failed to demonstrate the
impressive results expected based on physiologic data. The most recent
randomized clinical trials have demonstrated that dual-chamber devices, when
compared with single-chamber ventricutar pacing, do not prevent mortality or
stroke, and lead to an unexpectedly small reduction in heart failure
hospitalizations. Although improvements in quality of life have not been
consistently found when comparing ventricular-based versus atrial-based
pacing, a reduction in the incidence of newly diagnosed atrial fibrillation
in dual chamber-paced patients has been reported by most trials.
Dual-chamber pacing has been reported to reduce pacemaker syndrome in US
trials. The addition of rate modulation, in spite of attempting to replicate
the normal response to exercise, has not shown a consistently positive
impact on quality of life or treadmill time. The use of pacemakers for the
treatment of vasovagal syncope is controversial. Adding dual-chamber sensing
ability to current implanted defibrillators considerably reduces the number
of inappropriate shocks but may increase mortality if not programmed to
minimize ventricular stimulation. Copyright © 2004 by Current Science Inc.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
artificial heart pacemaker
bradycardia (surgery)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (surgery)
atrioventricular conduction
automation
cerebrovascular accident (complication, prevention)
clinical trial
defibrillation
equipment design
evidence based medicine
exercise
faintness (prevention, surgery)
heart failure (surgery)
heart hemodynamics
heart rate
heart ventricle function
hospitalization
human
intermethod comparison
medical decision making
meta analysis
mortality
practice guideline
quality of life
review
shock (complication, prevention)
surgical technique
systematic review
time
treadmill
treatment outcome
United States
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004438483
COPYRIGHT
Copyright 2014 Elsevier B.V., All rights reserved.
RECORD 474
TITLE
Coeliac disease presenting with tetany in an 87 year old patient
AUTHOR NAMES
Jani B.
Sivakumar R.
Ghosh P.
Khan S.A.
AUTHOR ADDRESSES
(Jani B.; Sivakumar R.; Ghosh P.; Khan S.A., shahidak@aol.com) Department of
Elderly Care, Lister Hospital, Corey's Mill Lane, Stevenage, Herts SG1 4AB,
United Kingdom.
CORRESPONDENCE ADDRESS
S.A. Khan, Department of Elderly Care, Lister Hospital, Corey's Mill Lane,
Stevenage, Herts SG1 4AB, United Kingdom. Email: shahidak@aol.com
SOURCE
CME Journal Geriatric Medicine (2003) 5:3 (127-128). Date of Publication:
2003
ISSN
1475-1453
ABSTRACT
Coeliac disease is a common condition which may affect 1 in 200 individuals.
The majority of patients are diagnosed in adulthood, many presenting with
atypical symptoms. Metabolic bone disease can be a feature of coeliac
disease but is generally under recognised. Clinical manifestations can be at
any age though first presentation at extreme old age is rare. We describe an
elderly patient who presented with severe hypocalcaemia secondary to coeliac
disease.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug combination, drug therapy)
calcium (drug combination, drug therapy, intravenous drug administration)
digoxin (drug combination, drug therapy)
folic acid (drug combination, drug therapy)
furosemide (drug combination, drug therapy)
magnesium (drug combination, drug therapy, intravenous drug administration)
multivitamin (drug combination, drug therapy)
vitamin D (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
celiac disease (drug therapy)
tetany (drug therapy)
EMTREE MEDICAL INDEX TERMS
aged
anamnesis
article
atrial fibrillation (drug therapy)
calcium blood level
case report
cataract (drug therapy)
coping behavior
disease severity
falling
female
geriatric patient
gluten free diet
human
hypocalcemia (drug therapy)
laboratory test
malaise
muscle cramp (drug therapy)
patient referral
psoriasis (drug therapy)
skin bruising
treatment outcome
vitamin supplementation
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
calcium (7440-70-2)
digoxin (20830-75-5, 57285-89-9)
folic acid (59-30-3, 6484-89-5)
furosemide (54-31-9)
magnesium (7439-95-4)
EMBASE CLASSIFICATIONS
Gerontology and Geriatrics (20)
Clinical and Experimental Biochemistry (29)
Endocrinology (3)
Drug Literature Index (37)
Gastroenterology (48)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004050271
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 475
TITLE
Cardiac Arrhythmia in a Professional Football Player: Was Ephedrine to
Blame?
AUTHOR NAMES
Krome C.N.
Tucker A.M.
AUTHOR ADDRESSES
(Krome C.N., ckrome@adelphia.net) Precision Orthopedic Specialties, .
(Tucker A.M.) Primary Care Sports Medicine, University of Maryland,
Timonium, MD, United States.
(Tucker A.M.) Department of Family Medicine, University of Maryland,
Baltimore, MD, United States.
(Krome C.N., ckrome@adelphia.net) 228 Manchester Dr, Aurora, OH 44202,
United States.
CORRESPONDENCE ADDRESS
C.N. Krome, 228 Manchester Dr, Aurora, OH 44202, United States. Email:
ckrome@adelphia.net
SOURCE
Physician and Sportsmedicine (2003) 31:12 (21-25+29). Date of Publication:
Dec 2003
ISSN
0091-3847
ABSTRACT
Sympathomimetic symptoms in an otherwise healthy patient, such as in this
case of a 27-year-old professional football player, may suggest an adverse
reaction to a dietary supplement containing ephedra. Awareness of supplement
use patterns and possible side effects in active patients may help
physicians intervene before catastrophic events occur.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
ephedrine
EMTREE DRUG INDEX TERMS
alkaloid
Ephedra extract
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
football
heart arrhythmia (diagnosis)
EMTREE MEDICAL INDEX TERMS
adult
article
artificial heart pacemaker
athlete
atrial fibrillation
cardiomyopathy
cardioversion
case report
consultation
diet supplementation
electrocardiography monitoring
fatality
heart hypertrophy
heart muscle necrosis
human
male
nephrolithiasis
seizure
sudden death
weight reduction
CAS REGISTRY NUMBERS
ephedrine (299-42-3, 50-98-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2003506176
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 476
TITLE
Preventing and treating stroke
AUTHOR NAMES
Zahn D.
AUTHOR ADDRESSES
(Zahn D.) B.C. Drug and Poison Info. Centre, .
CORRESPONDENCE ADDRESS
B.C. Drug and Poison Info. Centre, .
SOURCE
Canadian Pharmaceutical Journal (2003/2004) 136:10 (32). Date of
Publication: Dec 2003
ISSN
0828-6914
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction)
alteplase (drug therapy)
antithrombocytic agent
asasantine
clopidogrel
dipyridamole (adverse drug reaction)
heparin (adverse drug reaction)
herbaceous agent
plasminogen activator (drug therapy)
ticlopidine
warfarin (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
atrial fibrillation
bleeding (side effect)
blood clot lysis
diabetes mellitus
diet therapy
disease severity
drug choice
drug dose regimen
drug utilization
emergency treatment
exercise
gastrointestinal symptom (side effect)
human
hypercholesterolemia
hypertension
patient care
pharmacist
practice guideline
prescription
risk factor
short survey
smoking cessation
thrombocyte aggregation inhibition
weight reduction
DRUG TRADE NAMES
activase
asasantine
aspirin
coumadin
plavix
ticlid
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alteplase (105857-23-6)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
plasminogen activator (9039-53-6)
ticlopidine (53885-35-1, 55142-85-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Hematology (25)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2004102332
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 477
TITLE
Biventricular pacing in heart failure: Current status and future horizons
AUTHOR NAMES
Kaprielian R.
Lefroy D.C.
AUTHOR ADDRESSES
(Kaprielian R.) Department of Cardiology, West Middlesex Hospital, DuCane
Road, London W12 0HS, United Kingdom.
(Lefroy D.C.) Department of Cardiology, Hammersmith Hospital, DuCane Road,
London W12 0HS, United Kingdom.
CORRESPONDENCE ADDRESS
R. Kaprielian, Department of Cardiology, Hammersmith Hospitals NHS Trust,
DuCane Road, London W12 0HS, United Kingdom.
SOURCE
Continuing Medical Education - Cardiology (2003) 2:3 (177-184). Date of
Publication: 2003
ISSN
1463-0486
ABSTRACT
Biventricular pacing is a rapidly developing technique that offers hope for
a significant sub-group of patients with severe heart failure refractory to
medical treatment and intra-ventricular conduction delay (LBBB). This
technique is thought to improve cardiac function by reducing
intra-ventricular dysynchrony caused by intra-ventricular conduction block.
Technology is now available for low-risk implantation of atrio-biventricular
pacing systems with a high level of success in appropriately experienced
hands. The short-term haemodynamic effects of such pacing are favourable and
published randomised clinical trials have shown benefit with improvement in
symptoms and objective measures of exercise capacity. Many questions still
remain to be answered. Appropriate selection of patients who will respond to
this treatment, the localisation of ideal left ventricular pacing sites, and
the development of techniques for optimisation of atrioventricular and
interventricular pacing delays are current areas under investigation. Most
importantly, the effect of biventricular pacing on overall mortality is
unknown. Longer-term mortality studies are underway to investigate whether
multi-site pacing alters the natural history of heart failure. Furthermore,
combination devices that provide atrio-BV pacing and an ICD facility are
available. These devices promise to prevent heart failure progression as
well as sudden cardiac death through ventricular arrhythmia. The results of
these studies may have profound implications on the management of heart
failure in the future.
EMTREE DRUG INDEX TERMS
inotropic agent (clinical trial, drug therapy, pharmacology)
noradrenalin (clinical trial, drug therapy, pharmacology)
placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (disease management, drug therapy, surgery, therapy)
heart ventricle pacing
EMTREE MEDICAL INDEX TERMS
artificial heart pacemaker
atrial fibrillation (surgery, therapy)
clinical practice
clinical trial
congestive cardiomyopathy (disease management, surgery, therapy)
coronary artery bypass surgery
coronary vein
defibrillation
disease course
disease severity
drug effect
equipment design
exercise
heart assist device
heart atrium pacing
heart death (complication, prevention, therapy)
heart function
heart hemodynamics
heart left bundle branch block (therapy)
heart ventricle arrhythmia (complication, prevention, therapy)
heart ventricle conduction
human
medical technology
mortality
pacemaker failure (complication)
patient selection
quality of life
review
surgical approach
symptom
theoretical study
treatment failure
treatment indication
vein injury (complication)
vein perforation (complication)
vein thrombosis (complication)
CAS REGISTRY NUMBERS
noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2004058334
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 478
TITLE
Atrial flutter in a college football player: Return to play or not?
AUTHOR NAMES
Wen D.Y.
Flaker G.
Sharp R.L.
Smith P.A.
AUTHOR ADDRESSES
(Smith P.A.) Columbia Orthopedic Group, Columbia, MO, United States.
(Wen D.Y., wend@health.missouri.edu) Dept. of Fam. and Community Medicine,
University of Missouri-Columbia, M245 Medical Sciences Bldg., Columbia, MO
65212, United States.
(Flaker G.; Sharp R.L.)
CORRESPONDENCE ADDRESS
D.Y. Wen, Dept. of Fam. and Community Medicine, University of
Missouri-Columbia, M245 Medical Sciences Bldg., Columbia, MO 65212, United
States. Email: wend@health.missouri.edu
SOURCE
Physician and Sportsmedicine (2003) 31:10 (21-24+35). Date of Publication: 1
Oct 2003
ISSN
0091-3847
ABSTRACT
Exercise isn't thought to precipitate atrial fibrillation, yet
return-to-activity decisions can be complex. The case of a 19-year-old
college football player who had the condition demonstrates how new
treatments have made certain Bethesda conference recommendations outdated.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
esmolol (drug combination, drug therapy, intravenous drug administration)
ibutilide fumarate (drug therapy)
warfarin (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
football
heart atrium flutter (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
adult
article
atrial fibrillation
cardioversion
case report
catheter ablation
clinical feature
college student
decision making
disease course
exercise
human
male
practice guideline
sports medicine
treatment outcome
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
esmolol (81147-92-4, 81161-17-3)
ibutilide fumarate (130350-52-6)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2003406014
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 479
TITLE
Ximelagatran: A new era in oral anticoagulation
AUTHOR NAMES
McCall K.L.
MacLaughlin E.J.
AUTHOR ADDRESSES
(McCall K.L., kenneth@ama.ttuhsc.edu; MacLaughlin E.J.) School of Pharmacy,
Texas Tech. Univ. Hlth. Sci. Center, Amarillo, TX, United States.
(McCall K.L., kenneth@ama.ttuhsc.edu) School of Pharmacy, Texas Tech. Univ.
Hlth. Sci. Center, 1300 Coulter Dr., Amarillo, TX 79106-1712, United States.
CORRESPONDENCE ADDRESS
K.L. McCall, School of Pharmacy, Texas Tech. Univ. Hlth. Sci. Center, 1300
Coulter Dr., Amarillo, TX 79106-1712, United States. Email:
kenneth@ama.ttuhsc.edu
SOURCE
Journal of Pharmacy Technology (2003) 19:4 (222-228). Date of Publication:
Jul 2003
ISSN
8755-1225
ABSTRACT
Objective: To review the pharmacology, pharmacokinetics, and clinical trials
of the oral direct thrombin inhibitor ximelagatran. Data Sources: All
primary articles involving ximelagatran or its active form, melagatran, and
indexed on MEDLINE or International Pharmaceutical Abstracts databases
(1966-December 2002) were evaluated. Recent ximelagatran and melagatran
abstracts were also obtained online from the American Society of Hematology
at www.hematology.org/meeting/abstracts.cfm (2001 and 2002). Data Synthesis:
Ximelagatran is an orally bioavailable prodrug of melagatran that directly
blocks unbound thrombin and fibrin-bound thrombin. Ximelagatran displays
predictable pharmacodynamic and pharmacokinetic properties with a linear
dose-response relationship and low interpatient variability. These
parameters allow fixed dosing of ximelagatran without routine coagulation
monitoring. Ximelagatran has yet to be approved by the FDA; however, several
major clinical trials have been completed. These clinical trials have
revealed that an easier-to-manage ximelagatran regimen is at least as
effective and has a similar safety profile as conventional therapy for
prevention of venous thromboembolism (VTE). The results of studies with
ximelagatran for treatment of VTE and prevention of thrombosis associated
with atrial fibrillation are promising, but need further investigation.
Conclusions: Ximelagatran possesses several advantages over warfarin
including fixed dosing and the lack of coagulation monitoring, the absence
of known diet or drug interactions, and a faster onset of action.
Ximelagatran appears to be at least as effective as warfarin for prevention
of VTE. Further research is needed with ximelagatran in the treatment of VTE
and atrial fibrillation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (adverse drug reaction, clinical trial, drug comparison,
drug dose, drug therapy, oral drug administration, pharmacokinetics,
pharmacology)
thrombin inhibitor (adverse drug reaction, clinical trial, drug comparison,
drug dose, drug therapy, oral drug administration, pharmacokinetics,
pharmacology)
ximelagatran (adverse drug reaction, clinical trial, drug comparison, drug
dose, drug therapy, oral drug administration, pharmacokinetics,
pharmacology)
EMTREE DRUG INDEX TERMS
dalteparin (drug comparison, drug therapy, subcutaneous drug administration)
enoxaparin (adverse drug reaction, drug comparison, drug therapy,
subcutaneous drug administration)
melagatran (pharmacokinetics)
warfarin (drug comparison, drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulation
EMTREE MEDICAL INDEX TERMS
bleeding (side effect)
cerebrovascular accident (prevention)
clinical trial
dose response
drug efficacy
food and drug administration
human
multicenter study
pharmacodynamics
review
thromboembolism (drug therapy, prevention)
thrombosis (drug therapy, prevention)
thrombosis prevention
CAS REGISTRY NUMBERS
enoxaparin (9041-08-1)
melagatran (159776-70-2)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2003295432
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 480
TITLE
7-oxo-DHEA and Raynaud's phenomenon
AUTHOR NAMES
Ihler G.
Chami-Stemmann H.
AUTHOR ADDRESSES
(Ihler G., gmihler@tamu.edu; Chami-Stemmann H.) Dept. of Med. Biochem./Med.
Genetics, Texas A and M College of Medicine, College Station, TX, United
States.
(Ihler G., gmihler@tamu.edu) Dept. of Med. Biochem./Med. Genetics, Texas A
and M College of Medicine, College Station, TX 77843-1114, United States.
(Chami-Stemmann H.) Department of Rheumatology, C.H.U Nice, Rte St. Antoine
La Ginestiere, Nice, France.
CORRESPONDENCE ADDRESS
G. Ihler, Dept. of Med. Biochem./Med. Genetics, Texas A and M College of
Medicine, College Station, TX 77843-1114, United States. Email:
gmihler@tamu.edu
SOURCE
Medical Hypotheses (2003) 60:3 (391-397). Date of Publication: 1 Mar 2003
ISSN
0306-9877
BOOK PUBLISHER
Churchill Livingstone, 1-3 Baxter's Place, Leith Walk, Edinburgh, United
Kingdom.
ABSTRACT
Patients with Raynaud's phenomenon have abnormal digital vasoconstriction in
response to cold. The pathogenesis remains unknown but may involve a local
neurovascular defect leading to vasoconstriction. Diagnosis of primary
Raynaud's phenomenon is based on typical symptomatology coupled with normal
physical examination, normal laboratory studies and lack of observable
pathology by nail fold capillaroscopy. Secondary Raynaud's phenomenon is
known to occur associated with several connective tissue diseases, vascular
injury due to repeated vibrational trauma, and other causes which produce
demonstrable vascular and microcirculatory damage. Treatment of Raynaud's
symptoms is conservative and aimed at prevention of attacks. Patients are
advised to remain warm and, if possible, to live in warm climates. We
suggest that an ergogenic (thermogenic) steroid, 7-oxo-DHEA
(3-acetoxyandrost-5-ene-7,17-dione), which is available without prescription
as the trademarked 7-keto DHEA, may be very helpful in prevention of primary
Raynaud's attacks by increasing the basal metabolic rate and inhibiting
vasospasm. © 2002 Elsevier Science Ltd. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
3beta acetoxyandrost 5 ene 7,17 dione (adverse drug reaction, clinical
trial, drug dose, drug therapy, oral drug administration, pharmacokinetics,
pharmacology)
alpha adrenergic receptor blocking agent (adverse drug reaction, drug
therapy)
calcium channel blocking agent (adverse drug reaction, drug therapy)
nifedipine (adverse drug reaction, drug therapy)
steroid (adverse drug reaction, clinical trial, drug dose, drug therapy,
oral drug administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
adenosine triphosphate
antidiabetic agent (pharmacology)
beta adrenergic receptor stimulating agent (drug therapy)
dihydropyridine derivative (adverse drug reaction, drug therapy)
glucose
levothyroxine (drug therapy)
liothyronine (clinical trial, drug dose, drug therapy)
metformin (pharmacology)
nitrate (drug therapy)
placebo
prostaglandin (drug therapy)
proton transporting adenosine triphosphate synthase
reduced nicotinamide adenine dinucleotide
serotonin antagonist (drug therapy)
thromboxane synthase
thyroid hormone (clinical trial, drug dose, drug therapy)
unclassified drug
uncoupling protein 1
uncoupling protein 2
uncoupling protein 3
vasodilator agent (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
Raynaud phenomenon (diagnosis, drug therapy, etiology, prevention, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
acupuncture
animal model
article
atrial fibrillation (complication)
clinical article
clinical trial
controlled clinical trial
controlled study
drug mechanism
drug safety
edema (side effect)
faintness (side effect)
feedback system
flushing
gluconeogenesis
headache (side effect)
heart palpitation (side effect)
Horner syndrome (complication)
human
hypothyroidism (drug therapy)
microcirculation
muscle weakness (side effect)
nonhuman
patient education
peripheral vascular disease (diagnosis, drug therapy, etiology, prevention,
surgery, therapy)
pleura effusion (complication)
pneumothorax (complication)
priority journal
rat
relaxation training
side effect (side effect)
steroid therapy
stress
sympathectomy
symptomatology
tachycardia (side effect)
thermogenesis
vasoconstriction
vasospasm (etiology)
CAS REGISTRY NUMBERS
adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
glucose (50-99-7, 84778-64-3)
levothyroxine (51-48-9)
liothyronine (6138-47-2, 6893-02-3)
metformin (1115-70-4, 657-24-9)
nifedipine (21829-25-4)
nitrate (14797-55-8)
proton transporting adenosine triphosphate synthase (37205-63-3)
reduced nicotinamide adenine dinucleotide (58-68-4)
thromboxane synthase (60832-04-4, 61276-89-9)
EMBASE CLASSIFICATIONS
Internal Medicine (6)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2003087207
MEDLINE PMID
12581618 (http://www.ncbi.nlm.nih.gov/pubmed/12581618)
FULL TEXT LINK
http://dx.doi.org/10.1016/S0306-9877(02)00409-7
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 481
TITLE
Sports and lone atrial fibrillation
AUTHOR NAMES
Mont L.
Sambola A.
Brugada J.
Vacca M.
Marrugat J.
Elosua R.
Paré C.
Azqueta M.
Sanz G.
AUTHOR ADDRESSES
(Mont L.; Sambola A.; Brugada J.; Vacca M.; Marrugat J.; Elosua R.; Paré C.;
Azqueta M.; Sanz G.) Hospital Clínic, University of Barcelona, Cardiovasc.
Epidemiology Res. Unit, Barcelona, Spain.
CORRESPONDENCE ADDRESS
L. Mont, Hospital Clínic, University of Barcelona, Cardiovasc. Epidemiology
Res. Unit, Barcelona, Spain.
SOURCE
Cardiology Review (2003) 20:1 (15-18). Date of Publication: Jan 2003
ISSN
1092-6607
ABSTRACT
We noticed that several patients with lone atrial fibrillation practiced
sports on a regular basis and sought to determine whether long-term sports
practice predisposed these patients to this arrhythmia. After evaluating the
records of 51 male patients with lone atrial fibrillation, we found 32 men
(63%) had been practicing sports on a regular basis. The percentage of
athletic men in the same age group in the general population is only 15%.
These data suggest that long-term sports practice may play a role in the
development of lone atrial fibrillation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
acenocoumarol
anticoagulant agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (diagnosis, therapy)
sport
EMTREE MEDICAL INDEX TERMS
adult
anticoagulant therapy
article
athlete
bradycardia (diagnosis)
brain embolism (complication)
cardioversion
controlled study
disease predisposition
echocardiography
electrophysiology
exercise
heart atrium flutter (diagnosis, therapy)
heart ventricle hypertrophy (complication, diagnosis)
human
major clinical study
male
sex ratio
Spain
vagus tone
CAS REGISTRY NUMBERS
acenocoumarol (152-72-7)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2003053934
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 482
TITLE
Older woman with worsening weakness, dyspnea on exertion, and syncope
AUTHOR NAMES
Rubin R.N.
AUTHOR ADDRESSES
(Rubin R.N.) Temple University School of Medicine, Department of Medicine,
Temple University Hospital, Philadelphia, PA, United States.
CORRESPONDENCE ADDRESS
R.N. Rubin, Temple University School of Medicine, Department of Medicine,
Temple University Hospital, Philadelphia, PA, United States.
SOURCE
Consultant (2003) 43:1 (105-106). Date of Publication: Jan 2003
ISSN
0010-7069
EMTREE DRUG INDEX TERMS
amiodarone (drug interaction, drug therapy)
cotrimoxazole (drug interaction, drug therapy)
metoprolol (drug therapy)
nifedipine (drug therapy)
warfarin (drug interaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
dyspnea
faintness
muscle weakness
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation (drug therapy)
bradycardia
case report
drug effect
electrocardiogram
fatigue
female
human
hypertension (drug therapy)
patient monitoring
priority journal
telemetry
urinary tract infection (drug therapy)
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
cotrimoxazole (8064-90-2)
metoprolol (37350-58-6)
nifedipine (21829-25-4)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2003068191
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 483
TITLE
Follow-up of patients with suspected transient ischaemic attack who
underwent fast-track carotid doppler scanning but did not proceed to carotid
endarterectomy
AUTHOR NAMES
Demetriades A.K.
Cameron A.
Osman I.
Phillips P.
AUTHOR ADDRESSES
(Demetriades A.K.; Cameron A.; Osman I.; Phillips P.,
peter.phillips@ntlworld.com) Ipswich Hospital NHS Trust, Heath Road,
Ipswich, Suffolk IP4 2XA, United Kingdom.
CORRESPONDENCE ADDRESS
P. Phillips, Ipswich Hospital NHS Trust, Heath Road, Ipswich, Suffolk IP4
2XA, United Kingdom. Email: peter.phillips@ntlworld.com
SOURCE
Journal of Clinical Excellence (2002) 4:2 (245-250). Date of Publication:
2002
ISSN
1465-9883
ABSTRACT
Objectives: To determine the clinical outcomes and effectiveness of medical
interventions following suspected transient ischaemic attack (TIA) or minor
stroke. Design: Questionnaires were sent to the general practitioners (GPs)
of the 217 patients who suffered from TIA or minor stroke in 1997 and who
were found not to have surgically treatable carotid stenosis after carotid
duplex scan. Setting: GPs' referrals to the fast-track carotid doppler
service at the Ipswich Hospital. Main outcome measures: Accuracy of original
diagnosis, effectiveness of secondary prevention, incidence of further
vascular events and mortality over a four-year follow-up period. Results: Of
the total 217 questionnaires sent out, 149 (69%) were returned fully
completed. Mortality data were obtained on a total of 178 (82%) patients. Of
the 149 patients studied, 13 were found to have non-cerebrovascular causes
for their presenting symptoms. Fifty-two were prescribed antiplatelet
medication, 38 were given advice on exercise, 13 out of 26 smokers quit, 49
out of 73 patients with systolic pressure over 150 mm Hg were controlled
within that target, 25 out of 41 patients with a total fasting cholesterol
over 5 mmol/L were controlled within that limit. Twelve out of 14 patients
in atrial fibrillation were anticoagulated. Fifty-two patients suffered
further cerebrovascular, coronary or peripheral vascular events during the
four-year follow-up. Thirty-four (19%) of 178 patients for whom mortality
data were available died during the four-year follow-up. This compares with
a mortality rate of 1.35% in the population of East Suffolk matched for age
and followed up for the same four-year period. Eighteen deaths (53%) were
due to vascular causes. Conclusions: Patients presenting with suspected TIA
or minor stroke have greatly increased morbidity and mortality rates
particularly due to vascular causes. Various service models in primary and
secondary care need to be evaluated in order to determine the most effective
system for minimising the burden of disease in this group of patients.
EMTREE DRUG INDEX TERMS
anticoagulant agent (drug therapy)
antithrombocytic agent (drug therapy)
cholesterol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
carotid endarterectomy
Doppler echography
transient ischemic attack (diagnosis, drug therapy, epidemiology, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation (drug therapy)
cerebrovascular accident (diagnosis, drug therapy, epidemiology, surgery,
therapy)
cerebrovascular disease (drug therapy)
clinical trial
coronary artery disease (drug therapy)
diagnostic accuracy
diet restriction
exercise
follow up
general practitioner
hospital service
human
incidence
major clinical study
morbidity
mortality
patient referral
peripheral vascular disease (drug therapy)
prescription
primary medical care
questionnaire
secondary prevention
smoking cessation
statistical model
stenosis
systolic blood pressure
United Kingdom
CAS REGISTRY NUMBERS
cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
Radiology (14)
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2003406464
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 484
TITLE
Chronic heart failure: 10 Questions physicians often ask
AUTHOR NAMES
Tang W.H.W.
Francis G.S.
AUTHOR ADDRESSES
(Tang W.H.W.; Francis G.S.) Cleveland Clinic Foundation, Cleveland, OH,
United States.
CORRESPONDENCE ADDRESS
W.H.W. Tang, Cleveland Clinic Foundation, Cleveland, OH, United States.
SOURCE
Consultant (2002) 42:6 (678-686). Date of Publication: 2002
ISSN
0010-7069
ABSTRACT
The key test in the initial evaluation is the standard echocardiogram.
Elevated plasma levels of B-type natriuretic peptide strongly suggest
underlying cardiac dysfunction in patients with symptoms of heart failure
(HF). Consider angiotensinconverting enzyme (ACE) inhibitors and B-blockers
for all patients with HF, unless contraindicated. High doses of ACE
inhibitors have not been shown to be more effective than lower ones; the
goal is to reach target dosages comparable to those used in clinical trials.
Angiotensin II receptor blockers do not reduce mortality more effectively
than standard doses of ACE inhibitors, which remain first-line agents. Oral
coagulation is not routinely recommended for patients with HF, although
high-risk patients (such as those with atrial fibrillation) may benefit.
Patient education, self-monitoring, and compliance with medication and
dietary regimens are vital components of treatment.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
aldosterone antagonist (adverse drug reaction, clinical trial, drug dose,
drug therapy)
angiotensin receptor antagonist (clinical trial, drug dose, drug therapy)
beta adrenergic receptor blocking agent (clinical trial, drug comparison,
drug dose, drug therapy)
brain natriuretic peptide (endogenous compound)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical
trial, drug comparison, drug dose, drug therapy)
spironolactone (adverse drug reaction, clinical trial, drug dose, drug
therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (clinical trial, drug comparison, drug therapy)
amlodipine (clinical trial, drug dose, drug therapy)
anticoagulant agent (clinical trial, drug comparison, drug therapy)
antithrombocytic agent (clinical trial, drug comparison, drug therapy)
bisoprolol (clinical trial, drug dose, drug therapy)
candesartan (clinical trial, drug dose, drug therapy)
captopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
carvedilol (clinical trial, drug comparison, drug dose, drug therapy)
clopidogrel (clinical trial, drug comparison, drug therapy)
digoxin (clinical trial, drug dose, drug therapy)
enalapril (adverse drug reaction, clinical trial, drug dose, drug therapy)
glyceryl trinitrate (drug comparison, drug therapy, pharmacoeconomics)
lisinopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
losartan (clinical trial, drug comparison, drug dose, drug therapy)
metoprolol (clinical trial, drug comparison, drug dose, drug therapy)
milrinone (drug comparison, drug therapy, pharmacoeconomics)
nesiritide (clinical trial, drug administration, drug comparison, drug
therapy, pharmacoeconomics)
nitroprusside sodium (drug comparison, drug therapy, pharmacoeconomics)
nonsteroid antiinflammatory agent (adverse drug reaction)
placebo
ramipril (adverse drug reaction, clinical trial, drug dose, drug therapy)
unindexed drug
valsartan (clinical trial, drug comparison, drug dose, drug therapy)
warfarin (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart arrhythmia (diagnosis, disease management, drug therapy, therapy)
heart failure (diagnosis, disease management, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
angioneurotic edema (side effect)
cardiovascular disease (diagnosis, disease management, drug therapy,
epidemiology, prevention, rehabilitation, therapy)
cardioversion
chronic disease
clinical trial
controlled study
coughing (side effect)
defibrillation
diagnostic test
diet restriction
disease severity
drug cost
drug induced disease (side effect)
drug megadose
electrocardiogram
exercise
heart pacing
heart rehabilitation
heart ventricle fibrillation (diagnosis, disease management, drug therapy,
therapy)
human
major clinical study
multicenter study
nephrotoxicity (side effect)
patient education
practice guideline
priority journal
randomized controlled trial
review
treatment indication
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amlodipine (88150-42-9)
bisoprolol (66722-44-9)
brain natriuretic peptide (114471-18-0)
candesartan (139481-59-7)
captopril (62571-86-2)
carvedilol (72956-09-3)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
digoxin (20830-75-5, 57285-89-9)
enalapril (75847-73-3)
glyceryl trinitrate (55-63-0)
lisinopril (76547-98-3, 83915-83-7)
losartan (114798-26-4)
metoprolol (37350-58-6)
milrinone (78415-72-2)
nesiritide (124584-08-3, 189032-40-4)
nitroprusside sodium (14402-89-2, 15078-28-1)
ramipril (87333-19-5)
spironolactone (52-01-7)
valsartan (137862-53-4)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2002191296
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 485
TITLE
Management of stroke in the new millennium
AUTHOR NAMES
Ho R.T.K.
AUTHOR ADDRESSES
(Ho R.T.K.) The Brain Centre, Canossa Hospital, No. 1 Old Peak Road, Hong
Kong, Hong Kong.
CORRESPONDENCE ADDRESS
R.T.K. Ho, The Brain Centre, Canossa Hospital, No. 1 Old Peak Road, Hong
Kong, Hong Kong.
SOURCE
Hong Kong Practitioner (2002) 24:2 (83-91). Date of Publication: 2002
ISSN
1027-3948
ABSTRACT
Stroke (brain attack) is the number 3 killer worldwide. It is the leading
cause of disability in adults. It is estimated that up to one half of all
strokes can be prevented through stroke risk detection and risk management.
Therefore in spite of new and exciting treatments for acute stroke,
prevention remains the key objective.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
antidiabetic agent (drug therapy)
antihypertensive agent (drug therapy)
antilipemic agent (drug therapy)
clopidogrel (drug therapy)
dipyridamole (drug therapy)
hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
lipid (endogenous compound)
ticlopidine (drug therapy)
tissue plasminogen activator (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (diagnosis, drug therapy, prevention, surgery,
therapy)
EMTREE MEDICAL INDEX TERMS
adult
age
alcohol consumption
article
atrial fibrillation (drug therapy)
brain hemorrhage (surgery)
brain surgery
carotid artery obstruction (drug therapy, surgery, therapy)
carotid endarterectomy
cause of death
cerebrovascular accident (drug therapy, prevention, therapy)
computer assisted tomography
diabetes mellitus (drug therapy)
diet therapy
exercise
family history
female
gender
human
hyperlipidemia (drug therapy)
hypertension (drug therapy)
male
nuclear magnetic resonance imaging
obesity
patient education
physical activity
physical disability
race
risk assessment
risk factor
risk management
smoking cessation
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
lipid (66455-18-3)
ticlopidine (53885-35-1, 55142-85-3)
tissue plasminogen activator (105913-11-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2002176943
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 486
TITLE
The National Service Framework for Coronary Heart Disease
AUTHOR NAMES
Hobbs F.D.R.
AUTHOR ADDRESSES
(Hobbs F.D.R.) Medical School, University of Birmingham, Edgbaston,
Birmingham B15 2TT, United Kingdom.
CORRESPONDENCE ADDRESS
F.D.R. Hobbs, Medical School, University of Birmingham, Edgbaston,
Birmingham B15 2TT, United Kingdom. Email: F.D.R.Hobbs@bham.ac.uk
SOURCE
British Journal of Cardiology (2002) 9:SUPPL. 3 (S29-S32). Date of
Publication: 2002
ISSN
0969-6113
ABSTRACT
Cardiovascular disease is the most important cause of illness in Britain.
The focus of the National Service Framework for Coronary Heart Disease (NSF
for CHD) is appropriate since the burden of CHD is high in the UK.
Interventions for primary and secondary prevention include advice on
reducing modifiable risk factors, smoking, maintaining blood pressure <
140/85 mmHg and using statins and dietary advice to lower serum cholesterol.
Identification of those at greatest risk will require practice-based
registers. Audits will be needed to ensure that the stipulated interventions
are offered to those on the disease registers. The biggest implication for
primary prevention will be selection of patients at increased risk of CHD.
Implementation of the NSF will increase GPs' workload.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug dose, drug therapy)
antilipemic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
cholesterol (endogenous compound)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
glucose (endogenous compound)
low density lipoprotein (endogenous compound)
nicotine (drug therapy)
nitrate (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
ischemic heart disease (disease management, drug therapy, prevention)
national health service
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (drug therapy)
blood pressure monitoring
cardiovascular disease (disease management, drug therapy, prevention)
cardiovascular risk
cholesterol blood level
cost effectiveness analysis
diabetes mellitus (drug therapy)
diet therapy
dose response
general practitioner
heart infarction (drug therapy)
heart left ventricle failure (drug therapy)
high risk population
human
nicotine replacement therapy
patient selection
primary health care
register
review
risk factor
secondary prevention
smoking
United Kingdom
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
cholesterol (57-88-5)
glucose (50-99-7, 84778-64-3)
nicotine (54-11-5)
nitrate (14797-55-8)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2002150788
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 487
TITLE
Non-toxic multinondular goitres
AUTHOR NAMES
Kalk W.J.
Vangu M.D.T.H.
AUTHOR ADDRESSES
(Kalk W.J.; Vangu M.D.T.H.) Division of Endocrinol./Metabolism, University
of Witwatersrand, Johannesburg, South Africa.
CORRESPONDENCE ADDRESS
W.J. Kalk, Division of Endocrinol./Metabolism, University of Witwatersrand,
Johannesburg, South Africa.
SOURCE
South African Journal of Obstetrics and Gynaecology (2002) 8:1 (10-13). Date
of Publication: Apr 2002
ISSN
0038-2469
ABSTRACT
Thyroid nodules, are common, especially in women, and most are benign (∼7%
are malignant). Recent research into the pathogenesis of simple, nodular
goitres has shown a strong genetic predisposition which interacts with
environmental factors such as dietary goitrogens, smoking, and iodine
deficiency. Most benign nodules in multinodular goitres seem to result from
genetic mutations which result in monoclonal overgrowth of thyrocytes with a
growth advantage but a range of function, resulting in cold, warm or hot
nodules seen on isotopic thyroid scans. In most mutations thyrocyte growth
appears to be autonomous and independent of thyrotrophin stimulation.
Management options for multinodular goitres include regular clinical and
functional assessment only (for small euthyroid goitres), surgery and
radio-iodine. Suppression of thyrotrophin with thyroxine therapy is often
ineffective, must be lifelong, and is associated with serious potential
hazards (osteoporosis and an increased risk of atrial fibrillation). Total
thyroidectomy eliminates the high risk of recurrent goitre (up to 60% at 10
years), but requires a practiced surgeon. Radio-iodine therapy (2.2 GBq, 60
mCi, single or fractionated dose) is effective in safely reducing goitre
size (by ∼50%) and relieving obstructive symptoms. Fine-needle aspiration
cytological evaluation is essential for all apparently single nodules and
for dominant nodules.
EMTREE DRUG INDEX TERMS
iodine (endogenous compound)
iodine 131 (adverse drug reaction, drug comparison, drug dose, drug therapy)
radioactive iodine (adverse drug reaction, drug comparison, drug dose, drug
therapy)
recombinant thyrotropin (drug combination, drug dose, drug therapy,
pharmacology)
thyrotropin (endogenous compound)
thyroxine (adverse drug reaction, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
nodular goiter (diagnosis, drug therapy, etiology, radiotherapy, surgery)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (side effect)
benign tumor
clinical examination
dietary intake
dose response
drug efficacy
drug safety
environmental factor
fine needle aspiration biopsy
gene mutation
genetic predisposition
heart left ventricle function
heart left ventricle hypertrophy (side effect)
human
hypothyroidism (side effect)
iodine deficiency
osteoporosis (side effect)
pathogenesis
radioiodination
recurrence risk
review
smoking
symptomatology
thyroid function test
thyroid scintiscanning
thyroidectomy
tumor volume
CAS REGISTRY NUMBERS
iodine 131 (10043-66-0, 15124-39-7)
iodine (7553-56-2)
recombinant thyrotropin (194100-83-9)
thyrotropin (9002-71-5)
thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Drug Literature Index (37)
Adverse Reactions Titles (38)
General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2002304812
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 488
TITLE
Non-toxic multinodular goitres
AUTHOR NAMES
Kalk W.J.
Vangu M.D.T.H.
AUTHOR ADDRESSES
(Kalk W.J.) Div. of Endocrinology and Metabolism, University of the
Witwatersrand, Johannesburg, South Africa.
(Vangu M.D.T.H.) Department of Nuclear Medicine, University of the
Witwatersrand, Johannesburg, South Africa.
CORRESPONDENCE ADDRESS
W.J. Kalk, Div. of Endocrinology and Metabolism, University of the
Witwatersrand, Johannesburg, South Africa.
SOURCE
Journal of Endocrinology, Metabolism and Diabetes of South Africa (2002) 7:1
(10-13). Date of Publication: Apr 2002
ISSN
1608-9677
ABSTRACT
Thyroid nodules are common, especially in women, and most are benign (∼7%
are malignant). Recent research into the pathogenesis of simple, nodular
goitres has shown a strong generic predisposition which interacts with
environmental factors such as dietary goitrogerts, smoking, and iodine
deficiency. Most benign nodules in multinodular goitres seem to result from
generic mutations which result in monoclonal overgrowth of thyrocytes with a
growth advantage but a range of function, resulting in cold, warm or hot
nodules seen on isotopic thyroid scans. In most mutations thyrocyte growth
appears to be autonomous and independent of thyrotrophin stimulation.
Management options for multinodular goitres include regular clinical and
functional assessment only (for small euthyroid goitres), surgery and
radio-iodine. Suppression of thyrotrophin with thyroxine therapy is often
ineffective, must be lifelong, and is associated with serious potential
hazards (osteoporosis and an increased risk of atrial fibrillation). Total
thyroidectomy eliminates the high risk of recurrent goitre (up to 60% at 10
years), but requires a practiced surgeon. Radio-iodine therapy (2.2 GBq, 60
mCi, single or fractionated dose) is effective in safely reducing goitre
size (by ∼50%) and relieving obstructive symptoms. Fine-needle aspiration
cytological evaluation is essential for all apparently single nodules and
for dominant nodules.
EMTREE DRUG INDEX TERMS
radioactive iodine
recombinant thyrotropin (drug dose, drug therapy, pharmacology)
thyroxine (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
nodular goiter (disease management, drug therapy, radiotherapy, surgery)
toxic goiter (disease management, drug therapy, radiotherapy, surgery)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (side effect)
biosafety
correlation analysis
cytology
drug effect
follow up
gene mutation
genetic polymorphism
human
hypothyroidism (complication)
low drug dose
needle biopsy
osteoporosis (side effect)
pathogenesis
pathophysiology
radiation dose fractionation
review
risk factor
side effect (side effect)
thyroidectomy
CAS REGISTRY NUMBERS
recombinant thyrotropin (194100-83-9)
thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
Endocrinology (3)
Clinical and Experimental Pharmacology (30)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2005004529
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 489
TITLE
Alternative medicine - Boom or bust?
AUTHOR NAMES
Olshansky B.
AUTHOR ADDRESSES
(Olshansky B., brian-olshansky@uiowa.edu) Section of Electrophysiology,
Division of Cardiology, University of Iowa Hospitals, Iowa City, IA, United
States.
CORRESPONDENCE ADDRESS
B. Olshansky, The Section of Electophysiology, Division of Cardiology, The
University of Iowa Hospitals, 200 Hawkins Drive, Iowa City, IA 52242, United
States. Email: brian-olshansky@uiowa.edu
SOURCE
Cardiac Electrophysiology Review (2002) 6:1-2 (170-173). Date of
Publication: 2002
ISSN
1385-2264
BOOK PUBLISHER
Kluwer Academic Publishers, Van Godewijckstraat 30, Dordrecht, Netherlands.
EMTREE DRUG INDEX TERMS
1,4 butanediol
amino acid
antidepressant agent (drug interaction)
antioxidant
beta adrenergic receptor blocking agent (drug interaction)
carnitine (drug therapy)
cyclosporin (drug interaction)
digoxin (drug interaction)
Ephedra extract (adverse drug reaction, drug interaction)
fish oil (drug therapy)
Ginkgo biloba extract (drug interaction, pharmacology)
Glycyrrhiza extract (adverse drug reaction, drug therapy, pharmacology)
herbaceous agent (adverse drug reaction, drug interaction, drug therapy,
pharmacology)
Hypericum perforatum extract (adverse drug reaction, drug interaction, drug
therapy, pharmacology)
isoflavone derivative
mineral
nandrolone (oral drug administration)
nonsteroid antiinflammatory agent (drug interaction)
omega 3 fatty acid (drug therapy)
phytoestrogen
proteinase inhibitor (drug interaction)
pseudoephedrine (drug interaction)
serotonin uptake inhibitor (drug interaction)
testosterone derivative (oral drug administration)
tyramine (drug interaction)
ubidecarenone (adverse drug reaction, drug therapy)
vitamin
yohimbine (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alternative medicine
EMTREE MEDICAL INDEX TERMS
acupuncture
article
atrial fibrillation (drug therapy)
Chinese medicine
diagnostic error
diet supplementation
diet therapy
doctor patient relation
drug antagonism
drug marketing
drug mechanism
drug potentiation
extrasystole
faintness (drug therapy)
heart arrhythmia (drug therapy)
homeopathy
hospitalization
human
hypertension (side effect)
meditation
patient attitude
primary medical care
torsade des pointes (side effect)
CAS REGISTRY NUMBERS
1,4 butanediol (110-63-4)
amino acid (65072-01-7)
carnitine (461-06-3, 541-15-1, 56-99-5)
cyclosporin (79217-60-0)
digoxin (20830-75-5, 57285-89-9)
fish oil (8016-13-5)
nandrolone (434-22-0)
proteinase inhibitor (37205-61-1)
pseudoephedrine (345-78-8, 7460-12-0, 90-82-4)
tyramine (51-67-2, 60-19-5)
ubidecarenone (303-98-0)
yohimbine (146-48-5, 65-19-0)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
2002096794
MEDLINE PMID
11984042 (http://www.ncbi.nlm.nih.gov/pubmed/11984042)
FULL TEXT LINK
http://dx.doi.org/10.1023/A:1017984532559
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 490
TITLE
Prevention of vascular disease following acute ischaemic stroke
AUTHOR NAMES
Rodgers H.
AUTHOR ADDRESSES
(Rodgers H.) Centre for Health Services Research, University, 21 Claremont
Place, Newcastle-Upon-Tyne NE2 4AA, United Kingdom.
CORRESPONDENCE ADDRESS
H. Rodgers, Centre for Health Services Research, University, 21 Claremont
Place, Newcastle-Upon-Tyne NE2 4AA, United Kingdom. Email:
helen.rodgers@newcastle.ac.uk
SOURCE
British Journal of Cardiology (2001) 8:12 (704-705+708-711). Date of
Publication: 2001
ISSN
0969-6113
ABSTRACT
Considerable progress has been made in identifying stroke risk factors and
factors associated with recurrence. Because aspirin is only moderately
effective in secondary prevention, other agents such as dipyridamole and
clopidogrel have been evaluated. Warfarin is of benefit in patients who have
valvular and non-valvular atrial fibrillation. Carotid endarterectomy is
beneficial to the small number of patients with transient ischaemic attack
(TIA) or non-disabling stroke who have a significant carotid stenosis.
Recent evidence suggests that all patients with TIA or ischaemic stroke may
benefit from blood pressure and cholesterol lowering (including those who
are normotensive or who have a 'normal cholesterol'). All patients should be
given appropriate advice on lifestyle factors such as diet, regular exercise
and stopping smoking.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (clinical trial, drug combination, drug comparison, drug
therapy, oral drug administration, pharmacology)
antithrombocytic agent (adverse drug reaction, clinical trial, drug
comparison, drug dose, drug therapy, pharmaceutics, pharmacology)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (adverse drug reaction, clinical trial, drug
combination, drug comparison, drug dose, drug therapy, pharmacology)
cholesterol (endogenous compound)
clopidogrel (clinical trial, drug comparison, drug dose, drug therapy,
pharmacology)
dipyridamole (clinical trial, drug combination, drug comparison, drug dose,
drug therapy, pharmaceutics, pharmacology)
homocysteine (endogenous compound)
hypocholesterolemic agent (drug therapy)
indapamide (clinical trial, drug combination, drug comparison, drug dose,
drug therapy, pharmacology)
lipid (endogenous compound)
nicotine derivative (drug therapy)
perindopril (clinical trial, drug combination, drug comparison, drug dose,
drug therapy, pharmacology)
placebo
simvastatin (clinical trial, drug dose, drug therapy, pharmacology)
warfarin (clinical trial, drug combination, drug comparison, drug therapy,
oral drug administration, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, prevention, surgery)
vascular disease (complication, drug therapy, prevention, surgery)
EMTREE MEDICAL INDEX TERMS
atrial fibrillation (drug therapy)
blood regurgitation
carotid artery obstruction (surgery)
carotid artery surgery
carotid endarterectomy
cerebrovascular accident (complication, drug therapy, prevention)
clinical protocol
clinical trial
diabetes mellitus
diet
disability
drug choice
drug contraindication
drug effect
drug efficacy
drug indication
drug release
evaluation study
evidence based medicine
exercise
human
hypertension (drug therapy)
lifestyle
meta analysis
patient counseling
practice guideline
recurrent disease (drug therapy, prevention)
review
risk factor
secondary prevention
side effect (side effect)
smoking cessation
tobacco dependence (drug therapy)
transient ischemic attack (complication, drug therapy, surgery)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
cholesterol (57-88-5)
clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
dipyridamole (58-32-2)
homocysteine (454-28-4, 6027-13-0)
indapamide (26807-65-8)
lipid (66455-18-3)
perindopril (82834-16-0)
simvastatin (79902-63-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Internal Medicine (6)
Pharmacy (39)
Adverse Reactions Titles (38)
Drug Literature Index (37)
Clinical and Experimental Pharmacology (30)
Clinical and Experimental Biochemistry (29)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Public Health, Social Medicine and Epidemiology (17)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2002024290
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 491
TITLE
Interaction between warfarin and a vitamin K-containing nutritional
supplement: A case report
AUTHOR NAMES
Bransgrove L.L.
AUTHOR ADDRESSES
(Bransgrove L.L.) Department of Pharmacy, Veterans Affairs Medical Center,
6010 Amarillo Boulevard West, Amarillo, TX 79106, United States.
CORRESPONDENCE ADDRESS
L.L. Bransgrove, Department of Pharmacy, Veterans Affairs Medical Center,
6010 Amarillo Boulevard West, Amarillo, TX 79106, United States.
SOURCE
Journal of Herbal Pharmacotherapy (2001) 1:1 (85-89). Date of Publication:
2001
ISSN
1522-8940
ABSTRACT
A 72-year-old man receiving warfarin to prevent thromboembolism related to
atrial fibrillation/flutter experienced a significant increase in the
international normalized ratio (INR) after discontinuing an over the counter
nutritional supplement containing vitamin K. Laboratory testing revealed
critical elevations of INR and prothrombin time. After resumption of the
nutritional supplement, the patient's laboratory values returned to within
the desired range. With the explosion in popularity of herbal products,
practitioners need to be aware of all nutritional supplements being consumed
by patients as well as over the counter drugs.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
vitamin K group (drug interaction, pharmaceutics, pharmacology)
warfarin (drug dose, drug interaction, drug therapy, pharmacology)
EMTREE DRUG INDEX TERMS
amcinonide (drug therapy, topical drug administration)
amitriptyline (drug therapy)
benazepril (drug therapy)
clobetasol (drug therapy, topical drug administration)
coal tar (drug therapy, topical drug administration)
diltiazem (drug therapy)
fluocinolone (drug therapy)
hydrochlorothiazide (drug therapy)
insulin (drug therapy)
isophane insulin (drug therapy)
isosorbide (drug therapy)
ketoconazole (drug therapy, topical drug administration)
metformin (drug therapy)
natures life green
non prescription drug (drug interaction)
paracetamol (drug therapy)
simvastatin (drug therapy)
unclassified drug
urea (drug therapy, topical drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diet supplementation
herb (drug interaction, pharmaceutics, pharmacology)
nutritional support
EMTREE MEDICAL INDEX TERMS
aged
alfalfa
Arthrospira platensis
article
atrial fibrillation (drug therapy)
barley
Brassica
case report
Chlorella
dyslipidemia (drug therapy)
Fucus
garlic
heart atrium flutter (drug therapy)
human
hypertension (drug therapy)
international standard unit
laboratory test
Laminaria
male
non insulin dependent diabetes mellitus (drug therapy)
onion
pea
pepper
priority journal
prothrombin time
psoriasis (drug therapy)
spinach
tea
thromboembolism (drug therapy, prevention)
vegetable
DRUG TRADE NAMES
coumadin DuPont
natures life green , United StatesNatures Life
DRUG MANUFACTURERS
DuPont
(United States)Natures Life
CAS REGISTRY NUMBERS
amcinonide (51022-69-6)
amitriptyline (50-48-6, 549-18-8)
benazepril (86541-75-5)
clobetasol (25122-41-2)
coal tar (8007-45-2)
diltiazem (33286-22-5, 42399-41-7)
fluocinolone (807-38-5)
hydrochlorothiazide (58-93-5)
insulin (9004-10-8)
isophane insulin (9004-17-5)
isosorbide (652-67-5)
ketoconazole (65277-42-1)
metformin (1115-70-4, 657-24-9)
paracetamol (103-90-2)
simvastatin (79902-63-9)
urea (57-13-6)
vitamin K group (12001-79-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Biochemistry (29)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Pharmacy (39)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2001083884
FULL TEXT LINK
http://dx.doi.org/10.1300/J157v01n01_07
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 492
TITLE
Management of hyperlipidaemia in primary care: The implications of the
National Service Framework for Coronary Heart Disease
AUTHOR NAMES
Hobbs R.
AUTHOR ADDRESSES
(Hobbs R.) Dept. Prim. Care and Gen. Practice, Medical School, University of
Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
CORRESPONDENCE ADDRESS
R. Hobbs, Dept. Prim. Care and Gen. Practice, Medical School, University of
Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
SOURCE
British Journal of Cardiology (2000) 7:SUPPL. 4 (S6-S10). Date of
Publication: 2000
ISSN
0969-6113
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
acetylsalicylic acid (drug dose, drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
statin (protein) (drug therapy)
warfarin (drug therapy)
EMTREE DRUG INDEX TERMS
glucose (endogenous compound)
low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hyperlipidemia (drug therapy, therapy)
ischemic heart disease (drug therapy, prevention, therapy)
risk management
EMTREE MEDICAL INDEX TERMS
alcohol consumption
atrial fibrillation (drug therapy)
blood pressure monitoring
body weight
cholesterol diet
diabetes mellitus
diet
heart infarction (drug therapy)
heart left ventricle failure (drug therapy)
human
medical audit
physical activity
primary health care
primary prevention
review
risk factor
secondary prevention
smoking cessation
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
glucose (50-99-7, 84778-64-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2000427298
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 493
TITLE
VVI versus physiologic pacing. New data on an old topic
AUTHOR NAMES
Wiegand U.K.H.
AUTHOR ADDRESSES
(Wiegand U.K.H.) Medizinische Universität zu Lübeck, Medizinische Klinik II,
Ratzeburger Allee 160, 23538 Lübeck, Germany.
CORRESPONDENCE ADDRESS
U.K.H. Wiegand, Medizinische Universitat zu Lubeck, Medizinische Klinik II,
Ratzeburger Allee 160, 23538 Lubeck, Germany.
SOURCE
Herzschrittmachertherapie und Elektrophysiologie (2000) 11:SUPPL. 2
(II43-II48). Date of Publication: 2000
ISSN
0938-7412
ABSTRACT
Aim: Review of current literature on physiologic versus VVI pacing. Methods:
Data of five prospective randomized trials including recently reported
PAC-A-TACH and CTOPP results were summarized and interpreted. Results:
According to CTOPP results, mortality was not substantially improved by
physiologic pacing (PP) as compared to VVI pacing in a general population of
pacemaker recipients. In patients with sinus node disease, the influence of
pacing mode on survival was inconsistent among randomised trials, and there
is little prospective data on patients with AV-block. Sub-groups like
patients < 75 years and pacemaker dependent patients however benefited from
PP. Incidence of atrial fibrillation was reduced by PP, particularly in
patients with sinus node disease. Heart failure, exercise capacity and
quality of life were not substantially improved by PP except in the subgroup
of pacemaker dependent patients. Conclusions: Benefit of PPis less extensive
as suggested by retrospective trials. However, there is evidence that
relevant sub-groups such as patients with sinus node disease or with
persistent bradycardia benefit from PP.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
supraventricular tachycardia
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
atrioventricular block
bradycardia
clinical trial
controlled study
exercise
health care cost
heart failure
human
meta analysis
mortality
pacemaker
quality of life
sinus node disease
survival
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2000423935
FULL TEXT LINK
http://dx.doi.org/10.1007/s003990070007
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 494
TITLE
Pivotal research in cardiovascular syndromes in the elderly
AUTHOR NAMES
McKay C.R.
Rich M.W.
Vlietstra R.E.
Kitzman D.W.
Fleg J.L.
Krumholz H.M.
Lakatta E.G.
Cooke J.P.
Cannon C.P.
Ezekowitz M.D.
Frolich E.D.
Jalife J.
Kass D.A.
Kottke B.A.
Muller J.E.
Saltin B.
Shen W.K.
Somers V.K.
AUTHOR ADDRESSES
(McKay C.R.; Rich M.W.; Vlietstra R.E.; Kitzman D.W.; Fleg J.L.; Krumholz
H.M.; Lakatta E.G.; Cooke J.P.; Cannon C.P.; Ezekowitz M.D.; Frolich E.D.;
Jalife J.; Kass D.A.; Kottke B.A.; Muller J.E.; Saltin B.; Shen W.K.; Somers
V.K.) Harbor UCLA Medical Center-REI, 1124 West Carson Street, Torrance, CA
90502, United States.
CORRESPONDENCE ADDRESS
C.R. McKay, Harbor UCLA Medical Center-REI, 1124 West Carson Street,
Torrance, CA 90502, United States.
SOURCE
American Journal of Geriatric Cardiology (2000) 9:5 (243-250). Date of
Publication: 2000
ISSN
1076-7460
ABSTRACT
The PRICE-1 conference was designed to identify near term priorities for
funding cardiovascular research in the elderly. Twenty topics were
identified with either break throughs in fundamental mechanisms of aging
with cardiovascular systems or with, critical importance to cardiovascular
carve of the elderly. © 2000 by Cardiovascular Reviews & Reports, Inc.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiovascular system
elderly care
EMTREE MEDICAL INDEX TERMS
acute heart failure
aged
atrial fibrillation
exercise
faintness
financial management
heart muscle ischemia
human
medical research
organization
review
systolic hypertension
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2001055683
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 495
TITLE
An elderly man with progressive dyspnea on exertion and atrial fibrillation
as manifestations of senile cardiac amyloidosis
AUTHOR NAMES
Yunis N.A.
Petrasko M.S.
Cannistra L.B.
AUTHOR ADDRESSES
(Yunis N.A.; Petrasko M.S.; Cannistra L.B.) Department of Medicine, Brown
University School of Medicine, Memorial Hospital of Rhode Island, 111
Brewster Street, Pawtucket, RI 02860, United States.
CORRESPONDENCE ADDRESS
L.B. Cannistra, Department of Medicine, Brown University School of Medicine,
Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860,
United States.
SOURCE
American Journal of Geriatric Cardiology (2000) 9:2 (69-72). Date of
Publication: 2000
ISSN
1076-7460
ABSTRACT
Senile cardiac amyloidosis is a form of amyloidosis seen more commonly in
the elderly population. It was previously believed to have no functional
significance, but more recent studies suggest that it is an important cause
for cardiovascular morbidity and mortality in the elderly. The diagnosis may
be challenging and it is important to have a high suspicion for this disease
in the proper clinical setting. A patient with cardiac amyloidosis is
presented in this paper to illustrate the clinical context in which one
should consider this diagnosis. Information regarding diagnostic evaluation
and a brief review of senile cardiac amyloidosis is presented. (C) 2000 by
Cardiovascular Reviews and Reports, Inc.
EMTREE DRUG INDEX TERMS
digoxin
furosemide
hydrochlorothiazide
prealbumin (endogenous compound)
warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aging
atrial fibrillation
dyspnea
heart amyloidosis (diagnosis, etiology)
EMTREE MEDICAL INDEX TERMS
aged
article
case report
clinical feature
electrocardiogram
exercise test
heart muscle biopsy
human
human tissue
immunoelectrophoresis
isoelectric focusing
male
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
furosemide (54-31-9)
hydrochlorothiazide (58-93-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Gerontology and Geriatrics (20)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2000303872
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 496
TITLE
The development of polypharmacy. A longitudinal study
AUTHOR NAMES
Veehof L.J.G.
Stewart R.E.
Haaijer-Ruskamp F.M.
Meyboom-de Jong B.
AUTHOR ADDRESSES
(Veehof L.J.G.) Ant. Deusinglaan 4, 9713 AW Groningen, Netherlands.
(Stewart R.E.; Haaijer-Ruskamp F.M.; Meyboom-de Jong B.)
CORRESPONDENCE ADDRESS
L.J.G. Veehof, Ant. Deusinglaan 4, 9713 AW Groningen, Netherlands.
SOURCE
Family Practice (2000) 17:3 (261-267). Date of Publication: June 2000
ISSN
0263-2136
BOOK PUBLISHER
Oxford University Press, Great Clarendon Street, Oxford, United Kingdom.
ABSTRACT
Background. To date, only a few studies have been carried out on the
development and progress of polypharmacy in relation to morbidity in general
practices in The Netherlands. Objective. The aim of this study was to
investigate the relationship between an increase in long-term drug use and
the incidence and severity of some chronic diseases, particularly in the
elderly. Methods. Data on medication and morbidity of 1544 elderly people
were collected for the period 1994-1997 from three family practices in the
medication and morbidity Registration Network of Groningen (RNG) in the
northern part of The Netherlands. Polypharmacy is defined as the long-term
simultaneous use of two or more drugs; long-term is defined as > 240 days in
a year. We looked for differences in incidences of some chronic diseases in
those subgroups of the elderly in whom multiple long-term drug use
respectively increased, stayed constant or did not exist. Polypharmacy at
the end of the period was predicted using regression analysis. Results.
Polypharmacy occurred in 42% of the elderly at the end of 1997, with major
polypharmacy (> 5 drugs) in only 4%. The average number of drugs used
long-term increased from 1.3 to 1.8 in 4 years. Predictors for the increase
of polypharmacy were the number of drugs at the start, age, diabetes,
coronary ischaemic diseases and use of medication without a clear indication
(P < 0.005). The average number of diseases also increased, especially in
the elderly who showed the greatest increase in long-term drug use; however,
there was no significant difference from the groups with a slow or no
increase in drug use. Discussion. Polypharmacy showed a slow increase over 4
years: almost 20% of the elderly developed polypharmacy, i.e. going from no
drugs or one drug to two or more drugs. Polypharmacy develops mainly in
elderly patients who already use several drugs, who are known to suffer from
cardiovascular diseases, diabetes or stomach symptoms, those who often take
drugs (especially sedatives/hypnotics) without clear indication and those
who develop hypertension or atrial fibrillation over time.
EMTREE DRUG INDEX TERMS
analgesic agent
antidepressant agent
antidiabetic agent (drug therapy)
antihypertensive agent (drug therapy)
cardiovascular agent (drug therapy)
gastrointestinal agent (drug therapy)
hypnotic agent
laxative
sedative agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
polypharmacy
EMTREE MEDICAL INDEX TERMS
aged
article
atrial fibrillation (drug therapy)
cardiovascular disease (drug therapy)
chronic disease
diabetes mellitus (drug therapy)
disease severity
drug use
female
general practice
heart muscle ischemia (drug therapy)
human
hypertension (drug therapy)
incidence
longitudinal study
major clinical study
male
morbidity
Netherlands
registration
regression analysis
stomach disease (drug therapy)
treatment indication
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Gerontology and Geriatrics (20)
Health Policy, Economics and Management (36)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2000209329
MEDLINE PMID
10846147 (http://www.ncbi.nlm.nih.gov/pubmed/10846147)
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 497
TITLE
Secondary prevention of myocardial infarction
AUTHOR ADDRESSES
SOURCE
MeReC Bulletin (1999) 10:2 (5-8). Date of Publication: 1999
ISSN
1465-5659
ABSTRACT
Many patients do not receive optimal secondary prevention after myocardial
infarction (MI), despite good evidence that certain interventions reduce
mortality. After an MI, patients should be advised to stop smoking and,
provided there are no contraindications, take aspirin and a beta- blocker.
ACE inhibitors are likely to benefit patients with signs of heart failure or
evidence of left ventricular dysfunction. The use of statins post- MI, along
with dietary advice, should be considered when total cholesterol is ≥
5mmol/l and/or LDL-cholesterol is ≥ 3mmol/l. Before prescribing statins, GPs
should ensure that all suitable patients are receiving aspirin and a
beta-blocker as a first priority. Lifestyle measures, such as eating a
Mediterranean diet and oily fish, may also reduce mortality post-MI as can
cardiac rehabilitation programmes. Maintaining blood pressure below 140/85mm
Hg reduces the risk of further cardiovascular events. Anticoagulants are
usually reserved for those post-MI patients with, for example, a large
anterior infarction or atrial fibrillation, as they are no more beneficial
than aspirin alone. Calcium-channel blockers should not be used routinely
post-MI. However, diltiazem or verapamil may benefit patients without heart
failure who have continuing angina, if beta-blockers are inappropriate.
Amiodarone may be of benefit to patients with severe, symptomatic arrythmias
post-MI. However, class I antiarrythmics, such as flecainide, should be
avoided as they increase mortality post-MI.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
anticoagulant agent (drug therapy)
antithrombocytic agent (drug therapy)
beta adrenergic receptor blocking agent (drug therapy)
calcium channel blocking agent (drug therapy)
EMTREE DRUG INDEX TERMS
acebutolol (drug therapy)
acetylsalicylic acid (drug therapy)
amiodarone (drug therapy)
antilipemic agent (drug therapy)
atenolol (drug therapy)
diltiazem (drug therapy)
dipeptidyl carboxypeptidase inhibitor (drug therapy)
insulin
metoprolol (drug therapy)
pravastatin (drug therapy)
propranolol (drug therapy)
simvastatin (drug therapy)
timolol (drug therapy)
verapamil (drug therapy)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart infarction (drug therapy, prevention)
heart reinfarction (drug therapy, prevention)
secondary prevention
EMTREE MEDICAL INDEX TERMS
clinical trial
diet
exercise
heart arrhythmia (drug therapy)
human
hyperlipidemia (drug therapy)
ischemic heart disease (prevention)
lifestyle
meta analysis
mortality
review
risk factor
smoking cessation
CAS REGISTRY NUMBERS
acebutolol (34381-68-5, 37517-30-9)
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
atenolol (29122-68-7)
diltiazem (33286-22-5, 42399-41-7)
insulin (9004-10-8)
metoprolol (37350-58-6)
pravastatin (81131-74-0)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
simvastatin (79902-63-9)
timolol (26839-75-8)
verapamil (152-11-4, 52-53-9)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1999249198
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 498
TITLE
Preventing a first stroke: The NSA's recommendations
AUTHOR ADDRESSES
SOURCE
Journal of Critical Illness (1999) 14:7 (407-410). Date of Publication: 1999
ISSN
1040-0257
ABSTRACT
Consider these measures to reduce risk from conditions that contribute to
the 731,000 strokes in the United States each year.
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
cholesterol (endogenous compound)
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
alcohol consumption
anticoagulation
atrial fibrillation
diabetes mellitus
exercise
heart infarction
human
hypercholesterolemia
hypertension
lifestyle
patient education
primary prevention
review
risk factor
risk management
secondary prevention
smoking
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
cholesterol (57-88-5)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1999248813
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 499
TITLE
Case reports in heart failure
AUTHOR NAMES
Vokonas P.S.
AUTHOR ADDRESSES
(Vokonas P.S.) Boston University School of Medicine, Vet. Affairs Norm.
Aging Study Dept., Boston, MA, United States.
CORRESPONDENCE ADDRESS
P.S. Vokonas, Boston University School of Medicine, Vet. Affairs Norm. Aging
Study Dept., Boston, MA, United States.
SOURCE
Cardiology Review (1998) 15:9 (26-27). Date of Publication: 1998
ISSN
1092-6607
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (complication)
valvular heart disease (diagnosis)
EMTREE MEDICAL INDEX TERMS
abdominal discomfort
adult
article
atrial fibrillation (diagnosis)
case report
clinical feature
disease association
dyspnea
electrocardiogram
exercise
exercise test
fatigue
female
heart murmur (diagnosis)
human
male
mitral valve regurgitation (complication)
vein occlusion plethysmography
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1998380937
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 500
TITLE
Achieving optimum outcomes in the treatment of stroke
AUTHOR NAMES
Barnett H.J.M.
Meldrum H.E.
AUTHOR ADDRESSES
(Barnett H.J.M.; Meldrum H.E.) John P. Robarts Research Institute, London,
Ont., Canada.
(Barnett H.J.M.) John P. Robarts Research Institute, 100 Perth Drive,
London, Ont. N6A 5K8, Canada.
CORRESPONDENCE ADDRESS
H.J.M. Barnett, John P. Robarts Research Institute, 100 Perth Drive, London,
Ont. N6A 5K8, Canada.
SOURCE
CNS Drugs (1998) 9:SUPPL. 1 (11-18). Date of Publication: 1998
ISSN
1172-7047
ABSTRACT
Treatment for patients with ischaemic stroke is one of the rapidly advancing
frontiers in the struggle against disability from brain disease. Transient
ischaemic attack and minor stroke have been identified, and the fact that
they are a warning of more serious stroke or potentially fatal stroke has
been recognised. Patients with these symptoms should receive urgent
treatment, including management of risk factors and administration of
properly selected antithrombotic agents. Investigations must be performed to
determine whether or not the patient is an appropriate candidate for carotid
endarterectomy. Serious ischaemic lesions no longer represent universally
and discouragingly untreatable situations. Every patient with a developing
or recently developed ischaemic stroke must be urgently transferred to a
specialised unit providing expert surveillance and investigation. Experience
has shown that the care of these patients in a specialised stroke unit is
the ideal, and the development of such units should be encouraged. General
measures play a major role in reducing the extent of the disability
resulting from stroke and in expediting the rehabilitation of patients. The
following are each of vital importance: care of the airway; careful
monitoring of patients so that pneumonia and pulmonary emboli are avoided;
maintenance of adequate fluid intake and nutrition; maintenance of normal
systemic circulation (maintaining cardiac output and treating rhythm
disorders); and avoidance of pressure sores. Some patients with certain
types of ischaemic strokes, especially those caused by cardiac embolisation
(with and without atrial fibrillation), will benefit from anticoagulation.
Recent studies suggest that aspirin has prophylactic benefit for the
majority of non- embolic strokes. Traditional therapy with corticosteroids,
as anti-oedema agents, does not help patients with ischaemic infarction and
is not advised. Other agents that reduce brain oedema or alter blood volume
are of unproven value and are not advised as routine measures for ischaemic
stroke victims. Intravenous hyperglycaemic therapy should be avoided. The
most exciting finding in recent years is the proven benefit of intravenous
administration of alteplase (recombinant tissue plasminogen activator;
rt-PA) in patients with ischaemic stroke. The lesion must be of no more than
3 hours' duration, and there should be no evidence of infarction on
computerised tomography scan. This potentially dangerous therapy requires
expert management, since there is a high risk of severe and fatal
haemorrhage if the strict principles for its use are not scrupulously
adhered to. Neuroresuscitation is an exciting prospect and recent trials
suggest that useful agents will be available in the near future. These
putative therapies will be used to reduce the amount of brain damage and
thus diminish the degree of functional impairment. Rehabilitation should
begin as soon as the neurological disability is stabilised and, ideally,
should involve a multidisciplinary team approach.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
acetylsalicylic acid (drug therapy)
alteplase (drug therapy)
anticoagulant agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (diagnosis, drug therapy, prevention, surgery)
treatment outcome
EMTREE MEDICAL INDEX TERMS
anticoagulation
bleeding (complication)
brain edema (complication)
brain injury (complication)
carotid endarterectomy
cerebrovascular accident (drug therapy)
computer assisted tomography
fluid intake
human
lung embolism (complication)
nutritional support
patient monitoring
pneumonia (complication)
practice guideline
priority journal
review
risk factor
scoring system
transient ischemic attack (drug therapy)
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alteplase (105857-23-6)
EMBASE CLASSIFICATIONS
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1998204305
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 501
TITLE
A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM
sleep behavior disorder in 33 polysomnographically confirmed cases
AUTHOR NAMES
Schenck C.H.
Boyd J.L.
Mahowald T.W.
AUTHOR ADDRESSES
(Schenck C.H.; Boyd J.L.) Department of Psychiatry, Hennepin County Medical
Center, .
(Mahowald T.W.) Department of Neurology, Hennepin County Medical Center, .
(Schenck C.H.) Hennepin County Medical Center, Department of Psychiatry
(844), 701 Park Avenue South, Minneapolis, MN 55415, United States.
CORRESPONDENCE ADDRESS
C.H. Schenck, Hennepin County Medical Center, Department of Psychiatry, 701
Park Avenue South, Minneapolis, MN 55415, United States.
SOURCE
Sleep (1997) 20:11 (972-981). Date of Publication: 1997
ISSN
0161-8105
BOOK PUBLISHER
American Academy of Sleep Medicine, 1 Westbrook Corporate Center, Suite 920,
Westchester, United States.
ABSTRACT
A series of 33 patients with combined (injurious) sleepwalking, sleep
terrors, and rapid eye movement (REM) sleep behavior disorder (viz.
'parasomnia overlap disorder') was gathered over an 8-year period. Patients
underwent clinical and polysomnographic evaluations. Mean age was 34 ± 14
(SD) years; mean age of parasomnia onset was 15 ± 16 years (range 1-66); 70%
(n = 23) were males. An idiopathic subgroup (n = 22) had a significantly
earlier mean age of parasomnia onset (9 ± 7 years) than a symptomatic
subgroup (n = 11) (27 ± 23 years, p = 0.002), whose parasomnia began with
either of the following: neurologic disorders, n = 6 [congenital Mobius
syndrome, narcolepsy, multiple sclerosis, brain tumor (and treatment), brain
trauma, indeterminate disorder (exaggerated startle response/atypical
cataplexy)]; nocturnal paroxysmal atrial fibrillation, n = 1; posttraumatic
stress disorder/major depression, n = 1; chronic ethanol/amphetamine abuse
and withdrawal, n = 1; or mixed disorders (schizophrenia, brain trauma,
substance abuse), n = 2. The rate of DSM-III-R (Diagnostic and Statistical
Manual, 3rd edition, revised) Axis I psychiatric disorders was not elevated;
group scores on various psychometric tests were not elevated. Forty-five
percent (n = 15) had previously received psychologic or psychiatric therapy
for their parasomnia, without benefit. Treatment outcome was available for n
= 20 patients; 90% (n = 18) had substantial parasomnia control with bedtime
clonazepam (n = 13), alprazolam and/or carbamazepine (n = 4), or self-
hypnosis (n = 1). Thus, 'parasomnia overlap disorder' is a treatable
condition that emerges in various clinical settings and can be understood
within the context of current knowledge on parasomnias and motor
control/dyscontrol during sleep.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
REM sleep
sleep disorder (diagnosis)
sleep walking (diagnosis)
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
clinical article
human
Moebius syndrome
neurologic disease
polysomnography
priority journal
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Psychiatry (32)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1998029002
MEDLINE PMID
9456462 (http://www.ncbi.nlm.nih.gov/pubmed/9456462)
COPYRIGHT
Copyright 2009 Elsevier B.V., All rights reserved.
RECORD 502
TITLE
Managing symptomatic heart failure in 1997: Strategies for the end- stage
patient
AUTHOR NAMES
McNamara D.
Alvarez R.J.
Rosenblum W.
Murali S.
Feldman A.
AUTHOR ADDRESSES
(McNamara D.; Alvarez R.J.; Rosenblum W.; Murali S.; Feldman A.) Heart
Institute, Univ. of Pittsburgh Medical Center, Pittsburgh, PA, United
States.
CORRESPONDENCE ADDRESS
D. McNamara, Heart Institute, Univ. of Pittsburgh Medical Center,
Pittsburgh, PA, United States.
SOURCE
IM - Internal Medicine (1997) 18:6 (18-24). Date of Publication: 1997
ISSN
1056-9286
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
captopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
digoxin (clinical trial, drug dose, drug therapy)
dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical
trial, drug dose, drug therapy)
diuretic agent (adverse drug reaction, drug dose, drug therapy)
furosemide (adverse drug reaction, drug dose, drug therapy)
inotropic agent (clinical trial, drug dose, drug therapy)
EMTREE DRUG INDEX TERMS
amiodarone (clinical trial, drug dose, drug therapy)
amlodipine (clinical trial, drug therapy)
angiotensin receptor antagonist (clinical trial, drug dose, drug therapy)
beta adrenergic receptor blocking agent (clinical trial, drug therapy)
bucindolol (clinical trial, drug therapy)
bumetanide (adverse drug reaction, drug dose, drug therapy)
calcium channel blocking agent (clinical trial, drug therapy)
cardiac glycoside (clinical trial, drug therapy)
carvedilol (clinical trial, drug therapy)
enalapril (adverse drug reaction, clinical trial, drug dose, drug therapy)
etacrynic acid (adverse drug reaction, drug dose, drug therapy)
hydralazine (clinical trial, drug combination, drug dose, drug therapy)
hydrochlorothiazide (adverse drug reaction, drug dose, drug therapy)
isosorbide dinitrate (clinical trial, drug combination, drug dose, drug
therapy)
lisinopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
losartan (clinical trial, drug dose, drug therapy)
metolazone (adverse drug reaction, drug dose, drug therapy)
phosphodiesterase inhibitor (adverse drug reaction, clinical trial, drug
therapy)
piperanometozine (clinical trial, drug dose, drug therapy, pharmacology)
potassium sparing diuretic agent (drug dose, drug therapy)
spironolactone (drug dose, drug therapy)
triamterene (drug dose, drug therapy)
unindexed drug
warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart failure (drug therapy, surgery)
EMTREE MEDICAL INDEX TERMS
anticoagulant therapy
assisted circulation
atrial fibrillation (drug therapy)
cardiovascular disease (drug therapy, surgery)
clinical trial
controlled study
coughing (side effect)
dietary intake
exercise
female
heart transplantation
heart ventricle arrhythmia (drug therapy, side effect)
human
hypokalemia (side effect)
hypomagnesemia (side effect)
intravenous drug administration
major clinical study
male
multicenter study
oral drug administration
patient education
review
sudden death
survival rate
thromboembolism (complication, drug therapy, prevention)
treatment planning
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
amlodipine (88150-42-9)
bucindolol (71119-11-4)
bumetanide (28395-03-1)
captopril (62571-86-2)
carvedilol (72956-09-3)
digoxin (20830-75-5, 57285-89-9)
enalapril (75847-73-3)
etacrynic acid (58-54-8)
furosemide (54-31-9)
hydralazine (304-20-1, 86-54-4)
hydrochlorothiazide (58-93-5)
isosorbide dinitrate (87-33-2)
lisinopril (76547-98-3, 83915-83-7)
losartan (114798-26-4)
metolazone (17560-51-9)
piperanometozine (81840-15-5)
spironolactone (52-01-7)
triamterene (396-01-0)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cancer (16)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1997243470
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 503
TITLE
Stroke is an emergency
AUTHOR ADDRESSES
SOURCE
Disease-a-Month (1996) 42:4 (202-264). Date of Publication: 1996
ISSN
0011-5029
BOOK PUBLISHER
Mosby Inc., 11830 Westline Industrial Drive, St. Louis, United States.
ABSTRACT
Stroke is an emergency. Ischemic stroke is similar to myocardial infarction
in that the pathogenesis is loss of blood supply to the tissue, which can
result in irreversible damage if blood flow is not restored quickly. Public
education is needed to emphasize the warning signs of stroke. Patients
should seek medical help immediately, using emergency transport systems.
Therapy geared toward minimizing the damage from an acute stroke should be
started without delay in the emergency room. This includes measures to
protect brain tissue, support perfusion pressure, and minimize cerebral
edema. Strategies for improving recovery should also begin immediately. All
major medical centers need stroke teams and stroke units. Stroke prevention
should be given high priority as a public health strategy. Risk factor
management should be part of general health care and should begin in
childhood, with emphasis on nutrition, exercise, weight control, and
avoidance of tobacco. Health screening and early treatment of hypertension
and hypercholesterolemia has decreased the incidence of stroke and heart
disease, but these efforts need to be expanded to reach all segments of the
population. Basic research has opened the door to new therapies aimed at
re-establishing blood flow and limiting tissue damage. Clinical trials have
already led to changes in stroke prevention, including studies of carotid
endarterectomy and ticlopidine and warfarin therapy (for patients with
atrial fibrillation). Trials in progress are testing the usefulness of
ancrod, neuroprotective agents, antioxidant agents, anti- inflammatory
agents, low-molecular-weight heparin, thrombolytic drugs, and angioplasty.
Any delay starting therapy after an acute stroke will result in progressive,
irreversible loss of brain tissue. Clinicians should remember that for a
stroke patient, time is brain tissue.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
acetylsalicylic acid (drug comparison, drug dose, drug therapy,
pharmacology)
ancrod (clinical trial, drug therapy, pharmacology)
glutamate receptor antagonist (adverse drug reaction, clinical trial,
pharmacology)
heparin (drug administration, drug comparison, drug therapy)
intercellular adhesion molecule 1 antibody (clinical trial, pharmacology)
low molecular weight heparin (clinical trial, drug combination, drug
comparison, drug therapy)
ticlopidine (adverse drug reaction, clinical trial, drug comparison, drug
therapy, pharmacology)
warfarin (adverse drug reaction, clinical trial, drug administration, drug
therapy, pharmacology)
EMTREE DRUG INDEX TERMS
antibiotic agent
anticoagulant agent (drug combination, drug therapy)
antiinflammatory agent (clinical trial)
antioxidant (clinical trial)
antithrombocytic agent (drug combination, drug therapy)
blood clotting factor (endogenous compound)
clonidine
codeine (drug therapy)
estrogen (clinical trial, endogenous compound)
fibrin (endogenous compound)
fibrinolytic agent (clinical trial, drug combination, drug therapy)
free radical
glucose (endogenous compound)
glutamic acid (drug toxicity)
glyceryl trinitrate (drug administration, drug therapy)
hydrogen peroxide
insulin (drug therapy)
phospholipid antibody (endogenous compound)
prazosin
steroid (drug therapy)
unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cerebrovascular accident (diagnosis, drug therapy, epidemiology, etiology,
prevention, rehabilitation, surgery)
EMTREE MEDICAL INDEX TERMS
angioplasty
bleeding (side effect)
bypass surgery
carotid endarterectomy
clinical trial
computer assisted tomography
echography
education
embolism (drug therapy, prevention)
emergency ward
heart infarction (drug therapy)
human
hyperglycemia (drug therapy)
hypertension (diagnosis, drug therapy)
intravenous drug administration
nonhuman
nuclear magnetic resonance imaging
oral drug administration
prothrombin time
review
risk factor
subcutaneous drug administration
tobacco
transient ischemic attack (drug therapy)
DRUG TRADE NAMES
coumadin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
ancrod (9046-56-4)
clonidine (4205-90-7, 4205-91-8, 57066-25-8)
codeine (76-57-3)
fibrin (9001-31-4)
glucose (50-99-7, 84778-64-3)
glutamic acid (11070-68-1, 138-15-8, 56-86-0, 6899-05-4)
glyceryl trinitrate (55-63-0)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
hydrogen peroxide (7722-84-1)
insulin (9004-10-8)
prazosin (19216-56-9, 19237-84-4)
ticlopidine (53885-35-1, 55142-85-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Neurology and Neurosurgery (8)
Radiology (14)
Rehabilitation and Physical Medicine (19)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1996133105
COPYRIGHT
Copyright 2011 Elsevier B.V., All rights reserved.
RECORD 504
TITLE
Cardioversion of atrial fibrillation
AUTHOR NAMES
Lip G.Y.H.
Watson R.D.S.
Singh S.P.
AUTHOR ADDRESSES
(Lip G.Y.H.; Watson R.D.S.; Singh S.P.) University Department of Medicine,
City Hospital, Birmingham, United Kingdom.
CORRESPONDENCE ADDRESS
G.Y.H. Lip, University Department of Medicine, City Hospital, Birmingham,
United Kingdom.
SOURCE
British Medical Journal (1996) 312:7023 (112-115). Date of Publication: 1996
ISSN
0959-8146
ABSTRACT
Cardioversion to sinus rhythm should be considered for all suitable patients
in atrial fibrillation. In the short term both pharmacological and
electrical cardioversion restore sinus rhythm. Prophylactic treatment with
antiarrhythmic drugs is advisable after cardioversion in high risk patients
in view of the high relapse rate. Anticoagulants should be started before
non-emergency cardioversion - ideally two to three weeks before - and
continued for at least four weeks after cardioversion in patients with
atrial fibrillation of > 48 hours' duration.
EMTREE DRUG INDEX TERMS
amiodarone (drug therapy)
antiarrhythmic agent (adverse drug reaction, drug therapy)
anticoagulant agent (drug therapy)
digoxin (adverse drug reaction, drug therapy)
flecainide (adverse drug reaction, drug therapy)
heparin (drug therapy)
propafenone (drug therapy)
quinidine (adverse drug reaction, drug therapy)
verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, therapy)
cardioversion
sinus rhythm
EMTREE MEDICAL INDEX TERMS
article
electrocardiography
exercise
heart repolarization
high risk patient
human
intravenous drug administration
oral drug administration
priority journal
prognosis
recurrence risk
side effect
thromboembolism (complication, drug therapy, prevention)
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
digoxin (20830-75-5, 57285-89-9)
flecainide (54143-55-4)
heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
propafenone (34183-22-7, 54063-53-5)
quinidine (56-54-2)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1996021205
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 505
TITLE
Control of rapid ventricular response by laser catheter modification of the
atrioventricular node in a patient with medically refractory atrial
fibrillation
AUTHOR NAMES
Weber H.P.
Heinze A.
AUTHOR ADDRESSES
(Weber H.P.; Heinze A.) Laser Electrophysiology Laboratory, Medical
Department, Harlaching Hosp., University of Munich, Munich, Germany.
CORRESPONDENCE ADDRESS
H.P. Weber, Laser Electrophysiology Laboratory, Medical Department,
Harlaching Hosp., University of Munich, Munich, Germany.
SOURCE
European Journal of Cardiac Pacing and Electrophysiology (1995) 5:4
(215-217). Date of Publication: 1995
ISSN
0939-6780
ABSTRACT
An 84-year-old female with chronic atrial fibrillation and drug resistant
rapid ventricular response underwent laser catheter modification of the
atrioventricular node. The procedure reduced mean heart rate during exercise
from 148 ± 50 to 89 ± 25 beats min(-1) and was without complication.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (therapy)
catheter ablation
heart atrioventricular node
laser coagulation
EMTREE MEDICAL INDEX TERMS
aged
article
case report
exercise
female
heart muscle
heart rate
human
priority journal
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1995353916
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 506
TITLE
Safety and antithrombotic effects of fixed low-dose warfarin-aspirin
combination in rheumatic mitral stenosis associated with atrial fibrillation
AUTHOR NAMES
Handjani A.M.
Khosropanah S.
Habibzadeh F.
AUTHOR ADDRESSES
(Handjani A.M.; Khosropanah S.; Habibzadeh F.) Division of Cardiology,
Department of Internal Medicine, Shiraz Univ. of Medical Sciences, Shiraz,
Iran.
CORRESPONDENCE ADDRESS
A.M. Handjani, Division of Cardiology, Department of Internal Medicine,
Shiraz Univ. of Medical Sciences, Shiraz, Iran.
SOURCE
Iranian Journal of Medical Sciences (1995) 20:3-4 (93-95). Date of
Publication: 1995
ISSN
0253-0716
ABSTRACT
The incidence of thromboembolic complications in cases of mitral stenosis
(MS) associated with atrial fibrillation (AF) is around 20%. To prevent this
complication, warfarin and aspirin is administered to keep the INR between 2
and 3. However, this treatment is associated with increased risk of
hemorrhagic episodes. Fifty-five patients with both rheumatic MS and AF,
were randomly divided into two groups; Twenty-five patients received 2,5-mg
of warfarin and 100-mg of aspirin daily, and thirty patients served as
control. The mean ± SD INR in the treatment group (1.58 ± 0.45) was
significantly higher than that of the control group (1.175 ± 0.21) (p <
0.001). Twenty per cent of the control group developed thromboembolic
complications. However, none of the patients in the treatment group had any
thromboembolic or hemorrhagic events. No inter- or intra-patient INR
variability was seen. Therefore, the use of low-dose warfarin-aspirin
combination for the prevention of thromboembolic complications in patients
with MS associated with AF is effective and safe, and thus, is strongly
suggested.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
acetylsalicylic acid (drug combination, drug therapy)
warfarin (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy)
mitral valve stenosis (drug therapy)
thromboembolism (complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
clinical trial
controlled study
drug efficacy
drug safety
human
major clinical study
randomized controlled trial
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1996181202
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 507
TITLE
Clinical interest of once-daily felodipine extended-release in patients with
mixed and exertional angina: Results of a double-blind crossover study
versus amlodipine
AUTHOR NAMES
Corradi L.
Colombo G.
Ravera E.
Lotto A.
AUTHOR ADDRESSES
(Corradi L.; Colombo G.; Ravera E.; Lotto A.) Schering-Plough SpA, Via
Ripamonti 89, 20141 Milan, Italy.
CORRESPONDENCE ADDRESS
E. Ravera, Schering-Plough SpA, Via Ripamonti 89, 20141 Milan, Italy.
SOURCE
Clinical Drug Investigation (1995) 9:6 (324-333). Date of Publication: 1995
ISSN
0114-2402
ABSTRACT
24 patients with mixed or exertional angina pectoris were enrolled in a
double-blind crossover clinical study to compare the efficacy and safety of
felodipine extended-release (ER) 10 mg once daily versus amlodipine 10 mg
once daily. Admission criteria did not restrict patient selection according
to exercise endurance. The crossover treatment with two 4-week phases
started after washout of all antianginal drugs except sublingual nitrates.
Maximal multistage exercise tests were performed before initial
administration at baseline and 23 hours after the last dose of each of the 2
study drugs. Two patients dropped out, so that efficacy could be evaluated
on an intention-to-treat basis in 22 patients (15 with mixed and 7 with
exertional angina). At baseline the ischaemic threshold (time to onset of ST
depression 21 mm) was high, with a mean of 485.3 ± 174.8 seconds (n = 22,
range 180 to 840 seconds). After 4 weeks of treatment, time to test
termination showed an increase with both drugs, which attained statistical
significance only with felodipine ER (n = 22, +9.03%; p < 0.05). The
duration of ischaemia showed a decrease that was more evident with
felodipine ER (n = 17, -31.19%) than with amlodipine (n = 18, -16.70%),
without straining statistical significance in either case. The significant
decrease in maximal ST depression was more evident with felodipine ER (n =
17, -27.72%; p < 0.001) than with amlodipine (n = 18, -19.12%; p < 0.01).
Furthermore, the increase in the time to onset of angina attained
statistical significance with felodipine ER (n = 7, +34.25%; p < 0.05) and
not with amlodipine (n = 10, +20.72%). The decrease in the duration of
angina also attained statistical significance with felodipine ER (n = 7,
-24.34%; p < 0.05) and not with amlodipine (n = 10, -24.58%. Adverse
reactions occurred with felodipine ER in 2 of 24 (8.3%) cases and with
amlodipine in 6 of 24 (25%) cases. The most frequent adverse reaction was
mild to moderate peripheral oedema that occurred only during treatment with
amlodipine (16.7% cases). The possible pharmacological rationale for the
better therapeutic results obtained with felodipine ER is discussed by
considering both its efficacy and safety.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
amlodipine (adverse drug reaction, clinical trial, drug comparison, drug
therapy)
felodipine (adverse drug reaction, clinical trial, drug comparison, drug
therapy, pharmaceutics)
EMTREE DRUG INDEX TERMS
antacid agent
antilipemic agent
antithrombocytic agent
anxiolytic agent
glyceryl trinitrate (drug therapy)
nonsteroid antiinflammatory agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
angina pectoris (drug therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
atrial fibrillation (side effect)
clinical article
clinical trial
controlled study
crossover procedure
disease duration
double blind procedure
drug efficacy
drug formulation
drug safety
edema (side effect)
exercise test
female
headache (side effect)
heart muscle ischemia (drug therapy)
heart palpitation (side effect)
human
male
oral drug administration
patient selection
priority journal
randomized controlled trial
ST segment depression
statistical analysis
sublingual drug administration
time
CAS REGISTRY NUMBERS
amlodipine (88150-42-9)
felodipine (72509-76-3)
glyceryl trinitrate (55-63-0)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1995180228
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 508
TITLE
Atrial tissue conductivity and refractoriness in patients with lone
paroxysmal atrial fibrillation
AUTHOR NAMES
Papadopoulos C.L.
Sakadamis G.C.
Kononidis I.E.
Kotridis P.S.
Kyriakou P.A.
Koukoulekidis G.N.
Poulantzas N.
Gitsios C.T.
AUTHOR ADDRESSES
(Papadopoulos C.L.; Sakadamis G.C.; Kononidis I.E.; Kotridis P.S.; Kyriakou
P.A.; Koukoulekidis G.N.; Poulantzas N.; Gitsios C.T.) Second Department of
Cardiology, Aristotle University, Thessaloniki, Greece.
CORRESPONDENCE ADDRESS
C.L. Papadopoulos, Second Department of Cardiology, Aristotle University,
Thessaloniki, Greece.
SOURCE
European Journal of Cardiac Pacing and Electrophysiology (1995) 5:2 (90-96).
Date of Publication: 1995
ISSN
0939-6780
ABSTRACT
Eighty three patients were submitted to electrophysiological study during
which induction of atrial fibrillation was attempted and atrial
electrophysiological parameters (effective refractory period and intraatrial
conduction time) were evaluated. According to the results of the
electrophysiological study and medical history patients were divided into
four groups: a) Group SI comprised 19 patients with spontaneous and induced
episodes of atrial fibrillation. b) Group S comprised 23 patients with
spontaneous but not induced episodes of atrial fibrillation. c) Group I
comprised 13 patients with only induced episodes of atrial fibrillation. d)
Group C comprised 28 patients without spontaneous or induced episodes of
atrial. fibrillation who served as controls. Group SI had a normal effective
refractory period but a long intra-atrial conduction time. Group I had an
effective refractory period shorter than normal under basal conditions which
was even shorter during rapid pacing. Intra-atrial conduction time in this
group was normal under basal conditions but was highly increased during
rapid pacing. Group S had a normal effective refractory period and a
slightly but not significantly shorter intra-atrial conduction time compared
with normal values. In conclusion a long intra-atrial conduction time is a
determinant factor in the pathogenesis of atrial fibrillation while
effective refractory period plays a facilitating role. Other extrinsic
factors (e.g. parasympathetic activity) not operating during the
electrophysiological study might also play a critical role in the induction
of atrial fibrillation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (etiology)
heart atrium conduction
heart electrophysiology
EMTREE MEDICAL INDEX TERMS
adolescent
adult
aged
article
controlled study
female
heart pacing
human
major clinical study
male
priority journal
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1995175478
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 509
TITLE
Short term amiodarone treatment facilitates electrical cardioversion in
patients with chronic atrial flutter/fibrillation
AUTHOR NAMES
Jong G.-P.
Hou Z.-Y.
Juang G.-H.
Chen C.-Y.
AUTHOR ADDRESSES
(Jong G.-P.; Hou Z.-Y.; Juang G.-H.; Chen C.-Y.) Division of Cardiology,
Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813, Taiwan.
CORRESPONDENCE ADDRESS
C.-Y. Chen, Division of Cardiology, Veterans General Hospital, 386 Ta-Chung
1st Road, Kaohsiung 813, Taiwan.
SOURCE
Acta Cardiologica Sinica (1995) 11:1 (39-46). Date of Publication: 1995
ISSN
1011-6842
ABSTRACT
Background. Conversion of atrial flutter/fibrillation, either by electrical
cardioversion or by drugs, often ameliorates patients' symptoms, reduces the
risk of ischemic stroke and improves cardiovascular hemodynamics. To
evaluate whether four week therapy of amiodarone (200 mg Tid, PO) can
facilitate the success of electrical cardioversion (EC), a prospective trial
was performed for two groups of patients. Methods. Eighty-seven cases were
collected from December 1991 to October 1993, all with chronic atrial
flutter (AF)/fibrillation(Af) for more than six months and adequate
anticoagulation. For AF, EC started with energy 10, then 20, 50, 100, 200,
300 and up to 360 Joules; for Af, EC started with 100, and then 200, 300,
and up to 360 Joules. Success of cardioversion indicated the restoration of
normal sinus rhythm (NSR), and lasted for at least 24 hours. Group 1, 43
patients (36 males, 7 females, and aged 62 ± 11 years) served as controls,
receiving no amiodarone. Group 2, 44 patients (38 males, 6 females, aged 63
± 12 years) received amiodarone therapy before EC was carried out. Results.
Seven patients (16%) in Group 2, converted on amiodarone alone. Success rate
of EC was 58% and 87%, respectively, for Groups 1 and 2. The target and
accumulated energy required for successful EC were significantly higher in
Group 1 (293 ± 63 and 596 ±240 J) than in Group 2 (176 ± 93 and 318 ± 220 J)
(p < 0.05). There was no difference between surgery and balloon
valvuloplasty patients in the success rate or energy required for EC. No
Group 2 patient suffered any side effect from amiodarone throughout the
course of the study. Conclusion. Short-term amiodarone does facilitate the
success of EC and maintenance of NSR during short-term follow-up, without
significant side effect.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
amiodarone (drug comparison, drug therapy)
EMTREE DRUG INDEX TERMS
placebo (drug comparison)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation (drug therapy, therapy)
heart atrium flutter (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
adult
aged
article
cardioversion
chronic disease
clinical trial
controlled study
drug effect
facilitation
female
human
major clinical study
male
CAS REGISTRY NUMBERS
amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, Chinese
EMBASE ACCESSION NUMBER
1995122138
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 510
TITLE
A comparison between single atrial and dual chamber rate adaptive (AAIR and
DDDR) and non adaptive AAI and DDD cardiac pacing using cardiopulmonary
exercise testing in patients with atrial chronotropic incompetence
AUTHOR NAMES
Lamaison D.
Page E.
Aupetit J.F.
Defaye P.
Rozand J.Y.
Mouton E.
Salvi R.
AUTHOR ADDRESSES
(Lamaison D.; Page E.; Aupetit J.F.; Defaye P.; Rozand J.Y.; Mouton E.;
Salvi R.) Service de Cardiologie, Hopital G Montpied Place, H Dunant, 63000
Clermont-Ferrand, France.
CORRESPONDENCE ADDRESS
D. Lamaison, Service de Cardiologie, Hopital G Montpied Place, H Dunant,
63000 Clermont-Ferrand, France.
SOURCE
European Journal of Cardiac Pacing and Electrophysiology (1993) 3:3
(197-204). Date of Publication: 1993
ISSN
0939-6780
ABSTRACT
In 19 patients in whom atrial chronotropic incompetence had been
demonstrated before pacemaker implantation, (defined as heart rate during
maximal treadmill exercise < 100 beats/mn) a minute ventilation sensor, dual
chamber rate-adaptive pacemaker was implanted (META DDDR 1250, Telectronics,
Englewood, Colorado). Eleven had associated sino-atrial block, 7 had
brady-tachy syndrome, 2 had second or third degree atrioventricular block.
An incremental, symptom-limited, single blind randomly assigned
cardiopulmonary exercise test using a bicycle ergometer was performed in
respectively DDD and DDDR or AAI and AAIR modes on the same day, 137 days
(32-418) after pacemaker implantation in 14 patients. Exercise tests could
not be achieved in five patients, due to permanent atrial fibrillation in 4
and pacemaker failure in one. Despite partial regression or complete
disappearance of the atrial chronotropic incompetence in some patients, the
rate adaptive, as compared with the non adaptive mode, significantly
improved exercise duration (512 ± 41 s vs 471 ± 38 s p = 0.028), maximal
work rate (96.7 ± 41.4 W vs 88.5-38.7 W, p = 0.001), the time of occurrence
of anaerobic threshold (398 ± 148 s vs 327 ± 133 s p = 0.0015), the oxygen
uptake at anaerobic threshold (14.97 ± 5.11 ml/kg/mn vs 12.96 ± 4.55
ml/kg/mn, p = 0.0015), and the work rate at anaerobic threshold (75 ± 42 W
vs 57.14 ± 37 W, p = 0.0032). Thus AAIR or DDDR mode is strongly recommended
in patients with atrial chronotropic incompetence.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart atrium
heart failure (therapy)
heart pacing
EMTREE MEDICAL INDEX TERMS
adult
aged
article
artificial heart pacemaker
atrial fibrillation (complication)
atrioventricular block (complication, therapy)
bicycle ergometry
clinical article
clinical trial
controlled study
exercise test
female
heart rate
heart sinoatrial block (complication, therapy)
human
intermethod comparison
lung minute volume
male
oxygen consumption
pacemaker failure (complication)
randomized controlled trial
sinus node disease (therapy)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English, French, German
EMBASE ACCESSION NUMBER
1993351284
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 511
TITLE
Weekly clinicopathological exercises
AUTHOR NAMES
Nash I.S.
Dinsmore R.E.
Fallon J.T.
Hansell D.M.
Gilbert J.
AUTHOR ADDRESSES
(Nash I.S.; Dinsmore R.E.; Fallon J.T.; Hansell D.M.; Gilbert J.)
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United
States.
CORRESPONDENCE ADDRESS
I.S. Nash, Massachusetts General Hospital, Harvard Medical School, Boston,
MA, United States.
SOURCE
New England Journal of Medicine (1993) 330:2 (126-134). Date of Publication:
1993
ISSN
0028-4793
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
constrictive pericarditis (diagnosis, etiology, therapy)
mitral valve regurgitation (diagnosis, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
adult
amyloidosis
angiocardiography
article
asbestosis
atrial fibrillation
calcification
case report
clinical feature
differential diagnosis
heart muscle biopsy
hemochromatosis
human
male
pericardiectomy
priority journal
recurrent disease
sarcoidosis
tuberculosis
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1994027950
FULL TEXT LINK
http://dx.doi.org/10.1056/NEJM199401133300209
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 512
TITLE
The safety and utility of exercise testing in octogenarians
AUTHOR NAMES
Martin D.
Graboys T.B.
AUTHOR ADDRESSES
(Martin D.; Graboys T.B.) Lown Cardiovascular Laboratory, 21 Longwood
Avenue, Boston, MA 02115, United States.
CORRESPONDENCE ADDRESS
T.B. Graboys, Lown Cardiovascular Laboratory, 21 Longwood Avenue, Boston, MA
02115, United States.
SOURCE
American Journal of Noninvasive Cardiology (1992) 6:6 (345-348). Date of
Publication: 1992
ISSN
0258-4425
ABSTRACT
We reviewed 112 treadmill exercise tests performed by 62 octogenarian
patients between 1980 and 1988. Forty were male, and mean age was 82 with
range 80-88. The indications for testing were comparable to those in a
younger population. The average exercise duration was 252 s, and there was a
wide range of hemodynamic responses to exercise with a peak heart rate range
of 50-210 bpm, and peak blood pressure range of 90-250/40-120 mm Hg.
Exercise provoked repetitive ventricular ectopy in 23 (21%) tests, and
atrial fibrillation was present during 13 (12%). No life-threatening
complications were provoked by exercise, and no tests led to
hospitalization. No patient required cardioversion. We conclude that
symptom-limited treadmill testing in octogenarians can be safely and
usefully performed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aged
exercise test
safety
EMTREE MEDICAL INDEX TERMS
article
atrial fibrillation
blood pressure
female
heart rate
heart ventricle extrasystole
hemodynamics
human
human experiment
male
treadmill exercise
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1993040357
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 513
TITLE
Lone atrial fibrillation. It needn't slow down an active patient
AUTHOR NAMES
Cantwell J.D.
Lammert S.
Kessler C.
AUTHOR ADDRESSES
(Cantwell J.D.; Lammert S.; Kessler C.) Preventive Medicine Center, Georgia
Baptist Hospital, 300 Boulevard NE, Atlanta, GA 30312
CORRESPONDENCE ADDRESS
Preventive Medicine Center, Georgia Baptist Hospital, 300 Boulevard NE,
Atlanta, GA 30312
SOURCE
Physician and Sportsmedicine (1991) 19:8 (71-72+75-76+78-82). Date of
Publication: 1991
ISSN
0091-3847
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
alcohol
atenolol (drug therapy)
caffeine
digoxin (drug therapy)
quinidine gluconate (drug therapy)
warfarin (drug therapy)
EMTREE DRUG INDEX TERMS
acetylsalicylic acid (drug therapy)
antiarrhythmic agent (drug therapy)
propranolol (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
atrial fibrillation (complication, drug therapy, etiology, rehabilitation,
therapy)
cold
drinking
exercise
jogging
sports medicine
Wolff Parkinson White syndrome (complication)
EMTREE MEDICAL INDEX TERMS
adult
article
cerebrovascular accident (etiology)
clinical article
heart arrhythmia (complication, drug therapy, etiology, rehabilitation,
therapy)
human
male
paroxysmal supraventricular tachycardia (drug therapy, etiology,
rehabilitation)
thyrotoxicosis (complication)
DRUG TRADE NAMES
aspirin
CAS REGISTRY NUMBERS
acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
alcohol (64-17-5)
atenolol (29122-68-7)
caffeine (30388-07-9, 58-08-2)
digoxin (20830-75-5, 57285-89-9)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
quinidine gluconate (7054-25-3)
warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Occupational Health and Industrial Medicine (35)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1991349342
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 514
TITLE
Superior vena cava and ventricular inflow in constrictive pericarditis and
restrictive cardiomyopathy as measured by pulsed doppler echocardiography
AUTHOR NAMES
Izumi S.
Miyatake K.
Beppu S.
Morioka S.
Nagata S.
Sakakibara H.
Moriyama K.
Nimura Y.
AUTHOR ADDRESSES
(Izumi S.; Miyatake K.; Beppu S.; Morioka S.; Nagata S.; Sakakibara H.;
Moriyama K.; Nimura Y.) National Cardiovascular Center, Research Institute
and Hospital, Osaka
CORRESPONDENCE ADDRESS
National Cardiovascular Center, Research Institute and Hospital, Osaka
SOURCE
Journal of Cardiovascular Technology (1990) 9:1 (19-24). Date of
Publication: 1990
ISSN
0730-8396
ABSTRACT
In patients with either constrictive pericarditis (13 cases) or restrictive
cardiomyopathy (6 cases), right atrial filling and both right and left
ventricular filling were analyzed by pulsed Doppler echocardiography.
Sixteen healthy volunteers, and 14 cases with lone atrial fibrillation,
served as controls. In patients with constrictive pericarditis, a reduction
in the right atrial filling velocity during ventricular systole, and a
shortening in the right atrial filling time during systole and diastole,
were noted. In patients with restrictive myocardial disease, similar
findings were noted during ventricular systole, but no difference from
healthy subjects was noted during diastole. Regarding ventricular filling,
in constrictive pericarditis a shortening of the rapid filling time in the
right ventricle was noted, while the restrictive myocardial disease patients
showed an abnormality only in the early phase of the left ventricular rapid
filling and no abnormality in right ventricular rapid filling. We conclude
that right atrial and ventricular fillings in constrictive pericarditis and
restrictive myocardial disease are different from normal and from each
other.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardiomyopathy
pericarditis
EMTREE MEDICAL INDEX TERMS
adult
article
clinical article
Doppler echocardiography
female
human
male
methodology
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Physiology (2)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1990331971
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 515
TITLE
Adaptive rate pacing at submaximal exercise: The importance of the
programmed upper rate
AUTHOR NAMES
Lau C.-P.
Leung W.-H.
Wong C.-K.
Cheng C.-H.
Tai Y.-T.
AUTHOR ADDRESSES
(Lau C.-P.; Leung W.-H.; Wong C.-K.; Cheng C.-H.; Tai Y.-T.) Department of
Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
CORRESPONDENCE ADDRESS
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong
Kong
SOURCE
Journal of Electrophysiology (1989) 3:4 (283-288). Date of Publication: 1989
ISSN
0892-1059
ABSTRACT
The contributions of rate response and different programmed upper rates to
submaximal exercise were studied in 12 patients with implanted adaptive rate
pacemakers (9 Meta, 3 Activitrax). Their median age was 69 years (range
33-80). All were paced from the right ventricle except for one patient with
sinoatrial disease who received an atrial Meta pacemaker. In the constant
rate pacing (SSI) mode, the reproducibility of a submaximal stress test
(maximum distance covered within a 12-minute walking test) was investigated
by repeating the test three times. An initial training effect was observed
between the first and the second test, but no further increase in walking
distance occurred between the second and third test and the distances
covered were highly reproducible (r = 0.99). The rate adaptive function was
activated with the upper rate randomly programmed to 100, 125, 150, and 165
beats/min. Compared with exercise in the SSI mode, rate adaptive pacing with
the upper rate programmed to 125 and 150 beats/min resulted in enhancement
of exercise distance (4.7% ± 1.2% and 4.4% ± 1.2%, respectively, P < 0.005).
Upper rates of 100 and 165 beats/min did not improve submaximal exercise
performance, and at an upper rate of 165 beats/min, three patients developed
complications (angina, dyspnea, and atrial fibrillation). It is concluded
that the 12-minute walking test is a reproducible method to assess exercise
capacity in pacemaker patients. Adaptive rate pacing improved exercise
performance during daily activities, although the extent of the benefit
appeared to be small and dependent on the programmed upper rate. An exercise
test such as a 12-minute walking test should be performed before a high
upper rate is programmed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart rate
pacemaker
tachycardia
EMTREE MEDICAL INDEX TERMS
adult
aged
clinical article
clinical trial
controlled study
human
randomized controlled trial
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1989261149
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 516
TITLE
Comparison of VVIR, DDD, and DDDR pacing
AUTHOR NAMES
Jutzy R.V.
Isaeff D.M.
Bansal R.C.
Florio J.
Marsa R.J.
Jutzy K.R.
AUTHOR ADDRESSES
(Jutzy R.V.; Isaeff D.M.; Bansal R.C.; Florio J.; Marsa R.J.; Jutzy K.R.)
Section of Cardiology, Department of Medicine, Loma Linda University Medical
Center, Loma Linda, CA 92354
CORRESPONDENCE ADDRESS
Section of Cardiology, Department of Medicine, Loma Linda University Medical
Center, Loma Linda, CA 92354
SOURCE
Journal of Electrophysiology (1989) 3:3 (194-201). Date of Publication: 1989
ISSN
0892-1059
ABSTRACT
In the past several years there has been continued improvement in pacemaker
technology, resulting in the availability of a large variety of pacemaker
generators and pacing modes. The introduction of single-chamber rate
modulated pacemakers provided a further improvement in pacing therapy. With
the recent introduction of dual-chamber rate responsive pacemakers, it is
now possible to more closely restore physiological function with pacing in a
large number of patients. In deciding which pacing mode is most beneficial
to a given patient, it is essential to understand the various
characteristics of the different pacing modes that are available. It is
essential to have knowledge of the underlying electrophysiological
characteristics of the patient and how they would be affected by the
different modes available. The VVIR mode will control bradycardia and
provide rate adaptation but at the expense of AV synchrony. The DDD mode
will control bradycardia and provide AV synchrony, but will not provide rate
adaptation in patients with chronotropic incompetence. The DDDR mode will
control bradycardia, maintain AV synchrony, and provide for rate adaptation
in the presence of chronotropic incompetence. The chronotropic response to
physiological stress and/or pacemaker syndrome are major determining factors
in the choice of the best pacing mode. The primary goal of pacing therapy is
to restore the heart function as close as possible to normal. When at all
possible, this should include provision of both AV synchrony and rate
modulation. The DDDR mode is preferable in most patients since it is capable
of providing both AV synchrony and rate response (except those with chronic
supraventricular arrhythmias). The VVIR mode is as effective in patients who
have chronic atrial fibrillation or frequent episodes of supraventricular
arrhythmias.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
artificial heart pacemaker
heart rate
EMTREE MEDICAL INDEX TERMS
exercise
human
short survey
therapy
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1989191770
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 517
TITLE
Rehabilitation in patients after commissurotomy and artificial valve
replacement
AUTHOR NAMES
Rudnicki S.
Slipko Z.
Wojtkowska E.
Latuchowska B.
Bilinska M.
AUTHOR ADDRESSES
(Rudnicki S.; Slipko Z.; Wojtkowska E.; Latuchowska B.; Bilinska M.)
Institute of Cardiology, 04-628 Warsaw
CORRESPONDENCE ADDRESS
Institute of Cardiology, 04-628 Warsaw
SOURCE
Rehabilitacia Supplementum (1988) 21:36-37 (20-26). Date of Publication:
1988
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
breathing exercise
ergometry
heart valve replacement
heart valve surgery
kinesiotherapy
valvuloplasty
EMTREE MEDICAL INDEX TERMS
adult
complication
education
female
human
major clinical study
male
rehabilitation
sex difference
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1989018396
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 518
TITLE
Maximal steptreadmill exercise and treadmill exercise by patients with
coronary heart disease: A comparison
AUTHOR NAMES
Holland G.J.
Weber F.
Heng M.K.
Reese S.S.
Marin J.J.
Vincent W.J.
Mayers M.M.
Hoffmann J.J.
Caston A.L.
AUTHOR ADDRESSES
(Holland G.J.; Weber F.; Heng M.K.; Reese S.S.; Marin J.J.; Vincent W.J.;
Mayers M.M.; Hoffmann J.J.; Caston A.L.) Exercise Physiology Laboratory,
California State University, Northridge, CA 91330
CORRESPONDENCE ADDRESS
Exercise Physiology Laboratory, California State University, Northridge, CA
91330
SOURCE
Journal of Cardiopulmonary Rehabilitation (1988) 8:2 (58+63-68). Date of
Publication: 1988
ISSN
0883-9212
ABSTRACT
Thirteen male patients from a phase III community cardiac rehabilitation
program were maximally exercise tested by use of a modified Bruce treadmill
protocol and a newly developed revolving-stair ergometer. The study design
provided for approximately equivalent metabolic work in each of four stages
on the two test modes. Results showed that there were no significant
differences in peak response to the two test modes as measured by maximal
oxygen consumption, maximal heart rate, maximal systolic blood pressure,
maximal ventilation, respiratory exchange ratio, and peak work time.
Significant differences in physiologic response were manifest only between
stages in the same exercise mode. The patients with cardiac disease did not
achieve predicted MET response on either of the two ergometry modes at
higher stages of work. No significant differences in clinical manifestations
were observed between conventional treadmill exercise and revolving-stair
ergometer exercise. Steptreadmill ergometry may be a valid alternative
ergometry mode for testing and training clinically stable and moderately fit
populations of patients with cardiac disease.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
coronary artery bypass graft
exercise test
heart infarction (rehabilitation)
ischemic heart disease
treadmill
EMTREE MEDICAL INDEX TERMS
adult
aged
clinical article
education
human
male
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
1988068595
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 519
TITLE
Transient thickening of left ventricular wall of the heart accompanied with
arrhythmias, atrio-ventricular conduction disturbances and decrease of
physical exercise capacity during the endurance training of 13 years old boy
AUTHOR NAMES
Karvonen J.
Uusitalo A.
AUTHOR ADDRESSES
(Karvonen J.; Uusitalo A.) Department of Clinical Physiology, University
Hospital, Tampere
CORRESPONDENCE ADDRESS
Department of Clinical Physiology, University Hospital, Tampere
SOURCE
International Journal of Sports Cardiology (1985) 2:1 (61-66). Date of
Publication: 1985
ISSN
0393-6066
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrioventricular block
endurance
heart arrhythmia
heart left ventricle hypertrophy
EMTREE MEDICAL INDEX TERMS
adolescent
age
case report
controlled study
diagnosis
etiology
heart
human
training
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Occupational Health and Industrial Medicine (35)
Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1986036957
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 520
TITLE
Induction of supraventricular tachyarrhythmia at rest and during exercise
with transesophageal atrial pacing in the electrophysiological evaluation of
asymptomatic athletes with cardiac preexcitation: Report on 56 consecutive
athletes
AUTHOR NAMES
Vergara G.
Disertori M.
Bettini R.
AUTHOR ADDRESSES
(Vergara G.; Disertori M.; Bettini R.) Divisione di Cardiologia e Centro
Aritmologico, Ospedale S. Chiara, Trento
CORRESPONDENCE ADDRESS
Divisione di Cardiologia e Centro Aritmologico, Ospedale S. Chiara, Trento
SOURCE
New Trends in Arrhythmias (1985) 1:3 (315-319). Date of Publication: 1985
ISSN
0393-5302
ABSTRACT
56 symptom-free athletes with cardiac preexcitation (W.P.W.) and without
heart disease underwent a study protocol whose end-point was the induction
of supraventricular tachyarrhythmia (S.T.A.), i.e. atrial fibrillation or,
if not possible, atrial flutter or atrial tachycardia, in basal state and
under ergometric stress test, with the evaluation of the shortest R-R
interval between preexcited beats. This study was carried out in order to
evaluate the electrophysiological patterns of the athletes and their fitness
for sports activity. In 52 subjects an atrial fibrillation and in 2 a S.T.A.
at synchronized electrical activity were induced; in 2 subjects it was not
possible to induce any S.T.A. According to our criterion, i.e. shortest R-R
interval ≤ 240 ms in basal state, and/or ≤ 210 ms under ergometric stress
test, 22/54 athletes (40.7%) were judged as being at risk. The discrepancy
with respect to the usual non-invasive evaluation (i.e. Holter monitoring,
ergometric stress test, ajmaline test) was of 37%. On the basis of the basal
state evaluation, we were able to identify only 15 athletes as being at
risk, while on the basis of the complete study protocol 22 athletes were
judged as such. Therefore, the induction of S.T.A. under ergometric stress
test increased the diagnosis power by 31.8%. On the basis of our results we
conclude: the non-invasive evaluation of the electrophysiological patterns
of the W.P.W. athletes is inadequate. The induction of hyperkinetic
supraventricular arrhythmia under ergometric stress test gives a remarkable
increase of the diagnostic power with respect to the evaluation only in
basal state. Since it is simple to execute and economical, and because of
its high diagnostic yield, we regard this protocol as fundamental for the
electrophysiological evaluation of W.P.W. athletes. The method is also able
to the systematic study of W.P.W. in non-athletes.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
esophagus
heart pacing
supraventricular tachycardia
Wolff Parkinson White syndrome
EMTREE MEDICAL INDEX TERMS
diagnosis
heart
heart ventricle fibrillation
human
major clinical study
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1987037694
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 521
TITLE
Physical capacity of older patients with atrial flutter and fibrillation
AUTHOR NAMES
Schwela H.
Oltmanns G.
Gerlach B.
AUTHOR ADDRESSES
(Schwela H.; Oltmanns G.; Gerlach B.)
SOURCE
Rehabilitacia Supplementum (1985) 18:30-31 (114-124). Date of Publication:
1985
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
bicycle ergometry
exercise
heart arrhythmia
heart rate
oxygen consumption
EMTREE MEDICAL INDEX TERMS
adult
aged
cardiovascular system
diagnosis
heart
human
human experiment
normal human
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1986021253
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 522
TITLE
Progress in the study of Wolff-Parkinson-White syndrome of the athletes. The
transesophageal atrial pacing during bicycle exercise
AUTHOR NAMES
Furlanello F.
Vergara G.
Bettini R.
AUTHOR ADDRESSES
(Furlanello F.; Vergara G.; Bettini R.) Divisione di Cardiologia, Ospedale
S. Chiara, 38100 Trento
CORRESPONDENCE ADDRESS
Divisione di Cardiologia, Ospedale S. Chiara, 38100 Trento
SOURCE
International Journal of Sports Cardiology (1984) 1:2 (102-110). Date of
Publication: 1984
ISSN
0393-6066
ABSTRACT
When the talk about 'siletn arrhythmogenic cardiopathy of the athlete', we
mean the existence of risk of sudden dropout of the cardiac electric
stability which may result in sudden death during or immediately after the
athletic effort. This implies the presence of a cardiopathy, even totally
asymptomatic, or of a primary electrical cardiac alteration such as the
Wolff-Parkinson-White (W.P.W.) syndrome. The prognostic arrhythmologic
evaluation of the athletes must include the study of the arrhythmias in a
situation as similar as possible to that of the athletic effort of the
subject. We have developed a method which can be adapted for the athletes,
for the electrophysiological study of the W.P.W. This method involves
inducing atrial fibrillation by means of transesophageal pacing during
bicycle ergometer tests. With this method it is possible to see immediately
the electrophysiological and clinical consequences of the atrial
fibrillation in each athlete with W.P.W. during physical effort, even though
asymptomatic. The advantage of this simple and rapid method, which does not
require X-ray control for positioning of the catheter, is that it does not
require 'hospitalisation', thus permitting frequent check-ups of
electrophysiological characteristics of arrhythmias both for subjects at
risk and for ones who appear to be fit.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
athlete
heart arrhythmia
heart disease
sudden death
Wolff Parkinson White syndrome
EMTREE MEDICAL INDEX TERMS
adult
case report
clinical article
diagnosis
electrocardiography
esophagus
etiology
exercise test
fatality
heart
heart atrium pacing
human
methodology
EMBASE CLASSIFICATIONS
Public Health, Social Medicine and Epidemiology (17)
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1985090612
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 523
TITLE
Exercise test in patients with atrial flutter and fibrillation
AUTHOR NAMES
Schwela H.
Oltmanns G.
Gerlach B.
AUTHOR ADDRESSES
(Schwela H.; Oltmanns G.; Gerlach B.) Dep. Cardiol., Med. Acad., Erfurt
CORRESPONDENCE ADDRESS
Dep. Cardiol., Med. Acad., Erfurt
SOURCE
Rehabilitacia Supplementum (1982) 15:25 (36-43). Date of Publication: 1982
ABSTRACT
Our experience permits to raise the questions for the characteristics of the
exercise response of patients with atrial fibrillation or flutter. The
following statements should be made: Patients with atrial fibrillation and
flutter can be stressed on a bicycle ergometer by giving consideration to
the usual indications and contra-indications. A higher risk in the
examination that can be deduced from the relative frequency of additional
dysrhythmias could not be observed in our patients. Exact monitoring of the
cardiac rhythm, however, is essential. The exercise capacity as compared to
untrained healthy subjects is considerably reduced however, in single
patients it must be considered normal or even outstanding. General physical
exhaustion, dyspnea and muscular fatigue dominate as symptoms limiting the
exercise. A tendency towards tachycardic exercise response is markedly
dominating, especially in cases with valvular heart disease. No conclusion
as to the maximum stress tolerance of the single patient can be drawn from
the heart rate response: Maximal or almost maximal mean heart rates can be
tolerated for a longer time under exercise, in some cases even an increase
in the work loads is tolerated. Relative bradycardia and the inability to
change the heart rate were to be considered as rare findings. The
recommendation of an exercise stop at fixed boundary heart rates must be
considered inadequate in evaluating patients with artial fibrillation and
flutter. Blood pressure regulation in most cases was normotensive or
hypertensive, respectively. An excessive stress hypertension was observed
regardless of the heart rate response. The double product shows a broad
range of scatter and correlates to the exercise tolerance and oxygen uptake
only in rough. Repoloarisation abnormalities in the ECG appear in 85 p.c. of
the patients, considerably more frequently when being treated with
glycoside. For the differentiation of a myocardial ischemic exercise
response the repolarisation patterns in patients with atrial fibrillation
and flutter apparently is not mainly determined by the hemodynamic effects
of the dysrhythmias, but by the degree of severity of the basic heart
disease with its hemodynamic and myocardial factors instead.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
bicycle ergometry
exercise electrocardiography
heart rate
oxygen consumption
EMTREE MEDICAL INDEX TERMS
cardiovascular system
heart
human
major clinical study
therapy
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1983084426
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 524
TITLE
Safety of exercise testing volunteer subjects: the Lipid Research Clinics'
Prevalence Study experience
AUTHOR NAMES
Sheffield L.T.
Haskel W.
Heiss G.
AUTHOR ADDRESSES
(Sheffield L.T.; Haskel W.; Heiss G.) Cent. Electrocardiogr. Lab., Univ.
Alabama Sch. Med., Univ. Alabama, Birmingham, AL 35294
CORRESPONDENCE ADDRESS
Cent. Electrocardiogr. Lab., Univ. Alabama Sch. Med., Univ. Alabama,
Birmingham, AL 35294
SOURCE
Journal of Cardiac Rehabilitation (1982) 2:5 (395-400). Date of Publication:
1982
ISSN
0275-1429
ABSTRACT
Previous reports of the complication rates of near-maximal and maximal
exercise tests have involved the limited experience of one or a few
coordinated laboratories or have represented surveys of facilities employing
diverse protocols and instrumentation. We report the experience of 12 widely
separated laboratories employing identical protocols and equipment.
Near-maximal graded treadmill exercise tests were performed by 9,464 men and
women participants in the Lipid Research Clinics' Prevalence Survey.
Subjects were randomly selected (N = 5,317) or were hyperlipidemic (N =
4,147). Participants exercised to 85% to 90% of age-adjusted predicted
maximal heart rate unless medical contraindication to continued exercise or
limiting symptoms occurred first. Electrocardiographic data, blood pressure,
appearance, and symptoms were monitored at rest and during exercise and
recovery. No deaths, myocardial infarctions, or cardiac arrests occurred
during or within 24 hours following testing. Runs of two or more ventricular
premature complexes occurred in 127 tests, but all spontaneously reverted to
normal sinus rhythm. Ten subjects experienced chest discomfort that lasted
10 minutes or longer without further complications. Atrial fibrillation,
vasovagal collapse, and nausea with chest pain lasting 24 hours without
sequelae occurred once each. These data indicate that near-maximal and
maximal testing can be performed safely with proper screening and
monitoring.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise electrocardiography
hyperlipidemia
treadmill ergometry
EMTREE MEDICAL INDEX TERMS
adult
aged
cardiovascular system
diagnosis
heart
human
human experiment
normal human
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Physiology (2)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1983225367
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 525
TITLE
Arrhythmias caused by exercise
AUTHOR NAMES
Goldschlager N.
AUTHOR ADDRESSES
(Goldschlager N.) Dep. Med., Univ. California, San Francisco, CA
CORRESPONDENCE ADDRESS
Dep. Med., Univ. California, San Francisco, CA
SOURCE
Primary Cardiology (1982) 8:7 (97-108). Date of Publication: 1982
ISSN
0363-5104
ABSTRACT
In patients with coronary artery disease, exercise-induced ventricular
arrhythmias serve as a marker for severe vascular involvement and left
ventricular dysfunction. Such arrhythmias include ventricular and
supraventricular tachyarrhythmias, bradyarrhythmias, and atrioventricular
block. Ventricular arrhythmias may be of greater concern, but the discovery
and management of supraventricular arrhythmias and AV conduction
disturbances are also highly significant in individual patient management.
Supraventricular arrhythmias do not necessarily connote heart disease -
specifically coronary artery disease - but ventricular arrhythmias are often
associated with serious heart disease. Management of exercise-induced
arrhythmias is usually accomplished with the use of a beta-blocking agent or
a Type 1 antiarrhythmic agent, although total suppression of the arrhythmia
is not always achieved.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart arrhythmia
EMTREE MEDICAL INDEX TERMS
etiology
heart
therapy
EMBASE CLASSIFICATIONS
Rehabilitation and Physical Medicine (19)
Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1982226706
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 526
TITLE
Arrhythmias caused by exercise. Part II
AUTHOR NAMES
Goldschlager N.
AUTHOR ADDRESSES
(Goldschlager N.) Univ. California, San Francisco, CA
CORRESPONDENCE ADDRESS
Univ. California, San Francisco, CA
SOURCE
Primary Cardiology (1982) 8:8 (15-25). Date of Publication: 1982
ISSN
0363-5104
ABSTRACT
In patients with coronary artery disease, exercise induced ventricular
arrhythmias serve as a marker for severe vascular involvement and left
ventricular dysfunction. Such arrhythmias include ventricular and
supraventricular tachyarrhythmias, bradyarrhythmias, and atrioventricular
block. Ventricular arrhythmias may be of greater concern, but the discovery
and management of supraventricular arrhythmias and AV conduction
disturbances are also highly significant in individual patient management.
Supraventricular arrhythmias do not necessarily connote heart disease -
specifically coronary artery disease - but ventricular arrhythmias are often
associated with serious heart disease. Management of exercise-induced
arrhythmias is usually accomplished with the use of a beta-blocking agent or
a Type 1 antiarrhythmic agent, although total suppression of the arrhythmia
is not always achieved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
antiarrhythmic agent
beta adrenergic receptor blocking agent
calcium antagonist
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart arrhythmia
ischemic heart disease
EMTREE MEDICAL INDEX TERMS
clinical study
heart
short survey
survey
therapy
EMBASE CLASSIFICATIONS
Occupational Health and Industrial Medicine (35)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1982208881
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 527
TITLE
Effect of propranolol on exercise capacity in chronic atrial fibrillation
AUTHOR NAMES
Brink L.S.
Moss K.A.
Ustby P.A.
AUTHOR ADDRESSES
(Brink L.S.; Moss K.A.; Ustby P.A.) La Crosse Exercise Program, Res. Unit,
Univ. Wisconsin, La Crosse, Wis.
CORRESPONDENCE ADDRESS
La Crosse Exercise Program, Res. Unit, Univ. Wisconsin, La Crosse, Wis.
SOURCE
Medicine and Science in Sports and Exercise (1979) 11:1 (110). Date of
Publication: 1979
ISSN
0195-9131
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digoxin
propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
work capacity
EMTREE MEDICAL INDEX TERMS
abstract report
case report
exercise
heart
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
EMBASE CLASSIFICATIONS
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1979253188
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 528
TITLE
Role of exercise stress testing in assessing digoxin dosage in chronic
atrial fibrillation
AUTHOR NAMES
Davidson D.M.
Hagan A.D.
AUTHOR ADDRESSES
(Davidson D.M.; Hagan A.D.) Div. Cardiol., Nav. Reg. Med. Cent., San Diego,
Calif.
CORRESPONDENCE ADDRESS
Div. Cardiol., Nav. Reg. Med. Cent., San Diego, Calif.
SOURCE
Cardiovascular Medicine (1979) 4:6 (671-678). Date of Publication: 1979
ISSN
0199-6614
ABSTRACT
Relying on the resting ventricular rate as an index to digoxin efficacy in
patients with chronic atrial fibrillation may result in suboptimal dosage.
Conversely, signs of digitalis toxicity are often overlooked in these
patients. To determine optimal daily dosage, 11 patients were studied by
serial multistage maximal exercise treadmill tests. All patients were taking
at least 0.25 mg digoxin daily when the study was begun, but in each case
the dosage appeared suboptimal. When their doses were increased, all
patients showed both subjective and objective improvement in exercise
tolerance; the mean heart rate and systolic blood pressure, and the
rate-pressure product, were lowered in the resting, exercise, and recovery
states, and maximal tolerable exercise levels were increased. Thus exercise
testing provides a useful means of assessing digitalis dosage so as to
ensure optimal cardiac performance and exercise capacity in the patient with
chronic atrial fibrillation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digoxin
furosemide
propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise
exercise electrocardiography
exercise test
heart ventricle rate
EMTREE MEDICAL INDEX TERMS
drug dose
drug therapy
heart
therapy
DRUG TRADE NAMES
inderal
lanoxin
lasix
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
furosemide (54-31-9)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Rehabilitation and Physical Medicine (19)
Clinical and Experimental Pharmacology (30)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1979234752
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 529
TITLE
Wolff Parkinson White syndrome. (Study of 20 symptomatic cases)
AUTHOR NAMES
Das J.P.
AUTHOR ADDRESSES
(Das J.P.) Dept. Cardiol., SCB Med. Coll., Cuttack
CORRESPONDENCE ADDRESS
Dept. Cardiol., SCB Med. Coll., Cuttack
SOURCE
Indian Heart Journal (1973) 25:sup (237-242). Date of Publication: 1973
ISSN
0019-4832
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
procainamide
propranolol
quinidine
EMTREE DRUG INDEX TERMS
verapamil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
clinical study
diagnosis
drug therapy
electrocardiography
exercise
heart failure
internal medicine
paroxysmal tachycardia
Wolff Parkinson White syndrome
EMTREE MEDICAL INDEX TERMS
drug administration
major clinical study
methodology
therapy
DRUG TRADE NAMES
isoptin
CAS REGISTRY NUMBERS
procainamide (51-06-9, 614-39-1)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
quinidine (56-54-2)
verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
Cardiovascular Diseases and Cardiovascular Surgery (18)
Drug Literature Index (37)
Internal Medicine (6)
LANGUAGE OF ARTICLE
English
EMBASE ACCESSION NUMBER
1975079792
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 530
TITLE
Acupuncture for cardioversion.
AUTHOR NAMES
Berman R.H.
AUTHOR ADDRESSES
(Berman R.H.)
CORRESPONDENCE ADDRESS
R.H. Berman,
SOURCE
Annals of internal medicine (1973) 79:2 (285). Date of Publication: Aug 1973
ISSN
0003-4819
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
acupuncture
atrial fibrillation (therapy)
tachycardia (therapy)
EMTREE MEDICAL INDEX TERMS
aged
article
female
human
male
middle aged
LANGUAGE OF ARTICLE
English
MEDLINE PMID
4726548 (http://www.ncbi.nlm.nih.gov/pubmed/4726548)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 531
TITLE
The prognostic significance of certain clinical and roentgenological data
for assessment of danger from mitral commissurotomy
AUTHOR NAMES
Putov N.V.
Gorentsvit I.E.
Koblents Mishke A.I.
AUTHOR ADDRESSES
(Putov N.V.; Gorentsvit I.E.; Koblents Mishke A.I.) Kaf. Obshch. Khir.,
Voenno Med. Akad., Leningrad, Russian Federation.
CORRESPONDENCE ADDRESS
N.V. Putov, Kaf. Obshch. Khir., Voenno Med. Akad., Leningrad, Russian
Federation.
SOURCE
Kardiologiya (1972) 12:10 (53-57). Date of Publication: 1972
ISSN
0022-9040
ABSTRACT
A study was made of 57 cases of severely ill patients (27 with lethal
outcome, 30 survivals) who had had at least one of the three following signs
of severity of circulatory failure: (1) auricular fibrillation (40
patients); (2) cardiomegaly with a cardiothoracic index not less than Wt (20
cases); and (3) terminal (dystrophic) stage of circulatory failure (21
patients). An electronic computer was used to study all the paired
combinations from 18 clinical and X ray signs. A number of unusual
relationships were recorded. For instance, any considerable degree of
dyspnea was an unfavorable prognostic sign only when the volume of the heart
exceeded 1400 cm' and when corresponding disorders had already affected the
state of general nutrition of the patient. A substantial increase of the
size of the liver unprovoked by a secondary pulmonary hypertension proved to
be more dangerous than a similar increase of the liver size in patients with
considerable widening of the pulmonary artery. A bad prognosis was noted in
cases of marked dilatation of the left atrium, which is always accompanied
by auricular fibrillation. When no such dilatation existed an operation was
roughly equally dangerous with sinus rhythm as with auricular fibrillation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mitral valve commissurotomy
EMTREE MEDICAL INDEX TERMS
angiocardiography
atrial fibrillation
cardiomegaly
computer
dyspnea
heart
heart left atrium
ischemia
liver
liver size
nutrition
patient
prognosis
pulmonary artery
pulmonary hypertension
sinus rhythm
survival
thorax radiography
X ray
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008449458
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 532
TITLE
The effect of digitalis on the heart rate during exercise in patients with
atrial fiberillation
AUTHOR NAMES
Aberg H.
Strom G.
Werner I.
AUTHOR ADDRESSES
(Aberg H.; Strom G.; Werner I.) Dept Int. Med, Univ. Hasp, Uppsala, Sweden.
CORRESPONDENCE ADDRESS
H. Aberg, Dept Int. Med, Univ. Hasp, Uppsala, Sweden.
SOURCE
Acta Mbd. Acand. (1972) 191:5 (109-113). Date of Publication: 1972
ABSTRACT
Twenty eight clinically compensated cardiac patients with atrial
fibrillation were investigated with the graded exercise teat Twenty four
patients had one test with a lowci doae of digitalis and one with a higher
dose, both doae rates being within the therapeutic range. Four panents
performed one exercise teat with and one without digital!s. The heart
(ventricular) rate attained at a given exercise load was significantly lower
(with a difference of 5-25 beats/min at the different loads) with the higher
dose. This was interpreted as a beneficial effect on working capacity. The
individual beat to beat variability of heart rate was not influenced. The
beneficial effect of an increase in digitalis dose thus seems to depend on a
decrease in average ventricular rate during exercise and not on a decreased
degree of arrhythmia.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart rate
patient
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiac patient
exercise test
heart arrhythmia
nipple
work capacity
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008772619
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 533
TITLE
Effects of practolol administration on cardiac and renal function in
patients with chronic atrial fibrillation
AUTHOR NAMES
Gibson D.G.
AUTHOR ADDRESSES
(Gibson D.G.) Dept. Cardiol., St Bartholomew's Hospn, London.
CORRESPONDENCE ADDRESS
D.G. Gibson, Dept. Cardiol., St Bartholomew's Hospn, London.
SOURCE
Acta Cardiol (1972) 15 (139-148). Date of Publication: 1972
ABSTRACT
Studies in patients with chronic atrial fibrillation suggest that practolol
is tees likely than propranolol to cause a reduction in cardiac output, an
increase in left ventricular filling pressure or renal sodium retention.
These results suggest that practolol has a place in the treatment of
patients with chronic atrial fibrillation, particularly in those in whom
inappropriate tachycardia on exercise is a significant cause of symptoms.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
practolol
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
kidney function
patient
EMTREE MEDICAL INDEX TERMS
aged
aging
angina pectoris
athlete
exercise
exercise tolerance
heart arrhythmia
heart disease
heart left ventricle filling pressure
heart output
kidney
sodium retention
tachycardia
CAS REGISTRY NUMBERS
practolol (6673-35-4)
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008772623
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 534
TITLE
Evaluation of the pulse contour method of determining stroke volume in man
AUTHOR NAMES
Alderman E.L.
Branzi A.
Sanders W.
AUTHOR ADDRESSES
(Alderman E.L.; Branzi A.; Sanders W.) Cardiol. Biostatist. Div., Stanford
Univ., Sch. Med., Stanford, CA, United States.
CORRESPONDENCE ADDRESS
E.L. Alderman, Cardiol. Biostatist. Div., Stanford Univ., Sch. Med.,
Stanford, CA, United States.
SOURCE
Circulation (1972) 46:3 (1243-1245). Date of Publication: 1972
ISSN
0009-7322
ABSTRACT
The pulse contour method for determining stroke volume has been employed as
a continuous rapid method of monitoring the cardiovascular status of
patients. Twenty one patients with ischemic heart disease and 21 patients
with mitral valve disease were subjected to a variety of hemodynamic
interventions. These included exercise, isoproterenol infusion, and
practolol, morphine or pentazocine administration. The pulse contour
estimations, using 3 different formulae derived by Warner, Kouchoukos, and
Herd, were compared with indicator dilution outputs. The pressure pulse
contour computations were performed by a small on line cardiac
catheterization laboratory computer. A comparison of the results of the 2
methods for determining stroke volume yielded correlation coefficients
ranging from 0.59 to 0.84. The better performing Warner formula yielded a
coefficient of variation of about 20% The type of hemodynamic interventions
employed did not significantly affect the results using the pulse contour
method. This method yielded nearly as reliable results with the catheter
positioned in the axillary artery as in the central aorta. Good results were
obtained using the pulse contour method in patients with atrial fibrillation
as compared to those with sinus rhythm. Although the correlation of the
pulse contour and indicator dilution stroke volumes is high, the coefficient
of variation is such that small changes in stroke volume cannot be
accurately assessed by the pulse contour method. However, the simplicity and
rapidity of this method compared to determination of cardiac output by Fick
or indicator dilution methods makes it a potentially useful adjunct for
monitoring critically ill patients.
EMTREE DRUG INDEX TERMS
isoprenaline
morphine
pentazocine
practolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart stroke volume
human
pulse rate
EMTREE MEDICAL INDEX TERMS
aorta
atrial fibrillation
axillary artery
blood
blood pressure
catheter
computer
correlation coefficient
critically ill patient
dilution
exercise
heart
heart catheterization
heart disease
heart output
herd
indicator dilution curve
infusion
ischemic heart disease
laboratory
mitral valve disease
monitoring
patient
sinus rhythm
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008637576
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 535
TITLE
Hemodynamic effects of cardioversion in chroaic atrical fibrillation.
special reference to ceronary artery disease
AUTHOR NAMES
Khaja F.
AUTHOR ADDRESSES
(Khaja F.) Parker Univ., Kingston.
CORRESPONDENCE ADDRESS
F. Khaja, Parker Univ., Kingston.
SOURCE
Arch. Intern.Med. (1972) 129:3 (419-422). Date of Publication: 1972
ABSTRACT
The heroodynamic effects of conversion in chronic «trial fibrillation (AF)
were studied in eight patients with coronary artery disease (CAD) (group 1)
and five patients with AF of varied etiology (group 2). The resting stroke
index (SI) in group 1 increased from 28 2 ml/sq m to 34.6 ml/sq m (p>) 30
minutes after conversion but the other parameters did not change. In
patients who maintained normal sinus rhythm (NSR) three weeks following
cardioversion the response to exercise was improved, with lower heart rate
and higher cardiac index (CIX SI and stroke work (SWX In relating filling
pressures to SW, ventricular function was improved with NSR Right atrial a
waves returned simultaneously with NSR in 75% of patients whereas left
atrial a waves appeared in 55%. Patients who failed to develop left atrial a
waves immediately after cardioversion reverted to AF within three weeks.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
artery disease
cardioversion
hemodynamics
EMTREE MEDICAL INDEX TERMS
A wave
atrial fibrillation
cerebrovascular accident
coronary artery disease
etiology
exercise
exercise test
heart arrhythmia
heart disease
heart index
heart rate
heart ventricle function
ischemic heart disease
patient
sinus rhythm
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008772664
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 536
TITLE
Influence of nitrazepam on oral anticoagulation with phenprocoumon
AUTHOR NAMES
Bieger R.
De Jonge H.
Loeliger E.A.
AUTHOR ADDRESSES
(Bieger R.; De Jonge H.; Loeliger E.A.) Haematology Division, Department of
Internal Medicine, Department of Medical Statistics, Leiden University
Hospital, Leiden, Netherlands.
SOURCE
Clinical Pharmacology and Therapeutics (1972) 13:3 (361-365). Date of
Publication: 1 May 1972
ISSN
1532-6535 (electronic)
0009-9236
BOOK PUBLISHER
Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
A double-blind trial was carried out on 22 volunteer patients to observe the
influence of nitrazepam on the course of long-term anticoagulant therapy
with phenprocoumon. Dosage of phenprocoumon remained unchanged for all
patients during the 8 week trial. Nitrazepam or placebo, assigned at random,
was taken every night for a 2 week period; a subsequent 2 week period
without test drugs was followed by a second series with the other tablet.
The last 2 weeks of the trial were without test drugs. There was no
difference between the effects of the placebo and the nitrazepam on the
hypocoagulability due to the oral anticoagulant therapy. It is concluded
that nitrazepam can safely be prescribed as a hypnotic for patients on
long-term anticoagulant therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
nitrazepam (clinical trial, drug comparison - placebo, drug interaction)
phenprocoumon (clinical trial, drug interaction, drug therapy, oral drug
administration)
EMTREE DRUG INDEX TERMS
placebo
prothrombin complex (endogenous compound)
secbutabarbital
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
anticoagulant therapy
EMTREE MEDICAL INDEX TERMS
adult
aged
anesthesia level
angina pectoris (drug therapy)
article
atrial fibrillation (drug therapy)
blood clotting test
blood clotting time
clinical article
controlled study
double blind procedure
evening dosage
heart infarction (drug therapy)
human
middle aged
outcome assessment
peripheral occlusive artery disease (drug therapy)
pilot study
priority journal
randomized controlled trial
DRUG TRADE NAMES
liquamar
marcumar
mogadon
CAS REGISTRY NUMBERS
nitrazepam (146-22-5)
phenprocoumon (435-97-2)
prothrombin complex (37224-63-8)
secbutabarbital (125-40-6, 143-81-7)
EMBASE CLASSIFICATIONS
Anesthesiology (24)
Hematology (25)
Drug Literature Index (37)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
20160024650
MEDLINE PMID
4554660 (http://www.ncbi.nlm.nih.gov/pubmed/4554660)
FULL TEXT LINK
http://dx.doi.org/10.1002/cpt1972133361
COPYRIGHT
Copyright 2016 Elsevier B.V., All rights reserved.
RECORD 537
TITLE
Efectroversion of lone atrial fibrillation and flutter including
haemodynaniic studies at rest and on exercise -
AUTHOR NAMES
Resnekov L.
McDonald L.
AUTHOR ADDRESSES
(Resnekov L.; McDonald L.) Inst. Cardiol., Nat Heart Hosp., London.
CORRESPONDENCE ADDRESS
L. Resnekov, Inst. Cardiol., Nat Heart Hosp., London.
SOURCE
Britheart J. (1971) 33:3 (339-350). Date of Publication: 1971
ABSTRACT
Thirty patients with atrial fibrillation and seven with atrial flutter, all
of whom were carefully examined to exclude any associated underlying heart
disease, were treated by direct current shock. Sinus rhythm was achieved in
24 of the 30 patients with atrial fibrillation; all patients with atrial
flutter were brought into sinus rhythm. The incidence of complications was
particularly high in those with lone atrial fibrillation and could be
related to the higher energy level setting required. No complications
occurred in the group treated for lone atrial flutter in whom low energy
level settings were uniformly successful. Only 4 patients treated for atrial
fibrillation remained in sinus rhythm at the end of a 36 mth followup.
Reversion to the dysrhythmia occurred within minutes or days of
electroversion and the majority who reverted did so within the first month.
Quinidine was of little use in maintaining sinus rhythm. In contrast,
patients with lone atrial flutter maintained sinus rhythm for a
significantly longer period of time. Four of the patients with atrial
fibrillation and 2 with atrial flutter were studied at rest and on graded
exercise before and after conversion to sinus rhythm. Clear hemodynamic
evidence of the benefit of sinus rhythm was obtained, particularly at the
higher levels of exercise which could be related not only to the longer
diastolic filling time in sinus rhythm, but also to the booster action of
atrial systole. Despite the evidence of hemodynamic benefit in sinus rhythm,
it is concluded that there is no indication for attempting to convert
asymptomatic lone atrial fibrillation to sinus rhythm by direct current
shock. This dysrhythmia is relatively resistant to treatment, complications
are frequent, and sinus rhythm is maintained for a disappointingly short
time. Patients with lone atrial flutter, however, are converted to sinus
rhythm with relatively low electrical energies; complications are therefore
fewer and sinus rhythm is maintained more frequently. Thus with lone atrial
flutter, electroversion is usually indicated.
EMTREE DRUG INDEX TERMS
quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise
EMTREE MEDICAL INDEX TERMS
direct current
follow up
heart atrium contraction
heart atrium flutter
heart disease
patient
sinus rhythm
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008469645
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 538
TITLE
R/R interval analysis at rest and during exercise in patients with atrial
fibrillation and in healthy subjects
AUTHOR NAMES
Bootsma B.K.
AUTHOR ADDRESSES
(Bootsma B.K.)
SOURCE
Van Gorcum. Assen (1971). Date of Publication: 1971
ABSTRACT
In this monograph the electrophysiological properties of atrial activation
in atrial fibrillation are discussed. Studying healthy subjects and patients
with atrial fibrillation both with and without the use of digitalis, the
author concludes that the absolute irregular ventricular rhythm in atrial
fibrillation is not determined exclusively by properties of the
atrioventricular node. The statement is made that the irregular ventricular
rhythm is mainly determined by the occurrence of random spaced series of
atrial activation of random strength. The given facts are statistically
analyzed.
EMTREE DRUG INDEX TERMS
cardiac glycoside
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise
normal human
patient
EMTREE MEDICAL INDEX TERMS
atrioventricular conduction
book
heart atrioventricular node
heart atrium arrhythmia
heart atrium conduction
heart muscle refractory period
hypertension
rhythm
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008528498
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 539
TITLE
Phannacokinetics of gentamicin. distribution and plasma and renal clearance
AUTHOR NAMES
Gyselynck A.M.
Forrey A.
Cutler R.
AUTHOR ADDRESSES
(Gyselynck A.M.; Forrey A.; Cutler R.) Dept. Med., Harborview Med. Cent,
Seattle, WA, United States.
CORRESPONDENCE ADDRESS
A.M. Gyselynck, Dept. Med., Harborview Med. Cent, Seattle, WA, United
States.
SOURCE
J.Infect.Dis. (1971) 124 (s70-s76). Date of Publication: 1971
ABSTRACT
The renal clearance and volume of distribution of gentamicin was measured by
the continuous infusion technique in 18 patients with different degrees of
renal function. Renal clearance of gentamicin did not differ from that of
inulin. Because 20%-30% of gentamicin in serum is bound to protein, it is
likely that some of the antibiotic is secreted by the renal tubules. The
mean apparent volume of distribution of gentamicin was 24% of the body
weight and was comparable to that of inulin. Twenty additional patients were
studied; gentamicin, inulin, and radioactive iothalamate were injected by a
single injection technique. The clearance of these compounds from plasma was
slightly greater than their renal clearance, which suggests extrarenal
elimination. Confirmatory evidence was seen in the lack of total urinary
excretion. The half life in plasma of all compounds correlated well except
in cases of severe renal failure, where half life of gentamicin was
unusually prolonged due to a larger distribution volume. A formula for the
calculation of half life of gentamicin in plasma is given.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
gentamicin
EMTREE DRUG INDEX TERMS
antibiotic agent
digoxin
inulin
iotalamic acid
protein
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
plasma
renal clearance
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
body weight
continuous infusion
ergometry
exercise
half life time
injection
kidney failure
kidney function
kidney tubule
patient
serum
urinary excretion
volume of distribution
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008445576
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 540
TITLE
Sinus brsdycardia
AUTHOR NAMES
Eraut D.
Shaw D.B.
AUTHOR ADDRESSES
(Eraut D.; Shaw D.B.) Cardiac Dept., Roy ai Devon and Exeter Hosp., Exeter.
CORRESPONDENCE ADDRESS
D. Eraut, Cardiac Dept., Roy ai Devon and Exeter Hosp., Exeter.
SOURCE
British Heart Journal (1971) 33:5 (742-749). Date of Publication: 1971
ISSN
0007-0769
ABSTRACT
This paper presents the features of 46 patients with unexplained
bradycardia. Patients were admitted to the study if their resting atrial
rate was below 56 a min on two consecutive occasions. Previous
electrocardiograms and the response to exercise, atropine, and isoprenaline
were studied. The ages of the patients varied from 13 to 88 years. Only 8
had a past history of cardiovascular disease other than bradycardia, but 36
had syncopal or dizzy attacks. Of the 46 patients, 35 had another arrhythmia
in addition to bradycardia; at some stage, 16 had sinus arrest, 15 had
junctional rhythm, 12 had fast atrial arrhythmia, 16 had frequent
extrasystoles, and 6 had atrioventricular block. None had the classical
features of sinoatrial block. Arrhythmias were often produced by exercise,
atropine, or isoprenaline. Drug treatment was rarely satisfactory, but only
1 patient needed a permanent pacemaker. It is suggested that the majority of
the patients were suffering from a pathological form of sinus bradycardia.
The aetiology remains unproven, but the most likely explanation is a loss of
the inherent rhythmicity of the sinoatrial node due to a primary
degenerative disease. The descriptive title of the lazy sinus syndrome1 is
suggested.
EMTREE DRUG INDEX TERMS
atropine
isoprenaline
EMTREE MEDICAL INDEX TERMS
Arthus phenomenon
artificial heart pacemaker
aspergillosis
atrioventricular block
atrioventricular junction arrhythmia
bradycardia
cardiovascular disease
degenerative disease
drug therapy
electrocardiogram
etiology
exercise
extrasystole
heart arrhythmia
heart atrium arrhythmia
heart sinoatrial block
lung disease
patient
sinus arrest
sinus bradycardia
sinus node
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008444402
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 541
TITLE
Effect of propranolol on exercise tolerance of patients with alrial
fibrillation
AUTHOR NAMES
Brown R.W.
Goble A.J.
AUTHOR ADDRESSES
(Brown R.W.; Goble A.J.) Roy. Melbourne Hosp., Melbourne.
CORRESPONDENCE ADDRESS
R.W. Brown, Roy. Melbourne Hosp., Melbourne.
SOURCE
Britmed.J. (1969) 2:5652 (496-499). Date of Publication: 1969
ABSTRACT
Six patients with atrial fibrillation who were taking digitalis were
exercised before and after 30 mg of propranolol twice daily. Though there
was a lower pulse rate at rest and on exercise in all patients, three
suffered deterioration of exercise tolerance. It is concluded that
propranolol does not improve the exercise tolerance of patients with atrial
fibrillation whose resting ventricular rate is controlled with digitalis.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
propranolol
EMTREE DRUG INDEX TERMS
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise tolerance
patient
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
deterioration
exercise
exercise test
pulse rate
CAS REGISTRY NUMBERS
propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008755819
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 542
TITLE
Effects of ouabain on the memodynamic kesponse to exercise in patients with
mitral stenosis in normal sinus rhythm
AUTHOR NAMES
Beiser G.D.
Epstein S.E.
Stampfer M.
Robinson B.
Braunwald E.
AUTHOR ADDRESSES
(Beiser G.D.; Epstein S.E.; Stampfer M.; Robinson B.; Braunwald E.) C
Ardiol. Branch, Nat. Heart Inst., Bethesda, MD, United States.
CORRESPONDENCE ADDRESS
G.D. Beiser, C Ardiol. Branch, Nat. Heart Inst., Bethesda, MD, United
States.
SOURCE
New England journal of medicine (Print) (1968) 278:3 (131-137). Date of
Publication: 1968
ISSN
0028-4793
ABSTRACT
The efficacy of cardiac glycosides was evaluated in 8 symptomatic patients
with pure mitral stenosis in normal sinus rhythm and in 3 patients in atrial
fibrillation. The patients were studied at rest and during moderate and
intense levels of treadmill exercise before and after the acute i.v.
administration of ouabain. During maximal exercise ouabain slowed the
ventricular rate considerably in 2 of the 3 patients in atrial fibrillation,
and this reduction was associated with significant hemodynamic improvement.
However, in the patients in sinus rhythm ouabain produced no significant
change in heart rate and had no beneficial effect on cardiac output, oxygen
consumption or severity of pulmonary hypertension either at rest or during
exercise. Since patients with pure mitral stenosis in normal sinus rhythm
are not benefited by the acute administration of ouabain, there is a
reasonable doubt whether the routine use of digitalis in the medical
management of such patients is advisable.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
ouabain
EMTREE DRUG INDEX TERMS
cardiac glycoside
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
mitral valve stenosis
patient
sinus rhythm
EMTREE MEDICAL INDEX TERMS
acute drug administration
atrial fibrillation
disease management
heart output
heart performance
heart rate
oxygen consumption
pulmonary hypertension
treadmill exercise
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007811844
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 543
TITLE
Diazepam. A useful hypnotic drug for direct-current cardioversion.
AUTHOR NAMES
Winters Jr. W.L.
McDonough M.T.
Hafer J.
Dietz R.
AUTHOR ADDRESSES
(Winters Jr. W.L.; McDonough M.T.; Hafer J.; Dietz R.)
CORRESPONDENCE ADDRESS
W.L. Winters,
SOURCE
JAMA : the journal of the American Medical Association (1968) 204:10
(926-928). Date of Publication: 3 Jun 1968
ISSN
0098-7484
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
diazepam (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
cardioversion
heart arrhythmia (therapy)
EMTREE MEDICAL INDEX TERMS
adolescent
adult
aged
article
atrial fibrillation (therapy)
blood pressure
breathing
drug effect
female
heart atrium flutter (therapy)
heart rate
heart ventricle fibrillation (therapy)
human
male
middle aged
tachycardia (therapy)
CAS REGISTRY NUMBERS
diazepam (439-14-5)
LANGUAGE OF ARTICLE
English
MEDLINE PMID
5694607 (http://www.ncbi.nlm.nih.gov/pubmed/5694607)
COPYRIGHT
MEDLINE® is the source for the citation and abstract of this record.
RECORD 544
TITLE
Electrolyte and water distribution in familial hypokalaemic periodic
paralysis
AUTHOR NAMES
Coppen A.J.
AUTHOR ADDRESSES
(Coppen A.J.) Med. Res. Counc, Neuropsychiat. Res. CJnIt4 West Park Hoep,
Epsom.
CORRESPONDENCE ADDRESS
A.J. Coppen, Med. Res. Counc, Neuropsychiat. Res. CJnIt4 West Park Hoep,
Epsom.
SOURCE
Journal of Neurology, Neurosurgery and Psychiatry (1966) 29:2 (107-112).
Date of Publication: 1966
ISSN
0022-3050
ABSTRACT
Distribution of water, sodium, and potassium was studied by a multiple
isotope technique in apatients with familial hypokalemic periodic paralysis.
One patient aged 60, had developed a proximal myopathy confirmed by biopsy,
he had moreover a mild hypertension, cardiac enlargement, auricular
fibrillation and inversion of ã-waves on his ECG. It remains unsettled
whether these cardiac abnormalities are part of the periodic paralysis. Ail
patients had a low total body potassium (K) and low intracellular K
concentration between attacks. Residual sodium (Na) concentration was
normal. Total body water, and its partition between intracellular and
extracellular spaces were normal. Treatment with a low-Na diet and K
supplements in one patient resulted in the return of intracellular K to
normal, considerable elevation of residual Na and decrease in the volume of
intracellular water. Marked clinical improvement was seen.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
electrolyte
EMTREE DRUG INDEX TERMS
isotope
potassium
sodium
water
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
periodic paralysis
water supply
EMTREE MEDICAL INDEX TERMS
A wave
aged
atrial fibrillation
biopsy
borderline hypertension
cardiomegaly
case study
diet
electrocardiogram
electrocorticography
extracellular space
hypokalemic periodic paralysis
myopathy
patient
total body potassium
total body water
CAS REGISTRY NUMBERS
water (7732-18-5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007907346
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 545
TITLE
Treatment of cardiac arrhythmias in unanesthetized patients. Role of
adrenergic beta receptor blockade
AUTHOR NAMES
Bath J.C.J.L.
AUTHOR ADDRESSES
(Bath J.C.J.L.) Cardiac Dept., West. Gen. Hosp., Edinburgh.
CORRESPONDENCE ADDRESS
Cardiac Dept., West. Gen. Hosp., Edinburgh.
SOURCE
American journal of cardiology (1966) 18:3 (416-425). Date of Publication:
1966
ISSN
0002-9149
ABSTRACT
Fifty-two patients with cardiac arrhythmia were treated by the β adrenergic
blocking agents, propranolol and pronethalol. The overall conversion rate to
sinus rhythm was 44%. Conversion was more frequent in atrial tachycardia
with atrioventricular block and paroxysmal supraventricular tachycardia
(71%) than in ventricular tachycardia (55%) and in atrial fibrillation or
flutter (13%). Severe side effects developed in 4 cases: hypotension twice
and pulmonary edema twice. There were 4 deaths within approximately 24 hr of
starting treatment, but beta blockade therapy was considered a possible
contributory factor in only one. Moderate side effects occurred in a further
9 patients and included nausea, dizziness, headache, weakness and epigastric
discomfort. It is concluded that propranolol is the treatment of choice for
atrial tachycardia with atrioventricular block. It is also of use in the
management of recurrent paroxysmal supraventricular tachycardia not
controlled by digitalis. It is effective for the control of fast ventricular
rates in atrial fibrillation and atrial flutter, but clinical improvement
does not necessarily follow and conversion to sinus rhythm is unusual.
Ventricular extrasystoles are reduced in number in some patients, and the
response may depend on their mode of production. Adrenergic beta blockade
can be effective in terminating ventricular tachycardia but severe
hypotension may occur, and other methods of treatment are preferable. It may
prevent recurrent bouts of ventricular tachycardia, especially those due to
drugs or exercise.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
beta adrenergic receptor
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
digitalis
pronetalol
propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
beta adrenergic receptor blocking
heart arrhythmia
patient
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
atrioventricular block
death
dizziness
epigastric discomfort
exercise
headache
heart atrium flutter
heart ventricle extrasystole
heart ventricle tachycardia
hypotension
lung edema
nausea
paroxysmal supraventricular tachycardia
pressoreceptor
side effect
sinus rhythm
supraventricular tachycardia
therapy
weakness
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007873596
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 546
TITLE
Alcoholic cardiomyopathy
AUTHOR NAMES
Dines D.E.
AUTHOR ADDRESSES
(Dines D.E.)
CORRESPONDENCE ADDRESS
D.E. Dines, Rochester, MN, United States.
SOURCE
Rocky Mtn Med. J. (1965) 62:1 (617-621). Date of Publication: 1965
ABSTRACT
A case of alcoholic cardiomyopathy is reported. Electrocardiograms of this
patient were typical of the entity, consisting of sinus tachycardia, supra
ventricular tachycardia, atrial fibrillation, and abnormal P-wave and T-wave
changes. These electrocardiographic changes occurred in an alcoholic male
each time following heavy alcohol intake. The electrocardiographic
abnormalities were associated clinically with a rapid pulse rate and an
increase in the mean blood pressure. The electrocardiogram reversed to
normal prior to discharge from the hospital. The patient herein described
has had a balanced diet and been physically active. It is thought that in
this case alcohol has a direct toxic effect on the myocardium and that
neither nutrition nor vitamin deficiency has played a role. Alcoholic
cardiomyopathy has been reviewed.
EMTREE DRUG INDEX TERMS
alcohol
corticotropin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alcoholic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
alcohol consumption
alcoholism
atrial fibrillation
cardiomyopathy
diet
ECG abnormality
electrocardiogram
heart disease
heart muscle
heart ventricle tachycardia
hospital
male
mean arterial pressure
nutrition
P wave
patient
pulse rate
sinus tachycardia
T wave
toxicity
vitamin deficiency
CAS REGISTRY NUMBERS
alcohol (64-17-5)
corticotropin (11136-52-0, 9002-60-2, 9061-27-2)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007871445
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 547
TITLE
Some data on atherosclerotic cardiosclerosis in very old people (Russian)
AUTHOR NAMES
Chebotarev D.F.
Korkuehko O.V.
Sachuk N.N.
Voloshchenko I.I.
AUTHOR ADDRESSES
(Chebotarev D.F.; Korkuehko O.V.; Sachuk N.N.; Voloshchenko I.I.) Inet.
Ofgerontol, USSR Acad. of Med. Scis, Kiev, Ukraine.
CORRESPONDENCE ADDRESS
D.F. Chebotarev, Inet. Ofgerontol, USSR Acad. of Med. Scis, Kiev, Ukraine.
SOURCE
Krovoobrashchenie Starost (1965) (159-166). Date of Publication: 1965
ABSTRACT
Data were obtained on cardiovascular function and its anomalies in subjects
aged 80- 89 and 90 yr. and over on a mass survey basis in Ukraine embracing
12.600 subjects of these ages with special detailed investigation of 181 of
them. More than 1/2 the subjects had clinical evidence of cardiosclerosis
and 10% had hypertension; these were more pronounced infernales than in
males, and were more frequent in town dwellers than in rural inhabitants.
Cardiosclerosis was more frequent in those who had formerly been occupied in
mental work, and it was less frequent among those who had habitually
subsisted on a milk and vegetable dietary regime. More detailed
(instrumental) investigation showed atherosclerotic cardiosclerosis to be
present in all of the 181 cases so investigated, itsgrade being mild to
moderate in 83% and severe in 17%. Clinical manifestations and pain were
infrequent. Electrocardiography was performed: the pulse rate was below
70/min. in 43%. 70- 90/min. in 50% and over 90/min. in 7%. Arrhythmia was
noted in 36% of cases of mild cardiosclerosis and in 50% of those with
severe cardiosclerosis. most often in the form of auricular extrasystole,
less often ventricular extrasystole and and least often auricular
fibrillation. Duration of electric systole of the heart was prolonged in
65.2% of cases, and there was left deviation of the electric axis in 84%,
The systemic blood pressure was not greatly influenced by the
atherosclerosis of vessels. In the event of acute myocardial infarction
acute cardiovascular failure frequently ensued rapidly. Kozhura - Kiev.
EMTREE DRUG INDEX TERMS
adenosine triphosphate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart muscle fibrosis
very elderly
EMTREE MEDICAL INDEX TERMS
acute heart infarction
aged
atherosclerosis
atrial fibrillation
blood pressure
cardiovascular function
city
coronary artery atherosclerosis
electrocardiography
extrasystole
heart
heart arrhythmia
heart ventricle extrasystole
hypertension
male
milk
pain
pulse rate
systole
Ukraine
vegetable
CAS REGISTRY NUMBERS
adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008131551
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 548
TITLE
Acquired heart disease and cerebral embolism
AUTHOR NAMES
Nakayama K.
AUTHOR ADDRESSES
(Nakayama K.) Tokyo Wom. Med. Coll., Tokyo, Japan.
CORRESPONDENCE ADDRESS
K. Nakayama, Tokyo Wom. Med. Coll., Tokyo, Japan.
SOURCE
Resp. Circulat. (1965) 13:5 (343-349). Date of Publication: 1965
ABSTRACT
Among 878 patients hospitalized for heart disease, 67 (7.6%) developed 91
attacks of cerebral embolism. The incidence was highest (8%) in cases of
mitral stenosis. Atrial fibrillation was an important predisposing factor.
In more than half of the cases, cerebral embolism occurred within 1 yr.
after the onset of atrial fibrillation. Cerebral embolism occurring within 1
yr. after the start of digitalis treatment was found in 87%. Its incidence
was especially high in patients who had been fully digitalized rapidly. The
degree of cardiac enlargement and the cerebral embolism were not correlated,
but cerebral embolism was frequent in cases of heart disease with cardiac
enlargement other than mitral stenosis. There was little correlation between
the severity of heart disease and the incidence of cerebral embolism. There
was no relationship between physical exertion and cerebral embolism. The
initial attack of cerebral embolism was seen most frequently in patients
aged 14-35 yr., especially 31-35 yr. The male/female ratio for hemiplegia
was 39/28. Paralysis was seen on the left side in 42 and on the right side
in 46. Repeated episodes of cerebral embolism occurred in 17 cases. The
interval between episodes wap usually less than 6 months. In 54.3%,
paralysis disappeared completely or almost completely within 1 yr. Cerebral
embolism was detected in 26 (19.3%) of 135 autopsy cases. The middle
cerebral artery was the most frequent site of embolism.
EMTREE DRUG INDEX TERMS
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
brain embolism
heart disease
EMTREE MEDICAL INDEX TERMS
aged
atrial fibrillation
autopsy
cardiomegaly
cerebrovascular accident
disease predisposition
embolism
exercise
hemiplegia
middle cerebral artery
mitral valve stenosis
paralysis
patient
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007790891
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 549
TITLE
Alcoholic heart disease
AUTHOR NAMES
Brigden W.
Robinson J.
AUTHOR ADDRESSES
(Brigden W.; Robinson J.) Nat. Heart Hosp., London.
CORRESPONDENCE ADDRESS
W. Brigden, Nat. Heart Hosp., London.
SOURCE
British medical Journal (1857) (1964) 5420 (1283-1289). Date of Publication:
1964
ISSN
0007-1447
ABSTRACT
Fifty patients with evidence of myocardial disease and a long-standing high
consumption of alcohol were seen over a 10-year period. The usual causes of
myocardial disease were excluded as far as possible. All but one were male,
and their ages ranged from the 4th to 8th decades. Three clinical syndromes
which depend on the dominant derangement of circulatory function at any one
time were recognized. Cardiac beriberi (aneurin-responsive disease) was the
least frequent and least serious disorder. It occurred in 5 heavy
beer-drinkers and 2 of these had had a previous gastrectomy, which was
thought to provide an additional adverse nutritional factor. Therapeutic
response to aneurin and withdrawal of alcohol was good in these patients,
but relapse has occurred following resumption of previous habits in at least
one, and another has cardiographic evidence of persistent myocardial
abnormality. A second, larger, group of patients presented with arrhythmia -
especially atrial fibrillation - with or without varying degrees of heart
failure. The ventricular rate tended to be fast and multifocal ventricular
ectopics were common. Spontaneous return to sinus rhythm occurred in some,
but usually relapse followed after a variable period. Fast heart rates,
frequent extrasystoles, cardiomegaly, and abnormal QRST complexes on the
cardiogram distinguished the condition from so-called idiopathic atrial
fibrillation. Treatment with digitalis, diuretics, and conversion of rhythm
met with variable success in this group. Reasonable health has been
maintained in some when total abstinence has been observed and when the
disease process was not far advanced on first presentation. The development
of an arrhythmia with accompanying palpitation may draw attention to
alcoholic heart disease before irreversible damage has been done. A third
group of patients presented with hypokinetic heart failure, cardiomegaly,
and electrocardiographic evidence of severe myocardial disease. Response to
treatment was moderate at first but an episodic downhill course was usual.
The electrocardiogram showed a wide range of abnormality as in other forms
of cardiomyopathy. There was a fairly close correlation between the degree
of cardiographic abnormality and the severity of the myocardial disease as
judged by heart size and response to treatment. Mild polycythemia was
observed in many patients, and was thought to be a response to low-grade
chronic cardiac insufficiency. Serum cholesterol levels tended to be lower
than average and were believed to be the result of dietary replacement by
ethanol. The pathological findings on 9 necropsy cases are described and
possible mechanisms of pathogenesis discussed. It is concluded that the
association of high alcohol consumption for a long time and myocardial
disease, manifest by arrhythmia and heart failure, is not fortuitous but
causal. However, there is no evidence on the pathogenesis of the process or
on the nature of individual susceptibility.
EMTREE DRUG INDEX TERMS
alcohol
digitalis
diuretic agent
thiamine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
alcoholic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
abstinence
alcohol consumption
atrial fibrillation
autopsy
beer
beriberi
cardiomegaly
cardiomyopathy
cholesterol blood level
electrocardiogram
extrasystole
gastrectomy
habit
health
heart arrhythmia
heart failure
heart palpitation
heart rate
heart size
male
myocardial disease
pathogenesis
patient
polycythemia
relapse
rhythm
sinus rhythm
treatment response
CAS REGISTRY NUMBERS
alcohol (64-17-5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007767026
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 550
TITLE
Response of the heart to exercise
AUTHOR NAMES
Sowton E.
AUTHOR ADDRESSES
(Sowton E.) Inst. of Cardiol., London.
CORRESPONDENCE ADDRESS
Inst. of Cardiol., London.
SOURCE
Res. Rev. Clin. Trials (1964/1965) (41-47). Date of Publication: 1964
ABSTRACT
There is some evidence to show that the maximum heart rate reached by
patients who have undergone cardiac surgery is lower than normal. At the
same time there is a subnormal increment in stroke volume, substantiated by
investigators who found no increase in stroke volume on exercise, but that
there was a subnormal rise in cardiac output mediated entirely by heart
rate. The subnormal increment in stroke volume found on exercise when heart
disease is present is a constant finding and this effect has been used to
distinguish normal individuals from those with mild cardiac lesions. The
response of the heart during exercise, expressed in terms of the
relationships between stroke volume and cardiac rate and their effects upon
cardiac output and work load, is discussed for atrial fibrillation, mitral
stenosis, atrio-ventricular block and ischemic heart disease. Discussion is
also included of the response of the normal heart to exercise in terms of
heart rate, stroke volume, ventricular filling and the effect of training
upon cardiac output, oxygen uptake and external power produced.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
exercise
heart
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
atrioventricular block
heart disease
heart injury
heart output
heart rate
heart stroke volume
heart surgery
ischemic heart disease
mitral valve stenosis
oxygen consumption
patient
workload
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007912035
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 551
TITLE
Mitral valvular disease. Hemodynamic studies of the consequences for the
circulation
AUTHOR NAMES
Werkö L.
AUTHOR ADDRESSES
(Werkö L.)
CORRESPONDENCE ADDRESS
L. Werkö, Göteborg, Sweden.
SOURCE
Almquist Wiksell (1964). Date of Publication: 1964
ABSTRACT
Personal studies are presented of the hemodynamics of naturally occurring
mitral valve disease. Pulmonary artery and wedge pressures, and
arteriovenous oxygen differences correlated directly with the degree of
disablement; cardiac output did so reciprocally. The wedge pressure was,
however, of little value in differentiating stenosis from incompetence.
Stressful procedures such as exercise, tilting, or the injection of plasma
expanders also had effects which correlated closely with disability. But
these effects were not specific for mitral valve as compared with other
cardiac disease. The degree of elevation of pulmonary artery pressure at
rest and its further rise on exercise were good guides to the severity of
the mitral valve disease, whilst the low state of the cardiac output at rest
and its failure to rise on stress reflected poor condition of the
myocardium. Digitalis given to cases of acute failure increased cardiac
output and lowered pulmonary artery pressure, both when the heart was in
sinus rhythm and when the atria were fibrillating, though more so in the
latter circumstances. Its effect was mostly on the myocardium. When the
atria were fibrillating but the patient was not in failure, digitalis
lowered pulmonary artery pressure but did not increase output. Its effect
then was mostly on the conduction of impulses. The lower cardiac output of
cases of atrial fibrillation as compared with sinus rhythm even when
digitalization was optimal was also clearly demonstrated. Renal blood flow
was reduced proportionately to the severity of the disease and glomerular
filtration rate also but less quickly. Exercise exaggerated these effects
and sodium excretion was diminished. With successful valvotomy these changes
were reversed. Digitalis glycosides intravenously also improved renal
circulation and did so before they improved the systemic one, thus,
indicating a direct effect of the drug upon the kidneys. In pregnancy both
cardiac output and renal blood flow were substantially increased despite
valve obstruction, and it is this increased output which tends to lead to
pulmonary edema.
EMTREE DRUG INDEX TERMS
digitalis
digitalis glycoside
oxygen
plasma substitute
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mitral valve disease
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
digitalization
disability
exercise
glomerulus filtration rate
heart
heart atrium
heart disease
heart muscle
heart output
hemodynamics
injection
kidney
kidney blood flow
kidney circulation
lung artery pressure
lung edema
mitral valve
obstruction
patient
pregnancy
pulmonary artery
sinus rhythm
sodium excretion
stenosis
tilting
valvuloplasty
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007766266
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 552
TITLE
Hypertensive heart disease
AUTHOR NAMES
Fleming P.R.
AUTHOR ADDRESSES
(Fleming P.R.) Dept. of Med., Westminster Hosp., Med. Sch, London.
CORRESPONDENCE ADDRESS
P.R. Fleming, Dept. of Med., Westminster Hosp., Med. Sch, London.
SOURCE
Practitioner (1964) 193:1153 (441-451). Date of Publication: 1964
ISSN
0032-6518
ABSTRACT
Persistent hypertension leads to hypertrophy and usually some dilatation of
the left ventricle in response to the increased load. Diffusion of oxygen
into the bulky myocardiai fibres is impeded, resulting, especially if
coronary arteriosclerosis co-exists, in patchy ischaemic fibrosis of the
myocardium. Symptoms: Dyspnoea on exertion arises from secondary
hypertension in the left atrium. Left ventricular failure or congestive
heart failure is often superadded. Signs: Auricular fibrillation in about
10% of cases. Pulsus alternate in incipient left ventricular failure. Left
displacement and increased force of apex beat. A third heart sound is often
heard ('gallop rhythm'). X-rays show the enlarged heart, with signs of
pulmonary venous hypertension if failure is present. In the
electrocardiogram the characteristic findings are left axis deviation and
heightened R-waves. Prognosis is closely correlated with retinopathy and
evidence of renal failure. It is improved by hypotensive treatment, which
should always be given. Ottley - Hove.
EMTREE DRUG INDEX TERMS
antihypertensive agent
oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart disease
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
congestive heart failure
coronary artery atherosclerosis
diffusion
dyspnea
electrocardiogram
exercise
fiber
fibrosis
heart
heart left atrium
heart left ventricle
heart left ventricle failure
heart muscle
heart sound
hypertension
hypertrophy
kidney failure
prognosis
R wave
retinopathy
rhythm
X ray
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007749578
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 553
TITLE
Mitral valvular disease. hemodynainic studies of tue conséquences for the
circulation
AUTHOR NAMES
Werko L.
AUTHOR ADDRESSES
(Werko L.)
SOURCE
Almquist Wiksell (1964) (83-97). Date of Publication: 1964
ABSTRACT
Personal studies are presented of the haemodynamics of naturally occurring
mitral valve disease. Pulmonary artery and wedge pressures, and
arteriovenous oxygen differences correlated directly with the degree of
disablement; cardiac output did so reciprocally. The wedge pressure was,
however, of little value in differentiating stenosis from incompetence.
Stressful procedures such as exercise, tilting, or the injection of plasma
expanders also had effects which correlated closely with disability. But
these effects were not spécifie for mitral valve as compared with other
cardiac diseases. The degree of elevation of pulmonary artery pressure at
rest and its further rise on exercise were good guides to the severity of
the mitral valve disease, whilst the low state of the cardiac output at rest
and its failure to rise on stress reflected poor condition of the
myocardium. Digitalis given to cases of acute failure increased cardiac
output and lowered pulmonary artery pressure, both when the heart was in
sinus rhythm and when the atria were fibrillating, though more so in the
latter circumstances. Its effect was mostly on the myocardium. When the
atria were fibrillating but the patient was not in failure, digitalis
lowered pulmonary artery pressure but did not increase output. Its effect
then was mostly on the conduction of impulses. The lower cardiac output of
cases of atrial fibrillation as compared with sinus rhythm even when
digitalisation was optimal was also clearly demonstrated. Renal blood flow
was reduced proportionately to the severity of the disease and glomerular
filtration rate also, but less quickly. Exercise exaggerated these effects
and sodium secretion was diminished. With successful valvotomy these changes
were reversed. Digitalis glycosides i.v. also improved renal circulation and
did so before they improved the systemic one, thus indicating a direct
effect of the drug upon the kidneys. In pregnancy both cardiac output and
renal blood flow were substantially increased despite valve obstruction, and
it is this increased output which tends to lead to pulmonary oedema. Dewar -
Newcastle-upon-Tyne (XVIII, 6, 9).
EMTREE DRUG INDEX TERMS
digitalis
digitalis glycoside
oxygen
plasma substitute
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mitral valve disease
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
digitalization
disability
exercise
glomerulus filtration rate
heart
heart atrium
heart disease
heart muscle
heart output
hemodynamics
injection
kidney
kidney blood flow
kidney circulation
lung artery pressure
lung edema
mitral valve
obstruction
patient
pregnancy
pulmonary artery
sinus rhythm
sodium excretion
stenosis
tilting
valvuloplasty
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007870443
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 554
TITLE
A diffuse endocardial fibro-elastosis with marked dilatation of the atrium
observed in an adult
AUTHOR NAMES
Yoshida T.
Nimura Y.
Sakakibara H.
Matsutani K.
Nishizaki K.
Nakata T.
AUTHOR ADDRESSES
(Yoshida T.; Nimura Y.; Sakakibara H.; Matsutani K.; Nishizaki K.; Nakata
T.) First Dept. of Int. Med., Osaka Univ. Med. Sch, Osaka, Japan.
CORRESPONDENCE ADDRESS
T. Yoshida, First Dept. of Int. Med., Osaka Univ. Med. Sch, Osaka, Japan.
SOURCE
Japanese Heart Journal (1964) 5:1 (85-92). Date of Publication: 1964
ISSN
0021-4868
ABSTRACT
A 39-year-old woman complained of severe abdominal distension and dyspnea on
exertion. Physical examination revealed slight cyanosis, slight peripheral
edema and marked distension of the cervical veins. The third heart sound was
audible at the apex but there was no murmur. The abdomen was markedly
distended with shifting dulness and a fluid wave. The liver was palpable 7
cm. below the right costal margin. X-ray of the chest revealed marked
globular enlargement of the heart and pulmonary congestion, and the ECG
showed atrial fibrillation. Marked enlargement of the right atrium was noted
by angiocardiography. The right atrial pressure determined by cardiac
catheterization was 3018 mm. Hg. Treatment with dig it ox in, mercurial
diuretics, chlorothiazides and salt restriction had only little effect, and
the patient died about 10 mth. after admission. Post-mortem examination
revealed a markedly dilated right atrium, a dilated left atrium and small
ventricles. Diffuse endocardial fibro-elastosis and peripheral fibrosis of
the liver were seen histologic-ally.
EMTREE DRUG INDEX TERMS
chlorothiazide
diuretic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
adult
elastosis
endocardium
heart atrium
EMTREE MEDICAL INDEX TERMS
abdomen
abdominal distension
angiocardiography
atrial fibrillation
autopsy
cyanosis
dyspnea
electrocardiogram
endocardial fibroelastosis
exercise
female
fibrosis
heart
heart catheterization
heart left atrium
heart right atrium
heart right atrium pressure
heart sound
liquid
liver
lung congestion
patient
peripheral edema
physical examination
sodium restriction
thorax
vein
X ray
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007742648
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 555
TITLE
Diagnosis and treatment of tricospid stenosis
AUTHOR NAMES
Kitchin A.
Turner R.
AUTHOR ADDRESSES
(Kitchin A.; Turner R.) Cardiac Dept, Western Gen. Hosp., Edinburgh.
CORRESPONDENCE ADDRESS
A. Kitchin, Cardiac Dept, Western Gen. Hosp., Edinburgh.
SOURCE
British Heart Journal (1964) 26:3 (354-379). Date of Publication: 1964
ISSN
0007-0769
ABSTRACT
The diagnosis, circulatory effects, and surgical treatment of rheumatic
tricuspid stenosis associated with mitral stenosis is discussed in relation
to 17 patients subjected to combined valvotomy. The diagnosis of tricuspid
stenosis may be difficult and is frequently overlooked. Although a large
flicking 'a* wave in the venous pulses a tricuspid diastolic murmurs right
atrial enlargement in the radiograph, right atrial hypertrophy hi the ECG,
and a pressure gradient across the tricuspid valve in diastote, offer
presumptive evidence for tricuspid stenosis, each of these features may
occur in other conditions. Large *a* waves occur in pulmonary stenosis, in
pulmonary hypertension, including that of mitral stenosis, and in organic
tricuspid incompetence. There is, however, a particular pattern of a
flicking V wave unaccompanied by a systolic wave which is characteristic of
severe tricuspid stenosis. Tricuspid diastolic murmurs may occur in dominant
tricuspid incompetence. They indicate organic tricuspid disease but are no
guide to the severity of the stenosis. Tall P waves in the ECG and right
atrial enlargement in the radiograph though present in tricuspid stenosis
are common findings in tricuspid incompetence and in right ventricular
hypertrophy with a normal tricuspid valve. Enlargement of the pulmonary
artery, congestion of the lung fields, and right ventricular hypertrophy do
not exclude severe tricuspid stenosis. A pressure gradient in diastole
across the tricuspid valve occurs both in dominant stenosis and in dominant
organic incompetence and is unreliable as a guide to tricuspid stenosis of a
severity requiring operation. Valve area calculations are similarly
unreliable if incompetence is present. Atrial fibrillation increases the
difficulty of diagnosis. When tricuspid disease is present with
fibrillation, a prominent systolic wave in the venous pulse may be
associated with severe stenosis and only minor régurgitation. The presence
of any one of these features should raise the suspicion of severe tricuspid
stenosis, and a combination is strongly suggestive. The most consistent
confirmatory evidence of severe stenosis in the presence of a tricuspid
pressure gradient proved to be the dissociation of right atrial and right
ventricular diastolic pressures during respiration. The relation of
tricuspid murmurs to respiration is discussed, and it is pointed out that in
severe tricuspid stenosis a systolic murmur from associated tricuspid
incompetence tends to decrease on inspiration. The explanation for this is
discussed in detail. Tricuspid stenosis causes a disability similar to that
in mitral stenosis but which may be unrelieved by mitral valvotomy. The
cardiac output is severely restricted both at rest and on exercise. When
atrial fibrillation occurs the venous pressure remains permanently raised.
Symptoms were relieved in 12 patients after operation. Cardiac
catheterization was repeated after operation in 5, and showed a reduction
but not complete abolition of the valve gradient. Right atrial size did not
decrease. Regression of the P pulmonate pattern in the electrocardiogram was
usual but not always complete. Three patients died during the operation, but
no death was considered to be due to the tricuspid valvotomy itself.
Traumatic, i.e. operative valvular incompetence of significant degree, only
resulted in one case. Two patients subsequently died, after éand 2 years
respectively, and this was considered to be due to the overall effects of
severe rheumatic heart disease, pleven of the 12 remaining survivors have
remained weO 2 to 6 years later: one had only a fair result. (XVIII, 6).
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diagnosis
stenosis
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
death
diastole
disability
dissociation
electrocardiogram
exercise
heart atrium enlargement
heart catheterization
heart output
heart right ventricle hypertrophy
heart ventricle enddiastolic pressure
lung
mitral valve commissurotomy
mitral valve stenosis
P wave
patient
pressure gradient
pulmonary artery
pulmonary hypertension
pulmonary valve stenosis
pulse rate
rheumatic heart disease
surgery
survivor
systolic heart murmur
tricuspid valve
tricuspid valve disease
tricuspid valve stenosis
valvuloplasty
venous pressure
X ray film
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007747607
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 556
TITLE
Statistical and clinical analysis of 405 cases of myocardial infarction
treated in the period 1948-1960 in the ist and 2nd medical clinics in lublin
ocena statystyczno-kliniczna 405 przypadkow zawalu serca (leczonych w latach
1948-1960 w i i ii klinice choroob wewnětrznych a.m. w lublinie)
AUTHOR NAMES
Kedra K.
Kolber-Postepska B.
Wielfus R.
AUTHOR ADDRESSES
(Kedra K.; Kolber-Postepska B.; Wielfus R.) Klin. Chor. Wewn. AM, .
CORRESPONDENCE ADDRESS
K. Kedra, Klin. Chor. Wewn. AM, .
SOURCE
Lublin Pol. Tyg. Uk. (1963) 18:9 (1117-1137). Date of Publication: 1963
ABSTRACT
In the period 1948-1960, 30,912 patients were treated in the ist and 2nd
Medical Clinics in Lublin. Recent myocardial infarction occurred in 405
(1.31%). The ratio of the patients with myocardial infarction to the other
patients had increased 3 times in 1951 and twice in 1956 compared with 1950.
No further increase of this ratio is reported since 1956. There are probably
multiple causes of this increase in 1951 and 1956 (improved diagnosis,
changes in habit, nutrition, etc.). The male: female ratio among patients
with recent myocardial infarction was 3.5 : i. The men were mostly in the
50-60 age group, the women in the 60-70 53.2% were workers and farmers, and
46.8% were employees and pensioners. No seasonal effect was noticed.
Adiposity occurred in 33% of the cases (45.5% in women and 20.3% in men).
Diabetes was noted in 3.2% of the patients, hypertension in 17 Smoking
occurred in 67.5% of the patients. The following clinical forms of acute
myocardial infarction were noted: anginal attack (69.3%), status asthmaticus
(7.8%), gastralgia (8.3%). Collapse was observed in 11.9% and asymptomatic
form of myocardial infarction in 1.7%. Cardiac rhythm disorders occurred in
11.6%. Atrial fibrillation was the most common form of arrhythmia but it has
had no prognostic significance. The greatest mortality rate occurred among
patients with complete atrio-ventricular block and branch block (66.7% and
50%, respectively). Thrombi and emboli were noted in 8.9% of the cases,
pneumonia in 7.6%, chronic circulatory failure in 4.9%. 108 patients died in
hospital, 44.4% of the deaths occurring during the first 2 days. Death was
due to shock with acute left-sided failure (75%), ventricular fibrillation
(13.1%), embolism, heart rupture and Stokes-Adams syndrome (12.9%). The
mortality among 278 patients who were given anticoagulants was 2.5 times
higher than among the 127 persons who did not receive them. No effect of the
anticoagulants on the appearance of emboli and thrombi was noted. In 4
patients who had received anticoagulants severe renal haemorrhage appeared,
and several blood transfusions were necessary. The followup of 71.7% of
discharged patients is reported. The mortality after éand 5 yr. was 37.6 and
49.3%, respectively. Autopsy was performed in 51 cases (47.1%). Complete
confirmation of the clinical diagnosis was noted in 82.3% of the cases. The
partial discrepancy observed in 11.7% of the cases concerned localization of
the infarct. In 6 cases, in spite of undoubted clinical signs of infarct,
autopsy did not reveal characteristic changes as death had occurred within
an hour of onset. (XVII, 19).
EMTREE DRUG INDEX TERMS
anticoagulant agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart infarction
hospital
EMTREE MEDICAL INDEX TERMS
acute heart infarction
Adams Stokes attack
agricultural worker
angina pectoris
asthmatic state
atrial fibrillation
atrioventricular block
autopsy
blood transfusion
death
diabetes mellitus
diagnosis
embolism
employee
female
follow up
groups by age
habit
heart arrhythmia
heart rhythm
heart rupture
heart ventricle fibrillation
hypertension
infarction
ischemia
kidney hemorrhage
male
mortality
nutrition
obesity
patient
pensioner
pneumonia
smoking
statistics
stomach pain
thrombus
worker
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007745608
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 557
TITLE
Beta-adrenergic receptor blockade in cardiac arrhythmias
AUTHOR NAMES
Stock J.P.P.
Dale N.
AUTHOR ADDRESSES
(Stock J.P.P.; Dale N.)
SOURCE
British medical Journal (1857) (1963) 5367 (1230-1233). Date of Publication:
1963
ISSN
0007-1447
ABSTRACT
The effect of a beta-receptor adrenergic blocking agent, pronethalol, has
been studied in patients with atrial fibrillation and other cardiac
arrhythmias. In atrial fibrillation pronethalol effectively controls the
ventricular rate, and when combined with digitalis the action of the two
drugs summmate. When the two drugs are given together they prevent the
excessive rise in ventricular rate on exercise which often occurs with
digitalis alone. This action appears to be of therapeutic value in some
patients with mitral or tricuspid stenosis. The drug seems to have little
effect in atrial flutter or paroxysmal tachycardia, but will abolish some
forms of atrial and ventricular extrasystoles. In seven patients with
digitalis-induced arrhythmias the toxic rhythm was immediately suppressed by
the drug. Pronethalol should be given with great care to patients with
incipient or established heart failure.
EMTREE DRUG INDEX TERMS
beta adrenergic receptor blocking agent
digitalis
pronetalol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
beta adrenergic receptor blocking
heart arrhythmia
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
exercise
heart atrium flutter
heart failure
heart ventricle extrasystole
paroxysmal tachycardia
patient
rhythm
tricuspid valve stenosis
CAS REGISTRY NUMBERS
pronetalol (51-02-5, 54-80-8)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007741823
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 558
TITLE
Digitalis in surgery: extension of classical indications
AUTHOR NAMES
Wheat Jr. M.W.
Burford T.K.
AUTHOR ADDRESSES
(Wheat Jr. M.W.; Burford T.K.)
SOURCE
J.Thorac.Cardiov.Surg. (1961) 41:2 (67-74). Date of Publication: 1961
ABSTRACT
It is a well-known clinical experience that in patients over the age of 60
intrathoracic resections are often followed by cardiac complications. These
arrhythmias are predominantly atrial fibrillation or flutter that uniformly
respond to digitalis. In the study of patients with or without digitalis
preparation before thoracic surgery a reduction of cardiac arrhythmias from
20 to 10% in patients over the age of 55 after digitalis preparation was
demonstrated. All patients over 60 years of age in whom a major
intrathoracic resection is contemplated should be digitalised routinely pre
operative Iy. KIe in t - Prague.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
surgery
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
diet
digestive system
feeding
heart arrhythmia
nutrition
patient
thorax surgery
CAS REGISTRY NUMBERS
digitalis (8031-42-3, 8053-83-6)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008477264
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 559
TITLE
Cardiac amyloidosis
AUTHOR NAMES
Eliot R.S.
McGee H.J.
Blount Jr. S.G.
AUTHOR ADDRESSES
(Eliot R.S.; McGee H.J.; Blount Jr. S.G.)
SOURCE
Circulation (1961) 23:4 (613-622). Date of Publication: 1961
ISSN
0009-7322
ABSTRACT
A case of cardiac amyloidosis with a i ,ogo-g. heart is presented in detail.
This is believed to be the largest amyloid heart reported, especially since
the heart represented 2.7% of the patient's total body weight, or 5 times
the normal. Eighty-two cases from the literature and 20 personal cases are
analysed, and the literature on cardiac amyloidosis reviewed. Most patients
are men over 70 yr. of age, in poor nutritional state, who have
predominantly intractable left ventricular failure, a systolic cardiac
murmur, minimal coronary atherosclerosis, cardiomegaly (av. 452 gr.),
variably positive Congo-red tests, and cardinal involvement of the heart
over other organs. ECGs in 31 cases of cardiac amyloidpsis are analysed, and
some useful correlations of special interest are made. Left axis deviation,
parietal block, and a heart weight 01450 g. or more appear in a significant
number of cases in which cardiac amyloidosis is the primary cause of death.
Atrial fibrillation is frequently found in patients with cardiac amyloid
with or without significant coronary atherosclerosis.
EMTREE DRUG INDEX TERMS
amyloid
congo red
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart amyloidosis
EMTREE MEDICAL INDEX TERMS
amyloidosis
atrial fibrillation
body weight
cardiomegaly
cause of death
coronary artery atherosclerosis
heart
heart left ventricle failure
heart weight
nutritional status
patient
systolic heart murmur
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007501404
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 560
TITLE
Cardiac amyloidorsis
AUTHOR NAMES
Eliot R.S.
AUTHOR ADDRESSES
(Eliot R.S.)
SOURCE
Circulation (1961) 23:4 (613-622). Date of Publication: 1961
ISSN
0009-7322
ABSTRACT
A case of cardiac amyloidosis with a i,ogo-g. heart is presented in detail.
This is believed to be the largest amyloid heart reported especially since
the heart represented 2.7% of the patient's total body weight, or 5 times
the normal. Eightytwo cases from the literature and 20 personal cases are
analysed, and the literature on cardiac amyloidosis reviewed. Most patients
are men over 70 yr. of age, in poor nutritional state, who have
predominantly intractable left ventricular failure, a systolic cardiac
murmur, minimal coronary atherosclerosis, cardiomegaly (av. 452 g.),
variably positive Congo-red tests, and cardinal involvement of the heart
over other organs. EGGs in 31 cases of cardiac amyloidosis are analysed, and
some useful correlations of special interest are made. Left axis deviation,
parietal block, and a heart weight 0/450 g. or more appear in a significant
number of cases in which cardiac amyloidosis is the primary cause of death.
Atrial fibrillation is frequently found in patients with cardiac amyloid
with or without significant coronary atherosclerosis. (XVIII, 5, 6, 20).
EMTREE DRUG INDEX TERMS
amyloid
congo red
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
body weight
cardiomegaly
cause of death
coronary artery atherosclerosis
egg
heart
heart amyloidosis
heart left ventricle failure
heart weight
nutritional status
patient
systolic heart murmur
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007404152
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 561
TITLE
A correlation of clinical and hemodynamic studies in pahents with
hyperthyroidism with and without congestive heart failure
AUTHOR NAMES
Graettinger J.S.
Muenster J.J.
Selverstone L.A.
Campbell J.A.
AUTHOR ADDRESSES
(Graettinger J.S.; Muenster J.J.; Selverstone L.A.; Campbell J.A.)
Cardio-Resp. Div., Dept. of Med., Presbytcnan Hosp., Boston, MA, United
States.
CORRESPONDENCE ADDRESS
J.S. Graettinger, Cardio-Resp. Div., Dept. of Med., Presbytcnan Hosp.,
Boston, MA, United States.
SOURCE
J. Din. Invesl. (1959) 38:8 (190-200). Date of Publication: 1959
ABSTRACT
Twenty thyrotoxic patients were studied before and after they were rendered
euthyroid, in order to attempt to determine the mechanism of heart failure
in thyrotoxicosis. Fourteen of the patients did not have congestive heart
failure, and, although 6 of them had antecedent heart disease, all
demonstrated normai haemodynamic responses to exercise. All of the patients
who had been in congestive failure showed inadequate response of the cardiac
output to exercise, but only 3 of them had an elevated cardiac output at
rest. Atrial fibrillation was not found in the thyrotoxic patients without
heart disease. The authors feel that the excessive load on the peripheral
circulation that occurs in thyrotoxicosis is of similar iaagrntude to that
which occurs in systemic arterio-venous fistulae. They conclude that the
increased circulatory load of thvrotoxicosis may lead to congestive heart
failure in the following circumstances. (1) When myocarchal reserve has been
impaired by heart disease of other aetiology. (2) When the thyrotoxicosis
itself becomes so severe that it causes a temporary myocardial failure. (3)
When the peripheral circulatory load is increased so much by thyrotoxicosis
that it overcomes the reserve of the previously normal heart.
EMTREE DRUG INDEX TERMS
phosphorus
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure
hyperthyroidism
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
blood pressure
etiology
exercise
fistula
heart
heart disease
heart failure
heart output
patient
peripheral circulation
thyrotoxicosis
CAS REGISTRY NUMBERS
phosphorus (7723-14-0)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007679459
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 562
TITLE
The use of ganglionblocking substance (promethazine and diethazine) in
operations on the thyroid gland in patients with thyrotoxicosis under local
anaesthesia with 0.5% novocaine solution
AUTHOR NAMES
Agafonov F.A.
AUTHOR ADDRESSES
(Agafonov F.A.)
SOURCE
Problemy Endokrinologii (1958) 4:4 (104-106). Date of Publication: 1958
ISSN
0375-9660
ABSTRACT
Promethazine and diethazine, phenothiazine derivatives, were administered
before the operation to 62 patients with thyrotoxicosis aged from 11 to 60
yr. These included 27 cases with a grave form of thyrotoxicosis, 31 with
thyrotoxicosis of average severity and 4 with a mild form of this disease.
After the usual breakfast the patients were given 0.025 g. of promethazine
and 0.15% of diethazine in tablets (children under 15 yr. received a lower
dose). In about an hour after administration of the drugs the patients
exhibited drowsiness with decreased reaction to external stimulations. This
condition lasted 4 to 6 hr. after the operation. Patients with
thyrotoxicosis and auricular fibrillation have a poor tolerance to
ganglion-blocking preparations.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
diethazine
procaine
promethazine
EMTREE DRUG INDEX TERMS
ganglion blocking agent
phenothiazine derivative
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
local anesthesia
patient
thyroid gland
thyrotoxicosis
EMTREE MEDICAL INDEX TERMS
aged
anesthesia
atrial fibrillation
child
drowsiness
gallbladder
ganglion block
meal
stimulation
surgery
tablet
thyroid surgery
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007927778
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 563
TITLE
Experience with intramuscular digoxin
AUTHOR NAMES
Fletcher E.
Brennan C.F.
AUTHOR ADDRESSES
(Fletcher E.; Brennan C.F.) Belfast City Hosp., Belfast, United Kingdom.
CORRESPONDENCE ADDRESS
E. Fletcher, Belfast City Hosp., Belfast, United Kingdom.
SOURCE
Irish Journal of Medical Science (1958) 6:290 (273-280). Date of
Publication: 1958
ISSN
0021-1265
ABSTRACT
Intramuscular digoxin in doses of 1-2 mg. reduced the ventricular frequency
to less than 90/min. within 5 to 19 hr. in 15 of 18 cardiac patients with
atrial fibrillation. 0.5 mg. every 8 to 24 hr. was sufficient as a
maintenance dose in 9 out of 10 cases. Comparative examinations of the heart
frequency in 17 patients showed no significant difference between the
effects of 1 mg. digoxin administered i.v. and i.m. in the same patients
during an observation period of 10 hr. Combination with a mercurial diuretic
(mersalyl) increased the effect of i.m. administered digoxin. In this series
of experiments, 2 types of systolic retardation occurred : one, with rapid
onset, lasting from 2 to 3 hr., which was attributed to a vagus function and
was eliminated by physical exercise or atropine injections; and a 2nd type,
provoked by digoxin, and seen most markedly 6 hr. after injection of the
drug. Toxic arrhythmias were caused in 3 cases within 6-14 hr., by doses of
1 to 1.5 mg. In 2 cases nausea was observed following doses of over 4 mg.
The otherwise effective i.m. digoxin therapy imposes certain restrictions,
because of consistent painfulness of the injection, starting one-half to 3
hr. after administration and sometimes lasting 2 weeks or more. Frequent
injections increased the painlulness. finally necessitating discontinuation
of the therapy. The pain is a direct result of the effect of digoxin on the
skeletal muscles; the solvent has no painful effect.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digoxin
EMTREE DRUG INDEX TERMS
atropine
diuretic agent
mersalyl
solvent
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiac patient
examination
exercise
heart arrhythmia
heart rate
injection
intramuscular drug administration
maintenance drug dose
nausea
pain
patient
skeletal muscle
therapy
vagus nerve
CAS REGISTRY NUMBERS
digoxin (20830-75-5, 57285-89-9)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008306752
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 564
TITLE
The effect of 2-diethylaminoethyl-isonicolimamide on cardiac arrhythmia in
man
AUTHOR NAMES
Werner I.
AUTHOR ADDRESSES
(Werner I.) Med. Clin., Univ. of Uppsala, .
CORRESPONDENCE ADDRESS
Med. Clin., Univ. of Uppsala, .
SOURCE
Acta medica Scandinavica (1957) 158:3-4 (225-233). Date of Publication: 1957
ISSN
0001-6101
ABSTRACT
The drug was administered orally in gelatmated capsules containing 0.250 g.
and i.v. in an aqueous solution containing 0.100 g./ml. The oral
administration, in which the dose varied from 2 to 5 g. daily, was totally
ineffective. Slow i.v. administration of a total dose of 1 to 2 g., at a
speed not exceeding 0.100 g. per min. was effective only in 1 out of 8 cases
of paroxysmal tachycardia. As these results were not in accordance with
those obtained experimentally, the speed of the injection was increased to
0.1 g. in 1 to 2 sec. A very good effect was then observed in atrial
paroxysmal tachycardia, the change in rhythm being instantaneous in all
cases. Four patients with other types of atrial tachycardia and not
presenting a history of paroxysmal onset did not benefit from the treatment.
One case of atrial flutter was treated 7 times with rapid i.v. injections,
with good results each time. Of fourteen cases with atrial fibrillation and
a high ventricular rate normal rhythm was restored in 5, in 3 a definite
slowing of the ventricular rate was observed. In 6 cases no effect was
observed. In ventricular arrhythmia no beneficial effects were obtained.
One-third of the cases presented a transitory fall in the systolic pressure,
between 5 and 15 mm. Hg, which lasted only a few minutes. In 2 cases of
atrial fibrillation there were ventricular extrasystoles before normal sinus
rhythm was established. Subjectively, the majority of the patients
experienced a feeling of heat in the face and the upper part of the trunk,
which lasted 5 to 15 min. only. Nausea and vomiting occurred. The mode of
action of the drug is not clear. It has been suggested that the principal
effect is to prolong the refractory period without significantly influencing
the conductivity. Probably there is also a direct depressing effect on
ectopic atrial foci.
EMTREE DRUG INDEX TERMS
cortisone
isonicotinamide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart arrhythmia
human
EMTREE MEDICAL INDEX TERMS
aortography
aqueous solution
atrial fibrillation
conductance
heart atrium flutter
heart ventricle arrhythmia
heart ventricle extrasystole
heat
injection
nausea and vomiting
oral drug administration
paroxysmal supraventricular tachycardia
paroxysmal tachycardia
patient
refractory period
rhythm
sinus rhythm
supraventricular tachycardia
systolic blood pressure
velocity
CAS REGISTRY NUMBERS
cortisone (53-06-5)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007428608
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 565
TITLE
Falls in the elderly
AUTHOR NAMES
Firth S.J.
AUTHOR ADDRESSES
(Firth S.J.)
SOURCE
Medical Press (1957) 238:15 (343-346). Date of Publication: 1957
ISSN
0368-9492
ABSTRACT
A fall or a tendency to fall may be the first symptoms of pathological
processes in the elderly. They can be localized in: (1) The cardiovascular
system. Degenerative changes in the arteries may lead to transient cerebral
anaemia. Iron deficiency anaemia, often present in the elderly, may
contribute to attacks of giddiness and a tendency to fall. Many cases of
syncope are of cardiac origin and an ECG may reveal evidence of a recent
myocardial infarction. (2) Skeletal system. Corns, burtons, hallux rigidus
and pes planus contribute to unsteadiness. Rheumatoid and osteo-arthritic
changes in joints may lead to disuse atrophy in groups of muscles and so
predispose to a fall. Paget's disease and generalized osteoporosis
predispose to spontaneous fracture of the femoral neck with a resultant
fall. Generalized muscle weakness caused by inoperable growths or advanced
pulmonary or cardiac conditions may lead to a shuffling gait and tripping.
Obesity is often associated with weakening of muscle groups. (3) CNS.
Defects of vision become a serious handicap. Cerebrovascular accidents
produce more dramatic falls. These may be due to cerebral haemorrhage,
cerebral embolus, usually as a consequence of auricular fibrillation and
cerebral thrombosis, by far the most frequent cause of cerebral catastrophe
and often leading to dizziness and falling as early symptoms. Parkinson's
disease, epilepsy, cerebral tumour and alcoholism are also causes of falls.
Prevention: better housing and accommodation, non-slip floors and short
handrails in bathroom and lavatory. A sensible amount of physical exercise
is necessary to maintain physical fitness and is very important for the
prevention of accidents. Regular contact with other people, good nutritional
standards and good standards of personal hygiene may also contribute to the
prevention of falls.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aged
EMTREE MEDICAL INDEX TERMS
accident
accommodation
alcoholism
anemia
artery
atrial fibrillation
atrophy
bath
brain hemorrhage
callosity
cardiovascular system
catheter
central nervous system
cerebrovascular accident
disability
disaster
dizziness
electrocardiogram
embolism
epilepsy
exercise
faintness
femur neck
fitness
flatfoot
gait
hallux rigidus
heart infarction
housing
iron deficiency anemia
muscle
muscle weakness
neoplasm
obesity
occlusive cerebrovascular disease
osteoporosis
Parkinson disease
pathologic fracture
personal hygiene
prevention
skeleton
unsteadiness
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007929116
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 566
TITLE
Disease of the sinoatrial node associated with bradycardia, asystole,
syncope, and paroxysmal atrial fibrillation
AUTHOR NAMES
Birchfield R.I.
Menefee E.E.
Bryant G.D.
AUTHOR ADDRESSES
(Birchfield R.I.; Menefee E.E.; Bryant G.D.) N. Dept. of Med., Duke Univ.,
Durham, NC, United States.
CORRESPONDENCE ADDRESS
R.I. Birchfield, N. Dept. of Med., Duke Univ., Durham, NC, United States.
SOURCE
Circulation (1957) 16:1 (20-26). Date of Publication: 1957
ISSN
0009-7322
ABSTRACT
The clinical picture produced by disease of the sinoatrial (S-A) node is
described and illustrated by a case report. Disease of the S-A node has been
implicated as the cause of the persistent bradycardia. Autonomic influences
over the A-V node have been implicated in the production of asystole. In
this patient any manoeuvre decreasing vagal tone was of benefit because
these circumstances allowed the rhythm of the heart to be controlled by the
A-V node. Sitting up, exercise, and atropine were all effective means of
initiating nodal rhythm.
EMTREE DRUG INDEX TERMS
atropine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
bradycardia
faintness
heart arrest
sinus node
EMTREE MEDICAL INDEX TERMS
atrioventricular junction arrhythmia
case report
exercise
heart
patient
rhythm
sitting
vagus tone
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007427011
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 567
TITLE
The pathogenesis of systemic arterial embolism in rheumatic heart disease
AUTHOR NAMES
Askey J.M.
AUTHOR ADDRESSES
(Askey J.M.) Univ. of Southern California, Sch. of Med., Los Angeles, CA,
United States.
CORRESPONDENCE ADDRESS
J.M. Askey, Univ. of Southern California, Sch. of Med., Los Angeles, CA,
United States.
SOURCE
Modern Concepts of Cardiovascular Disease (1957) 26:7 (399-402). Date of
Publication: 1957
ISSN
0026-7600
ABSTRACT
The origin of clots in the cardiac chambers is discussed. In about half the
cases quoted from Söderström definite lesions of the heart chamber were
found in atrial clots. The right-atrial clots were mainly non-rheumatic in
type and the majority of the left were of rheumatic origin. Myocardial
infarction following coronary disease produces a large percentage of thrombi
being limited to the left ventricle and right atrium. The majority of left
atrial thrombi due to rheumatic disease (84%) are in association with mitral
stenosis and atrial fibrillation. There is no greater incidence of rheumatic
disease of the chamber in fibrillation and consequently the factors of
relative stasis or disturbed atrioventricular flow must also be included.
Atrial dilatation also occurs with its consequent greater contained volume.
Apparently only half of the left-atrial thrombi are detached into the
general circulation. The reason for this proportion is conjectural. The
initiation of an attack of fibrillation causes as many emboli as does the
conversion of fibrillation into normal rhythm. This refutes the notion
formerly held that most emboli occur in conversion of fibrillation to normal
rhythm. No correlation has been found in the dislodgment of thrombi due to
rapid heart beat or exercise and it is concluded that the mobilization of an
embolus is in the main a fortuitous event.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
artery embolism
pathogenesis
rheumatic heart disease
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
coronary artery disease
embolism
exercise
heart
heart atrium enlargement
heart atrium thrombosis
heart beat
heart disease
heart infarction
heart left ventricle
heart right atrium
mitral valve stenosis
mobilization
rheumatic disease
rhythm
thrombus
weight reduction
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007925405
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 568
TITLE
Cardiorespiratory function two years after mitral valvotomy
AUTHOR NAMES
Donald K.W.
Bishop J.M.
Wade O.L.
Wormald P.N.
AUTHOR ADDRESSES
(Donald K.W.; Bishop J.M.; Wade O.L.; Wormald P.N.) Dept. of Med., Univ. of
Birmingham, Queen Elizabeth Hosp., Birmingham, United Kingdom.
CORRESPONDENCE ADDRESS
K.W. Donald, Dept. of Med., Univ. of Birmingham, Queen Elizabeth Hosp.,
Birmingham, United Kingdom.
SOURCE
Clinical Science (1957) 16:2 (325-350). Date of Publication: 1957
ISSN
0143-5221
ABSTRACT
Measurements of the cardiac output, the pulmonary vascular pressures,
ventilation and oxygen uptake at rest and on exercise have been made in 28
patients with mitral stenosis before and 17-51 months after the operation of
mitral valvotomy in which the surgeon considered that the patency and
function of the mitral valve had been satisfactorily improved. Twenty-four
of the 28 patients were greatly improved, as judged clinically, by the
operation. Calcification of the mitral valve, auricular fibrillation, a
raised sedimentation rate or a history of cardiac failure did not preclude a
good result. The most striking finding was that ventilation at rest and on
exercise was greatly reduced after operation in the large majority of
patients. Despite the marked clinical improvement the resting cardiac output
fell after operation in 24 of the 28 patients and in 20 it was below 2.5
l./min./sq.m.. The response of the cardiac output to exercise was greater
than before operation in only 6 patients. Before operation the resting
oxygen uptake was considerably above the normal values in a number of these
patients. This was attributed to the increased work of breathing. After
operation the resting oxygen uptake fell in 24 of the 28 patients and was
now normal in all but one instance. The wedge pressure was lower after
operation in all but 2 of the series but remained abnormally high in almost
all patients. On exercise the wedge pressure was extremely elevated even in
those patients who now had no disability. The mean pulmonary arterial
pressure at rest lea after the operation in all except 2 patients but
remained abnormally high in all but 3 instances. The fall in pulmonary
arterial pressure was greater than the fall in wedge pressure. The
exercising pulmonary arterial pressure was lower after the operation in most
patients but remained highly abnormal even in those who now had little or no
disability. There was a marked reduction of the work of the right ventricle
at rest after operation and it was now within normal limits in 24 of the 28
patients. Reduction of the work of the right ventricle on exercise was not
so marked. Intermediate post-operative studies were carried out in 9
patients. There was objective evidence of some deterioration between the
first and second postoperative studies in 6 patients of whom only 2 showed
parallel clinical deterioration.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mitral valve commissurotomy
EMTREE MEDICAL INDEX TERMS
air conditioning
atrial fibrillation
blood pressure
calcification
cardiomegaly
deterioration
disability
exercise
heart failure
heart output
heart right ventricle
lung artery pressure
lung function test
mitral valve
mitral valve stenosis
normal value
oxygen consumption
patient
sedimentation rate
surgeon
vagus nerve
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007426563
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 569
TITLE
A clinical study of one hundred cases of severe aortic insufficiency
AUTHOR NAMES
Segal J.
Harvey W.P.
Hufnagel C.
AUTHOR ADDRESSES
(Segal J.; Harvey W.P.; Hufnagel C.) Depts of Mod. (Sect, of Cardiol.) and
Surg., Georgetown Univ. Med. Center, Washington, DC, United States.
CORRESPONDENCE ADDRESS
J. Segal, Depts of Mod. (Sect, of Cardiol.) and Surg., Georgetown Univ. Med.
Center, Washington, DC, United States.
SOURCE
American Journal of Medicine (1956) 21:2 (200-210). Date of Publication:
1956
ISSN
0002-9343
ABSTRACT
The clinical features in 100 cases of severe aortic insufficiency are
reviewed. Eightythree cases were rheumatic, 12 syphilitic, 4 congenital and
one traumatic. The average age of the patients was 34 yr. The natural
clinical course of rheumatic aortic insufficiency and syphilitic aortic
insufficiency are compared. The progression of symptoms in syphilitic aortic
insufficiency was twice as rapid as in the rheumatic group. In the rheumatic
group, the average patient had rheumatic fever at age 13, developed
haemodynamically significant aortic insufficiency at age 20, and noted
symptoms at age 30. The symptomatic period ranged from 2 months to 30 yr.,
averaging 6.4 yr. Cardiac palpitation and dyspnoea on exertion were the
earliest and most frequent symptoms in aortic insufficiency of any
aetiology. Angina pectoris occurred in almost 50% of the rheumatic group.
This was not related to coronary artery disease or to coronary ostial
involvement. The average blood pressure was 155/37 mm. Hg, An aortic
systolic and diastolic murmur, apical systolic murmur, ventricular diastolic
gallop and Austin Flint murmur were present in every case. Hepatomegaly
occurred in over 50% of the cases. Radiologie findings included left
ventricular enlargement, aortic "jump" and "rocking" motion of the heart.
Posterior displacement of the oesophagus occurred in approximately 50% of
the patients and 60% of these had systolic expansion of the left auricle.
ECG's usually demonstrated normal sinus rhythm, left ventricular hypertrophy
and, frequently, first degree AV block. Auricular fibrillation or a vertical
electrical axis with large P waves often indicated mitral stenosis.
Bacterial endocarditis had occurred in 22% of the rheumatic group and was
frequently followed by progressive cardiac, decompensation. The following
factors indicated a poor prognosis: (1) recent occurrence of bacterial
endocarditis with subsequently increasing signs of aortic insufficiency; (2)
coexistence of angina pectoris and congestive heart failure; (3) syphilitic
aetiology; (4) marked cardiomegaly; (5) increasing age (over 40) and/ or
increasing duration of symptoms. The authors' experience, like that of
others, indicates that patients with "free" aortic insufficiency often
remain asymptomatic for many years. Congestive failure and/or angina
pectoris frequently were present for many years, often with remissions and
exacerbations which were related to rheumatic activity. Some patients were
maintained for years on conservative medical management but usually
progressive failure occurred.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aorta valve regurgitation
clinical study
EMTREE MEDICAL INDEX TERMS
angina pectoris
atrial fibrillation
atrioventricular block
bacterial endocarditis
blood pressure
cardiomegaly
clinical feature
congestive heart failure
coronary artery disease
disease course
disease management
dyspnea
electrocardiogram
esophagus
etiology
exercise
heart
heart failure
heart left ventricle hypertrophy
heart palpitation
hepatomegaly
mitral valve stenosis
P wave
patient
prognosis
remission
rheumatic fever
sinus rhythm
systolic heart murmur
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007393132
FULL TEXT LINK
http://dx.doi.org/10.1016/0002-9343(56)90053-5
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 570
TITLE
Auricular fibrillation with special reference to rheumatic heart disease
AUTHOR NAMES
Eraser H.R.L.
Turner R.W.D.
AUTHOR ADDRESSES
(Eraser H.R.L.; Turner R.W.D.)
SOURCE
British medical Journal (1857) (1955) 4953 (1414-1418). Date of Publication:
1955
ISSN
0007-1447
ABSTRACT
Over a period of 5 years a study has been made of auricular fibrillation (A.
F. ) in relation to 500 patients with rheumatic mitral disease. Of these 250
were treated surgically. Factors which may precipitate A. F. include
exercise, emotion, infection and active carditis, but usually no cause is
apparent. The onset of A. F. may pass unnoticed or be responsible for
dyspnoea., pulmonary oedema, pulmonary infarction, systemic embolism,
cardiac failure, loss of consciousness, or anxiety. Relative advantages of
established A. F. include freedom from paroxysmal attacks, ease of control
of heart rate with digitalis, and comparative freedom from bacterial
endocarditis. Persons with A. F. tend to have larger hearts than those in
sinus rhythm, but reasons are given for concluding that enlargement is not
directly related to the arrhythmia. Possible factors in the pathogenesis of
A. F. are reviewed, and it is concluded that there is presumptive evidence
that myocardial damage may be the most important. A. F. is not a
contraindication to valvotomy, but a disadvantage from the presumed presence
of myocardial damage and the increased probability of clot being present,
with the consequent risk of embolism. A. F. had occurred pre-operatively in
42% of the surgical series. In these 106 patients clot was found in the left
auricle or atrium in 40%, but in only 3 of 144 patients in sinus rhythm. The
presence of a régurgitant jet seems to militate against thrombus formation.
Good operative results may be obtained in cases of A. F. and life thereby
prolonged, but the operative risk is greater and the ultimate prognosis
poorer than in cases with sinus rhythm. Post-operative A. F. occurred in 23%
of those previously in sinus rhythm. In the first 10 postoperative days it
is rarely possible to restore sinus rhythm with quinidine, but thereafter
success is almost always obtained. Pre-operative prophylactic quinidine is
ineffective.
EMTREE DRUG INDEX TERMS
digitalis
quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
rheumatic heart disease
EMTREE MEDICAL INDEX TERMS
anxiety
bacterial endocarditis
blood clotting
carditis
consciousness
dyspnea
embolism
emotion
exercise
heart
heart arrhythmia
heart atrium
heart failure
heart muscle injury
heart rate
infection
lung edema
lung infarction
mitral valve disease
pathogenesis
patient
prognosis
risk
sinus rhythm
surgical risk
valvuloplasty
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007385004
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 571
TITLE
Cardiac arrhythmias in the aged
AUTHOR NAMES
Scherf D.
AUTHOR ADDRESSES
(Scherf D.) Dept. of Med., New York Med. Coll., Metropolitan Hosp. Div., New
York, NY, United States.
CORRESPONDENCE ADDRESS
D. Scherf, Dept. of Med., New York Med. Coll., Metropolitan Hosp. Div., New
York, NY, United States.
SOURCE
Geriatrics (1954) 9:2 (47-56). Date of Publication: 1954
ISSN
0016-867X
ABSTRACT
There are no arrhythmias nor ECG changes characteristic of old age. Sinus
bradycardia may be present in 13% of subjects over the age of 70. As
atropine causes no increase of heart-rate it is possible that the
bradycardia is due to changes in the blood supply or metabolism of the sinus
node. Sinus tachycardia is present in 8% of subjects over 70. Sinus
arrhythmia which is unrelated to respiration may be found in the elderly and
it is believed to be associated with changes in the vessels supplying blood
to the sinus node tissue. Similar changes are believed to be the cause of
shifting of the pace-maker from sinus node to upper atrioventricular node
with the presence in the ECG of varying P waves. The carotid sinus syndrome
is probably no commoner in the elderly than in younger subjects, but its
symptoms are more severe. In the normal heart the ventricular centres which
are not under vagal control take over when auricular inhibition occurs. In
the elderly these centres do not perform so efficiently and prolonged
cardiac standstill occurs and is not without dangers. Extrasystoles are
commoner in the elderly than in the young; auricular extrasystoles sometimes
precede the appearance of auricular fibrillation. The appearance of
ventricular extrasystoles after exercise suggests the presence of
coronary-arterial disease as do the presence of multiple forms of
ventricular extrasystoles. 'Anarchie ventriculaire', the presence of
frequent and variable ventricular extrasystoles forebodes sudden death. It
is sometimes, but not invariably, caused by the administration of digitalis.
If not caused by digitalis, administration of this drug may be beneficial.
Quinidine seems to precipitate ventricular fibrillation and should be
avoided in this condition. Paroxysmal tachycardia is commoner in the elderly
than in the young and is often associated with the presence of
atrioventricular heart block which may be due to the administration of
digitalis. Conduction defects often cause slow ventricular rates in the
presence of auricular fibrillation in the elderly. Paroxysms of auricular
fibrillation or flutter are often missed clinically unless the patient is
questioned about transient palpitations, dizziness and chest pain.
Atrioventricular heart block is related to the presence of atherosclerosis.
Stokes-Adams attacks are more frequently found in the elderly because
idioventricular rhythm is not established as promptly as in the young. In
this condition quinidine, ephedrine and adrenaline sometimes precipitate
ventricular fibrillation.
EMTREE DRUG INDEX TERMS
adrenalin
atropine
digitalis
ephedrine
quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aged
heart arrhythmia
EMTREE MEDICAL INDEX TERMS
Adams Stokes attack
artery disease
atherosclerosis
atrial fibrillation
atrioventricular block
blood
bradycardia
carotid sinus syndrome
dizziness
electrocardiogram
exercise
extrasystole
heart
heart atrioventricular node
heart muscle conduction disturbance
heart palpitation
heart rate
heart ventricle extrasystole
heart ventricle fibrillation
metabolism
P wave
paroxysmal tachycardia
patient
rhythm
senescence
sinus arrhythmia
sinus bradycardia
sinus node
sinus tachycardia
sudden death
thorax pain
tissues
vascularization
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008546707
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 572
TITLE
Lone auricular fibrillation
AUTHOR NAMES
Evans W.
Swann P.
AUTHOR ADDRESSES
(Evans W.; Swann P.) Cardiac Dept., London Hosp., London, United Kingdom.
CORRESPONDENCE ADDRESS
W. Evans, Cardiac Dept., London Hosp., London, United Kingdom.
SOURCE
British Heart Journal (1954) 16:2 (189-194). Date of Publication: 1954
ISSN
0007-0769
ABSTRACT
The term 'lone auricular fibrillation' is suggested to describe auricular
fibrillation which occurs in the absence of heart disease or thyroid
toxaemia. This condition is not the same as paroxysmal fibrillation which
probably originates from a separate mechanism and requires different
management. 'Lone' fibrillation was not seen in women, all the 20 patients
observed being men. The basic heart rate is slow and the condition is often
symptom less until discovered by a routine examination: if symptoms do occur
palpitation is the predominant symptom, dependent on exertion and consequent
tachycardia for its production. Radiological examination reveals no general
cardiac enlargement or enlargement of the left auricle and no pulmonary
congestion. The condition does not jeopardise life or even prove a handicap
as a rule, but if the patient follows a heavy occupation where exertion
increases the heart rate sufficiently to cause palpitation, daily medication
with digitalis fol. is the treatment of choice. Attempts to restore normal
rhythm in elderly patients should not be made.
EMTREE DRUG INDEX TERMS
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
EMTREE MEDICAL INDEX TERMS
aged
cardiomegaly
disability
drug therapy
exercise
female
heart disease
heart palpitation
heart rate
lung congestion
medical examination
occupation
patient
radiodiagnosis
rhythm
tachycardia
thyroid gland
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007303551
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 573
TITLE
Ventricular rate response following exercise during auricular fibrillation
and after conversion to normal sinus rhythm
AUTHOR NAMES
Wetherbee D.G.
Brown M.G.
Holzman D.
AUTHOR ADDRESSES
(Wetherbee D.G.; Brown M.G.; Holzman D.) Med. Serv., Cushing Vet. Adm.
Hosp., Framingham, MA, United States.
CORRESPONDENCE ADDRESS
D.G. Wetherbee, Med. Serv., Cushing Vet. Adm. Hosp., Framingham, MA, United
States.
SOURCE
Amer. J. Med. Sci. (1952) 223:6 (667-670). Date of Publication: 1952
ABSTRACT
The ventricular rate response following exercise on die Master seeps was
studied during auricular fibrillation in 10 patients. Four had
arterio-sclerotic heart disease and 4 had rheumatic heart disease. Seven had
been in congestive heart failure but cardiac compensation was restored. The
exercise test was repeated after normal sinus rhythm was restored - by
quinidine in 9, spontaneously in one. All 10 patients had an exaggerated
ventricular peak rate response during fibrillation, whether or not they had
received digitalis, and all showed significantly reduced peak rate response
after restoration to normal sinus rhythm.
EMTREE DRUG INDEX TERMS
digitalis
quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise
sinus rhythm
EMTREE MEDICAL INDEX TERMS
compensation
congestive heart failure
exercise test
heart disease
malaria
multiple myeloma
patient
rheumatic heart disease
therapy
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2008917847
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 574
TITLE
Treatment of mitral stenosis by finger fracture valvulotomy
AUTHOR NAMES
Gerbode F.
Holman E.
Hultgren H.
AUTHOR ADDRESSES
(Gerbode F.; Holman E.; Hultgren H.) Dept. of Surg., Cardiovascular Lab.,
Stanford Univ. Sch. of Med., San Francisco.
CORRESPONDENCE ADDRESS
Dept. of Surg., Cardiovascular Lab., Stanford Univ. Sch. of Med., San
Francisco.
SOURCE
Trans. W. Surg. Ass. (1952) 59 (343-357). Date of Publication: 1952
ABSTRACT
Patients with mitral stenosis with little or no regurgitation who are
experiencing increasing disability from their disease should be considered
for operation. The mere diagnosis of mitral stenosis is insufficient reason
for operation, since many of these patients do extremely well on a proper
medical regimen. Contraindications to operation are: uncontrollable failure,
moderate to severe mitral regurgitation, other valvular involvement,
enlargement of the left ventricle, active rheumatic disease, and
endocarditis. Auricular fibrillation and slight mitral regurgitation are not
contraindications. Patients whose intake of salt and fluid has been markedly
restricted and who have received mercurial diuretics should probably be
allowed a liberalized salt intake for several days before operation. An
anterolateral approach through the fourth interspace with division of the
third and fourth costal cartilages is recommended. The finger fracture type
of valvulotomy is recommended because of its relative simplicity and the
excellent results which have followed its use in most instances. Forty-four
patients have had valvulotomy performed by this method, with 5 deaths.
Fourteen of these cases have been followed up for more than four months
after operation. Nine of these have had marked improvement in their physical
status, two have had only moderate improvement, and three have shown slight
or no improvement. Twelve patients have had extensive physiological studies
with the aid of cardiac catheterization before and at various intervals
after operation. From these data the following objective conclusions can be
drawn: 2 patients showed no improvement, 10 patients showed moderate to
striking degrees of improvement in cardiac function, as indicated by
increases in cardiac output at rest and with exercise and by decreases in
pulmonary artery and right ventricular diastolic pressures. Three patients
with severe pulmonary hypertension and some right ventricular failure showed
striking improvement. The physiological improvement is sustained and is
often progressive.
EMTREE DRUG INDEX TERMS
diuretic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
finger fracture
mitral valve stenosis
valvuloplasty
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
death
diagnosis
disability
endocarditis
exercise
heart catheterization
heart function
heart left ventricle
heart output
heart right ventricle failure
heart ventricle enddiastolic pressure
liquid
mitral valve regurgitation
patient
physiology
pulmonary artery
pulmonary hypertension
rheumatic disease
rib cartilage
salt intake
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007627251
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 575
TITLE
Clinical diagnosis of abnormal cardiac rhythms or cardiac arrhythmias
AUTHOR NAMES
Vakil R.J.
Golwalla A.
AUTHOR ADDRESSES
(Vakil R.J.; Golwalla A.) Cardiol. Unit., K. E. M. Hosp., Bombay, India.
CORRESPONDENCE ADDRESS
R.J. Vakil, Cardiol. Unit., K. E. M. Hosp., Bombay, India.
SOURCE
Indian Heart Journal (1952) 4:2 (72-88). Date of Publication: 1952
ISSN
0019-4832
ABSTRACT
Most arrhythmias encountered in practice can be accurately diagnosed without
the aid of an electrocardiogram if due attention is paid to the history,
physical signs and, less often, roentgenographic findings. Certain
disturbances of cardiac rhythm are prone to occur in definite age groups.
Others, auricular fibrillation for example, tend to be more common in
females when hyperthyroidism or mitral stenosis coexists. The mode of onset
(abrupt or slow) or the associated circumstances (premature ventricular
contractions shortly after coronary thrombosis) may prove informative. The
symptomatic manifestations (palpitation, vertigo, anginal pain and the like)
often provide clues to the diagnosis. The same situation prevails in respect
of the duration of the attack, drugs or poisons ingested, probable causes,
and methods of terminating the episode. Determination of the presence or
absence of an arrhythmia, the apical rate, type of jugular pulsations, the
effect of exercise or other cardiac accelerating measures, the effect of
carotid sinus stimulation and the character of the heart sounds constitute
essential items in the physical examination. The presence of associated
heart disease, pulse deficit, and character of the apex beat should also be
noted. A clinical classification of abnormal cardiac rhythms is also given.
There are regular, irregular and clinically silent rhythms. The regular
rhythms may be slow, fast, normal, or inconstant and so forth. The clinician
is urged to develop all sources of clinical information before resorting to
instrumental aids.
EMTREE DRUG INDEX TERMS
poison
sulfanilamide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
diagnosis
heart arrhythmia
heart rhythm
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
carotid sinus massage
clinical classification
coronary artery thrombosis
electrocardiogram
electroencephalogram
exercise
female
groups by age
heart disease
heart palpitation
heart sound
heart ventricle extrasystole
hyperthyroidism
mitral valve stenosis
pain
physical examination
pulse rate
rhythm
vertigo
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007293254
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 576
TITLE
Isolated mitral stenosis. A short summary of clinical, roentgenological,
phonocardiographic, electrocardiographic, and pathophysiologic examinations
of 200 cases
AUTHOR NAMES
Nylin G.
AUTHOR ADDRESSES
(Nylin G.)
SOURCE
Acta medica Scandinavica (1952) 142:SUPPL. 266 (797-815). Date of
Publication: 1952
ISSN
0001-6101
ABSTRACT
A study on 200 cases of mitral stenosis without associated disease of other
valves. They were divided into two main groups, those compensated and chose
decompensated at rest; the presence or absence of decompensation being
mainly determined by venous pressure measurements. The age at which they
came under observation was variable. The average known duration of mitral
stenosis was 5-20 years, but in some who had been followed up for many years
it was found that mitral stenosis had been present for from 40 to 60 years.
Acute rheumatic fever or chorea had occurred in 110 cases, endocarditis in 5
and syphilis in 5. Hypertension was found in at least 15 cases. Embolism,
cerebral, intestinal or peripheral, occurred in 19 cases. There were 21
autopsies, at which the size of the mitral valve opening was found to vary
from that of a little finger to a narrow chink. Left auricular enlargement
and right ventricular hypertrophy were present in all. The chief indications
for operation are (1) repeated attacks for several years of haemoptysis and
congestion of the lungs without marked cardiac enlargement, (2) very marked
dyspnoea of exertion over a long period. The diagnostic importance of the
presystolic murmur and rumbling diastolic murmur is emphasized. The use of
photocardiography to verify the sounds and to refer them to the right point
in the cardiac cycle is stressed. Photocardiography is also of use in
establishing the presence or absence of an 'opening snap'. The heart volumes
were estimated radiologically in every case, the maximum normal volume being
500 cm(3) per M(2) body surface. Most of the compensated cases had a volume
between 350 and 700 cm(3) per M(2) body surface. The majority of the
decompensated cases, however, had a volume between 550 and 1,200 cm(3). It
was concluded that cardiac enlargement preceded the signs of congestive
cardiac failure and was therefore an early and important sign of
decompensation. Auricular fibrillation was found to occur more frequently in
conjunction with large cardiac volumes. The roenterological appearances are
analysed. Backward bulging of the left auricle in the lateral view was noted
in 188 cases. The right border of the left auricle was clearly seen in the
frontal projection in 155 cases. The left auricular appendage formed a local
bulge in the upper left cardiac border in 81 cases. The frequent finding of
right axis deviation and broadening of the P waves in the ECG was considered
significant. Nylin's heart function test was used in an attempt to judge the
efficiency of the heart. In this test the oxygen uptake of the of the
subject before and after graded exercise is measured and hence the relative
oxygen debt estimated. It was thought that this test might be of importance
in decisions as to the management and treatment of cases of mitral stenosis.
EMTREE DRUG INDEX TERMS
buphenine
oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
examination
mitral valve stenosis
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
autopsy
body surface
cardiomegaly
chorea
congestive heart failure
diagnosis
dyspnea
electrocardiogram
embolism
endocarditis
exercise
heart
heart cycle
heart function test
heart right ventricle hypertrophy
heart volume
hemoptysis
hypertension
lung
mitral valve
oxygen consumption
P wave
pressure measurement
rheumatic fever
stenosis
stomach ulcer
syphilis
venous pressure
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007347477
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 577
TITLE
Observations on the daily changes in venous pressure and weight in a case of
chronic congestive heart failure
AUTHOR NAMES
Newman W.
Fishel L.
AUTHOR ADDRESSES
(Newman W.; Fishel L.) Cardiac Service, Vet. Adm. Hosp., Bronx, NY, United
States.
CORRESPONDENCE ADDRESS
W. Newman, Cardiac Service, Vet. Adm. Hosp., Bronx, NY, United States.
SOURCE
Circulation (1950) 1:4 (706-711). Date of Publication: 1950
ISSN
0009-7322
ABSTRACT
A patient with hypertensive and arteriosclerotic heart disease and auricular
fibrillation, who required digitalis, mercurials, and a low-sodium diet to
remain in cardiac compensation, was put into decompensation first by the
administration of salt and then by the withholding of digitalis. With salt
administration the patient's body weight and venous pressure (brachial) rose
simultaneously and was not accompanied by discomfort or dyspnoea. Salt
restriction brought about a simultaneous fall in both. However, with
discontinuation of digitalis the venous pressure rose but the body weight
remained unchanged and the patient became dyspnoeic. Mercurials were not of
much value, and digitalis had to be given to restore compensation. It is
suggested that two types of cardiac failure exist; one on the basis of salt
and water retention (forward failure) and the other due to a brief
discrepancy in the output of the two ventricles.
EMTREE DRUG INDEX TERMS
digitalis
mercury
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure
venous pressure
weight
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
body weight
compensation
coronary artery atherosclerosis
dyspnea
forward heart failure
heart failure
patient
sodium restriction
water retention
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007165648
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 578
TITLE
Studies on diethylaminoethanol. I. Physiological disposition and action on
cardiac arrhythmias
AUTHOR NAMES
Rosenberg B.
Kayden H.J.
Lief P.A.
Mark L.C.
Steele J.M.
Brodie B.B.
AUTHOR ADDRESSES
(Rosenberg B.; Kayden H.J.; Lief P.A.; Mark L.C.; Steele J.M.; Brodie B.B.)
SOURCE
Journal of Pharmacology and Experimental Therapeutics (1949) 95:1 (18-27).
Date of Publication: 1949
ISSN
0022-3565
ABSTRACT
When procaine, which has been used intravenously to control cardiac
arrhythmias during cyclopropane anesthesia, is hydrolysed in the body,
p-aminobenzoic acid and dimethylaminoethanol are produced. The latter was
procured as a pure substance (from Winthrop-Stearns) and tested to determine
whether the procaine results were due to this hydrolytic product. In dogs
ventricular premature beats and ventricular tachycardia were prevented by
its use, and in human subjects ventricular premature beats were suppressed
temporarily. Six cases of ventricular tachycardia were successfully treated.
There was no control of auricular fibrillation or supra-ventricular
tachycardia. This drug is less active than procaine but the effective dose
is safer. 25% is excreted in the urine, the fate of the remainder is still
unknown. A single dose is either metabolized or excreted within eight hours.
Considerable amounts are found in the organs. The control of the ventricular
activity occurs only when the plasma content is high, and lasts for about 20
minutes, hence the intravenous route is demanded. Some side reactions, e.g.
peculiar taste, warmth, dizziness, optical disturbance, nausea and fall in
blood pressure, were noted. None lasted over 20 minutes.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
2 diethylaminoethanol
EMTREE DRUG INDEX TERMS
4 aminobenzoic acid
cyclopropane
deanol
procaine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart arrhythmia
EMTREE MEDICAL INDEX TERMS
anesthesia
atrial fibrillation
blood pressure
dizziness
dog
dose response
heart fibrillation
heart ventricle contraction
heart ventricle extrasystole
heart ventricle tachycardia
human
nausea
optics
plasma
side effect
single drug dose
taste
urine
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007221765
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 579
TITLE
The heart rate with exercise in patients with auricular fibrillation
AUTHOR NAMES
Knox J.A.C.
AUTHOR ADDRESSES
(Knox J.A.C.) Dept. of Physiology, King's Coll., London.
CORRESPONDENCE ADDRESS
J.A.C. Knox, Dept. of Physiology, King's Coll., London.
SOURCE
British Heart Journal (1949) 11:2 (119-125). Date of Publication: 1949
ISSN
0007-0769
ABSTRACT
The effect of exercise on 13 ambulant patients with auricular fibrillation
was com-pared with the results in 100 normal subjects. In auricular
fibrillation there was occasionally an initial slowing of the heart but
there was always a later acceleration at about 12 seconds, the maximum heart
rate reaching a higher level and the subsequent secondary slowing taking
longer than in normal subjects. The response of a given patient remained
remarkably constant. Digitalis considerably decreased the excessive
acceleration in rate but did not abolish it.
EMTREE DRUG INDEX TERMS
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
atrial fibrillation
exercise
heart rate
patient
EMTREE MEDICAL INDEX TERMS
acceleration
heart
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007422991
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 580
TITLE
Heart disease in pregnancy
AUTHOR NAMES
Hudson K.
AUTHOR ADDRESSES
(Hudson K.)
SOURCE
Ulster Medical Journal (1949) 18:1 (93-100). Date of Publication: 1949
ISSN
0041-6193
ABSTRACT
The cases in this series, 31 primiparae and 39 multiparae, representing
together an incidence of 2.72% of admissions, were classified according to
the New York Heart Association classification. There were 22 cases (31.43%)
in Class 1, 42 (60%) in Class 2, 4 (5.72%) in Class 3 and 2 (2.85%) in Class
4. A history of rheumatic infection in one or another of its forms was noted
in 67.14% of the cases. A summary of the distribution of the vascular
lesions showed mitral stenosis present in 55 cases (79.57%), mitral
insufficiency in 3 (2.30%), mitral stenosis and aortic regurgitation in 11
(16.21%) and mitral stenosis and insufficiency in 1 (1.92%). A recent
reactivation of the lesion prior to or during pregnancy has an adverse
prognostic significance. The response of the heart to effort, and therefore
to pregnancy and parturition as shown by the response of the pulse rate and
blood pressure to exercise, constitutes a sign of greater importance
prognostically than the character of the lesion, heart sounds or area of
cardiac dullness. The only indication for interruption of pregnancy is heart
failure which doet nos respond to treatment and, if prior to the fourth
month of pregnancy, auricular fibrillation and recurrent heart failure. In
the absence of cardiac distress labour was allowed to proceed in the
ordinary manner. A pulse rate of 110 per minute and a respiratory rate of
over 24 per minute are considered omens of intra- or postpartum heart
failure and and for rapid digitalization. Further treatment consists of
oxygen therapy, the upright position and operative delivery as soon as
cervical dilatation permits. Forceps delivery was used in almost 30% of the
series, twice the rate of their clinic as a whole. Caesarean section was
done four times and then for obstetrical and not cardiac reasons. Three
deaths (4.28%) occurred in the series; two infants were lost. Although
pregnancy throws a heavy additional strain on the already reduced cardiac
reserve, it is a temporary strain, and rest and proper treatment may prevent
further inroads on the cardiac reserve. Repeated pregnancies, however, may
disastrously reduce the cardiac reserve. No statistical evidence is
available which satisfactorily proves that patients with one or two
pregnancies die at any earlier age than do nulliparous patients with
equivalent heart lesions. To reduce maternal mortality, all patients should
be under early supervision by both obstetrician and cardiologist. Previous
performance of the patient is all-important in the detection of progressive
deterioration of the cardiac reserve. Sound treatment rests on the early
supervision of such cases by trained personnel, the proper study and
evaluation of the cardiac condition, facilities for rest and treatment in
hospital prior to delivery and special care during labour.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart disease
pregnancy
EMTREE MEDICAL INDEX TERMS
aorta valve regurgitation
atrial fibrillation
birth
blood pressure
breathing rate
cardiologist
cesarean section
classification
death
deterioration
digitalization
exercise
forceps delivery
heart
heart failure
heart injury
heart sound
hospital
infant
infection
instrumental delivery
maternal mortality
mitral valve regurgitation
mitral valve stenosis
multipara
outpatient department
oxygen therapy
patient
personnel
primipara
pulse rate
standing
United States
uterine cervix dilatation
vascular lesion
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007065367
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 581
TITLE
Mitral stenosis in late life
AUTHOR NAMES
Cookson H.
AUTHOR ADDRESSES
(Cookson H.)
SOURCE
British Heart Journal (1949) 11:2 (155-164). Date of Publication: 1949
ISSN
0007-0769
ABSTRACT
This report concerns 37 patients with mitral stenosis and one with mitral
incompetence aged from 51 to 77 years. The females outnumbered the males by
3 to i, a ratio higher than that of mitral stenosis in general. Rheumatism
was believed to be the cause of the valvular lesion in all; 60% gave a clear
history of rheumatic fever or of a cardiac lesion having been discovered in
early life. The first recognized attack of rheumatic fever occurred over the
age of 30 in a few of the cases. All the cases had shown at least an average
capacity for work although some admitted to shortness of breath curtailing
strenuous exercise; 18 of the women had borne children (in one case, five).
Half the cases had arterial hypertension, taking a minimum diastolic
pressure of 100 mm., thus showing a relatively high incidence of this
disorder. Despite this feature anginal pain was present in only one case.
Auricular fibrillation or, in a few, auricular tachycardia, was seen in all
but two cases. The onset of arrhythmia seemed to mark the onset of serious
symptoms in most of the cases. The main point in the clinical diagnosis was
the presence of a low-pitched, usually but not invariably rough murmur,
heard in the neighbourhood of the mitral area. In the ten cases with aortic
incompetence as well, the diagnosis of mitral stenosis was not made unless
confirmatory radiological changes were present. The principal radiological
differences from those seen in the younger group of mitral stenosis cases
were due to the concomitant degenerative vascular changes and consisted of
broadening of the vascular pedicle, prominence of the aortic knob and left
ventricular enlargement. Sixteen cases died after an average duration of
symptoms of 4$ years, the average age at death being 62 years. Twelve died
with systemic congestion complicated in two by cerebral vascular lesions,
acute rheumatism in one and pulmonary infarction in one. Two died from acute
pulmonary congestion and two from a left auricular thrombus obstructing the
pulmonary orifice. It is suggested that mitral stenosis is not rare in
patients over 50 years of age and that careful auscultation of elderly
subjects with auricular fibrillation will reveal this lesion where formerly
it was not suspected.
EMTREE DRUG INDEX TERMS
sulfanilamide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
mitral valve stenosis
EMTREE MEDICAL INDEX TERMS
aged
aorta valve regurgitation
atrial fibrillation
auscultation
cerebrovascular disease
child
death
diagnosis
diastolic blood pressure
dyspnea
exercise
female
heart arrhythmia
heart injury
heart left ventricle hypertrophy
hypertension
lung congestion
lung infarction
male
mitral valve disease
mitral valve regurgitation
pain
patient
rheumatic disease
rheumatic fever
tachycardia
thrombus
vascular pedicle
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007422999
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 582
TITLE
Effect of lanatoside C on the circulation of patients with congestive
failure. A study using catheterization of the right side of the heart
AUTHOR NAMES
Stead E.A.
Warren J.V.
Brannon S.
AUTHOR ADDRESSES
(Stead E.A.; Warren J.V.; Brannon S.)
SOURCE
archives of internal medicine (1948) 81:3 (282-291). Date of Publication:
1948
ISSN
0730-188X
ABSTRACT
Presentation of the results in 22 patients with congestive heart failure
studied by right heart catheterization. The changes in the circulation
induced by the intravenous administration of 1.6 mg. of lanatoside G were
investigated on admission to the hospital. All patients had dyspnoea on
slight exertion prior to sedation. Right atrial pressure was elevated in 21.
Auricular fibrillation was present in three, auricular tachycardia in two;
the remainder had normal rhythm. The group included 13 patients with
hypertensive or coronary disease, four with rheumatic mitral stenosis, three
with luetic heart disease, and two unclassified. The first observed effect
was a fall in venous pressure (in 5-10 minutes). The fall in venous pressure
could not be related to a reduced blood volume or diuresis. The haematocrit
fell. The stroke volume increased in 20; the response of the cardiac rate
was variable. There were no consistent changes in oxygen consumption. The
mean arterial pressure increased in 16 patients (by 1-50 mm. Hg.). All
patients showed an increase in systolic blood pressure; the alterations in
diastolic pressure were inconstant. The peripheral mean pressure in mm.
resistance R = mean presure in mm Hg. 1332/ cardic putput in ml. fell in 18
patients. The arteno- cardiac output in ml. per second venous difference
decreased in all but one instance; in 16 the fall was at least 0.9 volume
per cent. The cardiac index rose in 20 instances. In eight of the 22
subjects the cardiac output increased significantly, the average increase
being 1.6 1. per minute. Patients with severe anaemia are discussed who had
a high cardiac output despite the presence of congestive heart failure; the
cardiac output increased further with digitalis. Attention is again called
to the disproportion between tissue need and cardiac output in the
initiation of congestive heart failure. The data indicate that lanatoside G
increases the output of the heart in the presence of a normal rhythm, and
that the prime effect of digitalis is on the ventricular muscle. The authors
classify cardiac output in congestive heart failure with regard to the
response to hospital therapy. Fishman - Chicago.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
lanatoside C
EMTREE DRUG INDEX TERMS
digitalis
lanatoside
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
catheterization
heart
patient
EMTREE MEDICAL INDEX TERMS
anemia
atrial fibrillation
blood volume
congestive heart failure
coronary artery disease
diastolic blood pressure
diuresis
dyspnea
exercise
giardiasis
heart catheterization
heart disease
heart failure
heart index
heart output
heart rate
heart right atrium pressure
heart stroke volume
hematocrit
hospital
intravenous drug administration
mean arterial pressure
mitral valve stenosis
muscle
oxygen consumption
rhythm
sedation
systolic blood pressure
tachycardia
therapy
tissues
United States
venous pressure
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007419297
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 583
TITLE
Aortic stenosis: A study of the clinical and pathologic aspects of 107
proved cases
AUTHOR NAMES
Kumpe C.W.
Bean W.B.
AUTHOR ADDRESSES
(Kumpe C.W.; Bean W.B.) Dept. of Internal Medicine, Univ. of Cincinnati,
Cincinnati Gen. Hosp., .
CORRESPONDENCE ADDRESS
C.W. Kumpe, Dept. of Internal Medicine, Univ. of Cincinnati, Cincinnati Gen.
Hosp., .
SOURCE
Medicine (1948) 27:2 (139-185). Date of Publication: 1948
ISSN
1357-3039
ABSTRACT
The conclusions of this monographic paper are: (i) A series of 107 proved
cases of aortic stenosis, uncomplicated by deforming lesions of other
valves, has been studied from the clinical and morphological aspects. (2)
Aortic stenosis found at autopsy is preponderantly a disease of the !ate
yeai* of life, although suine cases occur in the early decades. Roughly
three-fourths of the cases were males. Colour, anthropologie type and
occupation played no significant rôle in the disease. (3) A history of acute
rheumatic fever was obtained in two-thirds of the cases, with relevant data.
(4) Cases were divided into 'cardiac* (Group I) and 'non-cardiac* (Group II)
on the basis of history and status on hospital admission. Of the 78
cardiacs, 34 had chronic congestive failure, 10 had intermittent bouts of
failure, and 19 had an abrupt onset of failure shortly before they were
admitted. Severe epistaxes precipitated failure in three cases. Five
patients with congestive failure had chiefly complaints of mental disorders,
four had severe dizziness, four had repeated syncope, and cardiac pain was
responsible for the admission of three. In many cardiacs congestive failure
commenced or became more severe following strenuous exercise. (5) Three
grades of severity of the anatomical lesions were established. There was a
higher average admission rate for those with mild lesions ( é.37) than for
those with moderate (1.36) or severe lesions (1.34), many of the latter
being admitted only once and remaining until the fatal issue. (6) Group I
patients had an increased frequency of admission in the fall months of
September, October and November, but no such trend occurred in Group II. (7)
Group II patients were admitted for infection (endocarditis) and various
diseases of old age. Injury following syncope was a minor though significant
cause of admission. (8) Pulse rate was accelerated, but not to extreme
degrees, averaging 96 for cardiacs, 86 for the others. Respirations were
increased. Blood pressure was not characteristic; some had systolic
hypertension, and others had low diastolic pressures, but relatively few had
the low systolic, low pulse pressure described as typical of aortic
stenosis. (9) Enlargement of the heart was detected clinically in 78 % of
the cardiac patients and 52 % of the others. Muffling of the apical sounds
was common. At the base the second sound over the aortic valve was usually
absent or much reduced in intensity. Occasionally it was loud and must have
been transmitted from the pulmonary valve. Comparison of second sounds in
the right and left second interspaces was not always helpful, since loss
OfA1 or increase of P1 were not regular in occurrence. (10) A systolic
murmur was heard at the base in only 83 % of the cases, with transmission
into the neck vessels in slightly less than half. Basal diastolic murmurs
were heard in a third of the cases. Apical systolic murmurs were heard in 82
% of the cases, and an apical diastolic murmur was noted in slightly less
than a third. Thrills were felt in 33 cases. The systolic murmurs and
thrills were related in intensity to the degree of stenosis, but they were
absent in several cases with severe valvular obstruction, (u) Manifestations
of congestive heart failure were commonplace but were not of a peculiar
variety except for an unusual frequency of sweating. (12) Fluoroscopic
demonstration of calcified aortic valves verified the diagnosis five times.
With routine study a much larger number would have been found. (13)
Laboratory studies of blood and urine were not helpful in making a
diagnosis. (14) Nothing pathognomonic was found in the electrocardiograms.
Auricular fibrillation occurred in 19 % of the cases, a higher incidence
than reported elsewhere. Left axis deviation, conduction defects and signs
of myocardial disease were frequent. (15) The hospital course was
characterized by signs of congestive failure unusually refractory to
treatment with digitalis, oxygen or diuretics. Episodes of sweating,
cyanosis, restlessness and confusion occurred in 28 patients. They came and
went uninfluenced by special therapy. Signs and symptoms referable to the
brain were conspicuous in 13 patients. (16) Treatment was unsatisfactory.
Digitalis and oxygen gave poorer response than is usually seen in other
forms of congestive failure. Diuretics were only slightly more helpful. (17)
Cardiac pain occurred in 37 % of the patients before hospitalization and in
8 % while under observation. It differed from typical angina pectoris in its
lack ' of radiation or its radiation to the right, its advent after rather
than during exercise, and its refractoriness to nitroglycerine. It was much
more closely associated with severe aortic stenosis than with coronary
arteriosclerosis. (18) The type of sudden death which ended the life of 21 %
of the pauenls was uuTcicauaicu fïùiu iiislaui. syncopal death and
unexpected death where the terminal stage lasts for hours. In our material
sudden death occurred in a matter of minutes, usually between 5 and 30. In
contradistinction to those with instant death following myocardial
infarction, a history of syncopal attacks was not common in those bedfast
patients who died suddenly. Indeed, it was less than half as common in those
who died suddenly as in the whole group. (19) The lesions of aortic stenosis
were graded into three classes on the basis of severity. In every valve
calcium was found grossly or histologically, and it varied in quantity with
the severity of the lesion. In severe lesions the coronary ostia were
distorted. Fusion of cusps and nodule formation were common. The hearts were
enlarged in the majority of cases and the heart weight was related to the
extent of valvular obstruction. There was also a relation of heart weight to
congestive failure, the cardiacs with each grade of stenosis having heavier
hearts than the noncardiacs. (20) Coronary arteriosclerosis was common, and
had given rise to thrombosis and myocardial infarction in an appreciable
number, (21) Sclerosis was extensive in the abdominal and descending portion
of the thoracic aorta, but not in the ascending portion. (22) The remainder
of the lesions found at autopsy were related to advanced arterial disease,
congestive failure, bacterial endocarditis and the numerous intercurrent
diseases which proved lethal to those in Group II. (23) Clinical diagnosis
was made in only 24 % of all cases, reflecting both unfamiliarity with the
diagnostic criteria and too great acceptance of the classic triad of basal
systolic murmur, thrill, and small slowly rising pulse.
EMTREE DRUG INDEX TERMS
calcium
digitalis
diuretic agent
glyceryl trinitrate
oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
aorta stenosis
EMTREE MEDICAL INDEX TERMS
angina pectoris
aorta valve
artery disease
atrial fibrillation
autopsy
bacterial endocarditis
blood
blood pressure
brain
cardiac patient
color
congestive heart failure
coronary artery atherosclerosis
cyanosis
death
diagnosis
diastolic blood pressure
dizziness
electrocardiogram
endocarditis
exercise
faintness
heart
heart infarction
heart muscle conduction disturbance
heart weight
hospital
hospital admission
hospitalization
infection
injury
laboratory
male
mental disease
myocardial disease
neck
obstruction
occupation
pain
patient
physical disease by body function
pulmonary valve
pulse pressure
pulse rate
radiation
restlessness
rheumatic fever
sclerosis
senescence
stenosis
sudden death
sweating
systolic heart murmur
systolic hypertension
therapy
thoracic aorta
thrombosis
urine
valve
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007418650
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 584
TITLE
Endothelial dystrophy
AUTHOR NAMES
Colvin C.S.
AUTHOR ADDRESSES
(Colvin C.S.)
SOURCE
Transactions of the Ophthalmological Society of Australia, Sydney (1947) 7
(106). Date of Publication: 1947
ABSTRACT
A case of endothelial dystrophy is described. The patient was an elderly
woman, thin and a sufferer from chronic indigestion and auricular
fibrillation. Her vision had improved from 6/9 to 6/6 in the right eye, and
from 6/60 to 6/12 in the left eye. The treatment consisted of improved diet,
mixed glandular therapy and vitamin capsules. She had seen rainbows for
years, and a diagnosis of glaucoma had been made elsewhere. The tension and
the fields and the fundi were normal. The slit-lamp appearance was typical.
In discussion, six other patients with a similar condition were described by
members.
EMTREE DRUG INDEX TERMS
vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
dystrophy
EMTREE MEDICAL INDEX TERMS
aged
atrial fibrillation
cornea
cornea dystrophy
diagnosis
diet
endothelium
eye
female
glaucoma
indigestion
patient
slit lamp
therapy
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007280731
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 585
TITLE
The management of hyperihyroidism
AUTHOR NAMES
Davis H.H.
AUTHOR ADDRESSES
(Davis H.H.)
SOURCE
Rocky Mountain medical journal (1947) 44:3 (840-843). Date of Publication:
1947
ISSN
0035-760X
ABSTRACT
After introductory remarks on the relation of iodine to the pathogenesis of
goitre, the author presents a study of goitre cases at the Nebraska Hospital
over a ten-year period. 82 % were operated upon, with satisfactory results
in 91 %. The wellestablished pre-operative procedure of using Lugol's iodine
with a high caloric, high protein and high vitamin diet is discussed. 10 %
of auricular fibrillations are due to hyperthyroidism; such patients are
usually 35 years or older. This complication should not be treated with
quinidine, but with digitalis. When the patient recovers from the operation
the basal metabolic rate should be determined at monthly intervals, and
desiccated thyroid should be given when indicated. Postoperative
complications are haemorrhage, cyanosis, dyspnoea (due to haematoma or
injury of the laryngeal nerve), thyroid crisis and tetany. The author
discusses the use of thiouracil as a means of pre-operative care; it has a
depressant effect on the bone marrow. Additional therapeutic measures are
irradiation therapy, radioactive iodine may be given orally. It has the
taste of stale water and is absorbed and concentrated in the thyroid gland.
This radio-active substance may have a greater effect than roentgen rays
delivered through the skin and overlying tissues. Tolstoi - New York.
EMTREE DRUG INDEX TERMS
digitalis
iodine
lugol
protein
quinidine
radioactive iodine
thiouracil
vitamin
water
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
basal metabolic rate
bleeding
bone marrow
cyanosis
diet
dyspnea
goiter
hematoma
hospital
hyperthyroidism
injury
laryngeal nerve
pathogenesis
patient
postoperative complication
radiotherapy
skin
taste
tetany
thyroid crisis
thyroid gland
tissues
United States
X ray
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007417807
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 586
TITLE
The heart in thyroid disease
AUTHOR NAMES
Starr P.
AUTHOR ADDRESSES
(Starr P.) University of Southern California School of Medicine, Los
Angeles, CA, United States.
CORRESPONDENCE ADDRESS
P. Starr, University of Southern California School of Medicine, Los Angeles,
CA, United States.
SOURCE
Clinical Medicine (1947) 54:6 (179-181). Date of Publication: 1947
ISSN
0412-7994
ABSTRACT
Deficiency of the thyroid hormone produces its cardiovascular effects at two
levels. The slighter deficiency is associated with loss of the pharmacologic
function of the thyroid hormone in relation to the sympathetic cardiac
nervous mechanisms. The greater deficiency (myxoedema) produces degenerative
changes in the heart and blood vessels. The changes in myxoedema consist of
dilatation and pseudohypertrophy of the heart. There are interstitial oedema
and fibrosis, the fibres being widely separated and the myocardium friable.
The heart is enlarged in all diameters and roentgenoscopically it beats with
extreme feebleness. Cardiac output and circulation time are decreased in the
presence of myxoedema, the pulse pressure is low and rises with thyroid
treatment; arteriovenous oxygen difference is greatly increased in
myxoedema. The electrocardiographic manifestations of myxoedema are
decreased amplitude of P and QRS waves and absence or inversion of the T
wave in all leads. Clinically, the patients experience dyspnoea on effort,
and some have angina pectoris. Congestive failure does not result from
myxoedema in itself and when it does occur, it is because some other
pathologic cause exists. In the treatment of myxoedema, the daily dose of
thyroid is usually from a fraction of maintenance dose (0.25 grain U.S.P.
desiccated thyroid for two weeks; 0.5 grain for two weeks; 0.75 grain for
two weeks) up to a maintenance dose of 1 grain daily. By this means, the
full driving force of the maintenance dose is not reached until the
histopathologic changes have been corrected. If evidence of coronary
insufficiency develops under treatment, thyroid medication is discontinued
and is reinitiated at the previous lower level. Excess thyroid hormone also
produces its effects by two mechanisms, the pharmacologic and the
pathologic. The pathogenic action of hyperthyroidism on the heart is
summarized as follows: (1) Continuous day and night excessive work due to
elevated metabolism (no sleep relief); (2) pharmacologic effects due to
adrenergic synergism and peripheral capillary dilatation, and simulated
arteriovenous shunt in the goitre; (5) disturbance of cardiac rhythm;
auricular fibrillation in 20 per cent of all cases (two-third permanent;
one-third paroxysmal) and in 50 per cent of those with congestive failure;
(4) disorders of protein and carbohydrate storage in hyperthyroidism as
evidenced by creatinuria and insulin intensity. There are no established
histological changes in the heart due to hyperthyroidism, and in the absence
of auricular fibrillation or hypertension, the heart is not enlarged.
Congestive heart failure is frequently, though not always, associated with
some underlying cardiac disease. The diagnosis is based on the classic signs
and symptoms of hyperthyroidism, on the failure of a fibrillating heart to
slow on adequate administration of digitalis and on a history of
thyrotoxicity prior to the onset of congestive failure, especially in the
presence of auricular fibrillation. There are no characteristic
electrocardiographic signs of hyperthyroidism. The pre-operative management
of hyperthyroidism includes sedation (small doses of morphine) and the
restoration of compensation (salt-free diet, diuretic agents and digitalis).
During this time thiouracil could be used, to be combined with the
employment of iodine for ten days before operation.
EMTREE DRUG INDEX TERMS
carbohydrate
digitalis
diuretic agent
insulin
iodine
morphine
oxygen
protein
thiouracil
thyroid hormone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart
thyroid disease
EMTREE MEDICAL INDEX TERMS
angina pectoris
arteriovenous shunt
atrial fibrillation
blood vessel
capillary
cardiovascular effect
circulation time
compensation
congestive heart failure
diagnosis
diet
drug therapy
dyspnea
edema
employment
fiber
fibrosis
goiter
grain
heart disease
heart muscle
heart output
heart rhythm
hypertension
hyperthyroidism
ischemic heart disease
maintenance drug dose
metabolism
myxedema
night
patient
physical disease by body function
pulse pressure
sedation
sleep
storage
T wave
thyroid gland
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007024833
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 587
TITLE
Editorial. Rheumatic fever. Abridged interim report from the Royal College
of Physicians
AUTHOR ADDRESSES
SOURCE
Medical Press (1947) 109:5636 (418-421). Date of Publication: 1947
ISSN
0368-9492
ABSTRACT
Available evidence suggests that in Great Britain there are 300,000 persons
whose lives are or will be affected by rheumatic fever. It is the dominating
cause of heart disease under the age of 40, and usually begins between the
ages of five and fifteen years. Environment, and perhaps an inherited
susceptibility, may favour its occurrence. Infection of the supper
respiratory tract with haemolytic streptococci of the Lancefield A group
sometimes precedes the initial attack. The latent period between an
antecedent streptococcal infection and the rheumatic fever illness is
commonly two to three weeks. Modes of onset: (a) Failing health. Insidious
onset, sore throat, early fatigue, pallor, and loss of weight. (b) Multiple
arthritis. All grades, high fever. Subcutaneous rheumatic nodules, swelling
of joints. (c) Carditis, tachycardia and cardiac murmurs and later failing
health, pyrexia, nodules and arthritis. (d) Chorea. This seldom occurs at
the same time as joint manifestations, but may alternate with frank attacks
of rheumatic fever. The heart is less frequently involved. Clinical features
and general signs include carditis (essential lesion) pyrexia, pain and
tenderness in large joints; rapid pulse (regular), systolic murmurs and
sometimes a pericardial rub. Apart from the symptoms already mentioned blood
examination shows moderate reduction in red cells, to about 4 million per
cmm and haemoglobin may fall to 60 per cent or less. Leucocyte count varies
between 10,000 and 15,000 or more. Increased erythrocyte sedimentation rate
(E.S.R.) is found during the active stage of the disease. Inflammation of
the heart (carditis) is evidenced by tachycardia, murmurs, pericarditis,
cardiac enlargement, and electrocardiographic signs such as prolongation of
P.R. interval and changes in the form or duration of the QRS or in the T
waves. Auricular fibrillation is uncommon in children but in severe cases
signs of heart failure may appear, such as extreme tachycardia, dyspnoea,
venous distension, enlargement of liver and oedema of dependent parts;
vomiting and abdominal pain are grave developments. Differential diagnosis:
Congenital heart disease. History may be misleading but rheumatic fever
below the age of three is rare. The murmur is more often basal than apical.
Osteomyelitis: persistence of swelling at one joint should arouse suspicion.
Tuberculosis also affects a single joint. Rheumatoid arthritis occasionally
begins acutely and closely simulates rheumatic fever. Acute poliomyelitis in
its early stages may produce considerable pain in the limbs but seldom
selects joints. Course and prognosis: Pains and swellings in joints will
usually disappear with treatment, but carditis often continues for weeks or
months. Relapses are frequent. The younger the patient, the more certainly
will the heart be involved and severe signs of persistent carditis are
unfavourable. Treatment: Rest in bed is essential and in carditis the child
may be more comfortable in the semi-recumbent position with all voluntary
effort excluded. Diet: milk, custards, bread and butter and as soon as
possible a good mixed diet to combat anaemia. As a general rule 1.5 grains
of sodium salicylate should be given for every year of the child's age,
administered in three or four doses in 24 hours. An opiate should be given
if pain is severe and prevents sleep. Duration of rest in bed: Every patient
with carditis should remain in bed for four weeks after the disappearance of
the last sign of activity. The persistence of a systolic murmur is of little
significance. Resumption of activity must be watched with care. Return to
activity should be gradual but not too slow but a watch should be kept for
any indication of reactivation of the rheumatic disease. The importance of
open-air activity during suitable weather to raise resistance to further
attacks is stressed. Adequate rest each night, medical observation of
febrile attacks (especially of sore throats), of any septic condition, or
persistent anaemia is advisable. More strenuous competitive games, such as
running, cycling, swimming and hill climbing are inadvisable for the
majority of sufferers from heart disease, but football and other games need
not be ruled out automatically. Public health aspects: Co-ordinated action
between medical practitioners and local health and educational authorities
is advised, as also is the co-operation of the Institution of Rheumatic
Supervision Centres, Hospitals Schools and Special Schools including
residence for the child suffering from residual cardiac damage. Employment:
The school medical officer should explain to parents the advantage to be
gained by registration under the Disabled Persons (Employment) Act 1944 to
ensure receiving any necessary vocational training.
EMTREE DRUG INDEX TERMS
hemoglobin
opiate
salicylate sodium
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
college
physician
rheumatic fever
EMTREE MEDICAL INDEX TERMS
abdominal pain
anemia
arthritis
atrial fibrillation
blood examination
bread
butter
cardiomegaly
carditis
child
chorea
climbing
clinical feature
congenital heart disease
diet
differential diagnosis
disabled person
dyspnea
edema
employment
environment
erythrocyte
erythrocyte sedimentation rate
fatigue
fever
football
general aspects of disease
grain
health
heart
heart disease
heart failure
heart injury
heart murmur
hemolytic Streptococcus
hospital
infection
inflammation
latent period
leukocyte count
limb
liver
medical personnel
milk
night
osteomyelitis
pain
pallor
parent
patient
pericarditis
poliomyelitis
prognosis
public health
pulse rate
registration
relapse
respiratory system
rheumatic disease
rheumatoid arthritis
rheumatoid nodule
school
sleep
sore throat
Streptococcus infection
swelling
swimming
systolic heart murmur
T wave
tachycardia
tuberculosis
United Kingdom
vocational education
vomiting
weather
weight
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007189863
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 588
TITLE
Preoperative management of hyperthyroidism. Use of thiouracil and
thiobarbital
AUTHOR NAMES
Guthrie R.F.
AUTHOR ADDRESSES
(Guthrie R.F.)
SOURCE
Journal of the Medical Association of the State of Alabama (1947) 16:9
(281-285). Date of Publication: 1947
ABSTRACT
Twenty-five patients were treated with 0.2 Gm of thiouracil three times a
day and three patients with thiobarbital in daily doses of 50 to 100 mgm.
Lugol's solution, 10 minims three times a day, was given three weeks prior
to surgery, thiouracil being omitted one week before surgery. Improvement,
except for exophthalmos, was seen in all patients treated. High caloric diet
of 3,500 to 5,000 calories, supplemented by vitamins, was recommended. In
cardiac decompensation, thiouracil and iodine alone should be tried. If
these are unsuccessful ammonium chloride, aminophyllin or mercurial
diuretics can be used. In cases of chronic auricular fibrillation, digitalis
is the remedy of choice; in paroxysmal fibrillation or flutter, quinidine is
advised. Suitability for operation may be judged chiefly by gain in weight.
In patients treated with iodine alone, a pulse rate of under 110 is required
- in those on thiouracil, below 100 - plus improvement in symptoms.
Thiouracil provides greater safety when used in pre-operative preparation
than can be obtained by other means.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
thiobarbital
thiouracil
EMTREE DRUG INDEX TERMS
aminophylline
ammonium chloride
digitalis
diuretic agent
iodine
lugol
quinidine
vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
hyperthyroidism
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
calorie
diet
exophthalmos
heart failure
human
patient
preoperative treatment
pulse rate
safety
surgery
thyroidectomy
thyrotoxicosis
weight
CAS REGISTRY NUMBERS
thiobarbital (77-32-7)
thiouracil (141-90-2)
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007010776
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 589
TITLE
The efficacy of maintenance doses of digitalis in preventing the recurrence
of congestive heart failure
AUTHOR NAMES
Ladue J.S.
Carter S.B.
AUTHOR ADDRESSES
(Ladue J.S.; Carter S.B.)
SOURCE
Annals of Internal Medicine (1947) 27:6 (923-928). Date of Publication: 1947
ISSN
0003-4819
ABSTRACT
It is well known that congestive failure ensues in patients with heart
disease and auricular fibrillation if digitalis is withheld. Katz, Sokolow,
Weinberg and Plant were the first to investigate this effect of maintenance
doses of digitalis in such patients with normal rhythm. A similar study was
started by the present authors prior to the publication of this work. One
hundred and four patients with heart disease were studied following
discharge from the hospital, most of them had been receiving daily doses of
0.1 to 0.3 Gm digitalis. Measurements of venous pressure, circulation time,
vital capacity, and weight were made prior to and after omission of
digitalis. Signs and symptoms of congestive failure were noted, the patients
were cautioned against sudden exertion, and fluid and salt intake were
limited. Of the 104 patients studied 65 developed congestive heart failure
after omission of digitalis, but the levels of the selected objective
criteria of decompensation rarely indicated its approach. Confirming
previous observers it was found that cardiac patients not in failure have,
on the average, lower vital capacity and longer circulation times than
normals. Change in weight was as sensitive an indicator of failure as
changes in venous pressure, circulation time, or vital capacity. The latter
was of more value, however, in left ventricular failure. The symptoms and
clinical signs were more reliable in discovering congestive failure than
were repeated measurements of circulation time, venous pressure, or heart
size. The transverse diameter of the heart is not appreciably affected by
taking folia digitalis over a period of two to twenty-four months in the
fully compensated patient with heart disease and regular sinus rhythm.
Maintenance daily doses of 0.1 to 0.3 Gm digitalis leaf should be given to
those with sinus rhythm. None of the criteria selected for the study gives
any accurate appraisal of the proper maintenance dose for patients with
sinus rhythm.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
congestive heart failure
maintenance drug dose
EMTREE MEDICAL INDEX TERMS
atrial fibrillation
cardiac patient
circulation time
exercise
forced expiratory volume
heart
heart disease
heart left ventricle failure
heart size
hospital
liquid
patient
physical disease by body function
plant
plant leaf
rhythm
salt intake
sinus rhythm
therapy
venous pressure
vital capacity
weight
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007192442
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 590
TITLE
Recent myocardial infarction
AUTHOR NAMES
Mintz S.S.
Katz L.N.
AUTHOR ADDRESSES
(Mintz S.S.; Katz L.N.) Cardiovascular Department, Michael Reese Hospital, .
CORRESPONDENCE ADDRESS
Cardiovascular Department, Michael Reese Hospital, .
SOURCE
archives of internal medicine (1947) 80:2 (205-236). Date of Publication:
1947
ISSN
0730-188X
ABSTRACT
A study of 572 cases, extending over a five-year period from 1940-1945, of
unequivocal myocardial infarction. The ratio of men to women was 2.2:1 and
the average age was 62.4 years for the women and 58.4 for the men. The
immediate mortality (within the first two weeks) was 18.6 per cent for men
and 28.9 per cent for women. Seasonal incidence was an unimportant factor.
Although a possible precipitating factor (exertion, infection, emotion) was
present in 50 cases, the vast majority apparently occurred without
precipitating events. Hypertension was pre-existent in 49.4 per cent of the
women and 29.7 per cent of the men. There was a low incidence of
hypertension in the younger group (32-36 years). Hypertension incidence
increased with age, especially in the women. The hypertension had no
influence on the immediate mortality rate. Diabetes was present in 16.2 per
cent and these had a higher immediate mortality for both sexes, due entirely
to those who showed ketosis. Controlled diabetes had the same mortality rate
as the entire general series and a high blood sugar level per se appeared
advantageous. Syphilis was a possible factor rarely (0.8 per cent of the
cases). Angina pectoris prior to the infarction existed in 72.9 per cent but
had little, if any, prognostic significance. The presence of angina pectoris
following the infarction gave a grave prognosis. The absence of pain
('silent myocardial infarction') and the character, location, radiation, and
duration of the pain had no prognostic significance. The hypertensive
patients had a greater drop in blood pressure than the normotensive. The
pulse pressure fell in all groups and when it fell below 25 mm Hg, the
prognosis was grave. The degree of drop in systolic pressure was of no
significance provided the pressure was not below 100 mm Hg. If levels below
90 mm Hg persisted for several days the prognosis was poor. The presence of
shock, thought by the authors to be cardiogenic, in which forward failure
developed because of reduced cardiac output, was grave (77.8 per cent of
those in shock died). Although the mortality was about the same in anterior
(17.6 per cent) and posterior (23.1 per cent) infarction it was greatest in
septal and in the atypical and combined varieties. Most arrhythmias
increased the mortality rate. Patients with complete heart block or with
runs of ventricular premature systoles had 100 per cent mortality, with
auricular flutter 75 per cent, supraventricular tachycardia 66.6 per cent,
ventricular tachycardia 60 per cent, auricular fibrillation 29.4 per cent,
and auriculoventricular block 23.1 per cent. The mortality was apparently
increased in the arrhythmias treated with digitalis (50 per cent of the 30
treated) or quinidine (41.2 per cent of the 17 treated) and 58.2 per cent in
the 12 persons treated with both drugs. It is pointed cut that these drugs
were used in those patients who suffered cardiac failure besides the
arrhythmia. Occasional premature systoles (ventricular, auricular, or nodal)
had no significance in the immediate mortality. Intraventricular block
increased the mortality percentage. Congestive failure was an extremely
grave sign, more so in men (46.2 per cent) than in women (37.5 per cent).
Sinus tachycardia (a ventricular rate of over 100 in the first
electrocardiogram) was a grave prognostic sign. Of the 79 men and the 37
women in the entire series of 572 cases who developed this tachycardia the
mortality was 50.6 and 67.6 per cent respectively. Of the 116 cases of
tachycardia 56 had congestive heart failure and the mortality for this
combination was 71.4 per cent. Of the 213 patients with heart failure 101
received digitalis and 47 (46.5 per cent) died; of the 20 heart failures not
given digitalis only four died. This poor record for digitalis may be due to
the fact that only the graver cases received it, and the authors believe in
the careful use of the drug when there are clear indications of heart
failure (persistent dyspnoea, cyanosis, and râles in the bases of the lungs
when not due to pneumonia). Although digitalis may shorten coagulation time
of the blood its real danger is the initiation of ventricular fibrillation.
Forward failure and shock are centra-indications to use of digitalis. In the
572 cases there were 26 instances of pulmonary emboli, 11 of cerebral
emboli, and two patients with a combination of both with a mortality of
53.8, 81.8, and 100 per cent respectively. One patient had a mesenteric
thrombosis (fatal). The remainder of the 9.9 per cent of the series that
exhibited thrombo-embolism were distributed to the lower extremities,
kidneys, and spleen. Of 20 of the patients with thrombo-embolism who
received digitalis, 80 per cent died and 40.6 per cent of the 32 who did not
get digitalis died. The authors advise ligation of vessels and/or the use of
anticoagulants in indicated cases, but are not yet ready to advise
anticoagulants to every patient prophylactically. Proved pericarditis
developed in 26 cases in the series and had a death rate of 19.2 per cent,
which compared favourably with the rate for the entire series. Thus it was
not considered prognostically poor. Pneumonia developed in 52 (9.9 per cent)
of the cases and exhibited a mortality of 57.7 per cent. It is to be
considered a grave accompaniment, and penicillin therapy is indicated.
Proved glycosuria (non-diabetic) occurred in only 10 cases. It could
possibly be due to the release of epinephrine as a sequel to pain and fear
or to a decrease in the circulation of blood to the liver. Of the 125
patients who died, 46 were studied at autopsy. Eight cases showed cardiac
aneurysm and five heart ruptures with haemo-pericardium. The infarction was
posterior on the left ventricle in most cases which had exhibited partial
and complete A-V block although two such cases were infarcted anteriorly.
Most of the patients with intraventricular block showed the septum involved
by fibrosis or acute infarction. Most infarctions were located as indicated
by the electrocardiogram.
EMTREE DRUG INDEX TERMS
adrenalin
anticoagulant agent
digitalis
penicillin G
quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
heart infarction
EMTREE MEDICAL INDEX TERMS
angina pectoris
atrial fibrillation
atrioventricular block
autopsy
blood
blood clotting time
blood pressure
complete heart block
congestive heart failure
cyanosis
diabetes mellitus
dyspnea
electrocardiogram
embolism
emotion
epidemiology
exercise
fear
female
fibrosis
forward heart failure
glucose blood level
glucosuria
heart aneurysm
heart arrhythmia
heart atrium flutter
heart failure
heart left ventricle
heart output
heart rupture
heart ventricle fibrillation
heart ventricle tachycardia
hypertension
infarction
infection
ketoacidosis
kidney
leg
ligation
liver
lung
lung embolism
mortality
pain
patient
pericarditis
pericardium
pneumonia
prognosis
pulse pressure
radiation
seasonal variation
silent myocardial infarction
sinus tachycardia
spleen
supraventricular tachycardia
syphilis
systole
systolic blood pressure
tachycardia
therapy
thromboembolism
thrombosis
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007210772
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.
RECORD 591
TITLE
Early diagnosis of rheumatic valvular disease in recruits
AUTHOR NAMES
Parkinson J.
Hartley R.
AUTHOR ADDRESSES
(Parkinson J.; Hartley R.) Cardiac Department, London Hospital, .
CORRESPONDENCE ADDRESS
Cardiac Department, London Hospital, .
SOURCE
British Heart Journal (1946) 8:4 (212-232). Date of Publication: 1946
ISSN
0007-0769
ABSTRACT
This paper is based on 2,500 recruits referred for cardiological opinion to
Medical Boards. The commonest cause of reference was a systolic murmur
which, in 259 (10 per cent), was considered to be incidental or functional,
the criteria of benignity being softness and shortness, variability with
posture, respiration and heart rate. Normal radiological appearances were a
great help in regarding such murmurs as trivial. It is emphasized that a
split first sound, a loud or reduplicated second pulmonary sound, as well as
the normal third heart sound may all erroneously be regarded as evidence of
disease. An individual with an innocent systolic murmur runs a risk of a
'doctor made' cardiac neurosis, as many medical men fail to give the patient
firm reassurance. Minor degrees of scoliosis were frequently found to
displace the apex beat. In 72 cases a simple nervous tachycardia of 90 to
130 was noted falling on rest and as excitement abated. A persistent rate of
over 100 should lead to a careful search for a cause such as thyrotoxicosis,
pyrexia or pulmonary disease. Smoking or drinking to excess may be a cause.
Bradycardia was rarely worthy of note; when the patient is under 50 years of
age an attempt should be made to raise the rate by exercise and when under
40 years an electrocardiogram is indicated. Irregularity of the pulse was
the cause of reference in 31 out of 1,000 consecutive cases. The two
principal causes were extrasystoles (ten) and sinus arrhythmia (ten). In
discussing the thorny problem of what should be regarded as the upper limit
of normal blood-pressure the authors suggest that the limit of the systolic
pressure (after the exclusion of renal disease and coarctation of the aorta)
might with safety be placed higher than 160 mm provided that the diastolic
pressure is 90 or below and that the X-ray picture of the left ventricle is
normal. In the whole group a history of rheumatic fever, chorea or dyspnoea
was found unreliable, as the desires of the patient tended to cause error in
both directions. Of the purely clinical methods of examination auscultation
is the most important. Emphasis is placed on the value of listening in the
left lateral position immediately after exercise as a method of eliciting
the mitral presystolic murmur. Auscutation over the left border of the
sternum with the patient in the left lateral position during the falling
heart rate subsequent to exercise facilitated hearing the soft early murmur
of aortic incompetence. This murmur is also accentuated when the patient
leans forwards, expires and holds the breath. Formal exercise tolerance
tests were not employed. Electro-cardiography was in general not found
helpful and was abandoned as a routine procedure after the first 500 cases.
Radioscopy proved invaluable in early diagnosis in that 80-90 per cent of
cases furnished convincing X-ray evidence. Left auricular enlargement in
mitral stenosis proved equal in importance to the presystolic murmur in the
diagnosis of mitral stenosis. This enlargement is best seen in the right
oblique view with the oesophagus delineated by barium; this view also
demonstrates the prominent anterior cardiac border and the broadening of the
normal slim neck of the heart shadow. The A.P. view in early mitral stenosis
shows a characteristic 'filling in' of the left border with a small aortic
knuckle. Mention is made of the unreliability of 'buttressing' of the right
border and extent of hilar markings as evidence of early mitral disease.
Extension outwards and increased convexity of the left lower border are
regarded as the earliest signs - of the left ventricular enlargement - of
aortic incompetence; these features are best seen in the left oblique
position. Mention is made of the fact that a trivial scoliosis, a high
diaphragm or a simple bradycardia may result in the radiological simulation
of early mitral stenosis or aortic incompetence; conversely either lesion
may be concealed by a low diaphragm. Mitral valvular disease was diagnosed
in 264 of all rheumatic cases (609). It is considered that the weight of
pathological evidence supports the view that mitral incompetence without
stenosis is rare except perhaps in early life. This group was subdivided
into mitral stenosis with a presystolic murmur, numbering 104. All had a
loud first sound. Left auricular enlargement was the characteristic X-ray
sign. The authors include in this group five cases in which a loud first
sound and characteristic X-ray changes were present without a presystolic
murmur, and 13 cases in which a mitral diastolic murmur alone was heard.
Mitral stenosis with a systolic murmur. These amounted to 60 cases, of whom
more than half gave a strong rheumatic history; all had a loud systolic
murmur and 54 showed radiological evidence. Mitral valvular disease
(probable). In this group of 68 cases the history, symptoms and signs,
although not conclusive, were sufficiently suggestive to warrant rejection
for service. Mitral stenosis without murmur. In two cases, one with
auricular fibrillation, no abnormal auscultatory signs were noted, but the
left auricular enlargement was considered diagnostic. Aortic valvular
disease without mitral stenosis was found in 229 cases. Of these 202 had
pure aortic incompetence, all with an aortic diastolic murmur, half with an
additional apical systolic murmur of no great length or intensity. Left
ventricular enlargement was demonstrated in 169. Emphasis is placed on the
fact that aortic incompetence, either alone, or with mitral stenosis is far
more common than is thought. Pure aortic stenosis was found in 14 cases, 13
of whom had an aortic systolic thrill, and yet the arotic second sound was
present. Aortic stenosis and incompetence was combined in 13 cases. Combined
aortic and mitral valvular lesions were found in 76 cases, a figure which
the authors regard as disproportionately small, as the grosser cases are
easily recognized and were graded by the Medical Boards without reference to
a cardiologist. It is noteworthy that of the total of 2,500 cases seen, 71
had congenital cardiac lesions and only four syphilitic aortic incompetence.
EMTREE DRUG INDEX TERMS
barium
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
early diagnosis
rheumatic heart disease
EMTREE MEDICAL INDEX TERMS
aorta
aorta stenosis
aorta valve disease
aorta valve regurgitation
atrial fibrillation
auscultation
blood pressure
body posture
bradycardia
breathing
cardiac anxiety
cardiologist
chorea
diagnosis
diaphragm
diastolic blood pressure
drinking
dyspnea
electrocardiogram
electrocardiography
esophagus
examination
excitement
exercise
exercise tolerance
extrasystole
fever
hardness
hearing
heart
heart injury
heart left ventricle
heart left ventricle hypertrophy
heart rate
heart sound
kidney disease
lung disease
mitral valve disease
mitral valve regurgitation
mitral valve stenosis
neck
patient
physician
pulse rate
reassurance
rheumatic disease
rheumatic fever
risk
safety
scoliosis
simulation
sinus arrhythmia
smoking
stenosis
sternum
systolic blood pressure
systolic heart murmur
tachycardia
thyrotoxicosis
weight
X ray
X ray picture
LANGUAGE OF ARTICLE
English
LANGUAGE OF SUMMARY
English
EMBASE ACCESSION NUMBER
2007001890
COPYRIGHT
Copyright 2007 Elsevier B.V., All rights reserved.